amod||benzodiazepines-2/NNS||gaba-acting-1/JJ	nsubj||exert-3/VBD||benzodiazepines-2/NNS	ccomp||neurons-22/VBZ||exert-3/VBD	det||patients-6/NNS||some-5/DT	prep_in||exert-3/VBD||patients-6/NNS	nn||effects-10/NNS||autism-8/NN	nn||effects-10/NNS||paradoxical-9/NN	prep_with||exert-3/VBD||effects-10/NNS	xcomp||exert-3/VBD||raising-12/VBG	det||possibility-14/NN||the-13/DT	dobj||raising-12/VBG||possibility-14/NN	nsubj||like-16/VBP||possibility-14/NN	rcmod||possibility-14/NN||like-16/VBP	prep_in||like-16/VBP||epilepsies-18/NNS	nn||excites-21/NNS||gaba-20/NN	nsubj||neurons-22/VBZ||excites-21/NNS	root||ROOT-0/null||neurons-22/VBZ	amod||concentrations-27/NNS||elevated-25/JJ	nn||concentrations-27/NNS||intracellular-26/NN	prep_because_of||neurons-22/VBZ||concentrations-27/NNS	prep_of||concentrations-27/NNS||chloride-29/NN	benzodiazepines-2||epilepsies-18||no_rel||gaba-acting benzodiazepines exert in some patients with autism paradoxical effects, raising the possibility that like in epilepsies, gaba excites neurons because of elevated intracellular concentrations of chloride.
mark||use-14/VBP||although-1/IN	amod||groups-4/NNS||different-3/JJ	prep_in||use-14/VBP||groups-4/NNS	det||severeacuterespiratorysyndrome-coronavirus-8/NNS||the-6/DT	amod||severeacuterespiratorysyndrome-coronavirus-8/NNS||coronaviruses-7/JJ	nsubj||use-14/VBP||severeacuterespiratorysyndrome-coronavirus-8/NNS	appos||severeacuterespiratorysyndrome-coronavirus-8/NNS||sars-cov-10/NNP	conj_and||severeacuterespiratorysyndrome-coronavirus-8/NNS||nl63-13/NNS	nsubj||use-14/VBP||nl63-13/NNS	advcl||enzyme-21/VBP||use-14/VBP	det||receptor-17/NN||the-15/DT	amod||receptor-17/NN||same-16/JJ	dobj||use-14/VBP||receptor-17/NN	nn||converting-20/NNP||angiotensin-19/NNP	nsubj||enzyme-21/VBP||converting-20/NNP	root||ROOT-0/null||enzyme-21/VBP	dep||enzyme-21/VBP||ace-23/VB	dobj||enzyme-21/VBP||-2-25/CD	prep_for||enzyme-21/VBP||entry-28/NN	det||cell-32/NN||the-30/DT	nn||cell-32/NN||host-31/NN	prep_into||entry-28/NN||cell-32/NN	severeacuterespiratorysyndrome--1||coronavirus--1||no||although in different groups, the coronaviruses severeacuterespiratorysyndrome-coronavirus (sars-cov) and nl63 use the same receptor, angiotensin converting enzyme (ace)-2, for entry into the host cell.
det||findings-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||findings-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||reduce-12/VB||that-4/IN	det||bran-7/NN||both-5/DT	nn||bran-7/NN||rice-6/NN	nsubj||reduce-12/VB||bran-7/NN	amod||acid-10/NN||phytic-9/JJ	conj_and||bran-7/NN||acid-10/NN	nsubj||reduce-12/VB||acid-10/NN	aux||reduce-12/VB||could-11/MD	ccomp||demonstrate-3/VBP||reduce-12/VB	det||risk-14/NN||the-13/DT	dobj||reduce-12/VB||risk-14/NN	amod||hyperglycemia-19/NN||high-16/JJ	amod||hyperglycemia-19/NN||fat-17/JJ	amod||hyperglycemia-19/NN||diet-induced-18/JJ	prep_of||risk-14/NN||hyperglycemia-19/NN	prep_via||hyperglycemia-19/NN||regulation-21/NN	amod||activities-26/NNS||hepatic-23/JJ	amod||activities-26/NNS||glucose-regulating-24/JJ	nn||activities-26/NNS||enzyme-25/NN	prep_of||regulation-21/NN||activities-26/NNS	hyperglycemia-19||glucose--1||no||these findings demonstrate that both rice bran and phytic acid could reduce the risk of high fat diet-induced hyperglycemia via regulation of hepatic glucose-regulating enzyme activities.
aux||determine-2/VB||to-1/TO	advcl||tested-36/VBN||determine-2/VB	det||role-4/NN||the-3/DT	dobj||determine-2/VB||role-4/NN	amod||degradation-7/NN||metabolic-6/JJ	prep_of||role-4/NN||degradation-7/NN	det||mechanism-10/NN||a-9/DT	prep_as||determine-2/VB||mechanism-10/NN	amod||resistance-13/NN||acaricide-12/JJ	prep_for||mechanism-10/NN||resistance-13/NN	amod||mites-16/NNS||scabies-15/JJ	prep_in||determine-2/VB||mites-16/NNS	nsubjpass||tested-36/VBN||pbo-18/NN	appos||pbo-18/NN||piperonylbutoxide-20/NN	conj_and||pbo-18/NN||def-23/NN	nsubjpass||tested-36/VBN||def-23/NN	amod||phosphorotrithioate-26/NN||s,s,s-tributyl-25/JJ	appos||def-23/NN||phosphorotrithioate-26/NN	conj_and||pbo-18/NN||dem-29/NNP	nsubjpass||tested-36/VBN||dem-29/NNP	amod||maleate-32/NN||diethyl-31/JJ	appos||pbo-18/NN||maleate-32/NN	auxpass||tested-36/VBN||were-34/VBD	advmod||tested-36/VBN||first-35/RB	root||ROOT-0/null||tested-36/VBN	amod||activity-39/NN||synergistic-38/JJ	prep_for||tested-36/VBN||activity-39/NN	prep_with||tested-36/VBN||permethrin-41/NN	det||bioassay-44/NN||a-43/DT	prep_in||permethrin-41/NN||bioassay-44/NN	nn||killing-47/NN||mite-46/NN	prep_of||bioassay-44/NN||killing-47/NN	scabies-15||pbo-18||yes||to determine the role of metabolic degradation as a mechanism for acaricide resistance in scabies mites, pbo (piperonylbutoxide), def (s,s,s-tributyl phosphorotrithioate) and dem (diethyl maleate) were first tested for synergistic activity with permethrin in a bioassay of mite killing.
det||patients-3/NNS||all-1/DT	amod||patients-3/NNS||consecutive-2/JJ	prep_in||indicated-18/VBN||patients-3/NNS	nsubjpass||included-21/VBN||patients-3/NNS	det||diagnosis-6/NN||a-5/DT	prep_with||patients-3/NNS||diagnosis-6/NN	amod||sepsis-9/NN||severe-8/JJ	prep_of||diagnosis-6/NN||sepsis-9/NN	prep_of||diagnosis-6/NN||septicshock-11/NN	conj_or||sepsis-9/NN||septicshock-11/NN	nn||treatment-16/NN||amikacin-15/NN	nsubjpass||indicated-18/VBN||treatment-16/NN	auxpass||indicated-18/VBN||was-17/VBD	rcmod||patients-3/NNS||indicated-18/VBN	auxpass||included-21/VBN||were-20/VBD	root||ROOT-0/null||included-21/VBN	det||study-24/NN||the-23/DT	prep_in||included-21/VBN||study-24/NN	sepsis-9||amikacin-15||yes||all consecutive patients with a diagnosis of severe sepsis or septicshock, in whom amikacin treatment was indicated, were included in the study.
det||effect-3/NN||the-1/DT	amod||effect-3/NN||protective-2/JJ	nsubjpass||reversed-21/VBN||effect-3/NN	number||³-6/CD||ppar-î-5/CD	num||ligands-7/NNS||³-6/CD	prep_of||effect-3/NN||ligands-7/NNS	dep||12,14-prostaglandin-13/JJ||pioglitazone-9/JJ	conj_or||12,14-prostaglandin-13/JJ||15-deoxy-î-11/JJ	amod||j2-14/NNS||15-deoxy-î-11/JJ	amod||j2-14/NNS||12,14-prostaglandin-13/JJ	appos||ligands-7/NNS||j2-14/NNS	amod||injury-19/NN||gastric-17/JJ	amod||injury-19/NN||ischemia-reperfusion-18/JJ	prep_on||ligands-7/NNS||injury-19/NN	auxpass||reversed-21/VBN||was-20/VBD	root||ROOT-0/null||reversed-21/VBN	det||co-administration-24/NN||the-23/DT	agent||reversed-21/VBN||co-administration-24/NN	amod||antagonist-28/NN||ppar-î-26/JJ	amod||antagonist-28/NN||³-27/JJ	prep_with||co-administration-24/NN||antagonist-28/NN	prostaglandin--1||ischemia--1||no_rel||the protective effect of ppar-î³ ligands, pioglitazone or 15-deoxy-î”12,14-prostaglandin j2, on gastric ischemia-reperfusion injury was reversed by the co-administration with ppar-î³ antagonist.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||survey-5/NN||a-3/DT	amod||survey-5/NN||cross-sectional-4/JJ	dobj||conducted-2/VBD||survey-5/NN	amod||people-8/NNS||adult-7/JJ	prep_among||conducted-2/VBD||people-8/NNS	vmod||people-8/NNS||living-9/VBG	prep_with||living-9/VBG||hiv/aids-11/NNS	appos||hiv/aids-11/NNS||plwha-13/NNP	det||questionnaire-18/NN||a-16/DT	amod||questionnaire-18/NN||structured-17/JJ	prep_through||living-9/VBG||questionnaire-18/NN	aids--1||hiv--1||no||we conducted a cross-sectional survey among adult people living with hiv/aids (plwha) through a structured questionnaire.
num||patients-2/NNS||97-1/CD	nsubjpass||recruited-7/VBN||patients-2/NNS	nsubjpass||treated-14/VBN||patients-2/NNS	amod||falciparummalaria-5/NN||uncomplicated-4/JJ	prep_with||patients-2/NNS||falciparummalaria-5/NN	auxpass||recruited-7/VBN||were-6/VBD	root||ROOT-0/null||recruited-7/VBN	prep_from||recruited-7/VBN||april-9/NNP	prep_to||recruited-7/VBN||june-11/NNP	num||june-11/NNP||2006-12/CD	conj_and||recruited-7/VBN||treated-14/VBN	det||al-17/NNP||either-16/DT	prep_with||treated-14/VBN||al-17/NNP	amod||q-21/NN||quinine-19/JJ	prep_with||treated-14/VBN||q-21/NN	conj_or||al-17/NNP||q-21/NN	amod||ap-26/NN||atovaquone/proguanil-24/JJ	prep_with||treated-14/VBN||ap-26/NN	conj_or||al-17/NNP||ap-26/NN	nn||hospital-31/NN||jimma-29/NN	nn||hospital-31/NN||university-30/NN	prep_in||treated-14/VBN||hospital-31/NN	appos||hospital-31/NN||ethiopia-33/NN	falciparummalaria-5||quinine-19||yes||97 patients with uncomplicated falciparummalaria were recruited from april to june 2006 and treated with either al, quinine (q) or atovaquone/proguanil (ap) in jimma university hospital, ethiopia.
amod||feeding-3/NN||alternate-1/JJ	amod||feeding-3/NN||hc-con-2/JJ	nsubj||reproduced-4/VBD||feeding-3/NN	root||ROOT-0/null||reproduced-4/VBD	dobj||reproduced-4/VBD||most-5/JJS	det||effects-9/NNS||the-7/DT	amod||effects-9/NNS||beneficial-8/JJ	prep_of||most-5/JJS||effects-9/NNS	amod||diet-13/NN||daily-11/JJ	amod||diet-13/NN||cholesterol-free-12/JJ	prep_of||effects-9/NNS||diet-13/NN	advmod||diminished-17/VBN||strongly-16/RB	amod||hepatic-18/NN||diminished-17/VBN	prep_including||reproduced-4/VBD||hepatic-18/NN	appos||hepatic-18/NN||vascular-20/NN	amod||activation-23/NN||renal-22/JJ	appos||hepatic-18/NN||activation-23/NN	conj_and||vascular-20/NN||activation-23/NN	conj_and||vascular-20/NN||inflammation-25/NN	conj_and||activation-23/NN||inflammation-25/NN	advmod||reduced-30/VBN||also-27/RB	nsubjpass||reduced-30/VBN||atherosclerosis-28/NNS	auxpass||reduced-30/VBN||was-29/VBD	parataxis||reproduced-4/VBD||reduced-30/VBN	agent||reduced-30/VBN||half-32/NN	advmod||half-32/NN||as-33/RB	prep||reduced-30/VBN||compared-34/VBN	pcomp||compared-34/VBN||to-35/TO	pobj||to-35/TO||hc-36/NN	dep||higher-40/JJR||albeit-38/IN	dep||higher-40/JJR||still-39/RB	dep||hc-36/NN||higher-40/JJR	prepc_compared_to||hc-36/NN||to-42/TO	det||group-45/NN||the-43/DT	amod||group-45/NN||con-44/JJ	pobj||hc-36/NN||group-45/NN	inflammation-25||hc-36||yes||alternate hc-con feeding reproduced most of the beneficial effects of daily cholesterol-free diet, including strongly diminished hepatic, vascular and renal activation and inflammation; also atherosclerosis was reduced by half as compared to hc, albeit still higher compared to the con group.
nn||women-2/NNS||participants-1/NNS	nsubj||aged-3/VBN||women-2/NNS	root||ROOT-0/null||aged-3/VBN	num||years-5/NNS||15-44-4/CD	tmod||aged-3/VBN||years-5/NNS	amod||factors-9/NNS||major-7/JJ	nn||factors-9/NNS||risk-8/NN	prep_without||aged-3/VBN||factors-9/NNS	nsubj||started-14/VBD||factors-9/NNS	amod||thromboembolism-12/NN||venous-11/JJ	prep_for||factors-9/NNS||thromboembolism-12/NN	rcmod||factors-9/NNS||started-14/VBD	det||episode-17/NN||a-15/DT	amod||episode-17/NN||new-16/JJ	dobj||started-14/VBD||episode-17/NN	prep_of||episode-17/NN||use-19/NN	det||oralcontraceptive-22/NN||an-21/DT	prep_of||use-19/NN||oralcontraceptive-22/NN	vmod||oralcontraceptive-22/NN||containing-23/VBG	num||oestrogen-26/NN||30-24/CD	nn||oestrogen-26/NN||âµg-25/NN	dobj||containing-23/VBG||oestrogen-26/NN	prep_in||oestrogen-26/NN||combination-28/NN	preconj||drospirenone-31/NN||either-30/DT	prep_with||containing-23/VBG||drospirenone-31/NN	prep_with||containing-23/VBG||levonorgestrel-33/NN	conj_or||drospirenone-31/NN||levonorgestrel-33/NN	aux||2002-36/VB||may-35/MD	prep_between||drospirenone-31/NN||2002-36/VB	prep_between||drospirenone-31/NN||september-38/NNP	conj_and||2002-36/VB||september-38/NNP	num||september-38/NNP||2009-39/CD	thromboembolism-12||levonorgestrel-33||no||participants women aged 15-44 years without major risk factors for venous thromboembolism who started a new episode of use of an oralcontraceptive containing 30 âµg oestrogen in combination with either drospirenone or levonorgestrel between may 2002 and september 2009.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||assess-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||was-6/VBD||assess-8/VB	det||prevalence-10/NN||the-9/DT	dobj||assess-8/VB||prevalence-10/NN	prep_of||prevalence-10/NN||humanimmunodeficiencyvirus-12/NNS	appos||humanimmunodeficiencyvirus-12/NNS||hiv-14/NN	prep_of||prevalence-10/NN||hepatitisbvirus-17/NNS	conj_and||humanimmunodeficiencyvirus-12/NNS||hepatitisbvirus-17/NNS	appos||hepatitisbvirus-17/NNS||hbv-19/NN	amod||virus-23/NN||hepatitisc-22/JJ	prep_of||prevalence-10/NN||virus-23/NN	conj_and||humanimmunodeficiencyvirus-12/NNS||virus-23/NN	appos||virus-23/NN||hcv-25/NN	amod||markers-28/NNS||serological-27/JJ	dep||virus-23/NN||markers-28/NNS	det||prevalence-31/NN||the-30/DT	prep_of||prevalence-10/NN||prevalence-31/NN	conj_and||humanimmunodeficiencyvirus-12/NNS||prevalence-31/NN	amod||subjects-35/NNS||vdrl-33/JJ	amod||subjects-35/NNS||positive-34/JJ	prep_of||prevalence-31/NN||subjects-35/NNS	det||population-38/NN||a-37/DT	prep_in||assess-8/VB||population-38/NN	prep_of||population-38/NN||refugees-40/NNS	amod||nationalities-43/NNS||various-42/JJ	prep_of||refugees-40/NNS||nationalities-43/NNS	vmod||assess-8/VB||living-45/VBG	det||centre-50/NN||the-47/DT	nn||centre-50/NN||asylum-48/NN	nn||centre-50/NN||seeker-49/NN	prep_in||living-45/VBG||centre-50/NN	amod||palese-53/NN||bari-52/JJ	prep_in||centre-50/NN||palese-53/NN	amod||italy-56/NN||southern-55/JJ	appos||palese-53/NN||italy-56/NN	hbv-19||hepatitisbvirus-17||no||the aim of this study was to assess the prevalence of humanimmunodeficiencyvirus (hiv), hepatitisbvirus (hbv) and hepatitisc virus (hcv) serological markers and the prevalence of vdrl positive subjects in a population of refugees of various nationalities, living in the asylum seeker centre in bari palese, southern italy.
amod||vaccines-6/NNS||novel-1/JJ	nn||vaccines-6/NNS||tuberculosis-2/NNP	appos||vaccines-6/NNS||tb-4/NN	nsubjpass||designed-13/VBN||vaccines-6/NNS	nsubj||boost-15/VB||vaccines-6/NNS	advmod||tested-8/VBN||recently-7/RB	vmod||vaccines-6/NNS||tested-8/VBN	prep_in||tested-8/VBN||humans-10/NNS	aux||designed-13/VBN||have-11/VBP	auxpass||designed-13/VBN||been-12/VBN	ccomp||mycobacteriumbovis-23/VBZ||designed-13/VBN	aux||boost-15/VB||to-14/TO	xcomp||designed-13/VBN||boost-15/VB	dobj||boost-15/VB||immunity-16/NN	vmod||immunity-16/NN||induced-17/VBN	det||vaccine-21/NN||the-19/DT	amod||vaccine-21/NN||current-20/JJ	agent||induced-17/VBN||vaccine-21/NN	root||ROOT-0/null||mycobacteriumbovis-23/VBZ	amod||rin-27/NN||bacille-24/JJ	amod||rin-27/NN||calmette-guã-25/JJ	nn||rin-27/NN||©-26/NN	nsubj||mycobacteriumbovis-23/VBZ||rin-27/NN	appos||rin-27/NN||bcg-29/NN	tb-4||bcg-29||no||novel tuberculosis (tb) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, mycobacteriumbovis bacille calmette-guã©rin (bcg).
prep_in||improved-18/VBD||conclusion-2/NN	dep||improved-18/VBD||initiating-4/VBG	dobj||initiating-4/VBG||therapy-5/NN	det||combination-8/NN||a-7/DT	prep_with||initiating-4/VBG||combination-8/NN	nn||results-14/NNS||valsartan-10/NN	conj_and||valsartan-10/NN||low-dose-12/JJ	nn||results-14/NNS||low-dose-12/JJ	nn||results-14/NNS||hctz-13/NN	prep_of||combination-8/NN||results-14/NNS	prep_in||initiating-4/VBG||early-16/JJ	root||ROOT-0/null||improved-18/VBD	nn||efficacy-20/NN||bp-19/NN	dobj||improved-18/VBD||efficacy-20/NN	amod||tolerability-23/NN||similar-22/JJ	prep_with||improved-18/VBD||tolerability-23/NN	prep||improved-18/VBD||as-24/IN	prepc_compared_with||improved-18/VBD||with-26/IN	pcomp||improved-18/VBD||starting-27/VBG	dobj||starting-27/VBG||treatment-28/NN	det||dose-34/NN||a-30/DT	amod||dose-34/NN||low-31/JJ	conj_or||low-31/JJ||higher-33/JJR	amod||dose-34/NN||higher-33/JJR	prep_with||starting-27/VBG||dose-34/NN	prep_of||dose-34/NN||valsartan-36/NN	prep_for||valsartan-36/NN||patients-38/NNS	amod||hypertension-43/NN||stage-1-40/JJ	conj_and||stage-1-40/JJ||stage-2-42/JJ	amod||hypertension-43/NN||stage-2-42/JJ	prep_with||patients-38/NNS||hypertension-43/NN	hypertension-43||hctz-13||yes||in conclusion, initiating therapy with a combination of valsartan and low-dose hctz results in early, improved bp efficacy with similar tolerability as compared with starting treatment with a low or higher dose of valsartan for patients with stage-1 and stage-2 hypertension.
nsubj||inhibitor-8/NN||escitalopram-1/NN	cop||inhibitor-8/NN||is-2/VBZ	det||inhibitor-8/NN||an-3/DT	amod||inhibitor-8/NN||allosteric-4/JJ	amod||inhibitor-8/NN||selective-5/JJ	nn||inhibitor-8/NN||serotonin-6/NN	nn||inhibitor-8/NN||reuptake-7/NN	root||ROOT-0/null||inhibitor-8/NN	appos||inhibitor-8/NN||ssri-10/NNP	det||indication-14/NN||some-13/DT	prep_with||inhibitor-8/NN||indication-14/NN	amod||efficacy-17/NN||superior-16/JJ	prep_of||indication-14/NN||efficacy-17/NN	det||treatment-20/NN||the-19/DT	prep_in||efficacy-17/NN||treatment-20/NN	amod||depressivedisorder-23/NN||major-22/JJ	prep_of||treatment-20/NN||depressivedisorder-23/NN	depressivedisorder-23||escitalopram-1||yes||escitalopram is an allosteric selective serotonin reuptake inhibitor (ssri) with some indication of superior efficacy in the treatment of major depressivedisorder.
det||risk-2/NN||the-1/DT	nsubjpass||characterized-24/VBN||risk-2/NN	amod||events-7/NNS||nsaid-related-4/JJ	amod||events-7/NNS||upper-5/JJ	nn||events-7/NNS||gi-6/NN	prep_of||risk-2/NN||events-7/NNS	prep_such_as||risk-2/NN||dyspepsia-11/NN	prep_such_as||risk-2/NN||pepticulcer-13/NN	conj_or||dyspepsia-11/NN||pepticulcer-13/NN	prep_such_as||risk-2/NN||complications-15/NNS	conj_and||dyspepsia-11/NN||complications-15/NNS	prep_such_as||complications-15/NNS||perforation-18/NN	prep_such_as||complications-15/NNS||bleeding-20/NN	conj_or||perforation-18/NN||bleeding-20/NN	auxpass||characterized-24/VBN||is-22/VBZ	advmod||characterized-24/VBN||well-23/RB	root||ROOT-0/null||characterized-24/VBN	nsaid--1||pepticulcer-13||no_rel||the risk of nsaid-related upper gi events, such as dyspepsia or pepticulcer and complications such as perforation or bleeding, is well characterized.
nsubjpass||known-3/VBN||little-1/RB	auxpass||known-3/VBN||is-2/VBZ	root||ROOT-0/null||known-3/VBN	det||association-6/NN||the-5/DT	prep_about||known-3/VBN||association-6/NN	amod||cholesterol-10/NN||serum-8/JJ	amod||cholesterol-10/NN||total-9/JJ	prep_between||association-6/NN||cholesterol-10/NN	det||history-13/NN||a-12/DT	prep_about||known-3/VBN||history-13/NN	conj_or||association-6/NN||history-13/NN	nn||risk-23/NN||hypercholesterolemia-15/NN	conj_and||hypercholesterolemia-15/NN||parkinson-17/NN	nn||risk-23/NN||parkinson-17/NN	amod||risk-23/NN||sdisease-19/JJ	nn||risk-23/NN||pd-21/NNP	prep_of||history-13/NN||risk-23/NN	hypercholesterolemia-15||cholesterol-10||no||little is known about the association between serum total cholesterol or a history of hypercholesterolemia and parkinson'sdisease (pd) risk.
det||prionprotein-2/NN||the-1/DT	nsubj||plays-6/VBZ||prionprotein-2/NN	appos||prionprotein-2/NN||prnp/prp-4/NN	root||ROOT-0/null||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||crucial-8/JJ	dobj||plays-6/VBZ||role-9/NN	prep_in||role-9/NN||transmissiblespongiformencephalopathies-11/NNS	appos||transmissiblespongiformencephalopathies-11/NNS||tses-13/NNS	amod||disease-17/NN||creutzfeldt-jakob-16/JJ	prep_like||plays-6/VBZ||disease-17/NN	appos||disease-17/NN||cjd-19/NN	amod||disease-26/NN||scrapie-22/JJ	conj_and||scrapie-22/JJ||mad-24/JJ	amod||disease-26/NN||mad-24/JJ	nn||disease-26/NN||cow-25/NN	appos||disease-17/NN||disease-26/NN	transmissiblespongiformencephalopathies-11||prionprotein-2||no||the prionprotein (prnp/prp) plays a crucial role in transmissiblespongiformencephalopathies (tses) like creutzfeldt-jakob disease (cjd), scrapie and mad cow disease.
det||study-2/NN||this-1/DT	nsubj||identifies-6/VBZ||study-2/NN	nsubj||highlights-23/VBZ||study-2/NN	advmod||identifies-6/VBZ||thus-3/RB	neg||only-5/JJ||not-4/RB	preconj||identifies-6/VBZ||only-5/JJ	root||ROOT-0/null||identifies-6/VBZ	amod||inhibitors-9/NNS||novel-7/JJ	amod||inhibitors-9/NNS||potential-8/JJ	dobj||identifies-6/VBZ||inhibitors-9/NNS	nsubjpass||developed-13/VBN||inhibitors-9/NNS	aux||developed-13/VBN||could-11/MD	auxpass||developed-13/VBN||be-12/VB	rcmod||inhibitors-9/NNS||developed-13/VBN	det||control-16/NN||the-15/DT	prep_for||developed-13/VBN||control-16/NN	amod||infection-19/NN||yersinia-induced-18/JJ	prep_of||control-16/NN||infection-19/NN	advmod||highlights-23/VBZ||also-22/RB	conj_but||identifies-6/VBZ||highlights-23/VBZ	det||diversity-25/NN||the-24/DT	dobj||highlights-23/VBZ||diversity-25/NN	det||strategies-28/NNS||the-27/DT	prep_of||diversity-25/NN||strategies-28/NNS	vmod||strategies-28/NNS||used-29/VBN	agent||used-29/VBN||y.pestis-31/NNS	aux||evade-33/VB||to-32/TO	xcomp||used-29/VBN||evade-33/VB	det||system-36/NN||the-34/DT	amod||system-36/NN||immune-35/JJ	dobj||evade-33/VB||system-36/NN	det||hijacking-40/NN||the-39/DT	nsubj||mechanism-47/NN||hijacking-40/NN	amod||cytokines-43/NNS||pleiotropic-42/JJ	prep_of||hijacking-40/NN||cytokines-43/NNS	cop||mechanism-47/NN||being-44/VBG	det||mechanism-47/NN||a-45/DT	amod||mechanism-47/NN||long-range-46/JJ	prepc_with||used-29/VBN||mechanism-47/NN	nsubj||plays-50/VBZ||mechanism-47/NN	advmod||plays-50/VBZ||potentially-49/RB	rcmod||mechanism-47/NN||plays-50/VBZ	det||role-53/NN||a-51/DT	amod||role-53/NN||key-52/JJ	dobj||plays-50/VBZ||role-53/NN	det||severity-56/NN||the-55/DT	prep_in||role-53/NN||severity-56/NN	prep_of||severity-56/NN||plague-58/NNP	plague-58||y.pestis-31||no||this study thus not only identifies novel potential inhibitors that could be developed for the control of yersinia-induced infection , but also highlights the diversity of the strategies used by y.pestis to evade the immune system , with the hijacking of pleiotropic cytokines being a long-range mechanism that potentially plays a key role in the severity of plague .
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||abductor-10/NN||the-9/DT	nsubj||hallucis-11/VBZ||abductor-10/NN	ccomp||investigate-8/VB||hallucis-11/VBZ	nn||characteristics-13/NNS||muscle-12/NN	dobj||hallucis-11/VBZ||characteristics-13/NNS	vmod||characteristics-13/NNS||defined-15/VBN	amod||thickness-21/NN||dorso-plantar-17/JJ	appos||thickness-21/NN||dp-19/NN	prep_as||defined-15/VBN||thickness-21/NN	amod||width-27/NN||medio-lateral-23/JJ	appos||width-27/NN||ml-25/NN	prep_as||defined-15/VBN||width-27/NN	conj_and||thickness-21/NN||width-27/NN	amod||area-31/NN||cross-sectional-30/JJ	prep_as||defined-15/VBN||area-31/NN	conj_and||thickness-21/NN||area-31/NN	appos||area-31/NN||csa-33/NN	prep_in||defined-15/VBN||relation-36/NN	det||severity-39/NN||the-38/DT	prep_to||defined-15/VBN||severity-39/NN	nn||valgus-42/NNS||hallux-41/NN	prep_of||severity-39/NN||valgus-42/NNS	xcomp||defined-15/VBN||using-43/VBG	amod||ultrasound-45/NN||musculoskeletal-44/JJ	dobj||using-43/VBG||ultrasound-45/NN	cross--1||dp-19||no_rel||the aim of the study was to investigate the abductor hallucis muscle characteristics, defined as dorso-plantar (dp) thickness, medio-lateral (ml) width, and cross-sectional area (csa) in relation to the severity of hallux valgus using musculoskeletal ultrasound.
det||study-2/NN||this-1/DT	nsubj||focused-3/VBD||study-2/NN	root||ROOT-0/null||focused-3/VBD	det||selection-6/NN||the-5/DT	prep_on||focused-3/VBD||selection-6/NN	amod||genes-10/NNS||suitable-8/JJ	nn||genes-10/NNS||reference-9/NN	prep_of||selection-6/NN||genes-10/NNS	amod||pcr-13/NN||quantitative-12/JJ	prep_for||focused-3/VBD||pcr-13/NN	prep_in||focused-3/VBD||humanhepatitisbvirus-15/NNS	appos||humanhepatitisbvirus-15/NNS||hbv-17/NN	amod||carcinoma-22/NN||related-20/VBN	nn||carcinoma-22/NN||hepatocellular-21/NN	dep||humanhepatitisbvirus-15/NNS||carcinoma-22/NN	appos||carcinoma-22/NN||hcc-24/NN	amod||outcomes-29/NNS||different-27/JJ	amod||outcomes-29/NNS||clinical-28/JJ	prep_with||carcinoma-22/NN||outcomes-29/NNS	hbv-17||humanhepatitisbvirus-15||no||this study focused on the selection of suitable reference genes for quantitative pcr in humanhepatitisbvirus (hbv)-related hepatocellular carcinoma (hcc) with different clinical outcomes.
mark||likely-14/JJ||since-1/IN	det||part-4/NN||a-2/DT	amod||part-4/NN||significant-3/JJ	nsubj||likely-14/JJ||part-4/NN	nsubj||relate-16/VB||part-4/NN	det||diversity-8/NN||the-6/DT	amod||diversity-8/NN||clinicopathological-7/JJ	prep_of||part-4/NN||diversity-8/NN	vmod||diversity-8/NN||seen-9/VBN	amod||priondisease-12/NN||human-11/JJ	prep_in||seen-9/VBN||priondisease-12/NN	cop||likely-14/JJ||is-13/VBZ	advcl||compared-28/VBN||likely-14/JJ	aux||relate-16/VB||to-15/TO	xcomp||likely-14/JJ||relate-16/VB	det||propagation-19/NN||the-18/DT	prep_to||relate-16/VB||propagation-19/NN	amod||strains-24/NNS||distinct-21/JJ	amod||strains-24/NNS||human-22/JJ	nn||strains-24/NNS||prion-23/NN	prep_of||propagation-19/NN||strains-24/NNS	nsubj||compared-28/VBN||we-26/PRP	aux||compared-28/VBN||have-27/VBP	root||ROOT-0/null||compared-28/VBN	det||properties-31/NNS||the-29/DT	nn||properties-31/NNS||transmission-30/NN	dobj||compared-28/VBN||properties-31/NNS	amod||prions-34/NNS||kuru-33/JJ	prep_of||properties-31/NNS||prions-34/NNS	prep_with||compared-28/VBN||those-36/DT	vmod||those-36/DT||isolated-37/VBN	prep_from||isolated-37/VBN||patients-39/NNS	amod||cjd-46/NN||sporadic-41/JJ	conj_and||sporadic-41/JJ||iatrogenic-43/JJ	amod||cjd-46/NN||iatrogenic-43/JJ	conj_and||sporadic-41/JJ||variant-45/JJ	amod||cjd-46/NN||variant-45/JJ	prep_with||patients-39/NNS||cjd-46/NN	preconj||transgenic-49/JJ||both-48/DT	amod||mice-52/NNS||transgenic-49/JJ	conj_and||transgenic-49/JJ||wild-type-51/JJ	amod||mice-52/NNS||wild-type-51/JJ	prep_in||cjd-46/NN||mice-52/NNS	cjd-46||prions-34||no_rel||since a significant part of the clinicopathological diversity seen in human priondisease is likely to relate to the propagation of distinct human prion strains, we have compared the transmission properties of kuru prions with those isolated from patients with sporadic, iatrogenic and variant cjd in both transgenic and wild-type mice.
amod||asthmatics-2/NNS||twenty-eight-1/JJ	nsubjpass||given-4/VBN||asthmatics-2/NNS	nsubjpass||randomized-12/VBN||asthmatics-2/NNS	nsubj||challenge-14/VB||asthmatics-2/NNS	auxpass||given-4/VBN||were-3/VBD	dep||puffs-23/VBZ||given-4/VBN	amod||laba-6/NN||daily-5/JJ	dobj||given-4/VBN||laba-6/NN	num||weeks-9/NNS||12-8/CD	prep_in||given-4/VBN||weeks-9/NNS	auxpass||randomized-12/VBN||were-11/VBD	conj_and||given-4/VBN||randomized-12/VBN	dep||puffs-23/VBZ||randomized-12/VBN	aux||challenge-14/VB||to-13/TO	xcomp||randomized-12/VBN||challenge-14/VB	dobj||challenge-14/VB||test-15/NN	det||test-20/NN||either-17/DT	amod||test-20/NN||conventional-18/JJ	nn||test-20/NN||reversibility-19/NN	dobj||challenge-14/VB||test-20/NN	conj_and||test-15/NN||test-20/NN	prep_with||challenge-14/VB||2-22/CD	root||ROOT-0/null||puffs-23/VBZ	amod||test-27/NN||terbutaline-24/JJ	conj_or||terbutaline-24/JJ||reversibility-26/JJ	amod||test-27/NN||reversibility-26/JJ	dobj||puffs-23/VBZ||test-27/NN	amod||doses-30/NNS||refracted-29/JJ	prep_with||puffs-23/VBZ||doses-30/NNS	number||puff-33/CD||1-32/CD	dep||doses-30/NNS||puff-33/CD	det||min-37/NN||every-35/DT	num||min-37/NN||5-36/CD	nsubj||puffs-23/VBZ||min-37/NN	quantmod||4-40/CD||total-39/JJ	num||puffs-41/NNS||4-40/CD	appos||min-37/NN||puffs-41/NNS	asthmatics-2||terbutaline-24||yes||twenty-eight asthmatics were given daily laba in 12 weeks and were randomized to challenge test and either conventional reversibility test with 2 puffs terbutaline or reversibility test with refracted doses (1 puff) every 5 min, total 4 puffs.
det||model-4/NN||a-2/DT	nn||model-4/NN||rabbit-3/NN	prep_in||evaluated-27/VBN||model-4/NN	amod||osteoarthritis-7/NNS||collagenase-induced-6/JJ	prep_of||model-4/NN||osteoarthritis-7/NNS	det||effects-11/NNS||the-9/DT	amod||effects-11/NNS||additive-10/JJ	nsubjpass||evaluated-27/VBN||effects-11/NNS	amod||growthhormone-16/NN||intra-articular-13/JJ	amod||growthhormone-16/NN||recombinant-14/JJ	amod||growthhormone-16/NN||human-15/JJ	prep_of||effects-11/NNS||growthhormone-16/NN	dep||evaluated-27/VBN||gh-18/NN	nn||hyaluronicacid-22/NN||administration-20/NN	dep||hyaluronicacid-22/NN||to-21/TO	nsubjpass||evaluated-27/VBN||hyaluronicacid-22/NN	appos||hyaluronicacid-22/NN||ha-24/NN	auxpass||evaluated-27/VBN||were-26/VBD	root||ROOT-0/null||evaluated-27/VBN	collagenase--1||osteoarthritis-7||no_rel||in a rabbit model of collagenase-induced osteoarthritis, the additive effects of intra-articular recombinant human growthhormone (gh) administration to hyaluronicacid (ha) were evaluated.
nsubj||viruses-20/NNS||hepadnaviruses-1/NNS	amod||virus-5/NN||hepatitisb-4/JJ	prep_including||hepadnaviruses-1/NNS||virus-5/NN	appos||virus-5/NN||hbv-7/NN	det||pathogen-14/NN||a-10/DT	advmod||relevant-12/JJ||highly-11/RB	amod||pathogen-14/NN||relevant-12/JJ	amod||pathogen-14/NN||human-13/JJ	appos||virus-5/NN||pathogen-14/NN	cop||viruses-20/NNS||are-16/VBP	amod||viruses-20/NNS||small-17/JJ	amod||viruses-20/NNS||enveloped-18/JJ	nn||viruses-20/NNS||dna-19/NN	root||ROOT-0/null||viruses-20/NNS	nsubj||replicate-22/VBN||viruses-20/NNS	rcmod||viruses-20/NNS||replicate-22/VBN	amod||transcription-25/NN||reverse-24/JJ	prep_via||replicate-22/VBN||transcription-25/NN	hbv-7||viruses-20||no||hepadnaviruses, including hepatitisb virus (hbv), a highly relevant human pathogen, are small enveloped dna viruses that replicate via reverse transcription.
advmod||frequent-10/JJ||however-1/RB	det||âˆ-4/NN||the-3/DT	poss||variant-7/NN||âˆ-4/NN	amod||variant-7/NN||336a-6/JJ	nsubj||frequent-10/JJ||variant-7/NN	cop||frequent-10/JJ||was-8/VBD	advmod||frequent-10/JJ||more-9/RBR	root||ROOT-0/null||frequent-10/JJ	amod||patients-13/NNS||htlv-1-infected-12/JJ	prep_in||frequent-10/JJ||patients-13/NNS	amod||tropicalspasticparaparesis-17/NNS||-LSB--14/JJ	amod||tropicalspasticparaparesis-17/NNS||htlv-1-associatedmyelopathy-15/JJ	amod||tropicalspasticparaparesis-17/NNS||/-16/JJ	dep||patients-13/NNS||tropicalspasticparaparesis-17/NNS	appos||tropicalspasticparaparesis-17/NNS||ham/tsp-19/NN	quantmod||$-23/$||80â-22/RB	num||%-25/NN||$-23/$	num||$-23/$||š-24/CD	appos||tropicalspasticparaparesis-17/NNS||%-25/NN	amod||asymptomatic-28/JJ||healthy-27/JJ	amod||carriers-30/NNS||asymptomatic-28/JJ	amod||carriers-30/NNS||htlv-1-29/JJ	appos||tropicalspasticparaparesis-17/NNS||carriers-30/NNS	amod||-RSB--36/NNS||90â-32/JJ	dep||%-35/NN||$-33/$	num||$-33/$||š-34/CD	amod||-RSB--36/NNS||%-35/NN	appos||tropicalspasticparaparesis-17/NNS||-RSB--36/NNS	mark||70â-43/NNS||than-37/IN	det||group-41/NN||the-39/DT	nn||group-41/NN||control-40/NN	prep_in||70â-43/NNS||group-41/NN	dep||-RSB--36/NNS||70â-43/NNS	dep||%-46/NN||$-44/$	num||$-44/$||š-45/CD	amod||70â-43/NNS||%-46/NN	dep||70â-43/NNS||-LSB--48/FW	dep||70â-43/NNS||p-49/NN	dep||0.0197-51/CD||=-50/SYM	rcmod||p-49/NN||0.0197-51/CD	nn||ratio-54/NN||odds-53/NNS	appos||tropicalspasticparaparesis-17/NNS||ratio-54/NN	cc||=-58/NNP||or-56/CC	dep||ratio-54/NN||=-58/NNP	num||=-58/NNP||2.511-59/CD	num||=-58/NNP||95â-61/CD	dep||%-64/NN||$-62/$	num||$-62/$||š-63/CD	amod||interval-66/NN||%-64/NN	nn||interval-66/NN||confidence-65/NN	nsubj||=-70/VBZ||interval-66/NN	discourse||interval-66/NN||ci-68/UH	rcmod||=-58/NNP||=-70/VBZ	num||â-72/NNS||1.218-71/CD	dobj||=-70/VBZ||â-72/NNS	num||â-72/NNS||$-73/$	num||$-73/$||5.179-75/CD	htlv-1-associatedmyelopathy-15||htlv-1-29||no||however, the âˆ’336a variant was more frequent in htlv-1-infected patients [htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp), 80â€š%; healthy asymptomatic htlv-1 carriers, 90â€š%] than in the control group (70â€š%) [ p =0.0197, odds ratio (or)=2.511, 95â€š% confidence interval (ci)=1.218â€“5.179).
quantmod||two-thirds-3/NNS||fewer-1/JJR	quantmod||two-thirds-3/NNS||than-2/IN	nsubj||knew-4/VBD||two-thirds-3/NNS	root||ROOT-0/null||knew-4/VBD	mark||develop-27/VB||that-5/IN	quantmod||10-7/CD||about-6/RB	num||%-8/NN||10-7/CD	nsubj||develop-27/VB||%-8/NN	prep_of||%-8/NN||people-10/NNS	det||u.s.a.-13/NN||the-12/DT	prep_in||people-10/NNS||u.s.a.-13/NN	nsubj||have-15/VBP||u.s.a.-13/NN	rcmod||u.s.a.-13/NN||have-15/VBP	nn||-rrb--20/NNP||latent-16/NN	nn||-rrb--20/NNP||tuberculosisinfection-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||ltbi-19/NNP	dobj||have-15/VBP||-rrb--20/NNP	det||system-25/NN||a-22/DT	amod||system-25/NN||normal-23/JJ	amod||system-25/NN||immune-24/JJ	dobj||have-15/VBP||system-25/NN	conj_and||-rrb--20/NNP||system-25/NN	aux||develop-27/VB||will-26/MD	ccomp||knew-4/VBD||develop-27/VB	nn||disease-29/NN||tb-28/NN	dobj||develop-27/VB||disease-29/NN	mark||part-36/NN||that-32/IN	nsubj||part-36/NN||bcg-33/NN	cop||part-36/NN||is-34/VBZ	neg||part-36/NN||not-35/RB	ccomp||knew-4/VBD||part-36/NN	conj_or||develop-27/VB||part-36/NN	det||program-41/NN||the-38/DT	amod||program-41/NN||routine-39/JJ	nn||program-41/NN||vaccination-40/NN	prep_of||part-36/NN||program-41/NN	det||u.s.a.-44/NN||the-43/DT	prep_in||program-41/NN||u.s.a.-44/NN	mark||complicates-47/VBZ||because-45/IN	nsubj||complicates-47/VBZ||it-46/PRP	advcl||part-36/NN||complicates-47/VBZ	dobj||complicates-47/VBZ||surveillance-48/NN	amod||infection-52/NN||new-50/JJ	nn||infection-52/NN||tb-51/NN	prep_for||surveillance-48/NN||infection-52/NN	tb-51||bcg-33||yes||fewer than two-thirds knew that about 10 % of people in the u.s.a. who have latent tuberculosisinfection -lrb- ltbi -rrb- and a normal immune system will develop tb disease , or that bcg is not part of the routine vaccination program in the u.s.a. because it complicates surveillance for new tb infection .
det||data-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||expressed-8/VBN||that-4/IN	nn||proteins-6/NNS||socs-5/NNS	nsubjpass||expressed-8/VBN||proteins-6/NNS	auxpass||expressed-8/VBN||are-7/VBP	ccomp||demonstrate-3/VBP||expressed-8/VBN	amod||lines-13/NNS||human-10/JJ	nn||lines-13/NNS||melanoma-11/NN	nn||lines-13/NNS||cell-12/NN	prep_in||expressed-8/VBN||lines-13/NNS	poss||modulation-16/NN||their-15/PRP$	nsubj||influence-18/VB||modulation-16/NN	aux||influence-18/VB||can-17/MD	conj_and||demonstrate-3/VBP||influence-18/VB	det||responsiveness-20/NNS||the-19/DT	dobj||influence-18/VB||responsiveness-20/NNS	nn||cells-23/NNS||melanoma-22/NN	prep_of||responsiveness-20/NNS||cells-23/NNS	nn||±-26/NNP||ifn-î-25/NNP	prep_to||influence-18/VB||±-26/NNP	nn||³-29/NNP||ifn-î-28/NNP	prep_to||influence-18/VB||³-29/NNP	conj_and||±-26/NNP||³-29/NNP	melanoma-22||ifn--1||yes||these data demonstrate that socs proteins are expressed in human melanoma cell lines and their modulation can influence the responsiveness of melanoma cells to ifn-î± and ifn-î³.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	dm-35||cancer-14||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
mark||retard-6/VB||although-1/IN	amod||insulin-3/NN||nasal-2/JJ	nsubj||retard-6/VB||insulin-3/NN	aux||retard-6/VB||did-4/VBD	neg||retard-6/VB||not-5/RB	advcl||provides-29/VBZ||retard-6/VB	dobj||retard-6/VB||loss-7/NN	amod||²-11/NNS||residual-9/JJ	nn||²-11/NNS||î-10/NN	prep_of||loss-7/NN||²-11/NNS	nn||function-14/NN||cell-13/NN	dep||loss-7/NN||function-14/NN	prep_in||function-14/NN||adults-16/NNS	amod||type1diabetes-19/NNS||established-18/VBN	prep_with||adults-16/NNS||type1diabetes-19/NNS	nsubj||provides-29/VBZ||evidence-21/NN	mark||induced-24/VBN||that-22/IN	nsubj||induced-24/VBN||it-23/PRP	dep||evidence-21/NN||induced-24/VBN	amod||tolerance-26/NN||immune-25/JJ	dobj||induced-24/VBN||tolerance-26/NN	prep_to||induced-24/VBN||insulin-28/NN	root||ROOT-0/null||provides-29/VBZ	det||rationale-31/NN||a-30/DT	dobj||provides-29/VBZ||rationale-31/NN	poss||application-34/NN||its-33/PRP$	prep_for||rationale-31/NN||application-34/NN	aux||prevent-36/VB||to-35/TO	vmod||application-34/NN||prevent-36/VB	dobj||prevent-36/VB||diabetes-37/NN	amod||individuals-40/NNS||at-risk-39/JJ	prep_in||prevent-36/VB||individuals-40/NNS	type1diabetes-19||insulin-28||yes||although nasal insulin did not retard loss of residual î²-cell function in adults with established type1diabetes, evidence that it induced immune tolerance to insulin provides a rationale for its application to prevent diabetes in at-risk individuals.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-15/VBN||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	appos||infants-5/NNS||ipti-7/NNP	prep_with||infants-5/NNS||sulfadoxine-pyrimethamine-10/NN	appos||treatment-3/NN||sp-12/NN	auxpass||recommended-15/VBN||is-14/VBZ	root||ROOT-0/null||recommended-15/VBN	dobj||low-29/JJ||who-17/WP	advmod||high-24/JJ||where-18/WRB	nn||incidence-20/NN||malaria-19/NN	nsubj||high-24/JJ||incidence-20/NN	nsubj||sp-26/JJ||incidence-20/NN	prep_in||incidence-20/NN||infancy-22/NN	cop||high-24/JJ||is-23/VBZ	advcl||low-29/JJ||high-24/JJ	conj_and||high-24/JJ||sp-26/JJ	advcl||low-29/JJ||sp-26/JJ	nsubj||low-29/JJ||resistance-27/NN	cop||low-29/JJ||is-28/VBZ	agent||recommended-15/VBN||low-29/JJ	malaria-19||pyrimethamine--1||yes||intermittent preventive treatment in infants (ipti) with sulfadoxine-pyrimethamine (sp) is recommended by who where malaria incidence in infancy is high and sp resistance is low.
nsubj||bacterium-9/NN||orientiatsutsugamushi-1/NNS	nsubj||tsutsugamushidisease-24/VBD||orientiatsutsugamushi-1/NNS	appos||orientiatsutsugamushi-1/NNS||ot-3/NN	cop||bacterium-9/NN||is-5/VBZ	det||bacterium-9/NN||an-6/DT	amod||bacterium-9/NN||obligate-7/JJ	nn||bacterium-9/NN||intracellular-8/NN	root||ROOT-0/null||bacterium-9/NN	xcomp||bacterium-9/NN||belonging-10/VBG	det||rickettsiaceae-14/NN||the-12/DT	nn||rickettsiaceae-14/NN||family-13/NN	prep_to||belonging-10/VBG||rickettsiaceae-14/NN	cop||agent-19/NN||is-16/VBZ	det||agent-19/NN||the-17/DT	amod||agent-19/NN||causative-18/JJ	conj_and||bacterium-9/NN||agent-19/NN	prep_of||agent-19/NN||scrubtyphus-21/NNS	conj_or||bacterium-9/NN||tsutsugamushidisease-24/VBD	tsutsugamushidisease-24||orientiatsutsugamushi-1||no||orientiatsutsugamushi (ot) is an obligate intracellular bacterium belonging to the family rickettsiaceae and is the causative agent of scrubtyphus, or tsutsugamushidisease.
prep||seem-28/VBP||given-1/VBN	det||effort-4/NN||the-2/DT	amod||effort-4/NN||excess-3/JJ	pobj||given-1/VBN||effort-4/NN	pobj||given-1/VBN||cost-6/NN	conj_and||effort-4/NN||cost-6/NN	pobj||given-1/VBN||risk-9/NN	conj_and||effort-4/NN||risk-9/NN	vmod||risk-9/NN||involved-10/VBN	amod||correction-15/NN||rapid-12/JJ	conj_and||rapid-12/JJ||safe-14/JJ	amod||correction-15/NN||safe-14/JJ	prep_in||involved-10/VBN||correction-15/NN	prep_of||correction-15/NN||hyperglycemia-17/NN	amod||stroke-20/NN||acute-19/JJ	prep_during||involved-10/VBN||stroke-20/NN	advmod||aggressive-23/JJ||less-22/RBR	amod||treatments-24/NNS||aggressive-23/JJ	nsubj||seem-28/VBP||treatments-24/NNS	amod||insulin-27/NN||subcutaneous-26/JJ	prep_with||treatments-24/NNS||insulin-27/NN	root||ROOT-0/null||seem-28/VBP	acomp||seem-28/VBP||appropriate-29/JJ	det||time-32/NN||this-31/DT	prep_at||seem-28/VBP||time-32/NN	hyperglycemia-17||insulin-27||yes||given the excess effort, cost, and risk involved in rapid and safe correction of hyperglycemia during acute stroke, less aggressive treatments with subcutaneous insulin seem appropriate at this time.
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	irondeficiency-5||iron-13||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
nsubj||nonexistent-19/JJ||data-1/NNS	det||safety-4/NN||the-3/DT	prep_regarding||data-1/NNS||safety-4/NN	prep_of||safety-4/NN||methylphenidate-6/NN	amod||hyperactivitydisorder-11/NN||comorbid-8/JJ	nn||hyperactivitydisorder-11/NN||attention-9/NN	nn||hyperactivitydisorder-11/NN||deficit-10/NN	prep_in||methylphenidate-6/NN||hyperactivitydisorder-11/NN	dep||data-1/NNS||adhd-13/VBN	amod||retardation-17/NN||mental-16/JJ	conj_and||data-1/NNS||retardation-17/NN	nsubj||nonexistent-19/JJ||retardation-17/NN	cop||nonexistent-19/JJ||are-18/VBP	root||ROOT-0/null||nonexistent-19/JJ	adhd-13||methylphenidate-6||yes||data regarding the safety of methylphenidate in comorbid attention deficit hyperactivitydisorder (adhd) and mental retardation are nonexistent.
num||hundred-2/CD||one-1/CD	nsubjpass||randomized-10/VBN||hundred-2/CD	num||patients-5/NNS||twenty-4/CD	conj_and||hundred-2/CD||patients-5/NNS	nsubjpass||randomized-10/VBN||patients-5/NNS	amod||hypertension-8/NN||essential-7/JJ	prep_with||hundred-2/CD||hypertension-8/NN	auxpass||randomized-10/VBN||were-9/VBD	root||ROOT-0/null||randomized-10/VBN	num||groups-13/NNS||four-12/CD	prep_into||randomized-10/VBN||groups-13/NNS	vmod||groups-13/NNS||receiving-14/VBG	acomp||receiving-14/VBG||enalapril-15/JJ	acomp||receiving-14/VBG||lisinopril-17/JJ	conj_and||enalapril-15/JJ||lisinopril-17/JJ	acomp||receiving-14/VBG||ramipril-19/JJ	conj_and||enalapril-15/JJ||ramipril-19/JJ	acomp||receiving-14/VBG||fosinopril-22/JJ	conj_and||enalapril-15/JJ||fosinopril-22/JJ	hypertension-8||lisinopril-17||yes||one hundred and twenty patients with essential hypertension were randomized into four groups receiving enalapril, lisinopril, ramipril, and fosinopril.
nsubj||cause-5/NN||it-1/PRP	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||major-4/JJ	root||ROOT-0/null||cause-5/NN	det||transition-8/NN||the-7/DT	prep_of||cause-5/NN||transition-8/NN	det||infection-11/NN||the-10/DT	prep_from||transition-8/NN||infection-11/NN	amod||tuberculosis-16/NNP||active-13/JJ	nn||tuberculosis-16/NNP||disease-14/NN	nn||tuberculosis-16/NNP||-lrb--15/NNP	prep_to||infection-11/NN||tuberculosis-16/NNP	nn||-rrb--19/NNS||tb-18/NN	appos||tuberculosis-16/NNP||-rrb--19/NNS	det||transmission-24/NN||the-23/DT	conj_and||cause-5/NN||transmission-24/NN	prep_of||transmission-24/NN||m.tuberculosis-26/NNS	amod||persons-29/NNS||other-28/JJ	prep_to||m.tuberculosis-26/NNS||persons-29/NNS	tuberculosis-16||m.tuberculosis-26||no||it is a major cause of the transition from the infection to active disease -lrb- tuberculosis , tb -rrb- as well as the transmission of m.tuberculosis to other persons .
nsubj||found-5/VBD||analyses-1/NNS	nn||phenotypes-4/NNS||stress-3/NN	prep_of||analyses-1/NNS||phenotypes-4/NNS	root||ROOT-0/null||found-5/VBD	mark||abundant-23/JJ||that-6/IN	advmod||abundant-23/JJ||late-7/RB	prep_in||abundant-23/JJ||development-9/NN	amod||cotyledons-12/NNS||bps1-11/JJ	nsubj||abundant-23/JJ||cotyledons-12/NNS	vmod||cotyledons-12/NNS||produced-13/VBN	amod||lesions-15/NNS||necrotic-14/JJ	dobj||produced-13/VBN||lesions-15/NNS	advmod||hydrogenperoxide-19/JJ||however-17/RB	preconj||hydrogenperoxide-19/JJ||neither-18/DT	rcmod||lesions-15/NNS||hydrogenperoxide-19/JJ	rcmod||lesions-15/NNS||superoxide-21/JJ	conj_nor||hydrogenperoxide-19/JJ||superoxide-21/JJ	cop||abundant-23/JJ||were-22/VBD	ccomp||found-5/VBD||abundant-23/JJ	mark||underwent-26/VBD||as-24/IN	nsubj||underwent-26/VBD||leaves-25/NNS	advcl||abundant-23/JJ||underwent-26/VBD	dobj||underwent-26/VBD||arrest-27/NN	hydrogenperoxide-19||arrest-27||no_rel||analyses of stress phenotypes found that late in development, bps1 cotyledons produced necrotic lesions, however neither hydrogenperoxide nor superoxide were abundant as leaves underwent arrest.
det||burden-3/NN||the-1/DT	amod||burden-3/NN||global-2/JJ	nsubjpass||estimated-8/VBN||burden-3/NN	amod||cryptococcalmeningitis-6/NNS||hiv-associated-5/JJ	prep_of||burden-3/NN||cryptococcalmeningitis-6/NNS	auxpass||estimated-8/VBN||is-7/VBZ	root||ROOT-0/null||estimated-8/VBN	quantmod||million-12/CD||nearly-10/RB	number||million-12/CD||one-11/CD	num||cases-13/NNS||million-12/CD	prep_at||estimated-8/VBN||cases-13/NNS	prep_per||cases-13/NNS||year-15/NN	xcomp||estimated-8/VBN||causing-17/VBG	prt||causing-17/VBG||up-18/RP	det||third-21/JJ||a-20/DT	prep_to||causing-17/VBG||third-21/JJ	det||deaths-25/NNS||all-23/DT	amod||deaths-25/NNS||aids-related-24/JJ	prep_of||third-21/JJ||deaths-25/NNS	aids--1||hiv--1||no||the global burden of hiv-associated cryptococcalmeningitis is estimated at nearly one million cases per year, causing up to a third of all aids-related deaths.
det||burden-3/NN||the-1/DT	amod||burden-3/NN||global-2/JJ	nsubjpass||estimated-8/VBN||burden-3/NN	amod||cryptococcalmeningitis-6/NNS||hiv-associated-5/JJ	prep_of||burden-3/NN||cryptococcalmeningitis-6/NNS	auxpass||estimated-8/VBN||is-7/VBZ	root||ROOT-0/null||estimated-8/VBN	quantmod||million-12/CD||nearly-10/RB	number||million-12/CD||one-11/CD	num||cases-13/NNS||million-12/CD	prep_at||estimated-8/VBN||cases-13/NNS	prep_per||cases-13/NNS||year-15/NN	xcomp||estimated-8/VBN||causing-17/VBG	prt||causing-17/VBG||up-18/RP	det||third-21/JJ||a-20/DT	prep_to||causing-17/VBG||third-21/JJ	det||deaths-25/NNS||all-23/DT	amod||deaths-25/NNS||aids-related-24/JJ	prep_of||third-21/JJ||deaths-25/NNS	--1||--1||no_rel||the global burden of hiv-associated cryptococcalmeningitis is estimated at nearly one million cases per year, causing up to a third of all aids-related deaths.
nsubj||vitamin-5/NN||niacin-1/NN	cop||vitamin-5/NN||is-2/VBZ	det||vitamin-5/NN||a-3/DT	amod||vitamin-5/NN||b-complex-4/JJ	root||ROOT-0/null||vitamin-5/NN	nsubjpass||used-9/VBN||vitamin-5/NN	aux||used-9/VBN||has-7/VBZ	auxpass||used-9/VBN||been-8/VBN	rcmod||vitamin-5/NN||used-9/VBN	prep_for||used-9/VBN||decades-11/NNS	det||management-14/NN||the-13/DT	prep_for||decades-11/NNS||management-14/NN	amod||dyslipidemias-17/NNS||mixed-16/JJ	prep_of||management-14/NN||dyslipidemias-17/NNS	amod||hypercholesterolemia-20/NN||primary-19/JJ	prep_of||management-14/NN||hypercholesterolemia-20/NN	conj_and||dyslipidemias-17/NNS||hypercholesterolemia-20/NN	hypercholesterolemia-20||niacin-1||no_rel||niacin is a b-complex vitamin which has been used for decades for the management of mixed dyslipidemias and primary hypercholesterolemia.
amod||regimens-2/NNS||current-1/JJ	nsubjpass||thwarted-16/VBN||regimens-2/NNS	vmod||regimens-2/NNS||prescribed-3/VBN	aux||prevent-5/VB||to-4/TO	xcomp||prescribed-3/VBN||prevent-5/VB	amod||diseases-7/NNS||infection-associated-6/JJ	dobj||prevent-5/VB||diseases-7/NNS	prep_such_as||diseases-7/NNS||gastroduodenalulcers-10/NNS	amod||cancer-13/NN||gastric-12/JJ	prep_such_as||diseases-7/NNS||cancer-13/NN	conj_and||gastroduodenalulcers-10/NNS||cancer-13/NN	aux||thwarted-16/VBN||can-14/MD	auxpass||thwarted-16/VBN||be-15/VB	root||ROOT-0/null||thwarted-16/VBN	amod||resistance-19/NN||antibiotic-18/JJ	agent||thwarted-16/VBN||resistance-19/NN	cancer-13||antibiotic-18||no_rel||current regimens prescribed to prevent infection-associated diseases such as gastroduodenalulcers and gastric cancer can be thwarted by antibiotic resistance.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||prevention-5/NN||the-4/DT	dobj||examined-3/VBD||prevention-5/NN	prep_of||prevention-5/NN||pain-7/NN	amod||injection-11/NN||microemulsion-9/JJ	amod||injection-11/NN||propofol-10/JJ	prep_during||examined-3/VBD||injection-11/NN	prep_by||examined-3/VBD||pretreatment-13/NN	amod||doses-16/NNS||different-15/JJ	prep_with||examined-3/VBD||doses-16/NNS	prep_of||doses-16/NNS||remifentanil-18/JJ	prep_of||doses-16/NNS||saline-20/JJ	conj_or||remifentanil-18/JJ||saline-20/JJ	prep_of||doses-16/NNS||premixing-23/NN	conj_and||remifentanil-18/JJ||premixing-23/NN	prep_of||premixing-23/NN||lidocaine-25/NN	pain-7||lidocaine-25||yes||this study examined the prevention of pain during microemulsion propofol injection by pretreatment with different doses of remifentanil or saline, and premixing of lidocaine.
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	chickenpox-17||varicellazostervirus-2||no||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	collagen-38||oa-55||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
amod||reports-2/NNS||recent-1/JJ	nsubj||suggested-4/VBN||reports-2/NNS	aux||suggested-4/VBN||have-3/VBP	root||ROOT-0/null||suggested-4/VBN	mark||play-8/VB||that-5/IN	nsubj||play-8/VB||trpa1-6/NNS	aux||play-8/VB||may-7/MD	ccomp||suggested-4/VBN||play-8/VB	det||role-11/NN||an-9/DT	amod||role-11/NN||important-10/JJ	dobj||play-8/VB||role-11/NN	amod||formalin-14/NN||acute-13/JJ	prep_in||play-8/VB||formalin-14/NN	nn||pain-18/NN||cfa-16/NN	nn||pain-18/NN||induced-17/NNS	prep_in||play-8/VB||pain-18/NN	conj_and||formalin-14/NN||pain-18/NN	pain-18||formalin-14||no_rel||recent reports have suggested that trpa1 may play an important role in acute formalin and cfa induced pain.
poss||efficacy-6/NN||its-4/PRP$	amod||efficacy-6/NN||therapeutic-5/JJ	prep_in_spite_of||restrict-28/VB||efficacy-6/NN	prep_for||efficacy-6/NN||giardiasis-8/NNS	amod||compliance-12/NN||low-10/JJ	nn||compliance-12/NN||patient-11/NN	nsubj||restrict-28/VB||compliance-12/NN	advmod||compliance-12/NN||especially-14/RB	prep_in||especially-14/RB||children-16/NNS	nn||effects-19/NNS||side-18/NN	appos||children-16/NNS||effects-19/NNS	det||emergence-23/NN||the-22/DT	conj_and||compliance-12/NN||emergence-23/NN	nsubj||restrict-28/VB||emergence-23/NN	amod||strains-26/NNS||metronidazole-resistant-25/JJ	prep_of||emergence-23/NN||strains-26/NNS	aux||restrict-28/VB||may-27/MD	root||ROOT-0/null||restrict-28/VB	poss||use-30/NN||its-29/PRP$	dobj||restrict-28/VB||use-30/NN	giardiasis-8||metronidazole--1||yes||in spite of its therapeutic efficacy for giardiasis, low patient compliance, especially in children, side effects, and the emergence of metronidazole-resistant strains may restrict its use.
nsubj||continue-11/VB||changes-1/NNS	nsubj||progress-13/VB||changes-1/NNS	det||vitreous-4/NN||the-3/DT	prep_in||changes-1/NNS||vitreous-4/NN	vmod||vitreous-4/NN||caused-5/VBN	agent||caused-5/VBN||diabetesmellitus-7/NNS	agent||caused-5/VBN||diabeticretinopathy-9/NN	conj_and||diabetesmellitus-7/NNS||diabeticretinopathy-9/NN	aux||continue-11/VB||may-10/MD	root||ROOT-0/null||continue-11/VB	aux||progress-13/VB||to-12/TO	xcomp||continue-11/VB||progress-13/VB	dobj||progress-13/VB||independent-14/JJ	nn||status-18/NN||laser-16/NN	amod||status-18/NN||regressed-17/JJ	prep_of||independent-14/JJ||status-18/NN	prep_of||status-18/NN||retinopathy-20/NN	diabeticretinopathy-9||diabetesmellitus-7||no||changes in the vitreous caused by diabetesmellitus and diabeticretinopathy may continue to progress independent of laser regressed status of retinopathy.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||fat--1||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
nsubj||cause-8/NN||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	cop||cause-8/NN||is-5/VBZ	det||cause-8/NN||a-6/DT	amod||cause-8/NN||major-7/JJ	root||ROOT-0/null||cause-8/NN	nn||infection-11/NN||liver-10/NN	prep_of||cause-8/NN||infection-11/NN	prep_in||infection-11/NN||human-13/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) is a major cause of liver infection in human.
csubj||infection-10/NN||aids-associatedkaposi-1/VBG	dobj||aids-associatedkaposi-1/VBG||ssarcoma-3/NN	cop||infection-10/NN||is-4/VBZ	det||infection-10/NN||an-5/DT	amod||life-threatening-8/JJ||important-6/JJ	amod||infection-10/NN||life-threatening-8/JJ	amod||infection-10/NN||opportunistic-9/JJ	root||ROOT-0/null||infection-10/NN	prep_among||infection-10/NN||people-12/NNS	vmod||people-12/NNS||living-13/VBG	prep_with||living-13/VBG||hiv/aids-15/NNS	amod||settings-18/NNS||resource-limited-17/JJ	prep_in||hiv/aids-15/NNS||settings-18/NNS	aids-associatedkaposi'ssarcoma--1||hiv--1||no||aids-associatedkaposi'ssarcoma is an important, life-threatening opportunistic infection among people living with hiv/aids in resource-limited settings.
nsubj||cause-13/NN||staphylococcusaureus-1/NNS	advmod||s.aureus-5/NNS||particularly-3/RB	amod||s.aureus-5/NNS||methicillin-resistant-4/JJ	appos||staphylococcusaureus-1/NNS||s.aureus-5/NNS	nn||-rrb--8/NNP||-lrb--6/NNP	nn||-rrb--8/NNP||mrsa-7/NNP	dep||s.aureus-5/NNS||-rrb--8/NNP	cop||cause-13/NN||is-10/VBZ	det||cause-13/NN||an-11/DT	amod||cause-13/NN||important-12/JJ	root||ROOT-0/null||cause-13/NN	amod||skin-16/NN||pyogenic-15/JJ	prep_of||cause-13/NN||skin-16/NN	nn||-rrb--21/NNS||softtissueinfections-18/NNS	nn||-rrb--21/NNS||-lrb--19/NN	nn||-rrb--21/NNS||sstis-20/NN	prep_of||cause-13/NN||-rrb--21/NNS	conj_and||skin-16/NN||-rrb--21/NNS	mrsa-7||s.aureus-5||no||staphylococcusaureus , particularly methicillin-resistant s.aureus -lrb- mrsa -rrb- , is an important cause of pyogenic skin and softtissueinfections -lrb- sstis -rrb- .
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	det||model-5/NN||a-3/DT	nn||model-5/NN||threshold-4/NN	dobj||propose-2/VBP||model-5/NN	det||development-8/NN||the-7/DT	prep_for||model-5/NN||development-8/NN	prep_of||development-8/NN||celiacdisease-10/NN	prep_in||determines-24/VBZ||celiacdisease-10/NN	det||efficiency-15/NN||the-14/DT	nsubj||determines-24/VBZ||efficiency-15/NN	nn||presentation-18/NN||gluten-17/NN	prep_of||efficiency-15/NN||presentation-18/NN	amod||cells-23/NNS||cd4-20/JJ	amod||cells-23/NNS||+-21/JJ	nn||cells-23/NNS||t-22/NN	prep_to||presentation-18/NN||cells-23/NNS	rcmod||celiacdisease-10/NN||determines-24/VBZ	det||likelihood-26/NN||the-25/DT	dobj||determines-24/VBZ||likelihood-26/NN	amod||celiacdisease-29/NN||developing-28/VBG	prep_of||likelihood-26/NN||celiacdisease-29/NN	poss||complications-32/NNS||its-31/PRP$	prep_of||likelihood-26/NN||complications-32/NNS	conj_and||celiacdisease-29/NN||complications-32/NNS	celiacdisease-29||gluten-17||no||we propose a threshold model for the development of celiacdisease, in which the efficiency of gluten presentation to cd4+ t cells determines the likelihood of developing celiacdisease and its complications.
nsubj||concern-7/NN||hiv/aids-1/NNS	cop||concern-7/NN||is-2/VBZ	det||concern-7/NN||a-3/DT	amod||concern-7/NN||major-4/JJ	amod||concern-7/NN||public-5/JJ	nn||concern-7/NN||health-6/NN	root||ROOT-0/null||concern-7/NN	prep_in||concern-7/NN||uganda-9/NN	aids--1||hiv--1||no||hiv/aids is a major public health concern in uganda.
det||example-3/NN||an-1/DT	amod||example-3/NN||extreme-2/JJ	nsubjpass||found-8/VBN||example-3/NN	amod||change-6/NN||genetic-5/JJ	prep_of||example-3/NN||change-6/NN	auxpass||found-8/VBN||is-7/VBZ	root||ROOT-0/null||found-8/VBN	prep_in||found-8/VBN||defective-10/JJ	vmod||defective-10/JJ||interfering-11/VBG	appos||particles-16/NNS||di-13/NNP	amod||particles-16/NNS||viral-15/JJ	dobj||interfering-11/VBG||particles-16/NNS	advmod||deleted-30/VBN||where-18/WRB	amod||sections-20/NNS||large-19/JJ	nsubjpass||deleted-30/VBN||sections-20/NNS	det||genome-23/NN||the-22/DT	prep_of||sections-20/NNS||genome-23/NN	det||virus-27/NN||a-25/DT	amod||virus-27/NN||parental-26/JJ	prep_of||genome-23/NN||virus-27/NN	aux||deleted-30/VBN||have-28/VBP	auxpass||deleted-30/VBN||been-29/VBN	advcl||found-8/VBN||deleted-30/VBN	det||fragment-35/NN||the-32/DT	amod||fragment-35/NN||residual-33/JJ	amod||fragment-35/NN||sub-genome-34/JJ	nsubjpass||replicated-37/VBN||fragment-35/NN	auxpass||replicated-37/VBN||is-36/VBZ	advcl||found-8/VBN||replicated-37/VBN	conj_and||deleted-30/VBN||replicated-37/VBN	agent||replicated-37/VBN||complementation-39/NN	amod||viruses-43/NNS||co-infecting-41/JJ	amod||viruses-43/NNS||functional-42/JJ	agent||replicated-37/VBN||viruses-43/NNS	virus-27||viruses-43||no||an extreme example of genetic change is found in defective interfering (di) viral particles, where large sections of the genome of a parental virus have been deleted and the residual sub-genome fragment is replicated by complementation by co-infecting functional viruses.
det||utilization-5/NN||the-2/DT	nn||utilization-5/NN||diabetes-3/NN	nn||utilization-5/NN||therapy-4/NN	nsubj||researching-6/VBG||utilization-5/NN	prepc_in||exenatide-41/VBP||researching-6/VBG	dobj||researching-6/VBG||changes-7/NNS	nn||weight-11/NN||a1c-9/NNS	nn||factors-14/NNS||weight-11/NN	conj_and||weight-11/NN||other-13/JJ	nn||factors-14/NNS||other-13/JJ	prep_in||changes-7/NNS||factors-14/NNS	prep_through||researching-6/VBG||intervention-16/NN	amod||study-24/NN||exenatide-18/JJ	advmod||exenatide-18/JJ||once-19/RB	amod||study-24/NN||weekly-20/JJ	dep||study-24/NN||duration-1-22/JJ	prep_with||intervention-16/NN||study-24/NN	det||safety-27/NN||the-26/DT	nsubj||exenatide-41/VBP||safety-27/NN	conj_and||safety-27/NN||efficacy-29/NN	nsubj||exenatide-41/VBP||efficacy-29/NN	num||weeks-32/NNS||30-31/CD	prep_of||safety-27/NN||weeks-32/NNS	prep_of||weeks-32/NNS||treatment-34/NN	det||agonist-40/NN||the-36/DT	amod||agonist-40/NN||glucagon-like-37/JJ	amod||agonist-40/NN||peptide-1-38/JJ	nn||agonist-40/NN||receptor-39/NN	prep_with||treatment-34/NN||agonist-40/NN	root||ROOT-0/null||exenatide-41/VBP	mark||compared-52/VBN||once-42/IN	nsubjpass||compared-52/VBN||weekly-43/JJ	amod||qw-46/NN||exenatide-45/JJ	dep||weekly-43/JJ||qw-46/NN	num||mg-49/NN||2-48/CD	dep||qw-46/NN||mg-49/NN	auxpass||compared-52/VBN||was-51/VBD	advcl||exenatide-41/VBP||compared-52/VBN	amod||bid-55/NN||exenatide-54/JJ	prep_with||compared-52/VBN||bid-55/NN	amod||patients-58/NNS||295-57/JJ	prep_in||bid-55/NN||patients-58/NNS	prep_with||compared-52/VBN||type2diabetes-60/CD	type2diabetes-60||exenatide-54||yes||in the diabetes therapy utilization researching changes in a1c, weight and other factors through intervention with exenatide once weekly (duration-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide qw; 2 mg) was compared with exenatide bid in 295 patients with type2diabetes.
advmod||outline-3/VBZ||here-1/RB	nsubj||outline-3/VBZ||we-2/PRP	nsubj||discuss-47/VB||we-2/PRP	root||ROOT-0/null||outline-3/VBZ	det||ecology-6/NN||the-4/DT	amod||ecology-6/NN||known-5/JJ	dobj||outline-3/VBZ||ecology-6/NN	det||viruses-12/NNS||the-8/DT	amod||viruses-12/NNS||mosquito-borne-9/JJ	amod||viruses-12/NNS||equine-10/JJ	nn||viruses-12/NNS||encephalitis-11/NN	prep_of||ecology-6/NN||viruses-12/NNS	dep||viruses-12/NNS||weev-14/NNP	dep||viruses-12/NNS||eeev-16/NNP	conj_and||weev-14/NNP||eeev-16/NNP	dep||viruses-12/NNS||veev-19/NNP	conj_and||weev-14/NNP||veev-19/NNP	dobj||outline-3/VBZ||wnv-22/NN	conj_and||ecology-6/NN||wnv-22/NN	conj_and||ecology-6/NN||usuv-24/NNP	conj_and||wnv-22/NN||usuv-24/NNP	conj_and||ecology-6/NN||rvfv-26/NNP	conj_and||wnv-22/NN||rvfv-26/NNP	amod||virus-30/NN||japaneseencephalitis-29/JJ	conj_and||ecology-6/NN||virus-30/NN	conj_and||wnv-22/NN||virus-30/NN	amod||virus-36/NN||tick-borneencephalitis-35/JJ	dobj||outline-3/VBZ||virus-36/NN	conj_and||ecology-6/NN||virus-36/NN	poss||virus-43/NN||its-38/PRP$	nn||virus-43/NN||north-39/NN	num||virus-43/NN||american-40/CD	nn||virus-43/NN||counterpart-41/NN	nn||virus-43/NN||powassan-42/NN	conj_and||ecology-6/NN||virus-43/NN	conj_and||virus-36/NN||virus-43/NN	aux||discuss-47/VB||will-46/MD	conj_and||outline-3/VBZ||discuss-47/VB	det||mode-51/NN||the-48/DT	advmod||likely-50/JJ||most-49/RBS	amod||mode-51/NN||likely-50/JJ	dobj||discuss-47/VB||mode-51/NN	mark||expand-56/VB||that-52/IN	det||viruses-54/NNS||these-53/DT	nsubj||expand-56/VB||viruses-54/NNS	aux||expand-56/VB||could-55/MD	ccomp||discuss-47/VB||expand-56/VB	poss||range-60/NN||their-57/PRP$	amod||range-60/NN||respective-58/JJ	amod||range-60/NN||geographical-59/JJ	dobj||expand-56/VB||range-60/NN	tick-borneencephalitis-35||viruses-54||no||here we outline the known ecology of the mosquito-borne equine encephalitis viruses (weev, eeev, and veev), wnv, usuv, rvfv, and japaneseencephalitis virus, as well as tick-borneencephalitis virus and its north american counterpart powassan virus, and will discuss the most likely mode that these viruses could expand their respective geographical range.
nsubj||curves-2/VBZ||survival-1/NN	root||ROOT-0/null||curves-2/VBZ	csubj||showed-14/VBD||monitoring-4/VBG	det||percentage-6/NN||the-5/DT	dobj||monitoring-4/VBG||percentage-6/NN	amod||cells-10/NNS||human-8/JJ	nn||cells-10/NNS||leukemia-9/NN	prep_of||percentage-6/NN||cells-10/NNS	amod||blood-13/NN||peripheral-12/JJ	prep_in||monitoring-4/VBG||blood-13/NN	conj_and||curves-2/VBZ||showed-14/VBD	mark||inhibit-19/VB||that-15/IN	nsubj||inhibit-19/VB||resveratrol-16/NN	nsubj||influence-24/VB||resveratrol-16/NN	aux||inhibit-19/VB||did-17/VBD	neg||inhibit-19/VB||not-18/RB	ccomp||showed-14/VBD||inhibit-19/VB	nn||growth-22/NN||leukemia-20/NN	nn||growth-22/NN||cell-21/NN	dobj||inhibit-19/VB||growth-22/NN	ccomp||showed-14/VBD||influence-24/VB	conj_or||inhibit-19/VB||influence-24/VB	det||activity-26/NN||the-25/DT	dobj||influence-24/VB||activity-26/NN	prep_of||activity-26/NN||vincristine-28/NN	leukemia-20||vincristine-28||yes||survival curves and monitoring the percentage of human leukemia cells in peripheral blood showed that resveratrol did not inhibit leukemia cell growth or influence the activity of vincristine.
advmod||respond-18/VB||however-1/RB	advmod||respond-18/VB||âˆ-3/RB	number||20-5/CD||1/4-4/CD	num||%-6/NN||20-5/CD	nsubj||respond-18/VB||%-6/NN	prep_of||%-6/NN||patients-8/NNS	nn||breasttumors-12/NNS||hormone-10/NN	amod||breasttumors-12/NNS||receptor-positive-11/JJ	prep_with||patients-8/NNS||breasttumors-12/NNS	vmod||breasttumors-12/NNS||treated-13/VBN	prep_with||treated-13/VBN||anastrozole-15/NN	aux||respond-18/VB||do-16/VBP	neg||respond-18/VB||not-17/RB	root||ROOT-0/null||respond-18/VB	nsubj||remains-21/VBZ||it-20/PRP	conj_and||respond-18/VB||remains-21/VBZ	acomp||remains-21/VBZ||impossible-22/JJ	aux||predict-25/VB||to-23/TO	advmod||predict-25/VB||accurately-24/RB	xcomp||impossible-22/JJ||predict-25/VB	dobj||predict-25/VB||sensitivity-26/NN	breasttumors-12||anastrozole-15||yes||however, âˆ¼20% of patients with hormone receptor-positive breasttumors treated with anastrozole do not respond and it remains impossible to accurately predict sensitivity.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	prion-9||cjd-28||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||describe-8/VB||goal-2/NN	det||study-5/NN||this-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||describe-8/VB||to-7/TO	xcomp||was-6/VBD||describe-8/VB	advmod||reflected-32/VBD||how-9/WRB	nsubj||reflected-32/VBD||activists-10/NNS	vmod||activists-10/NNS||engaged-11/VBN	prep_in||engaged-11/VBN||campaigns-13/NNS	aux||change-15/VB||to-14/TO	xcomp||engaged-11/VBN||change-15/VB	nn||policies-17/NNS||alcohol-16/NN	dobj||change-15/VB||policies-17/NNS	dep||change-15/VB||in-18/IN	amod||areas-21/NNS||inner-19/JJ	nn||areas-21/NNS||city-20/NN	pobj||in-18/IN||areas-21/NNS	vmod||areas-21/NNS||framed-22/VBN	nn||problems-24/NNS||alcohol-23/NN	dobj||framed-22/VBN||problems-24/NNS	mark||not-29/RB||whether-27/IN	cc||not-29/RB||or-28/CC	dep||change-15/VB||not-29/RB	conj_and||in-18/IN||not-29/RB	poss||frameworks-31/NN||their-30/PRP$	dep||not-29/RB||frameworks-31/NN	ccomp||describe-8/VB||reflected-32/VBD	amod||models-34/NNS||major-33/JJ	dobj||reflected-32/VBD||models-34/NNS	vmod||models-34/NNS||used-35/VBN	det||field-38/NN||the-37/DT	prep_in||used-35/VBN||field-38/NN	det||alcoholism-43/NN||the-42/DT	prep_such_as||field-38/NN||alcoholism-43/NN	det||model-47/NN||a-45/DT	nn||model-47/NN||disease-46/NN	prep_as||alcoholism-43/NN||model-47/NN	det||perspective-52/NN||an-49/DT	nn||perspective-52/NN||alcohol-50/NN	nn||perspective-52/NN||problems-51/NNS	prep_as||alcoholism-43/NN||perspective-52/NN	conj_or||model-47/NN||perspective-52/NN	det||approach-58/NN||a-55/DT	amod||approach-58/NN||public-56/JJ	nn||approach-58/NN||health-57/NN	prep_as||alcoholism-43/NN||approach-58/NN	conj_or||model-47/NN||approach-58/NN	nn||problems-61/NNS||alcohol-60/NN	prep_to||used-35/VBN||problems-61/NNS	alcoholism-43||alcohol-60||no||the goal of this study was to describe how activists engaged in campaigns to change alcohol policies in inner city areas framed alcohol problems, and whether or not their frameworks reflected major models used in the field, such as the alcoholism as a disease model, an alcohol problems perspective, or a public health approach to alcohol problems.
nn||diagnosis-2/NN||pbc-1/NN	nsubjpass||established-4/VBN||diagnosis-2/NN	auxpass||established-4/VBN||was-3/VBD	root||ROOT-0/null||established-4/VBN	prepc_according_to||established-4/VBN||to-6/TO	det||profile-10/NN||the-7/DT	amod||profile-10/NN||cholestatic-8/JJ	amod||profile-10/NN||biochemical-9/JJ	pobj||established-4/VBN||profile-10/NN	amod||antibodies-13/NNS||anti-mitochondrial-12/JJ	appos||profile-10/NN||antibodies-13/NNS	appos||profile-10/NN||ama-15/NN	nn||histology-20/NN||positivity-17/NN	conj_and||positivity-17/NN||liver-19/NN	nn||histology-20/NN||liver-19/NN	dep||profile-10/NN||histology-20/NN	dep||histology-20/NN||first-22/JJ	dep||profile-10/NN||ama-26/NN	conj_and||histology-20/NN||ama-26/NN	conj_and||histology-20/NN||antinuclear-28/NN	conj_and||ama-26/NN||antinuclear-28/NN	appos||ama-26/NN||ana-30/NN	amod||antibodies-33/NNS||pbc-specific-32/JJ	dep||ama-26/NN||antibodies-33/NNS	dep||ama-26/NN||second-35/JJ	antibodies-33||pbc-1||no_rel||pbc diagnosis was established according to the cholestatic biochemical profile, anti-mitochondrial antibodies (ama) positivity and liver histology (first), and ama and antinuclear (ana) pbc-specific antibodies (second).
amod||radiotherapy-2/NN||adjuvant-1/JJ	nsubj||result-6/VB||radiotherapy-2/NN	prep_for||radiotherapy-2/NN||cancer-4/NN	aux||result-6/VB||can-5/MD	root||ROOT-0/null||result-6/VB	amod||effects-11/NNS||severe-8/JJ	amod||effects-11/NNS||adverse-9/JJ	nn||effects-11/NNS||side-10/NN	prep_in||result-6/VB||effects-11/NNS	amod||tissues-14/NNS||normal-13/JJ	prep_for||effects-11/NNS||tissues-14/NNS	cancer-4||adjuvant-1||no_rel||adjuvant radiotherapy for cancer can result in severe adverse side effects for normal tissues.
det||study-5/NN||a-2/DT	amod||study-5/NN||randomized-3/JJ	amod||study-5/NN||prospective-4/JJ	prep_in||enrolled-19/VBN||study-5/NN	num||patients-8/NNS||60-7/CD	nsubjpass||enrolled-19/VBN||patients-8/NNS	nsubj||determine-21/VB||patients-8/NNS	nn||i-ii-11/NN||asa-10/NN	dep||patients-8/NNS||i-ii-11/NN	appos||i-ii-11/NN||elder-13/JJR	num||years-16/NNS||65-15/CD	prep_than||elder-13/JJR||years-16/NNS	auxpass||enrolled-19/VBN||were-18/VBD	root||ROOT-0/null||enrolled-19/VBN	aux||determine-21/VB||to-20/TO	xcomp||enrolled-19/VBN||determine-21/VB	dobj||required-37/VBN||which-22/WDT	num||target-25/NN||two-24/CD	prep_of||required-37/VBN||target-25/NN	amod||concentrations-28/NNS||remifentanil-26/JJ	nn||concentrations-28/NNS||blood-27/NN	nsubjpass||required-37/VBN||concentrations-28/NNS	num||ng/ml-31/NN||3-30/CD	dep||concentrations-28/NNS||ng/ml-31/NN	num||ng/ml-34/NN||5-33/CD	appos||ng/ml-31/NN||ng/ml-34/NN	auxpass||required-37/VBN||was-36/VBD	ccomp||determine-21/VB||required-37/VBN	aux||blunt-39/VB||to-38/TO	ccomp||required-37/VBN||blunt-39/VB	amod||changes-41/NNS||hemodynamic-40/JJ	dobj||blunt-39/VB||changes-41/NNS	prep_during||blunt-39/VB||intubation-43/NN	aux||reduce-46/VB||to-45/TO	ccomp||required-37/VBN||reduce-46/VB	conj_and||blunt-39/VB||reduce-46/VB	amod||pain-48/NN||propofol-induced-47/JJ	dobj||reduce-46/VB||pain-48/NN	pain-48||propofol--1||yes||in a randomized prospective study, 60 patients (asa i-ii, elder than 65 years) were enrolled to determine which of two target remifentanil blood concentrations (3 ng/ml, 5 ng/ml) was required to blunt hemodynamic changes during intubation and to reduce propofol-induced pain.
nsubj||one-3/CD||mozambique-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||countries-6/NNS||the-5/DT	prep_of||one-3/CD||countries-6/NNS	det||burden-10/NN||the-8/DT	amod||burden-10/NN||highest-9/JJS	prep_with||countries-6/NNS||burden-10/NN	nn||tb-14/NN||tuberculosis-12/NNP	prep_of||burden-10/NN||tb-14/NN	amod||africa-18/NN||sub-saharan-17/JJ	prep_in||tb-14/NN||africa-18/NN	nsubj||important-33/JJ||information-21/NN	nsubj||understand-36/VB||information-21/NN	det||genotypes-25/NNS||the-23/DT	amod||genotypes-25/NNS||predominant-24/JJ	prep_on||information-21/NN||genotypes-25/NNS	prep_of||genotypes-25/NNS||mycobacteriumtuberculosis-27/NNS	vmod||mycobacteriumtuberculosis-27/NNS||circulating-28/VBG	det||country-31/NN||the-30/DT	prep_in||circulating-28/VBG||country-31/NN	cop||important-33/JJ||are-32/VBP	conj_and||one-3/CD||important-33/JJ	aux||understand-36/VB||to-34/TO	advmod||understand-36/VB||better-35/RBR	xcomp||important-33/JJ||understand-36/VB	det||epidemic-38/NN||the-37/DT	dobj||understand-36/VB||epidemic-38/NN	tuberculosis-12||mycobacteriumtuberculosis-27||no||mozambique is one of the countries with the highest burden of tuberculosis (tb) in sub-saharan africa, and information on the predominant genotypes of mycobacteriumtuberculosis circulating in the country are important to better understand the epidemic.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||here-2/RB	root||ROOT-0/null||show-3/VBP	mark||higher-25/JJR||that-4/IN	det||frequency-7/NN||the-5/DT	amod||frequency-7/NN||average-6/JJ	nsubj||higher-25/JJR||frequency-7/NN	amod||cells-14/NNS||total-9/JJ	conj_and||total-9/JJ||cd8-11/JJ	amod||cells-14/NNS||cd8-11/JJ	amod||cells-14/NNS||+-12/JJ	nn||cells-14/NNS||nkt-13/NN	prep_of||frequency-7/NN||cells-14/NNS	prep_in||cells-14/NNS||pbmcs-16/NNS	num||subjects-22/NNS||128-18/CD	amod||latent-20/JJ||healthy-19/JJ	amod||subjects-22/NNS||latent-20/JJ	amod||subjects-22/NNS||ebv-infected-21/JJ	prep_from||pbmcs-16/NNS||subjects-22/NNS	cop||higher-25/JJR||is-23/VBZ	advmod||higher-25/JJR||significantly-24/RB	ccomp||show-3/VBP||higher-25/JJR	prep||higher-25/JJR||than-26/IN	pcomp||than-26/IN||in-27/IN	num||patients-32/NNS||17-28/CD	amod||patients-32/NNS||acute-29/JJ	nn||patients-32/NNS||ebv-30/NN	nn||patients-32/NNS||infectiousmononucleosis-31/NN	pobj||in-27/IN||patients-32/NNS	num||patients-37/NNS||16-34/CD	amod||patients-37/NNS||ebv-associated-35/JJ	nn||patients-37/NNS||hodgkinlymphoma-36/NN	pobj||in-27/IN||patients-37/NNS	conj_and||patients-32/NNS||patients-37/NNS	num||subjects-44/NNS||16-40/CD	amod||subjects-44/NNS||ebv-negative-41/JJ	amod||subjects-44/NNS||normal-42/JJ	nn||subjects-44/NNS||control-43/NN	pobj||in-27/IN||subjects-44/NNS	conj_and||patients-32/NNS||subjects-44/NNS	infectiousmononucleosis-31||ebv-30||no||we here show that the average frequency of total and cd8+ nkt cells in pbmcs from 128 healthy latent ebv-infected subjects is significantly higher than in 17 acute ebv infectiousmononucleosis patients, 16 ebv-associated hodgkinlymphoma patients, and 16 ebv-negative normal control subjects.
nn||surveillance-2/NN||influenza-1/NN	nsubj||revealed-10/VBD||surveillance-2/NN	prep_of||surveillance-2/NN||pigs-4/NNS	nn||province-7/NN||jilin-6/NN	prep_in||pigs-4/NNS||province-7/NN	appos||province-7/NN||china-9/NN	root||ROOT-0/null||revealed-10/VBD	mark||detected-16/VBN||that-11/IN	amod||influenzaviruses-13/NNS||h3n2-12/JJ	nsubjpass||detected-16/VBN||influenzaviruses-13/NNS	auxpass||detected-16/VBN||were-14/VBD	advmod||detected-16/VBN||regularly-15/RB	ccomp||revealed-10/VBD||detected-16/VBN	amod||pigs-19/NNS||domestic-18/JJ	prep_from||detected-16/VBN||pigs-19/NNS	num||2008-23/CD||2007-21/CD	dep||2008-23/CD||to-22/TO	prep_during||detected-16/VBN||2008-23/CD	influenza-1||influenzaviruses-13||no||influenza surveillance of pigs in jilin province, china revealed that h3n2 influenzaviruses were regularly detected from domestic pigs during 2007 to 2008.
nsubj||due-13/JJ||we-1/PRP	nsubj||care-28/VB||we-1/PRP	cop||due-13/JJ||are-2/VBP	advmod||due-13/JJ||now-3/RB	det||era-7/NN||a-5/DT	amod||era-7/NN||new-6/JJ	prep_in||now-3/RB||era-7/NN	amod||surveillance-12/NN||antituberculosis-9/JJ	nn||surveillance-12/NN||drug-10/NN	nn||surveillance-12/NN||resistance-11/NN	prep_for||era-7/NN||surveillance-12/NN	root||ROOT-0/null||due-13/JJ	det||advent-16/NN||the-15/DT	prep_to||due-13/JJ||advent-16/NN	amod||tools-20/NNS||new-18/JJ	amod||tools-20/NNS||diagnostic-19/JJ	prep_of||advent-16/NN||tools-20/NNS	amod||commitment-23/NN||global-22/JJ	prep_to||due-13/JJ||commitment-23/NN	conj_and||advent-16/NN||commitment-23/NN	amod||access-26/NN||universal-25/JJ	prep_towards||commitment-23/NN||access-26/NN	aux||care-28/VB||to-27/TO	xcomp||due-13/JJ||care-28/VB	det||patients-31/NNS||all-30/DT	prep_for||care-28/VB||patients-31/NNS	prep_with||care-28/VB||tuberculosis-33/NNP	prep_including||care-28/VB||those-36/DT	amod||disease-39/NN||drug-resistant-38/JJ	prep_with||those-36/DT||disease-39/NN	tuberculosis-33||antituberculosis-9||yes||we are now in a new era for antituberculosis drug resistance surveillance due to the advent of new diagnostic tools and global commitment towards universal access to care for all patients with tuberculosis, including those with drug-resistant disease.
det||effort-2/NN||the-1/DT	nsubj||led-25/VBN||effort-2/NN	aux||develop-4/VB||to-3/TO	vmod||effort-2/NN||develop-4/VB	det||rin-20/NN||a-5/DT	nn||rin-20/NN||tuberculosis-6/NNP	appos||tuberculosis-6/NNP||tb-8/NN	nn||rin-20/NN||vaccine-10/NN	advmod||effective-12/JJ||more-11/RBR	amod||rin-20/NN||effective-12/JJ	det||bacille-17/NN||the-14/DT	advmod||used-16/VBN||widely-15/RB	amod||bacille-17/NN||used-16/VBN	prep_than||effective-12/JJ||bacille-17/NN	nn||rin-20/NN||calmette-guã-18/NNP	nn||rin-20/NN||©-19/NNP	dobj||develop-4/VB||rin-20/NN	appos||rin-20/NN||bcg-22/NN	aux||led-25/VBN||has-24/VBZ	root||ROOT-0/null||led-25/VBN	det||development-28/NN||the-27/DT	prep_to||led-25/VBN||development-28/NN	num||vaccines-35/NNS||two-30/CD	nn||vaccines-35/NNS||novel-31/NN	nn||vaccines-35/NNS||fusion-32/NN	nn||vaccines-35/NNS||protein-33/NN	nn||vaccines-35/NNS||subunit-34/NN	prep_of||development-28/NN||vaccines-35/NNS	amod||vaccines-35/NNS||ag85b-esat-6-36/JJ	amod||vaccines-35/NNS||ag85b-tb10-38/JJ	conj_and||ag85b-esat-6-36/JJ||ag85b-tb10-38/JJ	dobj||led-25/VBN||.4-39/CD	tuberculosis-6||bcg-22||yes||the effort to develop a tuberculosis (tb) vaccine more effective than the widely used bacille calmette-guã©rin (bcg) has led to the development of two novel fusion protein subunit vaccines ag85b-esat-6 and ag85b-tb10.4.
amod||--3/NNS||compounds-1/JJ	amod||--3/NNS||1-deoxy-1-2/JJ	dep||--3/NNS||6-5/CD	amod||â-9/NN||-LSB--7/JJ	nn||â-9/NN||n-8/NN	dep||--3/NNS||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||²-11/CD	dep||â-9/NN||furan-2-carbonyl-14/NN	nn||-RSB--18/NNS||hydrazino-17/NN	dep||furan-2-carbonyl-14/NN||-RSB--18/NNS	num||h-20/NN||-9-19/CD	dep||-RSB--18/NNS||h-20/NN	dep||furan-2-carbonyl-14/NN||purin-9-yl-22/JJ	amod||d-ribofuranuronamide-30/NN||n-ethyl-25/JJ	nn||²-28/NNP||î-27/NNP	dep||d-ribofuranuronamide-30/NN||²-28/NNP	dep||--3/NNS||d-ribofuranuronamide-30/NN	dep||d-ribofuranuronamide-30/NN||19-32/CD	amod||k-35/JJ||ha1-34/JJ	amod||iâ-71/NN||k-35/JJ	amod||iâ-71/NN||iâ-36/JJ	amod||iâ-71/NN||$-37/$	number||=-39/CD||‰-38/CD	num||$-37/$||=-39/CD	amod||iâ-71/NN||â-40/JJ	amod||iâ-71/NN||$-41/$	number||1050â-43/CD||‰-42/CD	num||$-41/$||1050â-43/CD	amod||iâ-71/NN||nm-44/JJ	amod||iâ-71/NN||ha2a-46/JJ	amod||iâ-71/NN||k-47/JJ	amod||iâ-71/NN||iâ-48/JJ	amod||iâ-71/NN||$-49/$	number||=-51/CD||‰-50/CD	num||$-49/$||=-51/CD	amod||iâ-71/NN||â-52/JJ	amod||iâ-71/NN||$-53/$	number||1550â-55/CD||‰-54/CD	num||$-53/$||1550â-55/CD	amod||iâ-71/NN||nm-56/JJ	amod||iâ-71/NN||ha2b-58/JJ	amod||iâ-71/NN||ec50â-59/JJ	amod||iâ-71/NN||$-60/$	number||=-62/CD||‰-61/CD	num||$-60/$||=-62/CD	amod||iâ-71/NN||â-63/JJ	amod||iâ-71/NN||$-64/$	number||82â-66/CD||‰-65/CD	num||$-64/$||82â-66/CD	amod||iâ-71/NN||nm-67/JJ	amod||iâ-71/NN||ha3-69/JJ	nn||iâ-71/NN||k-70/NN	appos||19-32/CD||iâ-71/NN	dep||iâ-71/NN||$-72/$	number||>-74/CD||‰-73/CD	num||$-72/$||>-74/CD	vmod||$-72/$||â-75/VBN	dep||m-81/NN||$-76/$	num||m-81/NN||‰-77/CD	num||m-81/NN||5â-78/CD	nn||m-81/NN||î-79/NN	num||m-81/NN||1/4-80/CD	dobj||â-75/VBN||m-81/NN	poss||analogue-86/NN||its-84/PRP$	amod||analogue-86/NN||2-chloro-85/JJ	dep||--3/NNS||analogue-86/NN	conj_and||d-ribofuranuronamide-30/NN||analogue-86/NN	nsubjpass||confirmed-139/VBN||23-87/CD	nsubj||agonists-146/NNS||23-87/CD	amod||iâ-91/NN||ha1-89/JJ	nn||iâ-91/NN||k-90/NN	dep||23-87/CD||iâ-91/NN	num||â-95/NN||$-92/$	number||=-94/CD||‰-93/CD	num||$-92/$||=-94/CD	prep||iâ-91/NN||â-95/NN	amod||î-134/NN||$-96/$	dep||$-96/$||‰-97/JJ	amod||î-134/NN||3500â-98/JJ	amod||î-134/NN||nm-99/JJ	amod||î-134/NN||ha2a-101/JJ	amod||î-134/NN||k-102/JJ	amod||î-134/NN||iâ-103/JJ	amod||î-134/NN||$-104/$	number||=-106/CD||‰-105/CD	num||$-104/$||=-106/CD	amod||î-134/NN||â-107/JJ	amod||î-134/NN||$-108/$	number||4950â-110/CD||‰-109/CD	num||$-108/$||4950â-110/CD	amod||î-134/NN||nm-111/JJ	amod||î-134/NN||ha2b-113/JJ	amod||î-134/NN||ec50â-114/JJ	amod||î-134/NN||$-115/$	number||=-117/CD||‰-116/CD	num||$-115/$||=-117/CD	amod||î-134/NN||â-118/JJ	amod||î-134/NN||$-119/$	number||210â-121/CD||‰-120/CD	num||$-119/$||210â-121/CD	amod||î-134/NN||nm-122/JJ	amod||î-134/NN||ha3-124/JJ	amod||î-134/NN||k-125/JJ	amod||î-134/NN||iâ-126/JJ	amod||î-134/NN||$-127/$	number||>-129/CD||‰-128/CD	num||$-127/$||>-129/CD	amod||î-134/NN||â-130/JJ	amod||î-134/NN||$-131/$	num||$-131/$||‰-132/CD	amod||î-134/NN||5â-133/JJ	dep||â-95/NN||î-134/NN	number||m-136/JJ||1/4-135/CD	amod||î-134/NN||m-136/JJ	auxpass||confirmed-139/VBN||were-138/VBD	rcmod||analogue-86/NN||confirmed-139/VBN	aux||agonists-146/NNS||to-140/TO	cop||agonists-146/NNS||be-141/VB	amod||agonists-146/NNS||potent-142/JJ	conj_and||potent-142/JJ||selective-144/JJ	amod||agonists-146/NNS||selective-144/JJ	amod||agonists-146/NNS||full-145/JJ	xcomp||confirmed-139/VBN||agonists-146/NNS	det||adenosinemonophosphate-150/NN||a-148/DT	amod||adenosinemonophosphate-150/NN||cyclic-149/JJ	prep_in||agonists-146/NNS||adenosinemonophosphate-150/NN	appos||adenosinemonophosphate-150/NN||camp-152/NN	amod||assay-155/JJ||functional-154/JJ	amod||adenosinemonophosphate-150/NN||assay-155/JJ	amod||cells-163/NNS||chinese-157/JJ	nn||cells-163/NNS||hamster-158/NN	nn||cells-163/NNS||ovary-159/NN	appos||cells-163/NNS||cho-161/NN	prep_in||agonists-146/NNS||cells-163/NNS	vmod||cells-163/NNS||expressing-164/VBG	amod||ar-166/NN||ha2b-165/JJ	dobj||expressing-164/VBG||ar-166/NN	nm-122||ar-166||no_rel||compounds 1-deoxy-1-{6-[ n â€²-(furan-2-carbonyl)-hydrazino]-9 h -purin-9-yl}-n-ethyl- î² -d-ribofuranuronamide ( 19 , ha1 k iâ€‰=â€‰1050â nm, ha2a k iâ€‰=â€‰1550â nm, ha2b ec50â€‰=â€‰82â nm, ha3 k iâ€‰>â€‰5â î¼m) and its 2-chloro analogue 23 (ha1 k iâ€‰=â€‰3500â nm, ha2a k iâ€‰=â€‰4950â nm, ha2b ec50â€‰=â€‰210â nm, ha3 k iâ€‰>â€‰5â î¼m) were confirmed to be potent and selective full agonists in a cyclic adenosinemonophosphate (camp) functional assay in chinese hamster ovary (cho) cells expressing ha2b ar.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||now-2/RB	root||ROOT-0/null||show-3/VBP	det||treatment-5/NN||that-4/DT	dobj||show-3/VBP||treatment-5/NN	amod||mice-8/NNS||tumor-bearing-7/JJ	prep_of||treatment-5/NN||mice-8/NNS	amod||cd40-24/NNS||il-2-10/JJ	punct||±-13/NNP||/-11/:	nn||±-13/NNP||î-12/NNP	dep||cd40-24/NNS||±-13/NNP	amod||cd40-24/NNS||cd40-15/JJ	neg||il-2-19/JJ||not-18/RB	dep||cd40-24/NNS||il-2-19/JJ	advmod||±-22/JJ||î-21/RB	conj_or||il-2-19/JJ||±-22/JJ	dep||cd40-24/NNS||±-22/JJ	prep_with||treatment-5/NN||cd40-24/NNS	vmod||treatment-5/NN||induced-26/VBN	amod||synthase-29/NN||significant-27/JJ	nn||synthase-29/NN||nitricoxide-28/NN	nsubj||expression-34/NN||synthase-29/NN	appos||synthase-29/NN||nos-31/NN	num||expression-34/NN||2-33/CD	xcomp||induced-26/VBN||expression-34/NN	amod||macrophages-37/NNS||tumor-associated-36/JJ	prep_in||expression-34/NN||macrophages-37/NNS	nitricoxide-28||tumor--1||no_rel||we now show that treatment of tumor-bearing mice with il-2/î±-cd40, but not il-2 or î±-cd40, induced significant nitricoxide synthase (nos) 2 expression in tumor-associated macrophages.
vmod||found-6/VBD||using-1/VBG	amod||analysis-3/NN||proteomic-2/JJ	dobj||using-1/VBG||analysis-3/NN	nsubj||found-6/VBD||we-5/PRP	root||ROOT-0/null||found-6/VBD	mark||increased-10/VBD||that-7/IN	nsubj||increased-10/VBD||aripiprazole-8/NN	advmod||increased-10/VBD||significantly-9/RB	ccomp||found-6/VBD||increased-10/VBD	dobj||increased-10/VBD||levels-11/NNS	det||±-18/NNS||the-13/DT	nn||±-18/NNS||heat-14/NN	nn||±-18/NNS||shock-15/NN	nn||±-18/NNS||protein-16/NN	amod||±-18/NNS||hsp90î-17/JJ	prep_of||levels-11/NNS||±-18/NNS	amod||cells-21/NNS||cultured-20/JJ	prep_in||increased-10/VBD||cells-21/NNS	shock-15||aripiprazole-8||no_rel||using proteomic analysis, we found that aripiprazole significantly increased levels of the heat shock protein hsp90î± in cultured cells.
nsubj||consequences-6/NNS||hypercalcemia-1/NN	nsubj||have-13/VBP||hypercalcemia-1/NN	conj_and||hypercalcemia-1/NN||hypercalciuria-3/NN	nsubj||consequences-6/NNS||hypercalciuria-3/NN	cop||consequences-6/NNS||are-4/VBP	amod||consequences-6/NNS||frequent-5/JJ	root||ROOT-0/null||consequences-6/NNS	nn||treatment-9/NN||pth-8/NN	prep_of||consequences-6/NNS||treatment-9/NN	advmod||have-13/VBP||rarely-12/RB	conj_but||consequences-6/NNS||have-13/VBP	amod||effects-15/NNS||clinical-14/JJ	dobj||have-13/VBP||effects-15/NNS	auxpass||controlled-20/VBN||are-17/VBP	advmod||controlled-20/VBN||usually-18/RB	advmod||controlled-20/VBN||well-19/RB	conj_but||consequences-6/NNS||controlled-20/VBN	conj_and||have-13/VBP||controlled-20/VBN	agent||controlled-20/VBN||reducing-22/VBG	nn||supplementation-26/NN||calcium-23/NN	conj_and||calcium-23/NN||vitamind-25/NN	nn||supplementation-26/NN||vitamind-25/NN	dobj||reducing-22/VBG||supplementation-26/NN	hypercalcemia-1||vitamind-25||no||hypercalcemia and hypercalciuria are frequent consequences of pth treatment, but rarely have clinical effects and are usually well controlled by reducing calcium and vitamind supplementation.
tmod||identified-11/VBN||1989-2/CD	prep_since||one-17/CD||1989-2/CD	advmod||identified-11/VBN||when-3/WRB	det||hivpositives-7/NNS||the-4/DT	amod||hivpositives-7/NNS||first-5/JJ	num||hivpositives-7/NNS||146-6/CD	nsubjpass||identified-11/VBN||hivpositives-7/NNS	prep_in||hivpositives-7/NNS||china-9/NN	auxpass||identified-11/VBN||were-10/VBD	rcmod||1989-2/CD||identified-11/VBN	amod||prefecture-14/NN||dehong-13/JJ	nsubj||one-17/CD||prefecture-14/NN	aux||one-17/CD||had-15/VBD	cop||one-17/CD||been-16/VBN	root||ROOT-0/null||one-17/CD	det||hardest-hit-21/NN||the-19/DT	nn||hardest-hit-21/NN||areas-20/NNS	prep_of||one-17/CD||hardest-hit-21/NN	prep_by||one-17/CD||hiv-23/NN	prep_in||hiv-23/NN||china-25/NN	hivpositives-7||hiv-23||no||since 1989 when the first 146 hivpositives in china were identified, dehong prefecture had been one of the areas hardest-hit by hiv in china.
nsubj||tried-6/VBN||youth-2/NN	nsubj||lose-8/VB||youth-2/NN	prep_among||common-35/JJ||youth-2/NN	aux||tried-6/VBN||had-4/VBD	advmod||tried-6/VBN||ever-5/RB	rcmod||youth-2/NN||tried-6/VBN	aux||lose-8/VB||to-7/TO	xcomp||tried-6/VBN||lose-8/VB	dobj||lose-8/VB||weight-9/NN	dep||youth-2/NN||n-11/VBN	dep||1,646-13/CD||=-12/SYM	ccomp||n-11/VBN||1,646-13/CD	amod||practices-18/NNS||healthy-16/JJ	amod||practices-18/NNS||weight-loss-17/JJ	nsubj||common-35/JJ||practices-18/NNS	dep||practices-18/NNS||diet-20/NN	number||76.5-22/CD||-LSB--21/CD	num||%-23/NN||76.5-22/CD	nsubj||-RSB--24/VBZ||%-23/NN	nsubj||exercise-26/VBP||%-23/NN	rcmod||diet-20/NN||-RSB--24/VBZ	rcmod||diet-20/NN||exercise-26/VBP	conj_and||-RSB--24/VBZ||exercise-26/VBP	number||94.8-28/CD||-LSB--27/CD	dep||%-29/NN||94.8-28/CD	dep||-RSB--30/NNS||%-29/NN	dobj||exercise-26/VBP||-RSB--30/NNS	cop||common-35/JJ||were-32/VBD	det||common-35/JJ||the-33/DT	advmod||common-35/JJ||most-34/RBS	root||ROOT-0/null||common-35/JJ	mark||common-75/JJ||whereas-37/IN	amod||practices-39/NNS||unhealthy-38/JJ	nsubj||common-75/JJ||practices-39/NNS	dep||practices-39/NNS||fasting-41/VBG	ccomp||fasting-41/VBG||-LSB--42/VBG	num||%-44/NN||8.6-43/CD	dobj||-LSB--42/VBG||%-44/NN	advmod||-LSB--42/VBG||-RSB--45/RB	ccomp||fasting-41/VBG||using-47/VBG	conj_and||-LSB--42/VBG||using-47/VBG	nn||aids-49/NNS||diet-48/NN	dobj||using-47/VBG||aids-49/NNS	vmod||aids-49/NNS||-LSB--50/VBN	number||%-52/NN||7.5-51/CD	amod||-RSB--62/NN||%-52/NN	nn||-RSB--62/NN||-RSB--53/JJ	conj_or||-RSB--53/JJ||vomiting-55/NN	nn||-RSB--62/NN||vomiting-55/NN	conj_or||-RSB--53/JJ||laxative-57/NN	nn||-RSB--62/NN||laxative-57/NN	nn||-RSB--62/NN||use-58/NN	num||-RSB--62/NN||-LSB--59/CD	number||%-61/NN||2.3-60/CD	amod||-RSB--62/NN||%-61/NN	dep||-LSB--50/VBN||-RSB--62/NN	ccomp||fasting-41/VBG||skipping-65/VBG	conj_and||-LSB--42/VBG||skipping-65/VBG	nn||doses-67/NNS||insulin-66/NN	dobj||skipping-65/VBG||doses-67/NNS	vmod||skipping-65/VBG||-LSB--68/VBG	number||%-70/NN||4.2-69/CD	amod||-RSB--71/NNS||%-70/NN	dobj||-LSB--68/VBG||-RSB--71/NNS	cop||common-75/JJ||were-73/VBD	advmod||common-75/JJ||less-74/RBR	advcl||common-35/JJ||common-75/JJ	insulin-66||aids-49||no_rel||among youth who had ever tried to lose weight ( n = 1,646), healthy weight-loss practices (diet [76.5%] and exercise [94.8%]) were the most common, whereas unhealthy practices (fasting [8.6%], using diet aids [7.5%], vomiting or laxative use [2.3%], and skipping insulin doses [4.2%]) were less common.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nn||outcomes-4/NNS||survival-3/NN	dobj||assessed-2/VBD||outcomes-4/NNS	nn||american-7/NN||african-6/NN	prep_for||assessed-2/VBD||american-7/NN	appos||american-7/NN||aa-9/NN	prep_versus||american-7/NN||caucasian-12/JJ	dep||caucasian-12/JJ||ca-14/MD	dep||caucasian-12/JJ||women-16/NNS	prep_with||women-16/NNS||tnbc-18/NN	vmod||tnbc-18/NN||treated-19/VBN	det||center-24/NN||an-21/DT	amod||center-24/NN||urban-22/JJ	nn||center-24/NN||cancer-23/NN	prep_at||treated-19/VBN||center-24/NN	prep_in||center-24/NN||memphis-26/NNS	dobj||assessed-2/VBD||tn-28/NN	det||population-34/NN||a-30/DT	amod||population-34/NN||predominant-31/JJ	nn||population-34/NN||aa-32/NN	nn||population-34/NN||patient-33/NN	prep_with||tn-28/NN||population-34/NN	cancer-23||ca-14||no_rel||we assessed survival outcomes for african american (aa) versus caucasian (ca) women with tnbc treated at an urban cancer center in memphis, tn with a predominant aa patient population.
det||protection-2/NN||the-1/DT	nsubjpass||restricted-14/VBN||protection-2/NN	prep_against||protection-2/NN||pneumococcalinfections-4/NNS	vmod||pneumococcalinfections-4/NNS||provided-5/VBN	advmod||available-8/JJ||currently-7/RB	amod||vaccines-12/NNS||available-8/JJ	amod||vaccines-12/NNS||pneumococcal-9/JJ	amod||vaccines-12/NNS||polysaccharide-10/JJ	nn||vaccines-12/NNS||conjugate-11/NN	agent||provided-5/VBN||vaccines-12/NNS	auxpass||restricted-14/VBN||are-13/VBP	root||ROOT-0/null||restricted-14/VBN	det||number-18/NN||the-16/DT	amod||number-18/NN||limited-17/JJ	prep_to||restricted-14/VBN||number-18/NN	det||serotypes-21/NNS||the-20/DT	prep_of||number-18/NN||serotypes-21/NNS	vmod||serotypes-21/NNS||included-22/VBN	det||vaccine-25/NN||the-24/DT	prep_in||included-22/VBN||vaccine-25/NN	pneumococcalinfections-4||pneumococcal-9||no||the protection against pneumococcalinfections provided by currently available pneumococcal polysaccharide conjugate vaccines are restricted to the limited number of the serotypes included in the vaccine.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||boy-5/NN||an-3/DT	amod||boy-5/NN||adolescent-4/JJ	dobj||report-2/VBP||boy-5/NN	amod||risk-9/NN||minimal-7/JJ	amod||risk-9/NN||pre-existing-8/JJ	prep_with||report-2/VBP||risk-9/NN	prep_for||risk-9/NN||thromboses-11/NNS	nsubj||suffered-13/VBD||thromboses-11/NNS	rcmod||thromboses-11/NNS||suffered-13/VBD	amod||occlusion-17/NN||central-14/JJ	amod||occlusion-17/NN||retinal-15/JJ	nn||occlusion-17/NN||vein-16/NN	dobj||suffered-13/VBD||occlusion-17/NN	vmod||occlusion-17/NN||associated-18/VBN	nn||use-21/NN||isotretinoin-20/NN	prep_with||associated-18/VBN||use-21/NN	prep_for||use-21/NN||acne-23/NN	acne-23||isotretinoin-20||yes||we report an adolescent boy with minimal pre-existing risk for thromboses who suffered central retinal vein occlusion associated with isotretinoin use for acne.
nsubj||response-37/NN||methods-1/NNS	nsubj||conducted-3/VBD||we-2/PRP	rcmod||methods-1/NNS||conducted-3/VBD	det||review-6/NN||a-4/DT	nn||review-6/NN||desk-5/NN	dobj||conducted-3/VBD||review-6/NN	nsubj||had-13/VBN||review-6/NN	amod||policies-10/NNS||key-8/JJ	amod||policies-10/NNS||national-level-9/JJ	prep_of||review-6/NN||policies-10/NNS	aux||had-13/VBN||have-12/VBP	rcmod||review-6/NN||had-13/VBN	det||impact-16/NN||a-14/DT	amod||impact-16/NN||major-15/JJ	dobj||had-13/VBN||impact-16/NN	prepc_on||had-13/VBN||chinaâ-18/VBG	dobj||chinaâ-18/VBG||$-19/$	num||$-19/$||™-20/CD	nsubj||hiv/aids-22/VBZ||s-21/PRP	nsubj||examined-26/VBD||s-21/PRP	rcmod||$-19/$||hiv/aids-22/VBZ	dobj||hiv/aids-22/VBZ||epidemic-23/NN	rcmod||$-19/$||examined-26/VBD	conj_and||hiv/aids-22/VBZ||examined-26/VBD	amod||data-29/NNS||recent-27/JJ	amod||data-29/NNS||epidemiological-28/JJ	nsubj||relevant-30/JJ||data-29/NNS	nsubj||chinaâ-32/VB||data-29/NNS	xcomp||examined-26/VBD||relevant-30/JJ	aux||chinaâ-32/VB||to-31/TO	xcomp||relevant-30/JJ||chinaâ-32/VB	dobj||chinaâ-32/VB||$-33/$	num||$-33/$||™-34/CD	cop||response-37/NN||s-35/VBZ	nn||response-37/NN||hiv-36/NN	root||ROOT-0/null||response-37/NN	aids--1||hiv-36||no||methods we conducted a desk review of key national-level policies that have had a major impact on chinaâ€™s hiv/aids epidemic, and examined recent epidemiological data relevant to chinaâ€™s hiv response.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||present-9/VB||aim-3/NN	det||study-6/NN||this-5/DT	prep_of||aim-3/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||present-9/VB||to-8/TO	xcomp||was-7/VBD||present-9/VB	det||results-11/NNS||the-10/DT	dobj||present-9/VB||results-11/NNS	det||analysis-15/NN||a-13/DT	amod||analysis-15/NN||prespecified-14/JJ	prep_of||results-11/NNS||analysis-15/NN	amod||endpoints-19/NNS||key-17/JJ	amod||endpoints-19/NNS||secondary-18/JJ	prep_of||analysis-15/NN||endpoints-19/NNS	det||study-27/NN||a-21/DT	amod||study-27/NN||12-week-22/JJ	amod||study-27/NN||open-label-24/JJ	amod||study-27/NN||single-arm-26/JJ	prep_from||present-9/VB||study-27/NN	vmod||study-27/NN||evaluating-28/VBG	det||efficacy-30/NN||the-29/DT	dobj||evaluating-28/VBG||efficacy-30/NN	dobj||evaluating-28/VBG||safety-32/NN	conj_and||efficacy-30/NN||safety-32/NN	amod||hydrochlorothiazide-36/NN||olmesartanmedoxomil-34/JJ	nn||hydrochlorothiazide-36/NN||plus-35/NN	prep_of||efficacy-30/NN||hydrochlorothiazide-36/NN	appos||hydrochlorothiazide-36/NN||hctz-38/NNP	prep_in||evaluating-28/VBG||patients-41/NNS	prep_with||patients-41/NNS||hypertension-43/NN	prep_with||patients-41/NNS||type2diabetes-45/NNS	conj_and||hypertension-43/NN||type2diabetes-45/NNS	hypertension-43||hctz-38||yes||objective the aim of this study was to present the results of a prespecified analysis of key secondary endpoints from a 12-week, open-label, single-arm study evaluating the efficacy and safety of olmesartanmedoxomil plus hydrochlorothiazide (hctz) in patients with hypertension and type2diabetes.
det||sequence-4/NN||the-1/DT	amod||sequence-4/NN||first-2/JJ	amod||sequence-4/NN||complete-3/JJ	nsubjpass||reported-8/VBN||sequence-4/NN	prep_of||sequence-4/NN||jcv-6/NN	auxpass||reported-8/VBN||is-7/VBZ	root||ROOT-0/null||reported-8/VBN	num||isolates-12/NNS||three-10/CD	amod||isolates-12/NNS||separate-11/JJ	prep_for||reported-8/VBN||isolates-12/NNS	det||level-18/NN||a-15/DT	advmod||high-17/JJ||relatively-16/RB	amod||level-18/NN||high-17/JJ	nsubjpass||observed-24/VBN||level-18/NN	amod||conservation-22/NN||aminoacid-20/JJ	nn||conservation-22/NN||sequence-21/NN	prep_of||level-18/NN||conservation-22/NN	auxpass||observed-24/VBN||was-23/VBD	conj_and||reported-8/VBN||observed-24/VBN	advmod||isolated-28/VBD||even-25/RB	mark||isolated-28/VBD||for-26/IN	nsubj||isolated-28/VBD||viruses-27/NNS	advcl||observed-24/VBN||isolated-28/VBD	num||years-30/NNS||57-29/CD	npadvmod||apart-31/RB||years-30/NNS	advmod||indicating-32/VBG||apart-31/RB	xcomp||isolated-28/VBD||indicating-32/VBG	mark||is-36/VBZ||that-33/IN	det||virus-35/NN||the-34/DT	nsubj||is-36/VBZ||virus-35/NN	ccomp||indicating-32/VBG||is-36/VBZ	amod||stasis-40/NNS||relative-38/JJ	amod||stasis-40/NNS||evolutionary-39/JJ	prep_in||is-36/VBZ||stasis-40/NNS	virus-35||viruses-27||no||the first complete sequence of jcv is reported for three separate isolates, and a relatively high level of aminoacid sequence conservation was observed even for viruses isolated 57 years apart indicating that the virus is in relative evolutionary stasis.
det||proportions-2/NNS||the-1/DT	nsubj||%-8/NN||proportions-2/NNS	amod||resistance-5/NN||mono-drug-4/JJ	prep_of||proportions-2/NNS||resistance-5/NN	cop||%-8/NN||were-6/VBD	num||%-8/NN||28.73-7/CD	root||ROOT-0/null||%-8/NN	prep_for||%-8/NN||isoniazid-10/NN	num||%-13/NN||19.41-12/CD	conj_and||%-8/NN||%-13/NN	prep_for||%-13/NN||rifampicin-15/NN	num||%-18/NN||29.33-17/CD	conj_and||%-8/NN||%-18/NN	prep_for||%-18/NN||streptomycin-20/NN	num||%-24/NN||13.98-23/CD	conj_and||%-8/NN||%-24/NN	prep_for||%-24/NN||ethambutol-26/NN	advmod||%-8/NN||respectively-28/RB	mono--1||rifampicin-15||no_rel||the proportions of mono-drug resistance were 28.73% for isoniazid, 19.41% for rifampicin, 29.33% for streptomycin, and 13.98% for ethambutol, respectively.
det||sample-4/NN||a-1/DT	nn||sample-4/NN||midstream-2/NN	nn||sample-4/NN||urine-3/NN	nsubj||detected-5/VBD||sample-4/NN	root||ROOT-0/null||detected-5/VBD	nn||cells-8/NNS||glomerular-6/NN	nn||cells-8/NNS||blood-7/NN	dobj||detected-5/VBD||cells-8/NNS	det||setting-11/NN||the-10/DT	prep_in||detected-5/VBD||setting-11/NN	amod||vasculitis-17/NNS||anti-neutrophil-13/JJ	amod||vasculitis-17/NNS||cytoplasmic-14/JJ	amod||vasculitis-17/NNS||antibody-positive-15/JJ	amod||vasculitis-17/NNS||renal-16/JJ	prep_of||setting-11/NN||vasculitis-17/NNS	amod||bacteremia-20/NN||streptococcuspyogenes-19/JJ	prep_of||setting-11/NN||bacteremia-20/NN	conj_and||vasculitis-17/NNS||bacteremia-20/NN	antibody--1||vasculitis-17||no_rel||a midstream urine sample detected glomerular blood cells in the setting of anti-neutrophil cytoplasmic antibody-positive renal vasculitis and streptococcuspyogenes bacteremia.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||awareness-4/NN||the-3/DT	dobj||assess-2/VB||awareness-4/NN	dobj||assess-2/VB||attitude-6/NN	conj_and||awareness-4/NN||attitude-6/NN	det||public-10/NN||the-8/DT	amod||public-10/NN||general-9/JJ	prep_of||awareness-4/NN||public-10/NN	prep_toward||assess-2/VB||people-12/NNS	vmod||people-12/NNS||living-13/VBG	prep_with||living-13/VBG||hiv/aids-15/NNS	appos||hiv/aids-15/NNS||plwha-17/NNP	prep_in||hiv/aids-15/NNS||mangalore-20/NN	det||city-23/NN||a-22/DT	appos||mangalore-20/NN||city-23/NN	amod||karnataka-26/NN||coastal-25/JJ	prep_in||city-23/NN||karnataka-26/NN	aids--1||hiv--1||no||to assess the awareness and attitude of the general public toward people living with hiv/aids (plwha) in mangalore, a city in coastal karnataka.
det||patient-2/NN||the-1/DT	nsubj||declined-3/VBD||patient-2/NN	root||ROOT-0/null||declined-3/VBD	amod||resection-5/NN||pancreatic-4/JJ	nsubjpass||prevented-12/VBN||resection-5/NN	amod||hypoglycaemia-9/NN||recurrent-7/JJ	amod||hypoglycaemia-9/NN||symptomatic-8/JJ	conj_and||resection-5/NN||hypoglycaemia-9/NN	nsubjpass||prevented-12/VBN||hypoglycaemia-9/NN	auxpass||prevented-12/VBN||was-10/VBD	advmod||prevented-12/VBN||successfully-11/RB	ccomp||declined-3/VBD||prevented-12/VBN	amod||octreotide-16/NN||low-14/JJ	nn||octreotide-16/NN||dose-15/NN	prep_with||prevented-12/VBN||octreotide-16/NN	hypoglycaemia-9||octreotide-16||no_rel||the patient declined pancreatic resection and recurrent symptomatic hypoglycaemia was successfully prevented with low dose octreotide.
amod||mites-2/NNS||hominis-1/JJ	nsubj||show-11/VBP||mites-2/NNS	vmod||mites-2/NNS||collected-3/VBN	amod||communities-7/NNS||scabies-5/JJ	amod||communities-7/NNS||endemic-6/JJ	prep_from||collected-3/VBN||communities-7/NNS	amod||australia-10/NN||northern-9/JJ	prep_in||communities-7/NNS||australia-10/NN	root||ROOT-0/null||show-11/VBP	xcomp||show-11/VBP||increasing-12/VBG	dobj||increasing-12/VBG||tolerance-13/NN	number||%-16/NN||5-15/CD	amod||permethrin-17/NN||%-16/NN	prep_to||increasing-12/VBG||permethrin-17/NN	amod||ivermectin-20/NN||oral-19/JJ	prep_to||increasing-12/VBG||ivermectin-20/NN	conj_and||permethrin-17/NN||ivermectin-20/NN	scabies-5||ivermectin-20||yes||hominis mites collected from scabies endemic communities in northern australia show increasing tolerance to 5% permethrin and oral ivermectin.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	interferon--1||melanoma-54||no_rel||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
nn||therapy-2/NN||statin-1/NN	nsubjpass||associated-8/VBN||therapy-2/NN	prep_in||therapy-2/NN||patients-4/NNS	prep_with||patients-4/NNS||cardiovasculardisease-6/NN	auxpass||associated-8/VBN||is-7/VBZ	root||ROOT-0/null||associated-8/VBN	amod||incidence-11/NN||reduced-10/VBN	prep_with||associated-8/VBN||incidence-11/NN	prep_of||incidence-11/NN||stroke-13/NN	statin-1||stroke-13||no_rel||statin therapy in patients with cardiovasculardisease is associated with reduced incidence of stroke.
dep||assess-4/VB||a-1/LS	aux||assess-4/VB||to-3/TO	root||ROOT-0/null||assess-4/VB	det||suitability-6/NN||the-5/DT	dobj||assess-4/VB||suitability-6/NN	det||content-10/NN||the-8/DT	nn||content-10/NN||curriculum-9/NN	prep_of||suitability-6/NN||content-10/NN	amod||quality-13/NN||didactical-12/JJ	nsubj||delivered-16/VBD||quality-13/NN	nsubj||educate-18/VB||quality-13/NN	prep_of||quality-13/NN||information-15/NN	conj_and||assess-4/VB||delivered-16/VBD	aux||educate-18/VB||to-17/TO	xcomp||delivered-16/VBD||educate-18/VB	dobj||educate-18/VB||journalists-19/NNS	det||program-23/NN||the-21/DT	amod||program-23/NN||j2j-22/JJ	prep_in||journalists-19/NNS||program-23/NN	prep_in||journalists-19/NNS||hiv/aids-25/NNS	nn||evaluation-28/NN||process-27/NN	appos||hiv/aids-25/NNS||evaluation-28/NN	prep_in||journalists-19/NNS||b-31/SYM	conj_and||hiv/aids-25/NNS||b-31/SYM	aux||explore-34/VB||to-33/TO	vmod||educate-18/VB||explore-34/VB	det||effects-36/NNS||the-35/DT	dobj||explore-34/VB||effects-36/NNS	amod||programs-39/NNS||such-38/JJ	prep_of||effects-36/NNS||programs-39/NNS	poss||reporting-43/NN||journalists-41/NNS	prep_on||explore-34/VB||reporting-43/NN	amod||related-46/JJ||hiv/aids-45/JJ	amod||information-47/NN||related-46/JJ	prep_of||reporting-43/NN||information-47/NN	nn||evaluation-50/NN||outcome-49/NN	appos||information-47/NN||evaluation-50/NN	aids--1||hiv--1||no||a) to assess the suitability of the curriculum content and didactical quality of information delivered to educate journalists in the j2j program in hiv/aids (process evaluation) and b) to explore the effects of such programs on journalists' reporting of hiv/aids related information (outcome evaluation).
nn||intake-3/NN||urticaria-1/NN	amod||intake-3/NN||following-2/VBG	nsubjpass||observed-7/VBN||intake-3/NN	nsubjpass||observed-7/VBN||intake-3/NN	prep_of||intake-3/NN||nsaids-5/NNS	auxpass||observed-7/VBN||was-6/VBD	root||ROOT-0/null||observed-7/VBN	conj_and||observed-7/VBN||observed-7/VBN	num||patients-10/NNS||four-9/CD	prep_in||observed-7/VBN||patients-10/NNS	amod||pills-14/NNS||oralcontraceptive-13/JJ	prep_with||observed-7/VBN||pills-14/NNS	num||patient-17/NN||one-16/CD	prep_in||pills-14/NNS||patient-17/NN	pills-14||urticaria-1||no_rel||urticaria following intake of nsaids was observed in four patients and with oralcontraceptive pills in one patient.
nsubj||cause-5/NN||staphylococcusaureus-1/NNS	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||common-4/JJ	ccomp||-lrb--25/VBD||cause-5/NN	amod||infection-8/NN||human-7/JJ	prep_of||cause-5/NN||infection-8/NN	nsubj||concern-18/NN||emergence-11/NN	amod||s.aureus-14/NNS||vancomycin-resistance-13/JJ	prep_of||emergence-11/NN||s.aureus-14/NNS	cop||concern-18/NN||is-15/VBZ	det||concern-18/NN||a-16/DT	amod||concern-18/NN||great-17/JJ	conj_and||cause-5/NN||concern-18/NN	ccomp||-lrb--25/VBD||concern-18/NN	prep_for||concern-18/NN||treatment-20/NN	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_of||treatment-20/NN||s.aureus-23/NNS	root||ROOT-0/null||-lrb--25/VBD	nn||-rrb--27/NNS||mrsa-26/NN	dobj||-lrb--25/VBD||-rrb--27/NNS	amod||years-30/NNS||recent-29/JJ	prep_in||-lrb--25/VBD||years-30/NNS	num||-rrb--33/NN||-lrb--31/CD	nn||-rrb--33/NN||mrsa-32/NN	nsubj||-lrb--25/VBD||-rrb--33/NN	mrsa-32||s.aureus-23||no||staphylococcusaureus is a common cause of human infection , and emergence of vancomycin-resistance s.aureus is a great concern for treatment of methicillin-resistant s.aureus , -lrb- mrsa -rrb- in recent years -lrb- mrsa -rrb- .
det||authorities-2/NNS||some-1/DT	nsubj||suggest-3/VBP||authorities-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||association-9/NN||that-4/IN	expl||association-9/NN||there-5/EX	aux||association-9/NN||may-6/MD	cop||association-9/NN||be-7/VB	det||association-9/NN||an-8/DT	ccomp||suggest-3/VBP||association-9/NN	prep_between||association-9/NN||eczema-11/NN	prep_between||association-9/NN||asthma-13/NN	conj_and||eczema-11/NN||asthma-13/NN	ccomp||suggest-3/VBP||antibiotics-15/NNS	conj_and||association-9/NN||antibiotics-15/NNS	vmod||antibiotics-15/NNS||prescribed-16/VBN	prep_in||prescribed-16/VBN||childhood-18/NN	advmod||disagree-23/VBP||however-20/RB	nsubj||disagree-23/VBP||others-22/NNS	parataxis||suggest-3/VBP||disagree-23/VBP	eczema-11||antibiotics-15||no_rel||some authorities suggest that there may be an association between eczema and asthma and antibiotics prescribed in childhood; however, others disagree.
mark||have-5/VB||as-1/IN	amod||ibs-3/NN||active-2/JJ	nsubj||have-5/VB||ibs-3/NN	aux||have-5/VB||may-4/MD	advcl||is-17/VBZ||have-5/VB	amod||advantages-8/NNS||many-6/JJ	amod||advantages-8/NNS||attractive-7/JJ	dobj||have-5/VB||advantages-8/NNS	amod||production-11/NN||enzyme-10/JJ	prep_in||advantages-8/NNS||production-11/NN	amod||applications-14/NNS||industrial-13/JJ	prep_in||advantages-8/NNS||applications-14/NNS	conj_and||production-11/NN||applications-14/NNS	nsubj||is-17/VBZ||it-16/PRP	nsubj||explore-22/VB||it-16/PRP	root||ROOT-0/null||is-17/VBZ	amod||interest-20/NN||considerable-19/JJ	prep_of||is-17/VBZ||interest-20/NN	aux||explore-22/VB||to-21/TO	xcomp||is-17/VBZ||explore-22/VB	dobj||explore-22/VB||them-23/PRP	advmod||explore-22/VB||further-24/RBR	enzyme-10||ibs-3||no_rel||as active ibs may have many attractive advantages in enzyme production and industrial applications, it is of considerable interest to explore them further.
aux||assess-2/VB||to-1/TO	csubj||methotrexate-11/VBP||assess-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||long-term-4/JJ	dobj||assess-2/VB||efficacy-5/NN	dobj||assess-2/VB||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	amod||plus-10/NN||infliximab-9/JJ	prep_of||efficacy-5/NN||plus-10/NN	root||ROOT-0/null||methotrexate-11/VBP	prep_in||methotrexate-11/VBP||juvenilerheumatoidarthritis-13/NNS	appos||juvenilerheumatoidarthritis-13/NNS||jra-15/NN	juvenilerheumatoidarthritis-13||methotrexate-11||yes||to assess the long-term efficacy and safety of infliximab plus methotrexate in juvenilerheumatoidarthritis (jra).
advmod||patients-4/NNS||totally-1/RB	num||patients-4/NNS||108-2/CD	amod||patients-4/NNS||aml-cr1-3/JJ	nsubjpass||randomized-8/VBN||patients-4/NNS	vmod||patients-4/NNS||undergoing-5/VBG	dobj||undergoing-5/VBG||allo-hsct-6/NN	auxpass||randomized-8/VBN||were-7/VBD	root||ROOT-0/null||randomized-8/VBN	advmod||mg/kg-14/NN||bucy-10/RB	amod||mg/kg-14/NN||busulfan-12/JJ	num||mg/kg-14/NN||1.6-13/CD	prep_into||randomized-8/VBN||mg/kg-14/NN	amod||hours-17/NNS||q12-16/JJ	appos||mg/kg-14/NN||hours-17/NNS	num||â-20/NN||-7-19/CD	appos||mg/kg-14/NN||â-20/NN	num||d-28/NNS||$-21/$	number||~-23/CD||‰-22/CD	num||$-21/$||~-23/CD	amod||d-28/NNS||â-24/JJ	num||d-28/NNS||$-25/$	number||-4-27/CD||‰-26/CD	num||$-25/$||-4-27/CD	dep||â-20/NN||d-28/NNS	amod||mg/kg-14/NN||cyclophosphamide-30/JJ	num||mg/kg-32/NN||60-31/CD	dep||mg/kg-14/NN||mg/kg-32/NN	aml--1||cyclophosphamide-30||yes||totally 108 aml-cr1 patients undergoing allo-hsct were randomized into bucy (busulfan 1.6 mg/kg, q12 hours, -7â€‰~â€‰-4d; cyclophosphamide 60 mg/kg.
amod||options-3/NNS||fewer-1/JJR	nn||options-3/NNS||arv-2/NN	nsubj||exist-4/VBP||options-3/NNS	root||ROOT-0/null||exist-4/VBP	amod||treatment-7/NN||hiv/aids-6/JJ	prep_for||exist-4/VBP||treatment-7/NN	prep_in||exist-4/VBP||children-9/NNS	prep_than||children-9/NNS||adults-11/NNS	aids--1||hiv--1||no||fewer arv options exist for hiv/aids treatment in children than adults.
nsubj||treatment-9/NN||bacilluscalmette-guerin-1/NN	appos||bacilluscalmette-guerin-1/NN||bcg-3/NN	cop||treatment-9/NN||is-5/VBZ	det||treatment-9/NN||the-6/DT	advmod||effective-8/JJ||most-7/RBS	amod||treatment-9/NN||effective-8/JJ	root||ROOT-0/null||treatment-9/NN	amod||cancer-14/NN||non-muscle-11/JJ	nn||cancer-14/NN||invasive-12/NN	nn||cancer-14/NN||bladder-13/NN	prep_for||treatment-9/NN||cancer-14/NN	bcg-3||cancer-14||no_rel||bacilluscalmette-guerin (bcg) is the most effective treatment for non-muscle invasive bladder cancer.
det||discovery-3/NN||the-1/DT	amod||discovery-3/NN||recent-2/JJ	det||type-11/NN||discovery-3/NN	nsubj||suggests-17/VBZ||discovery-3/NN	amod||proteins-8/NNS||structural-5/JJ	conj_and||structural-5/JJ||non-structural-7/JJ	amod||proteins-8/NNS||non-structural-7/JJ	prep_of||discovery-3/NN||proteins-8/NNS	amod||type-11/NN||suppress-10/JJ	nsubj||i-12/VBD||type-11/NN	rcmod||discovery-3/NN||i-12/VBD	nn||responses-14/NNS||interferon-13/NN	dobj||i-12/VBD||responses-14/NNS	prep_in||i-12/VBD||humans-16/NNS	root||ROOT-0/null||suggests-17/VBZ	mark||mediated-26/VBN||that-18/IN	amod||responses-20/NNS||immune-19/JJ	nsubjpass||mediated-26/VBN||responses-20/NNS	amod||hosts-23/NNS||rodent-22/JJ	prep_in||responses-20/NNS||hosts-23/NNS	aux||mediated-26/VBN||could-24/MD	auxpass||mediated-26/VBN||be-25/VB	ccomp||suggests-17/VBZ||mediated-26/VBN	advmod||mediated-26/VBN||directly-27/RB	det||virus-30/NN||the-29/DT	agent||mediated-26/VBN||virus-30/NN	interferon-13||virus-30||no_rel||the recent discovery of structural and non-structural proteins that suppress type i interferon responses in humans suggests that immune responses in rodent hosts could be mediated directly by the virus.
amod||children-3/NNS||black-1/JJ	amod||children-3/NNS||african-caribbean-2/JJ	nsubj||had-4/VBD||children-3/NNS	root||ROOT-0/null||had-4/VBD	amod||hdl-cholesterol-6/NN||higher-5/JJR	dobj||had-4/VBD||hdl-cholesterol-6/NN	amod||levels-10/NNS||lower-8/JJR	nn||levels-10/NNS||triglyceride-9/NN	dobj||had-4/VBD||levels-10/NNS	conj_and||hdl-cholesterol-6/NN||levels-10/NNS	amod||europeans-13/NNS||white-12/JJ	prep_than||had-4/VBD||europeans-13/NNS	amod||markers-16/NNS||adiposity-15/JJ	nsubjpass||increased-19/VBN||markers-16/NNS	auxpass||increased-19/VBN||were-17/VBD	neg||increased-19/VBN||not-18/RB	parataxis||had-4/VBD||increased-19/VBN	adiposity-15||triglyceride-9||no_rel||black african-caribbean children had higher hdl-cholesterol and lower triglyceride levels than white europeans; adiposity markers were not increased.
nsubj||entrapment-7/NN||venousairembolism-1/NN	appos||venousairembolism-1/NN||vae-3/NN	cop||entrapment-7/NN||is-5/VBZ	det||entrapment-7/NN||the-6/DT	root||ROOT-0/null||entrapment-7/NN	prep_of||entrapment-7/NN||air-9/NN	prep_of||entrapment-7/NN||medicalgases-11/NNS	conj_or||air-9/NN||medicalgases-11/NNS	det||system-15/NN||the-13/DT	amod||system-15/NN||venous-14/JJ	prep_into||entrapment-7/NN||system-15/NN	vmod||system-15/NN||causing-16/VBG	dobj||causing-16/VBG||symptoms-17/NNS	dobj||causing-16/VBG||signs-19/NNS	conj_and||symptoms-17/NNS||signs-19/NNS	amod||obstruction-23/NN||pulmonary-21/JJ	nn||obstruction-23/NN||vessel-22/NN	prep_of||symptoms-17/NNS||obstruction-23/NN	medicalgases-11||venousairembolism-1||no_rel||venousairembolism (vae) is the entrapment of air or medicalgases into the venous system causing symptoms and signs of pulmonary vessel obstruction.
det||internalization-2/NN||the-1/DT	nsubj||essential-15/JJ||internalization-2/NN	prep_of||internalization-2/NN||borreliaburgdorferi-4/NNS	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	appos||borreliaburgdorferi-4/NNS||agent-8/NN	prep_of||agent-8/NN||lymedisease-10/NN	prep_by||borreliaburgdorferi-4/NNS||phagocytes-13/NNS	cop||essential-15/JJ||is-14/VBZ	root||ROOT-0/null||essential-15/JJ	det||activation-19/NN||an-17/DT	amod||activation-19/NN||effective-18/JJ	prep_for||essential-15/JJ||activation-19/NN	det||response-23/NN||the-21/DT	amod||response-23/NN||immune-22/JJ	prep_of||activation-19/NN||response-23/NN	det||pathogen-26/NN||this-25/DT	prep_to||essential-15/JJ||pathogen-26/NN	lymedisease-10||borreliaburgdorferi-4||no||the internalization of borreliaburgdorferi , the causative agent of lymedisease, by phagocytes is essential for an effective activation of the immune response to this pathogen.
nsubjpass||known-8/VBN||resistance-1/NN	nsubjpass||associated-11/VBN||resistance-1/NN	prep_to||resistance-1/NN||chloroquine-3/NN	nn||strains-6/NNS||malaria-5/NN	prep_of||chloroquine-3/NN||strains-6/NNS	auxpass||known-8/VBN||is-7/VBZ	root||ROOT-0/null||known-8/VBN	aux||associated-11/VBN||to-9/TO	auxpass||associated-11/VBN||be-10/VB	xcomp||known-8/VBN||associated-11/VBN	det||protein-15/NN||a-13/DT	nn||protein-15/NN||parasite-14/NN	prep_with||associated-11/VBN||protein-15/NN	vmod||protein-15/NN||named-16/VBN	dobj||named-16/VBN||pfcrt-17/NN	det||form-21/NN||the-19/DT	amod||form-21/NN||mutated-20/JJ	appos||pfcrt-17/NN||form-21/NN	nsubj||able-25/JJ||which-23/WDT	nsubj||reduce-27/VB||which-23/WDT	cop||able-25/JJ||is-24/VBZ	prepc_of||form-21/NN||able-25/JJ	aux||reduce-27/VB||to-26/TO	xcomp||able-25/JJ||reduce-27/VB	amod||accumulation-29/NN||chloroquine-28/JJ	dobj||reduce-27/VB||accumulation-29/NN	det||vacuole-33/NN||the-31/DT	amod||vacuole-33/NN||digestive-32/JJ	prep_in||reduce-27/VB||vacuole-33/NN	det||pathogen-36/NN||the-35/DT	prep_of||vacuole-33/NN||pathogen-36/NN	malaria-5||chloroquine-28||yes||resistance to chloroquine of malaria strains is known to be associated with a parasite protein named pfcrt, the mutated form of which is able to reduce chloroquine accumulation in the digestive vacuole of the pathogen.
nn||profiles-3/NNS||dsp-1/NN	nn||profiles-3/NNS||toxin-2/NN	nsubj||showed-4/VBD||profiles-3/NNS	root||ROOT-0/null||showed-4/VBD	det||presence-6/NN||the-5/DT	dobj||showed-4/VBD||presence-6/NN	amod||oa-10/NN||okadaicacid-8/JJ	prep_of||presence-6/NN||oa-10/NN	prep_in||oa-10/NN||three-13/CD	dobj||showed-4/VBD||ytx-16/NN	conj_and||presence-6/NN||ytx-16/NN	prep_in||ytx-16/NN||four-18/CD	num||samples-22/NNS||nine-21/CD	prep_out_of||showed-4/VBD||samples-22/NNS	nsubjpass||analyzed-25/VBN||samples-22/NNS	auxpass||analyzed-25/VBN||were-24/VBD	rcmod||samples-22/NNS||analyzed-25/VBN	agent||analyzed-25/VBN||lc-ms/ms-27/NNS	dsp-1||oa-10||no_rel||dsp toxin profiles showed the presence of okadaicacid (oa) in three, and ytx in four out of nine samples that were analyzed by lc-ms/ms.
nsubj||some-10/DT||smoking-1/NN	nn||carcinogens-4/NNS||chemical-3/NN	appos||smoking-1/NN||carcinogens-4/NNS	prep_like||carcinogens-4/NNS||asbestos-6/NN	prep_like||carcinogens-4/NNS||organicsolvents-8/NNS	conj_or||asbestos-6/NN||organicsolvents-8/NNS	cop||some-10/DT||are-9/VBP	root||ROOT-0/null||some-10/DT	det||factors-13/NNS||these-12/DT	prep_of||some-10/DT||factors-13/NNS	nsubj||increase-15/VBP||factors-13/NNS	rcmod||factors-13/NNS||increase-15/VBP	det||risk-17/NN||the-16/DT	dobj||increase-15/VBP||risk-17/NN	det||rcc-20/NN||the-19/DT	prep_of||risk-17/NN||rcc-20/NN	chemical-3||rcc-20||no_rel||smoking, chemical carcinogens like asbestos or organicsolvents are some of these factors that increase the risk of the rcc.
prep_in||increases-19/VBZ||patients-2/NNS	nn||increases-9/NNS||alcoholicliverdisease-4/NN	nn||increases-9/NNS||liver-6/NN	amod||increases-9/NNS||adh3-7/JJ	nn||increases-9/NNS||activity-8/NN	prep_with||patients-2/NNS||increases-9/NNS	mark||decreases-14/VBZ||while-11/IN	amod||activity-13/NN||adh1-12/JJ	nsubj||decreases-14/VBZ||activity-13/NN	advcl||increases-19/VBZ||decreases-14/VBZ	amod||intake-18/NN||as-16/IN	nn||intake-18/NN||alcohol-17/NN	nsubj||increases-19/VBZ||intake-18/NN	root||ROOT-0/null||increases-19/VBZ	alcoholicliverdisease-4||alcohol-17||no||in patients with alcoholicliverdisease, liver adh3 activity increases, while adh1 activity decreases, as alcohol intake increases.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||level-4/NN||the-3/DT	dobj||evaluate-2/VB||level-4/NN	prep_of||level-4/NN||pain-6/NN	prep_during||evaluate-2/VB||phacoemulsification-8/NN	amod||implantation-13/NN||foldable-10/JJ	amod||implantation-13/NN||intraocular-11/JJ	nn||implantation-13/NN||lens-12/NN	prep_during||evaluate-2/VB||implantation-13/NN	conj_and||phacoemulsification-8/NN||implantation-13/NN	prep_under||evaluate-2/VB||instillation-15/NN	amod||eyedrops-20/NNS||tetracaine-17/JJ	number||%-19/NN||0.5-18/CD	amod||eyedrops-20/NNS||%-19/NN	prep_of||instillation-15/NN||eyedrops-20/NNS	det||combination-23/NN||a-22/DT	prep_versus||eyedrops-20/NNS||combination-23/NN	dep||%-27/NN||lidocaine-25/JJ	number||%-27/NN||2-26/CD	amod||gel-28/NN||%-27/NN	prep_of||combination-23/NN||gel-28/NN	prep_of||combination-23/NN||instillation-30/NN	conj_and||gel-28/NN||instillation-30/NN	amod||eyedrops-33/NNS||tetracaine-32/JJ	prep_of||eyedrops-20/NNS||eyedrops-33/NNS	pain-6||tetracaine-32||yes||to evaluate the level of pain during phacoemulsification and foldable intraocular lens implantation under instillation of tetracaine 0.5% eyedrops versus a combination of lidocaine 2% gel and instillation of tetracaine eyedrops.
nsubj||hivpositive-4/JJ||those-1/DT	nsubj||likely-7/JJ||those-1/DT	cop||hivpositive-4/JJ||were-3/VBD	rcmod||those-1/DT||hivpositive-4/JJ	cop||likely-7/JJ||were-5/VBD	advmod||likely-7/JJ||more-6/RBR	root||ROOT-0/null||likely-7/JJ	prep_than||likely-7/JJ||those-9/DT	nsubj||negative-13/JJ||those-9/DT	nsubjpass||infected-16/VBN||those-9/DT	nsubj||hepatitisb-20/VBZ||those-9/DT	cop||negative-13/JJ||were-11/VBD	advmod||negative-13/JJ||hiv-12/RB	rcmod||those-9/DT||negative-13/JJ	aux||infected-16/VBN||to-14/TO	auxpass||infected-16/VBN||be-15/VB	xcomp||negative-13/JJ||infected-16/VBN	prep_with||infected-16/VBN||syphilis-18/NNS	rcmod||those-9/DT||hepatitisb-20/VBZ	conj_and/or||negative-13/JJ||hepatitisb-20/VBZ	hivpositive-4||hiv-12||no||those who were hivpositive were more likely than those who were hiv negative to be infected with syphilis and/or hepatitisb.
nsubj||result-6/VBP||deficiencies-1/NNS	prep_in||deficiencies-1/NNS||gla-3/FW	prep_in||deficiencies-1/NNS||sda-5/FW	conj_and||gla-3/FW||sda-5/FW	root||ROOT-0/null||result-6/VBP	amod||susceptibility-9/NN||increased-8/VBN	prep_in||result-6/VBP||susceptibility-9/NN	prep_to||susceptibility-9/NN||bacterialinfection-11/NN	nsubjpass||associated-15/VBN||bacterialinfection-11/NN	auxpass||associated-15/VBN||is-14/VBZ	rcmod||bacterialinfection-11/NN||associated-15/VBN	amod||expression-19/NN||reduced-17/VBN	amod||expression-19/NN||basal-18/JJ	prep_with||associated-15/VBN||expression-19/NN	det||number-22/NN||a-21/DT	prep_of||expression-19/NN||number-22/NN	amod||$-26/NNS||immune-specific-24/JJ	amod||$-26/NNS||genesâ-25/JJ	prep_of||number-22/NN||$-26/NNS	dep||â-35/JJ||spp-1-29/JJ	conj_and||â-35/JJ||lys-7-31/JJ	amod||$-36/NNS||lys-7-31/JJ	conj_and||â-35/JJ||lys-2-34/JJ	amod||$-36/NNS||lys-2-34/JJ	amod||$-36/NNS||â-35/JJ	prep_including||$-26/NNS||$-36/NNS	nsubj||encode-39/VBP||$-36/NNS	rcmod||$-36/NNS||encode-39/VBP	amod||peptides-41/NNS||antimicrobial-40/JJ	dobj||encode-39/VBP||peptides-41/NNS	bacterialinfection-11||lys--1||no_rel||deficiencies in gla and sda result in increased susceptibility to bacterialinfection, which is associated with reduced basal expression of a number of immune-specific genesâ€”including spp-1 , lys-7 , and lys-2 â€”that encode antimicrobial peptides.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||yes||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
nn||status-2/NN||bmi-1/NN	nsubjpass||studied-4/VBN||status-2/NN	auxpass||studied-4/VBN||was-3/VBD	dep||reported-12/VBD||studied-4/VBN	advmod||studied-4/VBN||cross-sectionally-5/RB	prep_in||studied-4/VBN||relation-7/NN	det||parental-11/NN||the-9/DT	amod||parental-11/NN||following-10/JJ	prep_to||studied-4/VBN||parental-11/NN	root||ROOT-0/null||reported-12/VBD	dobj||reported-12/VBD||outcomes-13/NNS	det||index-17/NN||a-14/DT	amod||index-17/NN||general-15/JJ	nn||index-17/NN||health-16/NN	nsubj||reported-12/VBD||index-17/NN	nn||visits-20/NNS||gp-19/NN	appos||index-17/NN||visits-20/NNS	nn||absenteeism-23/NN||school-22/NN	appos||visits-20/NNS||absenteeism-23/NN	prep_due_to||absenteeism-23/NN||illness-26/NN	amod||limitations-30/NNS||health-related-28/JJ	amod||limitations-30/NNS||functional-29/JJ	prep_due_to||absenteeism-23/NN||limitations-30/NNS	conj_and||illness-26/NN||limitations-30/NNS	nn||respiratoryinfections-34/NNS||doctor-32/NN	nn||respiratoryinfections-34/NNS||diagnosed-33/NN	prep_due_to||absenteeism-23/NN||respiratoryinfections-34/NNS	conj_and||illness-26/NN||respiratoryinfections-34/NNS	prep_due_to||absenteeism-23/NN||use-36/NN	conj_and||illness-26/NN||use-36/NN	prep_of||use-36/NN||antibiotics-38/NNS	respiratoryinfections-34||antibiotics-38||no_rel||bmi status was studied cross-sectionally in relation to the following parental reported outcomes a general health index, gp visits, school absenteeism due to illness, health-related functional limitations, doctor diagnosed respiratoryinfections and use of antibiotics.
nsubj||discovered-3/VBD||we-1/PRP	advmod||discovered-3/VBD||previously-2/RB	root||ROOT-0/null||discovered-3/VBD	det||facet-7/NN||an-4/DT	amod||facet-7/NN||addictive-5/JJ	amod||facet-7/NN||molecular-6/JJ	dobj||discovered-3/VBD||facet-7/NN	prep_of||facet-7/NN||anorexia-9/NNP	vmod||discovered-3/VBD||involving-11/VBG	dobj||involving-11/VBG||production-12/NN	det||accumbens-17/NNS||the-15/DT	nn||accumbens-17/NNS||nucleus-16/NN	prep_in||discovered-3/VBD||accumbens-17/NNS	appos||accumbens-17/NNS||nac-19/NN	det||transcripts-25/NNS||the-23/DT	amod||transcripts-25/NNS||same-24/JJ	prep_of||accumbens-17/NNS||transcripts-25/NNS	vmod||transcripts-25/NNS||stimulated-26/VBN	prep_in||stimulated-26/VBN||response-28/NN	prep_to||stimulated-26/VBN||cocaine-30/NN	prep_to||stimulated-26/VBN||amphetamine-32/NN	conj_and||cocaine-30/NN||amphetamine-32/NN	appos||cocaine-30/NN||cart-34/NN	prep_upon||stimulated-26/VBN||stimulation-37/NN	det||receptors-41/NNS||the-39/DT	amod||receptors-41/NNS||5-ht4-40/JJ	prep_of||stimulation-37/NN||receptors-41/NNS	dep||receptors-41/NNS||5-htr4-43/JJ	prep_of||stimulation-37/NN||mdma-46/NN	conj_or||receptors-41/NNS||mdma-46/NN	appos||receptors-41/NNS||ecstasy-48/NN	anorexia-9||cocaine-30||no_rel||we previously discovered an addictive molecular facet of anorexia, involving production, in the nucleus accumbens (nac), of the same transcripts stimulated in response to cocaine and amphetamine (cart) upon stimulation of the 5-ht4 receptors (5-htr4) or mdma (ecstasy).
amod||budesonide-2/NN||nebulized-1/JJ	nsubjpass||used-5/VBN||budesonide-2/NN	aux||used-5/VBN||is-3/VBZ	auxpass||used-5/VBN||being-4/VBG	root||ROOT-0/null||used-5/VBN	det||attacks-9/NNS||the-7/DT	amod||attacks-9/NNS||acute-8/JJ	prep_in||used-5/VBN||attacks-9/NNS	prep_of||attacks-9/NNS||bronchialasthma-11/NN	preconj||used-5/VBN||either-12/CC	prep_in||used-5/VBN||children-14/NNS	conj_or||attacks-9/NNS||children-14/NNS	prep_in||used-5/VBN||adults-17/NNS	conj_or||attacks-9/NNS||adults-17/NNS	bronchialasthma-11||budesonide-2||no||nebulized budesonide is being used in the acute attacks of bronchialasthma either in children or in adults.
det||age-2/NN||the-1/DT	nsubj||2.8-23/CD||age-2/NN	vmod||age-2/NN||adjusted-3/VBN	nn||ratio-6/NN||incidence-4/NN	nn||ratio-6/NN||rate-5/NN	dobj||adjusted-3/VBN||ratio-6/NN	amod||thromboembolism-9/NN||venous-8/JJ	prep_for||ratio-6/NN||thromboembolism-9/NN	amod||use-12/NN||current-11/JJ	prep_for||adjusted-3/VBN||use-12/NN	prep_of||use-12/NN||oralcontraceptives-14/NNS	vmod||oralcontraceptives-14/NNS||containing-15/VBG	dobj||containing-15/VBG||drospirenone-16/NN	prepc_compared_with||containing-15/VBG||with-18/IN	pobj||containing-15/VBG||those-19/DT	vmod||those-19/DT||containing-20/VBG	acomp||containing-20/VBG||levonorgestrel-21/JJ	cop||2.8-23/CD||was-22/VBD	root||ROOT-0/null||2.8-23/CD	number||3.8-27/CD||2.1-25/CD	dep||3.8-27/CD||to-26/TO	dep||2.8-23/CD||3.8-27/CD	thromboembolism-9||drospirenone-16||no||the age adjusted incidence rate ratio for venous thromboembolism for current use of oralcontraceptives containing drospirenone compared with those containing levonorgestrel was 2.8 (2.1 to 3.8).
aux||elucidate-2/VB||to-1/TO	advcl||investigated-25/VBD||elucidate-2/VB	nn||mechanisms-4/NNS||novel-3/NN	dobj||elucidate-2/VB||mechanisms-4/NNS	vmod||mechanisms-4/NNS||contributing-5/VBG	det||complex-10/NN||the-7/DT	amod||complex-10/NN||htlv-1-8/JJ	amod||complex-10/NN||neurological-9/JJ	prep_to||contributing-5/VBG||complex-10/NN	poss||presentation-15/NN||its-12/PRP$	amod||presentation-15/NN||classic-13/JJ	amod||presentation-15/NN||neurological-14/JJ	prep_to||contributing-5/VBG||presentation-15/NN	conj_and||complex-10/NN||presentation-15/NN	vmod||presentation-15/NN||called-16/VBN	dobj||called-16/VBN||ham/tsp-17/NN	amod||myelopathy/tropicalspasticparaparesis-21/NNS||htlv-1-19/JJ	amod||myelopathy/tropicalspasticparaparesis-21/NNS||associated-20/JJ	appos||ham/tsp-17/NN||myelopathy/tropicalspasticparaparesis-21/NNS	nsubj||investigated-25/VBD||we-24/PRP	root||ROOT-0/null||investigated-25/VBD	det||expression-27/NN||the-26/DT	dobj||investigated-25/VBD||expression-27/NN	det||receptor-31/NN||the-29/DT	amod||receptor-31/NN||tim-3-30/JJ	prep_of||expression-27/NN||receptor-31/NN	amod||cells-36/NNS||cd8-33/JJ	amod||cells-36/NNS||+-34/JJ	nn||cells-36/NNS||t-35/NN	prep_on||receptor-31/NN||cells-36/NNS	det||cohort-39/NN||a-38/DT	prep_from||investigated-25/VBD||cohort-39/NN	amod||patients-46/NNS||htlv-1-41/JJ	amod||patients-46/NNS||seropositive-42/JJ	amod||patients-46/NNS||asymptomatic-43/JJ	conj_and||asymptomatic-43/JJ||symptomatic-45/JJ	amod||patients-46/NNS||symptomatic-45/JJ	prep_of||cohort-39/NN||patients-46/NNS	tropicalspasticparaparesis--1||htlv-1-41||no||to elucidate novel mechanisms contributing to the htlv-1 neurological complex and its classic neurological presentation called ham/tsp (htlv-1 associated myelopathy/tropicalspasticparaparesis), we investigated the expression of the tim-3 receptor on cd8+ t cells from a cohort of htlv-1 seropositive asymptomatic and symptomatic patients.
nn||cancer-2/NN||breast-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	advmod||cancer-8/NN||frequently-4/RB	det||cancer-8/NN||a-5/DT	advmod||dependent-7/JJ||hormonally-6/RB	amod||cancer-8/NN||dependent-7/JJ	root||ROOT-0/null||cancer-8/NN	nsubjpass||established-24/VBN||associations-11/NNS	prepc_of||associations-11/NNS||circulating-13/VBG	dobj||circulating-13/VBG||estrogens-14/NNS	dobj||circulating-13/VBG||androgens-16/NNS	conj_and||estrogens-14/NNS||androgens-16/NNS	amod||risk-21/NN||subsequent-18/JJ	nn||risk-21/NN||breast-19/NN	nn||risk-21/NN||cancer-20/NN	prep_with||circulating-13/VBG||risk-21/NN	auxpass||established-24/VBN||are-22/VBP	advmod||established-24/VBN||well-23/RB	conj_and||cancer-8/NN||established-24/VBN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||established-24/VBN||women-27/NNS	cancer-20||androgens-16||no_rel||breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women.
prep_despite||continues-8/VBZ||advances-2/NNS	nn||treatment-5/NN||hiv-4/NN	prep_in||advances-2/NNS||treatment-5/NN	nsubj||continues-8/VBZ||bacterialpneumonia-7/NN	nsubj||cause-10/VB||bacterialpneumonia-7/NN	root||ROOT-0/null||continues-8/VBZ	aux||cause-10/VB||to-9/TO	xcomp||continues-8/VBZ||cause-10/VB	amod||morbidity-12/NN||considerable-11/JJ	dobj||cause-10/VB||morbidity-12/NN	dobj||cause-10/VB||mortality-14/NN	conj_and||morbidity-12/NN||mortality-14/NN	prep_in||cause-10/VB||patients-16/NNS	prep_with||patients-16/NNS||hivinfection-18/NN	hivinfection-18||hiv-4||no||despite advances in hiv treatment, bacterialpneumonia continues to cause considerable morbidity and mortality in patients with hivinfection.
nsubj||similar-3/JJ||results-1/NNS	cop||similar-3/JJ||were-2/VBD	root||ROOT-0/null||similar-3/JJ	advmod||restricted-6/VBN||when-4/WRB	nsubj||restricted-6/VBN||we-5/PRP	advcl||similar-3/JJ||restricted-6/VBN	det||analyses-8/NNS||the-7/DT	dobj||restricted-6/VBN||analyses-8/NNS	nsubj||estrogen-10/VB||analyses-8/NNS	aux||estrogen-10/VB||to-9/TO	xcomp||restricted-6/VBN||estrogen-10/VB	amod||tumors-15/NNS||receptor-positive-11/JJ	conj_and||receptor-positive-11/JJ||progesterone-13/JJ	amod||tumors-15/NNS||progesterone-13/JJ	amod||tumors-15/NNS||receptor-positive-14/JJ	dobj||estrogen-10/VB||tumors-15/NNS	estrogen-10||tumors-15||no_rel||results were similar when we restricted the analyses to estrogen receptor-positive and progesterone receptor-positive tumors.
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||problem-18/NN||tb-3/NN	vmod||tb-3/NN||caused-6/VBN	agent||caused-6/VBN||mycobacteriumtuberculosis-8/NNS	appos||mycobacteriumtuberculosis-8/NNS||mtb-10/NN	cop||problem-18/NN||is-13/VBZ	det||problem-18/NN||an-14/DT	amod||problem-18/NN||enduring-15/VBG	amod||problem-18/NN||public-16/JJ	nn||problem-18/NN||health-17/NN	root||ROOT-0/null||problem-18/NN	advmod||problem-18/NN||globally-19/RB	advmod||problem-18/NN||particularly-21/RB	amod||africa-24/NN||sub-saharan-23/JJ	prep_in||problem-18/NN||africa-24/NN	tuberculosis-1||mtb-10||no||tuberculosis (tb), caused by mycobacteriumtuberculosis (mtb), is an enduring public health problem globally, particularly in sub-saharan africa.
advmod||based-2/VBN||physiologically-1/RB	root||ROOT-0/null||based-2/VBN	xcomp||based-2/VBN||modelling-3/VBG	vmod||modelling-3/VBG||using-4/VBG	dobj||using-4/VBG||debtox-5/NN	amod||budget-9/NN||dynamic-7/JJ	nn||budget-9/NN||energy-8/NN	dep||debtox-5/NN||budget-9/NN	prep_in||budget-9/NN||toxicology-11/NN	amod||profiling-15/NN||transcriptional-14/JJ	dobj||using-4/VBG||profiling-15/NN	conj_and||debtox-5/NN||profiling-15/NN	auxpass||used-17/VBN||were-16/VBD	auxpass||based-2/VBN||used-17/VBN	amod||elegans-20/NNS||caenorhabditis-19/JJ	prep_in||used-17/VBN||elegans-20/NNS	aux||identify-22/VB||to-21/TO	xcomp||used-17/VBN||identify-22/VB	advmod||associated-39/VBN||how-23/WRB	amod||modes-25/NNS||physiological-24/JJ	nsubjpass||associated-39/VBN||modes-25/NNS	prep_of||modes-25/NNS||action-27/NN	mark||indicated-30/VBD||as-29/IN	dep||action-27/NN||indicated-30/VBD	prep_by||indicated-30/VBD||effects-32/NNS	nn||allocation-37/NN||system-34/NN	nn||allocation-37/NN||level-35/NN	nn||allocation-37/NN||resource-36/NN	prep_on||indicated-30/VBD||allocation-37/NN	auxpass||associated-39/VBN||were-38/VBD	ccomp||identify-22/VB||associated-39/VBN	prep_with||associated-39/VBN||changes-41/NNS	nn||expression-44/NN||gene-43/NN	prep_in||changes-41/NNS||expression-44/NN	prep_following||expression-44/NN||exposure-46/NN	num||chemicals-50/NNS||three-48/CD	amod||chemicals-50/NNS||toxic-49/JJ	prep_to||exposure-46/NN||chemicals-50/NNS	nsubjpass||based-2/VBN||cadmium-51/NN	appos||cadmium-51/NN||fluoranthene-53/NN	appos||fluoranthene-53/NN||fa-55/NN	appos||cadmium-51/NN||atrazine-58/NN	conj_and||fluoranthene-53/NN||atrazine-58/NN	appos||atrazine-58/NN||az-60/NN	fa-55||chemicals-50||no_rel||physiologically based modelling using debtox (dynamic energy budget in toxicology) and transcriptional profiling were used in caenorhabditis elegans to identify how physiological modes of action, as indicated by effects on system level resource allocation were associated with changes in gene expression following exposure to three toxic chemicals cadmium, fluoranthene (fa) and atrazine (az).
nn||guidelines-2/NNS||hypertension-1/NN	nsubj||recommend-3/VBP||guidelines-2/NNS	root||ROOT-0/null||recommend-3/VBP	det||use-5/NN||the-4/DT	dobj||recommend-3/VBP||use-5/NN	prep_of||use-5/NN||thiazidediuretics-7/NNS	amod||therapy-10/NN||first-line-9/JJ	prep_as||thiazidediuretics-7/NNS||therapy-10/NN	amod||hypertension-13/NN||uncomplicated-12/JJ	prep_for||therapy-10/NN||hypertension-13/NN	nsubj||under-prescribed-18/JJ||diuretics-16/NNS	cop||under-prescribed-18/JJ||are-17/VBP	conj_yet||recommend-3/VBP||under-prescribed-18/JJ	nsubj||treated-25/JJ||hypertension-21/NN	cop||treated-25/JJ||is-22/VBZ	advmod||treated-25/JJ||frequently-23/RB	advmod||treated-25/JJ||inadequately-24/RB	conj_yet||recommend-3/VBP||treated-25/JJ	conj_and||under-prescribed-18/JJ||treated-25/JJ	hypertension-21||diuretics-16||no_rel||hypertension guidelines recommend the use of thiazidediuretics as first-line therapy for uncomplicated hypertension, yet diuretics are under-prescribed, and hypertension is frequently inadequately treated.
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	amod||levels-5/NNS||elevated-3/JJ	amod||levels-5/NNS||il-1ra-4/JJ	dobj||show-2/VBP||levels-5/NNS	num||years-8/NNS||13-7/CD	prep_for||levels-5/NNS||years-8/NNS	det||increase-12/NN||an-10/DT	amod||increase-12/NN||accelerated-11/JJ	prep_for||levels-5/NNS||increase-12/NN	conj_and||years-8/NNS||increase-12/NN	det||years-17/NNS||the-14/DT	amod||years-17/NNS||last-15/JJ	num||years-17/NNS||6-16/CD	prep_during||show-2/VBP||years-17/NNS	amod||diagnosis-20/NN||type2diabetes-19/JJ	prep_before||show-2/VBP||diagnosis-20/NN	vmod||show-2/VBP||indicating-22/VBG	det||presence-24/NN||the-23/DT	dobj||indicating-22/VBG||presence-24/NN	det||response-28/NN||an-26/DT	amod||response-28/NN||anti-inflammatory-27/JJ	prep_of||presence-24/NN||response-28/NN	nsubj||act-31/VB||response-28/NN	nsubj||counterbalance-33/VB||response-28/NN	aux||act-31/VB||may-30/MD	rcmod||response-28/NN||act-31/VB	aux||counterbalance-33/VB||to-32/TO	xcomp||act-31/VB||counterbalance-33/VB	det||disturbances-38/NNS||the-34/DT	amod||disturbances-38/NNS||metabolic-35/JJ	conj_and||metabolic-35/JJ||immunologic-37/JJ	amod||disturbances-38/NNS||immunologic-37/JJ	dobj||counterbalance-33/VB||disturbances-38/NNS	nsubj||precede-40/VB||disturbances-38/NNS	rcmod||disturbances-38/NNS||precede-40/VB	dobj||precede-40/VB||type2diabetes-41/NNS	anti-inflammatory-27||type2diabetes-41||no_rel||we show elevated il-1ra levels for 13 years and an accelerated increase during the last 6 years before type2diabetes diagnosis, indicating the presence of an anti-inflammatory response that may act to counterbalance the metabolic and immunologic disturbances that precede type2diabetes.
det||physician-traveler-3/NN||an-1/DT	nn||physician-traveler-3/NN||american-2/NN	nsubj||presented-7/VBD||physician-traveler-3/NN	nsubjpass||treated-15/VBN||physician-traveler-3/NN	amod||africa-6/NN||east-5/JJ	prep_to||physician-traveler-3/NN||africa-6/NN	root||ROOT-0/null||presented-7/VBD	prep_with||presented-7/VBD||manifestations-9/NNS	amod||malaria-12/NN||cerebral-11/JJ	prep_of||manifestations-9/NNS||malaria-12/NN	auxpass||treated-15/VBN||was-14/VBD	conj_and||presented-7/VBD||treated-15/VBN	amod||quinidine-18/NN||intravenous-17/JJ	prep_with||treated-15/VBN||quinidine-18/NN	amod||falciparummalaria-21/NN||chloroquine-resistant-20/JJ	prep_for||quinidine-18/NN||falciparummalaria-21/NN	falciparummalaria-21||chloroquine--1||yes||an american physician-traveler to east africa presented with manifestations of cerebral malaria and was treated with intravenous quinidine for chloroquine-resistant falciparummalaria.
det||mito-mice-3/NN||the-2/DT	prep_in||induced-10/VBN||mito-mice-3/NN	nsubj||induced-10/VBN||accumulation-5/NN	nn||mtdna-9/NN||î-7/NN	prep_of||accumulation-5/NN||mtdna-9/NN	root||ROOT-0/null||induced-10/VBN	amod||defects-13/NNS||mitochondrial-11/JJ	nn||defects-13/NNS||respiration-12/NN	dobj||induced-10/VBN||defects-13/NNS	amod||tissues-16/NNS||various-15/JJ	prep_in||defects-13/NNS||tissues-16/NNS	vmod||induced-10/VBN||resulting-18/VBG	amod||phenotypes-22/NNS||mitochondrial-20/JJ	nn||phenotypes-22/NNS||disease-21/NN	prep_in||resulting-18/VBG||phenotypes-22/NNS	amod||weight-28/NN||low-26/JJ	nn||weight-28/NN||body-27/NN	prep_such_as||phenotypes-22/NNS||weight-28/NN	amod||acidosis-31/NNS||lactic-30/JJ	prep_such_as||phenotypes-22/NNS||acidosis-31/NNS	conj_and||weight-28/NN||acidosis-31/NNS	prep_such_as||phenotypes-22/NNS||ischemia-33/NN	conj_and||weight-28/NN||ischemia-33/NN	prep_such_as||phenotypes-22/NNS||myopathy-35/NN	conj_and||weight-28/NN||myopathy-35/NN	nn||block-38/NN||heart-37/NN	prep_such_as||phenotypes-22/NNS||block-38/NN	conj_and||weight-28/NN||block-38/NN	prep_such_as||phenotypes-22/NNS||deafness-40/NNS	conj_and||weight-28/NN||deafness-40/NNS	prep_such_as||phenotypes-22/NNS||maleinfertility-42/NN	conj_and||weight-28/NN||maleinfertility-42/NN	prep_such_as||phenotypes-22/NNS||renalfailure-45/NN	conj_and||weight-28/NN||renalfailure-45/NN	mito--1||ischemia-33||no_rel||in the mito-mice, accumulation of î”mtdna induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, maleinfertility, and renalfailure.
det||rate-5/NN||the-1/DT	amod||rate-5/NN||minimum-2/JJ	amod||rate-5/NN||effective-3/JJ	nn||rate-5/NN||infusion-4/NN	nsubj||bupivacaine-9/VBP||rate-5/NN	num||%-8/NN||0.125-7/CD	prep_of||rate-5/NN||%-8/NN	root||ROOT-0/null||bupivacaine-9/VBP	prep_for||bupivacaine-9/VBP||cfnb-11/NN	mark||appears-14/VBZ||after-12/IN	nsubj||appears-14/VBZ||tkr-13/NN	nsubj||ml/h-18/NN||tkr-13/NN	advcl||bupivacaine-9/VBP||appears-14/VBZ	aux||ml/h-18/NN||to-15/TO	cop||ml/h-18/NN||be-16/VB	num||ml/h-18/NN||4-17/CD	xcomp||appears-14/VBZ||ml/h-18/NN	prepc_according_to||ml/h-18/NN||to-20/TO	det||scores-24/NNS||the-21/DT	amod||scores-24/NNS||vas-22/JJ	nn||scores-24/NNS||pain-23/NN	pobj||ml/h-18/NN||scores-24/NNS	pain-23||bupivacaine-9||yes||the minimum effective infusion rate of 0.125% bupivacaine for cfnb after tkr appears to be 4 ml/h according to the vas pain scores.
advmod||brought-16/VBN||however-1/RB	nsubj||brought-16/VBN||knowledge-3/NN	det||risk-6/NN||the-5/DT	prep_of||knowledge-3/NN||risk-6/NN	amod||transmission-12/NN||humanimmunodeficiencyvirus-8/JJ	appos||transmission-12/NN||hiv-10/NN	prep_of||risk-6/NN||transmission-12/NN	prep_through||transmission-12/NN||breastfeeding-14/NN	aux||brought-16/VBN||has-15/VBZ	root||ROOT-0/null||brought-16/VBN	prep_to||brought-16/VBN||attention-18/NN	det||controversy-20/NN||the-19/DT	dobj||brought-16/VBN||controversy-20/NN	mark||practiced-27/VBN||whether-22/IN	nsubjpass||practiced-27/VBN||breastfeeding-23/NN	aux||practiced-27/VBN||can-24/MD	auxpass||practiced-27/VBN||be-25/VB	advmod||practiced-27/VBN||safely-26/RB	prepc_of||controversy-20/NN||practiced-27/VBN	amod||mothers-30/NNS||hivpositive-29/JJ	agent||practiced-27/VBN||mothers-30/NNS	hivpositive-29||hiv-10||no||however, knowledge of the risk of humanimmunodeficiencyvirus (hiv) transmission through breastfeeding has brought to attention the controversy of whether breastfeeding can be safely practiced by hivpositive mothers.
prepc_based_on||used-14/VBN||on-2/IN	det||study-4/NN||this-3/DT	pobj||used-14/VBN||study-4/NN	nsubjpass||used-14/VBN||ceftriaxone-6/NN	conj_and||ceftriaxone-6/NN||cefixime-8/NN	nsubjpass||used-14/VBN||cefixime-8/NN	conj_and||ceftriaxone-6/NN||spectinomycin-11/NN	nsubjpass||used-14/VBN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	root||ROOT-0/null||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	nn||pakistan-25/NN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||pakistan-25/NN||bhutan-28/NN	mark||be-43/VB||whereas-30/IN	nsubj||be-43/VB||ciprofloxacin-31/NN	appos||ciprofloxacin-31/NN||penicilling-33/NN	appos||ciprofloxacin-31/NN||tetracycline-35/NN	conj_and||penicilling-33/NN||tetracycline-35/NN	appos||ciprofloxacin-31/NN||erythromycin-37/NN	conj_and||penicilling-33/NN||erythromycin-37/NN	appos||ciprofloxacin-31/NN||azithromycin-40/NN	conj_and||penicilling-33/NN||azithromycin-40/NN	aux||be-43/VB||should-41/MD	neg||be-43/VB||not-42/RB	rcmod||pakistan-25/NN||be-43/VB	gonorrhoea-21||penicilling-33||yes||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicilling, tetracycline, erythromycin, and azithromycin should not be.
nn||neurogenesis-2/NNS||adult-1/NN	nsubjpass||implicated-5/VBN||neurogenesis-2/NNS	aux||implicated-5/VBN||has-3/VBZ	auxpass||implicated-5/VBN||been-4/VBN	root||ROOT-0/null||implicated-5/VBN	prep_in||implicated-5/VBN||affectivedisorders-7/NNS	det||action-10/NN||the-9/DT	prep_in||implicated-5/VBN||action-10/NN	conj_and||affectivedisorders-7/NNS||action-10/NN	prep_of||action-10/NN||antidepressants-12/NNS	appos||antidepressants-12/NNS||ads-14/NNS	mark||unclear-25/JJ||although-16/IN	det||significance-19/NN||the-17/DT	amod||significance-19/NN||functional-18/JJ	nsubj||unclear-25/JJ||significance-19/NN	det||association-22/NN||this-21/DT	prep_of||significance-19/NN||association-22/NN	cop||unclear-25/JJ||is-23/VBZ	advmod||unclear-25/JJ||still-24/RB	advcl||implicated-5/VBN||unclear-25/JJ	antidepressants-12||affectivedisorders-7||no_rel||adult neurogenesis has been implicated in affectivedisorders and the action of antidepressants (ads) although the functional significance of this association is still unclear.
poss||studies-2/NNS||our-1/PRP$	nsubj||show-3/VBP||studies-2/NNS	root||ROOT-0/null||show-3/VBP	mark||induced-7/VBN||that-4/IN	amod||viruses-6/NNS||bac-derived-5/JJ	nsubj||induced-7/VBN||viruses-6/NNS	ccomp||show-3/VBP||induced-7/VBN	nsubj||similar-9/JJ||disease-8/NN	xcomp||induced-7/VBN||similar-9/JJ	det||virus-13/NN||the-11/DT	amod||virus-13/NN||wild-type-12/JJ	prep_to||induced-7/VBN||virus-13/NN	mark||were-17/VBD||though-15/IN	expl||were-17/VBD||there-16/EX	dep||virus-13/NN||were-17/VBD	nsubj||were-17/VBD||differences-18/NNS	det||levels-21/NNS||the-20/DT	prep_in||differences-18/NNS||levels-21/NNS	prep_of||levels-21/NNS||pathogenicity-23/NN	amod||viruses-26/NNS||individual-25/JJ	prep_between||pathogenicity-23/NN||viruses-26/NNS	virus-13||viruses-26||no||our studies show that bac-derived viruses induced disease similar to the wild-type virus, though there were differences in the levels of pathogenicity between individual viruses.
nsubj||modulates-2/VBZ||dopamine-1/NN	root||ROOT-0/null||modulates-2/VBZ	amod||function-4/NN||executive-3/JJ	dobj||modulates-2/VBZ||function-4/NN	prepc_including||function-4/NN||sustaining-7/VBG	amod||control-9/NN||cognitive-8/JJ	dobj||sustaining-7/VBG||control-9/NN	amod||fatigue-12/NN||mental-11/JJ	prep_during||sustaining-7/VBG||fatigue-12/NN	dopamine-1||fatigue-12||no_rel||dopamine modulates executive function, including sustaining cognitive control during mental fatigue.
det||cohort-6/NN||a-1/DT	amod||cohort-6/NN||12-matched-2/JJ	amod||cohort-6/NN||new-3/JJ	nn||cohort-6/NN||insulin-4/NN	nn||cohort-6/NN||user-5/NN	nsubjpass||selected-31/VBN||cohort-6/NN	prep_on||cohort-6/NN||age-8/NN	nn||±-11/NNS||â-10/NN	dep||age-8/NN||±-11/NNS	num||years-13/NNS||3-12/CD	dep||±-11/NNS||years-13/NNS	amod||status-17/NN||smoking-16/VBG	prep_on||cohort-6/NN||status-17/NN	conj_and||age-8/NN||status-17/NN	prep_on||cohort-6/NN||likelihood-20/NN	conj_and||age-8/NN||likelihood-20/NN	prepc_of||likelihood-20/NN||initiating-22/VBG	nn||therapy-24/NN||insulin-23/NN	dobj||initiating-22/VBG||therapy-24/NN	dep||selected-31/VBN||â-26/VB	num||0.05-28/CD||±-27/CD	dobj||â-26/VB||0.05-28/CD	auxpass||selected-31/VBN||was-30/VBD	root||ROOT-0/null||selected-31/VBN	det||cohort-34/NN||a-33/DT	prep_from||selected-31/VBN||cohort-34/NN	num||patients-38/NNS||4,623-36/CD	amod||patients-38/NNS||chinese-37/JJ	prep_of||cohort-34/NN||patients-38/NNS	prep_with||selected-31/VBN||type2diabetes-40/JJ	prep_with||selected-31/VBN||free-42/JJ	conj_and||type2diabetes-40/JJ||free-42/JJ	prep_of||free-42/JJ||cancer-44/NN	prep_with||selected-31/VBN||naive-47/JJ	conj_and||type2diabetes-40/JJ||naive-47/JJ	prep_to||naive-47/JJ||insulin-49/NN	prep_at||insulin-49/NN||enrollment-51/NN	insulin-49||cancer-44||no_rel||a 12-matched new insulin user cohort on age (â±3 years), smoking status, and likelihood of initiating insulin therapy (â±0.05) was selected from a cohort of 4,623 chinese patients with type2diabetes, free of cancer, and naive to insulin at enrollment.
advmod||have-7/VBP||clinically-1/RB	nsubj||have-7/VBP||patients-3/NNS	prep_with||patients-3/NNS||cgd-5/NN	advmod||have-7/VBP||usually-6/RB	root||ROOT-0/null||have-7/VBP	amod||bacterial-9/NNS||recurrent-8/JJ	dobj||have-7/VBP||bacterial-9/NNS	dobj||have-7/VBP||fungalinfections-11/NNS	conj_and||bacterial-9/NNS||fungalinfections-11/NNS	vmod||bacterial-9/NNS||causing-12/VBG	dobj||causing-12/VBG||abscess-13/NNS	nn||formation-16/NN||granuloma-15/NN	dobj||causing-12/VBG||formation-16/NN	conj_and||abscess-13/NNS||formation-16/NN	det||skin-19/NN||the-18/DT	prep_in||causing-12/VBG||skin-19/NN	nn||nodes-22/NNS||lymph-21/NN	prep_in||causing-12/VBG||nodes-22/NNS	conj_and||skin-19/NN||nodes-22/NNS	amod||organs-25/NNS||visceral-24/JJ	prep_in||causing-12/VBG||organs-25/NNS	conj_and||skin-19/NN||organs-25/NNS	abscess-13||bacterial-9||no||clinically, patients with cgd usually have recurrent bacterial and fungalinfections causing abscess and granuloma formation in the skin, lymph nodes and visceral organs.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	amod||analysis-5/NN||proteomic-4/JJ	prep_by||identified-2/VBD||analysis-5/NN	vmod||analysis-5/NN||using-6/VBG	amod||electrophoresis-8/NNS||2d-dige-7/JJ	dobj||using-6/VBG||electrophoresis-8/NNS	prep||using-6/VBG||combined-9/VBN	pcomp||combined-9/VBN||with-10/IN	amod||spectrometry-17/NN||maldi-tof-tof-11/JJ	conj_and||maldi-tof-tof-11/JJ||esi-linear-13/JJ	amod||spectrometry-17/NN||esi-linear-13/JJ	nn||spectrometry-17/NN||ion-14/NN	nn||spectrometry-17/NN||trap-15/NN	nn||spectrometry-17/NN||mass-16/NN	pobj||with-10/IN||spectrometry-17/NN	det||number-19/NN||a-18/DT	dobj||identified-2/VBD||number-19/NN	poss||expression-26/NN||number-19/NN	prep_of||number-19/NN||proteins-21/NNS	amod||functions-24/NNS||variable-23/JJ	prep_with||proteins-21/NNS||functions-24/NNS	nsubjpass||modulated-28/VBN||expression-26/NN	auxpass||modulated-28/VBN||is-27/VBZ	rcmod||number-19/NN||modulated-28/VBN	agent||modulated-28/VBN||snail1-30/NNS	amod||cells-36/NNS||sw480-adh-32/JJ	amod||cells-36/NNS||human-33/JJ	nn||cells-36/NNS||colon-34/NN	nn||cells-36/NNS||cancer-35/NN	prep_in||snail1-30/NNS||cells-36/NNS	tof--1||ion-14||no_rel||we identified by proteomic analysis using 2d-dige electrophoresis combined with maldi-tof-tof and esi-linear ion trap mass spectrometry a number of proteins with variable functions whose expression is modulated by snail1 in sw480-adh human colon cancer cells.
amod||expression-3/NN||granulocyte-1/JJ	amod||expression-3/NN||colony-stimulatingfactor-2/JJ	nsubjpass||correlated-6/VBN||expression-3/NN	auxpass||correlated-6/VBN||was-4/VBD	advmod||correlated-6/VBN||inversely-5/RB	root||ROOT-0/null||correlated-6/VBN	prep_with||correlated-6/VBN||interleukin-12p70-8/JJ	dep||interleukin-12p70-8/JJ||râ-10/VBN	dep||0.71-15/NNS||=-11/SYM	nn||0.71-15/NNS||â-12/NN	nn||0.71-15/NNS||âˆ-13/NN	ccomp||râ-10/VBN||0.71-15/NNS	ccomp||râ-10/VBN||p-17/VB	number||0.001-19/CD||<-18/CD	dobj||p-17/VB||0.001-19/CD	num||necrosis-23/NNS||tumor-22/CD	npadvmod||factor-î-24/JJ||necrosis-23/NNS	amod||expression-38/NN||factor-î-24/JJ	amod||expression-38/NN||±-25/JJ	dep||expression-38/NN||râ-27/VBN	dep||0.64-32/NNS||=-28/SYM	nn||0.64-32/NNS||â-29/NN	nn||0.64-32/NNS||âˆ-30/NN	ccomp||râ-27/VBN||0.64-32/NNS	ccomp||râ-27/VBN||p-34/VB	number||0.001-36/CD||<-35/CD	dobj||p-34/VB||0.001-36/CD	prep_with||correlated-6/VBN||expression-38/NN	conj_and||interleukin-12p70-8/JJ||expression-38/NN	nsubj||showed-41/VBD||interleukin-10-40/JJ	parataxis||correlated-6/VBN||showed-41/VBD	neg||correlation-44/NN||no-42/DT	amod||correlation-44/NN||significant-43/JJ	dobj||showed-41/VBD||correlation-44/NN	colony-stimulatingfactor-2||tumor-22||no_rel||granulocyte colony-stimulatingfactor expression was inversely correlated with interleukin-12p70 (râ =â âˆ’0.71, p <0.001) and tumor necrosis factor-î± (râ =â âˆ’0.64, p <0.001) expression; interleukin-10 showed no significant correlation.
det||kits-5/NNS||the-1/DT	num||kits-5/NNS||70-2/CD	amod||kits-5/NNS||hbsag-3/JJ	nn||kits-5/NNS||test-4/NN	nsubjpass||evaluated-11/VBN||kits-5/NNS	advmod||world-9/NN||around-7/RB	det||world-9/NN||the-8/DT	prep_from||kits-5/NNS||world-9/NN	auxpass||evaluated-11/VBN||were-10/VBD	root||ROOT-0/null||evaluated-11/VBN	amod||a-f-56/NNS||comparatively-12/RB	poss||sensitivity-16/NN||their-14/PRP$	amod||sensitivity-16/NN||clinical-15/JJ	prep_for||comparatively-12/RB||sensitivity-16/NN	amod||sensitivity-19/NN||analytical-18/JJ	prep_for||comparatively-12/RB||sensitivity-19/NN	conj_and||sensitivity-16/NN||sensitivity-19/NN	prep_for||comparatively-12/RB||sensitivity-21/NN	conj_and||sensitivity-16/NN||sensitivity-21/NN	nn||genotypes-24/NNS||hbv-23/NN	prep_to||sensitivity-21/NN||genotypes-24/NNS	nn||subtypes-27/NNS||hbsag-26/NN	prep_to||sensitivity-21/NN||subtypes-27/NNS	conj_and||genotypes-24/NNS||subtypes-27/NNS	prep_for||comparatively-12/RB||specificity-30/NN	conj_and||sensitivity-16/NN||specificity-30/NN	vmod||specificity-30/NN||using-31/VBG	amod||icbs-43/NNS||394-32/JJ	num||clinical-35/NNS||146-34/CD	dep||icbs-43/NNS||clinical-35/NNS	num||analytical-38/NNS||48-37/CD	conj_and||clinical-35/NNS||analytical-38/NNS	dep||icbs-43/NNS||analytical-38/NNS	num||negative-41/NN||200-40/CD	conj_and||clinical-35/NNS||negative-41/NN	dep||icbs-43/NNS||negative-41/NN	dobj||using-31/VBG||icbs-43/NNS	nn||members-46/NNS||master-44/NN	nn||members-46/NNS||panel-45/NN	dep||specificity-30/NN||members-46/NNS	amod||origin-50/NN||diverse-48/JJ	amod||origin-50/NN||geographical-49/JJ	prep_of||members-46/NNS||origin-50/NN	vmod||origin-50/NN||comprising-51/VBG	det||genotypes-55/NNS||the-52/DT	amod||genotypes-55/NNS||major-53/JJ	nn||genotypes-55/NNS||hbv-54/NN	dobj||comprising-51/VBG||genotypes-55/NNS	dobj||evaluated-11/VBN||a-f-56/NNS	det||subtypes-60/NNS||the-58/DT	amod||subtypes-60/NNS||hbsag-59/VBG	dobj||evaluated-11/VBN||subtypes-60/NNS	conj_and||a-f-56/NNS||subtypes-60/NNS	amod||subtypes-60/NNS||adw2-61/JJ	dep||adw2-61/JJ||,4-62/CD	num||,4-62/CD||adr-64/CD	dep||adw2-61/JJ||ayw1-4-66/CD	conj_and||,4-62/CD||ayw1-4-66/CD	hbv-54||hbsag-59||yes||the 70 hbsag test kits from around the world were evaluated comparatively for their clinical sensitivity, analytical sensitivity, sensitivity to hbv genotypes and hbsag subtypes, and specificity using 394 (146 clinical, 48 analytical and 200 negative) icbs master panel members of diverse geographical origin comprising the major hbv genotypes a-f and the hbsag subtypes adw2,4 , adr and ayw1-4 .
poss||patients-5/NNS||results-1/NNS	amod||patients-5/NNS||$-3/JJ	nsubj||had-15/VBD||patients-5/NNS	nsubj||had-62/VBD||patients-5/NNS	prep_with||patients-5/NNS||type1diabetes-7/CD	det||history-12/NN||a-9/DT	amod||history-12/NN||positive-10/JJ	amod||history-12/NN||parental-11/JJ	conj_and||patients-5/NNS||history-12/NN	nsubj||had-15/VBD||history-12/NN	prep_of||history-12/NN||type2diabetes-14/CD	root||ROOT-0/null||had-15/VBD	det||prevalence-18/NN||a-16/DT	amod||prevalence-18/NN||higher-17/JJR	dobj||had-15/VBD||prevalence-18/NN	det||syndrome-22/NN||the-20/DT	amod||syndrome-22/NN||metabolic-21/JJ	prep_of||prevalence-18/NN||syndrome-22/NN	amod||syndrome-22/NN||-lrb--23/NN	number||-lrb--23/NN||44-24/CD	num||%-27/NN||38-26/CD	prep_vs.||syndrome-22/NN||%-27/NN	dep||prevalence-18/NN||p-29/NN	dep||-rrb--32/NNS||=-30/SYM	num||-rrb--32/NNS||0.013-31/CD	rcmod||p-29/NN||-rrb--32/NNS	det||profile-36/NN||a-34/DT	amod||profile-36/NN||metabolic-35/JJ	dobj||had-15/VBD||profile-36/NN	conj_and||prevalence-18/NN||profile-36/NN	vmod||profile-36/NN||related-37/VBN	aux||insulinresistance-39/VB||to-38/TO	xcomp||related-37/VBN||insulinresistance-39/VB	amod||bmi-42/NN||-lrb--40/NN	dep||-lrb--40/NN||higher-41/JJR	dobj||insulinresistance-39/VB||bmi-42/NN	amod||circumference-46/NN||larger-44/JJR	nn||circumference-46/NN||waist-45/NN	conj_and||prevalence-18/NN||circumference-46/NN	conj_and||profile-36/NN||circumference-46/NN	amod||triglycerides-50/NNS||higher-49/JJR	conj_and||prevalence-18/NN||triglycerides-50/NNS	conj_and||profile-36/NN||triglycerides-50/NNS	conj_and||profile-36/NN||a1c-52/NNS	conj_and||triglycerides-50/NNS||a1c-52/NNS	conj_and||profile-36/NN||insulin-55/NN	conj_and||triglycerides-50/NNS||insulin-55/NN	nn||insulin-55/NN||dose-56/FW	nn||insulin-55/NN||per-57/FW	nn||insulin-55/NN||kilogram-58/FW	dep||insulin-55/NN||-rrb--59/FW	advmod||had-62/VBD||also-61/RB	conj_and||had-15/VBD||had-62/VBD	det||onset-65/NN||a-63/DT	amod||onset-65/NN||later-64/JJ	dobj||had-62/VBD||onset-65/NN	nsubjpass||confirmed-88/VBN||onset-65/NN	prep_of||onset-65/NN||type1diabetes-67/NN	nn||type1diabetes-67/NN||-lrb--68/FW	nn||type1diabetes-67/NN||17.2-69/FW	nn||type1diabetes-67/NN||â-70/FW	nn||type1diabetes-67/NN||±-71/FW	nn||type1diabetes-67/NN||9.2-72/FW	nn||type1diabetes-67/NN||vs.-73/FW	nn||type1diabetes-67/NN||16.1-74/FW	dep||type1diabetes-67/NN||â-75/FW	punct||type1diabetes-67/NN||±-76/``	num||years-78/NNS||8.9-77/CD	dep||type1diabetes-67/NN||years-78/NNS	vmod||onset-65/NN||p-80/VBN	dep||-rrb--83/NNS||=-81/SYM	num||-rrb--83/NNS||0.008-82/CD	ccomp||p-80/VBN||-rrb--83/NNS	auxpass||confirmed-88/VBN||was-86/VBD	advmod||confirmed-88/VBN||also-87/RB	rcmod||onset-65/NN||confirmed-88/VBN	det||control-94/NN||the-90/DT	advmod||available-92/JJ||publicly-91/RB	amod||control-94/NN||available-92/JJ	nn||control-94/NN||diabetes-93/NN	prep_in||confirmed-88/VBN||control-94/NN	nn||data-98/NN||complications-96/NNS	nn||data-98/NN||trial-97/NN	prep_in||confirmed-88/VBN||data-98/NN	conj_and||control-94/NN||data-98/NN	vmod||control-94/NN||set-99/VBN	type1diabetes-67||insulin-55||yes||results â $ '' patients with type1diabetes and a positive parental history of type2diabetes had a higher prevalence of the metabolic syndrome -lrb- 44 vs. 38 % ; p = 0.013 -rrb- and a metabolic profile related to insulinresistance -lrb- higher bmi , larger waist circumference , and higher triglycerides , a1c , and insulin dose per kilogram -rrb- and also had a later onset of type1diabetes -lrb- 17.2 â ± 9.2 vs. 16.1 â ± 8.9 years ; p = 0.008 -rrb- , which was also confirmed in the publicly available diabetes control and complications trial data set .
det||effect-4/NN||the-1/DT	amod||effect-4/NN||main-2/JJ	amod||effect-4/NN||biological-3/JJ	nsubj||is-8/VBZ||effect-4/NN	det||substitutions-7/NNS||these-6/DT	prep_of||effect-4/NN||substitutions-7/NNS	root||ROOT-0/null||is-8/VBZ	aux||attenuate-10/VB||to-9/TO	ccomp||is-8/VBZ||attenuate-10/VB	det||consequences-12/NNS||the-11/DT	dobj||attenuate-10/VB||consequences-12/NNS	det||activity-16/NN||the-14/DT	amod||activity-16/NN||mutagenic-15/JJ	prep_of||consequences-12/NNS||activity-16/NN	nn||$-20/NNP||ribavirin-18/NNP	nn||$-20/NNP||â-19/FW	prep_of||activity-16/NN||$-20/NNP	prepc_by||attenuate-10/VB||avoiding-23/VBG	det||repertoire-26/NN||the-24/DT	amod||repertoire-26/NN||biased-25/JJ	dobj||avoiding-23/VBG||repertoire-26/NN	nn||mutations-29/NNS||transition-28/NN	prep_of||repertoire-26/NN||mutations-29/NNS	vmod||mutations-29/NNS||produced-30/VBN	det||$-35/NN||this-32/DT	amod||$-35/NN||purine-33/JJ	amod||$-35/NN||analogueâ-34/JJ	agent||produced-30/VBN||$-35/NN	aux||maintain-39/VB||to-38/TO	ccomp||is-8/VBZ||maintain-39/VB	conj_and||attenuate-10/VB||maintain-39/VB	det||fitness-42/NN||the-40/DT	amod||fitness-42/NN||replicative-41/JJ	dobj||maintain-39/VB||fitness-42/NN	det||virus-45/NN||the-44/DT	prep_of||fitness-42/NN||virus-45/NN	nsubj||able-48/JJ||virus-45/NN	nsubj||escape-50/VB||virus-45/NN	cop||able-48/JJ||is-47/VBZ	rcmod||virus-45/NN||able-48/JJ	aux||escape-50/VB||to-49/TO	xcomp||able-48/JJ||escape-50/VB	dobj||escape-50/VB||extinction-51/NN	prep_by||escape-50/VB||ribavirin-53/NNP	virus-45||ribavirin-53||yes||the main biological effect of these substitutions is to attenuate the consequences of the mutagenic activity of ribavirin â€”by avoiding the biased repertoire of transition mutations produced by this purine analogueâ€”and to maintain the replicative fitness of the virus which is able to escape extinction by ribavirin.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||switch-7/NN||an-5/DT	nn||switch-7/NN||rna-6/NN	nsubj||utr-21/VBP||switch-7/NN	amod||3â-18/NNS||human-9/JJ	nn||3â-18/NNS||vascular-10/NN	nn||3â-18/NNS||endothelial-11/NN	nn||3â-18/NNS||growth-12/NN	amod||3â-18/NNS||factor-a-13/JJ	appos||3â-18/NNS||vegf-15/NN	nn||3â-18/NNS||mrna-17/NN	prep_in||switch-7/NN||3â-18/NNS	amod||3â-18/NNS||$-19/$	dep||$-19/$||™-20/JJ	ccomp||report-4/VBP||utr-21/VBP	mark||signals-24/VBZ||that-22/IN	nsubj||signals-24/VBZ||integrates-23/NNS	ccomp||utr-21/VBP||signals-24/VBZ	prep_from||signals-24/VBZ||interferon-26/NN	appos||interferon-26/NN||ifn-28/NN	nn||³-32/NNS||î-31/NN	dobj||signals-24/VBZ||³-32/NNS	nsubj||regulate-36/VB||³-32/NNS	dobj||signals-24/VBZ||hypoxia-34/NN	conj_and||³-32/NNS||hypoxia-34/NN	nsubj||regulate-36/VB||hypoxia-34/NN	aux||regulate-36/VB||to-35/TO	parataxis||signals-24/VBZ||regulate-36/VB	xcomp||signals-24/VBZ||regulate-36/VB	nn||translation-38/NN||vegf-37/NN	dobj||regulate-36/VB||translation-38/NN	amod||cells-41/NNS||myeloid-40/JJ	prep_in||regulate-36/VB||cells-41/NNS	interferon-26||hypoxia-34||no_rel||here, we report an rna switch in human vascular endothelial growth factor-a (vegf) mrna 3â€™utr that integrates signals from interferon (ifn)-î³ and hypoxia to regulate vegf translation in myeloid cells.
amod||insulin-2/NN||impaired-1/VBN	nsubj||feature-7/NN||insulin-2/NN	nsubjpass||associated-12/VBN||insulin-2/NN	vmod||insulin-2/NN||signaling-3/VBG	cop||feature-7/NN||is-4/VBZ	det||feature-7/NN||a-5/DT	amod||feature-7/NN||key-6/JJ	root||ROOT-0/null||feature-7/NN	prep_of||feature-7/NN||type2diabetes-9/CD	auxpass||associated-12/VBN||is-11/VBZ	conj_and||feature-7/NN||associated-12/VBN	amod||degradation-17/NN||increased-14/VBN	amod||degradation-17/NN||ubiquitin-proteasome-dependent-15/JJ	nn||degradation-17/NN||protein-16/NN	prep_with||associated-12/VBN||degradation-17/NN	amod||muscle-20/NN||skeletal-19/JJ	prep_in||degradation-17/NN||muscle-20/NN	type2diabetes-9||insulin-2||yes||impaired insulin signaling is a key feature of type2diabetes and is associated with increased ubiquitin-proteasome-dependent protein degradation in skeletal muscle.
mark||reduces-4/VBZ||while-1/IN	nsubj||reduces-4/VBZ||warfarin-2/NN	advmod||reduces-4/VBZ||significantly-3/RB	advcl||limit-16/VBP||reduces-4/VBZ	det||risk-6/NN||the-5/DT	dobj||reduces-4/VBZ||risk-6/NN	amod||stroke-9/NN||af-related-8/JJ	prep_of||risk-6/NN||stroke-9/NN	amod||risks-13/NNS||perceived-11/VBN	amod||risks-13/NNS||bleeding-12/VBG	nsubj||limit-16/VBP||risks-13/NNS	conj_and||risks-13/NNS||compliance-15/NN	nsubj||limit-16/VBP||compliance-15/NN	root||ROOT-0/null||limit-16/VBP	poss||use-19/NN||its-17/PRP$	amod||use-19/NN||widespread-18/JJ	dobj||limit-16/VBP||use-19/NN	det||population-24/NN||the-21/DT	amod||population-24/NN||high-risk-22/JJ	nn||population-24/NN||af-23/NN	prep_in||limit-16/VBP||population-24/NN	stroke-9||warfarin-2||yes||while warfarin significantly reduces the risk of af-related stroke, perceived bleeding risks and compliance limit its widespread use in the high-risk af population.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	prep_in||describe-2/VBP||detail-5/NN	poss||program-8/NN||our-7/PRP$	dobj||describe-2/VBP||program-8/NN	advmod||adapted-14/VBD||how-12/WRB	nsubj||adapted-14/VBD||we-13/PRP	nsubj||implemented-19/VBD||we-13/PRP	nsubj||developed-29/VBD||we-13/PRP	prepc_with_respect_to||program-8/NN||adapted-14/VBD	poss||settings-17/NNS||our-15/PRP$	amod||settings-17/NNS||clinical-16/JJ	dobj||adapted-14/VBD||settings-17/NNS	prepc_with_respect_to||program-8/NN||implemented-19/VBD	conj_and||adapted-14/VBD||implemented-19/VBD	amod||activities-22/NNS||psycho-social-20/JJ	nn||activities-22/NNS||support-21/NN	dobj||implemented-19/VBD||activities-22/NNS	prep_for||implemented-19/VBD||children-24/NNS	poss||caregivers-27/NNS||their-26/PRP$	prep_for||implemented-19/VBD||caregivers-27/NNS	conj_and||children-24/NNS||caregivers-27/NNS	prepc_with_respect_to||program-8/NN||developed-29/VBD	conj_and||adapted-14/VBD||developed-29/VBD	nn||literacy-31/NN||treatment-30/NN	dobj||developed-29/VBD||literacy-31/NN	prep_for||developed-29/VBD||children-33/NNS	prep_for||developed-29/VBD||teenagers-35/NNS	conj_and||children-33/NNS||teenagers-35/NNS	vmod||children-33/NNS||living-36/VBG	prep_with||living-36/VBG||hiv/aids-38/NNS	aids--1||hiv--1||no||we describe, in detail, our program with respect to how we adapted our clinical settings, implemented psycho-social support activities for children and their caregivers and developed treatment literacy for children and teenagers living with hiv/aids.
det||face-3/NN||the-2/DT	prep_in||attributes-36/NNS||face-3/NN	det||epidemic-7/NN||the-5/DT	amod||epidemic-7/NN||hiv/aids-6/JJ	prep_of||face-3/NN||epidemic-7/NN	nsubj||contributed-10/VBN||epidemic-7/NN	aux||contributed-10/VBN||has-9/VBZ	rcmod||epidemic-7/NN||contributed-10/VBN	det||increase-14/NN||the-12/DT	amod||increase-14/NN||dramatic-13/JJ	prep_to||contributed-10/VBN||increase-14/NN	prep_in||increase-14/NN||orphans-16/NNS	amod||children-19/NNS||abandoned-18/VBN	prep_of||face-3/NN||children-19/NNS	conj_and||epidemic-7/NN||children-19/NNS	nsubj||contributed-10/VBN||children-19/NNS	appos||children-19/NNS||oac-21/NN	advmod||children-19/NNS||worldwide-23/RB	nn||attitudes-26/NNS||caregiver-25/NN	nsubj||attributes-36/NNS||attitudes-26/NNS	prep_about||attitudes-26/NNS||hiv-28/NN	amod||stigma-32/NN||hiv-related-31/JJ	prep_about||attitudes-26/NNS||stigma-32/NN	conj_and||hiv-28/NN||stigma-32/NN	cop||attributes-36/NNS||are-34/VBP	num||attributes-36/NNS||two-35/CD	root||ROOT-0/null||attributes-36/NNS	nsubj||affect-39/VB||attributes-36/NNS	aux||affect-39/VB||may-38/MD	rcmod||attributes-36/NNS||affect-39/VB	dobj||affect-39/VB||caregiving-40/NN	aids--1||hiv-28||no||in the face of the hiv/aids epidemic that has contributed to the dramatic increase in orphans and abandoned children (oac) worldwide, caregiver attitudes about hiv, and hiv-related stigma, are two attributes that may affect caregiving.
num||2005-4/CD||2002-2/CD	dep||2005-4/CD||to-3/TO	prep_from||identified-9/VBD||2005-4/CD	num||reviews-8/NNS||two-6/CD	nn||reviews-8/NNS||literature-7/NN	appos||2005-4/CD||reviews-8/NNS	root||ROOT-0/null||identified-9/VBD	det||number-11/NN||a-10/DT	dobj||identified-9/VBD||number-11/NN	nsubj||appeared-16/VBD||number-11/NN	nsubj||neglected-20/JJ||number-11/NN	amod||issues-14/NNS||reproductive-health-13/JJ	prep_of||number-11/NN||issues-14/NNS	rcmod||number-11/NN||appeared-16/VBD	aux||neglected-20/JJ||to-17/TO	cop||neglected-20/JJ||be-18/VB	advmod||neglected-20/JJ||relatively-19/RB	xcomp||appeared-16/VBD||neglected-20/JJ	prep_in||neglected-20/JJ||relation-22/NN	amod||information-26/NN||hiv/aids-24/JJ	amod||information-26/NN||contraceptive-25/JJ	prep_to||neglected-20/JJ||information-26/NN	vmod||information-26/NN||tailored-27/VBN	det||needs-30/NNS||the-29/DT	prep_to||tailored-27/VBN||needs-30/NNS	amod||people-33/NNS||hiv-positive-32/JJ	prep_of||needs-30/NNS||people-33/NNS	amod||hiv-36/NN||voluntary-35/JJ	dobj||identified-9/VBD||hiv-36/NN	conj_and||number-11/NN||hiv-36/NN	nsubj||appeared-16/VBD||hiv-36/NN	nsubj||neglected-20/JJ||hiv-36/NN	vmod||hiv-36/NN||counselling-37/VBG	vmod||hiv-36/NN||testing-39/VBG	conj_and||counselling-37/VBG||testing-39/VBG	amod||care-42/NN||antenatal-41/JJ	prep_during||counselling-37/VBG||care-42/NN	prep_during||counselling-37/VBG||labour-44/NN	conj_and||care-42/NN||labour-44/NN	prep_during||counselling-37/VBG||delivery-47/NN	conj_and||care-42/NN||delivery-47/NN	nn||options-50/NNS||parenting-49/NN	dobj||identified-9/VBD||options-50/NNS	conj_and||number-11/NN||options-50/NNS	nsubj||appeared-16/VBD||options-50/NNS	nsubj||neglected-20/JJ||options-50/NNS	amod||people-53/NNS||hiv-positive-52/JJ	prep_for||options-50/NNS||people-53/NNS	dep||conception-62/NN||pregnancy-55/NNP	amod||-lrb--59/NNS||unprotected-57/JJ	nn||-lrb--59/NNS||intercourse-58/NN	prep_through||pregnancy-55/NNP||-lrb--59/NNS	advmod||assisted-61/VBN||i.e.-60/RB	amod||conception-62/NN||assisted-61/VBN	prep_besides||people-53/NNS||conception-62/NN	amod||adoption-65/NN||legal-64/JJ	dobj||identified-9/VBD||adoption-65/NN	conj_and||number-11/NN||adoption-65/NN	nsubj||appeared-16/VBD||adoption-65/NN	nsubj||neglected-20/JJ||adoption-65/NN	amod||care-68/NN||foster-67/JJ	conj_and||number-11/NN||care-68/NN	conj_or||adoption-65/NN||care-68/NN	nsubj||identified-9/VBD||-rrb--69/NNP	amod||pregnancy-72/NN||unwanted-71/JJ	nsubj||identified-9/VBD||pregnancy-72/NN	conj_and||-rrb--69/NNP||pregnancy-72/NN	amod||care-76/NN||abortion-related-75/JJ	nsubj||identified-9/VBD||care-76/NN	conj_and||-rrb--69/NNP||care-76/NN	aids--1||hiv-36||no||from 2002 to 2005 , two literature reviews identified a number of reproductive-health issues that appeared to be relatively neglected in relation to hiv/aids contraceptive information tailored to the needs of hiv-positive people ; voluntary hiv counselling and testing during antenatal care , labour , and delivery ; parenting options for hiv-positive people besides pregnancy through unprotected intercourse -lrb- i.e. assisted conception and legal adoption or foster care -rrb- ; unwanted pregnancy ; and abortion-related care .
amod||reads-3/NN||suspected-1/VBN	amod||reads-3/NN||bacterial-2/JJ	nsubj||low-14/JJ||reads-3/NN	prep_such_as||reads-3/NN||streptococcuspneumoniae-6/NN	amod||flora-11/NNS||other-8/JJ	amod||flora-11/NNS||oral-9/JJ	nn||flora-11/NNS||bacteria-10/NNS	prep_such_as||reads-3/NN||flora-11/NNS	conj_and||streptococcuspneumoniae-6/NN||flora-11/NNS	cop||low-14/JJ||were-12/VBD	advmod||low-14/JJ||very-13/RB	root||ROOT-0/null||low-14/JJ	num||%-17/NN||0.005-16/CD	prep_at||low-14/JJ||%-17/NN	det||bacterialinfection-22/NN||a-20/DT	amod||bacterialinfection-22/NN||significant-21/JJ	nsubj||observed-26/JJ||bacterialinfection-22/NN	cop||observed-26/JJ||was-23/VBD	neg||observed-26/JJ||not-24/RB	advmod||observed-26/JJ||histologically-25/RB	conj_and||low-14/JJ||observed-26/JJ	bacterialinfection-22||bacteria-10||no||suspected bacterial reads such as streptococcuspneumoniae and other oral bacteria flora were very low at 0.005%, and a significant bacterialinfection was not histologically observed.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||trial-8/NN||an-3/DT	amod||trial-8/NN||open-4/JJ	amod||trial-8/NN||randomized-6/JJ	amod||trial-8/NN||clinical-7/JJ	dobj||conducted-2/VBD||trial-8/NN	amod||dihydroartemisinin-piperaquine-11/NN||oral-10/JJ	prep_of||trial-8/NN||dihydroartemisinin-piperaquine-11/NN	appos||dihydroartemisinin-piperaquine-11/NN||dp-13/NN	prep_versus||dihydroartemisinin-piperaquine-11/NN||artesunate-mefloquine-16/NN	dep||dihydroartemisinin-piperaquine-11/NN||am-18/VBP	num||patients-22/NNS||300-21/CD	prep_in||conducted-2/VBD||patients-22/NNS	prep_in||patients-22/NNS||laos-24/NNS	amod||plasmodiumfalciparummalaria-27/NN||uncomplicated-26/JJ	prep_with||laos-24/NNS||plasmodiumfalciparummalaria-27/NN	prep_as||conducted-2/VBD||part-29/NN	det||study-33/NN||a-31/DT	amod||study-33/NN||multicentre-32/JJ	prep_of||part-29/NN||study-33/NN	prep_in||study-33/NN||asia-35/NN	plasmodiumfalciparummalaria-27||mefloquine--1||yes||we conducted an open, randomized clinical trial of oral dihydroartemisinin-piperaquine (dp) versus artesunate-mefloquine (am) in 300 patients in laos with uncomplicated plasmodiumfalciparummalaria as part of a multicentre study in asia.
det||ulcer-2/NN||the-1/DT	nsubj||improved-3/VBD||ulcer-2/NN	root||ROOT-0/null||improved-3/VBD	advmod||slightly-5/RB||only-4/RB	dobj||improved-3/VBD||slightly-5/RB	num||months-8/NNS||2-7/CD	prep_after||improved-3/VBD||months-8/NNS	amod||ointment-12/NN||povidone-iodine-10/JJ	nn||ointment-12/NN||sugar-11/NN	prep_with||improved-3/VBD||ointment-12/NN	amod||nausea-16/NN||severe-15/JJ	prep_because_of||ointment-12/NN||nausea-16/NN	prep_because_of||ointment-12/NN||anorexia-18/NN	conj_and||nausea-16/NN||anorexia-18/NN	sugar-11||ulcer-2||no_rel||the ulcer improved only slightly after 2 months with povidone-iodine sugar ointment because of severe nausea and anorexia.
nsubj||is-9/VBZ||epratuzumab-1/NN	det||antibody-7/NN||a-3/DT	amod||antibody-7/NN||humanized-4/JJ	amod||antibody-7/NN||anti-cd22-5/JJ	nn||antibody-7/NN||monoclonal-6/NN	appos||epratuzumab-1/NN||antibody-7/NN	root||ROOT-0/null||is-9/VBZ	prep_under||is-9/VBZ||investigation-11/NN	det||antibody-15/NN||a-13/DT	amod||antibody-15/NN||therapeutic-14/JJ	prep_as||investigation-11/NN||antibody-15/NN	poss||lymphoma-19/NNS||non-hodgkin-17/NN	prep_in||antibody-15/NN||lymphoma-19/NNS	prep_in||antibody-15/NN||systemiclupuserythematosus-21/NNS	conj_and||lymphoma-19/NNS||systemiclupuserythematosus-21/NNS	appos||lymphoma-19/NNS||sle-23/NN	poss||mechanism-28/NN||its-27/PRP$	nsubj||remains-33/VBZ||mechanism-28/NN	prep_of||mechanism-28/NN||action-30/NN	prep_on||action-30/NN||b-cells-32/NNS	conj_but||is-9/VBZ||remains-33/VBZ	acomp||remains-33/VBZ||elusive-34/JJ	systemiclupuserythematosus-21||antibody-15||no_rel||epratuzumab, a humanized anti-cd22 monoclonal antibody, is under investigation as a therapeutic antibody in non-hodgkin's lymphoma and systemiclupuserythematosus (sle), but its mechanism of action on b-cells remains elusive.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||male-5/NN||a-3/DT	amod||male-5/NN||37-year-old-4/JJ	dobj||report-2/VBP||male-5/NN	prep_with||report-2/VBP||hivinfection-7/NN	nsubj||developed-9/VBD||hivinfection-7/NN	nsubj||recovered-17/VBD||hivinfection-7/NN	rcmod||hivinfection-7/NN||developed-9/VBD	dobj||developed-9/VBD||prca-10/NN	num||weeks-12/NNS||6-11/CD	npadvmod||developed-9/VBD||weeks-12/NNS	prepc_after||developed-9/VBD||commencing-14/VBG	dobj||commencing-14/VBG||zidovudine-15/NN	rcmod||hivinfection-7/NN||recovered-17/VBD	conj_and||developed-9/VBD||recovered-17/VBD	amod||cessation-19/NN||following-18/JJ	dobj||recovered-17/VBD||cessation-19/NN	det||drug-22/NN||the-21/DT	prep_of||cessation-19/NN||drug-22/NN	hivinfection-7||zidovudine-15||yes||we report a 37-year-old male with hivinfection who developed prca 6 weeks after commencing zidovudine and recovered following cessation of the drug.
nsubj||mitigate-3/VB||treatments-1/NNS	nsubj||cancer-27/NN||treatments-1/NNS	rcmod||treatments-1/NNS||mitigate-3/VB	det||risk-5/NN||the-4/DT	dobj||mitigate-3/VB||risk-5/NN	amod||metastases-9/NNS||early-7/JJ	amod||metastases-9/NNS||distant-8/JJ	prep_of||risk-5/NN||metastases-9/NNS	appos||treatments-1/NNS||dm-11/NN	cop||cancer-27/NN||are-13/VBP	advmod||cancer-27/NN||therefore-15/RB	amod||cancer-27/NN||likely-17/JJ	aux||improve-19/VB||to-18/TO	xcomp||likely-17/JJ||improve-19/VB	amod||survival-21/NN||overall-20/JJ	dobj||improve-19/VB||survival-21/NN	prep_in||improve-19/VB||women-23/NNS	amod||breast-26/NN||early-25/JJ	prep_with||women-23/NNS||breast-26/NN	root||ROOT-0/null||cancer-27/NN	appos||cancer-27/NN||ebc-29/NN	cancer-27||dm-11||no_rel||treatments that mitigate the risk of early distant metastases (dm) are, therefore, likely to improve overall survival in women with early breast cancer (ebc).
amod||patients-3/NNS||hiv-1/JJ	amod||patients-3/NNS||infected-2/JJ	nsubj||have-4/VBP||patients-3/NNS	root||ROOT-0/null||have-4/VBP	det||susceptibility-7/NN||an-5/DT	amod||susceptibility-7/NN||increased-6/JJ	dobj||have-4/VBP||susceptibility-7/NN	aux||liverdisease-9/VB||to-8/TO	vmod||susceptibility-7/NN||liverdisease-9/VB	acomp||liverdisease-9/VB||due-10/JJ	prep_to||due-10/JJ||hepatitisbvirus-12/NNS	appos||hepatitisbvirus-12/NNS||hbv-14/NN	amod||virus-18/NN||hepatitisc-17/JJ	prep_to||due-10/JJ||virus-18/NN	conj_and||hepatitisbvirus-12/NNS||virus-18/NN	appos||virus-18/NN||hcv-20/NN	prep_to||due-10/JJ||alcoholic-23/JJ	conj_and||hepatitisbvirus-12/NNS||alcoholic-23/JJ	amod||steatohepatitis-27/NNS||non-alcoholic-26/JJ	prep_to||due-10/JJ||steatohepatitis-27/NNS	conj_and||hepatitisbvirus-12/NNS||steatohepatitis-27/NNS	hbv-14||hepatitisbvirus-12||no||hiv infected patients have an increased susceptibility to liverdisease due to hepatitisbvirus (hbv), hepatitisc virus (hcv), alcoholic, and non-alcoholic steatohepatitis.
amod||patients-3/NNS||chinese-2/JJ	prep_in||predicts-8/VBZ||patients-3/NNS	prep_with||patients-3/NNS||type2diabetes-5/CD	nsubj||predicts-8/VBZ||hyperglycemia-7/NN	root||ROOT-0/null||predicts-8/VBZ	dobj||predicts-8/VBZ||cancer-9/NN	mark||associated-15/VBN||whereas-11/IN	nn||usage-13/NN||insulin-12/NN	nsubjpass||associated-15/VBN||usage-13/NN	auxpass||associated-15/VBN||was-14/VBD	advcl||predicts-8/VBZ||associated-15/VBN	det||risk-20/NN||a-17/DT	amod||risk-20/NN||reduced-18/VBN	nn||risk-20/NN||cancer-19/NN	prep_with||associated-15/VBN||risk-20/NN	cancer-19||insulin-12||no_rel||in chinese patients with type2diabetes, hyperglycemia predicts cancer, whereas insulin usage was associated with a reduced cancer risk.
nsubj||common-10/JJ||co-infection-1/NN	amod||hcv-5/NN||hepatitisc-3/JJ	prep_with||co-infection-1/NN||hcv-5/NN	prep_with||co-infection-1/NN||hiv-8/NN	conj_and||hcv-5/NN||hiv-8/NN	cop||common-10/JJ||is-9/VBZ	root||ROOT-0/null||common-10/JJ	nsubj||accelerates-13/VBZ||hiv-12/NN	conj_and||common-10/JJ||accelerates-13/VBZ	amod||progression-16/NN||hepatic-14/JJ	nn||progression-16/NN||disease-15/NN	nsubj||due-17/JJ||progression-16/NN	xcomp||accelerates-13/VBZ||due-17/JJ	prep_to||due-17/JJ||hcv-19/NN	hepatitisc-3||hcv-19||no||co-infection with hepatitisc (hcv) and hiv is common and hiv accelerates hepatic disease progression due to hcv.
det||emergence-3/NN||the-1/DT	amod||emergence-3/NN||recent-2/JJ	nsubj||raised-16/VBD||emergence-3/NN	nsubj||resembles-36/VBZ||emergence-3/NN	det||coronavirus-8/NNS||a-5/DT	amod||coronavirus-8/NNS||novel-6/JJ	amod||coronavirus-8/NNS||human-7/JJ	prep_of||emergence-3/NN||coronavirus-8/NNS	dep||emergence-3/NN||hcov-emc-10/JJ	det||middle-14/NN||the-13/DT	prep_in||emergence-3/NN||middle-14/NN	advmod||raised-16/VBD||east-15/RB	root||ROOT-0/null||raised-16/VBD	amod||concerns-18/NNS||considerable-17/JJ	dobj||raised-16/VBD||concerns-18/NNS	mark||associated-23/VBN||as-20/IN	nsubjpass||associated-23/VBN||it-21/PRP	auxpass||associated-23/VBN||is-22/VBZ	advcl||raised-16/VBD||associated-23/VBN	amod||pneumonia-27/NN||severe-25/JJ	amod||pneumonia-27/NN||acute-26/JJ	prep_with||associated-23/VBN||pneumonia-27/NN	prep_with||associated-23/VBN||renalfailure-29/NN	conj_and||pneumonia-27/NN||renalfailure-29/NN	amod||outcome-33/NN||fatal-32/JJ	prep_with||associated-23/VBN||outcome-33/NN	conj_and||pneumonia-27/NN||outcome-33/NN	advmod||resembles-36/VBZ||thus-35/RB	conj_and||raised-16/VBD||resembles-36/VBZ	det||presentation-39/NN||the-37/DT	amod||presentation-39/NN||clinical-38/JJ	xcomp||resembles-36/VBZ||presentation-39/NN	amod||sars-43/NNS||severeacuterespiratorysyndrome-41/JJ	prep_of||presentation-39/NN||sars-43/NNS	vmod||sars-43/NNS||observed-45/VBN	prep_in||observed-45/VBN||2002-47/CD	prep_in||observed-45/VBN||2003-49/CD	conj_and||2002-47/CD||2003-49/CD	sars-43||coronavirus-8||no||the recent emergence of a novel human coronavirus (hcov-emc) in the middle east raised considerable concerns, as it is associated with severe acute pneumonia, renalfailure, and fatal outcome and thus resembles the clinical presentation of severeacuterespiratorysyndrome (sars) observed in 2002 and 2003.
nsubjpass||collected-12/VBN||samples-1/NNS	nsubj||provide-17/VBP||samples-1/NNS	prepc_of||samples-1/NNS||drinking-3/VBG	dobj||drinking-3/VBG||water-4/NN	nn||cages-7/NNS||poultry-6/NN	prep_from||drinking-3/VBG||cages-7/NNS	aux||collected-12/VBN||can-10/MD	auxpass||collected-12/VBN||be-11/VB	rcmod||samples-1/NNS||collected-12/VBN	xcomp||collected-12/VBN||conveniently-13/JJ	xcomp||collected-12/VBN||noninvasively-15/JJ	conj_and||conveniently-13/JJ||noninvasively-15/JJ	root||ROOT-0/null||provide-17/VBP	amod||rates-19/NNS||higher-18/JJR	dobj||provide-17/VBP||rates-19/NNS	nn||virusisolation-25/NN||influenza-21/NNP	appos||virusisolation-25/NN||h9n2-23/NNP	prep_of||rates-19/NNS||virusisolation-25/NN	mark||do-27/VBP||than-26/IN	advcl||provide-17/VBP||do-27/VBP	dobj||do-27/VBP||samples-28/NNS	amod||droppings-31/NNS||fecal-30/JJ	prep_of||samples-28/NNS||droppings-31/NNS	influenza-21||virusisolation-25||no_rel||samples of drinking water from poultry cages, which can be collected conveniently and noninvasively, provide higher rates of influenza (h9n2) virusisolation than do samples of fecal droppings.
nsubj||including-4/VBG||indexes-1/NNS	prep_of||indexes-1/NNS||inflammation-3/NN	root||ROOT-0/null||including-4/VBG	amod||factor-îºb-6/NN||nuclear-5/JJ	nsubj||binding-10/JJ||factor-îºb-6/NN	appos||factor-îºb-6/NN||nf-îºb-8/NNP	xcomp||including-4/VBG||binding-10/JJ	det||expression-14/NN||the-13/DT	nsubj||increased-38/VBN||expression-14/NN	prep_of||expression-14/NN||socs3-16/CD	nsubj||necrosis-19/VBZ||tumor-18/NN	parataxis||increased-38/VBN||necrosis-19/VBZ	nn||±-21/NNP||factor-î-20/NNP	dobj||necrosis-19/VBZ||±-21/NNP	nn||±-24/NNP||tnf-î-23/NNP	appos||±-21/NNP||±-24/NNP	dobj||necrosis-19/VBZ||interleukin-28/NN	conj_and||±-21/NNP||interleukin-28/NN	appos||interleukin-28/NN||il-30/NN	num||²-34/NNS||-1-32/CD	nn||²-34/NNS||î-33/NN	dep||±-21/NNP||²-34/NNS	prep_in||²-34/NNS||mncs-36/NNS	conj_and||including-4/VBG||increased-38/VBN	advmod||increased-38/VBN||significantly-39/RB	nn||intake-44/NN||glucose-41/NN	conj_and||glucose-41/NN||cream-43/NN	nn||intake-44/NN||cream-43/NN	prep_after||increased-38/VBN||intake-44/NN	amod||expression-48/NN||tlr-4-47/JJ	nsubj||increased-53/VBD||expression-48/NN	nn||concentrations-52/NNS||plasma-50/NN	nn||concentrations-52/NNS||lps-51/NN	conj_and||expression-48/NN||concentrations-52/NNS	nsubj||increased-53/VBD||concentrations-52/NNS	conj_but||including-4/VBG||increased-53/VBD	advmod||increased-53/VBD||only-54/RB	nn||intake-57/NN||cream-56/NN	prep_after||increased-53/VBD||intake-57/NN	inflammation-3||glucose-41||no_rel||indexes of inflammation including nuclear factor-îºb (nf-îºb) binding, and the expression of socs3, tumor necrosis factor-î± (tnf-î±), and interleukin (il)-1î² in mncs, increased significantly after glucose and cream intake, but tlr-4 expression and plasma lps concentrations increased only after cream intake.
nsubj||have-12/VBP||fluticasone/salmeterol-1/NN	conj_and||fluticasone/salmeterol-1/NN||budesonide/formoterol-3/NN	nsubj||have-12/VBP||budesonide/formoterol-3/NN	det||products-10/NNS||the-5/DT	advmod||available-7/JJ||currently-6/RB	amod||products-10/NNS||available-7/JJ	nn||products-10/NNS||ics/laba-8/NN	nn||products-10/NNS||combination-9/NN	appos||fluticasone/salmeterol-1/NN||products-10/NNS	root||ROOT-0/null||have-12/VBP	amod||efficacy-14/NN||similar-13/JJ	dobj||have-12/VBP||efficacy-14/NN	dobj||have-12/VBP||tolerability-16/NN	conj_and||efficacy-14/NN||tolerability-16/NN	prepc_based_on||have-12/VBP||on-18/IN	det||meta-analysis-21/NNS||a-19/DT	amod||meta-analysis-21/NNS||recent-20/JJ	pobj||have-12/VBP||meta-analysis-21/NNS	nn||trials-24/NNS||asthma-23/NN	prep_of||meta-analysis-21/NNS||trials-24/NNS	asthma-23||fluticasone--1||yes||fluticasone/salmeterol and budesonide/formoterol, the currently available ics/laba combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials.
det||findings-2/NNS||these-1/DT	nsubj||relevant-4/JJ||findings-2/NNS	nsubj||smallpox-14/VB||findings-2/NNS	nsubj||emergent-16/VB||findings-2/NNS	cop||relevant-4/JJ||are-3/VBP	root||ROOT-0/null||relevant-4/JJ	det||design-7/NN||the-6/DT	prep_for||relevant-4/JJ||design-7/NN	amod||vaccines-10/NNS||new-9/JJ	prep_of||design-7/NN||vaccines-10/NNS	prep_of||design-7/NN||therapeutics-12/NNS	conj_and||vaccines-10/NNS||therapeutics-12/NNS	aux||smallpox-14/VB||to-13/TO	xcomp||relevant-4/JJ||smallpox-14/VB	xcomp||relevant-4/JJ||emergent-16/VB	conj_and||smallpox-14/VB||emergent-16/VB	amod||orthopoxviruses-18/NNS||virulent-17/JJ	dobj||smallpox-14/VB||orthopoxviruses-18/NNS	mark||i-22/VBD||because-19/IN	det||type-21/NN||the-20/DT	nsubj||i-22/VBD||type-21/NN	advcl||smallpox-14/VB||i-22/VBD	amod||protein-24/NN||interferon-binding-23/JJ	nsubj||factor-29/NN||protein-24/NN	cop||factor-29/NN||is-25/VBZ	det||factor-29/NN||a-26/DT	amod||factor-29/NN||major-27/JJ	nn||factor-29/NN||virulence-28/NN	ccomp||i-22/VBD||factor-29/NN	nn||models-32/NNS||animal-31/NN	prep_in||factor-29/NN||models-32/NNS	nsubj||induces-38/VBZ||vaccination-34/NN	det||protein-37/NN||this-36/DT	prep_with||vaccination-34/NN||protein-37/NN	ccomp||relevant-4/JJ||induces-38/VBZ	conj_and||relevant-4/JJ||induces-38/VBZ	amod||immunity-40/NN||protective-39/JJ	dobj||induces-38/VBZ||immunity-40/NN	poss||neutralization-44/NN||its-43/PRP$	nsubj||prevents-45/VBZ||neutralization-44/NN	conj_and||relevant-4/JJ||prevents-45/VBZ	nn||progression-47/NN||disease-46/NN	dobj||prevents-45/VBZ||progression-47/NN	interferon--1||smallpox-14||no_rel||these findings are relevant for the design of new vaccines and therapeutics to smallpox and emergent virulent orthopoxviruses because the type i interferon-binding protein is a major virulence factor in animal models, vaccination with this protein induces protective immunity, and its neutralization prevents disease progression.
nsubj||showed-2/VBD||studies-1/NNS	root||ROOT-0/null||showed-2/VBD	mark||induce-7/VB||that-3/IN	amod||therapy-5/NN||prolonged-4/VBN	nsubj||induce-7/VB||therapy-5/NN	aux||induce-7/VB||could-6/MD	ccomp||showed-2/VBD||induce-7/VB	amod||variants-15/NNS||lamivudine-8/JJ	nn||variants-15/NNS||resistance-9/NN	nn||variants-15/NNS||hepatitisb-10/NN	nn||variants-15/NNS||virus-11/NN	appos||variants-15/NNS||hbv-13/NN	dobj||induce-7/VB||variants-15/NNS	amod||motif-18/NN||ymdd-17/JJ	appos||variants-15/NNS||motif-18/NN	hbv-13||lamivudine-8||yes||studies showed that prolonged therapy could induce lamivudine resistance hepatitisb virus (hbv) variants (ymdd motif).
amod||countries-4/NNS||many-2/JJ	amod||countries-4/NNS||malaria-endemic-3/JJ	prep_in||compromise-10/VB||countries-4/NNS	amod||resistance-7/NN||increasing-6/VBG	nsubj||compromise-10/VB||resistance-7/NN	aux||compromise-10/VB||may-8/MD	advmod||compromise-10/VB||soon-9/RB	root||ROOT-0/null||compromise-10/VB	det||efficacy-12/NN||the-11/DT	dobj||compromise-10/VB||efficacy-12/NN	amod||sp-16/NN||sulphadoxine-pyrimethamine-14/JJ	prep_of||efficacy-12/NN||sp-16/NN	amod||treatment-21/NN||intermittent-19/JJ	amod||treatment-21/NN||preventative-20/JJ	prep_for||sp-16/NN||treatment-21/NN	appos||treatment-21/NN||ipt-23/NN	prep_of||treatment-21/NN||malaria-26/NN	prep_in||compromise-10/VB||pregnancy-28/NN	malaria-26||pyrimethamine--1||no||in many malaria-endemic countries, increasing resistance may soon compromise the efficacy of sulphadoxine-pyrimethamine (sp) for intermittent preventative treatment (ipt) of malaria in pregnancy.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||case-4/NN||a-3/DT	dobj||describe-2/VBP||case-4/NN	amod||hepatitis-8/NN||acute-6/JJ	amod||hepatitis-8/NN||cholestatic-7/JJ	prep_of||case-4/NN||hepatitis-8/NN	det||man-13/NN||a-10/DT	amod||man-13/NN||68-year-old-11/JJ	amod||man-13/NN||caucasian-12/JJ	prep_in||describe-2/VBP||man-13/NN	nsubj||receiving-16/VBG||man-13/NN	aux||receiving-16/VBG||was-15/VBD	rcmod||man-13/NN||receiving-16/VBG	dobj||receiving-16/VBG||olmesartan-17/NN	dobj||receiving-16/VBG||hydrochlorothiazide-19/NN	conj_and||olmesartan-17/NN||hydrochlorothiazide-19/NN	prep_for||olmesartan-17/NN||arterialhypertension-21/NN	arterialhypertension-21||hydrochlorothiazide-19||yes||we describe a case of acute cholestatic hepatitis in a 68-year-old caucasian man who was receiving olmesartan and hydrochlorothiazide for arterialhypertension.
det||effects-2/NNS||the-1/DT	nsubjpass||investigated-28/VBN||effects-2/NNS	det||treatment-6/NN||an-4/DT	amod||treatment-6/NN||analgesic-5/JJ	prep_of||effects-2/NNS||treatment-6/NN	prep_of||effects-2/NNS||treatment-6/NN	conj_and||treatment-6/NN||treatment-6/NN	amod||patches-9/NNS||lidocaine-8/JJ	appos||treatment-6/NN||patches-9/NNS	nn||activity-13/NN||brain-12/NN	prep_on||treatment-6/NN||activity-13/NN	amod||lowbackpain-16/NN||chronic-15/JJ	prep_in||activity-13/NN||lowbackpain-16/NN	appos||lowbackpain-16/NN||cbp-18/NN	nn||osteoarthritis-23/NNS||knee-22/NN	prep_in||treatment-6/NN||osteoarthritis-23/NNS	appos||effects-2/NNS||oa-25/NN	auxpass||investigated-28/VBN||were-27/VBD	root||ROOT-0/null||investigated-28/VBN	xcomp||investigated-28/VBN||using-29/VBG	amod||fmri-31/NNS||serial-30/JJ	dobj||using-29/VBG||fmri-31/NNS	dep||fmri-31/NNS||contrasting-33/VBG	dobj||contrasting-33/VBG||fmri-34/NNS	advmod||weeks-40/NNS||before-36/RB	conj_and||before-36/RB||after-38/IN	advmod||weeks-40/NNS||after-38/IN	pobj||after-38/IN||two-39/CD	prep_between||fmri-34/NNS||weeks-40/NNS	prep_of||fmri-34/NNS||treatment-42/NN	lowbackpain-16||analgesic-5||no_rel||the effects of an analgesic treatment (lidocaine patches) on brain activity in chronic lowbackpain (cbp) and in knee osteoarthritis (oa) were investigated using serial fmri (contrasting fmri between before and after two weeks of treatment).
nsubjpass||proven-4/VBN||sitagliptin-1/NN	nsubj||effective-7/JJ||sitagliptin-1/NN	nsubj||safe-9/JJ||sitagliptin-1/NN	aux||proven-4/VBN||has-2/VBZ	auxpass||proven-4/VBN||been-3/VBN	root||ROOT-0/null||proven-4/VBN	aux||effective-7/JJ||to-5/TO	cop||effective-7/JJ||be-6/VB	xcomp||proven-4/VBN||effective-7/JJ	xcomp||proven-4/VBN||safe-9/JJ	conj_and||effective-7/JJ||safe-9/JJ	prepc_as||effective-7/JJ||add-on-11/VBG	prep_to||add-on-11/VBG||insulin-13/NN	amod||patients-16/NNS||adult-15/JJ	prep_in||insulin-13/NN||patients-16/NNS	prep_with||add-on-11/VBG||type2diabetes-18/NNS	amod||deficiency-22/NN||absolute-20/JJ	nn||deficiency-22/NN||insulin-21/NN	prep_with||add-on-11/VBG||deficiency-22/NN	conj_and||type2diabetes-18/NNS||deficiency-22/NN	type2diabetes-18||insulin-21||yes||sitagliptin has been proven to be effective and safe as add-on to insulin in adult patients with type2diabetes and absolute insulin deficiency.
aux||evaluate-2/VB||to-1/TO	csubj||standardâ-31/VBD||evaluate-2/VB	amod||antibodies-5/NNS||serum-3/JJ	amod||antibodies-5/NNS||anti-c1q-4/JJ	dobj||evaluate-2/VB||antibodies-5/NNS	det||biomarker-8/NN||a-7/DT	prep_as||evaluate-2/VB||biomarker-8/NN	prep_of||biomarker-8/NN||systemiclupuserythematosus-10/NNS	appos||systemiclupuserythematosus-10/NNS||sle-12/NN	amod||systemiclupuserythematosus-10/NNS||flare-14/JJ	amod||systemiclupuserythematosus-10/NNS||as-16/IN	conj_and||flare-14/JJ||as-16/IN	det||alternative-20/NN||a-17/DT	amod||alternative-20/NN||proposed-18/VBN	nn||alternative-20/NN||noninvasive-19/NN	pobj||as-16/IN||alternative-20/NN	nsubj||â-28/NN||alternative-20/NN	amod||biopsy-23/NN||renal-22/JJ	prep_to||alternative-20/NN||biopsy-23/NN	cop||â-28/NN||is-25/VBZ	advmod||â-28/NN||still-26/RB	det||â-28/NN||the-27/DT	rcmod||alternative-20/NN||â-28/NN	amod||â-28/NN||$-29/$	dep||$-29/$||œgold-30/JJ	root||ROOT-0/null||standardâ-31/VBD	dobj||standardâ-31/VBD||$-32/$	dep||determine-34/CD||to-33/TO	num||$-32/$||determine-34/CD	amod||activity-36/NN||renal-35/JJ	npadvmod||standardâ-31/VBD||activity-36/NN	prep_in||standardâ-31/VBD||sle-38/NN	systemiclupuserythematosus-10||gold--1||no||to evaluate serum anti-c1q antibodies as a biomarker of systemiclupuserythematosus (sle) flare and as a proposed noninvasive alternative to renal biopsy which is still the â€œgold standardâ€? to determine renal activity in sle.
nsubjpass||taken-3/VBN||data-1/NNS	auxpass||taken-3/VBN||were-2/VBD	root||ROOT-0/null||taken-3/VBN	det||study-8/NN||the-5/DT	amod||study-8/NN||cologne-6/JJ	nn||study-8/NN||smoking-7/NN	prep_from||taken-3/VBN||study-8/NN	det||study-12/NN||a-10/DT	amod||study-12/NN||case-control-11/JJ	appos||study-8/NN||study-12/NN	nsubj||examines-14/VBZ||study-12/NN	rcmod||study-12/NN||examines-14/VBZ	dobj||lead-18/VBP||which-15/WDT	amod||factors-17/NNS||genetic/psychosocial-16/JJ	nsubj||lead-18/VBP||factors-17/NNS	ccomp||examines-14/VBZ||lead-18/VBP	det||risk-22/NN||a-20/DT	amod||risk-22/NN||higher-21/JJR	prep_to||lead-18/VBP||risk-22/NN	prep_for||risk-22/NN||smokers-24/NNS	aux||suffer-26/VB||to-25/TO	ccomp||lead-18/VBP||suffer-26/VB	prep_from||suffer-26/VB||cardiacinfarction-28/NN	nn||cancer-31/NN||lung-30/NN	appos||cardiacinfarction-28/NN||cancer-31/NN	aux||become-34/VB||to-33/TO	ccomp||lead-18/VBP||become-34/VB	conj_and/or||suffer-26/VB||become-34/VB	acomp||become-34/VB||addicted-35/VBN	prep_to||suffer-26/VB||nicotine-37/NN	cardiacinfarction-28||nicotine-37||no||data were taken from the cologne smoking study, a case-control study that examines which genetic/psychosocial factors lead to a higher risk for smokers to suffer from cardiacinfarction, lung cancer and/or to become addicted to nicotine.
nsubj||lower-15/JJR||results-1/NNS	det||intention-4/NN||an-3/DT	prep_in||results-1/NNS||intention-4/NN	aux||treat-6/VB||to-5/TO	vmod||intention-4/NN||treat-6/VB	dobj||treat-6/VB||analysis-7/NN	det||risk-10/NN||the-9/DT	appos||analysis-7/NN||risk-10/NN	prep_of||risk-10/NN||death-12/NN	cop||lower-15/JJR||was-13/VBD	advmod||lower-15/JJR||significantly-14/RB	root||ROOT-0/null||lower-15/JJR	det||arm-20/NN||the-17/DT	amod||arm-20/NN||titrated-18/JJ	nn||arm-20/NN||oxygen-19/NN	prep_in||lower-15/JJR||arm-20/NN	prepc_compared_with||lower-15/JJR||with-22/IN	det||arm-27/NN||the-23/DT	amod||arm-27/NN||high-24/JJ	nn||arm-27/NN||flow-25/NN	nn||arm-27/NN||oxygen-26/NN	pobj||lower-15/JJR||arm-27/NN	det||patients-30/NNS||all-29/DT	prep_for||arm-27/NN||patients-30/NNS	amod||oxygen-34/NN||high-32/JJ	nn||oxygen-34/NN||flow-33/NN	nsubj||n-35/VBP||oxygen-34/NN	dep||arm-27/NN||n-35/VBP	number||226-37/CD||=-36/CD	dobj||n-35/VBP||226-37/CD	amod||n-41/NN||titrated-39/JJ	nn||n-41/NN||oxygen-40/NN	dep||226-37/CD||n-41/NN	number||179-43/CD||=-42/CD	dep||n-41/NN||179-43/CD	det||subgroup-48/NN||the-47/DT	prep_for||arm-27/NN||subgroup-48/NN	conj_and||patients-30/NNS||subgroup-48/NN	prep_of||subgroup-48/NN||patients-50/NNS	amod||obstructivepulmonarydisease-54/NN||confirmed-52/JJ	amod||obstructivepulmonarydisease-54/NN||chronic-53/JJ	prep_with||patients-50/NNS||obstructivepulmonarydisease-54/NN	amod||n-58/NN||high-56/JJ	nn||n-58/NN||flow-57/NN	nsubj||titrated-62/VBD||n-58/NN	number||117-60/CD||=-59/CD	dep||n-58/NN||117-60/CD	dep||subgroup-48/NN||titrated-62/VBD	nsubj||97-65/CD||n-63/NN	dep||97-65/CD||=-64/SYM	ccomp||titrated-62/VBD||97-65/CD	obstructivepulmonarydisease-54||oxygen-40||yes||results in an intention to treat analysis, the risk of death was significantly lower in the titrated oxygen arm compared with the high flow oxygen arm for all patients (high flow oxygen n=226; titrated oxygen n=179) and for the subgroup of patients with confirmed chronic obstructivepulmonarydisease (high flow n=117; titrated n=97).
csubj||make-9/VBP||emerging-1/VBG	det||mycobacteriumtuberculosis-5/NNS||the-2/DT	amod||resistant-4/JJ||multidrug-3/JJ	amod||mycobacteriumtuberculosis-5/NNS||resistant-4/JJ	dobj||emerging-1/VBG||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||mdr-tb-7/NNP	root||ROOT-0/null||make-9/VBP	dobj||make-9/VBP||us-10/PRP	nsubj||see-12/VB||us-10/PRP	aux||see-12/VB||to-11/TO	xcomp||make-9/VBP||see-12/VB	det||importance-14/NN||the-13/DT	dobj||see-12/VB||importance-14/NN	prep_of||importance-14/NN||vaccination-16/NN	prep_against||see-12/VB||tb-18/NN	amod||light-21/NN||new-20/JJ	prep_in||tb-18/NN||light-21/NN	tb-18||mycobacteriumtuberculosis-5||no||emerging the multidrug resistant mycobacteriumtuberculosis (mdr-tb) make us to see the importance of vaccination against tb in new light.
advmod||©-2/VBG||â-1/RB	root||ROOT-0/null||©-2/VBG	num||wiley-5/NN||2010-3/CD	nn||wiley-5/NN||john-4/NN	dobj||©-2/VBG||wiley-5/NN	dobj||©-2/VBG||sons-7/NNS	conj_and||wiley-5/NN||sons-7/NNS	dep||©-2/VBG||a/s-8/VBP	aux||elucidate-10/VB||to-9/TO	xcomp||a/s-8/VBP||elucidate-10/VB	det||mechanisms-12/NNS||the-11/DT	dobj||elucidate-10/VB||mechanisms-12/NNS	amod||bronchialasthma-16/NN||intractable-14/JJ	amod||bronchialasthma-16/NN||pediatric-15/JJ	prep_of||mechanisms-12/NNS||bronchialasthma-16/NN	det||indication-19/NN||the-18/DT	dobj||elucidate-10/VB||indication-19/NN	conj_and||mechanisms-12/NNS||indication-19/NN	amod||erythromycin-22/NN||low-dose-21/JJ	prep_of||indication-19/NN||erythromycin-22/NN	dep||©-2/VBG||em-24/NN	dep||©-2/VBG||therapy-26/NN	det||serum-29/NN||the-28/DT	npadvmod||chemokine-30/JJ||serum-29/NN	amod||levels-31/NNS||chemokine-30/JJ	appos||therapy-26/NN||levels-31/NNS	nsubjpass||treated-56/VBN||levels-31/NNS	cc||evaluated-38/VBN||and-33/CC	det||factor-36/NN||the-34/DT	amod||factor-36/NN||angiogenic-35/JJ	nsubjpass||evaluated-38/VBN||factor-36/NN	auxpass||evaluated-38/VBN||were-37/VBD	dep||levels-31/NNS||evaluated-38/VBN	num||patients-42/NNS||55-40/CD	amod||patients-42/NNS||pediatric-41/JJ	prep_in||evaluated-38/VBN||patients-42/NNS	prep_with||patients-42/NNS||bronchialasthma-44/NN	num||â-47/NN||7.4-46/CD	dep||patients-42/NNS||â-47/NN	prep_of||levels-31/NNS||±-48/NNP	num||±-48/NNP||3.5-49/CD	advmod||old-51/JJ||yr-50/RB	amod||levels-31/NNS||old-51/JJ	aux||treated-56/VBN||had-54/VBD	auxpass||treated-56/VBN||been-55/VBN	rcmod||levels-31/NNS||treated-56/VBN	amod||steroid-59/NN||inhaled-58/JJ	prep_with||treated-56/VBN||steroid-59/NN	amod||antagonist-63/NN||leukotriene-61/JJ	nn||antagonist-63/NN||receptor-62/NN	prep_with||treated-56/VBN||antagonist-63/NN	conj_and||steroid-59/NN||antagonist-63/NN	prep_with||treated-56/VBN||theophylline-65/NN	conj_and||steroid-59/NN||theophylline-65/NN	prep_with||treated-56/VBN||others-67/NNS	conj_and||steroid-59/NN||others-67/NNS	mwe||than-70/IN||more-69/JJR	quantmod||a-71/DT||than-70/IN	prep_for||treated-56/VBN||a-71/DT	tmod||treated-56/VBN||year-72/NN	bronchialasthma-44||theophylline-65||yes||â© 2010 john wiley & sons a/s to elucidate the mechanisms of intractable pediatric bronchialasthma and the indication of low-dose erythromycin (em) therapy, the serum chemokine levels of and the angiogenic factor were evaluated in 55 pediatric patients with bronchialasthma; 7.4 â± 3.5 yr old, who had been treated with inhaled steroid, leukotriene receptor antagonist, theophylline and others for more than a year.
amod||death-3/NN||macrophage-1/JJ	nn||death-3/NN||cell-2/NN	nsubj||plays-8/VBZ||death-3/NN	prep_following||death-3/NN||infection-5/NN	prep_with||infection-5/NN||mycobacteriumtuberculosis-7/NNS	root||ROOT-0/null||plays-8/VBZ	det||role-11/NN||a-9/DT	amod||role-11/NN||central-10/JJ	dobj||plays-8/VBZ||role-11/NN	nn||pathogenesis-15/NNS||tuberculosis-13/NNP	nn||pathogenesis-15/NNS||disease-14/NN	prep_in||role-11/NN||pathogenesis-15/NNS	tuberculosis-13||mycobacteriumtuberculosis-7||no||macrophage cell death following infection with mycobacteriumtuberculosis plays a central role in tuberculosis disease pathogenesis.
advmod||propose-20/VBP||moreover-1/RB	prepc_for||propose-20/VBP||influenza-4/VBG	amod||tables-6/NNS||hi-5/JJ	dobj||influenza-4/VBG||tables-6/NNS	nn||effect-10/NN||herd-8/NN	nn||effect-10/NN||immunity-9/NN	prep_with||influenza-4/VBG||effect-10/NN	prep_such_as||influenza-4/VBG||those-14/DT	prep_from||those-14/DT||humaninfluenzaviruses-16/NNS	nsubj||propose-20/VBP||we-19/PRP	root||ROOT-0/null||propose-20/VBP	det||model-23/NN||a-21/DT	amod||model-23/NN||temporal-22/JJ	dobj||propose-20/VBP||model-23/NN	aux||reduce-25/VB||to-24/TO	vmod||model-23/NN||reduce-25/VB	det||bias-29/NN||the-26/DT	amod||bias-29/NN||inherent-27/JJ	amod||bias-29/NN||temporal-28/JJ	dobj||reduce-25/VB||bias-29/NN	amod||tables-32/NNS||hi-31/JJ	prep_of||bias-29/NN||tables-32/NNS	vmod||tables-32/NNS||caused-33/VBN	nn||immunity-36/NN||herd-35/NN	agent||caused-33/VBN||immunity-36/NN	influenza-4||influenzaviruses--1||no||moreover, for influenza hi tables with herd immunity effect (such as those from humaninfluenzaviruses), we propose a temporal model to reduce the inherent temporal bias of hi tables caused by herd immunity.
nn||fdc-2/NN||repaglinide/metformin-1/NN	nsubj||represents-3/VBZ||fdc-2/NN	root||ROOT-0/null||represents-3/VBZ	det||option-6/NN||a-4/DT	amod||option-6/NN||new-5/JJ	dobj||represents-3/VBZ||option-6/NN	det||pursuit-9/NN||the-8/DT	prep_in||option-6/NN||pursuit-9/NN	prepc_of||pursuit-9/NN||achieving-11/VBG	nn||targets-13/NNS||glucose-12/NN	dobj||achieving-11/VBG||targets-13/NNS	prepc_of||pursuit-9/NN||reducing-15/VBG	conj_and||achieving-11/VBG||reducing-15/VBG	nn||risk-17/NN||vascular-16/NN	dobj||reducing-15/VBG||risk-17/NN	prep_in||risk-17/NN||type2diabetes-19/CD	det||advantage-23/NN||the-22/DT	prep_with||reducing-15/VBG||advantage-23/NN	prepc_of||advantage-23/NN||improving-25/VBG	dobj||improving-25/VBG||adherence-26/NN	type2diabetes-19||repaglinide--1||yes||repaglinide/metformin fdc represents a new option in the pursuit of achieving glucose targets and reducing vascular risk in type2diabetes, with the advantage of improving adherence.
prep||critical-42/JJ||given-1/VBN	det||role-4/NN||the-2/DT	amod||role-4/NN||significant-3/JJ	pobj||given-1/VBN||role-4/NN	prep_of||role-4/NN||dcs-6/NN	advmod||orchestrating-9/VBG||in-7/IN	advmod||in-7/IN||efficiently-8/RB	vmod||dcs-6/NN||orchestrating-9/VBG	amod||responses-12/NNS||intestinal-10/JJ	amod||responses-12/NNS||immune-11/JJ	dobj||orchestrating-9/VBG||responses-12/NNS	nsubj||critical-42/JJ||characterization-14/NN	det||signals-17/NNS||the-16/DT	prep_of||characterization-14/NN||signals-17/NNS	vmod||signals-17/NNS||induced-18/VBN	det||cells-21/NNS||these-20/DT	prep_within||induced-18/VBN||cells-21/NNS	det||molecules-26/NNS||the-23/DT	nn||molecules-26/NNS||surface-24/NN	nn||molecules-26/NNS||layer-25/NN	agent||induced-18/VBN||molecules-26/NNS	amod||-rrb--34/NNS||lipoteichoic-30/JJ	amod||-rrb--34/NNS||acid-31/JJ	amod||-rrb--34/NNS||-lrb--32/JJ	nn||-rrb--34/NNS||lta-33/NN	prep_such_as||signals-17/NNS||-rrb--34/NNS	prep_such_as||signals-17/NNS||proteins-37/NNS	conj_and||-rrb--34/NNS||proteins-37/NNS	nn||acidophilus-40/NNS||l.-39/NN	prep_of||proteins-37/NNS||acidophilus-40/NNS	cop||critical-42/JJ||is-41/VBZ	root||ROOT-0/null||critical-42/JJ	amod||treatment-45/NN||future-44/JJ	prep_for||critical-42/JJ||treatment-45/NN	prep_for||critical-42/JJ||prevention-47/NN	conj_and||treatment-45/NN||prevention-47/NN	prep_of||treatment-45/NN||gastrointestinaldiseases-49/NNS	acidophilus-40||gastrointestinaldiseases-49||no_rel||given the significant role of dcs in efficiently orchestrating intestinal immune responses , characterization of the signals induced within these cells by the surface layer molecules , such as lipoteichoic acid -lrb- lta -rrb- , and proteins of l. acidophilus is critical for future treatment and prevention of gastrointestinaldiseases .
prep_in||deregulated-7/VBG||fact-2/NN	nn||transporters-5/NNS||sugar-4/NN	nsubj||deregulated-7/VBG||transporters-5/NNS	aux||deregulated-7/VBG||are-6/VBP	root||ROOT-0/null||deregulated-7/VBG	nn||cells-10/NNS||cancer-9/NN	prep_in||deregulated-7/VBG||cells-10/NNS	mark||incorporate-13/VB||so-11/IN	nsubj||incorporate-13/VB||they-12/PRP	advcl||deregulated-7/VBG||incorporate-13/VB	amod||amounts-15/NNS||higher-14/JJR	dobj||incorporate-13/VB||amounts-15/NNS	prep_of||amounts-15/NNS||sugar-17/NN	amod||cells-20/NNS||normal-19/JJ	prep_than||incorporate-13/VB||cells-20/NNS	cancer-9||sugar-17||no_rel||in fact, sugar transporters are deregulated in cancer cells so they incorporate higher amounts of sugar than normal cells.
det||study-3/NN||this-2/DT	prep_in||investigated-7/VBN||study-3/NN	nsubj||investigated-7/VBN||we-5/PRP	aux||investigated-7/VBN||have-6/VBP	root||ROOT-0/null||investigated-7/VBN	det||presence-9/NN||the-8/DT	dobj||investigated-7/VBN||presence-9/NN	dobj||investigated-7/VBN||variability-11/NN	conj_and||presence-9/NN||variability-11/NN	nn||number-14/NN||copy-13/NN	prep_in||presence-9/NN||number-14/NN	amod||sequences-19/NNS||intragenic-16/JJ	amod||sequences-19/NNS||tandemly-17/JJ	amod||sequences-19/NNS||repeated-18/VBN	prep_of||number-14/NN||sequences-19/NNS	det||genome-22/NN||the-21/DT	prep_in||sequences-19/NNS||genome-22/NN	prep_of||genome-22/NN||legionellapneumophila-24/NN	det||agent-28/NN||the-26/DT	amod||agent-28/NN||etiological-27/JJ	appos||legionellapneumophila-24/NN||agent-28/NN	det||pneumonia-32/NN||a-30/DT	amod||pneumonia-32/NN||severe-31/JJ	prep_of||agent-28/NN||pneumonia-32/NN	vmod||pneumonia-32/NN||known-33/VBN	prep_as||known-33/VBN||legionnaires-35/NNS	dep||legionnaires-35/NNS||disease-37/NN	legionnaires'disease--1||legionellapneumophila-24||no||in this study, we have investigated the presence and variability in copy number of intragenic tandemly repeated sequences in the genome of legionellapneumophila , the etiological agent of a severe pneumonia known as legionnaires'disease.
nsubj||seen-7/VBN||management-1/NN	prep_of||management-1/NN||children-3/NNS	prep_with||children-3/NNS||type1diabetes-5/CD	aux||seen-7/VBN||has-6/VBZ	root||ROOT-0/null||seen-7/VBN	det||shift-9/NN||a-8/DT	dobj||seen-7/VBN||shift-9/NN	prep_in||seen-7/VBN||favor-11/NN	prepc_of||favor-11/NN||mimicking-13/VBG	amod||responses-17/NNS||normal-14/JJ	amod||responses-17/NNS||physiological-15/JJ	nn||responses-17/NNS||insulin-16/NN	dobj||mimicking-13/VBG||responses-17/NNS	amod||infusions-26/NNS||multiple-19/JJ	amod||infusions-26/NNS||daily-20/JJ	nn||infusions-26/NNS||injections-21/NNS	conj_or||injections-21/NNS||continuous-23/JJ	nn||infusions-26/NNS||continuous-23/JJ	amod||infusions-26/NNS||subcutaneous-24/JJ	nn||infusions-26/NNS||insulin-25/NN	prep_with||mimicking-13/VBG||infusions-26/NNS	appos||infusions-26/NNS||csii-28/NNP	type1diabetes-5||insulin-25||yes||management of children with type1diabetes has seen a shift in favor of mimicking normal physiological insulin responses with multiple daily injections or continuous subcutaneous insulin infusions (csii).
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||patients-2/NNS||all-1/DT	nsubjpass||treated-4/VBN||patients-2/NNS	auxpass||treated-4/VBN||were-3/VBD	root||ROOT-0/null||treated-4/VBN	amod||debridement-7/NN||surgical-6/JJ	agent||treated-4/VBN||debridement-7/NN	vmod||debridement-7/NN||followed-8/VBN	det||combination-11/NN||a-10/DT	agent||followed-8/VBN||combination-11/NN	nsubj||died-31/VBD||combination-11/NN	prep_of||combination-11/NN||antibiotics-13/NNS	dep||combination-11/NN||ceftazidime-16/NN	appos||ceftazidime-16/NN||amoxy-clavulanicacid-18/NN	appos||ceftazidime-16/NN||co-trimoxazole-20/NN	conj_and||amoxy-clavulanicacid-18/NN||co-trimoxazole-20/NN	appos||ceftazidime-16/NN||doxycycline-22/NN	conj_and||amoxy-clavulanicacid-18/NN||doxycycline-22/NN	num||months-26/NNS||six-25/CD	prep_for||ceftazidime-16/NN||months-26/NNS	prepc_except_for||months-26/NNS||for-28/IN	pobj||months-26/NNS||one-29/CD	rcmod||combination-11/NN||died-31/VBD	acomp||died-31/VBD||due-32/JJ	aux||fulminant-34/VB||to-33/TO	xcomp||due-32/JJ||fulminant-34/VB	dobj||fulminant-34/VB||septicemia-35/NN	septicemia-35||antibiotics-13||no_rel||all patients were treated by surgical debridement followed by a combination of antibiotics; (ceftazidime, amoxy-clavulanicacid, co-trimoxazole and doxycycline) for six months except for one who died due to fulminant septicemia.
nsubj||exhibited-8/VBD||voreloxin-1/NN	conj_and||voreloxin-1/NN||cytarabine-3/NN	nsubj||exhibited-8/VBD||cytarabine-3/NN	advmod||voreloxin-1/NN||alone-4/RB	advmod||voreloxin-1/NN||in-6/IN	conj_and||alone-4/RB||in-6/IN	pobj||in-6/IN||combination-7/NN	root||ROOT-0/null||exhibited-8/VBD	amod||activity-10/NN||cytotoxic-9/JJ	dobj||exhibited-8/VBD||activity-10/NN	amod||lines-15/NNS||human-12/JJ	nn||lines-15/NNS||leukemia-13/NN	nn||lines-15/NNS||cell-14/NN	prep_in||exhibited-8/VBD||lines-15/NNS	prep_in||exhibited-8/VBD||vivo-18/NN	conj_and||lines-15/NNS||vivo-18/NN	leukemia-13||cytarabine-3||yes||voreloxin and cytarabine alone and in combination exhibited cytotoxic activity in human leukemia cell lines and in vivo.
amod||feâˆ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâˆ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâˆ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâˆ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	irondeficiency-40||fe--1||yes||defective feâˆ’s cluster synthesis not only affects activities of many ironâˆ’sulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	cancer-14||tamoxifen-25||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
aux||extend-2/VB||to-1/TO	root||ROOT-0/null||extend-2/VB	det||association-6/NN||the-3/DT	advmod||identified-5/VBN||previously-4/RB	amod||association-6/NN||identified-5/VBN	dobj||extend-2/VB||association-6/NN	det||polymorphism-11/NN||a-8/DT	amod||polymorphism-11/NN||single-9/JJ	nn||polymorphism-11/NN||nucleotide-10/NN	prep_between||association-6/NN||polymorphism-11/NN	appos||polymorphism-11/NN||snp-13/NN	amod||receptor-18/NN||neuronal-16/JJ	nn||receptor-18/NN||acetylcholine-17/NN	prep_in||polymorphism-11/NN||receptor-18/NN	amod||alpha-5-20/JJ||subunit-19/JJ	amod||polymorphism-11/NN||alpha-5-20/JJ	appos||polymorphism-11/NN||chrna5-22/NNP	conj_and||extend-2/VB||nicotinedependence-25/VB	amod||smoking-28/NN||current-27/JJ	prep_to||nicotinedependence-25/VB||smoking-28/NN	amod||phenotypes-32/NNS||initial-30/JJ	amod||phenotypes-32/NNS||smoking-experience-31/JJ	prep_to||nicotinedependence-25/VB||phenotypes-32/NNS	conj_and||smoking-28/NN||phenotypes-32/NNS	nicotinedependence-25||acetylcholine-17||no_rel||to extend the previously identified association between a single nucleotide polymorphism (snp) in neuronal acetylcholine receptor subunit alpha-5 (chrna5) and nicotinedependence to current smoking and initial smoking-experience phenotypes.
amod||disease-3/NN||sporadic-1/JJ	amod||disease-3/NN||creutzfeldt-jakob-2/JJ	nsubj||â-7/VBP||disease-3/NN	dep||disease-3/NN||scjd-5/VBN	root||ROOT-0/null||â-7/VBP	dobj||â-7/VBP||$-8/$	num||$-8/$||affected-10/NNS	quantmod||affected-10/NNS||human-11/IN	quantmod||affected-10/NNS||brains-12/JJ	dep||â-7/VBP||show-13/VB	det||increase-16/NN||a-14/DT	amod||increase-16/NN||similar-15/JJ	dobj||show-13/VB||increase-16/NN	amod||iron-19/NN||total-18/JJ	prep_in||increase-16/NN||iron-19/NN	det||correlation-23/NN||a-21/DT	amod||correlation-23/NN||direct-22/JJ	dobj||show-13/VB||correlation-23/NN	conj_and||increase-16/NN||correlation-23/NN	nn||levels-28/NNS||prp-25/NN	conj_and||prp-25/NN||tf-27/NN	nn||levels-28/NNS||tf-27/NN	prep_between||correlation-23/NN||levels-28/NNS	xcomp||â-7/VBP||implicating-30/VBG	acomp||implicating-30/VBG||prpsc-31/JJ	det||cause-35/NN||the-33/DT	amod||cause-35/NN||underlying-34/VBG	prep_as||prpsc-31/JJ||cause-35/NN	prep_of||cause-35/NN||irondeficiency-37/NN	irondeficiency-37||iron-19||yes||sporadic creutzfeldt-jakob disease (scjd)â€“affected human brains show a similar increase in total iron and a direct correlation between prp and tf levels, implicating prpsc as the underlying cause of irondeficiency.
amod||methodology-2/NN||starhs-1/JJ	nsubj||uses-3/VBZ||methodology-2/NN	root||ROOT-0/null||uses-3/VBZ	det||bed-5/NN||the-4/DT	nsubj||capture-7/VB||bed-5/NN	dep||capture-7/VB||hiv-1-6/JJ	xcomp||uses-3/VBZ||capture-7/VB	acomp||capture-7/VB||enzyme-8/JJ	advmod||enzyme-8/JJ||immunoassay-9/RB	aux||determine-11/VB||to-10/TO	xcomp||enzyme-8/JJ||determine-11/VB	amod||hivinfections-13/NNS||recent-12/JJ	dobj||determine-11/VB||hivinfections-13/NNS	prepc_by||determine-11/VB||testing-15/VBG	amod||serum-17/NN||remnant-16/JJ	dobj||testing-15/VBG||serum-17/NN	prep_from||testing-15/VBG||persons-19/NNS	advmod||diagnosed-21/VBN||newly-20/RB	vmod||persons-19/NNS||diagnosed-21/VBN	prep_with||diagnosed-21/VBN||hiv-23/NN	hivinfections-13||hiv-23||no||starhs methodology uses the bed hiv-1 capture enzyme immunoassay to determine recent hivinfections by testing remnant serum from persons newly diagnosed with hiv.
cop||energy-saving-2/JJ||being-1/VBG	vmod||fit-8/VBP||energy-saving-2/JJ	conj_and||energy-saving-2/JJ||biodegradable-4/JJ	vmod||fit-8/VBP||biodegradable-4/JJ	amod||biocatalysts-7/NNS||laccase-based-6/JJ	nsubj||fit-8/VBP||biocatalysts-7/NNS	root||ROOT-0/null||fit-8/VBP	advmod||fit-8/VBP||well-9/RB	det||development-12/NN||the-11/DT	prep_with||fit-8/VBP||development-12/NN	advmod||efficient-15/JJ||highly-14/RB	amod||industries-21/NNS||efficient-15/JJ	conj_and||efficient-15/JJ||sustainable-17/JJ	amod||industries-21/NNS||sustainable-17/JJ	conj_and||efficient-15/JJ||eco-friendly-20/JJ	amod||industries-21/NNS||eco-friendly-20/JJ	prep_of||development-12/NN||industries-21/NNS	biocatalysts-7||fit-8||no_rel||being energy-saving and biodegradable, laccase-based biocatalysts fit well with the development of highly efficient, sustainable, and eco-friendly industries.
det||utilization-5/NN||the-2/DT	nn||utilization-5/NN||diabetes-3/NN	nn||utilization-5/NN||therapy-4/NN	nsubj||researching-6/VBG||utilization-5/NN	prepc_in||exenatide-41/VBP||researching-6/VBG	dobj||researching-6/VBG||changes-7/NNS	nn||weight-11/NN||a1c-9/NNS	nn||factors-14/NNS||weight-11/NN	conj_and||weight-11/NN||other-13/JJ	nn||factors-14/NNS||other-13/JJ	prep_in||changes-7/NNS||factors-14/NNS	prep_through||researching-6/VBG||intervention-16/NN	amod||study-24/NN||exenatide-18/JJ	advmod||exenatide-18/JJ||once-19/RB	amod||study-24/NN||weekly-20/JJ	dep||study-24/NN||duration-1-22/JJ	prep_with||intervention-16/NN||study-24/NN	det||safety-27/NN||the-26/DT	nsubj||exenatide-41/VBP||safety-27/NN	conj_and||safety-27/NN||efficacy-29/NN	nsubj||exenatide-41/VBP||efficacy-29/NN	num||weeks-32/NNS||30-31/CD	prep_of||safety-27/NN||weeks-32/NNS	prep_of||weeks-32/NNS||treatment-34/NN	det||agonist-40/NN||the-36/DT	amod||agonist-40/NN||glucagon-like-37/JJ	amod||agonist-40/NN||peptide-1-38/JJ	nn||agonist-40/NN||receptor-39/NN	prep_with||treatment-34/NN||agonist-40/NN	root||ROOT-0/null||exenatide-41/VBP	mark||compared-52/VBN||once-42/IN	nsubjpass||compared-52/VBN||weekly-43/JJ	amod||qw-46/NN||exenatide-45/JJ	dep||weekly-43/JJ||qw-46/NN	num||mg-49/NN||2-48/CD	dep||qw-46/NN||mg-49/NN	auxpass||compared-52/VBN||was-51/VBD	advcl||exenatide-41/VBP||compared-52/VBN	amod||bid-55/NN||exenatide-54/JJ	prep_with||compared-52/VBN||bid-55/NN	amod||patients-58/NNS||295-57/JJ	prep_in||bid-55/NN||patients-58/NNS	prep_with||compared-52/VBN||type2diabetes-60/CD	type2diabetes-60||exenatide-54||yes||in the diabetes therapy utilization researching changes in a1c, weight and other factors through intervention with exenatide once weekly (duration-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide qw; 2 mg) was compared with exenatide bid in 295 patients with type2diabetes.
det||studies-2/NNS||these-1/DT	nsubj||indicate-3/VBP||studies-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||useful-11/JJ||that-4/IN	amod||responses-6/NNS||anti-htlv-iantibody-5/JJ	nsubj||useful-11/JJ||responses-6/NNS	nsubj||suggest-15/VBP||responses-6/NNS	vmod||responses-6/NNS||detected-7/VBN	agent||detected-7/VBN||lips-9/NNS	cop||useful-11/JJ||are-10/VBP	ccomp||indicate-3/VBP||useful-11/JJ	prep_for||useful-11/JJ||diagnosis-13/NN	ccomp||indicate-3/VBP||suggest-15/VBP	conj_and||useful-11/JJ||suggest-15/VBP	mark||feature-23/NN||that-16/IN	amod||antibodies-19/NNS||elevated-17/JJ	amod||antibodies-19/NNS||anti-env-18/JJ	nsubj||feature-23/NN||antibodies-19/NNS	cop||feature-23/NN||are-20/VBP	det||feature-23/NN||a-21/DT	amod||feature-23/NN||common-22/JJ	ccomp||suggest-15/VBP||feature-23/NN	vmod||feature-23/NN||found-24/VBN	nn||patients-27/NNS||ham/tsp-26/NN	prep_in||found-24/VBN||patients-27/NNS	htlv-iantibody--1||ham--1||no_rel||these studies indicate that anti-htlv-iantibody responses detected by lips are useful for diagnosis and suggest that elevated anti-env antibodies are a common feature found in ham/tsp patients.
nsubj||indicate-2/VBP||studies-1/NNS	root||ROOT-0/null||indicate-2/VBP	mark||induced-7/VBN||that-3/IN	nsubjpass||induced-7/VBN||insulinresistance-4/NN	aux||induced-7/VBN||can-5/MD	auxpass||induced-7/VBN||be-6/VB	ccomp||indicate-2/VBP||induced-7/VBN	agent||induced-7/VBN||stimulating-9/VBG	det||degradation-11/NN||the-10/DT	dobj||stimulating-9/VBG||degradation-11/NN	amod||molecules-14/NNS||important-13/JJ	prep_of||degradation-11/NN||molecules-14/NNS	det||insulin-17/NN||the-16/DT	prep_in||stimulating-9/VBG||insulin-17/NN	vmod||insulin-17/NN||signaling-18/VBG	advmod||signaling-18/VBG||pathway-19/RB	amod||akt1-34/NNS||particular-22/JJ	det||irs1-28/NNS||the-23/DT	nn||irs1-28/NNS||insulin-24/NN	nn||irs1-28/NNS||receptor-25/NN	nn||irs1-28/NNS||substrate-26/NN	nn||irs1-28/NNS||proteins-27/NNS	dep||particular-22/JJ||irs1-28/NNS	dep||particular-22/JJ||irs2-30/NNS	conj_and||irs1-28/NNS||irs2-30/NNS	det||kinase-33/NN||the-32/DT	dep||particular-22/JJ||kinase-33/NN	conj_and||irs1-28/NNS||kinase-33/NN	prep_in||signaling-18/VBG||akt1-34/NNS	appos||akt1-34/NNS||akt-36/NN	insulin-24||insulinresistance-4||no_rel||studies indicate that insulinresistance can be induced by stimulating the degradation of important molecules in the insulin signaling pathway, in particular the insulin receptor substrate proteins irs1, irs2 and the kinase akt1 (akt).
nsubj||effective-10/JJ||chemotherapy-1/NN	prep_of||chemotherapy-1/NN||clonorchiasis-3/NNS	prep_with||clonorchiasis-3/NNS||praziquantel-5/NN	appos||praziquantel-5/NN||pzq-7/NN	cop||effective-10/JJ||is-9/VBZ	root||ROOT-0/null||effective-10/JJ	quantmod||15-13/CD||about-12/RB	num||%-14/NN||15-13/CD	nsubjpass||reported-20/VBN||%-14/NN	amod||cases-17/NNS||treated-16/JJ	prep_of||%-14/NN||cases-17/NNS	aux||reported-20/VBN||have-18/VBP	auxpass||reported-20/VBN||been-19/VBN	conj_but||effective-10/JJ||reported-20/VBN	xcomp||reported-20/VBN||uncured-21/JJ	clonorchiasis-3||praziquantel-5||yes||chemotherapy of clonorchiasis with praziquantel (pzq) is effective but about 15% of treated cases have been reported uncured.
nsubj||allows-2/VBZ||it-1/PRP	root||ROOT-0/null||allows-2/VBZ	dobj||allows-2/VBZ||us-3/PRP	nsubj||show-5/VB||us-3/PRP	aux||show-5/VB||to-4/TO	xcomp||allows-2/VBZ||show-5/VB	mark||related-12/VBN||that-6/IN	det||sars-cov-8/NN||the-7/DT	nsubj||related-12/VBN||sars-cov-8/NN	cop||related-12/VBN||is-9/VBZ	advmod||closely-11/RB||most-10/RBS	advmod||related-12/VBN||closely-11/RB	ccomp||show-5/VB||related-12/VBN	det||coronavirus-15/NNS||a-14/DT	prep_to||related-12/VBN||coronavirus-15/NNS	det||civet-19/NN||the-17/DT	nn||civet-19/NN||palm-18/NN	prep_from||coronavirus-15/NNS||civet-19/NN	neg||related-12/VBN||not-20/RB	det||bird-23/NN||a-22/DT	prep_from||related-12/VBN||bird-23/NN	mark||suspected-26/VBD||as-24/IN	advmod||suspected-26/VBD||initially-25/RB	dep||related-12/VBN||suspected-26/VBD	det||hcov-hku1-34/NN||the-29/DT	advmod||discovered-31/VBN||newly-30/RB	amod||hcov-hku1-34/NN||discovered-31/VBN	amod||hcov-hku1-34/NN||human-32/JJ	nn||hcov-hku1-34/NN||coronavirus-33/NNS	nsubj||related-38/VBN||hcov-hku1-34/NN	cop||related-38/VBN||is-35/VBZ	advmod||related-38/VBN||more-36/RBR	advmod||related-38/VBN||closely-37/RB	conj_and||allows-2/VBZ||related-38/VBN	prep_to||related-38/VBN||sars-40/NNS	advmod||related-38/VBN||than-41/IN	det||member-46/NN||any-43/DT	amod||member-46/NN||other-44/JJ	amod||member-46/NN||known-45/VBN	prep_to||than-41/IN||member-46/NN	nn||coronavirus-50/NNS||group-48/NN	num||coronavirus-50/NNS||2-49/CD	prep_of||member-46/NN||coronavirus-50/NNS	sars-40||coronavirus-50||no||it allows us to show that the sars-cov is most closely related to a coronavirus from the palm civet not from a bird as initially suspected, and the newly discovered human coronavirus hcov-hku1 is more closely related to sars than to any other known member of group 2 coronavirus.
det||approach-4/NN||a-1/DT	amod||approach-4/NN||proven-2/VBN	amod||approach-4/NN||successful-3/JJ	nsubj||disruption-11/NN||approach-4/NN	nsubjpass||used-20/VBN||approach-4/NN	nsubj||treat-22/VB||approach-4/NN	nn||management-7/NN||weight-6/NN	prep_in||approach-4/NN||management-7/NN	aux||disruption-11/NN||has-8/VBZ	cop||disruption-11/NN||been-9/VBN	det||disruption-11/NN||the-10/DT	root||ROOT-0/null||disruption-11/NN	amod||digestion-14/NN||nutrient-13/JJ	prep_of||disruption-11/NN||digestion-14/NN	prep_with||disruption-11/NN||orlistat-17/NN	aux||used-20/VBN||having-18/VBG	auxpass||used-20/VBN||been-19/VBN	xcomp||disruption-11/NN||used-20/VBN	aux||treat-22/VB||to-21/TO	xcomp||used-20/VBN||treat-22/VB	advmod||treat-22/VB||obesity-23/RB	det||years-28/NNS||the-25/DT	amod||years-28/NNS||last-26/JJ	num||years-28/NNS||10-27/CD	prep_for||treat-22/VB||years-28/NNS	obesity-23||orlistat-17||yes||a proven successful approach in weight management has been the disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years.
nsubjpass||comprised-31/VBN||prions-1/NNS	amod||agents-4/NNS||infectious-3/JJ	appos||prions-1/NNS||agents-4/NNS	vmod||agents-4/NNS||associated-5/VBN	prep_with||associated-5/VBN||priondiseases-7/NNS	amod||disease-11/NN||creutzfeldt-jakob-10/JJ	prep_such_as||priondiseases-7/NNS||disease-11/NN	prep_in||disease-11/NN||humans-13/NNS	prep_such_as||priondiseases-7/NNS||bovinespongiformencephalopathy-15/NN	conj_and||disease-11/NN||bovinespongiformencephalopathy-15/NN	appos||bovinespongiformencephalopathy-15/NN||bse-17/NN	prep_in||bovinespongiformencephalopathy-15/NN||cattle-20/NNS	prep_such_as||priondiseases-7/NNS||scrapie-23/NN	conj_and||disease-11/NN||scrapie-23/NN	prep_in||scrapie-23/NN||sheep-25/NN	prep_in||scrapie-23/NN||goats-27/NNS	conj_and||sheep-25/NN||goats-27/NNS	auxpass||comprised-31/VBN||are-29/VBP	advmod||comprised-31/VBN||primarily-30/RB	root||ROOT-0/null||comprised-31/VBN	prep_of||comprised-31/VBN||prpsc-33/NN	det||isoform-38/NN||a-35/DT	amod||isoform-38/NN||protease-resistant-36/JJ	amod||isoform-38/NN||misfolded-37/JJ	appos||prpsc-33/NN||isoform-38/NN	det||prpc-43/NN||the-40/DT	amod||prpc-43/NN||cellular-41/JJ	nn||prpc-43/NN||prionprotein-42/NN	prep_of||isoform-38/NN||prpc-43/NN	priondiseases-7||prionprotein-42||no||prions, infectious agents associated with priondiseases such as creutzfeldt-jakob disease in humans, bovinespongiformencephalopathy (bse) in cattle, and scrapie in sheep and goats, are primarily comprised of prpsc, a protease-resistant misfolded isoform of the cellular prionprotein prpc.
nsubjpass||known-14/VBN||rosiglitazone-1/NN	nsubj||have-16/VB||rosiglitazone-1/NN	appos||rosiglitazone-1/NN||rsg-3/NN	vmod||rosiglitazone-1/NN||developed-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||developed-6/VBN||treatment-9/NN	prep_of||treatment-9/NN||type2diabetesmellitus-11/CD	auxpass||known-14/VBN||is-13/VBZ	root||ROOT-0/null||known-14/VBN	aux||have-16/VB||to-15/TO	xcomp||known-14/VBN||have-16/VB	amod||effects-18/NNS||potent-17/JJ	dobj||have-16/VB||effects-18/NNS	nn||metabolism-23/NN||carbohydrate-20/NN	conj_and||carbohydrate-20/NN||lipid-22/NN	nn||metabolism-23/NN||lipid-22/NN	prep_on||have-16/VB||metabolism-23/NN	xcomp||have-16/VB||leading-24/VBG	det||improvement-27/NN||the-26/DT	prep_to||leading-24/VBG||improvement-27/NN	nn||sensitivity-30/NN||insulin-29/NN	prep_of||improvement-27/NN||sensitivity-30/NN	nn||tissues-33/NNS||target-32/NN	prep_in||sensitivity-30/NN||tissues-33/NNS	type2diabetesmellitus-11||rosiglitazone-1||yes||rosiglitazone (rsg), developed for the treatment of type2diabetesmellitus, is known to have potent effects on carbohydrate and lipid metabolism leading to the improvement of insulin sensitivity in target tissues.
amod||modifications-2/NNS||immune-1/JJ	nsubjpass||observed-17/VBN||modifications-2/NNS	prep_including||modifications-2/NNS||changes-5/NNS	prep_in||changes-5/NNS||interleukin-7/NN	appos||interleukin-7/NN||il-9/NN	num||levels-12/NNS||-6-11/CD	dep||interleukin-7/NN||levels-12/NNS	aux||observed-17/VBN||have-14/VBP	advmod||observed-17/VBN||often-15/RB	auxpass||observed-17/VBN||been-16/VBN	root||ROOT-0/null||observed-17/VBN	amod||depressivedisorder-20/NN||major-19/JJ	prep_in||observed-17/VBN||depressivedisorder-20/NN	appos||depressivedisorder-20/NN||mdd-22/NN	prep_during||observed-17/VBN||treatment-25/NN	amod||inhibitors-30/NNS||selective-27/JJ	nn||inhibitors-30/NNS||serotonin-28/NN	nn||inhibitors-30/NNS||reuptake-29/NN	prep_with||observed-17/VBN||inhibitors-30/NNS	appos||inhibitors-30/NNS||ssris-32/NNS	det||venlafaxine-43/NN||the-35/DT	amod||norepinephrine-37/JJ||serotonin-36/JJ	amod||venlafaxine-43/NN||norepinephrine-37/JJ	nn||venlafaxine-43/NN||reuptake-38/NN	nn||venlafaxine-43/NN||inhibitor-39/NN	appos||venlafaxine-43/NN||snri-41/NNP	prep_with||observed-17/VBN||venlafaxine-43/NN	conj_or||inhibitors-30/NNS||venlafaxine-43/NN	depressivedisorder-20||venlafaxine-43||yes||immune modifications, including changes in interleukin (il)-6 levels, have often been observed in major depressivedisorder (mdd) during treatment with selective serotonin reuptake inhibitors (ssris) or the serotonin norepinephrine reuptake inhibitor (snri) venlafaxine.
nsubj||factor-6/NN||insulinresistance-1/NN	cop||factor-6/NN||is-2/VBZ	det||factor-6/NN||a-3/DT	amod||factor-6/NN||major-4/JJ	nn||factor-6/NN||risk-5/NN	root||ROOT-0/null||factor-6/NN	amod||type2diabetes-9/NNS||developing-8/VBG	prep_for||factor-6/NN||type2diabetes-9/NNS	dep||type2diabetes-9/NNS||caused-10/VBN	det||inability-13/NN||the-12/DT	prep_by||caused-10/VBN||inability-13/NN	amod||tissues-16/NNS||insulin-target-15/JJ	prep_of||inability-13/NN||tissues-16/NNS	aux||respond-18/VB||to-17/TO	xcomp||caused-10/VBN||respond-18/VB	advmod||respond-18/VB||properly-19/RB	prep_to||respond-18/VB||insulin-21/NN	dep||type2diabetes-9/NNS||contributes-24/VBZ	conj_and||caused-10/VBN||contributes-24/VBZ	det||morbidity-27/NN||the-26/DT	prep_to||contributes-24/VBZ||morbidity-27/NN	prep_of||morbidity-27/NN||obesity-29/NN	type2diabetes-9||insulin-21||yes||insulinresistance is a major risk factor for developing type2diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.
prep_as||showed-12/VBD||part-2/NN	det||investigation-9/NN||a-4/DT	amod||investigation-9/NN||fatal-5/JJ	amod||investigation-9/NN||human-6/JJ	nn||investigation-9/NN||plague-7/NN	nn||investigation-9/NN||case-8/NN	prep_of||part-2/NN||investigation-9/NN	nsubj||showed-12/VBD||we-11/PRP	root||ROOT-0/null||showed-12/VBD	mark||survive-21/VB||that-13/IN	det||bacterium-16/NN||the-14/DT	amod||bacterium-16/NN||plague-15/JJ	nsubj||survive-21/VB||bacterium-16/NN	appos||bacterium-16/NN||yersiniapestis-18/NNS	aux||survive-21/VB||can-20/MD	ccomp||showed-12/VBD||survive-21/VB	quantmod||24-25/CD||at-23/IN	mwe||at-23/IN||least-24/JJS	pobj||at-23/IN||least-24/JJS	num||days-26/NNS||24-25/CD	prep_for||survive-21/VB||days-26/NNS	amod||soil-29/NN||contaminated-28/JJ	prep_in||days-26/NNS||soil-29/NN	amod||conditions-32/NNS||natural-31/JJ	prep_under||survive-21/VB||conditions-32/NNS	plague-15||yersiniapestis-18||no||as part of a fatal human plague case investigation, we showed that the plague bacterium, yersiniapestis, can survive for at least 24 days in contaminated soil under natural conditions.
dep||important-27/JJ||given-1/VBN	mark||suffer-9/VBP||that-2/IN	mwe||than-4/IN||more-3/JJR	quantmod||billion-6/CD||than-4/IN	number||billion-6/CD||2-5/CD	num||people-7/NNS||billion-6/CD	nsubj||suffer-9/VBP||people-7/NNS	advmod||suffer-9/VBP||worldwide-8/RB	pcomp||given-1/VBN||suffer-9/VBP	prep_from||suffer-9/VBP||irondeficiency-11/NN	mark||one-16/CD||that-13/IN	nsubj||one-16/CD||ironoverload-14/NN	cop||one-16/CD||is-15/VBZ	pcomp||given-1/VBN||one-16/CD	conj_and||suffer-9/VBP||one-16/CD	det||diseases-23/NNS||the-18/DT	advmod||common-20/JJ||most-19/RBS	amod||diseases-23/NNS||common-20/JJ	amod||diseases-23/NNS||single-gene-21/JJ	amod||diseases-23/NNS||inherited-22/VBN	prep_of||one-16/CD||diseases-23/NNS	nsubj||important-27/JJ||it-25/PRP	nsubj||understand-29/VB||it-25/PRP	cop||important-27/JJ||is-26/VBZ	root||ROOT-0/null||important-27/JJ	aux||understand-29/VB||to-28/TO	xcomp||important-27/JJ||understand-29/VB	mark||influence-35/VB||whether-30/IN	nn||status-33/NN||host-31/NN	nn||status-33/NN||iron-32/NN	nsubj||influence-35/VB||status-33/NN	aux||influence-35/VB||may-34/MD	ccomp||understand-29/VB||influence-35/VB	advmod||glabrata-37/JJ||c.-36/RB	amod||progression-40/NN||glabrata-37/JJ	amod||progression-40/NN||infectious-38/JJ	nn||progression-40/NN||disease-39/NN	dobj||influence-35/VB||progression-40/NN	irondeficiency-11||iron-32||yes||given that more than 2 billion people worldwide suffer from irondeficiency and that ironoverload is one of the most common single-gene inherited diseases , it is important to understand whether host iron status may influence c. glabrata infectious disease progression .
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||establish-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||establish-8/VB||to-7/TO	xcomp||is-6/VBZ||establish-8/VB	det||safety-10/NN||the-9/DT	dobj||establish-8/VB||safety-10/NN	dobj||establish-8/VB||efficacy-12/NN	conj_and||safety-10/NN||efficacy-12/NN	amod||medicine-16/NN||traditional-14/JJ	nn||medicine-16/NN||chinese-15/NN	prep_of||safety-10/NN||medicine-16/NN	vmod||medicine-16/NN||combined-17/VBN	prep_with||combined-17/VBN||glibenclamide-19/NN	aux||treat-21/VB||to-20/TO	xcomp||combined-17/VBN||treat-21/VB	dobj||treat-21/VB||type2diabetesmellitus-22/NNS	type2diabetesmellitus-22||glibenclamide-19||yes||the aim of this study is to establish the safety and efficacy of traditional chinese medicine combined with glibenclamide to treat type2diabetesmellitus.
nn||protein-3/NN||thioredoxin-1/NN	amod||protein-3/NN||interacting-2/VBG	nsubjpass||induced-16/VBN||protein-3/NN	nsubj||inhibits-20/VBZ||protein-3/NN	appos||protein-3/NN||txnip-5/NN	det||regulator-9/NN||a-8/DT	appos||protein-3/NN||regulator-9/NN	amod||stress-13/NN||cellular-11/JJ	nn||stress-13/NN||oxidative-12/NN	prep_of||regulator-9/NN||stress-13/NN	auxpass||induced-16/VBN||is-15/VBZ	root||ROOT-0/null||induced-16/VBN	agent||induced-16/VBN||hyperglycemia-18/NN	conj_and||induced-16/VBN||inhibits-20/VBZ	nn||uptake-22/NN||glucose-21/NN	dobj||inhibits-20/VBZ||uptake-22/NN	prep_into||inhibits-20/VBZ||fat-24/NN	prep_into||inhibits-20/VBZ||muscle-26/NN	conj_and||fat-24/NN||muscle-26/NN	vmod||inhibits-20/VBZ||suggesting-28/VBG	det||role-30/NN||a-29/DT	dobj||suggesting-28/VBG||role-30/NN	prep_for||suggesting-28/VBG||txnip-32/NN	amod||pathogenesis-35/NNS||type2diabetes-34/JJ	prep_in||txnip-32/NN||pathogenesis-35/NNS	hyperglycemia-18||glucose-21||no||thioredoxin interacting protein (txnip), a regulator of cellular oxidative stress, is induced by hyperglycemia and inhibits glucose uptake into fat and muscle, suggesting a role for txnip in type2diabetes pathogenesis.
amod||concentrations-3/NNS||increased-1/VBN	nn||concentrations-3/NNS||hepcidin-2/NN	nsubj||lead-4/VBP||concentrations-3/NNS	nsubj||iron-6/VB||concentrations-3/NNS	root||ROOT-0/null||lead-4/VBP	aux||iron-6/VB||to-5/TO	xcomp||lead-4/VBP||iron-6/VB	dobj||iron-6/VB||sequestration-7/NN	prep_in||sequestration-7/NN||macrophages-9/NNS	vmod||sequestration-7/NN||contributing-11/VBG	det||pathogenesis-14/NNS||the-13/DT	prep_to||contributing-11/VBG||pathogenesis-14/NNS	prep_of||pathogenesis-14/NNS||anaemia-16/NN	amod||disease-19/NN||chronic-18/JJ	prep_of||anaemia-16/NN||disease-19/NN	mark||observed-24/VBN||whereas-20/IN	amod||hepcidin-22/NN||decreased-21/VBN	nsubjpass||observed-24/VBN||hepcidin-22/NN	auxpass||observed-24/VBN||is-23/VBZ	advcl||contributing-11/VBG||observed-24/VBN	amod||ironoverloaddiseases-29/NNS||irondeficiency-26/JJ	conj_and||irondeficiency-26/JJ||primary-28/JJ	amod||ironoverloaddiseases-29/NNS||primary-28/JJ	prep_in||observed-24/VBN||ironoverloaddiseases-29/NNS	prep_such_as||ironoverloaddiseases-29/NNS||hereditaryhemochromatosis-32/NNS	irondeficiency-26||iron-6||yes||increased hepcidin concentrations lead to iron sequestration in macrophages, contributing to the pathogenesis of anaemia of chronic disease whereas decreased hepcidin is observed in irondeficiency and primary ironoverloaddiseases such as hereditaryhemochromatosis.
amod||monitoring-4/NN||continuous-1/JJ	amod||monitoring-4/NN||subcutaneous-2/JJ	nn||monitoring-4/NN||glucose-3/NN	nn||systems-8/NNS||monitoring-4/NN	appos||systems-8/NNS||cgm-6/NN	nsubj||provide-9/VBP||systems-8/NNS	nsubj||hyperglycemias-20/VBZ||systems-8/NNS	root||ROOT-0/null||provide-9/VBP	dobj||provide-9/VBP||information-10/NN	amod||excursions-14/NNS||postprandial-12/JJ	nn||excursions-14/NNS||glucose-13/NN	prep_on||provide-9/VBP||excursions-14/NNS	amod||hypo-17/NN||nocturnal-16/JJ	prep_on||provide-9/VBP||hypo-17/NN	conj_and||excursions-14/NNS||hypo-17/NN	conj_and/or||provide-9/VBP||hyperglycemias-20/VBZ	hyperglycemias-20||glucose-13||no||continuous subcutaneous glucose monitoring (cgm) systems provide information on postprandial glucose excursions and nocturnal hypo- and/or hyperglycemias.
amod||complications-2/NNS||other-1/JJ	nsubj||include-3/VBP||complications-2/NNS	root||ROOT-0/null||include-3/VBP	dobj||include-3/VBP||bradycardia-4/NN	nsubj||symptomatic-9/JJ||bradycardia-4/NN	nsubj||require-11/VB||bradycardia-4/NN	cop||symptomatic-9/JJ||is-6/VBZ	advmod||symptomatic-9/JJ||very-7/RB	advmod||symptomatic-9/JJ||infrequently-8/RB	rcmod||bradycardia-4/NN||symptomatic-9/JJ	aux||require-11/VB||to-10/TO	xcomp||symptomatic-9/JJ||require-11/VB	dobj||require-11/VB||atropine-12/NN	bradycardia-4||atropine-12||yes||other complications include bradycardia which is very infrequently symptomatic to require atropine.
mark||approved-6/VBN||although-1/IN	nsubjpass||approved-6/VBN||s-1-2/JJ	aux||approved-6/VBN||has-3/VBZ	neg||approved-6/VBN||not-4/RB	auxpass||approved-6/VBN||been-5/VBN	advcl||option-24/NN||approved-6/VBN	advmod||approved-6/VBN||yet-7/RB	det||treatment-11/NN||a-9/DT	amod||treatment-11/NN||standard-10/JJ	prep_as||approved-6/VBN||treatment-11/NN	nn||cancer-14/NN||colon-13/NN	prep_of||treatment-11/NN||cancer-14/NN	det||setting-18/NN||an-16/DT	amod||setting-18/NN||adjuvant-17/JJ	prep_in||cancer-14/NN||setting-18/NN	nsubj||option-24/NN||it-20/PRP	cop||option-24/NN||is-21/VBZ	det||option-24/NN||a-22/DT	amod||option-24/NN||promising-23/JJ	root||ROOT-0/null||option-24/NN	cancer-14||adjuvant-17||no_rel||although s-1 has not been approved yet as a standard treatment of colon cancer in an adjuvant setting, it is a promising option.
det||alemtuzumab-4/NN||the-1/DT	amod||alemtuzumab-4/NN||cd52-targeting-2/JJ	nn||alemtuzumab-4/NN||antibody-3/NN	nsubjpass||established-6/VBN||alemtuzumab-4/NN	auxpass||established-6/VBN||is-5/VBZ	root||ROOT-0/null||established-6/VBN	amod||practice-9/NN||clinical-8/JJ	prep_in||established-6/VBN||practice-9/NN	prepc_with||established-6/VBN||convincing-11/VBG	dobj||convincing-11/VBG||activity-12/NN	amod||chroniclymphocyticleukemia-17/NN||relapsed-14/JJ	conj_and||relapsed-14/JJ||refractory-16/JJ	amod||chroniclymphocyticleukemia-17/NN||refractory-16/JJ	prep_in||convincing-11/VBG||chroniclymphocyticleukemia-17/NN	appos||chroniclymphocyticleukemia-17/NN||cll-19/NN	dep||convincing-11/VBG||particularly-22/RB	prep_in||convincing-11/VBG||patients-24/NNS	amod||features-27/NNS||high-risk-26/JJ	prep_with||patients-24/NNS||features-27/NNS	amod||prognosis-30/NN||adverse-29/JJ	prep_with||patients-24/NNS||prognosis-30/NN	conj_and||features-27/NNS||prognosis-30/NN	cll-19||alemtuzumab-4||yes||the cd52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chroniclymphocyticleukemia (cll), particularly in patients with high-risk features and adverse prognosis.
nsubj||felt-2/VBD||we-1/PRP	root||ROOT-0/null||felt-2/VBD	expl||is-4/VBZ||there-3/EX	ccomp||felt-2/VBD||is-4/VBZ	det||need-6/NN||a-5/DT	nsubj||is-4/VBZ||need-6/NN	aux||discern-8/VB||to-7/TO	vmod||need-6/NN||discern-8/VB	dobj||discern-8/VB||patterns-9/NNS	det||markers-13/NNS||the-11/DT	amod||markers-13/NNS||biochemical-12/JJ	prep_in||discern-8/VB||markers-13/NNS	amod||studies-16/NNS||radiological-15/JJ	appos||markers-13/NNS||studies-16/NNS	appos||markers-13/NNS||co-infections-18/NNS	conj_or||studies-16/NNS||co-infections-18/NNS	appos||markers-13/NNS||length-20/NN	conj_or||studies-16/NNS||length-20/NN	prep_of||length-20/NN||stay-22/NN	appos||stay-22/NN||los-24/NN	prep_in||stay-22/NN||patients-27/NNS	prep_with||patients-27/NNS||hiv-29/NN	appos||markers-13/NNS||aids-31/NNS	conj_or||studies-16/NNS||aids-31/NNS	conj_or||studies-16/NNS||pancreatitis-33/NNS	conj_and||aids-31/NNS||pancreatitis-33/NNS	aids-31||hiv-29||no||we felt there is a need to discern patterns in the biochemical markers, radiological studies, co-infections, length of stay (los) in patients with hiv or aids and pancreatitis.
vmod||increased-9/VBD||reducing-1/VBG	amod||hyperglycemia-3/NN||systemic-2/JJ	dobj||reducing-1/VBG||hyperglycemia-3/NN	prep_to||reducing-1/VBG||euglycemia-5/NN	nsubj||increased-9/VBD||exenatide-7/NN	advmod||increased-9/VBD||still-8/RB	root||ROOT-0/null||increased-9/VBD	amod||turnover-12/NN||total-10/JJ	nn||turnover-12/NN||glucose-11/NN	dobj||increased-9/VBD||turnover-12/NN	nn||saline-19/NN||âˆ-14/NN	number||%-17/NN||1/4-15/CD	number||%-17/NN||20-16/CD	amod||saline-19/NN||%-17/NN	nn||saline-19/NN||-lrb--18/NNP	prep_by||increased-9/VBD||saline-19/NN	num||â-21/NN||13.2-20/CD	dobj||â-31/VBP||â-21/NN	number||1.9-23/CD||±-22/CD	num||â-21/NN||1.9-23/CD	prep||â-21/NN||vs.-24/FW	nn||±-28/NN||exenatide-25/NN	num||±-28/NN||15.6-26/CD	nn||±-28/NN||â-27/NN	pobj||vs.-24/FW||±-28/NN	num||mg-30/NN||2.1-29/CD	nsubj||â-31/VBP||mg-30/NN	rcmod||saline-19/NN||â-31/VBP	nn||kgâˆ-33/NNP||·-32/NNP	poss||·-37/NN||kgâˆ-33/NNP	num||·-37/NN||1-35/CD	nn||·-37/NN||â-36/NN	dobj||â-31/VBP||·-37/NN	dep||â-31/VBP||minâˆ-38/VBG	num||-rrb--45/NNS||1-40/CD	dep||-rrb--45/NNS||p-42/NNP	nn||-rrb--45/NNS||<-43/NNP	num||-rrb--45/NNS||0.05-44/CD	dobj||minâˆ-38/VBG||-rrb--45/NNS	det||presence-48/NN||the-47/DT	prep_in||-rrb--45/NNS||presence-48/NN	prep_of||presence-48/NN||hyperinsulinemia-50/NN	vmod||presence-48/NN||accompanied-52/VBN	amod||increments-55/NNS||smaller-54/JJR	agent||accompanied-52/VBN||increments-55/NNS	dep||-lrb--59/VBZ||r-57/LS	nsubj||-lrb--59/VBZ||d-58/SYM	nsubj||-rrb--73/JJ||d-58/SYM	prepc_in||minâˆ-38/VBG||-lrb--59/VBZ	number||%-61/NN||12-60/CD	amod||-rrb--62/NNS||%-61/NN	dobj||-lrb--59/VBZ||-rrb--62/NNS	amod||uptake-66/NN||net-64/JJ	amod||uptake-66/NN||hepatic-65/JJ	dep||-rrb--73/JJ||uptake-66/NN	amod||-lrb--70/NNS||exogenous-68/JJ	nn||-lrb--70/NNS||glucose-69/NN	prep_of||uptake-66/NN||-lrb--70/NNS	num||%-72/NN||45-71/CD	npadvmod||-rrb--73/JJ||%-72/NN	prepc_in||minâˆ-38/VBG||-rrb--73/JJ	conj_and||-lrb--59/VBZ||-rrb--73/JJ	hyperglycemia-3||glucose-69||no||reducing systemic hyperglycemia to euglycemia , exenatide still increased total glucose turnover by âˆ 1/4 20 % -lrb- saline 13.2 â ± 1.9 vs. exenatide 15.6 â ± 2.1 mg â · kgâˆ ' 1 â · minâˆ ' 1 , p < 0.05 -rrb- in the presence of hyperinsulinemia , accompanied by smaller increments in r d -lrb- 12 % -rrb- and net hepatic uptake of exogenous glucose -lrb- 45 % -rrb- .
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	carbohydrate--1||cvd-36||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
amod||subjects-2/NNS||hiv-infected-1/JJ	nsubj||â-16/VBP||subjects-2/NNS	amod||calmette-5/JJ||bacille-4/JJ	amod||scars-12/NNS||calmette-5/JJ	nn||scars-12/NNS||guã-6/NN	nn||scars-12/NNS||©-7/NNS	nn||scars-12/NNS||rin-8/NN	appos||scars-12/NNS||bcg-10/NN	prep_with||subjects-2/NNS||scars-12/NNS	amod||counts-15/NNS||cd4-14/JJ	prep_with||subjects-2/NNS||counts-15/NNS	conj_and||scars-12/NNS||counts-15/NNS	ccomp||release-58/VBP||â-16/VBP	xcomp||â-16/VBP||‰-17/VBG	number||200-19/CD||¥-18/CD	num||cells/mm3-20/NNS||200-19/CD	dobj||‰-17/VBG||cells/mm3-20/NNS	vmod||cells/mm3-20/NNS||entering-21/VBG	det||trial-26/NN||a-22/DT	nn||trial-26/NN||tb-23/NN	nn||trial-26/NN||booster-24/NN	nn||trial-26/NN||vaccine-25/NN	dobj||entering-21/VBG||trial-26/NN	prep_in||entering-21/VBG||tanzania-28/NN	vmod||tanzania-28/NN||had-29/VBN	dobj||had-29/VBN||baseline-30/NN	prep_in||baseline-30/NN||vivo-32/NN	npadvmod||immune-36/JJ||vitro-35/NN	amod||tests-37/NNS||immune-36/JJ	prep_in||entering-21/VBG||tests-37/NNS	conj_and||tanzania-28/NN||tests-37/NNS	vmod||tests-37/NNS||performed-38/VBN	amod||tests-41/NNS||tuberculin-39/JJ	nn||tests-41/NNS||skin-40/NN	dobj||performed-38/VBN||tests-41/NNS	appos||cells/mm3-20/NNS||tst-43/NN	nn||assays-50/NNS||lpa-46/NN	conj_and||lpa-46/NN||five-48/CD	nn||assays-50/NNS||five-48/CD	nn||assays-50/NNS||day-49/NN	nsubj||release-58/VBP||assays-50/NNS	nn||gamma-53/NN||interferon-52/NN	prep_of||assays-50/NNS||gamma-53/NN	nn||³-56/NNP||ifn-î-55/NNP	appos||gamma-53/NN||³-56/NNP	root||ROOT-0/null||release-58/VBP	tb-23||bcg-10||no||hiv-infected subjects with bacille calmette guã©rin (bcg) scars and cd4 counts â‰¥ 200 cells/mm3 entering a tb booster vaccine trial in tanzania had baseline in vivo and in vitro immune tests performed tuberculin skin tests (tst), lpa and five day assays of interferon gamma (ifn-î³) release.
amod||stimulation-2/NN||insulin-induced-1/JJ	nsubjpass||reduced-12/VBN||stimulation-2/NN	amod||uptake-6/NN||hepatic-4/JJ	nn||uptake-6/NN||glucose-5/NN	prep_of||stimulation-2/NN||uptake-6/NN	amod||synthesis-10/NN||hepatic-8/JJ	nn||synthesis-10/NN||glycogen-9/NN	prep_of||stimulation-2/NN||synthesis-10/NN	conj_and||uptake-6/NN||synthesis-10/NN	auxpass||reduced-12/VBN||are-11/VBP	root||ROOT-0/null||reduced-12/VBN	prep_in||reduced-12/VBN||people-14/NNS	amod||presumably-25/NNS||type2diabetes-16/JJ	advmod||presumably-25/NNS||primarily-17/RB	amod||uptake-21/NN||decreased-20/VBN	prep_due_to||presumably-25/NNS||uptake-21/NN	prep_of||uptake-21/NN||extracellular-23/NN	nn||presumably-25/NNS||glucose-24/NN	prep_with||reduced-12/VBN||presumably-25/NNS	amod||activation-29/NN||inadequate-28/JJ	prep_because_of||presumably-25/NNS||activation-29/NN	amod||glucokinase-32/NN||hepatic-31/JJ	prep_of||activation-29/NN||glucokinase-32/NN	type2diabetes-16||insulin--1||yes||insulin-induced stimulation of hepatic glucose uptake and hepatic glycogen synthesis are reduced in people with type2diabetes primarily due to decreased uptake of extracellular glucose presumably because of inadequate activation of hepatic glucokinase.
amod||survival-2/NN||cumulative-1/JJ	nsubjpass||analyzed-12/VBN||survival-2/NN	nsubjpass||analyzed-12/VBN||survival-2/NN	amod||rates-10/NNS||hepatocellular-4/JJ	amod||rates-10/NNS||carcinoma-5/JJ	appos||rates-10/NNS||hcc-7/NN	nn||rates-10/NNS||development-9/NN	conj_and||survival-2/NN||rates-10/NNS	nsubjpass||analyzed-12/VBN||rates-10/NNS	auxpass||analyzed-12/VBN||were-11/VBD	root||ROOT-0/null||analyzed-12/VBN	conj_or||analyzed-12/VBN||analyzed-12/VBN	nn||abusive-15/NNS||alcohol-14/NN	prep_in||analyzed-12/VBN||abusive-15/NNS	amod||patients-18/NNS||cirrhotic-17/JJ	appos||abusive-15/NNS||patients-18/NNS	nn||virusinfection-23/NN||hepatitis-22/NN	prep_with||analyzed-12/VBN||virusinfection-23/NN	prep_without||analyzed-12/VBN||virusinfection-23/NN	alcohol-14||carcinoma-5||no_rel||cumulative survival and hepatocellular carcinoma (hcc) development rates were analyzed in alcohol abusive, cirrhotic patients with or without hepatitis virusinfection.
amod||changes-2/NNS||monthly-1/JJ	nsubjpass||analyzed-12/VBN||changes-2/NNS	det||volume-5/NN||the-4/DT	prep_in||changes-2/NNS||volume-5/NN	amod||services-10/NNS||hiv-7/JJ	conj_and||hiv-7/JJ||non-hiv-9/JJ	amod||services-10/NNS||non-hiv-9/JJ	prep_of||volume-5/NN||services-10/NNS	auxpass||analyzed-12/VBN||were-11/VBD	root||ROOT-0/null||analyzed-12/VBN	agent||analyzed-12/VBN||using-14/VBG	amod||models-16/NNS||multilevel-15/JJ	dobj||using-14/VBG||models-16/NNS	aux||examine-18/VB||to-17/TO	vmod||using-14/VBG||examine-18/VB	det||effect-20/NN||the-19/DT	dobj||examine-18/VB||effect-20/NN	det||program-24/NN||an-22/DT	amod||program-24/NN||hiv/aids-23/JJ	prep_of||effect-20/NN||program-24/NN	nn||delivery-28/NN||health-26/NN	nn||delivery-28/NN||service-27/NN	prep_on||examine-18/VB||delivery-28/NN	aids--1||hiv-7||no||monthly changes in the volume of hiv and non-hiv services were analyzed by using multilevel models to examine the effect of an hiv/aids program on health service delivery.
amod||mice-2/NNS||apoe2ki-1/JJ	nsubjpass||protected-4/VBN||mice-2/NNS	auxpass||protected-4/VBN||were-3/VBD	root||ROOT-0/null||protected-4/VBN	amod||steatosis-8/NNS||high-fat-6/JJ	amod||steatosis-8/NNS||diet-induced-7/JJ	prep_against||protected-4/VBN||steatosis-8/NNS	prep_against||protected-4/VBN||hyperglycemia-10/NN	conj_and||steatosis-8/NNS||hyperglycemia-10/NN	advmod||fed-14/VBD||when-13/WRB	prepc_except||protected-4/VBN||fed-14/VBD	det||diet-17/NN||a-15/DT	nn||diet-17/NN||hoso-16/NN	dobj||fed-14/VBD||diet-17/NN	fat--1||hyperglycemia-10||no_rel||apoe2ki mice were protected against high-fat diet-induced steatosis and hyperglycemia, except when fed a hoso diet.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||decrease-7/VB||if-3/IN	amod||analogs-6/NNS||long-acting-4/JJ	nn||analogs-6/NNS||insulin-5/NN	nsubj||decrease-7/VB||analogs-6/NNS	advcl||investigate-2/VB||decrease-7/VB	det||risk-9/NN||the-8/DT	dobj||decrease-7/VB||risk-9/NN	prep_of||risk-9/NN||diabeticketoacidosis-11/NNS	appos||diabeticketoacidosis-11/NNS||dka-13/NN	amod||individuals-17/NNS||young-16/JJ	prep_in||diabeticketoacidosis-11/NNS||individuals-17/NNS	prep_with||individuals-17/NNS||type1diabetes-19/CD	type1diabetes-19||insulin-5||yes||to investigate if long-acting insulin analogs decrease the risk of diabeticketoacidosis (dka) in young individuals with type1diabetes.
advmod||decreased-9/VBN||notably-1/RB	nn||strains-5/NNS||s.â-3/NN	nn||strains-5/NNS||enterica-4/NN	nsubj||decreased-9/VBN||strains-5/NNS	vmod||strains-5/NNS||lacking-6/VBG	dobj||lacking-6/VBG||rida-7/NN	aux||decreased-9/VBN||have-8/VBP	root||ROOT-0/null||decreased-9/VBN	dobj||decreased-9/VBN||activity-10/NN	det||transaminase-14/NN||the-12/DT	amod||transaminase-14/NN||plp-dependent-13/JJ	prep_of||activity-10/NN||transaminase-14/NN	dep||activity-10/NN||b-15/SYM	amod||ilve-17/JJ||enzyme-16/JJ	amod||activity-10/NN||ilve-17/JJ	det||enzyme-20/NN||an-19/DT	appos||activity-10/NN||enzyme-20/NN	vmod||enzyme-20/NN||involved-21/VBN	amod||biosynthesis-25/NNS||branched-chain-23/JJ	amod||biosynthesis-25/NNS||aminoacid-24/JJ	prep_in||involved-21/VBN||biosynthesis-25/NNS	enzyme-20||rida-7||no_rel||notably, s.â enterica strains lacking rida have decreased activity of the plp-dependent transaminase b enzyme ilve, an enzyme involved in branched-chain aminoacid biosynthesis.
det||igm-6/NN||a-1/DT	amod||igm-6/NN||new-2/JJ	amod||igm-6/NN||commercial-3/JJ	amod||igm-6/NN||anti-japaneseencephalitis-4/JJ	nn||igm-6/NN||virus-5/NN	nsubjpass||evaluated-16/VBN||igm-6/NN	nn||test-11/NN||igg-8/NN	amod||test-11/NN||indirect-9/JJ	nn||test-11/NN||immunofluorescence-10/NN	conj_and||igm-6/NN||test-11/NN	nsubjpass||evaluated-16/VBN||test-11/NN	appos||igm-6/NN||iift-13/NN	auxpass||evaluated-16/VBN||was-15/VBD	root||ROOT-0/null||evaluated-16/VBN	det||detection-19/NN||the-18/DT	prep_for||evaluated-16/VBN||detection-19/NN	det||response-24/NN||the-21/DT	amod||response-24/NN||humoral-22/JJ	amod||response-24/NN||immune-23/JJ	prep_of||detection-19/NN||response-24/NN	amod||vaccination-27/NN||japaneseencephalitis-26/JJ	prep_after||evaluated-16/VBN||vaccination-27/NN	japaneseencephalitis-26||japaneseencephalitisvirus--1||no||a new commercial anti-japaneseencephalitis virus igm and igg indirect immunofluorescence test (iift) was evaluated for the detection of the humoral immune response after japaneseencephalitis vaccination.
ccomp||causes-10/VBZ||similar-1/JJ	nn||propofol-5/NN||lipid-3/NN	nn||propofol-5/NN||emulsion-4/NN	prep_to||similar-1/JJ||propofol-5/NN	nn||propofol-8/NN||microemulsion-7/NN	nsubj||causes-10/VBZ||propofol-8/NN	advmod||causes-10/VBZ||also-9/RB	root||ROOT-0/null||causes-10/VBZ	det||incidence-13/NN||a-11/DT	amod||incidence-13/NN||high-12/JJ	dobj||causes-10/VBZ||incidence-13/NN	prep_of||incidence-13/NN||pain-15/NN	amod||injection-18/NN||intravenous-17/JJ	prep_during||causes-10/VBZ||injection-18/NN	pain-15||propofol-8||yes||similar to lipid emulsion propofol, microemulsion propofol also causes a high incidence of pain during intravenous injection.
amod||knockdown-2/NN||mov10-1/JJ	nsubj||inhibited-3/VBD||knockdown-2/NN	root||ROOT-0/null||inhibited-3/VBD	nn||replication-5/NN||hdv-4/NN	dobj||inhibited-3/VBD||replication-5/NN	amod||translation-11/NN||hdag-9/VBG	nn||translation-11/NN||mrna-10/NN	dobj||inhibited-3/VBD||translation-11/NN	conj_negcc||replication-5/NN||translation-11/NN	vmod||translation-11/NN||supporting-12/VBG	det||role-14/NN||a-13/DT	dobj||supporting-12/VBG||role-14/NN	prep_for||role-14/NN||mov10-16/NNS	amod||transcription-19/NN||rna-directed-18/JJ	prep_in||mov10-16/NNS||transcription-19/NN	hdag-9||hdv-4||no||mov10 knockdown inhibited hdv replication, but not hdag mrna translation supporting a role for mov10 in rna-directed transcription.
nsubjpass||identified-11/VBN||criteria-1/NNS	nn||setting-4/NN||priority-3/NN	prep_for||criteria-1/NNS||setting-4/NN	amod||interventions-7/NNS||hiv/aids-6/JJ	prep_of||setting-4/NN||interventions-7/NNS	prep_in||interventions-7/NNS||thailand-9/NN	auxpass||identified-11/VBN||were-10/VBD	root||ROOT-0/null||identified-11/VBN	nn||discussions-14/NNS||group-13/NN	prep_in||identified-11/VBN||discussions-14/NNS	nn||makers-17/NNS||policy-16/NN	prep_with||identified-11/VBN||makers-17/NNS	appos||makers-17/NNS||people-19/NNS	vmod||people-19/NNS||living-20/VBG	amod||-rrb--25/NNS||hiv/aids-22/JJ	amod||-rrb--25/NNS||-lrb--23/JJ	nn||-rrb--25/NNS||plwha-24/NN	prep_with||living-20/VBG||-rrb--25/NNS	nn||members-29/NNS||community-28/NN	nsubj||-lrb--30/VBD||members-29/NNS	conj_and||identified-11/VBN||-lrb--30/VBD	amod||volunteers-34/NNS||i.e.-31/JJ	nn||volunteers-34/NNS||village-32/NN	nn||volunteers-34/NNS||health-33/NN	nsubj||vhvs-36/VBZ||volunteers-34/NNS	advmod||vhvs-36/VBZ||-lrb--35/RB	ccomp||-lrb--30/VBD||vhvs-36/VBZ	amod||-rrb--38/NNS||-rrb--37/JJ	dobj||vhvs-36/VBZ||-rrb--38/NNS	aids--1||hiv--1||no||criteria for priority setting of hiv/aids interventions in thailand were identified in group discussions with policy makers , people living with hiv/aids -lrb- plwha -rrb- , and community members -lrb- i.e. village health volunteers -lrb- vhvs -rrb- -rrb- .
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||rifampicin-17||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
det||paper-2/NN||this-1/DT	nsubj||provides-3/VBZ||paper-2/NN	ccomp||ironoverload-11/VBD||provides-3/VBZ	det||overview-5/NN||an-4/DT	dobj||provides-3/VBZ||overview-5/NN	amod||metabolism-9/NN||normal-7/JJ	nn||metabolism-9/NN||iron-8/NN	prep_of||overview-5/NN||metabolism-9/NN	root||ROOT-0/null||ironoverload-11/VBD	amod||patients-14/NNS||transfused-13/JJ	prep_in||ironoverload-11/VBD||patients-14/NNS	amod||disease-18/NN||sickle-16/JJ	nn||disease-18/NN||cell-17/NN	prep_with||ironoverload-11/VBD||disease-18/NN	appos||disease-18/NN||patterns-20/NNS	nn||organ-23/NN||end-22/NN	prep_of||patterns-20/NNS||organ-23/NN	nsubj||ironoverload-11/VBD||damage-24/NN	nsubj||ironoverload-11/VBD||diagnosis-26/NN	conj_and||damage-24/NN||diagnosis-26/NN	nsubj||ironoverload-11/VBD||treatment-28/NN	conj_and||damage-24/NN||treatment-28/NN	nsubj||ironoverload-11/VBD||prevention-31/NN	conj_and||damage-24/NN||prevention-31/NN	prep_of||damage-24/NN||ironoverload-33/NN	ironoverload-33||iron-8||no||this paper provides an overview of normal iron metabolism, ironoverload in transfused patients with sickle cell disease, patterns of end organ damage, diagnosis, treatment, and prevention of ironoverload.
det||analysis-6/NN||an-2/DT	amod||analysis-6/NN||unsupervised-3/JJ	amod||analysis-6/NN||hierarchical-4/JJ	nn||analysis-6/NN||cluster-5/NN	prep_in||identified-21/VBN||analysis-6/NN	amod||profiles-10/NNS||similar-8/JJ	amod||profiles-10/NNS||genomic-9/JJ	nsubjpass||identified-21/VBN||profiles-10/NNS	amod||clustering-13/NN||close-12/JJ	conj_and||profiles-10/NNS||clustering-13/NN	nsubjpass||identified-21/VBN||clustering-13/NN	det||sts-19/NN||the-15/DT	amod||sts-19/NN||first-16/JJ	conj_and||first-16/JJ||subsequent-18/JJ	amod||sts-19/NN||subsequent-18/JJ	prep_between||clustering-13/NN||sts-19/NN	auxpass||identified-21/VBN||were-20/VBD	root||ROOT-0/null||identified-21/VBN	num||cases-24/NNS||5-23/CD	prep_in||identified-21/VBN||cases-24/NNS	vmod||cases-24/NNS||suggesting-26/VBG	amod||disease-28/NN||metastatic-27/JJ	dobj||suggesting-26/VBG||disease-28/NN	mark||did-38/VBD||whereas-30/IN	det||tumors-32/NNS||the-31/DT	nsubj||did-38/VBD||tumors-32/NNS	nsubj||showed-42/VBD||tumors-32/NNS	det||patients-37/NNS||the-34/DT	amod||patients-37/NNS||remaining-35/VBG	num||patients-37/NNS||8-36/CD	prep_from||tumors-32/NNS||patients-37/NNS	advcl||suggesting-26/VBG||did-38/VBD	neg||cluster-40/NN||not-39/RB	dobj||did-38/VBD||cluster-40/NN	advcl||suggesting-26/VBG||showed-42/VBD	conj_and||did-38/VBD||showed-42/VBD	advmod||correlation-46/NN||only-43/RB	amod||correlation-46/NN||weak-44/JJ	amod||correlation-46/NN||pairwise-45/JJ	dobj||showed-42/VBD||correlation-46/NN	vmod||suggesting-26/VBG||suggesting-48/VBG	dobj||suggesting-48/VBG||development-49/NN	amod||sts-53/NN||second-51/JJ	amod||sts-53/NN||primary-52/JJ	prep_of||development-49/NN||sts-53/NN	tumors-32||sts-53||no||in an unsupervised hierarchical cluster analysis, similar genomic profiles and close clustering between the first and subsequent sts were identified in 5 cases, suggesting metastatic disease, whereas the tumors from the remaining 8 patients did not cluster and showed only weak pairwise correlation, suggesting development of second primary sts.
poss||patient-2/NN||our-1/PRP$	nsubj||responded-3/VBD||patient-2/NN	root||ROOT-0/null||responded-3/VBD	advmod||responded-3/VBD||well-4/RB	prep_to||well-4/RB||treatment-6/NN	nn||intervals-11/NNS||levothyroxine-8/NN	conj_and||levothyroxine-8/NN||qt-10/NN	nn||intervals-11/NNS||qt-10/NN	prep_with||responded-3/VBD||intervals-11/NNS	vmod||intervals-11/NNS||normalized-12/VBN	nsubjpass||abolished-16/VBN||ventriculartachycardia-14/NN	auxpass||abolished-16/VBN||was-15/VBD	conj_and||responded-3/VBD||abolished-16/VBN	num||months-18/NNS||two-17/CD	npadvmod||abolished-16/VBN||months-18/NNS	amod||therapy-21/NN||levothyroxine-20/JJ	prep_after||abolished-16/VBN||therapy-21/NN	ventriculartachycardia-14||levothyroxine-20||no_rel||our patient responded well to treatment with levothyroxine and qt intervals normalized and ventriculartachycardia was abolished two months after levothyroxine therapy.
nsubj||alternative-5/NN||daptomycin-1/NN	cop||alternative-5/NN||was-2/VBD	det||alternative-5/NN||an-3/DT	amod||alternative-5/NN||effective-4/JJ	root||ROOT-0/null||alternative-5/NN	aux||vancomycin/gentamicin-7/VB||to-6/TO	vmod||alternative-5/NN||vancomycin/gentamicin-7/VB	nn||bacteraemia-10/NN||mrsa-9/NN	prep_for||vancomycin/gentamicin-7/VB||bacteraemia-10/NN	amod||endocarditis-13/NNS||right-sided-12/JJ	prep_for||vancomycin/gentamicin-7/VB||endocarditis-13/NNS	conj_or||bacteraemia-10/NN||endocarditis-13/NNS	daptomycin-1||bacteraemia-10||no_rel||daptomycin was an effective alternative to vancomycin/gentamicin for mrsa bacteraemia or right-sided endocarditis.
nsubj||infection-9/NN||tineacapitis-1/NNS	appos||tineacapitis-1/NNS||tc-3/NN	cop||infection-9/NN||is-5/VBZ	det||infection-9/NN||a-6/DT	amod||infection-9/NN||common-7/JJ	nn||infection-9/NN||dermatophyte-8/NN	root||ROOT-0/null||infection-9/NN	vmod||infection-9/NN||affecting-10/VBG	advmod||children-13/NNS||primarily-11/RB	amod||children-13/NNS||prepubertal-12/JJ	dobj||affecting-10/VBG||children-13/NNS	tineacapitis-1||dermatophyte-8||no||tineacapitis (tc) is a common dermatophyte infection affecting primarily prepubertal children.
nsubj||have-4/VBP||patients-1/NNS	prep_with||patients-1/NNS||tsc-3/NN	root||ROOT-0/null||have-4/VBP	dobj||have-4/VBP||hamartomas-5/NNS	amod||organs-8/NNS||various-7/JJ	prep_in||hamartomas-5/NNS||organs-8/NNS	det||body-12/NN||the-10/DT	amod||body-12/NN||whole-11/JJ	prep_throughout||organs-8/NNS||body-12/NN	advmod||notably-15/RB||most-14/RBS	advmod||have-4/VBP||notably-15/RB	det||brain-18/NN||the-17/DT	prep_in||have-4/VBP||brain-18/NN	prep_in||have-4/VBP||skin-20/NN	conj_and||brain-18/NN||skin-20/NN	prep_in||have-4/VBP||eye-22/NN	conj_and||brain-18/NN||eye-22/NN	prep_in||have-4/VBP||heart-24/NN	conj_and||brain-18/NN||heart-24/NN	prep_in||have-4/VBP||kidney-26/NN	conj_and||brain-18/NN||kidney-26/NN	prep_in||have-4/VBP||lung-28/NN	conj_and||brain-18/NN||lung-28/NN	tsc-3||hamartomas-5||no||patients with tsc have hamartomas in various organs throughout the whole body, most notably in the brain, skin, eye, heart, kidney and lung.
amod||analyses-2/NNS||multiallelic-1/JJ	nsubj||showed-10/VBD||analyses-2/NNS	prepc_of||analyses-2/NNS||carrying-4/VBG	nn||alleles-6/NNS||risk-5/NN	dobj||carrying-4/VBG||alleles-6/NNS	amod||genes-9/NNS||multiple-8/JJ	prep_for||carrying-4/VBG||genes-9/NNS	root||ROOT-0/null||showed-10/VBD	dobj||showed-10/VBD||correlations-11/NNS	prep_between||correlations-11/NNS||number-13/NN	nn||alleles-16/NNS||risk-15/NN	prep_of||number-13/NN||alleles-16/NNS	prep_of||number-13/NN||type2diabetes-18/NNS	conj_and||alleles-16/NNS||type2diabetes-18/NNS	amod||secretion-22/NN||impaired-20/VBN	nn||secretion-22/NN||insulin-21/NN	prep_between||correlations-11/NNS||secretion-22/NN	conj_and||number-13/NN||secretion-22/NN	amod||subjects-25/NNS||normoglycemic-24/JJ	prep_in||secretion-22/NN||subjects-25/NNS	dep||secretion-22/NN||p-27/VBN	dep||0.006-29/CD||=-28/SYM	ccomp||p-27/VBN||0.006-29/CD	ccomp||p-27/VBN||0.0001-31/CD	conj_and||0.006-29/CD||0.0001-31/CD	prep_for||p-27/VBN||type2diabetes-33/NN	prep_for||p-27/VBN||air-35/NN	conj_and||type2diabetes-33/NN||air-35/NN	advmod||p-27/VBN||respectively-37/RB	vmod||showed-10/VBD||supporting-40/VBG	det||hypothesis-42/NNS||the-41/DT	dobj||supporting-40/VBG||hypothesis-42/NNS	mark||influence-48/VBP||that-43/IN	nsubj||influence-48/VBP||many-44/JJ	det||genes-47/NNS||these-46/DT	prep_of||many-44/JJ||genes-47/NNS	ccomp||supporting-40/VBG||influence-48/VBP	nn||risk-50/NN||diabetes-49/NN	dobj||influence-48/VBP||risk-50/NN	prepc_by||influence-48/VBP||affecting-52/VBG	nn||secretion-54/NN||insulin-53/NN	dobj||affecting-52/VBG||secretion-54/NN	type2diabetes-33||insulin-53||yes||multiallelic analyses of carrying risk alleles for multiple genes showed correlations between number of risk alleles and type2diabetes and impaired insulin secretion in normoglycemic subjects ( p = 0.006 and 0.0001 for type2diabetes and air, respectively), supporting the hypothesis that many of these genes influence diabetes risk by affecting insulin secretion.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-33/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-23/VBZ||levels-10/NNS	prep_of||levels-10/NNS||n-3fattyacids-12/JJ	appos||n-3fattyacids-12/JJ||fa-14/NN	possessive||fa-14/NN||'s-15/POS	amod||levels-19/NNS||higher-18/JJR	prep_of||levels-10/NNS||levels-19/NNS	conj_and||n-3fattyacids-12/JJ||levels-19/NNS	amod||fa-22/NN||n-6-21/JJ	prep_of||levels-19/NNS||fa-22/NN	ccomp||contained-8/VBD||'s-23/VBZ	det||diet-27/NN||the-25/DT	nn||diet-27/NN||control-26/NN	prep_than||'s-23/VBZ||diet-27/NN	appos||diet-27/NN||ctr-29/NN	nsubj||found-33/VBD||we-32/PRP	root||ROOT-0/null||found-33/VBD	amod||decreases-35/NNS||significant-34/JJ	nsubj||'s-46/VBZ||decreases-35/NNS	amod||acid-38/NN||docosahexaenoic-37/JJ	prep_in||decreases-35/NNS||acid-38/NN	appos||acid-38/NN||dha-40/NN	amod||fa-45/NN||total-43/JJ	amod||fa-45/NN||n-3-44/JJ	prep_in||decreases-35/NNS||fa-45/NN	conj_and||acid-38/NN||fa-45/NN	ccomp||found-33/VBD||'s-46/VBZ	nn||maternal-49/NN||hfd-48/NN	prep_in||'s-46/VBZ||maternal-49/NN	amod||plasma-52/NN||fetal-51/JJ	prep_in||'s-46/VBZ||plasma-52/NN	conj_and||maternal-49/NN||plasma-52/NN	fat--1||fa-45||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
advmod||acts-4/VBZ||chronically-1/RB	nsubj||acts-4/VBZ||insulin-3/NN	root||ROOT-0/null||acts-4/VBZ	det||brain-7/NN||the-6/DT	prep_in||acts-4/VBZ||brain-7/NN	aux||regulate-9/VB||to-8/TO	vmod||brain-7/NN||regulate-9/VB	det||response-12/NN||the-10/DT	amod||response-12/NN||counterregulatory-11/JJ	dobj||regulate-9/VB||response-12/NN	prep_to||regulate-9/VB||hypoglycemia-14/NN	advmod||altering-17/VBG||directly-16/RB	prepc_by||regulate-9/VB||altering-17/VBG	dobj||altering-17/VBG||glucose-18/NN	dep||altering-17/VBG||sensing-19/VBG	amod||neurons-22/NNS||hypothalamic-21/JJ	prep_in||sensing-19/VBG||neurons-22/NNS	dep||altering-17/VBG||shifting-24/VBG	conj_and||sensing-19/VBG||shifting-24/VBG	det||levels-27/NNS||the-25/DT	amod||levels-27/NNS||glycemic-26/JJ	nsubj||necessary-28/JJ||levels-27/NNS	nsubj||elicit-30/VB||levels-27/NNS	xcomp||shifting-24/VBG||necessary-28/JJ	aux||elicit-30/VB||to-29/TO	xcomp||necessary-28/JJ||elicit-30/VB	det||response-34/NN||a-31/DT	amod||response-34/NN||normal-32/JJ	amod||response-34/NN||sympathoadrenal-33/JJ	dobj||elicit-30/VB||response-34/NN	hypoglycemia-14||glucose-18||yes||chronically, insulin acts in the brain to regulate the counterregulatory response to hypoglycemia by directly altering glucose sensing in hypothalamic neurons and shifting the glycemic levels necessary to elicit a normal sympathoadrenal response.
det||kits-5/NNS||the-1/DT	num||kits-5/NNS||70-2/CD	amod||kits-5/NNS||hbsag-3/JJ	nn||kits-5/NNS||test-4/NN	nsubjpass||evaluated-11/VBN||kits-5/NNS	advmod||world-9/NN||around-7/RB	det||world-9/NN||the-8/DT	prep_from||kits-5/NNS||world-9/NN	auxpass||evaluated-11/VBN||were-10/VBD	root||ROOT-0/null||evaluated-11/VBN	amod||a-f-56/NNS||comparatively-12/RB	poss||sensitivity-16/NN||their-14/PRP$	amod||sensitivity-16/NN||clinical-15/JJ	prep_for||comparatively-12/RB||sensitivity-16/NN	amod||sensitivity-19/NN||analytical-18/JJ	prep_for||comparatively-12/RB||sensitivity-19/NN	conj_and||sensitivity-16/NN||sensitivity-19/NN	prep_for||comparatively-12/RB||sensitivity-21/NN	conj_and||sensitivity-16/NN||sensitivity-21/NN	nn||genotypes-24/NNS||hbv-23/NN	prep_to||sensitivity-21/NN||genotypes-24/NNS	nn||subtypes-27/NNS||hbsag-26/NN	prep_to||sensitivity-21/NN||subtypes-27/NNS	conj_and||genotypes-24/NNS||subtypes-27/NNS	prep_for||comparatively-12/RB||specificity-30/NN	conj_and||sensitivity-16/NN||specificity-30/NN	vmod||specificity-30/NN||using-31/VBG	amod||icbs-43/NNS||394-32/JJ	num||clinical-35/NNS||146-34/CD	dep||icbs-43/NNS||clinical-35/NNS	num||analytical-38/NNS||48-37/CD	conj_and||clinical-35/NNS||analytical-38/NNS	dep||icbs-43/NNS||analytical-38/NNS	num||negative-41/NN||200-40/CD	conj_and||clinical-35/NNS||negative-41/NN	dep||icbs-43/NNS||negative-41/NN	dobj||using-31/VBG||icbs-43/NNS	nn||members-46/NNS||master-44/NN	nn||members-46/NNS||panel-45/NN	dep||specificity-30/NN||members-46/NNS	amod||origin-50/NN||diverse-48/JJ	amod||origin-50/NN||geographical-49/JJ	prep_of||members-46/NNS||origin-50/NN	vmod||origin-50/NN||comprising-51/VBG	det||genotypes-55/NNS||the-52/DT	amod||genotypes-55/NNS||major-53/JJ	nn||genotypes-55/NNS||hbv-54/NN	dobj||comprising-51/VBG||genotypes-55/NNS	dobj||evaluated-11/VBN||a-f-56/NNS	det||subtypes-60/NNS||the-58/DT	amod||subtypes-60/NNS||hbsag-59/VBG	dobj||evaluated-11/VBN||subtypes-60/NNS	conj_and||a-f-56/NNS||subtypes-60/NNS	amod||subtypes-60/NNS||adw2-61/JJ	dep||adw2-61/JJ||,4-62/CD	num||,4-62/CD||adr-64/CD	dep||adw2-61/JJ||ayw1-4-66/CD	conj_and||,4-62/CD||ayw1-4-66/CD	hbv-54||hbsag-59||yes||the 70 hbsag test kits from around the world were evaluated comparatively for their clinical sensitivity, analytical sensitivity, sensitivity to hbv genotypes and hbsag subtypes, and specificity using 394 (146 clinical, 48 analytical and 200 negative) icbs master panel members of diverse geographical origin comprising the major hbv genotypes a-f and the hbsag subtypes adw2,4 , adr and ayw1-4 .
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effects-4/NNS||the-3/DT	dobj||investigated-2/VBD||effects-4/NNS	amod||lipoproteins-7/NNS||apob-containing-6/JJ	prep_of||effects-4/NNS||lipoproteins-7/NNS	amod||lipolysis-10/NNS||catecholamine-induced-9/JJ	prep_on||investigated-2/VBD||lipolysis-10/NNS	prep_in||lipolysis-10/NNS||adipocytes-12/NNS	amod||cells-16/NNS||subcutaneous-14/JJ	amod||cells-16/NNS||fat-15/JJ	prep_from||investigated-2/VBD||cells-16/NNS	amod||men-22/NNS||obese-18/JJ	advmod||healthy-21/JJ||otherwise-20/RB	conj_but||obese-18/JJ||healthy-21/JJ	amod||men-22/NNS||healthy-21/JJ	prep_of||cells-16/NNS||men-22/NNS	amod||pads-25/NNS||fat-24/JJ	appos||men-22/NNS||pads-25/NNS	prep_from||pads-25/NNS||mice-27/NNS	nn||lipoproteins-30/NNS||plasma-29/NN	prep_with||investigated-2/VBD||lipoproteins-30/NNS	vmod||lipoproteins-30/NNS||containing-31/VBG	amod||levels-35/NNS||high-32/JJ	conj_or||high-32/JJ||intermediate-34/JJ	amod||levels-35/NNS||intermediate-34/JJ	dobj||containing-31/VBG||levels-35/NNS	prep_of||levels-35/NNS||apob100-37/CD	neg||apob100-40/NN||no-39/DT	dobj||containing-31/VBG||apob100-40/NN	conj_or||levels-35/NNS||apob100-40/NN	amod||adipocytes-44/NNS||primary-42/JJ	amod||adipocytes-44/NNS||cultured-43/JJ	conj_or||levels-35/NNS||adipocytes-44/NNS	conj_and||apob100-40/NN||adipocytes-44/NNS	amod||cells-48/NNS||3t3-l1-47/JJ	conj_or||levels-35/NNS||cells-48/NNS	conj_and||apob100-40/NN||cells-48/NNS	obese-18||fat-24||no_rel||we investigated the effects of apob-containing lipoproteins on catecholamine-induced lipolysis in adipocytes from subcutaneous fat cells of obese but otherwise healthy men, fat pads from mice with plasma lipoproteins containing high or intermediate levels of apob100 or no apob100, primary cultured adipocytes, and 3t3-l1 cells.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type1diabetes-49||sitagliptin-20||no||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
amod||resistance-3/NN||primary-1/JJ	amod||resistance-3/NN||glucocorticoid-2/JJ	nsubj||hereditarydisease-11/NN||resistance-3/NN	appos||resistance-3/NN||omim-5/NN	num||omim-5/NN||138040-6/CD	cop||hereditarydisease-11/NN||is-8/VBZ	det||hereditarydisease-11/NN||a-9/DT	amod||hereditarydisease-11/NN||rare-10/JJ	root||ROOT-0/null||hereditarydisease-11/NN	nsubj||causes-13/VBZ||hereditarydisease-11/NN	rcmod||hereditarydisease-11/NN||causes-13/VBZ	det||insensitivity-17/NN||a-14/DT	amod||insensitivity-17/NN||generalized-15/JJ	amod||insensitivity-17/NN||partial-16/JJ	dobj||causes-13/VBZ||insensitivity-17/NN	amod||action-20/NN||glucocorticoid-19/JJ	prep_to||causes-13/VBZ||action-20/NN	acomp||causes-13/VBZ||due-22/JJ	amod||alterations-25/NNS||genetic-24/JJ	prep_to||due-22/JJ||alterations-25/NNS	det||receptor-29/NN||the-27/DT	amod||receptor-29/NN||glucocorticoid-28/JJ	prep_of||alterations-25/NNS||receptor-29/NN	appos||receptor-29/NN||gr-31/NN	hereditarydisease-11||glucocorticoid-28||no_rel||primary glucocorticoid resistance (omim 138040) is a rare hereditarydisease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (gr).
mark||expected-2/VBN||as-1/IN	advcl||reduced-6/VBD||expected-2/VBN	nn||therapy-5/NN||ribavirin-4/NNP	nsubj||reduced-6/VBD||therapy-5/NN	root||ROOT-0/null||reduced-6/VBD	dobj||reduced-6/VBD||levels-7/NNS	amod||virus-10/NN||infectious-9/JJ	prep_of||levels-7/NNS||virus-10/NN	nn||rna-13/NN||ri-12/NN	prep_of||levels-7/NNS||rna-13/NN	conj_and||virus-10/NN||rna-13/NN	det||lung-17/NN||the-15/DT	nn||lung-17/NN||mouse-16/NN	prep_in||reduced-6/VBD||lung-17/NN	virus-10||ribavirin-4||yes||as expected, ribavirin therapy reduced levels of infectious virus and ri rna in the mouse lung.
amod||analysis-3/NN||logistic-1/JJ	nn||analysis-3/NN||regression-2/NN	nsubj||yielded-4/VBD||analysis-3/NN	nsubj||had-17/VBD||analysis-3/NN	nsubj||unprotected-28/VBN||analysis-3/NN	nsubj||had-40/VBD||analysis-3/NN	nsubj||used-64/VBD||analysis-3/NN	nsubj||used-76/VBD||analysis-3/NN	root||ROOT-0/null||yielded-4/VBD	num||factors-6/NNS||eight-5/CD	dobj||yielded-4/VBD||factors-6/NNS	nsubjpass||associated-9/VBN||factors-6/NNS	auxpass||associated-9/VBN||were-8/VBD	rcmod||factors-6/NNS||associated-9/VBN	prep_with||associated-9/VBN||non-attendance-11/NN	amod||age-15/NN||gay-13/JJ	nn||age-15/NN||pride-14/NN	prep_of||non-attendance-11/NN||age-15/NN	conj_and||yielded-4/VBD||had-17/VBD	nn||high-20/NN||sex-18/NN	nn||high-20/NN||while-19/NN	dobj||had-17/VBD||high-20/NN	det||months-25/NNS||the-22/DT	amod||months-25/NNS||last-23/JJ	num||months-25/NNS||12â-24/CD	prep_in||high-20/NN||months-25/NNS	aux||unprotected-28/VBN||had-27/VBD	conj_and||yielded-4/VBD||unprotected-28/VBN	amod||intercourse-30/NN||anal-29/JJ	dobj||unprotected-28/VBN||intercourse-30/NN	appos||intercourse-30/NN||uai-32/NN	det||months-38/NNS||the-35/DT	amod||months-38/NNS||last-36/JJ	num||months-38/NNS||12â-37/CD	prep_in||unprotected-28/VBN||months-38/NNS	conj_and||yielded-4/VBD||had-40/VBD	dobj||had-40/VBD||sex-41/NN	prep_for||had-40/VBD||drugs/money-43/NN	det||months-48/NNS||the-45/DT	amod||months-48/NNS||last-46/JJ	num||months-48/NNS||12â-47/CD	prep_in||drugs/money-43/NN||months-48/NNS	auxpass||diagnosed-51/VBN||been-50/VBN	vmod||drugs/money-43/NN||diagnosed-51/VBN	det||sexuallytransmittedinfection-54/NN||a-53/DT	prep_with||diagnosed-51/VBN||sexuallytransmittedinfection-54/NN	appos||sexuallytransmittedinfection-54/NN||sti-56/NN	det||months-62/NNS||the-59/DT	amod||months-62/NNS||last-60/JJ	num||months-62/NNS||12â-61/CD	prep_in||had-40/VBD||months-62/NNS	conj_and||yielded-4/VBD||used-64/VBD	dobj||used-64/VBD||nitrites-65/NNS	appos||nitrites-65/NNS||poppers-67/NNS	det||months-73/NNS||the-70/DT	amod||months-73/NNS||last-71/JJ	num||months-73/NNS||12â-72/CD	prep_in||used-64/VBD||months-73/NNS	conj_and||yielded-4/VBD||used-76/VBD	dobj||used-76/VBD||methamphetamine-77/NN	det||months-82/NNS||the-79/DT	amod||months-82/NNS||last-80/JJ	num||months-82/NNS||12â-81/CD	prep_in||used-76/VBD||months-82/NNS	sexuallytransmittedinfection-54||methamphetamine-77||no_rel||logistic regression analysis yielded eight factors that were associated with non-attendance of gay pride age, had sex while high in the last 12â months, had unprotected anal intercourse (uai) in the last 12â months, had sex for drugs/money in the last 12â months, been diagnosed with a sexuallytransmittedinfection (sti) in the last 12â months, used nitrites (poppers) in the last 12â months, and used methamphetamine in the last 12â months.
det||structure-3/NN||the-1/DT	nn||structure-3/NN||crystal-2/NN	nsubj||consists-16/VBZ||structure-3/NN	nsubj||consists-16/VBZ||structure-3/NN	det||compound-7/NN||the-5/DT	nn||compound-7/NN||title-6/NN	prep_of||structure-3/NN||compound-7/NN	nn||-RSB--14/NNP||-LSB--9/NNP	nn||-RSB--14/NNP||zncl2-10/NNP	appos||-RSB--14/NNP||c10h8n2s-12/NNP	appos||structure-3/NN||-RSB--14/NNP	root||ROOT-0/null||consists-16/VBZ	conj_and||consists-16/VBZ||consists-16/VBZ	det||ring-21/NN||a-18/DT	amod||ring-21/NN||six-membered-19/JJ	nn||ring-21/NN||chelate-20/NN	prep_of||consists-16/VBZ||ring-21/NN	prep_in||tetraâhedrally-29/JJ||ring-21/NN	det||atom-26/NN||the-24/DT	nn||atom-26/NN||zn-25/NN	nsubj||tetraâhedrally-29/JJ||atom-26/NN	cop||tetraâhedrally-29/JJ||is-27/VBZ	advmod||tetraâhedrally-29/JJ||approximately-28/RB	rcmod||ring-21/NN||tetraâhedrally-29/JJ	dep||tetraâhedrally-29/JJ||coordinated-30/VBN	num||ions-34/NNS||two-32/CD	nn||ions-34/NNS||chloride-33/NN	prep_by||coordinated-30/VBN||ions-34/NNS	det||atoms-41/NNS||the-37/DT	num||atoms-41/NNS||two-38/CD	amod||atoms-41/NNS||pyridyl-39/JJ	nn||atoms-41/NNS||n-40/NN	prep_by||consists-16/VBZ||atoms-41/NNS	det||sulfide-46/NN||a-43/DT	amod||sulfide-46/NN||single-44/JJ	amod||sulfide-46/NN||di-2-pyridyl-45/JJ	prep_of||atoms-41/NNS||sulfide-46/NN	vmod||sulfide-46/NN||ligand-47/VBN	zncl2-10||di--1||no_rel||the crystal structure of the title compound, [zncl2(c10h8n2s)], consists of a six-membered chelate ring in which the zn atom is approximately tetraâ­hedrally coordinated by two chloride ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand.
nsubj||investigated-3/VBN||we-1/PRP	aux||investigated-3/VBN||have-2/VBP	root||ROOT-0/null||investigated-3/VBN	det||effect-5/NN||the-4/DT	dobj||investigated-3/VBN||effect-5/NN	amod||treatment-9/NN||intermittent-7/JJ	nn||treatment-9/NN||preventive-8/NN	prep_of||effect-5/NN||treatment-9/NN	prep_with||treatment-9/NN||sulphadoxine-pyrimethamine-11/NN	prep_with||treatment-9/NN||artesunate-13/NN	conj_or||sulphadoxine-pyrimethamine-11/NN||artesunate-13/NN	dobj||investigated-3/VBN||amodiaquine-15/NN	conj_plus||effect-5/NN||amodiaquine-15/NN	prep_on||amodiaquine-15/NN||anaemia-17/NN	prep_on||amodiaquine-15/NN||malaria-19/NN	conj_and||anaemia-17/NN||malaria-19/NN	prep_in||investigated-3/VBN||children-21/NNS	det||area-24/NN||an-23/DT	prep_in||children-21/NNS||area-24/NN	amod||transmission-32/NN||intense-26/JJ	amod||transmission-32/NN||prolonged-28/JJ	amod||transmission-32/NN||seasonal-30/JJ	nn||transmission-32/NN||malaria-31/NN	prep_of||area-24/NN||transmission-32/NN	prep_in||investigated-3/VBN||ghana-34/NN	malaria-31||pyrimethamine--1||yes||we have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in ghana.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	pain-42||lidocaine-4||yes||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
poss||results-2/NNS||our-1/PRP$	nsubj||indicate-3/VBP||results-2/NNS	ccomp||has-47/VBZ||indicate-3/VBP	mark||induce-12/VB||that-4/IN	det||co-existence-6/NN||the-5/DT	nsubj||induce-12/VB||co-existence-6/NN	prep_of||co-existence-6/NN||diabetes-8/NN	prep_of||co-existence-6/NN||hypertension-10/NN	conj_and||diabetes-8/NN||hypertension-10/NN	aux||induce-12/VB||could-11/MD	ccomp||indicate-3/VBP||induce-12/VB	advmod||induce-12/VB||cardiomyopathy-13/RB	nsubj||result-17/VB||which-14/WDT	aux||result-17/VB||could-15/MD	advmod||result-17/VB||further-16/RBR	ccomp||induce-12/VB||result-17/VB	amod||fibrosis-20/NN||cardiac-19/JJ	prep_in||result-17/VB||fibrosis-20/NN	mark||has-30/VBZ||that-23/IN	nn||treatment-25/NN||combination-24/NN	nsubj||has-30/VBZ||treatment-25/NN	prep_with||treatment-25/NN||rosiglitazone-27/NN	prep_with||treatment-25/NN||felodipine-29/NN	conj_and||rosiglitazone-27/NN||felodipine-29/NN	ccomp||induce-12/VB||has-30/VBZ	conj_and||result-17/VB||has-30/VBZ	det||role-34/NN||a-31/DT	amod||role-34/NN||great-32/JJ	amod||role-34/NN||protective-33/JJ	dobj||has-30/VBZ||role-34/NN	det||abnormalities-38/NNS||the-36/DT	amod||abnormalities-38/NNS||metabolic-37/JJ	prep_against||role-34/NN||abnormalities-38/NNS	advmod||has-30/VBZ||meanwhile-40/RB	det||treatment-43/NN||the-42/DT	nsubj||has-47/VBZ||treatment-43/NN	nsubj||has-59/VBZ||treatment-43/NN	prep_with||treatment-43/NN||rosiglitazone-45/NN	advmod||has-47/VBZ||alone-46/RB	root||ROOT-0/null||has-47/VBZ	det||role-50/NN||a-48/DT	amod||role-50/NN||protective-49/JJ	dobj||has-47/VBZ||role-50/NN	det||effect-54/NN||a-52/DT	amod||effect-54/NN||minimal-53/JJ	prep_with||has-47/VBZ||effect-54/NN	det||abnormalities-57/NNS||these-56/DT	prep_against||effect-54/NN||abnormalities-57/NNS	conj_and||has-47/VBZ||has-59/VBZ	neg||effect-61/NN||no-60/DT	dobj||has-59/VBZ||effect-61/NN	amod||bp-64/NN||decreasing-63/VBG	prep_on||effect-61/NN||bp-64/NN	det||cases-67/NNS||these-66/DT	prep_in||bp-64/NN||cases-67/NNS	nsubj||lead-70/VB||cases-67/NNS	aux||lead-70/VB||may-69/MD	rcmod||cases-67/NNS||lead-70/VB	prep_to||lead-70/VB||coronaryarterydiseases-72/NNS	appos||coronaryarterydiseases-72/NNS||cads-74/NNS	prep_in||lead-70/VB||future-77/NN	hypertension-10||felodipine-29||yes||our results indicate that the co-existence of diabetes and hypertension could induce cardiomyopathy which could further result in cardiac fibrosis, and that combination treatment with rosiglitazone and felodipine has a great protective role against the metabolic abnormalities, meanwhile, the treatment with rosiglitazone alone has a protective role with a minimal effect against these abnormalities and has no effect on decreasing bp in these cases which may lead to coronaryarterydiseases (cads) in future.
mark||modulated-4/VBD||after-1/IN	nsubj||modulated-4/VBD||we-2/PRP	advmod||modulated-4/VBD||transiently-3/RB	advcl||measured-37/VBN||modulated-4/VBD	nn||expression-6/NN||fmrp-5/NN	dobj||modulated-4/VBD||expression-6/NN	parataxis||modulated-4/VBD||silencing-8/VBG	parataxis||modulated-4/VBD||enhancing-10/VBG	conj_or||silencing-8/VBG||enhancing-10/VBG	prepc_by||modulated-4/VBD||using-13/VBG	amod||methods-16/NNS||molecular-14/JJ	amod||methods-16/NNS||biotechnological-15/JJ	dobj||using-13/VBG||methods-16/NNS	amod||rna-21/NN||small-19/JJ	nn||rna-21/NN||hairpin-20/NN	prep_such_as||methods-16/NNS||rna-21/NN	dep||rna-21/NN||virus-induced-22/VBN	ccomp||virus-induced-22/VBN||knock-23/VB	prt||knock-23/VB||down-24/RP	dep||rna-21/NN||overexpression-26/VBN	conj_and||virus-induced-22/VBN||overexpression-26/VBN	xcomp||overexpression-26/VBN||using-27/VBG	dobj||using-27/VBG||transfection-28/NN	nn||vectors-32/NNS||fmrp-30/NN	nn||vectors-32/NNS||expression-31/NN	prep_with||using-27/VBG||vectors-32/NNS	amod||viability-35/NN||cellular-34/JJ	nsubjpass||measured-37/VBN||viability-35/NN	auxpass||measured-37/VBN||was-36/VBD	root||ROOT-0/null||measured-37/VBN	xcomp||measured-37/VBN||using-38/VBG	nn||staining-41/NN||propidium-39/NN	nn||staining-41/NN||iodide-40/NN	dobj||using-38/VBG||staining-41/NN	amod||staining-44/NN||tunel-43/JJ	dobj||using-38/VBG||staining-44/NN	conj_and||staining-41/NN||staining-44/NN	amod||analysis-48/NN||facs-47/JJ	dobj||using-38/VBG||analysis-48/NN	conj_and||staining-41/NN||analysis-48/NN	det||level-52/NN||the-51/DT	prep_along_with||using-38/VBG||level-52/NN	prep_of||level-52/NN||activation-54/NN	amod||pathway-57/NN||pi3k-akt-56/JJ	prep_of||activation-54/NN||pathway-57/NN	amod||blot-60/NN||western-59/JJ	prep_by||pathway-57/NN||blot-60/NN	iodide-40||virus--1||no_rel||after we transiently modulated fmrp expression (silencing or enhancing) by using molecular biotechnological methods such as small hairpin rna virus-induced knock down and overexpression using transfection with fmrp expression vectors, cellular viability was measured using propidium iodide staining, tunel staining, and facs analysis along with the level of activation of pi3k-akt pathway by western blot.
det||upregulation-2/NN||the-1/DT	nsubjpass||proposed-15/VBN||upregulation-2/NN	nn||b1r-5/NNS||kinin-4/NN	prep_of||upregulation-2/NN||b1r-5/NNS	amod||microglia-10/NN||spinal-7/JJ	amod||microglia-10/NN||dorsal-8/JJ	nn||microglia-10/NN||horn-9/NN	prep_in||b1r-5/NNS||microglia-10/NN	amod||cytokines-13/NNS||pro-inflammatory-12/JJ	prep_by||microglia-10/NN||cytokines-13/NNS	auxpass||proposed-15/VBN||is-14/VBZ	root||ROOT-0/null||proposed-15/VBN	det||mechanism-19/NN||a-17/DT	amod||mechanism-19/NN||crucial-18/JJ	prep_as||proposed-15/VBN||mechanism-19/NN	amod||neuropathy-23/NN||early-21/JJ	nn||neuropathy-23/NN||pain-22/NN	prep_in||mechanism-19/NN||neuropathy-23/NN	amod||rats-26/NNS||stz-diabetic-25/JJ	prep_in||neuropathy-23/NN||rats-26/NNS	pain-22||stz--1||no_rel||the upregulation of kinin b1r in spinal dorsal horn microglia by pro-inflammatory cytokines is proposed as a crucial mechanism in early pain neuropathy in stz-diabetic rats.
nsubj||resulted-29/VBD||conclusion-1/NN	det||group-4/NN||a-3/DT	prep_in||conclusion-1/NN||group-4/NN	amod||patients-7/NNS||asymptomatic-6/JJ	prep_of||group-4/NN||patients-7/NNS	amod||psychosis-11/NNS||first-9/JJ	nn||psychosis-11/NNS||episode-10/NN	prep_with||patients-7/NNS||psychosis-11/NNS	advmod||year-16/NN||at-13/IN	pobj||at-13/IN||least-14/JJS	num||year-16/NN||one-15/CD	prep_of||group-4/NN||year-16/NN	conj_and||patients-7/NNS||year-16/NN	amod||treatment-20/NN||previous-18/JJ	nn||treatment-20/NN||antipsychoticdrug-19/NN	prep_of||year-16/NN||treatment-20/NN	nn||treatment-23/NN||maintenance-22/NN	appos||year-16/NN||treatment-23/NN	prep_with||treatment-23/NN||quetiapine-25/NN	prepc_compared_with||group-4/NN||with-27/IN	pobj||group-4/NN||placebo-28/NN	root||ROOT-0/null||resulted-29/VBD	det||rate-34/NN||a-31/DT	advmod||lower-33/JJR||substantially-32/RB	amod||rate-34/NN||lower-33/JJR	prep_in||resulted-29/VBD||rate-34/NN	prep_of||rate-34/NN||relapse-36/NN	det||year-40/NN||the-38/DT	amod||year-40/NN||following-39/JJ	prep_during||resulted-29/VBD||year-40/NN	psychosis-11||quetiapine-25||yes||conclusion in a group of asymptomatic patients with first episode psychosis and at least one year of previous antipsychoticdrug treatment, maintenance treatment with quetiapine compared with placebo resulted in a substantially lower rate of relapse during the following year.
vmod||present-16/VBP||using-1/VBG	det||$-10/FW||the-2/DT	nn||$-10/FW||caenorhabditis-3/FW	nn||$-10/FW||elegans-4/FW	nn||$-10/FW||â-5/FW	nn||$-10/FW||$-6/FW	nn||$-10/FW||pseudomonasaeruginosa-8/FW	nn||$-10/FW||hostâ-9/FW	dobj||using-1/VBG||$-10/FW	iobj||using-1/VBG||$-10/FW	nn||system-13/NN||pathogen-12/NN	dep||$-10/FW||system-13/NN	nsubj||present-16/VBP||we-15/PRP	root||ROOT-0/null||present-16/VBP	amod||evidence-18/NN||genetic-17/JJ	dobj||present-16/VBP||evidence-18/NN	mark||required-72/VBN||that-19/IN	det||fat-3-24/NNS||a-20/DT	nn||fat-3-24/NNS||î-21/NN	amod||fat-3-24/NNS||6-desaturase-23/JJ	nsubjpass||required-72/VBN||fat-3-24/NNS	poss||productsâ-30/NNS||its-27/PRP$	num||productsâ-30/NNS||two-28/CD	amod||productsâ-30/NNS||18-carbon-29/JJ	prep_through||fat-3-24/NNS||productsâ-30/NNS	dep||fat-3-24/NNS||$-31/$	num||$-31/$||gamma-linolenicacid-33/CD	dep||$-31/$||gla-35/NN	appos||gla-35/NN||183n6-37/NNS	amod||acid-41/NN||stearidonic-40/JJ	dep||fat-3-24/NNS||acid-41/NN	conj_and||$-31/$||acid-41/NN	dep||acid-41/NN||sda-43/NN	appos||sda-43/NN||184n3-45/NNS	det||acid-54/NN||the-50/DT	num||pufas-52/NNS||20-carbon-51/CD	npadvmod||arachidonic-53/JJ||pufas-52/NNS	amod||acid-54/NN||arachidonic-53/JJ	dep||fat-3-24/NNS||acid-54/NN	conj_negcc||$-31/$||acid-54/NN	dep||acid-54/NN||aa-56/NN	appos||aa-56/NN||204n6-58/NNS	amod||$-69/NNS||eicosapentaenoic-61/JJ	amod||$-69/NNS||acid-62/JJ	dep||$-69/NNS||epa-64/NN	appos||epa-64/NN||205n3-66/NNS	nn||$-69/NNS||â-68/NN	conj_negcc||$-31/$||$-69/NNS	conj_and||acid-54/NN||$-69/NNS	auxpass||required-72/VBN||is-71/VBZ	ccomp||present-16/VBP||required-72/VBN	amod||immunity-76/NN||basal-74/JJ	nn||immunity-76/NN||innate-75/NN	prep_for||required-72/VBN||immunity-76/NN	prep_in||immunity-76/NN||vivo-78/NN	sda-43||carbon--1||no_rel||using the caenorhabditis elegans â€“ pseudomonasaeruginosa hostâ€“pathogen system, we present genetic evidence that a î”6-desaturase fat-3, through its two 18-carbon productsâ€”gamma-linolenicacid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)â€”is required for basal innate immunity in vivo.
advmod||compared-14/VBN||recently-1/RB	det||trial-7/NN||a-4/DT	amod||trial-7/NN||double-5/JJ	amod||trial-7/NN||blind-6/JJ	prep_in||compared-14/VBN||trial-7/NN	det||efficacy-10/NN||the-9/DT	nsubjpass||compared-14/VBN||efficacy-10/NN	prep_of||efficacy-10/NN||taubr-12/NN	auxpass||compared-14/VBN||was-13/VBD	root||ROOT-0/null||compared-14/VBN	det||efficacy-17/NN||the-16/DT	prep_with||compared-14/VBN||efficacy-17/NN	prep_of||efficacy-17/NN||clindamycin-19/NN	appos||clindamycin-19/NN||one-21/CD	det||antibiotics-27/NNS||the-23/DT	amod||antibiotics-27/NNS||most-24/JJS	amod||antibiotics-27/NNS||common-25/JJ	amod||antibiotics-27/NNS||topical-26/JJ	prep_of||one-21/CD||antibiotics-27/NNS	vmod||antibiotics-27/NNS||used-28/VBN	amod||therapy-31/NN||acne-30/JJ	prep_in||used-28/VBN||therapy-31/NN	acne-30||clindamycin-19||yes||recently, in a double blind trial, the efficacy of taubr was compared with the efficacy of clindamycin, one of the most common topical antibiotics used in acne therapy.
nsubjpass||expressed-4/VBN||myb-1/NN	auxpass||expressed-4/VBN||is-2/VBZ	advmod||expressed-4/VBN||highly-3/RB	root||ROOT-0/null||expressed-4/VBN	amod||breasttumours-14/NNS||estrogen-6/JJ	nn||breasttumours-14/NNS||receptor-7/NN	nn||breasttumours-14/NNS||positive-8/NN	amod||ve-12/NN||er-10/JJ	amod||ve-12/NN||+-11/JJ	appos||breasttumours-14/NNS||ve-12/NN	prep_in||expressed-4/VBN||breasttumours-14/NNS	nn||lines-18/NNS||tumour-16/NN	nn||lines-18/NNS||cell-17/NN	prep_in||expressed-4/VBN||lines-18/NNS	conj_and||breasttumours-14/NNS||lines-18/NNS	breasttumours-14||estrogen-6||yes||myb is highly expressed in estrogen receptor positive (er + ve) breasttumours and tumour cell lines.
det||survey-8/NN||an-1/DT	amod||survey-8/NN||island-2/JJ	amod||survey-8/NN||wide-3/JJ	amod||survey-8/NN||cross-sectional-5/JJ	amod||survey-8/NN||community-based-7/JJ	nsubjpass||done-17/VBN||survey-8/NN	nn||symptoms-13/NNS||asthma-10/NN	prep_of||survey-8/NN||asthma-12/NN	conj_and||symptoms-13/NNS||asthma-12/NN	prep_of||survey-8/NN||symptoms-13/NNS	prep_of||survey-8/NN||allergies-15/NNS	conj_and||symptoms-13/NNS||allergies-15/NNS	auxpass||done-17/VBN||was-16/VBD	root||ROOT-0/null||done-17/VBN	prep_among||done-17/VBN||adults-19/NNS	prep_among||done-17/VBN||children-21/NNS	conj_and||adults-19/NNS||children-21/NNS	xcomp||done-17/VBN||using-22/VBG	det||questionnaire-29/NN||the-23/DT	nn||questionnaire-29/NN||european-24/NN	nn||questionnaire-29/NN||community-25/NN	nn||questionnaire-29/NN||respiratory-26/NN	nn||questionnaire-29/NN||health-27/NN	nn||questionnaire-29/NN||survey-28/NN	dobj||using-22/VBG||questionnaire-29/NN	prep_for||questionnaire-29/NN||adults-31/NNS	det||study-35/NN||the-33/DT	amod||study-35/NN||international-34/JJ	dobj||using-22/VBG||study-35/NN	conj_and||questionnaire-29/NN||study-35/NN	prep_of||study-35/NN||asthma-37/NN	prep_of||study-35/NN||allergies-39/NNS	conj_and||asthma-37/NN||allergies-39/NNS	prep_in||using-22/VBG||children-41/NNS	allergies-39||allergies-39||no||an island wide, cross-sectional, community-based survey of asthma, asthma symptoms and allergies was done among adults and children using the european community respiratory health survey questionnaire for adults and the international study of asthma and allergies in children.
amod||studies-2/NNS||clinical-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||effective-12/JJ||that-5/IN	nsubj||effective-12/JJ||naproxen-6/NN	conj_and||naproxen-6/NN||ibuprofen-8/NN	nsubj||effective-12/JJ||ibuprofen-8/NN	cop||effective-12/JJ||are-9/VBP	advmod||effective-12/JJ||significantly-10/RB	advmod||effective-12/JJ||more-11/RBR	ccomp||shown-4/VBN||effective-12/JJ	prepc_at||effective-12/JJ||reducing-14/VBG	nn||pain-16/NN||oa-15/NN	dobj||reducing-14/VBG||pain-16/NN	mark||acetaminophen-19/NN||than-17/IN	cop||acetaminophen-19/NN||is-18/VBZ	ccomp||effective-12/JJ||acetaminophen-19/NN	nsubj||has-27/VBZ||acetaminophen-19/NN	det||therapy-24/NN||the-21/DT	amod||therapy-24/NN||traditional-22/JJ	amod||therapy-24/NN||first-line-23/JJ	appos||acetaminophen-19/NN||therapy-24/NN	rcmod||acetaminophen-19/NN||has-27/VBZ	neg||activity-31/NN||no-28/DT	amod||activity-31/NN||apparent-29/JJ	amod||activity-31/NN||anti-inflammatory-30/JJ	dobj||has-27/VBZ||activity-31/NN	det||joints-34/NNS||the-33/DT	prep_in||activity-31/NN||joints-34/NNS	oa-15||ibuprofen-8||yes||clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing oa pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||outcome-4/NN||the-3/DT	dobj||investigated-2/VBD||outcome-4/NN	amod||chemotherapy-7/NN||atra/anthracycline-6/JJ	prep_of||outcome-4/NN||chemotherapy-7/NN	nn||correlations-10/NNS||clinicobiological-9/NN	prep_of||outcome-4/NN||correlations-10/NNS	conj_and||chemotherapy-7/NN||correlations-10/NNS	amod||itd-14/NN||flt3-12/JJ	amod||itd-14/NN||/-13/JJ	prep_of||chemotherapy-7/NN||itd-14/NN	amod||mutations-17/NNS||npm1-16/JJ	prep_of||chemotherapy-7/NN||mutations-17/NNS	conj_and||itd-14/NN||mutations-17/NNS	nn||patients-20/NNS||apl-19/NN	prep_in||investigated-2/VBD||patients-20/NNS	apl-19||atra--1||yes||we investigated the outcome of atra/anthracycline chemotherapy and clinicobiological correlations of flt3 /itd and npm1 mutations in apl patients.
nsubj||agent-8/NN||humant-celllymphotropicvirustype1-1/JJ	dep||humant-celllymphotropicvirustype1-1/JJ||htlv-1-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||etiological-7/JJ	root||ROOT-0/null||agent-8/NN	amod||leukemia-12/NN||adult-10/JJ	amod||leukemia-12/NN||t-cell-11/JJ	prep_of||agent-8/NN||leukemia-12/NN	appos||leukemia-12/NN||atl-14/NN	amod||tropicalspasticparaparesis-19/NNS||htlv-1-associatedmyelopathy-17/JJ	amod||tropicalspasticparaparesis-19/NNS||/-18/JJ	prep_of||agent-8/NN||tropicalspasticparaparesis-19/NNS	conj_and||leukemia-12/NN||tropicalspasticparaparesis-19/NNS	appos||leukemia-12/NN||ham/tsp-21/NN	ham--1||humant-celllymphotropicvirustype1-1||no||humant-celllymphotropicvirustype1 (htlv-1) is the etiological agent of adult t-cell leukemia (atl) and htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
advmod||observed-13/VBN||recently-1/RB	det||increase-4/NN||an-3/DT	nsubjpass||observed-13/VBN||increase-4/NN	amod||infections-7/NNS||severe-6/JJ	prep_of||increase-4/NN||infections-7/NNS	amod||subjects-10/NNS||healthy-9/JJ	prep_in||infections-7/NNS||subjects-10/NNS	aux||observed-13/VBN||has-11/VBZ	auxpass||observed-13/VBN||been-12/VBN	ccomp||caused-15/VBD||observed-13/VBN	root||ROOT-0/null||caused-15/VBD	amod||s.aureus-19/NNS||community-associated-17/JJ	amod||s.aureus-19/NNS||methicillin-resistant-18/JJ	prep_by||caused-15/VBD||s.aureus-19/NNS	num||-rrb--22/NN||-lrb--20/CD	amod||-rrb--22/NN||ca-mrsa-21/JJ	nsubj||caused-15/VBD||-rrb--22/NN	mrsa--1||s.aureus-19||no||recently , an increase of severe infections in healthy subjects has been observed , caused by community-associated methicillin-resistant s.aureus -lrb- ca-mrsa -rrb- .
nn||factors-2/NNS||risk-1/NN	nsubj||different-9/JJ||factors-2/NNS	prep_for||factors-2/NNS||atopic-4/NN	prep_for||factors-2/NNS||non-atopicasthma-6/NN	conj_and||atopic-4/NN||non-atopicasthma-6/NN	aux||different-9/JJ||may-7/MD	cop||different-9/JJ||be-8/VB	root||ROOT-0/null||different-9/JJ	atopicasthma--1||atopic-4||no||risk factors for atopic and non-atopicasthma may be different.
nsubjpass||treated-27/VBN||individuals-1/NNS	dep||individuals-1/NNS||n-3/VBN	dep||113-5/CD||=-4/SYM	ccomp||n-3/VBN||113-5/CD	amod||depressivedisorder-22/NN||dsm-iv-8/JJ	amod||manual-13/NN||diagnostic-10/JJ	conj_and||diagnostic-10/JJ||statistical-12/JJ	amod||manual-13/NN||statistical-12/JJ	dep||dsm-iv-8/JJ||manual-13/NN	amod||disorders-16/NNS||mental-15/JJ	prep_of||manual-13/NN||disorders-16/NNS	amod||edition-19/NN||fourth-18/JJ	appos||disorders-16/NNS||edition-19/NN	amod||depressivedisorder-22/NN||major-21/JJ	prep_with||individuals-1/NNS||depressivedisorder-22/NN	appos||depressivedisorder-22/NN||mdd-24/NN	auxpass||treated-27/VBN||were-26/VBD	root||ROOT-0/null||treated-27/VBN	prep_with||treated-27/VBN||escitalopram-29/NN	appos||escitalopram-29/NN||esc-31/NN	prep_with||treated-27/VBN||venlafaxine-34/NN	conj_or||escitalopram-29/NN||venlafaxine-34/NN	appos||escitalopram-29/NN||ven-36/NN	num||weeks-40/NNS||8-39/CD	prep_over||treated-27/VBN||weeks-40/NNS	depressivedisorder-22||escitalopram-29||yes||individuals ( n =113) with dsm-iv (diagnostic and statistical manual of mental disorders, fourth edition) major depressivedisorder (mdd) were treated with escitalopram (esc) or venlafaxine (ven) over 8 weeks.
amod||appearance-2/NN||palmitate-1/JJ	nsubjpass||determined-11/VBN||appearance-2/NN	nn||rates-5/NNS||oxidation-4/NN	conj_and||appearance-2/NN||rates-5/NNS	nsubjpass||determined-11/VBN||rates-5/NNS	amod||rate-9/NN||glycerol-7/JJ	nn||rate-9/NN||appearance-8/NN	conj_and||appearance-2/NN||rate-9/NN	nsubjpass||determined-11/VBN||rate-9/NN	auxpass||determined-11/VBN||were-10/VBD	root||ROOT-0/null||determined-11/VBN	amod||offspring-15/NN||eleven-13/VBN	amod||offspring-15/NN||healthy-14/JJ	prep_in||determined-11/VBN||offspring-15/NN	num||parents-18/NNS||two-17/CD	prep_of||offspring-15/NN||parents-18/NNS	prep_with||parents-18/NNS||t2d-20/CD	amod||history-24/NN||positive-22/JJ	nn||history-24/NN||family-23/NN	appos||offspring-15/NN||history-24/NN	nn||+-27/NNP||fh-26/NNP	dep||history-24/NN||+-27/NNP	num||subjects-32/NNS||13-30/CD	amod||subjects-32/NNS||healthy-31/JJ	prep_in||determined-11/VBN||subjects-32/NNS	conj_and||offspring-15/NN||subjects-32/NNS	amod||relatives-35/NNS||first-degree-34/JJ	prep_without||subjects-32/NNS||relatives-35/NNS	prep_with||relatives-35/NNS||t2d-37/NNS	dep||t2d-37/NNS||fh-39/RB	num||subjects-44/NNS||12-43/CD	prep_in||determined-11/VBN||subjects-44/NNS	conj_and||offspring-15/NN||subjects-44/NNS	prep_with||subjects-44/NNS||t2d-46/CD	prepc_at||determined-11/VBN||fasting-48/VBG	amod||clamp-53/NN||normoglycemic-51/JJ	amod||clamp-53/NN||hyperinsulinemic-52/JJ	prep_during||determined-11/VBN||clamp-53/NN	amod||intake-58/NN||continuous-56/JJ	amod||intake-58/NN||oral-57/JJ	prep_during||determined-11/VBN||intake-58/NN	conj_and||clamp-53/NN||intake-58/NN	det||meal-63/NN||a-60/DT	amod||meal-63/NN||standard-61/JJ	amod||meal-63/NN||liquid-62/JJ	prep_of||intake-58/NN||meal-63/NN	aux||achieve-65/VB||to-64/TO	vmod||intake-58/NN||achieve-65/VB	vmod||intake-58/NN||achieve-65/VB	conj_and||achieve-65/VB||achieve-65/VB	amod||postprandial-67/JJ||steady-66/JJ	amod||nefa-68/NNS||postprandial-67/JJ	dobj||achieve-65/VB||nefa-68/NNS	dobj||achieve-65/VB||triacylglycerols-70/NNS	conj_and||nefa-68/NNS||triacylglycerols-70/NNS	appos||nefa-68/NNS||tg-72/NN	nn||infusion-78/NN||insulin-77/NN	prep_with||achieve-65/VB||infusion-78/NN	prep_without||achieve-65/VB||infusion-78/NN	aux||maintain-80/VB||to-79/TO	vmod||achieve-65/VB||maintain-80/VB	amod||glycemia-82/NN||similar-81/JJ	dobj||maintain-80/VB||glycemia-82/NN	det||groups-86/NNS||all-84/DT	num||groups-86/NNS||three-85/CD	prep_in||maintain-80/VB||groups-86/NNS	t2d-46||insulin-77||yes||palmitate appearance and oxidation rates and glycerol appearance rate were determined in eleven healthy offspring of two parents with t2d (positive family history, fh+), 13 healthy subjects without first-degree relatives with t2d (fh-) and 12 subjects with t2d at fasting, during normoglycemic hyperinsulinemic clamp and during continuous oral intake of a standard liquid meal to achieve steady postprandial nefa and triacylglycerols (tg) without and with insulin infusion to maintain similar glycemia in all three groups.
det||profile-5/NN||the-1/DT	nn||profile-5/NN||safety-2/NN	conj_and||safety-2/NN||efficacy-4/NN	nn||profile-5/NN||efficacy-4/NN	nsubj||were-15/VBD||profile-5/NN	prep_of||profile-5/NN||caspofungin-7/NN	prep_of||profile-5/NN||micafungin-9/NN	conj_and||caspofungin-7/NN||micafungin-9/NN	amod||patients-12/NNS||japanese-11/JJ	prep_in||caspofungin-7/NN||patients-12/NNS	prep_with||patients-12/NNS||fungalinfections-14/NNS	root||ROOT-0/null||were-15/VBD	advmod||were-15/VBD||directly-16/RB	prep||were-15/VBD||compared-17/VBN	pcomp||compared-17/VBN||in-18/IN	det||study-25/NN||this-19/DT	amod||study-25/NN||prospective-20/JJ	amod||study-25/NN||randomized-22/JJ	amod||study-25/NN||double-blind-24/JJ	pobj||in-18/IN||study-25/NN	fungalinfections-14||caspofungin-7||yes||the safety and efficacy profile of caspofungin and micafungin in japanese patients with fungalinfections were directly compared in this prospective, randomized, double-blind study.
nsubj||effective-61/JJ||analysis-1/NN	amod||terbinafine-58/NN||total-3/JJ	num||trials-5/NNS||eight-4/CD	nsubj||state-9/NN||trials-5/NNS	num||patients-8/NNS||1181-7/CD	prep_including||trials-5/NNS||patients-8/NNS	ccomp||total-3/JJ||state-9/NN	mark||likely-17/JJ||that-10/IN	nsubj||likely-17/JJ||treatment-11/NN	nsubj||produce-19/VB||treatment-11/NN	amod||terbinafine-14/NN||continuous-13/JJ	prep_with||treatment-11/NN||terbinafine-14/NN	cop||likely-17/JJ||is-15/VBZ	advmod||likely-17/JJ||more-16/RBR	ccomp||state-9/NN||likely-17/JJ	aux||produce-19/VB||to-18/TO	xcomp||likely-17/JJ||produce-19/VB	amod||cure-23/NN||mycological-20/JJ	conj_and||mycological-20/JJ||clinical-22/JJ	amod||cure-23/NN||clinical-22/JJ	dobj||produce-19/VB||cure-23/NN	prepc_compared_to||produce-19/VB||to-25/TO	amod||itraconazole-27/NN||intermittent-26/JJ	pobj||produce-19/VB||itraconazole-27/NN	nn||2.3-31/NNS||odds-29/NNS	nn||2.3-31/NNS||ratio-30/NN	prep_with||itraconazole-27/NN||2.3-31/NNS	number||%-34/NN||95-33/CD	amod||ci-35/NN||%-34/NN	dep||likely-17/JJ||ci-35/NN	amod||ci-35/NN||1.7-37/CD	num||p-40/NNS||3.0-39/CD	prep_to||ci-35/NN||p-40/NNS	number||0.0001-42/CD||<-41/CD	num||p-40/NNS||0.0001-42/CD	mark||tolerated-51/JJ||though-44/IN	preconj||itraconazole-46/NN||both-45/DT	nsubj||tolerated-51/JJ||itraconazole-46/NN	conj_and||itraconazole-46/NN||terbinafine-48/NN	nsubj||tolerated-51/JJ||terbinafine-48/NN	cop||tolerated-51/JJ||are-49/VBP	advmod||tolerated-51/JJ||well-50/RB	ccomp||likely-17/JJ||tolerated-51/JJ	advmod||effective-54/JJ||highly-53/RB	conj_and||total-3/JJ||effective-54/JJ	amod||terbinafine-58/NN||effective-54/JJ	nn||terbinafine-58/NN||drugs-55/NNS	amod||terbinafine-58/NN||continuous-57/JJ	prep_of||analysis-1/NN||terbinafine-58/NN	cop||effective-61/JJ||is-59/VBZ	advmod||effective-61/JJ||more-60/RBR	root||ROOT-0/null||effective-61/JJ	amod||itraconazole-64/NN||intermittent-63/JJ	prep_than||effective-61/JJ||itraconazole-64/NN	prepc_at||effective-61/JJ||achieving-66/VBG	amod||cure-68/NN||mycological-67/JJ	dobj||achieving-66/VBG||cure-68/NN	amod||onychomycosis-71/NNS||toenail-70/JJ	prep_of||cure-68/NN||onychomycosis-71/NNS	onychomycosis-71||terbinafine-58||yes||analysis of total eight trials including 1181 patients state that treatment with continuous terbinafine is more likely to produce mycological and clinical cure compared to intermittent itraconazole with odds ratio 2.3(95% ci, 1.7 to 3.0 p <0.0001) though both itraconazole and terbinafine are well tolerated and highly effective drugs, continuous terbinafine is more effective than intermittent itraconazole at achieving mycological cure of toenail onychomycosis
nsubjpass||used-9/VBN||hydroxyethylstarch-1/NN	nsubj||induce-16/VB||hydroxyethylstarch-1/NN	appos||hydroxyethylstarch-1/NN||hes-3/NN	auxpass||used-9/VBN||is-7/VBZ	advmod||used-9/VBN||widely-8/RB	rcmod||hydroxyethylstarch-1/NN||used-9/VBN	nn||replacement-13/NN||blood-11/NN	nn||replacement-13/NN||volume-12/NN	prep_for||used-9/VBN||replacement-13/NN	aux||induce-16/VB||can-15/MD	root||ROOT-0/null||induce-16/VB	advmod||induce-16/VB||coagulopathy-17/RB	coagulopathy-17||hydroxyethylstarch-1||no||hydroxyethylstarch (hes), which is widely used for blood volume replacement, can induce coagulopathy.
det||strategy-4/NN||a-1/DT	amod||strategy-4/NN||nanoscale-2/JJ	nn||strategy-4/NN||modification-3/NN	nsubj||incorporate-7/VB||strategy-4/NN	nsubjpass||proposed-21/VBN||strategy-4/NN	nsubj||give-23/VB||strategy-4/NN	aux||incorporate-7/VB||can-6/MD	rcmod||strategy-4/NN||incorporate-7/VB	dobj||incorporate-7/VB||chondroitinsulfate-8/NN	appos||chondroitinsulfate-8/NN||cs-10/NN	det||materials-17/NNS||the-13/DT	amod||materials-17/NNS||cross-linked-14/JJ	amod||materials-17/NNS||porous-15/JJ	nn||materials-17/NNS||gelatin-16/NN	prep_into||incorporate-7/VB||materials-17/NNS	aux||proposed-21/VBN||has-18/VBZ	advmod||proposed-21/VBN||previously-19/RB	auxpass||proposed-21/VBN||been-20/VBN	root||ROOT-0/null||proposed-21/VBN	aux||give-23/VB||to-22/TO	xcomp||proposed-21/VBN||give-23/VB	amod||performance-25/NN||superior-24/JJ	dobj||give-23/VB||performance-25/NN	amod||scaffolds-30/NNS||designed-27/JJ	amod||scaffolds-30/NNS||corneal-28/JJ	nn||scaffolds-30/NNS||keratocyte-29/NN	prep_for||give-23/VB||scaffolds-30/NNS	cross--1||gelatin-16||no_rel||a nanoscale modification strategy that can incorporate chondroitinsulfate (cs) into the cross-linked porous gelatin materials has previously been proposed to give superior performance for designed corneal keratocyte scaffolds.
det||proportion-2/NN||the-1/DT	nsubj||count-7/VBP||proportion-2/NN	amod||cell-6/NN||cd4-4/JJ	amod||cell-6/NN||+-5/JJ	prep_of||proportion-2/NN||cell-6/NN	root||ROOT-0/null||count-7/VBP	xcomp||count-7/VBP||monitoring-8/VBG	mark||increased-15/VBD||for-9/IN	nsubj||increased-15/VBD||people-10/NNS	prep_with||people-10/NNS||hiv-12/NN	prep_with||people-10/NNS||aids-14/NNS	conj_and||hiv-12/NN||aids-14/NNS	advcl||monitoring-8/VBG||increased-15/VBD	num||%-20/NN||45.3-17/CD	conj_and||45.3-17/CD||10.1-19/CD	num||%-20/NN||10.1-19/CD	prep_from||increased-15/VBD||%-20/NN	num||54.2-24/CD||2007-22/CD	dep||54.2-24/CD||to-23/TO	prep_in||%-20/NN||54.2-24/CD	num||%-27/NN||62.5-26/CD	prep_from||increased-15/VBD||%-27/NN	conj_and||%-20/NN||%-27/NN	prep_in||%-27/NN||2009-29/CD	advmod||increased-15/VBD||respectively-31/RB	det||p-34/NN||both-33/DT	nsubj||<-35/VBZ||p-34/NN	parataxis||monitoring-8/VBG||<-35/VBZ	dobj||<-35/VBZ||0.001-36/CD	aids-14||hiv-12||no||the proportion of cd4+ cell count monitoring for people with hiv and aids increased from 45.3 and 10.1% in 2007 to 54.2 and 62.5% in 2009, respectively (both p < 0.001).
det||cohort-6/NN||a-1/DT	amod||cohort-6/NN||12-matched-2/JJ	amod||cohort-6/NN||new-3/JJ	nn||cohort-6/NN||insulin-4/NN	nn||cohort-6/NN||user-5/NN	nsubjpass||selected-31/VBN||cohort-6/NN	prep_on||cohort-6/NN||age-8/NN	nn||±-11/NNS||â-10/NN	dep||age-8/NN||±-11/NNS	num||years-13/NNS||3-12/CD	dep||±-11/NNS||years-13/NNS	amod||status-17/NN||smoking-16/VBG	prep_on||cohort-6/NN||status-17/NN	conj_and||age-8/NN||status-17/NN	prep_on||cohort-6/NN||likelihood-20/NN	conj_and||age-8/NN||likelihood-20/NN	prepc_of||likelihood-20/NN||initiating-22/VBG	nn||therapy-24/NN||insulin-23/NN	dobj||initiating-22/VBG||therapy-24/NN	dep||selected-31/VBN||â-26/VB	num||0.05-28/CD||±-27/CD	dobj||â-26/VB||0.05-28/CD	auxpass||selected-31/VBN||was-30/VBD	root||ROOT-0/null||selected-31/VBN	det||cohort-34/NN||a-33/DT	prep_from||selected-31/VBN||cohort-34/NN	num||patients-38/NNS||4,623-36/CD	amod||patients-38/NNS||chinese-37/JJ	prep_of||cohort-34/NN||patients-38/NNS	prep_with||selected-31/VBN||type2diabetes-40/JJ	prep_with||selected-31/VBN||free-42/JJ	conj_and||type2diabetes-40/JJ||free-42/JJ	prep_of||free-42/JJ||cancer-44/NN	prep_with||selected-31/VBN||naive-47/JJ	conj_and||type2diabetes-40/JJ||naive-47/JJ	prep_to||naive-47/JJ||insulin-49/NN	prep_at||insulin-49/NN||enrollment-51/NN	insulin-49||cancer-44||no_rel||a 12-matched new insulin user cohort on age (â±3 years), smoking status, and likelihood of initiating insulin therapy (â±0.05) was selected from a cohort of 4,623 chinese patients with type2diabetes, free of cancer, and naive to insulin at enrollment.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||screen-8/VB||aim-2/NN	poss||study-5/NN||our-4/PRP$	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||screen-8/VB||to-7/TO	xcomp||was-6/VBD||screen-8/VB	det||gene-12/NN||the-10/DT	nn||gene-12/NN||insulin-11/NN	prep_for||screen-8/VB||gene-12/NN	prep_in||screen-8/VB||patients-14/NNS	nsubjpass||classified-19/VBN||patients-14/NNS	aux||classified-19/VBN||had-16/VBD	auxpass||classified-19/VBN||been-17/VBN	advmod||classified-19/VBN||clinically-18/RB	rcmod||patients-14/NNS||classified-19/VBN	nn||diabetic-23/NN||type-21/NN	num||diabetic-23/NN||1-22/CD	prep_as||classified-19/VBN||diabetic-23/NN	nsubj||tested-26/VBD||who-25/WP	rcmod||patients-14/NNS||tested-26/VBD	conj_but||classified-19/VBN||tested-26/VBD	acomp||tested-26/VBD||negative-27/JJ	amod||autoantibodies-30/NNS||type1diabetes-29/JJ	prep_for||tested-26/VBD||autoantibodies-30/NNS	type1diabetes-29||insulin-11||yes||the aim of our study was to screen for the insulin gene in patients who had been clinically classified as type 1 diabetic but who tested negative for type1diabetes autoantibodies.
det||2009-3/CD||the-1/DT	amod||2009-3/CD||pandemic-2/JJ	nn||influenzavirus-7/NNS||2009-3/CD	appos||influenzavirus-7/NNS||h1n1-5/NNP	nsubj||spread-9/VBN||influenzavirus-7/NNS	nsubj||causing-16/VBG||influenzavirus-7/NNS	aux||spread-9/VBN||has-8/VBZ	root||ROOT-0/null||spread-9/VBN	det||world-12/NN||the-11/DT	prep_throughout||spread-9/VBN||world-12/NN	aux||causing-16/VBG||is-14/VBZ	advmod||causing-16/VBG||now-15/RB	conj_and||spread-9/VBN||causing-16/VBG	amod||influenza-18/NN||seasonal-17/JJ	dobj||causing-16/VBG||influenza-18/NN	influenza-18||influenzavirus-7||no||the pandemic 2009 (h1n1) influenzavirus has spread throughout the world and is now causing seasonal influenza.
nsubj||â-2/VBP||conclusions-1/NNS	nsubj||lowered-22/VBD||conclusions-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	prep_in||â-2/VBP||subjects-6/NNS	amod||liraglutide-11/NN||type2diabetes-8/JJ	amod||liraglutide-11/NN||once-daily-10/JJ	prep_with||subjects-6/NNS||liraglutide-11/NN	vmod||liraglutide-11/NN||induced-12/VBN	amod||control-15/NN||similar-13/JJ	amod||control-15/NN||glycemic-14/JJ	dobj||induced-12/VBN||control-15/NN	amod||weight-19/NN||reduced-17/VBN	nn||weight-19/NN||body-18/NN	appos||control-15/NN||weight-19/NN	conj_and||â-2/VBP||lowered-22/VBD	det||occurrence-24/NN||the-23/DT	dobj||lowered-22/VBD||occurrence-24/NN	prep_of||occurrence-24/NN||hypoglycemia-26/NN	prepc_compared_with||lowered-22/VBD||with-28/IN	pobj||lowered-22/VBD||glimepiride-29/NN	tmod||had-33/VBD||glimepiride-29/NN	advmod||had-33/VBD||when-31/WRB	nsubj||had-33/VBD||both-32/DT	rcmod||glimepiride-29/NN||had-33/VBD	nn||therapy-35/NN||background-34/NN	dobj||had-33/VBD||therapy-35/NN	prep_of||therapy-35/NN||metformin-37/NN	type2diabetes-8||glimepiride-29||yes||conclusions â€”in subjects with type2diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin.
nsubjpass||delayed-13/VBN||confirmation-1/NN	prep_of||confirmation-1/NN||tuberculousmeningitis-3/NNS	appos||tuberculousmeningitis-3/NNS||tbm-5/NN	prep_of||confirmation-1/NN||initiation-8/NN	conj_and||tuberculousmeningitis-3/NNS||initiation-8/NN	prep_of||initiation-8/NN||treatment-10/NN	auxpass||delayed-13/VBN||are-11/VBP	advmod||delayed-13/VBN||often-12/RB	root||ROOT-0/null||delayed-13/VBN	acomp||delayed-13/VBN||due-14/JJ	prep_to||due-14/JJ||limitations-16/NNS	amod||mycobacteriumtuberculosis-19/NNS||isolating-18/JJ	prep_in||limitations-16/NNS||mycobacteriumtuberculosis-19/NNS	amod||fluid-22/NN||cerebrospinal-21/JJ	prep_from||delayed-13/VBN||fluid-22/NN	appos||fluid-22/NN||csf-24/NN	tuberculousmeningitis-3||mycobacteriumtuberculosis-19||no||confirmation of tuberculousmeningitis (tbm) and initiation of treatment are often delayed due to limitations in isolating mycobacteriumtuberculosis from cerebrospinal fluid (csf).
prep_after||insulin-11/NN||accounting-2/NN	prep_for||accounting-2/NN||adiposity-4/NN	amod||factors-8/NNS||other-6/JJ	nn||factors-8/NNS||risk-7/NN	nsubj||insulin-11/NN||factors-8/NNS	cop||insulin-11/NN||were-9/VBD	amod||insulin-11/NN||high-10/JJ	root||ROOT-0/null||insulin-11/NN	conj_and||insulin-11/NN||insulinresistance-13/NN	amod||triglycerides-16/NNPS||high-15/JJ	conj_and||insulin-11/NN||triglycerides-16/NNPS	conj_and||insulin-11/NN||smoking-19/NN	nsubj||amenable-22/JJ||factors-21/NNS	nsubj||lifestyle-24/VB||factors-21/NNS	xcomp||insulin-11/NN||amenable-22/JJ	aux||lifestyle-24/VB||to-23/TO	xcomp||amenable-22/JJ||lifestyle-24/VB	dobj||lifestyle-24/VB||intervention-25/NN	adiposity-4||triglycerides-16||no_rel||after accounting for adiposity, other risk factors were high insulin, insulinresistance, high triglycerides, and smoking, factors amenable to lifestyle intervention.
nsubj||titrated-2/VBD||conclusions-1/NNS	root||ROOT-0/null||titrated-2/VBD	nn||treatment-4/NN||oxygen-3/NN	nsubj||reduced-6/VBD||treatment-4/NN	advmod||reduced-6/VBD||significantly-5/RB	ccomp||titrated-2/VBD||reduced-6/VBD	dobj||reduced-6/VBD||mortality-7/NN	dobj||reduced-6/VBD||hypercapnia-9/NN	conj_and||mortality-7/NN||hypercapnia-9/NN	dobj||reduced-6/VBD||respiratoryacidosis-12/NN	conj_and||mortality-7/NN||respiratoryacidosis-12/NN	prepc_compared_with||reduced-6/VBD||with-14/IN	amod||oxygen-17/NN||high-15/JJ	nn||oxygen-17/NN||flow-16/NN	pobj||reduced-6/VBD||oxygen-17/NN	amod||exacerbations-20/NNS||acute-19/JJ	prep_in||oxygen-17/NN||exacerbations-20/NNS	amod||obstructivepulmonarydisease-23/NN||chronic-22/JJ	prep_of||exacerbations-20/NNS||obstructivepulmonarydisease-23/NN	obstructivepulmonarydisease-23||oxygen-17||yes||conclusions titrated oxygen treatment significantly reduced mortality, hypercapnia, and respiratoryacidosis compared with high flow oxygen in acute exacerbations of chronic obstructivepulmonarydisease.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	alcohol-22||obesity-30||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	nsubj||report-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||report-8/VB||to-7/TO	xcomp||is-6/VBZ||report-8/VB	det||profile-11/NN||the-9/DT	nn||profile-11/NN||complication-10/NN	dobj||report-8/VB||profile-11/NN	nn||evaluation-14/NN||safety-13/NN	dobj||report-8/VB||evaluation-14/NN	conj_and||profile-11/NN||evaluation-14/NN	amod||chemotherapy-19/NN||supraselective-16/JJ	amod||chemotherapy-19/NN||intra-arterial-17/JJ	nn||chemotherapy-19/NN||melphalan-18/NN	prep_of||profile-11/NN||chemotherapy-19/NN	prep_in||chemotherapy-19/NN||children-21/NNS	vmod||children-21/NNS||undergoing-22/VBG	dobj||undergoing-22/VBG||treatment-23/NN	amod||retinoblastoma-26/NN||advanced-25/JJ	prep_with||undergoing-22/VBG||retinoblastoma-26/NN	melphalan-18||retinoblastoma-26||no_rel||the purpose of this study is to report the complication profile and safety evaluation of supraselective intra-arterial melphalan chemotherapy in children undergoing treatment with advanced retinoblastoma.
advmod||found-6/VBN||recently-1/RB	nsubjpass||found-6/VBN||dexamethasone-3/NN	nsubj||have-8/VB||dexamethasone-3/NN	aux||found-6/VBN||has-4/VBZ	auxpass||found-6/VBN||been-5/VBN	root||ROOT-0/null||found-6/VBN	aux||have-8/VB||to-7/TO	xcomp||found-6/VBN||have-8/VB	det||effect-11/NN||a-9/DT	amod||effect-11/NN||prophylactic-10/JJ	dobj||have-8/VB||effect-11/NN	amod||vomiting-14/NN||postoperative-13/JJ	prep_on||effect-11/NN||vomiting-14/NN	prep_on||effect-11/NN||pain-16/NN	conj_and||vomiting-14/NN||pain-16/NN	prep_in||effect-11/NN||children-18/NNS	vmod||children-18/NNS||undergoing-19/VBG	advmod||undergoing-19/VBG||tonsillectomy-20/RB	vomiting-14||dexamethasone-3||yes||recently, dexamethasone has been found to have a prophylactic effect on postoperative vomiting and pain in children undergoing tonsillectomy.
amod||patients-3/NNS||renal-1/JJ	nn||patients-3/NNS||transplant-2/NN	nsubj||require-10/VB||patients-3/NNS	vmod||patients-3/NNS||prescribed-4/VBN	acomp||prescribed-4/VBN||mycophenolatemofetil-5/JJ	appos||patients-3/NNS||mmf-7/NN	aux||require-10/VB||may-9/MD	root||ROOT-0/null||require-10/VB	dobj||require-10/VB||treatment-11/NN	prep_for||treatment-11/NN||tuberculosis-13/NNP	det||regimen-16/NN||a-15/DT	prep_with||require-10/VB||regimen-16/NN	det||rifampicin-21/NN||the-18/DT	amod||rifampicin-21/NN||tuberculocidal-19/JJ	nn||rifampicin-21/NN||drug-20/NN	prep_including||regimen-16/NN||rifampicin-21/NN	tuberculosis-13||rifampicin-21||yes||renal transplant patients prescribed mycophenolatemofetil (mmf) may require treatment for tuberculosis with a regimen including the tuberculocidal drug rifampicin.
amod||models-3/NNS||logistic-1/JJ	nn||models-3/NNS||regression-2/NN	nsubjpass||fitted-5/VBN||models-3/NNS	nsubj||assess-7/VB||models-3/NNS	auxpass||fitted-5/VBN||were-4/VBD	root||ROOT-0/null||fitted-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||fitted-5/VBN||assess-7/VB	det||association-9/NN||the-8/DT	dobj||assess-7/VB||association-9/NN	amod||geometric-12/JJ||stavudine-11/JJ	amod||ratio-14/NN||geometric-12/JJ	amod||ratio-14/NN||mean-13/JJ	prep_between||association-9/NN||ratio-14/NN	number||1-16/CD||>-15/CD	num||ratio-14/NN||1-16/CD	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	dobj||assess-7/VB||glucose-20/NN	conj_and||association-9/NN||glucose-20/NN	appos||glucose-20/NN||impairedglucosetolerance-22/NN	appos||glucose-20/NN||hyperlactataemia-24/NN	conj_and||impairedglucosetolerance-22/NN||hyperlactataemia-24/NN	appos||glucose-20/NN||hypertriglyceridaemia-26/NN	conj_and||impairedglucosetolerance-22/NN||hypertriglyceridaemia-26/NN	appos||glucose-20/NN||lipoatrophy-29/NN	conj_and||impairedglucosetolerance-22/NN||lipoatrophy-29/NN	impairedglucosetolerance-22||glucose-20||no_rel||logistic regression models were fitted to assess the association between stavudine geometric mean ratio > 1 and impaired fasting glucose, impairedglucosetolerance, hyperlactataemia, hypertriglyceridaemia, and lipoatrophy.
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	tumor-28||formaldehyde-14||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||consists-11/VBZ||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||infants-7/NNS	appos||infants-7/NNS||ipti-9/NNP	root||ROOT-0/null||consists-11/VBZ	det||administration-14/NN||the-13/DT	prep_of||consists-11/VBZ||administration-14/NN	det||dose-18/NN||a-16/DT	nn||dose-18/NN||treatment-17/NN	prep_of||administration-14/NN||dose-18/NN	amod||sp-22/NN||sulphadoxine-pyrimethamine-20/JJ	prep_of||dose-18/NN||sp-22/NN	det||time-26/NN||the-25/DT	prep_at||sp-22/NN||time-26/NN	amod||vaccinations-29/NNS||routine-28/JJ	prep_of||time-26/NN||vaccinations-29/NNS	malaria-5||pyrimethamine--1||yes||intermittent preventive treatment of malaria in infants (ipti) consists of the administration of a treatment dose of sulphadoxine-pyrimethamine (sp) at the time of routine vaccinations.
vmod||shown-12/VBN||using-1/VBG	nn||preparations-5/NNS||bloc-3/NN	nn||preparations-5/NNS||medullary-4/NN	prep_en||using-1/VBG||preparations-5/NNS	amod||mice-8/NNS||neonatal-7/JJ	prep_from||using-1/VBG||mice-8/NNS	nsubj||shown-12/VBN||we-10/PRP	aux||shown-12/VBN||have-11/VBP	root||ROOT-0/null||shown-12/VBN	det||time-16/NN||the-14/DT	amod||time-16/NN||first-15/JJ	prep_for||shown-12/VBN||time-16/NN	mark||abolished-24/VBN||that-17/IN	det||response-20/NN||the-18/DT	amod||response-20/NN||respiratory-19/JJ	nsubjpass||abolished-24/VBN||response-20/NN	prep_to||response-20/NN||acidosis-22/NNS	auxpass||abolished-24/VBN||is-23/VBZ	dep||time-16/NN||abolished-24/VBN	prep_after||abolished-24/VBN||pre-treatment-26/NN	det||fluoxetine-31/NN||the-28/DT	amod||fluoxetine-31/NN||serotonin-transporter-29/JJ	nn||fluoxetine-31/NN||blocker-30/NN	prep_with||abolished-24/VBN||fluoxetine-31/NN	dep||âµm-37/NN||25â-33/NNS	dep||âµm-37/NN||$-34/$	num||$-34/$||50-36/CD	dep||time-16/NN||âµm-37/NN	number||min-40/NN||20-39/CD	dep||âµm-37/NN||min-40/NN	det||antidepressant-46/NN||a-43/DT	advmod||used-45/VBN||commonly-44/RB	amod||antidepressant-46/NN||used-45/VBN	appos||time-16/NN||antidepressant-46/NN	acidosis-22||fluoxetine-31||no_rel||using en bloc medullary preparations from neonatal mice, we have shown for the first time that the respiratory response to acidosis is abolished after pre-treatment with the serotonin-transporter blocker fluoxetine (25â€“50 âµm, 20 min), a commonly used antidepressant.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||explored-4/VBD||study-3/NN	root||ROOT-0/null||explored-4/VBD	det||growth-24/NN||the-5/DT	nn||effect-9/NN||vivo-7/NN	nn||effect-9/NN||immunomodulatory-8/NN	prep_in||interleukin-17-17/JJ||effect-9/NN	prep_on||effect-9/NN||interferon-gamma-11/NN	nn||³-14/NNP||ifn-î-13/NNP	appos||interferon-gamma-11/NN||³-14/NNP	amod||growth-24/NN||interleukin-17-17/JJ	dep||interleukin-17-17/JJ||il-17-19/JJ	conj_and||interleukin-17-17/JJ||transforming-23/JJ	amod||growth-24/NN||transforming-23/JJ	nsubj||evoked-32/VBD||growth-24/NN	number||1-26/CD||factor-beta-25/CD	amod||growth-24/NN||1-26/CD	dep||1-26/CD||tgf-î-28/NNP	number||1-30/CD||²-29/CD	num||tgf-î-28/NNP||1-30/CD	ccomp||explored-4/VBD||evoked-32/VBD	num||water-extracts-35/NNS||two-34/CD	prep_by||evoked-32/VBD||water-extracts-35/NNS	vmod||water-extracts-35/NNS||prepared-36/VBN	nn||leaves-39/NNS||ej-38/NN	prep_from||prepared-36/VBN||leaves-39/NNS	det||tissues-42/NNS||the-41/DT	prep_in||leaves-39/NNS||tissues-42/NNS	amod||mice-48/NNS||normal-44/JJ	conj_and||normal-44/JJ||meth-a-fibrosarcoma-46/JJ	amod||mice-48/NNS||meth-a-fibrosarcoma-46/JJ	nn||mice-48/NNS||bearing-47/NN	prep_of||tissues-42/NNS||mice-48/NNS	ifn--1||fibrosarcoma--1||no_rel||the present study explored the in vivo immunomodulatory effect on interferon-gamma (ifn-î³), interleukin-17 (il-17), and transforming growth factor-beta 1 (tgf-î²1) evoked by two water-extracts prepared from ej leaves in the tissues of normal and meth-a-fibrosarcoma bearing mice.
nsubj||droplet-6/VBP||m.tuberculosisinfection-1/NN	dep||induced-4/NN||vitro-3/NN	amod||lipid-5/NN||induced-4/NN	prep_in||m.tuberculosisinfection-1/NN||lipid-5/NN	root||ROOT-0/null||droplet-6/VBP	dobj||droplet-6/VBP||formation-7/NN	amod||macrophages-12/NNS||murine-9/JJ	conj_and||murine-9/JJ||human-11/JJ	amod||macrophages-12/NNS||human-11/JJ	prep_in||formation-7/NN||macrophages-12/NNS	tuberculosisinfection--1||lipid-5||no_rel||m.tuberculosisinfection in vitro induced lipid droplet formation in murine and human macrophages .
advmod||compared-20/VBN||morphology-1/RB	dep||nucleotide-7/JJ||physiology-3/JJ	conj_and||nucleotide-7/JJ||dna-6/JJ	amod||composition-8/NN||dna-6/JJ	amod||composition-8/NN||nucleotide-7/JJ	nsubjpass||compared-20/VBN||composition-8/NN	amod||spirochetes-11/NNS||lymedisease-10/JJ	prep_of||composition-8/NN||spirochetes-11/NNS	appos||spirochetes-11/NNS||borrelia-13/NN	appos||spirochetes-11/NNS||treponema-15/NN	conj_and||borrelia-13/NN||treponema-15/NN	appos||spirochetes-11/NNS||leptospira-18/NN	conj_and||borrelia-13/NN||leptospira-18/NN	auxpass||compared-20/VBN||were-19/VBD	root||ROOT-0/null||compared-20/VBN	lymedisease-10||borrelia-13||no||morphology, physiology, and dna nucleotide composition of lymedisease spirochetes, borrelia, treponema, and leptospira were compared.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||œsix-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nevirapine--1||yes||we assessed nvp-resistance in indian infants enrolled in the â€œsix-week extended-dose nevirapineâ€? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
nsubjpass||recommended-3/VBN||it-1/PRP	auxpass||recommended-3/VBN||is-2/VBZ	root||ROOT-0/null||recommended-3/VBN	mark||receive-12/VBP||that-4/IN	nsubj||receive-12/VBP||patients-5/NNS	nsubj||repeated-15/VBD||patients-5/NNS	amod||adrenalinsufficiency-8/NN||known-7/JJ	prep_with||patients-5/NNS||adrenalinsufficiency-8/NN	poss||families-11/NNS||their-10/PRP$	prep_with||patients-5/NNS||families-11/NNS	conj_and||adrenalinsufficiency-8/NN||families-11/NNS	ccomp||recommended-3/VBN||receive-12/VBP	acomp||receive-12/VBP||careful-13/JJ	ccomp||recommended-3/VBN||repeated-15/VBD	conj_and||receive-12/VBP||repeated-15/VBD	dobj||repeated-15/VBD||education-16/NN	amod||management-20/NN||sick-day-18/JJ	amod||management-20/NN||glucocorticoid-19/JJ	prep_on||repeated-15/VBD||management-20/NN	adrenalinsufficiency-8||glucocorticoid-19||no_rel||it is recommended that patients with known adrenalinsufficiency and their families receive careful and repeated education on sick-day glucocorticoid management.
amod||injury-3/NN||acute-1/JJ	nn||injury-3/NN||lung-2/NN	nsubj||syndrome-9/NN||injury-3/NN	appos||injury-3/NN||ali-5/NN	cop||syndrome-9/NN||is-7/VBZ	det||syndrome-9/NN||a-8/DT	root||ROOT-0/null||syndrome-9/NN	nsubjpass||characterised-12/VBN||syndrome-9/NN	auxpass||characterised-12/VBN||is-11/VBZ	rcmod||syndrome-9/NN||characterised-12/VBN	amod||inflammation-15/NN||acute-14/JJ	agent||characterised-12/VBN||inflammation-15/NN	nsubj||affects-20/VBZ||inflammation-15/NN	nn||injury-18/NN||tissue-17/NN	agent||characterised-12/VBN||injury-18/NN	conj_and||inflammation-15/NN||injury-18/NN	nsubj||affects-20/VBZ||injury-18/NN	rcmod||inflammation-15/NN||affects-20/VBZ	amod||exchange-23/NN||normal-21/JJ	nn||exchange-23/NN||gas-22/NN	dobj||affects-20/VBZ||exchange-23/NN	det||lungs-26/NNS||the-25/DT	prep_in||exchange-23/NN||lungs-26/NNS	gas-22||inflammation-15||no_rel||acute lung injury (ali) is a syndrome that is characterised by acute inflammation and tissue injury that affects normal gas exchange in the lungs.
amod||effects-3/NNS||upper-1/JJ	nn||effects-3/NNS||gi-2/NN	nsubjpass||documented-18/VBN||effects-3/NNS	amod||treatment-7/NN||non-selective-5/JJ	amod||treatment-7/NN||nsaid-6/JJ	prep_of||effects-3/NNS||treatment-7/NN	vmod||documented-18/VBN||ranging-9/VBG	prep_from||ranging-9/VBG||abdominalpain-11/NN	prep_to||ranging-9/VBG||ulceration-13/NN	prep_to||ranging-9/VBG||bleeding-15/NN	conj_and||ulceration-13/NN||bleeding-15/NN	auxpass||documented-18/VBN||are-16/VBP	advmod||documented-18/VBN||extensively-17/RB	root||ROOT-0/null||documented-18/VBN	nsaid-6||ulceration-13||no_rel||upper gi effects of non-selective nsaid treatment, ranging from abdominalpain to ulceration and bleeding are extensively documented.
amod||chemotherapeutics-2/NNS||first-line-1/JJ	nsubj||dacarbazine-11/NN||chemotherapeutics-2/NNS	vmod||chemotherapeutics-2/NNS||used-3/VBN	nn||therapy-6/NN||melanoma-5/NN	prep_in||used-3/VBN||therapy-6/NN	cop||dacarbazine-11/NN||are-7/VBP	det||dacarbazine-11/NN||the-8/DT	amod||dacarbazine-11/NN||methylating-9/VBG	nn||dacarbazine-11/NN||agents-10/NNS	root||ROOT-0/null||dacarbazine-11/NN	dep||dacarbazine-11/NN||dtic-13/JJ	conj_and||dacarbazine-11/NN||temozolomide-16/NN	appos||temozolomide-16/NN||tmz-18/NN	det||agents-23/NNS||the-21/DT	amod||agents-23/NNS||chloroethylating-22/VBG	conj_and||dacarbazine-11/NN||agents-23/NNS	conj_and||temozolomide-16/NN||agents-23/NNS	amod||agents-23/NNS||bcnu-24/JJ	amod||agents-23/NNS||fotemustine-26/JJ	conj_and||bcnu-24/JJ||fotemustine-26/JJ	melanoma-5||tmz-18||yes||first-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (dtic) and temozolomide (tmz) and the chloroethylating agents bcnu and fotemustine.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||effectiveness-4/NN||the-3/DT	dobj||compare-2/VB||effectiveness-4/NN	prep_of||effectiveness-4/NN||ondansetron-6/NN	conj_and||compare-2/VB||prochlorperazine-8/VB	aux||treat-10/VB||to-9/TO	xcomp||prochlorperazine-8/VB||treat-10/VB	dobj||treat-10/VB||vomiting-11/NN	vomiting-11||prochlorperazine-8||yes||to compare the effectiveness of ondansetron and prochlorperazine to treat vomiting.
nsubj||mediated-11/JJ||damage-1/NN	amod||mucosa-4/NN||intestinal-3/JJ	prep_to||damage-1/NN||mucosa-4/NN	prep_in||mucosa-4/NN||celiacdisease-6/NN	appos||damage-1/NN||cd-8/NN	cop||mediated-11/JJ||is-10/VBZ	root||ROOT-0/null||mediated-11/JJ	preconj||mediated-11/JJ||both-12/DT	prep_by||mediated-11/JJ||inflammation-14/NN	amod||inflammation-14/NN||due-15/JJ	aux||adaptive-17/VB||to-16/TO	xcomp||due-15/JJ||adaptive-17/VB	xcomp||due-15/JJ||innate-19/VB	conj_and||adaptive-17/VB||innate-19/VB	amod||responses-21/NNS||immune-20/JJ	dobj||adaptive-17/VB||responses-21/NNS	prep_with||responses-21/NNS||il-15-24/CD	det||mediator-28/NN||a-26/DT	amod||mediator-28/NN||major-27/JJ	prep_as||adaptive-17/VB||mediator-28/NN	det||response-33/NN||the-30/DT	amod||response-33/NN||innate-31/JJ	amod||response-33/NN||immune-32/JJ	prep_of||mediator-28/NN||response-33/NN	nsubj||causing-48/VBG||proliferation-37/NN	amod||enterocytes-40/NNS||crypt-39/JJ	prep_of||proliferation-37/NN||enterocytes-40/NNS	det||alteration-44/NN||an-42/DT	amod||alteration-44/NN||early-43/JJ	prep_as||enterocytes-40/NNS||alteration-44/NN	nn||mucosa-47/NN||cd-46/NN	prep_of||alteration-44/NN||mucosa-47/NN	prep_by||mediated-11/JJ||causing-48/VBG	conj_and||inflammation-14/NN||causing-48/VBG	amod||hyperplasia-50/NN||crypts-49/JJ	dobj||causing-48/VBG||hyperplasia-50/NN	cd-46||celiacdisease-6||no_rel||damage to intestinal mucosa in celiacdisease (cd) is mediated both by inflammation due to adaptive and innate immune responses, with il-15 as a major mediator of the innate immune response, and by proliferation of crypt enterocytes as an early alteration of cd mucosa causing crypts hyperplasia.
preconj||mos-hiv-3/NN||both-1/CC	det||mos-hiv-3/NN||the-2/DT	nsubjpass||adapted-10/VBN||mos-hiv-3/NN	nsubjpass||showed-20/VBD||mos-hiv-3/NN	det||sf-12-7/NN||the-5/DT	amod||sf-12-7/NN||shorter-6/JJR	conj_and||mos-hiv-3/NN||sf-12-7/NN	nsubjpass||adapted-10/VBN||sf-12-7/NN	auxpass||adapted-10/VBN||were-8/VBD	advmod||adapted-10/VBN||successfully-9/RB	root||ROOT-0/null||adapted-10/VBN	prep_for||adapted-10/VBN||people-12/NNS	prep_with||people-12/NNS||hiv/aids-14/NNS	amod||thailand-17/NN||northern-16/JJ	prep_in||hiv/aids-14/NNS||thailand-17/NN	conj_and||adapted-10/VBN||showed-20/VBD	amod||evidence-22/NN||encouraging-21/JJ	dobj||showed-20/VBD||evidence-22/NN	prep_for||showed-20/VBD||reliability-24/NN	prep_for||showed-20/VBD||validity-26/NN	conj_and||reliability-24/NN||validity-26/NN	aids--1||hiv--1||no||both the mos-hiv and the shorter sf-12 were successfully adapted for people with hiv/aids in northern thailand, and showed encouraging evidence for reliability and validity.
prep_objectiveâ||suggested-7/VBN||$-2/$	nsubjpass||suggested-7/VBN||it-4/PRP	aux||suggested-7/VBN||has-5/VBZ	auxpass||suggested-7/VBN||been-6/VBN	root||ROOT-0/null||suggested-7/VBN	mark||links-15/VBZ||that-8/IN	amod||protein-10/NN||retinol-binding-9/JJ	nsubj||links-15/VBZ||protein-10/NN	num||protein-10/NN||4-11/CD	appos||protein-10/NN||rbp4-13/NNP	ccomp||suggested-7/VBN||links-15/VBZ	dobj||links-15/VBZ||adiposity-16/NN	dobj||links-15/VBZ||insulinresistance-18/NN	conj_and||adiposity-16/NN||insulinresistance-18/NN	dobj||links-15/VBZ||type2diabetes-21/NN	conj_and||adiposity-16/NN||type2diabetes-21/NN	retinol--1||adiposity-16||no_rel||objectiveâ€” it has been suggested that retinol-binding protein 4 (rbp4) links adiposity, insulinresistance, and type2diabetes.
nn||content-3/NN||bone-1/NN	nn||content-3/NN||mineral-2/NN	nsubj||different-21/JJ||content-3/NN	appos||content-3/NN||bmc-5/NN	nn||density-10/NN||bone-8/NN	nn||density-10/NN||mineral-9/NN	conj_and||content-3/NN||density-10/NN	nsubj||different-21/JJ||density-10/NN	appos||density-10/NN||bmd-12/NN	det||group-17/NN||the-15/DT	nn||group-17/NN||sle-16/NN	prep_in||density-10/NN||group-17/NN	cop||different-21/JJ||was-18/VBD	neg||different-21/JJ||not-19/RB	advmod||different-21/JJ||significantly-20/RB	root||ROOT-0/null||different-21/JJ	det||controls-24/NNS||the-23/DT	prep_from||different-21/JJ||controls-24/NNS	neg||relationship-28/NN||no-27/DT	nsubjpass||found-30/VBN||relationship-28/NN	auxpass||found-30/VBN||was-29/VBD	conj_and||different-21/JJ||found-30/VBN	det||exposure-34/NN||the-32/DT	amod||exposure-34/NN||glucocorticoid-33/JJ	prep_between||found-30/VBN||exposure-34/NN	det||bmc/bmd-37/NN||the-36/DT	prep_between||found-30/VBN||bmc/bmd-37/NN	conj_and||exposure-34/NN||bmc/bmd-37/NN	mineral-9||sle-16||no_rel||bone mineral content (bmc) and bone mineral density (bmd) in the sle group was not significantly different from the controls, and no relationship was found between the glucocorticoid exposure and the bmc/bmd.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	ccomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	amod||patients-26/NNS||tegaserod-12/JJ	prep_on||tegaserod-12/JJ||symptoms-14/NNS	prep_on||tegaserod-12/JJ||quality-16/NN	conj_and||symptoms-14/NNS||quality-16/NN	prep_of||symptoms-14/NNS||life-18/NN	appos||life-18/NN||qol-20/NN	prep_in||life-18/NN||korean-23/NN	amod||patients-26/NNS||female-24/JJ	nn||patients-26/NNS||ibs-25/NN	prep_of||effect-10/NN||patients-26/NNS	prep_with||evaluate-8/VB||constipation-28/NN	aux||evaluate-31/VB||to-30/TO	ccomp||was-6/VBD||evaluate-31/VB	conj_and||evaluate-8/VB||evaluate-31/VB	det||usefulness-33/NN||the-32/DT	dobj||evaluate-31/VB||usefulness-33/NN	det||ibs-qol-36/NN||the-35/DT	prep_of||usefulness-33/NN||ibs-qol-36/NN	amod||study-39/NN||clinical-38/JJ	prep_in||ibs-qol-36/NN||study-39/NN	constipation-28||tegaserod-12||yes||the aim of this study was to evaluate the effect of tegaserod on symptoms and quality of life (qol) in korean female ibs patients with constipation and to evaluate the usefulness of the ibs-qol in clinical study.
nsubj||revealed-10/VBD||assessment-1/NN	det||patients-5/NNS||the-3/DT	num||patients-5/NNS||69-4/CD	prep_of||assessment-1/NN||patients-5/NNS	amod||cancers-9/NNS||metastatic-7/JJ	nn||cancers-9/NNS||gi-8/NN	prep_with||patients-5/NNS||cancers-9/NNS	root||ROOT-0/null||revealed-10/VBD	dobj||revealed-10/VBD||cr-11/NN	dobj||revealed-10/VBD||pr-13/NN	conj_and||cr-11/NN||pr-13/NN	dobj||revealed-10/VBD||cr-16/NN	conj_and||cr-11/NN||cr-16/NN	xcomp||revealed-10/VBD||+-17/VBG	nn||rates-19/NNS||pr-18/NN	dobj||+-17/VBG||rates-19/NNS	num||%-22/NN||18-21/CD	prep_of||rates-19/NNS||%-22/NN	num||%-25/NN||42-24/CD	prep_of||rates-19/NNS||%-25/NN	conj_and||%-22/NN||%-25/NN	num||%-29/NN||61-28/CD	prep_of||rates-19/NNS||%-29/NN	conj_and||%-22/NN||%-29/NN	num||weeks-32/NNS||4-31/CD	prep_at||%-29/NN||weeks-32/NNS	num||%-35/NN||22-34/CD	prep_of||rates-19/NNS||%-35/NN	conj_and||%-22/NN||%-35/NN	num||%-38/NN||35-37/CD	prep_of||rates-19/NNS||%-38/NN	conj_and||%-22/NN||%-38/NN	num||%-42/NN||57-41/CD	prep_of||rates-19/NNS||%-42/NN	conj_and||%-22/NN||%-42/NN	num||weeks-45/NNS||8-44/CD	prep_at||%-42/NN||weeks-45/NNS	num||%-49/NN||50-48/CD	prep_of||rates-19/NNS||%-49/NN	conj_and||%-22/NN||%-49/NN	num||%-52/NN||21-51/CD	prep_of||rates-19/NNS||%-52/NN	conj_and||%-22/NN||%-52/NN	num||%-56/NN||71-55/CD	prep_of||rates-19/NNS||%-56/NN	conj_and||%-22/NN||%-56/NN	num||weeks-59/NNS||12-58/CD	prep_at||+-17/VBG||weeks-59/NNS	amod||patients-62/NNS||evaluable-61/JJ	prep_for||weeks-59/NNS||patients-62/NNS	cancers-9||cr-16||no_rel||assessment of the 69 patients with metastatic gi cancers revealed cr , pr , and cr + pr rates of 18%, 42%, and 61% at 4 weeks; 22%, 35%, and 57% at 8 weeks; and 50%, 21%, and 71% at 12 weeks for evaluable patients.
nsubj||responsible-4/JJ||vitaminc-2/NN	nsubjpass||obtained-12/VBN||vitaminc-2/NN	cop||responsible-4/JJ||was-3/VBD	ccomp||referred-34/VBD||responsible-4/JJ	det||cure-7/NN||the-6/DT	prep_for||responsible-4/JJ||cure-7/NN	prep_of||cure-7/NN||scurvy-9/NN	auxpass||obtained-12/VBN||was-11/VBD	conj_and||responsible-4/JJ||obtained-12/VBN	ccomp||referred-34/VBD||obtained-12/VBN	det||decoction-16/NN||an-14/DT	amod||decoction-16/NN||iroquois-15/JJ	prep_as||obtained-12/VBN||decoction-16/NN	det||bark-19/NN||the-18/DT	prep_from||decoction-16/NN||bark-19/NN	prep_as||obtained-12/VBN||leaves-21/NNS	conj_and||decoction-16/NN||leaves-21/NNS	prep_from||leaves-21/NNS||this-23/DT	prep_as||obtained-12/VBN||tree-26/NN	conj_and||decoction-16/NN||tree-26/NN	prep_of||tree-26/NN||life-28/NN	nsubj||referred-34/VBD||now-32/RB	advmod||referred-34/VBD||commonly-33/RB	root||ROOT-0/null||referred-34/VBD	advmod||arborvitae-37/JJ||as-36/RB	prep_to||referred-34/VBD||arborvitae-37/JJ	scurvy-9||vitaminc-2||yes||" vitaminc was responsible for the cure of scurvy and was obtained as an iroquois decoction from the bark and leaves from this ""tree of life"", now commonly referred to as arborvitae."
nn||criteria-2/NNS||inclusion-1/NN	nsubj||>-8/NNS||criteria-2/NNS	det||cohort-5/NN||the-4/DT	prep_in||criteria-2/NNS||cohort-5/NN	aux||>-8/NNS||were-6/VBD	nn||>-8/NNS||age-7/NN	root||ROOT-0/null||>-8/NNS	num||years-10/NNS||18-9/CD	dobj||>-8/NNS||years-10/NNS	amod||infection-13/NN||hiv-1-12/JJ	dobj||>-8/NNS||infection-13/NN	conj_or||years-10/NNS||infection-13/NN	amod||infection-20/NN||chronichepatitisc-15/JJ	nn||infection-20/NN||virus-16/NN	nn||infection-20/NN||hcv-18/NN	dobj||>-8/NNS||infection-20/NN	conj_or||years-10/NNS||infection-20/NN	amod||response-23/NN||sustained-22/JJ	dobj||>-8/NNS||response-23/NN	conj_or||years-10/NNS||response-23/NN	aux||hcv-25/VB||to-24/TO	vmod||>-8/NNS||hcv-25/VB	dobj||hcv-25/VB||treatment-26/NN	chronichepatitisc-15||hcv-25||no||inclusion criteria in the cohort were age > 18 years, hiv-1 infection, chronichepatitisc virus (hcv) infection or sustained response to hcv treatment.
det||risk-2/NN||the-1/DT	nsubjpass||characterized-24/VBN||risk-2/NN	amod||events-7/NNS||nsaid-related-4/JJ	amod||events-7/NNS||upper-5/JJ	nn||events-7/NNS||gi-6/NN	prep_of||risk-2/NN||events-7/NNS	prep_such_as||risk-2/NN||dyspepsia-11/NN	prep_such_as||risk-2/NN||pepticulcer-13/NN	conj_or||dyspepsia-11/NN||pepticulcer-13/NN	prep_such_as||risk-2/NN||complications-15/NNS	conj_and||dyspepsia-11/NN||complications-15/NNS	prep_such_as||complications-15/NNS||perforation-18/NN	prep_such_as||complications-15/NNS||bleeding-20/NN	conj_or||perforation-18/NN||bleeding-20/NN	auxpass||characterized-24/VBN||is-22/VBZ	advmod||characterized-24/VBN||well-23/RB	root||ROOT-0/null||characterized-24/VBN	nsaid--1||bleeding-20||no_rel||the risk of nsaid-related upper gi events, such as dyspepsia or pepticulcer and complications such as perforation or bleeding, is well characterized.
det||assay-2/NN||this-1/DT	nsubjpass||applied-5/VBN||assay-2/NN	nsubj||allows-17/VBZ||assay-2/NN	aux||applied-5/VBN||can-3/MD	auxpass||applied-5/VBN||be-4/VB	root||ROOT-0/null||applied-5/VBN	det||range-9/NN||a-7/DT	amod||range-9/NN||wide-8/JJ	prep_to||applied-5/VBN||range-9/NN	amod||viruses-13/NNS||plus-sense-11/JJ	nn||viruses-13/NNS||rna-12/NN	prep_of||range-9/NN||viruses-13/NNS	advmod||allows-17/VBZ||hence-16/RB	conj_and||applied-5/VBN||allows-17/VBZ	amod||studies-19/NNS||comparative-18/JJ	dobj||allows-17/VBZ||studies-19/NNS	nn||biology-22/NN||viralinfection-21/NN	prep_of||studies-19/NNS||biology-22/NN	amod||reagents-25/NNS||dedicated-24/JJ	prep_without||allows-17/VBZ||reagents-25/NNS	prep_without||allows-17/VBZ||procedures-27/NNS	conj_or||reagents-25/NNS||procedures-27/NNS	viralinfection-21||viruses-13||no||this assay can be applied to a wide range of plus-sense rna viruses, and hence allows comparative studies of viralinfection biology without dedicated reagents or procedures.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||no||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
det||â-5/NN||the-1/DT	advmod||famous-3/JJ||now-2/RB	amod||â-5/NN||famous-3/JJ	amod||â-5/NN||bland-sutton-4/JJ	nsubjpass||cured-20/VBN||â-5/NN	amod||â-5/NN||$-6/$	dep||$-6/$||œexperiment-7/JJ	prep_of||â-5/NN||nature-9/NN	amod||rickets-14/NNS||â-11/JJ	amod||rickets-14/NNS||$-12/$	dep||$-12/$||fatal-13/JJ	appos||â-5/NN||rickets-14/NNS	nn||cubs-17/NNS||lion-16/NN	prep_in||rickets-14/NNS||cubs-17/NNS	auxpass||cured-20/VBN||was-19/VBD	root||ROOT-0/null||cured-20/VBN	agent||cured-20/VBN||addition-22/NN	prep_of||addition-22/NN||minerals-24/NNS	agent||cured-20/VBN||vitamind-26/NNP	conj_and||addition-22/NN||vitamind-26/NNP	amod||salts-30/NNS||taurine-conjugated-28/JJ	nn||salts-30/NNS||bile-29/NN	nsubj||permitted-32/VBD||salts-30/NNS	advmod||permitted-32/VBD||undoubtedly-31/RB	rcmod||vitamind-26/NNP||permitted-32/VBD	dobj||permitted-32/VBD||absorption-33/NN	amod||a-36/DT||vitamins-35/JJ	prep_of||absorption-33/NN||a-36/DT	prep_of||absorption-33/NN||d-38/SYM	conj_and||a-36/DT||d-38/SYM	advmod||preventing-41/VBG||thus-40/RB	vmod||permitted-32/VBD||preventing-41/VBG	det||occurrence-43/NN||the-42/DT	dobj||preventing-41/VBG||occurrence-43/NN	amod||bonedisease-46/NN||metabolic-45/JJ	prep_of||occurrence-43/NN||bonedisease-46/NN	prep_of||occurrence-43/NN||rickets-48/NNS	conj_and||bonedisease-46/NN||rickets-48/NNS	rickets-48||vitamind-26||yes||the now famous bland-sutton â $ œexperiment of nature , â $ fatal rickets in lion cubs , was cured by addition of minerals and vitamind. taurine-conjugated bile salts undoubtedly permitted absorption of vitamins a and d , thus preventing the occurrence of metabolic bonedisease and rickets .
mark||recruited-5/VBN||while-1/IN	det||subjects-3/NNS||all-2/DT	nsubjpass||recruited-5/VBN||subjects-3/NNS	nsubj||free-8/JJ||subjects-3/NNS	auxpass||recruited-5/VBN||were-4/VBD	advcl||revealed-15/VBD||recruited-5/VBN	aux||free-8/JJ||to-6/TO	cop||free-8/JJ||be-7/VB	xcomp||recruited-5/VBN||free-8/JJ	prep_of||free-8/JJ||alcoholdependence-10/NN	amod||interviews-14/NNS||structured-12/JJ	amod||interviews-14/NNS||clinical-13/JJ	nsubj||revealed-15/VBD||interviews-14/NNS	root||ROOT-0/null||revealed-15/VBD	amod||patterns-17/NNS||significant-16/JJ	dobj||revealed-15/VBD||patterns-17/NNS	nn||use-20/NN||alcohol-19/NN	prep_of||patterns-17/NNS||use-20/NN	det||patients-23/NNS||the-22/DT	prep_in||revealed-15/VBD||patients-23/NNS	alcoholdependence-10||alcohol-19||no||while all subjects were recruited to be free of alcoholdependence, structured clinical interviews revealed significant patterns of alcohol use in the patients.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||pyrazinamide-48||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
mark||correction-2/NN||upon-1/IN	advcl||cause-8/NN||correction-2/NN	nsubj||cause-8/NN||stroke-4/NN	cop||cause-8/NN||is-5/VBZ	det||cause-8/NN||the-6/DT	amod||cause-8/NN||leading-7/VBG	root||ROOT-0/null||cause-8/NN	prep_of||cause-8/NN||death-10/NN	prep_in||cause-8/NN||thailand-12/NN	number||%-15/NN||10.7-14/CD	dep||thailand-12/NN||%-15/NN	vmod||thailand-12/NN||followed-18/VBN	amod||disease-22/NN||ischemic-20/JJ	nn||disease-22/NN||heart-21/NN	agent||followed-18/VBN||disease-22/NN	num||%-25/NN||7.8-24/CD	appos||disease-22/NN||%-25/NN	agent||followed-18/VBN||hiv/aids-28/NNS	conj_and||disease-22/NN||hiv/aids-28/NNS	num||%-31/NN||7.4-30/CD	appos||disease-22/NN||%-31/NN	aids--1||hiv--1||no||upon correction, stroke is the leading cause of death in thailand (10.7%), followed by ischemic heart disease (7.8%) and hiv/aids (7.4%).
mark||grows-4/VBZ||as-1/IN	amod||commitment-3/NN||global-2/JJ	nsubj||grows-4/VBZ||commitment-3/NN	nsubj||protect-6/VB||commitment-3/NN	nsubj||support-8/VB||commitment-3/NN	advcl||remain-17/VBP||grows-4/VBZ	aux||protect-6/VB||to-5/TO	xcomp||grows-4/VBZ||protect-6/VB	xcomp||grows-4/VBZ||support-8/VB	conj_and||protect-6/VB||support-8/VB	dobj||protect-6/VB||children-9/NNS	vmod||children-9/NNS||affected-10/VBN	agent||affected-10/VBN||hiv-12/NN	agent||affected-10/VBN||aids-14/NNS	conj_and||hiv-12/NN||aids-14/NNS	nsubj||remain-17/VBP||questions-16/NNS	root||ROOT-0/null||remain-17/VBP	advmod||meet-22/VB||how-19/WRB	nsubj||meet-22/VB||best-20/JJS	aux||meet-22/VB||to-21/TO	prepc_about||remain-17/VBP||meet-22/VB	det||needs-24/NNS||the-23/DT	dobj||meet-22/VB||needs-24/NNS	det||children-27/NNS||these-26/DT	prep_of||needs-24/NNS||children-27/NNS	amod||settings-31/NNS||low-29/JJ	nn||settings-31/NNS||prevalence-30/NN	prep_in||children-27/NNS||settings-31/NNS	mark||guide-41/VB||whether-33/IN	nsubj||guide-41/VB||information-34/NN	amod||countries-38/NNS||high-36/JJ	nn||countries-38/NNS||prevalence-37/NN	prep_from||information-34/NN||countries-38/NNS	aux||guide-41/VB||can-39/MD	advmod||guide-41/VB||appropriately-40/RB	prepc_about||remain-17/VBP||guide-41/VB	conj_and||meet-22/VB||guide-41/VB	dobj||guide-41/VB||programming-42/NN	det||settings-45/NNS||these-44/DT	prep_in||guide-41/VB||settings-45/NNS	aids-14||hiv-12||no||as global commitment grows to protect and support children affected by hiv and aids, questions remain about how best to meet the needs of these children in low prevalence settings and whether information from high prevalence countries can appropriately guide programming in these settings.
det||markers-3/NNS||these-1/DT	amod||markers-3/NNS||molecular-2/JJ	nsubj||indicate-4/VBP||markers-3/NNS	nsubj||high-14/JJ||markers-3/NNS	nsubj||rely-16/VB||markers-3/NNS	root||ROOT-0/null||indicate-4/VBP	mark||increasing-9/VBG||that-5/IN	amod||resistance-7/NN||pyrimethamine/sulfadoxine-6/JJ	nsubj||increasing-9/VBG||resistance-7/NN	aux||increasing-9/VBG||is-8/VBZ	ccomp||indicate-4/VBP||increasing-9/VBG	cop||high-14/JJ||is-11/VBZ	advmod||high-14/JJ||now-12/RB	advmod||high-14/JJ||too-13/RB	conj_and||indicate-4/VBP||high-14/JJ	aux||rely-16/VB||to-15/TO	xcomp||high-14/JJ||rely-16/VB	det||drug-19/NN||this-18/DT	prep_on||rely-16/VB||drug-19/NN	det||agent-24/NN||a-21/DT	amod||agent-24/NN||routine-22/JJ	amod||agent-24/NN||therapeutic-23/JJ	prep_as||drug-19/NN||agent-24/NN	aux||treat-26/VB||to-25/TO	xcomp||rely-16/VB||treat-26/VB	dobj||treat-26/VB||malaria-27/NN	prep_in||treat-26/VB||travelers-29/NNS	malaria-27||pyrimethamine--1||yes||these molecular markers indicate that pyrimethamine/sulfadoxine resistance is increasing and is now too high to rely on this drug as a routine therapeutic agent to treat malaria in travelers.
amod||variants-2/NNS||common-1/JJ	nsubjpass||associated-10/VBN||variants-2/NNS	prep_of||variants-2/NNS||mtnr1b-4/NNS	prep_of||variants-2/NNS||g6pc2-6/NNS	conj_and||mtnr1b-4/NNS||g6pc2-6/NNS	prep_of||variants-2/NNS||gck-8/NN	conj_and||mtnr1b-4/NNS||gck-8/NN	auxpass||associated-10/VBN||are-9/VBP	root||ROOT-0/null||associated-10/VBN	amod||fpg-13/NN||elevated-12/JJ	prep_with||associated-10/VBN||fpg-13/NN	amod||secretion-17/NN||impaired-15/VBN	nn||secretion-17/NN||insulin-16/NN	prep_with||associated-10/VBN||secretion-17/NN	conj_and||fpg-13/NN||secretion-17/NN	preconj||individually-20/RB||both-19/CC	advmod||associated-10/VBN||individually-20/RB	advmod||associated-10/VBN||jointly-22/RB	conj_and||individually-20/RB||jointly-22/RB	xcomp||associated-10/VBN||suggesting-24/VBG	mark||precipitate-30/VB||that-25/IN	det||alleles-28/NNS||these-26/DT	nn||alleles-28/NNS||risk-27/NN	nsubj||precipitate-30/VB||alleles-28/NNS	nsubj||perpetuate-32/VB||alleles-28/NNS	aux||precipitate-30/VB||may-29/MD	ccomp||suggesting-24/VBG||precipitate-30/VB	ccomp||suggesting-24/VBG||perpetuate-32/VB	conj_or||precipitate-30/VB||perpetuate-32/VB	dobj||precipitate-30/VB||hyperglycemia-33/NN	amod||individuals-36/NNS||predisposed-35/JJ	prep_in||hyperglycemia-33/NN||individuals-36/NNS	hyperglycemia-33||insulin-16||yes||common variants of mtnr1b , g6pc2 and gck are associated with elevated fpg and impaired insulin secretion, both individually and jointly, suggesting that these risk alleles may precipitate or perpetuate hyperglycemia in predisposed individuals.
det||study-2/NN||this-1/DT	nsubj||investigated-3/VBD||study-2/NN	root||ROOT-0/null||investigated-3/VBD	det||outcome-6/NN||the-4/DT	amod||outcome-6/NN||clinical-5/JJ	dobj||investigated-3/VBD||outcome-6/NN	advmod||diagnosed-9/JJ||newly-8/RB	amod||patients-11/NNS||diagnosed-9/JJ	nn||patients-11/NNS||apl-10/NN	prep_of||outcome-6/NN||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	amod||chemotherapy-15/NN||atra/anthracycline-14/JJ	prep_with||treated-12/VBN||chemotherapy-15/NN	apl-10||atra--1||yes||this study investigated the clinical outcome of newly diagnosed apl patients treated with atra/anthracycline chemotherapy.
amod||stimulation-4/NN||chronic-1/JJ	nn||stimulation-4/NN||cb-2/NN	nn||stimulation-4/NN||receptor-3/NN	nsubj||induces-8/VBZ||stimulation-4/NN	nsubj||stimulates-11/VBZ||stimulation-4/NN	nsubj||alters-15/VBZ||stimulation-4/NN	amod||conditions-7/NNS||basal-6/JJ	prep_under||stimulation-4/NN||conditions-7/NNS	root||ROOT-0/null||induces-8/VBZ	dobj||induces-8/VBZ||glucoseintolerance-9/NN	conj_and||induces-8/VBZ||stimulates-11/VBZ	amod||inflammation-13/NN||metabolic-12/JJ	dobj||stimulates-11/VBZ||inflammation-13/NN	conj_and||induces-8/VBZ||alters-15/VBZ	nn||metabolism-17/NN||lipid-16/NN	dobj||alters-15/VBZ||metabolism-17/NN	det||muscles-20/NNS||the-19/DT	prep_in||alters-15/VBZ||muscles-20/NNS	inflammation-13||lipid-16||no_rel||chronic cb receptor stimulation under basal conditions induces glucoseintolerance, stimulates metabolic inflammation and alters lipid metabolism in the muscles.
advmod||investigated-4/VBD||therefore-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	xcomp||investigated-4/VBD||using-5/VBG	amod||technology-8/NN||luciferase-6/JJ	nn||technology-8/NN||immunoprecipitation-7/NN	dobj||using-5/VBG||technology-8/NN	dep||investigated-4/VBD||lips-10/VB	nn||responses-13/NNS||antibody-12/NN	dobj||investigated-4/VBD||responses-13/NNS	num||proteins-17/NNS||seven-15/CD	amod||proteins-17/NNS||htlv-i-16/JJ	prep_to||responses-13/NNS||proteins-17/NNS	amod||controls-20/NNS||non-infected-19/JJ	prep_in||proteins-17/NNS||controls-20/NNS	amod||htlv-i-carriers-23/NNS||asymptomatic-22/JJ	prep_in||proteins-17/NNS||htlv-i-carriers-23/NNS	conj_and||controls-20/NNS||htlv-i-carriers-23/NNS	prep_in||proteins-17/NNS||atll-25/NN	conj_and||controls-20/NNS||atll-25/NN	nn||samples-29/NNS||ham/tsp-27/NN	nn||samples-29/NNS||sera-28/NN	prep_in||proteins-17/NNS||samples-29/NNS	conj_and||controls-20/NNS||samples-29/NNS	ham--1||htlv-i-16||no||therefore, we investigated using luciferase immunoprecipitation technology (lips) antibody responses to seven htlv-i proteins in non-infected controls, asymptomatic htlv-i-carriers, atll and ham/tsp sera samples.
nsubj||treatment-10/NN||chloroquine-1/NNP	conj_plus||chloroquine-1/NNP||primaqine-3/NNP	nsubj||treatment-10/NN||primaqine-3/NNP	cop||treatment-10/NN||is-4/VBZ	det||treatment-10/NN||an-5/DT	amod||treatment-10/NN||inexpensive-6/JJ	advmod||effective-9/JJ||highly-8/RB	conj_and||inexpensive-6/JJ||effective-9/JJ	amod||treatment-10/NN||effective-9/JJ	root||ROOT-0/null||treatment-10/NN	amod||infections-15/NNS||uncomplicated-12/JJ	amod||infections-15/NNS||knowlesi-13/JJ	nn||infections-15/NNS||malaria-14/NN	prep_for||treatment-10/NN||infections-15/NNS	prep_in||infections-15/NNS||humans-17/NNS	expl||is-20/VBZ||there-19/EX	conj_and||treatment-10/NN||is-20/VBZ	neg||evidence-22/NN||no-21/DT	nsubj||is-20/VBZ||evidence-22/NN	nn||resistance-25/NN||drug-24/NN	prep_of||evidence-22/NN||resistance-25/NN	malaria-14||chloroquine-1||yes||chloroquine plus primaqine is an inexpensive and highly effective treatment for uncomplicated knowlesi malaria infections in humans and there is no evidence of drug resistance.
nsubj||has-25/VBZ||identification-1/NN	prepc_of||identification-1/NN||neutralizing-3/VBG	dobj||neutralizing-3/VBG||antibodies-4/NNS	prep_with||antibodies-4/NNS||specificity-6/NN	det||mutation-11/NN||the-9/DT	amod||mutation-11/NN||traditional-10/JJ	prep_away_from||neutralizing-3/VBG||mutation-11/NN	amod||mutation-11/NN||prone-12/JJ	amod||regions-14/NNS||antigenic-13/JJ	dep||prone-12/JJ||regions-14/NNS	det||regions-19/NNS||the-17/DT	amod||regions-19/NNS||conserved-18/JJ	prep_against||regions-14/NNS||regions-19/NNS	prep_of||regions-19/NNS||hemagglutinin-21/NN	amod||influenzavirus-24/NNS||h5n1-23/JJ	prep_from||hemagglutinin-21/NN||influenzavirus-24/NNS	root||ROOT-0/null||has-25/VBZ	det||potential-27/NN||the-26/DT	dobj||has-25/VBZ||potential-27/NN	aux||provide-29/VB||to-28/TO	vmod||potential-27/NN||provide-29/VB	det||option-32/NN||a-30/DT	amod||option-32/NN||therapeutic-31/JJ	dobj||provide-29/VB||option-32/NN	nsubjpass||developed-36/VBN||option-32/NN	aux||developed-36/VBN||can-34/MD	auxpass||developed-36/VBN||be-35/VB	rcmod||option-32/NN||developed-36/VBN	prep_ahead_of||developed-36/VBN||time-39/NN	prep_in||time-39/NN||preparation-41/NN	det||pandemic-45/NN||a-43/DT	amod||pandemic-45/NN||possible-44/JJ	prep_for||developed-36/VBN||pandemic-45/NN	amod||viruses-49/NNS||h5n1-48/JJ	prep_due_to||pandemic-45/NN||viruses-49/NNS	h5n1-48||influenzavirus-24||no||identification of neutralizing antibodies with specificity away from the traditional mutation prone antigenic regions, against the conserved regions of hemagglutinin from h5n1 influenzavirus has the potential to provide a therapeutic option which can be developed ahead of time in preparation for a possible pandemic due to h5n1 viruses.
det||phenotype-2/NN||the-1/DT	nsubjpass||extended-12/VBN||phenotype-2/NN	nsubj||include-14/VB||phenotype-2/NN	vmod||phenotype-2/NN||associated-3/VBN	amod||mutations-8/NNS||heterozygous-5/JJ	amod||mutations-8/NNS||hnf4a-6/JJ	nn||mutations-8/NNS||gene-7/NN	prep_with||associated-3/VBN||mutations-8/NNS	aux||extended-12/VBN||has-9/VBZ	advmod||extended-12/VBN||recently-10/RB	auxpass||extended-12/VBN||been-11/VBN	root||ROOT-0/null||extended-12/VBN	aux||include-14/VB||to-13/TO	xcomp||extended-12/VBN||include-14/VB	amod||responsive-16/JJ||diazoxide-15/JJ	amod||hypoglycemia-18/NN||responsive-16/JJ	amod||hypoglycemia-18/NN||neonatal-17/JJ	dobj||include-14/VB||hypoglycemia-18/NN	prep_in||include-14/VB||addition-20/NN	amod||diabetes-23/NN||maturity-onset-22/JJ	prep_to||include-14/VB||diabetes-23/NN	det||mody-28/NN||the-25/DT	amod||mody-28/NN||young-26/JJ	prep_of||diabetes-23/NN||mody-28/NN	mody-28||diazoxide-15||no_rel||the phenotype associated with heterozygous hnf4a gene mutations has recently been extended to include diazoxide responsive neonatal hypoglycemia in addition to maturity-onset diabetes of the young (mody).
det||associations-3/NNS||the-1/DT	amod||associations-3/NNS||strongest-2/JJS	nsubjpass||found-10/VBN||associations-3/NNS	nn||responsiveness-8/NNS||atopy-5/NN	conj_and||atopy-5/NN||airway-7/NN	nn||responsiveness-8/NNS||airway-7/NN	prep_with||associations-3/NNS||responsiveness-8/NNS	auxpass||found-10/VBN||were-9/VBD	root||ROOT-0/null||found-10/VBN	amod||onset-13/NN||intermediate-12/JJ	prep_for||found-10/VBN||onset-13/NN	num||months-16/NNS||18-15/CD	appos||onset-13/NN||months-16/NNS	dep||onset-13/NN||wheezing-18/VBG	cc||for-21/IN||or-20/CC	dep||wheezing-18/VBG||for-21/IN	amod||8.36-23/CD||atopy-22/JJ	pobj||for-21/IN||8.36-23/CD	num||%-26/NN||95-25/CD	nsubj||ci-27/VBP||%-26/NN	dep||for-21/IN||ci-27/VBP	number||13.4-30/CD||5.2-28/CD	dep||13.4-30/CD||to-29/TO	dobj||ci-27/VBP||13.4-30/CD	amod||difference-33/NN||mean-32/JJ	dep||13.4-30/CD||difference-33/NN	nn||response-36/NN||dose-35/NN	prep_in||difference-33/NN||response-36/NN	aux||methacholine-38/VB||to-37/TO	vmod||ci-27/VBP||methacholine-38/VB	dobj||methacholine-38/VB||1.76-39/CD	number||%-42/NN||95-41/CD	amod||fev1-48/NNS||%-42/NN	nn||fev1-48/NNS||ci-43/NN	number||2.12-46/CD||1.41-44/CD	dep||2.12-46/CD||to-45/TO	dep||%-47/NN||2.12-46/CD	dep||fev1-48/NNS||%-47/NN	appos||1.76-39/CD||fev1-48/NNS	number||1/4-51/CD||î-50/CD	num||mol-52/NN||1/4-51/CD	prep_per||fev1-48/NNS||mol-52/NN	prepc_compared_with||methacholine-38/VB||with-55/IN	nn||phenotype-58/NN||infrequent/never-56/NN	nn||phenotype-58/NN||wheeze-57/NN	pobj||methacholine-38/VB||phenotype-58/NN	atopy-22||methacholine-38||no_rel||the strongest associations with atopy and airway responsiveness were found for intermediate onset (18 months) wheezing (or for atopy 8.36, 95% ci 5.2 to 13.4; mean difference in dose response to methacholine 1.76, 95% ci 1.41 to 2.12 %fev1 per î¼mol, compared with infrequent/never wheeze phenotype).
amod||reports-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||reports-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||feature-12/NN||that-4/IN	nsubj||feature-12/NN||imbalance-5/NN	nn||homeostasis-8/NNS||iron-7/NN	prep_of||imbalance-5/NN||homeostasis-8/NNS	cop||feature-12/NN||is-9/VBZ	det||feature-12/NN||a-10/DT	amod||feature-12/NN||common-11/JJ	ccomp||suggest-3/VBP||feature-12/NN	amod||cells-16/NNS||prion-14/JJ	amod||cells-16/NNS||infected-15/JJ	prep_of||feature-12/NN||cells-16/NNS	nn||models-19/NNS||mouse-18/NN	prep_of||feature-12/NN||models-19/NNS	conj_and||cells-16/NNS||models-19/NNS	vmod||feature-12/NN||implicating-21/VBG	dobj||implicating-21/VBG||redox-iron-22/NN	amod||pathogenesis-25/NNS||priondisease-24/JJ	prep_in||implicating-21/VBG||pathogenesis-25/NNS	priondisease-24||prion-14||no||recent reports suggest that imbalance of iron homeostasis is a common feature of prion infected cells and mouse models, implicating redox-iron in priondisease pathogenesis.
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||problem-18/NN||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	appos||tuberculosis-2/NNS||resistance-7/NN	aux||isoniazid-11/VB||to-8/TO	advmod||isoniazid-11/VB||at-9/IN	pobj||at-9/IN||least-10/JJS	vmod||resistance-7/NN||isoniazid-11/VB	vmod||resistance-7/NN||rifampin-13/VB	conj_and||isoniazid-11/VB||rifampin-13/VB	cop||problem-18/NN||is-15/VBZ	det||problem-18/NN||a-16/DT	amod||problem-18/NN||worldwide-17/JJ	root||ROOT-0/null||problem-18/NN	tb--1||rifampin-13||yes||multidrug-resistant tuberculosis (mdr-tb), resistance to at least isoniazid and rifampin, is a worldwide problem.
nn||nn414-4/NNS||resultsâ-1/NNP	nn||nn414-4/NNS||$-2/NNP	nsubj||delivered-5/VBD||nn414-4/NNS	nsubj||showed-14/VBD||nn414-4/NNS	root||ROOT-0/null||delivered-5/VBD	amod||responses-9/NNS||systemically-6/JJ	amod||responses-9/NNS||amplified-7/JJ	nn||responses-9/NNS||epinephrine-8/NN	dobj||delivered-5/VBD||responses-9/NNS	amod||hypoglycemia-12/NN||acute-11/JJ	prep_during||delivered-5/VBD||hypoglycemia-12/NN	conj_and||delivered-5/VBD||showed-14/VBD	det||effect-17/NN||a-15/DT	amod||effect-17/NN||persisting-16/JJ	dobj||showed-14/VBD||effect-17/NN	aux||amplify-19/VB||to-18/TO	vmod||showed-14/VBD||amplify-19/VB	det||response-22/NN||the-20/DT	amod||response-22/NN||epinephrine-21/JJ	dobj||amplify-19/VB||response-22/NN	advmod||given-24/VBN||when-23/WRB	advcl||amplify-19/VB||given-24/VBN	number||h-26/CD||24-25/CD	dobj||given-24/VBN||h-26/CD	det||study-30/NN||the-28/DT	amod||study-30/NN||hypoglycemic-29/JJ	prep_before||given-24/VBN||study-30/NN	hypoglycemia-12||epinephrine-21||no_rel||resultsâ€” nn414 delivered systemically amplified epinephrine responses during acute hypoglycemia and showed a persisting effect to amplify the epinephrine response when given 24 h before the hypoglycemic study.
advmod||observed-17/VBN||importantly-1/RB	neg||evidence-4/NN||no-3/DT	nsubjpass||observed-17/VBN||evidence-4/NN	nn||colonization-7/NN||lymphoreticular-6/NN	prep_for||evidence-4/NN||colonization-7/NN	prep_with||colonization-7/NN||prions-9/NNS	vmod||evidence-4/NN||seen-11/VBN	advmod||seen-11/VBN||uniformly-12/RB	prep_in||uniformly-12/RB||vcjd-14/JJ	auxpass||observed-17/VBN||was-16/VBD	root||ROOT-0/null||observed-17/VBN	det||patient-20/NN||a-19/DT	prep_in||observed-17/VBN||patient-20/NN	prep_with||patient-20/NN||kuru-22/NN	amod||biopsy-25/NN||tonsil-24/JJ	prep_at||observed-17/VBN||biopsy-25/NN	kuru-22||prions-9||no_rel||importantly, no evidence for lymphoreticular colonization with prions, seen uniformly in vcjd, was observed in a patient with kuru at tonsil biopsy.
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	cancer-55||fluorouracil--1||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
amod||drugs-3/NNS||other-1/JJ	amod||drugs-3/NNS||anti-tuberculous-2/JJ	nsubjpass||added-16/VBN||drugs-3/NNS	amod||ethambutol-7/JJ||pyrazinamide-5/JJ	dep||drugs-3/NNS||ethambutol-7/JJ	det||steroid-11/NN||a-10/DT	conj_and||drugs-3/NNS||steroid-11/NN	nsubjpass||added-16/VBN||steroid-11/NN	appos||steroid-11/NN||dexamethasone-13/NN	auxpass||added-16/VBN||were-15/VBD	root||ROOT-0/null||added-16/VBN	tuberculous--1||ethambutol-7||yes||other anti-tuberculous drugs (pyrazinamide, ethambutol) and a steroid (dexamethasone) were added.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||variable-2/JJ	nsubj||necessitates-28/VBZ||efficacy-3/NN	quantmod||$-6/$||0â-5/RB	num||%-9/NN||$-6/$	num||$-6/$||80-8/CD	appos||efficacy-3/NN||%-9/NN	nn||©-16/FW||mycobacteriumbovis-12/FW	nn||©-16/FW||bacille-13/FW	nn||©-16/FW||calmette-14/FW	nn||©-16/FW||gurã-15/FW	prep_of||efficacy-3/NN||©-16/FW	discourse||vaccine-21/NN||bcg-19/UH	prep_in||©-16/FW||vaccine-21/NN	amod||tuberculosis-24/NNP||adult-23/JJ	prep_against||efficacy-3/NN||tuberculosis-24/NNP	discourse||efficacy-3/NN||tb-26/UH	root||ROOT-0/null||necessitates-28/VBZ	dobj||necessitates-28/VBZ||development-29/NN	amod||candidates-33/NNS||alternative-31/JJ	nn||candidates-33/NNS||vaccine-32/NN	prep_of||development-29/NN||candidates-33/NNS	tb-26||bcg-19||no||the variable efficacy (0â€“80%) of mycobacteriumbovis bacille calmette gurã©in (bcg) vaccine against adult tuberculosis (tb) necessitates development of alternative vaccine candidates.
nsubj||agent-5/NN||rubellavirus-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||rubella-7/NN	det||illness-12/NN||a-9/DT	amod||illness-12/NN||mild-10/JJ	nn||illness-12/NN||rash-11/NN	prep_of||agent-5/NN||illness-12/NN	conj_and||rubella-7/NN||illness-12/NN	det||agent-18/NN||a-15/DT	amod||agent-18/NN||potent-16/JJ	amod||agent-18/NN||teratogenic-17/JJ	prep_of||agent-5/NN||agent-18/NN	conj_and||rubella-7/NN||agent-18/NN	advmod||contracted-20/VBD||when-19/WRB	advcl||agent-5/NN||contracted-20/VBD	det||woman-24/NN||a-22/DT	amod||woman-24/NN||pregnant-23/JJ	prep_by||contracted-20/VBD||woman-24/NN	rubella-7||rubellavirus-1||yes||rubellavirus is the causative agent of rubella, a mild rash illness, and a potent teratogenic agent when contracted by a pregnant woman.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	adrenocorticotropin-11||cushingdisease-27||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
det||exception-3/NN||the-2/DT	prep_with||observed-44/JJ||exception-3/NN	det||prevalence-7/NN||a-5/DT	amod||prevalence-7/NN||lower-6/JJR	prep_of||exception-3/NN||prevalence-7/NN	det||history-10/NN||a-9/DT	prep_of||prevalence-7/NN||history-10/NN	prep_of||history-10/NN||myocardialinfarction-12/NN	det||use-17/NN||a-14/DT	amod||use-17/NN||lower-15/JJR	nn||use-17/NN||preoperative-16/NN	prep_of||prevalence-7/NN||use-17/NN	conj_and||history-10/NN||use-17/NN	amod||heparin-20/NN||intravenous-19/JJ	prep_of||use-17/NN||heparin-20/NN	det||bicarbonate-group-23/NN||the-22/DT	prep_in||heparin-20/NN||bicarbonate-group-23/NN	neg||significant-26/JJ||no-25/DT	nsubj||observed-44/JJ||significant-26/JJ	nn||differences-29/NNS||group-28/NN	prep_between||significant-26/JJ||differences-29/NNS	amod||demographics-32/NNS||patient-31/JJ	prep_in||differences-29/NNS||demographics-32/NNS	amod||risk-35/NN||surgical-34/JJ	prep_in||differences-29/NNS||risk-35/NN	conj_and||demographics-32/NNS||risk-35/NN	prep_in||differences-29/NNS||type-37/NN	conj_and||demographics-32/NNS||type-37/NN	prep_in||differences-29/NNS||duration-40/NN	conj_and||demographics-32/NNS||duration-40/NN	prep_of||duration-40/NN||surgery-42/NN	cop||observed-44/JJ||were-43/VBD	root||ROOT-0/null||observed-44/JJ	myocardialinfarction-12||heparin-20||yes||with the exception of a lower prevalence of a history of myocardialinfarction and a lower preoperative use of intravenous heparin in the bicarbonate-group, no significant between group differences in patient demographics, surgical risk, type, and duration of surgery were observed.
advmod||showed-6/VBD||overall-1/RB	det||materials-5/NNS||the-3/DT	amod||materials-5/NNS||tested-4/JJ	nsubj||showed-6/VBD||materials-5/NNS	root||ROOT-0/null||showed-6/VBD	amod||potential-8/NN||great-7/JJ	dobj||showed-6/VBD||potential-8/NN	aux||developed-11/VBN||to-9/TO	auxpass||developed-11/VBN||be-10/VB	vmod||showed-6/VBD||developed-11/VBN	det||material-16/NN||a-13/DT	nn||material-16/NN||bone-14/NN	nn||material-16/NN||filler-15/NN	prep_into||developed-11/VBN||material-16/NN	det||treatment-19/NN||the-18/DT	prep_for||material-16/NN||treatment-19/NN	prep_of||treatment-19/NN||osteomyelitis-21/NNS	amod||bone-24/NN||other-23/JJ	prep_into||developed-11/VBN||bone-24/NN	conj_or||material-16/NN||bone-24/NN	vmod||bone-24/NN||related-25/VBN	dobj||related-25/VBN||infections-26/NNS	prep_in||infections-26/NNS||combination-28/NN	det||ciprofloxacin-31/NN||the-30/DT	prep_with||related-25/VBN||ciprofloxacin-31/NN	vmod||ciprofloxacin-31/NN||releasing-32/VBG	dobj||releasing-32/VBG||materials-33/NNS	osteomyelitis-21||ciprofloxacin-31||yes||overall, the tested materials showed great potential to be developed into a bone filler material for the treatment of osteomyelitis or other bone related infections in combination with the ciprofloxacin releasing materials.
amod||analyses-2/NNS||multiallelic-1/JJ	nsubj||showed-10/VBD||analyses-2/NNS	prepc_of||analyses-2/NNS||carrying-4/VBG	nn||alleles-6/NNS||risk-5/NN	dobj||carrying-4/VBG||alleles-6/NNS	amod||genes-9/NNS||multiple-8/JJ	prep_for||carrying-4/VBG||genes-9/NNS	root||ROOT-0/null||showed-10/VBD	dobj||showed-10/VBD||correlations-11/NNS	prep_between||correlations-11/NNS||number-13/NN	nn||alleles-16/NNS||risk-15/NN	prep_of||number-13/NN||alleles-16/NNS	prep_of||number-13/NN||type2diabetes-18/NNS	conj_and||alleles-16/NNS||type2diabetes-18/NNS	amod||secretion-22/NN||impaired-20/VBN	nn||secretion-22/NN||insulin-21/NN	prep_between||correlations-11/NNS||secretion-22/NN	conj_and||number-13/NN||secretion-22/NN	amod||subjects-25/NNS||normoglycemic-24/JJ	prep_in||secretion-22/NN||subjects-25/NNS	dep||secretion-22/NN||p-27/VBN	dep||0.006-29/CD||=-28/SYM	ccomp||p-27/VBN||0.006-29/CD	ccomp||p-27/VBN||0.0001-31/CD	conj_and||0.006-29/CD||0.0001-31/CD	prep_for||p-27/VBN||type2diabetes-33/NN	prep_for||p-27/VBN||air-35/NN	conj_and||type2diabetes-33/NN||air-35/NN	advmod||p-27/VBN||respectively-37/RB	vmod||showed-10/VBD||supporting-40/VBG	det||hypothesis-42/NNS||the-41/DT	dobj||supporting-40/VBG||hypothesis-42/NNS	mark||influence-48/VBP||that-43/IN	nsubj||influence-48/VBP||many-44/JJ	det||genes-47/NNS||these-46/DT	prep_of||many-44/JJ||genes-47/NNS	ccomp||supporting-40/VBG||influence-48/VBP	nn||risk-50/NN||diabetes-49/NN	dobj||influence-48/VBP||risk-50/NN	prepc_by||influence-48/VBP||affecting-52/VBG	nn||secretion-54/NN||insulin-53/NN	dobj||affecting-52/VBG||secretion-54/NN	type2diabetes-33||insulin-53||yes||multiallelic analyses of carrying risk alleles for multiple genes showed correlations between number of risk alleles and type2diabetes and impaired insulin secretion in normoglycemic subjects ( p = 0.006 and 0.0001 for type2diabetes and air, respectively), supporting the hypothesis that many of these genes influence diabetes risk by affecting insulin secretion.
advmod||produced-2/VBN||endogenously-1/RB	amod||interferons-3/NNS||produced-2/VBN	nsubj||regulate-5/VB||interferons-3/NNS	nsubjpass||administered-13/VBN||interferons-3/NNS	aux||regulate-5/VB||can-4/MD	root||ROOT-0/null||regulate-5/VB	det||growth-7/NN||the-6/DT	dobj||regulate-5/VB||growth-7/NN	nn||cells-10/NNS||melanoma-9/NN	prep_of||growth-7/NN||cells-10/NNS	auxpass||administered-13/VBN||are-12/VBP	conj_and||regulate-5/VB||administered-13/VBN	advmod||administered-13/VBN||exogenously-14/RB	amod||agents-17/NNS||therapeutic-16/JJ	prep_as||administered-13/VBN||agents-17/NNS	prep_to||administered-13/VBN||patients-19/NNS	amod||cancer-22/NN||advanced-21/JJ	prep_with||patients-19/NNS||cancer-22/NN	melanoma-9||interferons-3||yes||endogenously produced interferons can regulate the growth of melanoma cells and are administered exogenously as therapeutic agents to patients with advanced cancer.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||no||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
nsubj||led-9/VBD||over-expression-1/NN	amod||proteins-4/NNS||socs-3/JJ	prep_of||over-expression-1/NN||proteins-4/NNS	nn||lines-8/NNS||melanoma-6/NN	nn||lines-8/NNS||cell-7/NN	prep_in||proteins-4/NNS||lines-8/NNS	root||ROOT-0/null||led-9/VBD	amod||inhibition-12/NN||significant-11/JJ	prep_to||led-9/VBD||inhibition-12/NN	amod||stat1-15/NNS||tyr701-phosphorylated-14/JJ	prep_of||inhibition-12/NN||stat1-15/NNS	dep||stat1-15/NNS||p-stat1-17/JJ	nn||expression-21/NN||gene-20/NN	prep_to||led-9/VBD||expression-21/NN	conj_and||inhibition-12/NN||expression-21/NN	prep_following||expression-21/NN||stimulation-23/NN	nn||±-26/NNP||ifn-î-25/NNP	prep_with||stimulation-23/NN||±-26/NNP	dep||±-26/NNP||ifit2-28/NNP	dep||ifit2-28/NNP||oas-1-30/JJ	dep||ifit2-28/NNP||isg-15-32/JJ	nn||³-36/NNP||ifn-î-35/NNP	prep_with||stimulation-23/NN||³-36/NNP	conj_or||±-26/NNP||³-36/NNP	appos||±-26/NNP||irf1-38/NNP	melanoma-6||ifn--1||yes||over-expression of socs proteins in melanoma cell lines led to significant inhibition of tyr701-phosphorylated stat1 (p-stat1) and gene expression following stimulation with ifn-î± (ifit2, oas-1, isg-15) or ifn-î³ (irf1).
det||risk-2/NN||the-1/DT	nsubj||higher-6/JJR||risk-2/NN	prep_of||risk-2/NN||htlv-1infection-4/CD	cop||higher-6/JJR||was-5/VBD	root||ROOT-0/null||higher-6/JJR	prep_in||higher-6/JJR||subjects-8/NNS	det||mother-13/NN||an-10/DT	amod||mother-13/NN||htlv-1-11/JJ	amod||mother-13/NN||positive-12/JJ	prep_with||subjects-8/NNS||mother-13/NN	det||mother-17/NN||an-15/DT	amod||mother-17/NN||uninfected-16/JJ	prep_versus||mother-13/NN||mother-17/NN	dep||higher-6/JJR||or-19/CC	dep||or-19/CC||4.6-20/CD	dep||4.6-20/CD||ci-22/RB	num||.0-24/CD||2.6-8-23/CD	dep||4.6-20/CD||.0-24/CD	htlv-1infection-4||htlv-1-11||no||the risk of htlv-1infection was higher in subjects with an htlv-1 positive mother versus an uninfected mother (or 4.6, ci 2.6-8.0).
amod||analyses-5/NNS||case-control-2/JJ	conj_and||case-control-2/JJ||case-series-4/JJ	amod||analyses-5/NNS||case-series-4/JJ	prep_in||examined-8/VBD||analyses-5/NNS	nsubj||examined-8/VBD||we-7/PRP	root||ROOT-0/null||examined-8/VBD	nn||concentrations-10/NNS||serum-9/NN	dobj||examined-8/VBD||concentrations-10/NNS	amod||25ohd-14/NNS||25-hydroxyvitamind-12/JJ	prep_of||concentrations-10/NNS||25ohd-14/NNS	prep_in||25ohd-14/NNS||relation-17/NN	nn||characteristics-22/NNS||breast-19/NN	nn||characteristics-22/NNS||cancer-20/NN	amod||characteristics-22/NNS||prognostic-21/JJ	prep_to||examined-8/VBD||characteristics-22/NNS	amod||grade-26/NN||histologic-25/JJ	prep_including||examined-8/VBD||grade-26/NN	nn||receptor-29/NN||estrogen-28/NN	appos||grade-26/NN||receptor-29/NN	appos||receptor-29/NN||er-31/NN	amod||subtypes-36/NNS||molecular-35/JJ	nsubj||enrolled-67/VBD||subtypes-36/NNS	vmod||subtypes-36/NNS||defined-37/VBN	agent||defined-37/VBN||er-39/NN	amod||pr-44/NN||progesterone-41/JJ	nn||pr-44/NN||receptor-42/NN	agent||defined-37/VBN||pr-44/NN	conj_and||er-39/NN||pr-44/NN	agent||defined-37/VBN||her2-47/NNS	conj_and||er-39/NN||her2-47/NNS	num||women-51/NNS||579-50/CD	prep_among||defined-37/VBN||women-51/NNS	nn||cancer-55/NN||incident-53/NN	nn||cancer-55/NN||breast-54/NN	prep_with||women-51/NNS||cancer-55/NN	num||controls-58/NNS||574-57/CD	prep_among||defined-37/VBN||controls-58/NNS	conj_and||women-51/NNS||controls-58/NNS	vmod||controls-58/NNS||matched-59/VBN	prep_on||matched-59/VBN||age-61/NN	prep_on||matched-59/VBN||time-63/NN	conj_and||age-61/NN||time-63/NN	nn||draw-66/NN||blood-65/NN	prep_of||age-61/NN||draw-66/NN	conj_and||examined-8/VBD||enrolled-67/VBD	det||institute-73/NN||the-69/DT	amod||institute-73/NN||roswell-70/JJ	nn||institute-73/NN||park-71/NN	nn||institute-73/NN||cancer-72/NN	prep_in||enrolled-67/VBD||institute-73/NN	num||2008-77/CD||2003-75/CD	dep||2008-77/CD||to-76/TO	prep_from||enrolled-67/VBD||2008-77/CD	cancer-72||estrogen-28||no_rel||in case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamind (25ohd) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (er), and molecular subtypes defined by er, progesterone receptor (pr) and her2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the roswell park cancer institute from 2003 to 2008.
amod||infection-3/NN||anal-1/JJ	nn||infection-3/NN||hpv-2/NN	nsubj||contributes-6/VBZ||infection-3/NN	nsubjpass||known-18/VBN||infection-3/NN	nsubj||common-21/JJ||infection-3/NN	rcmod||infection-3/NN||contributes-6/VBZ	det||development-9/NN||the-8/DT	prep_to||contributes-6/VBZ||development-9/NN	prep_of||development-9/NN||analwarts-11/NNS	nn||cancer-14/NN||anal-13/NN	prep_of||development-9/NN||cancer-14/NN	conj_and||analwarts-11/NNS||cancer-14/NN	auxpass||known-18/VBN||is-16/VBZ	advmod||known-18/VBN||well-17/RB	root||ROOT-0/null||known-18/VBN	aux||common-21/JJ||to-19/TO	cop||common-21/JJ||be-20/VB	xcomp||known-18/VBN||common-21/JJ	prep_among||common-21/JJ||men-23/NNS	nsubj||have-25/VBP||men-23/NNS	rcmod||men-23/NNS||have-25/VBP	dobj||have-25/VBP||sex-26/NN	prep_with||sex-26/NN||men-28/NNS	appos||men-28/NNS||msm-30/NN	advmod||have-25/VBP||especially-33/RB	det||hivpositives-36/NNS||those-35/DT	prep_among||have-25/VBP||hivpositives-36/NNS	analwarts-11||hpv-2||no||anal hpv infection, which contributes to the development of analwarts and anal cancer, is well known to be common among men who have sex with men (msm), especially among those hivpositives.
det||antimalarialdrugs-4/NNS||the-2/DT	amod||antimalarialdrugs-4/NNS||various-3/JJ	prep_among||proven-24/VBN||antimalarialdrugs-4/NNS	amod||antimalarialdrugs-4/NNS||available-5/JJ	det||combination-9/NN||the-7/DT	amod||combination-9/NN||synergistic-8/JJ	nsubj||proven-24/VBN||combination-9/NN	prep_of||combination-9/NN||atovaquone-11/NN	prep_of||combination-9/NN||proguanil-13/NN	conj_and||atovaquone-11/NN||proguanil-13/NN	appos||atovaquone-11/NN||a/p-15/NN	nn||®-19/NNP||malaroneâ-18/NNP	dep||atovaquone-11/NN||®-19/NNP	dep||®-19/NNP||glaxo-smithkline-21/NN	aux||proven-24/VBN||has-23/VBZ	root||ROOT-0/null||proven-24/VBN	det||option-27/NN||a-25/DT	amod||option-27/NN||valuable-26/JJ	dobj||proven-24/VBN||option-27/NN	prep_in||proven-24/VBN||terms-29/NNS	amod||protection-32/NN||effective-31/JJ	prep_of||terms-29/NNS||protection-32/NN	prep_against||proven-24/VBN||chloroquine-34/NN	prep_against||proven-24/VBN||multi-drug-36/NN	conj_and||chloroquine-34/NN||multi-drug-36/NN	xcomp||proven-24/VBN||resistant-37/VBG	dobj||resistant-37/VBG||falciparummalaria-38/NN	dobj||resistant-37/VBG||safety-40/NN	conj_and||falciparummalaria-38/NN||safety-40/NN	dobj||resistant-37/VBG||tolerability-42/NN	conj_and||falciparummalaria-38/NN||tolerability-42/NN	dobj||resistant-37/VBG||ease-45/NN	conj_and||falciparummalaria-38/NN||ease-45/NN	prep_of||falciparummalaria-38/NN||use-47/NN	advmod||favoring-50/VBG||thus-49/RB	xcomp||proven-24/VBN||favoring-50/VBG	dobj||favoring-50/VBG||compliance-51/NN	falciparummalaria-38||chloroquine-34||yes||among the various antimalarialdrugs available, the synergistic combination of atovaquone and proguanil (a/p) (malaroneâ®; glaxo-smithkline) has proven a valuable option in terms of effective protection against chloroquine and multi-drug resistant falciparummalaria, safety, tolerability, and ease of use, thus favoring compliance.
amod||studies-3/NNS||basic-1/JJ	nn||studies-3/NNS||science-2/NN	nsubj||provided-20/VBD||studies-3/NNS	det||conference-8/NN||the-5/DT	amod||conference-8/NN||5th-6/JJ	nn||conference-8/NN||ias-7/NN	prep_at||studies-3/NNS||conference-8/NN	nn||pathogenesis-11/NNS||hiv-10/NN	prep_on||conference-8/NN||pathogenesis-11/NNS	prep_on||conference-8/NN||treatment-13/NN	conj_and||pathogenesis-11/NNS||treatment-13/NN	prep_on||conference-8/NN||prevention-15/NN	conj_and||pathogenesis-11/NNS||prevention-15/NN	appos||studies-3/NNS||ias-17/NN	num||ias-17/NN||2009-18/CD	root||ROOT-0/null||provided-20/VBD	amod||information-23/NN||important-21/JJ	amod||information-23/NN||new-22/JJ	dobj||provided-20/VBD||information-23/NN	nsubj||has-25/VBZ||information-23/NN	rcmod||information-23/NN||has-25/VBZ	dobj||has-25/VBZ||implications-26/NNS	neg||only-28/JJ||not-27/RB	preconj||has-25/VBZ||only-28/JJ	prep_for||has-25/VBZ||treatment-30/NN	advmod||understanding-36/VBG||better-35/RBR	prep_for||has-25/VBZ||understanding-36/VBG	conj_and||treatment-30/NN||understanding-36/VBG	det||dynamics-39/NNS||the-37/DT	amod||dynamics-39/NNS||complex-38/JJ	dobj||understanding-36/VBG||dynamics-39/NNS	prep_of||dynamics-39/NNS||hivinfection-41/NN	advmod||understanding-36/VBG||epidemiology-43/RB	det||impact-47/NN||the-46/DT	dobj||provided-20/VBD||impact-47/NN	conj_and||information-23/NN||impact-47/NN	nsubj||has-25/VBZ||impact-47/NN	prep_of||impact-47/NN||biology-49/NN	prep_of||impact-47/NN||genetics-51/NNS	conj_and||biology-49/NN||genetics-51/NNS	prep_on||provided-20/VBD||vulnerability-53/NN	prep_to||provided-20/VBD||hivinfection-55/NN	nn||progression-58/NN||disease-57/NN	prep_to||provided-20/VBD||progression-58/NN	conj_and||hivinfection-55/NN||progression-58/NN	det||risk-61/NN||the-60/DT	prep_to||provided-20/VBD||risk-61/NN	conj_and||hivinfection-55/NN||risk-61/NN	amod||transmission-64/NN||vertical-63/JJ	prep_of||risk-61/NN||transmission-64/NN	hivinfection-55||hiv-10||no||basic science studies at the 5th ias conference on hiv pathogenesis, treatment and prevention (ias 2009) provided important new information that has implications not only for treatment, but also for better understanding the complex dynamics of hivinfection, epidemiology, and the impact of biology and genetics on vulnerability to hivinfection, disease progression and the risk of vertical transmission.
prepc_compared_to||showed-8/VBD||to-2/TO	pobj||showed-8/VBD||hc-3/NN	det||group-7/NN||the-5/DT	nn||group-7/NN||alt-6/NN	nsubj||showed-8/VBD||group-7/NN	root||ROOT-0/null||showed-8/VBD	num||%-10/NN||62-9/CD	iobj||showed-8/VBD||%-10/NN	dep||hepatic-12/JJ||lower-11/JJR	amod||kappa-15/NNS||hepatic-12/JJ	amod||kappa-15/NNS||nuclear-13/JJ	nn||kappa-15/NNS||factor-14/NN	iobj||showed-8/VBD||kappa-15/NNS	dep||p-22/NNP||b-16/SYM	nn||p-22/NNP||-lrb--17/NNP	nn||p-22/NNP||nf-îºb-18/NNP	nn||p-22/NNP||-rrb--19/NNP	nn||p-22/NNP||activity-20/NN	nn||p-22/NNP||-lrb--21/NNP	dep||kappa-15/NNS||p-22/NNP	number||0.001-24/CD||<-23/CD	num||-rrb--25/NNS||0.001-24/CD	dobj||showed-8/VBD||-rrb--25/NNS	det||reduction-28/NN||a-27/DT	dobj||showed-8/VBD||reduction-28/NN	det||âˆ-36/NN||the-30/DT	advmod||inflammatory-32/JJ||circulating-31/RB	amod||âˆ-36/NN||inflammatory-32/JJ	amod||âˆ-36/NN||markers-33/JJ	nn||âˆ-36/NN||e-selectin-34/NN	nn||âˆ-36/NN||-lrb--35/NN	prep_of||reduction-28/NN||âˆ-36/NN	number||%-39/NN||20-38/CD	amod||âˆ-36/NN||%-39/NN	amod||molecule-49/NN||p-41/JJ	amod||molecule-49/NN||<-42/JJ	num||-rrb--44/NNS||0.05-43/CD	dep||<-42/JJ||-rrb--44/NNS	appos||-rrb--44/NNS||vascular-46/NN	nn||molecule-49/NN||cell-47/NN	nn||molecule-49/NN||adhesion-48/NN	dep||reduction-28/NN||molecule-49/NN	num||-lrb--51/NNS||1-50/CD	npadvmod||vcam-1-52/JJ||-lrb--51/NNS	amod||molecule-49/NN||vcam-1-52/JJ	dep||reduction-28/NN||âˆ-54/NNP	num||%-57/NN||15-56/CD	dep||âˆ-54/NNP||%-57/NN	amod||-rrb--62/NN||p-59/JJ	amod||-rrb--62/NN||<-60/JJ	dep||<-60/JJ||0.05-61/CD	dep||reduction-28/NN||-rrb--62/NN	nn||amyloid-65/NN||serum-64/NN	dep||reduction-28/NN||amyloid-65/NN	conj_and||-rrb--62/NN||amyloid-65/NN	det||saa-68/NN||a-66/DT	amod||saa-68/NN||-lrb--67/JJ	dep||-rrb--62/NN||saa-68/NN	dep||reduction-28/NN||âˆ-70/NNP	num||%-73/NN||31-72/CD	dep||âˆ-70/NNP||%-73/NN	amod||âˆ-85/NN||p-75/JJ	amod||âˆ-85/NN||<-76/JJ	num||-rrb--78/NNS||0.05-77/CD	dep||<-76/JJ||-rrb--78/NNS	amod||sizes-83/NNS||smaller-80/JJR	amod||sizes-83/NNS||atherosclerotic-81/JJ	nn||sizes-83/NNS||lesion-82/NN	appos||-rrb--78/NNS||sizes-83/NNS	nn||âˆ-85/NN||-lrb--84/NN	dep||reduction-28/NN||âˆ-85/NN	number||%-88/NN||51-87/CD	amod||âˆ-85/NN||%-88/NN	num||âµm2-93/NNS||46497â-90/CD	amod||âµm2-93/NNS||±-91/JJ	num||âµm2-93/NNS||10791-92/CD	dep||reduction-28/NN||âµm2-93/NNS	amod||âµm2-98/NNS||94664â-95/JJ	nn||âµm2-98/NNS||±-96/NNP	num||âµm2-98/NNS||16470-97/CD	prep_vs.||âµm2-93/NNS||âµm2-98/NNS	nn||<-101/NNS||p-100/NN	dep||reduction-28/NN||<-101/NNS	num||-rrb--103/NNS||0.05-102/CD	dep||<-101/NNS||-rrb--103/NNS	amod||expression-107/NN||diminished-105/JJ	amod||expression-107/NN||renal-106/JJ	dobj||showed-8/VBD||expression-107/NN	conj_and||reduction-28/NN||expression-107/NN	amod||inflammation-110/NN||specific-109/JJ	prep_of||expression-107/NN||inflammation-110/NN	nn||markers-113/NNS||activation-112/NN	prep_of||expression-107/NN||markers-113/NNS	conj_and||inflammation-110/NN||markers-113/NNS	advmod||vcam-1-115/JJ||-lrb--114/RB	amod||expression-107/NN||vcam-1-115/JJ	appos||expression-107/NN||âˆ-117/NNP	num||%-120/NN||27-119/CD	dep||âˆ-117/NNP||%-120/NN	nn||<-123/NNS||p-122/NN	dep||âˆ-117/NNP||<-123/NNS	dep||<-123/NNS||0.05-124/CD	amod||-lrb--129/NNS||monocyte-126/JJ	amod||-lrb--129/NNS||chemotactic-127/JJ	nn||-lrb--129/NNS||protein-1-128/NN	dep||âˆ-117/NNP||-lrb--129/NNS	amod||-rrb--131/NNS||mcp-1-130/JJ	dep||-lrb--129/NNS||-rrb--131/NNS	dep||âˆ-117/NNP||âˆ-133/NNP	num||%-136/NN||37-135/CD	dep||âˆ-133/NNP||%-136/NN	nn||<-139/NNS||p-138/NN	dep||âˆ-117/NNP||<-139/NNS	num||-rrb--141/NNS||0.01-140/CD	dep||<-139/NNS||-rrb--141/NNS	inflammation-110||hc-3||yes||compared to hc , the alt group showed 62 % lower hepatic nuclear factor kappa b -lrb- nf-îºb -rrb- activity -lrb- p < 0.001 -rrb- , a reduction of the circulating inflammatory markers e-selectin -lrb- âˆ ' 20 % ; p < 0.05 -rrb- , vascular cell adhesion molecule 1 -lrb- vcam-1 ; âˆ ' 15 % ; p < 0.05 -rrb- and serum amyloid a -lrb- saa ; âˆ ' 31 % ; p < 0.05 -rrb- , smaller atherosclerotic lesion sizes -lrb- âˆ ' 51 % ; 46497â ± 10791 âµm2 vs. 94664â ± 16470 âµm2 ; p < 0.05 -rrb- and diminished renal expression of specific inflammation and activation markers -lrb- vcam-1 , âˆ ' 27 % ; p < 0.05 ; monocyte chemotactic protein-1 -lrb- mcp-1 -rrb- ; âˆ ' 37 % ; p < 0.01 -rrb- .
nsubj||inconclusive-15/JJ||results-1/NNS	amod||studies-4/NNS||epidemiologic-3/JJ	prep_from||results-1/NNS||studies-4/NNS	det||relationship-7/NN||the-6/DT	prep_on||studies-4/NNS||relationship-7/NN	nn||risk-13/NN||vitamind-9/NN	conj_and||vitamind-9/NN||breast-11/NN	nn||risk-13/NN||breast-11/NN	nn||risk-13/NN||cancer-12/NN	prep_between||relationship-7/NN||risk-13/NN	cop||inconclusive-15/JJ||are-14/VBP	root||ROOT-0/null||inconclusive-15/JJ	cancer-12||vitamind-9||no_rel||results from epidemiologic studies on the relationship between vitamind and breast cancer risk are inconclusive.
amod||â-2/NN||objective-1/JJ	nsubj||$-3/VBD||â-2/NN	nsubj||characterize-6/VB||â-2/NN	root||ROOT-0/null||$-3/VBD	aux||characterize-6/VB||to-5/TO	xcomp||$-3/VBD||characterize-6/VB	nn||action-8/NN||insulin-7/NN	dobj||characterize-6/VB||action-8/NN	prep_in||characterize-6/VB||africans-10/NNS	amod||diabetes-13/NN||ketosis-prone-12/JJ	prep_with||africans-10/NNS||diabetes-13/NN	discourse||diabetes-13/NN||kpd-15/UH	prep_during||$-3/VBD||remission-18/NN	insulin-7||kpd-15||no_rel||objective â€”to characterize insulin action in africans with ketosis-prone diabetes (kpd) during remission.
nsubjpass||approved-9/VBN||atomoxetine-1/NN	dep||atomoxetine-1/NN||atomoxetinehydrochloride-3/NN	nn||®-6/NNP||stratteraâ-5/NNP	dep||atomoxetinehydrochloride-3/NN||®-6/NNP	auxpass||approved-9/VBN||was-8/VBD	root||ROOT-0/null||approved-9/VBN	prep_in||approved-9/VBN||2002-11/CD	prep_for||approved-9/VBN||treatment-13/NN	prep_of||treatment-13/NN||adhd-15/NN	cop||medication-22/NN||was-18/VBD	det||medication-22/NN||the-19/DT	amod||medication-22/NN||first-20/JJ	nn||medication-22/NN||nonstimulant-21/NN	conj_and||approved-9/VBN||medication-22/NN	vmod||medication-22/NN||approved-23/VBN	det||disorder-26/NN||this-25/DT	prep_for||approved-23/VBN||disorder-26/NN	adhd-15||atomoxetine-1||yes||atomoxetine (atomoxetinehydrochloride; stratteraâ®) was approved in 2002 for treatment of adhd, and was the first nonstimulant medication approved for this disorder.
prep_in||determined-23/VBN||adulthood-2/NN	nsubjpass||determined-23/VBN||effects-4/NNS	amod||response-8/NN||acoustic-6/JJ	nn||response-8/NN||startle-7/NN	prep_on||effects-4/NNS||response-8/NN	prep_on||effects-4/NNS||habituation-10/NN	conj_and||response-8/NN||habituation-10/NN	amod||ppi-15/NN||prepulse-12/JJ	nn||ppi-15/NN||inhibition-13/NN	prep_on||effects-4/NNS||ppi-15/NN	conj_and||response-8/NN||ppi-15/NN	nn||sensitization-21/NN||foot-19/NN	nn||sensitization-21/NN||shock-20/NN	prep_on||effects-4/NNS||sensitization-21/NN	conj_and||response-8/NN||sensitization-21/NN	auxpass||determined-23/VBN||were-22/VBD	root||ROOT-0/null||determined-23/VBN	ppi-15||habituation-10||no_rel||in adulthood, effects on acoustic startle response, habituation, prepulse inhibition (ppi), and foot shock sensitization were determined.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	ulcerativecolitis-10||enzyme--1||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
amod||cells-3/NNS||s2-2/JJ	prep_in||predominantly-17/RB||cells-3/NNS	amod||rnas-8/NNS||virus-derived-5/JJ	amod||rnas-8/NNS||small-6/JJ	amod||rnas-8/NNS||interfering-7/JJ	nsubj||predominantly-17/RB||rnas-8/NNS	appos||rnas-8/NNS||virnas-10/NNS	det||viruses-15/NNS||all-13/DT	num||viruses-15/NNS||three-14/CD	prep_from||rnas-8/NNS||viruses-15/NNS	cop||predominantly-17/RB||were-16/VBD	root||ROOT-0/null||predominantly-17/RB	num||nt-19/NNS||21-18/CD	dep||predominantly-17/RB||nt-19/NNS	prep_in||predominantly-17/RB||length-21/NN	det||hallmark-24/NN||a-23/DT	dep||predominantly-17/RB||hallmark-24/NN	det||pathway-28/NN||the-26/DT	amod||pathway-28/NN||rnai-27/JJ	prep_of||hallmark-24/NN||pathway-28/NN	virus--1||viruses-15||no||in s2 cells, virus-derived small interfering rnas (virnas) from all three viruses were predominantly 21 nt in length, a hallmark of the rnai pathway.
det||potential-7/NN||an-1/DT	advmod||high-3/JJ||unexpectedly-2/RB	amod||potential-7/NN||high-3/JJ	amod||potential-7/NN||seroprevalence-4/JJ	conj_and||seroprevalence-4/JJ||pathogenic-6/JJ	amod||potential-7/NN||pathogenic-6/JJ	nsubjpass||observed-16/VBN||potential-7/NN	amod||parvovirusb19-10/NNS||human-9/JJ	prep_of||potential-7/NN||parvovirusb19-10/NNS	appos||potential-7/NN||b19v-12/NNP	aux||observed-16/VBN||have-14/VBP	auxpass||observed-16/VBN||been-15/VBN	root||ROOT-0/null||observed-16/VBN	amod||countries-20/NNS||certain-18/JJ	amod||countries-20/NNS||malaria-endemic-19/JJ	prep_in||observed-16/VBN||countries-20/NNS	prep_in||countries-20/NNS||parallel-22/NN	amod||use-25/NN||local-24/JJ	prep_with||observed-16/VBN||use-25/NN	prep_of||use-25/NN||chloroquine-27/NN	appos||chloroquine-27/NN||cq-29/NN	amod||treatment-33/NN||first-line-32/JJ	prep_as||observed-16/VBN||treatment-33/NN	prep_for||treatment-33/NN||malaria-35/NN	malaria-35||chloroquine-27||yes||an unexpectedly high seroprevalence and pathogenic potential of human parvovirusb19 (b19v) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (cq) as first-line treatment for malaria.
amod||presentation-2/NN||clinical-1/JJ	nsubj||includes-3/VBZ||presentation-2/NN	root||ROOT-0/null||includes-3/VBZ	det||history-5/NN||a-4/DT	dobj||includes-3/VBZ||history-5/NN	prep_of||history-5/NN||asthma-7/NN	prep_after||includes-3/VBZ||ingestion-9/NN	prep_of||ingestion-9/NN||aspirin-11/NN	amod||congestion-14/NN||nasal-13/JJ	prep_of||ingestion-9/NN||congestion-14/NN	conj_and||aspirin-11/NN||congestion-14/NN	amod||rhinorrhea-17/NN||watery-16/JJ	prep_of||ingestion-9/NN||rhinorrhea-17/NN	conj_and||aspirin-11/NN||rhinorrhea-17/NN	prep_of||ingestion-9/NN||nasalpolyposis-19/NNS	conj_and||aspirin-11/NN||nasalpolyposis-19/NNS	nasalpolyposis-19||aspirin-11||no||clinical presentation includes a history of asthma after ingestion of aspirin, nasal congestion, watery rhinorrhea and nasalpolyposis.
advmod||sought-5/VBD||additionally-1/RB	det||study-4/NN||the-3/DT	nsubj||sought-5/VBD||study-4/NN	nsubj||identify-7/VB||study-4/NN	root||ROOT-0/null||sought-5/VBD	aux||identify-7/VB||to-6/TO	xcomp||sought-5/VBD||identify-7/VB	amod||processes-9/NNS||biological-8/JJ	dobj||identify-7/VB||processes-9/NNS	nsubjpass||associated-16/VBN||processes-9/NNS	dobj||identify-7/VB||pathways-11/NNS	conj_and||processes-9/NNS||pathways-11/NNS	nsubjpass||associated-16/VBN||pathways-11/NNS	auxpass||associated-16/VBN||are-13/VBP	advmod||significantly-15/RB||most-14/RBS	advmod||associated-16/VBN||significantly-15/RB	rcmod||processes-9/NNS||associated-16/VBN	amod||metastases-20/NNS||early-18/JJ	amod||metastases-20/NNS||distant-19/JJ	prep_with||associated-16/VBN||metastases-20/NNS	number||5-23/CD||<-22/CD	num||years-24/NNS||5-23/CD	appos||metastases-20/NNS||years-24/NNS	prep_in||metastases-20/NNS||women-27/NNS	amod||receptor-positive-30/JJ||estrogen-29/JJ	amod||breasttumors-35/NNS||receptor-positive-30/JJ	nn||+-33/NNP||er-32/NNP	appos||breasttumors-35/NNS||+-33/NNP	prep_with||women-27/NNS||breasttumors-35/NNS	breasttumors-35||estrogen-29||yes||additionally, the study sought to identify biological processes and pathways that are most significantly associated with early distant metastases (<5 years) in women with estrogen receptor-positive (er+) breasttumors.
nsubjpass||triggered-14/VBN||events-1/NNS	amod||events-1/NNS||similar-2/JJ	prep_to||similar-2/JJ||those-4/DT	vmod||those-4/DT||occurring-5/VBG	prep_in||occurring-5/VBG||er-7/NN	amod||events-12/NNS||stress-induced-10/JJ	nn||events-12/NNS||mh-11/NN	prep_in||occurring-5/VBG||events-12/NNS	conj_and||er-7/NN||events-12/NNS	auxpass||triggered-14/VBN||are-13/VBP	root||ROOT-0/null||triggered-14/VBN	prep_after||triggered-14/VBN||exposure-16/NN	prep_to||triggered-14/VBN||anestheticagents-18/NNS	amod||patients-24/NNS||mh-susceptible-20/JJ	appos||patients-24/NNS||mhs-22/NN	prep_in||anestheticagents-18/NNS||patients-24/NNS	mh-11||anestheticagents-18||no||events similar to those occurring in er and in stress-induced mh events are triggered after exposure to anestheticagents in mh-susceptible (mhs) patients.
det||induction-2/NN||the-1/DT	nsubjpass||prevented-17/VBN||induction-2/NN	prep_of||induction-2/NN||obesity-4/NN	prep_of||induction-2/NN||dyslipidemia-6/NN	conj_and||obesity-4/NN||dyslipidemia-6/NN	prep_of||induction-2/NN||insulinresistance-9/NN	conj_and||obesity-4/NN||insulinresistance-9/NN	amod||diet-12/NN||high-fat-11/JJ	prep_by||obesity-4/NN||diet-12/NN	prep_in||diet-12/NN||rodents-14/NNS	aux||prevented-17/VBN||can-15/MD	auxpass||prevented-17/VBN||be-16/VB	root||ROOT-0/null||prevented-17/VBN	amod||fattyacids-22/NNS||n-3-19/JJ	amod||fattyacids-22/NNS||long-chain-20/JJ	amod||fattyacids-22/NNS||polyunsaturated-21/JJ	agent||prevented-17/VBN||fattyacids-22/NNS	appos||fattyacids-22/NNS||lc-pufas-24/NNS	insulinresistance-9||fattyacids-22||no_rel||the induction of obesity, dyslipidemia, and insulinresistance by high-fat diet in rodents can be prevented by n-3 long-chain polyunsaturated fattyacids (lc-pufas).
det||man-3/NN||a-1/DT	amod||man-3/NN||65-year-old-2/JJ	nsubjpass||referred-7/VBN||man-3/NN	prep_with||man-3/NN||diabetes-5/NN	auxpass||referred-7/VBN||was-6/VBD	root||ROOT-0/null||referred-7/VBN	nsubj||lasting-16/VBG||cornealabscess-9/NNS	amod||cornealabscess-9/NNS||unresponsive-10/JJ	amod||treatment-15/NN||antibiotic-12/JJ	conj_and||antibiotic-12/JJ||antifungal-14/JJ	amod||treatment-15/NN||antifungal-14/JJ	prep_to||unresponsive-10/JJ||treatment-15/NN	prepc_for||referred-7/VBN||lasting-16/VBG	num||weeks-18/NNS||6-17/CD	tmod||lasting-16/VBG||weeks-18/NNS	antifungal-14||cornealabscess-9||no_rel||a 65-year-old man with diabetes was referred for cornealabscess unresponsive to antibiotic and antifungal treatment lasting 6 weeks.
det||study-9/NN||this-1/DT	amod||study-9/NN||open-label-2/JJ	amod||study-9/NN||26-week-4/JJ	amod||study-9/NN||multi-centre-6/JJ	amod||study-9/NN||randomised-8/JJ	nsubj||aripiprazole-11/VBP||study-9/NN	nsubj||soc-13/VB||study-9/NN	vmod||study-9/NN||compared-10/VBN	root||ROOT-0/null||aripiprazole-11/VBP	aux||soc-13/VB||to-12/TO	xcomp||aripiprazole-11/VBP||soc-13/VB	dobj||soc-13/VB||olanzapine-15/NN	dobj||soc-13/VB||quetiapine-17/NN	conj_or||olanzapine-15/NN||quetiapine-17/NN	dobj||soc-13/VB||risperidone-19/NN	conj_or||olanzapine-15/NN||risperidone-19/NN	prep_in||soc-13/VB||patients-22/NNS	prep_with||patients-22/NNS||schizophrenia-24/NN	amod||criteria-27/NNS||dsm-iv-tr-26/JJ	appos||schizophrenia-24/NN||criteria-27/NNS	schizophrenia-24||aripiprazole-11||yes||this open-label, 26-week, multi-centre, randomised study compared aripiprazole to soc (olanzapine, quetiapine or risperidone) in patients with schizophrenia (dsm-iv-tr criteria).
det||findings-2/NNS||these-1/DT	nsubj||provide-3/VBP||findings-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||support-5/NN||further-4/JJ	dobj||provide-3/VBP||support-5/NN	det||hypothesis-8/NNS||the-7/DT	prep_for||provide-3/VBP||hypothesis-8/NNS	nsubj||increased-10/VBN||hypothesis-8/NNS	rcmod||hypothesis-8/NNS||increased-10/VBN	nn||metabolism-12/NN||drug-11/NN	nsubj||mediate-15/VB||metabolism-12/NN	nsubj||highlight-24/VB||metabolism-12/NN	conj_and||metabolism-12/NN||efflux-14/NN	nsubj||mediate-15/VB||efflux-14/NN	ccomp||increased-10/VBN||mediate-15/VB	nn||resistance-19/NN||permethrin-16/NN	conj_and||permethrin-16/NN||ivermectin-18/NN	nn||resistance-19/NN||ivermectin-18/NN	dobj||mediate-15/VB||resistance-19/NN	amod||mites-22/NNS||scabies-21/JJ	prep_in||mediate-15/VB||mites-22/NNS	ccomp||increased-10/VBN||highlight-24/VB	conj_and||mediate-15/VB||highlight-24/VB	det||threat-26/NN||the-25/DT	dobj||highlight-24/VB||threat-26/NN	amod||resistance-30/NN||emerging-28/VBG	amod||resistance-30/NN||acaricide-29/JJ	prep_of||threat-26/NN||resistance-30/NN	det||treatment-33/NN||the-32/DT	prep_to||increased-10/VBN||treatment-33/NN	prep_of||treatment-33/NN||scabies-35/NNS	advmod||increased-10/VBN||worldwide-36/RB	scabies-35||ivermectin-18||yes||these findings provide further support for the hypothesis that increased drug metabolism and efflux mediate permethrin and ivermectin resistance in scabies mites and highlight the threat of emerging acaricide resistance to the treatment of scabies worldwide.
det||calcineurininhibitors-3/NNS||the-1/DT	amod||calcineurininhibitors-3/NNS||topical-2/JJ	nsubjpass||used-11/VBN||calcineurininhibitors-3/NNS	nsubj||treat-13/VB||calcineurininhibitors-3/NNS	nsubj||inhibit-20/VB||calcineurininhibitors-3/NNS	appos||calcineurininhibitors-3/NNS||tacrolimus-5/NNS	appos||calcineurininhibitors-3/NNS||pimecrolimus-7/NNS	conj_and||tacrolimus-5/NNS||pimecrolimus-7/NNS	aux||used-11/VBN||have-9/VBP	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||cutaneous-15/JJ||resistant-14/JJ	amod||lupus-16/NNS||cutaneous-15/JJ	dobj||treat-13/VB||lupus-16/NNS	prep_since||treat-13/VB||2002-18/CD	xcomp||used-11/VBN||inhibit-20/VB	conj_and||treat-13/VB||inhibit-20/VB	det||proliferation-22/NN||the-21/DT	dobj||inhibit-20/VB||proliferation-22/NN	dobj||inhibit-20/VB||activation-24/NN	conj_and||proliferation-22/NN||activation-24/NN	prep_of||proliferation-22/NN||t-cells-26/NNS	conj_and||treat-13/VB||suppress-28/VB	conj_and||inhibit-20/VB||suppress-28/VB	amod||cutaneousinflammation-30/NN||immune-mediated-29/JJ	dobj||suppress-28/VB||cutaneousinflammation-30/NN	cutaneousinflammation-30||calcineurininhibitors-3||no_rel||the topical calcineurininhibitors, tacrolimus and pimecrolimus, have been used to treat resistant cutaneous lupus since 2002 and inhibit the proliferation and activation of t-cells and suppress immune-mediated cutaneousinflammation.
det||ipp-5/NN||the-1/DT	amod||ipp-5/NN||meanâ-2/JJ	amod||ipp-5/NN||±-3/JJ	nn||ipp-5/NN||sd-4/NN	nsubj||±-27/NNS||ipp-5/NN	nn||volume-8/NN||prostate-7/NN	appos||ipp-5/NN||volume-8/NN	appos||volume-8/NN||pv-10/NN	nn||volume-16/NN||transition-14/NN	nn||volume-16/NN||zone-15/NN	appos||ipp-5/NN||volume-16/NN	conj_and||volume-8/NN||volume-16/NN	det||trilobar-19/NN||the-18/DT	prep_of||volume-16/NN||trilobar-19/NN	nn||groups-23/NNS||bilobar-21/NN	nn||groups-23/NNS||adenoma-22/NN	prep_of||volume-16/NN||groups-23/NNS	conj_and||trilobar-19/NN||groups-23/NNS	cop||±-27/NNS||were-24/VBD	number||â-26/CD||11.8-25/CD	num||±-27/NNS||â-26/CD	root||ROOT-0/null||±-27/NNS	num||mm-29/NN||5.2-28/CD	dep||±-27/NNS||mm-29/NN	num||â-32/NN||9.0-31/CD	conj_and||±-27/NNS||â-32/NN	number||3.8-34/CD||±-33/CD	num||mm-35/NN||3.8-34/CD	dep||â-32/NN||mm-35/NN	dep||±-27/NNS||p-37/VBN	dep||0.014-39/CD||=-38/SYM	ccomp||p-37/VBN||0.014-39/CD	num||±-44/NNS||81.1-42/CD	nn||±-44/NNS||â-43/NN	conj_and||±-27/NNS||±-44/NNS	num||g-46/CD||25.8-45/CD	num||g-52/NN||g-46/CD	num||22.5-51/CD||59.3-48/CD	num||22.5-51/CD||â-49/CD	num||22.5-51/CD||±-50/CD	conj_and||g-46/CD||22.5-51/CD	num||g-52/NN||22.5-51/CD	dep||±-44/NNS||g-52/NN	dep||±-27/NNS||p-54/VB	number||0.001-56/CD||<-55/CD	dobj||p-54/VB||0.001-56/CD	num||±-62/NNS||49.6-60/CD	nn||±-62/NNS||â-61/NN	conj_and||±-27/NNS||±-62/NNS	num||g-64/CD||20.6-63/CD	num||g-70/NN||g-64/CD	num||19.4-69/CD||34.8-66/CD	num||19.4-69/CD||â-67/CD	num||19.4-69/CD||±-68/CD	conj_and||g-64/CD||19.4-69/CD	num||g-70/NN||19.4-69/CD	dep||±-62/NNS||g-70/NN	dep||±-62/NNS||p-72/VBN	dep||0.003-74/CD||=-73/SYM	ccomp||p-72/VBN||0.003-74/CD	advmod||±-27/NNS||respectively-77/RB	ipp-5||pv-10||no_rel||the meanâ±sd ipp, prostate volume (pv), and transition zone volume of the trilobar and bilobar adenoma groups were 11.8â±5.2 mm and 9.0â±3.8 mm (p=0.014), 81.1â±25.8 g and 59.3â±22.5 g (p<0.001), and 49.6â±20.6 g and 34.8â±19.4 g (p=0.003), respectively.
det||period-5/NN||the-2/DT	amod||period-5/NN||6-month-3/JJ	nn||period-5/NN||study-4/NN	prep_following||decreased-20/VBN||period-5/NN	det||glucose-13/NN||the-7/DT	nn||glucose-13/NN||plasma-8/NN	nn||glucose-13/NN||tbars-9/NNS	nn||glucose-13/NN||levels-10/NNS	conj_and||glucose-13/NN||fasting-12/NN	nsubjpass||decreased-20/VBN||fasting-12/NN	nsubjpass||decreased-20/VBN||glucose-13/NN	nsubjpass||decreased-20/VBN||glucose-13/NN	conj_and||glucose-13/NN||hba1c-15/NN	nsubjpass||decreased-20/VBN||hba1c-15/NN	conj_and||glucose-13/NN||insulinresistance-17/NN	nsubjpass||decreased-20/VBN||insulinresistance-17/NN	auxpass||decreased-20/VBN||were-18/VBD	advmod||decreased-20/VBN||significantly-19/RB	root||ROOT-0/null||decreased-20/VBN	conj_but||decreased-20/VBN||decreased-20/VBN	det||cr-23/NN||the-22/DT	prep_in||decreased-20/VBN||cr-23/NN	nn||groups-32/NNS||crâ-25/NN	nn||groups-32/NNS||+-26/NNP	nn||groups-32/NNS||â-27/NN	nn||groups-32/NNS||câ-28/NN	nn||groups-32/NNS||+-29/NN	nn||groups-32/NNS||â-30/NN	amod||groups-32/NNS||e-31/JJ	prep_in||decreased-20/VBN||groups-32/NNS	conj_and||cr-23/NN||groups-32/NNS	neg||decreased-20/VBN||not-35/RB	det||group-39/NN||the-37/DT	nn||group-39/NN||placebo-38/NN	prep_for||decreased-20/VBN||group-39/NN	cr-23||insulinresistance-17||no_rel||following the 6-month study period, the plasma tbars levels, fasting glucose, hba1c and insulinresistance were significantly decreased in the cr and crâ +â câ +â e groups, but not for the placebo group.
det||injection-3/NN||a-1/DT	amod||injection-3/NN||monthly-2/JJ	nsubjpass||used-8/VBN||injection-3/NN	prep_of||injection-3/NN||palivizumab-5/NN	aux||used-8/VBN||has-6/VBZ	auxpass||used-8/VBN||been-7/VBN	root||ROOT-0/null||used-8/VBN	prep_for||used-8/VBN||prophylaxis-10/NNS	amod||rsvinfections-13/NNS||serious-12/JJ	prep_of||prophylaxis-10/NNS||rsvinfections-13/NNS	amod||children-16/NNS||high-risk-15/JJ	prep_among||used-8/VBN||children-16/NNS	num||countries-19/NNS||71-18/CD	prep_in||children-16/NNS||countries-19/NNS	prep_since||countries-19/NNS||1998-21/CD	nsubjpass||obtained-31/VBN||approval-23/NN	prep_for||approval-23/NN||use-25/NN	det||federation-29/NN||the-27/DT	nn||federation-29/NN||russian-28/NN	prep_in||use-25/NN||federation-29/NN	auxpass||obtained-31/VBN||was-30/VBD	conj_and||used-8/VBN||obtained-31/VBN	prep_in||obtained-31/VBN||february-33/NNP	num||february-33/NNP||2010-34/CD	rsvinfections-13||palivizumab-5||yes||a monthly injection of palivizumab has been used for prophylaxis of serious rsvinfections among high-risk children in 71 countries since 1998 and approval for use in the russian federation was obtained in february 2010.
det||influence-2/NN||the-1/DT	nsubj||antiretroviral-11/VBP||influence-2/NN	amod||sex-5/NN||biological-4/JJ	prep_of||influence-2/NN||sex-5/NN	prep_on||sex-5/NN||humanimmunodeficiencyvirus-7/NNS	discourse||humanimmunodeficiencyvirus-7/NNS||hiv-9/UH	root||ROOT-0/null||antiretroviral-11/VBP	nn||outcome-13/NN||treatment-12/NN	nsubjpass||described-17/VBN||outcome-13/NN	auxpass||described-17/VBN||is-14/VBZ	neg||described-17/VBN||not-15/RB	advmod||described-17/VBN||well-16/RB	ccomp||antiretroviral-11/VBP||described-17/VBN	poss||coinfection-26/NN||hivâ-19/NNP	amod||coinfection-26/NN||hepatitisc-22/JJ	discourse||coinfection-26/NN||hcv-24/UH	prep_in||described-17/VBN||coinfection-26/NN	hepatitisc-22||hcv-24||no||the influence of biological sex on humanimmunodeficiencyvirus (hiv) antiretroviral treatment outcome is not well described in hivâ€“hepatitisc (hcv) coinfection.
det||survey-4/NN||the-2/DT	amod||survey-4/NN||current-3/JJ	prep_in||isolates-10/VBZ||survey-4/NN	predet||mtc-9/NN||all-6/PDT	det||mtc-9/NN||the-7/DT	amod||mtc-9/NN||350-8/JJ	nsubj||isolates-10/VBZ||mtc-9/NN	root||ROOT-0/null||isolates-10/VBZ	csubjpass||determined-17/VBN||obtained-11/VBN	amod||patients-15/NNS||bangladesh-13/JJ	nn||patients-15/NNS||tb-14/NN	prep_from||obtained-11/VBN||patients-15/NNS	auxpass||determined-17/VBN||were-16/VBD	ccomp||isolates-10/VBZ||determined-17/VBN	mark||detected-25/VBN||as-18/IN	nsubjpass||detected-25/VBN||m.tuberculosis-19/NNS	neg||mtc-23/NN||no-21/DT	amod||mtc-23/NN||other-22/JJ	conj_and||m.tuberculosis-19/NNS||mtc-23/NN	nsubjpass||detected-25/VBN||mtc-23/NN	auxpass||detected-25/VBN||were-24/VBD	advcl||determined-17/VBN||detected-25/VBN	tb-14||m.tuberculosis-19||no||in the current survey , all the 350 mtc isolates obtained from bangladesh tb patients were determined as m.tuberculosis and no other mtc were detected .
det||combination-2/NN||the-1/DT	nsubj||premixed-6/VBD||combination-2/NN	nn||propofol-5/NN||microemulsion-4/NN	prep_of||combination-2/NN||propofol-5/NN	root||ROOT-0/null||premixed-6/VBD	prep_with||premixed-6/VBD||lidocaine-8/NN	mark||effective-16/JJ||after-9/IN	det||pretreatment-11/NN||a-10/DT	nsubj||effective-16/JJ||pretreatment-11/NN	prep_with||pretreatment-11/NN||remifentanil-13/NN	cop||effective-16/JJ||was-14/VBD	advmod||effective-16/JJ||more-15/RBR	advcl||premixed-6/VBD||effective-16/JJ	prepc_in||effective-16/JJ||reducing-18/VBG	det||incidence-20/NN||the-19/DT	dobj||reducing-18/VBG||incidence-20/NN	prep_of||incidence-20/NN||pain-22/NN	det||injection-25/NN||the-24/DT	prep_upon||reducing-18/VBG||injection-25/NN	nn||propofol-28/NN||microemulsion-27/NN	prep_of||injection-25/NN||propofol-28/NN	det||treatment-31/NN||either-30/DT	prep_than||reducing-18/VBG||treatment-31/NN	advmod||effective-16/JJ||alone-32/RB	pain-22||propofol-28||yes||the combination of microemulsion propofol premixed with lidocaine after a pretreatment with remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than either treatment alone.
prep_conclusionsâ||suggest-6/VBP||$-2/$	poss||data-5/NNS||our-4/PRP$	nsubj||suggest-6/VBP||data-5/NNS	root||ROOT-0/null||suggest-6/VBP	mark||sensitive-12/JJ||that-7/IN	det||hypothalamus-9/NNS||the-8/DT	nsubj||sensitive-12/JJ||hypothalamus-9/NNS	cop||sensitive-12/JJ||is-10/VBZ	advmod||sensitive-12/JJ||exquisitely-11/RB	ccomp||suggest-6/VBP||sensitive-12/JJ	amod||decrements-15/NNS||small-14/JJ	prep_to||sensitive-12/JJ||decrements-15/NNS	amod||levels-19/NNS||systemic-17/JJ	nn||levels-19/NNS||glucose-18/NN	prep_in||decrements-15/NNS||levels-19/NNS	amod||subjects-24/NNS||healthy-21/JJ	amod||subjects-24/NNS||nondiabetic-23/JJ	prep_in||levels-19/NNS||subjects-24/NNS	mark||precedes-36/VBZ||that-26/IN	amod||flow-29/NN||hypothalamic-27/JJ	nn||flow-29/NN||blood-28/NN	nsubj||precedes-36/VBZ||flow-29/NN	advmod||activity-34/NN||presumably-32/RB	amod||activity-34/NN||neuronal-33/JJ	conj_and||flow-29/NN||activity-34/NN	nsubj||precedes-36/VBZ||activity-34/NN	ccomp||suggest-6/VBP||precedes-36/VBZ	conj_and||sensitive-12/JJ||precedes-36/VBZ	det||rise-38/NN||the-37/DT	dobj||precedes-36/VBZ||rise-38/NN	amod||hormones-41/NNS||counterregulatory-40/JJ	prep_in||rise-38/NN||hormones-41/NNS	vmod||hormones-41/NNS||seen-42/VBN	prep_during||seen-42/VBN||hypoglycemia-44/NN	hypoglycemia-44||glucose-18||yes||conclusionsâ€” our data suggest that the hypothalamus is exquisitely sensitive to small decrements in systemic glucose levels in healthy, nondiabetic subjects and that hypothalamic blood flow, and presumably neuronal activity, precedes the rise in counterregulatory hormones seen during hypoglycemia.
det||system-5/NN||a-1/DT	amod||system-5/NN||continuous-2/JJ	nn||system-5/NN||glucose-3/NN	nn||system-5/NN||monitoring-4/NN	nsubj||have-7/VB||system-5/NN	aux||have-7/VB||may-6/MD	root||ROOT-0/null||have-7/VB	dobj||have-7/VB||utility-8/NN	amod||women-11/NNS||pregnant-10/JJ	prep_in||utility-8/NN||women-11/NNS	amod||diabetes-14/NN||insulin-treated-13/JJ	prep_with||have-7/VB||diabetes-14/NN	advmod||for-17/IN||especially-16/RB	dep||have-7/VB||for-17/IN	det||women-19/NNS||those-18/DT	pobj||for-17/IN||women-19/NNS	nsubj||difficult-25/JJ||women-19/NNS	nsubj||control-27/VB||women-19/NNS	nn||sugars-22/NNS||blood-21/NN	prep_with||women-19/NNS||sugars-22/NNS	cop||difficult-25/JJ||are-24/VBP	rcmod||women-19/NNS||difficult-25/JJ	aux||control-27/VB||to-26/TO	xcomp||difficult-25/JJ||control-27/VB	nsubj||experience-30/VBP||who-29/WP	dep||have-7/VB||experience-30/VBP	conj_or||for-17/IN||experience-30/VBP	amod||hypoglycemia-32/NN||nocturnal-31/JJ	dobj||experience-30/VBP||hypoglycemia-32/NN	advmod||need-40/VBP||however-34/RB	amod||systems-39/NNS||continuous-36/JJ	nn||systems-39/NNS||glucose-37/NN	nn||systems-39/NNS||monitoring-38/NN	nsubj||need-40/VBP||systems-39/NNS	parataxis||have-7/VB||need-40/VBP	amod||study-42/NN||additional-41/JJ	dobj||need-40/VBP||study-42/NN	prep_as||need-40/VBP||part-44/NN	amod||trials-49/NNS||larger-46/JJR	amod||trials-49/NNS||randomized-48/JJ	prep_of||part-44/NN||trials-49/NNS	sugars-22||hypoglycemia-32||no_rel||a continuous glucose monitoring system may have utility in pregnant women with insulin-treated diabetes, especially for those women with blood sugars that are difficult to control or who experience nocturnal hypoglycemia; however, continuous glucose monitoring systems need additional study as part of larger, randomized trials.
nsubj||lead-3/VB||denguevirusinfection-1/NN	aux||lead-3/VB||can-2/MD	root||ROOT-0/null||lead-3/VB	prep_to||lead-3/VB||denguefever-5/NN	appos||denguefever-5/NN||df-7/NN	prep_to||lead-3/VB||denguehemorrhagicfever-10/NN	conj_or||denguefever-5/NN||denguehemorrhagicfever-10/NN	appos||denguefever-5/NN||dhf-12/NN	denguefever-5||denguevirus--1||no||denguevirusinfection can lead to denguefever (df) or denguehemorrhagicfever (dhf).
num||eyes-2/NNS||twelve-1/CD	nsubjpass||treated-20/VBN||eyes-2/NNS	num||children-5/NNS||10-4/CD	prep_of||eyes-2/NNS||children-5/NNS	amod||retinoblastoma-8/NN||advanced-7/JJ	prep_with||children-5/NNS||retinoblastoma-8/NN	amod||vb-12/NN||reese-ellsworth-10/JJ	nn||vb-12/NN||group-11/NN	dep||eyes-2/NNS||vb-12/NN	amod||group-16/NN||international-14/JJ	nn||group-16/NN||classification-15/NN	dep||eyes-2/NNS||group-16/NN	conj_or||vb-12/NN||group-16/NN	dep||vb-12/NN||d-17/SYM	auxpass||treated-20/VBN||were-19/VBD	root||ROOT-0/null||treated-20/VBN	amod||infusion-25/NN||supraselective-22/JJ	amod||infusion-25/NN||intra-ophthalmic-23/JJ	nn||infusion-25/NN||artery-24/NN	prep_with||treated-20/VBN||infusion-25/NN	prep_of||infusion-25/NN||melphalan-27/NN	retinoblastoma-8||melphalan-27||no_rel||twelve eyes of 10 children with advanced retinoblastoma (reese-ellsworth group vb or international classification group d) were treated with supraselective intra-ophthalmic artery infusion of melphalan.
det||netb-5/NN||the-1/DT	amod||netb-5/NN||secreted-2/JJ	amod||netb-5/NN||pore-forming-3/JJ	nn||netb-5/NN||toxin-4/NN	nsubj||factor-10/NN||netb-5/NN	nsubj||similar-18/JJ||netb-5/NN	cop||factor-10/NN||is-6/VBZ	det||factor-10/NN||a-7/DT	amod||factor-10/NN||key-8/JJ	nn||factor-10/NN||virulence-9/NN	root||ROOT-0/null||factor-10/NN	det||pathogenesis-13/NNS||the-12/DT	prep_in||factor-10/NN||pathogenesis-13/NNS	prep_of||pathogenesis-13/NNS||aviannecroticenteritis-15/NNS	cop||similar-18/JJ||is-17/VBZ	conj_and||factor-10/NN||similar-18/JJ	prep_to||similar-18/JJ||alpha-hemolysin-20/NN	det||²-24/NN||a-22/DT	nn||²-24/NN||î-23/NN	appos||alpha-hemolysin-20/NN||²-24/NN	nn||toxin-28/NN||barrel-26/NN	amod||toxin-28/NN||pore-forming-27/JJ	dep||²-24/NN||toxin-28/NN	prep_from||toxin-28/NN||staphylococcusaureus-30/NNS	toxin-28||aviannecroticenteritis-15||no_rel||the secreted pore-forming toxin netb is a key virulence factor in the pathogenesis of aviannecroticenteritis and is similar to alpha-hemolysin, a î²-barrel pore-forming toxin from staphylococcusaureus .
det||aim-2/NN||the-1/DT	nsubj||was-3/VBD||aim-2/NN	nsubj||determine-5/VB||aim-2/NN	root||ROOT-0/null||was-3/VBD	aux||determine-5/VB||to-4/TO	xcomp||was-3/VBD||determine-5/VB	amod||aspects-9/NNS||qualitative-6/JJ	conj_and||qualitative-6/JJ||quantitative-8/JJ	amod||aspects-9/NNS||quantitative-8/JJ	dobj||determine-5/VB||aspects-9/NNS	amod||block-12/NN||caudal-11/JJ	prep_of||aspects-9/NNS||block-12/NN	amod||effects-15/NNS||haemodynamic-14/JJ	prep_of||aspects-9/NNS||effects-15/NNS	conj_and||block-12/NN||effects-15/NNS	amod||relief-19/NN||post-operativepain-18/JJ	prep_of||aspects-9/NNS||relief-19/NN	conj_and||block-12/NN||relief-19/NN	nn||ropivacaine-25/NN||ropivacaine-21/NN	number||%-23/NN||0.25-22/CD	amod||ropivacaine-25/NN||%-23/NN	nn||ropivacaine-25/NN||versus-24/NNP	prep_of||relief-19/NN||ropivacaine-25/NN	number||%-27/NN||0.25-26/CD	amod||ropivacaine-25/NN||%-27/NN	prep_with||determine-5/VB||clonidine-29/NN	amod||surgeries-33/NNS||lower-31/JJR	nn||surgeries-33/NNS||abdominal-32/NN	prep_for||determine-5/VB||surgeries-33/NNS	amod||patients-36/NNS||paediatric-35/JJ	prep_in||surgeries-33/NNS||patients-36/NNS	post-operativepain-18||ropivacaine-25||yes||the aim was to determine qualitative and quantitative aspects of caudal block, haemodynamic effects, and post-operativepain relief of ropivacaine 0.25% versus ropivacaine 0.25% with clonidine for lower abdominal surgeries in paediatric patients.
det||activity-5/NN||the-1/DT	dep||vitro-3/NN||in-2/IN	amod||activity-5/NN||vitro-3/NN	amod||activity-5/NN||anticandidal-4/JJ	nsubj||racemosus-8/VBZ||activity-5/NN	prep_of||activity-5/NN||asparagus-7/NNS	dep||investigated-14/VBN||racemosus-8/VBZ	nsubj||extract-12/VB||roots-9/NNS	conj_and||roots-9/NNS||tubers-11/NNS	nsubj||extract-12/VB||tubers-11/NNS	ccomp||racemosus-8/VBZ||extract-12/VB	auxpass||investigated-14/VBN||was-13/VBD	root||ROOT-0/null||investigated-14/VBN	prep_against||investigated-14/VBN||candidaalbicans-16/NNS	nn||tropicalis-19/NNS||candida-18/NN	prep_against||investigated-14/VBN||tropicalis-19/NNS	conj_and||candidaalbicans-16/NNS||tropicalis-19/NNS	nn||krusei-22/NNS||candida-21/NN	prep_against||investigated-14/VBN||krusei-22/NNS	conj_and||candidaalbicans-16/NNS||krusei-22/NNS	nn||guillermondii-25/NNS||candida-24/NN	prep_against||investigated-14/VBN||guillermondii-25/NNS	conj_and||candidaalbicans-16/NNS||guillermondii-25/NNS	nn||parapsilosis-28/NNS||candida-27/NN	prep_against||investigated-14/VBN||parapsilosis-28/NNS	conj_and||candidaalbicans-16/NNS||parapsilosis-28/NNS	prep_against||investigated-14/VBN||candida-30/NN	conj_and||candidaalbicans-16/NNS||candida-30/NN	nsubjpass||investigated-14/VBN||stellatoida-31/NN	nsubjpass||isolated-35/VBN||stellatoida-31/NN	auxpass||isolated-35/VBN||are-34/VBP	rcmod||stellatoida-31/NN||isolated-35/VBN	amod||patients-38/NNS||vaginalthrush-37/JJ	prep_from||isolated-35/VBN||patients-38/NNS	vaginalthrush-37||candida-30||no||the in vitro anticandidal activity of asparagus racemosus roots and tubers extract was investigated against candidaalbicans, candida tropicalis, candida krusei, candida guillermondii, candida parapsilosis and candida stellatoida, which are isolated from vaginalthrush patients.
nsubj||%-6/NN||prevalence-1/NN	prep_of||prevalence-1/NN||hivinfection-3/NN	cop||%-6/NN||was-4/VBD	num||%-6/NN||3.6-5/CD	root||ROOT-0/null||%-6/NN	nn||prevalence-9/NN||malaria-8/NN	nsubj||higher-12/JJR||prevalence-9/NN	cop||higher-12/JJR||was-10/VBD	advmod||higher-12/JJR||significantly-11/RB	conj_and||%-6/NN||higher-12/JJR	prep_among||higher-12/JJR||hiv-positive-14/NN	amod||women-17/NNS||hiv-negative-16/JJ	prep_than||higher-12/JJR||women-17/NNS	num||%-20/NN||37.5-19/CD	dep||women-17/NNS||%-20/NN	number||%-23/NN||95-22/CD	amod||ci-24/NN||%-23/NN	appos||%-20/NN||ci-24/NN	num||%-28/NN||4.0-71-26/CD	num||%-28/NN||.0-27/CD	appos||%-20/NN||%-28/NN	num||%-31/NN||14.3-30/CD	prep_versus||%-28/NN||%-31/NN	number||%-34/NN||95-33/CD	amod||ci.-35/NN||%-34/NN	appos||%-20/NN||ci.-35/NN	num||%-39/NN||9.6-19-37/CD	num||%-39/NN||.0-38/CD	appos||ci.-35/NN||%-39/NN	dep||women-17/NNS||ï-43/VB	number||2-45/CD||‡-44/CD	nsubj||<-50/NN||2-45/CD	dep||<-50/NN||=-46/SYM	amod||<-50/NN||13.3-47/JJ	amod||<-50/NN||p-49/JJ	ccomp||ï-43/VB||<-50/NN	num||<-50/NN||0.05-51/CD	hivinfection-3||hiv--1||no||prevalence of hivinfection was 3.6% and malaria prevalence was significantly higher among hiv-positive than hiv-negative women (37.5%, 95% ci, 4.0-71.0% versus 14.3%, 95% ci., 9.6-19.0%), (ï‡2 =13.3, p<0.05).
prep_in||shown-6/VBN||oasis-5-2/JJ	nsubjpass||shown-6/VBN||fondaparinux-4/NN	nsubj||noninferior-9/JJ||fondaparinux-4/NN	nsubj||enoxaparin-11/VB||fondaparinux-4/NN	auxpass||shown-6/VBN||was-5/VBD	root||ROOT-0/null||shown-6/VBN	aux||noninferior-9/JJ||to-7/TO	cop||noninferior-9/JJ||be-8/VB	xcomp||shown-6/VBN||noninferior-9/JJ	aux||enoxaparin-11/VB||to-10/TO	xcomp||noninferior-9/JJ||enoxaparin-11/VB	prep_in||enoxaparin-11/VB||terms-13/NNS	nn||mi-17/NN||death-15/NN	nn||ischemia-20/NN||mi-17/NN	conj_or||mi-17/NN||refractory-19/JJ	nn||ischemia-20/NN||refractory-19/JJ	prep_of||terms-13/NNS||ischemia-20/NN	num||days-23/NNS||9-22/CD	prep_at||ischemia-20/NN||days-23/NNS	ischemia-20||fondaparinux-4||no_rel||in oasis-5, fondaparinux was shown to be noninferior to enoxaparin in terms of death, mi or refractory ischemia at 9 days.
det||method-2/NN||the-1/DT	nsubjpass||optimized-5/VBN||method-2/NN	auxpass||optimized-5/VBN||was-3/VBD	advmod||optimized-5/VBN||first-4/RB	root||ROOT-0/null||optimized-5/VBN	xcomp||optimized-5/VBN||utilizing-6/VBG	amod||strains-9/NNS||borrelia-7/JJ	nn||strains-9/NNS||laboratory-8/NN	dobj||utilizing-6/VBG||strains-9/NNS	advmod||followed-25/VBD||later-12/RB	prepc_by||later-12/RB||demonstrating-14/VBG	dobj||demonstrating-14/VBG||growth-15/NN	prep_of||growth-15/NN||borrelia-17/NN	prep_from||demonstrating-14/VBG||sera-19/NN	amod||seropositive-22/NN||fifty-21/JJ	prep_from||demonstrating-14/VBG||seropositive-22/NN	amod||patients-24/NNS||lymedisease-23/JJ	nsubj||followed-25/VBD||patients-24/NNS	conj_and||optimized-5/VBN||followed-25/VBD	det||cohort-28/NN||another-27/DT	prep_by||followed-25/VBD||cohort-28/NN	num||patients-32/NNS||72-30/CD	amod||patients-32/NNS||lymedisease-31/JJ	prep_of||cohort-28/NN||patients-32/NNS	pobj||of-35/IN||patients-32/NNS	dep||of-35/IN||all-34/DT	nsubj||satisfied-37/VBD||of-35/IN	rcmod||patients-32/NNS||satisfied-37/VBD	det||definition-43/NN||the-38/DT	amod||definition-43/NN||strict-39/JJ	nn||definition-43/NN||cdc-40/NN	nn||definition-43/NN||surveillance-41/NN	nn||definition-43/NN||case-42/NN	dobj||satisfied-37/VBD||definition-43/NN	prep_for||satisfied-37/VBD||lymedisease-45/NN	lymedisease-45||borrelia-17||no||the method was first optimized utilizing borrelia laboratory strains, and later by demonstrating growth of borrelia from sera from fifty seropositive lymedisease patients followed by another cohort of 72 lymedisease patients, all of whom satisfied the strict cdc surveillance case definition for lymedisease.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||yes||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
nsubj||microorganisms-2/VBZ||eleven-1/NNS	root||ROOT-0/null||microorganisms-2/VBZ	acomp||microorganisms-2/VBZ||responsible-3/JJ	mark||tested-8/VBN||for-4/IN	amod||infections-6/NNS||nosocomial-5/JJ	nsubjpass||tested-8/VBN||infections-6/NNS	auxpass||tested-8/VBN||were-7/VBD	advcl||microorganisms-2/VBZ||tested-8/VBN	num||staphylococcusaureus-10/NNS||two-9/CD	prep||tested-8/VBN||staphylococcusaureus-10/NNS	dep||staphylococcusaureus-10/NNS||strains-11/NNS	det||strain-18/NN||the-13/DT	amod||strain-18/NN||hetero-vancomycin-14/JJ	amod||strain-18/NN||intermediate-15/JJ	nn||strain-18/NN||mrsa-16/NN	amod||strain-18/NN||mu50-17/JJ	dep||strains-11/NNS||strain-18/NN	det||strain-23/NN||a-20/DT	amod||strain-23/NN||st80-pvl-producing-21/JJ	nn||strain-23/NN||mrsa-22/NN	dep||strains-11/NNS||strain-23/NN	conj_and||strain-18/NN||strain-23/NN	det||van-28/NN||a-26/DT	amod||van-28/NN||vancomycin-resistant-27/JJ	dep||staphylococcusaureus-10/NNS||van-28/NN	conj_and||strains-11/NNS||van-28/NN	det||strain-32/NN||a-29/DT	amod||strain-32/NN||enterococcus-30/JJ	nn||strain-32/NN||faecium-31/NN	dep||van-28/NN||strain-32/NN	num||strains-38/NNS||three-34/CD	amod||strains-38/NNS||extended-spectrum-35/JJ	amod||strains-38/NNS||beta-lactamase-producing-36/JJ	nn||strains-38/NNS||enterobacteriaceae-37/NN	dep||staphylococcusaureus-10/NNS||strains-38/NNS	conj_and||strains-11/NNS||strains-38/NNS	det||strain-43/NN||a-40/DT	amod||strain-43/NN||mbl-producing-41/JJ	nn||strain-43/NN||pseudomonasaeruginosa-42/NN	dep||staphylococcusaureus-10/NNS||strain-43/NN	conj_and||strains-11/NNS||strain-43/NN	det||strain-49/NN||a-45/DT	amod||strain-49/NN||multidrug-resistant-46/JJ	nn||strain-49/NN||acinetobacter-47/NN	nn||strain-49/NN||baumannii-48/NN	dep||staphylococcusaureus-10/NNS||strain-49/NN	conj_and||strains-11/NNS||strain-49/NN	det||strain-54/NN||a-51/DT	amod||strain-54/NN||toxin-producing-52/JJ	nn||strain-54/NN||clostridiumdifficile-53/NN	dep||staphylococcusaureus-10/NNS||strain-54/NN	conj_and||strains-11/NNS||strain-54/NN	num||fungi-58/NNS||two-57/CD	dep||staphylococcusaureus-10/NNS||fungi-58/NNS	conj_and||strains-11/NNS||fungi-58/NNS	dep||fungi-58/NNS||candidaalbicans-60/NNS	amod||fumigatus-63/NNS||aspergillus-62/JJ	dep||fungi-58/NNS||fumigatus-63/NNS	conj_and||candidaalbicans-60/NNS||fumigatus-63/NNS	mrsa-22||staphylococcusaureus-10||no||eleven microorganisms responsible for nosocomial infections were tested two staphylococcusaureus strains (the hetero-vancomycin intermediate mrsa mu50 strain and a st80-pvl-producing mrsa strain); a vancomycin-resistant van a enterococcus faecium strain; three extended-spectrum beta-lactamase-producing enterobacteriaceae strains; a mbl-producing pseudomonasaeruginosa strain; a multidrug-resistant acinetobacter baumannii strain; a toxin-producing clostridiumdifficile strain; and two fungi ( candidaalbicans and aspergillus fumigatus ).
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	shingles-19||vzv-4||no||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
poss||nanoparticles-5/NNS||ironâˆ-1/NNP	nn||nanoparticles-5/NNS||platinum-3/NN	nn||nanoparticles-5/NNS||alloy-4/NN	nsubj||candidates-13/NNS||nanoparticles-5/NNS	amod||nps-8/NN||fept-7/JJ	appos||nanoparticles-5/NNS||nps-8/NN	cop||candidates-13/NNS||are-10/VBP	advmod||promising-12/JJ||extremely-11/RB	amod||candidates-13/NNS||promising-12/JJ	root||ROOT-0/null||candidates-13/NNS	det||generation-17/NN||the-15/DT	amod||generation-17/NN||next-16/JJ	prep_for||candidates-13/NNS||generation-17/NN	prep_of||generation-17/NN||contrastagents-19/NNS	amod||imaging-27/NN||magnetic-21/JJ	nn||imaging-27/NN||resonance-22/NN	nn||imaging-27/NN||mr-24/NN	amod||imaging-27/NN||diagnostic-26/JJ	prep_for||contrastagents-19/NNS||imaging-27/NN	amod||interventions-30/NNS||mr-guided-29/JJ	prep_for||contrastagents-19/NNS||interventions-30/NNS	conj_and||imaging-27/NN||interventions-30/NNS	amod||ablation-34/NN||hyperthermic-33/JJ	prep_including||candidates-13/NNS||ablation-34/NN	amod||cancers-37/NNS||solid-36/JJ	prep_of||ablation-34/NN||cancers-37/NNS	cancers-37||contrastagents-19||no_rel||ironâˆ’platinum alloy nanoparticles (fept nps) are extremely promising candidates for the next generation of contrastagents for magnetic resonance (mr) diagnostic imaging and mr-guided interventions, including hyperthermic ablation of solid cancers.
prep_above||noted-7/VBN||all-2/DT	nsubjpass||noted-7/VBN||it-4/PRP	aux||noted-7/VBN||should-5/MD	auxpass||noted-7/VBN||be-6/VB	root||ROOT-0/null||noted-7/VBN	det||ability-9/NN||the-8/DT	dobj||noted-7/VBN||ability-9/NN	amod||assay-13/NN||r5-enzyme-linked-11/JJ	nn||assay-13/NN||immunosorbent-12/NN	prep_of||ability-9/NN||assay-13/NN	amod||methods-17/NNS||other-16/JJ	prep_of||ability-9/NN||methods-17/NNS	conj_and||assay-13/NN||methods-17/NNS	aux||measure-20/VB||to-19/TO	vmod||noted-7/VBN||measure-20/VB	poss||toxicity-23/NN||gluten-21/NN	nsubj||validated-29/JJ||toxicity-23/NN	amod||patients-26/NNS||celiacdisease-25/JJ	prep_toward||toxicity-23/NN||patients-26/NNS	cop||validated-29/JJ||is-27/VBZ	neg||validated-29/JJ||not-28/RB	ccomp||measure-20/VB||validated-29/JJ	advmod||validated-29/JJ||clinically-30/RB	gluten-21||celiacdisease-25||no_rel||above all, it should be noted the ability of r5-enzyme-linked immunosorbent assay, and other methods, to measure gluten's toxicity toward celiacdisease patients is not validated clinically.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||safety-4/NN||the-3/DT	dobj||compare-2/VB||safety-4/NN	dobj||compare-2/VB||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	amod||ointment-10/NN||loteprednoletabonate-8/JJ	amod||ointment-10/NN||ophthalmic-9/JJ	prep_of||safety-4/NN||ointment-10/NN	number||%-12/NN||0.5-11/CD	amod||ointment-10/NN||%-12/NN	amod||ointment-15/NN||le-14/JJ	appos||ointment-10/NN||ointment-15/NN	det||formulation-22/NN||a-18/DT	amod||formulation-22/NN||new-19/JJ	amod||formulation-22/NN||topical-20/JJ	nn||formulation-22/NN||ointment-21/NN	appos||ointment-10/NN||formulation-22/NN	prep_with||compare-2/VB||vehicle-25/NN	det||treatment-28/NN||the-27/DT	prep_for||vehicle-25/NN||treatment-28/NN	prep_of||treatment-28/NN||inflammation-30/NN	prep_of||treatment-28/NN||pain-32/NN	conj_and||inflammation-30/NN||pain-32/NN	nn||surgery-35/NN||cataract-34/NN	prep_following||vehicle-25/NN||surgery-35/NN	vehicle-25||cataract-34||no_rel||to compare the safety and efficacy of loteprednoletabonate ophthalmic ointment 0.5% (le ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.
det||organization-4/NN||the-1/DT	nn||organization-4/NN||world-2/NN	nn||organization-4/NN||health-3/NN	nsubj||advises-8/VBZ||organization-4/NN	dep||organization-4/NN||who-6/WP	ccomp||called-15/VBD||advises-8/VBZ	dobj||advises-8/VBZ||treatment-9/NN	amod||disease-12/NN||mycobacteriumulcerans-11/JJ	prep_of||treatment-9/NN||disease-12/NN	advmod||called-15/VBD||also-14/RB	root||ROOT-0/null||called-15/VBD	advmod||called-15/VBD||â-16/RB	dobj||called-15/VBD||$-17/$	num||$-17/$||œburuliulcerâ-18/CD	nsubj||called-15/VBD||$-19/$	npadvmod||whether-39/IN||bu-21/NN	det||combination-26/NN||a-25/DT	prep_with||bu-21/NN||combination-26/NN	det||rifampicin-30/NN||the-28/DT	amod||rifampicin-30/NN||antibiotics-29/JJ	prep_of||combination-26/NN||rifampicin-30/NN	prep_of||combination-26/NN||streptomycin-32/NN	conj_and||rifampicin-30/NN||streptomycin-32/NN	nn||s-36/NNP||r-34/NNP	nn||s-36/NNP||+-35/NNP	appos||rifampicin-30/NN||s-36/NNP	dep||surgery-42/CD||whether-39/IN	dep||whether-39/IN||followed-40/CD	prep||whether-39/IN||by-41/IN	num||$-19/$||surgery-42/CD	nsubj||called-15/VBD||not-44/RB	conj_or||$-19/$||not-44/RB	buruliulcer--1||mycobacteriumulcerans-11||no||the world health organization (who) advises treatment of mycobacteriumulcerans disease, also called â€œburuliulcerâ€? (bu), with a combination of the antibiotics rifampicin and streptomycin (r+s), whether followed by surgery or not.
mark||accepted-5/VBN||although-1/IN	nsubjpass||accepted-5/VBN||it-2/PRP	aux||accepted-5/VBN||has-3/VBZ	auxpass||accepted-5/VBN||been-4/VBN	advcl||examined-61/VBN||accepted-5/VBN	mark||exhaust-11/VBP||that-6/IN	amod||exposure-8/NN||pulmonary-7/JJ	nsubj||exhaust-11/VBP||exposure-8/NN	prep_to||exposure-8/NN||diesel-10/NN	ccomp||accepted-5/VBN||exhaust-11/VBP	nsubj||exacerbates-37/VBZ||particles-12/NNS	appos||particles-12/NNS||dep-14/NN	amod||constituents-18/NNS||representative-17/JJ	appos||particles-12/NNS||constituents-18/NNS	amod||matter-21/NN||particulate-20/JJ	prep_in||constituents-18/NNS||matter-21/NN	amod||<-27/NNS||mass-23/JJ	amod||<-27/NNS||median-24/JJ	amod||<-27/NNS||aerodynamic-25/JJ	nn||<-27/NNS||diameter-26/NN	prep_of||matter-21/NN||<-27/NNS	num||âµm-31/NN||2.5-29/CD	nn||âµm-31/NN||â-30/NN	prep_of||matter-21/NN||âµm-31/NN	conj_or||<-27/NNS||âµm-31/NN	number||.5-34/CD||pm2-33/CD	dep||âµm-31/NN||.5-34/CD	ccomp||exhaust-11/VBP||exacerbates-37/VBZ	amod||allergicasthma-39/NN||murine-38/JJ	dobj||exacerbates-37/VBZ||allergicasthma-39/NN	nsubjpass||examined-61/VBN||the-41/DT	nn||effects-44/NNS||vivo-43/NN	prep_in||the-41/DT||effects-44/NNS	prep_of||effects-44/NNS||dep-46/NN	poss||events-50/NNS||their-48/PRP$	amod||events-50/NNS||cellular-49/JJ	prep_on||dep-46/NN||events-50/NNS	det||context-53/NN||the-52/DT	prep_in||events-50/NNS||context-53/NN	amod||response-57/NN||allergen-specific-55/JJ	nn||response-57/NN||th-56/NN	prep_of||context-53/NN||response-57/NN	aux||examined-61/VBN||have-58/VBP	neg||examined-61/VBN||never-59/RB	auxpass||examined-61/VBN||been-60/VBN	root||ROOT-0/null||examined-61/VBN	allergen--1||allergicasthma-39||no_rel||although it has been accepted that pulmonary exposure to diesel exhaust particles (dep), representative constituents in particulate matter of mass median aerodynamic diameter < or 2.5â âµm (pm2.5), exacerbates murine allergicasthma, the in vivo effects of dep on their cellular events in the context of allergen-specific th response have never been examined.
mark||understood-13/VBN||although-1/IN	det||details-3/NNS||the-2/DT	nsubjpass||understood-13/VBN||details-3/NNS	det||mechanism-6/NN||the-5/DT	prep_of||details-3/NNS||mechanism-6/NN	nn||propagation-9/NN||prion-8/NN	prep_of||mechanism-6/NN||propagation-9/NN	auxpass||understood-13/VBN||are-10/VBP	neg||understood-13/VBN||not-11/RB	advmod||understood-13/VBN||fully-12/RB	advcl||considered-33/VBN||understood-13/VBN	amod||conversion-16/NN||conformational-15/JJ	nsubjpass||considered-33/VBN||conversion-16/NN	amod||prionprotein-19/NN||cellular-18/JJ	prep_of||conversion-16/NN||prionprotein-19/NN	dep||prionprotein-19/NN||prpc-21/JJ	amod||prionprotein-28/NN||misfolded-24/JJ	amod||prionprotein-28/NN||disease-associated-26/JJ	nn||prionprotein-28/NN||scrapie-27/NN	prep_to||prionprotein-19/NN||prionprotein-28/NN	dep||conversion-16/NN||prpsc-30/JJ	auxpass||considered-33/VBN||is-32/VBZ	root||ROOT-0/null||considered-33/VBN	det||event-37/NN||the-34/DT	amod||event-37/NN||essential-35/JJ	amod||event-37/NN||biochemical-36/JJ	dobj||considered-33/VBN||event-37/NN	nn||replication-40/NN||prion-39/NN	prep_for||event-37/NN||replication-40/NN	prionprotein-28||scrapie-27||no_rel||although the details of the mechanism of prion propagation are not fully understood, conformational conversion of cellular prionprotein (prpc) to misfolded, disease-associated scrapie prionprotein (prpsc) is considered the essential biochemical event for prion replication.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||compounds-4/NNS||these-3/DT	nsubj||anticipating-9/VBG||compounds-4/NNS	det||model-8/NN||an-6/DT	nn||model-8/NN||avian-7/NN	prep_in||compounds-4/NNS||model-8/NN	dep||evaluated-2/VBN||anticipating-9/VBG	mark||yield-35/VB||that-10/IN	det||additive-13/NN||a-11/DT	amod||additive-13/NN||dietary-12/JJ	nsubj||yield-35/VB||additive-13/NN	vmod||additive-13/NN||combining-14/VBG	advmod||´-16/JJ||î-15/RB	acomp||combining-14/VBG||´-16/JJ	acomp||combining-14/VBG||tocotrienol-18/JJ	conj_or||´-16/JJ||tocotrienol-18/JJ	prep_with||tocotrienol-18/JJ||quercetin-20/NN	appos||quercetin-20/NN||riboflavin-22/NN	advmod||lactone-28/JJ||corey-27/RB	dep||tocotrienol-18/JJ||lactone-28/JJ	acomp||combining-14/VBG||amiloride-30/JJ	conj_or||´-16/JJ||amiloride-30/JJ	acomp||combining-14/VBG||dexamethasone-33/JJ	conj_or||´-16/JJ||dexamethasone-33/JJ	aux||yield-35/VB||would-34/MD	ccomp||anticipating-9/VBG||yield-35/VB	amod||reductions-37/NNS||greater-36/JJR	dobj||yield-35/VB||reductions-37/NNS	nn||levels-40/NNS||serum-39/NN	prep_in||evaluated-2/VBN||levels-40/NNS	amod||markers-48/NNS||total-42/JJ	nn||ldl-cholesterol-45/NN||cholesterol-43/NN	nn||markers-48/NNS||ldl-cholesterol-45/NN	conj_and||ldl-cholesterol-45/NN||inflammatory-47/JJ	nn||markers-48/NNS||inflammatory-47/JJ	prep_of||levels-40/NNS||markers-48/NNS	nn||necrosis-51/NNS||tumor-50/NN	dep||markers-48/NNS||necrosis-51/NNS	nn||-RSB--57/NNP||factor-î-52/NNP	nn||-RSB--57/NNP||±-53/NNP	nn||-RSB--57/NNP||-LSB--54/NNP	nn||-RSB--57/NNP||tnf-î-55/NNP	nn||-RSB--57/NNP||±-56/NNP	dep||necrosis-51/NNS||-RSB--57/NNP	amod||-LSB--61/NNS||nitricoxide-60/JJ	dep||markers-48/NNS||-LSB--61/NNS	conj_and||necrosis-51/NNS||-LSB--61/NNS	neg||-RSB--63/NN||no-62/DT	dep||-LSB--61/NNS||-RSB--63/NN	prep_than||evaluated-2/VBN||that-67/DT	vmod||that-67/DT||attained-68/VBN	det||compounds-72/NNS||the-70/DT	amod||compounds-72/NNS||individual-71/JJ	prep_with||attained-68/VBN||compounds-72/NNS	tumor-50||dexamethasone-33||yes||we evaluated these compounds in an avian model anticipating that a dietary additive combining î´-tocotrienol with quercetin, riboflavin, (-) corey lactone, amiloride, or dexamethasone would yield greater reductions in serum levels of total cholesterol, ldl-cholesterol and inflammatory markers (tumor necrosis factor-î± [tnf-î±], and nitricoxide [no]), than that attained with the individual compounds.
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	cancer-21||formaldehyde-14||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
nsubj||virus-9/NN||respiratorysyncytialvirus-1/NNS	appos||respiratorysyncytialvirus-1/NNS||rsv-3/NN	cop||virus-9/NN||is-5/VBZ	det||virus-9/NN||a-6/DT	advmod||contagious-8/JJ||highly-7/RB	amod||virus-9/NN||contagious-8/JJ	root||ROOT-0/null||virus-9/NN	cop||cause-15/NN||is-12/VBZ	det||cause-15/NN||the-13/DT	amod||cause-15/NN||major-14/JJ	conj_and||virus-9/NN||cause-15/NN	amod||infections-20/NNS||lower-17/JJR	amod||infections-20/NNS||respiratory-18/JJ	nn||infections-20/NNS||tract-19/NN	prep_of||cause-15/NN||infections-20/NNS	prep_in||infections-20/NNS||infants-22/NNS	prep_in||infections-20/NNS||toddlers-24/NNS	conj_and||infants-22/NNS||toddlers-24/NNS	nsubj||poses-26/VBZ||worldwide.rsvinfection-25/NN	rcmod||cause-15/NN||poses-26/VBZ	amod||risks-29/NNS||serious-27/JJ	nn||risks-29/NNS||health-28/NN	dobj||poses-26/VBZ||risks-29/NNS	amod||children-32/NNS||young-31/JJ	prep_to||poses-26/VBZ||children-32/NNS	det||years-37/NNS||the-34/DT	amod||years-37/NNS||first-35/JJ	num||years-37/NNS||2-36/CD	prep_during||cause-15/NN||years-37/NNS	prep_of||years-37/NNS||life-39/NN	rsvinfection--1||respiratorysyncytialvirus-1||no||respiratorysyncytialvirus (rsv) is a highly contagious virus, and is the major cause of lower respiratory tract infections in infants and toddlers worldwide.rsvinfection poses serious health risks to young children during the first 2 years of life.
nsubjpass||caused-3/VBN||type2diabetes-1/NNS	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	agent||caused-3/VBN||defects-5/NNS	preconj||signaling-9/NN||both-7/DT	nn||signaling-9/NN||insulin-8/NN	prep_in||defects-5/NNS||signaling-9/NN	nn||secretion-12/NN||insulin-11/NN	prep_in||defects-5/NNS||secretion-12/NN	conj_and||signaling-9/NN||secretion-12/NN	type2diabetes-1||insulin-11||yes||type2diabetes is caused by defects in both insulin signaling and insulin secretion.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||lidocaine-30||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||one-12/CD||tb-3/NN	vmod||tb-3/NN||caused-5/VBN	agent||caused-5/VBN||mycobacteriumtuberculosis-7/NNS	appos||tb-3/NN||mtb-9/NN	cop||one-12/CD||is-11/VBZ	root||ROOT-0/null||one-12/CD	det||causes-18/NNS||the-14/DT	amod||causes-18/NNS||leading-15/VBG	amod||causes-18/NNS||infectious-16/JJ	nn||causes-18/NNS||disease-17/NN	prep_of||one-12/CD||causes-18/NNS	nn||worldwide-23/NNS||morbidity-20/NN	conj_and||morbidity-20/NN||mortality-22/NN	nn||worldwide-23/NNS||mortality-22/NN	prep_of||causes-18/NNS||worldwide-23/NNS	tb-3||mycobacteriumtuberculosis-7||no||tuberculosis (tb) caused by mycobacteriumtuberculosis ( mtb ) is one of the leading infectious disease causes of morbidity and mortality worldwide.
nn||concentration-2/NN||muscle-1/NN	nsubj||different-18/JJ||concentration-2/NN	prep_of||concentration-2/NN||acylcarnitines-4/NNS	det||oxidation-14/NN||a-6/DT	dep||oxidation-14/NN||lipid-7/NNP	dep||lipid-7/NNP||intermediate-8/NNP	amod||²-12/NNS||fattyacid-10/JJ	nn||²-12/NNS||î-11/NN	prep_in||lipid-7/NNP||²-12/NNS	appos||concentration-2/NN||oxidation-14/NN	cop||different-18/JJ||was-16/VBD	neg||different-18/JJ||not-17/RB	root||ROOT-0/null||different-18/JJ	det||groups-22/NNS||the-20/DT	amod||groups-22/NNS||hpmc-21/JJ	prep_between||different-18/JJ||groups-22/NNS	nn||control-25/NN||obese-24/NN	prep_between||different-18/JJ||control-25/NN	conj_and||groups-22/NNS||control-25/NN	xcomp||different-18/JJ||suggesting-27/VBG	neg||oxidation-33/NN||no-28/DT	dep||oxidation-33/NN||change-29/NN	prep_in||change-29/NN||muscle-31/NN	amod||oxidation-33/NN||fattyacid-32/JJ	dobj||suggesting-27/VBG||oxidation-33/NN	prep_by||oxidation-33/NN||hpmc-35/NN	lipid-7||obese-24||no_rel||muscle concentration of acylcarnitines, a lipid intermediate in fattyacid î²-oxidation, was not different between the hpmc groups and obese control, suggesting no change in muscle fattyacid oxidation by hpmc.
prep_after||reach-7/VB||ingestion-2/NN	amod||proteins-6/NNS||degraded-4/JJ	nn||proteins-6/NNS||gluten-5/NN	nsubj||reach-7/VB||proteins-6/NNS	nsubj||trigger-12/VB||proteins-6/NNS	root||ROOT-0/null||reach-7/VB	det||intestine-10/NN||the-8/DT	amod||intestine-10/NN||small-9/JJ	dobj||reach-7/VB||intestine-10/NN	conj_and||reach-7/VB||trigger-12/VB	det||t-15/NN||an-13/DT	amod||t-15/NN||inappropriate-14/JJ	iobj||trigger-12/VB||t-15/NN	amod||response-18/NN||cell-mediated-16/JJ	amod||response-18/NN||immune-17/JJ	dobj||trigger-12/VB||response-18/NN	nsubj||result-22/VB||response-18/NN	aux||result-22/VB||can-21/MD	rcmod||response-18/NN||result-22/VB	amod||inflammation-26/NN||intestinal-24/JJ	amod||inflammation-26/NN||mucosal-25/JJ	prep_in||result-22/VB||inflammation-26/NN	nn||manifestations-29/NNS||extraintestinal-28/NN	prep_in||result-22/VB||manifestations-29/NNS	conj_and||inflammation-26/NN||manifestations-29/NNS	inflammation-26||gluten-5||no_rel||after ingestion, degraded gluten proteins reach the small intestine and trigger an inappropriate t cell-mediated immune response, which can result in intestinal mucosal inflammation and extraintestinal manifestations.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||effect-5/NN||the-4/DT	dobj||examined-3/VBD||effect-5/NN	amod||consumption-8/NN||chronic-7/JJ	prep_of||effect-5/NN||consumption-8/NN	det||viscous-11/NNS||the-10/DT	prep_of||consumption-8/NN||viscous-11/NNS	amod||fiber-15/NN||non-fermentable-13/JJ	nn||fiber-15/NN||dietary-14/NN	appos||consumption-8/NN||fiber-15/NN	appos||consumption-8/NN||hydroxypropylmethylcellulose-17/NN	dep||hydroxypropylmethylcellulose-17/NN||hpmc-19/JJ	nn||lipids-29/NNS||glucose-23/NN	nn||lipids-29/NNS||control-24/NN	conj_and||control-24/NN||insulinresistance-26/NN	nn||lipids-29/NNS||insulinresistance-26/NN	conj_and||control-24/NN||liver-28/NN	nn||lipids-29/NNS||liver-28/NN	prep_on||examined-3/VBD||lipids-29/NNS	det||model-35/NN||an-31/DT	amod||model-35/NN||obese-32/JJ	amod||model-35/NN||diabetic-33/JJ	nn||model-35/NN||rat-34/NN	prep_in||lipids-29/NNS||model-35/NN	obese-32||glucose-23||no_rel||this study examined the effect of chronic consumption of the viscous, non-fermentable dietary fiber, hydroxypropylmethylcellulose (hpmc), on glucose control, insulinresistance and liver lipids in an obese diabetic rat model.
nsubj||d-5/VBD||immunoglobulin-1/NN	nsubjpass||reported-21/VBN||immunoglobulin-1/NN	nsubjpass||associated-24/VBN||immunoglobulin-1/NN	appos||immunoglobulin-1/NN||ig-3/NN	root||ROOT-0/null||d-5/VBD	amod||accounts-10/NNS||multiplemyeloma-6/JJ	appos||accounts-10/NNS||mm-8/NN	dobj||d-5/VBD||accounts-10/NNS	num||%-13/NN||2-12/CD	prep_for||d-5/VBD||%-13/NN	det||cases-17/NNS||all-15/DT	nn||cases-17/NNS||mm-16/NN	prep_of||%-13/NN||cases-17/NNS	aux||reported-21/VBN||has-19/VBZ	auxpass||reported-21/VBN||been-20/VBN	conj_and||d-5/VBD||reported-21/VBN	aux||associated-24/VBN||to-22/TO	auxpass||associated-24/VBN||be-23/VB	xcomp||reported-21/VBN||associated-24/VBN	amod||prognosis-27/NN||poor-26/JJ	prep_with||associated-24/VBN||prognosis-27/NN	prepc_compared_with||associated-24/VBN||with-29/IN	amod||subtypes-32/NNS||other-30/JJ	nn||subtypes-32/NNS||mm-31/NN	pobj||associated-24/VBN||subtypes-32/NNS	ig-3||multiplemyeloma-6||no_rel||immunoglobulin (ig) d multiplemyeloma (mm) accounts for 2% of all mm cases and has been reported to be associated with poor prognosis compared with other mm subtypes.
amod||feâˆ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâˆ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâˆ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâˆ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	ironoverload-37||fe--1||no||defective feâˆ’s cluster synthesis not only affects activities of many ironâˆ’sulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
dep||sensitive-7/JJ||live-1/VB	amod||virus-3/NN||nipah-2/JJ	dobj||live-1/VB||virus-3/NN	amod||virus-3/NN||budding-4/VBG	cop||sensitive-7/JJ||was-5/VBD	advmod||sensitive-7/JJ||exquisitely-6/RB	root||ROOT-0/null||sensitive-7/JJ	aux||proteasome-9/VB||to-8/TO	xcomp||sensitive-7/JJ||proteasome-9/VB	dobj||proteasome-9/VB||inhibitors-10/NNS	nsubj||sensitive-7/JJ||bortezomib-11/NN	nsubj||proteasome-9/VB||bortezomib-11/NN	det||inhibitor-16/NN||an-13/DT	amod||inhibitor-16/NN||fda-approved-14/JJ	nn||inhibitor-16/NN||proteasome-15/NN	appos||bortezomib-11/NN||inhibitor-16/NN	prepc_for||inhibitor-16/NN||treating-18/VBG	dobj||treating-18/VBG||multiplemyeloma-19/NN	nsubj||100-fold-33/JJ||multiplemyeloma-19/NN	vmod||multiplemyeloma-19/NN||reduced-21/VBN	amod||titers-23/NNS||viral-22/JJ	dobj||reduced-21/VBN||titers-23/NNS	det||ic50-26/NN||an-25/DT	prep_with||reduced-21/VBN||ic50-26/NN	num||nm-29/NN||2.7-28/CD	prep_of||ic50-26/NN||nm-29/NN	cop||100-fold-33/JJ||is-32/VBZ	rcmod||multiplemyeloma-19/NN||100-fold-33/JJ	dep||100-fold-33/JJ||less-34/JJR	det||concentration-39/NN||the-36/DT	amod||concentration-39/NN||peak-37/JJ	nn||concentration-39/NN||plasma-38/NN	prep_than||100-fold-33/JJ||concentration-39/NN	nsubjpass||achieved-43/VBN||concentration-39/NN	aux||achieved-43/VBN||can-41/MD	auxpass||achieved-43/VBN||be-42/VB	rcmod||concentration-39/NN||achieved-43/VBN	prep_in||achieved-43/VBN||humans-45/NNS	multiplemyeloma-19||bortezomib-11||yes||live nipah virus budding was exquisitely sensitive to proteasome inhibitors bortezomib, an fda-approved proteasome inhibitor for treating multiplemyeloma, reduced viral titers with an ic50 of 2.7 nm, which is 100-fold less than the peak plasma concentration that can be achieved in humans.
det||detections-3/NNS||the-1/DT	amod||detections-3/NNS||infrequent-2/JJ	nsubj||suggest-17/VBP||detections-3/NNS	det||viruses-6/NNS||these-5/DT	prep_of||detections-3/NNS||viruses-6/NNS	amod||samples-9/NNS||multiple-8/JJ	prep_in||viruses-6/NNS||samples-9/NNS	amod||individuals-12/NNS||immunosuppressed-11/JJ	prep_from||samples-9/NNS||individuals-12/NNS	prep_including||individuals-12/NNS||those-14/DT	prep_with||those-14/DT||pml-16/NN	root||ROOT-0/null||suggest-17/VBP	mark||different-24/JJ||that-18/IN	poss||mechanisms-21/NNS||their-19/PRP$	nn||mechanisms-21/NNS||reactivation-20/NN	nsubj||different-24/JJ||mechanisms-21/NNS	aux||different-24/JJ||may-22/MD	cop||different-24/JJ||be-23/VB	ccomp||suggest-17/VBP||different-24/JJ	prep_from||different-24/JJ||that-26/DT	prep_of||that-26/DT||jcpolyomavirus-28/NNS	appos||jcpolyomavirus-28/NNS||jcpyv-30/NNP	mark||play-37/VB||that-33/IN	nsubj||play-37/VB||they-34/PRP	aux||play-37/VB||do-35/VBP	neg||play-37/VB||not-36/RB	ccomp||suggest-17/VBP||play-37/VB	conj_and||different-24/JJ||play-37/VB	det||role-39/NN||a-38/DT	dobj||play-37/VB||role-39/NN	det||pathogenesis-42/NNS||the-41/DT	prep_in||play-37/VB||pathogenesis-42/NNS	prep_of||pathogenesis-42/NNS||pml-44/NN	pml-44||jcpolyomavirus-28||no||the infrequent detections of these viruses in multiple samples from immunosuppressed individuals including those with pml suggest that their reactivation mechanisms may be different from that of jcpolyomavirus (jcpyv) and that they do not play a role in the pathogenesis of pml.
nsubjpass||excluded-3/VBN||patients-1/NNS	auxpass||excluded-3/VBN||were-2/VBD	root||ROOT-0/null||excluded-3/VBN	mark||had-6/VBD||if-4/IN	nsubj||had-6/VBD||they-5/PRP	advcl||excluded-3/VBN||had-6/VBD	dobj||had-6/VBD||active-7/JJ	dobj||had-6/VBD||chronichepatitisbvirus-9/JJ	conj_or||active-7/JJ||chronichepatitisbvirus-9/JJ	appos||active-7/JJ||hbv-11/NN	hbv-11||hepatitisbvirus--1||no||patients were excluded if they had active or chronichepatitisbvirus (hbv).
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-4/NN||a-3/DT	dobj||present-2/VBP||case-4/NN	amod||colitis-7/NNS||mycophenolatemofetil-6/JJ	prep_of||case-4/NN||colitis-7/NNS	vmod||colitis-7/NNS||mimicking-8/VBG	nn||gvhd-11/NN||grade-9/FW	nn||gvhd-11/NN||i-10/FW	dobj||mimicking-8/VBG||gvhd-11/NN	det||gut-14/NN||the-13/DT	prep_of||gvhd-11/NN||gut-14/NN	gvhd-11||mycophenolatemofetil-6||yes||we present a case of mycophenolatemofetil colitis mimicking grade i gvhd of the gut.
det||usefulness-2/NN||the-1/DT	nsubjpass||limited-12/VBN||usefulness-2/NN	amod||vaccine-5/NN||available-4/JJ	prep_of||usefulness-2/NN||vaccine-5/NN	nn||tests-8/NNS||serological-7/NN	prep_of||usefulness-2/NN||tests-8/NNS	conj_and||vaccine-5/NN||tests-8/NNS	prep_for||vaccine-5/NN||leptospirosis-10/NNS	auxpass||limited-12/VBN||is-11/VBZ	root||ROOT-0/null||limited-12/VBN	det||cross-reactivity-16/NN||the-14/DT	amod||cross-reactivity-16/NN||low-15/JJ	agent||limited-12/VBN||cross-reactivity-16/NN	prep_of||cross-reactivity-16/NN||antigens-18/NNS	amod||serovars-21/NNS||numerous-20/JJ	prep_from||limited-12/VBN||serovars-21/NNS	amod||spp-25/NN||pathogenic-23/JJ	nn||spp-25/NN||leptospira-24/NN	prep_of||serovars-21/NNS||spp-25/NN	leptospirosis-10||leptospira-24||no||the usefulness of available vaccine and serological tests for leptospirosis is limited by the low cross-reactivity of antigens from numerous serovars of pathogenic leptospira spp.
nsubjpass||shown-7/VBN||methylphenidate-1/NN	nsubj||block-9/VB||methylphenidate-1/NN	dep||methylphenidate-1/NN||mph-3/NN	aux||shown-7/VBN||has-5/VBZ	auxpass||shown-7/VBN||been-6/VBN	root||ROOT-0/null||shown-7/VBN	aux||block-9/VB||to-8/TO	xcomp||shown-7/VBN||block-9/VB	det||transporter-12/NN||the-10/DT	amod||transporter-12/NN||norepinephrine-11/JJ	dobj||block-9/VB||transporter-12/NN	appos||transporter-12/NN||net-14/NN	amod||investigations-19/NNS||genetic-18/JJ	nsubj||demonstrated-21/VBN||investigations-19/NNS	aux||demonstrated-21/VBN||have-20/VBP	conj_and||shown-7/VBN||demonstrated-21/VBN	mark||associated-31/VBN||that-22/IN	det||gene-26/NN||the-23/DT	amod||gene-26/NN||norepinephrine-24/JJ	nn||gene-26/NN||transporter-25/NN	nsubjpass||associated-31/VBN||gene-26/NN	appos||gene-26/NN||slc6a2-28/NNP	auxpass||associated-31/VBN||is-30/VBZ	ccomp||demonstrated-21/VBN||associated-31/VBN	prep_with||associated-31/VBN||adhd-33/NN	adhd-33||methylphenidate-1||yes||methylphenidate (mph) has been shown to block the norepinephrine transporter (net), and genetic investigations have demonstrated that the norepinephrine transporter gene ( slc6a2 ) is associated with adhd.
nn||snps-2/NNS||ifnk-1/NN	nsubjpass||associated-4/VBN||snps-2/NNS	auxpass||associated-4/VBN||were-3/VBD	root||ROOT-0/null||associated-4/VBN	amod||ifn-10/NN||increased-6/VBN	nn||ifn-10/NN||serum-7/NN	nn||ifn-10/NN||type-8/NN	nn||ifn-10/NN||i-9/NN	prep_with||associated-4/VBN||ifn-10/NN	nn||patients-16/NNS||ea-12/NN	conj_and||ea-12/NN||aa-14/NN	nn||patients-16/NNS||aa-14/NN	nn||patients-16/NNS||sle-15/NN	prep_in||ifn-10/NN||patients-16/NNS	ea-12||sle-15||no_rel||ifnk snps were associated with increased serum type i ifn in ea and aa sle patients.
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
nsubj||reviewed-2/VBN||we-1/PRP	nsubj||conducted-6/VBN||we-1/PRP	root||ROOT-0/null||reviewed-2/VBN	det||literature-4/NN||the-3/DT	dobj||reviewed-2/VBN||literature-4/NN	conj_and||reviewed-2/VBN||conducted-6/VBN	det||study-8/NN||this-7/DT	dobj||conducted-6/VBN||study-8/NN	aux||assess-10/VB||to-9/TO	vmod||study-8/NN||assess-10/VB	det||impact-12/NN||the-11/DT	dobj||assess-10/VB||impact-12/NN	prepc_of||impact-12/NN||xqlg-14/VBG	det||therapy-18/NN||an-16/DT	amod||therapy-18/NN||add-on-17/JJ	prep_as||xqlg-14/VBG||therapy-18/NN	prep_to||xqlg-14/VBG||treatment-20/NN	amod||seretide-24/NN||fluticasone/salmeterol-22/JJ	prep_with||assess-10/VB||seretide-24/NN	amod||patients-28/NNS||adult-27/JJ	prep_in||seretide-24/NN||patients-28/NNS	amod||asthma-33/NN||mild-to-moderate-30/JJ	amod||asthma-33/NN||persistent-32/JJ	prep_with||assess-10/VB||asthma-33/NN	asthma-33||salmeterol--1||no||we reviewed the literature and conducted this study to assess the impact of xqlg as an add-on therapy to treatment with fluticasone/salmeterol (seretide) in adult patients with mild-to-moderate, persistent asthma.
det||study-2/NN||the-1/DT	nsubj||comprised-3/VBN||study-2/NN	root||ROOT-0/null||comprised-3/VBN	amod||records-5/NNS||medical-4/JJ	dobj||comprised-3/VBN||records-5/NNS	num||outpatients-8/NNS||20-7/CD	prep_of||records-5/NNS||outpatients-8/NNS	amod||treatment-13/NN||mirtazapine-augmented-11/JJ	nn||treatment-13/NN||ssri-12/NN	prep_under||comprised-3/VBN||treatment-13/NN	poss||depressivedisorder-17/NN||their-15/PRP$	amod||depressivedisorder-17/NN||major-16/JJ	prep_for||treatment-13/NN||depressivedisorder-17/NN	nsubjpass||selected-22/VBN||depressivedisorder-17/NN	aux||selected-22/VBN||had-20/VBD	auxpass||selected-22/VBN||been-21/VBN	rcmod||depressivedisorder-17/NN||selected-22/VBN	det||patients-25/NNS||the-24/DT	prep_among||selected-22/VBN||patients-25/NNS	nsubj||developed-28/VBN||patients-25/NNS	aux||developed-28/VBN||had-27/VBD	rcmod||patients-25/NNS||developed-28/VBN	amod||dysfunction-30/NN||sexual-29/JJ	dobj||developed-28/VBN||dysfunction-30/NN	amod||treatment-33/NN||previous-32/JJ	prep_to||developed-28/VBN||treatment-33/NN	prep_as||developed-28/VBN||monotherapy-35/NN	prep_with||developed-28/VBN||ssri-38/NNS	quantmod||six-42/CD||at-40/IN	mwe||at-40/IN||least-41/JJS	pobj||at-40/IN||least-41/JJS	num||weeks-43/NNS||six-42/CD	prep_for||ssri-38/NNS||weeks-43/NNS	depressivedisorder-17||mirtazapine--1||yes||the study comprised medical records of 20 outpatients, under mirtazapine-augmented ssri treatment for their major depressivedisorder, who had been selected among the patients that had developed sexual dysfunction to previous treatment as monotherapy, with ssri for at least six weeks.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	urticaria-43||cu-63||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||influenza-3/NN||the-2/DT	prep_since||described-19/VBN||influenza-3/NN	det||pandemic-5/NN||a-4/DT	dep||influenza-3/NN||pandemic-5/NN	prep_in||pandemic-5/NN||1819-7/CD	det||association-10/NN||the-9/DT	nsubjpass||described-19/VBN||association-10/NN	det||influenzavirus-13/NNS||the-12/DT	prep_between||association-10/NN||influenzavirus-13/NNS	prep_between||association-10/NN||streptococcuspneumoniae-15/NN	conj_and||influenzavirus-13/NNS||streptococcuspneumoniae-15/NN	aux||described-19/VBN||has-16/VBZ	auxpass||described-19/VBN||been-17/VBN	advmod||described-19/VBN||well-18/RB	root||ROOT-0/null||described-19/VBN	prep_in||described-19/VBN||literature-21/NN	influenza-3||influenzavirus-13||no||since the influenza a pandemic in 1819, the association between the influenzavirus and streptococcuspneumoniae has been well described in literature.
amod||hyperglycemia-3/NN||chronic-2/JJ	prep_for||cultured-8/VBN||hyperglycemia-3/NN	amod||cells-6/NNS||ins-1-5/JJ	nsubjpass||cultured-8/VBN||cells-6/NNS	auxpass||cultured-8/VBN||were-7/VBD	root||ROOT-0/null||cultured-8/VBN	num||days-11/NNS||5-10/CD	prep_for||cultured-8/VBN||days-11/NNS	prep_with||days-11/NNS||changes-13/NNS	number||1640-16/CD||rpmi-15/CD	num||medium-17/NN||1640-16/CD	prep_of||changes-13/NNS||medium-17/NN	xcomp||cultured-8/VBN||containing-18/VBG	num||glucose-21/NN||33-19/CD	nn||glucose-21/NN||mm-20/NN	iobj||containing-18/VBG||glucose-21/NN	det||hours-24/NNS||every-22/DT	num||hours-24/NNS||12-23/CD	dobj||containing-18/VBG||hours-24/NNS	hyperglycemia-3||glucose-21||no||for chronic hyperglycemia, ins-1 cells were cultured for 5 days with changes of rpmi 1640 medium containing 33 mm glucose every 12 hours.
det||observations-2/NNS||these-1/DT	nsubjpass||confirmed-5/VBN||observations-2/NNS	auxpass||confirmed-5/VBN||were-3/VBD	advmod||confirmed-5/VBN||further-4/RBR	root||ROOT-0/null||confirmed-5/VBN	det||cohort-9/NN||a-7/DT	nn||cohort-9/NN||validation-8/NN	prep_on||confirmed-5/VBN||cohort-9/NN	nn||patients-12/NNS||cll-11/NN	prep_of||cohort-9/NN||patients-12/NNS	vmod||patients-12/NNS||treated-13/VBN	prep_with||treated-13/VBN||fludarabine-15/NN	prep_in||fludarabine-15/NN||vitro-17/NNP	cll-11||fludarabine-15||yes||these observations were further confirmed on a validation cohort of cll patients treated with fludarabine in vitro .
det||study-3/NN||a-1/DT	amod||study-3/NN||recent-2/JJ	nsubj||shown-5/VBN||study-3/NN	aux||shown-5/VBN||has-4/VBZ	root||ROOT-0/null||shown-5/VBN	mark||efficacious-30/JJ||that-6/IN	nsubj||efficacious-30/JJ||treatment-7/NN	prep_of||treatment-7/NN||visceralleishmaniasis-9/NNS	appos||visceralleishmaniasis-9/NNS||vl-11/NN	det||dose-16/NN||the-14/DT	amod||dose-16/NN||standard-15/JJ	prep_with||visceralleishmaniasis-9/NNS||dose-16/NN	num||mg/kg/day-19/NN||15-18/CD	prep_of||dose-16/NN||mg/kg/day-19/NN	prep_of||mg/kg/day-19/NN||paromomycinsulphate-21/NN	appos||paromomycinsulphate-21/NN||pm-23/NN	num||days-27/NNS||21-26/CD	prep_for||paromomycinsulphate-21/NN||days-27/NNS	cop||efficacious-30/JJ||was-28/VBD	neg||efficacious-30/JJ||not-29/RB	ccomp||shown-5/VBN||efficacious-30/JJ	prep_in||efficacious-30/JJ||patients-32/NNS	prep_in||patients-32/NNS||sudan-34/NN	paromomycinsulphate-21||visceralleishmaniasis-9||no_rel||a recent study has shown that treatment of visceralleishmaniasis (vl) with the standard dose of 15 mg/kg/day of paromomycinsulphate (pm) for 21 days was not efficacious in patients in sudan.
det||therapy-4/NN||the-1/DT	amod||therapy-4/NN||gold-2/JJ	amod||therapy-4/NN||standard-3/JJ	nsubjpass||pegylated-9/VBN||therapy-4/NN	amod||patients-7/NNS||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||patients-7/NNS	auxpass||pegylated-9/VBN||is-8/VBZ	root||ROOT-0/null||pegylated-9/VBN	dobj||pegylated-9/VBN||interferon-10/NN	prep||pegylated-9/VBN||combined-11/VBN	pcomp||combined-11/VBN||with-12/IN	det||drug-15/NN||an-13/DT	amod||drug-15/NN||anti-viral-14/JJ	pobj||with-12/IN||drug-15/NN	appos||drug-15/NN||ribavirin-17/NNP	interferon-10||chronichepatitisc-6||no_rel||the gold standard therapy for chronichepatitisc patients is pegylated interferon combined with an anti-viral drug (ribavirin).
nn||countries-2/NNS||sixteen-1/NN	nsubj||reported-3/VBD||countries-2/NNS	root||ROOT-0/null||reported-3/VBD	det||system-8/NN||an-4/DT	amod||behavioural-6/JJ||established-5/JJ	amod||system-8/NN||behavioural-6/JJ	nn||system-8/NN||surveillance-7/NN	dobj||reported-3/VBD||system-8/NN	dobj||reported-3/VBD||13-11/CD	conj_and||system-8/NN||13-11/CD	det||system-16/NN||a-12/DT	amod||system-16/NN||second-13/JJ	nn||system-16/NN||generation-14/NN	nn||system-16/NN||surveillance-15/NN	dep||13-11/CD||system-16/NN	dep||system-16/NN||combination-18/NN	amod||surveillance-21/NN||biological-20/JJ	prep_of||combination-18/NN||surveillance-21/NN	prep_of||surveillance-21/NN||hiv/aids-23/NNS	prep_of||surveillance-21/NN||sti-25/NN	conj_and||hiv/aids-23/NNS||sti-25/NN	amod||surveillance-28/NN||behavioural-27/JJ	prep_with||combination-18/NN||surveillance-28/NN	aids--1||hiv--1||no||sixteen countries reported an established behavioural surveillance system, and 13 a second generation surveillance system (combination of biological surveillance of hiv/aids and sti with behavioural surveillance).
det||study-3/NN||this-2/DT	prep_in||examined-6/VBD||study-3/NN	nsubj||examined-6/VBD||we-5/PRP	root||ROOT-0/null||examined-6/VBD	nn||responses-8/NNS||antibody-7/NN	dobj||examined-6/VBD||responses-8/NNS	prep_against||examined-6/VBD||hbz-10/NN	nn||samples-13/NNS||serum/plasma-12/NN	prep_in||hbz-10/NN||samples-13/NNS	num||subjects-16/NNS||436-15/CD	prep_from||examined-6/VBD||subjects-16/NNS	amod||donors-20/NNS||htlv-1-18/JJ	nn||donors-20/NNS||seronegative-19/NN	prep_including||subjects-16/NNS||donors-20/NNS	amod||carriers-23/NNS||asymptomatic-22/JJ	prep_from||examined-6/VBD||carriers-23/NNS	conj_and||subjects-16/NNS||carriers-23/NNS	appos||carriers-23/NNS||ac-25/NN	prep_from||examined-6/VBD||atl-28/NN	conj_and||subjects-16/NNS||atl-28/NN	nn||patients-32/NNS||ham/tsp-31/NN	prep_from||examined-6/VBD||patients-32/NNS	conj_and||subjects-16/NNS||patients-32/NNS	vmod||patients-32/NNS||using-33/VBG	det||system-37/NN||the-34/DT	amod||system-37/NN||luciferase-35/JJ	nn||system-37/NN||immunoprecipitation-36/NN	dobj||using-33/VBG||system-37/NN	ham--1||htlv-1-18||no||in this study, we examined antibody responses against hbz in serum/plasma samples from 436 subjects including htlv-1 seronegative donors, asymptomatic carriers (ac), atl, and ham/tsp patients using the luciferase immunoprecipitation system.
nsubj||alternative-5/NN||daptomycin-1/NN	cop||alternative-5/NN||was-2/VBD	det||alternative-5/NN||an-3/DT	amod||alternative-5/NN||effective-4/JJ	root||ROOT-0/null||alternative-5/NN	aux||vancomycin/gentamicin-7/VB||to-6/TO	vmod||alternative-5/NN||vancomycin/gentamicin-7/VB	nn||bacteraemia-10/NN||mrsa-9/NN	prep_for||vancomycin/gentamicin-7/VB||bacteraemia-10/NN	amod||endocarditis-13/NNS||right-sided-12/JJ	prep_for||vancomycin/gentamicin-7/VB||endocarditis-13/NNS	conj_or||bacteraemia-10/NN||endocarditis-13/NNS	vancomycin--1||bacteraemia-10||no_rel||daptomycin was an effective alternative to vancomycin/gentamicin for mrsa bacteraemia or right-sided endocarditis.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||improvement-4/NN||the-3/DT	dobj||assess-2/VB||improvement-4/NN	prep_in||improvement-4/NN||psychopathology-6/NN	amod||schizophrenia-9/NN||treatment-resistant-8/JJ	prep_of||psychopathology-6/NN||schizophrenia-9/NN	amod||therapy-12/NN||clozapine-11/JJ	prep_with||assess-2/VB||therapy-12/NN	aux||study-15/VB||to-14/TO	conj_and||assess-2/VB||study-15/VB	det||relationship-17/NN||the-16/DT	dobj||study-15/VB||relationship-17/NN	amod||variables-23/NNS||sociodemographic-19/JJ	conj_and||sociodemographic-19/JJ||various-21/JJ	amod||variables-23/NNS||various-21/JJ	nn||variables-23/NNS||psychopathology-22/NN	prep_between||relationship-17/NN||variables-23/NNS	prep_among||study-15/VB||patients-25/NNS	amod||schizophrenia-28/NN||treatment-resistant-27/JJ	prep_with||patients-25/NNS||schizophrenia-28/NN	schizophrenia-28||clozapine-11||yes||to assess the improvement in psychopathology of treatment-resistant schizophrenia with clozapine therapy and to study the relationship between sociodemographic and various psychopathology variables among patients with treatment-resistant schizophrenia.
aux||provide-2/VB||to-1/TO	ccomp||studied-36/VBD||provide-2/VB	amod||evidence-6/NN||molecular-3/JJ	conj_and||molecular-3/JJ||virologic-5/JJ	amod||evidence-6/NN||virologic-5/JJ	dobj||provide-2/VB||evidence-6/NN	mark||enzootic-14/JJ||that-7/IN	amod||rabies-10/NNS||domestic-8/JJ	nn||rabies-10/NNS||dog-9/NN	nsubj||enzootic-14/JJ||rabies-10/NNS	cop||enzootic-14/JJ||is-11/VBZ	neg||longer-13/RBR||no-12/RB	advmod||enzootic-14/JJ||longer-13/RBR	ccomp||provide-2/VB||enzootic-14/JJ	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_to||enzootic-14/JJ||states-18/NNS	aux||identify-21/VB||to-20/TO	conj_and||provide-2/VB||identify-21/VB	ccomp||studied-36/VBD||identify-21/VB	amod||relatives-23/NNS||putative-22/JJ	dobj||identify-21/VB||relatives-23/NNS	amod||rabiesviruses-26/NNS||dog-related-25/JJ	prep_of||relatives-23/NNS||rabiesviruses-26/NNS	appos||rabiesviruses-26/NNS||rvs-28/NN	vmod||rabiesviruses-26/NNS||circulating-30/VBG	amod||carnivores-33/NNS||other-32/JJ	prep_in||circulating-30/VBG||carnivores-33/NNS	nsubj||studied-36/VBD||we-35/PRP	root||ROOT-0/null||studied-36/VBD	dobj||studied-36/VBD||rvs-37/NN	vmod||rvs-37/NN||associated-38/VBN	amod||enzootics-45/NNS||recent-40/JJ	conj_and||recent-40/JJ||historic-42/JJ	amod||enzootics-45/NNS||historic-42/JJ	nn||enzootics-45/NNS||dog-43/NN	nn||enzootics-45/NNS||rabies-44/NN	prep_with||associated-38/VBN||enzootics-45/NNS	advmod||associated-38/VBN||worldwide-46/RB	rabies-44||rabiesviruses-26||no||to provide molecular and virologic evidence that domestic dog rabies is no longer enzootic to the united states and to identify putative relatives of dog-related rabiesviruses (rvs) circulating in other carnivores, we studied rvs associated with recent and historic dog rabies enzootics worldwide.
nsubj||cause-5/NN||neisseriameningitidis-1/NNS	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||major-4/JJ	root||ROOT-0/null||cause-5/NN	prep_of||cause-5/NN||meningitis-7/NNS	mark||agent-13/NN||while-9/IN	nsubj||agent-13/NN||neisseriagonorrhoeae-10/NN	cop||agent-13/NN||is-11/VBZ	det||agent-13/NN||the-12/DT	advcl||cause-5/NN||agent-13/NN	det||gonorrhea-19/NN||the-15/DT	advmod||gonorrhea-19/NN||sexually-16/RB	amod||gonorrhea-19/NN||transmitted-17/JJ	nn||gonorrhea-19/NN||disease-18/NN	prep_of||agent-13/NN||gonorrhea-19/NN	nn||lactamica-22/NN||neisseria-21/NN	nsubj||commensal-28/NN||lactamica-22/NN	cop||commensal-28/NN||is-23/VBZ	det||commensal-28/NN||a-24/DT	amod||harmless-27/JJ||common-25/JJ	amod||commensal-28/NN||harmless-27/JJ	conj_and||cause-5/NN||commensal-28/NN	prep_of||commensal-28/NN||children-30/NNS	gonorrhea-19||neisseriagonorrhoeae-10||no||neisseriameningitidis is a major cause of meningitis, while neisseriagonorrhoeae is the agent of the sexually transmitted disease gonorrhea and neisseria lactamica is a common, harmless commensal of children.
amod||domain-3/NN||bcr-abl-1/JJ	nn||domain-3/NN||kinase-2/NN	root||ROOT-0/null||domain-3/NN	appos||domain-3/NN||kd-5/NN	nsubj||mechanism-11/NN||mutation-7/NN	cop||mechanism-11/NN||is-8/VBZ	det||mechanism-11/NN||the-9/DT	amod||mechanism-11/NN||major-10/JJ	rcmod||domain-3/NN||mechanism-11/NN	vmod||mechanism-11/NN||contributing-12/VBG	aux||suboptimal-14/VB||to-13/TO	xcomp||contributing-12/VBG||suboptimal-14/VB	dobj||suboptimal-14/VB||response-15/NN	aux||tyrosine-17/VB||to-16/TO	vmod||suboptimal-14/VB||tyrosine-17/VB	amod||inhibitors-19/NNS||kinase-18/JJ	dobj||tyrosine-17/VB||inhibitors-19/NNS	appos||inhibitors-19/NNS||tki-21/NN	prep_in||inhibitors-19/NNS||bcr-abl-24/NN	amod||chronicmyeloidleukemia-27/NN||positive-26/JJ	dep||domain-3/NN||chronicmyeloidleukemia-27/NN	appos||chronicmyeloidleukemia-27/NN||cml-29/NN	dep||chronicmyeloidleukemia-27/NN||patients-31/NNS	kd-5||tyrosine-17||no_rel||bcr-abl kinase domain (kd) mutation is the major mechanism contributing to suboptimal response to tyrosine kinase inhibitors (tki) in bcr-abl -positive chronicmyeloidleukemia (cml) patients.
amod||investigation-2/NN||epidemiologic-1/JJ	nsubj||showed-3/VBD||investigation-2/NN	root||ROOT-0/null||showed-3/VBD	dobj||showed-3/VBD||that-4/DT	nsubj||provided-9/VBD||that-4/DT	amod||persons-7/NNS||789-6/JJ	prep_of||that-4/DT||persons-7/NNS	rcmod||that-4/DT||provided-9/VBD	nn||samples-11/NNS||blood-10/NN	dobj||provided-9/VBD||samples-11/NNS	nsubj||seropositive-19/JJ||195-13/CD	num||%-16/NN||25-15/CD	appos||195-13/CD||%-16/NN	cop||seropositive-19/JJ||were-18/VBD	ccomp||showed-3/VBD||seropositive-19/JJ	conj_and||showed-3/VBD||seropositive-19/JJ	nsubj||immunoglobulin-27/VBN||33-21/CD	num||%-24/NN||4-23/CD	appos||33-21/CD||%-24/NN	aux||immunoglobulin-27/VBN||had-26/VBD	ccomp||showed-3/VBD||immunoglobulin-27/VBN	conj_and||showed-3/VBD||immunoglobulin-27/VBN	amod||levels-32/NNS||-LSB--28/JJ	nn||levels-32/NNS||ig-29/NN	amod||levels-32/NNS||-RSB--30/JJ	nn||levels-32/NNS||m-31/NN	nsubj||consistent-33/JJ||levels-32/NNS	xcomp||immunoglobulin-27/VBN||consistent-33/JJ	amod||acuteinfection-36/NN||recent-35/JJ	prep_with||consistent-33/JJ||acuteinfection-36/NN	nsubj||symptomatic-43/JJ||11-38/CD	det||persons-41/NNS||these-40/DT	prep_of||11-38/CD||persons-41/NNS	cop||symptomatic-43/JJ||were-42/VBD	dep||acuteinfection-36/NN||symptomatic-43/JJ	nsubj||igg-53/VBN||162-47/CD	num||%-50/NN||21-49/CD	appos||162-47/CD||%-50/NN	aux||igg-53/VBN||had-52/VBD	conj_and||showed-3/VBD||igg-53/VBN	dep||igg-53/VBN||only-54/RB	acomp||igg-53/VBN||consistent-56/JJ	amod||infection-59/NN||past-58/JJ	prep_with||consistent-56/JJ||infection-59/NN	acuteinfection-36||ig-29||no_rel||epidemiologic investigation showed that of 789 persons who provided blood samples, 195 (25%) were seropositive, 33 (4%) had immunoglobulin [ig] m levels consistent with recent acuteinfection (11 of these persons were symptomatic), and 162 (21%) had igg only, consistent with past infection.
det||results-2/NNS||these-1/DT	nsubj||show-3/VBP||results-2/NNS	nsubj||genitalwarts-33/VBZ||results-2/NNS	root||ROOT-0/null||show-3/VBP	mark||reduce-19/VB||that-4/IN	det||vaccination-9/NN||the-5/DT	amod||vaccination-9/NN||current-6/JJ	amod||vaccination-9/NN||quadrivalent-7/JJ	nn||vaccination-9/NN||hpv-8/NN	nsubj||reduce-19/VB||vaccination-9/NN	amod||programmes-14/NNS||cervical-11/JJ	nn||programmes-14/NNS||cancer-12/NN	nn||programmes-14/NNS||screening-13/NN	conj_and||vaccination-9/NN||programmes-14/NNS	nsubj||reduce-19/VB||programmes-14/NNS	prep_in||programmes-14/NNS||germany-16/NN	aux||reduce-19/VB||will-17/MD	advmod||reduce-19/VB||substantially-18/RB	ccomp||show-3/VBP||reduce-19/VB	det||incidence-21/NN||the-20/DT	dobj||reduce-19/VB||incidence-21/NN	amod||cancer-24/NN||cervical-23/JJ	prep_of||incidence-21/NN||cancer-24/NN	amod||neoplasia-28/NN||cervical-26/JJ	amod||neoplasia-28/NN||intraepithelial-27/JJ	appos||cancer-24/NN||neoplasia-28/NN	appos||neoplasia-28/NN||cin-30/NN	conj_and||show-3/VBP||genitalwarts-33/VBZ	genitalwarts-33||hpv-8||no||these results show that the current quadrivalent hpv vaccination and cervical cancer screening programmes in germany will substantially reduce the incidence of cervical cancer, cervical intraepithelial neoplasia (cin) and genitalwarts.
mark||inactive-5/JJ||while-1/IN	nn||monotherapy-3/NN||cisplatin-2/NN	nsubj||inactive-5/JJ||monotherapy-3/NN	cop||inactive-5/JJ||was-4/VBD	advcl||abrogated-16/VBD||inactive-5/JJ	nsubj||abrogated-16/VBD||combination-7/NN	amod||silencing-10/NN||bmi-1-9/JJ	prep_of||combination-7/NN||silencing-10/NN	prep_along_with||completely-15/RB||cisplatin-13/NN	advmod||completely-15/RB||almost-14/RB	advmod||abrogated-16/VBD||completely-15/RB	root||ROOT-0/null||abrogated-16/VBD	nn||growth-18/NN||ovariantumor-17/NN	dobj||abrogated-16/VBD||growth-18/NN	ovariantumor-17||cisplatin-13||yes||while cisplatin monotherapy was inactive, combination of bmi-1 silencing along with cisplatin almost completely abrogated ovariantumor growth.
det||trial-8/NN||a-2/DT	amod||trial-8/NN||large-3/JJ	amod||trial-8/NN||acute-4/JJ	amod||trial-8/NN||coronary-5/JJ	nn||trial-8/NN||syndrome-6/NN	amod||trial-8/NN||clinical-7/JJ	prep_in||reduced-11/VBD||trial-8/NN	nsubj||reduced-11/VBD||ranolazine-10/NN	root||ROOT-0/null||reduced-11/VBD	det||incidence-13/NN||the-12/DT	dobj||reduced-11/VBD||incidence-13/NN	prep_of||incidence-13/NN||supraventriculartachycardia-15/NN	prep_of||incidence-13/NN||ventriculartachycardia-17/NN	conj_and||supraventriculartachycardia-15/NN||ventriculartachycardia-17/NN	amod||atrialfibrillation-20/NN||new-onset-19/JJ	prep_of||incidence-13/NN||atrialfibrillation-20/NN	conj_and||supraventriculartachycardia-15/NN||atrialfibrillation-20/NN	amod||events-24/NNS||bradycardic-23/JJ	prep_of||incidence-13/NN||events-24/NNS	conj_and||supraventriculartachycardia-15/NN||events-24/NNS	ranolazine-10||tachycardia--1||no_rel||in a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventriculartachycardia, ventriculartachycardia, new-onset atrialfibrillation, and bradycardic events.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||prevalence-10/NN||the-9/DT	dobj||evaluate-8/VB||prevalence-10/NN	prep_of||prevalence-10/NN||hivinfection-12/NN	amod||drivers-18/NNS||iranian-14/JJ	amod||drivers-18/NNS||long-15/JJ	nn||drivers-18/NNS||distance-16/NN	nn||drivers-18/NNS||truck-17/NN	prep_in||evaluate-8/VB||drivers-18/NNS	xcomp||evaluate-8/VB||using-19/VBG	amod||test-22/NN||rapid-20/JJ	nn||test-22/NN||hiv-21/NN	dobj||using-19/VBG||test-22/NN	hivinfection-12||hiv-21||no||the aim of this study was to evaluate the prevalence of hivinfection in iranian long distance truck drivers using rapid hiv test.
nsubj||spent-4/VBN||viruses-1/NNS	nsubj||have-17/VB||viruses-1/NNS	aux||spent-4/VBN||have-3/VBP	rcmod||viruses-1/NNS||spent-4/VBN	dobj||spent-4/VBN||most-5/JJS	poss||time-9/NN||their-7/PRP$	amod||time-9/NN||evolutionary-8/JJ	prep_of||most-5/JJS||time-9/NN	vmod||time-9/NN||associated-10/VBN	det||lineage-15/NN||a-12/DT	amod||lineage-15/NN||single-13/JJ	nn||lineage-15/NN||host-14/NN	prep_with||associated-10/VBN||lineage-15/NN	aux||have-17/VB||should-16/MD	root||ROOT-0/null||have-17/VB	dobj||have-17/VB||sequences-18/NNS	nsubj||reflect-20/VBP||sequences-18/NNS	rcmod||sequences-18/NNS||reflect-20/VBP	dobj||reflect-20/VBP||codivergence-21/NN	prep_of||codivergence-21/NN||virus-23/NN	prep_of||codivergence-21/NN||host-25/NN	conj_and||virus-23/NN||host-25/NN	virus-23||viruses-1||no||viruses that have spent most of their evolutionary time associated with a single host lineage should have sequences that reflect codivergence of virus and host.
amod||analyses-5/NNS||case-control-2/JJ	conj_and||case-control-2/JJ||case-series-4/JJ	amod||analyses-5/NNS||case-series-4/JJ	prep_in||examined-8/VBD||analyses-5/NNS	nsubj||examined-8/VBD||we-7/PRP	root||ROOT-0/null||examined-8/VBD	nn||concentrations-10/NNS||serum-9/NN	dobj||examined-8/VBD||concentrations-10/NNS	amod||25ohd-14/NNS||25-hydroxyvitamind-12/JJ	prep_of||concentrations-10/NNS||25ohd-14/NNS	prep_in||25ohd-14/NNS||relation-17/NN	nn||characteristics-22/NNS||breast-19/NN	nn||characteristics-22/NNS||cancer-20/NN	amod||characteristics-22/NNS||prognostic-21/JJ	prep_to||examined-8/VBD||characteristics-22/NNS	amod||grade-26/NN||histologic-25/JJ	prep_including||examined-8/VBD||grade-26/NN	nn||receptor-29/NN||estrogen-28/NN	appos||grade-26/NN||receptor-29/NN	appos||receptor-29/NN||er-31/NN	amod||subtypes-36/NNS||molecular-35/JJ	nsubj||enrolled-67/VBD||subtypes-36/NNS	vmod||subtypes-36/NNS||defined-37/VBN	agent||defined-37/VBN||er-39/NN	amod||pr-44/NN||progesterone-41/JJ	nn||pr-44/NN||receptor-42/NN	agent||defined-37/VBN||pr-44/NN	conj_and||er-39/NN||pr-44/NN	agent||defined-37/VBN||her2-47/NNS	conj_and||er-39/NN||her2-47/NNS	num||women-51/NNS||579-50/CD	prep_among||defined-37/VBN||women-51/NNS	nn||cancer-55/NN||incident-53/NN	nn||cancer-55/NN||breast-54/NN	prep_with||women-51/NNS||cancer-55/NN	num||controls-58/NNS||574-57/CD	prep_among||defined-37/VBN||controls-58/NNS	conj_and||women-51/NNS||controls-58/NNS	vmod||controls-58/NNS||matched-59/VBN	prep_on||matched-59/VBN||age-61/NN	prep_on||matched-59/VBN||time-63/NN	conj_and||age-61/NN||time-63/NN	nn||draw-66/NN||blood-65/NN	prep_of||age-61/NN||draw-66/NN	conj_and||examined-8/VBD||enrolled-67/VBD	det||institute-73/NN||the-69/DT	amod||institute-73/NN||roswell-70/JJ	nn||institute-73/NN||park-71/NN	nn||institute-73/NN||cancer-72/NN	prep_in||enrolled-67/VBD||institute-73/NN	num||2008-77/CD||2003-75/CD	dep||2008-77/CD||to-76/TO	prep_from||enrolled-67/VBD||2008-77/CD	progesterone-41||cancer-72||no_rel||in case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamind (25ohd) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (er), and molecular subtypes defined by er, progesterone receptor (pr) and her2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the roswell park cancer institute from 2003 to 2008.
nsubj||test-15/VBP||rhinoconjunctivitis-1/NNS	amod||symptoms-4/NNS||asthma-like-3/JJ	conj_and||rhinoconjunctivitis-1/NNS||symptoms-4/NNS	nsubj||test-15/VBP||symptoms-4/NNS	conj_and||rhinoconjunctivitis-1/NNS||fev1-6/NNS	nsubj||test-15/VBP||fev1-6/NNS	amod||challenge-11/NN||ar-8/JJ	amod||challenge-11/NN||post-methacholine-9/JJ	amod||challenge-11/NN||bronchial-10/JJ	conj_and||rhinoconjunctivitis-1/NNS||challenge-11/NN	nsubj||test-15/VBP||challenge-11/NN	appos||rhinoconjunctivitis-1/NNS||mbc-13/NN	root||ROOT-0/null||test-15/VBP	nn||measurements-19/NNS||results-16/NNS	conj_and||measurements-19/NNS||feno-18/NN	nsubjpass||investigated-24/VBN||feno-18/NN	nsubjpass||investigated-24/VBN||measurements-19/NNS	conj_and||measurements-19/NNS||ep-21/NN	nsubjpass||investigated-24/VBN||ep-21/NN	auxpass||investigated-24/VBN||were-22/VBD	advmod||investigated-24/VBN||all-23/RB	ccomp||test-15/VBP||investigated-24/VBN	amod||bakers-27/NNS||apprentice-26/JJ	prep_in||investigated-24/VBN||bakers-27/NNS	prep_in||investigated-24/VBN||pastry-makers-29/NNS	conj_and||bakers-27/NNS||pastry-makers-29/NNS	prep_in||investigated-24/VBN||hairdressers-31/NNS	conj_and||bakers-27/NNS||hairdressers-31/NNS	neg||suffering-33/VBG||not-32/RB	vmod||bakers-27/NNS||suffering-33/VBG	prep_from||suffering-33/VBG||asthma-35/NN	methacholine--1||asthma-35||no_rel||rhinoconjunctivitis, asthma-like symptoms, fev1 and ar post-methacholine bronchial challenge (mbc) test results, feno measurements and ep were all investigated in apprentice bakers, pastry-makers and hairdressers not suffering from asthma.
nsubjpass||related-7/VBN||myelitis-1/NNS	nsubj||responsive-15/JJ||myelitis-1/NNS	det||patients-4/NNS||these-3/DT	prep_in||myelitis-1/NNS||patients-4/NNS	auxpass||related-7/VBN||was-5/VBD	neg||related-7/VBN||not-6/RB	root||ROOT-0/null||related-7/VBN	amod||reconstitution-12/NN||graftversushostdisease-9/JJ	conj_or||graftversushostdisease-9/JJ||immune-11/JJ	amod||reconstitution-12/NN||immune-11/JJ	prep_to||related-7/VBN||reconstitution-12/NN	cop||responsive-15/JJ||was-14/VBD	conj_and||related-7/VBN||responsive-15/JJ	amod||methylprednisolone-18/NN||intravenous-17/JJ	prep_to||responsive-15/JJ||methylprednisolone-18/NN	prep_to||responsive-15/JJ||cyclophosphamide-20/NN	conj_and||methylprednisolone-18/NN||cyclophosphamide-20/NN	graftversushostdisease-9||methylprednisolone-18||yes||myelitis in these patients was not related to graftversushostdisease or immune reconstitution and was responsive to intravenous methylprednisolone and cyclophosphamide.
nsubj||common-7/JJ||vitamind-1/NN	amod||vitamind-1/NN||insufficiency-2/JJ	amod||vitamind-1/NN||hypovitaminosisd-4/JJ	conj_and||insufficiency-2/JJ||hypovitaminosisd-4/JJ	cop||common-7/JJ||are-5/VBP	advmod||common-7/JJ||extremely-6/RB	root||ROOT-0/null||common-7/JJ	amod||americans-10/NNS||arab-9/JJ	prep_among||common-7/JJ||americans-10/NNS	nsubjpass||associated-15/VBN||they-13/PRP	nsubj||glucoseintolerance-25/JJ||they-13/PRP	auxpass||associated-15/VBN||are-14/VBP	conj_and||common-7/JJ||associated-15/VBN	prep_with||associated-15/VBN||ir-17/NN	appos||ir-17/NN||components-19/NNS	det||ms-22/NN||the-21/DT	prep_of||components-19/NNS||ms-22/NN	conj_and||common-7/JJ||glucoseintolerance-25/JJ	conj_and||associated-15/VBN||glucoseintolerance-25/JJ	prep_in||glucoseintolerance-25/JJ||men-27/NNS	hypovitaminosisd-4||vitamind-1||yes||vitamind insufficiency and hypovitaminosisd are extremely common among arab americans, and they are associated with ir, components of the ms, and glucoseintolerance in men.
advmod||therapy-9/NN||therefore-1/RB	nsubj||therapy-9/NN||miglitol-3/NN	aux||therapy-9/NN||may-4/MD	cop||therapy-9/NN||be-5/VB	det||therapy-9/NN||a-6/DT	amod||adjuvant-8/JJ||useful-7/JJ	amod||therapy-9/NN||adjuvant-8/JJ	root||ROOT-0/null||therapy-9/NN	amod||patients-12/NNS||chinese-11/JJ	prep_for||therapy-9/NN||patients-12/NNS	prep_with||therapy-9/NN||type2diabetesmellitus-14/CD	advmod||controlled-16/JJ||inadequately-15/RB	amod||therapy-9/NN||controlled-16/JJ	nn||treatment-21/NN||diet-18/NN	conj_and||diet-18/NN||sulfonylurea-20/NN	nn||treatment-21/NN||sulfonylurea-20/NN	prep_by||therapy-9/NN||treatment-21/NN	type2diabetesmellitus-14||miglitol-3||yes||therefore, miglitol may be a useful adjuvant therapy for chinese patients with type2diabetesmellitus inadequately controlled by diet and sulfonylurea treatment.
mark||shown-6/VBN||although-1/IN	amod||reports-4/NNS||several-2/JJ	amod||reports-4/NNS||recent-3/JJ	nsubj||shown-6/VBN||reports-4/NNS	aux||shown-6/VBN||have-5/VBP	advcl||common-41/JJ||shown-6/VBN	mark||developed-13/VBD||that-7/IN	nn||carcinoma-9/NN||hepatocellular-8/NN	nsubj||developed-13/VBD||carcinoma-9/NN	appos||carcinoma-9/NN||hcc-11/NN	ccomp||shown-6/VBN||developed-13/VBD	prep_in||developed-13/VBD||patients-15/NNS	amod||response-27/NN||chronichepatitisc-17/JJ	dep||response-27/NN||ch-c-19/JJ	amod||response-27/NN||even-21/RB	prepc_after||even-21/RB||having-23/VBG	det||virological-26/NN||a-24/DT	amod||virological-26/NN||sustained-25/JJ	dobj||having-23/VBG||virological-26/NN	prep_with||patients-15/NNS||response-27/NN	appos||response-27/NN||svr-29/NN	nn||therapy-36/NN||interferon-32/NNP	appos||therapy-36/NN||ifn-34/NN	prep_to||developed-13/VBD||therapy-36/NN	nsubj||common-41/JJ||it-38/PRP	nsubj||develop-45/VB||it-38/PRP	cop||common-41/JJ||is-39/VBZ	neg||common-41/JJ||not-40/RB	root||ROOT-0/null||common-41/JJ	prep_for||common-41/JJ||hcc-43/NN	aux||develop-45/VB||to-44/TO	xcomp||common-41/JJ||develop-45/VB	mwe||than-47/IN||more-46/JJR	quantmod||10-48/CD||than-47/IN	num||years-49/NNS||10-48/CD	tmod||develop-45/VB||years-49/NNS	prep_after||develop-45/VB||svr-51/NN	chronichepatitisc-17||interferon-32||yes||although several recent reports have shown that hepatocellular carcinoma (hcc) developed in patients with chronichepatitisc (ch-c) even after having a sustained virological response (svr) to interferon (ifn) therapy, it is not common for hcc to develop more than 10 years after svr.
nn||mice-3/NNS||rictor-1/NN	nn||mice-3/NNS||null-2/NN	nsubj||exhibited-4/VBD||mice-3/NNS	root||ROOT-0/null||exhibited-4/VBD	amod||hyperglycemia-6/NN||mild-5/JJ	dobj||exhibited-4/VBD||hyperglycemia-6/NN	dobj||exhibited-4/VBD||glucoseintolerance-8/NN	conj_and||hyperglycemia-6/NN||glucoseintolerance-8/NN	vmod||hyperglycemia-6/NN||caused-9/VBN	det||reduction-12/NN||a-11/DT	agent||caused-9/VBN||reduction-12/NN	nn||²-15/NNS||î-14/NN	prep_in||reduction-12/NN||²-15/NNS	nn||mass-18/NN||cell-17/NN	dobj||exhibited-4/VBD||mass-18/NN	conj_and||hyperglycemia-6/NN||mass-18/NN	nn||²-21/NNS||î-20/NN	appos||mass-18/NN||²-21/NNS	nn||proliferation-24/NN||cell-23/NN	dobj||exhibited-4/VBD||proliferation-24/NN	conj_and||hyperglycemia-6/NN||proliferation-24/NN	amod||content-28/NN||pancreatic-26/JJ	nn||content-28/NN||insulin-27/NN	appos||proliferation-24/NN||content-28/NN	amod||secretion-33/NN||glucose-stimulated-31/JJ	nn||secretion-33/NN||insulin-32/NN	dobj||exhibited-4/VBD||secretion-33/NN	conj_and||hyperglycemia-6/NN||secretion-33/NN	hyperglycemia-6||glucose--1||no||rictor null mice exhibited mild hyperglycemia and glucoseintolerance caused by a reduction in î²-cell mass, î²-cell proliferation, pancreatic insulin content, and glucose-stimulated insulin secretion.
nsubjpass||obtained-3/VBN||serum-1/NN	auxpass||obtained-3/VBN||was-2/VBD	root||ROOT-0/null||obtained-3/VBN	amod||intervals-6/NNS||weekly-5/JJ	prep_at||obtained-3/VBN||intervals-6/NNS	nn||samples-9/NNS||tissue-8/NN	nsubjpass||obtained-11/VBN||samples-9/NNS	auxpass||obtained-11/VBN||were-10/VBD	conj_and||obtained-3/VBN||obtained-11/VBN	det||end-14/NN||the-13/DT	prep_at||obtained-11/VBN||end-14/NN	prep_of||end-14/NN||supplementation-16/NN	aux||evaluate-20/VB||to-17/TO	dep||evaluate-20/VB||1-18/LS	vmod||end-14/NN||evaluate-20/VB	dobj||evaluate-20/VB||tocopherol-21/NN	xcomp||evaluate-20/VB||concentrations-22/VBG	prep_in||concentrations-22/VBG||serum-24/NN	prep_in||concentrations-22/VBG||uterus-26/NN	conj_and||serum-24/NN||uterus-26/NN	prep_in||concentrations-22/VBG||placentome-28/NN	conj_and||serum-24/NN||placentome-28/NN	dep||expressions-35/NNS||2-30/LS	amod||expressions-35/NNS||evaluate-32/JJ	amod||expressions-35/NNS||relative-33/JJ	nn||expressions-35/NNS||mrna-34/NN	dep||end-14/NN||expressions-35/NNS	amod||factor-40/NN||vascular-37/JJ	amod||factor-40/NN||endothelial-38/JJ	nn||factor-40/NN||growth-39/NN	prep_of||expressions-35/NNS||factor-40/NN	appos||factor-40/NN||vegf-42/NN	amod||factor-47/NN||placental-45/JJ	nn||factor-47/NN||growth-46/NN	appos||factor-40/NN||factor-47/NN	appos||factor-47/NN||plgf-49/NN	amod||synthase-54/NN||endothelial-52/JJ	nn||synthase-54/NN||nitricoxide-53/NN	appos||factor-40/NN||synthase-54/NN	dep||synthase-54/NN||enos-56/VBZ	nn||factors-61/NNS||hypoxia-59/NN	nn||factors-61/NNS||inducible-60/NN	prep_of||expressions-35/NNS||factors-61/NNS	conj_and||factor-40/NN||factors-61/NNS	appos||factors-61/NNS||hif-63/NN	prep_in||factors-61/NNS||uterus-66/NN	prep_in||factors-61/NNS||caruncle-68/NN	conj_and||uterus-66/NN||caruncle-68/NN	prep_in||factors-61/NNS||cotyledon-70/NN	conj_and||uterus-66/NN||cotyledon-70/NN	dep||morphometry-76/NN||3-72/LS	advmod||morphometry-76/NN||analyze-74/RB	det||morphometry-76/NN||the-75/DT	dep||end-14/NN||morphometry-76/NN	det||network-81/NN||the-78/DT	amod||network-81/NN||placental-79/JJ	nn||network-81/NN||vascular-80/NN	prep_of||morphometry-76/NN||network-81/NN	hypoxia-59||nitricoxide-53||no_rel||serum was obtained at weekly intervals and tissue samples were obtained at the end of supplementation to 1) evaluate tocopherol concentrations in serum, uterus and placentome; 2) evaluate relative mrna expressions of vascular endothelial growth factor (vegf), placental growth factor (plgf), endothelial nitricoxide synthase (enos) and hypoxia inducible factors (hif) in uterus, caruncle and cotyledon; 3) analyze the morphometry of the placental vascular network.
det||study-2/NN||this-1/DT	nsubj||suggests-3/VBZ||study-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||maintained-16/VBN||that-4/IN	det||proportion-6/NN||a-5/DT	nsubjpass||maintained-16/VBN||proportion-6/NN	amod||patients-9/NNS||adolescent-8/JJ	prep_of||proportion-6/NN||patients-9/NNS	vmod||patients-9/NNS||diagnosed-10/VBN	prep_with||diagnosed-10/VBN||bipolardisorder-12/NN	aux||maintained-16/VBN||can-13/MD	auxpass||maintained-16/VBN||be-14/VB	advmod||maintained-16/VBN||successfully-15/RB	ccomp||suggests-3/VBZ||maintained-16/VBN	amod||monotherapy-19/NN||quetiapine-18/JJ	prep_on||maintained-16/VBN||monotherapy-19/NN	bipolardisorder-12||quetiapine-18||yes||this study suggests that a proportion of adolescent patients diagnosed with bipolardisorder can be successfully maintained on quetiapine monotherapy.
nsubj||compared-3/VBD||we-1/PRP	advmod||compared-3/VBD||retrospectively-2/RB	root||ROOT-0/null||compared-3/VBD	dobj||compared-3/VBD||outcomes-4/NNS	det||series-8/NN||a-6/DT	amod||series-8/NN||consecutive-7/JJ	prep_of||outcomes-4/NNS||series-8/NN	num||patients-12/NNS||51-10/CD	nn||patients-12/NNS||aml-11/NN	prep_of||series-8/NN||patients-12/NNS	vmod||patients-12/NNS||treated-13/VBN	amod||busulfan-16/NN||oral-15/JJ	prep_with||treated-13/VBN||busulfan-16/NN	num||hours-22/NNS||1-18/CD	amod||hours-22/NNS||mg/kg-19/JJ	quantmod||6-21/CD||every-20/DT	num||hours-22/NNS||6-21/CD	dep||busulfan-16/NN||hours-22/NNS	num||days-25/NNS||4-24/CD	prep_for||hours-22/NNS||days-25/NNS	prep_with||treated-13/VBN||cyclophosphamide-28/NN	conj_and||busulfan-16/NN||cyclophosphamide-28/NN	num||ã-33/NN||60-30/CD	amod||ã-33/NN||mg/kg-31/JJ	nn||ã-33/NN||iv-32/NN	dep||busulfan-16/NN||ã-33/NN	num||days-36/NNS||2-35/CD	dep||ã-33/NN||days-36/NNS	dep||series-8/NN||bu/cy-40/NN	num||patients-46/NNS||100-43/CD	amod||patients-46/NNS||consecutive-44/JJ	nn||patients-46/NNS||aml-45/NN	prep_with||bu/cy-40/NN||patients-46/NNS	vmod||bu/cy-40/NN||treated-47/VBN	amod||busulfan-52/NN||pharmacokinetic-49/JJ	amod||busulfan-52/NN||targeted-50/JJ	nn||busulfan-52/NN||iv-51/NN	prep_with||treated-47/VBN||busulfan-52/NN	nn||min-61/NNP||auc-54/NN	num||min-61/NNP||<-55/CD	num||min-61/NNP||6000-56/CD	num||min-61/NNP||î-57/CD	num||min-61/NNP||1/4-58/CD	nn||min-61/NNP||m/l-59/NNP	nn||min-61/NNP||*-60/NNP	dep||busulfan-52/NN||min-61/NNP	nn||ã-64/NN||day-63/NN	prep_per||min-61/NNP||ã-64/NN	num||days-67/NNS||4-66/CD	dep||ã-64/NN||days-67/NNS	prep_with||treated-47/VBN||fludarabine-70/NN	conj_and||busulfan-52/NN||fludarabine-70/NN	num||ã-74/NN||40-72/CD	amod||ã-74/NN||mg/m2-73/JJ	dep||busulfan-52/NN||ã-74/NN	num||days-77/NNS||4-76/CD	dep||ã-74/NN||days-77/NNS	amod||bu/flu-82/JJ||t-iv-81/JJ	dep||series-8/NN||bu/flu-82/JJ	aml-45||cyclophosphamide-28||yes||we retrospectively compared outcomes of a consecutive series of 51 aml patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg iv ã— 2 days) - (bu/cy) with 100 consecutive aml patients treated with pharmacokinetic targeted iv busulfan (auc < 6000 î¼m/l*min per day ã— 4 days) and fludarabine (40 mg/m2 ã— 4 days) - (t-iv bu/flu).
poss||objectives-2/NNS||our-1/PRP$	nsubj||were-3/VBD||objectives-2/NNS	root||ROOT-0/null||were-3/VBD	aux||describe-5/VB||to-4/TO	ccomp||were-3/VBD||describe-5/VB	det||arboviruses-7/NNS||the-6/DT	dobj||describe-5/VB||arboviruses-7/NNS	vmod||arboviruses-7/NNS||associated-8/VBN	amod||illness-13/NN||acute-10/JJ	amod||illness-13/NN||undifferentiated-11/JJ	nn||illness-13/NN||febrile-12/NN	prep_with||associated-8/VBN||illness-13/NN	prepc_in||illness-13/NN||participating-15/VBG	dobj||participating-15/VBG||clinics-16/NNS	num||countries-19/NNS||four-18/CD	prep_in||participating-15/VBG||countries-19/NNS	amod||america-22/NN||south-21/JJ	prep_in||countries-19/NNS||america-22/NN	aux||provide-25/VB||to-24/TO	ccomp||were-3/VBD||provide-25/VB	conj_and||describe-5/VB||provide-25/VB	amod||analysis-28/NN||detailed-26/JJ	amod||analysis-28/NN||epidemiological-27/JJ	dobj||provide-25/VB||analysis-28/NN	prep_of||analysis-28/NN||arbovirusinfection-30/NN	prep_in||provide-25/VB||iquitos-32/NNS	acomp||provide-25/VB||peru-34/JJ	advmod||conducted-41/VBN||where-36/WRB	advmod||extensive-38/JJ||more-37/RBR	amod||monitoring-39/NN||extensive-38/JJ	nsubjpass||conducted-41/VBN||monitoring-39/NN	auxpass||conducted-41/VBN||was-40/VBD	advcl||provide-25/VB||conducted-41/VBN	arbovirusinfection-30||arboviruses-7||no||our objectives were to describe the arboviruses associated with acute undifferentiated febrile illness in participating clinics in four countries in south america and to provide detailed epidemiological analysis of arbovirusinfection in iquitos, peru, where more extensive monitoring was conducted.
det||study-4/NN||the-2/DT	amod||study-4/NN||latter-3/JJ	prep_in||were-7/VBD||study-4/NN	expl||were-7/VBD||there-6/EX	root||ROOT-0/null||were-7/VBD	num||predictions-9/NNS||25-8/CD	nsubj||were-7/VBD||predictions-9/NNS	prep_of||predictions-9/NNS||hypoglycemia-11/NN	mark||had-15/VBD||because-12/IN	det||subjects-14/NNS||some-13/DT	nsubj||had-15/VBD||subjects-14/NNS	advcl||were-7/VBD||had-15/VBD	amod||events-18/NNS||multiple-16/JJ	amod||events-18/NNS||hypoglycemic-17/JJ	dobj||had-15/VBD||events-18/NNS	det||night-21/NN||a-20/DT	prep_during||events-18/NNS||night-21/NN	nsubjpass||prevented-26/VBN||hypoglycemia-24/NN	auxpass||prevented-26/VBN||was-25/VBD	conj_and||were-7/VBD||prevented-26/VBN	num||%-29/NN||84-28/CD	prep_for||prevented-26/VBN||%-29/NN	det||events-32/NNS||these-31/DT	prep_of||%-29/NN||events-32/NNS	hypoglycemic-17||hypoglycemia-24||no_rel||in the latter study, there were 25 predictions of hypoglycemia because some subjects had multiple hypoglycemic events during a night, and hypoglycemia was prevented for 84% of these events.
nsubj||one-3/CD||species-specificity-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||characteristics-7/NNS||the-5/DT	amod||characteristics-7/NNS||major-6/JJ	prep_of||one-3/CD||characteristics-7/NNS	prep_of||characteristics-7/NNS||cytomegaloviruses-9/NNS	appos||cytomegaloviruses-9/NNS||cmvs-11/NNS	cop||reason-17/NN||is-14/VBZ	det||reason-17/NN||the-15/DT	amod||reason-17/NN||primary-16/JJ	conj_and||one-3/CD||reason-17/NN	det||lack-20/NN||the-19/DT	prep_for||reason-17/NN||lack-20/NN	det||model-24/NN||a-22/DT	nn||model-24/NN||mouse-23/NN	prep_of||lack-20/NN||model-24/NN	det||infection-28/NN||the-26/DT	amod||infection-28/NN||direct-27/JJ	prep_for||model-24/NN||infection-28/NN	amod||cmv-31/NN||human-30/JJ	prep_of||infection-28/NN||cmv-31/NN	appos||cmv-31/NN||hcmv-33/NNP	cmv-31||cytomegaloviruses-9||no||species-specificity is one of the major characteristics of cytomegaloviruses (cmvs) and is the primary reason for the lack of a mouse model for the direct infection of human cmv (hcmv).
nsubjpass||classified-7/VBN||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	aux||classified-7/VBN||can-5/MD	auxpass||classified-7/VBN||be-6/VB	root||ROOT-0/null||classified-7/VBN	num||genotypes-10/NNS||nine-9/CD	prep_into||classified-7/VBN||genotypes-10/NNS	appos||genotypes-10/NNS||a-i-12/NNP	vmod||genotypes-10/NNS||defined-14/VBN	nn||divergence-17/NN||sequence-16/NN	agent||defined-14/VBN||divergence-17/NN	mwe||than-20/IN||more-19/JJR	quantmod||8-21/CD||than-20/IN	num||%-22/NN||8-21/CD	prep_of||divergence-17/NN||%-22/NN	prepc_based_on||defined-14/VBN||on-24/IN	det||genome-27/NN||the-25/DT	amod||genome-27/NN||complete-26/JJ	pobj||defined-14/VBN||genome-27/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) can be classified into nine genotypes (a-i) defined by sequence divergence of more than 8% based on the complete genome.
aux||study-2/VB||to-1/TO	csubj||refractory-14/VBD||study-2/VB	det||efficacy-4/NN||the-3/DT	dobj||study-2/VB||efficacy-4/NN	amod||patients-13/NNS||rituximab-6/JJ	amod||rheumatoidarthritis-9/NNS||active-8/JJ	prep_in||rituximab-6/JJ||rheumatoidarthritis-9/NNS	appos||patients-13/NNS||ra-11/NN	prep_of||efficacy-4/NN||patients-13/NNS	root||ROOT-0/null||refractory-14/VBD	prep_to||refractory-14/VBD||disease-16/NN	xcomp||refractory-14/VBD||modifying-17/VBG	amod||dmards-20/NNS||anti-rheumaticdrugs-18/JJ	dobj||modifying-17/VBG||dmards-20/NNS	det||factor-26/NN||the-23/DT	nn||factor-26/NN||tumor-24/NN	nn||factor-26/NN||necrosis-25/NNS	prep_including||dmards-20/NNS||factor-26/NN	appos||factor-26/NN||tnf-28/NN	nn||antagonists-33/NNS||î-31/NN	nn||antagonists-33/NNS||±-32/NN	dep||factor-26/NN||antagonists-33/NNS	anti-rheumaticdrugs-18||rheumatoidarthritis-9||no_rel||to study the efficacy of rituximab in active rheumatoidarthritis (ra) patients refractory to disease modifying anti-rheumaticdrugs (dmards) including the tumor necrosis factor (tnf)-î± antagonists.
mark||lowered-6/VBD||as-1/IN	amod||over-expression-3/NN||hepatic-2/JJ	nsubj||lowered-6/VBD||over-expression-3/NN	prep_of||over-expression-3/NN||cry-5/NN	advcl||suggest-21/VBP||lowered-6/VBD	amod||concentrations-8/NNS||bloodglucose-7/JJ	dobj||lowered-6/VBD||concentrations-8/NNS	amod||sensitivity-12/NN||improved-10/VBN	nn||sensitivity-12/NN||insulin-11/NN	dobj||lowered-6/VBD||sensitivity-12/NN	conj_and||concentrations-8/NNS||sensitivity-12/NN	nn||mice-17/NNS||insulin-14/NN	amod||mice-17/NNS||resistant-15/JJ	nn||mice-17/NNS||db/db-16/NN	prep_in||sensitivity-12/NN||mice-17/NNS	poss||results-20/NNS||our-19/PRP$	nsubj||suggest-21/VBP||results-20/NNS	root||ROOT-0/null||suggest-21/VBP	mark||provide-29/VB||that-22/IN	nsubj||enhance-25/VB||compounds-23/NNS	nsubj||provide-29/VB||compounds-23/NNS	rcmod||compounds-23/NNS||enhance-25/VB	nn||activity-27/NN||cry-26/NN	dobj||enhance-25/VB||activity-27/NN	aux||provide-29/VB||may-28/MD	ccomp||suggest-21/VBP||provide-29/VB	amod||benefit-31/NN||therapeutic-30/JJ	dobj||provide-29/VB||benefit-31/NN	prep_to||provide-29/VB||individuals-33/NNS	prep_with||individuals-33/NNS||typeiidiabetes-35/NNS	typeiidiabetes-35||insulin-14||yes||as hepatic over-expression of cry lowered bloodglucose concentrations and improved insulin sensitivity in insulin resistant db/db mice, our results suggest that compounds which enhance cry activity may provide therapeutic benefit to individuals with typeiidiabetes.
det||objectives-2/NNS||the-1/DT	nsubj||were-6/VBD||objectives-2/NNS	nsubj||determine-8/VB||objectives-2/NNS	det||study-5/NN||the-4/DT	prep_of||objectives-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||were-6/VBD||determine-8/VB	det||correlation-10/NN||the-9/DT	dobj||determine-8/VB||correlation-10/NN	nn||co2-14/NNS||end-12/NN	amod||co2-14/NNS||tidal-13/JJ	prep_between||correlation-10/NN||co2-14/NNS	prep_between||correlation-10/NN||paco2-16/NNS	conj_and||co2-14/NNS||paco2-16/NNS	amod||patients-21/NNS||non-intubated-18/JJ	advmod||breathless-20/JJ||acutely-19/RB	amod||patients-21/NNS||breathless-20/JJ	prep_in||co2-14/NNS||patients-21/NNS	breathless-20||co2-14||no||the objectives of the study were to determine the correlation between end tidal co2 and paco2 in non-intubated acutely breathless patients.
nsubj||food-5/NN||montelukast-1/NN	nsubj||has-14/VBZ||montelukast-1/NN	cop||food-5/NN||is-2/VBZ	dep||food-5/NN||a-3/DT	dep||food-5/NN||us-4/PRP	root||ROOT-0/null||food-5/NN	nn||asthma-9/NN||drug-7/NN	nn||asthma-9/NN||administration-approved-8/NN	conj_and||food-5/NN||asthma-9/NN	nn||controller-12/NN||eib-11/NN	conj_and||food-5/NN||controller-12/NN	conj_and||asthma-9/NN||controller-12/NN	conj_and||food-5/NN||has-14/VBZ	det||number-16/NN||a-15/DT	dobj||has-14/VBZ||number-16/NN	amod||advantages-19/NNS||potential-18/JJ	prep_of||number-16/NN||advantages-19/NNS	amod||medications-23/NNS||other-21/JJ	nn||medications-23/NNS||asthma-22/NN	prep_to||advantages-19/NNS||medications-23/NNS	amod||onset-26/NN||short-25/JJ	prep_including||medications-23/NNS||onset-26/NN	prep_of||onset-26/NN||action-28/NN	prep_including||medications-23/NNS||ease-30/NN	conj_and||onset-26/NN||ease-30/NN	prep_of||ease-30/NN||use-32/NN	prep_including||medications-23/NNS||lack-35/NN	conj_and||onset-26/NN||lack-35/NN	prep_of||lack-35/NN||tolerance-37/NN	asthma-22||montelukast-1||yes||montelukast is a us food and drug administration-approved asthma and eib controller and has a number of potential advantages to other asthma medications including short onset of action, ease of use, and lack of tolerance.
vmod||experience-12/VBP||living-1/VBG	det||depth-4/NN||a-3/DT	prep_at||living-1/VBG||depth-4/NN	quantmod||2500-7/CD||approximately-6/RB	num||meters-8/NNS||2500-7/CD	prep_of||depth-4/NN||meters-8/NNS	det||worms-11/NNS||these-10/DT	nsubj||experience-12/VBP||worms-11/NNS	root||ROOT-0/null||experience-12/VBP	amod||conditions-15/NNS||extreme-13/JJ	amod||conditions-15/NNS||environmental-14/JJ	dobj||experience-12/VBP||conditions-15/NNS	amod||temperature-19/NN||high-18/JJ	prep_including||conditions-15/NNS||temperature-19/NN	prep_including||conditions-15/NNS||pressure-21/NN	conj_and||temperature-19/NN||pressure-21/NN	amod||levels-26/NNS||high-25/JJ	dobj||experience-12/VBP||levels-26/NNS	conj_and||conditions-15/NNS||levels-26/NNS	prep_of||levels-26/NNS||sulfide-28/NN	prep_of||levels-26/NNS||heavymetals-30/NNS	conj_and||sulfide-28/NN||heavymetals-30/NNS	heavymetals-30||worms-11||no_rel||living at a depth of approximately 2500 meters, these worms experience extreme environmental conditions, including high temperature and pressure as well as high levels of sulfide and heavymetals.
prep_in||treated-11/VBD||fact-2/NN	det||risk-5/NN||the-4/DT	nsubj||treated-11/VBD||risk-5/NN	prep_of||risk-5/NN||myocardialinfarction-7/NN	det||statin-10/NN||these-9/DT	prep_in||myocardialinfarction-7/NN||statin-10/NN	root||ROOT-0/null||treated-11/VBD	nsubj||greater-16/JJR||patients-12/NNS	cop||greater-16/JJR||was-13/VBD	neg||greater-16/JJR||not-14/RB	advmod||greater-16/JJR||significantly-15/RB	ccomp||treated-11/VBD||greater-16/JJR	prep_than||greater-16/JJR||that-18/DT	det||sample-22/NN||an-20/DT	amod||sample-22/NN||age-matched-21/JJ	prep_in||that-18/DT||sample-22/NN	det||population-26/NN||the-24/DT	amod||population-26/NN||general-25/JJ	prep_from||sample-22/NN||population-26/NN	dep||sample-22/NN||hazard-28/NN	vmod||hazard-28/NN||ration-29/VBN	dobj||ration-29/VBN||1.44-30/CD	number||2.60-34/CD||0.80-32/CD	dep||2.60-34/CD||to-33/TO	dep||1.44-30/CD||2.60-34/CD	vmod||1.44-30/CD||p-37/VBN	dep||0.23-39/CD||=-38/SYM	ccomp||p-37/VBN||0.23-39/CD	myocardialinfarction-7||statin-10||no_rel||in fact, the risk of myocardialinfarction in these statin treated patients was not significantly greater than that in an age-matched sample from the general population (hazard ration 1.44 (0.80 to 2.60), p=0.23).
nn||propofol-2/NN||microemulsion-1/NN	nsubjpass||developed-4/VBN||propofol-2/NN	nsubj||avoid-6/VB||propofol-2/NN	auxpass||developed-4/VBN||was-3/VBD	root||ROOT-0/null||developed-4/VBN	aux||avoid-6/VB||to-5/TO	xcomp||developed-4/VBN||avoid-6/VB	det||effects-9/NNS||these-7/DT	nn||effects-9/NNS||side-8/NN	dobj||avoid-6/VB||effects-9/NNS	nsubj||is-18/VBZ||incidence-11/NN	conj_and||incidence-11/NN||severity-13/NN	nsubj||is-18/VBZ||severity-13/NN	prep_of||incidence-11/NN||pain-15/NN	prep_on||pain-15/NN||injection-17/NN	conj_but||developed-4/VBN||is-18/VBZ	dep||than-20/IN||higher-19/JJR	advmod||is-18/VBZ||than-20/IN	nn||propofol-24/NN||lipid-22/NN	nn||propofol-24/NN||emulsion-23/NN	prep_with||is-18/VBZ||propofol-24/NN	pain-15||propofol-24||yes||microemulsion propofol was developed to avoid these side effects but incidence and severity of pain on injection is higher than with lipid emulsion propofol.
det||mismatch-3/NN||an-1/DT	amod||mismatch-3/NN||allotype-2/JJ	nsubj||lead-13/VB||mismatch-3/NN	prep_between||mismatch-3/NN||adalimumab-5/NN	prep_between||mismatch-3/NN||igg-7/NN	conj_and||adalimumab-5/NN||igg-7/NN	amod||patients-10/NNS||adalimumab-treated-9/JJ	prep_in||adalimumab-5/NN||patients-10/NNS	aux||lead-13/VB||did-11/VBD	neg||lead-13/VB||not-12/RB	root||ROOT-0/null||lead-13/VB	det||frequency-17/NN||a-15/DT	amod||frequency-17/NN||higher-16/JJR	prep_to||lead-13/VB||frequency-17/NN	prep_of||frequency-17/NN||aaa-19/NN	aaa-19||adalimumab-5||no_rel||an allotype mismatch between adalimumab and igg in adalimumab-treated patients did not lead to a higher frequency of aaa.
nsubj||mg-8/VBP||dabigatran-1/NN	prep||dabigatran-1/NN||given-2/VBN	pcomp||given-2/VBN||at-3/IN	det||dose-5/NN||a-4/DT	pobj||at-3/IN||dose-5/NN	prep_of||dose-5/NN||150-7/CD	root||ROOT-0/null||mg-8/VBP	advmod||mg-8/VBP||twice-9/RB	advmod||mg-8/VBP||daily-10/RB	mark||associated-18/VBN||as-12/IN	prepc_compared_with||associated-18/VBN||with-14/IN	pobj||associated-18/VBN||warfarin-15/NN	auxpass||associated-18/VBN||was-17/VBD	advcl||mg-8/VBP||associated-18/VBN	amod||rates-21/NNS||lower-20/JJR	prep_with||associated-18/VBN||rates-21/NNS	prep_of||rates-21/NNS||stroke-23/NN	amod||embolism-26/NN||systemic-25/JJ	prep_with||associated-18/VBN||embolism-26/NN	conj_and||rates-21/NNS||embolism-26/NN	prep||embolism-26/NN||but-27/CC	amod||rates-29/NNS||similar-28/JJ	pobj||but-27/CC||rates-29/NNS	amod||hemorrhage-32/NN||major-31/JJ	prep_of||rates-29/NNS||hemorrhage-32/NN	stroke-23||warfarin-15||yes||dabigatran given at a dose of 150 mg twice daily, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.
amod||genes-10/NNS||polymorphisms-1/JJ	det||iron-8/NN||the-3/DT	amod||iron-8/NN||hemochromatosis-4/JJ	appos||iron-8/NN||hfe-6/NN	prep_in||polymorphisms-1/JJ||iron-8/NN	amod||genes-10/NNS||regulatory-9/JJ	nsubjpass||shown-13/VBN||genes-10/NNS	nsubj||modify-15/VB||genes-10/NNS	aux||shown-13/VBN||have-11/VBP	auxpass||shown-13/VBN||been-12/VBN	root||ROOT-0/null||shown-13/VBN	aux||modify-15/VB||to-14/TO	xcomp||shown-13/VBN||modify-15/VB	dobj||modify-15/VB||transport-16/NN	nsubjpass||known-23/VBN||transport-16/NN	nsubj||affect-25/VB||transport-16/NN	dobj||modify-15/VB||toxicity-18/NN	conj_and||transport-16/NN||toxicity-18/NN	nsubjpass||known-23/VBN||toxicity-18/NN	nsubj||affect-25/VB||toxicity-18/NN	prep_of||transport-16/NN||lead-20/NN	auxpass||known-23/VBN||is-22/VBZ	rcmod||transport-16/NN||known-23/VBN	aux||affect-25/VB||to-24/TO	xcomp||known-23/VBN||affect-25/VB	nn||weight-27/NN||birth-26/NN	dobj||affect-25/VB||weight-27/NN	hemochromatosis-4||iron-8||no||polymorphisms in the hemochromatosis ( hfe ) iron regulatory genes have been shown to modify transport and toxicity of lead which is known to affect birth weight.
mark||related-8/VBN||although-1/IN	det||presence-3/NN||the-2/DT	nsubjpass||related-8/VBN||presence-3/NN	prep_of||presence-3/NN||viremia-5/NN	auxpass||related-8/VBN||was-6/VBD	neg||related-8/VBN||not-7/RB	advcl||play-16/VB||related-8/VBN	amod||responses-12/NNS||hbv-specific-10/JJ	amod||responses-12/NNS||t-cell-11/JJ	prep_to||related-8/VBN||responses-12/NNS	nsubj||play-16/VB||ctls-14/NNS	aux||play-16/VB||might-15/MD	root||ROOT-0/null||play-16/VB	det||role-18/NN||a-17/DT	dobj||play-16/VB||role-18/NN	det||control-21/NN||the-20/DT	prep_in||role-18/NN||control-21/NN	nn||infection-24/NN||hbv-23/NN	prep_of||control-21/NN||infection-24/NN	prep_in||play-16/VB||children-26/NNS	vmod||children-26/NNS||born-27/VBN	amod||mothers-30/NNS||hbsag-positive-29/JJ	prep_to||born-27/VBN||mothers-30/NNS	amod||treatment-33/NN||immunoprophylactic-32/JJ	prep_after||born-27/VBN||treatment-33/NN	hbv-23||hbsag--1||yes||although the presence of viremia was not related to hbv-specific t-cell responses, ctls might play a role in the control of hbv infection in children born to hbsag-positive mothers after immunoprophylactic treatment.
nsubj||concern-5/NN||hiv/aids-1/NNS	cop||concern-5/NN||is-2/VBZ	det||concern-5/NN||a-3/DT	amod||concern-5/NN||critical-4/JJ	root||ROOT-0/null||concern-5/NN	amod||africa-8/NN||south-7/JJ	prep_in||concern-5/NN||africa-8/NN	advmod||determinants-18/NNS||where-10/WRB	amod||poverty-12/NN||extreme-11/JJ	nsubj||determinants-18/NNS||poverty-12/NN	nn||issues-15/NNS||gender-14/NN	conj_and||poverty-12/NN||issues-15/NNS	nsubj||determinants-18/NNS||issues-15/NNS	cop||determinants-18/NNS||are-16/VBP	amod||determinants-18/NNS||major-17/JJ	rcmod||africa-8/NN||determinants-18/NNS	prep_of||determinants-18/NNS||health-20/NN	aids--1||hiv--1||no||hiv/aids is a critical concern in south africa, where extreme poverty and gender issues are major determinants of health.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||investigate-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||relationship-10/NN||the-9/DT	dobj||investigate-8/VB||relationship-10/NN	prep_between||relationship-10/NN||a2ars-12/CD	det||system-16/NN||the-14/DT	amod||system-16/NN||dopaminergic-15/JJ	dobj||investigate-8/VB||system-16/NN	conj_and||relationship-10/NN||system-16/NN	det||striata-19/NN||the-18/DT	prep_in||system-16/NN||striata-19/NN	amod||patients-25/NNS||drug-naã-21/JJ	nn||patients-25/NNS||¯-22/NNP	nn||patients-25/NNS||ve-23/NN	nn||patients-25/NNS||pd-24/NN	prep_of||striata-19/NN||patients-25/NNS	nn||patients-28/NNS||pd-27/NN	prep_of||striata-19/NN||patients-28/NNS	conj_and||patients-25/NNS||patients-28/NNS	prep_with||system-16/NN||dyskinesia-30/NN	dobj||investigate-8/VB||alteration-33/NN	conj_and||relationship-10/NN||alteration-33/NN	det||receptors-36/NNS||these-35/DT	prep_of||alteration-33/NN||receptors-36/NNS	nn||therapy-39/NN||antiparkinsonian-38/NN	prep_after||investigate-8/VB||therapy-39/NN	dyskinesia-30||antiparkinsonian-38||no_rel||the purpose of this study was to investigate the relationship between a2ars and the dopaminergic system in the striata of drug-naã¯ve pd patients and pd patients with dyskinesia, and alteration of these receptors after antiparkinsonian therapy.
nn||analysis-2/NN||retrospective-1/NN	root||ROOT-0/null||analysis-2/NN	amod||outcomes-5/NNS||clinical-4/JJ	prep_of||analysis-2/NN||outcomes-5/NNS	dep||analysis-2/NN||in-6/IN	nsubj||attending-8/VBG||patients-7/NNS	pcomp||in-6/IN||attending-8/VBG	det||clinic-12/NN||an-9/DT	amod||clinic-12/NN||interventional-10/JJ	nn||clinic-12/NN||pain-11/NN	dobj||attending-8/VBG||clinic-12/NN	number||hundred-14/CD||one-13/CD	dep||clinic-12/NN||hundred-14/CD	amod||patients-18/NNS||ninety-four-16/JJ	amod||patients-18/NNS||consecutive-17/JJ	dobj||attending-8/VBG||patients-18/NNS	conj_and||clinic-12/NN||patients-18/NNS	prep_with||patients-18/NNS||neuropathicpain-20/NN	amod||neuropathicpain-20/NN||secondary-21/JJ	amod||imaging-25/NN||magnetic-23/JJ	nn||imaging-25/NN||resonance-24/NN	prep_to||attending-8/VBG||imaging-25/NN	dep||analysis-2/NN||mri-27/NN	amod||compression-31/NN||documented-30/VBN	nsubj||received-33/VBD||compression-31/NN	advmod||received-33/VBD||radiculopathy-32/RB	parataxis||analysis-2/NN||received-33/VBD	det||lyrica-35/NN||either-34/DT	nsubj||respectively-63/RB||lyrica-35/NN	appos||lyrica-35/NN||lyr-37/NN	det||brand-44/NN||a-40/DT	advmod||available-42/JJ||locally-41/RB	amod||brand-44/NN||available-42/JJ	amod||brand-44/NN||generic-43/JJ	appos||lyrica-35/NN||brand-44/NN	prep_of||brand-44/NN||pregabalin-46/NN	appos||pregabalin-46/NN||pgn-48/NN	det||brand-56/NN||a-52/DT	advmod||available-54/JJ||locally-53/RB	amod||brand-56/NN||available-54/JJ	amod||brand-56/NN||generic-55/JJ	prep_of||brand-44/NN||brand-56/NN	conj_or||pregabalin-46/NN||brand-56/NN	prep_of||brand-56/NN||gabapentin-58/NN	appos||gabapentin-58/NN||gbn-60/NN	xcomp||received-33/VBD||respectively-63/RB	pain-11||gabapentin-58||yes||retrospective analysis of clinical outcomes in patients attending an interventional pain clinic one hundred and ninety-four consecutive patients with neuropathicpain secondary to magnetic resonance imaging (mri)-documented compression radiculopathy received either lyrica (lyr), a locally available generic brand of pregabalin (pgn), or a locally available generic brand of gabapentin (gbn), respectively.
nsubj||agents-13/NNS||dengueviruses-1/NNS	amod||members-4/NNS||mosquito-borne-3/JJ	appos||dengueviruses-1/NNS||members-4/NNS	det||family-8/NN||the-6/DT	amod||family-8/NN||flaviviridae-7/JJ	prep_of||members-4/NNS||family-8/NN	cop||agents-13/NNS||are-10/VBP	det||agents-13/NNS||the-11/DT	amod||agents-13/NNS||causative-12/JJ	root||ROOT-0/null||agents-13/NNS	prep_of||agents-13/NNS||denguefever-15/NN	poss||complications-19/NNS||its-17/PRP$	amod||complications-19/NNS||associated-18/VBN	conj_and||agents-13/NNS||complications-19/NNS	conj_and||agents-13/NNS||denguehaemorrhagicfever-21/NN	conj_and||complications-19/NNS||denguehaemorrhagicfever-21/NN	conj_and||agents-13/NNS||dengueshocksyndrome-23/NN	conj_and||complications-19/NNS||dengueshocksyndrome-23/NN	denguefever-15||dengueviruses-1||no||dengueviruses, mosquito-borne members of the flaviviridae family, are the causative agents of denguefever and its associated complications, denguehaemorrhagicfever and dengueshocksyndrome.
prepc_by||prevents-13/VBZ||inhibiting-2/VBG	det||current-7/NN||the-3/DT	amod||current-7/NN||late-4/JJ	amod||current-7/NN||inward-5/JJ	nn||current-7/NN||sodium-6/NN	dobj||inhibiting-2/VBG||current-7/NN	appos||current-7/NN||ina-9/NN	nsubj||prevents-13/VBZ||ranolazine-12/NN	root||ROOT-0/null||prevents-13/VBZ	amod||accumulation-17/NN||pathologic-14/JJ	nn||accumulation-17/NN||intracellular-15/NN	nn||accumulation-17/NN||calcium-16/NN	dobj||prevents-13/VBZ||accumulation-17/NN	nsubj||leads-19/VBZ||accumulation-17/NN	rcmod||accumulation-17/NN||leads-19/VBZ	prep_to||leads-19/VBZ||ischemia-21/NN	amod||dysfunction-24/NN||myocardial-23/JJ	prep_to||leads-19/VBZ||dysfunction-24/NN	conj_and||ischemia-21/NN||dysfunction-24/NN	amod||instability-28/NN||electrical-27/JJ	prep_to||leads-19/VBZ||instability-28/NN	conj_and||ischemia-21/NN||instability-28/NN	ischemia-21||myocardial-23||no_rel||by inhibiting the late inward sodium current (ina), ranolazine prevents pathologic intracellular calcium accumulation that leads to ischemia, myocardial dysfunction, and electrical instability.
det||drawbacks-2/NNS||these-1/DT	nsubjpass||overcome-5/VBN||drawbacks-2/NNS	aux||overcome-5/VBN||may-3/MD	auxpass||overcome-5/VBN||be-4/VB	root||ROOT-0/null||overcome-5/VBN	agent||overcome-5/VBN||combining-7/VBG	dobj||combining-7/VBG||insulin-8/NN	amod||therapies-11/NNS||incretin-based-10/JJ	prep_with||combining-7/VBG||therapies-11/NNS	det||sensitivity-16/NN||these-13/DT	nn||sensitivity-16/NN||increase-14/NN	nn||sensitivity-16/NN||glucose-15/NN	prep_as||therapies-11/NNS||sensitivity-16/NN	det||cells-27/NNS||both-18/DT	det||î-20/NN||the-19/DT	npadvmod||±-21/JJ||î-20/NN	amod||cells-27/NNS||±-21/JJ	advmod||²-25/JJ||î-24/RB	conj_and||±-21/JJ||²-25/JJ	amod||cells-27/NNS||²-25/JJ	prep_of||sensitivity-16/NN||cells-27/NNS	dep||combining-7/VBG||resulting-29/VBG	amod||glycemia-33/NN||improved-31/JJ	amod||glycemia-33/NN||postprandial-32/JJ	prep_in||resulting-29/VBG||glycemia-33/NN	det||gain-39/NN||the-35/DT	nn||gain-39/NN||hypoglycemia-36/NN	conj_and||hypoglycemia-36/NN||weight-38/NN	nn||gain-39/NN||weight-38/NN	prep_without||resulting-29/VBG||gain-39/NN	vmod||gain-39/NN||associated-40/VBN	prepc_with||associated-40/VBN||increasing-42/VBG	det||dose-44/NN||the-43/DT	dobj||increasing-42/VBG||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	hypoglycemia-36||glucose-15||yes||these drawbacks may be overcome by combining insulin with incretin-based therapies as these increase glucose sensitivity of both the î±- and î²-cells, resulting in improved postprandial glycemia without the hypoglycemia and weight gain associated with increasing the dose of insulin.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||determine-8/VB||purpose-2/NN	det||study-5/NN||the-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||effectiveness-10/NN||the-9/DT	dobj||determine-8/VB||effectiveness-10/NN	dobj||determine-8/VB||tolerability-12/NN	conj_and||effectiveness-10/NN||tolerability-12/NN	prep_of||effectiveness-10/NN||quetiapine-14/NN	det||treatment-18/NN||a-16/DT	nn||treatment-18/NN||maintenance-17/NN	prep_as||determine-8/VB||treatment-18/NN	vmod||treatment-18/NN||preventing-19/VBG	prep_against||preventing-19/VBG||relapse-21/NN	prep_against||preventing-19/VBG||recurrence-23/NN	conj_or||relapse-21/NN||recurrence-23/NN	amod||episodes-27/NNS||acute-25/JJ	nn||episodes-27/NNS||mood-26/NN	prep_of||relapse-21/NN||episodes-27/NNS	amod||patients-30/NNS||adolescent-29/JJ	prep_in||preventing-19/VBG||patients-30/NNS	vmod||patients-30/NNS||diagnosed-31/VBN	prep_with||diagnosed-31/VBN||bipolardisorder-33/NN	bipolardisorder-33||quetiapine-14||yes||the purpose of the study was to determine the effectiveness and tolerability of quetiapine as a maintenance treatment preventing against relapse or recurrence of acute mood episodes in adolescent patients diagnosed with bipolardisorder.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||determine-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||dose-11/NN||the-9/DT	amod||dose-11/NN||optimal-10/JJ	dobj||determine-8/VB||dose-11/NN	prep_of||dose-11/NN||remifentanil-13/NN	prepc_for||determine-8/VB||minimizing-15/VBG	amod||changes-17/NNS||hemodynamic-16/JJ	dobj||minimizing-15/VBG||changes-17/NNS	prep_during||minimizing-15/VBG||intubation-19/NN	prepc_for||determine-8/VB||reducing-21/VBG	conj_and||minimizing-15/VBG||reducing-21/VBG	amod||pain-23/NN||propofol-induced-22/JJ	dobj||reducing-21/VBG||pain-23/NN	amod||patients-26/NNS||elderly-25/JJ	prep_in||reducing-21/VBG||patients-26/NNS	pain-23||propofol--1||yes||the purpose of this study was to determine the optimal dose of remifentanil for minimizing hemodynamic changes during intubation and reducing propofol-induced pain in elderly patients.
nsubj||suggested-2/VBD||this-1/DT	root||ROOT-0/null||suggested-2/VBD	mark||activates-11/VBZ||that-3/IN	amod||therapy-7/NN||current-4/JJ	nn||therapy-7/NN||androgen-5/NN	nn||therapy-7/NN||ablation-6/NN	nsubj||activates-11/VBZ||therapy-7/NN	nsubj||contribute-16/VB||therapy-7/NN	nn||cancer-10/NN||prostate-9/NN	prep_for||therapy-7/NN||cancer-10/NN	ccomp||suggested-2/VBD||activates-11/VBZ	amod||expression-13/NN||c-met-12/JJ	dobj||activates-11/VBZ||expression-13/NN	aux||contribute-16/VB||may-15/MD	ccomp||suggested-2/VBD||contribute-16/VB	conj_and||activates-11/VBZ||contribute-16/VB	prep_to||contribute-16/VB||development-18/NN	advmod||aggressive-21/JJ||more-20/RBR	amod||cancer-26/NN||aggressive-21/JJ	amod||resistant-24/JJ||castration-23/JJ	amod||cancer-26/NN||resistant-24/JJ	nn||cancer-26/NN||prostate-25/NN	prep_of||development-18/NN||cancer-26/NN	dep||development-18/NN||crpc-28/JJ	androgen-5||cancer-26||no_rel||this suggested that current androgen ablation therapy for prostate cancer activates c-met expression and may contribute to development of more aggressive, castration resistant prostate cancer (crpc).
nn||cancer-2/NN||breast-1/NN	nsubj||disease-6/NN||cancer-2/NN	nsubjpass||characterized-10/VBN||cancer-2/NN	cop||disease-6/NN||is-3/VBZ	det||disease-6/NN||a-4/DT	amod||disease-6/NN||heterogeneous-5/JJ	root||ROOT-0/null||disease-6/NN	aux||characterized-10/VBN||may-8/MD	auxpass||characterized-10/VBN||be-9/VB	conj_and||disease-6/NN||characterized-10/VBN	det||basis-13/NN||the-12/DT	prep_on||characterized-10/VBN||basis-13/NN	mark||expressed-22/VBN||whether-15/IN	nn||receptors-17/NNS||estrogen-16/NN	nsubjpass||expressed-22/VBN||receptors-17/NNS	appos||receptors-17/NNS||er-19/NN	auxpass||expressed-22/VBN||are-21/VBP	prepc_of||basis-13/NN||expressed-22/VBN	det||cells-26/NNS||the-24/DT	nn||cells-26/NNS||tumour-25/NN	prep_in||expressed-22/VBN||cells-26/NNS	tumour-25||estrogen-16||no_rel||breast cancer is a heterogeneous disease and may be characterized on the basis of whether estrogen receptors (er) are expressed in the tumour cells.
det||proof-3/NN||this-2/DT	prep_for||compared-9/VBD||proof-3/NN	amod||study-6/NN||principal-5/JJ	prep_of||proof-3/NN||study-6/NN	nsubj||compared-9/VBD||we-8/PRP	root||ROOT-0/null||compared-9/VBD	amod||clearance-11/NN||bacillary-10/JJ	dobj||compared-9/VBD||clearance-11/NN	det||lungs-14/NNS||the-13/DT	prep_from||compared-9/VBD||lungs-14/NNS	prep_of||lungs-14/NNS||mtb-16/NN	amod||mice-19/NNS||infected-18/JJ	nsubj||treated-20/VBN||mice-19/NNS	parataxis||compared-9/VBD||treated-20/VBN	det||isoniazid-25/NN||the-22/DT	amod||isoniazid-25/NN||anti-tb-23/JJ	nn||isoniazid-25/NN||drug-24/NN	prep_with||treated-20/VBN||isoniazid-25/NN	appos||isoniazid-25/NN||inh-27/NN	det||presence-31/NN||the-30/DT	prep_in||treated-20/VBN||presence-31/NN	prep_in||treated-20/VBN||absence-33/NN	conj_and||presence-31/NN||absence-33/NN	det||inhibitor-39/NN||an-35/DT	amod||inhibitor-39/NN||immunomodulatory-36/JJ	amod||inhibitor-39/NN||phosphodiesterase-37/JJ	dep||phosphodiesterase-37/JJ||4-38/CD	prep_of||presence-31/NN||inhibitor-39/NN	appos||inhibitor-39/NN||pde4i-41/NNP	dep||treated-20/VBN||cc-3052-44/JJ	tb--1||isoniazid-25||yes||for this proof of principal study, we compared bacillary clearance from the lungs of mtb -infected mice treated with the anti-tb drug isoniazid (inh) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (pde4i), cc-3052.
nsubj||suggest-6/VBP||results-1/NNS	det||study-4/NN||this-3/DT	prep_in||results-1/NNS||study-4/NN	advmod||suggest-6/VBP||also-5/RB	root||ROOT-0/null||suggest-6/VBP	mark||originate-13/VB||that-7/IN	amod||viruses-10/NNS||genotype-8/JJ	nn||viruses-10/NNS||ix-9/NN	nsubj||originate-13/VB||viruses-10/NNS	advmod||likely-12/JJ||most-11/RBS	amod||viruses-10/NNS||likely-12/JJ	ccomp||suggest-6/VBP||originate-13/VB	det||virus-18/NN||a-15/DT	amod||virus-18/NN||genotype-16/JJ	nn||virus-18/NN||iii-17/NN	prep_from||originate-13/VB||virus-18/NN	prep_by||originate-13/VB||insertion-20/NN	det||motif-24/NN||a-22/DT	amod||motif-24/NN||6-nt-23/JJ	prep_of||insertion-20/NN||motif-24/NN	det||5-27/CD||the-26/DT	prep_in||motif-24/NN||5-27/CD	dep||5-27/CD||ncr-30/NN	nsubj||occurred-37/VBN||ncr-30/NN	det||gene-34/NN||the-32/DT	nn||gene-34/NN||np-33/NN	prep_of||ncr-30/NN||gene-34/NN	aux||occurred-37/VBN||had-36/VBD	rcmod||ncr-30/NN||occurred-37/VBN	mark||s-43/VBZ||as-38/IN	advmod||as-40/RB||early-39/RB	nsubj||s-43/VBZ||as-40/RB	prep_in||as-40/RB||1940-42/CD	advcl||occurred-37/VBN||s-43/VBZ	aux||origin-50/NN||might-46/MD	cop||origin-50/NN||be-47/VB	det||origin-50/NN||the-48/DT	amod||origin-50/NN||common-49/JJ	advcl||occurred-37/VBN||origin-50/NN	conj_and||s-43/VBZ||origin-50/NN	amod||viruses-54/NNS||genotype-52/JJ	nn||viruses-54/NNS||v-viii-53/NN	prep_of||origin-50/NN||viruses-54/NNS	virus-18||viruses-54||no||results in this study also suggest that genotype ix viruses most likely originate from a genotype iii virus by insertion of a 6-nt motif in the 5'-ncr of the np gene which had occurred as early as in 1940 s, and might be the common origin of genotype v-viii viruses.
dep||alcohol-induced-10/VBN||icd-9-2/VB	dobj||icd-9-2/VB||codes-4/NNS	nsubj||icd-9-2/VB||alcoholabuse-6/NN	nsubj||icd-9-2/VB||dependence-8/NN	conj_and||alcoholabuse-6/NN||dependence-8/NN	root||ROOT-0/null||alcohol-induced-10/VBN	amod||disorder-12/NN||mental-11/JJ	dobj||alcohol-induced-10/VBN||disorder-12/NN	amod||conditions-17/NNS||alcohol-induced-15/JJ	amod||conditions-17/NNS||medical-16/JJ	dobj||alcohol-induced-10/VBN||conditions-17/NNS	conj_and||disorder-12/NN||conditions-17/NNS	alcoholabuse-6||alcohol--1||no||(icd-9) codes) alcoholabuse and dependence; alcohol-induced mental disorder; and alcohol-induced medical conditions.
amod||abnormalities-2/NNS||metabolic-1/JJ	nsubj||common-4/JJ||abnormalities-2/NNS	nsubj||occur-16/VB||abnormalities-2/NNS	cop||common-4/JJ||are-3/VBP	root||ROOT-0/null||common-4/JJ	det||course-7/NN||the-6/DT	prep_throughout||common-4/JJ||course-7/NN	nn||infection-13/NN||humanimmunodeficiencyvirus-9/NNP	appos||infection-13/NN||hiv-11/NN	prep_of||course-7/NN||infection-13/NN	aux||occur-16/VB||may-15/MD	conj_and||common-4/JJ||occur-16/VB	dep||effects-27/NNS||either-17/RB	prep_due_to||either-17/RB||hivinfection-20/NN	conj_or||either-17/RB||as-22/IN	dep||effects-27/NNS||as-22/IN	det||result-24/NN||a-23/DT	pobj||as-22/IN||result-24/NN	prep_of||result-24/NN||side-26/NN	dobj||occur-16/VB||effects-27/NNS	amod||therapy-30/NN||antiretroviral-29/JJ	prep_of||effects-27/NNS||therapy-30/NN	hivinfection-20||hiv-11||no||metabolic abnormalities are common throughout the course of humanimmunodeficiencyvirus (hiv) infection and may occur either due to hivinfection or as a result of side effects of antiretroviral therapy.
amod||numbers-2/NNS||total-1/JJ	nsubjpass||reduced-11/VBN||numbers-2/NNS	nsubj||p-25/VBP||numbers-2/NNS	nn||groupbacteria-6/NN||c.-4/NN	nn||groupbacteria-6/NN||leptum-5/NN	prep_of||numbers-2/NNS||groupbacteria-6/NN	nn||prausnitzii-9/NNS||f.-8/NN	prep_of||numbers-2/NNS||prausnitzii-9/NNS	conj_and||groupbacteria-6/NN||prausnitzii-9/NNS	auxpass||reduced-11/VBN||were-10/VBD	root||ROOT-0/null||reduced-11/VBN	preconj||cd-14/NN||both-13/DT	prep_in||reduced-11/VBN||cd-14/NN	prep_in||reduced-11/VBN||uc-16/NN	conj_and||cd-14/NN||uc-16/NN	prepc_compared_to||cd-14/NN||to-18/TO	nn||p-21/NN||hc-19/NN	amod||p-21/NN||-lrb--20/JJ	pobj||cd-14/NN||p-21/NN	dep||0.0036-23/CD||=-22/SYM	dep||p-21/NN||0.0036-23/CD	conj_and||reduced-11/VBN||p-25/VBP	number||0.0001-27/CD||<-26/CD	dobj||p-25/VBP||0.0001-27/CD	advmod||p-25/VBP||respectively-28/RB	acomp||reduced-11/VBN||-rrb--29/JJ	uc-16||hc-19||yes||total numbers of c. leptum groupbacteria and f. prausnitzii were reduced in both cd and uc compared to hc -lrb- p = 0.0036 and p < 0.0001 respectively -rrb- .
det||study-3/NN||this-2/DT	prep_in||investigated-10/VBD||study-3/NN	amod||monkeys-7/NNS||common-5/JJ	nn||monkeys-7/NNS||marmoset-6/NN	prep_with||study-3/NN||monkeys-7/NNS	nsubj||investigated-10/VBD||we-9/PRP	root||ROOT-0/null||investigated-10/VBD	amod||effects-15/NNS||neonatal-12/JJ	conj_and||neonatal-12/JJ||adulthood-14/JJ	amod||effects-15/NNS||adulthood-14/JJ	prep_for||investigated-10/VBD||effects-15/NNS	amod||treatment-19/NN||antenatal-17/JJ	nn||treatment-19/NN||dex-18/NN	prep_of||effects-15/NNS||treatment-19/NN	det||expression-22/NN||the-21/DT	prep_on||investigated-10/VBD||expression-22/NN	det||receptors-26/NNS||the-24/DT	amod||receptors-26/NNS||corticosteroid-25/JJ	prep_of||expression-22/NN||receptors-26/NNS	advmod||calcyon-29/NN||also-28/RB	prep_on||investigated-10/VBD||calcyon-29/NN	conj_and||expression-22/NN||calcyon-29/NN	det||gene-33/NN||a-31/DT	nn||gene-33/NN||risk-32/NN	appos||calcyon-29/NN||gene-33/NN	prep_for||gene-33/NN||attention-deficit/hyperactivitydisorder-35/NN	det||cortex-40/NN||the-38/DT	amod||cortex-40/NN||prefrontal-39/JJ	prep_in||calcyon-29/NN||cortex-40/NN	appos||cortex-40/NN||pfc-42/NN	corticosteroid-25||deficit--1||no_rel||in this study with common marmoset monkeys, we investigated for neonatal and adulthood effects of antenatal dex treatment on the expression of the corticosteroid receptors and also calcyon, a risk gene for attention-deficit/hyperactivitydisorder, in the prefrontal cortex (pfc).
nsubj||consisted-2/VBD||treatment-1/NN	root||ROOT-0/null||consisted-2/VBD	advmod||consisted-2/VBD||primarily-3/RB	prep_of||consisted-2/VBD||methyleneblue-5/NN	num||mg/kg-8/NN||1-7/CD	dep||methyleneblue-5/NN||mg/kg-8/NN	nn||doses-13/NNS||one-10/CD	conj_or||one-10/CD||two-12/CD	nn||doses-13/NNS||two-12/CD	prep_for||mg/kg-8/NN||doses-13/NNS	nn||transfusion-17/NN||exchange-16/NN	prep_of||consisted-2/VBD||transfusion-17/NN	conj_and||methyleneblue-5/NN||transfusion-17/NN	amod||care-20/NN||supportive-19/JJ	prep_of||consisted-2/VBD||care-20/NN	conj_and||methyleneblue-5/NN||care-20/NN	advmod||diagnosed-24/VBN||when-21/WRB	nsubjpass||diagnosed-24/VBN||methaemoglobinaemia-22/NN	auxpass||diagnosed-24/VBN||was-23/VBD	advcl||consisted-2/VBD||diagnosed-24/VBN	xcomp||diagnosed-24/VBN||clinically-25/JJ	methaemoglobinaemia-22||methyleneblue-5||yes||treatment consisted primarily of methyleneblue (1 mg/kg for one or two doses), exchange transfusion and supportive care when methaemoglobinaemia was diagnosed clinically.
nsubjpass||detected-7/VBN||differences-1/NNS	amod||markers-5/NNS||baseline-3/JJ	amod||markers-5/NNS||hepatitisbviral-4/JJ	prep_in||differences-1/NNS||markers-5/NNS	auxpass||detected-7/VBN||were-6/VBD	root||ROOT-0/null||detected-7/VBN	prep_in||detected-7/VBN||patients-9/NNS	amod||stages-13/NNS||various-11/JJ	amod||stages-13/NNS||clinical-12/JJ	prep_in||patients-9/NNS||stages-13/NNS	prep_of||stages-13/NNS||hepatitisbvirusinfection-15/NN	hepatitisbviral-4||hepatitisbvirus--1||no||differences in baseline hepatitisbviral markers were detected in patients in various clinical stages of hepatitisbvirusinfection.
num||subjects-2/NNS||fourteen-1/CD	nsubjpass||recruited-24/VBN||subjects-2/NNS	prepc_with||subjects-2/NNS||hbsag-4/VBG	dobj||hbsag-4/VBG||seroclearance-5/NN	amod||treatment-8/NN||antiviral-7/JJ	prep_following||seroclearance-5/NN||treatment-8/NN	prep_for||treatment-8/NN||chronichepatitisb-10/NN	num||carriers-16/NNS||7-12/CD	amod||carriers-16/NNS||hbeag-positive-13/JJ	nn||carriers-16/NNS||immunotolerant-14/NN	nn||carriers-16/NNS||hbv-15/NN	prep_for||treatment-8/NN||carriers-16/NNS	conj_and||chronichepatitisb-10/NN||carriers-16/NNS	num||carriers-22/NNS||9-18/CD	amod||carriers-22/NNS||hbeag-negative-19/JJ	amod||carriers-22/NNS||inactive-20/JJ	nn||carriers-22/NNS||hbsag-21/NN	prep_for||treatment-8/NN||carriers-22/NNS	conj_and||chronichepatitisb-10/NN||carriers-22/NNS	auxpass||recruited-24/VBN||were-23/VBD	root||ROOT-0/null||recruited-24/VBN	hbv-15||hbsag-21||yes||fourteen subjects with hbsag seroclearance following antiviral treatment for chronichepatitisb, 7 hbeag-positive immunotolerant hbv carriers and 9 hbeag-negative inactive hbsag carriers were recruited.
quantmod||99-2/CD||almost-1/RB	num||%-3/NN||99-2/CD	nsubj||heard-8/VBN||%-3/NN	det||respondents-6/NNS||the-5/DT	prep_of||%-3/NN||respondents-6/NNS	aux||heard-8/VBN||had-7/VBD	root||ROOT-0/null||heard-8/VBN	prep_of||heard-8/VBN||hiv/aids-10/NNS	num||%-14/NN||89-13/CD	nsubj||identify-16/VB||%-14/NN	aux||identify-16/VB||could-15/MD	conj_and||heard-8/VBN||identify-16/VB	dobj||identify-16/VB||ways-17/NNS	nsubj||protect-19/VB||ways-17/NNS	aux||protect-19/VB||to-18/TO	xcomp||identify-16/VB||protect-19/VB	dobj||protect-19/VB||oneself-20/PRP	advmod||hiv/aids-24/NNS||sexually-22/RB	amod||hiv/aids-24/NNS||transmitted-23/JJ	prep_against||protect-19/VB||hiv/aids-24/NNS	aids--1||hiv--1||no||almost 99% of the respondents had heard of hiv/aids, and 89% could identify ways to protect oneself against sexually transmitted hiv/aids.
det||types-2/NNS||all-1/DT	nsubjpass||included-8/VBN||types-2/NNS	amod||studies-6/NNS||prospective-4/JJ	amod||studies-6/NNS||clinical-5/JJ	prep_of||types-2/NNS||studies-6/NNS	auxpass||included-8/VBN||were-7/VBD	root||ROOT-0/null||included-8/VBN	mark||used-12/VBN||if-9/IN	nsubjpass||used-12/VBN||magnesiumsulfate-10/NN	nsubj||manage-14/VB||magnesiumsulfate-10/NN	auxpass||used-12/VBN||was-11/VBD	advcl||included-8/VBN||used-12/VBN	aux||manage-14/VB||to-13/TO	xcomp||used-12/VBN||manage-14/VB	dobj||manage-14/VB||pre-eclampsia-15/NN	dobj||manage-14/VB||eclampsia-17/NN	conj_or||pre-eclampsia-15/NN||eclampsia-17/NN	det||study-20/NN||the-19/DT	nsubjpass||conducted-22/VBN||study-20/NN	auxpass||conducted-22/VBN||was-21/VBD	dep||included-8/VBN||conducted-22/VBN	det||country-29/NN||a-24/DT	amod||country-29/NN||low-25/JJ	conj_or||low-25/JJ||middle-income-28/JJ	amod||country-29/NN||middle-income-28/JJ	prep_in||conducted-22/VBN||country-29/NN	det||study-33/NN||the-32/DT	nsubj||included-34/VBD||study-33/NN	conj_and||included-8/VBN||included-34/VBD	det||recording-36/NN||the-35/DT	dobj||included-34/VBD||recording-36/NN	det||incidence-39/NN||the-38/DT	prep_of||recording-36/NN||incidence-39/NN	det||effect-44/NN||any-41/DT	amod||effect-44/NN||adverse-42/JJ	nn||effect-44/NN||side-43/NN	prep_of||incidence-39/NN||effect-44/NN	vmod||effect-44/NN||resulting-45/VBG	amod||use-48/NN||magnesiumsulfate-47/JJ	prep_from||resulting-45/VBG||use-48/NN	pre-eclampsia-15||magnesiumsulfate-47||yes||all types of prospective clinical studies were included if magnesiumsulfate was used to manage pre-eclampsia or eclampsia, the study was conducted in a low- or middle-income country, and the study included the recording of the incidence of any adverse side effect resulting from magnesiumsulfate use.
nsubj||knowledge-4/NN||it-1/PRP	cop||knowledge-4/NN||is-2/VBZ	amod||knowledge-4/NN||common-3/JJ	root||ROOT-0/null||knowledge-4/NN	mark||causes-8/VBZ||that-5/IN	nn||exposure-7/NN||asbestos-6/NN	nsubj||causes-8/VBZ||exposure-7/NN	dep||knowledge-4/NN||causes-8/VBZ	amod||diseases-10/NNS||asbestos-related-9/JJ	dobj||causes-8/VBZ||diseases-10/NNS	prep_such_as||diseases-10/NNS||asbestosis-13/NNS	nn||cancer-16/NN||lung-15/NN	prep_such_as||diseases-10/NNS||cancer-16/NN	conj_and||asbestosis-13/NNS||cancer-16/NN	amod||mesothelioma-19/NN||malignant-18/JJ	prep_such_as||diseases-10/NNS||mesothelioma-19/NN	conj_and||asbestosis-13/NNS||mesothelioma-19/NN	appos||knowledge-4/NN||mm-21/NN	neg||only-24/RB||not-23/RB	dep||knowledge-4/NN||only-24/RB	dep||only-24/RB||in-25/IN	conj||knowledge-4/NN||people-26/NNS	nsubj||handled-29/VBN||people-26/NNS	aux||handled-29/VBN||have-28/VBP	rcmod||people-26/NNS||handled-29/VBN	dobj||handled-29/VBN||asbestos-30/NN	det||environment-34/NN||the-32/DT	nn||environment-34/NN||work-33/NN	prep_in||handled-29/VBN||environment-34/NN	cc||in-38/IN||but-36/CC	dep||in-38/IN||also-37/RB	dep||handled-29/VBN||in-38/IN	nsubj||living-40/VBG||residents-39/NNS	pcomp||in-38/IN||living-40/VBG	amod||factories-42/NNS||near-41/JJ	dobj||living-40/VBG||factories-42/NNS	mark||handle-44/VBP||that-43/IN	ccomp||handled-29/VBN||handle-44/VBP	dobj||handle-44/VBP||asbestos-45/NN	asbestosis-13||asbestos-45||no||it is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer and malignant mesothelioma (mm) not only in people who have handled asbestos in the work environment, but also in residents living near factories that handle asbestos.
det||phenotype-2/NN||the-1/DT	nsubjpass||extended-12/VBN||phenotype-2/NN	nsubj||include-14/VB||phenotype-2/NN	vmod||phenotype-2/NN||associated-3/VBN	amod||mutations-8/NNS||heterozygous-5/JJ	amod||mutations-8/NNS||hnf4a-6/JJ	nn||mutations-8/NNS||gene-7/NN	prep_with||associated-3/VBN||mutations-8/NNS	aux||extended-12/VBN||has-9/VBZ	advmod||extended-12/VBN||recently-10/RB	auxpass||extended-12/VBN||been-11/VBN	root||ROOT-0/null||extended-12/VBN	aux||include-14/VB||to-13/TO	xcomp||extended-12/VBN||include-14/VB	amod||responsive-16/JJ||diazoxide-15/JJ	amod||hypoglycemia-18/NN||responsive-16/JJ	amod||hypoglycemia-18/NN||neonatal-17/JJ	dobj||include-14/VB||hypoglycemia-18/NN	prep_in||include-14/VB||addition-20/NN	amod||diabetes-23/NN||maturity-onset-22/JJ	prep_to||include-14/VB||diabetes-23/NN	det||mody-28/NN||the-25/DT	amod||mody-28/NN||young-26/JJ	prep_of||diabetes-23/NN||mody-28/NN	hypoglycemia-18||diazoxide-15||no||the phenotype associated with heterozygous hnf4a gene mutations has recently been extended to include diazoxide responsive neonatal hypoglycemia in addition to maturity-onset diabetes of the young (mody).
amod||hypothyroidism-2/NN||subclinical-1/JJ	nsubj||common-33/JJ||hypothyroidism-2/NN	discourse||hypothyroidism-2/NN||sch-4/UH	vmod||hypothyroidism-2/NN||defined-7/VBN	det||total-11/NN||a-9/DT	amod||total-11/NN||normal-10/JJ	agent||defined-7/VBN||total-11/NN	amod||level-15/NN||free-13/JJ	amod||level-15/NN||t4-14/JJ	agent||defined-7/VBN||level-15/NN	conj_or||total-11/NN||level-15/NN	det||tsh-20/NN||a-17/DT	advmod||elevated-19/JJ||mildly-18/RB	amod||tsh-20/NN||elevated-19/JJ	agent||defined-7/VBN||tsh-20/NN	conj_and||total-11/NN||tsh-20/NN	dep||mu/l-29/JJ||typically-22/RB	amod||10â-26/NNS||5â-23/JJ	amod||10â-26/NNS||$-24/$	npadvmod||mu/l-29/JJ||10â-26/NNS	num||10â-26/NNS||$-27/$	num||$-27/$||‰-28/CD	dep||defined-7/VBN||mu/l-29/JJ	cop||common-33/JJ||is-32/VBZ	root||ROOT-0/null||common-33/JJ	prep_in||common-33/JJ||children-35/NNS	expl||is-39/VBZ||there-38/EX	conj_but||common-33/JJ||is-39/VBZ	advmod||is-39/VBZ||currently-40/RB	neg||consensus-42/NN||no-41/DT	nsubj||is-39/VBZ||consensus-42/NN	prep_on||consensus-42/NN||management-44/NN	hypothyroidism-2||t4-14||yes||subclinical hypothyroidism (sch), defined by a normal total or free t4 level and a mildly elevated tsh (typically 5â€“10â€‰mu/l), is common in children, but there is currently no consensus on management.
det||lesion-2/NN||the-1/DT	nsubjpass||improved-4/VBN||lesion-2/NN	auxpass||improved-4/VBN||was-3/VBD	root||ROOT-0/null||improved-4/VBN	nn||avoidance-7/NN||sun-6/NN	prep_after||improved-4/VBN||avoidance-7/NN	prep_after||improved-4/VBN||treatment-9/NN	conj_and||avoidance-7/NN||treatment-9/NN	amod||virusinfection-12/NN||hepatitisc-11/JJ	prep_of||avoidance-7/NN||virusinfection-12/NN	det||combination-15/NN||a-14/DT	prep_with||improved-4/VBN||combination-15/NN	prep_of||combination-15/NN||interferon-17/NN	prep_of||combination-15/NN||ribavirin-19/NN	conj_and||interferon-17/NN||ribavirin-19/NN	virusinfection-12||ribavirin-19||yes||the lesion was improved after sun avoidance and treatment of hepatitisc virusinfection with a combination of interferon and ribavirin.
prep_in||demonstrate-13/VBP||some-2/DT	det||communities-8/NNS||the-4/DT	advmod||affected-7/VBN||most-5/RBS	advmod||affected-7/VBN||severely-6/RB	amod||communities-8/NNS||affected-7/VBN	prep_of||some-2/DT||communities-8/NNS	advmod||studied-10/VBN||ever-9/RB	vmod||communities-8/NNS||studied-10/VBN	nsubj||demonstrate-13/VBP||we-12/PRP	root||ROOT-0/null||demonstrate-13/VBP	nsubj||repeated-15/VBD||that-14/WDT	advcl||demonstrate-13/VBP||repeated-15/VBD	amod||distributions-19/NNS||mass-16/JJ	amod||distributions-19/NNS||oral-17/JJ	nn||distributions-19/NNS||azithromycin-18/NN	nsubj||reduce-21/VB||distributions-19/NNS	advmod||reduce-21/VB||progressively-20/RB	ccomp||repeated-15/VBD||reduce-21/VB	nn||chlamydialinfection-23/NN||ocular-22/NN	dobj||reduce-21/VB||chlamydialinfection-23/NN	det||community-26/NN||a-25/DT	prep_in||reduce-21/VB||community-26/NN	advmod||long-29/RB||as-28/RB	advmod||repeated-15/VBD||long-29/RB	mark||given-34/VBN||as-30/IN	det||distributions-32/NNS||these-31/DT	nsubjpass||given-34/VBN||distributions-32/NNS	auxpass||given-34/VBN||are-33/VBP	dep||repeated-15/VBD||given-34/VBN	advmod||enough-36/RB||frequently-35/RB	advmod||given-34/VBN||enough-36/RB	advmod||given-34/VBN||at-38/IN	conj_and||enough-36/RB||at-38/IN	det||coverage-42/NN||a-39/DT	amod||coverage-42/NN||high-40/JJ	amod||coverage-42/NN||enough-41/JJ	pobj||at-38/IN||coverage-42/NN	chlamydialinfection-23||azithromycin-18||yes||in some of the most severely affected communities ever studied, we demonstrate that repeated mass oral azithromycin distributions progressively reduce ocular chlamydialinfection in a community, as long as these distributions are given frequently enough and at a high enough coverage.
poss||goal-2/NN||our-1/PRP$	nsubj||was-3/VBD||goal-2/NN	nsubj||evaluate-5/VB||goal-2/NN	root||ROOT-0/null||was-3/VBD	aux||evaluate-5/VB||to-4/TO	xcomp||was-3/VBD||evaluate-5/VB	det||effect-7/NN||the-6/DT	dobj||evaluate-5/VB||effect-7/NN	det||calciumchannelblocker-12/NN||a-9/DT	advmod||used-11/JJ||commonly-10/RB	amod||calciumchannelblocker-12/NN||used-11/JJ	prep_of||effect-7/NN||calciumchannelblocker-12/NN	prep_of||effect-7/NN||amlodipine-14/NN	conj_and||calciumchannelblocker-12/NN||amlodipine-14/NN	det||excretion-24/NN||an-17/DT	amod||excretion-24/NN||angiotensinconvertingenzymeinhibitor-18/JJ	amod||excretion-24/NN||lisinopril-20/JJ	amod||albumin-23/NN||urinary-22/JJ	prep_on||lisinopril-20/JJ||albumin-23/NN	prep_of||effect-7/NN||excretion-24/NN	conj_and||calciumchannelblocker-12/NN||excretion-24/NN	prep_in||evaluate-5/VB||patients-26/NNS	amod||moderate-30/JJ||mild-28/JJ	dep||moderate-30/JJ||to-29/TO	amod||hypertension-32/NN||moderate-30/JJ	amod||hypertension-32/NN||essential-31/JJ	prep_with||patients-26/NNS||hypertension-32/NN	hypertension-32||lisinopril-20||yes||our goal was to evaluate the effect of a commonly used calciumchannelblocker, amlodipine, and an angiotensinconvertingenzymeinhibitor, lisinopril on urinary albumin excretion in patients with mild to moderate essential hypertension.
aux||address-2/VB||to-1/TO	root||ROOT-0/null||address-2/VB	det||problems-5/NNS||the-3/DT	amod||problems-5/NNS||long-term-4/JJ	dobj||address-2/VB||problems-5/NNS	nn||wear-9/NN||bearing-7/NN	nn||wear-9/NN||surface-8/NN	prep_of||problems-5/NNS||wear-9/NN	prep_of||problems-5/NNS||osteolysis-11/NNS	conj_and||wear-9/NN||osteolysis-11/NNS	vmod||osteolysis-11/NNS||associated-12/VBN	amod||metal-polyethylene-15/NN||conventional-14/JJ	prep_with||associated-12/VBN||metal-polyethylene-15/NN	dep||metal-polyethylene-15/NN||m-pe-17/JJ	amod||arthroplasty-21/NN||total-19/JJ	nn||arthroplasty-21/NN||hip-20/NN	dep||metal-polyethylene-15/NN||arthroplasty-21/NN	appos||metal-polyethylene-15/NN||tha-23/NN	appos||metal-polyethylene-15/NN||metal-metal-26/NN	appos||metal-metal-26/NN||m-m-28/NNP	amod||bearings-36/NNS||ceramic-ceramic-32/JJ	appos||bearings-36/NNS||c-c-34/NNP	nsubjpass||introduced-39/VBN||bearings-36/NNS	aux||introduced-39/VBN||have-37/VBP	auxpass||introduced-39/VBN||been-38/VBN	conj_and||address-2/VB||introduced-39/VBN	osteolysis-11||metal--1||no_rel||to address the long-term problems of bearing surface wear and osteolysis associated with conventional metal-polyethylene (m-pe) total hip arthroplasty (tha), metal-metal (m-m), and ceramic-ceramic (c-c) bearings have been introduced.
aux||clarify-2/VB||to-1/TO	advcl||screened-7/VBD||clarify-2/VB	det||issues-4/NNS||these-3/DT	dobj||clarify-2/VB||issues-4/NNS	nsubj||screened-7/VBD||we-6/PRP	root||ROOT-0/null||screened-7/VBD	det||library-11/NN||a-8/DT	amod||library-11/NN||random-9/JJ	nn||library-11/NN||peptide-10/NN	dobj||screened-7/VBD||library-11/NN	prep_with||screened-7/VBD||sera-13/NN	vmod||sera-13/NN||obtained-14/VBN	num||patients-17/NNS||58-16/CD	prep_from||obtained-14/VBN||patients-17/NNS	amod||type1diabetes-21/NNS||recent-19/JJ	nn||type1diabetes-21/NNS||onset-20/NN	prep_with||obtained-14/VBN||type1diabetes-21/NNS	nn||therapy-25/NN||insulin-24/NN	prep_before||obtained-14/VBN||therapy-25/NN	type1diabetes-21||insulin-24||yes||to clarify these issues, we screened a random peptide library with sera obtained from 58 patients with recent onset type1diabetes, before insulin therapy.
nsubj||have-4/VBP||patients-1/NNS	prep_with||patients-1/NNS||hiv/aids-3/NNS	root||ROOT-0/null||have-4/VBP	det||risk-7/NN||a-5/DT	amod||risk-7/NN||higher-6/JJR	dobj||have-4/VBP||risk-7/NN	amod||b-celllymphomas-11/NNS||developing-9/VBG	amod||b-celllymphomas-11/NNS||aggressive-10/JJ	prep_of||risk-7/NN||b-celllymphomas-11/NNS	amod||b-celllymphoma-17/NN||diffuse-15/JJ	amod||b-celllymphoma-17/NN||large-16/JJ	prep_such_as||risk-7/NN||b-celllymphoma-17/NN	dep||b-celllymphoma-17/NN||dlbcl-19/JJ	aids--1||hiv--1||no||patients with hiv/aids have a higher risk of developing aggressive b-celllymphomas, such as diffuse large b-celllymphoma (dlbcl).
amod||swineinfluenzaviruses-2/NNS||triple-reassortant-1/JJ	nsubj||contain-8/VBP||swineinfluenzaviruses-2/NNS	vmod||swineinfluenzaviruses-2/NNS||circulating-3/VBG	nn||pigs-7/NNS||north-5/NN	nn||pigs-7/NNS||american-6/NN	prep_in||circulating-3/VBG||pigs-7/NNS	root||ROOT-0/null||contain-8/VBP	det||genes-11/NNS||the-9/DT	amod||genes-11/NNS||internal-10/JJ	dobj||contain-8/VBP||genes-11/NNS	iobj||contain-8/VBP||genes-11/NNS	vmod||genes-11/NNS||derived-12/VBN	prep_from||derived-12/VBN||swine-14/NNS	dep||swine-14/NNS||matrix-16/NN	dep||matrix-16/NN||non-structural-18/JJ	dep||matrix-16/NN||nucleoprotein-20/JJ	conj_and||non-structural-18/JJ||nucleoprotein-20/JJ	amod||polymerase-25/NN||human-23/JJ	amod||polymerase-25/NN||-LSB--24/JJ	appos||swine-14/NNS||polymerase-25/NN	number||1-27/CD||basic-26/CD	num||-RSB--31/NN||1-27/CD	appos||-RSB--31/NN||pb1-29/NNP	dep||polymerase-25/NN||-RSB--31/NN	nn||influenzaviruses-40/NNS||avian-33/NN	nn||acidic-36/NNS||polymerase-35/NN	dep||influenzaviruses-40/NNS||acidic-36/NNS	conj_and||acidic-36/NNS||pb2-38/NNS	dep||influenzaviruses-40/NNS||pb2-38/NNS	dep||polymerase-25/NN||influenzaviruses-40/NNS	conj_and||-RSB--31/NN||influenzaviruses-40/NNS	xcomp||derived-12/VBN||forming-41/VBG	det||constellation-43/NN||a-42/DT	dobj||forming-41/VBG||constellation-43/NN	prep_of||constellation-43/NN||genes-45/NNS	nsubj||conserved-49/JJ||genes-45/NNS	nsubjpass||called-52/VBN||genes-45/NNS	cop||conserved-49/JJ||is-47/VBZ	advmod||conserved-49/JJ||well-48/RB	rcmod||genes-45/NNS||conserved-49/JJ	auxpass||called-52/VBN||is-51/VBZ	rcmod||genes-45/NNS||called-52/VBN	conj_and||conserved-49/JJ||called-52/VBN	det||gene-56/NN||the-53/DT	amod||gene-56/NN||triple-reassortant-54/JJ	amod||gene-56/NN||internal-55/JJ	dobj||called-52/VBN||gene-56/NN	dep||genes-11/NNS||trig-58/VBG	dep||genes-11/NNS||cassette-60/NN	swineinfluenza--1||influenzaviruses-40||no||triple-reassortant swineinfluenzaviruses circulating in north american pigs contain the internal genes derived from swine (matrix, non-structural and nucleoprotein), human [polymerase basic 1 (pb1)] and avian (polymerase acidic and pb2) influenzaviruses forming a constellation of genes that is well conserved and is called the triple-reassortant internal gene (trig) cassette.
poss||results-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||augmented-8/VBD||that-4/IN	number||%-6/NN||3-5/CD	amod||o2-7/NNS||%-6/NN	nsubj||augmented-8/VBD||o2-7/NNS	ccomp||demonstrate-3/VBP||augmented-8/VBD	dobj||augmented-8/VBD||proliferation-9/NN	prep_of||proliferation-9/NN||bmsc-11/NN	det||formation-17/NN||the-16/DT	dobj||augmented-8/VBD||formation-17/NN	conj_and||proliferation-9/NN||formation-17/NN	prep_of||formation-17/NN||colonies-19/NNS	det||assay-24/NN||the-21/DT	amod||assay-24/NN||colony-forming-22/JJ	nn||assay-24/NN||unit-23/NN	prep_in||colonies-19/NNS||assay-24/NN	appos||assay-24/NN||cfu-a-26/NNP	det||percentage-30/NN||the-29/DT	prep_of||formation-17/NN||percentage-30/NN	conj_and||colonies-19/NNS||percentage-30/NN	amod||cells-33/NNS||quiescent-32/JJ	prep_of||percentage-30/NN||cells-33/NNS	det||expression-37/NN||the-36/DT	prep_of||formation-17/NN||expression-37/NN	conj_and||colonies-19/NNS||expression-37/NN	amod||markers-40/NNS||stemness-39/JJ	prep_of||expression-37/NN||markers-40/NNS	amod||formation-17/NN||rex-1-41/JJ	amod||formation-17/NN||oct-4-43/JJ	conj_and||rex-1-41/JJ||oct-4-43/JJ	advmod||suggesting-46/VBG||thereby-45/RB	vmod||formation-17/NN||suggesting-46/VBG	det||increase-48/NN||an-47/DT	dobj||suggesting-46/VBG||increase-48/NN	det||stemness-51/NNS||the-50/DT	prep_in||increase-48/NN||stemness-51/NNS	prep_of||stemness-51/NNS||culture-53/NN	advmod||exposed-55/VBN||when-54/WRB	advcl||augmented-8/VBD||exposed-55/VBN	prep_to||exposed-55/VBN||hypoxia-57/NN	o2-7||hypoxia-57||no_rel||our results demonstrate that 3% o2 augmented proliferation of bmsc, as well as the formation of colonies in the colony-forming unit assay (cfu-a), the percentage of quiescent cells, and the expression of stemness markers rex-1 and oct-4, thereby suggesting an increase in the stemness of culture when exposed to hypoxia.
nsubjpass||identified-11/VBN||criteria-1/NNS	nn||setting-4/NN||priority-3/NN	prep_for||criteria-1/NNS||setting-4/NN	amod||interventions-7/NNS||hiv/aids-6/JJ	prep_of||setting-4/NN||interventions-7/NNS	prep_in||interventions-7/NNS||thailand-9/NN	auxpass||identified-11/VBN||were-10/VBD	root||ROOT-0/null||identified-11/VBN	nn||discussions-14/NNS||group-13/NN	prep_in||identified-11/VBN||discussions-14/NNS	nn||makers-17/NNS||policy-16/NN	prep_with||identified-11/VBN||makers-17/NNS	appos||makers-17/NNS||people-19/NNS	vmod||people-19/NNS||living-20/VBG	amod||-rrb--25/NNS||hiv/aids-22/JJ	amod||-rrb--25/NNS||-lrb--23/JJ	nn||-rrb--25/NNS||plwha-24/NN	prep_with||living-20/VBG||-rrb--25/NNS	nn||members-29/NNS||community-28/NN	nsubj||-lrb--30/VBD||members-29/NNS	conj_and||identified-11/VBN||-lrb--30/VBD	amod||volunteers-34/NNS||i.e.-31/JJ	nn||volunteers-34/NNS||village-32/NN	nn||volunteers-34/NNS||health-33/NN	nsubj||vhvs-36/VBZ||volunteers-34/NNS	advmod||vhvs-36/VBZ||-lrb--35/RB	ccomp||-lrb--30/VBD||vhvs-36/VBZ	amod||-rrb--38/NNS||-rrb--37/JJ	dobj||vhvs-36/VBZ||-rrb--38/NNS	aids--1||hiv--1||no||criteria for priority setting of hiv/aids interventions in thailand were identified in group discussions with policy makers , people living with hiv/aids -lrb- plwha -rrb- , and community members -lrb- i.e. village health volunteers -lrb- vhvs -rrb- -rrb- .
amod||children-3/NNS||black-1/JJ	amod||children-3/NNS||african-caribbean-2/JJ	nsubj||had-4/VBD||children-3/NNS	root||ROOT-0/null||had-4/VBD	amod||hdl-cholesterol-6/NN||higher-5/JJR	dobj||had-4/VBD||hdl-cholesterol-6/NN	amod||levels-10/NNS||lower-8/JJR	nn||levels-10/NNS||triglyceride-9/NN	dobj||had-4/VBD||levels-10/NNS	conj_and||hdl-cholesterol-6/NN||levels-10/NNS	amod||europeans-13/NNS||white-12/JJ	prep_than||had-4/VBD||europeans-13/NNS	amod||markers-16/NNS||adiposity-15/JJ	nsubjpass||increased-19/VBN||markers-16/NNS	auxpass||increased-19/VBN||were-17/VBD	neg||increased-19/VBN||not-18/RB	parataxis||had-4/VBD||increased-19/VBN	cholesterol--1||adiposity-15||no_rel||black african-caribbean children had higher hdl-cholesterol and lower triglyceride levels than white europeans; adiposity markers were not increased.
advmod||inhibits-4/VBZ||moreover-1/RB	nsubj||inhibits-4/VBZ||curcumin-3/NN	root||ROOT-0/null||inhibits-4/VBZ	amod||angiogenesis-8/NNS||microvascular-5/JJ	amod||angiogenesis-8/NNS||endothelial-6/JJ	nn||angiogenesis-8/NNS||cell-7/NN	dobj||inhibits-4/VBZ||angiogenesis-8/NNS	prep_through||inhibits-4/VBZ||inhibition-10/NN	amod||expression-13/NN||cox-2-12/JJ	prep_of||inhibition-10/NN||expression-13/NN	amod||production-16/NN||pge2-15/JJ	prep_of||inhibition-10/NN||production-16/NN	conj_and||expression-13/NN||production-16/NN	vmod||inhibits-4/VBZ||suggesting-18/VBG	mark||possesses-23/VBZ||that-19/IN	det||product-22/NN||this-20/DT	amod||product-22/NN||natural-21/JJ	nsubj||possesses-23/VBZ||product-22/NN	ccomp||suggesting-18/VBG||possesses-23/VBZ	amod||properties-25/NNS||antiangiogenic-24/JJ	dobj||possesses-23/VBZ||properties-25/NNS	nsubj||warrants-28/VBZ||properties-25/NNS	rcmod||properties-25/NNS||warrants-28/VBZ	amod||investigation-30/NN||further-29/JJ	dobj||warrants-28/VBZ||investigation-30/NN	amod||treatment-33/NN||adjuvant-32/JJ	prep_as||warrants-28/VBZ||treatment-33/NN	prep_of||treatment-33/NN||ibd-35/NN	prep_of||treatment-33/NN||cancer-37/NN	conj_and||ibd-35/NN||cancer-37/NN	cancer-37||pge2-15||no_rel||moreover, curcumin inhibits microvascular endothelial cell angiogenesis through inhibition of cox-2 expression and pge2 production, suggesting that this natural product possesses antiangiogenic properties, which warrants further investigation as adjuvant treatment of ibd and cancer.
num||%-2/NN||18.1-1/CD	nsubj||performed-11/VBN||%-2/NN	appos||%-2/NN||799/4416-4/CD	det||respondents-8/NNS||the-7/DT	prep_of||%-2/NN||respondents-8/NNS	aux||performed-11/VBN||had-9/VBD	advmod||performed-11/VBN||ever-10/RB	root||ROOT-0/null||performed-11/VBN	det||self-test-13/NN||a-12/DT	dobj||performed-11/VBN||self-test-13/NN	det||tests-19/NNS||the-15/DT	advmod||frequently-17/RB||most-16/RBS	advmod||used-18/VBN||frequently-17/RB	amod||tests-19/NNS||used-18/VBN	appos||self-test-13/NN||tests-19/NNS	aux||those-21/DT||being-20/VBG	vmod||tests-19/NNS||those-21/DT	prep_for||those-21/DT||diabetes-23/NN	num||%-26/NN||5.3-25/CD	appos||diabetes-23/NN||%-26/NN	prep_for||those-21/DT||kidneydisease-29/NN	conj_and||diabetes-23/NN||kidneydisease-29/NN	num||%-32/NN||4.9-31/CD	appos||kidneydisease-29/NN||%-32/NN	prep_for||those-21/DT||cholesterol-35/NN	conj_and||diabetes-23/NN||cholesterol-35/NN	num||%-38/NN||4.5-37/CD	appos||cholesterol-35/NN||%-38/NN	prep_for||those-21/DT||urinarytractinfection-41/NN	conj_and||diabetes-23/NN||urinarytractinfection-41/NN	num||%-44/NN||1.9-43/CD	appos||urinarytractinfection-41/NN||%-44/NN	prep_for||those-21/DT||hiv/aids-47/NNS	conj_and||diabetes-23/NN||hiv/aids-47/NNS	conj_and||diabetes-23/NN||chlamydia-49/NNS	conj_and||hiv/aids-47/NNS||chlamydia-49/NNS	dep||%-53/NN||both-51/DT	number||%-53/NN||1.6-52/CD	dep||hiv/aids-47/NNS||%-53/NN	aids--1||hiv--1||no||18.1% (799/4416) of the respondents had ever performed a self-test, the most frequently used tests being those for diabetes (5.3%), kidneydisease (4.9%), cholesterol (4.5%), urinarytractinfection (1.9%) and hiv/aids and chlamydia (both 1.6%).
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VB||viruses-7/NNS	nsubj||denguefever/dengue-21/VB||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VB	prep_to||lead-16/VB||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/dengue-21/VB	conj_and||lead-16/VB||denguefever/dengue-21/VB	dobj||denguefever/dengue-21/VB||hemorrhagicfever-22/NN	advmod||denguefever/dengue-21/VB||respectively-23/RB	det||two-27/CD||the-25/DT	amod||two-27/CD||other-26/JJ	nsubj||viruses-30/NNS||two-27/CD	cop||viruses-30/NNS||are-28/VBP	amod||viruses-30/NNS||tick-borne-29/JJ	parataxis||viruses-7/NNS||viruses-30/NNS	nsubj||contribute-49/VBP||viruses-30/NNS	advmod||virus-34/NN||namely-32/RB	amod||virus-34/NN||tick-borneencephalitis-33/JJ	parataxis||viruses-7/NNS||virus-34/NN	conj_and||viruses-30/NNS||virus-34/NN	nsubj||contribute-49/VBP||virus-34/NN	amod||virus-38/NN||crimean-congo-36/JJ	nn||virus-38/NN||hemorrhagicfever-37/NN	parataxis||viruses-7/NNS||virus-38/NN	conj_and||viruses-30/NNS||virus-38/NN	nsubj||contribute-49/VBP||virus-38/NN	advmod||known-41/VBN||also-40/RB	dep||viruses-30/NNS||known-41/VBN	prepc_as||known-41/VBN||xinjiang-43/VBG	nn||virus-45/NN||hemorrhagicfever-44/NN	dobj||xinjiang-43/VBG||virus-45/NN	rcmod||viruses-30/NNS||contribute-49/VBP	prep_to||contribute-49/VBP||tick-borneencephalitis-51/NNS	nn||hemorrhagicfever-54/NN||xinjiang-53/NN	prep_to||contribute-49/VBP||hemorrhagicfever-54/NN	conj_and||tick-borneencephalitis-51/NNS||hemorrhagicfever-54/NN	advmod||contribute-49/VBP||respectively-55/RB	hemorrhagicfever-54||viruses-30||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/dengue hemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
amod||levels-3/NNS||bcar4-1/JJ	nn||levels-3/NNS||mrna-2/NN	nsubjpass||measured-5/VBN||levels-3/NNS	nsubjpass||evaluated-11/VBN||levels-3/NNS	auxpass||measured-5/VBN||were-4/VBD	root||ROOT-0/null||measured-5/VBN	amod||breasttumours-8/NNS||primary-7/JJ	prep_in||measured-5/VBN||breasttumours-8/NNS	conj_and||measured-5/VBN||evaluated-11/VBN	prep_for||evaluated-11/VBN||association-13/NN	amod||survival-16/NN||progression-free-15/JJ	prep_with||evaluated-11/VBN||survival-16/NN	appos||survival-16/NN||pfs-18/NN	amod||benefit-22/NN||clinical-21/JJ	prep_with||evaluated-11/VBN||benefit-22/NN	conj_and||survival-16/NN||benefit-22/NN	prep_in||benefit-22/NN||patients-24/NNS	nn||receptor-27/NN||oestrogen-26/NN	prep_with||patients-24/NNS||receptor-27/NN	nn||±-31/NNS||er-29/NN	nn||±-31/NNS||î-30/NN	appos||receptor-27/NN||±-31/NNS	amod||tumours-35/NNS||positive-34/JJ	dep||benefit-22/NN||tumours-35/NNS	vmod||tumours-35/NNS||receiving-36/VBG	dobj||receiving-36/VBG||tamoxifen-37/NN	amod||monotherapy-40/NN||first-line-39/JJ	prep_as||receiving-36/VBG||monotherapy-40/NN	amod||disease-43/NN||advanced-42/JJ	prep_for||monotherapy-40/NN||disease-43/NN	breasttumours-8||oestrogen-26||yes||bcar4 mrna levels were measured in primary breasttumours, and evaluated for association with progression-free survival (pfs) and clinical benefit in patients with oestrogen receptor (er î± )-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease.
nsubj||autoimmunedisease-4/NN||type1diabetesmellitus-1/NNS	cop||autoimmunedisease-4/NN||is-2/VBZ	det||autoimmunedisease-4/NN||an-3/DT	root||ROOT-0/null||autoimmunedisease-4/NN	dep||autoimmunedisease-4/NN||caused-5/VBN	prep_by||caused-5/VBN||destruction-7/NN	amod||cells-11/NNS||pancreatic-9/JJ	nn||cells-11/NNS||beta-10/NN	prep_of||destruction-7/NN||cells-11/NNS	dep||autoimmunedisease-4/NN||characterized-13/VBN	conj_and||caused-5/VBN||characterized-13/VBN	prep_by||characterized-13/VBN||defect-15/NN	nn||secretion-18/NN||insulin-17/NN	prep_in||defect-15/NN||secretion-18/NN	mark||and/or-27/VBZ||while-19/IN	amod||results-21/NNS||type2diabetesmellitus-20/JJ	nsubj||and/or-27/VBZ||results-21/NNS	prep_from||results-21/NNS||abnormalities-23/NNS	nn||secretion-26/NN||insulin-25/NN	prep_in||abnormalities-23/NNS||secretion-26/NN	advcl||characterized-13/VBN||and/or-27/VBZ	nn||action-29/NN||insulin-28/NN	dobj||and/or-27/VBZ||action-29/NN	dobj||and/or-27/VBZ||both-31/DT	conj_or||action-29/NN||both-31/DT	type2diabetesmellitus-20||insulin-28||yes||type1diabetesmellitus is an autoimmunedisease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type2diabetesmellitus results from abnormalities in insulin secretion and/or insulin action or both.
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||artemether--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
det||technique-2/NN||the-1/DT	nsubj||has-3/VBZ||technique-2/NN	root||ROOT-0/null||has-3/VBZ	amod||advantages-5/NNS||certain-4/JJ	dobj||has-3/VBZ||advantages-5/NNS	amod||scintigraphy-8/NN||radioiodine-7/JJ	prep_over||advantages-5/NNS||scintigraphy-8/NN	det||treatment-12/NN||the-10/DT	amod||treatment-12/NN||surgical-11/JJ	nsubj||need-16/VBP||treatment-12/NN	prep_of||treatment-12/NN||thyroidtumors-14/NNS	advmod||thyroidtumors-14/NNS||no-15/RB	prepc_after||advantages-5/NNS||need-16/VBP	prep_for||need-16/VBP||withdrawal-18/NN	nn||substitution-21/NN||thyroxin-20/NN	prep_of||withdrawal-18/NN||substitution-21/NN	det||possibility-24/NN||a-23/DT	dobj||has-3/VBZ||possibility-24/NN	conj_and||advantages-5/NNS||possibility-24/NN	aux||diagnose-26/VB||to-25/TO	vmod||possibility-24/NN||diagnose-26/VB	dobj||diagnose-26/VB||metastases-27/NNS	prep_of||metastases-27/NNS||tumors-29/NNS	nsubj||concentrate-33/VB||tumors-29/NNS	aux||concentrate-33/VB||do-31/VBP	neg||concentrate-33/VB||not-32/RB	rcmod||tumors-29/NNS||concentrate-33/VB	dobj||concentrate-33/VB||radioiodine-34/NN	parataxis||diagnose-26/VB||mtc-36/VB	dep||mtc-36/VB||hã-38/VB	num||cancer-42/NN||1/4-39/CD	amod||cancer-42/NN||rthle-40/JJ	nn||cancer-42/NN||cell-41/NN	dobj||mtc-36/VB||cancer-42/NN	amod||information-47/NN||complementary-46/JJ	dobj||has-3/VBZ||information-47/NN	conj_and||advantages-5/NNS||information-47/NN	amod||sites-50/NNS||metastatic-49/JJ	prep_about||information-47/NN||sites-50/NNS	amod||cancer-54/NN||non-medullary-52/JJ	nn||cancer-54/NN||thyroid-53/NN	prep_of||sites-50/NNS||cancer-54/NN	dep||cancer-54/NN||papillary-56/NN	nn||tumors-59/NNS||follicular-58/NN	dep||cancer-54/NN||tumors-59/NNS	conj_and||papillary-56/NN||tumors-59/NNS	thyroidtumors-14||thyroxin-20||yes||the technique has certain advantages over radioiodine scintigraphy after the surgical treatment of thyroidtumors no need for withdrawal of thyroxin substitution; a possibility to diagnose metastases of tumors that do not concentrate radioiodine (mtc, hã¼rthle cell cancer); and complementary information about metastatic sites of non-medullary thyroid cancer (papillary and follicular tumors).
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-8/VBD||aim-3/NN	nsubj||observe-10/VB||aim-3/NN	nsubj||compare-12/VB||aim-3/NN	det||study-7/NN||the-5/DT	amod||study-7/NN||present-6/JJ	prep_of||aim-3/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||observe-10/VB||to-9/TO	xcomp||was-8/VBD||observe-10/VB	xcomp||was-8/VBD||compare-12/VB	conj_and||observe-10/VB||compare-12/VB	det||effects-14/NNS||the-13/DT	dobj||compare-12/VB||effects-14/NNS	amod||crl183-18/NNS||enterococcus-16/JJ	nn||crl183-18/NNS||faecium-17/NN	prep_of||effects-14/NNS||crl183-18/NNS	amod||microorganism-21/NN||probiotic-20/JJ	appos||effects-14/NNS||microorganism-21/NN	det||mixture-26/NN||an-24/DT	amod||mixture-26/NN||isoflavones-25/JJ	dobj||compare-12/VB||mixture-26/NN	conj_and||effects-14/NNS||mixture-26/NN	dobj||compare-12/VB||simvastatin-28/NN	conj_and||effects-14/NNS||simvastatin-28/NN	dep||effects-14/NNS||drug-30/NN	vmod||drug-30/NN||used-31/VBN	aux||treat-33/VB||to-32/TO	xcomp||used-31/VBN||treat-33/VB	dobj||treat-33/VB||hypercholesterolemia-34/NN	nn||parameters-38/NNS||lipid-37/NN	prep_on||compare-12/VB||parameters-38/NNS	prep_on||compare-12/VB||atherosclerosis-40/NNS	conj_and||parameters-38/NNS||atherosclerosis-40/NNS	dobj||observe-10/VB||development-41/NN	prep_in||observe-10/VB||rabbits-43/NNS	amod||hypercholesterolemia-46/NN||induced-45/JJ	prep_with||rabbits-43/NNS||hypercholesterolemia-46/NN	hypercholesterolemia-46||simvastatin-28||yes||objective the aim of the present study was to observe and compare the effects of enterococcus faecium crl183 (probiotic microorganism), an isoflavones mixture and simvastatin (drug used to treat hypercholesterolemia) on lipid parameters and atherosclerosis development in rabbits with induced hypercholesterolemia.
det||levels-3/NNS||the-1/DT	nn||levels-3/NNS||expression-2/NN	nsubjpass||downregulated-41/VBN||levels-3/NNS	amod||cells-9/NNS||gga-mir-26a-5/JJ	prep_in||gga-mir-26a-5/JJ||chicken-7/NN	nn||cells-9/NNS||lymphoma-8/NN	prep_of||levels-3/NNS||cells-9/NNS	vmod||cells-9/NNS||transformed-10/VBN	number||distinct-13/JJ||3-12/CD	amod||viruses-16/NNS||distinct-13/JJ	amod||viruses-16/NNS||avian-14/JJ	amod||viruses-16/NNS||oncogenic-15/JJ	agent||transformed-10/VBN||viruses-16/NNS	amod||mdv-24/NN||viz-18/JJ	nn||mdv-24/NN||marek-19/NN	nn||mdv-24/NN||sdisease-21/NN	nn||mdv-24/NN||virus-22/NN	agent||transformed-10/VBN||mdv-24/NN	conj_and||viruses-16/NNS||mdv-24/NN	nn||virus-29/NN||avian-27/NN	nn||virus-29/NN||leukosis-28/NN	agent||transformed-10/VBN||virus-29/NN	conj_and||viruses-16/NNS||virus-29/NN	appos||virus-29/NN||alv-31/NN	amod||virus-35/NN||reticuloendotheliosis-34/JJ	agent||transformed-10/VBN||virus-35/NN	conj_and||viruses-16/NNS||virus-35/NN	appos||virus-35/NN||rev-37/NN	auxpass||downregulated-41/VBN||were-39/VBD	advmod||downregulated-41/VBN||consistently-40/RB	root||ROOT-0/null||downregulated-41/VBN	prepc_compared_to||downregulated-41/VBN||to-43/TO	det||levels-45/NNS||the-44/DT	pobj||downregulated-41/VBN||levels-45/NNS	det||lymphocytes-49/NNS||the-47/DT	amod||lymphocytes-49/NNS||normal-48/JJ	prep_in||levels-45/NNS||lymphocytes-49/NNS	virus-35||viruses-16||no||the expression levels of gga-mir-26a in chicken lymphoma cells transformed by 3 distinct avian oncogenic viruses, viz marek'sdisease virus (mdv), avian leukosis virus (alv) and reticuloendotheliosis virus (rev) were consistently downregulated compared to the levels in the normal lymphocytes.
prep_in||mtb-9/VBP||total-2/NN	nsubj||mtb-9/VBP||692-4/CD	num||%-7/NN||64-6/CD	appos||692-4/CD||%-7/NN	root||ROOT-0/null||mtb-9/VBP	nsubjpass||tested-16/VBN||strains-10/NNS	prep_from||strains-10/NNS||cases-12/NNS	prep_with||cases-12/NNS||pulmonarytb-14/NN	auxpass||tested-16/VBN||were-15/VBD	ccomp||mtb-9/VBP||tested-16/VBN	prep_for||tested-16/VBN||susceptibility-18/NN	prep_against||tested-16/VBN||rifampicin-20/NN	prep_against||tested-16/VBN||isoniazid-22/NN	conj_and||rifampicin-20/NN||isoniazid-22/NN	prep_against||tested-16/VBN||ethambutol-24/NN	conj_and||rifampicin-20/NN||ethambutol-24/NN	prep_against||tested-16/VBN||streptomycin-27/NN	conj_and||rifampicin-20/NN||streptomycin-27/NN	vmod||rifampicin-20/NN||using-28/VBG	det||instrument-32/NN||the-29/DT	amod||instrument-32/NN||mgit-30/JJ	dep||mgit-30/JJ||960-31/CD	dobj||using-28/VBG||instrument-32/NN	pulmonarytb-14||mtb-9||no||in total, 692 (64%) mtb strains from cases with pulmonarytb were tested for susceptibility against rifampicin, isoniazid, ethambutol, and streptomycin using the mgit 960 instrument.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||level-4/NN||the-3/DT	dobj||evaluate-2/VB||level-4/NN	prep_of||level-4/NN||pain-6/NN	prep_during||evaluate-2/VB||phacoemulsification-8/NN	amod||implantation-13/NN||foldable-10/JJ	amod||implantation-13/NN||intraocular-11/JJ	nn||implantation-13/NN||lens-12/NN	prep_during||evaluate-2/VB||implantation-13/NN	conj_and||phacoemulsification-8/NN||implantation-13/NN	prep_under||evaluate-2/VB||instillation-15/NN	amod||eyedrops-20/NNS||tetracaine-17/JJ	number||%-19/NN||0.5-18/CD	amod||eyedrops-20/NNS||%-19/NN	prep_of||instillation-15/NN||eyedrops-20/NNS	det||combination-23/NN||a-22/DT	prep_versus||eyedrops-20/NNS||combination-23/NN	dep||%-27/NN||lidocaine-25/JJ	number||%-27/NN||2-26/CD	amod||gel-28/NN||%-27/NN	prep_of||combination-23/NN||gel-28/NN	prep_of||combination-23/NN||instillation-30/NN	conj_and||gel-28/NN||instillation-30/NN	amod||eyedrops-33/NNS||tetracaine-32/JJ	prep_of||eyedrops-20/NNS||eyedrops-33/NNS	pain-6||tetracaine-32||yes||to evaluate the level of pain during phacoemulsification and foldable intraocular lens implantation under instillation of tetracaine 0.5% eyedrops versus a combination of lidocaine 2% gel and instillation of tetracaine eyedrops.
nsubj||causes-6/VBZ||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||causes-6/VBZ||infection-5/RB	root||ROOT-0/null||causes-6/VBZ	amod||amount-8/NN||large-7/JJ	dobj||causes-6/VBZ||amount-8/NN	prep_of||amount-8/NN||unfolding-10/VBG	amod||accumulation-14/NN||false-folding-12/JJ	nn||accumulation-14/NN||protein-13/NN	prep_of||amount-8/NN||accumulation-14/NN	conj_or||unfolding-10/VBG||accumulation-14/NN	det||reticulum-18/NN||the-16/DT	amod||reticulum-18/NN||endoplasmic-17/JJ	prep_in||accumulation-14/NN||reticulum-18/NN	nsubj||induces-26/VBZ||reticulum-18/NN	appos||reticulum-18/NN||er-20/NN	prep_in||induces-26/VBZ||turn-25/NN	rcmod||reticulum-18/NN||induces-26/VBZ	det||expression-28/NN||the-27/DT	dobj||induces-26/VBZ||expression-28/NN	amod||protein-31/NN||glucose-regulated-30/JJ	prep_of||expression-28/NN||protein-31/NN	num||protein-31/NN||78-32/CD	appos||protein-31/NN||grp78-34/NNP	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infection causes large amount of unfolding or false-folding protein accumulation in the endoplasmic reticulum (er), which in turn induces the expression of glucose-regulated protein 78 (grp78).
amod||regimen-3/NN||current-1/JJ	nn||regimen-3/NN||treatment-2/NN	nsubj||succeed-13/VB||regimen-3/NN	nsubj||eliminate-15/VB||regimen-3/NN	vmod||regimen-3/NN||consisting-4/VBG	prep_of||consisting-4/VBG||interferon-6/NN	amod||interferon-6/NN||alpha-7/NN	amod||interferon-6/NN||ribavirin-9/NN	conj_and||alpha-7/NN||ribavirin-9/NN	aux||succeed-13/VB||does-10/VBZ	neg||succeed-13/VB||not-11/RB	advmod||succeed-13/VB||always-12/RB	root||ROOT-0/null||succeed-13/VB	aux||eliminate-15/VB||to-14/TO	xcomp||succeed-13/VB||eliminate-15/VB	dobj||eliminate-15/VB||virus-16/NN	advmod||eliminate-15/VB||completely-17/RB	det||patient-20/NN||the-19/DT	poss||body-22/NN||patient-20/NN	prep_from||eliminate-15/VB||body-22/NN	virus-16||ribavirin-9||yes||current treatment regimen consisting of interferon alpha and ribavirin does not always succeed to eliminate virus completely from the patient's body.
nsubj||suppressed-8/VBD||ablation-1/NN	amod||levels-4/NNS||e2f4-3/JJ	prep_of||ablation-1/NN||levels-4/NNS	nn||methodology-7/NN||sirna-6/NN	prep_by||levels-4/NNS||methodology-7/NN	root||ROOT-0/null||suppressed-8/VBD	amod||arrest-11/NN||capsaicin-induced-9/JJ	amod||arrest-11/NN||g1-10/JJ	dobj||suppressed-8/VBD||arrest-11/NN	capsaicin--1||arrest-11||no_rel||ablation of e2f4 levels by sirna methodology suppressed capsaicin-induced g1 arrest.
nsubj||studied-2/VBD||we-1/PRP	nsubj||metformin-controlled-11/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	num||men-4/NNS||10-3/CD	dobj||studied-2/VBD||men-4/NNS	dobj||studied-2/VBD||women-6/NNS	conj_and||men-4/NNS||women-6/NNS	prep_with||studied-2/VBD||diet-8/NN	conj_and/or||studied-2/VBD||metformin-controlled-11/VBD	dobj||metformin-controlled-11/VBD||type2diabetes-12/NNS	type2diabetes-12||metformin--1||yes||we studied 10 men and women with diet- and/or metformin-controlled type2diabetes.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	poss||disease-53/NN||graves-51/NNS	prep_with||gene-44/NN||disease-53/NN	conj_and||type1diabetesmellitus-46/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	dm-48||type1diabetesmellitus-46||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves' disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
det||goal-3/NN||the-1/DT	amod||goal-3/NN||primary-2/JJ	nsubj||was-7/VBD||goal-3/NN	nsubj||determine-9/VB||goal-3/NN	det||study-6/NN||this-5/DT	prep_of||goal-3/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||determine-9/VB||to-8/TO	xcomp||was-7/VBD||determine-9/VB	mark||regulates-13/VBZ||whether-10/IN	nn||glp-1-12/NNS||endogenous-11/NNS	nsubj||regulates-13/VBZ||glp-1-12/NNS	ccomp||determine-9/VB||regulates-13/VBZ	nn||secretion-15/NN||insulin-14/NN	dobj||regulates-13/VBZ||secretion-15/NN	prep_in||secretion-15/NN||type2diabetes-17/CD	type2diabetes-17||insulin-14||yes||the primary goal of this study was to determine whether endogenous glp-1 regulates insulin secretion in type2diabetes.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	irondeficiency-11||iron-47||yes||we present data drawn from four different conditionsâ€”irondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâ€”both in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
amod||patients-2/NNS||sixty-1/JJ	nsubjpass||divided-12/VBN||patients-2/NNS	prep_with||patients-2/NNS||psychoticdisorder-4/NN	nsubjpass||assigned-7/VBN||psychoticdisorder-4/NN	auxpass||assigned-7/VBN||were-6/VBD	rcmod||psychoticdisorder-4/NN||assigned-7/VBN	amod||treatment-10/NN||6-month-9/JJ	prep_to||assigned-7/VBN||treatment-10/NN	auxpass||divided-12/VBN||were-11/VBD	root||ROOT-0/null||divided-12/VBN	num||groups-15/NNS||two-14/CD	prep_in||divided-12/VBN||groups-15/NNS	num||haloperidol-18/NN||30-16/CD	amod||haloperidol-18/NN||received-17/VBN	dobj||divided-12/VBN||haloperidol-18/NN	amod||antipsychotic-22/NN||first-20/JJ	nn||antipsychotic-22/NN||generation-21/NN	appos||haloperidol-18/NN||antipsychotic-22/NN	num||olanzapine-27/NN||30-25/CD	amod||olanzapine-27/NN||received-26/VBN	dobj||divided-12/VBN||olanzapine-27/NN	conj_and||haloperidol-18/NN||olanzapine-27/NN	amod||antipsychotic-31/NN||second-29/JJ	nn||antipsychotic-31/NN||generation-30/NN	appos||olanzapine-27/NN||antipsychotic-31/NN	psychoticdisorder-4||olanzapine-27||yes||sixty patients with psychoticdisorder who were assigned to 6-month treatment were divided in two groups 30 received haloperidol (first generation antipsychotic) and 30 received olanzapine (second generation antipsychotic).
nsubj||constructed-3/VBN||we-1/PRP	aux||constructed-3/VBN||have-2/VBP	dep||take-52/VB||constructed-3/VBN	det||model-5/NN||a-4/DT	dobj||constructed-3/VBN||model-5/NN	prep_of||model-5/NN||hivinfection-7/NN	mark||types-13/VBZ||that-8/IN	nsubj||types-13/VBZ||differentiates-9/NNS	nsubj||used-17/VBN||differentiates-9/NNS	det||hla-12/NN||these-11/DT	prep_between||differentiates-9/NNS||hla-12/NN	ccomp||constructed-3/VBN||types-13/VBZ	aux||used-17/VBN||have-16/VBP	ccomp||constructed-3/VBN||used-17/VBN	conj_and||types-13/VBZ||used-17/VBN	amod||estimates-19/NNS||reported-18/VBN	dobj||used-17/VBN||estimates-19/NNS	det||number-22/NN||the-21/DT	prep_of||estimates-19/NNS||number-22/NN	prep_of||number-22/NN||people-24/NNS	vmod||people-24/NNS||infected-25/VBN	prep_with||infected-25/VBN||hiv-27/NN	det||rates-31/NNS||the-29/DT	amod||rates-31/NNS||different-30/JJ	prep_with||infected-25/VBN||rates-31/NNS	conj_and||hiv-27/NN||rates-31/NNS	prep_of||rates-31/NNS||progression-33/NN	aux||acquiredimmunodeficiencysyndrome-35/VB||to-34/TO	xcomp||infected-25/VBN||acquiredimmunodeficiencysyndrome-35/VB	dobj||acquiredimmunodeficiencysyndrome-35/VB||aids-37/NNS	nsubj||provide-40/VB||aids-37/NNS	aux||provide-40/VB||to-39/TO	xcomp||acquiredimmunodeficiencysyndrome-35/VB||provide-40/VB	det||estimate-44/NN||a-41/DT	dep||bound-43/VBN||lower-42/JJR	amod||estimate-44/NN||bound-43/VBN	dobj||provide-40/VB||estimate-44/NN	det||length-47/NN||the-46/DT	prep_on||provide-40/VB||length-47/NN	prep_of||length-47/NN||time-49/NN	nsubj||take-52/VB||it-50/PRP	nsubj||impose-56/VB||it-50/PRP	aux||take-52/VB||would-51/MD	root||ROOT-0/null||take-52/VB	prep_for||take-52/VB||hiv-54/NN	aux||impose-56/VB||to-55/TO	xcomp||take-52/VB||impose-56/VB	amod||change-59/NN||major-57/JJ	amod||change-59/NN||genetic-58/JJ	dobj||impose-56/VB||change-59/NN	prep_in||impose-56/VB||humans-61/NNS	acquiredimmunodeficiencysyndrome-35||hiv-54||no||we have constructed a model of hivinfection that differentiates between these hla types, and have used reported estimates of the number of people infected with hiv and the different rates of progression to acquiredimmunodeficiencysyndrome (aids) to provide a lower bound estimate on the length of time it would take for hiv to impose major genetic change in humans.
det||combination-3/NN||a-1/DT	amod||combination-3/NN||fixed-dose-2/JJ	nsubj||shown-13/VBN||combination-3/NN	prep_of||combination-3/NN||artemether-lumefantrine-5/NN	appos||combination-3/NN||al-7/NNP	nn||®-10/NNP||coartemâ-9/NNP	dep||al-7/NNP||®-10/NNP	aux||shown-13/VBN||has-12/VBZ	root||ROOT-0/null||shown-13/VBN	amod||efficacy-15/NN||high-14/JJ	dobj||shown-13/VBN||efficacy-15/NN	amod||tolerability-18/NN||good-17/JJ	dobj||shown-13/VBN||tolerability-18/NN	conj_and||efficacy-15/NN||tolerability-18/NN	dobj||shown-13/VBN||cost-effectiveness-20/NNS	conj_and||efficacy-15/NN||cost-effectiveness-20/NNS	prep_in||shown-13/VBN||adults-22/NNS	prep_in||shown-13/VBN||children-24/NNS	conj_and||adults-22/NNS||children-24/NNS	amod||malaria-27/NN||uncomplicated-26/JJ	prep_with||shown-13/VBN||malaria-27/NN	vmod||malaria-27/NN||caused-28/VBN	nn||falciparum-31/NN||plasmodium-30/NN	agent||caused-28/VBN||falciparum-31/NN	malaria-27||lumefantrine--1||yes||a fixed-dose combination of artemether-lumefantrine (al, coartemâ®) has shown high efficacy, good tolerability and cost-effectiveness in adults and children with uncomplicated malaria caused by plasmodium falciparum .
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||explore-8/VB||purpose-2/NN	det||work-5/NN||this-4/DT	prep_of||purpose-2/NN||work-5/NN	root||ROOT-0/null||was-6/VBD	aux||explore-8/VB||to-7/TO	xcomp||was-6/VBD||explore-8/VB	det||knowledge-10/NN||the-9/DT	dobj||explore-8/VB||knowledge-10/NN	dobj||explore-8/VB||acceptance-12/NN	conj_and||knowledge-10/NN||acceptance-12/NN	prep_of||knowledge-10/NN||varicellazostervirus-14/NNS	appos||varicellazostervirus-14/NNS||vzv-16/NN	amod||vaccination-23/NN||herpeszoster-19/JJ	appos||vaccination-23/NN||hz-21/NN	dep||varicellazostervirus-14/NNS||vaccination-23/NN	det||population-28/NN||the-25/DT	amod||population-28/NN||general-26/JJ	amod||population-28/NN||italian-27/JJ	prep_in||vaccination-23/NN||population-28/NN	advmod||distributed-38/VBN||where-30/WRB	det||vaccine-33/NN||the-31/DT	nn||vaccine-33/NN||hz-32/NN	nsubjpass||distributed-38/VBN||vaccine-33/NN	aux||distributed-38/VBN||has-34/VBZ	neg||distributed-38/VBN||not-35/RB	advmod||distributed-38/VBN||yet-36/RB	auxpass||distributed-38/VBN||been-37/VBN	rcmod||population-28/NN||distributed-38/VBN	vmod||varicellazostervirus-14/NNS||using-40/VBG	det||study-43/NN||a-41/DT	amod||study-43/NN||prevalence-42/JJ	dobj||using-40/VBG||study-43/NN	prep_of||study-43/NN||subjects-45/NNS	num||regions-48/NNS||two-47/CD	prep_from||using-40/VBG||regions-48/NNS	prep_in||regions-48/NNS||italy-50/NN	herpeszoster-19||vzv-16||no||the purpose of this work was to explore the knowledge and acceptance of varicellazostervirus (vzv)-herpeszoster (hz) vaccination in the general italian population, where the hz vaccine has not yet been distributed, using a prevalence study of subjects from two regions in italy.
det||effort-2/NN||the-1/DT	nsubj||led-25/VBN||effort-2/NN	aux||develop-4/VB||to-3/TO	vmod||effort-2/NN||develop-4/VB	det||rin-20/NN||a-5/DT	nn||rin-20/NN||tuberculosis-6/NNP	appos||tuberculosis-6/NNP||tb-8/NN	nn||rin-20/NN||vaccine-10/NN	advmod||effective-12/JJ||more-11/RBR	amod||rin-20/NN||effective-12/JJ	det||bacille-17/NN||the-14/DT	advmod||used-16/VBN||widely-15/RB	amod||bacille-17/NN||used-16/VBN	prep_than||effective-12/JJ||bacille-17/NN	nn||rin-20/NN||calmette-guã-18/NNP	nn||rin-20/NN||©-19/NNP	dobj||develop-4/VB||rin-20/NN	appos||rin-20/NN||bcg-22/NN	aux||led-25/VBN||has-24/VBZ	root||ROOT-0/null||led-25/VBN	det||development-28/NN||the-27/DT	prep_to||led-25/VBN||development-28/NN	num||vaccines-35/NNS||two-30/CD	nn||vaccines-35/NNS||novel-31/NN	nn||vaccines-35/NNS||fusion-32/NN	nn||vaccines-35/NNS||protein-33/NN	nn||vaccines-35/NNS||subunit-34/NN	prep_of||development-28/NN||vaccines-35/NNS	amod||vaccines-35/NNS||ag85b-esat-6-36/JJ	amod||vaccines-35/NNS||ag85b-tb10-38/JJ	conj_and||ag85b-esat-6-36/JJ||ag85b-tb10-38/JJ	dobj||led-25/VBN||.4-39/CD	tuberculosis-6||bcg-22||no||the effort to develop a tuberculosis (tb) vaccine more effective than the widely used bacille calmette-guã©rin (bcg) has led to the development of two novel fusion protein subunit vaccines ag85b-esat-6 and ag85b-tb10.4.
nsubj||growing-25/VBG||evidence-1/NN	det||utility-4/NN||the-3/DT	prep_for||evidence-1/NN||utility-4/NN	det||mycobacteriumtuberculosis-8/NNS||the-6/DT	amod||mycobacteriumtuberculosis-8/NNS||new-7/JJ	prep_of||utility-4/NN||mycobacteriumtuberculosis-8/NNS	dep||mycobacteriumtuberculosis-8/NNS||mtb-10/VBN	amod||assays-16/NNS||specific-12/JJ	amod||assays-16/NNS||ifn-î-13/JJ	amod||assays-16/NNS||³-14/JJ	nn||assays-16/NNS||release-15/NN	dep||mycobacteriumtuberculosis-8/NNS||assays-16/NNS	prepc_in||assays-16/NNS||diagnosing-18/VBG	nn||tuberculosisinfection-20/NN||latent-19/NN	dobj||diagnosing-18/VBG||tuberculosisinfection-20/NN	appos||tuberculosisinfection-20/NN||ltbi-22/NNP	cop||growing-25/VBG||is-24/VBZ	root||ROOT-0/null||growing-25/VBG	tuberculosisinfection-20||mtb-10||no||evidence for the utility of the new mycobacteriumtuberculosis (mtb) specific ifn-î³ release assays in diagnosing latent tuberculosisinfection (ltbi) is growing.
amod||experiments-2/NNS||previous-1/JJ	nsubj||showed-3/VBD||experiments-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||reduced-10/VBD||that-4/IN	amod||heparin-6/NN||ultra-low-molecular-weight-5/JJ	nsubj||reduced-10/VBD||heparin-6/NN	appos||heparin-6/NN||ulmwh-8/NN	ccomp||showed-3/VBD||reduced-10/VBD	det||deficit-15/NN||the-11/DT	amod||deficit-15/NN||infarct-12/JJ	conj_and||infarct-12/JJ||neurologic-14/JJ	amod||deficit-15/NN||neurologic-14/JJ	dobj||reduced-10/VBD||deficit-15/NN	prep_in||reduced-10/VBD||rats-17/NNS	vmod||rats-17/NNS||followed-18/VBN	amod||cerebralischemia-21/NN||transient-20/JJ	agent||followed-18/VBN||cerebralischemia-21/NN	det||mechanisms-25/NNS||the-24/DT	nsubj||unclear-31/JJ||mechanisms-25/NNS	poss||effect-29/NN||its-27/PRP$	amod||effect-29/NN||neuroprotective-28/JJ	prep_of||mechanisms-25/NNS||effect-29/NN	cop||unclear-31/JJ||are-30/VBP	conj_but||showed-3/VBD||unclear-31/JJ	heparin-6||deficit-15||no_rel||previous experiments showed that ultra-low-molecular-weight heparin (ulmwh) reduced the infarct and neurologic deficit in rats followed by transient cerebralischemia, but the mechanisms of its neuroprotective effect are unclear.
mark||dependent-9/JJ||although-1/IN	det||response-3/NN||the-2/DT	nsubj||dependent-9/JJ||response-3/NN	nn||treatment-6/NN||interferon-5/NN	prep_to||response-3/NN||treatment-6/NN	cop||dependent-9/JJ||is-7/VBZ	advmod||dependent-9/JJ||largely-8/RB	advcl||remains-31/VBZ||dependent-9/JJ	csubj||remains-31/VBZ||dependent-9/JJ	nn||genotypes-12/NNS||hcv-11/NN	prep_on||dependent-9/JJ||genotypes-12/NNS	mark||exists-19/VBZ||whether-14/IN	ccomp||dependent-9/JJ||not-16/RB	conj_or||exists-19/VBZ||not-16/RB	det||relationship-18/NN||a-17/DT	nsubj||exists-19/VBZ||relationship-18/NN	ccomp||dependent-9/JJ||exists-19/VBZ	nn||variability-23/NN||hcv-21/NN	nn||variability-23/NN||genome-22/NN	prep_between||exists-19/VBZ||variability-23/NN	amod||course-26/NN||clinical-25/JJ	prep_between||exists-19/VBZ||course-26/NN	conj_and||variability-23/NN||course-26/NN	amod||disease-29/NN||hepatitisc-28/JJ	prep_of||variability-23/NN||disease-29/NN	advmod||remains-31/VBZ||still-30/RB	root||ROOT-0/null||remains-31/VBZ	acomp||remains-31/VBZ||unknown-32/JJ	hepatitisc-28||hcv-21||no||although the response to interferon treatment is largely dependent on hcv genotypes, whether or not a relationship exists between hcv genome variability and clinical course of hepatitisc disease still remains unknown.
det||study-3/NN||this-2/DT	prep_in||used-13/VBN||study-3/NN	nsubjpass||used-13/VBN||assessment-5/NN	nsubj||identify-15/VB||assessment-5/NN	amod||plasmablasts-10/NNS||bcg-specific-7/JJ	amod||plasmablasts-10/NNS||igg-secreting-8/JJ	amod||plasmablasts-10/NNS||peripheral-9/JJ	prep_of||assessment-5/NN||plasmablasts-10/NNS	auxpass||used-13/VBN||was-12/VBD	root||ROOT-0/null||used-13/VBN	aux||identify-15/VB||to-14/TO	xcomp||used-13/VBN||identify-15/VB	amod||tb-17/NN||active-16/JJ	dobj||identify-15/VB||tb-17/NN	det||groups-21/NNS||these-19/DT	amod||groups-21/NNS||high-risk-20/JJ	prep_in||identify-15/VB||groups-21/NNS	tb-17||bcg--1||no||in this study, assessment of bcg-specific igg-secreting peripheral plasmablasts, was used to identify active tb in these high-risk groups.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	type2diabetes-33||insulin-27||yes||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
advmod||reconsidered-25/VBN||therefore-1/RB	det||use-4/NN||the-3/DT	nsubjpass||reconsidered-25/VBN||use-4/NN	nsubjpass||investigated-27/VBN||use-4/NN	prep_of||use-4/NN||amp-6/NN	prep_of||use-4/NN||tmp/smx-8/NN	conj_or||amp-6/NN||tmp/smx-8/NN	det||choice-12/NN||the-10/DT	amod||choice-12/NN||first-11/JJ	prep_as||amp-6/NN||choice-12/NN	amod||treatment-17/NN||empirical-14/JJ	conj_and||empirical-14/JJ||prophylactic-16/JJ	amod||treatment-17/NN||prophylactic-16/JJ	prep_in||choice-12/NN||treatment-17/NN	nn||uti-20/NN||childhood-19/NN	prep_of||treatment-17/NN||uti-20/NN	prep_in||uti-20/NN||korea-22/NN	aux||reconsidered-25/VBN||should-23/MD	auxpass||reconsidered-25/VBN||be-24/VB	root||ROOT-0/null||reconsidered-25/VBN	conj_and||reconsidered-25/VBN||investigated-27/VBN	advmod||reconsidered-25/VBN||further-28/RBR	uti-20||smx--1||yes||therefore, the use of amp or tmp/smx as the first choice in empirical and prophylactic treatment of childhood uti in korea should be reconsidered and investigated further.
nn||design-2/NN||research-1/NN	nsubj||examine-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||examine-8/VB||$-5/NNP	aux||examine-8/VB||to-7/TO	advcl||generated-19/VBD||examine-8/VB	det||effects-10/NNS||the-9/DT	dobj||examine-8/VB||effects-10/NNS	amod||specific-13/NN||insulinresistance-12/JJ	prep_of||effects-10/NNS||specific-13/NN	det||endothelium-16/NN||the-15/DT	prep_to||examine-8/VB||endothelium-16/NN	nsubj||generated-19/VBD||we-18/PRP	root||ROOT-0/null||generated-19/VBD	det||mouse-22/NN||a-20/DT	amod||mouse-22/NN||transgenic-21/JJ	dobj||generated-19/VBD||mouse-22/NN	amod||overexpression-25/NN||endothelium-targeted-24/JJ	prep_with||generated-19/VBD||overexpression-25/NN	det||receptor-31/NN||a-27/DT	amod||receptor-31/NN||dominant-negative-28/JJ	amod||receptor-31/NN||mutant-29/JJ	nn||receptor-31/NN||humaninsulin-30/NN	prep_of||overexpression-25/NN||receptor-31/NN	discourse||receptor-31/NN||esmiro-33/UH	humaninsulin-30||insulinresistance-12||no_rel||research design and methodsâ€” to examine the effects of insulinresistance specific to the endothelium, we generated a transgenic mouse with endothelium-targeted overexpression of a dominant-negative mutant humaninsulin receptor (esmiro).
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	det||review-5/NN||this-4/DT	prep_of||purpose-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||address-8/VB||to-7/TO	dep||is-6/VBZ||address-8/VB	det||number-10/NN||a-9/DT	dobj||address-8/VB||number-10/NN	nn||strategies-13/NNS||counseling-12/NN	prep_of||number-10/NN||strategies-13/NNS	vmod||strategies-13/NNS||used-14/VBN	prep_for||used-14/VBN||education-16/NN	prep_for||used-14/VBN||counseling-18/NN	conj_and||education-16/NN||counseling-18/NN	prep_of||education-16/NN||individuals-20/NNS	prep_at||used-14/VBN||risk-22/NN	prepc_of||risk-22/NN||getting-24/VBG	dobj||getting-24/VBG||hiv/aids-25/NNS	advmod||among-28/IN||also-27/RB	dep||is-6/VBZ||among-28/IN	conj_and||address-8/VB||among-28/IN	pobj||among-28/IN||those-29/DT	nsubj||hiv-infected-32/JJ||those-29/DT	cop||hiv-infected-32/JJ||are-31/VBP	rcmod||those-29/DT||hiv-infected-32/JJ	aids--1||hiv--1||no||the purpose of this review is to address a number of counseling strategies used for education and counseling of individuals at risk of getting hiv/aids and also among those who are hiv-infected.
prep_from||had-12/VBD||january-2/NNP	num||january-2/NNP||2004-3/CD	prep_to||had-12/VBD||june-5/NNP	num||june-5/NNP||2005-6/CD	num||patients-9/NNS||254-8/CD	nsubj||had-12/VBD||patients-9/NNS	nsubj||received-25/VBD||patients-9/NNS	prep_with||patients-9/NNS||stemi-11/NNS	root||ROOT-0/null||had-12/VBD	amod||reversal-14/NN||immediate-13/JJ	dobj||had-12/VBD||reversal-14/NN	prep_of||reversal-14/NN||anticoagulation-16/NN	amod||administration-19/NN||protamine-18/JJ	prep_by||had-12/VBD||administration-19/NN	amod||stenting-23/NN||infarct-21/JJ	nn||stenting-23/NN||artery-22/NN	prep_after||administration-19/NN||stenting-23/NN	conj_and||had-12/VBD||received-25/VBD	amod||therapy-27/NN||abciximab-26/JJ	dobj||received-25/VBD||therapy-27/NN	nn||infusion-30/NN||heparin-29/NN	prep_without||received-25/VBD||infusion-30/NN	appos||infusion-30/NN||group-32/NN	num||group-32/NN||1-33/CD	infarct-21||protamine-18||no_rel||from january 2004 to june 2005, 254 patients with stemi had immediate reversal of anticoagulation by protamine administration after infarct artery stenting and received abciximab therapy without heparin infusion (group 1).
advmod||dissatisfied-10/VBN||however-1/RB	quantmod||10-4/CD||approximately-3/RB	num||%-5/NN||10-4/CD	nsubjpass||dissatisfied-10/VBN||%-5/NN	amod||patients-8/NNS||hypothyroid-7/JJ	prep_of||%-5/NN||patients-8/NNS	auxpass||dissatisfied-10/VBN||are-9/VBP	root||ROOT-0/null||dissatisfied-10/VBN	det||outcome-13/NN||the-12/DT	prep_with||dissatisfied-10/VBN||outcome-13/NN	amod||monotherapy-16/NN||levothyroxine-15/JJ	prep_of||outcome-13/NN||monotherapy-16/NN	nsubj||continue-20/VBP||physicians-19/NNS	nsubj||report-22/VB||physicians-19/NNS	conj_and||dissatisfied-10/VBN||continue-20/VBP	aux||report-22/VB||to-21/TO	xcomp||continue-20/VBP||report-22/VB	dobj||report-22/VB||benefits-23/NNS	amod||therapy-27/NN||combined-25/VBN	amod||therapy-27/NN||levothyroxine-triidothyronine-26/JJ	prep_from||report-22/VB||therapy-27/NN	det||patients-31/NNS||some-29/DT	amod||patients-31/NNS||hypothyroid-30/JJ	prep_for||therapy-27/NN||patients-31/NNS	hypothyroid-30||levothyroxine-15||yes||however, approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients.
amod||meta-analysis-2/NNS||prospective-1/JJ	root||ROOT-0/null||meta-analysis-2/NNS	amod||trials-6/NNS||randomized-4/JJ	amod||trials-6/NNS||clinical-5/JJ	prep_of||meta-analysis-2/NNS||trials-6/NNS	nsubj||evaluated-11/VBN||trials-6/NNS	appos||trials-6/NNS||rcts-8/NNS	rcmod||trials-6/NNS||evaluated-11/VBN	det||effectiveness-13/NN||the-12/DT	dobj||evaluated-11/VBN||effectiveness-13/NN	amod||chemoprophylaxis-16/NNS||isoniazid-15/JJ	prep_of||effectiveness-13/NN||chemoprophylaxis-16/NNS	prep_versus||chemoprophylaxis-16/NNS||placebo-18/NN	prepc_for||evaluated-11/VBN||preventing-20/VBG	det||incidence-22/NN||the-21/DT	dobj||preventing-20/VBG||incidence-22/NN	nn||disease-25/NN||tuberculosis-24/NNP	prep_of||incidence-22/NN||disease-25/NN	prep_among||preventing-20/VBG||humanimmunodeficiencyvirus-27/NNS	appos||humanimmunodeficiencyvirus-27/NNS||hiv-29/NN	amod||individuals-33/NNS||positive-32/JJ	nsubj||testing-34/VBG||individuals-33/NNS	dep||meta-analysis-2/NNS||testing-34/VBG	amod||derivative-37/NN||purified-35/JJ	nn||derivative-37/NN||protein-36/NN	nsubj||negative-38/JJ||derivative-37/NN	xcomp||testing-34/VBG||negative-38/JJ	tuberculosis-24||isoniazid-15||yes||prospective meta-analysis of randomized clinical trials (rcts) that evaluated the effectiveness of isoniazid chemoprophylaxis versus placebo for preventing the incidence of tuberculosis disease among humanimmunodeficiencyvirus (hiv)-positive individuals testing purified protein derivative negative.
amod||exposure-2/NN||maternal-1/JJ	nsubj||results-10/VBZ||exposure-2/NN	nsubj||drugsofabuse-27/VB||exposure-2/NN	advmod||low-5/JJ||even-4/RB	amod||doses-6/NNS||low-5/JJ	prep_to||exposure-2/NN||doses-6/NNS	amod||compounds-9/NNS||cannabinoid-8/JJ	prep_of||doses-6/NNS||compounds-9/NNS	root||ROOT-0/null||results-10/VBZ	amod||activity-14/NN||atypical-12/JJ	nn||activity-14/NN||locomotor-13/NN	prep_in||results-10/VBZ||activity-14/NN	amod||impairments-17/NNS||cognitive-16/JJ	prep_in||results-10/VBZ||impairments-17/NNS	conj_and||activity-14/NN||impairments-17/NNS	amod||behavior-21/NN||altered-19/JJ	amod||behavior-21/NN||emotional-20/JJ	prep_in||results-10/VBZ||behavior-21/NN	conj_and||activity-14/NN||behavior-21/NN	amod||sensitivity-25/NN||enhanced-24/JJ	prep_in||results-10/VBZ||sensitivity-25/NN	conj_and||activity-14/NN||sensitivity-25/NN	aux||drugsofabuse-27/VB||to-26/TO	xcomp||results-10/VBZ||drugsofabuse-27/VB	det||offspring-32/NN||the-29/DT	amod||offspring-32/NN||adult-30/JJ	nn||offspring-32/NN||rodent-31/NN	prep_in||drugsofabuse-27/VB||offspring-32/NN	cannabinoid-8||drugsofabuse-27||no_rel||maternal exposure to even low doses of cannabinoid compounds results in atypical locomotor activity, cognitive impairments, altered emotional behavior, and enhanced sensitivity to drugsofabuse in the adult rodent offspring.
amod||appearance-2/NN||palmitate-1/JJ	nsubjpass||determined-11/VBN||appearance-2/NN	nn||rates-5/NNS||oxidation-4/NN	conj_and||appearance-2/NN||rates-5/NNS	nsubjpass||determined-11/VBN||rates-5/NNS	amod||rate-9/NN||glycerol-7/JJ	nn||rate-9/NN||appearance-8/NN	conj_and||appearance-2/NN||rate-9/NN	nsubjpass||determined-11/VBN||rate-9/NN	auxpass||determined-11/VBN||were-10/VBD	root||ROOT-0/null||determined-11/VBN	amod||offspring-15/NN||eleven-13/VBN	amod||offspring-15/NN||healthy-14/JJ	prep_in||determined-11/VBN||offspring-15/NN	num||parents-18/NNS||two-17/CD	prep_of||offspring-15/NN||parents-18/NNS	prep_with||parents-18/NNS||t2d-20/CD	amod||history-24/NN||positive-22/JJ	nn||history-24/NN||family-23/NN	appos||offspring-15/NN||history-24/NN	nn||+-27/NNP||fh-26/NNP	dep||history-24/NN||+-27/NNP	num||subjects-32/NNS||13-30/CD	amod||subjects-32/NNS||healthy-31/JJ	prep_in||determined-11/VBN||subjects-32/NNS	conj_and||offspring-15/NN||subjects-32/NNS	amod||relatives-35/NNS||first-degree-34/JJ	prep_without||subjects-32/NNS||relatives-35/NNS	prep_with||relatives-35/NNS||t2d-37/NNS	dep||t2d-37/NNS||fh-39/RB	num||subjects-44/NNS||12-43/CD	prep_in||determined-11/VBN||subjects-44/NNS	conj_and||offspring-15/NN||subjects-44/NNS	prep_with||subjects-44/NNS||t2d-46/CD	prepc_at||determined-11/VBN||fasting-48/VBG	amod||clamp-53/NN||normoglycemic-51/JJ	amod||clamp-53/NN||hyperinsulinemic-52/JJ	prep_during||determined-11/VBN||clamp-53/NN	amod||intake-58/NN||continuous-56/JJ	amod||intake-58/NN||oral-57/JJ	prep_during||determined-11/VBN||intake-58/NN	conj_and||clamp-53/NN||intake-58/NN	det||meal-63/NN||a-60/DT	amod||meal-63/NN||standard-61/JJ	amod||meal-63/NN||liquid-62/JJ	prep_of||intake-58/NN||meal-63/NN	aux||achieve-65/VB||to-64/TO	vmod||intake-58/NN||achieve-65/VB	vmod||intake-58/NN||achieve-65/VB	conj_and||achieve-65/VB||achieve-65/VB	amod||postprandial-67/JJ||steady-66/JJ	amod||nefa-68/NNS||postprandial-67/JJ	dobj||achieve-65/VB||nefa-68/NNS	dobj||achieve-65/VB||triacylglycerols-70/NNS	conj_and||nefa-68/NNS||triacylglycerols-70/NNS	appos||nefa-68/NNS||tg-72/NN	nn||infusion-78/NN||insulin-77/NN	prep_with||achieve-65/VB||infusion-78/NN	prep_without||achieve-65/VB||infusion-78/NN	aux||maintain-80/VB||to-79/TO	vmod||achieve-65/VB||maintain-80/VB	amod||glycemia-82/NN||similar-81/JJ	dobj||maintain-80/VB||glycemia-82/NN	det||groups-86/NNS||all-84/DT	num||groups-86/NNS||three-85/CD	prep_in||maintain-80/VB||groups-86/NNS	t2d-46||insulin-77||yes||palmitate appearance and oxidation rates and glycerol appearance rate were determined in eleven healthy offspring of two parents with t2d (positive family history, fh+), 13 healthy subjects without first-degree relatives with t2d (fh-) and 12 subjects with t2d at fasting, during normoglycemic hyperinsulinemic clamp and during continuous oral intake of a standard liquid meal to achieve steady postprandial nefa and triacylglycerols (tg) without and with insulin infusion to maintain similar glycemia in all three groups.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||cloned-12/VBN||study-4/NN	amod||rv1985c-8/NNS||recombinant-6/JJ	nn||rv1985c-8/NNS||protein-7/NN	nsubjpass||cloned-12/VBN||rv1985c-8/NNS	nsubjpass||expressed-14/VBN||rv1985c-8/NNS	nsubjpass||purified-16/VBN||rv1985c-8/NNS	nsubjpass||characterized-19/VBN||rv1985c-8/NNS	nsubjpass||investigated-21/VBN||rv1985c-8/NNS	prep_from||rv1985c-8/NNS||rd2-10/CD	auxpass||cloned-12/VBN||was-11/VBD	root||ROOT-0/null||cloned-12/VBN	conj_and||cloned-12/VBN||expressed-14/VBN	conj_and||cloned-12/VBN||purified-16/VBN	advmod||characterized-19/VBN||immunologically-18/RB	conj_and||cloned-12/VBN||characterized-19/VBN	conj_and||cloned-12/VBN||investigated-21/VBN	poss||value-26/NN||its-23/PRP$	advmod||diagnostic-25/JJ||potentially-24/RB	amod||value-26/NN||diagnostic-25/JJ	prep_for||investigated-21/VBN||value-26/NN	nn||infection-32/NN||tuberculosis-28/NNP	appos||infection-32/NN||tb-30/NN	prep_for||value-26/NN||infection-32/NN	amod||individuals-35/NNS||bcg-vaccinated-34/JJ	prep_among||investigated-21/VBN||individuals-35/NNS	tb-30||bcg--1||yes||in the present study, recombinant protein rv1985c from rd2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic value for tuberculosis (tb) infection among bcg-vaccinated individuals.
advmod||high-2/JJ||significantly-1/RB	amod||prevalence-3/NN||high-2/JJ	nsubjpass||observed-7/VBN||prevalence-3/NN	prep_of||prevalence-3/NN||hbsag-5/NN	auxpass||observed-7/VBN||was-6/VBD	root||ROOT-0/null||observed-7/VBN	prep_among||observed-7/VBN||individuals-9/NNS	nsubj||had-11/VBD||individuals-9/NNS	rcmod||individuals-9/NNS||had-11/VBD	dobj||had-11/VBD||history-12/NN	amod||procedures-15/NNS||invasive-14/JJ	prep_of||history-12/NN||procedures-15/NNS	nn||extraction-19/NN||tooth-18/NN	prep_like||had-11/VBD||extraction-19/NN	appos||individuals-9/NNS||abortion-21/NN	appos||individuals-9/NNS||ear-23/NN	conj_and||abortion-21/NN||ear-23/NN	vmod||abortion-21/NN||piercing-24/VBG	dep||individuals-9/NNS||history-26/NN	nn||admission-29/NN||hospital-28/NN	prep_of||history-26/NN||admission-29/NN	appos||individuals-9/NNS||history-31/NN	amod||inject-34/NNS||unsafe-33/JJ	prep_of||history-31/NN||inject-34/NNS	prep_of||history-31/NN||hivpositives-36/NNS	conj_and||inject-34/NNS||hivpositives-36/NNS	hivpositives-36||hbsag-5||no_rel||significantly high prevalence of hbsag was observed among individuals who had history of invasive procedures, like tooth extraction, abortion and ear piercing; history of hospital admission, history of unsafe inject and hivpositives.
csubj||occurred-5/VBD||persisting-1/VBG	conj_or||persisting-1/VBG||relapsing-3/VBG	csubj||occurred-5/VBD||relapsing-3/VBG	dobj||persisting-1/VBG||bacteraemia-4/NN	root||ROOT-0/null||occurred-5/VBD	num||%-8/NN||27-7/CD	prep_in||occurred-5/VBD||%-8/NN	prep_of||%-8/NN||daptomycin-10/NN	num||%-13/NN||21-12/CD	prep_in||occurred-5/VBD||%-13/NN	conj_and||%-8/NN||%-13/NN	nn||patients-16/NNS||vancomycin/gentamicin-15/NN	prep_of||%-13/NN||patients-16/NNS	det||patients-20/NNS||these-19/DT	prep_among||occurred-29/VBD||patients-20/NNS	nsubj||occurred-29/VBD||mics-22/NNS	nn||¥-26/NNP||â-24/NNP	nn||¥-26/NNP||‰-25/NNP	prep_of||mics-22/NNS||¥-26/NNP	number||mg/l-28/JJ||2-27/CD	amod||¥-26/NNP||mg/l-28/JJ	parataxis||occurred-5/VBD||occurred-29/VBD	num||daptomycin-32/NN||five-31/CD	prep_in||occurred-29/VBD||daptomycin-32/NN	num||patients-36/NNS||four-34/CD	nn||patients-36/NNS||vancomycin/gentamicin-35/NN	prep_in||occurred-29/VBD||patients-36/NNS	conj_and||daptomycin-32/NN||patients-36/NNS	bacteraemia-4||vancomycin--1||no_rel||persisting or relapsing bacteraemia occurred in 27% of daptomycin and 21% of vancomycin/gentamicin patients; among these patients, mics of â‰¥2 mg/l occurred in five daptomycin and four vancomycin/gentamicin patients.
det||hemagglutinin-6/NN||the-1/DT	amod||hemagglutinin-6/NN||main-2/JJ	amod||hemagglutinin-6/NN||influenzavirus-3/JJ	nn||hemagglutinin-6/NN||surface-4/NN	nn||hemagglutinin-6/NN||glycoprotein-5/NN	nsubjpass||shown-18/VBN||hemagglutinin-6/NN	nsubj||susceptible-22/JJ||hemagglutinin-6/NN	appos||hemagglutinin-6/NN||ha-8/NN	advmod||pathogenic-12/JJ||highly-11/RB	amod||avianinfluenzaviruses-13/NNS||pathogenic-12/JJ	prep_of||hemagglutinin-6/NN||avianinfluenzaviruses-13/NNS	appos||avianinfluenzaviruses-13/NNS||hpaiv-15/NNP	auxpass||shown-18/VBN||was-17/VBD	root||ROOT-0/null||shown-18/VBN	aux||susceptible-22/JJ||to-19/TO	cop||susceptible-22/JJ||be-20/VB	advmod||susceptible-22/JJ||more-21/RBR	xcomp||shown-18/VBN||susceptible-22/JJ	amod||treatment-26/NN||acidic-24/JJ	nn||treatment-26/NN||ph-25/NN	prep_to||susceptible-22/JJ||treatment-26/NN	prep_than||treatment-26/NN||that-28/DT	amod||avianinfluenzaviruses-34/NNS||human-30/JJ	conj_or||human-30/JJ||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||pathogenic-33/JJ	prep_of||that-28/DT||avianinfluenzaviruses-34/NNS	avianinfluenza--1||influenzaviruses--1||no||the main influenzavirus surface glycoprotein hemagglutinin (ha) of highly pathogenic avianinfluenzaviruses (hpaiv) was shown to be more susceptible to acidic ph treatment than that of human or low pathogenic avianinfluenzaviruses.
nsubj||disease-10/NN||infectiousbursaldisease-1/NN	appos||infectiousbursaldisease-1/NN||ibd-3/NN	cop||disease-10/NN||is-5/VBZ	det||disease-10/NN||a-6/DT	advmod||contagious-8/JJ||highly-7/RB	amod||disease-10/NN||contagious-8/JJ	nn||disease-10/NN||immunosuppressive-9/NN	root||ROOT-0/null||disease-10/NN	amod||chickens-13/NNS||young-12/JJ	prep_in||disease-10/NN||chickens-13/NNS	vmod||chickens-13/NNS||caused-14/VBN	amod||virus-17/NN||infectiousbursaldisease-16/JJ	agent||caused-14/VBN||virus-17/NN	appos||virus-17/NN||ibdv-19/NNP	infectiousbursaldisease-16||infectiousbursaldiseasevirus--1||no||infectiousbursaldisease (ibd) is a highly contagious immunosuppressive disease in young chickens caused by infectiousbursaldisease virus (ibdv).
nsubj||addictive-4/JJ||smoking-1/NN	cop||addictive-4/JJ||is-2/VBZ	advmod||addictive-4/JJ||highly-3/RB	root||ROOT-0/null||addictive-4/JJ	nn||abstinence-8/NN||nicotine-7/NN	nsubjpass||associated-10/VBN||abstinence-8/NN	auxpass||associated-10/VBN||is-9/VBZ	conj_and||addictive-4/JJ||associated-10/VBN	prep_with||associated-10/VBN||withdrawalsyndrome-12/NN	amod||patients-15/NNS||hospitalized-14/JJ	prep_in||withdrawalsyndrome-12/NN||patients-15/NNS	withdrawalsyndrome-12||nicotine-7||yes||smoking is highly addictive, and nicotine abstinence is associated with withdrawalsyndrome in hospitalized patients.
nsubjpass||shown-7/VBN||hydrogensulfide-1/NN	nsubj||have-9/VB||hydrogensulfide-1/NN	appos||hydrogensulfide-1/NN||h2s-3/NNP	aux||shown-7/VBN||has-5/VBZ	auxpass||shown-7/VBN||been-6/VBN	root||ROOT-0/null||shown-7/VBN	aux||have-9/VB||to-8/TO	xcomp||shown-7/VBN||have-9/VB	amod||effects-11/NNS||cytoprotective-10/JJ	dep||sdisease-21/JJ||effects-11/NNS	prep_in||effects-11/NNS||models-13/NNS	prep_of||models-13/NNS||hypertension-15/NN	prep_of||models-13/NNS||ischemia/reperfusion-17/NN	conj_and||hypertension-15/NN||ischemia/reperfusion-17/NN	prep_of||models-13/NNS||alzheimer-19/NN	conj_and||hypertension-15/NN||alzheimer-19/NN	dep||have-9/VB||sdisease-21/JJ	alzheimer'sdisease--1||hydrogensulfide-1||no_rel||hydrogensulfide (h2s) has been shown to have cytoprotective effects in models of hypertension, ischemia/reperfusion and alzheimer'sdisease.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||administration-4/NN||the-3/DT	dobj||evaluate-2/VB||administration-4/NN	prep_of||administration-4/NN||antipyretics-6/NNS	prep_to||evaluate-2/VB||children-8/NNS	prep_with||children-8/NNS||upperrespiratorytractinfections-10/NNS	appos||upperrespiratorytractinfections-10/NNS||urti-12/NNP	poss||parents-16/NNS||their-15/PRP$	prep_by||evaluate-2/VB||parents-16/NNS	prep_by||evaluate-2/VB||guardians-18/NNS	conj_or||parents-16/NNS||guardians-18/NNS	prep_without||evaluate-2/VB||consultation-20/NN	prep_with||consultation-20/NN||physicians-22/NNS	conj_and||evaluate-2/VB||compare-25/VB	amod||characteristics-29/NNS||epidemiological-26/JJ	conj_and||epidemiological-26/JJ||clinical-28/JJ	amod||characteristics-29/NNS||clinical-28/JJ	dobj||compare-25/VB||characteristics-29/NNS	prep_of||characteristics-29/NNS||patients-31/NNS	nsubj||received-33/VBD||patients-31/NNS	rcmod||patients-31/NNS||received-33/VBD	dobj||received-33/VBD||antipyretics-34/NNS	dep||evaluate-2/VB||of-36/IN	pcomp||of-36/IN||untreated-37/VBG	dobj||untreated-37/VBG||patients-38/NNS	antipyretics-34||urti-12||no_rel||to evaluate the administration of antipyretics to children with upperrespiratorytractinfections (urti) by their parents or guardians without consultation with physicians, and compare epidemiological and clinical characteristics of patients who received antipyretics and of untreated patients.
prep_in||lower-13/VB||contrast-2/NN	amod||therapy-6/NN||optimistic-4/JJ	amod||therapy-6/NN||antiretroviral-5/JJ	nsubj||lower-13/VB||therapy-6/NN	nn||campaigns-9/NNS||vaccination-8/NN	conj_or||therapy-6/NN||campaigns-9/NNS	nsubj||lower-13/VB||campaigns-9/NNS	advmod||lower-13/VB||alone-10/RB	aux||lower-13/VB||could-11/MD	advmod||lower-13/VB||only-12/RB	root||ROOT-0/null||lower-13/VB	amod||prevalence-15/NN||hiv/aids-14/JJ	dobj||lower-13/VB||prevalence-15/NN	nn||years-21/NNS||<-17/NNP	num||years-21/NNS||2-fold-18/CD	amod||years-21/NNS||over-19/IN	num||years-21/NNS||50-20/CD	prep_by||lower-13/VB||years-21/NNS	aids--1||hiv--1||no||in contrast, optimistic antiretroviral therapy or vaccination campaigns alone could only lower hiv/aids prevalence by <2-fold over 50 years.
num||investigations-3/NNS||five-1/CD	amod||investigations-3/NNS||main-2/JJ	nsubj||mantoux-5/VBZ||investigations-3/NNS	nsubjpass||carried-31/VBN||investigations-3/NNS	nsubj||diagnose-34/VB||investigations-3/NNS	advmod||mantoux-5/VBZ||namely-4/RB	root||ROOT-0/null||mantoux-5/VBZ	nn||rate-16/NN||test-6/NN	dep||rate-16/NN||bcg-8/NN	nn||rate-16/NN||test-9/NN	dep||rate-16/NN||chest-11/NN	nn||rate-16/NN||radiograph-12/NN	dep||rate-16/NN||erythrocyte-14/NN	nn||rate-16/NN||sedimentation-15/NN	dobj||mantoux-5/VBZ||rate-16/NN	appos||rate-16/NN||esr-18/NN	amod||cytology-24/NN||fine-21/JJ	nn||cytology-24/NN||needle-22/NN	nn||cytology-24/NN||aspiration-23/NN	dobj||mantoux-5/VBZ||cytology-24/NN	conj_and||rate-16/NN||cytology-24/NN	dep||cytology-24/NN||fnac-26/JJ	advmod||carried-31/VBN||biopsy-29/RB	auxpass||carried-31/VBN||were-30/VBD	conj_or||mantoux-5/VBZ||carried-31/VBN	prt||carried-31/VBN||out-32/RP	aux||diagnose-34/VB||to-33/TO	xcomp||carried-31/VBN||diagnose-34/VB	dobj||diagnose-34/VB||tb-35/NN	tb-35||bcg-8||no||five main investigations namely mantoux test, bcg test, chest radiograph, erythrocyte sedimentation rate (esr) and fine needle aspiration cytology (fnac) or biopsy were carried out to diagnose tb.
det||nature-6/NN||the-1/DT	amod||nature-6/NN||strong-2/JJ	amod||nature-6/NN||invasive-3/JJ	conj_and||invasive-3/JJ||metastatic-5/JJ	amod||nature-6/NN||metastatic-5/JJ	nsubj||implies-9/VBZ||nature-6/NN	prep_of||nature-6/NN||cutaneousmelanoma-8/NN	root||ROOT-0/null||implies-9/VBZ	det||interplay-12/NN||a-10/DT	amod||interplay-12/NN||deregulated-11/VBN	dobj||implies-9/VBZ||interplay-12/NN	nn||adhesion-15/NN||intercellular-14/NN	prep_between||interplay-12/NN||adhesion-15/NN	amod||molecules-18/NNS||migration-related-17/JJ	dobj||implies-9/VBZ||molecules-18/NNS	conj_and||interplay-12/NN||molecules-18/NNS	det||study-21/NN||this-20/DT	prep_in||molecules-18/NNS||study-21/NN	nsubj||performed-23/VBD||we-22/PRP	rcmod||study-21/NN||performed-23/VBD	det||analysis-26/NN||a-24/DT	amod||analysis-26/NN||microarray-25/JJ	dobj||performed-23/VBD||analysis-26/NN	aux||compare-28/VB||to-27/TO	vmod||performed-23/VBD||compare-28/VB	det||profile-32/NN||the-29/DT	nn||profile-32/NN||mrna-30/NN	nn||profile-32/NN||expression-31/NN	dobj||compare-28/VB||profile-32/NN	det||line-39/NN||an-34/DT	amod||line-39/NN||invasive-35/JJ	nn||line-39/NN||blm-36/NN	nn||line-39/NN||melanoma-37/NN	nn||line-39/NN||cell-38/NN	prep_of||profile-32/NN||line-39/NN	nn||lie-42/NN||blm-41/NN	appos||line-39/NN||lie-42/NN	det||variant-49/NN||the-45/DT	amod||p-cadherin-47/JJ||non-invasive-46/JJ	amod||variant-49/NN||p-cadherin-47/JJ	amod||variant-49/NN||over-expression-48/JJ	prep_of||profile-32/NN||variant-49/NN	conj_and||line-39/NN||variant-49/NN	nn||p-cad-52/NN||blm-51/NN	appos||variant-49/NN||p-cad-52/NN	cutaneousmelanoma-8||blm-51||yes||the strong invasive and metastatic nature of cutaneousmelanoma implies a deregulated interplay between intercellular adhesion and migration-related molecules in this study we performed a microarray analysis to compare the mrna expression profile of an invasive blm melanoma cell line (blm lie) and the non-invasive p-cadherin over-expression variant (blm p-cad).
det||study-3/NN||the-1/DT	amod||study-3/NN||current-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	nsubj||determine-7/VB||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	aux||determine-7/VB||to-6/TO	xcomp||conducted-5/VBN||determine-7/VB	nn||serostatus-9/NNS||rubella-8/NN	dobj||determine-7/VB||serostatus-9/NNS	amod||schoolgirls-12/NNS||peripubertal-11/JJ	prep_in||determine-7/VB||schoolgirls-12/NNS	vmod||schoolgirls-12/NNS||aged-13/VBN	xcomp||aged-13/VBN||11â-14/VBG	dobj||11â-14/VBG||$-15/$	num||years-18/NNS||18-17/CD	npadvmod||immunogenicity-23/JJ||years-18/NNS	conj_and||years-18/NNS||also-20/RB	npadvmod||immunogenicity-23/JJ||also-20/RB	prep||years-18/NNS||to-21/TO	num||years-18/NNS||assess-22/CD	amod||institute-33/NNS||immunogenicity-23/JJ	conj_and||immunogenicity-23/JJ||safety-25/NN	amod||institute-33/NNS||safety-25/NN	prep_of||safety-25/NN||rubellavaccine-27/NN	dep||rubellavaccine-27/NN||r-vac-29/JJ	prep_of||rubellavaccine-27/NN||serum-32/NN	npadvmod||of-34/RB||institute-33/NNS	dep||india-35/CD||of-34/RB	num||$-15/$||india-35/CD	advmod||11â-14/VBG||ltd.-36/RB	acomp||aged-13/VBN||pune-38/JJ	amod||girls-42/NNS||seronegative-41/JJ	prep_in||aged-13/VBN||girls-42/NNS	rubella-8||rubellavaccine-27||yes||the current study was conducted to determine rubella serostatus in peripubertal schoolgirls aged 11â€“18 years and also to assess immunogenicity and safety of rubellavaccine (r-vac) of serum institute of india ltd., pune, in seronegative girls.
nn||policies-3/NNS||results-1/NNS	nn||policies-3/NNS||national-level-2/NN	nsubj||had-6/VBN||policies-3/NNS	nsubj||response-16/NN||policies-3/NNS	aux||had-6/VBN||have-5/VBP	rcmod||policies-3/NNS||had-6/VBN	det||impact-9/NN||a-7/DT	amod||impact-9/NN||major-8/JJ	dobj||had-6/VBN||impact-9/NN	prepc_on||had-6/VBN||chinaâ-11/VBG	dobj||chinaâ-11/VBG||$-12/$	num||$-12/$||™-13/CD	cop||response-16/NN||s-14/VBZ	amod||response-16/NN||hiv/aids-15/JJ	dep||include-17/VBP||response-16/NN	root||ROOT-0/null||include-17/VBP	amod||frees-21/NNS||â-18/JJ	amod||frees-21/NNS||$-19/$	dep||$-19/$||˜four-20/JJ	dobj||include-17/VBP||frees-21/NNS	num||careâ-24/NNS||one-23/CD	dobj||include-17/VBP||careâ-24/NNS	conj_and||frees-21/NNS||careâ-24/NNS	nsubj||include-17/VBP||$-25/$	num||$-25/$||™-26/CD	amod||plans-30/NNS||5-year-28/JJ	nn||plans-30/NNS||action-29/NN	nsubj||include-17/VBP||plans-30/NNS	conj_and||$-25/$||plans-30/NNS	amod||regulation-34/NN||hiv/aids-33/JJ	nsubj||include-17/VBP||regulation-34/NN	conj_and||$-25/$||regulation-34/NN	aids--1||hiv--1||no||results national-level policies that have had a major impact on chinaâ€™s hiv/aids response include â€˜four frees and one careâ€™; 5-year action plans; and hiv/aids regulation.
nsubj||occurs-2/VBZ||neuroinflammation-1/NN	nsubj||declined-27/VBD||neuroinflammation-1/NN	root||ROOT-0/null||occurs-2/VBZ	amod||injury-5/NN||following-3/JJ	nn||injury-5/NN||brain-4/NN	dobj||occurs-2/VBZ||injury-5/NN	prep_including||injury-5/NN||soman-8/NN	appos||soman-8/NN||gd-10/NN	dep||soman-8/NN||induced-12/VBN	dobj||induced-12/VBN||statusepilepticus-13/NNS	appos||statusepilepticus-13/NNS||se-15/NNP	aux||contribute-20/VB||may-19/MD	dep||soman-8/NN||contribute-20/VB	conj_and||induced-12/VBN||contribute-20/VB	prep_to||contribute-20/VB||loss-22/NN	amod||tissue-25/NN||neural-24/JJ	prep_of||loss-22/NN||tissue-25/NN	conj_and||occurs-2/VBZ||declined-27/VBD	amod||function-29/NN||behavioral-28/JJ	dobj||declined-27/VBD||function-29/NN	statusepilepticus-13||soman-8||no_rel||neuroinflammation occurs following brain injury, including soman (gd) induced statusepilepticus (se), and may contribute to loss of neural tissue and declined behavioral function.
nsubj||due-3/JJ||this-1/DT	cop||due-3/JJ||is-2/VBZ	root||ROOT-0/null||due-3/JJ	prep_in||due-3/JJ||part-5/NN	amod||suppression-9/NN||impaired-7/VBN	amod||suppression-9/NN||insulin-induced-8/JJ	prep_to||due-3/JJ||suppression-9/NN	amod||production-13/NN||endogenous-11/JJ	nn||production-13/NN||glucose-12/NN	prep_of||suppression-9/NN||production-13/NN	nsubjpass||observed-17/VBN||production-13/NN	auxpass||observed-17/VBN||is-16/VBZ	rcmod||production-13/NN||observed-17/VBN	advmod||observed-17/VBN||early-18/RB	det||evolution-21/NN||the-20/DT	prep_in||observed-17/VBN||evolution-21/NN	prep_of||evolution-21/NN||type2diabetes-23/CD	type2diabetes-23||insulin--1||yes||this is due in part to impaired insulin-induced suppression of endogenous glucose production, which is observed early in the evolution of type2diabetes.
nsubj||drug-6/NN||bivalirudin-1/NN	cop||drug-6/NN||is-2/VBZ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||synthetic-4/JJ	nn||drug-6/NN||anticoagulant-5/NN	root||ROOT-0/null||drug-6/NN	nsubj||cause-21/VB||drug-6/NN	advmod||employed-8/VBN||sometimes-7/RB	vmod||drug-6/NN||employed-8/VBN	det||substitute-11/NN||a-10/DT	prep_as||employed-8/VBN||substitute-11/NN	prep_for||substitute-11/NN||heparin-13/NN	det||anticoagulant-18/NN||a-15/DT	advmod||used-17/VBN||commonly-16/RB	amod||anticoagulant-18/NN||used-17/VBN	appos||heparin-13/NN||anticoagulant-18/NN	aux||cause-21/VB||can-20/MD	rcmod||drug-6/NN||cause-21/VB	det||heparin-inducedthrombocytopenia-25/NN||a-22/DT	nn||heparin-inducedthrombocytopenia-25/NN||condition-23/NN	amod||heparin-inducedthrombocytopenia-25/NN||called-24/VBN	dobj||cause-21/VB||heparin-inducedthrombocytopenia-25/NN	dep||heparin-inducedthrombocytopenia-25/NN||hit-27/VBN	heparin-inducedthrombocytopenia-25||heparin-13||no||bivalirudin is a synthetic anticoagulant drug sometimes employed as a substitute for heparin, a commonly used anticoagulant that can cause a condition called heparin-inducedthrombocytopenia (hit).
det||progress-2/NN||this-1/DT	nsubj||resulted-3/VBD||progress-2/NN	root||ROOT-0/null||resulted-3/VBD	nn||interventions-8/NNS||lobbying-5/NN	conj_and||lobbying-5/NN||innovative-7/JJ	nn||interventions-8/NNS||innovative-7/JJ	prep_from||resulted-3/VBD||interventions-8/NNS	amod||activists-11/NNS||hiv/aids-10/JJ	prep_from||resulted-3/VBD||activists-11/NNS	amod||organizations-15/NNS||civil-13/JJ	nn||organizations-15/NNS||society-14/NN	prep_from||resulted-3/VBD||organizations-15/NNS	conj_and||activists-11/NNS||organizations-15/NNS	amod||organizations-19/NNS||international-18/JJ	prep_from||resulted-3/VBD||organizations-19/NNS	conj_and||activists-11/NNS||organizations-19/NNS	aids--1||hiv--1||no||this progress resulted from lobbying and innovative interventions from hiv/aids activists, civil society organizations, and international organizations.
nsubj||reported-4/VBN||we-1/PRP	aux||reported-4/VBN||have-2/VBP	advmod||reported-4/VBN||previously-3/RB	root||ROOT-0/null||reported-4/VBN	mark||alter-12/VB||that-5/IN	amod||inhibition-7/NN||allopurinol-6/JJ	nsubj||alter-12/VB||inhibition-7/NN	prep_of||inhibition-7/NN||xo-9/NN	aux||alter-12/VB||does-10/VBZ	neg||alter-12/VB||not-11/RB	ccomp||reported-4/VBN||alter-12/VB	det||progression-14/NN||the-13/DT	dobj||alter-12/VB||progression-14/NN	amod||acetate-17/NN||deoxycorticosterone-16/JJ	prep_of||progression-14/NN||acetate-17/NN	appos||acetate-17/NN||doca-19/NNP	nn||hypertension-23/NN||salt-22/NN	dep||progression-14/NN||hypertension-23/NN	prep_in||hypertension-23/NN||rats-25/NNS	deoxycorticosterone-16||hypertension-23||no_rel||we have previously reported that allopurinol inhibition of xo does not alter the progression of deoxycorticosterone acetate (doca)-salt hypertension in rats.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||literature-4/NN||the-3/DT	dobj||review-2/VB||literature-4/NN	det||treatment-7/NN||the-6/DT	prep_on||literature-4/NN||treatment-7/NN	prep_of||treatment-7/NN||gastroesophagealrefluxdisease-9/NN	dep||treatment-7/NN||gerd-11/VBN	prep_with||review-2/VB||emphasis-14/NN	prep_on||emphasis-14/NN||protonpumpinhibitors-16/NNS	appos||protonpumpinhibitors-16/NNS||ppis-18/NNS	advmod||review-2/VB||particularly-21/RB	amod||esomeprazole-24/NN||delayed-release-23/JJ	prep_on||review-2/VB||esomeprazole-24/NN	aux||identify-28/VB||to-27/TO	conj_and||review-2/VB||identify-28/VB	dobj||identify-28/VB||properties-29/NNS	amod||effects-32/NNS||adverse-31/JJ	nsubj||observed-35/VBD||effects-32/NNS	prep_of||effects-32/NNS||ppis-34/NNS	conj_and||review-2/VB||observed-35/VBD	det||treatment-38/NN||the-37/DT	prep_in||observed-35/VBD||treatment-38/NN	prep_of||treatment-38/NN||gerd-40/NN	prep_in||observed-35/VBD||children-42/NNS	prep_in||observed-35/VBD||adolescents-44/NNS	conj_and||children-42/NNS||adolescents-44/NNS	gerd-40||esomeprazole-24||yes||to review the literature on the treatment of gastroesophagealrefluxdisease (gerd) with emphasis on protonpumpinhibitors (ppis), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of ppis observed in the treatment of gerd in children and adolescents.
det||mainstay-2/NN||the-1/DT	nsubj||includes-8/VBZ||mainstay-2/NN	amod||therapy-5/NN||pharmacologic-4/JJ	prep_of||mainstay-2/NN||therapy-5/NN	prep_for||therapy-5/NN||rheumatoidarthritis-7/NNS	root||ROOT-0/null||includes-8/VBZ	det||use-10/NN||the-9/DT	dobj||includes-8/VBZ||use-10/NN	amod||agents-13/NNS||disease-modifying-12/JJ	prep_of||use-10/NN||agents-13/NNS	prep_like||agents-13/NNS||sulfasalazine-15/NN	prep_like||agents-13/NNS||methothrexate-17/NN	conj_and||sulfasalazine-15/NN||methothrexate-17/NN	advmod||recently-21/RB||more-20/RBR	advmod||factor-î-25/VBZ||recently-21/RB	amod||necrosis-24/NNS||anti-tumor-23/JJ	nsubj||factor-î-25/VBZ||necrosis-24/NNS	conj_and||includes-8/VBZ||factor-î-25/VBZ	amod||agents-27/NNS||±-26/JJ	dobj||factor-î-25/VBZ||agents-27/NNS	rheumatoidarthritis-7||sulfasalazine-15||yes||the mainstay of pharmacologic therapy for rheumatoidarthritis includes the use of disease-modifying agents like sulfasalazine and methothrexate, and more recently, anti-tumor necrosis factor-î± agents.
nsubj||live-3/VB||plha-1/NN	nsubjpass||associated-165/VBN||plha-1/NN	rcmod||plha-1/NN||live-3/VB	poss||-LSB--7/NN||their-5/PRP$	nn||-LSB--7/NN||families-6/NNS	prep_with||live-3/VB||-LSB--7/NN	prep_with||live-3/VB||=-9/NNP	conj_or||-LSB--7/NN||=-9/NNP	num||=-9/NNP||3.29-10/CD	num||%-13/NN||95-12/CD	dobj||live-3/VB||%-13/NN	vmod||%-13/NN||ci-14/VBN	num||-RSB--18/NNS||1.28-8-15/CD	nn||-RSB--18/NNS||.45-16/CD	dobj||ci-14/VBN||-RSB--18/NNS	dobj||ci-14/VBN||lived-20/VBN	conj_or||-RSB--18/NNS||lived-20/VBN	vmod||-RSB--18/NNS||lived-20/VBN	det||-LSB--25/NN||a-22/DT	amod||-LSB--25/NN||rented-23/VBN	nn||-LSB--25/NN||house-24/NN	prep_in||lived-20/VBN||-LSB--25/NN	number||2.52-28/CD||=-27/CD	num||-RSB--35/NN||2.52-28/CD	number||%-31/NN||95-30/CD	amod||-RSB--35/NN||%-31/NN	amod||-RSB--35/NN||ci-32/JJ	nn||-RSB--35/NN||1.09-5-33/NN	num||-RSB--35/NN||.79-34/CD	prep_in||lived-20/VBN||-RSB--35/NN	conj_or||-LSB--25/NN||-RSB--35/NN	dobj||have-54/VBP||-RSB--35/NN	amod||women-38/NNS||non-pregnant-37/JJ	appos||-RSB--35/NN||women-38/NNS	num||women-38/NNS||-LSB--39/CD	num||9.3-42/CD||=-41/CD	num||women-38/NNS||9.3-42/CD	conj_or||-LSB--39/CD||9.3-42/CD	number||%-45/NN||95-44/CD	amod||ci-46/NN||%-45/NN	appos||-RSB--35/NN||ci-46/NN	num||-RSB--49/NNS||1.93-44-47/CD	num||-RSB--49/NNS||.82-48/CD	dep||ci-46/NN||-RSB--49/NNS	amod||art-53/NN||perceived-52/VBN	nsubj||have-54/VBP||art-53/NN	rcmod||-RSB--35/NN||have-54/VBP	amod||effects-57/NNS||many-55/JJ	nn||effects-57/NNS||side-56/NN	dobj||have-54/VBP||effects-57/NNS	vmod||effects-57/NNS||-LSB--58/VBN	dep||6.23-61/CD||=-60/SYM	dobj||have-54/VBP||6.23-61/CD	conj_or||effects-57/NNS||6.23-61/CD	num||%-64/NN||95-63/CD	prep_in||lived-20/VBN||%-64/NN	conj_or||-LSB--25/NN||%-64/NN	num||-RSB--68/NNS||ci1-65/CD	nn||-RSB--68/NNS||.63,23.82-66/CD	dep||%-64/NN||-RSB--68/NNS	nsubj||perceived-71/VBD||who-70/WP	prep_in||lived-20/VBN||perceived-71/VBD	conj_or||-LSB--25/NN||perceived-71/VBD	amod||-LSB--92/NNS||hiv-72/JJ	prepc_as||hiv-72/JJ||stigmatizing-74/VBG	nn||-LSB--76/NNS||disease-75/NN	iobj||stigmatizing-74/VBG||-LSB--76/NNS	number||3.1-79/CD||=-78/CD	num||ci-83/NN||3.1-79/CD	number||%-82/NN||95-81/CD	amod||ci-83/NN||%-82/NN	iobj||stigmatizing-74/VBG||ci-83/NN	conj_or||-LSB--76/NNS||ci-83/NN	num||-RSB--86/NNS||1.09-8-84/CD	num||-RSB--86/NNS||.76-85/CD	dobj||stigmatizing-74/VBG||-RSB--86/NNS	nsubj||tested-89/VBN||-RSB--86/NNS	rcmod||-RSB--86/NNS||tested-89/VBN	prep_with||tested-89/VBN||sickness/symptoms-91/NNS	dobj||perceived-71/VBD||-LSB--92/NNS	dep||2.62-95/CD||=-94/SYM	dobj||perceived-71/VBD||2.62-95/CD	conj_or||-LSB--92/NNS||2.62-95/CD	number||%-98/NN||95-97/CD	amod||-RSB--102/NNS||%-98/NN	nn||-RSB--102/NNS||ci-99/NN	amod||-RSB--102/NNS||1.26-5-100/JJ	num||-RSB--102/NNS||.44-101/CD	dobj||ci-14/VBN||-RSB--102/NNS	conj_or||-RSB--18/NNS||-RSB--102/NNS	nsubj||disclose-107/VB||-RSB--102/NNS	aux||disclose-107/VB||did-105/VBD	neg||disclose-107/VB||not-106/RB	rcmod||-RSB--102/NNS||disclose-107/VB	poss||status-110/NN||their-108/PRP$	nn||status-110/NN||hiv-109/NN	dobj||disclose-107/VB||status-110/NN	poss||-LSB--114/NN||their-112/PRP$	nn||-LSB--114/NN||partner-113/NN	prep_for||disclose-107/VB||-LSB--114/NN	number||2.78-117/CD||=-116/CD	num||ci-121/NN||2.78-117/CD	number||%-120/NN||95-119/CD	amod||ci-121/NN||%-120/NN	dobj||ci-14/VBN||ci-121/NN	conj_or||-RSB--18/NNS||ci-121/NN	num||-LSB--129/NNS||1.02-7-122/CD	num||-LSB--129/NNS||.56-123/CD	nn||-LSB--129/NNS||-RSB--124/NNP	amod||-LSB--129/NNS||frequent-126/JJ	nn||-LSB--129/NNS||alcohol-127/NN	nn||-LSB--129/NNS||users-128/NNS	dep||ci-121/NN||-LSB--129/NNS	dep||3.55-132/CD||=-131/SYM	dobj||live-3/VB||3.55-132/CD	conj_or||%-13/NN||3.55-132/CD	number||%-135/NN||95-134/CD	amod||-LSB--152/NN||%-135/NN	amod||-LSB--152/NN||ci-136/JJ	amod||-LSB--152/NN||1.63-7-137/JJ	num||-RSB--139/NNS||.71-138/CD	nn||-LSB--152/NN||-RSB--139/NNS	nsubj||spent-142/VBD||who-141/WP	conj_and||-RSB--139/NNS||spent-142/VBD	nn||-LSB--152/NN||spent-142/VBD	mwe||than-144/IN||more-143/JJR	quantmod||120-145/CD||than-144/IN	num||months-146/NNS||120-145/CD	tmod||spent-142/VBD||months-146/NNS	prep_with||spent-142/VBD||partner-148/NN	nn||diagnosis-151/NN||hiv-150/NN	prep_at||spent-142/VBD||diagnosis-151/NN	dobj||live-3/VB||-LSB--152/NN	dep||5.86-155/CD||=-154/SYM	dobj||live-3/VB||5.86-155/CD	conj_or||-LSB--152/NN||5.86-155/CD	number||%-158/NN||95-157/CD	amod||-RSB--162/NNS||%-158/NN	amod||-RSB--162/NNS||ci-159/JJ	number||.41-161/CD||1.35-25-160/CD	num||-RSB--162/NNS||.41-161/CD	dobj||live-3/VB||-RSB--162/NNS	auxpass||associated-165/VBN||were-163/VBD	advmod||associated-165/VBN||significantly-164/RB	root||ROOT-0/null||associated-165/VBN	amod||presentation-168/NN||late-167/JJ	prep_with||associated-165/VBN||presentation-168/NN	amod||care-171/NN||hiv/aids-170/JJ	prep_to||associated-165/VBN||care-171/NN	aids--1||hiv-150||no||plha who live with their families [or = 3.29, 95%ci 1.28-8.45)], lived in a rented house [or = 2.52, 95%ci 1.09-5.79], non-pregnant women [or = 9.3, 95% ci 1.93-44.82], who perceived art have many side effects [or = 6.23, 95%ci1.63,23.82)], who perceived hiv as stigmatizing disease [or = 3.1, 95% ci 1.09-8.76], who tested with sickness/symptoms [or = 2.62, 95% ci 1.26-5.44], who did not disclose their hiv status for their partner [or = 2.78, 95% ci 1.02-7.56], frequent alcohol users [or = 3.55, 95% ci 1.63-7.71] and who spent more than 120 months with partner at hiv diagnosis[or = 5.86, 95% ci 1.35-25.41] were significantly associated with late presentation to hiv/aids care.
nsubj||estimates-11/VBZ||methods-1/NNS	det||method-4/NN||the-2/DT	nn||method-4/NN||workbook-3/NN	nsubjpass||used-6/VBN||method-4/NN	nsubj||generate-8/VB||method-4/NN	auxpass||used-6/VBN||was-5/VBD	rcmod||methods-1/NNS||used-6/VBN	aux||generate-8/VB||to-7/TO	xcomp||used-6/VBN||generate-8/VB	amod||hiv/aids-10/NNS||national-9/JJ	dobj||generate-8/VB||hiv/aids-10/NNS	root||ROOT-0/null||estimates-11/VBZ	aids--1||hiv--1||no||methods the workbook method was used to generate national hiv/aids estimates.
det||evaluation-4/NN||the-2/DT	nn||evaluation-4/NN||process-3/NN	prep_for||evaluated-11/VBN||evaluation-4/NN	det||curriculum-9/NN||each-6/DT	amod||curriculum-9/NN||j2j-7/JJ	nn||curriculum-9/NN||program-8/NN	nsubjpass||evaluated-11/VBN||curriculum-9/NN	auxpass||evaluated-11/VBN||was-10/VBD	root||ROOT-0/null||evaluated-11/VBN	prep_for||evaluated-11/VBN||accuracy-13/NN	prep_for||evaluated-11/VBN||pertinence-15/NN	conj_and||accuracy-13/NN||pertinence-15/NN	agent||evaluated-11/VBN||individuals-17/NNS	amod||familiarity-20/NN||high-19/JJ	prep_with||individuals-17/NNS||familiarity-20/NN	amod||research-23/NN||hiv/aids-22/JJ	prep_with||evaluated-11/VBN||research-23/NN	aids--1||hiv--1||no||for the process evaluation, each j2j program curriculum was evaluated for accuracy and pertinence by individuals with high familiarity with hiv/aids research.
det||trial-5/NN||this-1/DT	amod||trial-5/NN||prospective-2/JJ	amod||trial-5/NN||us-3/JJ	nn||trial-5/NN||multicenter-4/NN	nsubj||utilized-23/VBD||trial-5/NN	amod||depot-9/NN||leuprolideacetate-7/JJ	amod||depot-9/NN||1-month-8/JJ	prep_of||trial-5/NN||depot-9/NN	num||â-12/NN||7.5-11/CD	dep||depot-9/NN||â-12/NN	dep||â-12/NN||$-13/$	num||$-13/$||15â-15/CD	dep||$-13/$||$-16/$	number||mg-18/CD||‰-17/CD	num||$-16/$||mg-18/CD	amod||precociouspuberty-22/NN||central-21/JJ	prep_for||depot-9/NN||precociouspuberty-22/NN	root||ROOT-0/null||utilized-23/VBD	det||period-27/NN||an-24/DT	amod||period-27/NN||open-label-25/JJ	nn||period-27/NN||treatment-26/NN	dobj||utilized-23/VBD||period-27/NN	amod||follow-up-30/NN||long-term-29/JJ	dobj||utilized-23/VBD||follow-up-30/NN	conj_and||period-27/NN||follow-up-30/NN	amod||callback-34/NN||adult-33/JJ	dobj||utilized-23/VBD||callback-34/NN	conj_and||period-27/NN||callback-34/NN	precociouspuberty-22||leuprolideacetate-7||yes||this prospective us multicenter trial of leuprolideacetate 1-month depot (7.5â€“15â€‰mg) for central precociouspuberty utilized an open-label treatment period, long-term follow-up, and adult callback.
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||adefovir-38||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
nsubj||endemic-10/JJ||burkholderiapseudomallei-1/NNS	nsubj||cause-19/VB||burkholderiapseudomallei-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiologic-4/JJ	appos||burkholderiapseudomallei-1/NNS||agent-5/NN	prep_of||agent-5/NN||melioidosis-7/NNS	cop||endemic-10/JJ||is-9/VBZ	root||ROOT-0/null||endemic-10/JJ	amod||australia-13/NN||northern-12/JJ	prep_in||endemic-10/JJ||australia-13/NN	nn||asia-16/NN||southeast-15/NN	prep_in||endemic-10/JJ||asia-16/NN	conj_and||australia-13/NN||asia-16/NN	aux||cause-19/VB||can-18/MD	conj_and||endemic-10/JJ||cause-19/VB	amod||septicemia-21/NN||severe-20/JJ	dobj||cause-19/VB||septicemia-21/NN	nsubj||lead-24/VB||septicemia-21/NN	aux||lead-24/VB||may-23/MD	rcmod||septicemia-21/NN||lead-24/VB	prep_to||lead-24/VB||death-26/NN	number||%-32/NN||20-28/CD	dep||%-32/NN||%-29/NN	dep||%-32/NN||to-30/TO	number||%-32/NN||50-31/CD	prep_in||lead-24/VB||%-32/NN	prep_of||%-32/NN||cases-34/NNS	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei , the etiologic agent of melioidosis, is endemic in northern australia and southeast asia and can cause severe septicemia that may lead to death in 20% to 50% of cases.
nsubj||caused-9/VBN||yersiniapestis-1/NNS	nsubj||poses-17/VBZ||yersiniapestis-1/NNS	det||agent-4/NN||the-3/DT	appos||yersiniapestis-1/NNS||agent-4/NN	prep_of||agent-4/NN||plague-6/NNP	aux||caused-9/VBN||has-8/VBZ	root||ROOT-0/null||caused-9/VBN	amod||millions-11/NNS||many-10/JJ	dobj||caused-9/VBN||millions-11/NNS	amod||deaths-14/NNS||human-13/JJ	prep_of||millions-11/NNS||deaths-14/NNS	advmod||poses-17/VBZ||still-16/RB	conj_and||caused-9/VBN||poses-17/VBZ	det||threat-20/NN||a-18/DT	amod||threat-20/NN||serious-19/JJ	dobj||poses-17/VBZ||threat-20/NN	amod||health-24/NN||global-22/JJ	amod||health-24/NN||public-23/JJ	prep_to||poses-17/VBZ||health-24/NN	plague-6||yersiniapestis-1||no||yersiniapestis , the agent of plague, has caused many millions of human deaths and still poses a serious threat to global public health.
prep||remains-33/VBZ||given-1/VBN	det||efficacy-3/NN||the-2/DT	pobj||given-1/VBN||efficacy-3/NN	pobj||given-1/VBN||safety-5/NN	conj_and||efficacy-3/NN||safety-5/NN	amod||issues-9/NNS||tolerability-8/JJ	pobj||given-1/VBN||issues-9/NNS	conj_and||efficacy-3/NN||issues-9/NNS	vmod||issues-9/NNS||associated-10/VBN	prep_with||associated-10/VBN||nsaids-12/NNS	nsubj||remains-33/VBZ||development-14/NN	amod||agents-17/NNS||new-16/JJ	prep_of||development-14/NN||agents-17/NNS	aux||manage-19/VB||to-18/TO	vmod||development-14/NN||manage-19/VB	det||pain-21/NN||the-20/DT	dobj||manage-19/VB||pain-21/NN	vmod||pain-21/NN||associated-22/VBN	vmod||pain-21/NN||associated-22/VBN	conj_but||associated-22/VBN||associated-22/VBN	prep_with||associated-22/VBN||arthritis-24/NN	det||cardiovascular-28/JJ||the-27/DT	prep_without||associated-22/VBN||cardiovascular-28/JJ	amod||events-32/NNS||gastrointestinal-30/JJ	amod||events-32/NNS||adverse-31/JJ	prep_without||associated-22/VBN||events-32/NNS	conj_and||cardiovascular-28/JJ||events-32/NNS	root||ROOT-0/null||remains-33/VBZ	det||priority-35/NN||a-34/DT	xcomp||remains-33/VBZ||priority-35/NN	arthritis-24||nsaids-12||no_rel||given the efficacy, safety, and tolerability issues associated with nsaids, development of new agents to manage the pain associated with arthritis but without the cardiovascular and gastrointestinal adverse events remains a priority.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||interferon--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
advmod||predict-13/VB||moreover-1/RB	det||cut-off-4/NN||a-3/DT	nsubj||predict-13/VB||cut-off-4/NN	amod||levels-8/NNS||serum-6/JJ	amod||levels-8/NNS||s100a12-7/JJ	prep_for||cut-off-4/NN||levels-8/NNS	amod||ng/ml-11/NN||54.4-10/JJ	prep_of||levels-8/NNS||ng/ml-11/NN	aux||predict-13/VB||could-12/MD	root||ROOT-0/null||predict-13/VB	preconj||uc-15/NN||both-14/DT	dobj||predict-13/VB||uc-15/NN	dobj||predict-13/VB||cd-17/NN	conj_and||uc-15/NN||cd-17/NN	det||sensitivity-22/NN||a-19/DT	number||%-21/NN||66.7-20/CD	amod||sensitivity-22/NN||%-21/NN	prep_with||predict-13/VB||sensitivity-22/NN	det||specificity-27/NN||a-24/DT	num||specificity-27/NN||64.4-25/CD	nn||specificity-27/NN||%-26/NN	prep_with||predict-13/VB||specificity-27/NN	conj_and||sensitivity-22/NN||specificity-27/NN	uc-15||cd-17||no_rel||moreover, a cut-off for serum s100a12 levels of 54.4 ng/ml could predict both uc and cd with a 66.7% sensitivity and a 64.4% specificity.
num||cases-2/NNS||seven-1/CD	nsubjpass||caused-6/VBN||cases-2/NNS	prep_of||cases-2/NNS||candidaemia-4/NN	auxpass||caused-6/VBN||were-5/VBD	root||ROOT-0/null||caused-6/VBN	nn||dubliniensis-9/NNS||candida-8/NN	agent||caused-6/VBN||dubliniensis-9/NNS	nsubj||prevalent-14/JJ||dubliniensis-9/NNS	cop||prevalent-14/JJ||was-12/VBD	advmod||prevalent-14/JJ||more-13/RBR	rcmod||dubliniensis-9/NNS||prevalent-14/JJ	advmod||prevalent-14/JJ||even-15/RB	amod||lusitaniae-18/NN||candida-17/JJ	prep_than||prevalent-14/JJ||lusitaniae-18/NN	nn||tropicalis-21/NNS||candida-20/NN	prep_than||prevalent-14/JJ||tropicalis-21/NNS	conj_and||lusitaniae-18/NN||tropicalis-21/NNS	num||cases-24/NNS||six-23/CD	dep||lusitaniae-18/NN||cases-24/NNS	dep||cases-24/NNS||each-25/DT	candidaemia-4||candida-20||no||seven cases of candidaemia were caused by candida dubliniensis , which was more prevalent even than candida lusitaniae and candida tropicalis (six cases each).
poss||understanding-2/NN||our-1/PRP$	nsubjpass||revolutionized-10/VBN||understanding-2/NN	det||treatment-5/NN||the-4/DT	prep_of||understanding-2/NN||treatment-5/NN	nn||cancer-8/NN||ovarian-7/NN	prep_of||treatment-5/NN||cancer-8/NN	auxpass||revolutionized-10/VBN||was-9/VBD	root||ROOT-0/null||revolutionized-10/VBN	det||discovery-13/NN||the-12/DT	prep_with||revolutionized-10/VBN||discovery-13/NN	amod||regimens-21/NNS||platinum-15/JJ	conj_and||platinum-15/JJ||taxane-based-18/JJ	amod||regimens-21/NNS||taxane-based-18/JJ	amod||regimens-21/NNS||adjuvant-19/JJ	nn||regimens-21/NNS||chemotherapy-20/NN	prep_of||discovery-13/NN||regimens-21/NNS	cancer-8||adjuvant-19||no_rel||our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant chemotherapy regimens.
det||data-2/NNS||these-1/DT	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||allow-18/VB||that-4/IN	det||technique-9/NN||a-5/DT	amod||technique-9/NN||novel-6/JJ	conj_and||novel-6/JJ||commercially-scalable-8/JJ	amod||technique-9/NN||commercially-scalable-8/JJ	nsubj||allow-18/VB||technique-9/NN	prepc_for||technique-9/NN||preparing-11/VBG	dobj||preparing-11/VBG||ab-12/NN	amod||colostrum-16/NN||hyperimmune-14/JJ	amod||colostrum-16/NN||bovine-15/JJ	prep_from||preparing-11/VBG||colostrum-16/NN	aux||allow-18/VB||could-17/MD	ccomp||suggest-3/VBP||allow-18/VB	dobj||allow-18/VB||production-19/NN	nsubj||control-27/VB||production-19/NN	det||substitute-23/NN||a-21/DT	amod||substitute-23/NN||valuable-22/JJ	prep_of||production-19/NN||substitute-23/NN	prep_for||substitute-23/NN||antiviraldrugs-25/NNS	aux||control-27/VB||to-26/TO	xcomp||allow-18/VB||control-27/VB	dobj||control-27/VB||influenza-28/NN	det||advantage-31/NN||the-30/DT	prep_with||control-27/VB||advantage-31/NN	prepc_of||advantage-31/NN||eliminating-33/VBG	det||need-35/NN||the-34/DT	dobj||eliminating-33/VBG||need-35/NN	amod||administration-38/NN||daily-37/JJ	prep_for||need-35/NN||administration-38/NN	influenza-28||antiviraldrugs-25||no_rel||these data suggest that a novel and commercially-scalable technique for preparing ab from hyperimmune bovine colostrum could allow production of a valuable substitute for antiviraldrugs to control influenza with the advantage of eliminating the need for daily administration.
amod||adrenalinsufficiency-2/NN||relative-1/JJ	nsubjpass||defined-4/VBN||adrenalinsufficiency-2/NN	auxpass||defined-4/VBN||was-3/VBD	root||ROOT-0/null||defined-4/VBN	mark||â-11/VBP||as-5/IN	det||rise-7/NN||a-6/DT	nsubj||â-11/VBP||rise-7/NN	nn||cortisol-10/NN||serum-9/NN	prep_in||rise-7/NN||cortisol-10/NN	advcl||defined-4/VBN||â-11/VBP	amod||g-25/NN||‰-12/JJ	amod||g-25/NN||$-13/$	number||$-13/$||9-14/CD	nn||g-25/NN||î-15/NN	num||g-25/NN||1/4-16/CD	amod||g-25/NN||g/dl-17/JJ	det||administration-20/NN||the-19/DT	prep_after||g/dl-17/JJ||administration-20/NN	num||î-23/NN||250-22/CD	prep_of||administration-20/NN||î-23/NN	dep||g/dl-17/JJ||1/4-24/CD	dobj||â-11/VBP||g-25/NN	prep_of||g-25/NN||consyntropin-27/NN	adrenalinsufficiency-2||cortisol-10||yes||relative adrenalinsufficiency was defined as a rise in serum cortisol â‰¤ 9 î¼g/dl after the administration of 250 î¼g of consyntropin.
det||study-3/NN||this-2/DT	prep_in||defined-7/VBN||study-3/NN	nsubj||defined-7/VBN||we-5/PRP	aux||defined-7/VBN||have-6/VBP	root||ROOT-0/null||defined-7/VBN	det||history-10/NN||the-8/DT	amod||history-10/NN||evolutionary-9/JJ	dobj||defined-7/VBN||history-10/NN	amod||anthrax-18/NN||western-12/JJ	nn||anthrax-18/NN||north-13/NN	nn||anthrax-18/NN||american-14/NN	num||anthrax-18/NN||-lrb--15/CD	nn||anthrax-18/NN||wna-16/NN	nn||anthrax-18/NN||-rrb--17/NN	prep_of||history-10/NN||anthrax-18/NN	vmod||anthrax-18/NN||using-19/VBG	num||polymorphisms-23/NNS||2,850-20/CD	amod||polymorphisms-23/NNS||single-21/JJ	nn||polymorphisms-23/NNS||nucleotide-22/NN	dobj||using-19/VBG||polymorphisms-23/NNS	num||snps-25/NNS||-lrb--24/CD	npadvmod||-rrb--26/JJ||snps-25/NNS	amod||polymorphisms-23/NNS||-rrb--26/JJ	num||b.anthracis-31/NNS||285-28/CD	amod||b.anthracis-31/NNS||geographically-29/JJ	amod||b.anthracis-31/NNS||diverse-30/JJ	nsubj||isolates-32/VBZ||b.anthracis-31/NNS	conj_and||defined-7/VBN||isolates-32/VBZ	anthrax-18||b.anthracis-31||no||in this study , we have defined the evolutionary history of western north american -lrb- wna -rrb- anthrax using 2,850 single nucleotide polymorphisms -lrb- snps -rrb- and 285 geographically diverse b.anthracis isolates .
amod||evidence-2/NN||clear-1/JJ	nsubj||shows-3/VBZ||evidence-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||improves-6/VBZ||that-4/IN	nsubj||improves-6/VBZ||vildagliptin-5/NN	ccomp||shows-3/VBZ||improves-6/VBZ	amod||control-8/NN||glycemic-7/JJ	dobj||improves-6/VBZ||control-8/NN	dep||control-8/NN||measured-10/VBN	amod||hemoglobin-13/NN||glycosylated-12/JJ	prep_by||measured-10/VBN||hemoglobin-13/NN	nn||levels-16/NNS||bloodglucose-15/NN	prep_by||measured-10/VBN||levels-16/NNS	conj_and||hemoglobin-13/NN||levels-16/NNS	mwe||than-19/IN||more-18/JJR	quantmod||placebo-20/CD||than-19/IN	npadvmod||control-8/NN||placebo-20/CD	prep_in||control-8/NN||adults-22/NNS	prep_with||adults-22/NNS||type2diabetes-24/NNS	dep||type2diabetes-24/NNS||either-26/RB	advmod||monotherapy-28/JJ||as-27/RB	dep||either-26/RB||monotherapy-28/JJ	dep||type2diabetes-24/NNS||in-30/IN	conj_or||either-26/RB||in-30/IN	pobj||in-30/IN||combination-31/NN	prep_with||type2diabetes-24/NNS||metformin-33/NN	type2diabetes-24||metformin-33||yes||clear evidence shows that vildagliptin improves glycemic control (measured by glycosylated hemoglobin and bloodglucose levels) more than placebo in adults with type2diabetes, either as monotherapy or in combination with metformin.
det||variables-3/NNS||the-1/DT	amod||variables-3/NNS||perinatal-2/JJ	nsubj||weight-10/NN||variables-3/NNS	vmod||variables-3/NNS||considered-4/VBN	det||study-7/NN||the-6/DT	prep_for||considered-4/VBN||study-7/NN	cop||weight-10/NN||were-8/VBD	nn||weight-10/NN||birth-9/NN	root||ROOT-0/null||weight-10/NN	dep||weight-10/NN||ga-12/NN	dep||ga-12/NN||gender-14/NN	aux||small-18/JJ||to-16/TO	cop||small-18/JJ||be-17/VB	vmod||weight-10/NN||small-18/JJ	prep_for||small-18/JJ||ga-20/NN	appos||ga-20/NN||sga-22/NN	nn||gain-26/NN||weight-25/NN	dep||small-18/JJ||gain-26/NN	prep_from||gain-26/NN||birth-28/NN	det||week-32/NN||the-30/DT	amod||week-32/NN||sixth-31/JJ	prep_to||birth-28/NN||week-32/NN	prep_of||week-32/NN||life-34/NN	dep||small-18/JJ||use-36/NN	prep_of||use-36/NN||oxygen-38/NN	amod||ventilation-41/NN||mechanical-40/JJ	prep_in||oxygen-38/NN||ventilation-41/NN	nn||cpap-44/NN||nasal-43/NN	prep_in||oxygen-38/NN||cpap-44/NN	conj_or||ventilation-41/NN||cpap-44/NN	amod||gestations-47/NNS||multiple-46/JJ	dep||small-18/JJ||gestations-47/NNS	amod||use-50/NN||therapeutic-49/JJ	dep||gestations-47/NNS||use-50/NN	prep_of||use-50/NN||surfactant-52/NN	prep_of||use-50/NN||indomethacin-54/NN	conj_and||surfactant-52/NN||indomethacin-54/NN	prep_of||use-50/NN||erythropoietin-57/NN	conj_and||surfactant-52/NN||erythropoietin-57/NN	dep||small-18/JJ||occurrence-59/NN	prep_of||occurrence-59/NN||sepsis-61/NN	prep_of||occurrence-59/NN||meningitis-63/NNS	conj_and||sepsis-61/NN||meningitis-63/NNS	nn||hemorrhage-66/NN||intraventricular-65/NN	prep_of||occurrence-59/NN||hemorrhage-66/NN	conj_and||sepsis-61/NN||hemorrhage-66/NN	prep_of||occurrence-59/NN||patentductusarteriosus-69/NNS	conj_and||sepsis-61/NN||patentductusarteriosus-69/NNS	dep||small-18/JJ||need-71/NN	prep||need-71/NN||for-72/IN	vmod||weight-10/NN||volume-74/NN	conj_and||small-18/JJ||volume-74/NN	nn||transfusion-77/NN||blood-76/NN	prep_of||volume-74/NN||transfusion-77/NN	amod||score-82/NN||10-min-80/JJ	nn||score-82/NN||apgar-81/NN	vmod||weight-10/NN||score-82/NN	conj_and||small-18/JJ||score-82/NN	patentductusarteriosus-69||indomethacin-54||yes||the perinatal variables considered for the study were birth weight; ga; gender; to be small for ga (sga); weight gain from birth to the sixth week of life; use of oxygen in mechanical ventilation or nasal cpap; multiple gestations; therapeutic use of surfactant, indomethacin, and erythropoietin; occurrence of sepsis, meningitis, intraventricular hemorrhage, and patentductusarteriosus; need for and volume of blood transfusion; and 10-min apgar score.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||budesonide-17||yes||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
amod||injection-3/NN||propofol-2/JJ	prep_before||injected-10/VBD||injection-3/NN	prep_for||injection-3/NN||induction-5/NN	prep_of||induction-5/NN||anesthesia-7/NN	nsubj||injected-10/VBD||we-9/PRP	root||ROOT-0/null||injected-10/VBD	number||%-12/NN||1-11/CD	amod||iv-16/NN||%-12/NN	amod||iv-16/NN||lidocaine-13/JJ	num||iv-16/NN||50-14/CD	nn||iv-16/NN||mg-15/NN	dobj||injected-10/VBD||iv-16/NN	nn||relief-19/NN||pain-18/NN	prep_for||iv-16/NN||relief-19/NN	pain-18||propofol-2||yes||before propofol injection for induction of anesthesia, we injected 1% lidocaine 50 mg iv for pain relief.
nsubj||evolved-14/VBN||resistance-1/NN	det||falciparum-7/NN||the-3/DT	nn||falciparum-7/NN||malaria-4/NN	nn||falciparum-7/NN||parasite-5/NN	nn||falciparum-7/NN||plasmodium-6/NN	prep_of||resistance-1/NN||falciparum-7/NN	prep_to||falciparum-7/NN||sulfadoxine-pyrimethamine-9/NN	appos||resistance-1/NN||sp-11/NN	aux||evolved-14/VBN||has-13/VBZ	root||ROOT-0/null||evolved-14/VBN	advmod||evolved-14/VBN||worldwide-15/RB	malaria-4||pyrimethamine--1||yes||resistance of the malaria parasite plasmodium falciparum to sulfadoxine-pyrimethamine (sp) has evolved worldwide.
nsubj||mediated-11/JJ||damage-1/NN	amod||mucosa-4/NN||intestinal-3/JJ	prep_to||damage-1/NN||mucosa-4/NN	prep_in||mucosa-4/NN||celiacdisease-6/NN	appos||damage-1/NN||cd-8/NN	cop||mediated-11/JJ||is-10/VBZ	root||ROOT-0/null||mediated-11/JJ	preconj||mediated-11/JJ||both-12/DT	prep_by||mediated-11/JJ||inflammation-14/NN	amod||inflammation-14/NN||due-15/JJ	aux||adaptive-17/VB||to-16/TO	xcomp||due-15/JJ||adaptive-17/VB	xcomp||due-15/JJ||innate-19/VB	conj_and||adaptive-17/VB||innate-19/VB	amod||responses-21/NNS||immune-20/JJ	dobj||adaptive-17/VB||responses-21/NNS	prep_with||responses-21/NNS||il-15-24/CD	det||mediator-28/NN||a-26/DT	amod||mediator-28/NN||major-27/JJ	prep_as||adaptive-17/VB||mediator-28/NN	det||response-33/NN||the-30/DT	amod||response-33/NN||innate-31/JJ	amod||response-33/NN||immune-32/JJ	prep_of||mediator-28/NN||response-33/NN	nsubj||causing-48/VBG||proliferation-37/NN	amod||enterocytes-40/NNS||crypt-39/JJ	prep_of||proliferation-37/NN||enterocytes-40/NNS	det||alteration-44/NN||an-42/DT	amod||alteration-44/NN||early-43/JJ	prep_as||enterocytes-40/NNS||alteration-44/NN	nn||mucosa-47/NN||cd-46/NN	prep_of||alteration-44/NN||mucosa-47/NN	prep_by||mediated-11/JJ||causing-48/VBG	conj_and||inflammation-14/NN||causing-48/VBG	amod||hyperplasia-50/NN||crypts-49/JJ	dobj||causing-48/VBG||hyperplasia-50/NN	cd-46||inflammation-14||no_rel||damage to intestinal mucosa in celiacdisease (cd) is mediated both by inflammation due to adaptive and innate immune responses, with il-15 as a major mediator of the innate immune response, and by proliferation of crypt enterocytes as an early alteration of cd mucosa causing crypts hyperplasia.
det||objective-3/NN||the-1/DT	amod||objective-3/NN||principal-2/JJ	nsubj||was-25/VBD||objective-3/NN	nsubj||develop-27/VB||objective-3/NN	nsubj||implement-29/VB||objective-3/NN	det||studies-7/NNS||these-5/DT	amod||studies-7/NNS||multisite-6/JJ	prep_of||objective-3/NN||studies-7/NNS	dep||studies-7/NNS||florida-9/NN	amod||york-12/NN||new-11/JJ	appos||florida-9/NN||york-12/NN	amod||epicenters-16/NNS||new-14/JJ	nn||epicenters-16/NNS||jersey-15/NN	dep||florida-9/NN||epicenters-16/NNS	amod||-RSB--21/NNS||humanimmunodeficiencyvirus-18/JJ	amod||-RSB--21/NNS||-LSB--19/JJ	nn||-RSB--21/NNS||hiv-20/NN	prep_for||epicenters-16/NNS||-RSB--21/NNS	prep_among||-RSB--21/NNS||women-23/NNS	root||ROOT-0/null||was-25/VBD	aux||develop-27/VB||to-26/TO	xcomp||was-25/VBD||develop-27/VB	xcomp||was-25/VBD||implement-29/VB	conj_and||develop-27/VB||implement-29/VB	amod||combinations-31/NNS||effective-30/JJ	dobj||develop-27/VB||combinations-31/NNS	amod||interventions-34/NNS||behavioral-33/JJ	prep_of||combinations-31/NNS||interventions-34/NNS	aux||optimize-36/VB||to-35/TO	vmod||develop-27/VB||optimize-36/VB	det||status-39/NN||the-37/DT	nn||status-39/NN||health-38/NN	dobj||optimize-36/VB||status-39/NN	det||population-46/NN||the-41/DT	advmod||neglected-43/JJ||most-42/RBS	amod||population-46/NN||neglected-43/JJ	conj_and||neglected-43/JJ||understudied-45/JJ	amod||population-46/NN||understudied-45/JJ	prep_of||status-39/NN||population-46/NN	vmod||population-46/NN||affected-47/VBN	det||epidemic-54/NN||the-49/DT	amod||epidemic-54/NN||acquiredimmunodeficiencysyndrome-50/JJ	appos||epidemic-54/NN||aids-52/NNS	agent||affected-47/VBN||epidemic-54/NN	det||states-58/NNS||the-56/DT	amod||states-58/NNS||united-57/VBN	prep_in||affected-47/VBN||states-58/NNS	amod||women-60/NNS||poor-59/JJ	dep||was-25/VBD||women-60/NNS	prep_of||women-60/NNS||color-62/NN	vmod||color-62/NN||living-63/VBG	prep_with||living-63/VBG||hiv-65/NN	aids-52||humanimmunodeficiencyvirus-18||no||the principal objective of these multisite studies (florida, new york, new jersey epicenters for humanimmunodeficiencyvirus [hiv] among women) was to develop and implement effective combinations of behavioral interventions to optimize the health status of the most neglected and understudied population affected by the acquiredimmunodeficiencysyndrome (aids) epidemic in the united states poor women of color living with hiv.
poss||study-3/NN||our-2/PRP$	det||bupivacaine-9/NN||study-3/NN	prep_from||provides-16/VBZ||study-3/NN	nsubjpass||concluded-7/VBN||it-4/PRP	aux||concluded-7/VBN||can-5/MD	auxpass||concluded-7/VBN||be-6/VB	rcmod||study-3/NN||concluded-7/VBN	npadvmod||concluded-7/VBN||bupivacaine-9/NN	prep_along_with||concluded-7/VBN||clonidine-12/NN	amod||doses-15/NNS||low-14/JJ	prep_in||clonidine-12/NN||doses-15/NNS	root||ROOT-0/null||provides-16/VBZ	conj_and||provides-16/VBZ||provides-16/VBZ	amod||sedation-18/NN||good-17/JJ	dobj||provides-16/VBZ||sedation-18/NN	dobj||provides-16/VBZ||analgesia-20/NN	conj_and||sedation-18/NN||analgesia-20/NN	amod||period-25/NN||intraoperative-22/JJ	conj_and||intraoperative-22/JJ||post-operative-24/JJ	amod||period-25/NN||post-operative-24/JJ	prep_in||provides-16/VBZ||period-25/NN	det||abolishes-31/NNS||the-28/DT	amod||abolishes-31/NNS||same-29/JJ	nn||abolishes-31/NNS||time-30/NN	prep_at||provides-16/VBZ||abolishes-31/NNS	nn||pain-34/NN||shoulder-32/NN	nn||pain-34/NN||tip-33/NN	nsubj||provides-16/VBZ||pain-34/NN	nsubj||provides-16/VBZ||pain-34/NN	amod||procedures-37/NNS||laparoscopic-36/JJ	prep_during||pain-34/NN||procedures-37/NNS	pain-34||bupivacaine-9||yes||from our study it can be concluded that bupivacaine along with clonidine in low doses provides good sedation and analgesia in intraoperative and post-operative period and at the same time abolishes shoulder tip pain during laparoscopic procedures.
det||studies-2/NNS||these-1/DT	nsubj||define-3/VB||studies-2/NNS	nsubj||reveal-12/VB||studies-2/NNS	root||ROOT-0/null||define-3/VB	det||mechanism-5/NN||the-4/DT	dobj||define-3/VB||mechanism-5/NN	amod||recognition-8/NN||scaffold-7/JJ	prep_of||mechanism-5/NN||recognition-8/NN	prep_by||define-3/VB||p-tefb-10/NN	conj_and||define-3/VB||reveal-12/VB	det||pocket-16/NN||an-13/DT	amod||pocket-16/NN||unanticipated-14/JJ	nn||pocket-16/NN||intersubunit-15/NN	dobj||reveal-12/VB||pocket-16/NN	det||sec-20/NN||the-18/DT	amod||sec-20/NN||aff4-19/JJ	prep_on||reveal-12/VB||sec-20/NN	nsubj||represents-23/VBZ||sec-20/NN	advmod||represents-23/VBZ||potentially-22/RB	rcmod||sec-20/NN||represents-23/VBZ	det||target-25/NN||a-24/DT	dobj||represents-23/VBZ||target-25/NN	amod||intervention-28/NN||therapeutic-27/JJ	prep_for||target-25/NN||intervention-28/NN	prep_against||intervention-28/NN||hiv/aids-30/NNS	aids--1||hiv--1||no||these studies define the mechanism of scaffold recognition by p-tefb and reveal an unanticipated intersubunit pocket on the aff4 sec that potentially represents a target for therapeutic intervention against hiv/aids.
amod||adjustment-3/NN||further-2/JJ	prep_after||associated-23/VBN||adjustment-3/NN	det||covariates-7/NNS||all-5/DT	amod||covariates-7/NNS||other-6/JJ	prep_for||adjustment-3/NN||covariates-7/NNS	prep_for||adjustment-3/NN||covariates-7/NNS	conj_less||covariates-7/NNS||covariates-7/NNS	det||value-11/NN||a-9/DT	nn||value-11/NN||p-10/NN	prep_with||covariates-7/NNS||value-11/NN	amod||associations-17/NNS||0.3-14/CD	conj_and||0.3-14/CD||nonlinear-16/JJR	amod||associations-17/NNS||nonlinear-16/JJR	prep_than||covariates-7/NNS||associations-17/NNS	prep_with||associations-17/NNS||cancer-19/NN	nsubjpass||associated-23/VBN||a1c-21/NNS	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||cancer-27/NN	prep_with||associated-23/VBN||risk-28/NN	dep||hr-30/NN||-lrb--29/NN	amod||risk-28/NN||hr-30/NN	prep_per||risk-28/NN||percentage-32/NN	num||percentage-32/NN||1.26-33/CD	num||%-36/NN||95-35/CD	npadvmod||ci-37/RB||%-36/NN	advmod||â-39/NN||ci-37/RB	num||â-39/NN||1.03-38/CD	appos||percentage-32/NN||â-39/NN	dep||-rrb--43/NN||$-40/$	num||$-40/$||1.55-42/CD	amod||â-39/NN||-rrb--43/NN	mark||associated-50/VBN||whereas-45/IN	nsubjpass||associated-50/VBN||use-46/NN	prep_of||use-46/NN||insulin-48/NN	auxpass||associated-50/VBN||was-49/VBD	dep||percentage-32/NN||associated-50/VBN	det||risk-55/NN||a-52/DT	amod||risk-55/NN||decreased-53/VBN	nn||risk-55/NN||cancer-54/NN	prep_with||associated-50/VBN||risk-55/NN	dep||hr-57/NN||-lrb--56/NN	amod||risk-55/NN||hr-57/NN	nn||users-60/NNS||insulin-59/NN	prep_of||risk-55/NN||users-60/NNS	prep_vs.||users-60/NNS||nonusers-62/NNP	num||nonusers-62/NNP||0.17-63/CD	num||nonusers-62/NNP||0.09-65/CD	quantmod||$-67/$||â-66/RB	dep||-rrb--70/NN||$-67/$	num||$-67/$||0.32-69/CD	amod||risk-55/NN||-rrb--70/NN	cancer-54||insulin-59||no_rel||after further adjustment for all other covariates with a p value less than 0.3 and nonlinear associations with cancer , a1c was associated with an increased cancer risk -lrb- hr per percentage 1.26 , 95 % ci 1.03 â $ `` 1.55 -rrb- , whereas use of insulin was associated with a decreased cancer risk -lrb- hr of insulin users vs. nonusers 0.17 , 0.09 â $ `` 0.32 -rrb- .
nn||supplement-2/NN||zinc-1/NN	nsubj||reduce-7/VB||supplement-2/NN	amod||countries-5/NNS||developing-4/VBG	prep_in||supplement-2/NN||countries-5/NNS	aux||reduce-7/VB||did-6/VBD	root||ROOT-0/null||reduce-7/VB	det||incidence-9/NN||the-8/DT	dobj||reduce-7/VB||incidence-9/NN	dobj||reduce-7/VB||prevalence-11/NN	conj_and||incidence-9/NN||prevalence-11/NN	prep_of||incidence-9/NN||diarrhea-13/NN	zinc-1||diarrhea-13||no_rel||zinc supplement in developing countries did reduce the incidence and prevalence of diarrhea.
det||review-2/NN||this-1/DT	nsubj||focuses-3/VBZ||review-2/NN	nsubj||analyzes-17/VBZ||review-2/NN	root||ROOT-0/null||focuses-3/VBZ	amod||strategies-6/NNS||current-5/JJ	prep_on||focuses-3/VBZ||strategies-6/NNS	vmod||strategies-6/NNS||employed-7/VBN	amod||trials-11/NNS||recent-9/JJ	amod||trials-11/NNS||clinical-10/JJ	agent||employed-7/VBN||trials-11/NNS	amod||vaccines-15/NNS||therapeutic-13/JJ	nn||vaccines-15/NNS||cancer-14/NN	prep_of||trials-11/NNS||vaccines-15/NNS	conj_and||focuses-3/VBZ||analyzes-17/VBZ	dobj||analyzes-17/VBZ||them-18/PRP	preconj||clinically-20/JJ||both-19/DT	acomp||analyzes-17/VBZ||clinically-20/JJ	acomp||analyzes-17/VBZ||immunologically-22/JJ	conj_and||clinically-20/JJ||immunologically-22/JJ	cancer-14||vaccines-15||no_rel||this review focuses on current strategies employed by recent clinical trials of therapeutic cancer vaccines and analyzes them both clinically and immunologically.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||outcomes-5/NNS||the-3/DT	amod||outcomes-5/NNS||long-term-4/JJ	dobj||describe-2/VBP||outcomes-5/NNS	num||patients-9/NNS||510-7/CD	amod||patients-9/NNS||diabetic-8/JJ	prep_of||outcomes-5/NNS||patients-9/NNS	amod||ischemia-13/NN||critical-11/JJ	nn||ischemia-13/NN||limb-12/NN	prep_with||patients-9/NNS||ischemia-13/NN	appos||ischemia-13/NN||cli-15/NN	det||footulcer-20/NN||an-18/DT	amod||footulcer-20/NN||active-19/JJ	prep_with||patients-9/NNS||footulcer-20/NN	conj_and||ischemia-13/NN||footulcer-20/NN	conj_and||ischemia-13/NN||gangrene-22/NN	conj_or||footulcer-20/NN||gangrene-22/NN	vmod||patients-9/NNS||seen-24/VBN	det||hospital-28/NN||the-26/DT	nn||hospital-28/NN||university-27/NN	prep_at||seen-24/VBN||hospital-28/NN	amod||vergata-32/NN||rome-30/JJ	nn||vergata-32/NN||tor-31/NN	prep_of||hospital-28/NN||vergata-32/NN	det||clinic-37/NN||a-34/DT	amod||clinic-37/NN||tertiary-35/JJ	nn||clinic-37/NN||care-36/NN	appos||vergata-32/NN||clinic-37/NN	gangrene-22||tor-31||no_rel||we describe the long-term outcomes of 510 diabetic patients with critical limb ischemia (cli) and an active footulcer or gangrene, seen at the university hospital of rome tor vergata, a tertiary care clinic.
det||patients-2/NNS||the-1/DT	nsubj||received-19/VBD||patients-2/NNS	det||group-9/NN||the-4/DT	amod||preemptive-6/JJ||multimodal-5/JJ	amod||group-9/NN||preemptive-6/JJ	nn||group-9/NN||pain-7/NN	nn||group-9/NN||relief-8/NN	prep_in||patients-2/NNS||group-9/NN	det||group-13/NN||the-11/DT	nn||group-13/NN||study-12/NN	dep||group-9/NN||group-13/NN	nn||121-17/NNP||n-15/NNP	nn||121-17/NNP||=-16/NNP	appos||group-13/NN||121-17/NNP	root||ROOT-0/null||received-19/VBD	amod||blockade-22/NN||regional-20/JJ	nn||blockade-22/NN||nerve-21/NN	dobj||received-19/VBD||blockade-22/NN	number||%-25/NN||0.25-24/CD	amod||bupivacaine-26/NN||%-25/NN	prep_with||received-19/VBD||bupivacaine-26/NN	prep||received-19/VBD||combined-27/VBN	pcomp||combined-27/VBN||with-28/IN	amod||mg/kg-34/NN||preoperative-29/JJ	advmod||administered-31/JJ||rectally-30/RB	amod||mg/kg-34/NN||administered-31/JJ	nn||mg/kg-34/NN||paracetamol-32/NN	num||mg/kg-34/NN||45-33/CD	pobj||with-28/IN||mg/kg-34/NN	amod||min-40/NN||diclofenac-36/JJ	num||min-40/NN||1-37/CD	amod||min-40/NN||mg/kg-38/JJ	dep||mg/kg-38/JJ||60-39/CD	pobj||with-28/IN||min-40/NN	conj_or||mg/kg-34/NN||min-40/NN	prep_before||mg/kg-34/NN||surgery-42/NN	prep_for||surgery-42/NN||cases-44/NNS	nsubj||were-46/VBD||cases-44/NNS	nsubj||undergo-48/VB||cases-44/NNS	rcmod||cases-44/NNS||were-46/VBD	aux||undergo-48/VB||to-47/TO	xcomp||were-46/VBD||undergo-48/VB	amod||surgery-51/NN||lower-49/JJR	nn||surgery-51/NN||abdominal-50/NN	dobj||undergo-48/VB||surgery-51/NN	pain-7||bupivacaine-26||yes||the patients in the multimodal preemptive pain relief group (the study group, n = 121) received regional nerve blockade with 0.25% bupivacaine combined with preoperative rectally administered paracetamol 45 mg/kg or diclofenac 1 mg/kg 60 min before surgery for cases that were to undergo lower abdominal surgery.
prep_over||become-10/VBP||time-2/NN	advmod||become-10/VBP||however-4/RB	advmod||patients-9/NNS||virtually-6/RB	det||patients-9/NNS||all-7/DT	nn||patients-9/NNS||cll-8/NN	nsubj||become-10/VBP||patients-9/NNS	root||ROOT-0/null||become-10/VBP	xcomp||become-10/VBP||fludarabine-refractory-11/NN	cll-8||fludarabine--1||yes||over time, however, virtually all cll patients become fludarabine-refractory.
aux||describe-2/VB||to-1/TO	csubj||replaced-24/VBN||describe-2/VB	det||case-management-9/NN||the-3/DT	dep||case-management-9/NN||quality-4/NN	prep_of||quality-4/NN||outpatient-6/NN	amod||case-management-9/NN||paediatric-7/JJ	nn||case-management-9/NN||malaria-8/NN	dobj||describe-2/VB||case-management-9/NN	advmod||4â-11/JJ||approximately-10/RB	amod||case-management-9/NN||4â-11/JJ	num||months-15/NNS||$-12/$	num||$-12/$||6-14/CD	npadvmod||describe-2/VB||months-15/NNS	nn||$-18/NNP||artemetherâ-17/NNP	prep_after||describe-2/VB||$-18/NNP	dep||$-18/NNP||lumefantrine-20/NN	appos||$-18/NNP||al-22/NNP	root||ROOT-0/null||replaced-24/VBN	nn||$-26/NNP||sulfadoxineâ-25/NNP	dep||pyrimethamine-28/NN||$-26/NNP	dep||replaced-24/VBN||pyrimethamine-28/NN	discourse||pyrimethamine-28/NN||sp-30/UH	det||therapy-37/NN||the-33/DT	amod||therapy-37/NN||nationally-34/JJR	amod||therapy-37/NN||recommended-35/VBN	amod||therapy-37/NN||first-line-36/JJ	prep_as||replaced-24/VBN||therapy-37/NN	prep_in||therapy-37/NN||kenya-39/NN	malaria-8||pyrimethamine-28||yes||to describe the quality of outpatient paediatric malaria case-management approximately 4â€“6 months after artemetherâ€“lumefantrine (al) replaced sulfadoxineâ€“pyrimethamine (sp) as the nationally recommended first-line therapy in kenya.
mark||understand-5/VB||in-1/IN	dep||understand-5/VB||order-2/NN	aux||understand-5/VB||to-3/TO	advmod||understand-5/VB||well-4/RB	advcl||conducted-15/VBN||understand-5/VB	det||knowledge-8/NN||the-6/DT	amod||knowledge-8/NN||hiv/aids-7/JJ	dobj||understand-5/VB||knowledge-8/NN	prep_among||knowledge-8/NN||detainees-10/NNS	det||survey-13/NN||a-12/DT	nsubjpass||conducted-15/VBN||survey-13/NN	auxpass||conducted-15/VBN||was-14/VBD	root||ROOT-0/null||conducted-15/VBN	amod||settings-19/NNS||different-17/JJ	nn||settings-19/NNS||detention-18/NN	prep_in||conducted-15/VBN||settings-19/NNS	nn||province-22/NN||hunan-21/NN	prep_in||settings-19/NNS||province-22/NN	prep_in||province-22/NN||2008-24/CD	aux||assess-26/VB||to-25/TO	ccomp||conducted-15/VBN||assess-26/VB	dobj||assess-26/VB||knowledge-27/NN	dobj||assess-26/VB||attitudes-29/NNS	conj_and||knowledge-27/NN||attitudes-29/NNS	prep_about||assess-26/VB||hiv-31/NN	prep_among||hiv-31/NN||detainees-33/NNS	aux||provide-36/VB||to-35/TO	ccomp||conducted-15/VBN||provide-36/VB	conj_and||assess-26/VB||provide-36/VB	amod||information-38/NN||useful-37/JJ	dobj||provide-36/VB||information-38/NN	nn||prevention-41/NN||hiv-40/NN	prep_for||information-38/NN||prevention-41/NN	nn||strategies-44/NNS||intervention-43/NN	prep_for||information-38/NN||strategies-44/NNS	conj_and||prevention-41/NN||strategies-44/NNS	nn||centers-47/NNS||detention-46/NN	prep_in||provide-36/VB||centers-47/NNS	aids--1||hiv-40||no||in order to well understand the hiv/aids knowledge among detainees, a survey was conducted in different detention settings in hunan province in 2008 to assess knowledge and attitudes about hiv among detainees and to provide useful information for hiv prevention and intervention strategies in detention centers.
advmod||specific-36/NN||furthermore-1/RB	amod||a-4/DT||papuamide-3/JJ	nsubj||specific-36/NN||a-4/DT	cop||able-6/JJ||was-5/VBD	rcmod||a-4/DT||able-6/JJ	aux||inhibit-8/VB||to-7/TO	xcomp||able-6/JJ||inhibit-8/VB	nn||viruses-11/NNS||hiv-9/NN	nn||viruses-11/NNS||pseudotype-10/NN	dobj||inhibit-8/VB||viruses-11/NNS	xcomp||inhibit-8/VB||expressing-12/VBG	nn||glycoproteins-14/NNS||envelope-13/NN	dobj||expressing-12/VBG||glycoproteins-14/NNS	nn||virus-18/NN||vesicular-16/NN	nn||virus-18/NN||stomatitis-17/NN	prep_from||expressing-12/VBG||virus-18/NN	amod||virus-23/NN||amphotropic-20/JJ	amod||virus-23/NN||murine-21/JJ	nn||virus-23/NN||leukemia-22/NN	prep_from||expressing-12/VBG||virus-23/NN	conj_or||virus-18/NN||virus-23/NN	vmod||a-4/DT||indicating-24/VBG	det||mechanism-26/NN||the-25/DT	dobj||indicating-24/VBG||mechanism-26/NN	amod||inhibition-30/NN||viral-28/JJ	nn||inhibition-30/NN||entry-29/NN	prep_of||mechanism-26/NN||inhibition-30/NN	cop||specific-36/NN||is-31/VBZ	neg||specific-36/NN||not-32/RB	amod||specific-36/NN||hiv-1-33/JJ	nn||specific-36/NN||envelope-34/NN	nn||specific-36/NN||glycoprotein-35/NN	root||ROOT-0/null||specific-36/NN	virus-23||viruses-11||no||furthermore, papuamide a was able to inhibit hiv pseudotype viruses expressing envelope glycoproteins from vesicular stomatitis virus or amphotropic murine leukemia virus indicating the mechanism of viral entry inhibition is not hiv-1 envelope glycoprotein specific.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	glucose-8||insulinresistance-35||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
det||model-2/NN||this-1/DT	nsubjpass||used-5/VBN||model-2/NN	nsubj||track-7/VB||model-2/NN	aux||used-5/VBN||has-3/VBZ	auxpass||used-5/VBN||been-4/VBN	root||ROOT-0/null||used-5/VBN	aux||track-7/VB||to-6/TO	xcomp||used-5/VBN||track-7/VB	det||production-9/NN||the-8/DT	dobj||track-7/VB||production-9/NN	amod||cells-15/NNS||gene-containing-11/JJ	amod||cells-15/NNS||cd4-12/JJ	nn||cells-15/NNS||+-13/NN	nn||cells-15/NNS||t-14/NN	prep_of||production-9/NN||cells-15/NNS	det||degree-18/NN||the-17/DT	dobj||track-7/VB||degree-18/NN	conj_and||production-9/NN||degree-18/NN	prep_of||degree-18/NN||hivinfection-20/NN	det||development-24/NN||the-23/DT	dobj||track-7/VB||development-24/NN	conj_and||production-9/NN||development-24/NN	nn||resistance-27/NN||hiv-26/NN	prep_of||development-24/NN||resistance-27/NN	amod||tissue-30/NN||lymphoid-29/JJ	prep_in||track-7/VB||tissue-30/NN	num||years-33/NNS||13-32/CD	prep_for||tissue-30/NN||years-33/NNS	hivinfection-20||hiv-26||no||this model has been used to track the production of gene-containing cd4+ t cells, the degree of hivinfection, and the development of hiv resistance in lymphoid tissue for 13 years.
det||patients-4/NNS||the-2/DT	amod||patients-4/NNS||137-3/JJ	prep_among||identified-23/VBD||patients-4/NNS	prep_with||patients-4/NNS||acuteqfever-6/NN	appos||acuteqfever-6/NN||89-8/CD	num||%-11/NN||65.0-10/CD	dep||89-8/CD||%-11/NN	prep_with||patients-4/NNS||scrubtyphus-14/NNS	conj_or||acuteqfever-6/NN||scrubtyphus-14/NNS	appos||acuteqfever-6/NN||43-16/CD	num||%-19/NN||31.4-18/CD	dep||43-16/CD||%-19/NN	nsubj||identified-23/VBD||we-22/PRP	root||ROOT-0/null||identified-23/VBD	num||patients-25/NNS||5-24/CD	dobj||identified-23/VBD||patients-25/NNS	nsubjpass||co-infected-32/VBN||patients-25/NNS	num||%-28/NN||3.6-27/CD	appos||patients-25/NNS||%-28/NN	auxpass||co-infected-32/VBN||were-31/VBD	rcmod||patients-25/NNS||co-infected-32/VBN	prep_with||co-infected-32/VBN||coxiellaburnetii-34/NNS	prep_with||co-infected-32/VBN||orientiatsutsugamushi-36/NNS	conj_and||coxiellaburnetii-34/NNS||orientiatsutsugamushi-36/NNS	acuteqfever-6||coxiellaburnetii-34||no||among the 137 patients with acuteqfever (89, 65.0%) or scrubtyphus (43, 31.4%), we identified 5 patients (3.6%) who were co-infected with coxiellaburnetii and orientiatsutsugamushi .
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||designed-5/VBN||study-3/NN	nsubj||assess-7/VB||study-3/NN	auxpass||designed-5/VBN||was-4/VBD	root||ROOT-0/null||designed-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||designed-5/VBN||assess-7/VB	dobj||assess-7/VB||tolerance-8/NN	dobj||assess-7/VB||cross-tolerance-10/NN	conj_and||tolerance-8/NN||cross-tolerance-10/NN	det||effects-14/NNS||the-12/DT	amod||effects-14/NNS||neurocognitive-13/JJ	prep_to||assess-7/VB||effects-14/NNS	prep_of||effects-14/NNS||thc-16/NN	prep_of||effects-14/NNS||alcohol-18/NN	conj_and||thc-16/NN||alcohol-18/NN	amod||users-22/NNS||heavy-20/JJ	nn||users-22/NNS||cannabis-21/NN	prep_in||assess-7/VB||users-22/NNS	cross--1||alcohol-18||no_rel||the present study was designed to assess tolerance and cross-tolerance to the neurocognitive effects of thc and alcohol in heavy cannabis users.
det||turkeys-3/NNS||all-1/DT	amod||turkeys-3/NNS||virus-exposed-2/JJ	nsubj||developed-4/VBD||turkeys-3/NNS	root||ROOT-0/null||developed-4/VBD	amod||response-7/NN||positive-5/JJ	nn||response-7/NN||antibody-6/NN	dobj||developed-4/VBD||response-7/NN	num||dpi-10/NN||14-9/CD	prep_by||developed-4/VBD||dpi-10/NN	virus--1||antibody-6||no_rel||all virus-exposed turkeys developed positive antibody response by 14 dpi.
prep_in||improves-5/VBZ||vivo-2/NN	nsubj||improves-5/VBZ||ascorbate-4/NN	nsubj||produces-12/VBZ||ascorbate-4/NN	root||ROOT-0/null||improves-5/VBZ	poss||effect-8/NN||albuterol-6/NNP	dobj||improves-5/VBZ||effect-8/NN	prep_on||improves-5/VBZ||heaves-10/NNP	conj_and||improves-5/VBZ||produces-12/VBZ	det||enhancement-15/NN||a-13/DT	amod||enhancement-15/NN||10-fold-14/JJ	dobj||produces-12/VBZ||enhancement-15/NN	amod||activity-18/NN||albuterol-17/JJ	prep_of||enhancement-15/NN||activity-18/NN	prep_in||produces-12/VBZ||â-20/NN	dobj||improves-5/VBZ||$-21/$	num||$-21/$||œasthmaticâ-22/CD	amod||$-21/$||$-23/$	number||$-23/$||sheep-24/CD	asthmatic--1||albuterol-17||yes||in vivo , ascorbate improves albuterol's effect on heaves and produces a 10-fold enhancement of albuterol activity in â€œasthmaticâ€? sheep.
det||ups-2/NNS||the-1/DT	nsubj||appears-4/VBZ||ups-2/NNS	nsubjpass||involved-7/VBN||ups-2/NNS	nsubj||influence-22/VB||ups-2/NNS	advmod||appears-4/VBZ||also-3/RB	root||ROOT-0/null||appears-4/VBZ	aux||involved-7/VBN||to-5/TO	auxpass||involved-7/VBN||be-6/VB	xcomp||appears-4/VBZ||involved-7/VBN	prepc_in||involved-7/VBN||regulating-9/VBG	nn||synthesis-11/NN||lipid-10/NN	dobj||regulating-9/VBG||synthesis-11/NN	prep_in||synthesis-11/NN||adipocytes-13/NNS	nn||production-16/NN||lipid-15/NN	prep_in||synthesis-11/NN||production-16/NN	conj_and||adipocytes-13/NNS||production-16/NN	det||liver-19/NN||the-18/DT	prep_by||regulating-9/VBG||liver-19/NN	aux||influence-22/VB||could-21/MD	conj_and||appears-4/VBZ||influence-22/VB	det||development-24/NN||the-23/DT	dobj||influence-22/VB||development-24/NN	prep_of||development-24/NN||obesity-26/NN	obesity-26||lipid-15||no_rel||the ups also appears to be involved in regulating lipid synthesis in adipocytes and lipid production by the liver and could influence the development of obesity.
nsubj||diagnosed-4/VBN||patients-1/NNS	nsubjpass||recruited-20/VBN||patients-1/NNS	nsubjpass||randomized-22/VBN||patients-1/NNS	nsubj||receive-24/VB||patients-1/NNS	aux||diagnosed-4/VBN||have-3/VBP	rcmod||patients-1/NNS||diagnosed-4/VBN	prep_with||diagnosed-4/VBN||rheumatoidarthritis-6/NNS	nn||college-10/NN||american-9/NN	prep_as_per||diagnosed-4/VBN||college-10/NN	advmod||aged-13/VBN||rheumatology-12/RB	amod||years-18/NNS||aged-13/VBN	prep_between||aged-13/VBN||18-15/CD	prep_between||aged-13/VBN||60-17/CD	conj_and||18-15/CD||60-17/CD	prep_of||college-10/NN||years-18/NNS	auxpass||recruited-20/VBN||were-19/VBD	root||ROOT-0/null||recruited-20/VBN	conj_and||recruited-20/VBN||randomized-22/VBN	aux||receive-24/VB||to-23/TO	xcomp||randomized-22/VBN||receive-24/VB	amod||-lrb--26/NNS||leflunomide-25/JJ	dobj||receive-24/VB||-lrb--26/NNS	num||-rrb--30/NNS||10-27/CD	amod||-rrb--30/NNS||mg/day-28/JJ	nn||-rrb--30/NNS||p.o.-29/NN	dep||-lrb--26/NNS||-rrb--30/NNS	det||combination-33/NN||a-32/DT	dobj||receive-24/VB||combination-33/NN	conj_or||-lrb--26/NNS||combination-33/NN	amod||p.o.-41/NN||methotrexate-35/JJ	conj_and||methotrexate-35/JJ||hydroxychloroquine-37/JJ	amod||p.o.-41/NN||hydroxychloroquine-37/JJ	amod||p.o.-41/NN||-lrb--38/JJ	num||p.o.-41/NN||7.5-39/CD	nn||p.o.-41/NN||mg/week-40/NN	prep_of||combination-33/NN||p.o.-41/NN	num||p.o.-45/NN||200-43/CD	amod||p.o.-45/NN||mg/day-44/JJ	prep_of||combination-33/NN||p.o.-45/NN	conj_and||p.o.-41/NN||p.o.-45/NN	advmod||-rrb--48/VBG||respectively-47/RB	vmod||recruited-20/VBN||-rrb--48/VBG	amod||supplementation-52/NN||folate-51/JJ	prep_along_with||-rrb--48/VBG||supplementation-52/NN	num||weeks-55/NNS||12-54/CD	prep_for||supplementation-52/NN||weeks-55/NNS	rheumatoidarthritis-6||methotrexate-35||yes||patients who have diagnosed with rheumatoidarthritis as per american college of rheumatology aged between 18 and 60 years were recruited and randomized to receive leflunomide -lrb- 10 mg/day p.o. -rrb- or a combination of methotrexate and hydroxychloroquine -lrb- 7.5 mg/week p.o. and 200 mg/day p.o. , respectively -rrb- along with folate supplementation for 12 weeks .
amod||studies-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-10/VBZ||that-4/IN	det||induction-6/NN||the-5/DT	nsubj||plays-10/VBZ||induction-6/NN	amod||expression-9/NN||ho-1-8/JJ	prep_of||induction-6/NN||expression-9/NN	ccomp||suggest-3/VBP||plays-10/VBZ	det||role-14/NN||a-11/DT	amod||role-14/NN||critical-12/JJ	amod||role-14/NN||protective-13/JJ	dobj||plays-10/VBZ||role-14/NN	amod||models-18/NNS||intestinal-16/JJ	nn||models-18/NNS||damage-17/NN	prep_in||plays-10/VBZ||models-18/NNS	vmod||models-18/NNS||induced-19/VBN	agent||induced-19/VBN||ischemia-reperfusion-21/NN	agent||induced-19/VBN||indomethacin-23/NN	conj_and||ischemia-reperfusion-21/NN||indomethacin-23/NN	amod||sepsis-26/NN||lipopolysaccharide-associated-25/JJ	agent||induced-19/VBN||sepsis-26/NN	conj_and||ischemia-reperfusion-21/NN||sepsis-26/NN	amod||acid-30/NN||trinitrobenzene-28/JJ	amod||acid-30/NN||sulfonic-29/JJ	agent||induced-19/VBN||acid-30/NN	conj_and||ischemia-reperfusion-21/NN||acid-30/NN	nn||sodium-35/NN||dextran-33/NN	nn||sodium-35/NN||sulfate-34/NN	agent||induced-19/VBN||sodium-35/NN	conj_and||ischemia-reperfusion-21/NN||sodium-35/NN	vmod||plays-10/VBZ||indicating-37/VBG	mark||act-43/VB||that-38/IN	nsubj||act-43/VB||activation-39/NN	nsubj||reduce-50/VB||activation-39/NN	prep_of||activation-39/NN||ho-1-41/CD	aux||act-43/VB||may-42/MD	ccomp||indicating-37/VBG||act-43/VB	det||mechanism-48/NN||an-45/DT	amod||mechanism-48/NN||endogenous-46/JJ	amod||mechanism-48/NN||defensive-47/JJ	prep_as||act-43/VB||mechanism-48/NN	aux||reduce-50/VB||to-49/TO	xcomp||act-43/VB||reduce-50/VB	nn||injury-54/NN||inflammation-51/NN	conj_and||inflammation-51/NN||tissue-53/NN	nn||injury-54/NN||tissue-53/NN	dobj||reduce-50/VB||injury-54/NN	det||tract-58/NN||the-56/DT	amod||tract-58/NN||gastrointestinal-57/JJ	prep_in||reduce-50/VB||tract-58/NN	dextran-33||ischemia--1||no_rel||recent studies suggest that the induction of ho-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of ho-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract.
nsubjpass||classified-3/VBN||breasttumors-1/NNS	auxpass||classified-3/VBN||are-2/VBP	root||ROOT-0/null||classified-3/VBN	prepc_based_on||classified-3/VBN||on-5/IN	det||status-15/NN||the-6/DT	amod||status-15/NN||estrogen-7/JJ	dep||alpha-9/NN||receptor-8/JJ	amod||status-15/NN||alpha-9/NN	number||±-12/CD||erî-11/CD	dep||alpha-9/NN||±-12/CD	nn||status-15/NN||expression-14/NN	pobj||classified-3/VBN||status-15/NN	advmod||negative-18/JJ||er-17/RB	amod||tumors-22/NNS||negative-18/JJ	advmod||positive-21/JJ||er-20/RB	conj_and||negative-18/JJ||positive-21/JJ	amod||tumors-22/NNS||positive-21/JJ	prep_into||status-15/NN||tumors-22/NNS	breasttumors-1||estrogen-7||no||breasttumors are classified based on the estrogen receptor alpha (erî±) expression status into er negative and er positive tumors.
amod||patients-3/NNS||antiretroviral-naive-1/JJ	amod||patients-3/NNS||hiv-infected-2/JJ	nsubjpass||recruited-7/VBN||patients-3/NNS	prep_with||patients-3/NNS||tb-5/NN	auxpass||recruited-7/VBN||were-6/VBD	root||ROOT-0/null||recruited-7/VBN	det||trial-10/NN||a-9/DT	prep_to||recruited-7/VBN||trial-10/NN	amod||inhibitor-15/NN||once-daily-12/JJ	amod||inhibitor-15/NN||nonnucleoside-13/JJ	amod||inhibitor-15/NN||reverse-transcriptase-14/JJ	prep_of||trial-10/NN||inhibitor-15/NN	appos||inhibitor-15/NN||nnrti-17/NNP	advmod||based-22/VBN||â-19/RB	pobj||â-19/RB||$-20/$	dep||inhibitor-15/NN||based-22/VBN	dobj||based-22/VBN||art-23/NN	dep||inhibitor-15/NN||treated-25/VBN	conj_and||based-22/VBN||treated-25/VBN	amod||treatment-30/NN||rifampicin-based-27/JJ	amod||treatment-30/NN||thrice-weekly-28/JJ	nn||treatment-30/NN||antituberculosis-29/NNS	prep_with||treated-25/VBN||treatment-30/NN	discourse||treatment-30/NN||att-32/UH	nsubjpass||randomized-37/VBN||participants-35/NNS	nsubj||receive-39/VB||participants-35/NNS	auxpass||randomized-37/VBN||were-36/VBD	parataxis||recruited-7/VBN||randomized-37/VBN	aux||receive-39/VB||to-38/TO	xcomp||randomized-37/VBN||receive-39/VB	dobj||receive-39/VB||didanosine-40/NN	number||mg-43/CD||250/400-42/CD	dep||didanosine-40/NN||mg-43/CD	dobj||receive-39/VB||lamivudine-46/NN	conj_and||didanosine-40/NN||lamivudine-46/NN	number||mg-49/CD||300-48/CD	dep||lamivudine-46/NN||mg-49/CD	det||efavirenz-53/NN||either-52/DT	prep_with||receive-39/VB||efavirenz-53/NN	number||mg-56/CD||600-55/CD	dep||efavirenz-53/NN||mg-56/CD	amod||once-daily-64/NN||nevirapine-59/JJ	number||mg-62/CD||400-61/CD	dep||once-daily-64/NN||mg-62/CD	prep_with||receive-39/VB||once-daily-64/NN	conj_or||efavirenz-53/NN||once-daily-64/NN	det||phase-68/NN||an-66/DT	amod||phase-68/NN||intensive-67/JJ	prep_after||receive-39/VB||phase-68/NN	prep_of||phase-68/NN||att-70/NN	tb-5||rifampicin--1||yes||antiretroviral-naive hiv-infected patients with tb were recruited to a trial of once-daily nonnucleoside reverse-transcriptase inhibitor (nnrti)â€“based art and treated with rifampicin-based thrice-weekly antituberculosis treatment (att); participants were randomized to receive didanosine (250/400 mg) and lamivudine (300 mg) with either efavirenz (600 mg) or nevirapine (400 mg) once-daily after an intensive phase of att.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	num||hypotheses-4/NNS||two-3/CD	dobj||investigated-2/VBD||hypotheses-4/NNS	appos||hypotheses-4/NNS||1-6/CD	mark||result-18/VB||that-8/IN	amod||inoculation-10/NN||oral-9/JJ	nsubj||result-18/VB||inoculation-10/NN	amod||mice-16/NNS||il10-12/JJ	dep||mice-16/NNS||/-14/NNP	prep_of||inoculation-10/NN||mice-16/NNS	aux||result-18/VB||would-17/MD	ccomp||investigated-2/VBD||result-18/VB	amod||inflammation-25/NN||greater-20/JJR	advmod||consistent-23/JJ||more-22/RBR	conj_and||greater-20/JJR||consistent-23/JJ	amod||inflammation-25/NN||consistent-23/JJ	amod||inflammation-25/NN||intestinal-24/JJ	prep_in||result-18/VB||inflammation-25/NN	mark||observed-28/VBD||than-26/IN	nsubj||observed-28/VBD||that-27/DT	advcl||result-18/VB||observed-28/VBD	ccomp||result-18/VB||observed-28/VBD	amod||mice-34/NNS||il10-30/JJ	dep||mice-34/NNS||/-32/NNP	prep_in||observed-28/VBD||mice-34/NNS	prep||observed-28/VBD||not-35/RB	pcomp||not-35/RB||receiving-36/VBG	det||inoculation-38/NN||this-37/DT	dobj||receiving-36/VBG||inoculation-38/NN	dep||observed-28/VBD||2-42/CD	mark||associated-49/VBN||that-44/IN	det||inflammation-46/NN||this-45/DT	nsubjpass||associated-49/VBN||inflammation-46/NN	aux||associated-49/VBN||would-47/MD	auxpass||associated-49/VBN||be-48/VB	advcl||result-18/VB||associated-49/VBN	ccomp||result-18/VB||associated-49/VBN	conj_and||observed-28/VBD||associated-49/VBN	prep_with||associated-49/VBN||changes-51/NNS	nn||levels-56/NNS||colon-53/NN	nn||levels-56/NNS||gene-54/NN	nn||levels-56/NNS||expression-55/NN	prep_in||changes-51/NNS||levels-56/NNS	dep||associated-49/VBN||similar-57/JJ	prep_to||similar-57/JJ||those-59/DT	advmod||observed-61/VBN||previously-60/RB	vmod||those-59/DT||observed-61/VBN	amod||studies-64/NNS||human-63/JJ	prep_in||observed-61/VBN||studies-64/NNS	det||mice-68/NNS||these-67/DT	nsubj||model-74/NN||mice-68/NNS	aux||model-74/NN||would-69/MD	advmod||model-74/NN||therefore-70/RB	cop||model-74/NN||be-71/VB	det||model-74/NN||an-72/DT	amod||model-74/NN||appropriate-73/JJ	conj_and||investigated-2/VBD||model-74/NN	amod||cd-77/NN||human-76/JJ	prep_for||model-74/NN||cd-77/NN	cd-77||inflammation-46||no_rel||we investigated two hypotheses (1) that oral inoculation of il10 -/- mice would result in greater and more consistent intestinal inflammation than that observed in il10 -/- mice not receiving this inoculation, and (2) that this inflammation would be associated with changes in colon gene expression levels similar to those previously observed in human studies, and these mice would therefore be an appropriate model for human cd.
poss||results-2/NNS||our-1/PRP$	nsubj||show-3/VBP||results-2/NNS	root||ROOT-0/null||show-3/VBP	mark||prevent-7/VB||that-4/IN	amod||lc-pufas-6/NNS||n-3-5/JJ	nsubj||prevent-7/VB||lc-pufas-6/NNS	nsubj||support-17/VB||lc-pufas-6/NNS	ccomp||show-3/VBP||prevent-7/VB	amod||insulinresistance-9/NN||hepatic-8/JJ	dobj||prevent-7/VB||insulinresistance-9/NN	det||manner-15/NN||an-11/DT	nn||manner-15/NN||ampkî-12/NNP	nn||manner-15/NN||±-13/NNP	amod||manner-15/NN||2-dependent-14/JJ	prep_in||prevent-7/VB||manner-15/NN	ccomp||show-3/VBP||support-17/VB	conj_and||prevent-7/VB||support-17/VB	det||role-19/NN||the-18/DT	dobj||support-17/VB||role-19/NN	amod||diacylglycerols-24/NNS||adiponectin-21/JJ	conj_and||adiponectin-21/JJ||hepatic-23/JJ	amod||diacylglycerols-24/NNS||hepatic-23/JJ	prep_of||role-19/NN||diacylglycerols-24/NNS	det||regulation-27/NN||the-26/DT	prep_in||support-17/VB||regulation-27/NN	nn||sensitivity-30/NN||insulin-29/NN	prep_of||regulation-27/NN||sensitivity-30/NN	insulin-29||insulinresistance-9||no_rel||our results show that n-3 lc-pufas prevent hepatic insulinresistance in an ampkî±2-dependent manner and support the role of adiponectin and hepatic diacylglycerols in the regulation of insulin sensitivity.
amod||polyol-2/NN||petroleum-based-1/JJ	nsubjpass||replaced-4/VBN||polyol-2/NN	auxpass||replaced-4/VBN||was-3/VBD	root||ROOT-0/null||replaced-4/VBN	nn||lignin-9/NN||hardwood-6/NN	nn||lignin-9/NN||ethanol-7/NN	nn||lignin-9/NN||organosolv-8/NN	prep_with||replaced-4/VBN||lignin-9/NN	appos||lignin-9/NN||hel-11/NN	nn||lignin-16/NN||hardwood-14/NN	nn||lignin-16/NN||kraft-15/NN	prep_with||replaced-4/VBN||lignin-16/NN	conj_or||lignin-9/NN||lignin-16/NN	appos||lignin-9/NN||hkl-18/NN	number||%-25/NN||25-21/CD	dep||%-25/NN||%-22/NN	dep||%-25/NN||to-23/TO	number||%-25/NN||70-24/CD	prep_from||replaced-4/VBN||%-25/NN	nn||percentage-28/NN||molar-27/NN	appos||%-25/NN||percentage-28/NN	prepc_in||replaced-4/VBN||preparing-31/VBG	amod||foam-34/NN||rigid-32/JJ	nn||foam-34/NN||polyurethane-33/NN	dobj||preparing-31/VBG||foam-34/NN	petroleum--1||rigid-32||no_rel||petroleum-based polyol was replaced with hardwood ethanol organosolv lignin (hel) or hardwood kraft lignin (hkl) from 25% to 70% (molar percentage) in preparing rigid polyurethane foam.
num||approach-2/NN||one-1/CD	nsubj||application-6/NN||approach-2/NN	cop||application-6/NN||is-3/VBZ	det||application-6/NN||the-4/DT	amod||application-6/NN||systemic-5/JJ	root||ROOT-0/null||application-6/NN	prep_of||application-6/NN||prostaglandins-8/NNS	nsubjpass||demonstrated-12/VBN||prostaglandins-8/NNS	nsubj||beneficial-15/JJ||prostaglandins-8/NNS	auxpass||demonstrated-12/VBN||were-11/VBD	rcmod||prostaglandins-8/NNS||demonstrated-12/VBN	aux||beneficial-15/JJ||to-13/TO	cop||beneficial-15/JJ||be-14/VB	xcomp||demonstrated-12/VBN||beneficial-15/JJ	prepc_in||beneficial-15/JJ||reducing-17/VBG	amod||injury-19/NN||ischemia-reperfusion-18/JJ	dobj||reducing-17/VBG||injury-19/NN	prostaglandins-8||ischemia--1||no_rel||one approach is the systemic application of prostaglandins, which were demonstrated to be beneficial in reducing ischemia-reperfusion injury.
nsubj||accounted-23/VBD||questions-1/NNS	vmod||questions-1/NNS||related-2/VBN	prep_to||related-2/VBN||co-morbidities-4/NNS	prep_in||co-morbidities-4/NNS||hiv/aids-6/NNS	amod||cancers-10/NNS||non-aids-8/JJ	amod||cancers-10/NNS||related-9/JJ	dep||hiv/aids-6/NNS||cancers-10/NNS	amod||diseases-13/NNS||systemic-12/JJ	dep||hiv/aids-6/NNS||diseases-13/NNS	conj_and||cancers-10/NNS||diseases-13/NNS	amod||toxicities-19/NNS||chronic-16/JJ	amod||toxicities-19/NNS||antiretroviral-17/JJ	nn||toxicities-19/NNS||treatment-18/NN	prep_in||co-morbidities-4/NNS||toxicities-19/NNS	conj_and||hiv/aids-6/NNS||toxicities-19/NNS	dep||hiv/aids-6/NNS||metabolicdisorders-21/NNS	root||ROOT-0/null||accounted-23/VBD	advmod||lower-26/JJR||significantly-25/RB	amod||scores-27/NNS||lower-26/JJR	prep_for||accounted-23/VBD||scores-27/NNS	dep||scores-27/NNS||mean-29/NN	num||%-32/NN||41.7-31/CD	appos||mean-29/NN||%-32/NN	num||%-35/NN||95-34/CD	npadvmod||ci-36/RB||%-35/NN	advmod||mean-29/NN||ci-36/RB	num||%-38/NN||39.3-37/CD	dep||mean-29/NN||%-38/NN	quantmod||$-40/$||â-39/RB	num||%-43/NN||$-40/$	num||$-40/$||44-42/CD	dep||%-38/NN||%-43/NN	prepc_compared_to||accounted-23/VBD||to-46/TO	nn||epidemiology-48/NN||hiv/aids-47/NNS	pobj||accounted-23/VBD||epidemiology-48/NN	pobj||accounted-23/VBD||prevention-50/NN	conj_and||epidemiology-48/NN||prevention-50/NN	dep||epidemiology-48/NN||mean-52/VB	num||%-55/NN||65.7-54/CD	nsubj||$-63/VBG||%-55/NN	number||%-58/NN||95-57/CD	amod||ci-59/NN||%-58/NN	appos||%-55/NN||ci-59/NN	num||%-61/NN||63.7-60/CD	npadvmod||â-62/RB||%-61/NN	advmod||$-63/VBG||â-62/RB	ccomp||mean-52/VB||$-63/VBG	num||%-66/NN||67.7-65/CD	dobj||$-63/VBG||%-66/NN	aids--1||hiv--1||no||questions related to co-morbidities in hiv/aids (non-aids related cancers and systemic diseases) and chronic antiretroviral treatment toxicities (metabolicdisorders) accounted for significantly lower scores (mean, 41.7%, 95% ci 39.3%â€“44%) compared to hiv/aids epidemiology and prevention (mean, 65.7%, 95% ci 63.7%â€“67.7%).
det||burden-3/NN||the-1/DT	nn||burden-3/NN||disease-2/NN	nsubj||highest-15/JJS||burden-3/NN	prep_of||burden-3/NN||humanimmunodeficiencyvirus-5/NNS	appos||humanimmunodeficiencyvirus-5/NNS||hiv-7/NN	amod||aids-12/NNS||acquiredimmunodeficiencysyndrome-10/JJ	dep||humanimmunodeficiencyvirus-5/NNS||aids-12/NNS	cop||highest-15/JJS||is-14/VBZ	root||ROOT-0/null||highest-15/JJS	amod||africa-18/NN||sub-saharan-17/JJ	prep_in||highest-15/JJS||africa-18/NN	expl||are-21/VBP||there-20/EX	conj_but||highest-15/JJS||are-21/VBP	amod||studies-23/NNS||few-22/JJ	nsubj||are-21/VBP||studies-23/NNS	det||disorders-28/NNS||the-25/DT	amod||disorders-28/NNS||associated-26/VBN	amod||disorders-28/NNS||neurocognitive-27/JJ	prep_on||studies-23/NNS||disorders-28/NNS	det||region-31/NN||this-30/DT	prep_in||disorders-28/NNS||region-31/NN	aids-12||humanimmunodeficiencyvirus-5||no||the disease burden of humanimmunodeficiencyvirus (hiv) - acquiredimmunodeficiencysyndrome (aids) is highest in sub-saharan africa but there are few studies on the associated neurocognitive disorders in this region.
det||outcome-2/NN||the-1/DT	nsubj||revealed-8/VBD||outcome-2/NN	det||study-7/NN||this-4/DT	amod||study-7/NN||full-5/JJ	nn||study-7/NN||genome-6/NN	prep_of||outcome-2/NN||study-7/NN	root||ROOT-0/null||revealed-8/VBD	det||event-12/NN||a-9/DT	amod||event-12/NN||unique-10/JJ	nn||event-12/NN||reassortment-11/NN	dobj||revealed-8/VBD||event-12/NN	advmod||acquired-17/VBD||where-13/WRB	det||virus-16/NN||the-14/DT	amod||virus-16/NN||n-1289-15/JJ	nsubj||acquired-17/VBD||virus-16/NN	advcl||revealed-8/VBD||acquired-17/VBD	xcomp||acquired-17/VBD||itâ-18/VB	num||gene-23/NN||$-19/$	number||s-21/CD||™-20/CD	num||$-19/$||s-21/CD	nn||gene-23/NN||ha-22/NN	dobj||itâ-18/VB||gene-23/NN	det||virus-29/NN||a-25/DT	num||virus-29/NN||2009-26/CD	amod||virus-29/NN||pandemic-27/JJ	amod||virus-29/NN||h1n1-28/JJ	prep_from||itâ-18/VB||virus-29/NN	amod||origin-32/NN||swine-31/JJ	prep_with||virus-29/NN||origin-32/NN	det||genes-36/NNS||the-34/DT	amod||genes-36/NNS||other-35/JJ	prep_with||virus-29/NN||genes-36/NNS	conj_and||origin-32/NN||genes-36/NNS	amod||viruses-39/NNS||h3n2-like-38/JJ	prep_from||itâ-18/VB||viruses-39/NNS	amod||origin-42/NN||human-41/JJ	prep_of||viruses-39/NNS||origin-42/NN	virus-29||viruses-39||no||the outcome of this full genome study revealed a unique reassortment event where the n-1289 virus acquired itâ€™s ha gene from a 2009 pandemic h1n1 virus with swine origin and the other genes from h3n2-like viruses of human origin.
amod||africa-3/NN||south-2/JJ	prep_in||depends-11/VBZ||africa-3/NN	det||impact-6/NN||the-5/DT	nsubj||depends-11/VBZ||impact-6/NN	prep_of||impact-6/NN||hiv/aids-8/NNS	prep_on||hiv/aids-8/NNS||households-10/NNS	root||ROOT-0/null||depends-11/VBZ	prt||depends-11/VBZ||on-12/RP	dobj||depends-11/VBZ||race-13/NN	dobj||depends-11/VBZ||class-15/NN	conj_and||race-13/NN||class-15/NN	dobj||depends-11/VBZ||place-18/NN	conj_and||race-13/NN||place-18/NN	aids--1||hiv--1||no||in south africa, the impact of hiv/aids on households depends on race, class, and place.
nsubj||worse-18/JJR||aureus-1/NN	appos||aureus-1/NN||mrsa-3/NNP	nsubj||increasing-7/VBG||infection-5/NN	aux||increasing-7/VBG||are-6/VBP	rcmod||aureus-1/NN||increasing-7/VBG	nn||outcomes-10/NNS||treatment-9/NN	conj_and||aureus-1/NN||outcomes-10/NNS	nsubj||worse-18/JJR||outcomes-10/NNS	prep_for||outcomes-10/NNS||bacteraemia-12/NN	vmod||bacteraemia-12/NN||caused-13/VBN	agent||caused-13/VBN||mrsa-15/NN	cop||worse-18/JJR||are-16/VBP	advmod||worse-18/JJR||generally-17/RB	root||ROOT-0/null||worse-18/JJR	mark||observed-21/VBD||than-19/IN	nsubj||observed-21/VBD||those-20/DT	ccomp||worse-18/JJR||observed-21/VBD	amod||s-24/NNS||methicillin-susceptible-23/JJ	prep_with||observed-21/VBD||s-24/NNS	methicillin--1||bacteraemia-12||no_rel||aureus (mrsa) infection are increasing and treatment outcomes for bacteraemia caused by mrsa are generally worse than those observed with methicillin-susceptible s .
nsubj||found-10/VBD||comparison-1/NN	det||status-5/NN||the-3/DT	amod||status-5/NN||replicative-4/JJ	prep_of||comparison-1/NN||status-5/NN	det||viruses-9/NNS||the-7/DT	num||viruses-9/NNS||two-8/CD	prep_of||status-5/NN||viruses-9/NNS	root||ROOT-0/null||found-10/VBD	amod||load-14/NN||low-11/JJ	nn||load-14/NN||hbv-12/NN	amod||load-14/NN||viral-13/JJ	dobj||found-10/VBD||load-14/NN	det||patients-18/NNS||all-16/DT	amod||patients-18/NNS||co-infected-17/JJ	prep_in||found-10/VBD||patients-18/NNS	amod||patients-18/NNS||as-19/IN	prepc_compared_to||found-10/VBD||to-21/TO	pobj||found-10/VBD||patients-22/NNS	amod||infection-26/NN||single-24/JJ	nn||infection-26/NN||hbv-25/NN	prep_with||patients-22/NNS||infection-26/NN	hbv-25||viruses-9||no||comparison of the replicative status of the two viruses found low hbv viral load in all co-infected patients as compared to patients with single hbv infection.
det||divergence-5/NN||the-3/DT	nn||divergence-5/NN||sequence-4/NN	prep_due_to||have-19/VBP||divergence-5/NN	det||virus-9/NN||this-7/DT	amod||virus-9/NN||new-8/JJ	prep_of||divergence-5/NN||virus-9/NN	amod||virus-9/NN||relative-10/JJ	det||ebolaviruses-15/NNS||all-12/DT	advmod||recognized-14/VBN||previously-13/RB	amod||ebolaviruses-15/NNS||recognized-14/VBN	prep_to||relative-10/JJ||ebolaviruses-15/NNS	det||findings-18/NNS||these-17/DT	nsubj||have-19/VBP||findings-18/NNS	root||ROOT-0/null||have-19/VBP	amod||implications-21/NNS||important-20/JJ	dobj||have-19/VBP||implications-21/NNS	prep_for||implications-21/NNS||design-23/NN	amod||assays-27/NNS||future-25/JJ	amod||assays-27/NNS||diagnostic-26/JJ	prep_of||design-23/NN||assays-27/NNS	aux||monitor-29/VB||to-28/TO	vmod||implications-21/NNS||monitor-29/VB	nn||disease-32/NN||ebola-30/NN	nn||disease-32/NN||hf-31/NN	dobj||monitor-29/VB||disease-32/NN	prep_in||disease-32/NN||humans-34/NNS	prep_in||disease-32/NN||animals-36/NNS	conj_and||humans-34/NNS||animals-36/NNS	amod||efforts-40/NNS||ongoing-39/JJ	dobj||have-19/VBP||efforts-40/NNS	conj_and||implications-21/NNS||efforts-40/NNS	aux||develop-42/VB||to-41/TO	vmod||efforts-40/NNS||develop-42/VB	amod||antivirals-44/NNS||effective-43/JJ	dobj||develop-42/VB||antivirals-44/NNS	dobj||develop-42/VB||vaccines-46/NNS	conj_and||antivirals-44/NNS||vaccines-46/NNS	virus-9||vaccines-46||no_rel||due to the sequence divergence of this new virus relative to all previously recognized ebolaviruses, these findings have important implications for design of future diagnostic assays to monitor ebola hf disease in humans and animals, and ongoing efforts to develop effective antivirals and vaccines.
det||clamp-4/NN||the-1/DT	amod||clamp-4/NN||modified-2/VBN	nn||clamp-4/NN||glucose-3/NN	nsubjpass||performed-6/VBN||clamp-4/NN	auxpass||performed-6/VBN||was-5/VBD	root||ROOT-0/null||performed-6/VBN	det||presence-9/NN||the-8/DT	prep_in||performed-6/VBN||presence-9/NN	amod||hyperinsulinemia-12/NN||postprandial-11/JJ	prep_of||presence-9/NN||hyperinsulinemia-12/NN	prep_of||presence-9/NN||hyperglycemia-14/NN	conj_and||hyperinsulinemia-12/NN||hyperglycemia-14/NN	prep_with||performed-6/VBN||exenatide-16/NN	num||î-19/NN||20-18/CD	dep||exenatide-16/NN||î-19/NN	num||g-21/NN||1/4-20/CD	dep||î-19/NN||g-21/NN	prep_with||performed-6/VBN||saline-24/NN	conj_or||exenatide-16/NN||saline-24/NN	vmod||saline-24/NN||injected-25/VBN	num||min-28/NN||0-27/CD	prep_at||injected-25/VBN||min-28/NN	hyperglycemia-14||glucose-3||no||the modified glucose clamp was performed in the presence of postprandial hyperinsulinemia and hyperglycemia with exenatide (20 î¼g) or saline injected at 0 min.
det||dengueviruses-3/NNS||the-1/DT	num||dengueviruses-3/NNS||four-2/CD	nsubjpass||transmitted-15/VBN||dengueviruses-3/NNS	det||agents-6/NNS||the-5/DT	appos||dengueviruses-3/NNS||agents-6/NNS	prep_of||agents-6/NNS||denguefever-8/NN	prep_of||agents-6/NNS||denguehemorrhagicfever-10/NN	conj_and||denguefever-8/NN||denguehemorrhagicfever-10/NN	prep_in||agents-6/NNS||humans-12/NNS	auxpass||transmitted-15/VBN||are-14/VBP	root||ROOT-0/null||transmitted-15/VBN	advmod||transmitted-15/VBN||predominantly-16/RB	det||aegypti-21/NN||the-18/DT	nn||aegypti-21/NN||mosquito-19/NN	nn||aegypti-21/NN||aedes-20/NNS	agent||transmitted-15/VBN||aegypti-21/NN	denguefever-8||dengueviruses-3||no||the four dengueviruses, the agents of denguefever and denguehemorrhagicfever in humans, are transmitted predominantly by the mosquito aedes aegypti .
det||mice-3/NNS||these-1/DT	amod||mice-3/NNS||transgenic-2/JJ	nsubjpass||utilized-6/VBN||mice-3/NNS	nsubj||susceptible-18/JJ||mice-3/NNS	nsubj||bse-20/VB||mice-3/NNS	aux||utilized-6/VBN||have-4/VBP	auxpass||utilized-6/VBN||been-5/VBN	root||ROOT-0/null||utilized-6/VBN	amod||studies-10/NNS||extensive-8/JJ	nn||studies-10/NNS||transmission-9/NN	prep_in||utilized-6/VBN||studies-10/NNS	nn||priondisease-15/NN||human-12/NN	conj_and||human-12/NN||animal-14/NN	nn||priondisease-15/NN||animal-14/NN	prep_of||studies-10/NNS||priondisease-15/NN	cop||susceptible-18/JJ||are-17/VBP	conj_and||utilized-6/VBN||susceptible-18/JJ	aux||bse-20/VB||to-19/TO	xcomp||susceptible-18/JJ||bse-20/VB	xcomp||susceptible-18/JJ||vcjd-22/VB	conj_and||bse-20/VB||vcjd-22/VB	dobj||bse-20/VB||prions-23/NNS	vmod||bse-20/VB||allowing-25/VBG	dobj||allowing-25/VBG||comparison-26/NN	prep_with||allowing-25/VBG||cwd-28/NN	priondisease-15||prions-23||no||these transgenic mice have been utilized in extensive transmission studies of human and animal priondisease and are susceptible to bse and vcjd prions, allowing comparison with cwd.
nsubj||heparin-6/NN||enoxaparin-1/NN	cop||heparin-6/NN||is-2/VBZ	det||heparin-6/NN||the-3/DT	advmod||heparin-6/NN||only-4/RB	amod||heparin-6/NN||low-molecular-weight-5/JJ	root||ROOT-0/null||heparin-6/NN	nsubjpass||licensed-9/VBN||heparin-6/NN	auxpass||licensed-9/VBN||is-8/VBZ	rcmod||heparin-6/NN||licensed-9/VBN	det||prophylaxis-14/NNS||both-11/DT	amod||prophylaxis-14/NNS||venous-12/JJ	nn||prophylaxis-14/NNS||thromboembolism-13/NN	prep_for||licensed-9/VBN||prophylaxis-14/NNS	prep_for||licensed-9/VBN||treatment-16/NN	conj_and||prophylaxis-14/NNS||treatment-16/NN	thromboembolism-13||heparin-6||yes||enoxaparin is the only low-molecular-weight heparin that is licensed for both venous thromboembolism prophylaxis and treatment.
nsubj||infection-7/NN||buruliulcer-1/NN	vmod||buruliulcer-1/NN||caused-2/VBN	agent||caused-2/VBN||mycobacteriumulcerans-4/NNS	cop||infection-7/NN||is-5/VBZ	det||infection-7/NN||an-6/DT	root||ROOT-0/null||infection-7/NN	det||tissue-11/NN||the-9/DT	amod||tissue-11/NN||subcutaneous-10/JJ	prep_of||infection-7/NN||tissue-11/NN	vmod||tissue-11/NN||leading-12/VBG	amod||ulcers-17/NNS||chronic-14/JJ	nn||ulcers-17/NNS||necrotising-15/NN	nn||ulcers-17/NNS||skin-16/NN	prep_to||leading-12/VBG||ulcers-17/NNS	buruliulcer-1||mycobacteriumulcerans-4||no||buruliulcer caused by mycobacteriumulcerans is an infection of the subcutaneous tissue leading to chronic necrotising skin ulcers.
amod||hips-2/NNS||painful-1/JJ	nsubjpass||caused-8/VBN||hips-2/NNS	amod||masses-5/NNS||periprosthetic-4/JJ	prep_with||hips-2/NNS||masses-5/NNS	aux||caused-8/VBN||may-6/MD	auxpass||caused-8/VBN||be-7/VB	root||ROOT-0/null||caused-8/VBN	amod||wear-11/NN||high-10/JJ	agent||caused-8/VBN||wear-11/NN	mark||ruled-18/VBN||if-14/IN	nsubjpass||ruled-18/VBN||this-15/DT	aux||ruled-18/VBN||can-16/MD	auxpass||ruled-18/VBN||be-17/VB	advcl||considered-25/VBN||ruled-18/VBN	prt||ruled-18/VBN||out-19/RP	nn||hypersensitivity-22/NN||metal-21/NN	nsubjpass||considered-25/VBN||hypersensitivity-22/NN	aux||considered-25/VBN||should-23/MD	auxpass||considered-25/VBN||be-24/VB	conj_but||caused-8/VBN||considered-25/VBN	painful-1||metal-21||no_rel||painful hips with periprosthetic masses may be caused by high wear, but if this can be ruled out, metal hypersensitivity should be considered.
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||previously-2/RB	root||ROOT-0/null||reported-3/VBD	det||efficacy-5/NN||the-4/DT	dobj||reported-3/VBD||efficacy-5/NN	amod||transplantation-9/NN||nonmyeloablative-7/JJ	amod||transplantation-9/NN||allogeneic-8/JJ	prep_of||efficacy-5/NN||transplantation-9/NN	num||recipients-13/NNS||2-11/CD	amod||recipients-13/NNS||hivpositive-12/JJ	prep_in||reported-3/VBD||recipients-13/NNS	prep_of||one-15/CD||recipients-13/NNS	nsubj||received-18/VBD||one-15/CD	rcmod||recipients-13/NNS||received-18/VBD	nsubj||transduced-20/VBD||retrovirus-19/NNS	ccomp||received-18/VBD||transduced-20/VBD	amod||cells-23/NNS||hematopoietic-21/JJ	nn||cells-23/NNS||stem-22/NN	dobj||transduced-20/VBD||cells-23/NNS	aux||confer-25/VB||to-24/TO	vmod||transduced-20/VBD||confer-25/VB	dobj||confer-25/VB||resistance-26/NN	prep_to||confer-25/VB||hiv-28/NN	hivpositive-12||hiv-28||no||we previously reported the efficacy of nonmyeloablative allogeneic transplantation in 2 hivpositive recipients, one of whom received retrovirus transduced hematopoietic stem cells to confer resistance to hiv.
det||participants-3/NNS||all-2/DT	prep_among||associated-12/VBN||participants-3/NNS	det||number-7/NN||a-5/DT	amod||number-7/NN||higher-6/JJR	nsubj||associated-12/VBN||number-7/NN	amod||alleles-11/NNS||type2diabetes-9/JJ	nn||alleles-11/NNS||risk-10/NN	prep_of||number-7/NN||alleles-11/NNS	root||ROOT-0/null||associated-12/VBN	det||prevalence-16/NN||a-14/DT	amod||prevalence-16/NN||higher-15/JJR	prep_with||associated-12/VBN||prevalence-16/NN	prep_of||prevalence-16/NN||diabetes-18/NN	dep||prevalence-16/NN||p-20/VBN	dep||0.011-22/CD||=-21/SYM	ccomp||p-20/VBN||0.011-22/CD	amod||concentration-27/NN||higher-25/JJR	nn||concentration-27/NN||serum-26/NN	prep_with||associated-12/VBN||concentration-27/NN	conj_and||prevalence-16/NN||concentration-27/NN	prep_of||concentration-27/NN||glucose-29/NN	appos||glucose-29/NN||p-31/NNP	number||0.016-33/CD||<-32/CD	num||p-31/NNP||0.016-33/CD	conj_and||prevalence-16/NN||insulin-37/NN	conj_negcc||concentration-27/NN||insulin-37/NN	dep||insulin-37/NN||p-39/VBN	dep||0.450-41/CD||=-40/SYM	ccomp||p-39/VBN||0.450-41/CD	type2diabetes-9||insulin-37||yes||among all participants, a higher number of type2diabetes risk alleles associated with a higher prevalence of diabetes (p=0.011) and higher serum concentration of glucose (p<0.016) but not insulin (p=0.450).
advmod||develop-8/VB||yet-1/RB	amod||users-5/NNS||heavy-3/JJ	nn||users-5/NNS||cannabis-4/NN	nsubj||develop-8/VB||users-5/NNS	aux||develop-8/VB||did-6/VBD	neg||develop-8/VB||not-7/RB	root||ROOT-0/null||develop-8/VB	acomp||develop-8/VB||cross-tolerance-9/JJ	det||effects-13/NNS||the-11/DT	amod||effects-13/NNS||impairing-12/VBG	prep_to||cross-tolerance-9/JJ||effects-13/NNS	prep_of||effects-13/NNS||alcohol-15/NN	det||presence-19/NN||the-18/DT	prep_to||cross-tolerance-9/JJ||presence-19/NN	conj_and||effects-13/NNS||presence-19/NN	det||latter-22/NN||the-21/DT	prep_of||presence-19/NN||latter-22/NN	advmod||potentiated-25/VBD||even-23/RB	advmod||potentiated-25/VBD||selectively-24/RB	dep||latter-22/NN||potentiated-25/VBD	nn||effects-27/NNS||thc-26/NN	dobj||potentiated-25/VBD||effects-27/NNS	prep_on||potentiated-25/VBD||measures-29/NNS	amod||attention-32/NN||divided-31/VBN	prep_of||measures-29/NNS||attention-32/NN	cross--1||thc-26||no_rel||yet, heavy cannabis users did not develop cross-tolerance to the impairing effects of alcohol, and the presence of the latter even selectively potentiated thc effects on measures of divided attention.
det||toxin-2/NN||the-1/DT	nsubjpass||composed-14/VBN||toxin-2/NN	vmod||toxin-2/NN||produced-3/VBN	agent||produced-3/VBN||bacillusanthracis-5/NNS	det||agent-9/NN||the-7/DT	amod||agent-9/NN||causative-8/JJ	appos||toxin-2/NN||agent-9/NN	prep_of||agent-9/NN||anthrax-11/NN	auxpass||composed-14/VBN||is-13/VBZ	root||ROOT-0/null||composed-14/VBN	num||proteins-17/NNS||three-16/CD	prep_of||composed-14/VBN||proteins-17/NNS	nsubj||allows-37/VBZ||proteins-17/NNS	det||channel-21/NN||a-18/DT	amod||channel-21/NN||translocase-19/JJ	amod||channel-21/NN||heptameric-20/JJ	dep||proteins-17/NNS||channel-21/NN	appos||proteins-17/NNS||pa63-24/NNP	amod||proteins-17/NNS||7-26/CD	vmod||proteins-17/NNS||formed-28/VBN	amod||antigen-31/NN||protective-30/JJ	prep_from||formed-28/VBN||antigen-31/NN	appos||antigen-31/NN||pa-33/NN	rcmod||proteins-17/NNS||allows-37/VBZ	det||proteins-41/NNS||the-38/DT	amod||proteins-41/NNS||other-39/JJ	num||proteins-41/NNS||two-40/CD	dobj||allows-37/VBZ||proteins-41/NNS	nsubj||translocate-54/VB||proteins-41/NNS	amod||factors-46/NNS||lethal-43/JJ	conj_and||lethal-43/JJ||edema-45/JJ	amod||factors-46/NNS||edema-45/JJ	appos||proteins-41/NNS||factors-46/NNS	dep||factors-46/NNS||lf-48/NN	dep||factors-46/NNS||ef-50/NN	conj_and||lf-48/NN||ef-50/NN	aux||translocate-54/VB||to-53/TO	xcomp||allows-37/VBZ||translocate-54/VB	det||cell-58/NN||a-56/DT	nn||cell-58/NN||host-57/NN	poss||membrane-61/NN||cell-58/NN	amod||membrane-61/NN||endosomal-60/JJ	prep_across||translocate-54/VB||membrane-61/NN	xcomp||translocate-54/VB||disrupting-63/VBG	amod||homeostasis-65/NNS||cellular-64/JJ	dobj||disrupting-63/VBG||homeostasis-65/NNS	anthrax-11||bacillusanthracis-5||no||the toxin produced by bacillusanthracis , the causative agent of anthrax, is composed of three proteins a translocase heptameric channel, (pa63)7, formed from protective antigen (pa), which allows the other two proteins, lethal and edema factors (lf and ef), to translocate across a host cell's endosomal membrane, disrupting cellular homeostasis.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||trial-6/NN||a-3/DT	amod||trial-6/NN||16-week-4/JJ	nn||trial-6/NN||intervention-5/NN	dobj||performed-2/VBD||trial-6/NN	det||diet-12/NN||a-8/DT	amod||diet-12/NN||hypocaloric-9/JJ	amod||diet-12/NN||low-fat-11/JJ	prep_of||trial-6/NN||diet-12/NN	dobj||performed-2/VBD||10-14/CD	conj_plus||trial-6/NN||10-14/CD	advmod||ezetimibe-16/JJ||mg/day-15/RB	amod||10-14/CD||ezetimibe-16/JJ	dep||10-14/CD||n-18/VBN	dep||15-20/CD||=-19/SYM	ccomp||n-18/VBN||15-20/CD	det||diet-27/NN||a-23/DT	amod||diet-27/NN||hypocaloric-24/JJ	amod||diet-27/NN||low-fat-26/JJ	conj_plus||trial-6/NN||diet-27/NN	conj_versus||10-14/CD||diet-27/NN	amod||diet-27/NN||alone-28/RB	dep||trial-6/NN||n-30/VBN	dep||10-32/CD||=-31/SYM	ccomp||n-30/VBN||10-32/CD	amod||triglyceride-36/NN||intrahepatic-35/JJ	prep_on||performed-2/VBD||triglyceride-36/NN	appos||triglyceride-36/NN||ihtg-38/NN	amod||triglyceride-36/NN||content-40/JJ	vmod||triglyceride-36/NN||plasma-42/VBN	amod||subjects-67/NNS||high-43/JJ	dep||$-45/$||sensitivityâ-44/RB	dep||subjects-67/NNS||$-45/$	npadvmod||in-65/RB||c-reactive-47/NN	advmod||c-reactive-47/NN||protein-48/RB	pobj||protein-48/RB||hs-crp-50/NN	appos||hs-crp-50/NN||adipocytokines-53/NNS	amod||concentrations-57/NNS||fetuin-a-56/JJ	pobj||protein-48/RB||concentrations-57/NNS	conj_and||hs-crp-50/NN||concentrations-57/NNS	conj_and||hs-crp-50/NN||apolipoprotein-59/NNS	conj_and||concentrations-57/NNS||apolipoprotein-59/NNS	appos||concentrations-57/NNS||apo-61/NN	amod||kinetics-64/NNS||b-100-63/JJ	dep||concentrations-57/NNS||kinetics-64/NNS	dep||obese-66/CD||in-65/RB	num||$-45/$||obese-66/CD	dobj||plasma-42/VBN||subjects-67/NNS	obese-66||fat--1||no_rel||we performed a 16-week intervention trial of a hypocaloric, low-fat diet plus 10 mg/day ezetimibe ( n = 15) versus a hypocaloric, low-fat diet alone ( n = 10) on intrahepatic triglyceride (ihtg) content, plasma high sensitivityâ€“c-reactive protein (hs-crp), adipocytokines, and fetuin-a concentrations and apolipoprotein (apo)b-100 kinetics in obese subjects.
advmod||recently-2/RB||more-1/RBR	advmod||emerging-13/VBG||recently-2/RB	nsubj||emerging-13/VBG||gonadotropins-4/NNS	cc||lh/hcg-10/NN||and-6/CC	dep||lh/hcg-10/NN||in-8/RB	amod||lh/hcg-10/NN||particular-9/JJ	dep||gonadotropins-4/NNS||lh/hcg-10/NN	aux||emerging-13/VBG||are-12/VBP	root||ROOT-0/null||emerging-13/VBG	nn||regulators-16/NNS||novel-15/NN	prep_as||emerging-13/VBG||regulators-16/NNS	nn||progression-19/NN||tumor-18/NN	prep_of||regulators-16/NNS||progression-19/NN	gonadotropins-4||tumor-18||no_rel||more recently, gonadotropins, and, in particular lh/hcg, are emerging as novel regulators of tumor progression.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	det||therapy-9/NN||a-6/DT	amod||therapy-9/NN||4-week-7/JJ	nn||therapy-9/NN||adjunctive-8/NN	prep_of||effect-4/NN||therapy-9/NN	amod||exe-13/NN||exenatide-11/JJ	prep_of||therapy-9/NN||exe-13/NN	dep||exe-13/NN||5â-16/NNS	nn||metformin-57/NN||$-17/$	num||î-20/NN||10-19/CD	npadvmod||response-37/RB||î-20/NN	num||b.i.d.-23/NNP||1/4-21/CD	nn||b.i.d.-23/NNP||g-22/NNP	npadvmod||in-36/IN||b.i.d.-23/NNP	conj_or||b.i.d.-23/NNP||sitagliptin-26/NN	npadvmod||in-36/IN||sitagliptin-26/NN	appos||sitagliptin-26/NN||sita-28/NNP	num||mg-32/NN||100-31/CD	npadvmod||once-33/RB||mg-32/NN	dep||sitagliptin-26/NN||once-33/RB	dep||once-33/RB||daily-34/RB	advmod||î-20/NN||in-36/IN	dep||+-56/CD||response-37/RB	det||challenge-43/NN||a-39/DT	amod||challenge-43/NN||standardized-40/JJ	nn||challenge-43/NN||breakfast-41/NN	nn||challenge-43/NN||meal-42/NN	prep_to||response-37/RB||challenge-43/NN	num||men-46/NNS||48-45/CD	prep_in||response-37/RB||men-46/NNS	prep_in||response-37/RB||women-48/NNS	conj_or||men-46/NNS||women-48/NNS	amod||insulinglargine-52/NN||type2diabetes-50/JJ	nn||insulinglargine-52/NN||receiving-51/NN	prep_with||men-46/NNS||insulinglargine-52/NN	appos||insulinglargine-52/NN||glar-54/NN	num||$-17/$||+-56/CD	dep||5â-16/NNS||metformin-57/NN	dep||exe-13/NN||met-59/VBN	type2diabetes-50||sitagliptin-26||yes||to assess the effect of a 4-week adjunctive therapy of exenatide (exe) (5â€“10 î¼g b.i.d.) or sitagliptin (sita) (100 mg once daily) in response to a standardized breakfast meal challenge in 48 men or women with type2diabetes receiving insulinglargine (glar) + metformin (met).
amod||meningitis-2/NNS||neoplastic-1/JJ	nsubj||developed-6/VBD||meningitis-2/NNS	appos||meningitis-2/NNS||nm-4/NN	root||ROOT-0/null||developed-6/VBD	num||months-8/NNS||31-7/CD	tmod||developed-6/VBD||months-8/NNS	amod||diagnosis-11/NN||first-10/JJ	prep_after||developed-6/VBD||diagnosis-11/NN	amod||recurrence-18/NN||simultaneous-13/JJ	amod||recurrence-18/NN||extra-14/JJ	conj_and||extra-14/JJ||intracranial-17/JJ	amod||recurrence-18/NN||intracranial-17/JJ	prep_of||diagnosis-11/NN||recurrence-18/NN	nn||cancer-21/NN||kidney-20/NN	prep_of||recurrence-18/NN||cancer-21/NN	amod||resection-24/NN||surgical-23/JJ	prep_of||diagnosis-11/NN||resection-24/NN	conj_and||recurrence-18/NN||resection-24/NN	det||metastasis-28/NNS||a-26/DT	nn||metastasis-28/NNS||cerebellar-27/NN	prep_of||resection-24/NN||metastasis-28/NNS	metastasis-28||nm-4||yes||neoplastic meningitis (nm) developed 31 months after first diagnosis of simultaneous extra- and intracranial recurrence of kidney cancer and surgical resection of a cerebellar metastasis.
amod||insulinresistance-2/NN||peripheral-1/JJ	nsubjpass||linked-4/VBN||insulinresistance-2/NN	auxpass||linked-4/VBN||is-3/VBZ	root||ROOT-0/null||linked-4/VBN	det||increase-7/NN||an-6/DT	prep_to||linked-4/VBN||increase-7/NN	amod||species-11/NNS||reactive-9/JJ	nn||species-11/NNS||oxygen-10/NN	prep_in||increase-7/NN||species-11/NNS	appos||species-11/NNS||ros-13/NN	vmod||increase-7/NN||leading-16/VBG	prep_in||leading-16/VBG||part-18/NN	det||production-21/NN||the-20/DT	prep_to||part-18/NN||production-21/NN	amod||aldehydes-25/NNS||reactive-23/JJ	nn||aldehydes-25/NNS||lipid-24/NN	prep_of||production-21/NN||aldehydes-25/NNS	mark||termed-37/VBD||that-26/IN	csubj||termed-37/VBD||modify-27/VB	det||chains-30/NNS||the-28/DT	nn||chains-30/NNS||side-29/NN	dobj||modify-27/VB||chains-30/NNS	nn||aminoacids-33/NNS||protein-32/NN	prep_of||chains-30/NNS||aminoacids-33/NNS	det||reaction-36/NN||a-35/DT	prep_in||aminoacids-33/NNS||reaction-36/NN	ccomp||leading-16/VBG||termed-37/VBD	nn||carbonylation-39/NN||protein-38/NN	dobj||termed-37/VBD||carbonylation-39/NN	lipid-24||insulinresistance-2||no_rel||peripheral insulinresistance is linked to an increase in reactive oxygen species (ros), leading in part to the production of reactive lipid aldehydes that modify the side chains of protein aminoacids in a reaction termed protein carbonylation.
amod||pruritus-2/NNS||chloroquine-induced-1/JJ	nsubj||remains-3/VBZ||pruritus-2/NNS	root||ROOT-0/null||remains-3/VBZ	xcomp||remains-3/VBZ||one-4/CD	det||side-effects-9/NNS||the-6/DT	advmod||side-effects-9/NNS||most-7/RBS	amod||side-effects-9/NNS||common-8/JJ	prep_of||one-4/CD||side-effects-9/NNS	det||use-12/NN||the-11/DT	prep_in||side-effects-9/NNS||use-12/NN	prep_of||use-12/NN||chloroquine-14/NN	det||prophylaxis-17/NN||the-16/DT	prep_in||chloroquine-14/NN||prophylaxis-17/NN	prep_in||chloroquine-14/NN||treatment-19/NN	conj_and||prophylaxis-17/NN||treatment-19/NN	amod||malaria-22/NN||uncomplicated-21/JJ	prep_of||prophylaxis-17/NN||malaria-22/NN	det||advent-25/NN||the-24/DT	prep_before||remains-3/VBZ||advent-25/NN	amod||therapies-29/NNS||artemisinin-based-27/JJ	nn||therapies-29/NNS||combination-28/NN	prep_of||advent-25/NN||therapies-29/NNS	malaria-22||chloroquine-14||yes||chloroquine-induced pruritus remains one of the most common side-effects in the use of chloroquine in the prophylaxis and treatment of uncomplicated malaria before the advent of artemisinin-based combination therapies.
det||end-3/NN||the-2/DT	prep_in||hope-6/VBP||end-3/NN	nsubj||hope-6/VBP||i-5/FW	nsubj||strike-8/VB||i-5/FW	root||ROOT-0/null||hope-6/VBP	aux||strike-8/VB||to-7/TO	xcomp||hope-6/VBP||strike-8/VB	det||note-11/NN||a-9/DT	amod||note-11/NN||positive-10/JJ	dobj||strike-8/VB||note-11/NN	advmod||going-17/VBG||where-13/WRB	det||procedure-15/NN||this-14/DT	nsubj||going-17/VBG||procedure-15/NN	aux||going-17/VBG||is-16/VBZ	prepc_about||strike-8/VB||going-17/VBG	advmod||applied-24/VBN||how-20/WRB	nsubjpass||applied-24/VBN||it-21/PRP	nsubj||establish-26/VB||it-21/PRP	aux||applied-24/VBN||will-22/MD	auxpass||applied-24/VBN||be-23/VB	prepc_about||strike-8/VB||applied-24/VBN	conj_and||going-17/VBG||applied-24/VBN	aux||establish-26/VB||to-25/TO	xcomp||applied-24/VBN||establish-26/VB	nn||independence-28/NN||insulin-27/NN	dobj||establish-26/VB||independence-28/NN	prep_in||establish-26/VB||patients-30/NNS	prep_with||patients-30/NNS||type1diabetes-32/CD	type1diabetes-32||insulin-27||yes||in the end, i hope to strike a positive note about where this procedure is going, and how it will be applied to establish insulin independence in patients with type1diabetes.
det||objective-3/NN||the-1/DT	amod||objective-3/NN||main-2/JJ	nsubj||is-8/VBZ||objective-3/NN	nsubj||monitor-10/VB||objective-3/NN	det||study-7/NN||the-5/DT	amod||study-7/NN||current-6/JJ	prep_of||objective-3/NN||study-7/NN	ccomp||â-36/VBP||is-8/VBZ	aux||monitor-10/VB||to-9/TO	xcomp||is-8/VBZ||monitor-10/VB	det||status-13/NN||the-11/DT	amod||status-13/NN||auditory-12/JJ	dobj||monitor-10/VB||status-13/NN	det||group-16/NN||a-15/DT	prep_in||status-13/NN||group-16/NN	prep_of||group-16/NN||adults-18/NNS	prep_with||monitor-10/VB||aids-20/NNS	vmod||monitor-10/VB||receiving-22/VBG	advmod||active-24/JJ||highly-23/RB	amod||therapy-26/NN||active-24/JJ	amod||therapy-26/NN||antiretroviral-25/JJ	dobj||receiving-22/VBG||therapy-26/NN	appos||therapy-26/NN||haart-28/NN	dep||therapy-26/NN||3tc-31/NNP	dep||3tc-31/NNP||lamivudine-33/NN	nsubj||â-36/VBP||d4t-35/NNS	root||ROOT-0/null||â-36/VBP	dobj||â-36/VBP||$-37/$	npadvmod||outpatient-47/JJ||stavudine-39/NN	conj_and||stavudine-39/NN||efavirenz-42/NN	npadvmod||outpatient-47/JJ||efavirenz-42/NN	quantmod||hospital-46/NN||in-44/IN	quantmod||hospital-46/NN||a-45/DT	num||stavudine-39/NN||hospital-46/NN	amod||clinic-48/NNS||outpatient-47/JJ	npadvmod||in-49/RB||clinic-48/NNS	dep||gauteng-50/CD||in-49/RB	num||$-37/$||gauteng-50/CD	aids-20||stavudine-39||yes||the main objective of the current study is to monitor the auditory status in a group of adults with aids, receiving highly active antiretroviral therapy (haart) (3tc -lamivudine, d4t â€“ stavudine, and efavirenz) in a hospital outpatient clinic in gauteng.
advmod||conclude-4/VBP||thus-1/RB	nsubj||conclude-4/VBP||we-3/PRP	root||ROOT-0/null||conclude-4/VBP	mark||was-7/VBD||that-5/IN	expl||was-7/VBD||there-6/EX	ccomp||conclude-4/VBP||was-7/VBD	neg||evidence-10/NN||no-8/DT	amod||evidence-10/NN||serological-9/JJ	nsubj||was-7/VBD||evidence-10/NN	prep_of||evidence-10/NN||infection-12/NN	prep_with||infection-12/NN||hiv-14/NN	prep_with||infection-12/NN||htlv-i-16/NN	conj_or||hiv-14/NN||htlv-i-16/NN	det||women-20/NNS||the-18/DT	amod||women-20/NNS||pregnant-19/JJ	prep_in||evidence-10/NN||women-20/NNS	vmod||women-20/NNS||studied-21/VBN	advmod||present-28/JJ||however-23/RB	nn||antibody-26/NN||hiv-25/NN	nsubj||present-28/JJ||antibody-26/NN	cop||present-28/JJ||was-27/VBD	parataxis||conclude-4/VBP||present-28/JJ	det||patients-32/NNS||all-30/DT	nn||patients-32/NNS||aids-31/NNS	prep_in||present-28/JJ||patients-32/NNS	vmod||patients-32/NNS||tested-33/VBN	nsubjpass||found-38/VBN||htlv-iantibody-36/NN	auxpass||found-38/VBN||was-37/VBD	parataxis||conclude-4/VBP||found-38/VBN	conj_and||present-28/JJ||found-38/VBN	det||majority-41/NN||the-40/DT	prep_in||found-38/VBN||majority-41/NN	prep_of||majority-41/NN||patients-43/NNS	prep_with||patients-43/NNS||tsp-45/NN	htlv-iantibody-36||htlv-i-16||no||thus, we conclude that there was no serological evidence of infection with hiv or htlv-i in the pregnant women studied; however, hiv antibody was present in all aids patients tested, and htlv-iantibody was found in the majority of patients with tsp.
nsubj||â-2/VBP||conclusions-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	nsubj||found-6/VBD||we-5/PRP	rcmod||$-3/$||found-6/VBD	det||association-9/NN||a-7/DT	amod||association-9/NN||close-8/JJ	dobj||found-6/VBD||association-9/NN	nsubjpass||reduced-21/VBN||association-9/NN	amod||metabolism-12/NN||carbohydrate-11/JJ	prep_between||association-9/NN||metabolism-12/NN	nn||antibodies-16/NNS||igm-14/NN	nn||antibodies-16/NNS||anti-oxldl-15/NN	prep_between||association-9/NN||antibodies-16/NNS	conj_and||metabolism-12/NN||antibodies-16/NNS	auxpass||reduced-21/VBN||were-19/VBD	advmod||reduced-21/VBN||significantly-20/RB	rcmod||association-9/NN||reduced-21/VBN	det||patients-26/NNS||the-23/DT	advmod||obese-25/JJ||morbidly-24/RB	amod||patients-26/NNS||obese-25/JJ	prep_in||reduced-21/VBN||patients-26/NNS	prep_with||patients-26/NNS||diabetes-28/NN	carbohydrate-11||obese-25||no_rel||conclusions â€”we found a close association between carbohydrate metabolism and igm anti-oxldl antibodies, which were significantly reduced in the morbidly obese patients with diabetes.
amod||vaccination-5/NN||proper-4/JJ	prep_in_spite_of||developed-22/VBD||vaccination-5/NN	prep_with||vaccination-5/NN||mono-7/NN	nn||vaccines-11/NNS||bivalent-10/NN	prep_with||vaccination-5/NN||vaccines-11/NNS	conj_or||mono-7/NN||vaccines-11/NNS	prep_against||vaccination-5/NN||marek-13/NN	dep||marek-13/NN||sdisease-15/NN	appos||marek-13/NN||md-17/NN	det||chickens-21/NNS||the-20/DT	nsubj||developed-22/VBD||chickens-21/NNS	root||ROOT-0/null||developed-22/VBD	dobj||developed-22/VBD||symptoms-23/NNS	prep_of||symptoms-23/NNS||md-25/NN	prep_with||developed-22/VBD||paralysis-27/NN	marek'sdisease--1||vaccines-11||no_rel||in spite of proper vaccination with mono- or bivalent vaccines against marek'sdisease (md), the chickens developed symptoms of md with paralysis.
amod||coverage-4/NN||increasing-2/VBG	nn||coverage-4/NN||art-3/NN	prep_with||underscore-16/VBP||coverage-4/NN	amod||quality-8/NN||subsequent-6/JJ	amod||quality-8/NN||improved-7/VBN	conj_and||coverage-4/NN||quality-8/NN	prep_with||underscore-16/VBP||quality-8/NN	prep_of||quality-8/NN||life-10/NN	prep_of||quality-8/NN||plwha-12/NN	det||findings-15/NNS||these-14/DT	nsubj||underscore-16/VBP||findings-15/NNS	root||ROOT-0/null||underscore-16/VBP	det||importance-18/NN||the-17/DT	dobj||underscore-16/VBP||importance-18/NN	prepc_of||importance-18/NN||integrating-20/VBG	amod||services-23/NNS||reproductive-21/JJ	nn||services-23/NNS||health-22/NN	dobj||integrating-20/VBG||services-23/NNS	det||care-27/NN||the-25/DT	amod||care-27/NN||routine-26/JJ	prep_in||services-23/NNS||care-27/NN	prep_in||services-23/NNS||treatment-29/NN	conj_and||care-27/NN||treatment-29/NN	prep_of||care-27/NN||hiv/aids-31/NNS	advmod||integrating-20/VBG||worldwide-32/RB	aids--1||hiv--1||no||with increasing art coverage and subsequent improved quality of life of plwha, these findings underscore the importance of integrating reproductive health services in the routine care and treatment of hiv/aids worldwide.
nsubj||demonstrated-2/VBD||we-1/PRP	root||ROOT-0/null||demonstrated-2/VBD	mark||employed-7/VBN||that-3/IN	nsubjpass||employed-7/VBN||bmscs-4/NNS	aux||employed-7/VBN||might-5/MD	auxpass||employed-7/VBN||be-6/VB	ccomp||demonstrated-2/VBD||employed-7/VBN	det||vehicle-11/NN||a-9/DT	amod||vehicle-11/NN||promising-10/JJ	prep_as||employed-7/VBN||vehicle-11/NN	nn||therapy-15/NN||tumor-13/NN	nn||therapy-15/NN||gene-14/NN	prep_for||vehicle-11/NN||therapy-15/NN	nsubj||improve-21/VB||therapy-15/NN	nsubj||modify-32/VB||therapy-15/NN	aux||improve-21/VB||can-17/MD	advmod||improve-21/VB||effectively-18/RB	neg||improve-21/VB||not-19/RB	advmod||improve-21/VB||only-20/RB	rcmod||therapy-15/NN||improve-21/VB	det||concentration-23/NN||the-22/DT	dobj||improve-21/VB||concentration-23/NN	amod||therapeutics-26/NNS||anticancer-25/JJ	prep_of||concentration-23/NN||therapeutics-26/NNS	prep_in||therapeutics-26/NNS||tumors-28/NNS	advmod||modify-32/VB||also-31/RB	rcmod||therapy-15/NN||modify-32/VB	conj_but||improve-21/VB||modify-32/VB	det||microenvironment-35/NN||the-33/DT	nn||microenvironment-35/NN||tumor-34/NN	dobj||modify-32/VB||microenvironment-35/NN	vehicle-11||tumors-28||no_rel||we demonstrated that bmscs might be employed as a promising vehicle for tumor gene therapy which can effectively not only improve the concentration of anticancer therapeutics in tumors, but also modify the tumor microenvironment.
nsubj||threaten-12/VB||influenzaviruses-1/NNS	advmod||pathogenic-5/JJ||highly-4/RB	amod||avianinfluenzavirus-6/NNS||pathogenic-5/JJ	prep_including||influenzaviruses-1/NNS||avianinfluenzavirus-6/NNS	appos||avianinfluenzavirus-6/NNS||h5n1-8/NNP	aux||threaten-12/VB||could-11/MD	root||ROOT-0/null||threaten-12/VB	nn||safety-14/NN||blood-13/NN	dobj||threaten-12/VB||safety-14/NN	h5n1-8||avianinfluenzavirus-6||no||influenzaviruses, including highly pathogenic avianinfluenzavirus (h5n1), could threaten blood safety.
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||problem-18/NN||tb-3/NN	vmod||tb-3/NN||caused-6/VBN	agent||caused-6/VBN||mycobacteriumtuberculosis-8/NNS	appos||mycobacteriumtuberculosis-8/NNS||mtb-10/NN	cop||problem-18/NN||is-13/VBZ	det||problem-18/NN||an-14/DT	amod||problem-18/NN||enduring-15/VBG	amod||problem-18/NN||public-16/JJ	nn||problem-18/NN||health-17/NN	root||ROOT-0/null||problem-18/NN	advmod||problem-18/NN||globally-19/RB	advmod||problem-18/NN||particularly-21/RB	amod||africa-24/NN||sub-saharan-23/JJ	prep_in||problem-18/NN||africa-24/NN	tb-3||mtb-10||no||tuberculosis (tb), caused by mycobacteriumtuberculosis (mtb), is an enduring public health problem globally, particularly in sub-saharan africa.
det||co-infection-2/NN||a-1/DT	nsubj||occur-6/VB||co-infection-2/NN	prep_in||co-infection-2/NN||humans-4/NNS	aux||occur-6/VB||can-5/MD	root||ROOT-0/null||occur-6/VB	det||bite-9/NN||the-8/DT	prep_following||occur-6/VB||bite-9/NN	num||mosquitoes-12/NNS||two-11/CD	prep_of||bite-9/NN||mosquitoes-12/NNS	vmod||mosquitoes-12/NNS||infected-13/VBN	vmod||mosquitoes-12/NNS||infected-13/VBN	conj_or||infected-13/VBN||infected-13/VBN	num||virus-16/NN||one-15/CD	prep_with||infected-13/VBN||virus-16/NN	det||bite-20/NN||the-19/DT	prep_to||infected-13/VBN||bite-20/NN	det||mosquito-23/NN||a-22/DT	prep_of||bite-20/NN||mosquito-23/NN	vmod||mosquito-23/NN||infected-24/VBN	num||viruses-27/NNS||two-26/CD	prep_with||infected-24/VBN||viruses-27/NNS	virus-16||viruses-27||no||a co-infection in humans can occur following the bite of two mosquitoes infected with one virus or to the bite of a mosquito infected with two viruses.
det||probability-3/NN||the-1/DT	amod||probability-3/NN||cumulative-2/JJ	nsubj||%-23/NN||probability-3/NN	prep_of||probability-3/NN||hivinfection-5/NN	nsubjpass||tested-15/VBN||hivinfection-5/NN	prep_among||hivinfection-5/NN||babies-7/NNS	amod||regimen-12/NN||single-9/JJ	nn||regimen-12/NN||dose-10/NN	nn||regimen-12/NN||nevirapine-11/NN	prep_on||babies-7/NNS||regimen-12/NN	auxpass||tested-15/VBN||were-14/VBD	rcmod||hivinfection-5/NN||tested-15/VBN	prepc_at||tested-15/VBN||>-17/VBG	dep||months-20/NNS||=-18/SYM	num||months-20/NNS||18-19/CD	ccomp||>-17/VBG||months-20/NNS	cop||%-23/NN||was-21/VBD	num||%-23/NN||15.0-22/CD	root||ROOT-0/null||%-23/NN	num||%-26/NN||95-25/CD	dep||%-23/NN||%-26/NN	vmod||%-26/NN||ci-27/VBN	num||.1-29/CD||9.8-22-28/CD	dobj||ci-27/VBN||.1-29/CD	prep_in||%-23/NN||2007-32/CD	mark||%-38/NN||whereas-34/IN	nsubj||%-38/NN||it-35/PRP	cop||%-38/NN||was-36/VBD	num||%-38/NN||8.2-37/CD	advcl||%-23/NN||%-38/NN	num||%-41/NN||95-40/CD	dep||%-38/NN||%-41/NN	vmod||%-41/NN||ci-42/VBN	num||.97-44/CD||5.55-11-43/CD	dobj||ci-42/VBN||.97-44/CD	prep_among||%-38/NN||babies-47/NNS	nsubjpass||tested-53/VBN||babies-47/NNS	amod||regimen-50/NN||zidovudine-49/JJ	prep_on||babies-47/NNS||regimen-50/NN	auxpass||tested-53/VBN||were-52/VBD	rcmod||babies-47/NNS||tested-53/VBN	prepc_at||tested-53/VBN||>-55/VBG	dep||days-58/NNS||=-56/SYM	num||days-58/NNS||45-57/CD	ccomp||>-55/VBG||days-58/NNS	prep_in||>-55/VBG||2009-60/CD	hivinfection-5||zidovudine-49||yes||the cumulative probability of hivinfection among babies on single dose nevirapine regimen who were tested at >=18 months was 15.0% (95% ci 9.8-22.1) in 2007, whereas it was 8.2% (95% ci 5.55-11.97) among babies on zidovudine regimen who were tested at >=45 days in 2009.
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	infectiousmononucleosis-12||ebv-6||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
amod||lesions-2/NNS||premalignant-1/JJ	nsubjpass||induced-7/VBN||lesions-2/NNS	nn||carcinomas-5/NNS||mammary-4/NN	conj_and||lesions-2/NNS||carcinomas-5/NNS	nsubjpass||induced-7/VBN||carcinomas-5/NNS	auxpass||induced-7/VBN||were-6/VBD	root||ROOT-0/null||induced-7/VBN	amod||-LSB--12/NNS||medroxyprogesteroneacetate-9/JJ	conj_and||medroxyprogesteroneacetate-9/JJ||7,12-dimethylbenz-11/JJ	amod||-LSB--12/NNS||7,12-dimethylbenz-11/JJ	agent||induced-7/VBN||-LSB--12/NNS	det||treatment-16/NN||a-13/DT	advmod||anthracene-15/JJ||-RSB--14/RB	amod||treatment-16/NN||anthracene-15/JJ	dep||-LSB--12/NNS||treatment-16/NN	medroxyprogesteroneacetate-9||carcinomas-5||no_rel||premalignant lesions and mammary carcinomas were induced by medroxyprogesteroneacetate and 7,12-dimethylbenz[a]anthracene treatment.
advmod||provide-5/VBP||therefore-1/RB	det||agents-4/NNS||these-3/DT	nsubj||provide-5/VBP||agents-4/NNS	root||ROOT-0/null||provide-5/VBP	det||option-9/NN||a-6/DT	amod||option-9/NN||potential-7/JJ	amod||option-9/NN||therapeutic-8/JJ	dobj||provide-5/VBP||option-9/NN	nsubj||require-15/VBP||option-9/NN	prep_for||option-9/NN||patients-11/NNS	prep_with||patients-11/NNS||arthritis-13/NN	rcmod||option-9/NN||require-15/VBP	amod||therapy-18/NN||long-term-16/JJ	amod||therapy-18/NN||nsaid-17/JJ	dobj||require-15/VBP||therapy-18/NN	arthritis-13||nsaid-17||no_rel||therefore, these agents provide a potential therapeutic option for patients with arthritis who require long-term nsaid therapy.
dep||found-18/VBN||independent-1/JJ	det||severity-4/NN||the-3/DT	prep_from||independent-1/JJ||severity-4/NN	det||seasons-9/NNS||the-6/DT	num||seasons-9/NNS||four-7/CD	nn||seasons-9/NNS||epidemic-8/NN	prep_of||severity-4/NN||seasons-9/NNS	num||predictors-12/NNS||seven-11/CD	appos||seasons-9/NNS||predictors-12/NNS	prep_for||predictors-12/NNS||hospitalization-14/NN	prep_for||hospitalization-14/NN||rsvinfection-16/NN	auxpass||found-18/VBN||were-17/VBD	root||ROOT-0/null||found-18/VBN	det||number-23/NN||the-20/DT	amod||number-23/NN||bivariate-21/JJ	nn||number-23/NN||analysis-22/NN	prep_in||found-18/VBN||number-23/NN	prep_of||number-23/NN||children-25/NNS	det||family-28/NN||the-27/DT	prep_in||children-25/NNS||family-28/NN	amod||age-31/NN||chronological-30/JJ	appos||family-28/NN||age-31/NN	det||onset-34/NN||the-33/DT	prep_at||age-31/NN||onset-34/NN	nn||season-37/NN||rsv-36/NN	prep_of||onset-34/NN||season-37/NN	nn||weight-40/NN||birth-39/NN	prep_of||onset-34/NN||weight-40/NN	conj_and||season-37/NN||weight-40/NN	amod||age-43/NN||gestational-42/JJ	prep_of||onset-34/NN||age-43/NN	conj_and||season-37/NN||age-43/NN	nn||order-46/NN||birth-45/NN	nsubjpass||found-18/VBN||order-46/NN	nn||attendance-49/NN||daycare-48/NN	appos||order-46/NN||attendance-49/NN	amod||rsvinfections-52/NNS||previous-51/JJ	appos||attendance-49/NN||rsvinfections-52/NNS	rsvinfection-16||rsv-36||no||independent from the severity of the four epidemic seasons, seven predictors for hospitalization for rsvinfection were found in the bivariate analysis number of children in the family, chronological age at the onset of rsv season, birth weight and gestational age, birth order, daycare attendance, previous rsvinfections.
nsubj||demonstrated-2/VBD||we-1/PRP	root||ROOT-0/null||demonstrated-2/VBD	mark||employed-7/VBN||that-3/IN	nsubjpass||employed-7/VBN||bmscs-4/NNS	aux||employed-7/VBN||might-5/MD	auxpass||employed-7/VBN||be-6/VB	ccomp||demonstrated-2/VBD||employed-7/VBN	det||vehicle-11/NN||a-9/DT	amod||vehicle-11/NN||promising-10/JJ	prep_as||employed-7/VBN||vehicle-11/NN	nn||therapy-15/NN||tumor-13/NN	nn||therapy-15/NN||gene-14/NN	prep_for||vehicle-11/NN||therapy-15/NN	nsubj||improve-21/VB||therapy-15/NN	nsubj||modify-32/VB||therapy-15/NN	aux||improve-21/VB||can-17/MD	advmod||improve-21/VB||effectively-18/RB	neg||improve-21/VB||not-19/RB	advmod||improve-21/VB||only-20/RB	rcmod||therapy-15/NN||improve-21/VB	det||concentration-23/NN||the-22/DT	dobj||improve-21/VB||concentration-23/NN	amod||therapeutics-26/NNS||anticancer-25/JJ	prep_of||concentration-23/NN||therapeutics-26/NNS	prep_in||therapeutics-26/NNS||tumors-28/NNS	advmod||modify-32/VB||also-31/RB	rcmod||therapy-15/NN||modify-32/VB	conj_but||improve-21/VB||modify-32/VB	det||microenvironment-35/NN||the-33/DT	nn||microenvironment-35/NN||tumor-34/NN	dobj||modify-32/VB||microenvironment-35/NN	vehicle-11||tumor-34||no_rel||we demonstrated that bmscs might be employed as a promising vehicle for tumor gene therapy which can effectively not only improve the concentration of anticancer therapeutics in tumors, but also modify the tumor microenvironment.
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	irondeficiency-5||iron-13||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
advmod||achieved-25/VBN||moreover-1/RB	advmod||added-6/VBN||when-3/WRB	nsubjpass||added-6/VBN||thioridazine-4/NN	auxpass||added-6/VBN||was-5/VBD	advcl||achieved-25/VBN||added-6/VBN	det||regimen-9/NN||a-8/DT	prep_to||added-6/VBN||regimen-9/NN	vmod||regimen-9/NN||containing-10/VBG	dobj||containing-10/VBG||rifampicin-11/NN	dobj||containing-10/VBG||isoniazid-13/NN	conj_and||rifampicin-11/NN||isoniazid-13/NN	dobj||containing-10/VBG||pyrazinamide-15/NN	conj_and||rifampicin-11/NN||pyrazinamide-15/NN	nn||tuberculosis-18/NNP||susceptible-17/NNP	prep_for||containing-10/VBG||tuberculosis-18/NNP	det||effect-23/NN||a-20/DT	amod||effect-23/NN||significant-21/JJ	amod||effect-23/NN||synergistic-22/JJ	nsubjpass||achieved-25/VBN||effect-23/NN	auxpass||achieved-25/VBN||was-24/VBD	root||ROOT-0/null||achieved-25/VBN	poss||âˆ-31/NNP||âˆ-27/NNP	nn||âˆ-31/NNP||6.2-29/NNP	nn||âˆ-31/NNP||vs-30/NNP	poss||cfu-35/NN||âˆ-31/NNP	number||log-34/CD||5.9-33/CD	num||cfu-35/NN||log-34/CD	dep||achieved-25/VBN||cfu-35/NN	nn||0.01-39/NNP||p-37/NNP	nn||0.01-39/NNP||<-38/NNP	appos||cfu-35/NN||0.01-39/NNP	tuberculosis-18||rifampicin-11||yes||moreover, when thioridazine was added to a regimen containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved (âˆ’6.2 vs âˆ’5.9 log cfu, p<0.01).
det||study-2/NN||this-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||higher-18/JJR||that-4/IN	csubj||higher-18/JJR||circulating-5/VBG	nn||plasmablasts-8/NNS||igg-6/NN	nn||plasmablasts-8/NNS||+-7/NN	dobj||circulating-5/VBG||plasmablasts-8/NNS	amod||secretion-11/NN||spontaneous-10/JJ	dobj||circulating-5/VBG||secretion-11/NN	conj_and||plasmablasts-8/NNS||secretion-11/NN	amod||antibodies-15/NNS||bcg-specific-13/JJ	nn||antibodies-15/NNS||igg-14/NN	prep_of||secretion-11/NN||antibodies-15/NNS	cop||higher-18/JJR||were-16/VBD	advmod||higher-18/JJR||significantly-17/RB	ccomp||demonstrated-3/VBD||higher-18/JJR	prep_in||higher-18/JJR||patients-20/NNS	amod||tb-23/NN||active-22/JJ	prep_with||patients-20/NNS||tb-23/NN	prepc_compared_with||higher-18/JJR||with-25/IN	nn||cases-28/NNS||latent-26/NN	nn||cases-28/NNS||tb-27/NN	pobj||higher-18/JJR||cases-28/NNS	amod||controls-31/NNS||non-tb-30/JJ	pobj||higher-18/JJR||controls-31/NNS	conj_and||cases-28/NNS||controls-31/NNS	tb-27||bcg--1||yes||this study demonstrated that circulating igg+ plasmablasts and spontaneous secretion of bcg-specific igg antibodies were significantly higher in patients with active tb compared with latent tb cases and non-tb controls.
amod||patients-3/NNS||chinese-2/JJ	prep_in||predicts-8/VBZ||patients-3/NNS	prep_with||patients-3/NNS||type2diabetes-5/CD	nsubj||predicts-8/VBZ||hyperglycemia-7/NN	root||ROOT-0/null||predicts-8/VBZ	dobj||predicts-8/VBZ||cancer-9/NN	mark||associated-15/VBN||whereas-11/IN	nn||usage-13/NN||insulin-12/NN	nsubjpass||associated-15/VBN||usage-13/NN	auxpass||associated-15/VBN||was-14/VBD	advcl||predicts-8/VBZ||associated-15/VBN	det||risk-20/NN||a-17/DT	amod||risk-20/NN||reduced-18/VBN	nn||risk-20/NN||cancer-19/NN	prep_with||associated-15/VBN||risk-20/NN	hyperglycemia-7||insulin-12||yes||in chinese patients with type2diabetes, hyperglycemia predicts cancer, whereas insulin usage was associated with a reduced cancer risk.
amod||reduction-2/NN||comparable-1/JJ	nsubjpass||observed-7/VBN||reduction-2/NN	amod||lesions-5/NNS||acne-4/JJ	prep_of||reduction-2/NN||lesions-5/NNS	auxpass||observed-7/VBN||was-6/VBD	root||ROOT-0/null||observed-7/VBN	det||groups-13/NNS||the-9/DT	nn||groups-13/NNS||taubr-10/NN	conj_and||taubr-10/NN||clindamycin-12/NN	nn||groups-13/NNS||clindamycin-12/NN	prep_in||observed-7/VBN||groups-13/NNS	prep_of||groups-13/NNS||patients-15/NNS	amod||acnevulgaris-22/NNS||mild-17/JJ	conj_and||mild-17/JJ||moderate-19/JJ	amod||acnevulgaris-22/NNS||moderate-19/JJ	amod||acnevulgaris-22/NNS||inflammatory-20/JJ	amod||acnevulgaris-22/NNS||facial-21/JJ	prep_with||patients-15/NNS||acnevulgaris-22/NNS	acne-4||clindamycin-12||yes||comparable reduction of acne lesions was observed in the taubr and clindamycin groups of patients with mild and moderate inflammatory facial acnevulgaris.
det||receptor-8/NN||the-1/DT	amod||receptor-8/NN||insulin-like-2/JJ	nn||receptor-8/NN||growth-3/NN	nn||receptor-8/NN||factor-4/NN	num||receptor-8/NN||1-5/CD	nn||receptor-8/NN||tyrosine-6/NN	nn||receptor-8/NN||kinase-7/NN	nsubjpass||shown-22/VBN||receptor-8/NN	nsubj||play-24/VB||receptor-8/NN	dep||receptor-8/NN||igf-1r-10/JJ	det||receptor-17/NN||the-13/DT	amod||receptor-17/NN||chemokine-14/JJ	amod||receptor-17/NN||g-protein-15/JJ	nn||receptor-17/NN||coupled-16/NN	conj_and||receptor-8/NN||receptor-17/NN	nsubjpass||shown-22/VBN||receptor-17/NN	nsubj||play-24/VB||receptor-17/NN	appos||receptor-17/NN||cxcr4-19/NNS	aux||shown-22/VBN||have-20/VBP	auxpass||shown-22/VBN||been-21/VBN	root||ROOT-0/null||shown-22/VBN	aux||play-24/VB||to-23/TO	xcomp||shown-22/VBN||play-24/VB	det||role-27/NN||an-25/DT	amod||role-27/NN||important-26/JJ	dobj||play-24/VB||role-27/NN	nn||metastasis-31/NNS||breast-29/NN	nn||metastasis-31/NNS||cancer-30/NN	prep_in||play-24/VB||metastasis-31/NNS	cancer-30||tyrosine-6||no_rel||the insulin-like growth factor 1 tyrosine kinase receptor (igf-1r) and the chemokine g-protein coupled receptor, cxcr4 have been shown to play an important role in breast cancer metastasis.
nsubj||requires-5/VBZ||treatment-1/NN	prep_for||treatment-1/NN||oa-3/NN	advmod||requires-5/VBZ||often-4/RB	root||ROOT-0/null||requires-5/VBZ	amod||use-7/NN||chronic-6/JJ	dobj||requires-5/VBZ||use-7/NN	nsubjpass||associated-20/VBN||use-7/NN	amod||nonsteroidalanti-inflammatorydrugs-12/NNS||selective-9/JJ	conj_or||selective-9/JJ||nonselective-11/JJ	amod||nonsteroidalanti-inflammatorydrugs-12/NNS||nonselective-11/JJ	prep_of||use-7/NN||nonsteroidalanti-inflammatorydrugs-12/NNS	appos||nonsteroidalanti-inflammatorydrugs-12/NNS||nsaids-14/NNS	aux||associated-20/VBN||have-18/VBP	auxpass||associated-20/VBN||been-19/VBN	rcmod||use-7/NN||associated-20/VBN	amod||complications-25/NNS||gastrointestinal-22/JJ	conj_and||gastrointestinal-22/JJ||cardiovascular-24/JJ	amod||complications-25/NNS||cardiovascular-24/JJ	prep_with||associated-20/VBN||complications-25/NNS	nonsteroidalanti-inflammatorydrugs-12||oa-3||no_rel||treatment for oa often requires chronic use of selective or nonselective nonsteroidalanti-inflammatorydrugs (nsaids), which have been associated with gastrointestinal and cardiovascular complications.
nsubj||suggest-28/VBP||comparison-1/NN	det||expression-4/NN||the-3/DT	prep_of||comparison-1/NN||expression-4/NN	amod||dachshund-9/NN||tc-prd-6/JJ	amod||dachshund-9/NN||tribolium-8/JJ	prep_of||expression-4/NN||dachshund-9/NN	dep||dachshund-9/NN||tc-dac-11/JJ	nn||wingless-15/NNS||tribolium-14/NN	prep_of||expression-4/NN||wingless-15/NNS	conj_and||dachshund-9/NN||wingless-15/NNS	appos||dachshund-9/NN||tc-wg-17/NN	det||endites-21/NNS||the-20/DT	prep_between||expression-4/NN||endites-21/NNS	det||maxilla-24/NN||the-23/DT	prep_of||endites-21/NNS||maxilla-24/NN	det||mandible-27/NN||the-26/DT	prep_of||endites-21/NNS||mandible-27/NN	conj_and||maxilla-24/NN||mandible-27/NN	root||ROOT-0/null||suggest-28/VBP	mark||is-43/VBZ||that-29/IN	mark||are-33/VBP||while-31/IN	expl||are-33/VBP||there-32/EX	advcl||is-43/VBZ||are-33/VBP	num||endites-35/NNS||two-34/CD	nsubj||are-33/VBP||endites-35/NNS	det||maxilla-38/NN||the-37/DT	prep_in||endites-35/NNS||maxilla-38/NN	advmod||endite-42/NN||only-39/RB	det||endite-42/NN||a-40/DT	amod||endite-42/NN||single-41/JJ	nsubj||is-43/VBZ||endite-42/NN	ccomp||suggest-28/VBP||is-43/VBZ	acomp||is-43/VBZ||present-44/JJ	det||mandible-47/NN||the-46/DT	prep_in||present-44/JJ||mandible-47/NN	wg--1||prd--1||no_rel||comparison of the expression of tc-prd, tribolium dachshund (tc-dac) and tribolium wingless ( tc-wg) between the endites of the maxilla and the mandible suggest that, while there are two endites in the maxilla only a single endite is present in the mandible.
nsubj||suspect-2/VBP||all-1/DT	root||ROOT-0/null||suspect-2/VBP	amod||cases-4/NNS||h5n1-3/JJ	nsubjpass||tested-6/VBN||cases-4/NNS	auxpass||tested-6/VBN||were-5/VBD	ccomp||suspect-2/VBP||tested-6/VBN	nn||assays-14/NNS||polymerase-8/NN	nn||assays-14/NNS||chain-9/NN	nn||assays-14/NNS||reaction-10/NN	nn||assays-14/NNS||pcr-12/NN	prep_with||tested-6/VBN||assays-14/NNS	prepc_for||tested-6/VBN||influenza-16/VBG	det||h5n1-19/NNS||a-17/DT	dobj||influenza-16/VBG||h5n1-19/NNS	dobj||influenza-16/VBG||humaninfluenzaviruses-22/NNS	conj_and||h5n1-19/NNS||humaninfluenzaviruses-22/NNS	h5n1-19||influenzaviruses--1||no||all suspect h5n1 cases were tested with polymerase chain reaction (pcr) assays for influenza a(h5n1) and humaninfluenzaviruses.
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	uc-12||enzyme--1||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
amod||drugs-2/NNS||several-1/JJ	nsubj||lead-16/VB||drugs-2/NNS	vmod||drugs-2/NNS||used-3/VBN	det||management-6/NN||the-5/DT	prep_in||used-3/VBN||management-6/NN	prep_of||management-6/NN||aids-8/NNS	prep_such_as||aids-8/NNS||nevirapine-11/NN	prep_such_as||aids-8/NNS||indinavir-13/NN	conj_or||nevirapine-11/NN||indinavir-13/NN	aux||lead-16/VB||can-14/MD	advmod||lead-16/VB||themselves-15/PRP	root||ROOT-0/null||lead-16/VB	amod||inflammation-19/NN||severe-18/JJ	prep_to||lead-16/VB||inflammation-19/NN	det||segment-23/NN||the-21/DT	nn||segment-23/NN||anterior-22/NN	prep_in||lead-16/VB||segment-23/NN	prep_in||lead-16/VB||adnexa-25/NN	conj_and||segment-23/NN||adnexa-25/NN	det||eye-28/NN||the-27/DT	prep_of||segment-23/NN||eye-28/NN	aids-8||nevirapine-11||yes||several drugs used in the management of aids such as nevirapine or indinavir can themselves lead to severe inflammation in the anterior segment and adnexa of the eye.
det||control-3/NN||the-1/DT	amod||control-3/NN||profound-2/JJ	nsubj||oxidant-9/VB||control-3/NN	nsubj||ros-32/VB||control-3/NN	prep_of||control-3/NN||aunps-5/NNS	det||anti-8/NN||the-7/DT	prep_over||aunps-5/NNS||anti-8/NN	root||ROOT-0/null||oxidant-9/VB	dobj||oxidant-9/VB||enzymes-10/NNS	prep_such_as||enzymes-10/NNS||gsh-13/NN	prep_such_as||enzymes-10/NNS||sod-15/NN	conj_and||gsh-13/NN||sod-15/NN	prep_such_as||enzymes-10/NNS||catalase-17/NN	conj_and||gsh-13/NN||catalase-17/NN	prep_such_as||enzymes-10/NNS||gpx-19/NN	conj_and||gsh-13/NN||gpx-19/NN	amod||mice-22/NNS||diabetic-21/JJ	prep_in||oxidant-9/VB||mice-22/NNS	prep_to||oxidant-9/VB||normal-24/JJ	prep_by||oxidant-9/VB||inhibition-27/NN	nn||peroxidation-30/NN||lipid-29/NN	prep_of||inhibition-27/NN||peroxidation-30/NN	conj_and||oxidant-9/VB||ros-32/VB	dobj||ros-32/VB||generation-33/NN	nn||evidence-36/NN||hyperglycemia-35/NN	prep_during||ros-32/VB||evidence-36/NN	poss||effect-39/NN||their-37/PRP$	amod||effect-39/NN||anti-oxidant-38/JJ	dobj||oxidant-9/VB||effect-39/NN	prep_during||oxidant-9/VB||hyperglycemia-41/NN	enzymes-10||hyperglycemia-41||no_rel||the profound control of aunps over the anti oxidant enzymes such as gsh, sod, catalase and gpx in diabetic mice to normal, by inhibition of lipid peroxidation and ros generation during hyperglycemia evidence their anti-oxidant effect during hyperglycemia.
nsubj||drug-4/NN||magnesiumsulfate-1/NN	cop||drug-4/NN||is-2/VBZ	det||drug-4/NN||the-3/DT	root||ROOT-0/null||drug-4/NN	prep_of||drug-4/NN||choice-6/NN	prep_for||choice-6/NN||prevention-8/NN	prep_of||prevention-8/NN||seizures-10/NNS	prep_as||seizures-10/NNS||part-12/NN	amod||management-15/NN||comprehensive-14/JJ	prep_of||part-12/NN||management-15/NN	det||disease-18/NN||the-17/DT	prep_of||management-15/NN||disease-18/NN	seizures-10||magnesiumsulfate-1||yes||magnesiumsulfate is the drug of choice for prevention of seizures as part of comprehensive management of the disease.
det||incidence-2/NN||the-1/DT	nsubj||lower-17/JJR||incidence-2/NN	conj_and||incidence-2/NN||severity-4/NN	nsubj||lower-17/JJR||severity-4/NN	prep_of||incidence-2/NN||pain-6/NN	det||injection-10/NN||the-8/DT	amod||injection-10/NN||propofol-9/JJ	prep_from||pain-6/NN||injection-10/NN	det||group-14/NN||the-12/DT	nn||group-14/NN||combination-13/NN	prep_in||injection-10/NN||group-14/NN	cop||lower-17/JJR||was-15/VBD	advmod||lower-17/JJR||significantly-16/RB	root||ROOT-0/null||lower-17/JJR	prep_than||lower-17/JJR||that-19/DT	det||remifentanil-22/NN||the-21/DT	prep_in||that-19/DT||remifentanil-22/NN	amod||groups-25/NNS||cold-24/JJ	prep_in||that-19/DT||groups-25/NNS	conj_and||remifentanil-22/NN||groups-25/NNS	pain-6||propofol-9||yes||the incidence and severity of pain from the propofol injection in the combination group was significantly lower than that in the remifentanil and cold groups.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||sample-12/NN||this-8/DT	cop||sample-12/NN||was-9/VBD	det||sample-12/NN||a-10/DT	amod||sample-12/NN||cross-sectional-11/JJ	rcmod||$-6/$||sample-12/NN	amod||individuals-15/NNS||281-14/JJ	prep_of||sample-12/NN||individuals-15/NNS	amod||metabolism-19/NN||normal-17/JJ	nn||metabolism-19/NN||glucose-18/NN	prep_with||individuals-15/NNS||metabolism-19/NN	discourse||metabolism-19/NN||ngm-21/UH	num||individuals-25/NNS||181-24/CD	dobj||â-5/VBP||individuals-25/NNS	conj_and||$-6/$||individuals-25/NNS	amod||metabolism-29/NN||impaired-27/VBN	nn||metabolism-29/NN||glucose-28/NN	prep_with||individuals-25/NNS||metabolism-29/NN	discourse||metabolism-29/NN||igm-31/UH	num||subjects-36/NNS||107-35/CD	dobj||â-5/VBP||subjects-36/NNS	conj_and||$-6/$||subjects-36/NNS	prep_with||subjects-36/NNS||type2diabetes-38/CD	glucose-28||type2diabetes-38||no_rel||research design and methods â€”this was a cross-sectional sample of 281 individuals with normal glucose metabolism (ngm), 181 individuals with impaired glucose metabolism (igm), and 107 subjects with type2diabetes.
det||effect-2/NN||this-1/DT	nsubj||results-3/VBZ||effect-2/NN	root||ROOT-0/null||results-3/VBZ	det||stimulation-7/NN||a-5/DT	amod||stimulation-7/NN||glucose-dependent-6/JJ	prep_in||results-3/VBZ||stimulation-7/NN	nn||secretion-10/NN||insulin-9/NN	prep_of||stimulation-7/NN||secretion-10/NN	det||inhibition-13/NN||an-12/DT	prep_in||results-3/VBZ||inhibition-13/NN	conj_and||stimulation-7/NN||inhibition-13/NN	nn||secretion-16/NN||glucagon-15/NN	prep_of||inhibition-13/NN||secretion-16/NN	det||risk-20/NN||an-18/DT	amod||risk-20/NN||intrinsic-19/JJ	prep_without||results-3/VBZ||risk-20/NN	prep_for||risk-20/NN||hypoglycemia-22/NN	hypoglycemia-22||glucagon-15||yes||this effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia.
advmod||shown-5/VBN||hiv-1/RB	nsubjpass||shown-5/VBN||itself-2/PRP	aux||shown-5/VBN||has-3/VBZ	auxpass||shown-5/VBN||been-4/VBN	root||ROOT-0/null||shown-5/VBN	aux||increase-7/VB||to-6/TO	ccomp||shown-5/VBN||increase-7/VB	dobj||increase-7/VB||lipogenesis-8/NNS	det||liver-11/NN||the-10/DT	prep_in||increase-7/VB||liver-11/NN	aux||alter-14/VB||to-13/TO	ccomp||shown-5/VBN||alter-14/VB	conj_and||increase-7/VB||alter-14/VB	det||profile-17/NN||the-15/DT	nn||profile-17/NN||lipid-16/NN	dobj||alter-14/VB||profile-17/NN	mark||increases-33/VBZ||while-19/IN	det||presence-21/NN||the-20/DT	nsubj||increases-33/VBZ||presence-21/NN	amod||habits-24/NNS||unsafe-23/JJ	prep_of||presence-21/NN||habits-24/NNS	prep_of||presence-21/NN||addiction-26/NN	conj_and||habits-24/NNS||addiction-26/NN	prep_of||presence-21/NN||comorbidities-28/NNS	conj_and||habits-24/NNS||comorbidities-28/NNS	amod||diseases-32/NNS||aids-related-31/JJ	prep_of||presence-21/NN||diseases-32/NNS	conj_and||habits-24/NNS||diseases-32/NNS	advcl||shown-5/VBN||increases-33/VBZ	advmod||increases-33/VBZ||substantially-34/RB	det||risk-36/NN||the-35/DT	dobj||increases-33/VBZ||risk-36/NN	prep_of||risk-36/NN||cardiovasculardisease-38/NN	appos||cardiovasculardisease-38/NN||cvd-40/NN	det||population-45/NN||the-43/DT	amod||population-45/NN||hiv-infected-44/JJ	prep_in||cardiovasculardisease-38/NN||population-45/NN	aids--1||hiv-1||no||hiv itself has been shown to increase lipogenesis in the liver and to alter the lipid profile, while the presence of unsafe habits, addiction, comorbidities, and aids-related diseases increases substantially the risk of cardiovasculardisease (cvd) in the hiv-infected population.
nsubj||indicates-15/VBZ||increased-1/VBN	amod||increased-1/VBN||binding-2/VBG	amod||neurons-10/NNS||tf-4/JJ	det||purkinje-8/NN||the-6/DT	nn||purkinje-8/NN||cerebellar-7/NN	prep_to||tf-4/JJ||purkinje-8/NN	nn||neurons-10/NNS||cell-9/NN	prep_of||increased-1/VBN||neurons-10/NNS	amod||brains-13/NNS||scjd-12/JJ	prep_of||neurons-10/NNS||brains-13/NNS	advmod||indicates-15/VBZ||further-14/RB	root||ROOT-0/null||indicates-15/VBZ	dobj||indicates-15/VBZ||upregulation-16/NN	prep_of||upregulation-16/NN||tfr-18/NN	det||phenotype-21/NN||a-20/DT	dobj||indicates-15/VBZ||phenotype-21/NN	conj_and||upregulation-16/NN||phenotype-21/NN	amod||irondeficiency-24/NN||neuronal-23/JJ	prep_of||phenotype-21/NN||irondeficiency-24/NN	amod||brains-27/NNS||diseased-26/JJ	prep_in||irondeficiency-24/NN||brains-27/NNS	amod||levels-31/NNS||increased-29/VBN	nn||levels-31/NNS||iron-30/NN	prep_despite||indicates-15/VBZ||levels-31/NNS	irondeficiency-24||iron-30||yes||increased binding of tf to the cerebellar purkinje cell neurons of scjd brains further indicates upregulation of tfr and a phenotype of neuronal irondeficiency in diseased brains despite increased iron levels.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||determine-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||rate-10/NN||the-9/DT	dobj||determine-8/VB||rate-10/NN	amod||response-14/NN||sustained-12/VBN	amod||response-14/NN||virological-13/JJ	prep_of||rate-10/NN||response-14/NN	appos||response-14/NN||svr-16/NN	amod||factors-20/NNS||various-19/JJ	prep_of||rate-10/NN||factors-20/NNS	conj_and||response-14/NN||factors-20/NNS	vmod||factors-20/NNS||associated-21/VBN	nn||rates-24/NNS||response-23/NN	prep_with||associated-21/VBN||rates-24/NNS	amod||patients-28/NNS||chronichepatitisc-26/JJ	amod||patients-28/NNS||infected-27/JJ	prep_in||associated-21/VBN||patients-28/NNS	vmod||patients-28/NNS||treated-29/VBN	nn||therapy-36/NN||interferon-31/NN	amod||therapy-36/NN||alpha-32/NN	conj_and||alpha-32/NN||ribavirin-34/NN	amod||therapy-36/NN||ribavirin-34/NN	nn||therapy-36/NN||combination-35/NN	prep_with||treated-29/VBN||therapy-36/NN	chronichepatitisc-26||ribavirin-34||yes||the aim of this study was to determine the rate of sustained virological response (svr) and various factors associated with response rates in chronichepatitisc infected patients treated with interferon alpha and ribavirin combination therapy.
mark||understood-13/VBN||although-1/IN	det||details-3/NNS||the-2/DT	nsubjpass||understood-13/VBN||details-3/NNS	det||mechanism-6/NN||the-5/DT	prep_of||details-3/NNS||mechanism-6/NN	nn||propagation-9/NN||prion-8/NN	prep_of||mechanism-6/NN||propagation-9/NN	auxpass||understood-13/VBN||are-10/VBP	neg||understood-13/VBN||not-11/RB	advmod||understood-13/VBN||fully-12/RB	advcl||considered-33/VBN||understood-13/VBN	amod||conversion-16/NN||conformational-15/JJ	nsubjpass||considered-33/VBN||conversion-16/NN	amod||prionprotein-19/NN||cellular-18/JJ	prep_of||conversion-16/NN||prionprotein-19/NN	dep||prionprotein-19/NN||prpc-21/JJ	amod||prionprotein-28/NN||misfolded-24/JJ	amod||prionprotein-28/NN||disease-associated-26/JJ	nn||prionprotein-28/NN||scrapie-27/NN	prep_to||prionprotein-19/NN||prionprotein-28/NN	dep||conversion-16/NN||prpsc-30/JJ	auxpass||considered-33/VBN||is-32/VBZ	root||ROOT-0/null||considered-33/VBN	det||event-37/NN||the-34/DT	amod||event-37/NN||essential-35/JJ	amod||event-37/NN||biochemical-36/JJ	dobj||considered-33/VBN||event-37/NN	nn||replication-40/NN||prion-39/NN	prep_for||event-37/NN||replication-40/NN	scrapie-27||prion-39||no_rel||although the details of the mechanism of prion propagation are not fully understood, conformational conversion of cellular prionprotein (prpc) to misfolded, disease-associated scrapie prionprotein (prpsc) is considered the essential biochemical event for prion replication.
nsubj||case-4/NN||this-1/DT	cop||case-4/NN||is-2/VBZ	det||case-4/NN||the-3/DT	root||ROOT-0/null||case-4/NN	amod||mycobacteriumtuberculosis-7/NNS||automated-6/JJ	prep_for||case-4/NN||mycobacteriumtuberculosis-7/NNS	appos||case-4/NN||mtb-9/NN	amod||systems-13/NNS||liquid-11/JJ	nn||systems-13/NNS||culture-12/NN	dep||case-4/NN||systems-13/NNS	nsubjpass||developed-20/VBN||systems-13/NNS	nsubjpass||used-24/VBN||systems-13/NNS	nsubjpass||beginning-32/VBG||systems-13/NNS	nsubjpass||applied-35/VBN||systems-13/NNS	nn||detection-17/NN||tuberculosis-15/NNP	nn||detection-17/NN||case-16/NN	prep_for||systems-13/NNS||detection-17/NN	auxpass||developed-20/VBN||were-19/VBD	rcmod||systems-13/NNS||developed-20/VBN	auxpass||used-24/VBN||are-22/VBP	advmod||used-24/VBN||widely-23/RB	rcmod||systems-13/NNS||used-24/VBN	conj_and||developed-20/VBN||used-24/VBN	amod||settings-28/NNS||low-26/JJ	nn||settings-28/NNS||burden-27/NN	prep_in||used-24/VBN||settings-28/NNS	aux||beginning-32/VBG||are-30/VBP	advmod||beginning-32/VBG||only-31/RB	rcmod||systems-13/NNS||beginning-32/VBG	conj_but||developed-20/VBN||beginning-32/VBG	aux||applied-35/VBN||to-33/TO	auxpass||applied-35/VBN||be-34/VB	xcomp||beginning-32/VBG||applied-35/VBN	det||scale-39/NN||a-37/DT	amod||scale-39/NN||large-38/JJ	prep_on||applied-35/VBN||scale-39/NN	amod||settings-43/NNS||high-41/JJ	nn||settings-43/NNS||burden-42/NN	prep_in||scale-39/NN||settings-43/NNS	tuberculosis-15||mtb-9||no||this is the case for automated mycobacteriumtuberculosis (mtb) liquid culture systems for tuberculosis case detection which were developed and are widely used in low burden settings but are only beginning to be applied on a large scale in high burden settings.
num||patients-2/NNS||ten-1/CD	nsubj||maintained-20/VBD||patients-2/NNS	det||uc-group-5/NN||the-4/DT	prep_in||patients-2/NNS||uc-group-5/NN	num||%-8/NN||66-7/CD	appos||uc-group-5/NN||%-8/NN	num||patients-12/NNS||16-11/CD	prep_in||patients-2/NNS||patients-12/NNS	conj_and||uc-group-5/NN||patients-12/NNS	det||cd-group-15/NN||the-14/DT	prep_in||patients-12/NNS||cd-group-15/NN	num||%-18/NN||64-17/CD	appos||cd-group-15/NN||%-18/NN	root||ROOT-0/null||maintained-20/VBD	amod||remission-24/NNS||clinical-21/JJ	conj_and||clinical-21/JJ||endoscopic-23/JJ	amod||remission-24/NNS||endoscopic-23/JJ	dobj||maintained-20/VBD||remission-24/NNS	det||average-27/NN||an-26/DT	prep_for||maintained-20/VBD||average-27/NN	num||months-30/NNS||14-29/CD	prep_of||average-27/NN||months-30/NNS	cd--1||ten-1||no_rel||ten patients in the uc-group (66%) and 16 patients in the cd-group (64%) maintained clinical and endoscopic remission for an average of 14 months.
advmod||given-19/VBN||however-1/RB	det||lack-4/NN||the-3/DT	nsubj||given-19/VBN||lack-4/NN	det||improvement-7/NN||any-6/DT	prep_of||lack-4/NN||improvement-7/NN	prep_of||improvement-7/NN||omissions-9/NNS	amod||responses-12/NNS||premature-11/JJ	prep_of||lack-4/NN||responses-12/NNS	conj_and||improvement-7/NN||responses-12/NNS	amod||mice-18/NNS||nk1r-14/JJ	dep||mice-18/NNS||/-16/NNP	prep_in||responses-12/NNS||mice-18/NNS	root||ROOT-0/null||given-19/VBN	dobj||given-19/VBN||d-20/SYM	nsubj||suggests-23/VBZ||amphetamine-22/NN	dep||d-20/SYM||suggests-23/VBZ	mark||need-39/VBP||that-24/IN	amod||effects-26/NNS||beneficial-25/JJ	nsubj||need-39/VBP||effects-26/NNS	det||psychostimulant-29/NN||this-28/DT	prep_of||effects-26/NNS||psychostimulant-29/NN	amod||models-33/NNS||other-31/JJ	nn||models-33/NNS||rodent-32/NN	prep_in||psychostimulant-29/NN||models-33/NNS	amod||patients-37/NNS||adhd-36/JJ	prep_in||psychostimulant-29/NN||patients-37/NNS	conj_and||models-33/NNS||patients-37/NNS	ccomp||suggests-23/VBZ||need-39/VBP	amod||nk1r-41/NNS||functional-40/JJ	dobj||need-39/VBP||nk1r-41/NNS	adhd-36||amphetamine-22||yes||however, the lack of any improvement of omissions and premature responses in nk1r-/- mice given d -amphetamine suggests that beneficial effects of this psychostimulant in other rodent models, and adhd patients, need functional nk1r.
det||epidemic-6/NN||the-1/DT	amod||epidemic-6/NN||humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome-2/JJ	nn||epidemic-6/NN||hiv/aids-4/NN	nsubj||is-7/VBZ||epidemic-6/NN	nsubj||reached-14/VBN||epidemic-6/NN	root||ROOT-0/null||is-7/VBZ	poss||decade-11/NN||its-9/PRP$	amod||decade-11/NN||third-10/JJ	prep_in||is-7/VBZ||decade-11/NN	aux||reached-14/VBN||has-13/VBZ	conj_and||is-7/VBZ||reached-14/VBN	amod||proportions-17/NNS||alarming-16/JJ	prep_to||reached-14/VBN||proportions-17/NNS	advmod||reached-14/VBN||worldwide-18/RB	aids--1||humanimmunodeficiencyvirus--1||no||the humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome (hiv/aids) epidemic is in its third decade and has reached to alarming proportions worldwide.
det||ratio-4/NN||the-1/DT	nn||ratio-4/NN||food-2/NN	nn||ratio-4/NN||efficiency-3/NN	nsubj||greater-6/JJR||ratio-4/NN	cop||greater-6/JJR||was-5/VBD	root||ROOT-0/null||greater-6/JJR	amod||feeding-9/NN||hpmc-8/JJ	prep_with||greater-6/JJR||feeding-9/NN	prepc_compared_to||greater-6/JJR||to-11/TO	det||control-14/NN||the-12/DT	amod||control-14/NN||obese-13/JJ	pobj||greater-6/JJR||control-14/NN	amod||excretion-17/NN||urinary-16/JJ	nsubjpass||reduced-24/VBN||excretion-17/NN	nn||bodies-22/NNS||glucose-19/NN	conj_and||glucose-19/NN||ketone-21/NN	nn||bodies-22/NNS||ketone-21/NN	prep_of||excretion-17/NN||bodies-22/NNS	auxpass||reduced-24/VBN||was-23/VBD	conj_and||greater-6/JJR||reduced-24/VBN	obese-13||glucose-19||no_rel||the food efficiency ratio was greater with hpmc feeding compared to the obese control and urinary excretion of glucose and ketone bodies was reduced.
nsubjpass||proven-4/VBN||sitagliptin-1/NN	nsubj||effective-7/JJ||sitagliptin-1/NN	nsubj||safe-9/JJ||sitagliptin-1/NN	aux||proven-4/VBN||has-2/VBZ	auxpass||proven-4/VBN||been-3/VBN	root||ROOT-0/null||proven-4/VBN	aux||effective-7/JJ||to-5/TO	cop||effective-7/JJ||be-6/VB	xcomp||proven-4/VBN||effective-7/JJ	xcomp||proven-4/VBN||safe-9/JJ	conj_and||effective-7/JJ||safe-9/JJ	prepc_as||effective-7/JJ||add-on-11/VBG	prep_to||add-on-11/VBG||insulin-13/NN	amod||patients-16/NNS||adult-15/JJ	prep_in||insulin-13/NN||patients-16/NNS	prep_with||add-on-11/VBG||type2diabetes-18/NNS	amod||deficiency-22/NN||absolute-20/JJ	nn||deficiency-22/NN||insulin-21/NN	prep_with||add-on-11/VBG||deficiency-22/NN	conj_and||type2diabetes-18/NNS||deficiency-22/NN	type2diabetes-18||insulin-21||yes||sitagliptin has been proven to be effective and safe as add-on to insulin in adult patients with type2diabetes and absolute insulin deficiency.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||budesonide-17||yes||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
det||nature-6/NN||the-1/DT	amod||nature-6/NN||strong-2/JJ	amod||nature-6/NN||invasive-3/JJ	conj_and||invasive-3/JJ||metastatic-5/JJ	amod||nature-6/NN||metastatic-5/JJ	nsubj||implies-9/VBZ||nature-6/NN	prep_of||nature-6/NN||cutaneousmelanoma-8/NN	root||ROOT-0/null||implies-9/VBZ	det||interplay-12/NN||a-10/DT	amod||interplay-12/NN||deregulated-11/VBN	dobj||implies-9/VBZ||interplay-12/NN	nn||adhesion-15/NN||intercellular-14/NN	prep_between||interplay-12/NN||adhesion-15/NN	amod||molecules-18/NNS||migration-related-17/JJ	dobj||implies-9/VBZ||molecules-18/NNS	conj_and||interplay-12/NN||molecules-18/NNS	det||study-21/NN||this-20/DT	prep_in||molecules-18/NNS||study-21/NN	nsubj||performed-23/VBD||we-22/PRP	rcmod||study-21/NN||performed-23/VBD	det||analysis-26/NN||a-24/DT	amod||analysis-26/NN||microarray-25/JJ	dobj||performed-23/VBD||analysis-26/NN	aux||compare-28/VB||to-27/TO	vmod||performed-23/VBD||compare-28/VB	det||profile-32/NN||the-29/DT	nn||profile-32/NN||mrna-30/NN	nn||profile-32/NN||expression-31/NN	dobj||compare-28/VB||profile-32/NN	det||line-39/NN||an-34/DT	amod||line-39/NN||invasive-35/JJ	nn||line-39/NN||blm-36/NN	nn||line-39/NN||melanoma-37/NN	nn||line-39/NN||cell-38/NN	prep_of||profile-32/NN||line-39/NN	nn||lie-42/NN||blm-41/NN	appos||line-39/NN||lie-42/NN	det||variant-49/NN||the-45/DT	amod||p-cadherin-47/JJ||non-invasive-46/JJ	amod||variant-49/NN||p-cadherin-47/JJ	amod||variant-49/NN||over-expression-48/JJ	prep_of||profile-32/NN||variant-49/NN	conj_and||line-39/NN||variant-49/NN	nn||p-cad-52/NN||blm-51/NN	appos||variant-49/NN||p-cad-52/NN	melanoma-37||blm-51||yes||the strong invasive and metastatic nature of cutaneousmelanoma implies a deregulated interplay between intercellular adhesion and migration-related molecules in this study we performed a microarray analysis to compare the mrna expression profile of an invasive blm melanoma cell line (blm lie) and the non-invasive p-cadherin over-expression variant (blm p-cad).
num||patients-2/NNS||six-1/CD	nsubj||had-7/VBD||patients-2/NNS	amod||results-6/NNS||discordant-4/JJ	nn||results-6/NNS||test-5/NN	prep_with||patients-2/NNS||results-6/NNS	root||ROOT-0/null||had-7/VBD	preconj||tst-14/NN||either-8/DT	dep||tst-14/NN||1-10/LS	det||tst-14/NN||a-12/DT	amod||tst-14/NN||negative-13/JJ	dobj||had-7/VBD||tst-14/NN	amod||igra-17/NN||positive-16/JJ	dobj||had-7/VBD||igra-17/NN	conj_and||tst-14/NN||igra-17/NN	prep_in||tst-14/NN||combination-19/NN	det||history-23/NN||a-21/DT	amod||history-23/NN||medical-22/JJ	prep_with||combination-19/NN||history-23/NN	nn||exposure-26/NN||tuberculosis-25/NNP	prep_of||history-23/NN||exposure-26/NN	nn||â-29/NN||n-28/NN	dep||combination-19/NN||â-29/NN	nsubj||â-33/VBP||$-30/$	number||=-32/CD||‰-31/CD	num||$-30/$||=-32/CD	rcmod||â-29/NN||â-33/VBP	dobj||â-33/VBP||$-34/$	number||1-36/CD||‰-35/CD	num||$-34/$||1-36/CD	dep||tst-44/NN||2-40/LS	det||tst-44/NN||a-42/DT	amod||tst-44/NN||positive-43/JJ	prep_in||tst-14/NN||tst-44/NN	conj_or||combination-19/NN||tst-44/NN	amod||igra-47/NN||negative-46/JJ	conj_or||combination-19/NN||igra-47/NN	conj_and||tst-44/NN||igra-47/NN	prep_in||tst-44/NN||combination-49/NN	nn||vaccination-52/NN||bcg-51/NN	prep_with||combination-49/NN||vaccination-52/NN	nn||â-55/NN||n-54/NN	dep||combination-49/NN||â-55/NN	nsubj||â-59/VBP||$-56/$	number||=-58/CD||‰-57/CD	num||$-56/$||=-58/CD	rcmod||â-55/NN||â-59/VBP	dobj||â-59/VBP||$-60/$	number||3-62/CD||‰-61/CD	num||$-60/$||3-62/CD	det||history-67/NN||a-65/DT	amod||history-67/NN||medical-66/JJ	dobj||had-7/VBD||history-67/NN	conj_or||tst-14/NN||history-67/NN	nn||exposure-70/NN||tuberculosis-69/NNP	prep_of||history-67/NN||exposure-70/NN	nn||â-73/NN||n-72/NN	dep||history-67/NN||â-73/NN	nsubj||â-77/VBP||$-74/$	number||=-76/CD||‰-75/CD	num||$-74/$||=-76/CD	rcmod||â-73/NN||â-77/VBP	dobj||â-77/VBP||$-78/$	number||2-80/CD||‰-79/CD	num||$-78/$||2-80/CD	tuberculosis-69||bcg-51||yes||six patients with discordant test results had either (1) a negative tst and positive igra in combination with a medical history of tuberculosis exposure ( n â€‰=â€‰1) or (2) a positive tst and negative igra in combination with bcg vaccination ( n â€‰=â€‰3) or a medical history of tuberculosis exposure ( n â€‰=â€‰2).
det||relevance-3/NN||the-1/DT	amod||relevance-3/NN||clinical-2/JJ	nsubj||infection-24/NN||relevance-3/NN	amod||polymorphisms-7/NNS||single-5/JJ	nn||polymorphisms-7/NNS||nucleotide-6/NN	prep_of||relevance-3/NN||polymorphisms-7/NNS	appos||polymorphisms-7/NNS||snps-9/NNS	det||gene-14/NN||the-12/DT	amod||gene-14/NN||il28b-13/JJ	prep_near||polymorphisms-7/NNS||gene-14/NN	cop||infection-24/NN||is-15/VBZ	amod||infection-24/NN||controversial-16/JJ	prep_in||controversial-16/JJ||patients-18/NNS	prep_with||patients-18/NNS||hepatitisbvirus-20/NNS	appos||hepatitisbvirus-20/NNS||hbv-22/NN	root||ROOT-0/null||infection-24/NN	hbv-22||hepatitisbvirus-20||no||the clinical relevance of single nucleotide polymorphisms (snps) near the il28b gene is controversial in patients with hepatitisbvirus (hbv) infection.
nsubjpass||complicated-14/VBN||treatment-1/NN	nn||patients-4/NNS||cancer-3/NN	prep_of||treatment-1/NN||patients-4/NNS	amod||doxorubicin-8/NN||anthracycline-6/JJ	amod||doxorubicin-8/NN||antibiotic-7/JJ	prep_with||patients-4/NNS||doxorubicin-8/NN	appos||treatment-1/NN||dox-10/NN	aux||complicated-14/VBN||may-12/MD	auxpass||complicated-14/VBN||be-13/VB	root||ROOT-0/null||complicated-14/VBN	agent||complicated-14/VBN||development-16/NN	amod||congestiveheartfailure-21/NN||acute-18/JJ	conj_and||acute-18/JJ||chronic-20/JJ	amod||congestiveheartfailure-21/NN||chronic-20/JJ	prep_of||development-16/NN||congestiveheartfailure-21/NN	appos||congestiveheartfailure-21/NN||chf-23/NN	amod||arrhythmias-27/NNS||malignant-26/JJ	prep_of||development-16/NN||arrhythmias-27/NNS	conj_and||congestiveheartfailure-21/NN||arrhythmias-27/NNS	prep_of||development-16/NN||death-29/NN	conj_and||congestiveheartfailure-21/NN||death-29/NN	chf-23||doxorubicin-8||no||treatment of cancer patients with anthracycline antibiotic doxorubicin (dox) may be complicated by development of acute and chronic congestiveheartfailure (chf), malignant arrhythmias and death.
poss||terbutaline-5/NN||conclusions-1/NNS	amod||terbutaline-5/NN||$-3/JJ	nsubjpass||shown-8/VBN||terbutaline-5/NN	nsubj||effective-11/JJ||terbutaline-5/NN	nsubj||safe-13/JJ||terbutaline-5/NN	aux||shown-8/VBN||may-6/MD	auxpass||shown-8/VBN||be-7/VB	root||ROOT-0/null||shown-8/VBN	aux||effective-11/JJ||to-9/TO	cop||effective-11/JJ||be-10/VB	xcomp||shown-8/VBN||effective-11/JJ	xcomp||shown-8/VBN||safe-13/JJ	conj_and||effective-11/JJ||safe-13/JJ	det||prevention-16/NN||the-15/DT	prep_in||effective-11/JJ||prevention-16/NN	amod||hypoglycemia-19/NN||nocturnal-18/JJ	prep_of||prevention-16/NN||hypoglycemia-19/NN	prep_in||hypoglycemia-19/NN||type1diabetes-21/NNS	det||trial-28/NN||a-23/DT	advmod||powered-25/VBN||suitably-24/RB	amod||trial-28/NN||powered-25/VBN	amod||trial-28/NN||randomized-26/JJ	amod||trial-28/NN||controlled-27/VBN	prep_in||type1diabetes-21/NNS||trial-28/NN	terbutaline-5||hypoglycemia-19||no_rel||conclusions â€”terbutaline may be shown to be effective and safe in the prevention of nocturnal hypoglycemia in type1diabetes in a suitably powered randomized controlled trial.
mark||have-6/VBP||since-1/IN	det||majority-3/NN||a-2/DT	nsubj||have-6/VBP||majority-3/NN	prep_of||majority-3/NN||humans-5/NNS	advcl||crucial-28/JJ||have-6/VBP	neg||antibody-9/NN||no-7/DT	amod||antibody-9/NN||neutralizing-8/VBG	dobj||have-6/VBP||antibody-9/NN	det||virus-22/NN||the-11/DT	amod||virus-22/NN||pandemic-12/JJ	dep||pandemic-12/JJ||h1n1-14/CD	amod||virus-22/NN||2009-16/JJ	nn||virus-22/NN||influenza-17/NN	appos||virus-22/NN||pandemic-19/NN	num||pandemic-19/NN||2009-20/CD	prep_against||antibody-9/NN||virus-22/NN	amod||immunity-25/NN||innate-24/JJ	nsubj||crucial-28/JJ||immunity-25/NN	aux||crucial-28/JJ||may-26/MD	cop||crucial-28/JJ||be-27/VB	root||ROOT-0/null||crucial-28/JJ	nsubj||influence-34/VB||mbl-30/NN	advmod||influence-34/VB||susceptibility-31/RB	aux||influence-34/VB||may-32/MD	advmod||influence-34/VB||therefore-33/RB	conj_and||crucial-28/JJ||influence-34/VB	amod||pathogenesis-36/NNS||viral-35/JJ	dobj||influence-34/VB||pathogenesis-36/NNS	virus-22||antibody-9||no_rel||since a majority of humans have no neutralizing antibody against the pandemic (h1n1) 2009 influenza (pandemic 2009) virus, innate immunity may be crucial and mbl susceptibility may therefore influence viral pathogenesis.
amod||care-4/NN||benzodiazepines-1/JJ	conj_and||benzodiazepines-1/JJ||supportive-3/JJ	amod||care-4/NN||supportive-3/JJ	nsubjpass||used-11/VBN||care-4/NN	nsubj||treat-13/VB||care-4/NN	amod||nutritional-7/JJ||vitaminand-6/JJ	amod||support-8/NN||nutritional-7/JJ	prep_including||care-4/NN||support-8/NN	auxpass||used-11/VBN||are-9/VBP	advmod||used-11/VBN||mainly-10/RB	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	dobj||treat-13/VB||alcoholwithdrawal-14/NN	prep_in||treat-13/VB||korea-16/NN	benzodiazepines-1||alcoholwithdrawal-14||no_rel||benzodiazepines and supportive care including vitaminand nutritional support are mainly used to treat alcoholwithdrawal in korea.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	toxin-34||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||rifampicin-8||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	cjd-28||prions-29||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
det||research-3/NN||this-2/DT	prep_in||designed-5/VBD||research-3/NN	nsubj||designed-5/VBD||we-4/PRP	nsubj||implemented-7/VBD||we-4/PRP	root||ROOT-0/null||designed-5/VBD	conj_and||designed-5/VBD||implemented-7/VBD	det||oidr-9/NN||the-8/DT	dobj||implemented-7/VBD||oidr-9/NN	advmod||implemented-7/VBD||reflectometry-10/RB	xcomp||implemented-7/VBD||measuring-11/VBG	dobj||measuring-11/VBG||system-12/NN	det||source-21/NN||a-14/DT	amod||source-21/NN||650â-15/JJ	amod||source-21/NN||$-16/$	number||nm-18/CD||‰-17/CD	num||$-16/$||nm-18/CD	nn||source-21/NN||diode-19/NN	nn||source-21/NN||laser-20/NN	prep_with||measuring-11/VBG||source-21/NN	nn||physicians-24/NNS||aid-23/NN	prep_to||source-21/NN||physicians-24/NNS	prepc_in||measuring-11/VBG||diagnosing-26/VBG	det||squamouscellcarcinomas-28/NNS||both-27/DT	dobj||diagnosing-26/VBG||squamouscellcarcinomas-28/NNS	appos||squamouscellcarcinomas-28/NNS||scc-30/NN	dobj||diagnosing-26/VBG||basalcellcarcinomas-33/NNS	conj_and||squamouscellcarcinomas-28/NNS||basalcellcarcinomas-33/NNS	appos||basalcellcarcinomas-33/NNS||bcc-35/NN	nm-18||bcc-35||no_rel||in this research we designed and implemented the oidr reflectometry measuring system with a 650â€‰ nm diode laser source to aid physicians in diagnosing both squamouscellcarcinomas (scc) and basalcellcarcinomas(bcc).
vmod||examines-15/VBZ||using-1/VBG	dobj||using-1/VBG||data-2/NNS	det||updates-7/NNS||the-4/DT	amod||updates-7/NNS||monthly-5/JJ	nn||updates-7/NNS||hiv/aids-6/NNS	prep_in||using-1/VBG||updates-7/NNS	vmod||updates-7/NNS||issued-8/VBN	det||moh-11/NN||the-10/DT	agent||issued-8/VBN||moh-11/NN	det||paper-14/NN||this-13/DT	nsubj||examines-15/VBZ||paper-14/NN	root||ROOT-0/null||examines-15/VBZ	det||distribution-20/NN||the-16/DT	amod||distribution-20/NN||spatial-17/JJ	conj_and||spatial-17/JJ||temporal-19/JJ	amod||distribution-20/NN||temporal-19/JJ	dobj||examines-15/VBZ||distribution-20/NN	prep_of||distribution-20/NN||art-22/NN	det||basis-26/NN||a-24/DT	nn||basis-26/NN||population-25/NN	prep_on||art-22/NN||basis-26/NN	nn||towns-29/NNS||ethiopian-28/NN	prep_for||basis-26/NN||towns-29/NNS	amod||zones-32/NNS||administrative-31/JJ	prep_on||art-22/NN||zones-32/NNS	conj_and||basis-26/NN||zones-32/NNS	conj_and||basis-26/NN||regions-34/NNS	conj_and||zones-32/NNS||regions-34/NNS	det||period-37/NN||the-36/DT	prep_for||zones-32/NNS||period-37/NN	tmod||examines-15/VBZ||february-38/NNP	prep_to||examines-15/VBZ||december-40/NNP	num||december-40/NNP||2006-41/CD	aids--1||hiv--1||no||using data in the monthly hiv/aids updates issued by the moh, this paper examines the spatial and temporal distribution of art on a population basis for ethiopian towns and administrative zones and regions for the period february to december 2006.
det||prevention-2/NN||the-1/DT	nsubj||suggests-11/VBZ||prevention-2/NN	amod||neovascularization-6/NN||dysfunctional-4/JJ	amod||neovascularization-6/NN||cerebral-5/JJ	prep_of||prevention-2/NN||neovascularization-6/NN	amod||control-10/NN||early-8/JJ	nn||control-10/NN||glucose-9/NN	prep_by||neovascularization-6/NN||control-10/NN	root||ROOT-0/null||suggests-11/VBZ	mark||mediator-16/NN||that-12/IN	nsubj||mediator-16/NN||hyperglycemia-13/NN	cop||mediator-16/NN||is-14/VBZ	det||mediator-16/NN||a-15/DT	ccomp||suggests-11/VBZ||mediator-16/NN	det||response-19/NN||this-18/DT	prep_of||mediator-16/NN||response-19/NN	hyperglycemia-13||glucose-9||no||the prevention of dysfunctional cerebral neovascularization by early glucose control suggests that hyperglycemia is a mediator of this response.
nsubj||effect-11/NN||pain-1/NN	det||injection-4/NN||the-3/DT	prep_upon||pain-1/NN||injection-4/NN	prep_of||injection-4/NN||propofol-6/NN	cop||effect-11/NN||is-7/VBZ	det||effect-11/NN||a-8/DT	amod||effect-11/NN||common-9/JJ	amod||effect-11/NN||adverse-10/JJ	root||ROOT-0/null||effect-11/NN	pain-1||propofol-6||yes||pain upon the injection of propofol is a common adverse effect.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||conducted-4/VBN||evaluate-6/VB	det||safety-9/NN||the-7/DT	amod||safety-9/NN||long-term-8/JJ	dobj||evaluate-6/VB||safety-9/NN	amod||inhaler-18/NN||mometasonefuroate/formoterol-11/JJ	appos||inhaler-18/NN||mf/f-13/NN	amod||inhaler-18/NN||administered-15/VBN	prep_through||administered-15/VBN||metered-dose-17/NN	prep_of||safety-9/NN||inhaler-18/NN	appos||inhaler-18/NN||mdi-20/NN	prep_in||evaluate-6/VB||patients-23/NNS	amod||asthma-26/NN||persistent-25/JJ	prep_with||evaluate-6/VB||asthma-26/NN	advmod||asthma-26/NN||previously-27/RB	prep_on||asthma-26/NN||medium-29/NN	amod||ics-33/NN||high-dose-32/JJ	prep_to||asthma-26/NN||ics-33/NN	asthma-26||formoterol--1||yes||this study was conducted to evaluate the long-term safety of mometasonefuroate/formoterol (mf/f) administered through metered-dose inhaler (mdi) in patients with persistent asthma previously on medium- to high-dose ics.
det||majority-2/NN||the-1/DT	nsubjpass||infected-14/VBN||majority-2/NN	prep_of||majority-2/NN||decedents-4/NNS	nsubj||remained-6/VBD||decedents-4/NNS	rcmod||decedents-4/NNS||remained-6/VBD	xcomp||remained-6/VBD||culture-7/NN	amod||culture-7/NN||positive-8/JJ	prepc_despite||positive-8/JJ||receiving-10/VBG	nn||treatment-12/NN||tuberculosis-11/NNP	dobj||receiving-10/VBG||treatment-12/NN	auxpass||infected-14/VBN||were-13/VBD	root||ROOT-0/null||infected-14/VBN	amod||m.tuberculosis-17/NNS||pan-susceptible-16/JJ	prep_with||infected-14/VBN||m.tuberculosis-17/NNS	xcomp||infected-14/VBN||suggesting-19/VBG	mark||made-26/VBN||that-20/IN	det||diagnosis-22/NN||the-21/DT	nsubjpass||made-26/VBN||diagnosis-22/NN	nsubj||alter-30/VB||diagnosis-22/NN	prep_of||diagnosis-22/NN||tuberculosis-24/NNP	auxpass||made-26/VBN||was-25/VBD	ccomp||suggesting-19/VBG||made-26/VBN	advmod||late-28/RB||too-27/RB	advmod||made-26/VBN||late-28/RB	aux||alter-30/VB||to-29/TO	xcomp||made-26/VBN||alter-30/VB	det||course-33/NN||the-31/DT	amod||course-33/NN||fatal-32/JJ	dobj||alter-30/VB||course-33/NN	det||infection-36/NN||the-35/DT	prep_of||course-33/NN||infection-36/NN	tuberculosis-24||m.tuberculosis-17||no||the majority of decedents who remained culture positive despite receiving tuberculosis treatment were infected with pan-susceptible m.tuberculosis , suggesting that the diagnosis of tuberculosis was made too late to alter the fatal course of the infection .
prep_in||improves-10/VBZ||contrast-2/NN	nsubj||improves-10/VBZ||treatment-4/NN	det||int-747-9/NN||the-6/DT	nn||int-747-9/NN||fxr-7/NN	nn||int-747-9/NN||agonist-8/NN	prep_with||treatment-4/NN||int-747-9/NN	root||ROOT-0/null||improves-10/VBZ	amod||injury-12/NN||renal-11/JJ	dobj||improves-10/VBZ||injury-12/NN	prepc_by||improves-10/VBZ||decreasing-14/VBG	dobj||decreasing-14/VBG||proteinuria-15/NN	dobj||decreasing-14/VBG||glomerulosclerosis-17/NNS	conj_and||proteinuria-15/NN||glomerulosclerosis-17/NNS	amod||fibrosis-21/NN||tubulointerstitial-20/JJ	dobj||decreasing-14/VBG||fibrosis-21/NN	conj_and||proteinuria-15/NN||fibrosis-21/NN	prepc_by||improves-10/VBZ||modulating-24/VBG	conj_and||decreasing-14/VBG||modulating-24/VBG	amod||metabolism-27/NN||renal-25/JJ	nn||metabolism-27/NN||lipid-26/NN	dobj||modulating-24/VBG||metabolism-27/NN	amod||infiltration-30/NN||macrophage-29/JJ	dobj||modulating-24/VBG||infiltration-30/NN	conj_and||metabolism-27/NN||infiltration-30/NN	amod||expression-34/NN||renal-33/JJ	dobj||modulating-24/VBG||expression-34/NN	conj_and||metabolism-27/NN||expression-34/NN	prep_of||expression-34/NN||srebps-36/NNS	amod||factors-40/NNS||profibrotic-38/JJ	nn||factors-40/NNS||growth-39/NN	prep_of||expression-34/NN||factors-40/NNS	conj_and||srebps-36/NNS||factors-40/NNS	amod||enzymes-45/NNS||oxidative-43/JJ	nn||enzymes-45/NNS||stress-44/NN	prep_of||expression-34/NN||enzymes-45/NNS	conj_and||srebps-36/NNS||enzymes-45/NNS	det||strain-50/NN||the-47/DT	amod||strain-50/NN||diabetic-48/JJ	amod||strain-50/NN||dba/2j-49/JJ	prep_in||enzymes-45/NNS||strain-50/NN	fibrosis-21||enzymes-45||no_rel||in contrast, treatment with the fxr agonist int-747 improves renal injury by decreasing proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis, and modulating renal lipid metabolism, macrophage infiltration, and renal expression of srebps, profibrotic growth factors, and oxidative stress enzymes in the diabetic dba/2j strain.
nn||therapy-2/NN||sitagliptin-1/NN	nsubjpass||found-9/VBN||therapy-2/NN	nsubj||lower-11/VB||therapy-2/NN	prep_in||therapy-2/NN||individuals-4/NNS	prep_with||individuals-4/NNS||type2diabetes-6/CD	aux||found-9/VBN||has-7/VBZ	auxpass||found-9/VBN||been-8/VBN	root||ROOT-0/null||found-9/VBN	aux||lower-11/VB||to-10/TO	xcomp||found-9/VBN||lower-11/VB	advmod||hemoglobin-13/JJ||significantly-12/RB	amod||levels-18/NNS||hemoglobin-13/JJ	nn||levels-18/NNS||a1c-14/NN	appos||levels-18/NNS||hb1c-16/NNP	dobj||lower-11/VB||levels-18/NNS	det||minimum-21/NN||a-20/DT	prep_with||lower-11/VB||minimum-21/NN	amod||effects-25/NNS||adverse-23/JJ	nn||effects-25/NNS||side-24/NN	prep_of||minimum-21/NN||effects-25/NNS	nn||gain-29/NN||weight-28/NN	prep_such_as||effects-25/NNS||gain-29/NN	prep_such_as||effects-25/NNS||hypoglycemia-31/NN	conj_or||gain-29/NN||hypoglycemia-31/NN	type2diabetes-6||sitagliptin-1||yes||sitagliptin therapy in individuals with type2diabetes has been found to lower significantly hemoglobin a1c (hb1c) levels with a minimum of adverse side effects such as weight gain or hypoglycemia.
nsubjpass||associated-5/VBN||obesity-1/NN	auxpass||associated-5/VBN||was-2/VBD	advmod||associated-5/VBN||also-3/RB	advmod||associated-5/VBN||significantly-4/RB	root||ROOT-0/null||associated-5/VBN	prep_with||associated-5/VBN||bronchitis-7/NNS	dep||bronchitis-7/NNS||adjusted-9/VBN	nn||ratio-11/NN||odds-10/NNS	nn||1.79-44/NNS||ratio-11/NN	appos||ratio-11/NN||aor-13/NN	number||%-17/NN||95-16/CD	amod||intervals-19/NNS||%-17/NN	nn||intervals-19/NNS||confidence-18/NN	conj_and||ratio-11/NN||intervals-19/NNS	nn||1.79-44/NNS||intervals-19/NNS	num||%-22/NN||95-21/CD	npadvmod||ci-23/JJ||%-22/NN	dep||intervals-19/NNS||ci-23/JJ	dep||intervals-19/NNS||5.29-25/CD	dep||intervals-19/NNS||2.58-27/NNP	dep||2.58-27/NNP||10.85-29/CD	conj_and||ratio-11/NN||with-32/IN	nn||1.79-44/NNS||with-32/IN	det||use-34/NN||the-33/DT	pobj||with-32/IN||use-34/NN	prep_of||use-34/NN||antibiotics-36/NNS	dep||antibiotics-36/NNS||aor-38/NN	num||%-41/NN||95-40/CD	npadvmod||ci-42/JJ||%-41/NN	dep||antibiotics-36/NNS||ci-42/JJ	dobj||adjusted-9/VBN||1.79-44/NNS	dep||1.79-44/NNS||1.09-46/CD	dep||1.09-46/CD||2.93-48/CD	bronchitis-7||antibiotics-36||no_rel||obesity was also significantly associated with bronchitis (adjusted odds ratio (aor) and 95% confidence intervals (95%ci) 5.29 (2.58;10.85) and with the use of antibiotics (aor (95%ci) 1.79 (1.09;2.93)).
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||pyrimethamine--1||no||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
det||antibodies-2/NNS||these-1/DT	nsubj||able-4/JJ||antibodies-2/NNS	nsubj||neutralize-6/VB||antibodies-2/NNS	cop||able-4/JJ||were-3/VBD	root||ROOT-0/null||able-4/JJ	aux||neutralize-6/VB||to-5/TO	xcomp||able-4/JJ||neutralize-6/VB	det||virus-8/NN||the-7/DT	dobj||neutralize-6/VB||virus-8/NN	amod||protection-14/NN||vitro-10/NN	conj_and||vitro-10/NN||provided-12/VBN	amod||protection-14/NN||provided-12/VBN	amod||protection-14/NN||partial-13/JJ	prep_in||virus-8/NN||protection-14/NN	det||challenge-17/NN||a-16/DT	prep_from||neutralize-6/VB||challenge-17/NN	det||dose-21/NN||a-19/DT	amod||dose-21/NN||lethal-20/JJ	prep_with||neutralize-6/VB||dose-21/NN	prep_of||dose-21/NN||wnv-23/NN	virus-8||antibodies-2||no_rel||these antibodies were able to neutralize the virus in vitro and provided partial protection from a challenge with a lethal dose of wnv.
nsubj||has-2/VBZ||azathioprine-1/NN	root||ROOT-0/null||has-2/VBZ	acomp||has-2/VBZ||equivalent-3/JJ	advmod||equivalent-3/JJ||efficacy-4/RB	det||agent-8/NN||a-6/DT	nn||agent-8/NN||maintenance-7/NN	prep_as||equivalent-3/JJ||agent-8/NN	aux||cyclophosphamide-10/VB||to-9/TO	xcomp||equivalent-3/JJ||cyclophosphamide-10/VB	amod||episodes-13/NNS||fewer-12/JJR	prep_with||cyclophosphamide-10/VB||episodes-13/NNS	prep_of||episodes-13/NNS||leukopenia-15/NN	leukopenia-15||cyclophosphamide-10||no_rel||azathioprine has equivalent efficacy as a maintenance agent to cyclophosphamide with fewer episodes of leukopenia.
poss||goal-2/NN||our-1/PRP$	nsubj||was-3/VBD||goal-2/NN	nsubj||evaluate-5/VB||goal-2/NN	root||ROOT-0/null||was-3/VBD	aux||evaluate-5/VB||to-4/TO	xcomp||was-3/VBD||evaluate-5/VB	det||effect-7/NN||the-6/DT	dobj||evaluate-5/VB||effect-7/NN	det||calciumchannelblocker-12/NN||a-9/DT	advmod||used-11/JJ||commonly-10/RB	amod||calciumchannelblocker-12/NN||used-11/JJ	prep_of||effect-7/NN||calciumchannelblocker-12/NN	prep_of||effect-7/NN||amlodipine-14/NN	conj_and||calciumchannelblocker-12/NN||amlodipine-14/NN	det||excretion-24/NN||an-17/DT	amod||excretion-24/NN||angiotensinconvertingenzymeinhibitor-18/JJ	amod||excretion-24/NN||lisinopril-20/JJ	amod||albumin-23/NN||urinary-22/JJ	prep_on||lisinopril-20/JJ||albumin-23/NN	prep_of||effect-7/NN||excretion-24/NN	conj_and||calciumchannelblocker-12/NN||excretion-24/NN	prep_in||evaluate-5/VB||patients-26/NNS	amod||moderate-30/JJ||mild-28/JJ	dep||moderate-30/JJ||to-29/TO	amod||hypertension-32/NN||moderate-30/JJ	amod||hypertension-32/NN||essential-31/JJ	prep_with||patients-26/NNS||hypertension-32/NN	hypertension-32||amlodipine-14||yes||our goal was to evaluate the effect of a commonly used calciumchannelblocker, amlodipine, and an angiotensinconvertingenzymeinhibitor, lisinopril on urinary albumin excretion in patients with mild to moderate essential hypertension.
det||advances-3/NNS||the-2/DT	prep_despite||remains-19/VBZ||advances-3/NNS	det||treatment-6/NN||the-5/DT	prep_in||advances-3/NNS||treatment-6/NN	nn||infection-12/NN||chronichepatitisbvirus-8/NNP	appos||infection-12/NN||hbv-10/NN	prep_of||treatment-6/NN||infection-12/NN	nn||transplantation-15/NN||liver-14/NN	nsubj||remains-19/VBZ||transplantation-15/NN	appos||transplantation-15/NN||lt-17/NN	root||ROOT-0/null||remains-19/VBZ	det||hope-22/NN||the-20/DT	amod||hope-22/NN||only-21/JJ	xcomp||remains-19/VBZ||hope-22/NN	amod||patients-25/NNS||many-24/JJ	prep_for||hope-22/NN||patients-25/NNS	amod||liverdiseases-28/NNS||end-stage-27/JJ	prep_with||remains-19/VBZ||liverdiseases-28/NNS	vmod||liverdiseases-28/NNS||resulting-29/VBG	prep_from||resulting-29/VBG||hbv-31/NN	hbv-31||hepatitisbvirus--1||no||despite the advances in the treatment of chronichepatitisbvirus (hbv) infection, liver transplantation (lt) remains the only hope for many patients with end-stage liverdiseases resulting from hbv.
amod||once-weekly-2/NN||exenatide-1/JJ	nsubj||mimetic-6/NN||once-weekly-2/NN	cop||mimetic-6/NN||is-3/VBZ	det||mimetic-6/NN||an-4/DT	nn||mimetic-6/NN||incretin-5/NN	root||ROOT-0/null||mimetic-6/NN	nsubj||undergoing-10/VBG||mimetic-6/NN	nsubjpass||shown-19/VBN||mimetic-6/NN	nsubj||improve-21/VB||mimetic-6/NN	aux||undergoing-10/VBG||is-8/VBZ	advmod||undergoing-10/VBG||currently-9/RB	rcmod||mimetic-6/NN||undergoing-10/VBG	ccomp||undergoing-10/VBG||phase-11/VB	num||trials-14/NNS||3-12/CD	amod||trials-14/NNS||clinical-13/JJ	dobj||phase-11/VB||trials-14/NNS	aux||shown-19/VBN||has-17/VBZ	auxpass||shown-19/VBN||been-18/VBN	rcmod||mimetic-6/NN||shown-19/VBN	conj_and||undergoing-10/VBG||shown-19/VBN	aux||improve-21/VB||to-20/TO	xcomp||shown-19/VBN||improve-21/VB	amod||parameters-23/NNS||glycemic-22/JJ	nsubj||causes-40/VBZ||parameters-23/NNS	dep||parameters-23/NNS||hba1c-25/NNS	amod||levels-31/NNS||fasting-27/JJ	conj_and||fasting-27/JJ||postprandial-29/JJ	amod||levels-31/NNS||postprandial-29/JJ	nn||levels-31/NNS||glucose-30/NN	dep||parameters-23/NNS||levels-31/NNS	conj_and||hba1c-25/NNS||levels-31/NNS	amod||risk-36/NN||low-35/JJ	prep_with||parameters-23/NNS||risk-36/NN	prep_of||risk-36/NN||hypoglycemia-38/NN	ccomp||improve-21/VB||causes-40/VBZ	nn||loss-42/NN||weight-41/NN	dobj||causes-40/VBZ||loss-42/NN	nsubjpass||associated-47/VBN||use-45/NN	auxpass||associated-47/VBN||was-46/VBD	conj_and||mimetic-6/NN||associated-47/VBN	nsubj||undergoing-10/VBG||associated-47/VBN	prep_with||associated-47/VBN||improvements-49/NNS	nsubj||have-55/VB||improvements-49/NNS	amod||satisfaction-52/NN||patient-51/JJ	prep_in||improvements-49/NNS||satisfaction-52/NN	aux||have-55/VB||might-54/MD	rcmod||improvements-49/NNS||have-55/VB	det||impact-58/NN||a-56/DT	amod||impact-58/NN||positive-57/JJ	dobj||have-55/VB||impact-58/NN	nn||compliance-61/NN||treatment-60/NN	prep_on||impact-58/NN||compliance-61/NN	hypoglycemia-38||glucose-30||yes||exenatide once-weekly is an incretin mimetic that is currently undergoing phase 3 clinical trials, and has been shown to improve glycemic parameters (hba1c and fasting and postprandial glucose levels), with low risk of hypoglycemia, causes weight loss, and use was associated with improvements in patient satisfaction which might have a positive impact on treatment compliance.
det||form-4/NN||the-1/DT	amod||form-4/NN||primary-2/JJ	amod||form-4/NN||circulating-3/JJ	nsubj||-RSB--15/VBZ||form-4/NN	prep_of||form-4/NN||vitamind-6/NN	amod||-LSB--9/NN||25-hydroxy-vitamind-8/JJ	appos||vitamind-6/NN||-LSB--9/NN	num||-LSB--9/NN||25-10/CD	discourse||vitamind-6/NN||oh-12/UH	dep||vitamind-6/NN||d-14/SYM	root||ROOT-0/null||-RSB--15/VBZ	auxpass||associated-18/VBN||is-17/VBZ	dep||-RSB--15/VBZ||associated-18/VBN	amod||outcomes-22/NNS||multiple-20/JJ	amod||outcomes-22/NNS||medical-21/JJ	prep_with||associated-18/VBN||outcomes-22/NNS	prep_including||-RSB--15/VBZ||rickets-25/NNS	prep_including||-RSB--15/VBZ||osteoporosis-27/NNS	conj_and||rickets-25/NNS||osteoporosis-27/NNS	prep_including||-RSB--15/VBZ||multiplesclerosis-29/NNS	conj_and||rickets-25/NNS||multiplesclerosis-29/NNS	prep_including||-RSB--15/VBZ||cancer-31/NN	conj_and||rickets-25/NNS||cancer-31/NN	rickets-25||vitamind-6||yes||the primary circulating form of vitamind, 25-hydroxy-vitamind [25(oh)d], is associated with multiple medical outcomes, including rickets, osteoporosis, multiplesclerosis and cancer.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	osteoarthritis-29||chondroitinsulfate-44||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
det||variant-2/NN||a-1/DT	nsubjpass||reported-8/VBN||variant-2/NN	nsubjpass||associated-11/VBN||variant-2/NN	det||gene-6/NN||the-4/DT	amod||gene-6/NN||cdkal1-5/JJ	prep_of||variant-2/NN||gene-6/NN	auxpass||reported-8/VBN||was-7/VBD	root||ROOT-0/null||reported-8/VBN	aux||associated-11/VBN||to-9/TO	auxpass||associated-11/VBN||be-10/VB	xcomp||reported-8/VBN||associated-11/VBN	prep_with||associated-11/VBN||type2diabetes-13/NNS	amod||release-17/NN||reduced-15/VBN	nn||release-17/NN||insulin-16/NN	prep_with||associated-11/VBN||release-17/NN	conj_and||type2diabetes-13/NNS||release-17/NN	prep_in||release-17/NN||humans-19/NNS	advmod||unknown-33/JJ||however-21/RB	det||role-24/NN||the-23/DT	nsubj||unknown-33/JJ||role-24/NN	prep_of||role-24/NN||cdkal1-26/NNS	nn||cells-30/NNS||î-28/NN	nn||cells-30/NNS||²-29/NN	prep_in||cdkal1-26/NNS||cells-30/NNS	cop||unknown-33/JJ||is-31/VBZ	advmod||unknown-33/JJ||largely-32/RB	parataxis||reported-8/VBN||unknown-33/JJ	type2diabetes-13||insulin-16||yes||a variant of the cdkal1 gene was reported to be associated with type2diabetes and reduced insulin release in humans; however, the role of cdkal1 in î² cells is largely unknown.
det||emulsion-3/NN||the-1/DT	nn||emulsion-3/NN||lipid-2/NN	nsubj||safe-9/JJ||emulsion-3/NN	nsubj||tolerated-12/JJ||emulsion-3/NN	vmod||emulsion-3/NN||enriched-4/VBN	amod||fattyacids-7/NNS||omega-3-6/JJ	prep_with||enriched-4/VBN||fattyacids-7/NNS	cop||safe-9/JJ||was-8/VBD	root||ROOT-0/null||safe-9/JJ	advmod||tolerated-12/JJ||well-11/RB	conj_and||safe-9/JJ||tolerated-12/JJ	amod||administration-15/NN||short-term-14/JJ	prep_in||safe-9/JJ||administration-15/NN	prep_to||safe-9/JJ||patients-17/NNS	prep_with||patients-17/NNS||ards-19/NNS	lipid-2||ards-19||no_rel||the lipid emulsion enriched with omega-3 fattyacids was safe and well tolerated in short-term administration to patients with ards.
nsubj||protein-6/NN||adiponectin-1/NN	cop||protein-6/NN||is-2/VBZ	det||protein-6/NN||an-3/DT	advmod||related-5/VBN||obesity-4/RB	amod||protein-6/NN||related-5/VBN	root||ROOT-0/null||protein-6/NN	nsubj||mediates-8/VBZ||that-7/WDT	ccomp||protein-6/NN||mediates-8/VBZ	det||risk-10/NN||the-9/DT	dobj||mediates-8/VBZ||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/NNS	amod||individuals-15/NNS||obese-14/JJ	prep_in||type2diabetes-12/NNS||individuals-15/NNS	poss||anti-inflammatory-18/NN||its-17/PRP$	prep_with||mediates-8/VBZ||anti-inflammatory-18/NN	nn||properties-21/NNS||insulin-sensitizing-20/NN	prep_with||mediates-8/VBZ||properties-21/NNS	conj_and||anti-inflammatory-18/NN||properties-21/NNS	anti-inflammatory-18||obese-14||no_rel||adiponectin is an obesity related protein that mediates the risk of type2diabetes in obese individuals with its anti-inflammatory and insulin-sensitizing properties.
prep_in||introduced-10/VBD||2001-2/CD	det||service-6/NN||the-3/DT	amod||service-6/NN||national-4/JJ	nn||service-6/NN||health-5/NN	nsubj||introduced-10/VBD||service-6/NN	det||uk-9/NN||the-8/DT	prep_in||service-6/NN||uk-9/NN	root||ROOT-0/null||introduced-10/VBD	det||scheme-15/NN||a-11/DT	amod||scheme-15/NN||mandatory-12/JJ	nn||scheme-15/NN||bacteraemia-13/NN	nn||scheme-15/NN||surveillance-14/NN	dobj||introduced-10/VBD||scheme-15/NN	det||reporting-18/NN||the-17/DT	prep_for||introduced-10/VBD||reporting-18/NN	prep_of||reporting-18/NN||s.aureus-20/NNS	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_for||introduced-10/VBD||s.aureus-23/NNS	conj_and||reporting-18/NN||s.aureus-23/NNS	nn||-rrb--26/NNP||-lrb--24/NNP	nn||-rrb--26/NNP||mrsa-25/NNP	dep||s.aureus-23/NNS||-rrb--26/NNP	methicillin--1||bacteraemia-13||no_rel||in 2001 the national health service in the uk introduced a mandatory bacteraemia surveillance scheme for the reporting of s.aureus and methicillin-resistant s.aureus -lrb- mrsa -rrb- .
nsubjpass||increased-18/VBN||enrolment-1/NN	det||hiv/aids-4/NNS||the-3/DT	prep_in||enrolment-1/NN||hiv/aids-4/NNS	nn||programme-7/NN||art-6/NN	prep_in||enrolment-1/NN||programme-7/NN	conj_and||hiv/aids-4/NNS||programme-7/NN	nn||testing-10/NN||hiv-9/NN	prep_through||hiv/aids-4/NNS||testing-10/NN	amod||care-14/NN||general-12/JJ	amod||care-14/NN||primary-13/JJ	prep_in||testing-10/NN||care-14/NN	auxpass||increased-18/VBN||was-15/VBD	neg||increased-18/VBN||not-16/RB	advmod||increased-18/VBN||significantly-17/RB	root||ROOT-0/null||increased-18/VBN	num||%-21/NN||53-20/CD	dep||increased-18/VBN||%-21/NN	dep||%-21/NN||v-22/NN	number||%-24/NN||50-23/CD	amod||v-22/NN||%-24/NN	dep||v-22/NN||1.19-26/CD	num||2.77-30/CD||0.51-28/CD	dep||2.77-30/CD||to-29/TO	appos||1.19-26/CD||2.77-30/CD	aids--1||hiv-9||no||enrolment in the hiv/aids and art programme through hiv testing in general primary care was not significantly increased (53% v 50%; 1.19, 0.51 to 2.77).
det||study-5/NN||this-2/DT	amod||study-5/NN||hospital-based-3/JJ	amod||study-5/NN||cross-sectional-4/JJ	prep_in||subjected-30/VBN||study-5/NN	num||females-10/NNS||93-7/CD	amod||females-10/NNS||known-8/VBN	nn||females-10/NNS||hivpositive-9/NN	nsubjpass||subjected-30/VBN||females-10/NNS	nsubj||study-32/VB||females-10/NNS	vmod||females-10/NNS||attending-11/VBG	det||clinic-15/NN||a-12/DT	amod||clinic-15/NN||pre-art-13/JJ	nn||clinic-15/NN||registration-14/NN	nsubj||attending-21/VBG||clinic-15/NN	number||hiv-18/CD||1106-17/CD	num||females-20/NNS||hiv-18/CD	amod||females-20/NNS||negative-19/JJ	conj_and||clinic-15/NN||females-20/NNS	nsubj||attending-21/VBG||females-20/NNS	vmod||attending-11/VBG||attending-21/VBG	det||reproductive-23/JJ||a-22/DT	dobj||attending-21/VBG||reproductive-23/JJ	nn||clinic-28/NN||child-25/NN	nn||clinic-28/NN||health-26/NN	nn||clinic-28/NN||care-27/NN	dobj||attending-21/VBG||clinic-28/NN	conj_and||reproductive-23/JJ||clinic-28/NN	auxpass||subjected-30/VBN||were-29/VBD	root||ROOT-0/null||subjected-30/VBN	aux||study-32/VB||to-31/TO	xcomp||subjected-30/VBN||study-32/VB	hivpositive-9||hiv-18||no||in this hospital-based cross-sectional study, 93 known hivpositive females attending a pre-art registration clinic and 1106 hiv negative females attending a reproductive and child health care clinic were subjected to study.
predet||data-3/NNS||all-1/PDT	det||data-3/NNS||these-2/DT	nsubj||corroborate-4/VBP||data-3/NNS	nsubj||confirm-14/VBP||data-3/NNS	nsubj||suggest-26/VBP||data-3/NNS	root||ROOT-0/null||corroborate-4/VBP	det||impact-6/NN||the-5/DT	dobj||corroborate-4/VBP||impact-6/NN	prep_of||impact-6/NN||bvrr/bvrs-8/NNS	nn||modulation-12/NN||cell-10/NN	nn||modulation-12/NN||envelope-11/NN	prep_on||bvrr/bvrs-8/NNS||modulation-12/NN	conj_and||corroborate-4/VBP||confirm-14/VBP	mark||controls-18/VBZ||that-15/IN	det||system-17/NN||this-16/DT	nsubj||controls-18/VBZ||system-17/NN	ccomp||confirm-14/VBP||controls-18/VBZ	det||metabolism-23/NN||the-19/DT	nn||metabolism-23/NN||carbon-20/NN	conj_and||carbon-20/NN||nitrogen-22/NN	nn||metabolism-23/NN||nitrogen-22/NN	dobj||controls-18/VBZ||metabolism-23/NN	conj_and||corroborate-4/VBP||suggest-26/VBP	det||cross-talk-28/NN||a-27/DT	dobj||suggest-26/VBP||cross-talk-28/NN	det||regulators-31/NNS||some-30/DT	prep_among||cross-talk-28/NN||regulators-31/NNS	aux||adjust-33/VB||to-32/TO	vmod||suggest-26/VBP||adjust-33/VB	det||physiology-36/NN||the-34/DT	nn||physiology-36/NN||brucella-35/NN	dobj||adjust-33/VB||physiology-36/NN	det||shift-39/NN||the-38/DT	prep_to||adjust-33/VB||shift-39/NN	vmod||shift-39/NN||expected-40/VBN	aux||occur-42/VB||to-41/TO	xcomp||expected-40/VBN||occur-42/VB	det||transit-45/NN||the-44/DT	prep_during||occur-42/VB||transit-45/NN	det||extracellular-48/NN||the-47/DT	prep_from||transit-45/NN||extracellular-48/NN	det||niche-52/NN||the-50/DT	nn||niche-52/NN||intracellular-51/NN	prep_to||occur-42/VB||niche-52/NN	cross--1||carbon-20||no_rel||all these data corroborate the impact of bvrr/bvrs on cell envelope modulation, confirm that this system controls the carbon and nitrogen metabolism, and suggest a cross-talk among some regulators to adjust the brucella physiology to the shift expected to occur during the transit from the extracellular to the intracellular niche.
advmod||show-9/VBP||here-1/RB	vmod||show-9/VBP||using-3/VBG	amod||analysis-6/NN||novel-4/JJ	amod||analysis-6/NN||statistical-5/JJ	dobj||using-3/VBG||analysis-6/NN	nsubj||show-9/VBP||we-8/PRP	root||ROOT-0/null||show-9/VBP	mark||exist-15/VBP||that-10/IN	amod||abnormalities-14/NNS||subtle-11/JJ	conj_but||subtle-11/JJ||significant-13/JJ	amod||abnormalities-14/NNS||significant-13/JJ	nsubj||exist-15/VBP||abnormalities-14/NNS	ccomp||show-9/VBP||exist-15/VBP	det||composition-18/NN||the-17/DT	prep_in||exist-15/VBP||composition-18/NN	prep_of||composition-18/NN||fattyacids-20/NNS	appos||fattyacids-20/NNS||fas-22/NN	amod||acid-27/NN||docosapentaenoic-26/JJ	prep_including||exist-15/VBP||acid-27/NN	num||-3-31/NN||225-29/CD	nn||-3-31/NN||n-30/NN	appos||acid-27/NN||-3-31/NN	appos||acid-27/NN||one-34/CD	det||fas-39/NN||the-36/DT	amod||fas-39/NN||omega-3-37/JJ	amod||fas-39/NN||polyunsaturated-38/JJ	prep_of||one-34/CD||fas-39/NN	vmod||fas-39/NN||found-41/VBN	det||cortex-46/NN||the-43/DT	amod||cortex-46/NN||post-mortem-44/JJ	nn||cortex-46/NN||frontopolar-45/NN	prep_in||found-41/VBN||cortex-46/NN	appos||cortex-46/NN||fpc-48/NN	prep_of||cortex-46/NN||subjects-51/NNS	prep_with||found-41/VBN||bipolar-53/NNP	amod||depressivedisorders-56/NNS||major-55/JJ	prep_with||found-41/VBN||depressivedisorders-56/NNS	conj_or||bipolar-53/NNP||depressivedisorders-56/NNS	mark||in-60/IN||although-58/IN	dep||in-60/IN||not-59/RB	advcl||exist-15/VBP||in-60/IN	pobj||in-60/IN||those-61/DT	prep_with||those-61/DT||schizophrenia-63/NN	omega-3-37||depressivedisorders-56||no_rel||here, using novel statistical analysis, we show that subtle but significant abnormalities exist in the composition of fattyacids (fas), including docosapentaenoic acid (225 n -3), one of the omega-3 polyunsaturated fas, found in the post-mortem frontopolar cortex (fpc) of subjects with bipolar or major depressivedisorders, although not in those with schizophrenia.
det||method-2/NN||the-1/DT	nsubjpass||optimized-5/VBN||method-2/NN	auxpass||optimized-5/VBN||was-3/VBD	advmod||optimized-5/VBN||first-4/RB	root||ROOT-0/null||optimized-5/VBN	xcomp||optimized-5/VBN||utilizing-6/VBG	amod||strains-9/NNS||borrelia-7/JJ	nn||strains-9/NNS||laboratory-8/NN	dobj||utilizing-6/VBG||strains-9/NNS	advmod||followed-25/VBD||later-12/RB	prepc_by||later-12/RB||demonstrating-14/VBG	dobj||demonstrating-14/VBG||growth-15/NN	prep_of||growth-15/NN||borrelia-17/NN	prep_from||demonstrating-14/VBG||sera-19/NN	amod||seropositive-22/NN||fifty-21/JJ	prep_from||demonstrating-14/VBG||seropositive-22/NN	amod||patients-24/NNS||lymedisease-23/JJ	nsubj||followed-25/VBD||patients-24/NNS	conj_and||optimized-5/VBN||followed-25/VBD	det||cohort-28/NN||another-27/DT	prep_by||followed-25/VBD||cohort-28/NN	num||patients-32/NNS||72-30/CD	amod||patients-32/NNS||lymedisease-31/JJ	prep_of||cohort-28/NN||patients-32/NNS	pobj||of-35/IN||patients-32/NNS	dep||of-35/IN||all-34/DT	nsubj||satisfied-37/VBD||of-35/IN	rcmod||patients-32/NNS||satisfied-37/VBD	det||definition-43/NN||the-38/DT	amod||definition-43/NN||strict-39/JJ	nn||definition-43/NN||cdc-40/NN	nn||definition-43/NN||surveillance-41/NN	nn||definition-43/NN||case-42/NN	dobj||satisfied-37/VBD||definition-43/NN	prep_for||satisfied-37/VBD||lymedisease-45/NN	lymedisease-45||borrelia-17||no||the method was first optimized utilizing borrelia laboratory strains, and later by demonstrating growth of borrelia from sera from fifty seropositive lymedisease patients followed by another cohort of 72 lymedisease patients, all of whom satisfied the strict cdc surveillance case definition for lymedisease.
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||treatment-13/NN||that-4/IN	nsubj||treatment-13/NN||ivermectin-5/NNP	conj_plus||ivermectin-5/NNP||albendazole-7/NNP	nsubj||treatment-13/NN||albendazole-7/NNP	cop||treatment-13/NN||is-8/VBZ	det||treatment-13/NN||a-9/DT	amod||treatment-13/NN||safe-10/JJ	conj_and||safe-10/JJ||tolerable-12/JJ	amod||treatment-13/NN||tolerable-12/JJ	ccomp||suggest-3/VBP||treatment-13/NN	prep_for||treatment-13/NN||co-infection-15/NN	nn||filariasis-18/NNS||bancroftian-17/NN	prep_of||co-infection-15/NN||filariasis-18/NNS	prep_of||co-infection-15/NN||onchocerciasis-20/NNS	conj_and||filariasis-18/NNS||onchocerciasis-20/NNS	onchocerciasis-20||ivermectin-5||yes||our findings suggest that ivermectin plus albendazole is a safe and tolerable treatment for co-infection of bancroftian filariasis and onchocerciasis.
amod||conditions-3/NNS||basal-2/JJ	prep_under||induced-20/VBN||conditions-3/NNS	nn||diet-6/NN||control-5/NN	appos||conditions-3/NNS||diet-6/NN	amod||treatment-13/NN||chronic-9/JJ	nn||treatment-13/NN||cb-10/NN	nn||treatment-13/NN||receptor-11/NN	nn||treatment-13/NN||agonist-12/NN	nsubj||induced-20/VBN||treatment-13/NN	appos||treatment-13/NN||i.e.-15/NNP	num||weeks-18/NNS||6-17/CD	dep||i.e.-15/NNP||weeks-18/NNS	root||ROOT-0/null||induced-20/VBN	dobj||induced-20/VBN||glucoseintolerance-21/NN	vmod||glucoseintolerance-21/NN||stimulated-23/VBN	amod||endotoxaemia-25/NN||metabolic-24/JJ	dobj||stimulated-23/VBN||endotoxaemia-25/NN	amod||infiltration-30/NN||increased-28/VBN	amod||infiltration-30/NN||macrophage-29/JJ	dobj||induced-20/VBN||infiltration-30/NN	conj_and||glucoseintolerance-21/NN||infiltration-30/NN	dep||infiltration-30/NN||cd11c-32/NNS	amod||expression-35/NN||f4/80-34/JJ	dep||infiltration-30/NN||expression-35/NN	conj_and||cd11c-32/NNS||expression-35/NN	det||muscles-39/NNS||the-38/DT	prep_in||infiltration-30/NN||muscles-39/NNS	det||phenomenon-42/NN||this-41/DT	nsubjpass||associated-44/VBN||phenomenon-42/NN	auxpass||associated-44/VBN||was-43/VBD	parataxis||induced-20/VBN||associated-44/VBN	det||metabolism-49/NN||an-46/DT	amod||metabolism-49/NN||altered-47/VBN	nn||metabolism-49/NN||lipid-48/NN	prep_with||associated-44/VBN||metabolism-49/NN	dep||metabolism-49/NN||increased-51/VBN	amod||expression-54/NN||pgc-1î-52/JJ	amod||expression-54/NN||±-53/JJ	dobj||increased-51/VBN||expression-54/NN	amod||expression-58/NN||decreased-56/VBN	amod||expression-58/NN||cpt-1b-57/JJ	dobj||increased-51/VBN||expression-58/NN	conj_and||expression-54/NN||expression-58/NN	det||tissue-62/NN||this-61/DT	prep_in||metabolism-49/NN||tissue-62/NN	cpt--1||glucoseintolerance-21||no_rel||under basal conditions (control diet), chronic cb receptor agonist treatment (i.e., 6 weeks) induced glucoseintolerance, stimulated metabolic endotoxaemia, and increased macrophage infiltration ( cd11c and f4/80 expression) in the muscles; this phenomenon was associated with an altered lipid metabolism (increased pgc-1î± expression and decreased cpt-1b expression) in this tissue.
amod||oxidase-2/NN||xanthine-1/JJ	nsubjpass||implicated-14/VBN||oxidase-2/NN	poss||products-5/NNS||its-4/PRP$	conj_and||oxidase-2/NN||products-5/NNS	nsubjpass||implicated-14/VBN||products-5/NNS	amod||acid-8/NN||uric-7/JJ	appos||oxidase-2/NN||acid-8/NN	appos||oxidase-2/NN||ros-10/NN	conj_and||acid-8/NN||ros-10/NN	aux||implicated-14/VBN||have-12/VBP	auxpass||implicated-14/VBN||been-13/VBN	root||ROOT-0/null||implicated-14/VBN	det||pathogenesis-17/NNS||the-16/DT	prep_in||implicated-14/VBN||pathogenesis-17/NNS	prep_of||pathogenesis-17/NNS||cardiovasculardisease-19/NN	prep_such_as||pathogenesis-17/NNS||hypertension-23/NN	xanthine-1||hypertension-23||no_rel||xanthine oxidase and its products, uric acid and ros, have been implicated in the pathogenesis of cardiovasculardisease, such as hypertension.
amod||finding-2/NN||histological-1/JJ	nsubj||observed-3/VBD||finding-2/NN	root||ROOT-0/null||observed-3/VBD	amod||inflammation-6/NN||mild-4/JJ	amod||inflammation-6/NN||chronic-5/JJ	dobj||observed-3/VBD||inflammation-6/NN	vmod||inflammation-6/NN||surrounding-7/VBG	det||deposition-9/NN||the-8/DT	dobj||surrounding-7/VBG||deposition-9/NN	det||particles-13/NNS||the-11/DT	nn||particles-13/NNS||metal-12/NN	prep_of||deposition-9/NN||particles-13/NNS	det||macrophages-20/NNS||the-15/DT	amod||macrophages-20/NNS||anti-16/JJ	amod||macrophages-20/NNS||cotrel-dubousset-17/JJ	num||macrophages-20/NNS||68-18/CD	amod||macrophages-20/NNS||positive-19/JJ	nsubjpass||observed-22/VBN||macrophages-20/NNS	auxpass||observed-22/VBN||were-21/VBD	conj_and||observed-3/VBD||observed-22/VBN	prep_at||observed-22/VBN||tissue-24/NN	amod||tissue-24/NN||adjacent-25/JJ	det||particles-29/NNS||the-27/DT	nn||particles-29/NNS||metal-28/NN	prep_to||adjacent-25/JJ||particles-29/NNS	num||patients-32/NNS||5-31/CD	prep_in||particles-29/NNS||patients-32/NNS	inflammation-6||metal-28||no_rel||histological finding observed mild chronic inflammation surrounding the deposition of the metal particles and the anti cotrel-dubousset 68 positive macrophages were observed at tissue adjacent to the metal particles in 5 patients.
det||data-2/NNS||the-1/DT	nsubj||indicate-3/VBP||data-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||occur-9/VBP||that-4/IN	nsubj||occur-9/VBP||changes-5/NNS	nn||metabolism-8/NN||lipid-7/NN	prep_in||changes-5/NNS||metabolism-8/NN	ccomp||indicate-3/VBP||occur-9/VBP	det||cortex-16/NN||the-11/DT	amod||cortex-16/NN||parkinson-12/JJ	nn||cortex-16/NN||sdisease-14/NN	amod||cortex-16/NN||visual-15/JJ	prep_in||occur-9/VBP||cortex-16/NN	det||absence-19/NN||the-18/DT	prep_in||cortex-16/NN||absence-19/NN	amod||pathology-22/NN||obvious-21/JJ	prep_of||absence-19/NN||pathology-22/NN	lipid-7||parkinson'sdisease--1||no_rel||the data indicate that changes in lipid metabolism occur in the parkinson'sdisease visual cortex in the absence of obvious pathology.
amod||variants-2/NNS||ask1-1/JJ	nsubj||increase-4/VB||variants-2/NNS	aux||increase-4/VB||may-3/MD	root||ROOT-0/null||increase-4/VB	advmod||increase-4/VB||susceptibility-5/RB	prep_to||increase-4/VB||type2diabetes-7/CD	amod||sensitivity-11/NN||decreasing-9/VBG	nn||sensitivity-11/NN||insulin-10/NN	prep_by||increase-4/VB||sensitivity-11/NN	amod||expression-15/NN||reduced-13/JJ	amod||expression-15/NN||ask1-14/JJ	prep_via||sensitivity-11/NN||expression-15/NN	type2diabetes-7||insulin-10||yes||ask1 variants may increase susceptibility to type2diabetes by decreasing insulin sensitivity via reduced ask1 expression.
amod||analysis-4/NN||stratified-1/JJ	nn||analysis-4/NN||cox-2/NN	nn||analysis-4/NN||regression-3/NN	nsubjpass||used-10/VBN||analysis-4/NN	nsubj||obtain-12/VB||analysis-4/NN	det||pairs-8/NNS||the-6/DT	amod||pairs-8/NNS||matched-7/VBN	prep_on||analysis-4/NN||pairs-8/NNS	auxpass||used-10/VBN||was-9/VBD	root||ROOT-0/null||used-10/VBN	aux||obtain-12/VB||to-11/TO	xcomp||used-10/VBN||obtain-12/VB	nn||ratios-14/NNS||hazard-13/NN	dobj||obtain-12/VB||ratios-14/NNS	appos||ratios-14/NNS||hrs-16/NN	nn||therapy-20/NN||insulin-19/NN	prep_of||ratios-14/NNS||therapy-20/NN	prep_of||ratios-14/NNS||a1c-22/NN	conj_and||therapy-20/NN||a1c-22/NN	nn||risk-25/NN||cancer-24/NN	prep_for||obtain-12/VB||risk-25/NN	insulin-19||cancer-24||no_rel||stratified cox regression analysis on the matched pairs was used to obtain hazard ratios (hrs) of insulin therapy and a1c for cancer risk.
det||test-4/NN||the-2/DT	amod||test-4/NN||second-3/JJ	prep_in||reported-11/VBD||test-4/NN	nsubj||examined-9/VBD||participants-6/NNS	nsubj||reported-11/VBD||participants-6/NNS	nsubj||tolerated-17/VBD||participants-6/NNS	advmod||examined-9/VBD||previously-8/RB	rcmod||participants-6/NNS||examined-9/VBD	dobj||examined-9/VBD||ibuprofen-10/NN	root||ROOT-0/null||reported-11/VBD	xcomp||reported-11/VBD||experiencing-12/VBG	advmod||intense-14/JJ||less-13/RBR	amod||pain-15/NN||intense-14/JJ	dobj||experiencing-12/VBG||pain-15/NN	conj_and||reported-11/VBD||tolerated-17/VBD	dobj||tolerated-17/VBD||immersion-18/NN	advmod||tolerated-17/VBD||longer-19/RBR	dep||longer-19/RBR||relative-21/JJ	prep_to||relative-21/JJ||baseline-23/NN	prep_than||tolerated-17/VBD||those-26/DT	nsubj||examined-28/VBD||those-26/DT	rcmod||those-26/DT||examined-28/VBD	det||control-30/NN||the-29/DT	nsubj||object-31/VBP||control-30/NN	ccomp||examined-28/VBD||object-31/VBP	pain-15||ibuprofen-10||yes||in the second test, participants who previously examined ibuprofen reported experiencing less intense pain and tolerated immersion longer (relative to baseline) than those who examined the control object.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-14/VBZ||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	appos||infants-5/NNS||ipti-7/NNP	prep_with||infants-5/NNS||sulphadoxine-pyrimethamine-10/NN	appos||treatment-3/NN||sp-12/NN	root||ROOT-0/null||reduces-14/VBZ	det||incidence-16/NN||the-15/DT	dobj||reduces-14/VBZ||incidence-16/NN	nn||episodes-19/NNS||malaria-18/NN	prep_of||incidence-16/NN||episodes-19/NNS	amod||children-22/NNS||young-21/JJ	prep_in||episodes-19/NNS||children-22/NNS	malaria-18||pyrimethamine--1||no||intermittent preventive treatment in infants (ipti) with sulphadoxine-pyrimethamine (sp) reduces the incidence of malaria episodes in young children.
nsubj||repair-3/VB||it-1/PRP	nsubj||protect-5/VB||it-1/PRP	aux||repair-3/VB||might-2/MD	ccomp||used-29/VBN||repair-3/VB	conj_and||repair-3/VB||protect-5/VB	ccomp||used-29/VBN||protect-5/VB	amod||cartilage-8/NN||early-6/JJ	nn||cartilage-8/NN||osteoarthritis-7/NNS	dobj||repair-3/VB||cartilage-8/NN	prepc_by||repair-3/VB||delaying-10/VBG	nn||degeneration-12/NN||cartilage-11/NN	dobj||delaying-10/VBG||degeneration-12/NN	prepc_by||repair-3/VB||impairing-14/VBG	conj_and||delaying-10/VBG||impairing-14/VBG	det||function-16/NN||the-15/DT	dobj||impairing-14/VBG||function-16/NN	amod||mediators-19/NNS||inflammatory-18/JJ	prep_of||function-16/NN||mediators-19/NNS	advmod||repair-3/VB||therefore-21/RB	amod||injection-24/NN||intra-articular-23/JJ	nsubjpass||used-29/VBN||injection-24/NN	prep_of||injection-24/NN||celecoxib-26/NN	aux||used-29/VBN||can-27/MD	auxpass||used-29/VBN||be-28/VB	root||ROOT-0/null||used-29/VBN	det||alternative-32/NN||an-31/DT	prep_as||used-29/VBN||alternative-32/NN	det||treatment-36/NN||the-34/DT	amod||treatment-36/NN||current-35/JJ	prep_to||used-29/VBN||treatment-36/NN	prep_of||treatment-36/NN||osteoarthritis-38/NNS	osteoarthritis-38||celecoxib-26||yes||it might repair and protect early osteoarthritis cartilage by delaying cartilage degeneration and impairing the function of inflammatory mediators, therefore, intra-articular injection of celecoxib can be used as an alternative to the current treatment of osteoarthritis.
nn||index-2/NN||augmentation-1/NN	nsubjpass||measured-32/VBN||index-2/NN	discourse||index-2/NN||aix-4/UH	amod||velocity-10/NN||aortic-7/JJ	nn||velocity-10/NN||pulse-8/NN	nn||velocity-10/NN||wave-9/NN	appos||index-2/NN||velocity-10/NN	discourse||velocity-10/NN||pwv-12/UH	amod||function-17/NN||renal-15/JJ	amod||function-17/NN||hemodynamic-16/JJ	appos||index-2/NN||function-17/NN	dep||function-17/NN||inulin-19/NN	amod||clearances-22/NNS||paraaminohippurate-21/JJ	dep||function-17/NN||clearances-22/NNS	conj_and||inulin-19/NN||clearances-22/NNS	amod||cgmp-30/NN||urinary-26/JJ	conj_and||urinary-26/JJ||circulating-28/JJ	amod||cgmp-30/NN||circulating-28/JJ	nn||cgmp-30/NN||plasma-29/NN	conj_and||index-2/NN||cgmp-30/NN	nsubjpass||measured-32/VBN||cgmp-30/NN	auxpass||measured-32/VBN||were-31/VBD	root||ROOT-0/null||measured-32/VBN	amod||subjects-35/NNS||normoalbuminuric-34/JJ	prep_in||measured-32/VBN||subjects-35/NNS	prep_with||measured-32/VBN||type1diabetes-37/CD	amod||euglycemia-40/NN||clamped-39/JJ	prep_during||measured-32/VBN||euglycemia-40/NN	nn||4â-43/NNS||glucose-42/NN	dep||mmol/l-47/JJ||4â-43/NNS	npadvmod||mmol/l-47/JJ||$-44/$	num||$-44/$||6-46/CD	dep||euglycemia-40/NN||mmol/l-47/JJ	prep_during||measured-32/VBN||hyperglycemia-50/NN	conj_and||euglycemia-40/NN||hyperglycemia-50/NN	nn||9â-53/NNS||glucose-52/NN	dep||mmol/l-57/JJ||9â-53/NNS	npadvmod||mmol/l-57/JJ||$-54/$	num||$-54/$||11-56/CD	dep||euglycemia-40/NN||mmol/l-57/JJ	hyperglycemia-50||glucose-52||no||augmentation index (aix), aortic pulse wave velocity (pwv), renal hemodynamic function (inulin and paraaminohippurate clearances), and urinary and circulating plasma cgmp were measured in normoalbuminuric subjects with type1diabetes during clamped euglycemia (glucose 4â€“6 mmol/l) and hyperglycemia (glucose 9â€“11 mmol/l).
det||study-2/NN||this-1/DT	nsubjpass||performed-4/VBN||study-2/NN	nsubj||determine-6/VB||study-2/NN	auxpass||performed-4/VBN||was-3/VBD	root||ROOT-0/null||performed-4/VBN	aux||determine-6/VB||to-5/TO	xcomp||performed-4/VBN||determine-6/VB	mark||affects-10/VBZ||whether-7/IN	amod||ahr-9/NN||methacholine-8/JJ	nsubj||affects-10/VBZ||ahr-9/NN	ccomp||determine-6/VB||affects-10/VBZ	det||response-12/NN||the-11/DT	dobj||affects-10/VBZ||response-12/NN	prep_of||response-12/NN||asthmatics-14/NNS	amod||aspirin-17/NN||inhaled-16/JJ	prep_to||affects-10/VBZ||aspirin-17/NN	asthmatics-14||aspirin-17||no||this study was performed to determine whether methacholine ahr affects the response of asthmatics to inhaled aspirin.
prep_in||attend-20/VBP||addition-2/NN	prep_in||attend-20/VBP||australia-5/NN	advmod||%-8/NN||only-6/RB	num||%-8/NN||20-30-7/CD	nsubj||attend-20/VBP||%-8/NN	prep_of||%-8/NN||people-10/NNS	vmod||people-10/NNS||requiring-11/VBG	amod||rehabilitation-13/NN||cardiac-12/JJ	dobj||requiring-11/VBG||rehabilitation-13/NN	appos||rehabilitation-13/NN||cr-15/NN	prep_for||rehabilitation-13/NN||cvd-18/NN	advmod||requiring-11/VBG||actually-19/RB	root||ROOT-0/null||attend-20/VBP	cr-15||cvd-18||no_rel||in addition, in australia only 20-30% of people requiring cardiac rehabilitation (cr) for cvd actually attend.
nsubj||used-3/VBN||we-1/PRP	aux||used-3/VBN||have-2/VBP	root||ROOT-0/null||used-3/VBN	det||kit-8/NN||the-4/DT	amod||kit-8/NN||api-5/JJ	amod||kit-8/NN||staph-6/JJ	nn||kit-8/NN||identification-7/NN	dobj||used-3/VBN||kit-8/NN	nsubj||depends-17/VBZ||kit-8/NN	nsubj||isolates-32/VBZ||kit-8/NN	amod||rieux-12/NN||biomã-10/JJ	amod||rieux-12/NN||©-11/JJ	dep||kit-8/NN||rieux-12/NN	appos||rieux-12/NN||france-14/NN	rcmod||kit-8/NN||depends-17/VBZ	det||expression-20/NN||the-19/DT	prep_on||depends-17/VBZ||expression-20/NN	amod||activities-23/NNS||metabolic-22/JJ	prep_of||expression-20/NN||activities-23/NNS	cc||features-27/VBZ||or-25/CC	nsubj||features-27/VBZ||morphological-26/NN	nsubj||identify-29/VB||morphological-26/NN	parataxis||depends-17/VBZ||features-27/VBZ	parataxis||isolates-32/VBZ||features-27/VBZ	aux||identify-29/VB||to-28/TO	xcomp||features-27/VBZ||identify-29/VB	det||staphylococcus-31/NN||the-30/DT	dobj||identify-29/VB||staphylococcus-31/NN	rcmod||kit-8/NN||isolates-32/VBZ	conj_and||depends-17/VBZ||isolates-32/VBZ	staph-6||staphylococcus-31||no||we have used the api staph identification kit (biomã©rieux, france) which depends on the expression of metabolic activities and or morphological features to identify the staphylococcus isolates.
nsubj||has-2/VBZ||insulin-1/NN	root||ROOT-0/null||has-2/VBZ	amod||effects-4/NNS||mitogenic-3/JJ	dobj||has-2/VBZ||effects-4/NNS	mark||factor-12/NN||although-6/IN	nsubj||factor-12/NN||hyperglycemia-7/NN	aux||factor-12/NN||may-8/MD	cop||factor-12/NN||be-9/VB	det||factor-12/NN||a-10/DT	nn||factor-12/NN||risk-11/NN	advcl||has-2/VBZ||factor-12/NN	prep_for||factor-12/NN||cancer-14/NN	prep_in||cancer-14/NN||type2diabetes-16/CD	type2diabetes-16||insulin-1||yes||insulin has mitogenic effects, although hyperglycemia may be a risk factor for cancer in type2diabetes.
nn||accumulation-2/NN||iron-1/NN	nsubj||result-7/NN||accumulation-2/NN	prep_in||accumulation-2/NN||aceruloplasminemia-4/NN	cop||result-7/NN||is-5/VBZ	det||result-7/NN||a-6/DT	root||ROOT-0/null||result-7/NN	amod||export-12/NN||defective-9/JJ	amod||export-12/NN||cellular-10/JJ	nn||export-12/NN||iron-11/NN	prep_of||result-7/NN||export-12/NN	advmod||appropriate-18/JJ||where-14/WRB	nn||regulation-16/NN||hepcidin-15/NN	nsubj||appropriate-18/JJ||regulation-16/NN	cop||appropriate-18/JJ||is-17/VBZ	rcmod||export-12/NN||appropriate-18/JJ	det||degree-21/NN||the-20/DT	prep_for||appropriate-18/JJ||degree-21/NN	prep_of||degree-21/NN||ironoverload-23/NN	ironoverload-23||iron-11||no||iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of ironoverload.
det||group-4/NN||the-1/DT	amod||group-4/NN||elevated-2/JJ	nn||group-4/NN||crp-3/NN	nsubj||had-5/VBD||group-4/NN	root||ROOT-0/null||had-5/VBD	nn||cell-10/NN||iron-6/NN	conj_and||iron-6/NN||red-8/JJ	nn||cell-10/NN||red-8/JJ	nn||cell-10/NN||blood-9/NN	dobj||had-5/VBD||cell-10/NN	appos||cell-10/NN||rbc-12/NN	advmod||characteristic-15/JJ||profiles-14/RB	amod||cell-10/NN||characteristic-15/JJ	amod||stimulation-19/NN||chronic-17/JJ	amod||stimulation-19/NN||immune-18/JJ	prep_of||had-5/VBD||stimulation-19/NN	appos||stimulation-19/NN||cis-21/NN	det||group-28/NN||the-25/DT	amod||group-28/NN||normal-26/JJ	nn||group-28/NN||crp-27/NN	prep_of||had-5/VBD||group-28/NN	conj_and||stimulation-19/NN||group-28/NN	appos||group-28/NN||profiles-30/NNS	amod||irondeficiency-33/NN||true-32/JJ	prep_of||profiles-30/NNS||irondeficiency-33/NN	irondeficiency-33||iron-6||yes||the elevated crp group had iron and red blood cell (rbc) profiles characteristic of chronic immune stimulation (cis), and the normal crp group, profiles of true irondeficiency.
det||study-2/NN||this-1/DT	nsubjpass||designed-4/VBN||study-2/NN	auxpass||designed-4/VBN||was-3/VBD	root||ROOT-0/null||designed-4/VBN	aux||evaluate-6/VB||to-5/TO	ccomp||designed-4/VBN||evaluate-6/VB	det||role-8/NN||the-7/DT	dobj||evaluate-6/VB||role-8/NN	amod||methadone-lidocaine-11/NN||epidural-10/JJ	prep_of||role-8/NN||methadone-lidocaine-11/NN	nn||pain-14/NN||cancer-13/NN	prep_in||evaluate-6/VB||pain-14/NN	vmod||pain-14/NN||combined-15/VBN	neg||epidural-19/VB||not-17/RB	aux||epidural-19/VB||to-18/TO	ccomp||designed-4/VBN||epidural-19/VB	conj_or||evaluate-6/VB||epidural-19/VB	dobj||epidural-19/VB||dexamethasone-20/NN	pain-14||lidocaine--1||yes||this study was designed to evaluate the role of epidural methadone-lidocaine in cancer pain combined or not to epidural dexamethasone.
nn||adenoma-5/NNS||somatostatin-1/NN	nn||adenoma-5/NNS||receptor-2/NN	amod||adenoma-5/NNS||positive-3/JJ	nn||adenoma-5/NNS||parathyroid-4/NN	nsubj||show-7/VB||adenoma-5/NNS	aux||show-7/VB||may-6/MD	root||ROOT-0/null||show-7/VB	amod||uptake-9/NN||octreotide-8/JJ	dobj||show-7/VB||uptake-9/NN	adenoma-5||octreotide-8||yes||somatostatin receptor positive parathyroid adenoma may show octreotide uptake.
nn||scores-2/NNS||pain-1/NN	nsubjpass||assessed-6/VBN||scores-2/NNS	auxpass||assessed-6/VBN||were-3/VBD	advmod||commonly-5/RB||most-4/RBS	advmod||assessed-6/VBN||commonly-5/RB	root||ROOT-0/null||assessed-6/VBN	prep_in||assessed-6/VBN||studies-8/NNS	prep_including||studies-8/NNS||pregabalin-10/NN	nsubj||reported-19/VBD||trials-12/NNS	prep_of||trials-12/NNS||pregabalin-14/NN	det||plaster-18/NN||the-16/DT	amod||plaster-18/NN||lidocaine-17/JJ	prep_of||trials-12/NNS||plaster-18/NN	conj_and||pregabalin-14/NN||plaster-18/NN	parataxis||assessed-6/VBN||reported-19/VBD	det||proportion-21/NN||the-20/DT	dobj||reported-19/VBD||proportion-21/NN	prep_of||proportion-21/NN||responders-23/NNS	pain-1||lidocaine-17||yes||pain scores were most commonly assessed in studies including pregabalin; trials of pregabalin and the lidocaine plaster reported the proportion of responders.
nsubjpass||associated-3/VBN||insulinresistance-1/NN	auxpass||associated-3/VBN||is-2/VBZ	root||ROOT-0/null||associated-3/VBN	amod||dysfunction-6/NN||endothelial-5/JJ	prep_with||associated-3/VBN||dysfunction-6/NN	advmod||remains-27/VBZ||however-8/RB	det||relationship-12/NN||the-10/DT	amod||relationship-12/NN||mechanistic-11/JJ	nsubj||remains-27/VBZ||relationship-12/NN	det||abnormalities-15/NNS||these-14/DT	prep_between||relationship-12/NN||abnormalities-15/NNS	det||role-18/NN||the-17/DT	prep_between||relationship-12/NN||role-18/NN	conj_and||abnormalities-15/NNS||role-18/NN	amod||insulin-22/NN||impaired-20/VBN	amod||insulin-22/NN||endothelial-21/JJ	prep_of||role-18/NN||insulin-22/NN	vmod||insulin-22/NN||signaling-23/VBG	prep||signaling-23/VBG||versus-24/CC	amod||insulinresistance-26/NN||global-25/JJ	pobj||versus-24/CC||insulinresistance-26/NN	parataxis||associated-3/VBN||remains-27/VBZ	acomp||remains-27/VBZ||unclear-28/JJ	insulin-22||insulinresistance-26||no_rel||insulinresistance is associated with endothelial dysfunction; however, the mechanistic relationship between these abnormalities and the role of impaired endothelial insulin signaling versus global insulinresistance remains unclear.
det||centre-3/NN||the-1/DT	amod||centre-3/NN||national-2/JJ	nsubj||consolidating-15/VBG||centre-3/NN	amod||control-6/NN||aids/std-5/JJ	prep_for||centre-3/NN||control-6/NN	prep_for||centre-3/NN||prevention-8/NN	conj_and||control-6/NN||prevention-8/NN	appos||centre-3/NN||ncaids-10/NNS	prep_in||centre-3/NN||china-13/NN	aux||consolidating-15/VBG||is-14/VBZ	root||ROOT-0/null||consolidating-15/VBG	det||projects-18/NNS||all-16/DT	amod||projects-18/NNS||international-17/JJ	dobj||consolidating-15/VBG||projects-18/NNS	amod||activities-27/NNS||national-20/JJ	nn||activities-27/NNS||hiv-21/NN	nn||activities-27/NNS||prevention-22/NN	conj_and||prevention-22/NN||treatment-24/NN	nn||activities-27/NNS||treatment-24/NN	conj_and||prevention-22/NN||care-26/NN	nn||activities-27/NNS||care-26/NN	prep_into||consolidating-15/VBG||activities-27/NNS	aids--1||hiv-21||no||the national centre for aids/std control and prevention (ncaids) in china is consolidating all international projects into national hiv prevention, treatment and care activities.
amod||analyses-2/NNS||secondary-1/JJ	nsubj||compare-4/VB||analyses-2/NNS	aux||compare-4/VB||will-3/MD	ccomp||hiv-15/VBP||compare-4/VB	det||rates-6/NNS||the-5/DT	dobj||compare-4/VB||rates-6/NNS	prep_of||rates-6/NNS||change-8/NN	amod||count-11/NN||cd4-10/JJ	prep_in||compare-4/VB||count-11/NN	amod||log10-14/NNS||median-13/JJ	nsubj||hiv-15/VBP||log10-14/NNS	root||ROOT-0/null||hiv-15/VBP	amod||load-17/NN||viral-16/JJ	dobj||hiv-15/VBP||load-17/NN	amod||events-21/NNS||drug-related-19/JJ	amod||events-21/NNS||adverse-20/JJ	appos||load-17/NN||events-21/NNS	dobj||hiv-15/VBP||frequency-23/NN	conj_and||load-17/NN||frequency-23/NN	nn||reactivations-26/NNS||hsv-25/NN	prep_of||frequency-23/NN||reactivations-26/NNS	dobj||hiv-15/VBP||rate-28/NN	conj_and||load-17/NN||rate-28/NN	amod||hsv-31/NN||acyclovir-resistant-30/JJ	prep_of||rate-28/NN||hsv-31/NN	dobj||hiv-15/VBP||quality-34/NN	conj_and||load-17/NN||quality-34/NN	prep_of||quality-34/NN||life-36/NN	nn||arms-39/NNS||study-38/NN	prep_between||life-36/NN||arms-39/NNS	hsv-31||acyclovir--1||yes||secondary analyses will compare the rates of change in cd4 count, median log10 hiv viral load, drug-related adverse events, frequency of hsv reactivations, rate of acyclovir-resistant hsv, and quality of life between study arms.
nn||hemorrhagicfeverwithrenalsyndrome-3/NN||hantaanvirusinfection-1/NN	amod||hemorrhagicfeverwithrenalsyndrome-3/NN||causing-2/VBG	nsubj||common-8/JJ||hemorrhagicfeverwithrenalsyndrome-3/NN	appos||hemorrhagicfeverwithrenalsyndrome-3/NN||hfrs-5/NNS	cop||common-8/JJ||is-7/VBZ	root||ROOT-0/null||common-8/JJ	amod||korea-11/NN||south-10/JJ	prep_in||common-8/JJ||korea-11/NN	poss||pathogenesis-14/NNS||its-13/PRP$	nsubjpass||suggested-16/VBN||pathogenesis-14/NNS	nsubj||mechanism-21/NN||pathogenesis-14/NNS	auxpass||suggested-16/VBN||is-15/VBZ	conj_and||common-8/JJ||suggested-16/VBN	aux||mechanism-21/NN||to-17/TO	cop||mechanism-21/NN||be-18/VB	det||mechanism-21/NN||an-19/DT	amod||mechanism-21/NN||immunologic-20/JJ	xcomp||suggested-16/VBN||mechanism-21/NN	hemorrhagicfeverwithrenalsyndrome-3||hantaanvirus--1||no||hantaanvirusinfection causing hemorrhagicfeverwithrenalsyndrome (hfrs) is common in south korea and its pathogenesis is suggested to be an immunologic mechanism.
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||inh-27||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||effect-5/NN||the-4/DT	dobj||examined-3/VBD||effect-5/NN	amod||consumption-8/NN||chronic-7/JJ	prep_of||effect-5/NN||consumption-8/NN	det||viscous-11/NNS||the-10/DT	prep_of||consumption-8/NN||viscous-11/NNS	amod||fiber-15/NN||non-fermentable-13/JJ	nn||fiber-15/NN||dietary-14/NN	appos||consumption-8/NN||fiber-15/NN	appos||consumption-8/NN||hydroxypropylmethylcellulose-17/NN	dep||hydroxypropylmethylcellulose-17/NN||hpmc-19/JJ	nn||lipids-29/NNS||glucose-23/NN	nn||lipids-29/NNS||control-24/NN	conj_and||control-24/NN||insulinresistance-26/NN	nn||lipids-29/NNS||insulinresistance-26/NN	conj_and||control-24/NN||liver-28/NN	nn||lipids-29/NNS||liver-28/NN	prep_on||examined-3/VBD||lipids-29/NNS	det||model-35/NN||an-31/DT	amod||model-35/NN||obese-32/JJ	amod||model-35/NN||diabetic-33/JJ	nn||model-35/NN||rat-34/NN	prep_in||lipids-29/NNS||model-35/NN	obese-32||lipids-29||no_rel||this study examined the effect of chronic consumption of the viscous, non-fermentable dietary fiber, hydroxypropylmethylcellulose (hpmc), on glucose control, insulinresistance and liver lipids in an obese diabetic rat model.
mark||trigger-9/NN||since-1/IN	nsubj||trigger-9/NN||inflammation-2/NN	amod||fat-5/NN||visceral-4/JJ	prep_of||inflammation-2/NN||fat-5/NN	cop||trigger-9/NN||is-6/VBZ	det||trigger-9/NN||a-7/DT	amod||trigger-9/NN||crucial-8/JJ	advcl||explain-23/VB||trigger-9/NN	prep_of||trigger-9/NN||atherogenesis-11/NNS	amod||fat-15/NN||decreased-13/VBN	amod||fat-15/NN||visceral-14/JJ	appos||atherogenesis-11/NNS||fat-15/NN	amod||±-18/NNS||pgc-1î-17/JJ	prep_in||fat-15/NN||±-18/NNS	nn||mice-21/NNS||deficient-20/NN	nsubj||explain-23/VB||mice-21/NNS	aux||explain-23/VB||may-22/MD	root||ROOT-0/null||explain-23/VB	advmod||develop-29/VB||why-24/WRB	det||mice-26/NNS||these-25/DT	nsubj||develop-29/VB||mice-26/NNS	aux||develop-29/VB||do-27/VBP	neg||develop-29/VB||not-28/RB	advcl||explain-23/VB||develop-29/VB	amod||atherosclerosis-31/NNS||enhanced-30/JJ	dobj||develop-29/VB||atherosclerosis-31/NNS	atherosclerosis-31||fat-15||no_rel||since inflammation of visceral fat is a crucial trigger of atherogenesis, decreased visceral fat in pgc-1î± -deficient mice may explain why these mice do not develop enhanced atherosclerosis.
amod||ac-2/NN||accelerated-1/VBN	nsubj||regimens-11/NNS||ac-2/NN	conj_and||ac-2/NN||ec-4/NN	nsubj||regimens-11/NNS||ec-4/NN	prep_with||ac-2/NN||pegfilgrastim-6/NN	cop||regimens-11/NNS||are-7/VBP	amod||regimens-11/NNS||safe-8/JJ	conj_and||safe-8/JJ||feasible-10/JJ	amod||regimens-11/NNS||feasible-10/JJ	root||ROOT-0/null||regimens-11/NNS	det||treatment-14/NN||the-13/DT	prep_in||regimens-11/NNS||treatment-14/NN	amod||cancer-18/NN||early-16/JJ	nn||cancer-18/NN||breast-17/NN	prep_of||treatment-14/NN||cancer-18/NN	advmod||neutropenia-21/JJ||less-20/RBR	amod||schedules-26/NNS||neutropenia-21/JJ	amod||3-24/CD||conventional-23/JJ	prep_than||neutropenia-21/JJ||3-24/CD	amod||schedules-26/NNS||weekly-25/JJ	prep_with||cancer-18/NN||schedules-26/NNS	neutropenia-21||pegfilgrastim-6||yes||accelerated ac and ec with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules.
advmod||attenuated-12/VBN||however-1/RB	det||mutant-5/NN||a-3/DT	amod||mutant-5/NN||y.pestis-4/JJ	nsubjpass||attenuated-12/VBN||mutant-5/NN	det||y1858-1862-10/NN||the-7/DT	nn||y1858-1862-10/NN||chaperone/usher-8/NN	nn||y1858-1862-10/NN||locus-9/NNS	prep_in||mutant-5/NN||y1858-1862-10/NN	auxpass||attenuated-12/VBN||was-11/VBD	root||ROOT-0/null||attenuated-12/VBN	prep_for||attenuated-12/VBN||virulence-14/NN	prep_in||attenuated-12/VBN||mice-16/NNS	det||route-20/NN||the-18/DT	amod||route-20/NN||intravenous-19/JJ	prep_via||mice-16/NNS||route-20/NN	prep_of||route-20/NN||infection-22/NN	xcomp||attenuated-12/VBN||suggesting-24/VBG	mark||sufficient-36/JJ||that-25/IN	nsubj||sufficient-36/JJ||expression-26/NN	nsubj||affect-38/VB||expression-26/NN	det||locus-29/NNS||this-28/DT	prep_of||expression-26/NN||locus-29/NNS	cop||sufficient-36/JJ||is-30/VBZ	det||stage-34/NN||some-33/DT	prep_at||sufficient-36/JJ||stage-34/NN	ccomp||suggesting-24/VBG||sufficient-36/JJ	aux||affect-38/VB||to-37/TO	xcomp||sufficient-36/JJ||affect-38/VB	det||outcome-40/NN||the-39/DT	dobj||affect-38/VB||outcome-40/NN	det||infection-44/NN||a-42/DT	amod||infection-44/NN||plague-43/JJ	prep_of||outcome-40/NN||infection-44/NN	plague-43||y.pestis-4||no||however , a y.pestis mutant in the chaperone/usher locus y1858-1862 was attenuated for virulence in mice via the intravenous route of infection , suggesting that expression of this locus is , at some stage , sufficient to affect the outcome of a plague infection .
mark||reached-11/VBN||after-1/IN	det||concentration-6/NN||the-2/DT	nn||concentration-6/NN||target-3/NN	nn||concentration-6/NN||effect-4/NN	nn||concentration-6/NN||site-5/NN	nsubjpass||reached-11/VBN||concentration-6/NN	prep_of||concentration-6/NN||remifentanil-8/NN	aux||reached-11/VBN||had-9/VBD	auxpass||reached-11/VBN||been-10/VBN	advcl||controlled-15/VBD||reached-11/VBN	det||target-14/NN||the-13/DT	nsubj||controlled-15/VBD||target-14/NN	root||ROOT-0/null||controlled-15/VBD	nsubjpass||started-20/VBN||infusion-16/NN	prep_of||infusion-16/NN||propofol-18/NN	auxpass||started-20/VBN||was-19/VBD	dep||controlled-15/VBD||started-20/VBN	amod||pain-23/NN||propofol-induced-22/JJ	nsubjpass||recorded-25/VBN||pain-23/NN	auxpass||recorded-25/VBN||was-24/VBD	dep||controlled-15/VBD||recorded-25/VBN	conj_and||started-20/VBN||recorded-25/VBN	pain-23||propofol-18||yes||after the target effect site concentration of remifentanil had been reached, the target controlled infusion of propofol was started and propofol-induced pain was recorded.
nsubjpass||divided-3/VBN||patients-1/NNS	auxpass||divided-3/VBN||were-2/VBD	root||ROOT-0/null||divided-3/VBN	num||groups-6/NNS||two-5/CD	prep_into||divided-3/VBN||groups-6/NNS	amod||content-10/NN||hepatic-8/JJ	nn||content-10/NN||triglyceride-9/NN	prep_with||groups-6/NNS||content-10/NN	prep||divided-3/VBN||below-11/IN	dep||below-11/IN||type2diabetes-low-13/JJ	conj_or||divided-3/VBN||above-16/IN	dep||above-16/IN||type2diabetes-high-18/JJ	det||median-21/NN||the-20/DT	pobj||above-16/IN||median-21/NN	num||%-24/NN||8.6-23/CD	prep_of||median-21/NN||%-24/NN	type2diabetes--1||triglyceride-9||no_rel||patients were divided into two groups with hepatic triglyceride content below (type2diabetes-low) or above (type2diabetes-high) the median of 8.6%.
nsubj||condition-9/NN||congenitalshortbowelsyndrome-1/NN	appos||congenitalshortbowelsyndrome-1/NN||sbs-3/NN	cop||condition-9/NN||is-5/VBZ	det||condition-9/NN||a-6/DT	advmod||rare-8/JJ||relatively-7/RB	amod||condition-9/NN||rare-8/JJ	root||ROOT-0/null||condition-9/NN	advmod||condition-9/NN||as-10/RB	prepc_compared_to||condition-9/NN||to-12/TO	amod||sbs-14/NN||acquired-13/VBN	pobj||condition-9/NN||sbs-14/NN	congenitalshortbowelsyndrome-1||sbs-14||no_rel||congenitalshortbowelsyndrome (sbs) is a relatively rare condition as compared to acquired sbs.
advmod||optimised-23/VBN||therefore-1/RB	det||step-6/NN||a-4/DT	amod||step-6/NN||first-5/JJ	prep_as||optimised-23/VBN||step-6/NN	det||application-9/NN||the-8/DT	prep_in||step-6/NN||application-9/NN	det||technology-12/NN||this-11/DT	prep_of||application-9/NN||technology-12/NN	det||study-15/NN||the-14/DT	prep_to||technology-12/NN||study-15/NN	prep_of||study-15/NN||mycobacterialinfection-17/NN	prep_in||mycobacterialinfection-17/NN||vivo-19/NN	nsubj||optimised-23/VBN||we-21/PRP	aux||optimised-23/VBN||have-22/VBP	root||ROOT-0/null||optimised-23/VBN	det||use-25/NN||the-24/DT	dobj||optimised-23/VBN||use-25/NN	nn||gaussia-29/NN||firefly-27/NN	nn||luciferases-32/NNS||gaussia-29/NN	conj_and||gaussia-29/NN||bacterial-31/JJ	nn||luciferases-32/NNS||bacterial-31/JJ	prep_of||use-25/NN||luciferases-32/NNS	prep_in||luciferases-32/NNS||mycobacteria-34/NN	vmod||mycobacteria-34/NN||using-35/VBG	det||combination-37/NN||a-36/DT	dobj||using-35/VBG||combination-37/NN	prep_of||combination-37/NN||vectors-39/NNS	prep_of||combination-37/NN||promoters-41/NNS	conj_and||vectors-39/NNS||promoters-41/NNS	amod||genes-45/NNS||codon-optimised-44/JJ	prep_of||combination-37/NN||genes-45/NNS	conj_and||vectors-39/NNS||genes-45/NNS	mycobacterialinfection-17||mycobacteria-34||no||therefore, as a first step in the application of this technology to the study of mycobacterialinfection in vivo , we have optimised the use of firefly, gaussia and bacterial luciferases in mycobacteria using a combination of vectors, promoters, and codon-optimised genes.
det||gas-19/NN||the-1/DT	nn||gas-19/NN||impacts-2/NNS	amod||treatments-5/NNS||post-metallisation-4/JJ	prep_of||impacts-2/NNS||treatments-5/NNS	amod||acid-9/NN||phosphoric-8/JJ	prep_such_as||treatments-5/NNS||acid-9/NN	appos||impacts-2/NNS||h3po4-11/NNP	amod||gas-19/NN||etching-13/JJ	dep||gas-19/NN||nitrogen-15/NN	appos||gas-19/NN||n2-17/NNP	nsubj||anneal-20/VBP||gas-19/NN	root||ROOT-0/null||anneal-20/VBP	dep||investigated-39/VBN||forming-22/VBG	dobj||forming-22/VBG||gas-23/NN	appos||gas-23/NN||ar-25/NN	num||ar-25/NN||h2-26/CD	amod||gas-23/NN||anneal-28/JJ	det||$-32/$||the-30/DT	amod||$-32/$||cellsâ-31/JJ	prep_on||anneal-28/JJ||$-32/$	num||$-32/$||™-33/CD	amod||properties-37/NNS||electrical-34/JJ	conj_and||electrical-34/JJ||photovoltaic-36/JJ	amod||properties-37/NNS||photovoltaic-36/JJ	nsubjpass||investigated-39/VBN||properties-37/NNS	auxpass||investigated-39/VBN||are-38/VBP	conj_and||anneal-20/VBP||investigated-39/VBN	nitrogen-15||ar-25||no_rel||the impacts of post-metallisation treatments such as phosphoric acid (h3po4) etching, nitrogen (n2) gas anneal and forming gas (ar h2) anneal on the cellsâ€™ electrical and photovoltaic properties are investigated.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	dobj||tested-2/VBD||this-3/DT	det||evaluation-8/NN||an-5/DT	amod||evaluation-8/NN||open-6/JJ	nn||evaluation-8/NN||label-7/NN	prep_in||this-3/DT||evaluation-8/NN	prepc_by||tested-2/VBD||assessing-10/VBG	det||changes-12/NNS||the-11/DT	dobj||assessing-10/VBG||changes-12/NNS	det||severity-15/NN||the-14/DT	prep_in||assessing-10/VBG||severity-15/NN	prep_of||severity-15/NN||osa-17/NN	prep_in||assessing-10/VBG||patients-19/NNS	amod||hypertension-22/NN||resistant-21/JJ	prep_with||patients-19/NNS||hypertension-22/NN	prep_following||hypertension-22/NN||treatment-24/NN	prep_with||treatment-24/NN||spironolactone-26/NN	hypertension-22||spironolactone-26||yes||we tested this in an open label evaluation by assessing the changes in the severity of osa in patients with resistant hypertension following treatment with spironolactone.
det||combination-2/NN||the-1/DT	nsubj||reduced-12/VBD||combination-2/NN	amod||propofol-5/NN||cold-4/JJ	prep_of||combination-2/NN||propofol-5/NN	prep_of||combination-2/NN||pretreatment-7/NN	conj_and||propofol-5/NN||pretreatment-7/NN	prep_with||propofol-5/NN||remifentanil-9/NN	advmod||effectively-11/RB||more-10/RBR	advmod||reduced-12/VBD||effectively-11/RB	root||ROOT-0/null||reduced-12/VBD	det||incidence-14/NN||the-13/DT	dobj||reduced-12/VBD||incidence-14/NN	prep_of||incidence-14/NN||pain-16/NN	det||injection-19/NN||the-18/DT	prep_upon||reduced-12/VBD||injection-19/NN	prep_of||injection-19/NN||propofol-21/NN	det||treatment-24/NN||either-23/DT	prep_than||reduced-12/VBD||treatment-24/NN	advmod||reduced-12/VBD||alone-25/RB	pain-16||propofol-21||yes||the combination of cold propofol and pretreatment with remifentanil more effectively reduced the incidence of pain upon the injection of propofol than either treatment alone.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	insulin-2||hyperglycemia-24||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
amod||patients-3/NNS||t2dm-2/JJ	prep_in||compare-14/VBP||patients-3/NNS	csubj||compare-14/VBP||lowering-5/VBG	amod||hyperglycemia-10/NN||hba1c-7/JJ	conj_and||hba1c-7/JJ||postprandial-9/JJ	amod||hyperglycemia-10/NN||postprandial-9/JJ	prep_of||lowering-5/VBG||hyperglycemia-10/NN	prep_with||lowering-5/VBG||biasp-12/NN	num||biasp-12/NN||30-13/CD	root||ROOT-0/null||compare-14/VBP	advmod||compare-14/VBP||favorably-15/RB	amod||antidiabetes-19/NNS||optimized-17/JJ	amod||antidiabetes-19/NNS||oral-18/JJ	prep_with||compare-14/VBP||antidiabetes-19/NNS	nn||treatment-21/NN||drug-20/NN	dep||antidiabetes-19/NNS||treatment-21/NN	advmod||antidiabetes-19/NNS||insulinglargine-23/RB	prep_with||compare-14/VBP||in-27/IN	conj_and||antidiabetes-19/NNS||in-27/IN	amod||patients-29/NNS||obese-28/JJ	prep_in||antidiabetes-19/NNS||patients-29/NNS	amod||premix-32/NN||human-31/JJ	prep_with||compare-14/VBP||premix-32/NN	conj_and||antidiabetes-19/NNS||premix-32/NN	hyperglycemia-10||insulinglargine-23||yes||in t2dm patients, lowering of hba1c and postprandial hyperglycemia with biasp 30 compare favorably with optimized oral antidiabetes drug treatment, insulinglargine, and, in obese patients, human premix.
prepc_compared_to||increased-37/VBN||to-2/TO	pobj||increased-37/VBN||baseline-3/NN	nsubjpass||increased-37/VBN||adc-5/NN	conj_and||adc-5/NN||naa/cho-7/NN	nsubjpass||increased-37/VBN||naa/cho-7/NN	conj_and||adc-5/NN||naa/cr-10/NN	nsubjpass||increased-37/VBN||naa/cr-10/NN	auxpass||reduced-13/VBN||were-11/VBD	advmod||reduced-13/VBN||significantly-12/RB	rcmod||adc-5/NN||reduced-13/VBN	num||hours-16/NNS||7-15/CD	prep_after||reduced-13/VBN||hours-16/NNS	nn||<-19/NNP||p-18/NNP	dep||hours-16/NNS||<-19/NNP	num||<-19/NNP||0.001-20/CD	num||<-19/NNP||p-22/CD	dep||00.01-24/CD||=-23/SYM	rcmod||<-19/NNP||00.01-24/CD	dep||hours-16/NNS||p-27/NN	conj_and||<-19/NNP||p-27/NN	dep||00.05-29/CD||=-28/SYM	rcmod||p-27/NN||00.05-29/CD	advmod||<-19/NNP||respectively-31/RB	nn||values-35/NNS||fa-34/NN	prep_after||reduced-13/VBN||values-35/NNS	conj_and||hours-16/NNS||values-35/NNS	auxpass||increased-37/VBN||were-36/VBD	root||ROOT-0/null||increased-37/VBN	dep||<-40/JJ||p-39/RB	dep||increased-37/VBN||<-40/JJ	dep||<-40/JJ||0.025-41/CD	cr--1||fa-34||no_rel||compared to baseline, adc, naa/cho, and naa/cr were significantly reduced after 7 hours ( p < 0.001, p = 00.01, and p = 00.05, respectively) and fa values were increased ( p <0.025).
det||results-2/NNS||the-1/DT	nsubj||indicate-3/VBP||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||interacts-6/VBZ||that-4/IN	nsubj||interacts-6/VBZ||nf90-5/NNS	ccomp||indicate-3/VBP||interacts-6/VBZ	det||structure-13/NN||the-8/DT	amod||structure-13/NN||3â-9/JJ	amod||structure-13/NN||$-10/$	number||sl-12/CD||²-11/CD	num||$-10/$||sl-12/CD	prep_with||interacts-6/VBZ||structure-13/NN	det||rna-17/NN||the-15/DT	amod||rna-17/NN||dengue-16/JJ	prep_of||structure-13/NN||rna-17/NN	cop||regulator-22/NN||is-19/VBZ	det||regulator-22/NN||a-20/DT	amod||regulator-22/NN||positive-21/JJ	ccomp||indicate-3/VBP||regulator-22/NN	conj_and||interacts-6/VBZ||regulator-22/NN	amod||replication-25/NN||denguevirus-24/JJ	prep_of||regulator-22/NN||replication-25/NN	dengue-16||denguevirus-24||no||the results indicate that nf90 interacts with the 3â€² sl structure of the dengue rna and is a positive regulator of denguevirus replication.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
prep_in||associated-34/VBN||patients-2/NNS	amod||inflammation-5/NN||acute-4/JJ	prep_without||patients-2/NNS||inflammation-5/NN	nn||irondeficiency-8/NN||overt-7/NN	prep_without||patients-2/NNS||irondeficiency-8/NN	conj_and||inflammation-5/NN||irondeficiency-8/NN	dep||<-13/NNS||c-10/SYM	amod||<-13/NNS||reactive-11/JJ	nn||<-13/NNS||protein-12/NN	dep||inflammation-5/NN||<-13/NNS	amod||mg/dl-15/NN||1â-14/JJ	dep||<-13/NNS||mg/dl-15/NN	nn||>-18/NNS||ferritin-17/NN	dep||<-13/NNS||>-18/NNS	conj_and||mg/dl-15/NN||>-18/NNS	amod||ng/ml-20/NN||30â-19/JJ	dep||mg/dl-15/NN||ng/ml-20/NN	dep||mg/dl-15/NN||nâ-22/NN	num||â-26/NN||$-23/$	number||=-25/CD||‰-24/CD	num||$-23/$||=-25/CD	dep||nâ-22/NN||â-26/NN	num||â-26/NN||$-27/$	number||86-29/CD||‰-28/CD	num||$-27/$||86-29/CD	nsubjpass||associated-34/VBN||hepcidin-32/NN	auxpass||associated-34/VBN||was-33/VBD	root||ROOT-0/null||associated-34/VBN	amod||volume-39/NN||lower-36/JJR	amod||volume-39/NN||mean-37/JJ	nn||volume-39/NN||corpuscular-38/NN	prep_with||associated-34/VBN||volume-39/NN	dep||volume-39/NN||pâ-41/VBN	dobj||pâ-41/VBN||$-42/$	number||=-44/CD||‰-43/CD	num||$-42/$||=-44/CD	dep||pâ-41/VBN||â-45/VB	dobj||â-45/VB||$-46/$	number||0.002-48/CD||‰-47/CD	num||$-46/$||0.002-48/CD	xcomp||associated-34/VBN||suggesting-51/VBG	mark||contributed-54/VBD||that-52/IN	nsubj||contributed-54/VBD||it-53/PRP	ccomp||suggesting-51/VBG||contributed-54/VBD	amod||erythropoiesis-57/NNS||iron-restricted-56/JJ	prep_to||contributed-54/VBD||erythropoiesis-57/NNS	irondeficiency-8||iron--1||yes||in patients without acute inflammation and overt irondeficiency (c reactive protein <1â mg/dl and ferritin >30â ng/ml; nâ€‰=â€‰86), hepcidin was associated with lower mean corpuscular volume (pâ€‰=â€‰0.002), suggesting that it contributed to iron-restricted erythropoiesis.
nsubj||is-2/VBZ||it-1/PRP	root||ROOT-0/null||is-2/VBZ	advmod||is-2/VBZ||however-4/RB	advmod||compromised-7/VBN||frequently-6/RB	ccomp||is-2/VBZ||compromised-7/VBN	amod||predictable-10/JJ||due-8/JJ	dep||predictable-10/JJ||to-9/TO	amod||scenarios-15/NNS||predictable-10/JJ	conj_but||predictable-10/JJ||adverse-13/JJ	amod||scenarios-15/NNS||adverse-13/JJ	dobj||compromised-7/VBN||scenarios-15/NNS	det||countries-18/NNS||the-17/DT	prep_in||scenarios-15/NNS||countries-18/NNS	advmod||affected-21/VBN||most-19/RBS	advmod||affected-21/VBN||severely-20/RB	amod||scenarios-15/NNS||affected-21/VBN	prep_by||compromised-7/VBN||hiv/aids-23/NNS	aids--1||hiv--1||no||it is, however, frequently compromised due to predictable, but adverse, scenarios in the countries most severely affected by hiv/aids.
nn||policies-3/NNS||results-1/NNS	nn||policies-3/NNS||national-level-2/NN	nsubj||had-6/VBN||policies-3/NNS	nsubj||response-16/NN||policies-3/NNS	aux||had-6/VBN||have-5/VBP	rcmod||policies-3/NNS||had-6/VBN	det||impact-9/NN||a-7/DT	amod||impact-9/NN||major-8/JJ	dobj||had-6/VBN||impact-9/NN	prepc_on||had-6/VBN||chinaâ-11/VBG	dobj||chinaâ-11/VBG||$-12/$	num||$-12/$||™-13/CD	cop||response-16/NN||s-14/VBZ	amod||response-16/NN||hiv/aids-15/JJ	dep||include-17/VBP||response-16/NN	root||ROOT-0/null||include-17/VBP	amod||frees-21/NNS||â-18/JJ	amod||frees-21/NNS||$-19/$	dep||$-19/$||˜four-20/JJ	dobj||include-17/VBP||frees-21/NNS	num||careâ-24/NNS||one-23/CD	dobj||include-17/VBP||careâ-24/NNS	conj_and||frees-21/NNS||careâ-24/NNS	nsubj||include-17/VBP||$-25/$	num||$-25/$||™-26/CD	amod||plans-30/NNS||5-year-28/JJ	nn||plans-30/NNS||action-29/NN	nsubj||include-17/VBP||plans-30/NNS	conj_and||$-25/$||plans-30/NNS	amod||regulation-34/NN||hiv/aids-33/JJ	nsubj||include-17/VBP||regulation-34/NN	conj_and||$-25/$||regulation-34/NN	aids--1||hiv--1||no||results national-level policies that have had a major impact on chinaâ€™s hiv/aids response include â€˜four frees and one careâ€™; 5-year action plans; and hiv/aids regulation.
amod||gattii-2/NNS||cryptococcus-1/JJ	nsubj||cause-5/VBP||gattii-2/NNS	conj_and||gattii-2/NNS||c.neoformans-4/NNS	nsubj||cause-5/VBP||c.neoformans-4/NNS	root||ROOT-0/null||cause-5/VBP	dobj||cause-5/VBP||pulmonary-6/NNS	dobj||cause-5/VBP||systemiccryptococcosis-8/NNS	conj_and||pulmonary-6/NNS||systemiccryptococcosis-8/NNS	systemiccryptococcosis-8||c.neoformans-4||no||cryptococcus gattii and c.neoformans cause pulmonary and systemiccryptococcosis .
det||review-2/NN||this-1/DT	nsubj||highlights-3/VBZ||review-2/NN	nsubj||summarises-25/VBZ||review-2/NN	root||ROOT-0/null||highlights-3/VBZ	det||developments-6/NNS||the-4/DT	amod||developments-6/NNS||recent-5/JJ	dobj||highlights-3/VBZ||developments-6/NNS	prep_in||highlights-3/VBZ||relation-8/NN	amod||effects-12/NNS||proposed-10/VBN	amod||effects-12/NNS||anti-tumour-11/JJ	prep_to||highlights-3/VBZ||effects-12/NNS	prep_of||effects-12/NNS||bisphosphonates-14/NNS	vmod||bisphosphonates-14/NNS||reported-15/VBN	prep||reported-15/VBN||from-16/IN	pcomp||from-16/IN||in-17/IN	amod||models-22/NNS||vitro-18/NN	conj_and||vitro-18/NN||in-20/IN	amod||models-22/NNS||in-20/IN	pobj||in-20/IN||vivo-21/NN	pobj||in-17/IN||models-22/NNS	conj_and||highlights-3/VBZ||summarises-25/VBZ	det||data-27/NNS||the-26/DT	dobj||summarises-25/VBZ||data-27/NNS	amod||studies-32/NNS||key-29/JJ	nn||studies-32/NNS||breast-30/NN	nn||studies-32/NNS||cancer-31/NN	prep_from||summarises-25/VBZ||studies-32/NNS	cancer-31||bisphosphonates-14||no_rel||this review highlights the recent developments in relation to proposed anti-tumour effects of bisphosphonates reported from in vitro and in vivo models, and summarises the data from key breast cancer studies.
mark||drug-11/NN||although-1/IN	nsubj||drug-11/NN||warfarin-2/NN	cop||drug-11/NN||is-3/VBZ	det||drug-11/NN||an-4/DT	amod||drug-11/NN||effective-5/JJ	amod||drug-11/NN||oral-6/JJ	nn||drug-11/NN||anticoagulation-7/NN	appos||drug-11/NN||oac-9/NN	advcl||scarce-32/JJ||drug-11/NN	aux||reduce-13/VB||to-12/TO	vmod||drug-11/NN||reduce-13/VB	det||risk-15/NN||the-14/DT	dobj||reduce-13/VB||risk-15/NN	prep_of||risk-15/NN||thromboembolism-17/NN	prep_in||reduce-13/VB||patients-19/NNS	amod||atrialfibrillation-22/NN||non-valvular-21/JJ	prep_with||patients-19/NNS||atrialfibrillation-22/NN	appos||atrialfibrillation-22/NN||nvaf-24/NN	amod||data-30/NNS||long-27/JJ	nn||data-30/NNS||term-28/NN	nn||data-30/NNS||follow-up-29/NN	nsubj||scarce-32/JJ||data-30/NNS	nsubj||certain-35/JJ||data-30/NNS	cop||scarce-32/JJ||are-31/VBP	root||ROOT-0/null||scarce-32/JJ	aux||certain-35/JJ||to-33/TO	cop||certain-35/JJ||be-34/VB	xcomp||scarce-32/JJ||certain-35/JJ	mark||maintained-42/VBN||whether-36/IN	det||level-40/NN||the-37/DT	nn||level-40/NN||target-38/NN	nn||level-40/NN||inr-39/NN	nsubjpass||maintained-42/VBN||level-40/NN	auxpass||maintained-42/VBN||is-41/VBZ	ccomp||certain-35/JJ||maintained-42/VBN	amod||patients-45/NNS||warfarin-treated-44/JJ	prep_in||maintained-42/VBN||patients-45/NNS	prep_in||patients-45/NNS||korea-47/NN	thromboembolism-17||warfarin-2||yes||although warfarin is an effective oral anticoagulation (oac) drug to reduce the risk of thromboembolism in patients with non-valvular atrialfibrillation (nvaf), long term follow-up data are scarce to be certain whether the target inr level is maintained in warfarin-treated patients in korea.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||âˆ-14/VB	num||±-17/NN||’14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||âˆ-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||âˆ-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||âˆ-37/NN	num||±-40/NN||’14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||âˆ-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||âˆ-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||âˆ-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	insulin-82||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (âˆ’14 â± 3 pg/ml [âˆ’4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (âˆ’14 â± 2 pg/ml [âˆ’4.0 â± 0.6 pmol/l]) but increased to âˆ’3 â± 3 pg/ml (âˆ’0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||isoniazid-15||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
nsubj||messenger-6/NN||c-di-gmp-1/NN	cop||messenger-6/NN||is-2/VBZ	det||messenger-6/NN||a-3/DT	amod||messenger-6/NN||bacterial-4/JJ	amod||messenger-6/NN||second-5/JJ	root||ROOT-0/null||messenger-6/NN	vmod||messenger-6/NN||regulating-7/VBG	amod||phenotypes-10/NNS||diverse-8/JJ	amod||phenotypes-10/NNS||bacterial-9/JJ	dobj||regulating-7/VBG||phenotypes-10/NNS	advmod||phenotypes-10/NNS||notably-12/RB	nn||formation-16/NN||motility-13/NN	conj_and||motility-13/NN||biofilm-15/NN	nn||formation-16/NN||biofilm-15/NN	dep||phenotypes-10/NNS||formation-16/NN	prep_in||regulating-7/VBG||proteobacteria-19/NN	prep_such_as||proteobacteria-19/NN||vibriocholerae-22/NN	prep_such_as||proteobacteria-19/NN||pseudomonasaeruginosa-24/NN	conj_and||vibriocholerae-22/NN||pseudomonasaeruginosa-24/NN	prep_such_as||proteobacteria-19/NN||salmonella-27/NN	conj_and||vibriocholerae-22/NN||salmonella-27/NN	vibriocholerae-22||bacterial-9||no||c-di-gmp is a bacterial second messenger regulating diverse bacterial phenotypes, notably motility and biofilm formation, in proteobacteria such as vibriocholerae, pseudomonasaeruginosa , and salmonella .
amod||injections-3/NNS||intravitreal-1/JJ	nn||injections-3/NNS||ganciclovir-2/NN	nsubj||strategy-10/NN||injections-3/NNS	aux||strategy-10/NN||may-4/MD	cop||strategy-10/NN||be-5/VB	det||strategy-10/NN||the-6/DT	amod||strategy-10/NN||most-7/JJS	nn||strategy-10/NN||cost-8/NN	amod||strategy-10/NN||effective-9/JJ	root||ROOT-0/null||strategy-10/NN	aux||treat-12/VB||to-11/TO	vmod||strategy-10/NN||treat-12/VB	dobj||treat-12/VB||cmvretinitis-13/NNS	det||areas-16/NNS||these-15/DT	prep_in||treat-12/VB||areas-16/NNS	cmvretinitis-13||ganciclovir-2||yes||intravitreal ganciclovir injections may be the most cost effective strategy to treat cmvretinitis in these areas.
nsubj||tgf-î-4/VBD||addition-1/NN	prep_of||addition-1/NN||exogenous-3/NNS	root||ROOT-0/null||tgf-î-4/VBD	acomp||tgf-î-4/VBD||²-5/JJ	amod||mortality-14/NN||h5n1-7/JJ	dep||$-9/$||influenzavirusâ-8/RB	dep||mortality-14/NN||$-9/$	num||$-9/$||infected-11/NNS	quantmod||infected-11/NNS||mice-12/IN	quantmod||infected-11/NNS||delayed-13/JJ	prep_to||²-5/JJ||mortality-14/NN	amod||titers-18/NNS||reduced-16/VBN	amod||titers-18/NNS||viral-17/JJ	prep_to||²-5/JJ||titers-18/NNS	conj_and||mortality-14/NN||titers-18/NNS	mark||increased-31/VBD||whereas-19/IN	nsubj||increased-31/VBD||neutralization-20/NN	nn||²-23/NNP||tgf-î-22/NNP	prep_of||neutralization-20/NN||²-23/NNP	prep_during||²-23/NNP||h5n1-25/NNS	amod||infection-30/NN||pandemic-27/JJ	num||infection-30/NN||2009-28/CD	amod||infection-30/NN||h1n1-29/JJ	prep_during||²-23/NNP||infection-30/NN	conj_and||h5n1-25/NNS||infection-30/NN	advcl||tgf-î-4/VBD||increased-31/VBD	dobj||increased-31/VBD||morbidity-32/NN	h5n1-25||influenzavirus--1||no||addition of exogenous tgf-î² to h5n1 influenzavirusâ€“infected mice delayed mortality and reduced viral titers whereas neutralization of tgf-î² during h5n1 and pandemic 2009 h1n1 infection increased morbidity.
prep_since||reported-15/VBN||2003-2/CD	mwe||than-5/IN||more-4/JJR	quantmod||380-6/CD||than-5/IN	num||cases-7/NNS||380-6/CD	nsubjpass||reported-15/VBN||cases-7/NNS	amod||influenzavirusinfection-10/NN||h5n1-9/JJ	prep_of||cases-7/NNS||influenzavirusinfection-10/NN	prep_of||influenzavirusinfection-10/NN||humans-12/NNS	aux||reported-15/VBN||have-13/VBP	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	h5n1-9||influenzavirus--1||no||since 2003, more than 380 cases of h5n1 influenzavirusinfection of humans have been reported.
amod||practices-2/NNS||sexual-1/JJ	nsubj||factors-18/NNS||practices-2/NNS	vmod||practices-2/NNS||leading-3/VBG	aux||rectal-5/VB||to-4/TO	xcomp||leading-3/VBG||rectal-5/VB	ccomp||rectal-5/VB||bleeding-6/VBG	ccomp||rectal-5/VB||snorting-9/VBG	conj_and||bleeding-6/VBG||snorting-9/VBG	dobj||snorting-9/VBG||drugs-10/NNS	prep_in||snorting-9/VBG||settings-12/NNS	amod||hcv-prevalence-15/NN||increased-14/VBN	prep_of||settings-12/NNS||hcv-prevalence-15/NN	cop||factors-18/NNS||are-16/VBP	nn||factors-18/NNS||risk-17/NN	root||ROOT-0/null||factors-18/NNS	prep_for||factors-18/NNS||acutehepatitisc-20/NN	acutehepatitisc-20||hcv--1||no||sexual practices leading to rectal bleeding, and snorting drugs in settings of increased hcv-prevalence are risk factors for acutehepatitisc.
det||patient-4/NN||a-1/DT	amod||patient-4/NN||50-year-old-2/JJ	amod||patient-4/NN||female-3/JJ	nsubj||had-8/VBN||patient-4/NN	nsubj||years-20/NNS||patient-4/NN	aux||had-8/VBN||had-7/VBD	rcmod||patient-4/NN||had-8/VBN	dobj||had-8/VBN||cancer-9/NN	det||breast-13/NN||the-11/DT	amod||breast-13/NN||left-12/JJ	prep_of||cancer-9/NN||breast-13/NN	cop||years-20/NNS||was-15/VBD	nn||therapy-18/NN||hormone-17/NN	prep_on||years-20/NNS||therapy-18/NN	num||years-20/NNS||2-19/CD	root||ROOT-0/null||years-20/NNS	prep_after||years-20/NNS||treatment-22/NN	prep_with||treatment-22/NN||surgery-24/NN	prep_with||treatment-22/NN||radiotherapy-26/NN	conj_and||surgery-24/NN||radiotherapy-26/NN	prep_with||treatment-22/NN||chemotherapy-28/NN	conj_and||surgery-24/NN||chemotherapy-28/NN	cancer-9||hormone-17||no_rel||a 50-year-old female patient, who had had cancer of the left breast, was on hormone therapy 2 years after treatment with surgery, radiotherapy and chemotherapy.
amod||analysis-2/NN||immunohistological-1/JJ	nsubj||confirmed-6/VBD||analysis-2/NN	det||granulomas-5/NNS||these-4/DT	prep_of||analysis-2/NN||granulomas-5/NNS	root||ROOT-0/null||confirmed-6/VBD	det||abundance-9/NN||the-7/DT	amod||abundance-9/NN||disproportionate-8/JJ	dobj||confirmed-6/VBD||abundance-9/NN	det||proteins-12/NNS||the-11/DT	prep_of||abundance-9/NN||proteins-12/NNS	vmod||proteins-12/NNS||involved-13/VBN	nn||metabolism-16/NN||lipid-15/NN	prep_in||involved-13/VBN||metabolism-16/NN	prep_in||involved-13/VBN||cells-18/NNS	vmod||cells-18/NNS||surrounding-19/VBG	det||caseum-21/NN||the-20/DT	dobj||surrounding-19/VBG||caseum-21/NN	advmod||biochemical-36/VBP||namely-23/RB	nn||member-31/NN||adipophilin-25/NN	amod||member-31/NN||acyl-coa-27/JJ	nn||member-31/NN||synthetase-28/NN	amod||member-31/NN||long-chain-29/JJ	nn||member-31/NN||family-30/NN	nsubj||biochemical-36/VBP||member-31/NN	num||member-31/NN||1-32/CD	amod||c.-35/NN||saposin-34/JJ	conj_and||member-31/NN||c.-35/NN	nsubj||biochemical-36/VBP||c.-35/NN	parataxis||confirmed-6/VBD||biochemical-36/VBP	dobj||biochemical-36/VBP||analysis-37/NN	det||species-41/NN||the-39/DT	nn||species-41/NN||lipid-40/NN	prep_of||analysis-37/NN||species-41/NN	det||caseum-44/NN||the-43/DT	prep_within||biochemical-36/VBP||caseum-44/NN	nsubj||implicated-56/VBN||caseum-44/NN	vmod||caseum-44/NN||identified-45/VBN	dobj||identified-45/VBN||cholesterol-46/NN	amod||esters-49/NNS||cholesteryl-48/JJ	dobj||identified-45/VBN||esters-49/NNS	conj_and||cholesterol-46/NN||esters-49/NNS	dobj||identified-45/VBN||triacylglycerols-51/NNS	conj_and||cholesterol-46/NN||triacylglycerols-51/NNS	dobj||identified-45/VBN||lactosylceramide-53/NN	conj_and||cholesterol-46/NN||lactosylceramide-53/NN	rcmod||caseum-44/NN||implicated-56/VBN	amod||lipids-59/NNS||low-density-57/JJ	amod||lipids-59/NNS||lipoprotein-derived-58/JJ	dobj||implicated-56/VBN||lipids-59/NNS	det||source-64/NN||the-61/DT	advmod||likely-63/JJ||most-62/RBS	amod||source-64/NN||likely-63/JJ	prep_as||implicated-56/VBN||source-64/NN	granulomas-5||triacylglycerols-51||no_rel||immunohistological analysis of these granulomas confirmed the disproportionate abundance of the proteins involved in lipid metabolism in cells surrounding the caseum ; namely , adipophilin , acyl-coa synthetase long-chain family member 1 and saposin c. biochemical analysis of the lipid species within the caseum identified cholesterol , cholesteryl esters , triacylglycerols and lactosylceramide , which implicated low-density lipoprotein-derived lipids as the most likely source .
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	hodgkinlymphoma-6||bleomycin-15||yes||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
det||concern-4/NN||the-1/DT	nn||concern-4/NN||case-2/NN	nn||concern-4/NN||studies-3/NNS	nsubj||westnilevirus-5/VBZ||concern-4/NN	root||ROOT-0/null||westnilevirus-5/VBZ	dobj||westnilevirus-5/VBZ||transmission-6/NN	prep_in||transmission-6/NN||senegal-8/NN	amod||incidence-11/NN||tick-borneencephalitis-10/JJ	dobj||westnilevirus-5/VBZ||incidence-11/NN	conj_and||transmission-6/NN||incidence-11/NN	prep_in||incidence-11/NN||latvia-13/NN	amod||abundance-16/NN||sandfly-15/JJ	dobj||westnilevirus-5/VBZ||abundance-16/NN	conj_and||transmission-6/NN||abundance-16/NN	det||pyrenees-20/NNS||the-18/DT	amod||pyrenees-20/NNS||french-19/JJ	prep_in||abundance-16/NN||pyrenees-20/NNS	nn||fever-24/NN||rift-22/NN	nn||fever-24/NN||valley-23/NN	dobj||westnilevirus-5/VBZ||fever-24/NN	conj_and||transmission-6/NN||fever-24/NN	det||ferlo-27/NN||the-26/DT	prep_in||fever-24/NN||ferlo-27/NN	dep||fever-24/NN||senegal-29/JJ	conj_and||transmission-6/NN||westnilefever-32/NN	conj_and||fever-24/NN||westnilefever-32/NN	det||risk-35/NN||the-34/DT	conj_and||transmission-6/NN||risk-35/NN	conj_and||fever-24/NN||risk-35/NN	nn||re-emergence-38/NN||malaria-37/NN	prep_of||risk-35/NN||re-emergence-38/NN	det||camargue-41/NN||the-40/DT	prep_in||re-emergence-38/NN||camargue-41/NN	amod||puumalahantavirus-45/NNS||rodent-borne-44/JJ	dobj||westnilevirus-5/VBZ||puumalahantavirus-45/NNS	conj_and||transmission-6/NN||puumalahantavirus-45/NNS	conj_and||transmission-6/NN||lymeborreliosis-47/NNS	conj_and||puumalahantavirus-45/NNS||lymeborreliosis-47/NNS	prep_in||puumalahantavirus-45/NNS||belgium-49/NN	westnilefever-32||westnilevirus-5||no||the case studies concern westnilevirus transmission in senegal, tick-borneencephalitis incidence in latvia, sandfly abundance in the french pyrenees, rift valley fever in the ferlo (senegal), westnilefever and the risk of malaria re-emergence in the camargue, and rodent-borne puumalahantavirus and lymeborreliosis in belgium.
det||treatment-2/NN||the-1/DT	nsubj||undergone-6/VBN||treatment-2/NN	prep_of||treatment-2/NN||psoriasis-4/NNS	aux||undergone-6/VBN||has-5/VBZ	root||ROOT-0/null||undergone-6/VBN	det||revolution-8/NN||a-7/DT	dobj||undergone-6/VBN||revolution-8/NN	det||advent-11/NN||the-10/DT	prep_with||undergone-6/VBN||advent-11/NN	amod||therapies-14/NNS||biologic-13/JJ	prep_of||advent-11/NN||therapies-14/NNS	prep_including||undergone-6/VBN||infliximab-17/NN	appos||infliximab-17/NN||etanercept-19/NN	appos||infliximab-17/NN||adalimumab-21/NN	conj_and||etanercept-19/NN||adalimumab-21/NN	appos||infliximab-17/NN||efalizumab-23/NN	conj_and||etanercept-19/NN||efalizumab-23/NN	appos||infliximab-17/NN||alefacept-26/NN	conj_and||etanercept-19/NN||alefacept-26/NN	psoriasis-4||alefacept-26||yes||the treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept.
det||characteristics-3/NNS||the-1/DT	amod||characteristics-3/NNS||demographic-2/JJ	nsubj||similar-23/JJ||characteristics-3/NNS	prep_of||characteristics-3/NNS||patients-5/NNS	amod||class-10/NN||asa-7/JJ	amod||class-10/NN||physical-8/JJ	nn||class-10/NN||status-9/NN	prep_of||characteristics-3/NNS||class-10/NN	conj_and||patients-5/NNS||class-10/NN	prep_of||characteristics-3/NNS||duration-12/NN	conj_and||patients-5/NNS||duration-12/NN	prep_of||duration-12/NN||surgery-14/NN	det||score-21/NN||the-17/DT	amod||score-21/NN||basal-18/JJ	nn||score-21/NN||vas-19/NN	nn||score-21/NN||pain-20/NN	prep_of||characteristics-3/NNS||score-21/NN	conj_and||patients-5/NNS||score-21/NN	cop||similar-23/JJ||were-22/VBD	root||ROOT-0/null||similar-23/JJ	det||groups-27/NNS||the-25/DT	num||groups-27/NNS||two-26/CD	prep_in||similar-23/JJ||groups-27/NNS	pain-20||asa-7||yes||the demographic characteristics of patients, asa physical status class, duration of surgery, and the basal vas pain score were similar in the two groups.
nn||odns-2/NNS||sup-1/NN	nsubj||had-3/VBD||odns-2/NNS	root||ROOT-0/null||had-3/VBD	det||effect-7/NN||a-4/DT	amod||effect-7/NN||significant-5/JJ	amod||effect-7/NN||synergistic-6/JJ	dobj||had-3/VBD||effect-7/NN	prep_with||effect-7/NN||5-fluorouracil-9/NN	prep_with||effect-7/NN||vinorelbine-11/NN	conj_and||5-fluorouracil-9/NN||vinorelbine-11/NN	prep_with||effect-7/NN||gemcitabine-13/NN	conj_and||5-fluorouracil-9/NN||gemcitabine-13/NN	prep_with||effect-7/NN||paclitaxel-15/NN	conj_and||5-fluorouracil-9/NN||paclitaxel-15/NN	prep_with||effect-7/NN||irinotecan-17/NN	conj_and||5-fluorouracil-9/NN||irinotecan-17/NN	det||index-23/NN||a-20/DT	amod||index-23/NN||mean-21/JJ	nn||index-23/NN||combination-22/NN	prep_with||had-3/VBD||index-23/NN	prep_of||index-23/NN||0.43-25/CD	dep||$-27/$||â-26/RB	dep||0.43-25/CD||$-27/$	npadvmod||indicates-33/RB||0.78-29/NNP	dep||0.78-29/NNP||<-31/RB	prep||<-31/RB||1.0-32/IN	dep||synergism-34/CD||indicates-33/RB	num||$-27/$||synergism-34/CD	det||line-41/NN||the-37/DT	amod||line-41/NN||a549-38/JJ	amod||line-41/NN||nsclc-39/JJ	nn||line-41/NN||cell-40/NN	prep_in||0.43-25/CD||line-41/NN	nsclc-39||irinotecan-17||yes||sup odns had a significant synergistic effect with 5-fluorouracil, vinorelbine, gemcitabine, paclitaxel and irinotecan, with a mean combination index of 0.43â€“0.78 (<1.0 indicates synergism) in the a549 nsclc cell line.
nn||hbp-2/NN||baseline-1/NN	nsubj||â-18/NN||hbp-2/NN	nn||s.d.-6/NNP||meanâ-4/NNP	nn||s.d.-6/NNP||±-5/NNP	appos||hbp-2/NN||s.d.-6/NNP	det||morning-10/NN||the-9/DT	prep_in||hbp-2/NN||morning-10/NN	det||measurement-14/NN||the-12/DT	amod||measurement-14/NN||first-13/JJ	appos||morning-10/NN||measurement-14/NN	cop||â-18/NN||was-16/VBD	num||â-18/NN||151.6-17/CD	root||ROOT-0/null||â-18/NN	number||16.4-20/CD||±-19/CD	dep||â-18/NN||16.4-20/CD	punct||â-38/NNS||/-21/:	number||â-23/CD||87.1-22/CD	num||â-26/NNS||â-23/CD	nn||â-26/NNS||±-24/NNP	num||â-26/NNS||11.8-25/CD	nsubj||â-38/NNS||â-26/NNS	num||â-26/NNS||$-27/$	number||mmâ-29/CD||‰-28/CD	num||$-27/$||mmâ-29/CD	amod||â-26/NNS||$-30/$	number||hg-32/CD||‰-31/CD	num||$-30/$||hg-32/CD	advmod||bedtime-35/JJ||at-34/IN	amod||â-26/NNS||bedtime-35/JJ	conj_and||$-30/$||bedtime-35/JJ	cop||â-38/NNS||was-36/VBD	num||â-38/NNS||144.3-37/CD	dep||â-18/NN||â-38/NNS	number||16.8-40/CD||±-39/CD	num||â-38/NNS||16.8-40/CD	punct||â-38/NNS||/-41/:	number||â-43/CD||82.8-42/CD	num||â-46/NN||â-43/CD	nn||â-46/NN||±-44/NNP	num||â-46/NN||11.9-45/CD	dep||â-18/NN||â-46/NN	dep||â-18/NN||$-47/$	num||$-47/$||‰-48/CD	vmod||$-47/$||mmâ-49/VBN	dobj||mmâ-49/VBN||$-50/$	number||hg-52/CD||‰-51/CD	num||$-50/$||hg-52/CD	mark||â-58/NN||whereas-54/IN	nsubj||â-58/NN||cbp-55/NN	cop||â-58/NN||was-56/VBD	num||â-58/NN||153.6-57/CD	dep||â-18/NN||â-58/NN	num||19.0-60/CD||±-59/CD	dep||â-58/NN||19.0-60/CD	punct||19.0-60/CD||/-61/:	number||â-63/CD||87.1-62/CD	num||â-66/NN||â-63/CD	nn||â-66/NN||±-64/NNP	num||â-66/NN||13.4-65/CD	nsubj||mmâ-69/VBP||â-66/NN	amod||â-66/NN||$-67/$	dep||$-67/$||‰-68/JJ	dep||19.0-60/CD||mmâ-69/VBP	dobj||mmâ-69/VBP||$-70/$	number||hg-72/CD||‰-71/CD	num||$-70/$||hg-72/CD	hg-72||hbp-2||no_rel||baseline hbp (meanâ±s.d.) in the morning (the first measurement) was 151.6â±16.4/87.1â±11.8â€‰mmâ€‰hg and at bedtime was 144.3â±16.8/82.8â±11.9â€‰mmâ€‰hg, whereas cbp was 153.6â±19.0/87.1â±13.4â€‰mmâ€‰hg.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||data-4/NNS||limited-3/VBN	nsubj||is-2/VBZ||data-4/NNS	prep_on||data-4/NNS||lamivudine-6/NN	amod||patients-10/NNS||renal-8/JJ	nn||patients-10/NNS||transplant-9/NN	prep_in||data-4/NNS||patients-10/NNS	nn||infection-13/NN||hbv-12/NN	prep_with||data-4/NNS||infection-13/NN	neg||report-17/NN||no-15/DT	amod||report-17/NN||published-16/VBN	nsubj||is-2/VBZ||report-17/NN	conj_and||data-4/NNS||report-17/NN	prep_from||report-17/NN||india-19/NN	hbv-12||lamivudine-6||yes||there is limited data on lamivudine in renal transplant patients with hbv infection and no published report from india.
amod||mesalamine-2/NN||extended-release-1/JJ	nsubj||mesalamineproduct-8/NN||mesalamine-2/NN	cop||mesalamineproduct-8/NN||is-3/VBZ	det||mesalamineproduct-8/NN||the-4/DT	amod||mesalamineproduct-8/NN||first-5/JJ	advmod||daily-7/JJ||once-6/RB	amod||mesalamineproduct-8/NN||daily-7/JJ	root||ROOT-0/null||mesalamineproduct-8/NN	vmod||mesalamineproduct-8/NN||approved-9/VBN	det||administration-15/NN||the-11/DT	nn||administration-15/NN||food-12/NN	conj_and||food-12/NN||drug-14/NN	nn||administration-15/NN||drug-14/NN	agent||approved-9/VBN||administration-15/NN	det||maintenance-18/NN||the-17/DT	prep_for||administration-15/NN||maintenance-18/NN	nn||remission-21/NN||uc-20/NN	prep_of||maintenance-18/NN||remission-21/NN	uc-20||mesalamine-2||yes||extended-release mesalamine is the first once daily mesalamineproduct approved by the food and drug administration for the maintenance of uc remission.
det||step-3/NN||a-1/DT	amod||step-3/NN||major-2/JJ	nsubj||elimination-16/NN||step-3/NN	prep_towards||step-3/NN||elimination-5/NN	nn||toxicity-8/NN||gluten-7/NN	prep_of||elimination-5/NN||toxicity-8/NN	amod||patients-11/NNS||celiacdisease-10/JJ	prep_for||toxicity-8/NN||patients-11/NNS	aux||elimination-16/NN||would-12/MD	advmod||elimination-16/NN||thus-13/RB	cop||elimination-16/NN||be-14/VB	det||elimination-16/NN||the-15/DT	root||ROOT-0/null||elimination-16/NN	amod||epitopes-19/NNS||such-18/JJ	prep_of||elimination-16/NN||epitopes-19/NNS	nn||±-22/NNS||î-21/NN	prep_from||epitopes-19/NNS||±-22/NNS	dep||elimination-16/NN||gliadins-24/NNS	celiacdisease-10||gluten-7||no||a major step towards elimination of gluten toxicity for celiacdisease patients would thus be the elimination of such epitopes from î±-gliadins.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||prevention-5/NN||the-4/DT	dobj||examined-3/VBD||prevention-5/NN	prep_of||prevention-5/NN||pain-7/NN	amod||injection-11/NN||microemulsion-9/JJ	amod||injection-11/NN||propofol-10/JJ	prep_during||examined-3/VBD||injection-11/NN	prep_by||examined-3/VBD||pretreatment-13/NN	amod||doses-16/NNS||different-15/JJ	prep_with||examined-3/VBD||doses-16/NNS	prep_of||doses-16/NNS||remifentanil-18/JJ	prep_of||doses-16/NNS||saline-20/JJ	conj_or||remifentanil-18/JJ||saline-20/JJ	prep_of||doses-16/NNS||premixing-23/NN	conj_and||remifentanil-18/JJ||premixing-23/NN	prep_of||premixing-23/NN||lidocaine-25/NN	pain-7||lidocaine-25||yes||this study examined the prevention of pain during microemulsion propofol injection by pretreatment with different doses of remifentanil or saline, and premixing of lidocaine.
det||paper-2/NN||this-1/DT	nsubj||explores-3/VBZ||paper-2/NN	root||ROOT-0/null||explores-3/VBZ	advmod||informed-19/VBD||how-4/WRB	nn||information-6/NN||research-5/NN	nsubj||informed-19/VBD||information-6/NN	amod||findings-10/NNS||particular-9/JJ	prep_in||information-6/NN||findings-10/NNS	amod||trials-14/NNS||randomised-12/JJ	amod||trials-14/NNS||controlled-13/JJ	prep_from||findings-10/NNS||trials-14/NNS	amod||reviews-17/NNS||systematic-16/JJ	prep_from||findings-10/NNS||reviews-17/NNS	conj_and||trials-14/NNS||reviews-17/NNS	ccomp||explores-3/VBZ||informed-19/VBD	nn||making-21/NN||policy-20/NN	dobj||informed-19/VBD||making-21/NN	amod||development-25/NN||clinical-23/JJ	nn||development-25/NN||guideline-24/NN	dobj||informed-19/VBD||development-25/NN	conj_and||making-21/NN||development-25/NN	det||use-28/NN||the-27/DT	prep_for||making-21/NN||use-28/NN	prep_of||use-28/NN||magnesiumsulphate-30/NN	det||treatment-33/NN||the-32/DT	prep_in||informed-19/VBD||treatment-33/NN	prep_of||treatment-33/NN||eclampsia-35/NN	prep_of||treatment-33/NN||pre-eclampsia-37/NN	conj_and||eclampsia-35/NN||pre-eclampsia-37/NN	amod||africa-40/NN||south-39/JJ	prep_in||informed-19/VBD||africa-40/NN	pre-eclampsia-37||magnesiumsulphate-30||yes||this paper explores how research information, in particular findings from randomised controlled trials and systematic reviews, informed policy making and clinical guideline development for the use of magnesiumsulphate in the treatment of eclampsia and pre-eclampsia in south africa.
det||streptococcuspyogenes-4/NNS||the-1/DT	amod||streptococcuspyogenes-4/NNS||gram-positive-2/JJ	nn||streptococcuspyogenes-4/NNS||bacterium-3/NN	nsubj||pathogen-8/NN||streptococcuspyogenes-4/NNS	cop||pathogen-8/NN||is-5/VBZ	det||pathogen-8/NN||a-6/DT	amod||pathogen-8/NN||common-7/JJ	root||ROOT-0/null||pathogen-8/NN	prep_of||pathogen-8/NN||humans-10/NNS	nsubj||causes-12/VBZ||humans-10/NNS	rcmod||humans-10/NNS||causes-12/VBZ	amod||infections-14/NNS||invasive-13/JJ	dobj||causes-12/VBZ||infections-14/NNS	amod||syndrome-17/NN||toxic-shock-16/JJ	dobj||causes-12/VBZ||syndrome-17/NN	conj_and||infections-14/NNS||syndrome-17/NN	dobj||causes-12/VBZ||rheumaticfever-19/NN	conj_and||infections-14/NNS||rheumaticfever-19/NN	dobj||causes-12/VBZ||necrotizingfasciitis-21/NNS	conj_and||infections-14/NNS||necrotizingfasciitis-21/NNS	amod||diseases-24/NNS||other-23/JJ	dobj||causes-12/VBZ||diseases-24/NNS	conj_and||infections-14/NNS||diseases-24/NNS	necrotizingfasciitis-21||streptococcuspyogenes-4||no||the gram-positive bacterium streptococcuspyogenes is a common pathogen of humans that causes invasive infections, toxic-shock syndrome, rheumaticfever, necrotizingfasciitis and other diseases.
nsubjpass||shown-17/VBN||xaracoll-1/NN	nsubj||reduce-19/VB||xaracoll-1/NN	det||implant-5/NN||a-3/DT	amod||implant-5/NN||collagen-based-4/JJ	appos||xaracoll-1/NN||implant-5/NN	nsubj||delivers-7/VBZ||implant-5/NN	rcmod||implant-5/NN||delivers-7/VBZ	acomp||delivers-7/VBZ||bupivacaine-8/JJ	prep_to||bupivacaine-8/JJ||sites-10/NNS	amod||trauma-13/NN||surgical-12/JJ	prep_of||sites-10/NNS||trauma-13/NN	aux||shown-17/VBN||has-15/VBZ	auxpass||shown-17/VBN||been-16/VBN	root||ROOT-0/null||shown-17/VBN	aux||reduce-19/VB||to-18/TO	xcomp||shown-17/VBN||reduce-19/VB	dobj||reduce-19/VB||postoperativepain-20/NN	dobj||reduce-19/VB||use-22/NN	conj_and||postoperativepain-20/NN||use-22/NN	amod||analgesia-25/NN||opioid-24/JJ	prep_of||postoperativepain-20/NN||analgesia-25/NN	prep_in||reduce-19/VB||patients-27/NNS	vmod||patients-27/NNS||undergoing-28/VBG	amod||surgery-30/NN||open-29/JJ	dobj||undergoing-28/VBG||surgery-30/NN	postoperativepain-20||collagen--1||no_rel||xaracoll, a collagen-based implant that delivers bupivacaine to sites of surgical trauma, has been shown to reduce postoperativepain and use of opioid analgesia in patients undergoing open surgery.
nsubjpass||proposed-4/VBN||it-1/PRP	aux||proposed-4/VBN||has-2/VBZ	auxpass||proposed-4/VBN||been-3/VBN	root||ROOT-0/null||proposed-4/VBN	mark||allows-29/VBZ||that-5/IN	det||doxorubicin-9/NN||the-6/DT	amod||doxorubicin-9/NN||liposomal-7/JJ	amod||doxorubicin-9/NN||formulated-8/JJ	nsubj||allows-29/VBZ||doxorubicin-9/NN	dep||doxorubicin-9/NN||ie-11/NN	appos||ie-11/NN||doxil-13/NN	prep||doxorubicin-9/NN||given-16/VBN	pcomp||given-16/VBN||at-17/IN	det||stage-20/NN||the-18/DT	amod||stage-20/NN||menstrual/estrous-19/JJ	pobj||at-17/IN||stage-20/NN	det||vascular-26/NN||the-22/DT	amod||vascular-26/NN||predicted-23/JJ	amod||vascular-26/NN||highest-24/JJS	nn||vascular-26/NN||tumor-25/NN	prep_with||stage-20/NN||vascular-26/NN	advmod||vascular-26/NN||permeability-27/RB	ccomp||proposed-4/VBN||allows-29/VBZ	advmod||allows-29/VBZ||significantly-30/RB	amod||retention-33/NN||increased-31/VBN	nn||retention-33/NN||drug-32/NN	dobj||allows-29/VBZ||retention-33/NN	det||breasttumor-36/NN||the-35/DT	prep_in||retention-33/NN||breasttumor-36/NN	breasttumor-36||doxorubicin-9||yes||it has been proposed that the liposomal formulated doxorubicin (ie, doxil), given at the menstrual/estrous stage with the predicted highest tumor vascular permeability, allows significantly increased drug retention in the breasttumor.
advmod||decreased-9/VBN||notably-1/RB	nn||strains-5/NNS||s.â-3/NN	nn||strains-5/NNS||enterica-4/NN	nsubj||decreased-9/VBN||strains-5/NNS	vmod||strains-5/NNS||lacking-6/VBG	dobj||lacking-6/VBG||rida-7/NN	aux||decreased-9/VBN||have-8/VBP	root||ROOT-0/null||decreased-9/VBN	dobj||decreased-9/VBN||activity-10/NN	det||transaminase-14/NN||the-12/DT	amod||transaminase-14/NN||plp-dependent-13/JJ	prep_of||activity-10/NN||transaminase-14/NN	dep||activity-10/NN||b-15/SYM	amod||ilve-17/JJ||enzyme-16/JJ	amod||activity-10/NN||ilve-17/JJ	det||enzyme-20/NN||an-19/DT	appos||activity-10/NN||enzyme-20/NN	vmod||enzyme-20/NN||involved-21/VBN	amod||biosynthesis-25/NNS||branched-chain-23/JJ	amod||biosynthesis-25/NNS||aminoacid-24/JJ	prep_in||involved-21/VBN||biosynthesis-25/NNS	aminoacid-24||rida-7||no_rel||notably, s.â enterica strains lacking rida have decreased activity of the plp-dependent transaminase b enzyme ilve, an enzyme involved in branched-chain aminoacid biosynthesis.
det||element-3/NN||a-1/DT	amod||element-3/NN||chemical-2/JJ	nsubjpass||found-7/VBN||element-3/NN	nsubjpass||associated-10/VBN||element-3/NN	prep_besides||element-3/NN||fluoride-5/NN	auxpass||found-7/VBN||was-6/VBD	root||ROOT-0/null||found-7/VBN	aux||associated-10/VBN||to-8/TO	auxpass||associated-10/VBN||be-9/VB	xcomp||found-7/VBN||associated-10/VBN	parataxis||associated-10/VBN||p-12/VB	num||0.05-14/CD||>-13/CD	dobj||p-12/VB||0.05-14/CD	det||prevalence-18/NN||the-17/DT	prep_to||associated-10/VBN||prevalence-18/NN	prep_of||prevalence-18/NN||dentalfluorosis-20/NNS	mark||interpreted-28/VBN||although-22/IN	det||finding-25/NN||this-23/DT	amod||finding-25/NN||last-24/JJ	nsubjpass||interpreted-28/VBN||finding-25/NN	aux||interpreted-28/VBN||should-26/MD	auxpass||interpreted-28/VBN||be-27/VB	advcl||associated-10/VBN||interpreted-28/VBN	prep_with||interpreted-28/VBN||caution-30/NN	poss||value-35/NN||its-33/PRP$	nn||value-35/NN||p-34/NN	prep_due_to||caution-30/NN||value-35/NN	dentalfluorosis-20||fluoride-5||no||a chemical element besides fluoride was found to be associated (p > 0.05) to the prevalence of dentalfluorosis, although this last finding should be interpreted with caution due to its p value.
nn||patients-2/NNS||results-1/NNS	nsubj||referred-3/VBD||patients-2/NNS	root||ROOT-0/null||referred-3/VBD	det||programme-7/NN||the-5/DT	amod||programme-7/NN||hiv/aids-6/JJ	prep_to||referred-3/VBD||programme-7/NN	amod||care-11/NN||general-9/JJ	amod||care-11/NN||primary-10/JJ	prep_through||referred-3/VBD||care-11/NN	nn||clinics-14/NNS||intervention-13/NN	prep_at||referred-3/VBD||clinics-14/NNS	cop||likely-17/JJ||were-15/VBD	advmod||likely-17/JJ||more-16/RBR	rcmod||clinics-14/NNS||likely-17/JJ	prep_than||likely-17/JJ||those-19/DT	nn||clinics-22/NNS||control-21/NN	prep_at||those-19/DT||clinics-22/NNS	aux||receive-24/VB||to-23/TO	xcomp||likely-17/JJ||receive-24/VB	amod||prophylaxis-26/NNS||co-trimoxazole-25/JJ	dobj||receive-24/VB||prophylaxis-26/NNS	num||%-29/NN||41-28/CD	nsubj||v-34/VBP||%-29/NN	appos||%-29/NN||2253/5523-32/CD	dep||clinics-14/NNS||v-34/VBP	num||%-36/NN||32-35/CD	dobj||v-34/VBP||%-36/NN	appos||%-36/NN||1340/4210-38/CD	dep||%-36/NN||odds-41/NNS	nsubj||interval-48/VBP||ratio-42/NN	num||ratio-42/NN||1.95-43/CD	number||%-46/NN||95-45/CD	amod||confidence-47/NN||%-46/NN	appos||ratio-42/NN||confidence-47/NN	rcmod||odds-41/NNS||interval-48/VBP	number||3.40-51/CD||1.11-49/CD	dep||3.40-51/CD||to-50/TO	dobj||interval-48/VBP||3.40-51/CD	nsubj||likely-58/JJ||tuberculosis-55/NNP	nsubjpass||diagnosed-61/VBN||tuberculosis-55/NNP	cop||likely-58/JJ||was-56/VBD	advmod||likely-58/JJ||more-57/RBR	conj_and||referred-3/VBD||likely-58/JJ	aux||diagnosed-61/VBN||to-59/TO	auxpass||diagnosed-61/VBN||be-60/VB	xcomp||likely-58/JJ||diagnosed-61/VBN	prep_among||diagnosed-61/VBN||patients-63/NNS	prep_with||patients-63/NNS||hiv/aids/art-65/NN	num||%-68/NN||7-67/CD	nsubj||v-72/VBP||%-68/NN	appos||%-68/NN||417/5793-70/CD	dep||patients-63/NNS||v-72/VBP	num||%-74/NN||6-73/CD	dobj||v-72/VBP||%-74/NN	appos||%-74/NN||245/4343-76/CD	dep||%-74/NN||1.25-79/CD	number||1.55-83/CD||1.01-81/CD	dep||1.55-83/CD||to-82/TO	appos||1.25-79/CD||1.55-83/CD	aids--1||hiv--1||no||results patients referred to the hiv/aids programme through general primary care at intervention clinics were more likely than those at control clinics to receive co-trimoxazole prophylaxis (41%, (2253/5523) v 32% (1340/4210); odds ratio 1.95, 95% confidence interval 1.11 to 3.40), and tuberculosis was more likely to be diagnosed among patients with hiv/aids/art (7% (417/5793) v 6% (245/4343); 1.25, 1.01 to 1.55).
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	mark||responsible-12/JJ||that-3/IN	advmod||number-7/NN||only-4/RB	det||number-7/NN||a-5/DT	amod||number-7/NN||limited-6/JJ	nsubj||responsible-12/JJ||number-7/NN	amod||cells-10/NNS||infected-9/JJ	prep_of||number-7/NN||cells-10/NNS	cop||responsible-12/JJ||are-11/VBP	ccomp||show-2/VBP||responsible-12/JJ	det||production-15/NN||the-14/DT	prep_for||responsible-12/JJ||production-15/NN	prep_of||production-15/NN||ifn-17/NN	mark||feature-26/NN||that-20/IN	det||production-23/NN||this-21/DT	nn||production-23/NN||heterocellular-22/NN	nsubj||feature-26/NN||production-23/NN	cop||feature-26/NN||is-24/VBZ	det||feature-26/NN||a-25/DT	ccomp||show-2/VBP||feature-26/NN	conj_and||responsible-12/JJ||feature-26/NN	det||virus-30/NN||the-28/DT	amod||virus-30/NN||infecting-29/VBG	prep_of||feature-26/NN||virus-30/NN	advmod||opposed-32/VBN||as-31/RB	amod||virus-30/NN||opposed-32/VBN	det||property-36/NN||an-34/DT	amod||property-36/NN||intrinsic-35/JJ	prep_to||opposed-32/VBN||property-36/NN	det||cells-39/NNS||the-38/DT	prep_of||property-36/NN||cells-39/NNS	ifn-17||virus-30||no_rel||we show that only a limited number of infected cells are responsible for the production of ifn, and that this heterocellular production is a feature of the infecting virus as opposed to an intrinsic property of the cells.
nsubj||diseases-9/NNS||priondiseases-1/NNS	conj_or||priondiseases-1/NNS||transmissiblespongiformencephalopathies-3/NNS	nsubj||diseases-9/NNS||transmissiblespongiformencephalopathies-3/NNS	appos||priondiseases-1/NNS||tses-5/NNS	cop||diseases-9/NNS||are-7/VBP	amod||diseases-9/NNS||fatal-8/JJ	root||ROOT-0/null||diseases-9/NNS	vmod||diseases-9/NNS||associated-10/VBN	det||conversion-13/NN||the-12/DT	prep_with||associated-10/VBN||conversion-13/NN	det||prionprotein-17/NN||the-15/DT	amod||prionprotein-17/NN||cellular-16/JJ	prep_of||conversion-13/NN||prionprotein-17/NN	dep||prionprotein-17/NN||prpc-19/JJ	det||prionprotein-24/NN||the-22/DT	amod||prionprotein-24/NN||abnormal-23/JJ	prep_to||associated-10/VBN||prionprotein-24/NN	dep||prionprotein-24/NN||prpsc-26/JJ	priondiseases-1||prionprotein-24||no||priondiseases or transmissiblespongiformencephalopathies (tses) are fatal diseases associated with the conversion of the cellular prionprotein (prpc) to the abnormal prionprotein (prpsc).
aux||evaluate-3/VB||to-1/TO	advmod||evaluate-3/VB||further-2/RBR	advcl||analyzed-13/VBD||evaluate-3/VB	det||strategy-6/NN||the-4/DT	nn||strategy-6/NN||sga-5/NN	dobj||evaluate-3/VB||strategy-6/NN	prepc_for||strategy-6/NN||identifying-8/VBG	nn||viruses-10/NNS||transmitted/founder-9/NN	dobj||identifying-8/VBG||viruses-10/NNS	nsubj||analyzed-13/VBD||we-12/PRP	root||ROOT-0/null||analyzed-13/VBD	num||5â-16/NNS||239-14/CD	amod||5â-16/NNS||overlapping-15/VBG	dobj||analyzed-13/VBD||5â-16/NNS	amod||5â-16/NNS||$-17/$	number||$-17/$||²-18/CD	amod||genome-24/NNS||3â-20/VBD	amod||genome-24/NNS||$-21/$	number||$-21/$||²-22/CD	nn||genome-24/NNS||half-23/NN	dobj||analyzed-13/VBD||genome-24/NNS	conj_and||5â-16/NNS||genome-24/NNS	dobj||analyzed-13/VBD||env-26/NN	conj_or||5â-16/NNS||env-26/NN	amod||sequences-29/NNS||only-28/JJ	dep||env-26/NN||sequences-29/NNS	nn||rna-33/NN||plasma-31/NN	amod||rna-33/NN||viral-32/JJ	prep_from||sequences-29/NNS||rna-33/NN	appos||rna-33/NN||vrna-35/NNP	nn||dna-41/NN||blood-38/NN	nn||dna-41/NN||mononuclear-39/NN	nn||dna-41/NN||cell-40/NN	prep_from||sequences-29/NNS||dna-41/NN	conj_and||rna-33/NN||dna-41/NN	det||subject-45/NN||an-43/DT	nn||subject-45/NN||msm-44/NN	prep_in||dna-41/NN||subject-45/NN	nsubj||had-47/VBD||who-46/WP	dep||rna-33/NN||had-47/VBD	det||days-58/NNS||a-48/DT	advmod||well-documented-50/JJ||particularly-49/RB	amod||days-58/NNS||well-documented-50/JJ	nn||days-58/NNS||virus-51/NN	nn||days-58/NNS||exposure-52/NN	nn||days-58/NNS||history-53/NN	amod||days-58/NNS||3â-54/JJ	num||days-58/NNS||$-55/$	num||$-55/$||6-57/CD	dobj||had-47/VBD||days-58/NNS	nn||onset-61/NN||symptom-60/NN	prep_before||days-58/NNS||onset-61/NN	dobj||had-47/VBD||14â-63/NNS	conj_and||days-58/NNS||14â-63/NNS	num||days-67/NNS||$-64/$	num||$-64/$||17-66/CD	dep||14â-63/NNS||days-67/NNS	amod||viremia-71/NN||peak-69/JJ	nn||viremia-71/NN||plasma-70/NN	prep_before||had-47/VBD||viremia-71/NN	num||molecules/ml-75/NN||47,600,000-73/CD	nn||molecules/ml-75/NN||vrna-74/NN	appos||viremia-71/NN||molecules/ml-75/NN	virus-51||viruses-10||no||to further evaluate the sga strategy for identifying transmitted/founder viruses, we analyzed 239 overlapping 5â€² and 3â€² half genome or env -only sequences from plasma viral rna (vrna) and blood mononuclear cell dna in an msm subject who had a particularly well-documented virus exposure history 3â€“6 days before symptom onset and 14â€“17 days before peak plasma viremia (47,600,000 vrna molecules/ml).
mark||correlate-16/VBP||although-1/IN	amod||levels-3/NNS||increased-2/VBN	nsubj||correlate-16/VBP||levels-3/NNS	amod||interferon-8/NN||systemic-5/JJ	nn||interferon-8/NN||type-6/NN	nn||interferon-8/NN||i-7/NN	prep_of||levels-3/NNS||interferon-8/NN	amod||±-11/NN||ifnî-10/JJ	dep||interferon-8/NN||±-11/NN	nn||²-14/NN||î-13/NN	dep||interferon-8/NN||²-14/NN	conj_and||±-11/NN||²-14/NN	advcl||demonstrated-36/VBN||correlate-16/VBP	amod||resolution-19/NN||accelerated-18/VBN	prep_with||correlate-16/VBP||resolution-19/NN	prep_of||resolution-19/NN||rotavirusdisease-21/NN	amod||strains-25/NNS||multiple-23/JJ	nn||strains-25/NNS||rotavirus-24/NNS	nsubjpass||demonstrated-36/VBN||strains-25/NNS	nsubj||antagonize-38/VB||strains-25/NNS	amod||rotavirus-29/NNS||rhesus-28/JJ	prep_including||strains-25/NNS||rotavirus-29/NNS	appos||rotavirus-29/NNS||rrv-31/NN	aux||demonstrated-36/VBN||have-34/VBP	auxpass||demonstrated-36/VBN||been-35/VBN	root||ROOT-0/null||demonstrated-36/VBN	aux||antagonize-38/VB||to-37/TO	xcomp||demonstrated-36/VBN||antagonize-38/VB	nn||production-42/NN||type-39/FW	nn||production-42/NN||i-40/FW	nn||production-42/NN||ifn-41/NN	dobj||antagonize-38/VB||production-42/NN	det||variety-45/NN||a-44/DT	prep_in||production-42/NN||variety-45/NN	amod||types-51/NNS||epithelial-47/JJ	conj_and||epithelial-47/JJ||fibroblast-49/JJ	amod||types-51/NNS||fibroblast-49/JJ	nn||types-51/NNS||cell-50/NN	prep_of||variety-45/NN||types-51/NNS	amod||mechanisms-54/NNS||several-53/JJ	prep_through||antagonize-38/VB||mechanisms-54/NNS	prep_including||antagonize-38/VB||degradation-57/NN	amod||factors-62/NNS||multiple-59/JJ	amod||factors-62/NNS||interferon-60/JJ	amod||factors-62/NNS||regulatory-61/JJ	prep_of||degradation-57/NN||factors-62/NNS	det||protein-67/NN||a-64/DT	amod||protein-67/NN||viral-65/JJ	amod||protein-67/NN||nonstructural-66/JJ	prep_by||factors-62/NNS||protein-67/NN	rotavirusdisease-21||rotavirus-29||yes||although increased levels of systemic type i interferon (ifnî± and î²) correlate with accelerated resolution of rotavirusdisease, multiple rotavirus strains, including rhesus rotavirus (rrv), have been demonstrated to antagonize type i ifn production in a variety of epithelial and fibroblast cell types through several mechanisms, including degradation of multiple interferon regulatory factors by a viral nonstructural protein.
amod||subjects-3/NNS||male-2/JJ	prep_in||persisted-32/VBD||subjects-3/NNS	det||associations-6/NNS||the-5/DT	nsubj||persisted-32/VBD||associations-6/NNS	prep_of||associations-6/NNS||retinopathy-8/NN	prep_with||retinopathy-8/NN||g-10/NN	prep_with||speed-24/NN||tests-14/NNS	amod||fluency-17/NN||verbal-16/JJ	prep_of||tests-14/NNS||fluency-17/NN	amod||flexibility-20/NN||mental-19/JJ	prep_of||tests-14/NNS||flexibility-20/NN	conj_and||fluency-17/NN||flexibility-20/NN	prep_of||tests-14/NNS||processing-23/NN	conj_and||fluency-17/NN||processing-23/NN	dep||associations-6/NNS||speed-24/NN	nn||reasoning-30/NN||memory-27/NN	conj_and||memory-27/NN||nonverbal-29/NN	nn||reasoning-30/NN||nonverbal-29/NN	dep||associations-6/NNS||reasoning-30/NN	conj_negcc||speed-24/NN||reasoning-30/NN	root||ROOT-0/null||persisted-32/VBD	dep||<-35/JJ||p-34/RB	dep||persisted-32/VBD||<-35/JJ	dep||<-35/JJ||0.05-36/CD	advmod||adjusted-40/VBN||when-38/WRB	advmod||adjusted-40/VBN||further-39/RB	advcl||persisted-32/VBD||adjusted-40/VBN	prep_for||adjusted-40/VBN||vocabulary-42/NN	nn||cognitivedecline-47/NN||estimate-45/NN	nn||cognitivedecline-47/NN||lifetime-46/NN	prep_to||vocabulary-42/NN||cognitivedecline-47/NN	prep_for||adjusted-40/VBN||depression-50/NN	conj_and||vocabulary-42/NN||depression-50/NN	amod||characteristics-53/NNS||sociodemographic-52/JJ	prep_for||adjusted-40/VBN||characteristics-53/NNS	conj_and||vocabulary-42/NN||characteristics-53/NNS	amod||factors-57/NNS||cardiovascular-55/JJ	nn||factors-57/NNS||risk-56/NN	prep_for||adjusted-40/VBN||factors-57/NNS	conj_and||vocabulary-42/NN||factors-57/NNS	prep_for||adjusted-40/VBN||macrovasculardisease-60/NN	conj_and||vocabulary-42/NN||macrovasculardisease-60/NN	retinopathy-8||speed-24||no_rel||in male subjects, the associations of retinopathy with g (and with tests of verbal fluency, mental flexibility, and processing speed but not memory and nonverbal reasoning) persisted ( p < 0.05) when further adjusted for vocabulary (to estimate lifetime cognitivedecline), depression, sociodemographic characteristics, cardiovascular risk factors, and macrovasculardisease.
mark||studied-6/VBN||although-1/IN	nsubjpass||studied-6/VBN||retroviruses-2/NNS	aux||studied-6/VBN||have-3/VBP	auxpass||studied-6/VBN||been-4/VBN	advmod||studied-6/VBN||extensively-5/RB	advcl||remain-34/VBP||studied-6/VBN	amod||years-9/NNS||many-8/JJ	prep_for||studied-6/VBN||years-9/NNS	amod||questions-12/NNS||basic-11/JJ	nsubj||remain-34/VBP||questions-12/NNS	advmod||detected-17/VBN||how-14/WRB	nsubjpass||detected-17/VBN||retroviralinfections-15/NNS	auxpass||detected-17/VBN||are-16/VBP	prepc_about||questions-12/NNS||detected-17/VBN	det||system-21/NN||the-19/DT	amod||system-21/NN||immune-20/JJ	agent||detected-17/VBN||system-21/NN	dobj||required-27/VBN||which-23/WDT	amod||pathways-25/NNS||innate-24/JJ	nsubjpass||required-27/VBN||pathways-25/NNS	auxpass||required-27/VBN||are-26/VBP	prepc_about||questions-12/NNS||required-27/VBN	conj_and||detected-17/VBN||required-27/VBN	det||generation-30/NN||the-29/DT	prep_for||required-27/VBN||generation-30/NN	amod||responses-33/NNS||immune-32/JJ	prep_of||generation-30/NN||responses-33/NNS	root||ROOT-0/null||remain-34/VBP	acomp||remain-34/VBP||unanswered-35/JJ	retroviralinfections-15||retroviruses-2||no||although retroviruses have been extensively studied for many years, basic questions about how retroviralinfections are detected by the immune system and which innate pathways are required for the generation of immune responses remain unanswered.
nsubj||evolved-12/VBN||borreliarecurrentis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiologic-4/JJ	appos||borreliarecurrentis-1/NNS||agent-5/NN	prep_of||agent-5/NN||louse-bornerelapsingfever-7/NN	prep_in||louse-bornerelapsingfever-7/NN||humans-9/NNS	aux||evolved-12/VBN||has-11/VBZ	root||ROOT-0/null||evolved-12/VBN	dobj||evolved-12/VBN||strategies-13/NNS	amod||variation-17/NN||antigenic-16/JJ	prep_including||strategies-13/NNS||variation-17/NN	aux||evade-20/VB||to-19/TO	vmod||evolved-12/VBN||evade-20/VB	amod||defence-22/NN||immune-21/JJ	dobj||evade-20/VB||defence-22/NN	advmod||causing-25/VBG||thereby-24/RB	vmod||evade-20/VB||causing-25/VBG	amod||diseases-27/NNS||severe-26/JJ	dobj||causing-25/VBG||diseases-27/NNS	amod||rates-31/NNS||high-29/JJ	nn||rates-31/NNS||mortality-30/NN	prep_with||causing-25/VBG||rates-31/NNS	louse-bornerelapsingfever-7||borreliarecurrentis-1||no||borreliarecurrentis , the etiologic agent of louse-bornerelapsingfever in humans, has evolved strategies, including antigenic variation, to evade immune defence, thereby causing severe diseases with high mortality rates.
nsubj||bleedingdisorder-6/NN||hemophiliaa-1/NN	cop||bleedingdisorder-6/NN||is-2/VBZ	det||bleedingdisorder-6/NN||a-3/DT	amod||bleedingdisorder-6/NN||rare-4/JJ	amod||bleedingdisorder-6/NN||x-linked-5/JJ	root||ROOT-0/null||bleedingdisorder-6/NN	vmod||bleedingdisorder-6/NN||caused-7/VBN	agent||caused-7/VBN||lack-9/NN	agent||caused-7/VBN||dysfunction-11/NN	conj_or||lack-9/NN||dysfunction-11/NN	prep_of||lack-9/NN||coagulationfactorviii-13/NNS	appos||coagulationfactorviii-13/NNS||fviii-15/NNP	hemophiliaa-1||coagulationfactorviii-13||yes||hemophiliaa is a rare x-linked bleedingdisorder caused by lack or dysfunction of coagulationfactorviii (fviii).
advmod||report-3/VBP||here-1/RB	nsubj||report-3/VBP||we-2/PRP	root||ROOT-0/null||report-3/VBP	mark||renders-7/VBZ||that-4/IN	det||bacterialinfection-6/NN||a-5/DT	nsubj||renders-7/VBZ||bacterialinfection-6/NN	ccomp||report-3/VBP||renders-7/VBZ	nn||melanogaster-9/NN||d.-8/NN	nsubj||resistant-11/JJ||melanogaster-9/NN	advmod||resistant-11/JJ||more-10/RBR	xcomp||renders-7/VBZ||resistant-11/JJ	nn||virus-15/NN||drosophila-13/NN	nn||virus-15/NN||c-14/NN	prep_to||resistant-11/JJ||virus-15/NN	xcomp||renders-7/VBZ||reducing-17/VBG	det||load-19/NN||the-18/DT	dobj||reducing-17/VBG||load-19/NN	prep_of||load-19/NN||viruses-21/NNS	amod||flies-24/NNS||infected-23/JJ	prep_in||viruses-21/NNS||flies-24/NNS	virus-15||viruses-21||no||here we report that a bacterialinfection renders d. melanogaster more resistant to drosophila c virus , reducing the load of viruses in infected flies .
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||problem-18/NN||tb-3/NN	vmod||tb-3/NN||caused-6/VBN	agent||caused-6/VBN||mycobacteriumtuberculosis-8/NNS	appos||mycobacteriumtuberculosis-8/NNS||mtb-10/NN	cop||problem-18/NN||is-13/VBZ	det||problem-18/NN||an-14/DT	amod||problem-18/NN||enduring-15/VBG	amod||problem-18/NN||public-16/JJ	nn||problem-18/NN||health-17/NN	root||ROOT-0/null||problem-18/NN	advmod||problem-18/NN||globally-19/RB	advmod||problem-18/NN||particularly-21/RB	amod||africa-24/NN||sub-saharan-23/JJ	prep_in||problem-18/NN||africa-24/NN	tb-3||mycobacteriumtuberculosis-8||no||tuberculosis (tb), caused by mycobacteriumtuberculosis (mtb), is an enduring public health problem globally, particularly in sub-saharan africa.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-9/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-9/VB||to-7/TO	advmod||compare-9/VB||directly-8/RB	xcomp||was-6/VBD||compare-9/VB	det||effects-11/NNS||the-10/DT	dobj||compare-9/VB||effects-11/NNS	prep_of||effects-11/NNS||cr-13/NN	amod||exercise-16/NN||endurance-15/JJ	dobj||compare-9/VB||exercise-16/NN	conj_and||effects-11/NNS||exercise-16/NN	det||model-20/NN||a-18/DT	nn||model-20/NN||mouse-19/NN	prep_in||exercise-16/NN||model-20/NN	amod||obesity-23/NN||diet-induced-22/JJ	prep_of||model-20/NN||obesity-23/NN	prep_of||model-20/NN||insulinresistance-25/NN	conj_and||obesity-23/NN||insulinresistance-25/NN	cr-13||obesity-23||no_rel||the aim of this study was to directly compare the effects of cr and endurance exercise in a mouse model of diet-induced obesity and insulinresistance.
nsubj||agent-9/NN||clozapine-1/NN	cop||agent-9/NN||is-2/VBZ	det||agent-9/NN||a-3/DT	amod||agent-9/NN||second-generation-4/JJ	dep||agent-9/NN||atypical-6/JJ	amod||agent-9/NN||antipsychotic-8/JJ	root||ROOT-0/null||agent-9/NN	nsubjpass||proven-14/VBN||agent-9/NN	aux||proven-14/VBN||has-12/VBZ	auxpass||proven-14/VBN||been-13/VBN	rcmod||agent-9/NN||proven-14/VBN	xcomp||proven-14/VBN||efficient-15/JJ	det||symptoms-21/NNS||the-17/DT	amod||symptoms-21/NNS||positive-18/JJ	conj_and||positive-18/JJ||negative-20/JJ	amod||symptoms-21/NNS||negative-20/JJ	prep_against||proven-14/VBN||symptoms-21/NNS	prep_of||symptoms-21/NNS||schizophrenia-23/NN	det||propensity-28/NN||a-26/DT	amod||propensity-28/NN||low-27/JJ	prep_with||proven-14/VBN||propensity-28/NN	aux||induce-30/VB||to-29/TO	vmod||propensity-28/NN||induce-30/VB	amod||dyskinesia-32/NN||tardive-31/JJ	dobj||induce-30/VB||dyskinesia-32/NN	appos||dyskinesia-32/NN||td-34/NN	schizophrenia-23||clozapine-1||yes||clozapine is a second-generation (atypical) antipsychotic agent, which has been proven efficient against the positive and negative symptoms of schizophrenia, with a low propensity to induce tardive dyskinesia (td).
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||âˆ-17/JJ	dep||âˆ-17/JJ||’60-18/CD	num||min-21/NN||180-20/CD	prep_through||âˆ-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||âˆ-36/JJ	dep||âˆ-36/JJ||’30-37/CD	dep||âˆ-36/JJ||1-39/CD	conj_and||’30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||glucagon-9||yes||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from âˆ’60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at âˆ’30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
det||allergen-5/NN||the-1/DT	amod||allergen-5/NN||major-2/JJ	amod||allergen-5/NN||birch-3/JJ	nn||allergen-5/NN||pollen-4/NN	nsubj||agent-15/NN||allergen-5/NN	appos||allergen-5/NN||betv1-7/NNS	nn||verrucosa-10/NN||betula-9/NN	prep_of||betv1-7/NNS||verrucosa-10/NN	cop||agent-15/NN||is-11/VBZ	det||agent-15/NN||the-12/DT	amod||agent-15/NN||main-13/JJ	nn||agent-15/NN||causative-14/NN	root||ROOT-0/null||agent-15/NN	amod||pollenallergy-18/NN||birch-17/JJ	prep_of||agent-15/NN||pollenallergy-18/NN	prep_in||pollenallergy-18/NN||humans-20/NNS	pollenallergy-18||pollen-4||no||the major birch pollen allergen, betv1 of betula verrucosa is the main causative agent of birch pollenallergy in humans.
prep_in||difficult-6/JJ||practice-2/NN	nsubj||difficult-6/JJ||it-4/PRP	nsubj||compare-8/VB||it-4/PRP	cop||difficult-6/JJ||is-5/VBZ	root||ROOT-0/null||difficult-6/JJ	aux||compare-8/VB||to-7/TO	xcomp||difficult-6/JJ||compare-8/VB	det||effectiveness-10/NN||the-9/DT	dobj||compare-8/VB||effectiveness-10/NN	amod||treatment-14/NN||traditional-12/JJ	nn||treatment-14/NN||antihypertensive-13/NN	prep_of||effectiveness-10/NN||treatment-14/NN	prep_with||compare-8/VB||that-16/DT	nn||promotion-19/NN||health-18/NN	prep_of||that-16/DT||promotion-19/NN	prepc_in||compare-8/VB||reducing-21/VBG	nn||rate-23/NN||incidence-22/NN	dobj||reducing-21/VBG||rate-23/NN	prep_of||rate-23/NN||cardiovasculardisease-25/NN	dep||compare-8/VB||ircvd-27/NN	appos||ircvd-27/NN||events/year-29/NN	antihypertensive-13||cardiovasculardisease-25||no_rel||in practice, it is difficult to compare the effectiveness of traditional antihypertensive treatment with that of health promotion in reducing incidence rate of cardiovasculardisease (ircvd, events/year).
advmod||resemble-5/VBP||morphologically-1/RB	amod||spirochetes-4/NNS||lymedisease-3/JJ	nsubj||resemble-5/VBP||spirochetes-4/NNS	root||ROOT-0/null||resemble-5/VBP	xcomp||resemble-5/VBP||borrelia-6/NN	lymedisease-3||borrelia-6||no||morphologically, lymedisease spirochetes resemble borrelia.
det||study-3/NN||this-2/DT	prep_in||demonstrate-6/VBP||study-3/NN	nsubj||demonstrate-6/VBP||we-5/PRP	root||ROOT-0/null||demonstrate-6/VBP	mark||elicits-15/VBZ||that-7/IN	nsubj||elicits-15/VBZ||vaccination-8/NN	det||vaccine-14/NN||the-10/DT	num||vaccine-14/NN||2009-11/CD	amod||vaccine-14/NN||pandemic-12/JJ	nn||vaccine-14/NN||h1n1-13/NN	prep_with||vaccination-8/NN||vaccine-14/NN	ccomp||demonstrate-6/VBP||elicits-15/VBZ	num||antibodies-19/NNS||1918-16/CD	nn||antibodies-19/NNS||virus-17/NN	nn||antibodies-19/NNS||cross-protective-18/NN	dobj||elicits-15/VBZ||antibodies-19/NNS	prep_in||antibodies-19/NNS||mice-21/NNS	prep_in||antibodies-19/NNS||humans-23/NNS	conj_and||mice-21/NNS||humans-23/NNS	mark||reduced-34/VBD||that-26/IN	nn||transfer-30/NN||vaccination-27/NN	conj_or||vaccination-27/NN||passive-29/JJ	nn||transfer-30/NN||passive-29/JJ	nsubj||reduced-34/VBD||transfer-30/NN	nsubj||conferred-37/VBD||transfer-30/NN	amod||sera-33/NN||human-positive-32/JJ	prep_of||transfer-30/NN||sera-33/NN	ccomp||demonstrate-6/VBP||reduced-34/VBD	conj_and||elicits-15/VBZ||reduced-34/VBD	dobj||reduced-34/VBD||morbidity-35/NN	conj_and||elicits-15/VBZ||conferred-37/VBD	conj_and||reduced-34/VBD||conferred-37/VBD	amod||protection-39/NN||full-38/JJ	dobj||conferred-37/VBD||protection-39/NN	amod||challenge-42/NN||lethal-41/JJ	prep_from||conferred-37/VBD||challenge-42/NN	det||virus-46/NN||the-44/DT	num||virus-46/NN||1918-45/CD	prep_with||challenge-42/NN||virus-46/NN	prep_in||conferred-37/VBD||mice-48/NNS	virus-46||antibodies-19||no_rel||in this study, we demonstrate that vaccination with the 2009 pandemic h1n1 vaccine elicits 1918 virus cross-protective antibodies in mice and humans, and that vaccination or passive transfer of human-positive sera reduced morbidity and conferred full protection from lethal challenge with the 1918 virus in mice.
nsubj||defect-22/NN||insulinresistance-1/NN	appos||insulinresistance-1/NN||ir-3/NN	det||response-14/NN||an-6/DT	amod||response-14/NN||impaired-7/JJ	amod||tissue-10/NN||cellular-8/JJ	nn||response-14/NN||tissue-10/NN	conj_and||tissue-10/NN||whole-12/JJ	nn||response-14/NN||whole-12/JJ	nn||response-14/NN||body-13/NN	appos||insulinresistance-1/NN||response-14/NN	prep_to||response-14/NN||insulin-16/NN	cop||defect-22/NN||is-18/VBZ	det||defect-22/NN||a-19/DT	amod||defect-22/NN||major-20/JJ	amod||defect-22/NN||pathophysiological-21/JJ	root||ROOT-0/null||defect-22/NN	prep_of||defect-22/NN||type2diabetesmellitus-24/CD	type2diabetesmellitus-24||insulin-16||yes||insulinresistance (ir), an impaired cellular, tissue and whole body response to insulin, is a major pathophysiological defect of type2diabetesmellitus.
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
predet||viruses-3/NNS||all-1/PDT	det||viruses-3/NNS||these-2/DT	nsubj||have-4/VBP||viruses-3/NNS	ccomp||adapted-19/VBN||have-4/VBP	det||epidemiology-7/NN||a-5/DT	amod||epidemiology-7/NN||different-6/JJ	dobj||have-4/VBP||epidemiology-7/NN	amod||species-11/NNS||different-9/JJ	nn||species-11/NNS||vector-10/NN	prep_as||epidemiology-7/NN||species-11/NNS	amod||hosts-14/NNS||reservoir-13/JJ	nsubj||adapted-19/VBN||hosts-14/NNS	nn||types-17/NNS||virus-16/NN	conj_and||hosts-14/NNS||types-17/NNS	nsubj||adapted-19/VBN||types-17/NNS	aux||adapted-19/VBN||have-18/VBP	root||ROOT-0/null||adapted-19/VBN	amod||cycles-29/NNS||promiscuous-21/JJ	conj_and||promiscuous-21/JJ||robust-23/JJ	amod||cycles-29/NNS||robust-23/JJ	advmod||fine-balanced-27/JJ||rather-25/RB	advmod||fine-balanced-27/JJ||very-26/RB	conj_or||promiscuous-21/JJ||fine-balanced-27/JJ	amod||cycles-29/NNS||fine-balanced-27/JJ	nn||cycles-29/NNS||transmission-28/NN	prep_to||adapted-19/VBN||cycles-29/NNS	virus-16||viruses-3||no||all these viruses have a different epidemiology as different vector species, reservoir hosts and virus types have adapted to promiscuous and robust or rather very fine-balanced transmission cycles.
det||envelope-3/NN||the-1/DT	nn||envelope-3/NN||cell-2/NN	nsubjpass||composed-10/VBN||envelope-3/NN	prep_of||envelope-3/NN||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||m.tuberculosis-7/NNS	auxpass||composed-10/VBN||is-9/VBZ	root||ROOT-0/null||composed-10/VBN	det||variety-13/NN||a-12/DT	prep_of||composed-10/VBN||variety-13/NN	prep_of||variety-13/NN||lipids-15/NNS	amod||acids-18/NNS||mycolic-17/JJ	prep_including||lipids-15/NNS||acids-18/NNS	nsubj||impart-27/VBP||acids-18/NNS	nn||lipoarabinomannans-22/NNS||sulpholipids-20/NNS	dep||acids-18/NNS||lipoarabinomannans-22/NNS	dep||lipoarabinomannans-22/NNS||etc.-24/FW	rcmod||acids-18/NNS||impart-27/VBP	nsubj||crucial-29/JJ||rigidity-28/NN	xcomp||impart-27/VBP||crucial-29/JJ	poss||survival-32/NN||its-31/PRP$	prep_for||crucial-29/JJ||survival-32/NN	prep_for||crucial-29/JJ||pathogenesis-34/NNS	conj_and||survival-32/NN||pathogenesis-34/NNS	tuberculosis--1||mycobacteriumtuberculosis-5||no||the cell envelope of mycobacteriumtuberculosis ( m.tuberculosis ) is composed of a variety of lipids including mycolic acids, sulpholipids, lipoarabinomannans, etc., which impart rigidity crucial for its survival and pathogenesis.
det||patient-2/NN||the-1/DT	nsubj||underwent-3/VBD||patient-2/NN	nsubj||alive-22/JJ||patient-2/NN	root||ROOT-0/null||underwent-3/VBD	amod||chemotherapy-5/NN||adjuvant-4/JJ	dobj||underwent-3/VBD||chemotherapy-5/NN	prep_with||underwent-3/VBD||irinotecan-7/NN	prep_with||underwent-3/VBD||cisplatin-9/NN	conj_and||irinotecan-7/NN||cisplatin-9/NN	prep_in||irinotecan-7/NN||accordance-11/NN	det||diagnosis-14/NN||the-13/DT	prep_with||underwent-3/VBD||diagnosis-14/NN	det||lcnec-18/NN||a-16/DT	nn||lcnec-18/NN||lung-17/NN	prep_of||diagnosis-14/NN||lcnec-18/NN	cop||alive-22/JJ||is-21/VBZ	conj_and||underwent-3/VBD||alive-22/JJ	prep_without||alive-22/JJ||recurrence-24/NN	prep_without||alive-22/JJ||metastasis-26/NNS	conj_or||recurrence-24/NN||metastasis-26/NNS	num||months-28/NNS||16-27/CD	npadvmod||alive-22/JJ||months-28/NNS	prep_after||alive-22/JJ||surgery-30/NN	metastasis-26||irinotecan-7||yes||the patient underwent adjuvant chemotherapy with irinotecan and cisplatin in accordance with the diagnosis of a lung lcnec, and is alive without recurrence or metastasis 16 months after surgery.
amod||levels-3/NNS||total-1/JJ	nn||levels-3/NNS||cholesterol-2/NN	nsubjpass||correlated-10/VBN||levels-3/NNS	num||mg/dl-6/NN||200-5/CD	prep_above||levels-3/NNS||mg/dl-6/NN	aux||correlated-10/VBN||have-7/VBP	advmod||correlated-10/VBN||repeatedly-8/RB	auxpass||correlated-10/VBN||been-9/VBN	root||ROOT-0/null||correlated-10/VBN	det||factor-15/NN||an-12/DT	amod||factor-15/NN||independent-13/JJ	nn||factor-15/NN||risk-14/NN	prep_as||correlated-10/VBN||factor-15/NN	prep_for||factor-15/NN||development-17/NN	amod||vascular-20/NN||peripheral-19/JJ	prep_of||development-17/NN||vascular-20/NN	appos||vascular-20/NN||pvd-22/NN	prep_of||development-17/NN||coronaryarterydisease-25/NN	conj_and||vascular-20/NN||coronaryarterydisease-25/NN	appos||vascular-20/NN||cad-27/NN	amod||attention-32/NN||considerable-31/JJ	nsubjpass||directed-35/VBN||attention-32/NN	aux||directed-35/VBN||has-33/VBZ	auxpass||directed-35/VBN||been-34/VBN	conj_and||correlated-10/VBN||directed-35/VBN	prepc_toward||directed-35/VBN||evaluating-37/VBG	dobj||evaluating-37/VBG||mechanisms-38/NNS	dobj||impact-43/VB||which-40/WDT	nsubj||impact-43/VB||hypercholesterolemia-41/NN	aux||impact-43/VB||may-42/MD	prepc_by||evaluating-37/VBG||impact-43/VB	nn||outcomes-45/NNS||vascular-44/NN	dobj||impact-43/VB||outcomes-45/NNS	nsubj||include-48/VBP||these-47/DT	parataxis||correlated-10/VBN||include-48/VBP	det||results-50/NNS||both-49/DT	dobj||include-48/VBP||results-50/NNS	amod||cholesterol-53/NN||direct-52/JJ	prep_of||results-50/NNS||cholesterol-53/NN	vmod||cholesterol-53/NN||lowering-54/VBG	dobj||lowering-54/VBG||therapies-55/NNS	nn||interventions-58/NNS||alternative-57/NN	dobj||lowering-54/VBG||interventions-58/NNS	conj_and||therapies-55/NNS||interventions-58/NNS	prepc_for||lowering-54/VBG||improving-60/VBG	nn||function-62/NN||vascular-61/NN	dobj||improving-60/VBG||function-62/NN	hypercholesterolemia-41||cholesterol-53||no||total cholesterol levels above 200 mg/dl have repeatedly been correlated as an independent risk factor for development of peripheral vascular (pvd) and coronaryarterydisease (cad), and considerable attention has been directed toward evaluating mechanisms by which hypercholesterolemia may impact vascular outcomes; these include both results of direct cholesterol lowering therapies and alternative interventions for improving vascular function.
nsubjpass||confirmed-3/VBN||hypothyroidism-1/NN	auxpass||confirmed-3/VBN||was-2/VBD	root||ROOT-0/null||confirmed-3/VBN	amod||concentration-8/NN||increased-5/VBN	nn||concentration-8/NN||tsh-6/NN	nn||concentration-8/NN||blood-7/NN	agent||confirmed-3/VBN||concentration-8/NN	dep||concentration-8/NN||brahms-10/NNS	appos||brahms-10/NNS||germany-12/NN	vmod||concentration-8/NN||measured-15/VBN	amod||therapy-18/NN||131i-17/JJ	prep_before||measured-15/VBN||therapy-18/NN	hypothyroidism-1||tsh-6||no_rel||hypothyroidism was confirmed by increased tsh blood concentration (brahms, germany), measured before 131i therapy.
det||government-2/NN||the-1/DT	nsubjpass||urged-5/VBN||government-2/NN	nsubj||include-7/VB||government-2/NN	aux||urged-5/VBN||should-3/MD	auxpass||urged-5/VBN||be-4/VB	root||ROOT-0/null||urged-5/VBN	aux||include-7/VB||to-6/TO	xcomp||urged-5/VBN||include-7/VB	det||people-9/NNS||these-8/DT	dobj||include-7/VB||people-9/NNS	amod||services-13/NNS||most-11/JJS	nn||services-13/NNS||prevention-12/NN	prep_in||people-9/NNS||services-13/NNS	amod||prevention-17/NN||hiv/aids-16/JJ	prep_including||people-9/NNS||prevention-17/NN	prep_including||people-9/NNS||treatment-19/NN	conj_and||prevention-17/NN||treatment-19/NN	aids--1||hiv--1||no||the government should be urged to include these people in most prevention services, including hiv/aids prevention and treatment.
aux||test-2/VB||to-1/TO	advcl||detected-7/VBD||test-2/VB	det||hypothesis-4/NNS||this-3/DT	dobj||test-2/VB||hypothesis-4/NNS	nsubj||detected-7/VBD||we-6/PRP	root||ROOT-0/null||detected-7/VBD	xcomp||detected-7/VBD||î-8/VB	number||2,3-10/CD||±-9/CD	dobj||î-8/VB||2,3-10/CD	nn||acid-17/NN||î-13/NN	amod||acid-17/NN||±-14/JJ	amod||acid-17/NN||2,6-linked-15/JJ	amod||acid-17/NN||sialic-16/JJ	dobj||î-8/VB||acid-17/NN	conj_and||2,3-10/CD||acid-17/NN	amod||polyp-21/NN||human-19/JJ	amod||polyp-21/NN||nasal-20/JJ	prep_in||acid-17/NN||polyp-21/NN	amod||tissues-26/NNS||normal-23/JJ	amod||tissues-26/NNS||nasal-24/JJ	amod||tissues-26/NNS||mucosal-25/JJ	dobj||î-8/VB||tissues-26/NNS	conj_and||2,3-10/CD||tissues-26/NNS	nn||staining-29/NN||lectin-28/NN	prep_by||tissues-26/NNS||staining-29/NN	amod||explants-32/NNS||infected-31/JJ	conj_and||2,3-10/CD||explants-32/NNS	conj_and||tissues-26/NNS||explants-32/NNS	det||tissues-35/NNS||those-34/DT	prep_of||explants-32/NNS||tissues-35/NNS	amod||h5n1-38/NNS||avianinfluenzaviruses-37/JJ	prep_with||î-8/VB||h5n1-38/NNS	amod||influenzaviruses-41/NNS||seasonal-40/JJ	prep_with||î-8/VB||influenzaviruses-41/NNS	conj_and||h5n1-38/NNS||influenzaviruses-41/NNS	avianinfluenza--1||influenzaviruses-41||no||to test this hypothesis, we detected î±2,3- and î±2,6-linked sialic acid in human nasal polyp and normal nasal mucosal tissues by lectin staining and infected explants of those tissues with avianinfluenzaviruses h5n1 and seasonal influenzaviruses.
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	impairedglucosetolerance-29||dm-44||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
prepc_based_on||become-18/VBN||on-2/IN	det||results-4/NNS||the-3/DT	pobj||become-18/VBN||results-4/NNS	amod||trials-8/NNS||several-6/JJ	amod||trials-8/NNS||randomized-7/JJ	prep_of||results-4/NNS||trials-8/NNS	nsubj||become-18/VBN||abciximab-10/NN	prep_with||abciximab-10/NN||uh-12/NN	prep_with||abciximab-10/NN||aspirin-14/NN	conj_and||uh-12/NN||aspirin-14/NN	prep_with||abciximab-10/NN||clopidogrel-16/NN	conj_and||uh-12/NN||clopidogrel-16/NN	aux||become-18/VBN||have-17/VBP	root||ROOT-0/null||become-18/VBN	det||therapy-22/NN||a-19/DT	amod||therapy-22/NN||standard-20/JJ	nn||therapy-22/NN||adjunctive-21/NN	xcomp||become-18/VBN||therapy-22/NN	amod||pci-25/NN||primary-24/JJ	prep_with||become-18/VBN||pci-25/NN	prep_for||pci-25/NN||ami-27/NN	ami-27||clopidogrel-16||yes||based on the results of several randomized trials, abciximab with uh, aspirin and clopidogrel have become a standard adjunctive therapy with primary pci for ami.
mark||used-7/VBN||although-1/IN	amod||drugs-4/NNS||many-2/JJ	amod||drugs-4/NNS||anti-diabetic-3/JJ	nsubjpass||used-7/VBN||drugs-4/NNS	nsubj||control-9/VB||drugs-4/NNS	aux||used-7/VBN||have-5/VBP	auxpass||used-7/VBN||been-6/VBN	advcl||has-27/VBZ||used-7/VBN	aux||control-9/VB||to-8/TO	xcomp||used-7/VBN||control-9/VB	dobj||control-9/VB||hyperglycemia-10/NN	prep_for||control-9/VB||decades-12/NNS	det||efficacy-15/NN||the-14/DT	nsubj||has-27/VBZ||efficacy-15/NN	nsubjpass||demonstrated-32/VBN||efficacy-15/NN	amod||agents-20/NNS||commonly-used-17/JJ	amod||agents-20/NNS||oral-18/JJ	amod||agents-20/NNS||glucose-lowering-19/JJ	prep_of||efficacy-15/NN||agents-20/NNS	amod||patients-26/NNS||korean-22/JJ	nn||patients-26/NNS||type-23/NN	num||patients-26/NNS||2-24/CD	amod||patients-26/NNS||diabetic-25/JJ	prep_in||agents-20/NNS||patients-26/NNS	root||ROOT-0/null||has-27/VBZ	advmod||has-27/VBZ||yet-28/RB	aux||demonstrated-32/VBN||to-29/TO	auxpass||demonstrated-32/VBN||be-30/VB	advmod||demonstrated-32/VBN||clearly-31/RB	xcomp||has-27/VBZ||demonstrated-32/VBN	hyperglycemia-10||glucose--1||no||although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in korean type 2 diabetic patients has yet to be clearly demonstrated.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||measured-9/VBD||we-8/PRP	rcmod||$-6/$||measured-9/VBD	nn||secretion-11/NN||insulin-10/NN	dobj||measured-9/VBD||secretion-11/NN	dobj||measured-9/VBD||action-13/NN	conj_and||secretion-11/NN||action-13/NN	nn||effectiveness-18/NN||glucose-17/NN	dobj||measured-9/VBD||effectiveness-18/NN	conj_and||secretion-11/NN||effectiveness-18/NN	num||subjects-21/NNS||14-20/CD	prep_in||measured-9/VBD||subjects-21/NNS	prep_with||subjects-21/NNS||type2diabetes-23/NNS	nsubj||received-25/VBD||type2diabetes-23/NNS	rcmod||type2diabetes-23/NNS||received-25/VBD	dobj||received-25/VBD||vildagliptin-26/NN	num||b.i.d.-30/NN||50-28/CD	nn||b.i.d.-30/NN||mg-29/NN	appos||vildagliptin-26/NN||b.i.d.-30/NN	dobj||received-25/VBD||placebo-33/NN	conj_or||vildagliptin-26/NN||placebo-33/NN	num||days-36/NNS||10-35/CD	prep_for||placebo-33/NN||days-36/NNS	amod||order-39/NN||random-38/JJ	prep_in||received-25/VBD||order-39/NN	vmod||order-39/NN||separated-40/VBN	det||washout-44/NN||a-42/DT	amod||washout-44/NN||3-week-43/JJ	agent||separated-40/VBN||washout-44/NN	type2diabetes-23||insulin-10||yes||research design and methods â€”we measured insulin secretion and action as well as glucose effectiveness in 14 subjects with type2diabetes who received vildagliptin (50 mg b.i.d.) or placebo for 10 days in random order separated by a 3-week washout.
nsubj||detected-2/VBD||we-1/PRP	root||ROOT-0/null||detected-2/VBD	number||1-4/CD||>-3/CD	num||virus-5/NN||1-4/CD	dobj||detected-2/VBD||virus-5/NN	prep_in||detected-2/VBD||120-7/CD	num||%-10/NN||53-9/CD	appos||120-7/CD||%-10/NN	amod||cases-14/NNS||ha-age-13/JJ	prep_of||120-7/CD||cases-14/NNS	nsubj||viruses-38/NNS||rotavirus-16/NNS	num||%-19/NN||31-18/CD	appos||rotavirus-16/NNS||%-19/NN	conj_and||rotavirus-16/NNS||norovirus-22/NNS	nsubj||viruses-38/NNS||norovirus-22/NNS	num||%-25/NN||16-24/CD	appos||norovirus-22/NNS||%-25/NN	conj_and||rotavirus-16/NNS||adenovirus-29/NNS	nsubj||viruses-38/NNS||adenovirus-29/NNS	dep||adenovirus-29/NNS||40/41-30/CD	num||%-33/NN||15-32/CD	appos||rotavirus-16/NNS||%-33/NN	cop||viruses-38/NNS||were-35/VBD	det||viruses-38/NNS||the-36/DT	amod||viruses-38/NNS||predominant-37/JJ	parataxis||detected-2/VBD||viruses-38/NNS	vmod||viruses-38/NNS||identified-39/VBN	virus-5||viruses-38||no||we detected > 1 virus in 120 (53%) of ha-age cases; rotavirus (31%), norovirus (16%), and adenovirus 40/41 (15%) were the predominant viruses identified.
det||extracts-3/NNS||the-1/DT	num||extracts-3/NNS||three-2/CD	nsubj||effective-6/JJ||extracts-3/NNS	cop||effective-6/JJ||were-4/VBD	advmod||effective-6/JJ||also-5/RB	ccomp||micrococcus-15/VBZ||effective-6/JJ	det||bacteria-10/NNS||all-8/DT	amod||bacteria-10/NNS||gram-positive-9/JJ	prep_against||effective-6/JJ||bacteria-10/NNS	vmod||bacteria-10/NNS||tested-11/VBN	amod||cereus-13/NNS||bacillus-12/JJ	dobj||tested-11/VBN||cereus-13/NNS	root||ROOT-0/null||micrococcus-15/VBZ	nsubj||micrococcus-15/VBZ||luteus-16/NNS	amod||staphylococcusaureus-19/NNS||methicillin-susceptible-18/JJ	appos||luteus-16/NNS||staphylococcusaureus-19/NNS	appos||staphylococcusaureus-19/NNS||mssa-21/NNP	amod||staphylococcusaureus-25/NNS||methicillin-resistant-24/JJ	appos||luteus-16/NNS||staphylococcusaureus-25/NNS	conj_and||staphylococcusaureus-19/NNS||staphylococcusaureus-25/NNS	appos||staphylococcusaureus-25/NNS||mrsa-27/NNP	amod||epidermidis-31/NNS||stapylococcus-30/JJ	appos||luteus-16/NNS||epidermidis-31/NNS	conj_and||staphylococcusaureus-19/NNS||epidermidis-31/NNS	amod||g/ml-40/NN||minimum-33/JJ	nn||g/ml-40/NN||inhibitory-34/NN	nn||g/ml-40/NN||concentration-35/NN	nn||g/ml-40/NN||mic-36/NN	num||g/ml-40/NN||15.6-250-37/CD	amod||g/ml-40/NN||î-38/JJ	num||g/ml-40/NN||1/4-39/CD	dep||epidermidis-31/NNS||g/ml-40/NN	amod||g/ml-49/NN||minimum-42/JJ	nn||g/ml-49/NN||bactericidal-43/NN	nn||g/ml-49/NN||concentration-44/NN	nn||g/ml-49/NN||mbc-45/NN	num||g/ml-49/NN||15.6-250-46/CD	amod||g/ml-49/NN||î-47/JJ	num||g/ml-49/NN||1/4-48/CD	dep||g/ml-40/NN||g/ml-49/NN	mrsa-27||staphylococcusaureus-25||no||the three extracts were also effective against all gram-positive bacteria tested bacillus cereus, micrococcus luteus , methicillin-susceptible staphylococcusaureus (mssa), methicillin-resistant staphylococcusaureus (mrsa) and stapylococcus epidermidis (minimum inhibitory concentration mic 15.6-250 î¼g/ml; minimum bactericidal concentration mbc 15.6-250 î¼g/ml).
det||strain-3/NN||the-1/DT	amod||strain-3/NN||h5n1-2/JJ	nsubjpass||involved-8/VBN||strain-3/NN	nsubjpass||found-20/VBN||strain-3/NN	prep_of||strain-3/NN||avianinfluenzavirus-5/NNS	aux||involved-8/VBN||has-6/VBZ	auxpass||involved-8/VBN||been-7/VBN	root||ROOT-0/null||involved-8/VBN	amod||mortality-11/NN||severe-10/JJ	prep_in||involved-8/VBN||mortality-11/NN	amod||poultry-14/NN||domestic-13/JJ	prep_in||mortality-11/NN||poultry-14/NN	aux||found-20/VBN||has-17/VBZ	advmod||found-20/VBN||also-18/RB	auxpass||found-20/VBN||been-19/VBN	conj_and||involved-8/VBN||found-20/VBN	amod||species-23/NNS||different-22/JJ	prep_in||found-20/VBN||species-23/NNS	prep_of||species-23/NNS||wildlife-25/NN	prep_in||found-20/VBN||europe-27/NN	h5n1-2||avianinfluenzavirus-5||no||the h5n1 strain of avianinfluenzavirus has been involved in severe mortality in domestic poultry, and has also been found in different species of wildlife in europe.
nsubj||indicate-5/VBP||findings-1/NNS	det||study-4/NN||this-3/DT	prep_from||findings-1/NNS||study-4/NN	root||ROOT-0/null||indicate-5/VBP	mark||limited-15/JJ||that-6/IN	amod||knowledge-8/NN||adequate-7/JJ	nsubjpass||limited-15/JJ||knowledge-8/NN	nsubjpass||associated-17/VBN||knowledge-8/NN	prep_of||knowledge-8/NN||hiv/aids-10/NNS	prep_among||hiv/aids-10/NNS||iraqi-12/NNS	auxpass||limited-15/JJ||is-13/VBZ	cop||limited-15/JJ||is-13/VBZ	advmod||limited-15/JJ||very-14/RB	ccomp||indicate-5/VBP||limited-15/JJ	ccomp||indicate-5/VBP||associated-17/VBN	conj_and||limited-15/JJ||associated-17/VBN	amod||status-20/NN||marital-19/JJ	prep_with||associated-17/VBN||status-20/NN	appos||status-20/NN||education-22/NN	appos||status-20/NN||wealth-24/NN	conj_and||education-22/NN||wealth-24/NN	appos||status-20/NN||place-27/NN	conj_and||education-22/NN||place-27/NN	prep_of||education-22/NN||residence-29/NN	aids--1||hiv--1||no||findings from this study indicate that adequate knowledge of hiv/aids among iraqi is very limited and associated with marital status, education, wealth, and place of residence.
expl||were-2/VBD||there-1/EX	ccomp||had-21/VBD||were-2/VBD	advmod||significant-4/JJ||statistically-3/RB	amod||differences-5/NNS||significant-4/JJ	nsubj||were-2/VBD||differences-5/NNS	det||groups-9/NNS||the-7/DT	num||groups-9/NNS||two-8/CD	prep_between||differences-5/NNS||groups-9/NNS	prepc_as||were-2/VBD||regard-11/NN	det||vas-14/NN||the-12/DT	amod||vas-14/NN||mean-13/JJ	dobj||regard-11/NN||vas-14/NN	num||hours-17/NNS||1,2,3,4-16/CD	prep_in||vas-14/NN||hours-17/NNS	amod||group-20/NN||fentanyl-19/JJ	nsubj||had-21/VBD||group-20/NN	root||ROOT-0/null||had-21/VBD	amod||score-25/NN||lower-22/JJR	amod||score-25/NN||median-23/JJ	nn||score-25/NN||pain-24/NN	dobj||had-21/VBD||score-25/NN	nn||group-28/NN||control-27/NN	prep_than||score-25/NN||group-28/NN	pain-24||fentanyl-19||yes||there were statistically significant differences between the two groups as regard the mean vas in 1,2,3,4 hours, fentanyl group had lower median pain score than control group.
amod||africa-2/NN||sub-saharan-1/JJ	nsubjpass||affected-6/VBN||africa-2/NN	aux||affected-6/VBN||has-3/VBZ	auxpass||affected-6/VBN||been-4/VBN	advmod||affected-6/VBN||severely-5/RB	root||ROOT-0/null||affected-6/VBN	det||pandemic-12/NN||the-8/DT	nn||pandemic-12/NN||hiv-9/NN	conj_and||hiv-9/NN||aids-11/NNS	nn||pandemic-12/NN||aids-11/NNS	agent||affected-6/VBN||pandemic-12/NN	aids-11||hiv-9||no||sub-saharan africa has been severely affected by the hiv and aids pandemic.
nsubj||reviewed-2/VBN||we-1/PRP	root||ROOT-0/null||reviewed-2/VBN	num||eyes-4/NNS||40-3/CD	dobj||reviewed-2/VBN||eyes-4/NNS	num||patients-7/NNS||39-6/CD	prep_of||eyes-4/NNS||patients-7/NNS	amod||diagnosis-10/NN||underlying-9/VBG	prep_with||reviewed-2/VBN||diagnosis-10/NN	nn||glaucoma-13/NN||neovascular-12/NN	prep_of||diagnosis-10/NN||glaucoma-13/NN	vmod||diagnosis-10/NN||divided-15/VBN	num||groups-18/NNS||two-17/CD	prep_into||divided-15/VBN||groups-18/NNS	vmod||groups-18/NNS||ahmed-19/VBN	nn||valve-21/NN||glaucoma-20/NN	dobj||ahmed-19/VBN||valve-21/NN	dep||valve-21/NN||n-23/VBN	dep||20-25/CD||=-24/SYM	ccomp||n-23/VBN||20-25/CD	dobj||ahmed-19/VBN||trabeculectomy-28/NN	conj_and||valve-21/NN||trabeculectomy-28/NN	prep_with||trabeculectomy-28/NN||mitomycinc-30/JJ	dep||trabeculectomy-28/NN||n-32/VBN	dep||20-34/CD||=-33/SYM	ccomp||n-32/VBN||20-34/CD	glaucoma-20||mitomycinc-30||yes||we reviewed 40 eyes of 39 patients with underlying diagnosis of neovascular glaucoma, divided into two groups ahmed glaucoma valve (n = 20) and trabeculectomy with mitomycinc (n = 20).
det||effort-2/NN||the-1/DT	nsubj||led-25/VBN||effort-2/NN	aux||develop-4/VB||to-3/TO	vmod||effort-2/NN||develop-4/VB	det||rin-20/NN||a-5/DT	nn||rin-20/NN||tuberculosis-6/NNP	appos||tuberculosis-6/NNP||tb-8/NN	nn||rin-20/NN||vaccine-10/NN	advmod||effective-12/JJ||more-11/RBR	amod||rin-20/NN||effective-12/JJ	det||bacille-17/NN||the-14/DT	advmod||used-16/VBN||widely-15/RB	amod||bacille-17/NN||used-16/VBN	prep_than||effective-12/JJ||bacille-17/NN	nn||rin-20/NN||calmette-guã-18/NNP	nn||rin-20/NN||©-19/NNP	dobj||develop-4/VB||rin-20/NN	appos||rin-20/NN||bcg-22/NN	aux||led-25/VBN||has-24/VBZ	root||ROOT-0/null||led-25/VBN	det||development-28/NN||the-27/DT	prep_to||led-25/VBN||development-28/NN	num||vaccines-35/NNS||two-30/CD	nn||vaccines-35/NNS||novel-31/NN	nn||vaccines-35/NNS||fusion-32/NN	nn||vaccines-35/NNS||protein-33/NN	nn||vaccines-35/NNS||subunit-34/NN	prep_of||development-28/NN||vaccines-35/NNS	amod||vaccines-35/NNS||ag85b-esat-6-36/JJ	amod||vaccines-35/NNS||ag85b-tb10-38/JJ	conj_and||ag85b-esat-6-36/JJ||ag85b-tb10-38/JJ	dobj||led-25/VBN||.4-39/CD	tb-8||bcg-22||no||the effort to develop a tuberculosis (tb) vaccine more effective than the widely used bacille calmette-guã©rin (bcg) has led to the development of two novel fusion protein subunit vaccines ag85b-esat-6 and ag85b-tb10.4.
amod||frequencies-2/NNS||genotype-1/JJ	nsubj||quartiles-22/VBZ||frequencies-2/NNS	conj_and||frequencies-2/NNS||measures-4/NNS	nsubj||quartiles-22/VBZ||measures-4/NNS	nn||secretion-7/NN||insulin-6/NN	prep_of||measures-4/NNS||secretion-7/NN	amod||traits-11/NNS||metabolic-10/JJ	conj_and||frequencies-2/NNS||traits-11/NNS	nsubj||quartiles-22/VBZ||traits-11/NNS	prep_within||traits-11/NNS||lada-13/NN	vmod||lada-13/NN||differed-14/VBN	prepc_according_to||differed-14/VBN||to-16/TO	nn||antibody-18/NN||gad-17/NN	pobj||differed-14/VBN||antibody-18/NN	appos||frequencies-2/NNS||gada-20/NNP	root||ROOT-0/null||quartiles-22/VBZ	cc||even-25/RB||but-24/CC	dep||quartiles-22/VBZ||even-25/RB	det||quartile-28/NN||the-26/DT	amod||quartile-28/NN||highest-27/JJS	dobj||quartiles-22/VBZ||quartile-28/NN	vmod||quartile-28/NN||differed-29/VBN	prep_from||differed-29/VBN||type1diabetes-31/CD	type1diabetes-31||insulin-6||yes||genotype frequencies, measures of insulin secretion, and metabolic traits within lada differed according to gad antibody (gada) quartiles, but even the highest quartile differed from type1diabetes.
nn||consortium-3/NN||tuberculosis-1/NNP	nn||consortium-3/NN||trials-2/NNS	nsubj||study-4/VBP||consortium-3/NN	ccomp||phase-16/NN||study-4/VBP	dobj||study-4/VBP||28-5/CD	cop||phase-16/NN||was-7/VBD	det||phase-16/NN||a-8/DT	amod||phase-16/NN||double-9/JJ	amod||phase-16/NN||blind-10/JJ	amod||phase-16/NN||randomized-12/JJ	amod||phase-16/NN||placebo-controlled-14/JJ	root||ROOT-0/null||phase-16/NN	num||trial-19/NN||2-17/CD	amod||trial-19/NN||clinical-18/JJ	nsubj||phase-16/NN||trial-19/NN	dep||phase-16/NN||examining-20/VBG	amod||mycobacteriumtuberculosis-24/NNS||smear-21/JJ	amod||mycobacteriumtuberculosis-24/NNS||positive-22/JJ	amod||mycobacteriumtuberculosis-24/NNS||pulmonary-23/JJ	dobj||examining-20/VBG||mycobacteriumtuberculosis-24/NNS	tuberculosis-1||mycobacteriumtuberculosis-24||no||tuberculosis trials consortium study 28, was a double blind, randomized, placebo-controlled, phase 2 clinical trial examining smear positive pulmonary mycobacteriumtuberculosis.
det||practice-2/NN||the-1/DT	nsubj||explanation-14/NN||practice-2/NN	prepc_of||practice-2/NN||combining-4/VBG	dobj||combining-4/VBG||agents-5/NNS	nsubj||counteract-7/VB||agents-5/NNS	rcmod||agents-5/NNS||counteract-7/VB	amod||mechanisms-9/NNS||different-8/JJ	dobj||counteract-7/VB||mechanisms-9/NNS	cop||explanation-14/NN||is-10/VBZ	det||explanation-14/NN||the-11/DT	advmod||likely-13/JJ||most-12/RBS	amod||explanation-14/NN||likely-13/JJ	root||ROOT-0/null||explanation-14/NN	det||fact-17/NN||the-16/DT	prep_for||explanation-14/NN||fact-17/NN	mark||have-23/VBP||that-18/IN	advmod||available-20/JJ||most-19/RBS	amod||combinations-22/NNS||available-20/JJ	amod||combinations-22/NNS||two-drug-21/JJ	nsubj||have-23/VBP||combinations-22/NNS	ccomp||explanation-14/NN||have-23/VBP	det||agent-25/NN||an-24/DT	dobj||have-23/VBP||agent-25/NN	nsubj||addresses-27/VBZ||agent-25/NN	rcmod||agent-25/NN||addresses-27/VBZ	nn||secretion-29/NN||renin-28/NN	dobj||addresses-27/VBZ||secretion-29/NN	dep||agent-25/NN||beta-blocker-31/NN	appos||beta-blocker-31/NN||angiotensinconvertingenzymeinhibitor-33/NN	nn||blocker-38/NN||angiotensin-35/NN	nn||blocker-38/NN||ii-36/NN	nn||blocker-38/NN||receptor-37/NN	appos||beta-blocker-31/NN||blocker-38/NN	amod||inhibitor-42/NN||direct-40/JJ	nn||inhibitor-42/NN||renin-41/NN	appos||beta-blocker-31/NN||inhibitor-42/NN	conj_or||blocker-38/NN||inhibitor-42/NN	det||one-46/NN||another-45/DT	conj_and||agent-25/NN||one-46/NN	nsubj||effective-50/JJ||one-46/NN	cop||effective-50/JJ||is-48/VBZ	advmod||effective-50/JJ||more-49/RBR	rcmod||one-46/NN||effective-50/JJ	amod||hypertension-53/NN||renin-independent-52/JJ	prep_in||effective-50/JJ||hypertension-53/NN	nn||calciumchannelblocker-60/NN||diuretic-55/NN	conj_or||diuretic-55/NN||dihydropyridine-57/NN	nn||calciumchannelblocker-60/NN||dihydropyridine-57/NN	conj_or||diuretic-55/NN||non-dihydropyridine-59/NN	nn||calciumchannelblocker-60/NN||non-dihydropyridine-59/NN	appos||one-46/NN||calciumchannelblocker-60/NN	hypertension-53||diuretic-55||no_rel||the practice of combining agents that counteract different mechanisms is the most likely explanation for the fact that most available two-drug combinations have an agent that addresses renin secretion (beta-blocker, angiotensinconvertingenzymeinhibitor, angiotensin ii receptor blocker or direct renin inhibitor) and another one that is more effective in renin-independent hypertension (diuretic, dihydropyridine or non-dihydropyridine calciumchannelblocker).
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||provides-11/VBZ||that-4/IN	det||combination-6/NN||the-5/DT	nsubj||provides-11/VBZ||combination-6/NN	amod||olmesartanmedoxomil-10/NN||amlodipine-8/JJ	amod||olmesartanmedoxomil-10/NN||+-9/JJ	prep_of||combination-6/NN||olmesartanmedoxomil-10/NN	ccomp||suggest-3/VBP||provides-11/VBZ	det||option-16/NN||a-12/DT	amod||option-16/NN||safe-13/JJ	conj_and||safe-13/JJ||effective-15/JJ	amod||option-16/NN||effective-15/JJ	dobj||provides-11/VBZ||option-16/NN	det||treatment-19/NN||the-18/DT	prep_for||option-16/NN||treatment-19/NN	prep_of||treatment-19/NN||hypertension-21/NN	prepc_in||provides-11/VBZ||challenging-23/VBG	amod||populations-25/NNS||patient-24/JJ	dobj||challenging-23/VBG||populations-25/NNS	olmesartanmedoxomil-10||hypertension-21||no_rel||these results suggest that the combination of amlodipine+olmesartanmedoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations.
det||model-6/NN||the-2/DT	amod||model-6/NN||simple-3/JJ	amod||model-6/NN||logistic-4/JJ	nn||model-6/NN||regression-5/NN	prep_in||found-52/VBN||model-6/NN	nsubjpass||found-52/VBN||age-8/NN	nsubj||significant-56/JJ||age-8/NN	appos||age-8/NN||p-10/NNP	number||0.0001-12/CD||<-11/CD	num||p-10/NNP||0.0001-12/CD	conj_and||age-8/NN||sex-15/NN	nsubjpass||found-52/VBN||sex-15/NN	nsubj||significant-56/JJ||sex-15/NN	dep||sex-15/NN||p-17/NN	dep||0.02-19/CD||=-18/SYM	rcmod||p-17/NN||0.02-19/CD	conj_and||age-8/NN||hypertension-22/NN	nsubjpass||found-52/VBN||hypertension-22/NN	nsubj||significant-56/JJ||hypertension-22/NN	appos||hypertension-22/NN||p-24/NNP	number||0.0001-26/CD||<-25/CD	num||p-24/NNP||0.0001-26/CD	conj_and||age-8/NN||diabetes-29/NN	nsubjpass||found-52/VBN||diabetes-29/NN	nsubj||significant-56/JJ||diabetes-29/NN	appos||diabetes-29/NN||p-31/NNP	number||.0001-33/CD||<-32/CD	num||p-31/NNP||.0001-33/CD	conj_and||age-8/NN||dyslipidemia-36/NN	nsubjpass||found-52/VBN||dyslipidemia-36/NN	nsubj||significant-56/JJ||dyslipidemia-36/NN	dep||dyslipidemia-36/NN||p-38/VBN	dep||.01-40/CD||=-39/SYM	ccomp||p-38/VBN||.01-40/CD	nn||albumin-45/NN||serum-44/NN	conj_and||age-8/NN||albumin-45/NN	nsubjpass||found-52/VBN||albumin-45/NN	nsubj||significant-56/JJ||albumin-45/NN	appos||age-8/NN||p-47/NNP	number||.0001-49/CD||<-48/CD	num||p-47/NNP||.0001-49/CD	auxpass||found-52/VBN||were-51/VBD	root||ROOT-0/null||found-52/VBN	aux||significant-56/JJ||to-53/TO	cop||significant-56/JJ||be-54/VB	advmod||significant-56/JJ||statistically-55/RB	xcomp||found-52/VBN||significant-56/JJ	hypertension-22||albumin-45||no_rel||in the simple logistic regression model, age (p<0.0001), sex (p= 0.02), hypertension (p<0.0001), diabetes (p<.0001), dyslipidemia (p=.01), and serum albumin (p<.0001) were found to be statistically significant.
advmod||determined-24/VBN||however-1/RB	prep_for||determined-24/VBN||duckenteritisvirus-4/NNS	appos||duckenteritisvirus-4/NNS||dev-6/NN	det||agent-11/NN||the-9/DT	amod||agent-11/NN||causative-10/JJ	appos||duckenteritisvirus-4/NNS||agent-11/NN	prep_of||agent-11/NN||duckviralenteritis-13/NNS	appos||duckviralenteritis-13/NNS||dve-15/NN	det||sequence-20/NN||the-18/DT	amod||sequence-20/NN||genomic-19/JJ	nsubjpass||determined-24/VBN||sequence-20/NN	auxpass||determined-24/VBN||was-21/VBD	neg||determined-24/VBN||not-22/RB	advmod||determined-24/VBN||completely-23/RB	root||ROOT-0/null||determined-24/VBN	prep_until||determined-24/VBN||most-26/JJS	advmod||most-26/JJS||recently-27/RB	duckviralenteritis-13||duckenteritisvirus-4||no||however, for duckenteritisvirus (dev), the causative agent of duckviralenteritis (dve), the genomic sequence was not completely determined until most recently.
nsubj||reduced-8/VBD||ticagrelor-1/NN	advmod||compared-4/VBN||when-3/WRB	rcmod||ticagrelor-1/NN||compared-4/VBN	prep_with||compared-4/VBN||clopidogrel-6/NN	root||ROOT-0/null||reduced-8/VBD	amod||events-10/NNS||ischaemic-9/JJ	dobj||reduced-8/VBD||events-10/NNS	nn||patients-13/NNS||acs-12/NN	prep_in||reduced-8/VBD||patients-13/NNS	amod||status-17/NN||diabetic-16/JJ	prep_irrespective_of||patients-13/NNS||status-17/NN	amod||control-20/NN||glycaemic-19/JJ	prep_irrespective_of||patients-13/NNS||control-20/NN	conj_and||status-17/NN||control-20/NN	det||increase-24/NN||an-23/DT	prep_without||reduced-8/VBD||increase-24/NN	amod||events-28/NNS||major-26/JJ	amod||events-28/NNS||bleeding-27/VBG	prep_in||increase-24/NN||events-28/NNS	bleeding-27||clopidogrel-6||no||ticagrelor, when compared with clopidogrel, reduced ischaemic events in acs patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events.
det||anthracycline-9/NN||all-1/DT	dep||anthracycline-9/NN||trans-3/NNS	amod||atra-6/NN||retinoicacid-4/JJ	dep||trans-3/NNS||atra-6/NN	punct||trans-3/NNS||/-8/:	nsubj||beneficial-12/JJ||anthracycline-9/NN	advmod||beneficial-12/JJ||chemotherapy-10/RB	cop||beneficial-12/JJ||is-11/VBZ	root||ROOT-0/null||beneficial-12/JJ	advmod||diagnosed-15/JJ||newly-14/RB	amod||acutepromyelocyticleukemia-16/NN||diagnosed-15/JJ	prep_in||beneficial-12/JJ||acutepromyelocyticleukemia-16/NN	appos||acutepromyelocyticleukemia-16/NN||apl-18/NN	advmod||important-25/JJ||however-21/RB	nsubj||important-25/JJ||it-23/PRP	nsubj||identify-27/VB||it-23/PRP	cop||important-25/JJ||is-24/VBZ	parataxis||beneficial-12/JJ||important-25/JJ	aux||identify-27/VB||to-26/TO	xcomp||important-25/JJ||identify-27/VB	dobj||identify-27/VB||patients-28/NNS	amod||disease-31/NN||high-risk-30/JJ	prep_with||patients-28/NNS||disease-31/NN	aux||increase-33/VB||to-32/TO	vmod||identify-27/VB||increase-33/VB	det||rate-36/NN||the-34/DT	nn||rate-36/NN||cure-35/NN	dobj||increase-33/VB||rate-36/NN	apl-18||atra-6||yes||all- trans retinoicacid (atra)/anthracycline chemotherapy is beneficial in newly diagnosed acutepromyelocyticleukemia (apl); however, it is important to identify patients with high-risk disease to increase the cure rate.
nsubj||lower-7/JJR||severity-1/NN	nn||pain-4/NN||injection-3/NN	prep_of||severity-1/NN||pain-4/NN	cop||lower-7/JJR||was-5/VBD	advmod||lower-7/JJR||significantly-6/RB	root||ROOT-0/null||lower-7/JJR	det||group-25/NN||the-9/DT	amod||group-25/NN||sufentanil-10/JJ	dep||sufentanil-10/JJ||0.3-11/CD	nn||group-25/NN||âµg-12/NN	punct||group-15/NN||/-13/:	nn||group-15/NN||kg-14/NN	dep||group-25/NN||group-15/NN	amod||saline-18/NN||normal-17/JJ	prep_than||group-15/NN||saline-18/NN	amod||âµg-22/NN||sufentanil-20/JJ	num||âµg-22/NN||0.1-21/CD	prep_than||group-15/NN||âµg-22/NN	conj_and||saline-18/NN||âµg-22/NN	punct||group-15/NN||/-23/:	amod||group-25/NN||kg-24/JJ	prep_in||lower-7/JJR||group-25/NN	pain-4||sufentanil-20||yes||severity of injection pain was significantly lower in the sufentanil 0.3 âµg/kg group than normal saline and sufentanil 0.1 âµg/kg group.
num||controls-3/NNS||seventeen-1/CD	amod||controls-3/NNS||healthy-2/JJ	nsubj||participated-27/VBD||controls-3/NNS	appos||controls-3/NNS||hc-5/NN	num||patients-9/NNS||20-8/CD	conj_and||controls-3/NNS||patients-9/NNS	nsubj||participated-27/VBD||patients-9/NNS	amod||disease-15/NN||crohnâ-11/JJ	amod||disease-15/NN||$-12/$	number||s-14/CD||™-13/CD	num||$-12/$||s-14/CD	prep_with||patients-9/NNS||disease-15/NN	appos||patients-9/NNS||cd-17/NN	num||patients-21/NNS||22-20/CD	conj_and||controls-3/NNS||patients-21/NNS	nsubj||participated-27/VBD||patients-21/NNS	prep_with||patients-21/NNS||ulcerativecolitis-23/NNS	appos||controls-3/NNS||uc-25/NN	root||ROOT-0/null||participated-27/VBD	det||study-30/NN||the-29/DT	prep_in||participated-27/VBD||study-30/NN	cd-17||ulcerativecolitis-23||no_rel||seventeen healthy controls (hc), 20 patients with crohnâ€™s disease (cd) and 22 patients with ulcerativecolitis (uc) participated in the study.
det||index-4/NN||the-1/DT	amod||index-4/NN||simplified-2/VBN	nn||index-4/NN||tf-3/NN	nsubj||proved-5/VBD||index-4/NN	root||ROOT-0/null||proved-5/VBD	acomp||proved-5/VBD||suitable-6/JJ	prepc_for||suitable-6/JJ||determining-8/VBG	det||prevalence-10/NN||the-9/DT	dobj||determining-8/VBG||prevalence-10/NN	prep_of||prevalence-10/NN||dentalfluorosis-12/NNS	prep_in||dentalfluorosis-12/NNS||regions-14/NNS	amod||fluorosis-17/NNS||endemic-16/JJ	prep_with||determining-8/VBG||fluorosis-17/NNS	vmod||fluorosis-17/NNS||caused-18/VBN	det||ingestion-21/NN||the-20/DT	agent||caused-18/VBN||ingestion-21/NN	prep_of||ingestion-21/NN||water-23/NN	amod||concentrations-26/NNS||high-25/JJ	prep_with||caused-18/VBN||concentrations-26/NNS	prep_of||concentrations-26/NNS||fluoride-28/NN	dentalfluorosis-12||fluoride-28||no||the simplified tf index proved suitable for determining the prevalence of dentalfluorosis in regions with endemic fluorosis caused by the ingestion of water with high concentrations of fluoride.
aux||characterize-2/VB||to-1/TO	csubj||randomized-38/VBD||characterize-2/VB	det||amount-4/NN||the-3/DT	dobj||characterize-2/VB||amount-4/NN	amod||hypoglycemia-7/NN||nocturnal-6/JJ	prep_of||amount-4/NN||hypoglycemia-7/NN	conj_and||characterize-2/VB||evaluate-9/VB	csubj||randomized-38/VBD||evaluate-9/VB	dobj||evaluate-9/VB||factors-10/NNS	vmod||factors-10/NNS||associated-11/VBN	amod||hypoglycemia-14/NN||nocturnal-13/JJ	prep_with||associated-11/VBN||hypoglycemia-14/NN	vmod||hypoglycemia-14/NN||assessed-15/VBN	amod||monitoring-19/NN||continuous-17/JJ	nn||monitoring-19/NN||glucose-18/NN	prep_with||assessed-15/VBN||monitoring-19/NN	appos||monitoring-19/NN||cgm-21/NN	prep_in||monitoring-19/NN||adults-24/NNS	prep_in||monitoring-19/NN||children-26/NNS	conj_and||adults-24/NNS||children-26/NNS	prep_with||assessed-15/VBN||type1diabetes-28/NNS	nsubj||participated-30/VBD||type1diabetes-28/NNS	rcmod||type1diabetes-28/NNS||participated-30/VBD	det||cgm-37/NN||the-32/DT	amod||cgm-37/NN||juvenile-33/JJ	nn||cgm-37/NN||diabetes-34/NN	nn||cgm-37/NN||research-35/NN	nn||cgm-37/NN||foundation-36/NN	prep_in||participated-30/VBD||cgm-37/NN	root||ROOT-0/null||randomized-38/VBD	amod||trial-40/NN||clinical-39/JJ	dobj||randomized-38/VBD||trial-40/NN	glucose-18||type1diabetes-28||no_rel||to characterize the amount of nocturnal hypoglycemia and evaluate factors associated with nocturnal hypoglycemia assessed with continuous glucose monitoring (cgm) in adults and children with type1diabetes who participated in the juvenile diabetes research foundation cgm randomized clinical trial.
nsubjpass||demonstrated-5/VBN||it-1/PRP	aux||demonstrated-5/VBN||has-2/VBZ	advmod||demonstrated-5/VBN||recently-3/RB	auxpass||demonstrated-5/VBN||been-4/VBN	root||ROOT-0/null||demonstrated-5/VBN	mark||neuroendocrine-10/VBP||that-6/IN	amod||cell-9/NN||early-7/JJ	amod||cell-9/NN||small-8/JJ	nsubj||neuroendocrine-10/VBP||cell-9/NN	ccomp||demonstrated-5/VBN||neuroendocrine-10/VBP	nsubj||shows-15/VBZ||cancer-11/NN	det||breast-14/NN||the-13/DT	prep_of||cancer-11/NN||breast-14/NN	ccomp||neuroendocrine-10/VBP||shows-15/VBZ	det||prognosis-18/NN||a-16/DT	amod||prognosis-18/NN||good-17/JJ	dobj||shows-15/VBZ||prognosis-18/NN	amod||treatments-21/NNS||adjuvant-20/JJ	prep_with||shows-15/VBZ||treatments-21/NNS	amod||survival-26/NN||high-23/JJ	nn||survival-26/NN||disease-24/NN	amod||survival-26/NN||free-25/JJ	prep_with||treatments-21/NNS||survival-26/NN	cancer-11||adjuvant-20||no_rel||it has recently been demonstrated that early small cell neuroendocrine cancer of the breast shows a good prognosis with adjuvant treatments with high disease free survival.
nsubj||appear-4/VBP||prochlorperazine-1/NN	nsubj||effective-8/JJ||prochlorperazine-1/NN	conj_and||prochlorperazine-1/NN||ondansetron-3/NN	nsubj||appear-4/VBP||ondansetron-3/NN	nsubj||effective-8/JJ||ondansetron-3/NN	root||ROOT-0/null||appear-4/VBP	aux||effective-8/JJ||to-5/TO	cop||effective-8/JJ||be-6/VB	advmod||effective-8/JJ||equally-7/RB	xcomp||appear-4/VBP||effective-8/JJ	prepc_at||effective-8/JJ||treating-10/VBG	dobj||treating-10/VBG||vomiting-11/NN	det||department-15/NN||the-13/DT	nn||department-15/NN||emergency-14/NN	prep_in||treating-10/VBG||department-15/NN	vomiting-11||prochlorperazine-1||yes||prochlorperazine and ondansetron appear to be equally effective at treating vomiting in the emergency department.
amod||resonance-4/NN||manganese-enhanced-1/JJ	amod||resonance-4/NN||cardiovascular-2/JJ	amod||resonance-4/NN||magnetic-3/JJ	nsubj||assess-10/VB||resonance-4/NN	appos||resonance-4/NN||mecmr-6/NN	aux||assess-10/VB||can-8/MD	advmod||assess-10/VB||non-invasively-9/RB	root||ROOT-0/null||assess-10/VB	amod||influx-13/NN||myocardial-11/JJ	nn||influx-13/NN||calcium-12/NN	dobj||assess-10/VB||influx-13/NN	nn||levels-17/NNS||calcium-16/NN	nsubjpass||known-19/VBN||levels-17/NNS	nsubjpass||elevated-22/VBN||levels-17/NNS	auxpass||known-19/VBN||are-18/VBP	conj_and||assess-10/VB||known-19/VBN	aux||elevated-22/VBN||to-20/TO	auxpass||elevated-22/VBN||be-21/VB	xcomp||known-19/VBN||elevated-22/VBN	amod||cardiomyopathy-25/NN||musculardystrophy-24/JJ	prep_in||elevated-22/VBN||cardiomyopathy-25/NN	prepc_based_on||elevated-22/VBN||on-27/IN	amod||studies-29/NNS||cellular-28/JJ	pobj||elevated-22/VBN||studies-29/NNS	manganese--1||cardiomyopathy-25||no_rel||manganese-enhanced cardiovascular magnetic resonance (mecmr) can non-invasively assess myocardial calcium influx, and calcium levels are known to be elevated in musculardystrophy cardiomyopathy based on cellular studies.
nsubjpass||tested-3/VBN||replication-1/NN	auxpass||tested-3/VBN||was-2/VBD	root||ROOT-0/null||tested-3/VBN	num||patients-8/NNS||390-5/CD	amod||patients-8/NNS||white-6/JJ	nn||patients-8/NNS||canadian-7/NN	prep_in||tested-3/VBN||patients-8/NNS	prep_with||patients-8/NNS||peanutallergy-10/NN	dep||patients-8/NNS||defined-12/VBN	prep||defined-12/VBN||by-13/IN	nn||challenge-15/NN||food-14/NN	pobj||by-13/IN||challenge-15/NN	amod||history-19/NN||clinical-18/JJ	prep||defined-12/VBN||history-19/NN	conj_or||by-13/IN||history-19/NN	pobj||by-13/IN||history-19/NN	nn||test-23/NN||skin-21/NN	nn||test-23/NN||prick-22/NN	conj_or||by-13/IN||test-23/NN	pobj||by-13/IN||test-23/NN	conj_and||history-19/NN||test-23/NN	amod||history-19/NN||wheal-24/JJ	nn||kulâˆ-39/NNS||peanut-26/NN	nn||kulâˆ-39/NNS||â-27/NN	nn||kulâˆ-39/NNS||‰-28/NNP	nn||kulâˆ-39/NNS||¥-29/NNP	num||kulâˆ-39/NNS||8-30/CD	nn||kulâˆ-39/NNS||mm-31/NN	nn||kulâˆ-39/NNS||and/or-32/NN	nn||kulâˆ-39/NNS||peanut-specific-33/NN	nn||kulâˆ-39/NNS||ige-34/NN	nn||kulâˆ-39/NNS||â-35/NN	nn||kulâˆ-39/NNS||‰-36/NNP	nn||kulâˆ-39/NNS||¥-37/NNP	num||kulâˆ-39/NNS||15-38/CD	prep_to||wheal-24/JJ||kulâˆ-39/NNS	dobj||defined-12/VBN||1-41/CD	num||controls-48/NNS||891-44/CD	amod||controls-48/NNS||white-45/JJ	nn||controls-48/NNS||canadian-46/NN	nn||controls-48/NNS||population-47/NN	prep_in||tested-3/VBN||controls-48/NNS	conj_and||patients-8/NNS||controls-48/NNS	peanutallergy-10||peanut-26||no||replication was tested in 390 white canadian patients with peanutallergy (defined by food challenge, or clinical history and skin prick test wheal to peanut â‰¥8 mm and/or peanut-specific ige â‰¥15 kulâˆ’1) and 891 white canadian population controls.
num||patients-2/NNS||ten-1/CD	nsubj||maintained-20/VBD||patients-2/NNS	det||uc-group-5/NN||the-4/DT	prep_in||patients-2/NNS||uc-group-5/NN	num||%-8/NN||66-7/CD	appos||uc-group-5/NN||%-8/NN	num||patients-12/NNS||16-11/CD	prep_in||patients-2/NNS||patients-12/NNS	conj_and||uc-group-5/NN||patients-12/NNS	det||cd-group-15/NN||the-14/DT	prep_in||patients-12/NNS||cd-group-15/NN	num||%-18/NN||64-17/CD	appos||cd-group-15/NN||%-18/NN	root||ROOT-0/null||maintained-20/VBD	amod||remission-24/NNS||clinical-21/JJ	conj_and||clinical-21/JJ||endoscopic-23/JJ	amod||remission-24/NNS||endoscopic-23/JJ	dobj||maintained-20/VBD||remission-24/NNS	det||average-27/NN||an-26/DT	prep_for||maintained-20/VBD||average-27/NN	num||months-30/NNS||14-29/CD	prep_of||average-27/NN||months-30/NNS	uc--1||cd--1||no_rel||ten patients in the uc-group (66%) and 16 patients in the cd-group (64%) maintained clinical and endoscopic remission for an average of 14 months.
det||role-4/NN||a-1/DT	amod||role-4/NN||key-2/JJ	amod||role-4/NN||pathogenic-3/JJ	nsubjpass||proposed-8/VBN||role-4/NN	prep_in||role-4/NN||priondiseases-6/NNS	auxpass||proposed-8/VBN||was-7/VBD	root||ROOT-0/null||proposed-8/VBN	det||form-12/NN||a-10/DT	amod||form-12/NN||cytosolic-11/JJ	prep_for||proposed-8/VBN||form-12/NN	det||prionprotein-15/NN||the-14/DT	prep_of||form-12/NN||prionprotein-15/NN	appos||prionprotein-15/NN||prp-17/NN	priondiseases-6||prionprotein-15||no||a key pathogenic role in priondiseases was proposed for a cytosolic form of the prionprotein (prp).
mark||available-6/JJ||although-1/IN	det||budget-4/NN||a-2/DT	amod||budget-4/NN||sizeable-3/JJ	nsubj||available-6/JJ||budget-4/NN	cop||available-6/JJ||is-5/VBZ	advcl||resources-18/NNS||available-6/JJ	amod||control-9/NN||hiv/aids-8/JJ	prep_for||available-6/JJ||control-9/NN	prep_in||control-9/NN||thailand-11/NN	expl||resources-18/NNS||there-13/EX	aux||resources-18/NNS||will-14/MD	neg||resources-18/NNS||never-15/RB	cop||resources-18/NNS||be-16/VB	amod||resources-18/NNS||enough-17/JJ	root||ROOT-0/null||resources-18/NNS	aux||implement-20/VB||to-19/TO	vmod||resources-18/NNS||implement-20/VB	det||programme-22/NN||every-21/DT	dobj||implement-20/VB||programme-22/NN	det||groups-26/NNS||all-24/DT	nn||groups-26/NNS||target-25/NN	prep_for||programme-22/NN||groups-26/NNS	amod||scale-29/NN||full-28/JJ	prep_at||implement-20/VB||scale-29/NN	aids--1||hiv--1||no||although a sizeable budget is available for hiv/aids control in thailand, there will never be enough resources to implement every programme for all target groups at full scale.
nn||obesus-3/NNS||p.-2/NN	prep_in||²-6/VBZ||obesus-3/NNS	det||ikkî-5/NN||the-4/DT	nsubj||²-6/VBZ||ikkî-5/NN	root||ROOT-0/null||²-6/VBZ	nsubj||prevented-9/VBD||inhibitor-8/NN	nsubj||maintained-18/VBD||inhibitor-8/NN	parataxis||²-6/VBZ||prevented-9/VBD	det||development-11/NN||the-10/DT	dobj||prevented-9/VBD||development-11/NN	prep_of||development-11/NN||hyperglycaemia-13/NN	prep_of||development-11/NN||hyperinsulinaemia-15/NN	conj_and||hyperglycaemia-13/NN||hyperinsulinaemia-15/NN	parataxis||²-6/VBZ||maintained-18/VBD	conj_and||prevented-9/VBD||maintained-18/VBD	amod||stores-21/NNS||pancreatic-19/JJ	nn||stores-21/NNS||insulin-20/NN	dobj||maintained-18/VBD||stores-21/NNS	neg||effect-24/NN||no-23/DT	prep_with||maintained-18/VBD||effect-24/NN	nn||weight-27/NN||body-26/NN	prep_on||effect-24/NN||weight-27/NN	hyperglycaemia-13||insulin-20||yes||in p. obesus the ikkî ² - inhibitor prevented the development of hyperglycaemia and hyperinsulinaemia , and maintained pancreatic insulin stores with no effect on body weight .
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-14/VBZ||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	appos||infants-5/NNS||ipti-7/NNP	prep_with||infants-5/NNS||sulphadoxine-pyrimethamine-10/NN	appos||treatment-3/NN||sp-12/NN	root||ROOT-0/null||reduces-14/VBZ	det||incidence-16/NN||the-15/DT	dobj||reduces-14/VBZ||incidence-16/NN	nn||episodes-19/NNS||malaria-18/NN	prep_of||incidence-16/NN||episodes-19/NNS	amod||children-22/NNS||young-21/JJ	prep_in||episodes-19/NNS||children-22/NNS	malaria-18||pyrimethamine--1||yes||intermittent preventive treatment in infants (ipti) with sulphadoxine-pyrimethamine (sp) reduces the incidence of malaria episodes in young children.
nsubjpass||related-7/VBN||myelitis-1/NNS	nsubj||responsive-15/JJ||myelitis-1/NNS	det||patients-4/NNS||these-3/DT	prep_in||myelitis-1/NNS||patients-4/NNS	auxpass||related-7/VBN||was-5/VBD	neg||related-7/VBN||not-6/RB	root||ROOT-0/null||related-7/VBN	amod||reconstitution-12/NN||graftversushostdisease-9/JJ	conj_or||graftversushostdisease-9/JJ||immune-11/JJ	amod||reconstitution-12/NN||immune-11/JJ	prep_to||related-7/VBN||reconstitution-12/NN	cop||responsive-15/JJ||was-14/VBD	conj_and||related-7/VBN||responsive-15/JJ	amod||methylprednisolone-18/NN||intravenous-17/JJ	prep_to||responsive-15/JJ||methylprednisolone-18/NN	prep_to||responsive-15/JJ||cyclophosphamide-20/NN	conj_and||methylprednisolone-18/NN||cyclophosphamide-20/NN	graftversushostdisease-9||methylprednisolone-18||yes||myelitis in these patients was not related to graftversushostdisease or immune reconstitution and was responsive to intravenous methylprednisolone and cyclophosphamide.
det||majority-3/NN||the-1/DT	amod||majority-3/NN||great-2/JJ	nsubj||are-9/VBP||majority-3/NN	nn||complications-6/NNS||lung-5/NN	prep_of||majority-3/NN||complications-6/NNS	prep_of||complications-6/NNS||hiv/aids-8/NNS	root||ROOT-0/null||are-9/VBP	amod||etiology-12/NN||infectious-11/JJ	prep_of||are-9/VBP||etiology-12/NN	nsubj||add-23/VBP||neoplasm-14/NN	amod||pneumonias-17/NNS||interstitial-16/JJ	conj_and||neoplasm-14/NN||pneumonias-17/NNS	nsubj||add-23/VBP||pneumonias-17/NNS	amod||sarcoma-20/NN||kaposi-19/JJ	conj_and||neoplasm-14/NN||sarcoma-20/NN	nsubj||add-23/VBP||sarcoma-20/NN	conj_and||neoplasm-14/NN||lymphomas-22/NNS	nsubj||add-23/VBP||lymphomas-22/NNS	conj_but||are-9/VBP||add-23/VBP	advmod||add-23/VBP||significantly-24/RB	nn||morbidity-27/NN||patient-26/NN	prep_to||add-23/VBP||morbidity-27/NN	prep_to||add-23/VBP||mortality-29/NN	conj_and||morbidity-27/NN||mortality-29/NN	aids--1||hiv--1||no||the great majority of lung complications of hiv/aids are of infectious etiology but neoplasm, interstitial pneumonias, kaposi sarcoma and lymphomas add significantly to patient morbidity and mortality.
aux||evaluate-2/VB||to-1/TO	advcl||evaluated-27/VBN||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	prep_of||effects-4/NNS||cyclosporina-6/NN	appos||cyclosporina-6/NN||cya-8/NN	amod||outcome-12/NN||clinical-11/JJ	prep_on||evaluate-2/VB||outcome-12/NN	amod||changes-15/NNS||pathologic-14/JJ	prep_on||evaluate-2/VB||changes-15/NNS	conj_and||outcome-12/NN||changes-15/NNS	prep_in||outcome-12/NN||children-17/NNS	nn||nephropathy-20/NN||iga-19/NN	prep_with||children-17/NNS||nephropathy-20/NN	appos||nephropathy-20/NN||igan-22/NN	nsubj||evaluated-27/VBN||we-25/PRP	advmod||evaluated-27/VBN||retrospectively-26/RB	root||ROOT-0/null||evaluated-27/VBN	num||children-29/NNS||14-28/CD	dobj||evaluated-27/VBN||children-29/NNS	nsubjpass||treated-47/VBN||children-29/NNS	dep||children-29/NNS||mean-31/VB	nn||±-35/NN||age-32/NN	num||±-35/NN||8.9-33/CD	nn||±-35/NN||â-34/NN	dobj||mean-31/VB||±-35/NN	num||yr-37/NN||2.9-36/CD	dep||±-35/NN||yr-37/NN	num||males-40/NNS||eight-39/CD	dep||±-35/NN||males-40/NNS	num||females-43/NNS||six-42/CD	appos||males-40/NNS||females-43/NNS	auxpass||treated-47/VBN||were-46/VBD	rcmod||children-29/NNS||treated-47/VBN	prep_with||treated-47/VBN||cya-49/NN	prep_with||treated-47/VBN||steroids-51/NNS	conj_and||cya-49/NN||steroids-51/NNS	nephropathy-20||cyclosporina-6||no_rel||to evaluate the effects of cyclosporina (cya) on clinical outcome and pathologic changes in children with iga nephropathy (igan), we retrospectively evaluated 14 children (mean age 8.9â±2.9 yr; eight males, six females) who were treated with cya and steroids.
nsubj||bioequivalent-3/JJ||fosaprepitant-1/NN	nsubj||aprepitant-5/VB||fosaprepitant-1/NN	nsubj||offer-9/VB||fosaprepitant-1/NN	cop||bioequivalent-3/JJ||is-2/VBZ	root||ROOT-0/null||bioequivalent-3/JJ	aux||aprepitant-5/VB||to-4/TO	xcomp||bioequivalent-3/JJ||aprepitant-5/VB	aux||offer-9/VB||could-8/MD	conj_and||bioequivalent-3/JJ||offer-9/VB	amod||benefits-11/NNS||potential-10/JJ	dobj||offer-9/VB||benefits-11/NNS	prep_for||offer-9/VB||patients-13/NNS	nsubj||unable-17/JJ||patients-13/NNS	nsubj||tolerate-19/VB||patients-13/NNS	aux||unable-17/JJ||may-15/MD	cop||unable-17/JJ||be-16/VB	rcmod||patients-13/NNS||unable-17/JJ	aux||tolerate-19/VB||to-18/TO	xcomp||unable-17/JJ||tolerate-19/VB	amod||administration-21/NN||oral-20/JJ	dobj||tolerate-19/VB||administration-21/NN	prep_of||administration-21/NN||antiemetics-23/NNS	det||episode-26/NN||an-25/DT	prep_during||tolerate-19/VB||episode-26/NN	prep_of||episode-26/NN||nausea-28/NN	prep_of||episode-26/NN||vomiting-30/NN	conj_or||nausea-28/NN||vomiting-30/NN	nausea-28||antiemetics-23||no_rel||fosaprepitant is bioequivalent to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting.
det||results-2/NNS||the-1/DT	nsubj||provide-6/VBP||results-2/NNS	det||study-5/NN||this-4/DT	prep_of||results-2/NNS||study-5/NN	root||ROOT-0/null||provide-6/VBP	amod||evidence-8/NN||preliminary-7/JJ	dobj||provide-6/VBP||evidence-8/NN	det||efficacy-11/NN||the-10/DT	prep_for||provide-6/VBP||efficacy-11/NN	prep_of||efficacy-11/NN||lacosamide-13/NN	prep_in||lacosamide-13/NN||children-15/NNS	amod||epilepsy-18/NN||refractory-17/JJ	prep_with||children-15/NNS||epilepsy-18/NN	epilepsy-18||lacosamide-13||yes||the results of this study provide preliminary evidence for the efficacy of lacosamide in children with refractory epilepsy.
det||patient-2/NN||a-1/DT	nsubj||one-10/CD||patient-2/NN	det||valproicacid-8/NN||an-4/DT	amod||valproicacid-8/NN||early-5/JJ	amod||valproicacid-8/NN||diagnosed-6/JJ	nn||valproicacid-8/NN||epilepsy-7/NN	prep_with||patient-2/NN||valproicacid-8/NN	cop||one-10/CD||is-9/VBZ	root||ROOT-0/null||one-10/CD	det||drugs-17/NNS||the-12/DT	advmod||used-15/VBN||most-13/RBS	advmod||used-15/VBN||widely-14/RB	amod||drugs-17/NNS||used-15/VBN	amod||drugs-17/NNS||antiepileptic-16/JJ	prep_of||one-10/CD||drugs-17/NNS	epilepsy-7||valproicacid-8||yes||a patient with an early diagnosed epilepsy valproicacid is one of the most widely used antiepileptic drugs.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	amod||isolates-5/NNS||consecutive-3/JJ	nn||isolates-5/NNS||falciparummalaria-4/NN	dobj||analyzed-2/VBD||isolates-5/NNS	nn||travelers-8/NNS||canadian-7/NN	prep_from||analyzed-2/VBD||travelers-8/NNS	num||2000-12/CD||1994-10/CD	dep||2000-12/CD||to-11/TO	prep_from||analyzed-2/VBD||2000-12/CD	prep_for||analyzed-2/VBD||polymorphisms-15/NNS	prep_in||polymorphisms-15/NNS||pfcrt-17/NN	prep_in||polymorphisms-15/NNS||dhfr-19/NN	conj_and||pfcrt-17/NN||dhfr-19/NN	prep_in||polymorphisms-15/NNS||dhps-22/NN	conj_and||pfcrt-17/NN||dhps-22/NN	vmod||pfcrt-17/NN||linked-23/VBN	aux||chloroquine-25/VB||to-24/TO	xcomp||linked-23/VBN||chloroquine-25/VB	xcomp||linked-23/VBN||pyrimethamine/sulfadoxine-27/VB	conj_and||chloroquine-25/VB||pyrimethamine/sulfadoxine-27/VB	dobj||chloroquine-25/VB||resistance-28/NN	falciparummalaria-4||chloroquine-25||yes||we analyzed consecutive falciparummalaria isolates from canadian travelers from 1994 to 2000, for polymorphisms in pfcrt, dhfr, and dhps linked to chloroquine and pyrimethamine/sulfadoxine resistance.
nn||activity-2/NN||dgc-1/NN	nsubjpass||required-5/VBN||activity-2/NN	nsubjpass||required-17/VBN||activity-2/NN	auxpass||required-5/VBN||was-3/VBD	advmod||required-5/VBN||also-4/RB	root||ROOT-0/null||required-5/VBN	det||phenotype-10/NN||the-7/DT	amod||phenotype-10/NN||hms-independent-8/JJ	nn||phenotype-10/NN||autoaggregation-9/NN	prep_for||required-5/VBN||phenotype-10/NN	prep_of||phenotype-10/NN||y.pestis-12/NNS	auxpass||required-17/VBN||was-15/VBD	neg||required-17/VBN||not-16/RB	conj_but||required-5/VBN||required-17/VBN	prep_for||required-17/VBN||virulence-19/NN	det||model-23/NN||a-21/DT	nn||model-23/NN||mouse-22/NN	prep_in||required-17/VBN||model-23/NN	prep_of||model-23/NN||bubonicplague-25/NN	bubonicplague-25||y.pestis-12||no||dgc activity was also required for the hms-independent autoaggregation phenotype of y.pestis , but was not required for virulence in a mouse model of bubonicplague .
nsubjpass||expressed-4/VBN||mrp7-1/NNS	auxpass||expressed-4/VBN||is-2/VBZ	advmod||expressed-4/VBN||highly-3/RB	root||ROOT-0/null||expressed-4/VBN	amod||cells-7/NNS||non-smallcelllungcancer-6/JJ	prep_in||expressed-4/VBN||cells-7/NNS	amod||mice-11/NNS||mrp7-ko-10/JJ	nsubj||sensitive-14/JJ||mice-11/NNS	cop||sensitive-14/JJ||are-12/VBP	advmod||sensitive-14/JJ||highly-13/RB	conj_and||expressed-4/VBN||sensitive-14/JJ	prep_to||sensitive-14/JJ||paclitaxel-16/NN	xcomp||sensitive-14/JJ||making-18/VBG	amod||target-23/NN||mrp7-19/JJ	det||target-23/NN||an-20/DT	amod||chemotherapeutic-22/JJ||attractive-21/JJ	amod||target-23/NN||chemotherapeutic-22/JJ	dobj||making-18/VBG||target-23/NN	prep_of||target-23/NN||non-smallcelllungcancer-25/NN	non-smallcelllungcancer-25||paclitaxel-16||no_rel||mrp7 is highly expressed in non-smallcelllungcancer cells, and mrp7-ko mice are highly sensitive to paclitaxel, making mrp7 an attractive chemotherapeutic target of non-smallcelllungcancer.
mark||focused-10/VBN||while-1/IN	amod||mechanisms-3/NNS||prior-2/JJ	nsubj||focused-10/VBN||mechanisms-3/NNS	prep_of||mechanisms-3/NNS||apoptosis-5/NNS	vmod||apoptosis-5/NNS||induced-6/VBN	agent||induced-6/VBN||taxol-8/NN	aux||focused-10/VBN||have-9/VBP	advcl||find-18/VBP||focused-10/VBN	prep_on||focused-10/VBN||changes-12/NNS	nn||levels-15/NNS||bim-14/NN	prep_in||changes-12/NNS||levels-15/NNS	nsubj||find-18/VBP||we-17/PRP	root||ROOT-0/null||find-18/VBP	mark||required-24/VBN||that-19/IN	det||increase-21/NN||an-20/DT	nsubjpass||required-24/VBN||increase-21/NN	auxpass||required-24/VBN||is-22/VBZ	neg||required-24/VBN||not-23/RB	ccomp||find-18/VBP||required-24/VBN	amod||killing-27/NN||paclitaxel-26/JJ	prep_for||required-24/VBN||killing-27/NN	nn||cells-31/NNS||breast-29/NN	nn||cells-31/NNS||cancer-30/NN	prep_of||killing-27/NN||cells-31/NNS	cancer-30||paclitaxel-26||no_rel||while prior mechanisms of apoptosis induced by taxol have focused on changes in bim levels, we find that an increase is not required for paclitaxel killing of breast cancer cells.
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
aux||investigate-2/VB||to-1/TO	advcl||determined-7/VBD||investigate-2/VB	det||hypothesis-4/NNS||this-3/DT	dobj||investigate-2/VB||hypothesis-4/NNS	nsubj||determined-7/VBD||we-6/PRP	root||ROOT-0/null||determined-7/VBD	det||activities-9/NNS||the-8/DT	dobj||determined-7/VBD||activities-9/NNS	det||enzymes-14/NNS||the-11/DT	amod||enzymes-14/NNS||key-12/JJ	amod||enzymes-14/NNS||mitochondrial-13/JJ	prep_of||activities-9/NNS||enzymes-14/NNS	amod||synthase-17/NN||citrate-16/JJ	prep_of||activities-9/NNS||synthase-17/NN	conj_and||enzymes-14/NNS||synthase-17/NN	amod||dehydrogenase-20/NN||malate-19/JJ	prep_of||activities-9/NNS||dehydrogenase-20/NN	conj_and||enzymes-14/NNS||dehydrogenase-20/NN	amod||cells-25/NNS||astrocytoma-23/JJ	amod||cells-25/NNS||u87-24/JJ	prep_in||determined-7/VBD||cells-25/NNS	vmod||cells-25/NNS||treated-26/VBN	nn||nanoparticles-30/NNS||silicon-28/NN	nn||nanoparticles-30/NNS||dioxide-29/NN	prep_with||treated-26/VBN||nanoparticles-30/NNS	enzymes-14||astrocytoma-23||no_rel||to investigate this hypothesis, we determined the activities of the key mitochondrial enzymes, citrate synthase and malate dehydrogenase, in astrocytoma u87 cells treated with silicon dioxide nanoparticles.
det||test-4/NN||the-1/DT	nn||test-4/NN||institm-2/NN	nn||test-4/NN||poc-3/NN	nsubj||performs-5/VBZ||test-4/NN	root||ROOT-0/null||performs-5/VBZ	advmod||performs-5/VBZ||well-6/RB	prepc_compared_with||performs-5/VBZ||with-8/IN	amod||tests-11/NNS||other-9/JJ	nn||tests-11/NNS||poc-10/NN	pobj||performs-5/VBZ||tests-11/NNS	det||detection-14/NN||the-13/DT	prep_for||tests-11/NNS||detection-14/NN	amod||hivinfection-18/NN||early-16/JJ	amod||hivinfection-18/NN||sero-conversion-17/JJ	prep_of||detection-14/NN||hivinfection-18/NN	nsubj||miss-23/VB||it-21/PRP	aux||miss-23/VB||may-22/MD	conj_but||performs-5/VBZ||miss-23/VB	number||%-28/NN||20-24/CD	dep||%-28/NN||%-25/NN	dep||%-28/NN||to-26/TO	number||%-28/NN||30-27/CD	dobj||miss-23/VB||%-28/NN	prep_of||%-28/NN||those-30/DT	vmod||those-30/DT||detected-31/VBN	amod||tests-37/NNS||laboratory-based-33/JJ	amod||tests-37/NNS||3rd-34/JJ	nn||tests-37/NNS||generation-35/NN	amod||tests-37/NNS||anti-hiv-36/JJ	agent||detected-31/VBN||tests-37/NNS	hivinfection-18||hiv--1||no||the institm poc test performs well compared with other poc tests for the detection of early sero-conversion hivinfection, but it may miss 20% to 30% of those detected by laboratory-based 3rd generation anti-hiv tests.
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	enzyme-35||mono--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
det||injection-3/NN||a-1/DT	amod||injection-3/NN||single-2/JJ	nsubj||sufficient-10/JJ||injection-3/NN	nsubj||inhibit-12/VB||injection-3/NN	num||precursor-8/NN||0.5-5/CD	amod||precursor-8/NN||nm-6/JJ	amod||precursor-8/NN||mir-200b-7/JJ	prep_of||injection-3/NN||precursor-8/NN	cop||sufficient-10/JJ||was-9/VBD	root||ROOT-0/null||sufficient-10/JJ	aux||inhibit-12/VB||to-11/TO	xcomp||sufficient-10/JJ||inhibit-12/VB	det||increase-14/NN||the-13/DT	nsubj||i-18/JJ||increase-14/NN	nsubj||iii-20/JJ||increase-14/NN	nsubj||fibronectin-22/JJ||increase-14/NN	nn||types-17/NNS||collagen-16/NN	prep_of||increase-14/NN||types-17/NNS	xcomp||inhibit-12/VB||i-18/JJ	xcomp||inhibit-12/VB||iii-20/JJ	conj_and||i-18/JJ||iii-20/JJ	xcomp||inhibit-12/VB||fibronectin-22/JJ	conj_and||i-18/JJ||fibronectin-22/JJ	amod||kidneys-25/NNS||obstructed-24/VBN	prep_in||inhibit-12/VB||kidneys-25/NNS	nsubjpass||confirmed-32/VBN||amelioration-28/NN	prep_of||amelioration-28/NN||fibrosis-30/NN	auxpass||confirmed-32/VBN||was-31/VBD	conj_and||sufficient-10/JJ||confirmed-32/VBN	agent||confirmed-32/VBN||observation-34/NN	det||kidneys-37/NNS||the-36/DT	prep_of||observation-34/NN||kidneys-37/NNS	nn||staining-40/NN||azan-39/NN	prep_with||confirmed-32/VBN||staining-40/NN	collagen-16||fibrosis-30||no_rel||a single injection of 0.5 nm mir-200b precursor was sufficient to inhibit the increase of collagen types i, iii and fibronectin in obstructed kidneys, and amelioration of fibrosis was confirmed by observation of the kidneys with azan staining.
amod||artery-2/NN||infarct-1/JJ	nsubjpass||used-10/VBN||artery-2/NN	vmod||artery-2/NN||stenting-3/VBG	amod||therapy-7/NN||adjunctive-5/JJ	nn||therapy-7/NN||abciximab-6/NN	prep_with||stenting-3/VBG||therapy-7/NN	auxpass||used-10/VBN||is-8/VBZ	advmod||used-10/VBN||widely-9/RB	root||ROOT-0/null||used-10/VBN	dobj||used-10/VBN||treatment-11/NN	prep_for||used-10/VBN||patients-13/NNS	prep_with||patients-13/NNS||acutemyocardialinfarction-15/NN	appos||acutemyocardialinfarction-15/NN||ami-17/NN	abciximab-6||acutemyocardialinfarction-15||no_rel||infarct artery stenting with adjunctive abciximab therapy is widely used treatment for patients with acutemyocardialinfarction (ami).
nsubj||agent-6/NN||mycobacteriumtuberculosis-1/NNS	cop||agent-6/NN||is-2/VBZ	det||agent-6/NN||the-3/DT	amod||agent-6/NN||principal-4/JJ	amod||agent-6/NN||etiologic-5/JJ	root||ROOT-0/null||agent-6/NN	amod||-rrb--12/NNP||human-8/JJ	nn||-rrb--12/NNP||tuberculosis-9/NNP	nn||-rrb--12/NNP||-lrb--10/NNP	nn||-rrb--12/NNP||tb-11/NNP	prep_of||agent-6/NN||-rrb--12/NNP	det||member-15/NN||a-14/DT	conj_and||agent-6/NN||member-15/NN	det||-rrb--22/NNS||the-17/DT	amod||complex-19/JJ||m.tuberculosis-18/JJ	amod||-rrb--22/NNS||complex-19/JJ	amod||-rrb--22/NNS||-lrb--20/JJ	nn||-rrb--22/NNS||mtc-21/NN	prep_of||member-15/NN||-rrb--22/NNS	tuberculosis-9||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis is the principal etiologic agent of human tuberculosis -lrb- tb -rrb- and a member of the m.tuberculosis complex -lrb- mtc -rrb- .
det||francisellatularensis-5/NNS||the-1/DT	amod||francisellatularensis-5/NNS||intracellular-2/JJ	amod||francisellatularensis-5/NNS||gram-negative-3/JJ	nn||francisellatularensis-5/NNS||pathogen-4/NN	nsubj||agent-9/NN||francisellatularensis-5/NNS	nsubj||prevalent-14/JJ||francisellatularensis-5/NNS	cop||agent-9/NN||is-6/VBZ	det||agent-9/NN||the-7/DT	amod||agent-9/NN||causative-8/JJ	root||ROOT-0/null||agent-9/NN	prep_of||agent-9/NN||tularaemia-11/NN	cop||prevalent-14/JJ||is-13/VBZ	conj_and||agent-9/NN||prevalent-14/JJ	amod||countries-17/NNS||many-16/JJ	prep_in||prevalent-14/JJ||countries-17/NNS	det||hemisphere-21/NN||the-19/DT	amod||hemisphere-21/NN||northern-20/JJ	prep_in||prevalent-14/JJ||hemisphere-21/NN	tularaemia-11||francisellatularensis-5||no||the intracellular gram-negative pathogen francisellatularensis is the causative agent of tularaemia and is prevalent in many countries in the northern hemisphere.
amod||evidence-2/NN||available-1/JJ	nsubj||shows-8/VBZ||evidence-2/NN	amod||treatment-5/NN||symptomatic-4/JJ	prep_on||evidence-2/NN||treatment-5/NN	prep_of||treatment-5/NN||vomiting-7/NN	root||ROOT-0/null||shows-8/VBZ	det||efficacy-10/NN||the-9/DT	dobj||shows-8/VBZ||efficacy-10/NN	det||molecule-16/NN||the-12/DT	advmod||registered-15/VBN||most-13/RBS	advmod||registered-15/VBN||recently-14/RB	amod||molecule-16/NN||registered-15/VBN	prep_of||efficacy-10/NN||molecule-16/NN	appos||molecule-16/NN||ondansetron-18/NN	det||evaluation-23/NN||a-21/DT	amod||evaluation-23/NN||proper-22/JJ	nsubj||lacking-38/VBG||evaluation-23/NN	amod||drugs-26/NNS||antiemetics-25/JJ	prep_of||evaluation-23/NN||drugs-26/NNS	advmod||used-28/VBN||largely-27/RB	vmod||drugs-26/NNS||used-28/VBN	amod||practice-31/NN||clinical-30/JJ	prep_in||used-28/VBN||practice-31/NN	prep_such_as||evaluation-23/NN||domperidone-35/NN	aux||lacking-38/VBG||is-37/VBZ	conj_but||shows-8/VBZ||lacking-38/VBG	ondansetron-18||vomiting-7||no_rel||available evidence on symptomatic treatment of vomiting shows the efficacy of the most recently registered molecule (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical practice, such as domperidone, is lacking.
nsubj||effective-4/JJ||caspofungin-1/NN	nsubj||tolerated-7/JJ||caspofungin-1/NN	cop||effective-4/JJ||was-2/VBD	dep||effective-4/JJ||both-3/DT	root||ROOT-0/null||effective-4/JJ	advmod||tolerated-7/JJ||well-6/RB	conj_and||effective-4/JJ||tolerated-7/JJ	amod||groups-11/NNS||high-risk-9/JJ	nn||groups-11/NNS||patient-10/NN	prep_among||effective-4/JJ||groups-11/NNS	prep_such_as||groups-11/NNS||those-14/DT	amod||malignancies-19/NNS||neutropenia-16/JJ	conj_and||neutropenia-16/JJ||active-18/JJ	amod||malignancies-19/NNS||active-18/JJ	prep_with||those-14/DT||malignancies-19/NNS	malignancies-19||caspofungin-1||no_rel||caspofungin was both effective and well tolerated among high-risk patient groups such as those with neutropenia and active malignancies.
nn||index-2/NN||augmentation-1/NN	nsubjpass||measured-32/VBN||index-2/NN	discourse||index-2/NN||aix-4/UH	amod||velocity-10/NN||aortic-7/JJ	nn||velocity-10/NN||pulse-8/NN	nn||velocity-10/NN||wave-9/NN	appos||index-2/NN||velocity-10/NN	discourse||velocity-10/NN||pwv-12/UH	amod||function-17/NN||renal-15/JJ	amod||function-17/NN||hemodynamic-16/JJ	appos||index-2/NN||function-17/NN	dep||function-17/NN||inulin-19/NN	amod||clearances-22/NNS||paraaminohippurate-21/JJ	dep||function-17/NN||clearances-22/NNS	conj_and||inulin-19/NN||clearances-22/NNS	amod||cgmp-30/NN||urinary-26/JJ	conj_and||urinary-26/JJ||circulating-28/JJ	amod||cgmp-30/NN||circulating-28/JJ	nn||cgmp-30/NN||plasma-29/NN	conj_and||index-2/NN||cgmp-30/NN	nsubjpass||measured-32/VBN||cgmp-30/NN	auxpass||measured-32/VBN||were-31/VBD	root||ROOT-0/null||measured-32/VBN	amod||subjects-35/NNS||normoalbuminuric-34/JJ	prep_in||measured-32/VBN||subjects-35/NNS	prep_with||measured-32/VBN||type1diabetes-37/CD	amod||euglycemia-40/NN||clamped-39/JJ	prep_during||measured-32/VBN||euglycemia-40/NN	nn||4â-43/NNS||glucose-42/NN	dep||mmol/l-47/JJ||4â-43/NNS	npadvmod||mmol/l-47/JJ||$-44/$	num||$-44/$||6-46/CD	dep||euglycemia-40/NN||mmol/l-47/JJ	prep_during||measured-32/VBN||hyperglycemia-50/NN	conj_and||euglycemia-40/NN||hyperglycemia-50/NN	nn||9â-53/NNS||glucose-52/NN	dep||mmol/l-57/JJ||9â-53/NNS	npadvmod||mmol/l-57/JJ||$-54/$	num||$-54/$||11-56/CD	dep||euglycemia-40/NN||mmol/l-57/JJ	hyperglycemia-50||glucose-52||no||augmentation index (aix), aortic pulse wave velocity (pwv), renal hemodynamic function (inulin and paraaminohippurate clearances), and urinary and circulating plasma cgmp were measured in normoalbuminuric subjects with type1diabetes during clamped euglycemia (glucose 4â€“6 mmol/l) and hyperglycemia (glucose 9â€“11 mmol/l).
prepc_based_on||tested-28/VBD||on-2/IN	det||premise-4/NN||the-3/DT	pobj||tested-28/VBD||premise-4/NN	mark||receiving-21/VBG||that-5/IN	amod||patients-7/NNS||postabsorptive-6/JJ	nsubj||receiving-21/VBG||patients-7/NNS	prep_with||patients-7/NNS||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||receiving-10/VBG	amod||insulin-12/NN||intravenous-11/JJ	dobj||receiving-10/VBG||insulin-12/NN	det||dose-15/NN||a-14/DT	prep_in||receiving-10/VBG||dose-15/NN	nsubj||maintains-17/VBZ||dose-15/NN	rcmod||dose-15/NN||maintains-17/VBZ	amod||euglycemia-19/NN||stable-18/JJ	dobj||maintains-17/VBZ||euglycemia-19/NN	aux||receiving-21/VBG||are-20/VBP	dep||premise-4/NN||receiving-21/VBG	advmod||optimal-23/JJ||biologically-22/RB	amod||replacement-25/NN||optimal-23/JJ	nn||replacement-25/NN||insulin-24/NN	dobj||receiving-21/VBG||replacement-25/NN	nsubj||tested-28/VBD||we-27/PRP	root||ROOT-0/null||tested-28/VBD	det||hypothesis-30/NNS||the-29/DT	dobj||tested-28/VBD||hypothesis-30/NNS	mark||supports-33/VBZ||that-31/IN	nsubj||supports-33/VBZ||glucagon-32/NN	ccomp||tested-28/VBD||supports-33/VBZ	amod||concentrations-37/NNS||postabsorptive-34/JJ	nn||concentrations-37/NNS||plasma-35/NN	nn||concentrations-37/NNS||glucose-36/NN	dobj||supports-33/VBZ||concentrations-37/NNS	prep_in||concentrations-37/NNS||humans-39/NNS	glucose-36||type1diabetes-9||no_rel||based on the premise that postabsorptive patients with type1diabetes receiving intravenous insulin in a dose that maintains stable euglycemia are receiving biologically optimal insulin replacement, we tested the hypothesis that glucagon supports postabsorptive plasma glucose concentrations in humans.
aux||investigate-2/VB||to-1/TO	advcl||studied-22/VBD||investigate-2/VB	mark||factor-14/NN||whether-3/IN	amod||density-7/NN||increased-4/VBN	amod||density-7/NN||lymphatic-5/JJ	nn||density-7/NN||vessel-6/NN	nsubj||factor-14/NN||density-7/NN	appos||density-7/NN||lvd-9/NN	cop||factor-14/NN||is-11/VBZ	det||factor-14/NN||a-12/DT	amod||factor-14/NN||prognostic-13/JJ	ccomp||investigate-2/VB||factor-14/NN	amod||metastasis-17/NNS||nodal-16/JJ	prep_for||factor-14/NN||metastasis-17/NNS	prep_for||factor-14/NN||survival-19/NN	conj_and||metastasis-17/NNS||survival-19/NN	nsubj||studied-22/VBD||we-21/PRP	root||ROOT-0/null||studied-22/VBD	amod||lvd-24/NN||peritumoral-23/JJ	dobj||studied-22/VBD||lvd-24/NN	dep||lvd-24/NN||p-lvd-26/JJ	amod||lvd-30/NN||intratumoral-29/JJ	dobj||studied-22/VBD||lvd-30/NN	conj_and||lvd-24/NN||lvd-30/NN	dep||lvd-30/NN||i-lvd-32/JJ	prep_in||lvd-24/NN||samples-35/NNS	num||patients-38/NNS||102-37/CD	prep_from||samples-35/NNS||patients-38/NNS	amod||carcinoma-41/NN||endometrial-40/JJ	prep_with||patients-38/NNS||carcinoma-41/NN	amod||tissues-45/NNS||endometrial-43/JJ	nn||tissues-45/NNS||carcinoma-44/NN	nsubjpass||analyzed-47/VBN||tissues-45/NNS	auxpass||analyzed-47/VBN||were-46/VBD	dobj||studied-22/VBD||analyzed-47/VBN	conj_and||lvd-24/NN||analyzed-47/VBN	amod||vessels-50/NNS||lymphatic-49/JJ	prep_for||analyzed-47/VBN||vessels-50/NNS	amod||staining-53/NN||immunohistochemical-52/JJ	agent||analyzed-47/VBN||staining-53/NN	det||antibody-56/NN||an-55/DT	prep_with||analyzed-47/VBN||antibody-56/NN	prep_against||antibody-56/NN||lyve-1-58/CD	carcinoma-44||antibody-56||no_rel||to investigate whether increased lymphatic vessel density (lvd) is a prognostic factor for nodal metastasis and survival, we studied peritumoral lvd (p-lvd) and intratumoral lvd (i-lvd) in samples from 102 patients with endometrial carcinoma; endometrial carcinoma tissues were analyzed for lymphatic vessels by immunohistochemical staining with an antibody against lyve-1.
det||pin-3/NN||a-1/DT	nn||pin-3/NN||titanium-2/NN	nsubjpass||implanted-5/VBN||pin-3/NN	nsubj||mimic-11/VB||pin-3/NN	auxpass||implanted-5/VBN||was-4/VBD	root||ROOT-0/null||implanted-5/VBN	nn||tibia-9/NN||mouse-7/NN	nn||tibia-9/NN||proximal-8/NN	prep_into||implanted-5/VBN||tibia-9/NN	aux||mimic-11/VB||to-10/TO	xcomp||implanted-5/VBN||mimic-11/VB	det||arthroplasty-15/NN||a-12/DT	amod||arthroplasty-15/NN||weight-bearing-13/JJ	nn||arthroplasty-15/NN||knee-14/NN	dobj||mimic-11/VB||arthroplasty-15/NN	vmod||arthroplasty-15/NN||followed-17/VBN	amod||challenge-20/NN||titanium-particles-19/JJ	agent||followed-17/VBN||challenge-20/NN	aux||induce-22/VB||to-21/TO	xcomp||followed-17/VBN||induce-22/VB	amod||osteolysis-24/NNS||periprosthetic-23/JJ	dobj||induce-22/VB||osteolysis-24/NNS	titanium-2||osteolysis-24||no_rel||a titanium pin was implanted into mouse proximal tibia to mimic a weight-bearing knee arthroplasty, followed by titanium-particles challenge to induce periprosthetic osteolysis.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	dobj||analyzed-2/VBD||indicators-3/NNS	prep_of||indicators-3/NNS||knowledge-5/NN	prep_on||knowledge-5/NN||hiv/aids-7/NNS	nn||use-10/NN||condom-9/NN	prep_on||knowledge-5/NN||use-10/NN	conj_and||hiv/aids-7/NNS||use-10/NN	nn||populations-13/NNS||sub-12/NN	prep_among||analyzed-2/VBD||populations-13/NNS	vmod||populations-13/NNS||selected-14/VBN	amod||surveillance-17/NN||behavioral-16/JJ	prep_for||selected-14/VBN||surveillance-17/NN	prep_in||surveillance-17/NN||ethiopia-19/NN	aids--1||hiv--1||no||we analyzed indicators of knowledge on hiv/aids and condom use among sub populations selected for behavioral surveillance in ethiopia.
nsubj||cramp-13/NN||results-1/NNS	nn||adaptation-4/NN||base-3/NN	prep_for||results-1/NNS||adaptation-4/NN	vmod||adaptation-4/NN||performed-5/VBN	det||methods-10/NNS||the-7/DT	nn||methods-10/NNS||flask-8/NN	nn||methods-10/NNS||closure-9/NN	agent||performed-5/VBN||methods-10/NNS	cop||cramp-13/NN||were-11/VBD	amod||cramp-13/NN||traditional-12/JJ	root||ROOT-0/null||cramp-13/NN	dep||cramp-13/NN||non-disinfected-15/VBN	dep||mm-21/NN||=-16/SYM	num||mm-21/NN||0.21-17/CD	nn||mm-21/NN||â-18/NNP	nn||mm-21/NN||±-19/NNP	num||mm-21/NN||0.05-20/CD	ccomp||non-disinfected-15/VBN||mm-21/NN	dep||cramp-13/NN||disinfected-23/VBN	conj_and||non-disinfected-15/VBN||disinfected-23/VBN	dep||mm-29/NN||=-24/SYM	num||mm-29/NN||0.22-25/CD	nn||mm-29/NN||â-26/NNP	nn||mm-29/NN||±-27/NNP	num||mm-29/NN||0.05-28/CD	ccomp||disinfected-23/VBN||mm-29/NN	nn||system-34/NN||rs-33/NN	conj_and||cramp-13/NN||system-34/NN	dep||system-34/NN||non-disinfected-36/VBN	dep||±-40/NNS||=-37/SYM	num||±-40/NNS||0.16-38/CD	nn||±-40/NNS||â-39/NN	ccomp||non-disinfected-36/VBN||±-40/NNS	advmod||non-disinfected-36/VBN||0.05-41/CD	dep||system-34/NN||disinfected-43/VBN	conj_and||non-disinfected-36/VBN||disinfected-43/VBN	dep||mm-49/NN||=-44/SYM	num||mm-49/NN||0.17-45/CD	nn||mm-49/NN||â-46/NNP	nn||mm-49/NN||±-47/NNP	num||mm-49/NN||0.04-48/CD	ccomp||disinfected-43/VBN||mm-49/NN	base-3||cramp-13||no_rel||results for base adaptation performed by the flask closure methods were traditional cramp (non-disinfected = 0.21 â± 0.05mm and disinfected = 0.22 â± 0.05mm), and rs system (non-disinfected = 0.16 â± 0.05 and disinfected = 0.17 â± 0.04mm).
root||ROOT-0/null||increasing-1/VBG	det||dose-4/NN||the-2/DT	amod||dose-4/NN||lidocaine-3/JJ	dobj||increasing-1/VBG||dose-4/NN	advmod||increasing-1/VBG||significantly-5/RB	dep||increasing-1/VBG||reduced-6/VBD	nsubj||increasing-1/VBG||pain-7/NN	nn||0.05-11/NNP||p-9/NNP	nn||0.05-11/NNP||<-10/NNP	appos||pain-7/NN||0.05-11/NNP	pain-7||lidocaine-3||yes||increasing the lidocaine dose significantly reduced pain (p < 0.05).
prep_in||introduced-13/VBN||multiplemyeloma-2/NN	dep||introduced-13/VBN||mm-4/VB	det||range-7/NN||a-6/DT	nsubjpass||introduced-13/VBN||range-7/NN	nsubj||challenge-16/VB||range-7/NN	amod||drugs-10/NNS||new-9/JJ	prep_of||range-7/NN||drugs-10/NNS	aux||introduced-13/VBN||have-11/VBP	auxpass||introduced-13/VBN||been-12/VBN	root||ROOT-0/null||introduced-13/VBN	advmod||challenge-16/VB||now-15/RB	conj_and||introduced-13/VBN||challenge-16/VB	amod||therapy-18/NN||conventional-17/JJ	dobj||challenge-16/VB||therapy-18/NN	amod||melphalan-22/NN||high-20/JJ	nn||melphalan-22/NN||dose-21/NN	prep_including||therapy-18/NN||melphalan-22/NN	multiplemyeloma-2||melphalan-22||yes||in multiplemyeloma (mm) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan.
nsubj||bacterium-7/NN||coxiellaburnetii-1/NNS	cop||bacterium-7/NN||is-2/VBZ	det||bacterium-7/NN||an-3/DT	amod||bacterium-7/NN||obligate-4/JJ	nn||bacterium-7/NN||intracellular-5/NN	nn||bacterium-7/NN||gram-negative-6/NN	root||ROOT-0/null||bacterium-7/NN	nsubj||causes-9/VBZ||bacterium-7/NN	rcmod||bacterium-7/NN||causes-9/VBZ	nn||infections-13/NNS||acuteqfever-10/NN	conj_and||acuteqfever-10/NN||chronic-12/NN	nn||infections-13/NNS||chronic-12/NN	dobj||causes-9/VBZ||infections-13/NNS	prep_in||infections-13/NNS||humans-15/NNS	acuteqfever-10||coxiellaburnetii-1||no||coxiellaburnetii is an obligate intracellular gram-negative bacterium that causes acuteqfever and chronic infections in humans.
nsubj||increased-12/VBN||breasttumors-1/NNS	vmod||breasttumors-1/NNS||lacking-2/VBG	det||±-6/NN||the-3/DT	amod||±-6/NN||estrogen-4/JJ	amod||±-6/NN||receptor-î-5/JJ	dobj||lacking-2/VBG||±-6/NN	nn||±-9/NNP||er-î-8/NNP	appos||±-6/NN||±-9/NNP	aux||increased-12/VBN||have-11/VBP	root||ROOT-0/null||increased-12/VBN	dobj||increased-12/VBN||incidence-13/NN	prep_of||incidence-13/NN||resistance-15/NN	prep_to||increased-12/VBN||therapy-17/NN	amod||prognosis-21/NN||poorer-19/JJR	amod||prognosis-21/NN||clinical-20/JJ	prep_to||increased-12/VBN||prognosis-21/NN	conj_and||therapy-17/NN||prognosis-21/NN	breasttumors-1||estrogen-4||no||breasttumors lacking the estrogen receptor-î± (er-î±) have increased incidence of resistance to therapy and poorer clinical prognosis.
nsubj||replicate-6/VB||bovineherpesvirustype1-1/NNS	nsubj||cause-11/VB||bovineherpesvirustype1-1/NNS	dep||bovineherpesvirustype1-1/NNS||bohv-1-3/JJ	aux||replicate-6/VB||may-5/MD	root||ROOT-0/null||replicate-6/VB	det||sites-9/NNS||both-8/DT	prep_at||replicate-6/VB||sites-9/NNS	conj_and||replicate-6/VB||cause-11/VB	num||entities-15/NNS||two-12/CD	amod||entities-15/NNS||major-13/JJ	amod||entities-15/NNS||clinical-14/JJ	dobj||cause-11/VB||entities-15/NNS	vmod||entities-15/NNS||designated-16/VBN	amod||rhinotracheitis-20/NNS||infectious-18/JJ	amod||rhinotracheitis-20/NNS||bovine-19/JJ	prep_as||designated-16/VBN||rhinotracheitis-20/NNS	appos||rhinotracheitis-20/NNS||ibr-22/NN	prep_as||designated-16/VBN||infectiouspustularvulvovaginitis/balanoposthitis-25/NNS	conj_and||rhinotracheitis-20/NNS||infectiouspustularvulvovaginitis/balanoposthitis-25/NNS	appos||rhinotracheitis-20/NNS||ipv/ipb-27/NN	prep_in||designated-16/VBN||cattle-30/NNS	infectiouspustularvulvovaginitis--1||bovineherpesvirustype1-1||no||bovineherpesvirustype1 (bohv-1) may replicate at both sites and cause two major clinical entities designated as infectious bovine rhinotracheitis (ibr) and infectiouspustularvulvovaginitis/balanoposthitis (ipv/ipb) in cattle.
advmod||greater-2/JJR||significantly-1/RB	amod||reductions-3/NNS||greater-2/JJR	nsubjpass||observed-9/VBN||reductions-3/NNS	nsubjpass||observed-9/VBN||reductions-3/NNS	amod||bp-7/NN||seated-5/JJ	amod||bp-7/NN||diastolic-6/JJ	prep_in||reductions-3/NNS||bp-7/NN	auxpass||observed-9/VBN||were-8/VBD	root||ROOT-0/null||observed-9/VBN	conj_and||observed-9/VBN||observed-9/VBN	prep_between||observed-9/VBN||baseline-11/NN	num||weeks-15/NNS||eight-14/CD	prep_after||observed-9/VBN||weeks-15/NNS	prep_of||weeks-15/NNS||treatment-17/NN	prep_with||observed-9/VBN||olmesartan/amlodipine-19/NN	prepc_compared_with||observed-9/VBN||with-22/IN	nn||doses-24/NNS||equivalent-23/NN	pobj||observed-9/VBN||doses-24/NNS	amod||monotherapy-29/NN||olmesartan-26/JJ	conj_or||olmesartan-26/JJ||amolodipine-28/JJ	amod||monotherapy-29/NN||amolodipine-28/JJ	prep_of||doses-24/NNS||monotherapy-29/NN	appos||monotherapy-29/NN||p-31/NNP	number||0.001-33/CD||<-32/CD	num||p-31/NNP||0.001-33/CD	det||combination-39/NN||the-37/DT	amod||combination-39/NN||factorial-38/JJ	prep_in||observed-9/VBN||combination-39/NN	nn||trial-50/NN||olmesartanmedoxomil-41/NN	conj_and||olmesartanmedoxomil-41/NN||amlodipinebesylate-43/JJ	nn||trial-50/NN||amlodipinebesylate-43/JJ	amod||highbloodpressure-46/NN||controlling-45/VBG	prep_in||amlodipinebesylate-43/JJ||highbloodpressure-46/NN	appos||highbloodpressure-46/NN||coach-48/NN	prep_of||combination-39/NN||trial-50/NN	highbloodpressure-46||amlodipinebesylate-43||yes||significantly greater reductions in seated diastolic bp were observed between baseline and after eight weeks of treatment with olmesartan/amlodipine, compared with equivalent doses of olmesartan or amolodipine monotherapy ( p < 0.001), in the factorial combination of olmesartanmedoxomil and amlodipinebesylate in controlling highbloodpressure (coach) trial.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	amod||interviews-6/NNS||in-depth-3/JJ	amod||interviews-6/NNS||open-ended-5/JJ	dobj||conducted-2/VBD||interviews-6/NNS	num||individuals-9/NNS||47-8/CD	prep_with||conducted-2/VBD||individuals-9/NNS	num||women-12/NNS||30-11/CD	appos||individuals-9/NNS||women-12/NNS	num||men-15/NNS||17-14/CD	dep||women-12/NNS||men-15/NNS	dep||conducted-2/VBD||living-17/VBG	prep_with||living-17/VBG||hiv/aids-19/NNS	vmod||hiv/aids-19/NNS||recruited-20/VBN	nn||programs-24/NNS||aids-22/NNS	nn||programs-24/NNS||treatment-23/NN	prep_from||recruited-20/VBN||programs-24/NNS	prep_in||recruited-20/VBN||mbarara-26/NN	prep_in||recruited-20/VBN||kampala-28/NN	conj_and||mbarara-26/NN||kampala-28/NN	acomp||conducted-2/VBD||uganda-30/JJ	aux||understand-32/VB||to-31/TO	xcomp||uganda-30/JJ||understand-32/VB	advmod||interferes-36/VBZ||how-33/WRB	nn||insecurity-35/NN||food-34/NN	nsubj||interferes-36/VBZ||insecurity-35/NN	ccomp||understand-32/VB||interferes-36/VBZ	nn||regimens-40/NNS||arv-38/NN	nn||regimens-40/NNS||therapy-39/NN	prep_with||interferes-36/VBZ||regimens-40/NNS	aids-22||hiv--1||no||we conducted in-depth, open-ended interviews with 47 individuals (30 women, 17 men) living with hiv/aids recruited from aids treatment programs in mbarara and kampala, uganda to understand how food insecurity interferes with arv therapy regimens.
nsubjpass||identified-11/VBN||criteria-1/NNS	nn||setting-4/NN||priority-3/NN	prep_for||criteria-1/NNS||setting-4/NN	amod||interventions-7/NNS||hiv/aids-6/JJ	prep_of||setting-4/NN||interventions-7/NNS	prep_in||interventions-7/NNS||thailand-9/NN	auxpass||identified-11/VBN||were-10/VBD	root||ROOT-0/null||identified-11/VBN	nn||discussions-14/NNS||group-13/NN	prep_in||identified-11/VBN||discussions-14/NNS	nn||makers-17/NNS||policy-16/NN	prep_with||identified-11/VBN||makers-17/NNS	appos||makers-17/NNS||people-19/NNS	vmod||people-19/NNS||living-20/VBG	amod||-rrb--25/NNS||hiv/aids-22/JJ	amod||-rrb--25/NNS||-lrb--23/JJ	nn||-rrb--25/NNS||plwha-24/NN	prep_with||living-20/VBG||-rrb--25/NNS	nn||members-29/NNS||community-28/NN	nsubj||-lrb--30/VBD||members-29/NNS	conj_and||identified-11/VBN||-lrb--30/VBD	amod||volunteers-34/NNS||i.e.-31/JJ	nn||volunteers-34/NNS||village-32/NN	nn||volunteers-34/NNS||health-33/NN	nsubj||vhvs-36/VBZ||volunteers-34/NNS	advmod||vhvs-36/VBZ||-lrb--35/RB	ccomp||-lrb--30/VBD||vhvs-36/VBZ	amod||-rrb--38/NNS||-rrb--37/JJ	dobj||vhvs-36/VBZ||-rrb--38/NNS	aids--1||hiv--1||no||criteria for priority setting of hiv/aids interventions in thailand were identified in group discussions with policy makers , people living with hiv/aids -lrb- plwha -rrb- , and community members -lrb- i.e. village health volunteers -lrb- vhvs -rrb- -rrb- .
nsubj||â-2/VBP||conclusions-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	det||study-6/NN||this-5/DT	nsubj||provides-7/VBZ||study-6/NN	rcmod||$-3/$||provides-7/VBZ	dobj||provides-7/VBZ||evidence-8/NN	det||relationship-12/NN||a-10/DT	amod||relationship-12/NN||positive-11/JJ	prep_of||evidence-8/NN||relationship-12/NN	nn||intake-15/NN||zn-14/NN	prep_between||relationship-12/NN||intake-15/NN	prep_between||relationship-12/NN||osteocalcin-17/NN	conj_and||intake-15/NN||osteocalcin-17/NN	prep_in||provides-7/VBZ||type1diabetes-19/CD	type1diabetes-19||zn-14||no_rel||conclusions â€”this study provides evidence of a positive relationship between zn intake and osteocalcin in type1diabetes.
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	det||time-6/NN||the-4/DT	amod||time-6/NN||first-5/JJ	prep_for||show-2/VBP||time-6/NN	mark||induces-9/VBZ||that-7/IN	nsubj||induces-9/VBZ||tmz-8/NN	ccomp||show-2/VBP||induces-9/VBZ	dobj||induces-9/VBZ||apoptosis-10/NNS	nn||cells-13/NNS||melanoma-12/NN	prep_in||apoptosis-10/NNS||cells-13/NNS	vmod||induces-9/VBZ||using-15/VBG	amod||doses-17/NNS||therapeutic-16/JJ	dobj||using-15/VBG||doses-17/NNS	melanoma-12||tmz-8||yes||we show for the first time that tmz induces apoptosis in melanoma cells, using therapeutic doses.
nsubj||disease-6/NN||tuberculousmeningitis-1/NNS	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||a-3/DT	amod||disease-6/NN||frequent-4/JJ	nn||disease-6/NN||extrapulmonary-5/NN	root||ROOT-0/null||disease-6/NN	dep||disease-6/NN||caused-7/VBN	prep_by||caused-7/VBN||mycobacteriumtuberculosis-9/NNS	auxpass||associated-12/VBN||is-11/VBZ	dep||disease-6/NN||associated-12/VBN	conj_and||caused-7/VBN||associated-12/VBN	amod||rates-16/NNS||high-14/JJ	nn||rates-16/NNS||mortality-15/NN	prep_with||associated-12/VBN||rates-16/NNS	amod||sequelae-20/NN||severe-18/JJ	amod||sequelae-20/NN||neurological-19/JJ	prep_with||associated-12/VBN||sequelae-20/NN	conj_and||rates-16/NNS||sequelae-20/NN	tuberculousmeningitis-1||mycobacteriumtuberculosis-9||no||tuberculousmeningitis is a frequent extrapulmonary disease caused by mycobacteriumtuberculosis and is associated with high mortality rates and severe neurological sequelae.
num||rats-2/NNS||five-1/CD	nsubjpass||treated-11/VBN||rats-2/NNS	num||months-5/NNS||two-4/CD	prep_at||rats-2/NNS||months-5/NNS	prep_of||months-5/NNS||age-7/NN	prep_with||age-7/NN||hyperglycemia-9/NN	auxpass||treated-11/VBN||were-10/VBD	root||ROOT-0/null||treated-11/VBN	prep_with||treated-11/VBN||insulin-13/NN	num||weeks-16/NNS||eight-15/CD	prep_for||insulin-13/NN||weeks-16/NNS	hyperglycemia-9||insulin-13||yes||five rats at two months of age with hyperglycemia were treated with insulin for eight weeks.
amod||lupuserythematosus-2/NNS||systemic-1/JJ	nsubj||autoimmunedisease-9/NN||lupuserythematosus-2/NNS	appos||lupuserythematosus-2/NNS||sle-4/NN	cop||autoimmunedisease-9/NN||is-6/VBZ	det||autoimmunedisease-9/NN||a-7/DT	amod||autoimmunedisease-9/NN||systemic-8/JJ	root||ROOT-0/null||autoimmunedisease-9/NN	prep_in||has-17/VBZ||autoimmunedisease-9/NN	det||interferon-15/NN||the-12/DT	nn||interferon-15/NN||type-13/NN	nn||interferon-15/NN||i-14/NN	nsubj||has-17/VBZ||interferon-15/NN	advmod||has-17/VBZ||pathway-16/RB	rcmod||autoimmunedisease-9/NN||has-17/VBZ	det||role-20/NN||a-18/DT	amod||role-20/NN||crucial-19/JJ	dobj||has-17/VBZ||role-20/NN	autoimmunedisease-9||interferon-15||no||systemic lupuserythematosus (sle) is a systemic autoimmunedisease in which the type i interferon pathway has a crucial role.
det||control-3/NN||the-1/DT	amod||control-3/NN||profound-2/JJ	nsubj||oxidant-9/VB||control-3/NN	nsubj||ros-32/VB||control-3/NN	prep_of||control-3/NN||aunps-5/NNS	det||anti-8/NN||the-7/DT	prep_over||aunps-5/NNS||anti-8/NN	root||ROOT-0/null||oxidant-9/VB	dobj||oxidant-9/VB||enzymes-10/NNS	prep_such_as||enzymes-10/NNS||gsh-13/NN	prep_such_as||enzymes-10/NNS||sod-15/NN	conj_and||gsh-13/NN||sod-15/NN	prep_such_as||enzymes-10/NNS||catalase-17/NN	conj_and||gsh-13/NN||catalase-17/NN	prep_such_as||enzymes-10/NNS||gpx-19/NN	conj_and||gsh-13/NN||gpx-19/NN	amod||mice-22/NNS||diabetic-21/JJ	prep_in||oxidant-9/VB||mice-22/NNS	prep_to||oxidant-9/VB||normal-24/JJ	prep_by||oxidant-9/VB||inhibition-27/NN	nn||peroxidation-30/NN||lipid-29/NN	prep_of||inhibition-27/NN||peroxidation-30/NN	conj_and||oxidant-9/VB||ros-32/VB	dobj||ros-32/VB||generation-33/NN	nn||evidence-36/NN||hyperglycemia-35/NN	prep_during||ros-32/VB||evidence-36/NN	poss||effect-39/NN||their-37/PRP$	amod||effect-39/NN||anti-oxidant-38/JJ	dobj||oxidant-9/VB||effect-39/NN	prep_during||oxidant-9/VB||hyperglycemia-41/NN	enzymes-10||hyperglycemia-41||no_rel||the profound control of aunps over the anti oxidant enzymes such as gsh, sod, catalase and gpx in diabetic mice to normal, by inhibition of lipid peroxidation and ros generation during hyperglycemia evidence their anti-oxidant effect during hyperglycemia.
nsubjpass||relieved-3/VBN||withdrawal-1/NN	auxpass||relieved-3/VBN||is-2/VBZ	root||ROOT-0/null||relieved-3/VBN	det||dose-7/NN||a-5/DT	amod||dose-7/NN||low-6/JJ	agent||relieved-3/VBN||dose-7/NN	prep_of||dose-7/NN||alcohol-9/NN	det||reinforcement-13/NN||a-11/DT	amod||reinforcement-13/NN||negative-12/JJ	appos||alcohol-9/NN||reinforcement-13/NN	nsubj||contributes-15/VBZ||reinforcement-13/NN	nsubj||alcoholdependency-17/VB||reinforcement-13/NN	rcmod||reinforcement-13/NN||contributes-15/VBZ	aux||alcoholdependency-17/VB||to-16/TO	xcomp||contributes-15/VBZ||alcoholdependency-17/VB	alcoholdependency-17||alcohol-9||no||withdrawal is relieved by a low dose of alcohol, a negative reinforcement that contributes to alcoholdependency.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||mechanisms-6/NNS||the-3/DT	amod||mechanisms-6/NNS||possible-4/JJ	amod||mechanisms-6/NNS||anti-inflammatory-5/JJ	dobj||examined-2/VBD||mechanisms-6/NNS	prep_of||mechanisms-6/NNS||gabapentin-8/NN	det||attenuation-11/NN||the-10/DT	prep_in||examined-2/VBD||attenuation-11/NN	prep_of||attenuation-11/NN||neuropathicpain-13/NN	det||interaction-16/NN||the-15/DT	prep_in||examined-2/VBD||interaction-16/NN	conj_and||attenuation-11/NN||interaction-16/NN	det||effects-20/NNS||the-18/DT	amod||effects-20/NNS||anti-allodynic-19/JJ	prep_between||interaction-16/NN||effects-20/NNS	prep_of||effects-20/NNS||gabapentin-22/NN	amod||expression-28/NN||interleukin-10-24/JJ	dep||expression-28/NN||il-10-26/JJ	prep_between||interaction-16/NN||expression-28/NN	conj_and||effects-20/NNS||expression-28/NN	det||model-32/NN||a-30/DT	nn||model-32/NN||rat-31/NN	prep_in||expression-28/NN||model-32/NN	prep_of||model-32/NN||neuropathicpain-34/NN	gabapentin-22||neuropathicpain-34||no_rel||we examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathicpain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (il-10) expression in a rat model of neuropathicpain.
det||nature-5/NN||the-3/DT	amod||nature-5/NN||progressive-4/JJ	prep_due_to||need-11/VBP||nature-5/NN	prep_of||nature-5/NN||type2diabetes-7/CD	amod||patients-10/NNS||many-9/JJ	nsubj||need-11/VBP||patients-10/NNS	root||ROOT-0/null||need-11/VBP	dobj||need-11/VBP||insulin-12/NN	prep_as||need-11/VBP||add-on-14/JJ	amod||drugs-18/NNS||oral-16/JJ	amod||drugs-18/NNS||antidiabetic-17/JJ	prep_to||add-on-14/JJ||drugs-18/NNS	appos||drugs-18/NNS||oads-20/NNS	mark||maintain-25/VB||in-22/IN	dep||maintain-25/VB||order-23/NN	aux||maintain-25/VB||to-24/TO	advcl||need-11/VBP||maintain-25/VB	amod||control-28/NN||adequate-26/JJ	amod||control-28/NN||glycemic-27/JJ	dobj||maintain-25/VB||control-28/NN	type2diabetes-7||insulin-12||yes||due to the progressive nature of type2diabetes, many patients need insulin as add-on to oral antidiabetic drugs (oads) in order to maintain adequate glycemic control.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	fat--1||chf-60||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
det||result-2/NN||the-1/DT	nsubj||showed-3/VBD||result-2/NN	root||ROOT-0/null||showed-3/VBD	mark||had-17/VBD||that-4/IN	nsubj||had-17/VBD||c-5/SYM	num||mg/l-8/NN||128-7/CD	appos||c-5/SYM||mg/l-8/NN	prep||c-5/SYM||combined-10/VBN	pcomp||combined-10/VBN||with-11/IN	pobj||with-11/IN||ecg-12/NN	num||mg/l-15/NN||16-14/CD	appos||ecg-12/NN||mg/l-15/NN	ccomp||showed-3/VBD||had-17/VBD	det||effect-20/NN||the-18/DT	amod||effect-20/NN||greatest-19/JJS	dobj||had-17/VBD||effect-20/NN	det||combination-23/NN||the-22/DT	nsubj||reduced-25/VBD||combination-23/NN	advmod||reduced-25/VBD||also-24/RB	conj_and||showed-3/VBD||reduced-25/VBD	det||load-28/NN||the-26/DT	amod||load-28/NN||bacterial-27/JJ	dobj||reduced-25/VBD||load-28/NN	prep_in||reduced-25/VBD||blood-30/NN	amod||mice-33/NNS||septic-32/JJ	prep_of||blood-30/NN||mice-33/NNS	dep||mice-33/NNS||challenged-34/VBN	det||dose-38/NN||a-36/DT	amod||dose-38/NN||sublethal-37/JJ	prep_with||challenged-34/VBN||dose-38/NN	prep_of||dose-38/NN||mrsa-40/NN	dep||mice-33/NNS||increased-42/VBN	conj_and||challenged-34/VBN||increased-42/VBN	nn||accumulation-44/NN||daunomycin-43/NN	dobj||increased-42/VBN||accumulation-44/NN	prep_within||increased-42/VBN||mrsa-46/NN	dep||mice-33/NNS||down-regulated-48/VBN	conj_and||challenged-34/VBN||down-regulated-48/VBN	det||expression-51/NN||the-49/DT	nn||expression-51/NN||mrna-50/NN	dobj||down-regulated-48/VBN||expression-51/NN	prep_of||expression-51/NN||nora-53/NN	prep_of||expression-51/NN||norc-55/NN	conj_and||nora-53/NN||norc-55/NN	prep_of||expression-51/NN||abca-57/NN	conj_and||nora-53/NN||abca-57/NN	num||pumps-62/NNS||three-59/CD	amod||pumps-62/NNS||important-60/JJ	nn||pumps-62/NNS||efflux-61/NN	dobj||reduced-25/VBD||pumps-62/NNS	prep_of||pumps-62/NNS||mrsa-64/NN	daunomycin-43||mrsa-64||no_rel||the result showed that c (128 mg/l) combined with ecg (16 mg/l) had the greatest effect and the combination also reduced the bacterial load in blood of septic mice challenged with a sublethal dose of mrsa, increased daunomycin accumulation within mrsa and down-regulated the mrna expression of nora , norc and abca , three important efflux pumps of mrsa.
nsubj||yielded-10/VBD||cultures-1/NNS	prep_of||cultures-1/NNS||pbmcs-3/NNS	vmod||pbmcs-3/NNS||stimulated-4/VBN	prep_with||stimulated-4/VBN||m.tuberculosis-6/NNS	num||hours-9/NNS||24-8/CD	prep_for||m.tuberculosis-6/NNS||hours-9/NNS	root||ROOT-0/null||yielded-10/VBD	advmod||il-10-12/JJ||higher-11/RBR	amod||levels-20/NNS||il-10-12/JJ	conj_and||il-10-12/JJ||interleukin-14/JJ	amod||levels-20/NNS||interleukin-14/JJ	num||-lrb--16/NNS||22-15/CD	npadvmod||il-22-17/JJ||-lrb--16/NNS	amod||levels-20/NNS||il-22-17/JJ	amod||levels-20/NNS||-rrb--18/JJ	nn||levels-20/NNS||transcript-19/NN	dobj||yielded-10/VBD||levels-20/NNS	amod||patients-23/NNS||tuberculosis-iris-22/JJ	prep_for||levels-20/NNS||patients-23/NNS	prepc_compared_with||yielded-10/VBD||with-26/IN	amod||patients-28/NNS||non-iris-27/JJ	pobj||yielded-10/VBD||patients-28/NNS	tuberculosis--1||m.tuberculosis-6||no||cultures of pbmcs stimulated with m.tuberculosis for 24 hours yielded higher il-10 and interleukin 22 -lrb- il-22 -rrb- transcript levels for tuberculosis-iris patients , compared with non-iris patients .
nsubj||improved-7/VBN||patients-1/NNS	amod||dronedarone-5/NN||atrialfibrillation-3/JJ	nn||dronedarone-5/NN||receiving-4/NN	prep_with||patients-1/NNS||dronedarone-5/NN	aux||improved-7/VBN||had-6/VBD	root||ROOT-0/null||improved-7/VBN	nn||control-10/NN||ventricular-8/NN	nn||control-10/NN||rate-9/NN	dobj||improved-7/VBN||control-10/NN	prepc_compared_with||improved-7/VBN||with-12/IN	pobj||improved-7/VBN||patients-13/NNS	vmod||patients-13/NNS||receiving-14/VBG	dobj||receiving-14/VBG||placebo-15/NN	dronedarone-5||atrialfibrillation-3||no_rel||patients with atrialfibrillation receiving dronedarone had improved ventricular rate control compared with patients receiving placebo.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	amod||isolates-5/NNS||consecutive-3/JJ	nn||isolates-5/NNS||falciparummalaria-4/NN	dobj||analyzed-2/VBD||isolates-5/NNS	nn||travelers-8/NNS||canadian-7/NN	prep_from||analyzed-2/VBD||travelers-8/NNS	num||2000-12/CD||1994-10/CD	dep||2000-12/CD||to-11/TO	prep_from||analyzed-2/VBD||2000-12/CD	prep_for||analyzed-2/VBD||polymorphisms-15/NNS	prep_in||polymorphisms-15/NNS||pfcrt-17/NN	prep_in||polymorphisms-15/NNS||dhfr-19/NN	conj_and||pfcrt-17/NN||dhfr-19/NN	prep_in||polymorphisms-15/NNS||dhps-22/NN	conj_and||pfcrt-17/NN||dhps-22/NN	vmod||pfcrt-17/NN||linked-23/VBN	aux||chloroquine-25/VB||to-24/TO	xcomp||linked-23/VBN||chloroquine-25/VB	xcomp||linked-23/VBN||pyrimethamine/sulfadoxine-27/VB	conj_and||chloroquine-25/VB||pyrimethamine/sulfadoxine-27/VB	dobj||chloroquine-25/VB||resistance-28/NN	falciparummalaria-4||pyrimethamine--1||yes||we analyzed consecutive falciparummalaria isolates from canadian travelers from 1994 to 2000, for polymorphisms in pfcrt, dhfr, and dhps linked to chloroquine and pyrimethamine/sulfadoxine resistance.
nsubj||activates-2/VBZ||hypoxia-1/NN	nsubj||triggers-6/VBZ||hypoxia-1/NN	root||ROOT-0/null||activates-2/VBZ	nn||fks-4/NN||src-3/NN	dobj||activates-2/VBZ||fks-4/NN	conj_and||activates-2/VBZ||triggers-6/VBZ	nn||phosphorylation-9/NN||protein-7/NN	nn||phosphorylation-9/NN||tyrosine-8/NN	dobj||triggers-6/VBZ||phosphorylation-9/NN	prep_in||phosphorylation-9/NN||ipa-11/NN	tyrosine-8||hypoxia-1||no_rel||hypoxia activates src fks and triggers protein tyrosine phosphorylation in ipa.
det||virus-4/NN||a-2/DT	amod||virus-4/NN||blood-borne-3/JJ	prep_as||recognized-9/VBN||virus-4/NN	nsubjpass||recognized-9/VBN||hcv-6/NN	auxpass||recognized-9/VBN||is-7/VBZ	advmod||recognized-9/VBN||widely-8/RB	root||ROOT-0/null||recognized-9/VBN	det||agent-14/NN||a-11/DT	amod||agent-14/NN||major-12/JJ	nn||agent-14/NN||causative-13/NN	prep_as||recognized-9/VBN||agent-14/NN	amod||non-a-17/NN||post-transfusion-16/JJ	prep_of||agent-14/NN||non-a-17/NN	appos||non-a-17/NN||non-bhepatitis-19/NNS	non-a-17||non-bhepatitis-19||no||as a blood-borne virus, hcv is widely recognized as a major causative agent of post-transfusion non-a, non-bhepatitis.
nsubj||represent-3/VB||paracetamol-1/NNP	aux||represent-3/VB||may-2/MD	root||ROOT-0/null||represent-3/VB	det||alternative-5/NN||an-4/DT	dobj||represent-3/VB||alternative-5/NN	amod||surgery-16/NN||ketorolac-7/JJ	nn||prevention-10/NN||pain-9/NN	prep_for||ketorolac-7/JJ||prevention-10/NN	dep||mildly-12/RB||after-11/IN	amod||surgery-16/NN||mildly-12/RB	advmod||painful-15/JJ||moderately-14/RB	prep_to||mildly-12/RB||painful-15/JJ	prep_to||represent-3/VB||surgery-16/NN	prep_in||represent-3/VB||situations-18/NNS	advmod||unsuitable-25/JJ||where-19/WRB	det||use-21/NN||the-20/DT	nsubj||unsuitable-25/JJ||use-21/NN	prep_of||use-21/NN||nsaids-23/NNS	cop||unsuitable-25/JJ||is-24/VBZ	rcmod||situations-18/NNS||unsuitable-25/JJ	painful-15||paracetamol-1||yes||paracetamol may represent an alternative to ketorolac for pain prevention after mildly to moderately painful surgery in situations where the use of nsaids is unsuitable.
nsubjpass||associated-9/VBN||atopicasthma-1/NN	auxpass||associated-3/VBN||was-2/VBD	rcmod||atopicasthma-1/NN||associated-3/VBN	prep_with||associated-3/VBN||eosinophilia-5/NN	prep_with||associated-3/VBN||non-atopicasthma-7/NN	conj_and||eosinophilia-5/NN||non-atopicasthma-7/NN	auxpass||associated-9/VBN||was-8/VBD	root||ROOT-0/null||associated-9/VBN	nn||³-12/NNP||ifn-î-11/NNP	prep_with||associated-9/VBN||³-12/NNP	amod||monocytes-15/NNS||elevated-14/JJ	prep_with||associated-9/VBN||monocytes-15/NNS	conj_and||³-12/NNP||monocytes-15/NNS	prep_in||associated-9/VBN||blood-17/NN	atopicasthma-1||ifn--1||no_rel||atopicasthma was associated with eosinophilia and non-atopicasthma was associated with ifn-î³ and elevated monocytes in blood.
nsubjpass||suggested-12/VBN||selection-1/NN	nsubj||give-14/VB||selection-1/NN	nsubj||give-14/VB||selection-1/NN	prep_of||selection-1/NN||hepatitisbvirus-3/NNS	appos||hepatitisbvirus-3/NNS||hbv-5/NN	nn||immunity-9/NN||host-8/NN	prep_by||hepatitisbvirus-3/NNS||immunity-9/NN	aux||suggested-12/VBN||has-10/VBZ	auxpass||suggested-12/VBN||been-11/VBN	root||ROOT-0/null||suggested-12/VBN	aux||give-14/VB||to-13/TO	xcomp||suggested-12/VBN||give-14/VB	xcomp||suggested-12/VBN||give-14/VB	conj_or||give-14/VB||give-14/VB	dobj||give-14/VB||rise-15/NN	prep_to||rise-15/NN||variants-17/NNS	amod||substitutions-20/NNS||aminoacid-19/JJ	prep_with||variants-17/NNS||substitutions-20/NNS	det||determinant-28/NN||the-24/DT	nn||determinant-28/NN||a-26/NNP	prep_around||give-14/VB||determinant-28/NN	prep_at||give-14/VB||determinant-28/NN	det||antigen-32/NN||the-30/DT	nn||antigen-32/NN||surface-31/NN	prep_of||determinant-28/NN||antigen-32/NN	appos||determinant-28/NN||hbsag-34/NN	det||target-39/NN||the-37/DT	amod||target-39/NN||main-38/JJ	dobj||give-14/VB||target-39/NN	nn||neutralization-42/NN||antibody-41/NN	prep_of||target-39/NN||neutralization-42/NN	amod||assays-45/NNS||diagnostic-44/JJ	prep_of||target-39/NN||assays-45/NNS	conj_and||neutralization-42/NN||assays-45/NNS	hbv-5||hepatitisbvirus-3||no||selection of hepatitisbvirus (hbv) by host immunity has been suggested to give rise to variants with aminoacid substitutions at or around the 'a' determinant of the surface antigen (hbsag), the main target of antibody neutralization and diagnostic assays.
nsubj||affect-8/VB||treatment-1/NN	nsubj||blocked-13/VBD||treatment-1/NN	det||n-acetylcysteine-5/NN||the-3/DT	amod||n-acetylcysteine-5/NN||antioxidant-4/JJ	prep_with||treatment-1/NN||n-acetylcysteine-5/NN	aux||affect-8/VB||did-6/VBD	neg||affect-8/VB||not-7/RB	root||ROOT-0/null||affect-8/VB	amod||titers-11/NNS||diesel-enhanced-9/JJ	nn||titers-11/NNS||virus-10/NN	dobj||affect-8/VB||titers-11/NNS	conj_but||affect-8/VB||blocked-13/VBD	det||changes-16/NNS||the-14/DT	amod||changes-16/NNS||de-induced-15/JJ	dobj||blocked-13/VBD||changes-16/NNS	amod||profiles-19/NNS||cytokine-18/JJ	prep_in||blocked-13/VBD||profiles-19/NNS	prep_in||blocked-13/VBD||lunginflammation-21/NN	conj_and||profiles-19/NNS||lunginflammation-21/NN	lunginflammation-21||n-acetylcysteine-5||yes||treatment with the antioxidant n-acetylcysteine did not affect diesel-enhanced virus titers but blocked the de-induced changes in cytokine profiles and lunginflammation.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	prep_into||enrolled-3/VBN||one-5/CD	num||groups-8/NNS||four-7/CD	prep_of||one-5/CD||groups-8/NNS	det||basis-11/NN||the-10/DT	prep_on||groups-8/NNS||basis-11/NN	nn||status-16/NN||hiv-13/NN	conj_and||hiv-13/NN||ks-15/NN	nn||status-16/NN||ks-15/NN	prep_of||basis-11/NN||status-16/NN	nsubj||negative/ks-19/VBZ||hiv-18/NN	dep||groups-8/NNS||negative/ks-19/VBZ	acomp||negative/ks-19/VBZ||negative-20/JJ	amod||negative-23/JJ||hivpositive/ks-22/JJ	acomp||negative/ks-19/VBZ||negative-23/JJ	conj_and||negative-20/JJ||negative-23/JJ	num||negative/ks-26/NNS||hiv-25/CD	npadvmod||positive-27/JJ||negative/ks-26/NNS	acomp||negative/ks-19/VBZ||positive-27/JJ	conj_and||negative-20/JJ||positive-27/JJ	amod||positive-31/JJ||hivpositive/ks-30/JJ	acomp||negative/ks-19/VBZ||positive-31/JJ	conj_and||negative-20/JJ||positive-31/JJ	hivpositive--1||hiv-25||no||participants were enrolled into one of four groups on the basis of hiv and ks status (hiv negative/ks negative, hivpositive/ks negative, hiv negative/ks positive, and hivpositive/ks positive).
det||objective-3/NN||the-1/DT	amod||objective-3/NN||primary-2/JJ	nsubj||was-7/VBD||objective-3/NN	nsubj||determine-9/VB||objective-3/NN	det||study-6/NN||this-5/DT	prep_of||objective-3/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||determine-9/VB||to-8/TO	xcomp||was-7/VBD||determine-9/VB	det||prevalence-11/NN||the-10/DT	dobj||determine-9/VB||prevalence-11/NN	amod||impairment-14/NN||neurocognitive-13/JJ	prep_of||prevalence-11/NN||impairment-14/NN	amod||individuals-17/NNS||hiv-positive-16/JJ	prep_among||determine-9/VB||individuals-17/NNS	prep_in||individuals-17/NNS||botswana-19/NN	vmod||determine-9/VB||using-21/VBG	det||scale-25/NN||the-22/DT	amod||scale-25/NN||international-23/JJ	nn||scale-25/NN||hivdementia-24/NN	dobj||using-21/VBG||scale-25/NN	appos||scale-25/NN||ihds-27/NNS	hivdementia-24||hiv--1||no||the primary objective of this study was to determine the prevalence of neurocognitive impairment among hiv-positive individuals in botswana, using the international hivdementia scale (ihds).
num||rats-5/NNS||resultsâ-1/CD	amod||rats-5/NNS||$-2/JJ	nn||rats-5/NNS||zdf-4/NN	nsubj||have-10/VBP||rats-5/NNS	prepc_compared_with||rats-5/NNS||with-7/IN	nn||rats-9/NNS||zcl-8/NN	pobj||rats-5/NNS||rats-9/NNS	root||ROOT-0/null||have-10/VBP	amod||gk-13/NN||lower-11/JJR	amod||gk-13/NN||hepatic-12/JJ	dobj||have-10/VBP||gk-13/NN	nsubj||increased-73/VBD||activity-14/NN	nn||activity-14/NN||-lrb--15/FW	nn||activity-14/NN||11.6-16/FW	nn||activity-14/NN||â-17/FW	nn||activity-14/NN||±-18/FW	nn||activity-14/NN||1.9-19/FW	nn||activity-14/NN||vs.-20/FW	nn||activity-14/NN||32.5-21/FW	nn||activity-14/NN||â-22/FW	nn||activity-14/NN||±-23/FW	nn||activity-14/NN||3.2-24/FW	nn||activity-14/NN||mu/mg-25/FW	nn||activity-14/NN||protein-26/FW	nn||activity-14/NN||-rrb--27/FW	nn||activity-14/NN||marked-29/FW	nn||activity-14/NN||hyperglycemia-30/FW	nn||activity-14/NN||-lrb--31/FW	nn||activity-14/NN||23.9-32/FW	nn||activity-14/NN||â-33/FW	nn||activity-14/NN||±-34/FW	nn||activity-14/NN||1.2-35/FW	nn||activity-14/NN||vs.-36/FW	nn||activity-14/NN||7.4-37/FW	nn||activity-14/NN||â-38/FW	dep||activity-14/NN||±-39/FW	number||-rrb--42/NN||0.3-40/CD	dep||-rrb--42/NN||mmol/l-41/JJ	amod||activity-14/NN||-rrb--42/NN	amod||endogenous-45/NNS||higher-44/JJR	appos||activity-14/NN||endogenous-45/NNS	advmod||activity-14/NN||glucose-46/RB	dep||activity-14/NN||production-47/NN	nn||production-47/NN||-lrb--48/FW	nn||production-47/NN||80-49/FW	nn||production-47/NN||â-50/FW	nn||production-47/NN||±-51/FW	nn||production-47/NN||3-52/FW	nn||production-47/NN||vs.-53/FW	nn||production-47/NN||38-54/FW	nn||production-47/NN||â-55/FW	nn||production-47/NN||±-56/FW	nn||production-47/NN||3-57/FW	nn||production-47/NN||î-58/FW	nn||production-47/NN||1/4-59/FW	nn||production-47/NN||mol-60/FW	nn||production-47/NN||â-61/FW	dep||production-47/NN||·-62/FW	poss||-rrb--71/NN||kgâˆ-63/NNP	number||â-66/NN||1-65/CD	amod||-rrb--71/NN||â-66/NN	punct||-rrb--71/NN||·-67/``	nn||-rrb--71/NN||minâˆ-68/NN	num||-rrb--71/NN||1-70/CD	dep||production-47/NN||-rrb--71/NN	rcmod||gk-13/NN||increased-73/VBD	amod||â-78/NN||glucose-6-phosphatase-74/JJ	nn||â-78/NN||flux-75/NN	nn||â-78/NN||-lrb--76/NN	num||â-78/NN||150-77/CD	iobj||increased-73/VBD||â-78/NN	punct||â-78/NN||±-79/``	nn||â-78/NN||11-80/FW	nn||â-78/NN||vs.-81/FW	nn||â-78/NN||58-82/FW	nn||â-78/NN||â-83/FW	nn||â-78/NN||±-84/FW	nn||â-78/NN||8-85/FW	nn||â-78/NN||î-86/FW	nn||â-78/NN||1/4-87/FW	nn||â-78/NN||mol-88/FW	dep||â-78/NN||â-89/FW	punct||â-78/NN||·-90/''	poss||â-94/NN||kgâˆ-91/NNP	num||â-94/NN||1-93/CD	iobj||increased-73/VBD||â-94/NN	dep||â-94/NN||·-95/SYM	poss||production-113/NN||minâˆ-96/NNP	number||-rrb--99/NN||1-98/CD	amod||production-113/NN||-rrb--99/NN	cc||during-102/IN||and-101/CC	dep||-rrb--99/NN||during-102/IN	det||clamp-105/NN||a-103/DT	amod||clamp-105/NN||hyperglycemic-104/JJ	pobj||during-102/IN||clamp-105/NN	det||failure-108/NN||a-107/DT	appos||clamp-105/NN||failure-108/NN	amod||endogenous-111/NNS||suppress-110/JJ	prep_to||failure-108/NN||endogenous-111/NNS	nn||production-113/NN||glucose-112/NN	iobj||increased-73/VBD||production-113/NN	amod||production-113/NN||-lrb--114/NN	number||-lrb--114/NN||80-115/CD	iobj||increased-73/VBD||â-116/NN	punct||â-116/NN||±-117/``	nn||â-116/NN||7-118/FW	nn||â-116/NN||vs.-119/FW	nn||â-116/NN||âˆ-120/FW	nn||â-116/NN||7-122/FW	nn||â-116/NN||â-123/FW	nn||â-116/NN||±-124/FW	nn||â-116/NN||4-125/FW	nn||â-116/NN||î-126/FW	nn||â-116/NN||1/4-127/FW	nn||â-116/NN||mol-128/FW	dep||â-116/NN||â-129/FW	punct||â-116/NN||·-130/``	poss||â-134/NN||kgâˆ-131/NNP	num||â-134/NN||1-133/CD	dep||â-116/NN||â-134/NN	punct||â-116/NN||·-135/''	poss||incorporation-143/NN||minâˆ-136/NNP	number||-rrb--139/NN||1-138/CD	amod||incorporation-143/NN||-rrb--139/NN	conj_and||-rrb--139/NN||promote-141/JJ	amod||incorporation-143/NN||promote-141/JJ	nn||incorporation-143/NN||glucose-142/NN	dobj||increased-73/VBD||incorporation-143/NN	prep_into||increased-73/VBD||glycogen-145/NN	nn||glycogen-145/NN||-lrb--146/FW	nn||glycogen-145/NN||15-147/FW	nn||glycogen-145/NN||â-148/FW	nn||glycogen-145/NN||±-149/FW	nn||glycogen-145/NN||5-150/FW	nn||glycogen-145/NN||vs.-151/FW	nn||glycogen-145/NN||43-152/FW	nn||glycogen-145/NN||â-153/FW	nn||glycogen-145/NN||±-154/FW	nn||glycogen-145/NN||3-155/FW	dep||glycogen-145/NN||î-156/FW	dep||glycogen-145/NN||1/4-157/CD	xcomp||increased-73/VBD||mol/g-158/VBG	nn||-rrb--160/NNS||liver-159/NN	dobj||mol/g-158/VBG||-rrb--160/NNS	hyperglycemia-30||glucose-142||no||resultsâ $ '' zdf rats compared with zcl rats have lower hepatic gk activity -lrb- 11.6 â ± 1.9 vs. 32.5 â ± 3.2 mu/mg protein -rrb- , marked hyperglycemia -lrb- 23.9 â ± 1.2 vs. 7.4 â ± 0.3 mmol/l -rrb- , higher endogenous glucose production -lrb- 80 â ± 3 vs. 38 â ± 3 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- , increased glucose-6-phosphatase flux -lrb- 150 â ± 11 vs. 58 â ± 8 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- , and during a hyperglycemic clamp , a failure to suppress endogenous glucose production -lrb- 80 â ± 7 vs. âˆ ' 7 â ± 4 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- and promote glucose incorporation into glycogen -lrb- 15 â ± 5 vs. 43 â ± 3 î 1/4 mol/g liver -rrb- .
amod||expression-2/NN||gsta4-1/JJ	nsubjpass||downregulated-5/VBN||expression-2/NN	auxpass||downregulated-5/VBN||is-3/VBZ	advmod||downregulated-5/VBN||selectively-4/RB	root||ROOT-0/null||downregulated-5/VBN	amod||tissue-8/NN||adipose-7/JJ	prep_in||downregulated-5/VBN||tissue-8/NN	amod||mice-13/NNS||obese-10/JJ	amod||mice-13/NNS||insulin-resistant-11/JJ	amod||mice-13/NNS||c57bl/6j-12/JJ	prep_of||tissue-8/NN||mice-13/NNS	amod||insulinresistance-18/NN||human-16/JJ	amod||insulinresistance-18/NN||obesity-linked-17/JJ	prep_in||downregulated-5/VBN||insulinresistance-18/NN	conj_and||tissue-8/NN||insulinresistance-18/NN	insulin--1||insulinresistance-18||no_rel||gsta4 expression is selectively downregulated in adipose tissue of obese insulin-resistant c57bl/6j mice and in human obesity-linked insulinresistance.
nn||mice-3/NNS||rictor-1/NN	nn||mice-3/NNS||null-2/NN	nsubj||exhibited-4/VBD||mice-3/NNS	root||ROOT-0/null||exhibited-4/VBD	amod||hyperglycemia-6/NN||mild-5/JJ	dobj||exhibited-4/VBD||hyperglycemia-6/NN	dobj||exhibited-4/VBD||glucoseintolerance-8/NN	conj_and||hyperglycemia-6/NN||glucoseintolerance-8/NN	vmod||hyperglycemia-6/NN||caused-9/VBN	det||reduction-12/NN||a-11/DT	agent||caused-9/VBN||reduction-12/NN	nn||²-15/NNS||î-14/NN	prep_in||reduction-12/NN||²-15/NNS	nn||mass-18/NN||cell-17/NN	dobj||exhibited-4/VBD||mass-18/NN	conj_and||hyperglycemia-6/NN||mass-18/NN	nn||²-21/NNS||î-20/NN	appos||mass-18/NN||²-21/NNS	nn||proliferation-24/NN||cell-23/NN	dobj||exhibited-4/VBD||proliferation-24/NN	conj_and||hyperglycemia-6/NN||proliferation-24/NN	amod||content-28/NN||pancreatic-26/JJ	nn||content-28/NN||insulin-27/NN	appos||proliferation-24/NN||content-28/NN	amod||secretion-33/NN||glucose-stimulated-31/JJ	nn||secretion-33/NN||insulin-32/NN	dobj||exhibited-4/VBD||secretion-33/NN	conj_and||hyperglycemia-6/NN||secretion-33/NN	hyperglycemia-6||insulin-32||yes||rictor null mice exhibited mild hyperglycemia and glucoseintolerance caused by a reduction in î²-cell mass, î²-cell proliferation, pancreatic insulin content, and glucose-stimulated insulin secretion.
preconj||rotavirus-2/NNS||neither-1/CC	nsubjpass||detected-6/VBN||rotavirus-2/NNS	conj_nor||rotavirus-2/NNS||v.cholerae-4/NN	nsubjpass||detected-6/VBN||v.cholerae-4/NN	auxpass||detected-6/VBN||was-5/VBD	root||ROOT-0/null||detected-6/VBN	number||-lrb--9/CD||280-8/CD	amod||samples-13/NNS||-lrb--9/CD	num||%-11/NN||61-10/CD	dep||-lrb--9/CD||%-11/NN	nn||samples-13/NNS||-rrb--12/NN	prep_in||detected-6/VBN||samples-13/NNS	nsubjpass||termed-17/VBN||these-15/DT	auxpass||termed-17/VBN||were-16/VBD	parataxis||detected-6/VBN||termed-17/VBN	amod||diarrhoea-27/NN||â-18/JJ	amod||diarrhoea-27/NN||$-19/$	dep||$-19/$||˜non-20/JJ	dep||$-19/$||rotavirus-22/NNS	dep||$-19/$||non-choleraâ-24/NNS	conj_and||rotavirus-22/NNS||non-choleraâ-24/NNS	dep||rotavirus-22/NNS||$-25/$	num||$-25/$||™-26/CD	dobj||termed-17/VBN||diarrhoea-27/NN	cholera--1||v.cholerae-4||no||neither rotavirus nor v.cholerae was detected in 280 -lrb- 61 % -rrb- samples ; these were termed â $ ˜non - rotavirus and non-choleraâ $ ™ diarrhoea .
det||future-3/NN||the-2/DT	prep_in||have-6/VB||future-3/NN	nsubj||have-6/VB||we-4/PRP	nsubj||analyze-8/VB||we-4/PRP	aux||have-6/VB||will-5/MD	root||ROOT-0/null||have-6/VB	aux||analyze-8/VB||to-7/TO	xcomp||have-6/VB||analyze-8/VB	predet||possibilities-12/NNS||all-9/PDT	det||possibilities-12/NNS||these-10/DT	amod||possibilities-12/NNS||therapeutic-11/JJ	dobj||analyze-8/VB||possibilities-12/NNS	amod||targets-15/NNS||specific-14/JJ	prep_on||analyze-8/VB||targets-15/NNS	advmod||associated-18/VBN||probably-17/RB	dep||targets-15/NNS||associated-18/VBN	prep_with||associated-18/VBN||chemotherapy-20/NN	dep||targets-15/NNS||interferon-22/VBN	conj_and/or||associated-18/VBN||interferon-22/VBN	det||treatment-26/NN||the-24/DT	amod||treatment-26/NN||adjuvant-25/JJ	prep_in||interferon-22/VBN||treatment-26/NN	mark||want-30/VBP||if-28/IN	nsubj||want-30/VBP||we-29/PRP	nsubj||change-32/VB||we-29/PRP	advcl||have-6/VB||want-30/VBP	aux||change-32/VB||to-31/TO	xcomp||want-30/VBP||change-32/VB	det||history-35/NN||the-33/DT	amod||history-35/NN||natural-34/JJ	dobj||change-32/VB||history-35/NN	prep_of||history-35/NN||melanomas-37/NNS	melanomas-37||interferon-22||yes||in the future we will have to analyze all these therapeutic possibilities on specific targets, probably associated with chemotherapy and/or interferon in the adjuvant treatment, if we want to change the natural history of melanomas.
det||receptor-3/NN||the-1/DT	nn||receptor-3/NN||androgen-2/NN	nsubj||member-9/NN||receptor-3/NN	appos||receptor-3/NN||ar-5/NN	cop||member-9/NN||is-7/VBZ	det||member-9/NN||a-8/DT	root||ROOT-0/null||member-9/NN	nsubj||plays-20/VBZ||member-9/NN	det||family-15/NN||the-11/DT	amod||family-15/NN||nuclear-12/JJ	nn||family-15/NN||hormone-13/NN	nn||family-15/NN||receptor-14/NN	prep_of||member-9/NN||family-15/NN	nn||factors-18/NNS||transcription-17/NN	prep_of||family-15/NN||factors-18/NNS	rcmod||member-9/NN||plays-20/VBZ	det||role-23/NN||a-21/DT	amod||role-23/NN||critical-22/JJ	dobj||plays-20/VBZ||role-23/NN	prepc_in||plays-20/VBZ||regulating-25/VBG	dobj||regulating-25/VBG||expression-26/NN	prep_of||expression-26/NN||genes-28/NNS	vmod||genes-28/NNS||involved-29/VBN	nn||development-32/NN||prostate-31/NN	prep_in||involved-29/VBN||development-32/NN	prep_in||involved-29/VBN||transformation-34/NN	conj_and||development-32/NN||transformation-34/NN	androgen-2||ar-5||no_rel||the androgen receptor (ar) is a member of the nuclear hormone receptor family of transcription factors that plays a critical role in regulating expression of genes involved in prostate development and transformation.
advmod||diagnosed-4/VBN||when-1/WRB	nsubjpass||diagnosed-4/VBN||retinitis-2/NNS	auxpass||diagnosed-4/VBN||is-3/VBZ	advcl||started-10/VBN||diagnosed-4/VBN	nn||therapy-7/NN||haart-6/NN	nsubjpass||started-10/VBN||therapy-7/NN	nsubjpass||improved-12/VBN||therapy-7/NN	aux||started-10/VBN||should-8/MD	auxpass||started-10/VBN||be-9/VB	root||ROOT-0/null||started-10/VBN	conj_or||started-10/VBN||improved-12/VBN	amod||therapy-16/NN||anti-cmv-15/JJ	nsubjpass||administered-30/VBN||therapy-16/NN	amod||valganciclovir-19/NN||oral-18/JJ	prep_with||therapy-16/NN||valganciclovir-19/NN	amod||ganciclovir-22/NN||intravenous-21/JJ	prep_with||therapy-16/NN||ganciclovir-22/NN	conj_or||valganciclovir-19/NN||ganciclovir-22/NN	prep_with||therapy-16/NN||foscarnet-24/NN	conj_or||valganciclovir-19/NN||foscarnet-24/NN	prep_with||therapy-16/NN||cidofovir-27/NN	conj_or||valganciclovir-19/NN||cidofovir-27/NN	aux||administered-30/VBN||should-28/MD	auxpass||administered-30/VBN||be-29/VB	conj_and||started-10/VBN||administered-30/VBN	cmv--1||ganciclovir-22||yes||when retinitis is diagnosed, haart therapy should be started or improved, and anti-cmv therapy with oral valganciclovir, intravenous ganciclovir, foscarnet, or cidofovir should be administered.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	xcomp||â-5/VBP||$-6/VBG	quantmod||total-9/NN||a-8/DT	num||participants-18/NNS||total-9/NN	quantmod||total-9/NN||of-10/IN	number||total-9/NN||3,188-11/CD	nn||participants-18/NNS||diabetes-12/NN	nn||participants-18/NNS||prevention-13/NN	nn||participants-18/NNS||program-14/NN	discourse||participants-18/NNS||dpp-16/UH	dobj||$-6/VBG||participants-18/NNS	det||bmi-22/NN||a-20/DT	amod||bmi-22/NN||mean-21/JJ	prep_with||$-6/VBG||bmi-22/NN	num||kg/m2-25/NNS||34-24/CD	prep_of||bmi-22/NN||kg/m2-25/NNS	amod||glucose-29/NN||elevated-27/JJ	amod||glucose-29/NN||fasting-28/VBG	prep_with||$-6/VBG||glucose-29/NN	conj_and||bmi-22/NN||glucose-29/NN	appos||glucose-29/NN||impairedglucosetolerance-31/NN	amod||measurements-38/NNS||baseline-34/JJ	amod||measurements-38/NNS||urinary-35/JJ	nn||measurements-38/NNS||albumin-36/NN	nn||measurements-38/NNS||excretion-37/NN	nsubjpass||followed-40/VBN||measurements-38/NNS	auxpass||followed-40/VBN||were-39/VBD	conj_and||â-5/VBP||followed-40/VBN	nn||diabetes-43/NN||incident-42/NN	prep_for||followed-40/VBN||diabetes-43/NN	det||mean-46/NN||a-45/DT	prep_over||followed-40/VBN||mean-46/NN	num||years-49/NNS||3.2-48/CD	prep_of||mean-46/NN||years-49/NNS	impairedglucosetolerance-31||glucose-29||no_rel||research design and methods â€”a total of 3,188 diabetes prevention program (dpp) participants with a mean bmi of 34 kg/m2 and elevated fasting glucose, impairedglucosetolerance, and baseline urinary albumin excretion measurements were followed for incident diabetes over a mean of 3.2 years.
mark||drug-11/NN||although-1/IN	nsubj||drug-11/NN||warfarin-2/NN	cop||drug-11/NN||is-3/VBZ	det||drug-11/NN||an-4/DT	amod||drug-11/NN||effective-5/JJ	amod||drug-11/NN||oral-6/JJ	nn||drug-11/NN||anticoagulation-7/NN	appos||drug-11/NN||oac-9/NN	advcl||scarce-32/JJ||drug-11/NN	aux||reduce-13/VB||to-12/TO	vmod||drug-11/NN||reduce-13/VB	det||risk-15/NN||the-14/DT	dobj||reduce-13/VB||risk-15/NN	prep_of||risk-15/NN||thromboembolism-17/NN	prep_in||reduce-13/VB||patients-19/NNS	amod||atrialfibrillation-22/NN||non-valvular-21/JJ	prep_with||patients-19/NNS||atrialfibrillation-22/NN	appos||atrialfibrillation-22/NN||nvaf-24/NN	amod||data-30/NNS||long-27/JJ	nn||data-30/NNS||term-28/NN	nn||data-30/NNS||follow-up-29/NN	nsubj||scarce-32/JJ||data-30/NNS	nsubj||certain-35/JJ||data-30/NNS	cop||scarce-32/JJ||are-31/VBP	root||ROOT-0/null||scarce-32/JJ	aux||certain-35/JJ||to-33/TO	cop||certain-35/JJ||be-34/VB	xcomp||scarce-32/JJ||certain-35/JJ	mark||maintained-42/VBN||whether-36/IN	det||level-40/NN||the-37/DT	nn||level-40/NN||target-38/NN	nn||level-40/NN||inr-39/NN	nsubjpass||maintained-42/VBN||level-40/NN	auxpass||maintained-42/VBN||is-41/VBZ	ccomp||certain-35/JJ||maintained-42/VBN	amod||patients-45/NNS||warfarin-treated-44/JJ	prep_in||maintained-42/VBN||patients-45/NNS	prep_in||patients-45/NNS||korea-47/NN	thromboembolism-17||warfarin-2||yes||although warfarin is an effective oral anticoagulation (oac) drug to reduce the risk of thromboembolism in patients with non-valvular atrialfibrillation (nvaf), long term follow-up data are scarce to be certain whether the target inr level is maintained in warfarin-treated patients in korea.
det||vitamina-4/NN||the-2/DT	amod||vitamina-4/NN||national-3/JJ	prep_despite||continue-16/VBP||vitamina-4/NN	amod||programmes-8/NNS||antihelminthic-6/JJ	nn||programmes-8/NNS||prophylaxis-7/NNS	conj_and||vitamina-4/NN||programmes-8/NNS	prep_despite||continue-16/VBP||programmes-8/NNS	preconj||geo-helminths-12/NNS||both-10/DT	amod||geo-helminths-12/NNS||intestinal-11/JJ	nsubj||continue-16/VBP||geo-helminths-12/NNS	nsubj||prevalent-19/JJ||geo-helminths-12/NNS	nn||vitaminadeficiency-15/NN||subclinical-14/NN	conj_and||geo-helminths-12/NNS||vitaminadeficiency-15/NN	nsubj||continue-16/VBP||vitaminadeficiency-15/NN	nsubj||prevalent-19/JJ||vitaminadeficiency-15/NN	root||ROOT-0/null||continue-16/VBP	aux||prevalent-19/JJ||to-17/TO	cop||prevalent-19/JJ||be-18/VB	xcomp||continue-16/VBP||prevalent-19/JJ	prep_among||prevalent-19/JJ||children-21/NNS	amod||countries-24/NNS||developing-23/VBG	prep_in||children-21/NNS||countries-24/NNS	vitaminadeficiency-15||vitamina-4||yes||despite the national vitamina and antihelminthic prophylaxis programmes, both intestinal geo-helminths and subclinical vitaminadeficiency continue to be prevalent among children in developing countries.
nsubj||showed-3/VBD||this-1/DT	advmod||showed-3/VBD||clearly-2/RB	root||ROOT-0/null||showed-3/VBD	det||circulation-5/NN||the-4/DT	dobj||showed-3/VBD||circulation-5/NN	amod||v.cholerae-8/NN||sxt-containing-7/JJ	prep_of||circulation-5/NN||v.cholerae-8/NN	amod||agent-11/NN||causative-10/JJ	prep_as||showed-3/VBD||agent-11/NN	prep_for||agent-11/NN||cholera-13/NN	prep_in||showed-3/VBD||kolkata-15/NN	cholera-13||v.cholerae-8||no||this clearly showed the circulation of sxt-containing v.cholerae as causative agent for cholera in kolkata .
nsubjpass||collected-3/VBN||blood-1/NN	auxpass||collected-3/VBN||was-2/VBD	root||ROOT-0/null||collected-3/VBN	prep_from||collected-3/VBN||patients-5/NNS	amod||melanoma-8/NN||uveal-7/JJ	prep_with||collected-3/VBN||melanoma-8/NN	vmod||melanoma-8/NN||enrolled-9/VBN	det||trial-14/NN||an-11/DT	amod||trial-14/NN||adjuvant-12/JJ	nn||trial-14/NN||therapy-13/NN	prep_on||enrolled-9/VBN||trial-14/NN	prep_in||treated-19/VBN||trial-14/NN	nsubjpass||treated-19/VBN||they-17/PRP	auxpass||treated-19/VBN||were-18/VBD	rcmod||trial-14/NN||treated-19/VBN	advmod||treated-19/VBN||sequentially-20/RB	prep_with||treated-19/VBN||dacarbazine-22/JJ	prep_with||treated-19/VBN||interferon-alfa-2b-24/JJ	conj_and||dacarbazine-22/JJ||interferon-alfa-2b-24/JJ	melanoma-8||interferon--1||yes||blood was collected from patients with uveal melanoma enrolled on an adjuvant therapy trial in which they were treated sequentially with dacarbazine and interferon-alfa-2b.
nsubj||efficacious-13/JJ||febuxostat-1/NN	prep_at||febuxostat-1/NN||doses-4/NNS	vmod||doses-4/NNS||ranging-5/VBG	number||240-9/CD||40-7/CD	dep||240-9/CD||to-8/TO	prep_from||ranging-5/VBG||240-9/CD	advmod||ranging-5/VBG||mg/day-10/RB	cop||efficacious-13/JJ||is-12/VBZ	root||ROOT-0/null||efficacious-13/JJ	prepc_in||efficacious-13/JJ||reducing-15/VBG	nn||urate-17/NN||serum-16/NN	dobj||reducing-15/VBG||urate-17/NN	prep_in||reducing-15/VBG||patients-19/NNS	prep_with||patients-19/NNS||hyperuricemia-21/NN	prep_with||patients-19/NNS||gout-23/NN	conj_and||hyperuricemia-21/NN||gout-23/NN	dep||reducing-15/VBG||comparing-25/VBG	advmod||comparing-25/VBG||favorably-26/RB	amod||doses-29/NNS||fixed-28/VBN	prep_with||comparing-25/VBG||doses-29/NNS	prep_of||doses-29/NNS||allopurinol-31/NN	det||respect-34/NN||that-33/DT	prep_in||allopurinol-31/NN||respect-34/NN	gout-23||allopurinol-31||yes||febuxostat, at doses ranging from 40 to 240 mg/day, is efficacious in reducing serum urate in patients with hyperuricemia and gout, comparing favorably with fixed doses of allopurinol in that respect.
nn||patients-2/NNS||emf-1/NN	nsubj||showed-3/VBD||patients-2/NNS	root||ROOT-0/null||showed-3/VBD	amod||frequency-5/NN||greater-4/JJR	dobj||showed-3/VBD||frequency-5/NN	dobj||showed-3/VBD||reactivity-7/NN	conj_and||frequency-5/NN||reactivity-7/NN	nn||antibodies-10/NNS||igg-9/NN	prep_of||frequency-5/NN||antibodies-10/NNS	amod||proteins-13/NNS||myocardial-12/JJ	prep_against||showed-3/VBD||proteins-13/NNS	amod||weights-16/NNS||molecular-15/JJ	prep_of||proteins-13/NNS||weights-16/NNS	num||kd-18/NN||35-17/CD	dobj||showed-3/VBD||kd-18/NN	num||kd-21/NN||42-20/CD	appos||kd-18/NN||kd-21/NN	num||kd-24/NN||70-23/CD	appos||kd-18/NN||kd-24/NN	conj_and||kd-21/NN||kd-24/NN	nn||values-27/NNS||p-26/NN	nsubj||<-28/VBZ||values-27/NNS	dep||kd-21/NN||<-28/VBZ	dobj||<-28/VBZ||0.01-29/CD	dobj||<-28/VBZ||<-31/NNP	conj_and||0.01-29/CD||<-31/NNP	num||<-31/NNP||0.01-32/CD	dobj||<-28/VBZ||<-34/NNP	conj_and||0.01-29/CD||<-34/NNP	num||<-34/NNP||0.05-35/CD	advmod||<-28/VBZ||respectively-36/RB	kd-24||antibodies-10||no_rel||emf patients showed greater frequency and reactivity of igg antibodies against myocardial proteins of molecular weights 35 kd, 42 kd and 70 kd ( p values <0.01, <0.01 and <0.05 respectively).
nsubj||have-12/VBP||fluticasone/salmeterol-1/NN	conj_and||fluticasone/salmeterol-1/NN||budesonide/formoterol-3/NN	nsubj||have-12/VBP||budesonide/formoterol-3/NN	det||products-10/NNS||the-5/DT	advmod||available-7/JJ||currently-6/RB	amod||products-10/NNS||available-7/JJ	nn||products-10/NNS||ics/laba-8/NN	nn||products-10/NNS||combination-9/NN	appos||fluticasone/salmeterol-1/NN||products-10/NNS	root||ROOT-0/null||have-12/VBP	amod||efficacy-14/NN||similar-13/JJ	dobj||have-12/VBP||efficacy-14/NN	dobj||have-12/VBP||tolerability-16/NN	conj_and||efficacy-14/NN||tolerability-16/NN	prepc_based_on||have-12/VBP||on-18/IN	det||meta-analysis-21/NNS||a-19/DT	amod||meta-analysis-21/NNS||recent-20/JJ	pobj||have-12/VBP||meta-analysis-21/NNS	nn||trials-24/NNS||asthma-23/NN	prep_of||meta-analysis-21/NNS||trials-24/NNS	asthma-23||budesonide--1||no||fluticasone/salmeterol and budesonide/formoterol, the currently available ics/laba combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials.
nsubj||remained-9/VBD||changes-1/NNS	nn||control-6/NN||adiposity-3/NN	conj_and||adiposity-3/NN||glucose-5/NN	nn||control-6/NN||glucose-5/NN	prep_in||changes-1/NNS||control-6/NN	prep_with||control-6/NN||ili-8/NN	root||ROOT-0/null||remained-9/VBD	amod||predictors-11/NNS||independent-10/JJ	xcomp||remained-9/VBD||predictors-11/NNS	amod||change-14/NN||hs-crp-13/JJ	prep_of||predictors-11/NNS||change-14/NN	num||year-17/NN||1-16/CD	prep_at||change-14/NN||year-17/NN	dep||year-17/NN||p-19/VBN	number||0.0001-21/CD||<-20/CD	dobj||p-19/VBN||0.0001-21/CD	prep_for||0.0001-21/CD||each-23/DT	prep_after||remained-9/VBD||adjustment-26/NN	prep_for||adjustment-26/NN||demographics-28/NNS	prep_for||adjustment-26/NN||smoking-30/NN	conj_and||demographics-28/NNS||smoking-30/NN	amod||use-38/NN||cardiovascular-32/JJ	nn||use-38/NN||history-33/NN	conj_and||history-33/NN||statin-35/NN	nn||use-38/NN||statin-35/NN	conj_and||history-33/NN||thiazolidinedione-37/NN	nn||use-38/NN||thiazolidinedione-37/NN	prep_for||adjustment-26/NN||use-38/NN	conj_and||demographics-28/NNS||use-38/NN	prep_for||adjustment-26/NN||changes-41/NNS	conj_and||demographics-28/NNS||changes-41/NNS	nn||control-46/NN||fitness-43/NN	conj_and||fitness-43/NN||lipid-45/NN	nn||control-46/NN||lipid-45/NN	prep_in||remained-9/VBD||control-46/NN	adiposity-3||glucose-5||no_rel||changes in adiposity and glucose control with ili remained independent predictors of hs-crp change at 1 year ( p < 0.0001 for each) after adjustment for demographics, smoking, cardiovascular history, statin and thiazolidinedione use, and changes in fitness and lipid control.
det||outbreak-3/NN||an-2/DT	prep_during||revealed-17/VBD||outbreak-3/NN	amod||sars-7/NNS||severeacuterespiratorysyndrome-5/JJ	prep_of||outbreak-3/NN||sars-7/NNS	prep_in||sars-7/NNS||march-10/NN	num||march-10/NN||2003-11/CD	nsubj||revealed-17/VBD||hybridization-13/NN	det||microarray-16/NN||this-15/DT	prep_to||hybridization-13/NN||microarray-16/NN	root||ROOT-0/null||revealed-17/VBD	det||presence-19/NN||the-18/DT	dobj||revealed-17/VBD||presence-19/NN	det||coronavirus-24/NNS||a-21/DT	advmod||uncharacterized-23/JJ||previously-22/RB	amod||coronavirus-24/NNS||uncharacterized-23/JJ	prep_of||presence-19/NN||coronavirus-24/NNS	det||cultivated-29/NNS||a-26/DT	amod||cultivated-29/NNS||viral-27/JJ	num||cultivated-29/NNS||isolate-28/CD	prep_in||coronavirus-24/NNS||cultivated-29/NNS	det||patient-33/NN||a-31/DT	amod||patient-33/NN||sars-32/JJ	prep_from||revealed-17/VBD||patient-33/NN	severeacuterespiratorysyndrome-5||coronavirus-24||no||during an outbreak of severeacuterespiratorysyndrome (sars) in march 2003, hybridization to this microarray revealed the presence of a previously uncharacterized coronavirus in a viral isolate cultivated from a sars patient.
det||decades-5/NNS||the-2/DT	amod||decades-5/NNS||first-3/JJ	num||decades-5/NNS||two-4/CD	prep_during||lower-22/JJR||decades-5/NNS	det||epidemic-10/NN||the-7/DT	nn||epidemic-10/NN||u.s.-8/NN	nn||epidemic-10/NN||aids-9/NNS	prep_of||decades-5/NNS||epidemic-10/NN	det||malignancies-15/NNS||some-14/DT	prep_unlike||lower-22/JJR||malignancies-15/NNS	nn||risk-19/NN||breast-17/NN	nn||risk-19/NN||cancer-18/NN	nsubj||lower-22/JJR||risk-19/NN	nsubj||lower-22/JJR||risk-19/NN	cop||lower-22/JJR||was-20/VBD	advmod||lower-22/JJR||significantly-21/RB	root||ROOT-0/null||lower-22/JJR	conj_and||lower-22/JJR||lower-22/JJR	prep_for||lower-22/JJR||women-24/NNS	amod||infection-30/NN||humanimmunodeficiencyvirus-26/JJ	nn||infection-30/NN||-lrb--27/NNP	nn||infection-30/NN||hiv-28/NN	nn||infection-30/NN||-rrb--29/NN	prep_with||women-24/NNS||infection-30/NN	prepc_compared_to||lower-22/JJR||to-32/TO	det||population-35/NN||the-33/DT	amod||population-35/NN||general-34/JJ	pobj||lower-22/JJR||population-35/NN	aids-9||hiv-28||no||during the first two decades of the u.s. aids epidemic , and unlike some malignancies , breast cancer risk was significantly lower for women with humanimmunodeficiencyvirus -lrb- hiv -rrb- infection compared to the general population .
nsubj||drug-5/NN||chloroquine-1/NN	aux||drug-5/NN||has-2/VBZ	cop||drug-5/NN||been-3/VBN	det||drug-5/NN||the-4/DT	root||ROOT-0/null||drug-5/NN	prep_of||drug-5/NN||choice-7/NN	det||treatment-10/NN||the-9/DT	prep_for||drug-5/NN||treatment-10/NN	prep_of||treatment-10/NN||malaria-12/NN	amod||decades-15/NNS||many-14/JJ	prep_for||malaria-12/NN||decades-15/NNS	malaria-12||chloroquine-1||yes||chloroquine has been the drug of choice for the treatment of malaria for many decades.
advmod||investigated-4/VBD||additionally-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||role-6/NN||the-5/DT	dobj||investigated-4/VBD||role-6/NN	amod||mice-39/NNS||nf-îºb-8/JJ	nn||infection-11/NN||prion-10/NN	prep_after||nf-îºb-8/JJ||infection-11/NN	amod||â-14/NN||nfkb1-13/JJ	prep_of||infection-11/NN||â-14/NN	amod||mice-39/NNS||$-15/$	punct||$-19/$||/-17/:	dep||$-19/$||â-18/PRP	dep||$-15/$||$-19/$	amod||â-23/NN||nfkb2-22/JJ	dep||$-19/$||â-23/NN	dep||â-23/NN||$-24/$	punct||â-23/NN||/-26/:	dep||â-23/NN||â-27/NN	dep||â-27/NN||$-28/$	amod||â-32/NN||bcl3-31/JJ	dep||â-23/NN||â-32/NN	conj_and||â-27/NN||â-32/NN	dep||â-32/NN||$-33/$	punct||$-19/$||/-35/:	nn||mice-39/NNS||â-36/NN	amod||mice-39/NNS||$-37/$	prep_of||role-6/NN||mice-39/NNS	amod||mice-45/NNS||central-41/JJ	amod||system-specific-43/JJ||nervous-42/JJ	amod||mice-45/NNS||system-specific-43/JJ	amod||mice-45/NNS||p65-deleted-44/JJ	prep_of||role-6/NN||mice-45/NNS	conj_and||mice-39/NNS||mice-45/NNS	vmod||role-6/NN||revealing-46/VBG	det||priondisease-49/NN||an-47/DT	amod||priondisease-49/NN||accelerated-48/VBN	dobj||revealing-46/VBG||priondisease-49/NN	amod||mice-55/NNS||nf-îºb2-51/JJ	conj_and||nf-îºb2-51/JJ||bcl-3-deficient-54/JJ	amod||mice-55/NNS||bcl-3-deficient-54/JJ	prep_in||revealing-46/VBG||mice-55/NNS	nsubj||is-58/VBZ||mice-55/NNS	rcmod||mice-55/NNS||is-58/VBZ	prep_in||is-58/VBZ||line-60/NN	det||activity-65/NN||a-62/DT	amod||activity-65/NN||reduced-63/VBN	nn||activity-65/NN||neuroprotective-64/NN	prep_with||is-58/VBZ||activity-65/NN	nn||infection-68/NN||prion-67/NN	prep_in||activity-65/NN||infection-68/NN	priondisease-49||prion-67||no||additionally, we investigated the role of nf-îºb after prion infection of nfkb1 â€“/â€“, nfkb2 â€“/â€“ and bcl3 â€“/â€“ mice and central nervous system-specific p65-deleted mice revealing an accelerated priondisease in nf-îºb2- and bcl-3-deficient mice, which is in line with a reduced neuroprotective activity in prion infection.
nsubj||has-12/VBZ||chloroquine-1/NN	appos||chloroquine-1/NN||cq-3/NN	det||drug-10/NN||the-6/DT	amod||drug-10/NN||worldwide-7/JJ	amod||drug-10/NN||used-8/JJ	amod||drug-10/NN||anti-malarial-9/JJ	appos||chloroquine-1/NN||drug-10/NN	root||ROOT-0/null||has-12/VBZ	advmod||has-12/VBZ||recently-13/RB	auxpass||focused-15/VBN||being-14/VBG	xcomp||has-12/VBZ||focused-15/VBN	det||agent-20/NN||a-17/DT	amod||agent-20/NN||potential-18/JJ	amod||agent-20/NN||anti-cancer-19/JJ	prep_as||focused-15/VBN||agent-20/NN	det||chemosensitizer-25/NN||a-24/DT	prep_as||focused-15/VBN||chemosensitizer-25/NN	conj_and||agent-20/NN||chemosensitizer-25/NN	advmod||used-27/VBN||when-26/WRB	advcl||focused-15/VBN||used-27/VBN	prep_in||used-27/VBN||combination-29/NN	prep_with||used-27/VBN||anti-cancerdrugs-31/NNS	chloroquine-1||cancer--1||no_rel||chloroquine (cq), the worldwide used anti-malarial drug, has recently being focused as a potential anti-cancer agent as well as a chemosensitizer when used in combination with anti-cancerdrugs.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	obesity-30||diuretic-32||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
amod||hyperglycemia-2/NN||intermittent-1/JJ	nsubj||induced-3/VBZ||hyperglycemia-2/NN	nsubj||decreased-10/VBD||hyperglycemia-2/NN	root||ROOT-0/null||induced-3/VBZ	det||degree-6/NN||a-4/DT	amod||degree-6/NN||higher-5/JJR	dobj||induced-3/VBZ||degree-6/NN	prep_of||degree-6/NN||apoptosis-8/NNS	conj_and||induced-3/VBZ||decreased-10/VBD	det||insulin-12/NN||the-11/DT	dobj||decreased-10/VBD||insulin-12/NN	amod||capacity-14/NN||secretory-13/JJ	npadvmod||more-15/RBR||capacity-14/NN	advmod||decreased-10/VBD||more-15/RBR	amod||cells-19/NNS||pancreatic-17/JJ	nn||cells-19/NNS||beta-18/NN	prep_in||decreased-10/VBD||cells-19/NNS	amod||hyperglycemia-22/NN||chronic-21/JJ	prep_than||decreased-10/VBD||hyperglycemia-22/NN	hyperglycemia-22||insulin-12||yes||intermittent hyperglycemia induced a higher degree of apoptosis and decreased the insulin secretory capacity more in pancreatic beta cells than chronic hyperglycemia.
nsubj||ligand-5/VBD||alterations-1/NNS	nn||cxcr3-4/NNS||serum-3/NN	prep_in||alterations-1/NNS||cxcr3-4/NNS	root||ROOT-0/null||ligand-5/VBD	nsubjpass||examined-8/VBN||levels-6/NNS	auxpass||examined-8/VBN||were-7/VBD	ccomp||ligand-5/VBD||examined-8/VBN	amod||cystitis-11/NNS||interstitial-10/JJ	prep_in||examined-8/VBN||cystitis-11/NNS	appos||cystitis-11/NNS||ic-13/NN	dep||cystitis-11/NNS||patients-15/NNS	amod||patterns-19/NNS||similar-17/JJ	nn||patterns-19/NNS||expression-18/NN	dep||cystitis-11/NNS||patterns-19/NNS	prep_in||patterns-19/NNS||serum-21/NN	amod||ligands-28/NNS||cxcr3-25/JJ	amod||ligands-28/NNS||cxcr3-27/JJ	prep_in||examined-8/VBN||ligands-28/NNS	conj_and||cystitis-11/NNS||ligands-28/NNS	nsubjpass||characterized-40/VBN||cytokines-31/NNS	vmod||cytokines-31/NNS||expressed-32/VBN	amod||subpopulations-38/NNS||peripheral-34/JJ	conj_and||peripheral-34/JJ||local-36/JJ	amod||subpopulations-38/NNS||local-36/JJ	nn||subpopulations-38/NNS||leukocyte-37/NN	agent||expressed-32/VBN||subpopulations-38/NNS	auxpass||characterized-40/VBN||were-39/VBD	conj_and||ligand-5/VBD||characterized-40/VBN	prep_during||characterized-40/VBN||cyclophosphamide-42/NN	appos||cyclophosphamide-42/NN||cyp-44/NN	amod||cystitis-49/NNS||induced-47/JJ	amod||cystitis-49/NNS||acute-48/JJ	dep||cyclophosphamide-42/NN||cystitis-49/NNS	prep_in||cystitis-49/NNS||mice-51/NNS	cyclophosphamide-42||cystitis-49||no_rel||alterations in serum cxcr3 ligand levels were examined in interstitial cystitis (ic) patients; similar expression patterns in serum as well as cxcr3, cxcr3 ligands, and cytokines expressed by peripheral and local leukocyte subpopulations were characterized during cyclophosphamide (cyp)-induced acute cystitis in mice.
nsubj||alternative-5/NN||daptomycin-1/NN	cop||alternative-5/NN||was-2/VBD	det||alternative-5/NN||an-3/DT	amod||alternative-5/NN||effective-4/JJ	root||ROOT-0/null||alternative-5/NN	aux||vancomycin/gentamicin-7/VB||to-6/TO	vmod||alternative-5/NN||vancomycin/gentamicin-7/VB	nn||bacteraemia-10/NN||mrsa-9/NN	prep_for||vancomycin/gentamicin-7/VB||bacteraemia-10/NN	amod||endocarditis-13/NNS||right-sided-12/JJ	prep_for||vancomycin/gentamicin-7/VB||endocarditis-13/NNS	conj_or||bacteraemia-10/NN||endocarditis-13/NNS	mrsa-9||vancomycin--1||no_rel||daptomycin was an effective alternative to vancomycin/gentamicin for mrsa bacteraemia or right-sided endocarditis.
nsubj||infection-6/NN||dengue-1/NN	cop||infection-6/NN||is-2/VBZ	det||infection-6/NN||an-3/DT	amod||infection-6/NN||acute-4/JJ	amod||infection-6/NN||mosquito-borne-5/JJ	root||ROOT-0/null||infection-6/NN	vmod||infection-6/NN||caused-7/VBN	agent||caused-7/VBN||dengueviruses-9/NNS	det||flavivirus-13/NNS||the-11/DT	amod||flavivirus-13/NNS||genus-12/JJ	prep_from||dengueviruses-9/NNS||flavivirus-13/NNS	dengue-1||dengueviruses-9||no||dengue is an acute mosquito-borne infection caused by dengueviruses from the genus flavivirus.
advmod||reported-26/VBN||besides-1/RB	amod||hemangioma-4/NN||unilateral-3/JJ	nsubjpass||reported-26/VBN||hemangioma-4/NN	det||case-9/NN||a-6/DT	amod||case-9/NN||unique-7/JJ	amod||case-9/NN||concurrent-8/JJ	appos||hemangioma-4/NN||case-9/NN	prep_of||case-9/NN||tetracycline-11/NN	vmod||tetracycline-11/NN||induced-12/VBN	amod||toxicity-14/NN||gastric-13/JJ	dobj||induced-12/VBN||toxicity-14/NN	det||dog-17/NN||a-16/DT	prep_in||induced-12/VBN||dog-17/NN	vmod||dog-17/NN||characterized-19/VBN	agent||characterized-19/VBN||gastritis-21/NNS	agent||characterized-19/VBN||ulceration-23/NN	conj_and||gastritis-21/NNS||ulceration-23/NN	aux||reported-26/VBN||is-24/VBZ	auxpass||reported-26/VBN||being-25/VBG	root||ROOT-0/null||reported-26/VBN	advmod||reported-26/VBN||here-27/RB	hemangioma-4||tetracycline-11||no_rel||besides, unilateral hemangioma, a unique concurrent case of tetracycline induced gastric toxicity in a dog, characterized by gastritis and ulceration is being reported here.
nn||analysis-2/NN||sequence-1/NN	nsubj||revealed-6/VBD||analysis-2/NN	det||rnas-5/NNS||these-4/DT	prep_of||analysis-2/NN||rnas-5/NNS	root||ROOT-0/null||revealed-6/VBD	det||organization-9/NN||a-7/DT	amod||organization-9/NN||genome-8/JJ	nsubj||described-13/VBD||organization-9/NN	amod||organization-9/NN||similar-10/JJ	prep||similar-10/JJ||to-11/TO	pobj||to-11/TO||recently-12/RB	ccomp||revealed-6/VBD||described-13/VBD	dobj||described-13/VBD||torradoviruses-14/NNS	det||group-18/NN||a-16/DT	amod||group-18/NN||new-17/JJ	appos||torradoviruses-14/NNS||group-18/NN	amod||viruses-21/NNS||picorna-like-20/JJ	prep_of||group-18/NN||viruses-21/NNS	vmod||viruses-21/NNS||causing-22/VBG	amod||diseases-24/NNS||necrosis-associated-23/JJ	dobj||causing-22/VBG||diseases-24/NNS	prep_of||diseases-24/NNS||tomatoes-26/NNS	amod||-RSB--36/NNS||europe-28/JJ	amod||-RSB--36/NNS||-LSB--29/JJ	nn||-RSB--36/NNS||tomato-30/NN	nn||-RSB--36/NNS||torrado-31/NN	nn||-RSB--36/NNS||virus-32/NN	appos||-RSB--36/NNS||totv-34/NNP	prep_in||tomatoes-26/NNS||-RSB--36/NNS	nn||virus-43/NN||mexico-38/NNP	nn||virus-43/NN||-LSB--39/NNP	nn||virus-43/NN||tomato-40/NNP	nn||virus-43/NN||apex-41/NN	nn||virus-43/NN||necrosis-42/NNS	prep_in||tomatoes-26/NNS||virus-43/NN	conj_and||-RSB--36/NNS||virus-43/NN	appos||virus-43/NN||toanv-45/NNP	nn||virus-50/NN||tomato-48/NN	nn||virus-50/NN||marchitez-49/NN	prep_in||tomatoes-26/NNS||virus-50/NN	conj_and||-RSB--36/NNS||virus-50/NN	appos||virus-50/NN||tomarv-52/NNP	advmod||causing-22/VBG||-RSB--54/RB	virus-50||viruses-21||no||sequence analysis of these rnas revealed a genome organization similar to recently described torradoviruses, a new group of picorna-like viruses causing necrosis-associated diseases of tomatoes in europe [tomato torrado virus (totv)] and mexico [tomato apex necrosis virus (toanv) and tomato marchitez virus (tomarv)].
amod||concentration-3/NN||endogenous-1/JJ	nn||concentration-3/NN||formaldehyde-2/NN	nsubj||increased-4/VBD||concentration-3/NN	root||ROOT-0/null||increased-4/VBD	advmod||increased-4/VBD||significantly-5/RB	det||lines-12/NNS||the-7/DT	amod||lines-12/NNS||cultured-8/JJ	nn||lines-12/NNS||breast-9/NN	nn||lines-12/NNS||cancer-10/NN	nn||lines-12/NNS||cell-11/NN	prep_in||increased-4/VBD||lines-12/NNS	prep_in||lines-12/NNS||vitro-14/NNP	det||marrow-19/NN||the-17/DT	nn||marrow-19/NN||bone-18/NN	prep_in||increased-4/VBD||marrow-19/NN	prepc_of||marrow-19/NN||breast-21/VBG	amod||model-26/NN||mrmt-1-22/JJ	nn||model-26/NN||bone-23/NN	nn||model-26/NN||cancer-24/NN	nn||model-26/NN||pain-25/NN	dobj||breast-21/VBG||model-26/NN	prep_in||breast-21/VBG||rats-28/NNS	prep_in||breast-21/VBG||tissues-31/NNS	conj_and||rats-28/NNS||tissues-31/NNS	nn||cancer-34/NN||breast-33/NN	prep_from||tissues-31/NNS||cancer-34/NN	nn||patients-38/NNS||lung-36/NN	nn||patients-38/NNS||cancer-37/NN	prep_from||tissues-31/NNS||patients-38/NNS	conj_and||cancer-34/NN||patients-38/NNS	prep_in||breast-21/VBG||vivo-40/NN	cancer-37||formaldehyde-2||no_rel||endogenous formaldehyde concentration increased significantly in the cultured breast cancer cell lines in vitro , in the bone marrow of breast mrmt-1 bone cancer pain model in rats and in tissues from breast cancer and lung cancer patients in vivo .
amod||projects-4/NNS||yersiniapestis-1/JJ	amod||projects-4/NNS||genome-2/JJ	nn||projects-4/NNS||sequencing-3/NN	nsubj||revealed-6/VBN||projects-4/NNS	aux||revealed-6/VBN||have-5/VBP	root||ROOT-0/null||revealed-6/VBN	num||systems-11/NNS||six-7/CD	amod||systems-11/NNS||intact-8/JJ	amod||systems-11/NNS||uncharacterized-9/JJ	nn||systems-11/NNS||chaperone/usher-10/NN	dobj||revealed-6/VBN||systems-11/NNS	det||potential-14/NN||the-13/DT	prep_with||revealed-6/VBN||potential-14/NN	aux||play-16/VB||to-15/TO	vmod||potential-14/NN||play-16/VB	dobj||play-16/VB||roles-17/NNS	amod||pathogenesis-20/NNS||plague-19/JJ	prep_in||play-16/VB||pathogenesis-20/NNS	plague-19||yersiniapestis-1||no||yersiniapestis genome sequencing projects have revealed six intact uncharacterized chaperone/usher systems with the potential to play roles in plague pathogenesis.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	immunoglobulin-9||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
nn||intake-3/NN||urticaria-1/NN	amod||intake-3/NN||following-2/VBG	nsubjpass||observed-7/VBN||intake-3/NN	nsubjpass||observed-7/VBN||intake-3/NN	prep_of||intake-3/NN||nsaids-5/NNS	auxpass||observed-7/VBN||was-6/VBD	root||ROOT-0/null||observed-7/VBN	conj_and||observed-7/VBN||observed-7/VBN	num||patients-10/NNS||four-9/CD	prep_in||observed-7/VBN||patients-10/NNS	amod||pills-14/NNS||oralcontraceptive-13/JJ	prep_with||observed-7/VBN||pills-14/NNS	num||patient-17/NN||one-16/CD	prep_in||pills-14/NNS||patient-17/NN	oralcontraceptive-13||urticaria-1||no_rel||urticaria following intake of nsaids was observed in four patients and with oralcontraceptive pills in one patient.
nn||patients-2/NNS||patients-1/NNS	nsubj||carvedilol-naive-4/JJ||patients-2/NNS	nsubj||had-6/VBD||patients-2/NNS	cop||carvedilol-naive-4/JJ||were-3/VBD	root||ROOT-0/null||carvedilol-naive-4/JJ	conj_and||carvedilol-naive-4/JJ||had-6/VBD	amod||hypertension-8/NN||essential-7/JJ	dobj||had-6/VBD||hypertension-8/NN	amod||hypertension-12/NN||renal-10/JJ	amod||hypertension-12/NN||parenchymal-11/JJ	dobj||had-6/VBD||hypertension-12/NN	conj_or||hypertension-8/NN||hypertension-12/NN	hypertension-12||carvedilol--1||yes||patients patients were carvedilol-naive and had essential hypertension or renal parenchymal hypertension.
amod||reactions-4/NNS||pseudotumor-like-1/JJ	amod||reactions-4/NNS||periprosthetic-2/JJ	nn||reactions-4/NNS||tissue-3/NN	nsubj||cause-13/VB||reactions-4/NNS	nsubj||lead-16/VB||reactions-4/NNS	advmod||cause-13/VB||around-5/RB	amod||replacements-11/NNS||metal-on-metal-6/JJ	appos||replacements-11/NNS||m-m-8/NNP	amod||replacements-11/NNS||hip-10/JJ	nsubj||cause-13/VB||replacements-11/NNS	aux||cause-13/VB||can-12/MD	root||ROOT-0/null||cause-13/VB	dobj||cause-13/VB||pain-14/NN	conj_and||cause-13/VB||lead-16/VB	nn||surgery-19/NN||revision-18/NN	prep_to||lead-16/VB||surgery-19/NN	pain-14||metal--1||no_rel||pseudotumor-like periprosthetic tissue reactions around metal-on-metal (m-m) hip replacements can cause pain and lead to revision surgery.
amod||studies-2/NNS||further-1/JJ	nsubj||necessary-4/JJ||studies-2/NNS	nsubj||establish-6/VB||studies-2/NNS	cop||necessary-4/JJ||are-3/VBP	root||ROOT-0/null||necessary-4/JJ	aux||establish-6/VB||to-5/TO	xcomp||necessary-4/JJ||establish-6/VB	det||role-8/NN||the-7/DT	dobj||establish-6/VB||role-8/NN	amod||chemotherapy-13/NN||supraselective-10/JJ	amod||chemotherapy-13/NN||intra-arterial-11/JJ	nn||chemotherapy-13/NN||melphalan-12/NN	prep_of||role-8/NN||chemotherapy-13/NN	prep_for||chemotherapy-13/NN||children-15/NNS	prep_with||establish-6/VB||retinoblastoma-17/NN	melphalan-12||retinoblastoma-17||no_rel||further studies are necessary to establish the role of supraselective intra-arterial melphalan chemotherapy for children with retinoblastoma.
mark||used-8/VBN||as-1/IN	det||proteins-5/NNS||the-2/DT	amod||proteins-5/NNS||viral-3/JJ	amod||proteins-5/NNS||capsid-4/JJ	nsubjpass||used-8/VBN||proteins-5/NNS	auxpass||used-8/VBN||are-6/VBP	advmod||used-8/VBN||commonly-7/RB	advcl||-lrb--19/VBD||used-8/VBN	prep_in||used-8/VBN||classification-10/NN	advmod||discovered-13/VBN||newly-12/RB	amod||viruses-14/NNS||discovered-13/VBN	prep_of||classification-10/NN||viruses-14/NNS	det||proteins-18/NNS||the-16/DT	amod||proteins-18/NNS||capsid-17/JJ	nsubj||-lrb--19/VBD||proteins-18/NNS	root||ROOT-0/null||-lrb--19/VBD	nn||-rrb--21/NNS||cp-20/NN	nsubjpass||examined-30/VBN||-rrb--21/NNS	det||virus-24/NN||the-23/DT	prep_of||-rrb--21/NNS||virus-24/NN	vmod||virus-24/NN||discovered-25/VBN	nn||coagulata-28/NN||h.-27/NN	prep_in||discovered-25/VBN||coagulata-28/NN	auxpass||examined-30/VBN||was-29/VBD	ccomp||-lrb--19/VBD||examined-30/VBN	virus-24||viruses-14||no||as the viral capsid proteins are commonly used in classification of newly discovered viruses , the capsid proteins -lrb- cp -rrb- of the virus discovered in h. coagulata was examined .
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||aims-4/VBZ||study-3/NN	nsubj||demonstrate-6/VB||study-3/NN	root||ROOT-0/null||aims-4/VBZ	aux||demonstrate-6/VB||to-5/TO	xcomp||aims-4/VBZ||demonstrate-6/VB	mark||induces-13/VBZ||that-7/IN	det||formaldehyde-12/NN||the-8/DT	amod||formaldehyde-12/NN||tumor-9/JJ	amod||formaldehyde-12/NN||tissue-derived-10/JJ	nn||formaldehyde-12/NN||endogenous-11/NNS	nsubj||induces-13/VBZ||formaldehyde-12/NN	ccomp||demonstrate-6/VB||induces-13/VBZ	nn||pain-16/NN||bone-14/NN	nn||pain-16/NN||cancer-15/NN	dobj||induces-13/VBZ||pain-16/NN	amod||activation-19/NN||trpv1-18/JJ	prep_via||pain-16/NN||activation-19/NN	nn||environment-23/NN||tumor-21/NN	amod||environment-23/NN||acidic-22/JJ	prep_under||induces-13/VBZ||environment-23/NN	pain-16||formaldehyde-12||no_rel||the present study aims to demonstrate that the tumor tissue-derived endogenous formaldehyde induces bone cancer pain via trpv1 activation under tumor acidic environment.
amod||trials-2/NNS||many-1/JJ	nsubjpass||performed-5/VBN||trials-2/NNS	aux||performed-5/VBN||have-3/VBP	auxpass||performed-5/VBN||been-4/VBN	root||ROOT-0/null||performed-5/VBN	det||decade-9/NN||the-7/DT	amod||decade-9/NN||last-8/JJ	prep_over||performed-5/VBN||decade-9/NN	ccomp||performed-5/VBN||using-10/VBG	dobj||using-10/VBG||bendamustine-11/NN	neg||only-13/RB||not-12/RB	dep||using-10/VBG||only-13/RB	dep||only-13/RB||as-14/IN	conj||using-10/VBG||monotherapy-15/VBG	cc||in-19/IN||but-17/CC	dep||in-19/IN||also-18/RB	dep||monotherapy-15/VBG||in-19/IN	pobj||in-19/IN||combination-20/NN	amod||agents-23/NNS||other-22/JJ	prep_with||combination-20/NN||agents-23/NNS	amod||fludarabine-31/JJ||rituximab-25/JJ	amod||fludarabine-31/JJ||vincristine-27/JJ	amod||fludarabine-31/JJ||mitoxantrone-29/JJ	prep_including||agents-23/NNS||fludarabine-31/JJ	amod||agents-35/NNS||other-34/JJ	prep_including||agents-23/NNS||agents-35/NNS	conj_and||fludarabine-31/JJ||agents-35/NNS	prep_as||agents-35/NNS||therapy-37/NN	prep_for||therapy-37/NN||patients-39/NNS	amod||non-hodgkinâ-42/NNS||relapsed-41/JJ	prep_with||patients-39/NNS||non-hodgkinâ-42/NNS	dobj||monotherapy-15/VBG||$-43/$	num||$-43/$||™-44/CD	nsubj||lymphomas-46/VBZ||s-45/PRP	nsubjpass||approved-51/VBN||s-45/PRP	rcmod||$-43/$||lymphomas-46/VBZ	advmod||approved-51/VBN||recently-49/RB	auxpass||approved-51/VBN||was-50/VBD	rcmod||$-43/$||approved-51/VBN	conj_and||lymphomas-46/VBZ||approved-51/VBN	prep_for||approved-51/VBN||use-53/NN	prep_in||use-53/NN||therapy-55/NN	prep_of||therapy-55/NN||patients-57/NNS	amod||lymphomas-61/NNS||relapsed-59/JJ	nn||lymphomas-61/NNS||indolent-60/NN	prep_with||approved-51/VBN||lymphomas-61/NNS	vmod||lymphomas-61/NNS||considered-62/VBN	dobj||considered-62/VBN||refractory-63/JJ	amod||therapy-66/NN||rituximab-65/JJ	prep_to||considered-62/VBN||therapy-66/NN	lymphomas-61||mitoxantrone-29||yes||many trials have been performed over the last decade using bendamustine not only as monotherapy, but also in combination with other agents including rituximab, vincristine, mitoxantrone, fludarabine, and other agents as therapy for patients with relapsed non-hodgkinâ€™s lymphomas, and recently was approved for use in therapy of patients with relapsed indolent lymphomas considered refractory to rituximab therapy.
det||objective-2/NN||the-1/DT	nsubj||is-6/VBZ||objective-2/NN	nsubj||evaluate-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||benefits-11/NNS||the-9/DT	amod||benefits-11/NNS||economic-10/JJ	dobj||evaluate-8/VB||benefits-11/NNS	nn||therapy-15/NN||immunoglobulin-13/NN	nn||therapy-15/NN||replacement-14/NN	prep_of||benefits-11/NNS||therapy-15/NN	vmod||therapy-15/NN||achieved-16/VBN	advmod||achieved-16/VBN||subcutaneously-17/RB	amod||scig-22/NN||subcutaneous-19/JJ	nn||scig-22/NN||immunoglobulin-20/NN	appos||benefits-11/NNS||scig-22/NN	det||method-28/NN||the-25/DT	amod||method-28/NN||rapid-26/JJ	nn||method-28/NN||push-27/NN	prep_by||evaluate-8/VB||method-28/NN	prepc_compared_to||method-28/NN||to-30/TO	amod||therapy-33/NN||intravenous-31/JJ	nn||therapy-33/NN||infusion-32/NN	pobj||method-28/NN||therapy-33/NN	dep||therapy-33/NN||intravenousimmunoglobulin-35/NN	appos||intravenousimmunoglobulin-35/NN||ivig-37/NN	amod||patients-45/NNS||primary-40/JJ	nn||patients-45/NNS||immunedeficiency-41/NN	nn||patients-45/NNS||pid-43/NN	prep_in||therapy-33/NN||patients-45/NNS	det||perspective-50/NN||the-47/DT	nn||perspective-50/NN||healthcare-48/NN	nn||perspective-50/NN||system-49/NN	prep_from||evaluate-8/VB||perspective-50/NN	det||context-53/NN||the-52/DT	prep_in||perspective-50/NN||context-53/NN	det||program-60/NN||the-55/DT	amod||program-60/NN||adult-56/JJ	amod||program-60/NN||scig-57/JJ	nn||program-60/NN||home-58/NN	nn||program-60/NN||infusion-59/NN	prep_of||context-53/NN||program-60/NN	vmod||program-60/NN||based-61/VBN	amod||paul-64/NN||st-63/JJ	poss||hospital-66/NN||paul-64/NN	prep_at||based-61/VBN||hospital-66/NN	appos||hospital-66/NN||vancouver-68/NN	appos||vancouver-68/NN||canada-70/NN	immunedeficiency-41||immunoglobulin-20||yes||the objective of this study is to evaluate the economic benefits of immunoglobulin replacement therapy achieved subcutaneously (subcutaneous immunoglobulin, scig) by the rapid push method compared to intravenous infusion therapy (intravenousimmunoglobulin, ivig) in primary immunedeficiency (pid) patients from the healthcare system perspective in the context of the adult scig home infusion program based at st paul's hospital, vancouver, canada.
prep_among||hiv-infected-14/JJ||persons-2/NNS	amod||status-6/NN||known-4/JJ	nn||status-6/NN||hivinfection-5/NN	prep_with||persons-2/NNS||status-6/NN	nsubj||hiv-infected-14/JJ||39/59-8/CD	num||%-11/NN||66-10/CD	appos||39/59-8/CD||%-11/NN	cop||hiv-infected-14/JJ||were-13/VBD	root||ROOT-0/null||hiv-infected-14/JJ	hivinfection-5||hiv--1||no||among persons with known hivinfection status, 39/59 (66%) were hiv-infected.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||inh-14||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
nsubj||important-10/JJ||distribution-1/NN	nn||infectivity-4/NN||prion-3/NN	prep_of||distribution-1/NN||infectivity-4/NN	prep_in||infectivity-4/NN||organs-6/NNS	prep_in||infectivity-4/NN||tissues-8/NNS	conj_and||organs-6/NNS||tissues-8/NNS	cop||important-10/JJ||is-9/VBZ	root||ROOT-0/null||important-10/JJ	prepc_in||important-10/JJ||understanding-12/VBG	amod||pathogenesis-14/NNS||priondisease-13/JJ	dobj||understanding-12/VBG||pathogenesis-14/NNS	prepc_in||important-10/JJ||designing-16/VBG	conj_and||understanding-12/VBG||designing-16/VBG	dobj||designing-16/VBG||strategies-17/NNS	aux||prevent-19/VB||to-18/TO	vmod||designing-16/VBG||prevent-19/VB	nn||infection-21/NN||prion-20/NN	dobj||prevent-19/VB||infection-21/NN	prep_in||prevent-19/VB||animals-23/NNS	prep_in||prevent-19/VB||humans-25/NNS	conj_and||animals-23/NNS||humans-25/NNS	priondisease-13||prion-20||no||distribution of prion infectivity in organs and tissues is important in understanding priondisease pathogenesis and designing strategies to prevent prion infection in animals and humans.
det||population-4/NN||the-1/DT	amod||population-4/NN||final-2/JJ	nn||population-4/NN||study-3/NN	nsubj||included-5/VBD||population-4/NN	root||ROOT-0/null||included-5/VBD	num||discharges-8/NNS||1927-6/CD	nn||discharges-8/NNS||hiv/aids-7/NNS	dobj||included-5/VBD||discharges-8/NNS	aids--1||hiv--1||no||the final study population included 1927 hiv/aids discharges.
nsubj||therapy-10/NN||bacilluscalmette-guerin-1/NN	appos||bacilluscalmette-guerin-1/NN||bcg-3/NN	cop||therapy-10/NN||is-5/VBZ	det||therapy-10/NN||the-6/DT	advmod||effective-8/JJ||most-7/RBS	amod||therapy-10/NN||effective-8/JJ	nn||therapy-10/NN||adjuvant-9/NN	root||ROOT-0/null||therapy-10/NN	nn||bladdertumor-13/NN||nmi-12/NN	prep_in||therapy-10/NN||bladdertumor-13/NN	bladdertumor-13||bcg-3||yes||bacilluscalmette-guerin (bcg) is the most effective adjuvant therapy in nmi bladdertumor.
nsubj||observed-2/VBD||we-1/PRP	nsubj||formed-34/VBD||we-1/PRP	nsubj||expressed-41/VBD||we-1/PRP	root||ROOT-0/null||observed-2/VBD	nn||expression-5/NN||differential-3/NN	nn||expression-5/NN||hkmt-4/NN	dobj||observed-2/VBD||expression-5/NN	prep_in||immortal-32/JJ||expression-5/NN	det||model-10/NN||a-7/DT	nn||model-10/NN||lung-8/NN	nn||model-10/NN||cancer-9/NN	prep_in||expression-5/NN||model-10/NN	amod||cells-20/NNS||normal-13/JJ	amod||cells-20/NNS||human-14/JJ	nn||cells-20/NNS||bronchial-15/NN	nn||cells-20/NNS||epithelial-16/NN	appos||cells-20/NNS||nhbe-18/NN	nsubj||immortal-32/JJ||cells-20/NNS	vmod||cells-20/NNS||expressing-21/VBG	dobj||expressing-21/VBG||telomerase-22/NN	amod||antigen-27/NN||sv40-24/JJ	amod||antigen-27/NN||large-25/JJ	nn||antigen-27/NN||t-26/NN	dobj||expressing-21/VBG||antigen-27/NN	conj_and||telomerase-22/NN||antigen-27/NN	dobj||expressing-21/VBG||ras-30/NN	conj_and||telomerase-22/NN||ras-30/NN	cop||immortal-32/JJ||were-31/VBD	rcmod||expression-5/NN||immortal-32/JJ	conj_and||observed-2/VBD||formed-34/VBD	dobj||formed-34/VBD||colonies-35/NNS	amod||agar-38/NN||soft-37/JJ	prep_in||formed-34/VBD||agar-38/NN	conj_and||observed-2/VBD||expressed-41/VBD	amod||hkmts-43/NNS||specific-42/JJ	dobj||expressed-41/VBD||hkmts-43/NNS	amod||residues-50/NNS||h3-45/JJ	amod||residues-50/NNS||lysine-46/JJ	dep||lysine-46/JJ||9-47/CD	dep||lysine-46/JJ||27-49/CD	conj_and||9-47/CD||27-49/CD	prep_for||expressed-41/VBD||residues-50/NNS	amod||residue-57/NN||h3-54/JJ	nn||residue-57/NN||lysine-55/NN	num||residue-57/NN||4-56/CD	prep_for||expressed-41/VBD||residue-57/NN	conj_negcc||residues-50/NNS||residue-57/NN	cancer-9||lysine-55||no_rel||we observed differential hkmt expression in a lung cancer model in which normal human bronchial epithelial (nhbe) cells expressing telomerase, sv40 large t antigen, and ras were immortal, formed colonies in soft agar, and expressed specific hkmts for h3 lysine 9 and 27 residues but not for h3 lysine 4 residue.
aux||investigate-2/VB||to-1/TO	advcl||divided-29/VBN||investigate-2/VB	det||effect-4/NN||the-3/DT	dobj||investigate-2/VB||effect-4/NN	amod||expression-17/NN||budesonide-6/JJ	nn||p-9/NN||substance-8/NN	prep_on||budesonide-6/JJ||p-9/NN	dep||p-9/NN||nk-1-11/JJ	nn||expression-17/NN||receptor-13/NN	dep||expression-17/NN||nk-1r-15/JJ	prep_of||effect-4/NN||expression-17/NN	det||lung-20/NN||the-19/DT	prep_in||investigate-2/VB||lung-20/NN	prep_in||investigate-2/VB||asmcs-22/NNS	conj_and||lung-20/NN||asmcs-22/NNS	num||rats-26/NNS||45-24/CD	nn||rats-26/NNS||wistar-25/NN	nsubjpass||divided-29/VBN||rats-26/NNS	auxpass||divided-29/VBN||were-27/VBD	advmod||divided-29/VBN||randomly-28/RB	root||ROOT-0/null||divided-29/VBN	num||groups-32/NNS||three-31/CD	prep_into||divided-29/VBN||groups-32/NNS	dep||groups-32/NNS||control-33/NN	dep||groups-32/NNS||asthmatic-35/JJ	amod||control-33/NN||asthmatic-35/JJ	conj_and||control-33/NN||asthmatic-35/JJ	amod||treatment-39/NN||budesonide-38/JJ	dep||groups-32/NNS||treatment-39/NN	conj_and||control-33/NN||treatment-39/NN	asthmatic-35||budesonide-38||yes||to investigate the effect of budesonide on substance p (nk-1) receptor (nk-1r) expression in the lung and asmcs, 45 wistar rats were randomly divided into three groups control, asthmatic, and budesonide treatment.
det||findings-2/NNS||these-1/DT	nsubj||provide-3/VBP||findings-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||support-5/NN||further-4/JJ	dobj||provide-3/VBP||support-5/NN	det||hypothesis-8/NNS||the-7/DT	prep_for||provide-3/VBP||hypothesis-8/NNS	nsubj||increased-10/VBN||hypothesis-8/NNS	rcmod||hypothesis-8/NNS||increased-10/VBN	nn||metabolism-12/NN||drug-11/NN	nsubj||mediate-15/VB||metabolism-12/NN	nsubj||highlight-24/VB||metabolism-12/NN	conj_and||metabolism-12/NN||efflux-14/NN	nsubj||mediate-15/VB||efflux-14/NN	ccomp||increased-10/VBN||mediate-15/VB	nn||resistance-19/NN||permethrin-16/NN	conj_and||permethrin-16/NN||ivermectin-18/NN	nn||resistance-19/NN||ivermectin-18/NN	dobj||mediate-15/VB||resistance-19/NN	amod||mites-22/NNS||scabies-21/JJ	prep_in||mediate-15/VB||mites-22/NNS	ccomp||increased-10/VBN||highlight-24/VB	conj_and||mediate-15/VB||highlight-24/VB	det||threat-26/NN||the-25/DT	dobj||highlight-24/VB||threat-26/NN	amod||resistance-30/NN||emerging-28/VBG	amod||resistance-30/NN||acaricide-29/JJ	prep_of||threat-26/NN||resistance-30/NN	det||treatment-33/NN||the-32/DT	prep_to||increased-10/VBN||treatment-33/NN	prep_of||treatment-33/NN||scabies-35/NNS	advmod||increased-10/VBN||worldwide-36/RB	scabies-35||permethrin-16||yes||these findings provide further support for the hypothesis that increased drug metabolism and efflux mediate permethrin and ivermectin resistance in scabies mites and highlight the threat of emerging acaricide resistance to the treatment of scabies worldwide.
det||review-2/NN||this-1/DT	nsubj||seeks-3/VBZ||review-2/NN	nsubj||synthesise-5/VB||review-2/NN	root||ROOT-0/null||seeks-3/VBZ	aux||synthesise-5/VB||to-4/TO	xcomp||seeks-3/VBZ||synthesise-5/VB	poss||data-8/NNS||our-6/PRP$	amod||data-8/NNS||new-7/JJ	dobj||synthesise-5/VB||data-8/NNS	amod||nanotubes-12/NNS||multi-walled-10/JJ	nn||nanotubes-12/NNS||carbon-11/NN	prep_with||synthesise-5/VB||nanotubes-12/NNS	appos||nanotubes-12/NNS||cnt-14/NN	det||hypothesis-18/NNS||that-17/DT	prep_with||synthesise-5/VB||hypothesis-18/NNS	det||behaviour-21/NN||the-20/DT	prep_for||hypothesis-18/NNS||behaviour-21/NN	amod||fibres-24/NNS||long-23/JJ	prep_of||behaviour-21/NN||fibres-24/NNS	det||lung-27/NN||the-26/DT	prep_in||fibres-24/NNS||lung-27/NN	poss||retention-30/NN||their-29/PRP$	prep_with||synthesise-5/VB||retention-30/NN	conj_and||hypothesis-18/NNS||retention-30/NN	det||pleura-34/NN||the-32/DT	amod||pleura-34/NN||parietal-33/JJ	prep_in||retention-30/NN||pleura-34/NN	vmod||retention-30/NN||leading-35/VBG	det||initiation-38/NN||the-37/DT	prep_to||leading-35/VBG||initiation-38/NN	nn||pathology-43/NN||inflammation-40/NN	conj_and||inflammation-40/NN||pleural-42/NN	nn||pathology-43/NN||pleural-42/NN	prep_of||initiation-38/NN||pathology-43/NN	prep_such_as||retention-30/NN||mesothelioma-46/NN	mesothelioma-46||carbon-11||no_rel||this review seeks to synthesise our new data with multi-walled carbon nanotubes (cnt) with that hypothesis for the behaviour of long fibres in the lung and their retention in the parietal pleura leading to the initiation of inflammation and pleural pathology such as mesothelioma.
nsubj||immune-12/JJ||animals-1/NNS	advmod||infected-3/VBN||experimentally-2/RB	vmod||animals-1/NNS||infected-3/VBN	nn||typhus-6/NNS||epidemic-5/NN	prep_with||infected-3/VBN||typhus-6/NNS	nn||prowazeki-9/NNS||rickettsia-8/NN	appos||animals-1/NNS||prowazeki-9/NNS	cop||immune-12/JJ||are-11/VBP	root||ROOT-0/null||immune-12/JJ	prep_to||immune-12/JJ||murinetyphus-14/NNS	appos||murinetyphus-14/NNS||rickettsiatyphi-16/NNP	nn||versa-20/NNS||vice-19/NN	prep_to||immune-12/JJ||versa-20/NNS	conj_and||murinetyphus-14/NNS||versa-20/NNS	murinetyphus-14||rickettsiatyphi-16||no||animals experimentally infected with epidemic typhus (rickettsia prowazeki) are immune to murinetyphus (rickettsiatyphi) and vice versa.
amod||ovalbumin-2/NN||aerosolized-1/JJ	nsubjpass||used-4/VBN||ovalbumin-2/NN	nsubj||generate-6/VB||ovalbumin-2/NN	auxpass||used-4/VBN||was-3/VBD	root||ROOT-0/null||used-4/VBN	aux||generate-6/VB||to-5/TO	xcomp||used-4/VBN||generate-6/VB	det||model-10/NN||the-7/DT	amod||model-10/NN||asthmatic-8/JJ	nn||model-10/NN||rat-9/NN	dobj||generate-6/VB||model-10/NN	nsubjpass||administered-15/VBN||budesonide-13/NN	auxpass||administered-15/VBN||was-14/VBD	conj_and||used-4/VBN||administered-15/VBN	nn||inhalation-18/NN||ovalbumin-17/NN	prep_after||administered-15/VBN||inhalation-18/NN	asthmatic-8||budesonide-13||no||aerosolized ovalbumin was used to generate the asthmatic rat model, and budesonide was administered after ovalbumin inhalation.
det||spectrum-2/NN||the-1/DT	nsubj||wide-9/JJ||spectrum-2/NN	nsubj||fatal-13/JJ||spectrum-2/NN	amod||vasculitis-7/NNS||anti-neutrophil-4/JJ	amod||vasculitis-7/NNS||cytoplasmic-5/JJ	amod||vasculitis-7/NNS||antibody-associated-6/JJ	prep_of||spectrum-2/NN||vasculitis-7/NNS	cop||wide-9/JJ||is-8/VBZ	root||ROOT-0/null||wide-9/JJ	aux||fatal-13/JJ||can-11/MD	cop||fatal-13/JJ||be-12/VB	conj_and||wide-9/JJ||fatal-13/JJ	vasculitis-7||antibody--1||no_rel||the spectrum of anti-neutrophil cytoplasmic antibody-associated vasculitis is wide and can be fatal.
det||patients-2/NNS||the-1/DT	nsubjpass||allocated-4/VBN||patients-2/NNS	auxpass||allocated-4/VBN||were-3/VBD	root||ROOT-0/null||allocated-4/VBN	num||groups-7/NNS||two-6/CD	prep_into||allocated-4/VBN||groups-7/NNS	dep||groups-7/NNS||group-8/NN	dep||group-8/NN||a-9/DT	dep||groups-7/NNS||n-11/VBN	dep||60-13/CD||=-12/SYM	ccomp||n-11/VBN||60-13/CD	dobj||discontinued-21/VBN||whom-16/WP	det||agent-19/NN||the-17/DT	nn||agent-19/NN||beta-blocker-18/NN	nsubjpass||discontinued-21/VBN||agent-19/NN	auxpass||discontinued-21/VBN||was-20/VBD	prepc_in||groups-7/NNS||discontinued-21/VBN	prep_for||discontinued-21/VBN||72h-23/CD	prep_before||discontinued-21/VBN||dmpi-25/NN	prep_before||discontinued-21/VBN||groupb-27/NN	conj_and||dmpi-25/NN||groupb-27/NN	dep||discontinued-21/VBN||n-29/VBN	dep||60-31/CD||=-30/SYM	ccomp||n-29/VBN||60-31/CD	prep_without||discontinued-21/VBN||discontinuation-34/NN	prep_of||discontinuation-34/NN||beta-blockers-36/NNS	prep_prior_to||beta-blockers-36/NNS||dmpi-39/NNS	groupb-27||beta-blocker-18||no_rel||the patients were allocated into two groups group a (n=60) in whom the beta-blocker agent was discontinued for 72h before dmpi and groupb (n=60) without discontinuation of beta-blockers prior to dmpi.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type2diabetes-52||insulin-46||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
nsubj||genus-4/NNS||capnocytophaga-1/NN	cop||genus-4/NNS||are-2/VBP	det||genus-4/NNS||a-3/DT	root||ROOT-0/null||genus-4/NNS	prep_of||genus-4/NNS||bacteria-6/NNS	nsubjpass||found-10/VBN||bacteria-6/NNS	nsubj||organisms-15/NNS||bacteria-6/NNS	aux||found-10/VBN||have-8/VBP	auxpass||found-10/VBN||been-9/VBN	rcmod||bacteria-6/NNS||found-10/VBN	aux||organisms-15/NNS||to-11/TO	cop||organisms-15/NNS||be-12/VB	det||organisms-15/NNS||the-13/DT	amod||organisms-15/NNS||causative-14/JJ	xcomp||found-10/VBN||organisms-15/NNS	det||range-18/NN||a-17/DT	prep_in||organisms-15/NNS||range-18/NN	prep_of||range-18/NN||infections-20/NNS	amod||conditions-24/NNS||serious-23/JJ	prep_including||organisms-15/NNS||conditions-24/NNS	prep_such_as||conditions-24/NNS||bacteraemia-27/NN	prep_such_as||conditions-24/NNS||endocarditis-29/NNS	conj_and||bacteraemia-27/NN||endocarditis-29/NNS	prep_such_as||conditions-24/NNS||meningitis-31/NNS	conj_and||bacteraemia-27/NN||meningitis-31/NNS	bacteraemia-27||bacteria-6||no||capnocytophaga are a genus of bacteria that have been found to be the causative organisms in a range of infections, including serious conditions such as bacteraemia, endocarditis and meningitis.
det||factors-5/NNS||the-1/DT	num||factors-5/NNS||two-2/CD	advmod||consistent-4/JJ||most-3/RBS	amod||factors-5/NNS||consistent-4/JJ	nsubj||having-14/VBG||factors-5/NNS	vmod||factors-5/NNS||associated-6/VBN	nn||testing-9/NN||hiv-8/NN	prep_with||associated-6/VBN||testing-9/NN	det||countries-12/NNS||the-11/DT	prep_across||associated-6/VBN||countries-12/NNS	aux||having-14/VBG||were-13/VBD	root||ROOT-0/null||having-14/VBG	dep||having-14/VBG||heard-15/VBN	prep_about||heard-15/VBN||hiv/aids-17/NNS	det||centre-23/NN||a-19/DT	nn||centre-23/NN||clinic-20/NN	conj_or||clinic-20/NN||health-22/NN	nn||centre-23/NN||health-22/NN	prep_from||hiv/aids-17/NNS||centre-23/NN	aux||talked-27/VBN||having-26/VBG	dep||having-14/VBG||talked-27/VBN	conj_and||heard-15/VBN||talked-27/VBN	prep_to||talked-27/VBN||someone-29/NN	prep_about||someone-29/NN||hiv-31/NN	prep_about||someone-29/NN||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||the two most consistent factors associated with hiv testing across the countries were having heard about hiv/aids from a clinic or health centre, and having talked to someone about hiv and aids.
nsubj||causes-2/VBZ||clostridiumchauvoei-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||blackleg-3/NN	det||disease-7/NN||an-5/DT	amod||disease-7/NN||acute-6/JJ	appos||blackleg-3/NN||disease-7/NN	vmod||disease-7/NN||associated-8/VBN	amod||mortality-11/NN||high-10/JJ	prep_with||associated-8/VBN||mortality-11/NN	prep_in||mortality-11/NN||ruminants-13/NNS	blackleg-3||clostridiumchauvoei-1||no||clostridiumchauvoei causes blackleg, an acute disease associated with high mortality in ruminants.
nn||women-6/NNS||most-1/JJS	num||%-4/NN||89.5-3/CD	appos||women-6/NNS||%-4/NN	nsubj||reported-7/VBD||women-6/NNS	nsubj||believed-26/VBD||women-6/NNS	root||ROOT-0/null||reported-7/VBD	auxpass||trained-9/VBN||being-8/VBG	xcomp||reported-7/VBD||trained-9/VBN	det||importance-12/NN||the-11/DT	prep_on||trained-9/VBN||importance-12/NN	prep_of||importance-12/NN||nutrition-14/NN	prep_for||nutrition-14/NN||people-16/NNS	vmod||people-16/NNS||living-17/VBG	prep_with||living-17/VBG||hiv-19/NN	prep_with||living-17/VBG||aids-21/NNS	conj_and||hiv-19/NN||aids-21/NNS	appos||nutrition-14/NN||plwha-23/NNP	conj_and||reported-7/VBD||believed-26/VBD	mark||important-31/JJ||that-27/IN	nsubj||important-31/JJ||it-28/PRP	nsubj||consume-33/VB||it-28/PRP	cop||important-31/JJ||is-29/VBZ	advmod||important-31/JJ||very-30/RB	ccomp||believed-26/VBD||important-31/JJ	aux||consume-33/VB||to-32/TO	xcomp||important-31/JJ||consume-33/VB	det||diet-36/NN||a-34/DT	amod||diet-36/NN||balanced-35/JJ	dobj||consume-33/VB||diet-36/NN	num||%-39/NN||99.5-38/CD	appos||diet-36/NN||%-39/NN	aids-21||hiv-19||no||most (89.5%) women reported being trained on the importance of nutrition for people living with hiv and aids (plwha) and believed that it is very important to consume a balanced diet (99.5%).
num||hundred-2/CD||three-1/CD	nsubjpass||recruited-11/VBN||hundred-2/CD	amod||patients-5/NNS||fifty-five-4/JJ	conj_and||hundred-2/CD||patients-5/NNS	nsubjpass||recruited-11/VBN||patients-5/NNS	amod||oa-9/NN||symptomatic-7/JJ	nn||oa-9/NN||knee-8/NN	prep_with||patients-5/NNS||oa-9/NN	auxpass||recruited-11/VBN||were-10/VBD	root||ROOT-0/null||recruited-11/VBN	det||trial-20/NN||a-13/DT	amod||trial-20/NN||two-year-14/JJ	amod||trial-20/NN||double-blind-16/JJ	amod||trial-20/NN||randomised-18/JJ	amod||trial-20/NN||clinical-19/JJ	prep_for||recruited-11/VBN||trial-20/NN	vmod||trial-20/NN||evaluating-21/VBG	det||effect-23/NN||the-22/DT	dobj||evaluating-21/VBG||effect-23/NN	num||licofelone-27/NN||200-25/CD	nn||licofelone-27/NN||mg-26/NN	prep_of||effect-23/NN||licofelone-27/NN	advmod||daily-29/JJ||twice-28/RB	advmod||evaluating-21/VBG||daily-29/JJ	num||naproxen-33/NN||500-31/CD	nn||naproxen-33/NN||mg-32/NN	npadvmod||twice-34/RB||naproxen-33/NN	advmod||evaluating-21/VBG||twice-34/RB	conj_and||daily-29/JJ||twice-34/RB	advmod||evaluating-21/VBG||daily-35/RB	nn||loss-38/NN||cartilage-37/NN	prep_on||evaluating-21/VBG||loss-38/NN	num||patients-42/NNS||301-41/CD	nsubj||had-43/VBD||patients-42/NNS	conj_and||recruited-11/VBN||had-43/VBD	amod||mri-45/NN||baseline-44/JJ	dobj||had-43/VBD||mri-45/NN	oa-9||naproxen-33||yes||three hundred and fifty-five patients with symptomatic knee oa were recruited for a two-year, double-blind, randomised clinical trial evaluating the effect of 200 mg licofelone twice daily and 500 mg naproxen twice daily on cartilage loss, and 301 patients had baseline mri.
det||findings-2/NNS||these-1/DT	nsubj||extend-3/VB||findings-2/NNS	nsubj||possess-12/VB||findings-2/NNS	nsubj||highlight-18/VB||findings-2/NNS	root||ROOT-0/null||extend-3/VB	det||range-6/NN||the-4/DT	nn||range-6/NN||host-5/NN	dobj||extend-3/VB||range-6/NN	det||influenzavirus-10/NNS||the-8/DT	amod||influenzavirus-10/NNS||h5n1-9/JJ	prep_of||range-6/NN||influenzavirus-10/NNS	conj_and||extend-3/VB||possess-12/VB	dobj||possess-12/VB||implications-13/NNS	prep_for||implications-13/NNS||influenzavirus-15/NNS	advmod||possess-12/VB||epidemiology-16/RB	conj_and||extend-3/VB||highlight-18/VB	det||need-20/NN||the-19/DT	dobj||highlight-18/VB||need-20/NN	det||surveillance-24/NN||the-22/DT	amod||surveillance-24/NN||systematic-23/JJ	prep_for||need-20/NN||surveillance-24/NN	prep_of||surveillance-24/NN||h5n1-26/CD	prep_in||highlight-18/VB||animals-28/NNS	det||vicinity-31/NN||the-30/DT	prep_in||animals-28/NNS||vicinity-31/NN	nn||units-35/NNS||backyard-33/NN	nn||units-35/NNS||poultry-34/NN	prep_of||vicinity-31/NN||units-35/NNS	advmod||highlight-18/VB||especially-36/RB	amod||areas-39/NNS||endemic-38/JJ	prep_in||highlight-18/VB||areas-39/NNS	h5n1-26||influenzavirus-15||no||these findings extend the host range of the h5n1 influenzavirus, possess implications for influenzavirus epidemiology and highlight the need for the systematic surveillance of h5n1 in animals in the vicinity of backyard poultry units especially in endemic areas.
advmod||significantly-2/RB||more-1/RBR	advmod||open-6/VB||significantly-2/RB	nsubj||open-6/VB||this-4/DT	aux||open-6/VB||would-5/MD	root||ROOT-0/null||open-6/VB	det||door-8/NN||the-7/DT	dobj||open-6/VB||door-8/NN	det||â-12/NN||a-10/DT	amod||â-12/NN||wider-11/JJR	prep_to||open-6/VB||â-12/NN	amod||â-12/NN||$-13/$	dep||$-13/$||œanti-metastaticâ-14/JJ	dobj||open-6/VB||$-15/$	nsubj||have-19/VB||$-15/$	num||$-15/$||approach-16/CD	aux||have-19/VB||could-18/MD	rcmod||$-15/$||have-19/VB	advmod||greater-21/JJR||much-20/RB	amod||impact-22/NN||greater-21/JJR	dobj||have-19/VB||impact-22/NN	prep_in||impact-22/NN||patients-24/NNS	amod||disease-27/NN||minimal-26/JJ	prep_with||patients-24/NNS||disease-27/NN	auxpass||treated-29/VBN||being-28/VBG	vmod||disease-27/NN||treated-29/VBN	amod||settings-32/NNS||adjuvant-31/JJ	prep_in||treated-29/VBN||settings-32/NNS	det||malignancies-37/NNS||the-34/DT	advmod||common-36/JJ||more-35/RBR	amod||malignancies-37/NNS||common-36/JJ	prep_for||settings-32/NNS||malignancies-37/NNS	nn||cancer-43/NN||breast-40/NN	conj_and||breast-40/NN||colon-42/NN	nn||cancer-43/NN||colon-42/NN	prep_such_as||malignancies-37/NNS||cancer-43/NN	malignancies-37||adjuvant-31||no_rel||more significantly, this would open the door to a wider â€œanti-metastaticâ€? approach that could have much greater impact in patients with minimal disease being treated in adjuvant settings for the more common malignancies such as breast and colon cancer.
amod||interventions-2/NNS||potential-1/JJ	nsubj||improve-5/VB||interventions-2/NNS	nsubj||may-10/MD||interventions-2/NNS	aux||improve-5/VB||might-4/MD	rcmod||interventions-2/NNS||improve-5/VB	dobj||improve-5/VB||adherence-6/NN	nn||participants-9/NNS||trial-8/NN	prep_in||improve-5/VB||participants-9/NNS	root||ROOT-0/null||may-10/MD	ccomp||may-10/MD||includetargeting-11/VBG	nn||education-13/NN||health-12/NN	dobj||includetargeting-11/VBG||education-13/NN	prep_for||education-13/NN||men-15/NNS	ccomp||may-10/MD||reducing-17/VBG	conj_and||includetargeting-11/VBG||reducing-17/VBG	dobj||reducing-17/VBG||barriers-18/NNS	ccomp||may-10/MD||clarifying-20/VBG	conj_and||includetargeting-11/VBG||clarifying-20/VBG	nn||expectations-22/NNS||study-21/NN	dobj||clarifying-20/VBG||expectations-22/NNS	ccomp||may-10/MD||educating-24/VBG	conj_and||includetargeting-11/VBG||educating-24/VBG	dobj||educating-24/VBG||employers-25/NNS	prep_about||educating-24/VBG||hiv/aids-27/NNS	aux||help-29/VB||to-28/TO	vmod||educating-24/VBG||help-29/VB	xcomp||help-29/VB||reduce-30/VB	dobj||reduce-30/VB||stigma-31/NN	det||workplace-34/NN||the-33/DT	prep_in||reduce-30/VB||workplace-34/NN	ccomp||may-10/MD||encouraging-37/VBG	conj_and||includetargeting-11/VBG||encouraging-37/VBG	dobj||encouraging-37/VBG||employers-38/NNS	nsubj||support-40/VB||employers-38/NNS	aux||support-40/VB||to-39/TO	xcomp||encouraging-37/VBG||support-40/VB	nn||health-42/NN||employee-41/NN	dobj||support-40/VB||health-42/NN	aids--1||hiv--1||no||potential interventions that might improve adherence in trial participants may includetargeting health education for men, reducing barriers, clarifying study expectations, educating employers about hiv/aids to help reduce stigma in the workplace, and encouraging employers to support employee health.
amod||trials-2/NNS||many-1/JJ	nsubjpass||performed-5/VBN||trials-2/NNS	aux||performed-5/VBN||have-3/VBP	auxpass||performed-5/VBN||been-4/VBN	root||ROOT-0/null||performed-5/VBN	det||decade-9/NN||the-7/DT	amod||decade-9/NN||last-8/JJ	prep_over||performed-5/VBN||decade-9/NN	ccomp||performed-5/VBN||using-10/VBG	dobj||using-10/VBG||bendamustine-11/NN	neg||only-13/RB||not-12/RB	dep||using-10/VBG||only-13/RB	dep||only-13/RB||as-14/IN	conj||using-10/VBG||monotherapy-15/VBG	cc||in-19/IN||but-17/CC	dep||in-19/IN||also-18/RB	dep||monotherapy-15/VBG||in-19/IN	pobj||in-19/IN||combination-20/NN	amod||agents-23/NNS||other-22/JJ	prep_with||combination-20/NN||agents-23/NNS	amod||fludarabine-31/JJ||rituximab-25/JJ	amod||fludarabine-31/JJ||vincristine-27/JJ	amod||fludarabine-31/JJ||mitoxantrone-29/JJ	prep_including||agents-23/NNS||fludarabine-31/JJ	amod||agents-35/NNS||other-34/JJ	prep_including||agents-23/NNS||agents-35/NNS	conj_and||fludarabine-31/JJ||agents-35/NNS	prep_as||agents-35/NNS||therapy-37/NN	prep_for||therapy-37/NN||patients-39/NNS	amod||non-hodgkinâ-42/NNS||relapsed-41/JJ	prep_with||patients-39/NNS||non-hodgkinâ-42/NNS	dobj||monotherapy-15/VBG||$-43/$	num||$-43/$||™-44/CD	nsubj||lymphomas-46/VBZ||s-45/PRP	nsubjpass||approved-51/VBN||s-45/PRP	rcmod||$-43/$||lymphomas-46/VBZ	advmod||approved-51/VBN||recently-49/RB	auxpass||approved-51/VBN||was-50/VBD	rcmod||$-43/$||approved-51/VBN	conj_and||lymphomas-46/VBZ||approved-51/VBN	prep_for||approved-51/VBN||use-53/NN	prep_in||use-53/NN||therapy-55/NN	prep_of||therapy-55/NN||patients-57/NNS	amod||lymphomas-61/NNS||relapsed-59/JJ	nn||lymphomas-61/NNS||indolent-60/NN	prep_with||approved-51/VBN||lymphomas-61/NNS	vmod||lymphomas-61/NNS||considered-62/VBN	dobj||considered-62/VBN||refractory-63/JJ	amod||therapy-66/NN||rituximab-65/JJ	prep_to||considered-62/VBN||therapy-66/NN	lymphomas-61||mitoxantrone-29||yes||many trials have been performed over the last decade using bendamustine not only as monotherapy, but also in combination with other agents including rituximab, vincristine, mitoxantrone, fludarabine, and other agents as therapy for patients with relapsed non-hodgkinâ€™s lymphomas, and recently was approved for use in therapy of patients with relapsed indolent lymphomas considered refractory to rituximab therapy.
det||induction-2/NN||the-1/DT	nsubjpass||prevented-17/VBN||induction-2/NN	prep_of||induction-2/NN||obesity-4/NN	prep_of||induction-2/NN||dyslipidemia-6/NN	conj_and||obesity-4/NN||dyslipidemia-6/NN	prep_of||induction-2/NN||insulinresistance-9/NN	conj_and||obesity-4/NN||insulinresistance-9/NN	amod||diet-12/NN||high-fat-11/JJ	prep_by||obesity-4/NN||diet-12/NN	prep_in||diet-12/NN||rodents-14/NNS	aux||prevented-17/VBN||can-15/MD	auxpass||prevented-17/VBN||be-16/VB	root||ROOT-0/null||prevented-17/VBN	amod||fattyacids-22/NNS||n-3-19/JJ	amod||fattyacids-22/NNS||long-chain-20/JJ	amod||fattyacids-22/NNS||polyunsaturated-21/JJ	agent||prevented-17/VBN||fattyacids-22/NNS	appos||fattyacids-22/NNS||lc-pufas-24/NNS	insulinresistance-9||fat--1||no_rel||the induction of obesity, dyslipidemia, and insulinresistance by high-fat diet in rodents can be prevented by n-3 long-chain polyunsaturated fattyacids (lc-pufas).
amod||pruritus-2/NNS||chloroquine-induced-1/JJ	nsubj||remains-3/VBZ||pruritus-2/NNS	root||ROOT-0/null||remains-3/VBZ	xcomp||remains-3/VBZ||one-4/CD	det||side-effects-9/NNS||the-6/DT	advmod||side-effects-9/NNS||most-7/RBS	amod||side-effects-9/NNS||common-8/JJ	prep_of||one-4/CD||side-effects-9/NNS	det||use-12/NN||the-11/DT	prep_in||side-effects-9/NNS||use-12/NN	prep_of||use-12/NN||chloroquine-14/NN	det||prophylaxis-17/NN||the-16/DT	prep_in||chloroquine-14/NN||prophylaxis-17/NN	prep_in||chloroquine-14/NN||treatment-19/NN	conj_and||prophylaxis-17/NN||treatment-19/NN	amod||malaria-22/NN||uncomplicated-21/JJ	prep_of||prophylaxis-17/NN||malaria-22/NN	det||advent-25/NN||the-24/DT	prep_before||remains-3/VBZ||advent-25/NN	amod||therapies-29/NNS||artemisinin-based-27/JJ	nn||therapies-29/NNS||combination-28/NN	prep_of||advent-25/NN||therapies-29/NNS	malaria-22||chloroquine-14||yes||chloroquine-induced pruritus remains one of the most common side-effects in the use of chloroquine in the prophylaxis and treatment of uncomplicated malaria before the advent of artemisinin-based combination therapies.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	oil--1||chf-60||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
prepc_based_on||increased-13/VBN||on-2/IN	amod||vaccines-4/NNS||available-3/JJ	pobj||increased-13/VBN||vaccines-4/NNS	det||market-7/NN||the-6/DT	prep_on||vaccines-4/NNS||market-7/NN	det||vaccine-11/NN||the-9/DT	nn||vaccine-11/NN||bivalent-10/NN	nsubj||increased-13/VBN||vaccine-11/NN	aux||increased-13/VBN||had-12/VBD	root||ROOT-0/null||increased-13/VBN	dobj||increased-13/VBN||effectiveness-14/NN	det||range-18/NN||a-16/DT	amod||range-18/NN||wider-17/JJR	prep_against||increased-13/VBN||range-18/NN	nn||types-21/NNS||hpv-20/NN	prep_of||range-18/NN||types-21/NNS	mark||had-27/VBD||while-23/IN	det||vaccine-26/NN||the-24/DT	nn||vaccine-26/NN||quadrivalent-25/NN	nsubj||had-27/VBD||vaccine-26/NN	advcl||increased-13/VBN||had-27/VBD	dobj||had-27/VBD||effectiveness-28/NN	prep_against||effectiveness-28/NN||genitalwarts-30/NNS	genitalwarts-30||hpv-20||no||based on available vaccines on the market, the bivalent vaccine had increased effectiveness against a wider range of hpv types, while the quadrivalent vaccine had effectiveness against genitalwarts.
num||thousand-2/CD||two-1/CD	nsubj||diagnosed-6/VBD||thousand-2/CD	conj_and||thousand-2/CD||six-4/CD	nsubj||diagnosed-6/VBD||six-4/CD	advmod||diagnosed-6/VBD||newly-5/RB	root||ROOT-0/null||diagnosed-6/VBD	amod||patients-8/NNS||hiv/aids-7/JJ	nsubjpass||selected-17/VBN||patients-8/NNS	num||provinces-11/NNS||10-10/CD	prep_from||patients-8/NNS||provinces-11/NNS	prep_from||patients-8/NNS||municipalities-13/NNS	conj_and||provinces-11/NNS||municipalities-13/NNS	prep_in||provinces-11/NNS||china-15/NN	auxpass||selected-17/VBN||were-16/VBD	ccomp||diagnosed-6/VBD||selected-17/VBN	num||2010-21/CD||2009-19/CD	dep||2010-21/CD||to-20/TO	prep_during||selected-17/VBN||2010-21/CD	aids--1||hiv--1||no||two thousand and six newly diagnosed hiv/aids patients from 10 provinces and municipalities in china were selected during 2009 to 2010.
nsubjpass||expressed-3/VBN||jmjd2b-1/NNS	auxpass||expressed-3/VBN||is-2/VBZ	root||ROOT-0/null||expressed-3/VBN	det||proportion-7/NN||a-5/DT	amod||proportion-7/NN||high-6/JJ	prep_in||expressed-3/VBN||proportion-7/NN	amod||breasttumors-10/NNS||human-9/JJ	prep_of||proportion-7/NN||breasttumors-10/NNS	det||levels-15/NNS||that-13/DT	nn||levels-15/NNS||expression-14/NN	nsubj||correlate-17/VBP||levels-15/NNS	advmod||correlate-17/VBP||significantly-16/RB	conj_and||expressed-3/VBN||correlate-17/VBP	nn||receptor-20/NN||estrogen-19/NN	prep_with||correlate-17/VBP||receptor-20/NN	appos||receptor-20/NN||er-22/NN	advmod||correlate-17/VBP||positivity-24/RB	breasttumors-10||estrogen-19||no||jmjd2b is expressed in a high proportion of human breasttumors, and that expression levels significantly correlate with estrogen receptor (er) positivity.
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	paliperidone-6||restlessness-23||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
nsubj||retrovirus-13/NNS||humanimmunodeficiencyvirus-1/NNS	nsubj||is-29/VBZ||humanimmunodeficiencyvirus-1/NNS	appos||humanimmunodeficiencyvirus-1/NNS||hiv-3/NN	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	appos||humanimmunodeficiencyvirus-1/NNS||agent-8/NN	prep_of||agent-8/NN||aids-10/NNS	cop||retrovirus-13/NNS||is-11/VBZ	det||retrovirus-13/NNS||a-12/DT	root||ROOT-0/null||retrovirus-13/NNS	nn||genome-16/NN||rna-15/NN	prep_with||retrovirus-13/NNS||genome-16/NN	det||â-20/NN||a-18/DT	amod||â-20/NN||unique-19/JJ	conj_and||retrovirus-13/NNS||â-20/NN	num||enzymeâ-25/NNS||$-21/$	number||reverse-23/CD||²-22/CD	num||$-21/$||reverse-23/CD	amod||enzymeâ-25/NNS||transcriptase-24/JJ	dep||â-20/NN||enzymeâ-25/NNS	dep||â-20/NN||$-26/$	num||$-26/$||²-27/CD	conj_and||retrovirus-13/NNS||is-29/VBZ	num||types-32/NNS||two-31/CD	prep_of||is-29/VBZ||types-32/NNS	prep_of||is-29/VBZ||hiv-1-34/JJ	conj_and||types-32/NNS||hiv-1-34/JJ	prep_of||is-29/VBZ||2-36/CD	conj_and||types-32/NNS||2-36/CD	aids-10||humanimmunodeficiencyvirus-1||no||humanimmunodeficiencyvirus (hiv), the causative agent of aids is a retrovirus with rna genome and a unique â€²reverse transcriptase enzymeâ€² and is of two types, hiv-1 and 2.
advmod||highlighting-3/VBG||briefly-2/RB	prepc_after||discusses-27/VBZ||highlighting-3/VBG	det||risk-5/NN||the-4/DT	dobj||highlighting-3/VBG||risk-5/NN	prep_of||risk-5/NN||stroke-7/NN	prep_with||stroke-7/NN||af-9/NN	dobj||highlighting-3/VBG||problems-11/NNS	conj_and||risk-5/NN||problems-11/NNS	prep_with||problems-11/NNS||warfarin-13/NN	det||role-17/NN||the-16/DT	dobj||highlighting-3/VBG||role-17/NN	conj_and||risk-5/NN||role-17/NN	det||laa-20/NN||the-19/DT	prep_of||role-17/NN||laa-20/NN	amod||formation-23/NN||clot-22/JJ	prep_in||laa-20/NN||formation-23/NN	det||article-26/NN||this-25/DT	nsubj||discusses-27/VBZ||article-26/NN	root||ROOT-0/null||discusses-27/VBZ	det||feasibility-29/NN||the-28/DT	dobj||discusses-27/VBZ||feasibility-29/NN	nsubjpass||developed-38/VBN||feasibility-29/NN	dobj||discusses-27/VBZ||efficacy-31/NN	conj_and||feasibility-29/NN||efficacy-31/NN	nsubjpass||developed-38/VBN||efficacy-31/NN	amod||devices-34/NNS||various-33/JJ	prep_of||feasibility-29/NN||devices-34/NNS	aux||developed-38/VBN||have-36/VBP	auxpass||developed-38/VBN||been-37/VBN	rcmod||feasibility-29/NN||developed-38/VBN	amod||occlusion-42/NN||percutaneous-40/JJ	nn||occlusion-42/NN||laa-41/NN	prep_for||developed-38/VBN||occlusion-42/NN	stroke-7||warfarin-13||yes||after briefly highlighting the risk of stroke with af, problems with warfarin, and the role of the laa in clot formation, this article discusses the feasibility and efficacy of various devices which have been developed for percutaneous laa occlusion.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	rosiglitazone-10||type2diabetes-33||no_rel||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
nn||ebv-3/NN||type-1/NN	num||ebv-3/NN||1-2/CD	nsubj||genotypes-12/NNS||ebv-3/NN	amod||zp-p-6/NN||bzlf1-5/JJ	conj_and||ebv-3/NN||zp-p-6/NN	nsubj||genotypes-12/NNS||zp-p-6/NN	prep_of||zp-p-6/NN||ebv-8/NN	cop||genotypes-12/NNS||were-9/VBD	det||genotypes-12/NNS||the-10/DT	amod||genotypes-12/NNS||predominant-11/JJ	root||ROOT-0/null||genotypes-12/NNS	amod||ebv-15/NN||nonmalignant-14/JJ	prep_in||genotypes-12/NNS||ebv-15/NN	vmod||ebv-15/NN||associated-16/VBN	dobj||associated-16/VBN||diseases-17/NNS	amod||children-20/NNS||chinese-19/JJ	prep_in||diseases-17/NNS||children-20/NNS	amod||variant-23/NN||zp-v3-22/JJ	nsubj||correlates-25/VB||variant-23/NN	aux||correlates-25/VB||may-24/MD	conj_and||genotypes-12/NNS||correlates-25/VB	prep_with||correlates-25/VB||the-27/DT	amod||the-27/DT||developing-28/VBG	amod||diseases-32/NNS||severe-30/JJ	nn||diseases-32/NNS||ebvinfection-31/NN	prep_of||the-27/DT||diseases-32/NNS	prep_such_as||the-27/DT||caebv-36/NN	prep_such_as||the-27/DT||ebv-hlh-38/NN	conj_and||caebv-36/NN||ebv-hlh-38/NN	ebvinfection-31||ebv-15||no||type 1 ebv and bzlf1 zp-p of ebv were the predominant genotypes in nonmalignant ebv associated diseases in chinese children and zp-v3 variant may correlates with the developing of severe ebvinfection diseases, such as caebv and ebv-hlh.
nn||reactivation-5/NNS||humancytomegalovirus-1/NNS	appos||reactivation-5/NNS||cmv-3/NN	nsubj||continues-6/VBZ||reactivation-5/NNS	nsubj||influence-8/VB||reactivation-5/NNS	root||ROOT-0/null||continues-6/VBZ	aux||influence-8/VB||to-7/TO	xcomp||continues-6/VBZ||influence-8/VB	nn||outcomes-11/NNS||lung-9/NN	nn||outcomes-11/NNS||transplant-10/NN	dobj||influence-8/VB||outcomes-11/NNS	cmv-3||humancytomegalovirus-1||no||humancytomegalovirus (cmv) reactivation continues to influence lung transplant outcomes.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||abductor-10/NN||the-9/DT	nsubj||hallucis-11/VBZ||abductor-10/NN	ccomp||investigate-8/VB||hallucis-11/VBZ	nn||characteristics-13/NNS||muscle-12/NN	dobj||hallucis-11/VBZ||characteristics-13/NNS	vmod||characteristics-13/NNS||defined-15/VBN	amod||thickness-21/NN||dorso-plantar-17/JJ	appos||thickness-21/NN||dp-19/NN	prep_as||defined-15/VBN||thickness-21/NN	amod||width-27/NN||medio-lateral-23/JJ	appos||width-27/NN||ml-25/NN	prep_as||defined-15/VBN||width-27/NN	conj_and||thickness-21/NN||width-27/NN	amod||area-31/NN||cross-sectional-30/JJ	prep_as||defined-15/VBN||area-31/NN	conj_and||thickness-21/NN||area-31/NN	appos||area-31/NN||csa-33/NN	prep_in||defined-15/VBN||relation-36/NN	det||severity-39/NN||the-38/DT	prep_to||defined-15/VBN||severity-39/NN	nn||valgus-42/NNS||hallux-41/NN	prep_of||severity-39/NN||valgus-42/NNS	xcomp||defined-15/VBN||using-43/VBG	amod||ultrasound-45/NN||musculoskeletal-44/JJ	dobj||using-43/VBG||ultrasound-45/NN	cross--1||csa-33||no_rel||the aim of the study was to investigate the abductor hallucis muscle characteristics, defined as dorso-plantar (dp) thickness, medio-lateral (ml) width, and cross-sectional area (csa) in relation to the severity of hallux valgus using musculoskeletal ultrasound.
nsubjpass||related-3/VBN||these-1/DT	auxpass||related-3/VBN||are-2/VBP	root||ROOT-0/null||related-3/VBN	det||toxicity-7/NN||a-5/DT	amod||toxicity-7/NN||low-6/JJ	prep_to||related-3/VBN||toxicity-7/NN	nsubj||allows-16/VBZ||toxicity-7/NN	amod||toxicity-7/NN||combined-8/VBN	amod||specificity-11/NN||high-10/JJ	prep_with||toxicity-7/NN||specificity-11/NN	prep_with||toxicity-7/NN||versatility-13/NN	conj_and||specificity-11/NN||versatility-13/NN	rcmod||toxicity-7/NN||allows-16/VBZ	det||antibody-19/NN||a-17/DT	amod||antibody-19/NN||specific-18/JJ	dobj||allows-16/VBZ||antibody-19/NN	nsubj||mediate-21/VB||antibody-19/NN	aux||mediate-21/VB||to-20/TO	xcomp||allows-16/VBZ||mediate-21/VB	amod||effects-24/NNS||various-22/JJ	amod||effects-24/NNS||biological-23/JJ	dobj||mediate-21/VB||effects-24/NNS	xcomp||allows-16/VBZ||ranging-26/VBG	det||mechanisms-31/NNS||the-28/DT	nn||mechanisms-31/NNS||virus-29/NN	nn||mechanisms-31/NNS||neutralization-30/NN	prep_from||ranging-26/VBG||mechanisms-31/NNS	det||modulation-34/NN||the-33/DT	prep_to||ranging-26/VBG||modulation-34/NN	amod||responses-37/NNS||immune-36/JJ	prep_of||modulation-34/NN||responses-37/NNS	virus-29||antibody-19||no_rel||these are related to a low toxicity combined with high specificity and versatility, which allows a specific antibody to mediate various biological effects, ranging from the virus neutralization mechanisms to the modulation of immune responses.
det||centers-3/NNS||all-1/DT	nn||centers-3/NNS||detention-2/NN	nsubj||had-4/VBD||centers-3/NNS	root||ROOT-0/null||had-4/VBD	det||program-9/NN||an-5/DT	amod||program-9/NN||organized-6/VBN	nn||program-9/NN||hiv/aids-7/NN	nn||program-9/NN||education-8/NN	dobj||had-4/VBD||program-9/NN	aids--1||hiv--1||no||all detention centers had an organized hiv/aids education program.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VB||viruses-7/NNS	nsubj||denguefever/dengue-21/VB||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VB	prep_to||lead-16/VB||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/dengue-21/VB	conj_and||lead-16/VB||denguefever/dengue-21/VB	dobj||denguefever/dengue-21/VB||hemorrhagicfever-22/NN	advmod||denguefever/dengue-21/VB||respectively-23/RB	det||two-27/CD||the-25/DT	amod||two-27/CD||other-26/JJ	nsubj||viruses-30/NNS||two-27/CD	cop||viruses-30/NNS||are-28/VBP	amod||viruses-30/NNS||tick-borne-29/JJ	parataxis||viruses-7/NNS||viruses-30/NNS	nsubj||contribute-49/VBP||viruses-30/NNS	advmod||virus-34/NN||namely-32/RB	amod||virus-34/NN||tick-borneencephalitis-33/JJ	parataxis||viruses-7/NNS||virus-34/NN	conj_and||viruses-30/NNS||virus-34/NN	nsubj||contribute-49/VBP||virus-34/NN	amod||virus-38/NN||crimean-congo-36/JJ	nn||virus-38/NN||hemorrhagicfever-37/NN	parataxis||viruses-7/NNS||virus-38/NN	conj_and||viruses-30/NNS||virus-38/NN	nsubj||contribute-49/VBP||virus-38/NN	advmod||known-41/VBN||also-40/RB	dep||viruses-30/NNS||known-41/VBN	prepc_as||known-41/VBN||xinjiang-43/VBG	nn||virus-45/NN||hemorrhagicfever-44/NN	dobj||xinjiang-43/VBG||virus-45/NN	rcmod||viruses-30/NNS||contribute-49/VBP	prep_to||contribute-49/VBP||tick-borneencephalitis-51/NNS	nn||hemorrhagicfever-54/NN||xinjiang-53/NN	prep_to||contribute-49/VBP||hemorrhagicfever-54/NN	conj_and||tick-borneencephalitis-51/NNS||hemorrhagicfever-54/NN	advmod||contribute-49/VBP||respectively-55/RB	hemorrhagicfever-54||viruses-30||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/dengue hemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
det||exception-2/NN||an-1/DT	nsubj||infection-15/NN||exception-2/NN	cop||infection-15/NN||is-3/VBZ	det||treatment-6/NN||the-5/DT	prep_in||infection-15/NN||treatment-6/NN	amod||virus-9/NN||chronichepatitisc-8/JJ	prep_for||treatment-6/NN||virus-9/NN	appos||virus-9/NN||hcv-11/NN	amod||infection-15/NN||genotype-13/JJ	dep||genotype-13/JJ||1-14/CD	root||ROOT-0/null||infection-15/NN	amod||±-20/NNS||pegylated-17/JJ	nn||±-20/NNS||interferon-18/NN	nn||±-20/NNS||î-19/NN	prep_with||infection-15/NN||±-20/NNS	prep_with||infection-15/NN||ribavirin-22/NNP	conj_and||±-20/NNS||ribavirin-22/NNP	chronichepatitisc-8||interferon-18||yes||an exception is in the treatment for chronichepatitisc virus (hcv) genotype 1 infection with pegylated interferon î± and ribavirin.
det||proteins-2/NNS||both-1/DT	nsubjpass||folded-5/VBN||proteins-2/NNS	auxpass||folded-5/VBN||were-3/VBD	advmod||folded-5/VBN||properly-4/RB	root||ROOT-0/null||folded-5/VBN	mark||confirmed-7/VBD||as-6/IN	advcl||folded-5/VBN||confirmed-7/VBD	amod||h5n1-neutralizing-11/JJ||binding-9/JJ	dep||h5n1-neutralizing-11/JJ||to-10/TO	amod||antibodies-15/NNS||h5n1-neutralizing-11/JJ	amod||antibodies-15/NNS||conformation-dependent-12/JJ	amod||antibodies-15/NNS||human-13/JJ	amod||antibodies-15/NNS||monoclonal-14/JJ	prep_by||confirmed-7/VBD||antibodies-15/NNS	h5n1--1||antibodies-15||no_rel||both proteins were properly folded as confirmed by binding to h5n1-neutralizing conformation-dependent human monoclonal antibodies.
nsubjpass||recognized-4/VBN||non-vibriocholera-1/NN	aux||recognized-4/VBN||has-2/VBZ	auxpass||recognized-4/VBN||been-3/VBN	root||ROOT-0/null||recognized-4/VBN	mark||known-15/VBN||as-5/IN	det||entity-8/NN||a-6/DT	amod||entity-8/NN||clinical-7/JJ	nsubjpass||known-15/VBN||entity-8/NN	nsubjpass||caused-18/VBN||entity-8/NN	advmod||as-12/IN||as-10/RB	advmod||as-12/IN||long-11/JJ	quantmod||cholera-13/CD||as-12/IN	prep_for||entity-8/NN||cholera-13/CD	auxpass||known-15/VBN||was-14/VBD	advcl||recognized-4/VBN||known-15/VBN	aux||caused-18/VBN||to-16/TO	auxpass||caused-18/VBN||be-17/VB	xcomp||known-15/VBN||caused-18/VBN	agent||caused-18/VBN||vibriocholerae-20/NN	cholera-13||vibriocholera--1||no||non-vibriocholera has been recognized as a clinical entity for as long as cholera was known to be caused by vibriocholerae .
advmod||reported-3/VBD||here-1/RB	nsubj||reported-3/VBD||we-2/PRP	root||ROOT-0/null||reported-3/VBD	mark||choice-29/NN||that-4/IN	det||use-7/NN||the-5/DT	amod||use-7/NN||immediate-6/JJ	nsubj||choice-29/NN||use-7/NN	prep_of||use-7/NN||pamidronate-9/NN	amod||treatment-14/NN||classic-13/JJ	prep_in_addition_to||pamidronate-9/NN||treatment-14/NN	amod||intoxication-17/NN||dihydrotachysterol-16/JJ	prep_of||treatment-14/NN||intoxication-17/NN	amod||saline-20/NN||intravenous-19/JJ	prep_with||intoxication-17/NN||saline-20/NN	prep_with||intoxication-17/NN||diuretics-22/NNS	conj_and||saline-20/NN||diuretics-22/NNS	prep_with||intoxication-17/NN||glucocorticoids-24/NNS	conj_and||saline-20/NN||glucocorticoids-24/NNS	cop||choice-29/NN||is-25/VBZ	det||choice-29/NN||an-26/DT	amod||choice-29/NN||effective-27/JJ	nn||choice-29/NN||treatment-28/NN	ccomp||reported-3/VBD||choice-29/NN	nsubj||leads-31/VBZ||choice-29/NN	rcmod||choice-29/NN||leads-31/VBZ	amod||resolution-34/NN||rapid-33/JJ	prep_to||leads-31/VBZ||resolution-34/NN	prep_of||resolution-34/NN||hypercalcemia-36/NN	hypercalcemia-36||pamidronate-9||yes||here we reported that the immediate use of pamidronate in addition to classic treatment of dihydrotachysterol intoxication with intravenous saline, diuretics and glucocorticoids is an effective treatment choice that leads to rapid resolution of hypercalcemia.
csubj||make-9/VBP||emerging-1/VBG	det||mycobacteriumtuberculosis-5/NNS||the-2/DT	amod||resistant-4/JJ||multidrug-3/JJ	amod||mycobacteriumtuberculosis-5/NNS||resistant-4/JJ	dobj||emerging-1/VBG||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||mdr-tb-7/NNP	root||ROOT-0/null||make-9/VBP	dobj||make-9/VBP||us-10/PRP	nsubj||see-12/VB||us-10/PRP	aux||see-12/VB||to-11/TO	xcomp||make-9/VBP||see-12/VB	det||importance-14/NN||the-13/DT	dobj||see-12/VB||importance-14/NN	prep_of||importance-14/NN||vaccination-16/NN	prep_against||see-12/VB||tb-18/NN	amod||light-21/NN||new-20/JJ	prep_in||tb-18/NN||light-21/NN	tb-18||mycobacteriumtuberculosis-5||no||emerging the multidrug resistant mycobacteriumtuberculosis (mdr-tb) make us to see the importance of vaccination against tb in new light.
nn||prevention-3/NN||stroke-2/NN	prep_for||associated-21/VBN||prevention-3/NN	prep_in||prevention-3/NN||patients-5/NNS	vmod||patients-5/NNS||suffering-6/VBG	prep_from||suffering-6/VBG||atrialfibrillation-8/NN	nsubjpass||associated-21/VBN||dabigatran-10/NN	vmod||dabigatran-10/NN||administered-11/VBN	det||dose-14/NN||a-13/DT	prep_at||administered-11/VBN||dose-14/NN	number||mg-17/CD||110-16/CD	prep_of||dose-14/NN||mg-17/CD	advmod||daily-19/JJ||twice-18/RB	advmod||mg-17/CD||daily-19/JJ	auxpass||associated-21/VBN||was-20/VBD	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||rates-23/NNS	prep_of||rates-23/NNS||stroke-25/NN	amod||embolism-28/NN||systemic-27/JJ	prep_with||associated-21/VBN||embolism-28/NN	conj_and||rates-23/NNS||embolism-28/NN	nsubj||similar-31/JJ||embolism-28/NN	cop||similar-31/JJ||were-30/VBD	rcmod||embolism-28/NN||similar-31/JJ	prep_to||similar-31/JJ||those-33/DT	vmod||those-33/DT||associated-34/VBN	prep_with||associated-34/VBN||warfarin-36/NN	amod||rates-42/NNS||lower-41/JJR	prep_with||associated-34/VBN||rates-42/NNS	conj_and||warfarin-36/NN||rates-42/NNS	prep_of||rates-42/NNS||hemorrhage-44/NN	atrialfibrillation-8||warfarin-36||yes||for stroke prevention in patients suffering from atrialfibrillation, dabigatran administered at a dose of 110 mg twice daily was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of hemorrhage.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	adenoma-25||hormone-12||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
amod||inflammation-2/NN||modulating-1/VBG	nsubjpass||identified-5/VBN||inflammation-2/NN	aux||identified-5/VBN||has-3/VBZ	auxpass||identified-5/VBN||been-4/VBN	root||ROOT-0/null||identified-5/VBN	det||avenue-10/NN||a-7/DT	amod||avenue-10/NN||promising-8/JJ	amod||avenue-10/NN||therapeutic-9/JJ	prep_as||identified-5/VBN||avenue-10/NN	amod||avenue-10/NN||consistent-11/JJ	amod||success-14/NN||preliminary-13/JJ	prep_with||consistent-11/JJ||success-14/NN	amod||trials-18/NNS||ongoing-16/JJ	amod||trials-18/NNS||clinical-17/JJ	prep_of||success-14/NN||trials-18/NNS	amod||compounds-21/NNS||anti-inflammatory-20/JJ	prep_for||identified-5/VBN||compounds-21/NNS	prep_such_as||compounds-21/NNS||minocycline-24/NN	inflammation-2||anti-inflammatory-20||no_rel||modulating inflammation has been identified as a promising therapeutic avenue consistent with preliminary success of ongoing clinical trials for anti-inflammatory compounds such as minocycline.
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||âˆ-17/JJ	dep||âˆ-17/JJ||’60-18/CD	num||min-21/NN||180-20/CD	prep_through||âˆ-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||âˆ-36/JJ	dep||âˆ-36/JJ||’30-37/CD	dep||âˆ-36/JJ||1-39/CD	conj_and||’30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||glucose-79||yes||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from âˆ’60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at âˆ’30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
det||level-3/NN||the-2/DT	nsubj||hiv-infected-8/VBD||level-3/NN	prep_of||level-3/NN||adherence-5/NN	prep_of||adherence-5/NN||adults-7/NNS	ccomp||documented-35/VBN||hiv-infected-8/VBD	dobj||hiv-infected-8/VBD||patients-9/NNS	vmod||patients-9/NNS||treated-10/VBN	det||centres-16/NNS||the-12/DT	amod||centres-16/NNS||hiv/aids-13/JJ	nn||centres-16/NNS||health-14/NN	nn||centres-16/NNS||care-15/NN	prep_in||treated-10/VBN||centres-16/NNS	det||togo-24/NN||the-18/DT	nn||togo-24/NN||association-19/NN	nn||togo-24/NN||espoir-22/NN	nn||togo-24/NN||vie-23/NNS	prep_of||centres-16/NNS||togo-24/NN	prep_in||treated-10/VBN||togo-28/NN	nn||africa-31/NN||west-30/NN	nsubjpass||documented-35/VBN||africa-31/NN	auxpass||documented-35/VBN||is-32/VBZ	neg||documented-35/VBN||not-33/RB	advmod||documented-35/VBN||properly-34/RB	root||ROOT-0/null||documented-35/VBN	aids--1||hiv--1||no||" the level of adherence of adults hiv-infected patients treated in the hiv/aids health care centres of the association ""espoir vie togo"" in togo, west africa is not properly documented."
nsubj||member-8/NN||missing-in-metastasis-1/NNS	appos||missing-in-metastasis-1/NNS||mim-3/NN	cop||member-8/NN||is-5/VBZ	det||member-8/NN||a-6/DT	amod||member-8/NN||defining-7/VBG	root||ROOT-0/null||member-8/NN	det||subfamily-17/NN||the-10/DT	amod||subfamily-17/NN||inverse-11/JJ	nn||subfamily-17/NN||bin/amphiphysin/rvs-12/NNS	nn||subfamily-17/NN||domain-13/NN	appos||subfamily-17/NN||i-bar-15/NN	prep_of||member-8/NN||subfamily-17/NN	num||regulators-23/NNS||lipid-19/CD	amod||regulators-23/NNS||binding-20/JJ	amod||regulators-23/NNS||cytoskeletal-22/JJ	prep_of||member-8/NN||regulators-23/NNS	dep||altered-27/VBN||whose-24/WP$	nsubjpass||altered-27/VBN||levels-25/NNS	auxpass||altered-27/VBN||are-26/VBP	dep||regulators-23/NNS||altered-27/VBN	det||number-30/NN||a-29/DT	prep_in||altered-27/VBN||number-30/NN	prep_of||number-30/NN||cancers-32/NNS	i---1||metastasis--1||no_rel||missing-in-metastasis (mim) is a defining member of the inverse bin/amphiphysin/rvs domain (i-bar) subfamily of lipid binding, cytoskeletal regulators whose levels are altered in a number of cancers.
det||existence-2/NN||the-1/DT	nsubj||suggests-17/VBZ||existence-2/NN	amod||disorders-6/NNS||multiple-4/JJ	amod||disorders-6/NNS||inherited-5/VBN	prep_of||existence-2/NN||disorders-6/NNS	nn||metabolism-9/NN||iron-8/NN	prep_of||disorders-6/NNS||metabolism-9/NN	prep_in||metabolism-9/NN||man-11/NN	prep_in||metabolism-9/NN||rodents-13/NNS	conj_and||man-11/NN||rodents-13/NNS	amod||vertebrates-16/NNS||other-15/JJ	prep_in||metabolism-9/NN||vertebrates-16/NNS	conj_and||man-11/NN||vertebrates-16/NNS	root||ROOT-0/null||suggests-17/VBZ	amod||contributions-19/NNS||genetic-18/JJ	dobj||suggests-17/VBZ||contributions-19/NNS	prep_to||suggests-17/VBZ||irondeficiency-21/NN	irondeficiency-21||iron-8||yes||the existence of multiple inherited disorders of iron metabolism in man, rodents and other vertebrates suggests genetic contributions to irondeficiency.
num||subjects-2/NNS||fourteen-1/CD	nsubjpass||recruited-24/VBN||subjects-2/NNS	prepc_with||subjects-2/NNS||hbsag-4/VBG	dobj||hbsag-4/VBG||seroclearance-5/NN	amod||treatment-8/NN||antiviral-7/JJ	prep_following||seroclearance-5/NN||treatment-8/NN	prep_for||treatment-8/NN||chronichepatitisb-10/NN	num||carriers-16/NNS||7-12/CD	amod||carriers-16/NNS||hbeag-positive-13/JJ	nn||carriers-16/NNS||immunotolerant-14/NN	nn||carriers-16/NNS||hbv-15/NN	prep_for||treatment-8/NN||carriers-16/NNS	conj_and||chronichepatitisb-10/NN||carriers-16/NNS	num||carriers-22/NNS||9-18/CD	amod||carriers-22/NNS||hbeag-negative-19/JJ	amod||carriers-22/NNS||inactive-20/JJ	nn||carriers-22/NNS||hbsag-21/NN	prep_for||treatment-8/NN||carriers-22/NNS	conj_and||chronichepatitisb-10/NN||carriers-22/NNS	auxpass||recruited-24/VBN||were-23/VBD	root||ROOT-0/null||recruited-24/VBN	hbv-15||hbsag-21||yes||fourteen subjects with hbsag seroclearance following antiviral treatment for chronichepatitisb, 7 hbeag-positive immunotolerant hbv carriers and 9 hbeag-negative inactive hbsag carriers were recruited.
det||epidemic-2/NN||the-1/DT	nsubjpass||caused-9/VBN||epidemic-2/NN	prep_of||epidemic-2/NN||severeacuterespiratorysyndrome-4/NN	appos||epidemic-2/NN||sars-6/NNS	auxpass||caused-9/VBN||was-8/VBD	root||ROOT-0/null||caused-9/VBN	det||coronavirus-14/NNS||a-11/DT	advmod||emerged-13/JJ||newly-12/RB	amod||coronavirus-14/NNS||emerged-13/JJ	agent||caused-9/VBN||coronavirus-14/NNS	appos||coronavirus-14/NNS||sars-cov-16/NNP	sars-6||coronavirus-14||no||the epidemic of severeacuterespiratorysyndrome (sars) was caused by a newly emerged coronavirus (sars-cov).
nn||analyses-2/NNS||ihc-1/NN	nsubjpass||performed-4/VBN||analyses-2/NNS	auxpass||performed-4/VBN||were-3/VBD	root||ROOT-0/null||performed-4/VBN	det||block-8/NN||each-6/DT	nn||block-8/NN||cell-7/NN	prep_on||performed-4/VBN||block-8/NN	prep_with||block-8/NN||antibodies-10/NNS	nn||receptor-13/NN||estrogen-12/NN	prep_to||performed-4/VBN||receptor-13/NN	appos||receptor-13/NN||er-15/NN	amod||receptor-19/NN||progesterone-18/JJ	appos||receptor-13/NN||receptor-19/NN	appos||receptor-19/NN||pr-21/NN	amod||receptor-33/NN||her2-24/JJ	conj_and||her2-24/JJ||egfr-26/JJ	amod||receptor-33/NN||egfr-26/JJ	conj_and||her2-24/JJ||ck5/6-28/JJ	amod||receptor-33/NN||ck5/6-28/JJ	conj_and||her2-24/JJ||ki-67-30/JJ	amod||receptor-33/NN||ki-67-30/JJ	conj_and||her2-24/JJ||androgen-32/JJ	amod||receptor-33/NN||androgen-32/JJ	appos||receptor-13/NN||receptor-33/NN	appos||receptor-13/NN||ar-35/NN	androgen-32||ar-35||no_rel||ihc analyses were performed on each cell block with antibodies to estrogen receptor (er), progesterone receptor (pr), her2, egfr, ck5/6, ki-67 and androgen receptor (ar).
det||results-3/NNS||the-1/DT	nn||results-3/NNS||trial-2/NN	nsubj||provide-5/VB||results-3/NNS	aux||provide-5/VB||would-4/MD	root||ROOT-0/null||provide-5/VB	dobj||provide-5/VB||evidence-6/NN	det||efficacy-9/NN||the-8/DT	prep_on||provide-5/VB||efficacy-9/NN	prep_of||efficacy-9/NN||domperidone-11/NN	nsubjpass||used-16/VBN||domperidone-11/NN	auxpass||used-16/VBN||is-14/VBZ	advmod||used-16/VBN||largely-15/RB	rcmod||domperidone-11/NN||used-16/VBN	amod||practice-19/NN||clinical-18/JJ	prep_in||used-16/VBN||practice-19/NN	det||lack-22/NN||the-21/DT	prep_despite||used-16/VBN||lack-22/NN	amod||evaluation-25/NN||proper-24/JJ	prep_of||lack-22/NN||evaluation-25/NN	det||profile-30/NN||a-27/DT	amod||profile-30/NN||controversial-28/JJ	nn||profile-30/NN||safety-29/NN	prep_of||lack-22/NN||profile-30/NN	conj_and||evaluation-25/NN||profile-30/NN	dep||used-16/VBN||as-32/RB	prepc_compared_to||used-16/VBN||to-34/TO	prep_despite||used-16/VBN||ondansetron-35/NN	nsubjpass||authorized-41/VBN||which-37/WDT	auxpass||authorized-41/VBN||is-38/VBZ	neg||authorized-41/VBN||not-39/RB	advmod||authorized-41/VBN||yet-40/RB	dep||used-16/VBN||authorized-41/VBN	prep_in||authorized-41/VBN||italy-43/NN	prep_despite||authorized-41/VBN||evidence-45/NN	xcomp||authorized-41/VBN||supporting-46/VBG	poss||efficacy-48/NN||its-47/PRP$	dobj||supporting-46/VBG||efficacy-48/NN	prepc_in||supporting-46/VBG||treating-50/VBG	dobj||treating-50/VBG||vomiting-51/NN	domperidone-11||vomiting-51||no_rel||the trial results would provide evidence on the efficacy of domperidone, which is largely used in clinical practice despite the lack of proper evaluation and a controversial safety profile, as compared to ondansetron, which is not yet authorized in italy despite evidence supporting its efficacy in treating vomiting.
amod||shortstature-2/NN||idiopathic-1/JJ	nsubj||term-8/NN||shortstature-2/NN	appos||shortstature-2/NN||iss-4/NN	cop||term-8/NN||is-6/VBZ	det||term-8/NN||a-7/DT	root||ROOT-0/null||term-8/NN	nsubj||describes-10/VBZ||term-8/NN	rcmod||term-8/NN||describes-10/VBZ	dobj||describes-10/VBZ||shortstature-11/NN	prep_in||describes-10/VBZ||children-13/NNS	nsubj||have-17/VB||children-13/NNS	aux||have-17/VB||do-15/VBP	neg||have-17/VB||not-16/RB	rcmod||children-13/NNS||have-17/VB	amod||deficiency-22/NN||growthhormone-18/JJ	dep||growthhormone-18/JJ||gh-20/NN	dobj||have-17/VB||deficiency-22/NN	dobj||identified-33/VBN||whom-25/WP	det||etiology-27/NN||the-26/DT	nsubjpass||identified-33/VBN||etiology-27/NN	det||shortstature-30/NN||the-29/DT	prep_of||etiology-27/NN||shortstature-30/NN	auxpass||identified-33/VBN||is-31/VBZ	neg||identified-33/VBN||not-32/RB	prep_in||describes-10/VBZ||identified-33/VBN	conj_and||children-13/NNS||identified-33/VBN	nsubj||have-17/VB||identified-33/VBN	shortstature-30||growthhormone-18||yes||idiopathic shortstature (iss) is a term that describes shortstature in children who do not have growthhormone (gh) deficiency and in whom the etiology of the shortstature is not identified.
det||hand-4/NN||the-2/DT	amod||hand-4/NN||other-3/JJ	prep_on||occurred-32/VBD||hand-4/NN	advmod||treated-10/VBN||when-6/WRB	nsubjpass||treated-10/VBN||cells-7/NNS	nsubjpass||given-17/VBN||cells-7/NNS	auxpass||treated-10/VBN||were-8/VBD	advmod||treated-10/VBN||initially-9/RB	rcmod||hand-4/NN||treated-10/VBN	prep_with||treated-10/VBN||ammonia-12/NN	num||h-15/NN||24-14/CD	npadvmod||later-16/RB||h-15/NN	rcmod||hand-4/NN||later-16/RB	advmod||treated-10/VBN||later-16/RB	conj_and||treated-10/VBN||later-16/RB	rcmod||hand-4/NN||given-17/VBN	conj_and||treated-10/VBN||given-17/VBN	det||mixture-19/NN||a-18/DT	dobj||given-17/VBN||mixture-19/NN	prep_of||mixture-19/NN||cytokines-21/NNS	det||potentiation-25/NN||a-23/DT	amod||potentiation-25/NN||marked-24/JJ	nsubj||occurred-32/VBD||potentiation-25/NN	prep_in||potentiation-25/NN||cell-27/NN	amod||cell-27/NN||swelling-28/VBG	amod||activation-31/NN||nf-îºb-30/JJ	prep_in||potentiation-25/NN||activation-31/NN	conj_and||cell-27/NN||activation-31/NN	root||ROOT-0/null||occurred-32/VBD	ammonia-12||swelling-28||no_rel||on the other hand, when cells were initially treated with ammonia and 24 h later given a mixture of cytokines, a marked potentiation in cell swelling and nf-îºb activation occurred.
nsubj||prevalent-9/JJ||co-infection-1/NN	prep_with||co-infection-1/NN||hepatitisbvirus-3/NNS	appos||hepatitisbvirus-3/NNS||hbv-5/NN	cop||prevalent-9/JJ||is-7/VBZ	advmod||prevalent-9/JJ||highly-8/RB	root||ROOT-0/null||prevalent-9/JJ	prep_in||prevalent-9/JJ||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv-14/NN	amod||africa-17/NN||sub-saharan-16/JJ	prep_in||hiv-14/NN||africa-17/NN	hbv-5||hepatitisbvirus-3||no||co-infection with hepatitisbvirus (hbv) is highly prevalent in people living with hiv in sub-saharan africa.
amod||nsaids-2/NNS||non-selective-1/JJ	nsubjpass||prescribed-9/VBN||nsaids-2/NNS	nsubj||reduce-11/VB||nsaids-2/NNS	nsubj||alleviate-14/VB||nsaids-2/NNS	amod||inhibitors-6/NNS||cox-2-4/JJ	amod||inhibitors-6/NNS||selective-5/JJ	conj_or||nsaids-2/NNS||inhibitors-6/NNS	nsubjpass||prescribed-9/VBN||inhibitors-6/NNS	nsubj||reduce-11/VB||inhibitors-6/NNS	auxpass||prescribed-9/VBN||are-7/VBP	advmod||prescribed-9/VBN||widely-8/RB	root||ROOT-0/null||prescribed-9/VBN	aux||reduce-11/VB||to-10/TO	xcomp||prescribed-9/VBN||reduce-11/VB	dobj||reduce-11/VB||inflammation-12/NN	xcomp||prescribed-9/VBN||alleviate-14/VB	conj_and||reduce-11/VB||alleviate-14/VB	dobj||alleviate-14/VB||pain-15/NN	advmod||used-22/VBN||however-17/RB	nsubjpass||used-22/VBN||they-19/PRP	aux||used-22/VBN||must-20/MD	auxpass||used-22/VBN||be-21/VB	parataxis||prescribed-9/VBN||used-22/VBN	prep_with||used-22/VBN||caution-24/NN	prep_in||used-22/VBN||individuals-26/NNS	det||risk-38/NN||an-28/DT	amod||risk-38/NN||increased-29/JJ	amod||risk-38/NN||cardiovascular-30/JJ	conj_or||cardiovascular-30/JJ||renal-32/JJ	amod||risk-38/NN||renal-32/JJ	conj_or||cardiovascular-30/JJ||gastrointestinal-34/JJ	amod||risk-38/NN||gastrointestinal-34/JJ	nn||risk-38/NN||gi-36/NNP	prep_with||individuals-26/NNS||risk-38/NN	nsaids-2||pain-15||no_rel||non-selective nsaids or cox-2 selective inhibitors are widely prescribed to reduce inflammation and alleviate pain; however, they must be used with caution in individuals with an increased cardiovascular, renal or gastrointestinal (gi) risk.
nsubjpass||increased-18/VBN||enrolment-1/NN	det||hiv/aids-4/NNS||the-3/DT	prep_in||enrolment-1/NN||hiv/aids-4/NNS	nn||programme-7/NN||art-6/NN	prep_in||enrolment-1/NN||programme-7/NN	conj_and||hiv/aids-4/NNS||programme-7/NN	nn||testing-10/NN||hiv-9/NN	prep_through||hiv/aids-4/NNS||testing-10/NN	amod||care-14/NN||general-12/JJ	amod||care-14/NN||primary-13/JJ	prep_in||testing-10/NN||care-14/NN	auxpass||increased-18/VBN||was-15/VBD	neg||increased-18/VBN||not-16/RB	advmod||increased-18/VBN||significantly-17/RB	root||ROOT-0/null||increased-18/VBN	num||%-21/NN||53-20/CD	dep||increased-18/VBN||%-21/NN	dep||%-21/NN||v-22/NN	number||%-24/NN||50-23/CD	amod||v-22/NN||%-24/NN	dep||v-22/NN||1.19-26/CD	num||2.77-30/CD||0.51-28/CD	dep||2.77-30/CD||to-29/TO	appos||1.19-26/CD||2.77-30/CD	aids--1||hiv-9||no||enrolment in the hiv/aids and art programme through hiv testing in general primary care was not significantly increased (53% v 50%; 1.19, 0.51 to 2.77).
advmod||report-3/VBP||here-1/RB	nsubj||report-3/VBP||we-2/PRP	root||ROOT-0/null||report-3/VBP	advmod||report-3/VBP||yet-4/RB	det||reovirus-7/NNS||another-5/DT	amod||reovirus-7/NNS||melaka-like-6/JJ	dobj||report-3/VBP||reovirus-7/NNS	dep||reovirus-7/NNS||named-9/VBN	nn||virus-11/NN||kampar-10/NN	dobj||named-9/VBN||virus-11/NN	amod||reovirus-7/NNS||isolated-13/VBN	det||swab-17/NN||the-15/DT	nn||swab-17/NN||throat-16/NN	prep_from||isolated-13/VBN||swab-17/NN	nsubj||suffering-33/VBG||swab-17/NN	det||patient-24/NN||a-19/DT	number||old-22/JJ||54-20/CD	npadvmod||old-22/JJ||year-21/NN	amod||patient-24/NN||old-22/JJ	amod||patient-24/NN||male-23/JJ	prep_of||swab-17/NN||patient-24/NN	nn||malaysia-30/NN||kampar-26/NN	dep||malaysia-30/NN||perak-28/NN	prep_in||patient-24/NN||malaysia-30/NN	aux||suffering-33/VBG||was-32/VBD	rcmod||swab-17/NN||suffering-33/VBG	amod||fever-36/NN||high-35/JJ	prep_from||suffering-33/VBG||fever-36/NN	amod||respiratorydisease-39/NN||acute-38/JJ	prep_from||suffering-33/VBG||respiratorydisease-39/NN	conj_and||fever-36/NN||respiratorydisease-39/NN	prep_from||suffering-33/VBG||vomiting-41/NN	conj_and||fever-36/NN||vomiting-41/NN	det||time-44/NN||the-43/DT	prep_at||suffering-33/VBG||time-44/NN	prep_of||time-44/NN||virusisolation-46/NN	virusisolation-46||virus-11||no_rel||here we report yet another melaka-like reovirus (named kampar virus) isolated from the throat swab of a 54 year old male patient in kampar, perak, malaysia who was suffering from high fever, acute respiratorydisease and vomiting at the time of virusisolation.
amod||antibody-3/NN||anti-dengue-1/JJ	nn||antibody-3/NN||igg-2/NN	nsubj||detectable-5/JJ||antibody-3/NN	cop||detectable-5/JJ||was-4/VBD	root||ROOT-0/null||detectable-5/JJ	det||day-9/NN||the-7/DT	amod||day-9/NN||fifth-8/JJ	prep_on||detectable-5/JJ||day-9/NN	prepc_of||day-9/NN||onset-11/VBG	amod||level-14/NN||low-13/JJ	prep_with||onset-11/VBG||level-14/NN	det||week-18/NN||the-16/DT	amod||week-18/NN||first-17/JJ	prep_at||onset-11/VBG||week-18/NN	prep_of||week-18/NN||onset-20/NN	advmod||increasing-24/VBG||slowly-23/RB	prepc_of||day-9/NN||increasing-24/VBG	conj_and||onset-11/VBG||increasing-24/VBG	num||%-27/NN||100-26/CD	prep_to||increasing-24/VBG||%-27/NN	prep_by||increasing-24/VBG||day-29/NN	num||day-29/NN||15-30/CD	prep_of||day-29/NN||illness-32/NN	dengue--1||antibody-3||no_rel||anti-dengue igg antibody was detectable on the fifth day of onset with low level at the first week of onset, and slowly increasing to 100% by day 15 of illness.
csubj||occurred-5/VBD||persisting-1/VBG	conj_or||persisting-1/VBG||relapsing-3/VBG	csubj||occurred-5/VBD||relapsing-3/VBG	dobj||persisting-1/VBG||bacteraemia-4/NN	root||ROOT-0/null||occurred-5/VBD	num||%-8/NN||27-7/CD	prep_in||occurred-5/VBD||%-8/NN	prep_of||%-8/NN||daptomycin-10/NN	num||%-13/NN||21-12/CD	prep_in||occurred-5/VBD||%-13/NN	conj_and||%-8/NN||%-13/NN	nn||patients-16/NNS||vancomycin/gentamicin-15/NN	prep_of||%-13/NN||patients-16/NNS	det||patients-20/NNS||these-19/DT	prep_among||occurred-29/VBD||patients-20/NNS	nsubj||occurred-29/VBD||mics-22/NNS	nn||¥-26/NNP||â-24/NNP	nn||¥-26/NNP||‰-25/NNP	prep_of||mics-22/NNS||¥-26/NNP	number||mg/l-28/JJ||2-27/CD	amod||¥-26/NNP||mg/l-28/JJ	parataxis||occurred-5/VBD||occurred-29/VBD	num||daptomycin-32/NN||five-31/CD	prep_in||occurred-29/VBD||daptomycin-32/NN	num||patients-36/NNS||four-34/CD	nn||patients-36/NNS||vancomycin/gentamicin-35/NN	prep_in||occurred-29/VBD||patients-36/NNS	conj_and||daptomycin-32/NN||patients-36/NNS	vancomycin--1||bacteraemia-4||no_rel||persisting or relapsing bacteraemia occurred in 27% of daptomycin and 21% of vancomycin/gentamicin patients; among these patients, mics of â‰¥2 mg/l occurred in five daptomycin and four vancomycin/gentamicin patients.
amod||obstructivepulmonarydisease-2/NN||chronic-1/JJ	nsubj||disease-11/NN||obstructivepulmonarydisease-2/NN	dep||obstructivepulmonarydisease-2/NN||copd-4/VBN	cop||disease-11/NN||is-6/VBZ	det||disease-11/NN||a-7/DT	amod||disease-11/NN||preventable-8/JJ	conj_and||preventable-8/JJ||treatable-10/JJ	amod||disease-11/NN||treatable-10/JJ	root||ROOT-0/null||disease-11/NN	det||lung-14/NN||the-13/DT	prep_of||disease-11/NN||lung-14/NN	vmod||lung-14/NN||caused-15/VBN	advmod||caused-15/VBN||primarily-16/RB	agent||caused-15/VBN||exposure-18/NN	nn||smoke-21/NN||cigarette-20/NN	prep_to||caused-15/VBN||smoke-21/NN	obstructivepulmonarydisease-2||smoke-21||no_rel||chronic obstructivepulmonarydisease (copd) is a preventable and treatable disease of the lung caused primarily by exposure to cigarette smoke.
nsubj||provides-2/VBZ||this-1/DT	root||ROOT-0/null||provides-2/VBZ	dobj||provides-2/VBZ||support-3/NN	det||inclusion-6/NN||the-5/DT	prep_for||support-3/NN||inclusion-6/NN	amod||antibodies-9/NNS||anti-ccp-8/JJ	prep_of||inclusion-6/NN||antibodies-9/NNS	dobj||provides-2/VBZ||rf-13/NN	conj_and||support-3/NN||rf-13/NN	conj_and||support-3/NN||rf-13/NN	conj_and||rf-13/NN||rf-13/NN	det||criteria-17/NNS||the-15/DT	nn||criteria-17/NNS||classification-16/NN	prep_in||rf-13/NN||criteria-17/NNS	prep_for||criteria-17/NNS||rheumatoidarthritis-19/NNS	prep_for||rf-13/NN||stratification-22/NN	amod||status-26/NN||anti-ccp-24/JJ	nn||status-26/NN||antibody-25/NN	prep_by||provides-2/VBZ||status-26/NN	amod||trials-29/NNS||clinical-28/JJ	prep_in||status-26/NN||trials-29/NNS	rheumatoidarthritis-19||antibodies-9||no_rel||this provides support for the inclusion of anti-ccp antibodies as well as rf in the classification criteria for rheumatoidarthritis and for stratification by anti-ccp antibody status in clinical trials.
prepc_according_to||+-11/VBD||to-2/TO	det||sensitivity-5/NN||the-3/DT	amod||sensitivity-5/NN||different-4/JJ	pobj||+-11/VBD||sensitivity-5/NN	poss||bone-8/NN||their-7/PRP$	prep_of||sensitivity-5/NN||bone-8/NN	nn||cd34-10/NNS||marrow-9/NN	nsubj||+-11/VBD||cd34-10/NNS	root||ROOT-0/null||+-11/VBD	dobj||+-11/VBD||cells-12/NNS	dep||vitro-15/NN||in-14/IN	amod||treatment-16/NN||vitro-15/NN	prep_to||+-11/VBD||treatment-16/NN	nn||patients-26/NNS||etoposide-18/NN	conj_or||etoposide-18/NN||mafosfamide-20/NN	nn||patients-26/NNS||mafosfamide-20/NN	dep||patients-26/NNS||acutemyeloidleukaemia-22/NN	nn||patients-26/NNS||aml-24/NN	prep_with||+-11/VBD||patients-26/NNS	amod||remission-30/NN||apparent-28/JJ	amod||remission-30/NN||complete-29/JJ	prep_in||+-11/VBD||remission-30/NN	appos||remission-30/NN||cr-32/NN	amod||induction-36/NN||chemotherapy-35/JJ	nsubjpass||classified-39/VBN||induction-36/NN	aux||classified-39/VBN||may-37/MD	auxpass||classified-39/VBN||be-38/VB	prepc_after||remission-30/NN||classified-39/VBN	num||groups-42/NNS||three-41/CD	prep_into||classified-39/VBN||groups-42/NNS	appos||groups-42/NNS||i-44/NNP	advmod||responsive-47/JJ||normally-46/RB	amod||groups-42/NNS||responsive-47/JJ	appos||chemoresistant-52/NNS||ii-50/NN	dep||groups-42/NNS||chemoresistant-52/NNS	appos||remission-30/NN||iii-55/NN	advmod||chemosensitive-58/JJ||highly-57/RB	amod||remission-30/NN||chemosensitive-58/JJ	etoposide-18||aml-24||no_rel||according to the different sensitivity of their bone marrow cd34+ cells to in vitro treatment with etoposide or mafosfamide, acutemyeloidleukaemia (aml) patients in apparent complete remission (cr) after chemotherapy induction may be classified into three groups (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.
advmod||unclear-13/JJ||however-1/RB	det||origin-4/NN||the-3/DT	nsubj||unclear-13/JJ||origin-4/NN	prep_of||origin-4/NN||hbv-6/NN	amod||insertion-9/NN||4-aminoacid-8/JJ	prep_with||hbv-6/NN||insertion-9/NN	prep_in||insertion-9/NN||hbsag-11/NN	cop||unclear-13/JJ||was-12/VBD	root||ROOT-0/null||unclear-13/JJ	hbv-6||hbsag-11||yes||however, the origin of hbv with 4-aminoacid insertion in hbsag was unclear.
amod||ratios-2/NNS||femalemale-1/JJ	nsubj||1.5-4/CD||ratios-2/NNS	cop||1.5-4/CD||were-3/VBD	root||ROOT-0/null||1.5-4/CD	prep_for||1.5-4/CD||uc-6/NN	conj_and||1.5-4/CD||1.0-8/CD	prep_for||1.0-8/CD||cd-10/NN	uc-6||cd-10||no_rel||femalemale ratios were 1.5 for uc and 1.0 for cd.
det||bioactivity-2/NN||the-1/DT	nsubj||greater-20/JJR||bioactivity-2/NN	det||fraction-6/NN||the-4/DT	amod||fraction-6/NN||composite-5/JJ	prep_of||bioactivity-2/NN||fraction-6/NN	prepc_in||fraction-6/NN||enhancing-8/VBG	det||effect-11/NN||the-9/DT	amod||effect-11/NN||antibacterial-10/JJ	dobj||enhancing-8/VBG||effect-11/NN	prep_of||effect-11/NN||oxacillin-13/NN	prep_against||oxacillin-13/NN||methicillin-resistantstaphylococcusaureus-15/NNS	appos||methicillin-resistantstaphylococcusaureus-15/NNS||mrsa-17/NNP	cop||greater-20/JJR||was-19/VBD	root||ROOT-0/null||greater-20/JJR	mark||extract-30/VB||than-21/IN	nsubj||extract-30/VB||that-22/DT	det||monomer-26/NN||the-24/DT	amod||monomer-26/NN||individual-25/JJ	prep_of||that-22/DT||monomer-26/NN	det||hawthorn-29/NN||the-28/DT	prep_of||monomer-26/NN||hawthorn-29/NN	ccomp||greater-20/JJR||extract-30/VB	prep_in||extract-30/VB||vitro-32/NN	mrsa-17||antibacterial-10||no_rel||the bioactivity of the composite fraction in enhancing the antibacterial effect of oxacillin against methicillin-resistantstaphylococcusaureus (mrsa) was greater than that of the individual monomer of the hawthorn extract in vitro .
det||virus-2/NN||the-1/DT	nsubj||infected-5/VBD||virus-2/NN	nsubj||related-16/JJ||virus-2/NN	advmod||infected-5/VBD||likely-4/RB	rcmod||virus-2/NN||infected-5/VBD	dobj||infected-5/VBD||amphioxus-6/NNS	cop||related-16/JJ||is-7/VBZ	amod||analysis-12/NN||molecular-10/JJ	amod||analysis-12/NN||phylogenetic-11/JJ	prep_by||related-16/JJ||analysis-12/NN	advmod||related-16/JJ||more-14/RBR	advmod||related-16/JJ||closely-15/RB	root||ROOT-0/null||related-16/JJ	det||viruses-22/NNS||the-18/DT	amod||viruses-22/NNS||other-19/JJ	num||viruses-22/NNS||2-20/CD	amod||viruses-22/NNS||invertebrate-21/JJ	prep_to||related-16/JJ||viruses-22/NNS	advmod||related-16/JJ||than-23/IN	prep_to||than-23/IN||herpesviruses-25/NNS	vmod||herpesviruses-25/NNS||infecting-26/VBG	dobj||infecting-26/VBG||vertebrates-27/NNS	nn||chordates-30/NNS||ie-29/NN	appos||vertebrates-27/NNS||chordates-30/NNS	virus-2||viruses-22||no||the virus which likely infected amphioxus is, by molecular phylogenetic analysis, more closely related to the other 2 invertebrate viruses than to herpesviruses infecting vertebrates (ie chordates).
poss||study-2/NN||our-1/PRP$	nsubj||demonstrated-3/VBD||study-2/NN	nsubj||find-17/VB||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	amod||incidence-5/NN||increased-4/VBN	dobj||demonstrated-3/VBD||incidence-5/NN	amod||pancreatitis-8/NNS||acute-7/JJ	prep_of||incidence-5/NN||pancreatitis-8/NNS	prep_in||pancreatitis-8/NNS||diabetic-10/NN	amod||patients-13/NNS||nondiabetic-12/JJ	prep_versus||diabetic-10/NN||patients-13/NNS	aux||find-17/VB||did-15/VBD	neg||find-17/VB||not-16/RB	conj_but||demonstrated-3/VBD||find-17/VB	det||association-19/NN||an-18/DT	dobj||find-17/VB||association-19/NN	det||use-22/NN||the-21/DT	prep_between||association-19/NN||use-22/NN	dep||sitagliptin-26/JJ||exenatide-24/JJ	amod||pancreatitis-29/NNS||sitagliptin-26/JJ	conj_and||sitagliptin-26/JJ||acute-28/JJ	amod||pancreatitis-29/NNS||acute-28/JJ	prep_of||use-22/NN||pancreatitis-29/NNS	pancreatitis-29||exenatide-24||no_rel||our study demonstrated increased incidence of acute pancreatitis in diabetic versus nondiabetic patients but did not find an association between the use of exenatide or sitagliptin and acute pancreatitis.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	calcium-3||hypocalcemia-26||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
det||inhaler-3/NN||the-1/DT	nn||inhaler-3/NN||combination-2/NN	nsubj||product-11/NN||inhaler-3/NN	vmod||inhaler-3/NN||containing-4/VBG	acomp||containing-4/VBG||salmeterol-5/JJ	acomp||containing-4/VBG||fluticasone-7/JJ	conj_and||salmeterol-5/JJ||fluticasone-7/JJ	cop||product-11/NN||is-8/VBZ	num||product-11/NN||one-9/CD	amod||product-11/NN||such-10/JJ	root||ROOT-0/null||product-11/NN	nsubjpass||proven-15/VBN||product-11/NN	aux||proven-15/VBN||has-13/VBZ	auxpass||proven-15/VBN||been-14/VBN	rcmod||product-11/NN||proven-15/VBN	acomp||proven-15/VBN||safe-16/JJ	acomp||proven-15/VBN||effective-18/JJ	conj_and||safe-16/JJ||effective-18/JJ	nn||therapy-21/NN||asthma-20/NN	prep_for||proven-15/VBN||therapy-21/NN	asthma-20||fluticasone-7||yes||the combination inhaler containing salmeterol and fluticasone is one such product that has been proven safe and effective for asthma therapy.
advmod||evaluated-3/VBD||here-1/RB	nsubj||evaluated-3/VBD||we-2/PRP	root||ROOT-0/null||evaluated-3/VBD	amod||arrays-6/NNS||silver-4/JJ	amod||arrays-6/NNS||nanorod-5/JJ	nsubj||-lrb--7/VBZ||arrays-6/NNS	nsubj||-rrb--9/VB||arrays-6/NNS	ccomp||evaluated-3/VBD||-lrb--7/VBZ	aux||-rrb--9/VB||na-8/TO	xcomp||-lrb--7/VBZ||-rrb--9/VB	det||platform-13/NN||a-11/DT	amod||platform-13/NN||biosensing-12/VBG	prep_as||-rrb--9/VB||platform-13/NN	prep_for||platform-13/NN||detection-15/NN	prep_for||platform-13/NN||differentiation-17/NN	conj_and||detection-15/NN||differentiation-17/NN	amod||-rrb--38/NNS||m.-19/JJ	amod||-rrb--38/NNS||pneumoniae-20/JJ	prep_in||pneumoniae-20/JJ||culture-22/NN	conj_and||pneumoniae-20/JJ||in-24/IN	amod||-rrb--38/NNS||in-24/IN	amod||samples-31/NNS||spiked-25/JJ	conj_and||spiked-25/JJ||true-27/JJ	amod||samples-31/NNS||true-27/JJ	amod||samples-31/NNS||clinical-28/JJ	nn||samples-31/NNS||throat-29/NN	nn||samples-31/NNS||swab-30/NN	pobj||in-24/IN||samples-31/NNS	amod||sers-37/NNS||surface-enhanced-33/JJ	nn||sers-37/NNS||raman-34/NN	nn||sers-37/NNS||spectroscopy-35/NN	amod||sers-37/NNS||-lrb--36/JJ	prep_by||samples-31/NNS||sers-37/NNS	prep_of||platform-13/NN||-rrb--38/NNS	pneumoniae-20||silver-4||no_rel||here we evaluated silver nanorod arrays -lrb- na -rrb- as a biosensing platform for detection and differentiation of m. pneumoniae in culture and in spiked and true clinical throat swab samples by surface-enhanced raman spectroscopy -lrb- sers -rrb- .
amod||analyses-2/NNS||multivariable-1/JJ	nsubj||type-8/VBZ||analyses-2/NNS	nn||response-5/NN||treatment-4/NN	prep_of||analyses-2/NNS||response-5/NN	prep_in||response-5/NN||1,229-7/CD	root||ROOT-0/null||type-8/VBZ	num||patients-11/NNS||2-9/CD	amod||patients-11/NNS||diabetic-10/JJ	dobj||type-8/VBZ||patients-11/NNS	prep_with||type-8/VBZ||hypercholesterolemia-13/NN	nsubj||received-15/VBD||hypercholesterolemia-13/NN	rcmod||hypercholesterolemia-13/NN||received-15/VBD	dobj||received-15/VBD||ezetimibe/simvastatin-16/NN	dobj||received-15/VBD||atorvastatin-18/NN	conj_or||ezetimibe/simvastatin-16/NN||atorvastatin-18/NN	det||study-24/NN||a-20/DT	amod||study-24/NN||randomized-21/JJ	amod||study-24/NN||double-blind-22/JJ	amod||study-24/NN||6-week-23/JJ	prep_in||received-15/VBD||study-24/NN	hypercholesterolemia-13||ezetimibe--1||yes||multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin or atorvastatin in a randomized double-blind 6-week study.
nn||dynamics-2/NNS||dm-1/NN	nsubjpass||influenced-5/VBN||dynamics-2/NNS	nsubj||similar-16/JJ||dynamics-2/NNS	auxpass||influenced-5/VBN||is-3/VBZ	neg||influenced-5/VBN||not-4/RB	root||ROOT-0/null||influenced-5/VBN	det||extent-8/NN||the-7/DT	agent||influenced-5/VBN||extent-8/NN	amod||resection-13/NN||conservative-10/JJ	amod||resection-13/NN||primary-11/JJ	nn||resection-13/NN||tumour-12/NN	prep_of||extent-8/NN||resection-13/NN	cop||similar-16/JJ||is-15/VBZ	conj_and||influenced-5/VBN||similar-16/JJ	det||phenotypes-20/NNS||both-18/DT	nn||phenotypes-20/NNS||er-19/NN	prep_for||similar-16/JJ||phenotypes-20/NNS	amod||sites-24/NNS||different-22/JJ	amod||sites-24/NNS||metastatic-23/JJ	prep_across||phenotypes-20/NNS||sites-24/NNS	xcomp||similar-16/JJ||suggesting-26/VBG	amod||mechanisms-28/NNS||similar-27/JJ	dobj||suggesting-26/VBG||mechanisms-28/NNS	nn||development-31/NN||tumour-30/NN	prep_for||mechanisms-28/NNS||development-31/NN	amod||sites-34/NNS||distant-33/JJ	prep_at||suggesting-26/VBG||sites-34/NNS	advmod||different-37/JJ||apparently-36/RB	amod||microenvironments-38/NNS||different-37/JJ	prep_despite||suggesting-26/VBG||microenvironments-38/NNS	tumour-30||dm-1||yes||dm dynamics is not influenced by the extent of conservative primary tumour resection and is similar for both er phenotypes across different metastatic sites, suggesting similar mechanisms for tumour development at distant sites despite apparently different microenvironments.
amod||outcomes-2/NNS||secondary-1/JJ	nsubjpass||assessed-5/VBN||outcomes-2/NNS	auxpass||assessed-5/VBN||were-3/VBD	advmod||assessed-5/VBN||nausea-4/RB	root||ROOT-0/null||assessed-5/VBN	det||scale-10/NN||a-7/DT	amod||scale-10/NN||visual-8/JJ	amod||scale-10/NN||analog-9/JJ	agent||assessed-5/VBN||scale-10/NN	discourse||scale-10/NN||vas-12/UH	nsubj||31â-22/VBG||baseline-15/NN	amod||$-18/$||0â-17/JJ	appos||baseline-15/NN||$-18/$	num||$-18/$||30-20/CD	prepc_at||assessed-5/VBN||31â-22/VBG	dobj||31â-22/VBG||$-23/$	num||$-23/$||60-25/CD	dobj||31â-22/VBG||61â-28/NNS	conj_and||$-23/$||61â-28/NNS	num||minutes-32/NNS||$-29/$	num||$-29/$||120-31/CD	dep||61â-28/NNS||minutes-32/NNS	det||administration-35/NN||the-34/DT	prep_after||31â-22/VBG||administration-35/NN	prep_of||administration-35/NN||ondansetron-37/NN	prep_of||administration-35/NN||prochlorperazine-39/NN	conj_or||ondansetron-37/NN||prochlorperazine-39/NN	det||percentage-42/NN||the-41/DT	prep_after||31â-22/VBG||percentage-42/NN	conj_and||administration-35/NN||percentage-42/NN	prep_of||percentage-42/NN||patients-44/NNS	amod||effects-47/NNS||adverse-46/JJ	prep_with||patients-44/NNS||effects-47/NNS	nn||akathisia-53/NN||sedation-49/NN	dep||akathisia-53/NN||headache-51/NN	appos||effects-47/NNS||akathisia-53/NN	dep||akathisia-53/NN||dystonia-55/NNP	det||drug-59/NN||either-58/DT	prep_to||31â-22/VBG||drug-59/NN	nausea-4||ondansetron-37||yes||secondary outcomes were nausea assessed by a visual analog scale (vas) at baseline, 0â€“30, 31â€“60, and 61â€“120 minutes after the administration of ondansetron or prochlorperazine and the percentage of patients with adverse effects (sedation, headache, akathisia, dystonia) to either drug.
nsubj||reported-4/VBN||we-1/PRP	aux||reported-4/VBN||have-2/VBP	advmod||reported-4/VBN||previously-3/RB	root||ROOT-0/null||reported-4/VBN	mark||alter-12/VB||that-5/IN	amod||inhibition-7/NN||allopurinol-6/JJ	nsubj||alter-12/VB||inhibition-7/NN	prep_of||inhibition-7/NN||xo-9/NN	aux||alter-12/VB||does-10/VBZ	neg||alter-12/VB||not-11/RB	ccomp||reported-4/VBN||alter-12/VB	det||progression-14/NN||the-13/DT	dobj||alter-12/VB||progression-14/NN	amod||acetate-17/NN||deoxycorticosterone-16/JJ	prep_of||progression-14/NN||acetate-17/NN	appos||acetate-17/NN||doca-19/NNP	nn||hypertension-23/NN||salt-22/NN	dep||progression-14/NN||hypertension-23/NN	prep_in||hypertension-23/NN||rats-25/NNS	allopurinol-6||hypertension-23||no_rel||we have previously reported that allopurinol inhibition of xo does not alter the progression of deoxycorticosterone acetate (doca)-salt hypertension in rats.
amod||target-3/NN||aberrant-1/JJ	amod||target-3/NN||mammalian-2/JJ	nsubjpass||implicated-12/VBN||target-3/NN	nsubj||chemotherapy-27/VB||target-3/NN	amod||activation-9/NNS||rapamycin-5/JJ	appos||activation-9/NNS||mtor-7/NN	prep_of||target-3/NN||activation-9/NNS	aux||implicated-12/VBN||has-10/VBZ	auxpass||implicated-12/VBN||been-11/VBN	root||ROOT-0/null||implicated-12/VBN	prep_in||implicated-12/VBN||oncogenesis-14/NNS	prep_in||implicated-12/VBN||angiogenesis-16/NNS	conj_and||oncogenesis-14/NNS||angiogenesis-16/NNS	det||development-20/NN||the-19/DT	prep_in||implicated-12/VBN||development-20/NN	conj_and||oncogenesis-14/NNS||development-20/NN	nn||independence-23/NN||estrogen-22/NN	prep_of||development-20/NN||independence-23/NN	prep_of||development-20/NN||resistance-25/NN	conj_and||independence-23/NN||resistance-25/NN	aux||chemotherapy-27/VB||to-26/TO	xcomp||implicated-12/VBN||chemotherapy-27/VB	prep_in||chemotherapy-27/VB||breasttumors-29/NNS	breasttumors-29||estrogen-22||yes||aberrant mammalian target of rapamycin (mtor) activation has been implicated in oncogenesis, angiogenesis, and the development of estrogen independence and resistance to chemotherapy in breasttumors.
nsubj||received-9/VBD||patients-1/NNS	amod||hypertension-4/NN||uncontrolled-3/JJ	prep_with||patients-1/NNS||hypertension-4/NN	amod||risk-8/NN||added-6/VBN	amod||risk-8/NN||cardiovascular-7/JJ	prep_with||patients-1/NNS||risk-8/NN	conj_and||hypertension-4/NN||risk-8/NN	root||ROOT-0/null||received-9/VBD	det||combination-12/NN||a-10/DT	amod||combination-12/NN||fixed-dose-11/JJ	dobj||received-9/VBD||combination-12/NN	amod||mg-16/NN||candesartancilexetil-14/JJ	dep||candesartancilexetil-14/JJ||16-15/CD	prep_of||combination-12/NN||mg-16/NN	nn||mg-20/NN||hctz-18/NN	num||mg-20/NN||12.5-19/CD	prep_of||combination-12/NN||mg-20/NN	conj_and||mg-16/NN||mg-20/NN	nn||group-24/NN||combination-22/NN	nn||group-24/NN||therapy-23/NN	dep||mg-20/NN||group-24/NN	amod||monotherapy-28/NN||high-dose-27/JJ	dobj||received-9/VBD||monotherapy-28/NN	conj_or||combination-12/NN||monotherapy-28/NN	amod||mg-32/NN||candesartancilexetil-30/JJ	dep||candesartancilexetil-30/JJ||32-31/CD	prep_with||monotherapy-28/NN||mg-32/NN	amod||group-36/NN||high-dose-34/JJ	amod||group-36/NN||monotherapy-35/JJ	appos||mg-32/NN||group-36/NN	hypertension-4||hctz-18||yes||patients with uncontrolled hypertension and added cardiovascular risk received a fixed-dose combination of candesartancilexetil 16 mg and hctz 12.5 mg (combination therapy group) or high-dose monotherapy with candesartancilexetil 32 mg (high-dose monotherapy group).
advmod||considered-18/VBN||as-1/RB	prep_with||as-1/RB||sd-nvp-3/NN	det||value-6/NN||the-5/DT	nsubjpass||considered-18/VBN||value-6/NN	prepc_of||value-6/NN||preventing-8/VBG	dobj||preventing-8/VBG||hivinfection-9/NN	det||number-13/NN||a-11/DT	amod||number-13/NN||large-12/JJ	prep_in||preventing-8/VBG||number-13/NN	prep_of||number-13/NN||infants-15/NNS	aux||considered-18/VBN||should-16/MD	auxpass||considered-18/VBN||be-17/VB	root||ROOT-0/null||considered-18/VBN	det||risk-22/NN||the-20/DT	amod||risk-22/NN||high-21/JJ	prep_alongside||considered-18/VBN||risk-22/NN	prep_of||risk-22/NN||resistance-24/NN	vmod||resistance-24/NN||associated-25/VBN	amod||prophylaxis-29/NNS||extended-27/JJ	nn||prophylaxis-29/NNS||nvp-28/NN	prep_with||associated-25/VBN||prophylaxis-29/NNS	hivinfection-9||nvp-28||yes||as with sd-nvp, the value of preventing hivinfection in a large number of infants should be considered alongside the high risk of resistance associated with extended nvp prophylaxis.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||study-5/NN||an-3/DT	amod||study-5/NN||environmental-4/JJ	dobj||performed-2/VBD||study-5/NN	prep_of||study-5/NN||viruses-7/NNS	vmod||viruses-7/NNS||infecting-8/VBG	det||algae-12/NN||the-9/DT	amod||algae-12/NN||symbiotic-10/JJ	amod||algae-12/NN||single-celled-11/JJ	dobj||infecting-8/VBG||algae-12/NN	nn||bursaria-15/NN||paramecium-14/NN	prep_of||algae-12/NN||bursaria-15/NN	amod||virus-20/NN||paramecium-17/JJ	nn||virus-20/NN||bursaria-18/NN	nn||virus-20/NN||chlorella-19/NN	appos||bursaria-15/NN||virus-20/NN	dep||virus-20/NN||pbcv-22/NNP	nn||biwa-26/NN||lake-25/NN	prep_in||infecting-8/VBG||biwa-26/NN	det||lake-30/NN||the-28/DT	amod||lake-30/NN||largest-29/JJS	dobj||infecting-8/VBG||lake-30/NN	prep_in||lake-30/NN||japan-32/NN	virus-20||viruses-7||no||we performed an environmental study of viruses infecting the symbiotic single-celled algae of paramecium bursaria ( paramecium bursaria chlorella virus, pbcv) in lake biwa, the largest lake in japan.
nsubjpass||caused-3/VBN||celiacdisease-1/NN	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	det||response-8/NN||an-5/DT	amod||response-8/NN||uncontrolled-6/JJ	amod||response-8/NN||immune-7/JJ	agent||caused-3/VBN||response-8/NN	prep_to||caused-3/VBN||gluten-10/NN	det||mixture-14/NN||a-12/DT	amod||mixture-14/NN||heterogeneous-13/JJ	appos||gluten-10/NN||mixture-14/NN	nn||proteins-18/NNS||wheat-16/NN	nn||proteins-18/NNS||storage-17/NN	prep_of||mixture-14/NN||proteins-18/NNS	det||±-23/NN||the-21/DT	nn||±-23/NN||î-22/NN	prep_including||caused-3/VBN||±-23/NN	dep||±-23/NN||gliadins-25/NNS	celiacdisease-1||gluten-10||no||celiacdisease is caused by an uncontrolled immune response to gluten, a heterogeneous mixture of wheat storage proteins, including the î±-gliadins.
nsubj||signals-2/VBZ||it-1/PRP	root||ROOT-0/null||signals-2/VBZ	det||spreading-4/NN||the-3/DT	dobj||signals-2/VBZ||spreading-4/NN	amod||resistant-7/JJ||chloroquine-6/JJ	amod||strains-13/NNS||resistant-7/JJ	nn||strains-13/NNS||p.-8/NN	nn||strains-13/NNS||vivax-9/NN	nn||strains-13/NNS||-lrb--10/NNP	nn||strains-13/NNS||crpv-11/NNP	nn||strains-13/NNS||-rrb--12/NN	prep_of||spreading-4/NN||strains-13/NNS	amod||areas-17/NNS||malaria-15/JJ	amod||areas-17/NNS||endemic-16/JJ	prep_to||strains-13/NNS||areas-17/NNS	prep_of||areas-17/NNS||ethiopia-19/NN	malaria-15||chloroquine-6||yes||it signals the spreading of chloroquine resistant p. vivax -lrb- crpv -rrb- strains to malaria endemic areas of ethiopia .
nsubj||quantified-2/VBN||we-1/PRP	root||ROOT-0/null||quantified-2/VBN	det||hbz-4/NN||the-3/DT	dobj||quantified-2/VBN||hbz-4/NN	nn||levels-9/NNS||tax-6/NN	nn||levels-9/NNS||mrna-7/NN	nn||levels-9/NNS||expression-8/NN	dobj||quantified-2/VBN||levels-9/NNS	conj_and||hbz-4/NN||levels-9/NNS	amod||blood-12/NN||peripheral-11/JJ	prep_in||quantified-2/VBN||blood-12/NN	number||/-16/NN||56-14/CD	dep||/-16/NN||htlv-1-associatedmyelopathy-15/JJ	amod||patients-21/NNS||/-16/NN	nn||patients-21/NNS||tropicalspasticparaparesis-17/NN	appos||patients-21/NNS||ham/tsp-19/NN	prep_from||quantified-2/VBN||patients-21/NNS	number||atl-24/CD||10-23/CD	num||patients-25/NNS||atl-24/CD	prep_from||quantified-2/VBN||patients-25/NNS	conj_and||patients-21/NNS||patients-25/NNS	num||carriers-30/NNS||38-27/CD	amod||carriers-30/NNS||healthy-28/JJ	amod||carriers-30/NNS||asymptomatic-29/JJ	prep_from||quantified-2/VBN||carriers-30/NNS	conj_and||patients-21/NNS||carriers-30/NNS	appos||carriers-30/NNS||hcs-32/NN	num||controls-38/NNS||20-35/CD	amod||controls-38/NNS||normal-36/JJ	amod||controls-38/NNS||uninfected-37/JJ	prep_from||quantified-2/VBN||controls-38/NNS	conj_and||patients-21/NNS||controls-38/NNS	amod||lines-46/NNS||human-43/JJ	amod||lines-46/NNS||leukemic-44/JJ	amod||lines-46/NNS||t-cell-45/JJ	prep_from||quantified-2/VBN||lines-46/NNS	conj_and||patients-21/NNS||lines-46/NNS	amod||lines-50/NNS||htlv-1-infected-48/JJ	amod||lines-50/NNS||t-cell-49/JJ	conj_and||patients-21/NNS||lines-50/NNS	conj_and||lines-46/NNS||lines-50/NNS	det||data-54/NNS||the-53/DT	nsubjpass||correlated-56/VBN||data-54/NNS	auxpass||correlated-56/VBN||were-55/VBD	conj_and||quantified-2/VBN||correlated-56/VBN	amod||parameters-59/NNS||clinical-58/JJ	prep_with||correlated-56/VBN||parameters-59/NNS	htlv-1-associatedmyelopathy-15||htlv-1--1||no||we quantified the hbz and tax mrna expression levels in peripheral blood from 56 htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) patients, 10 atl patients, 38 healthy asymptomatic carriers (hcs) and 20 normal uninfected controls, as well as human leukemic t-cell lines and htlv-1-infected t-cell lines, and the data were correlated with clinical parameters.
amod||-lrb--2/NNS||epstein-barrvirus-1/JJ	nsubj||ebv-3/VBP||-lrb--2/NNS	root||ROOT-0/null||ebv-3/VBP	amod||infection-5/NN||-rrb--4/JJ	nsubj||finding-10/NN||infection-5/NN	cop||finding-10/NN||is-6/VBZ	det||finding-10/NN||an-7/DT	advmod||finding-10/NN||almost-8/RB	amod||finding-10/NN||universal-9/JJ	ccomp||ebv-3/VBP||finding-10/NN	prep_among||finding-10/NN||individuals-12/NNS	amod||ebvinfection-16/NN||ms.-14/JJ	amod||ebvinfection-16/NN||symptomatic-15/JJ	prep_with||individuals-12/NNS||ebvinfection-16/NN	mark||shown-26/VBN||as-17/IN	amod||-rrb--23/NNS||manifested-18/JJ	prep_by||manifested-18/JJ||infectiousmononucleosis-20/NNS	amod||-rrb--23/NNS||-lrb--21/JJ	nn||-rrb--23/NNS||im-22/NN	nsubjpass||shown-26/VBN||-rrb--23/NNS	nsubjpass||associated-33/VBN||-rrb--23/NNS	aux||shown-26/VBN||has-24/VBZ	auxpass||shown-26/VBN||been-25/VBN	advcl||finding-10/NN||shown-26/VBN	det||meta-analysis-30/NNS||a-28/DT	amod||meta-analysis-30/NNS||previous-29/JJ	prep_in||shown-26/VBN||meta-analysis-30/NNS	aux||associated-33/VBN||to-31/TO	auxpass||associated-33/VBN||be-32/VB	xcomp||shown-26/VBN||associated-33/VBN	det||risk-36/NN||the-35/DT	prep_with||associated-33/VBN||risk-36/NN	prep_of||risk-36/NN||ms-38/NN	advmod||published-50/VBN||however-40/RB	det||number-42/NN||a-41/DT	nsubjpass||published-50/VBN||number-42/NN	advmod||larger-45/JJR||much-44/RB	amod||studies-46/NNS||larger-45/JJR	prep_of||number-42/NN||studies-46/NNS	aux||published-50/VBN||have-47/VBP	advmod||published-50/VBN||since-48/IN	auxpass||published-50/VBN||been-49/VBN	parataxis||ebv-3/VBP||published-50/VBN	infectiousmononucleosis-20||ebv-3||no||epstein-barrvirus -lrb- ebv -rrb- infection is an almost universal finding among individuals with ms. symptomatic ebvinfection as manifested by infectiousmononucleosis -lrb- im -rrb- has been shown in a previous meta-analysis to be associated with the risk of ms , however a number of much larger studies have since been published .
root||ROOT-0/null||using-1/VBG	dobj||using-1/VBG||publications-2/NNS	det||institute-6/NN||the-4/DT	amod||institute-6/NN||national-5/JJ	prep_from||using-1/VBG||institute-6/NN	nn||diseases-11/NNS||allergy-8/NN	conj_and||allergy-8/NN||infectious-10/JJ	nn||diseases-11/NNS||infectious-10/JJ	prep_of||institute-6/NN||diseases-11/NNS	dep||using-1/VBG||niaid-13/VBN	dep||using-1/VBG||hiv/aids-15/VBZ	amod||trials-18/NNS||extramural-16/JJ	amod||trials-18/NNS||clinical-17/JJ	dobj||hiv/aids-15/VBZ||trials-18/NNS	nsubj||using-1/VBG||networks-19/NNS	appos||networks-19/NNS||we-21/PRP	vmod||we-21/PRP||assessed-22/VBN	det||presence-24/NN||the-23/DT	dobj||assessed-22/VBN||presence-24/NN	dobj||assessed-22/VBN||performance-26/NN	conj_and||presence-24/NN||performance-26/NN	dobj||assessed-22/VBN||impact-29/NN	conj_and||presence-24/NN||impact-29/NN	prep_of||presence-24/NN||papers-31/NNS	vmod||papers-31/NNS||published-32/VBN	amod||$-35/NNS||2006â-34/JJ	prep_in||published-32/VBN||$-35/NNS	dobj||published-32/VBN||2008-37/CD	aids--1||hiv--1||no||using publications from the national institute of allergy and infectious diseases (niaid) hiv/aids extramural clinical trials networks, we assessed the presence, performance, and impact of papers published in 2006â€“2008.
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	cancer-55||adjuvant-47||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
mark||enhance-4/VB||because-1/IN	nsubj||enhance-4/VB||iron-2/NN	aux||enhance-4/VB||can-3/MD	advcl||examined-12/VBD||enhance-4/VB	det||effects-7/NNS||the-5/DT	amod||effects-7/NNS||oxidative-6/JJ	dobj||enhance-4/VB||effects-7/NNS	prep_of||effects-7/NNS||lead-9/NN	nsubj||examined-12/VBD||we-11/PRP	root||ROOT-0/null||examined-12/VBD	mark||-LSB--19/VB||whether-13/IN	nsubj||-LSB--19/VB||polymorphisms-14/NNS	nsubj||transferrin-25/VB||polymorphisms-14/NNS	nsubj||heme-32/VB||polymorphisms-14/NNS	nn||genes-18/NNS||iron-16/NN	nn||genes-18/NNS||metabolism-17/NN	prep_in||polymorphisms-14/NNS||genes-18/NNS	ccomp||examined-12/VBD||-LSB--19/VB	dobj||-LSB--19/VB||hemochromatosis-20/NNS	appos||hemochromatosis-20/NNS||hfe-22/NN	ccomp||examined-12/VBD||transferrin-25/VB	conj_and||-LSB--19/VB||transferrin-25/VB	appos||c2-29/NNS||tf-27/NN	dobj||transferrin-25/VB||c2-29/NNS	ccomp||examined-12/VBD||heme-32/VB	conj_and||-LSB--19/VB||heme-32/VB	amod||susceptibility-39/NN||oxygenase-1-33/JJ	dep||oxygenase-1-33/JJ||hmox-1-35/JJ	amod||susceptibility-39/NN||-RSB--37/JJ	nn||susceptibility-39/NN||increase-38/NN	dobj||heme-32/VB||susceptibility-39/NN	det||effects-42/NNS||the-41/DT	prep_to||heme-32/VB||effects-42/NNS	prep_of||effects-42/NNS||lead-44/NN	nn||interval-47/NN||qt-46/NN	nsubj||community-dwelling-50/VBG||interval-47/NN	prep_in||interval-47/NN||613-49/CD	prepc_on||heme-32/VB||community-dwelling-50/VBG	amod||men-52/NNS||older-51/JJR	dobj||community-dwelling-50/VBG||men-52/NNS	hemochromatosis-20||iron-16||no||because iron can enhance the oxidative effects of lead, we examined whether polymorphisms in iron metabolism genes [hemochromatosis ( hfe ), transferrin ( tf ) c2, and heme oxygenase-1 ( hmox-1 )] increase susceptibility to the effects of lead on qt interval in 613 community-dwelling older men.
det||study-2/NN||this-1/DT	nsubj||kept-31/VBD||study-2/NN	vmod||study-2/NN||aimed-3/VBN	aux||analyze-5/VB||to-4/TO	xcomp||aimed-3/VBN||analyze-5/VB	det||effects-7/NNS||the-6/DT	dobj||analyze-5/VB||effects-7/NNS	prep_of||effects-7/NNS||exercise-9/NN	det||transition-13/NN||the-11/DT	amod||transition-13/NN||aerobic/anaerobic-12/JJ	prep_at||analyze-5/VB||transition-13/NN	det||markers-16/NNS||the-15/DT	prep_on||transition-13/NN||markers-16/NNS	amod||nafld-20/NN||non-alcoholicfattyliverdisease-18/JJ	prep_of||markers-16/NNS||nafld-20/NN	nn||sensitivity-24/NN||insulin-23/NN	prep_of||markers-16/NNS||sensitivity-24/NN	conj_and||nafld-20/NN||sensitivity-24/NN	det||chemistry-28/NN||the-26/DT	nn||chemistry-28/NN||blood-27/NN	prep_of||markers-16/NNS||chemistry-28/NN	conj_and||nafld-20/NN||chemistry-28/NN	prep_of||chemistry-28/NN||rats-30/NNS	root||ROOT-0/null||kept-31/VBD	det||diet-35/NN||a-33/DT	amod||diet-35/NN||fructose-rich-34/JJ	prep_on||kept-31/VBD||diet-35/NN	insulin-23||liverdisease--1||no_rel||this study aimed to analyze the effects of exercise at the aerobic/anaerobic transition on the markers of non-alcoholicfattyliverdisease (nafld), insulin sensitivity and the blood chemistry of rats kept on a fructose-rich diet.
nsubj||resulted-2/VBD||vaccination-1/NN	root||ROOT-0/null||resulted-2/VBD	prepc_in||resulted-2/VBD||neutralizing-4/VBG	nn||titers-6/NNS||antibody-5/NN	dobj||neutralizing-4/VBG||titers-6/NNS	nsubj||cross-neutralized-8/VBN||titers-6/NNS	rcmod||titers-6/NNS||cross-neutralized-8/VBN	det||type-10/NN||both-9/DT	nsubj||genotypes-16/NNS||type-10/NN	nn||genotypes-16/NNS||1-11/CD	conj_and||1-11/CD||type-13/NN	nn||genotypes-16/NNS||type-13/NN	num||genotypes-16/NNS||2-14/CD	nn||genotypes-16/NNS||bvd-15/NN	xcomp||cross-neutralized-8/VBN||genotypes-16/NNS	nn||vaccination-19/NN||booster-18/NN	prep_following||cross-neutralized-8/VBN||vaccination-19/NN	cross--1||antibody-5||no_rel||vaccination resulted in neutralizing antibody titers that cross-neutralized both type 1 and type 2 bvd genotypes following booster vaccination.
nsubjpass||determined-66/VBN||levels-1/NNS	amod||factor-7/NN||angiopoietin-2-3/JJ	nn||factor-7/NN||von-5/NNP	amod||factor-7/NN||willebrand-6/JJ	prep_of||levels-1/NNS||factor-7/NN	appos||factor-7/NN||vwf-9/NN	nn||propeptide-13/NN||vwf-12/NN	appos||levels-1/NNS||propeptide-13/NN	amod||molecule-1-21/NN||soluble-15/JJ	amod||molecule-1-21/NN||p-selectin-16/JJ	amod||molecule-1-21/NN||soluble-18/JJ	nn||molecule-1-21/NN||intercellular-19/NN	nn||molecule-1-21/NN||adhesion-20/NN	appos||levels-1/NNS||molecule-1-21/NN	dep||molecule-1-21/NN||icam-1-23/JJ	amod||kinase-1-32/NN||soluble-26/JJ	amod||kinase-1-32/NN||endoglin-27/JJ	amod||kinase-1-32/NN||soluble-29/JJ	amod||kinase-1-32/NN||fms-like-30/JJ	nn||kinase-1-32/NN||tyrosine-31/NN	appos||molecule-1-21/NN||kinase-1-32/NN	dep||kinase-1-32/NN||flt-1-34/JJ	amod||protein-41/NN||soluble-37/JJ	amod||protein-41/NN||tie-2-38/JJ	amod||protein-41/NN||c-reactive-40/JJ	appos||molecule-1-21/NN||protein-41/NN	appos||protein-41/NN||procalcitonin-43/NN	num||protein-49/NN||10-45/CD	amod||protein-49/NN||kda-46/JJ	amod||protein-49/NN||interferon-47/JJ	amod||protein-49/NN||gamma-induced-48/JJ	appos||molecule-1-21/NN||protein-49/NN	dep||protein-49/NN||ip-10-51/JJ	amod||receptor-57/NN||soluble-55/JJ	amod||receptor-57/NN||triggering-56/VBG	appos||molecule-1-21/NN||receptor-57/NN	conj_and||protein-49/NN||receptor-57/NN	vmod||receptor-57/NN||expressed-58/VBN	amod||cells-1-61/NN||myeloid-60/JJ	prep_on||expressed-58/VBN||cells-1-61/NN	dep||protein-49/NN||trem-1-63/JJ	auxpass||determined-66/VBN||were-65/VBD	root||ROOT-0/null||determined-66/VBN	agent||determined-66/VBN||elisa-68/NN	adhesion-20||vwf-12||no_rel||levels of angiopoietin-2, von willebrand factor (vwf), vwf propeptide, soluble p-selectin, soluble intercellular adhesion molecule-1 (icam-1), soluble endoglin, soluble fms-like tyrosine kinase-1 (flt-1), soluble tie-2, c-reactive protein, procalcitonin, 10 kda interferon gamma-induced protein (ip-10), and soluble triggering receptor expressed on myeloid cells-1 (trem-1) were determined by elisa.
amod||surveys-2/NNS||behavioral-1/JJ	nsubj||help-3/VBP||surveys-2/NNS	root||ROOT-0/null||help-3/VBP	xcomp||help-3/VBP||interpret-4/VB	det||magnitude-6/NN||the-5/DT	dobj||interpret-4/VB||magnitude-6/NN	prep_of||magnitude-6/NN||hiv/aids-8/NNS	aids--1||hiv--1||no||behavioral surveys help interpret the magnitude of hiv/aids.
num||type-3/NN||ten-1/CD	amod||type-3/NN||obese-2/JJ	nsubj||-lrb--11/VBD||type-3/NN	num||patients-6/NNS||2-4/CD	amod||patients-6/NNS||diabetic-5/JJ	nsubjpass||infused-8/VBN||patients-6/NNS	auxpass||infused-8/VBN||were-7/VBD	rcmod||type-3/NN||infused-8/VBN	prep_with||infused-8/VBN||insulin-10/NN	root||ROOT-0/null||-lrb--11/VBD	num||units/h-13/NN||2-12/CD	nsubjpass||infused-34/VBN||units/h-13/NN	nsubjpass||served-51/VBN||units/h-13/NN	num||ml-16/NN||100-15/CD	prep_with||units/h-13/NN||ml-16/NN	number||%-19/NN||5-18/CD	amod||-rrb--21/NNS||%-19/NN	nn||-rrb--21/NNS||dextrose/h-20/NN	prep_of||ml-16/NN||-rrb--21/NNS	number||h.-24/CD||4-23/CD	num||8-26/CD||h.-24/CD	quantmod||8-26/CD||another-25/DT	prep_for||-rrb--21/NNS||8-26/CD	num||type-29/NN||6-28/CD	prep_of||ml-16/NN||type-29/NN	conj_and||-rrb--21/NNS||type-29/NN	num||patients-32/NNS||2-30/CD	amod||patients-32/NNS||diabetic-31/JJ	dep||type-29/NN||patients-32/NNS	auxpass||infused-34/VBN||were-33/VBD	ccomp||-lrb--11/VBD||infused-34/VBN	num||ml-37/NN||100-36/CD	prep_with||infused-34/VBN||ml-37/NN	number||%-40/NN||5-39/CD	amod||dextrose/h-41/NN||%-40/NN	prep_of||ml-37/NN||dextrose/h-41/NN	prep_of||ml-37/NN||saline-43/NN	conj_or||dextrose/h-41/NN||saline-43/NN	num||h-46/NN||4-45/CD	prep_for||ml-37/NN||h-46/NN	advmod||infused-34/VBN||respectively-48/RB	ccomp||-lrb--11/VBD||served-51/VBN	conj_and||infused-34/VBN||served-51/VBN	nn||subjects-54/NNS||control-53/NN	prep_as||served-51/VBN||subjects-54/NNS	dextrose--1||ten-1||no_rel||ten obese type 2 diabetic patients were infused with insulin -lrb- 2 units/h with 100 ml of 5 % dextrose/h -rrb- for 4 h. another 8 and 6 type 2 diabetic patients were infused with 100 ml of 5 % dextrose/h or saline for 4 h , respectively , and served as control subjects .
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	det||diversity-4/NN||the-3/DT	dobj||analyzed-2/VBD||diversity-4/NN	dep||diversity-4/NN||simpsonâ-6/VBN	num||index-10/NN||$-7/$	number||s-9/CD||™-8/CD	num||$-7/$||s-9/CD	dobj||simpsonâ-6/VBN||index-10/NN	appos||index-10/NN||d-12/SYM	dobj||analyzed-2/VBD||distribution-15/NN	conj_and||diversity-4/NN||distribution-15/NN	prep_of||distribution-15/NN||listeriamonocytogenes-17/NNS	amod||cases-21/NNS||human-19/JJ	nn||cases-21/NNS||listeriosis-20/NNS	prep_in||listeriamonocytogenes-17/NNS||cases-21/NNS	amod||state-25/NN||new-23/JJ	nn||state-25/NN||york-24/NN	prep_in||cases-21/NNS||state-25/NN	amod||city-30/NN||new-28/JJ	nn||city-30/NN||york-29/NN	prep_excluding||distribution-15/NN||city-30/NN	prep_from||analyzed-2/VBD||november-33/NNP	num||november-33/NNP||1996-34/CD	prep_to||analyzed-2/VBD||june-36/NNP	num||june-36/NNP||2000-37/CD	prepc_by||analyzed-2/VBD||using-39/VBG	amod||ribotyping-41/NN||automated-40/JJ	dobj||using-39/VBG||ribotyping-41/NN	amod||electrophoresis-45/NNS||pulsed-field-43/JJ	nn||electrophoresis-45/NNS||gel-44/NN	dobj||using-39/VBG||electrophoresis-45/NNS	conj_and||ribotyping-41/NN||electrophoresis-45/NNS	appos||ribotyping-41/NN||pfge-47/NN	listeriosis-20||listeriamonocytogenes-17||no||we analyzed the diversity (simpsonâ€™s index, d) and distribution of listeriamonocytogenes in human listeriosis cases in new york state (excluding new york city) from november 1996 to june 2000 by using automated ribotyping and pulsed-field gel electrophoresis (pfge).
nsubjpass||associated-5/VBN||obesity-1/NN	auxpass||associated-5/VBN||was-2/VBD	advmod||associated-5/VBN||also-3/RB	advmod||associated-5/VBN||significantly-4/RB	root||ROOT-0/null||associated-5/VBN	prep_with||associated-5/VBN||bronchitis-7/NNS	dep||bronchitis-7/NNS||adjusted-9/VBN	nn||ratio-11/NN||odds-10/NNS	nn||1.79-44/NNS||ratio-11/NN	appos||ratio-11/NN||aor-13/NN	number||%-17/NN||95-16/CD	amod||intervals-19/NNS||%-17/NN	nn||intervals-19/NNS||confidence-18/NN	conj_and||ratio-11/NN||intervals-19/NNS	nn||1.79-44/NNS||intervals-19/NNS	num||%-22/NN||95-21/CD	npadvmod||ci-23/JJ||%-22/NN	dep||intervals-19/NNS||ci-23/JJ	dep||intervals-19/NNS||5.29-25/CD	dep||intervals-19/NNS||2.58-27/NNP	dep||2.58-27/NNP||10.85-29/CD	conj_and||ratio-11/NN||with-32/IN	nn||1.79-44/NNS||with-32/IN	det||use-34/NN||the-33/DT	pobj||with-32/IN||use-34/NN	prep_of||use-34/NN||antibiotics-36/NNS	dep||antibiotics-36/NNS||aor-38/NN	num||%-41/NN||95-40/CD	npadvmod||ci-42/JJ||%-41/NN	dep||antibiotics-36/NNS||ci-42/JJ	dobj||adjusted-9/VBN||1.79-44/NNS	dep||1.79-44/NNS||1.09-46/CD	dep||1.09-46/CD||2.93-48/CD	obesity-1||antibiotics-36||no_rel||obesity was also significantly associated with bronchitis (adjusted odds ratio (aor) and 95% confidence intervals (95%ci) 5.29 (2.58;10.85) and with the use of antibiotics (aor (95%ci) 1.79 (1.09;2.93)).
det||phase-4/NN||the-2/DT	amod||phase-4/NN||first-3/JJ	prep_in||conduct-10/VB||phase-4/NN	det||study-7/NN||this-6/DT	prep_of||phase-4/NN||study-7/NN	nsubj||conduct-10/VB||we-8/PRP	aux||conduct-10/VB||will-9/MD	root||ROOT-0/null||conduct-10/VB	amod||interviews-12/NNS||structured-11/JJ	dobj||conduct-10/VB||interviews-12/NNS	aux||determine-14/VB||to-13/TO	vmod||conduct-10/VB||determine-14/VB	poss||preferences-17/NNS||their-15/PRP$	nn||preferences-17/NNS||treatment-16/NN	dobj||determine-14/VB||preferences-17/NNS	prep_for||determine-14/VB||warfarin-19/NN	prep_vs.||warfarin-19/NN||aspirin-21/NN	aux||prevent-23/VB||to-22/TO	vmod||determine-14/VB||prevent-23/VB	dobj||prevent-23/VB||strokes-24/NNS	vmod||strokes-24/NNS||associated-25/VBN	prep_with||associated-25/VBN||atrialfibrillation-27/NN	xcomp||associated-25/VBN||using-28/VBG	det||technique-32/NN||the-29/DT	nn||technique-32/NN||probability-30/NN	nn||technique-32/NN||trade-off-31/NN	dobj||using-28/VBG||technique-32/NN	strokes-24||warfarin-19||yes||in the first phase of this study we will conduct structured interviews to determine their treatment preferences for warfarin vs. aspirin to prevent strokes associated with atrialfibrillation using the probability trade-off technique .
amod||combinations-4/NNS||docetaxel-1/JJ	conj_and||docetaxel-1/JJ||gemcitabine-3/JJ	amod||combinations-4/NNS||gemcitabine-3/JJ	nsubj||proven-6/VBN||combinations-4/NNS	aux||proven-6/VBN||have-5/VBP	root||ROOT-0/null||proven-6/VBN	acomp||proven-6/VBN||active-7/JJ	det||treatment-10/NN||the-9/DT	prep_for||proven-6/VBN||treatment-10/NN	prep_of||treatment-10/NN||non-smallcelllungcancer-12/NN	dep||non-smallcelllungcancer-12/NN||nsclc-14/JJ	gemcitabine-3||nsclc-14||no_rel||docetaxel and gemcitabine combinations have proven active for the treatment of non-smallcelllungcancer (nsclc).
nsubj||cause-9/NN||pneumonia-1/NN	num||%-4/NN||9.8-3/CD	prep_with||pneumonia-1/NN||%-4/NN	cop||cause-9/NN||was-5/VBD	det||cause-9/NN||the-6/DT	amod||cause-9/NN||second-7/JJ	amod||cause-9/NN||leading-8/VBG	root||ROOT-0/null||cause-9/NN	prep_of||cause-9/NN||death-11/NN	prepc_followed_by||cause-9/NN||by-14/IN	pobj||cause-9/NN||hiv/aids-15/NNS	num||%-18/NN||8.3-17/CD	appos||hiv/aids-15/NNS||%-18/NN	amod||diseases-22/NNS||diarrhoeal-21/JJ	pobj||cause-9/NN||diseases-22/NNS	conj_and||hiv/aids-15/NNS||diseases-22/NNS	num||%-25/NN||8-24/CD	prep_with||diseases-22/NNS||%-25/NN	aids--1||hiv--1||no||pneumonia with 9.8% was the second leading cause of death, followed by hiv/aids (8.3%) and diarrhoeal diseases with 8%.
nsubj||therapy-10/NN||bacilluscalmette-guerin-1/NN	appos||bacilluscalmette-guerin-1/NN||bcg-3/NN	cop||therapy-10/NN||is-5/VBZ	det||therapy-10/NN||the-6/DT	advmod||effective-8/JJ||most-7/RBS	amod||therapy-10/NN||effective-8/JJ	nn||therapy-10/NN||adjuvant-9/NN	root||ROOT-0/null||therapy-10/NN	nn||bladdertumor-13/NN||nmi-12/NN	prep_in||therapy-10/NN||bladdertumor-13/NN	bladdertumor-13||bacilluscalmette-guerin-1||yes||bacilluscalmette-guerin (bcg) is the most effective adjuvant therapy in nmi bladdertumor.
nsubj||azole-5/NN||posaconazole-1/NN	cop||azole-5/NN||is-2/VBZ	det||azole-5/NN||the-3/DT	amod||azole-5/NN||only-4/JJ	root||ROOT-0/null||azole-5/NN	prep_with||azole-5/NN||activity-7/NN	prep_against||activity-7/NN||zygomycetes-9/NNS	amod||fungi-13/NNS||other-11/JJ	amod||fungi-13/NNS||difficult-to-treat-12/JJ	prep_against||activity-7/NN||fungi-13/NNS	conj_and||zygomycetes-9/NNS||fungi-13/NNS	vmod||azole-5/NN||representing-15/VBG	det||option-19/NN||a-16/DT	amod||option-19/NN||potential-17/JJ	nn||option-19/NN||treatment-18/NN	dobj||representing-15/VBG||option-19/NN	amod||mycosis-23/NNS||refractory-21/JJ	nn||mycosis-23/NNS||invasive-22/NN	prep_for||representing-15/VBG||mycosis-23/NNS	zygomycetes-9||fungi-13||no||posaconazole is the only azole with activity against zygomycetes and other difficult-to-treat fungi, representing a potential treatment option for refractory invasive mycosis.
det||patients-2/NNS||all-1/DT	nsubjpass||treated-4/VBN||patients-2/NNS	auxpass||treated-4/VBN||were-3/VBD	root||ROOT-0/null||treated-4/VBN	amod||debridement-7/NN||surgical-6/JJ	agent||treated-4/VBN||debridement-7/NN	vmod||debridement-7/NN||followed-8/VBN	det||combination-11/NN||a-10/DT	agent||followed-8/VBN||combination-11/NN	nsubj||died-31/VBD||combination-11/NN	prep_of||combination-11/NN||antibiotics-13/NNS	dep||combination-11/NN||ceftazidime-16/NN	appos||ceftazidime-16/NN||amoxy-clavulanicacid-18/NN	appos||ceftazidime-16/NN||co-trimoxazole-20/NN	conj_and||amoxy-clavulanicacid-18/NN||co-trimoxazole-20/NN	appos||ceftazidime-16/NN||doxycycline-22/NN	conj_and||amoxy-clavulanicacid-18/NN||doxycycline-22/NN	num||months-26/NNS||six-25/CD	prep_for||ceftazidime-16/NN||months-26/NNS	prepc_except_for||months-26/NNS||for-28/IN	pobj||months-26/NNS||one-29/CD	rcmod||combination-11/NN||died-31/VBD	acomp||died-31/VBD||due-32/JJ	aux||fulminant-34/VB||to-33/TO	xcomp||due-32/JJ||fulminant-34/VB	dobj||fulminant-34/VB||septicemia-35/NN	septicemia-35||doxycycline-22||no_rel||all patients were treated by surgical debridement followed by a combination of antibiotics; (ceftazidime, amoxy-clavulanicacid, co-trimoxazole and doxycycline) for six months except for one who died due to fulminant septicemia.
nsubj||experience-3/VBP||individuals-1/NNS	nsubj||benefit-11/VBP||individuals-1/NNS	rcmod||individuals-1/NNS||experience-3/VBP	dobj||experience-3/VBP||flares-4/NNS	nn||while-7/NN||pain-6/NN	prep_of||flares-4/NNS||while-7/NN	amod||opioids-10/NNS||spinal-9/JJ	prep_on||while-7/NN||opioids-10/NNS	root||ROOT-0/null||benefit-11/VBP	amod||boluses-14/NNS||intrathecal-13/JJ	prep_from||benefit-11/VBP||boluses-14/NNS	amod||ketamine-19/NN||levobupivicaine-16/JJ	conj_or||levobupivicaine-16/JJ||sublingual-18/JJ	amod||ketamine-19/NN||sublingual-18/JJ	prep_of||boluses-14/NNS||ketamine-19/NN	pain-6||ketamine-19||yes||individuals who experience flares of pain while on spinal opioids benefit from intrathecal boluses of levobupivicaine or sublingual ketamine.
det||manuscript-2/NN||this-1/DT	nsubj||reviews-3/VBZ||manuscript-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||benefits-5/NNS||the-4/DT	dobj||reviews-3/VBZ||benefits-5/NNS	amod||control-9/NN||intensive-7/JJ	amod||control-9/NN||glycemic-8/JJ	prep_of||benefits-5/NNS||control-9/NN	amod||goals-14/NNS||type2diabetes-11/JJ	prep_in||control-9/NN||therapeutic-13/JJ	amod||goals-14/NNS||therapeutic-13/JJ	conj_and||goals-14/NNS||therapeutic-13/JJ	prep_in||control-9/NN||goals-14/NNS	prep_in||control-9/NN||guidelines-16/NNS	conj_and||goals-14/NNS||guidelines-16/NNS	dobj||reviews-3/VBZ||advances-18/NNS	conj_and||benefits-5/NNS||advances-18/NNS	nn||therapy-21/NN||insulin-20/NN	prep_in||advances-18/NNS||therapy-21/NN	dobj||reviews-3/VBZ||contribution-24/NN	conj_and||benefits-5/NNS||contribution-24/NN	prep_of||contribution-24/NN||nurses-26/NNS	prepc_in||reviews-3/VBZ||overcoming-28/VBG	dobj||overcoming-28/VBG||barriers-29/NNS	nn||initiation-32/NN||insulin-31/NN	prep_to||overcoming-28/VBG||initiation-32/NN	amod||aspects-35/NNS||related-34/VBN	prep_to||overcoming-28/VBG||aspects-35/NNS	conj_and||initiation-32/NN||aspects-35/NNS	nn||care-38/NN||diabetes-37/NN	prep_of||initiation-32/NN||care-38/NN	type2diabetes-11||insulin-31||yes||this manuscript reviews the benefits of intensive glycemic control in type2diabetes, therapeutic goals and guidelines, advances in insulin therapy, and contribution of nurses in overcoming barriers to insulin initiation and related aspects of diabetes care.
amod||seroprevalence-2/NN||overall-1/JJ	nsubjpass||found-29/VBN||seroprevalence-2/NN	nsubj||%-33/NN||seroprevalence-2/NN	vmod||seroprevalence-2/NN||evaluated-3/VBN	agent||evaluated-3/VBN||immunofluorescence-5/NN	vmod||immunofluorescence-5/NN||using-6/VBG	num||antigens-9/NNS||six-7/CD	amod||antigens-9/NNS||rickettsial-8/JJ	dobj||using-6/VBG||antigens-9/NNS	nn||group-14/NN||spottedfever-11/NN	conj_and||spottedfever-11/NN||typhus-13/NN	nn||group-14/NN||typhus-13/NN	appos||antigens-9/NNS||group-14/NN	amod||populations-18/NNS||rural-17/JJ	prep_in||antigens-9/NNS||populations-18/NNS	num||villages-21/NNS||two-20/CD	prep_of||populations-18/NNS||villages-21/NNS	det||region-25/NN||the-23/DT	amod||region-25/NN||sine-saloum-24/JJ	prep_of||villages-21/NNS||region-25/NN	prep_of||region-25/NN||senegal-27/NN	auxpass||found-29/VBN||was-28/VBD	root||ROOT-0/null||found-29/VBN	aux||%-33/NN||to-30/TO	cop||%-33/NN||be-31/VB	num||%-33/NN||21.4-32/CD	xcomp||found-29/VBN||%-33/NN	num||%-36/NN||51-35/CD	xcomp||found-29/VBN||%-36/NN	conj_and||%-33/NN||%-36/NN	nn||rickettsiae-40/NN||spottedfever-38/NN	nn||rickettsiae-40/NN||group-39/NN	prep_for||%-33/NN||rickettsiae-40/NN	nn||villages-45/NNS||dielmo-42/NN	conj_and||dielmo-42/NN||ndiop-44/NN	nn||villages-45/NNS||ndiop-44/NN	prep_for||rickettsiae-40/NN||villages-45/NNS	advmod||%-33/NN||respectively-47/RB	typhus-13||rickettsiae-40||no||overall seroprevalence evaluated by immunofluorescence using six rickettsial antigens (spottedfever and typhus group) in rural populations of two villages of the sine-saloum region of senegal was found to be 21.4% and 51% for spottedfever group rickettsiae for dielmo and ndiop villages, respectively.
nsubj||intracellular-5/NN||francisellatularensis-1/NNS	cop||intracellular-5/NN||is-2/VBZ	det||intracellular-5/NN||a-3/DT	amod||intracellular-5/NN||facultative-4/JJ	root||ROOT-0/null||intracellular-5/NN	amod||pathogen-7/NN||bacterial-6/JJ	dep||intracellular-5/NN||pathogen-7/NN	det||agent-11/NN||the-9/DT	amod||agent-11/NN||etiological-10/JJ	conj_and||intracellular-5/NN||agent-11/NN	prep_of||agent-11/NN||tularemia-13/NN	tularemia-13||francisellatularensis-1||no||francisellatularensis is a facultative intracellular bacterial pathogen and the etiological agent of tularemia.
nn||spirochetes-2/NNS||lymedisease-1/NN	nsubj||exhibited-5/VBD||spirochetes-2/NNS	conj_and||spirochetes-2/NNS||borrelia-4/NN	nsubj||exhibited-5/VBD||borrelia-4/NN	root||ROOT-0/null||exhibited-5/VBD	amod||homology-10/NN||little-6/JJ	conj_or||little-6/JJ||no-8/DT	amod||homology-10/NN||no-8/DT	nn||homology-10/NN||dna-9/NN	dobj||exhibited-5/VBD||homology-10/NN	num||percent-13/NN||0-2-12/CD	appos||homology-10/NN||percent-13/NN	det||treponema-17/NN||the-16/DT	prep_with||exhibited-5/VBD||treponema-17/NN	prep_with||exhibited-5/VBD||leptospira-19/NN	conj_or||treponema-17/NN||leptospira-19/NN	lymedisease-1||borrelia-4||no||lymedisease spirochetes and borrelia exhibited little or no dna homology (0-2 percent) with the treponema or leptospira.
amod||phosphorylation-3/NN||hypoxia-1/JJ	amod||phosphorylation-3/NN||enhanced-2/JJ	nsubj||src-6/VBP||phosphorylation-3/NN	prep_of||phosphorylation-3/NN||three-5/CD	root||ROOT-0/null||src-6/VBP	nn||proteins-8/NNS||fk-7/NN	dobj||src-6/VBP||proteins-8/NNS	prep_at||src-6/VBP||tyr-416-10/JJ	dep||tyr-416-10/JJ||60-12/CD	num||60-12/CD||59-14/CD	dep||tyr-416-10/JJ||54-17/CD	conj_and||60-12/CD||54-17/CD	dep||60-12/CD||kda-18/NN	dep||tyr-416-10/JJ||corresponding-20/JJ	conj_and||60-12/CD||corresponding-20/JJ	prep_to||corresponding-20/JJ||src-22/NN	dep||tyr-416-10/JJ||fyn-24/NN	conj_and||60-12/CD||fyn-24/NN	dep||tyr-416-10/JJ||yes-27/RB	conj_and||60-12/CD||yes-27/RB	advmod||yes-27/RB||respectively-29/RB	amod||phosphorylation-36/NN||enhanced-32/VBN	nn||phosphorylation-36/NN||src-33/NN	nn||phosphorylation-36/NN||fk-dependent-34/NN	nn||phosphorylation-36/NN||tyrosine-35/NN	prep_at||src-6/VBP||phosphorylation-36/NN	conj_and||tyr-416-10/JJ||phosphorylation-36/NN	amod||proteins-40/NNS||multiple-38/JJ	nn||proteins-40/NNS||target-39/NN	prep_of||phosphorylation-36/NN||proteins-40/NNS	tyrosine-35||hypoxia-1||no_rel||hypoxia enhanced phosphorylation of three src fk proteins at tyr-416 (60, 59, and 54 kda, corresponding to src , fyn , and yes , respectively) and enhanced src fk-dependent tyrosine phosphorylation of multiple target proteins.
quantmod||two-thirds-3/NNS||fewer-1/JJR	quantmod||two-thirds-3/NNS||than-2/IN	nsubj||knew-4/VBD||two-thirds-3/NNS	root||ROOT-0/null||knew-4/VBD	mark||develop-27/VB||that-5/IN	quantmod||10-7/CD||about-6/RB	num||%-8/NN||10-7/CD	nsubj||develop-27/VB||%-8/NN	prep_of||%-8/NN||people-10/NNS	det||u.s.a.-13/NN||the-12/DT	prep_in||people-10/NNS||u.s.a.-13/NN	nsubj||have-15/VBP||u.s.a.-13/NN	rcmod||u.s.a.-13/NN||have-15/VBP	nn||-rrb--20/NNP||latent-16/NN	nn||-rrb--20/NNP||tuberculosisinfection-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||ltbi-19/NNP	dobj||have-15/VBP||-rrb--20/NNP	det||system-25/NN||a-22/DT	amod||system-25/NN||normal-23/JJ	amod||system-25/NN||immune-24/JJ	dobj||have-15/VBP||system-25/NN	conj_and||-rrb--20/NNP||system-25/NN	aux||develop-27/VB||will-26/MD	ccomp||knew-4/VBD||develop-27/VB	nn||disease-29/NN||tb-28/NN	dobj||develop-27/VB||disease-29/NN	mark||part-36/NN||that-32/IN	nsubj||part-36/NN||bcg-33/NN	cop||part-36/NN||is-34/VBZ	neg||part-36/NN||not-35/RB	ccomp||knew-4/VBD||part-36/NN	conj_or||develop-27/VB||part-36/NN	det||program-41/NN||the-38/DT	amod||program-41/NN||routine-39/JJ	nn||program-41/NN||vaccination-40/NN	prep_of||part-36/NN||program-41/NN	det||u.s.a.-44/NN||the-43/DT	prep_in||program-41/NN||u.s.a.-44/NN	mark||complicates-47/VBZ||because-45/IN	nsubj||complicates-47/VBZ||it-46/PRP	advcl||part-36/NN||complicates-47/VBZ	dobj||complicates-47/VBZ||surveillance-48/NN	amod||infection-52/NN||new-50/JJ	nn||infection-52/NN||tb-51/NN	prep_for||surveillance-48/NN||infection-52/NN	tb-51||bcg-33||no||fewer than two-thirds knew that about 10 % of people in the u.s.a. who have latent tuberculosisinfection -lrb- ltbi -rrb- and a normal immune system will develop tb disease , or that bcg is not part of the routine vaccination program in the u.s.a. because it complicates surveillance for new tb infection .
vmod||produced-10/VBD||resultsâ-1/VBG	dobj||resultsâ-1/VBG||$-2/$	prep_with||resultsâ-1/VBG||hyperinsulinemia-5/FW	prep_with||resultsâ-1/VBG||hyperglycemia-7/FW	conj_and||hyperinsulinemia-5/FW||hyperglycemia-7/FW	nsubj||produced-10/VBD||exenatide-9/NN	root||ROOT-0/null||produced-10/VBD	det||increase-13/NN||a-11/DT	amod||increase-13/NN||significant-12/JJ	dobj||produced-10/VBD||increase-13/NN	amod||turnover-17/NN||total-15/JJ	nn||turnover-17/NN||glucose-16/NN	prep_in||produced-10/VBD||turnover-17/NN	quantmod||30-21/CD||âˆ-19/RB	number||30-21/CD||1/4-20/CD	num||%-22/NN||30-21/CD	prep_by||produced-10/VBD||%-22/NN	mark||indicated-25/VBD||as-24/IN	advcl||produced-10/VBD||indicated-25/VBD	amod||infusion-29/NN||portal-27/JJ	nn||infusion-29/NN||glucose-28/NN	prep_by||indicated-25/VBD||infusion-29/NN	dobj||indicated-25/VBD||rate-30/NN	nn||rate-30/NN||-lrb--31/FW	nn||rate-30/NN||saline-32/FW	nn||rate-30/NN||15.9-33/FW	nn||rate-30/NN||â-34/FW	nn||rate-30/NN||±-35/FW	nn||rate-30/NN||1.6-36/FW	nn||rate-30/NN||vs.-37/FW	nn||rate-30/NN||exenatide-38/FW	nn||rate-30/NN||20.4-39/FW	nn||rate-30/NN||â-40/FW	nn||rate-30/NN||±-41/FW	nn||rate-30/NN||2.1-42/FW	nn||rate-30/NN||mg-43/FW	nn||rate-30/NN||â-44/FW	nn||rate-30/NN||·-45/FW	nn||rate-30/NN||kgâˆ-46/FW	nn||rate-30/NN||1-48/FW	nn||rate-30/NN||â-49/FW	nn||rate-30/NN||·-50/FW	dep||rate-30/NN||minâˆ-51/FW	nsubj||âˆ-70/VBP||1-53/CD	nsubj||increased-76/VBD||1-53/CD	vmod||1-53/CD||p-55/VBN	dep||-rrb--58/NNS||<-56/SYM	num||-rrb--58/NNS||0.001-57/CD	ccomp||p-55/VBN||-rrb--58/NNS	xcomp||p-55/VBN||resulting-60/VBG	amod||d-68/NNP||increased-62/VBN	amod||d-68/NNP||whole-body-63/JJ	nn||d-68/NNP||glucose-64/NN	nn||d-68/NNP||disposal-65/NN	nn||d-68/NNP||-lrb--66/NN	nn||d-68/NNP||r-67/NNP	prep_from||resulting-60/VBG||d-68/NNP	rcmod||rate-30/NN||âˆ-70/VBP	number||20-72/CD||1/4-71/CD	num||%-73/NN||20-72/CD	nsubj||-rrb--74/NN||%-73/NN	xcomp||âˆ-70/VBP||-rrb--74/NN	rcmod||rate-30/NN||increased-76/VBD	conj_and||âˆ-70/VBP||increased-76/VBD	amod||uptake-79/NN||net-77/JJ	amod||uptake-79/NN||hepatic-78/JJ	nsubj||-rrb--88/NN||uptake-79/NN	nn||âˆ-84/FW||exogenous-81/FW	nn||âˆ-84/FW||glucose-82/FW	nn||âˆ-84/FW||-lrb--83/FW	prep_of||uptake-79/NN||âˆ-84/FW	number||%-87/NN||1/4-85/CD	number||%-87/NN||80-86/CD	amod||âˆ-84/FW||%-87/NN	xcomp||increased-76/VBD||-rrb--88/NN	hyperglycemia-7||glucose-82||no||resultsâ $ '' with hyperinsulinemia and hyperglycemia , exenatide produced a significant increase in total glucose turnover by âˆ 1/4 30 % , as indicated by portal glucose infusion rate -lrb- saline 15.9 â ± 1.6 vs. exenatide 20.4 â ± 2.1 mg â · kgâˆ ' 1 â · minâˆ ' 1 , p < 0.001 -rrb- , resulting from increased whole-body glucose disposal -lrb- r d , âˆ 1/4 20 % -rrb- and increased net hepatic uptake of exogenous glucose -lrb- âˆ 1/4 80 % -rrb- .
nn||profiling-2/NN||antibody-1/NN	nsubjpass||carried-4/VBN||profiling-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prep_with||carried-4/VBN||serum-6/NN	num||individuals-9/NNS||34-8/CD	prep_from||carried-4/VBN||individuals-9/NNS	amod||pulmonarytb-12/NN||active-11/JJ	prep_with||individuals-9/NNS||pulmonarytb-12/NN	num||individuals-16/NNS||35-14/CD	amod||individuals-16/NNS||healthy-15/JJ	prep_with||individuals-9/NNS||individuals-16/NNS	conj_and||pulmonarytb-12/NN||individuals-16/NNS	mark||obtain-20/VB||in-17/IN	dep||obtain-20/VB||order-18/NN	aux||obtain-20/VB||to-19/TO	advcl||carried-4/VBN||obtain-20/VB	det||view-23/NN||an-21/DT	amod||view-23/NN||unbiased-22/JJ	dobj||obtain-20/VB||view-23/NN	det||pattern-30/NN||the-25/DT	nn||pattern-30/NN||mtb-26/NN	nn||pattern-30/NN||epitope-27/NN	nn||pattern-30/NN||pattern-28/NN	nn||pattern-30/NN||recognition-29/NN	prep_of||view-23/NN||pattern-30/NN	pulmonarytb-12||mtb-26||no||antibody profiling was carried with serum from 34 individuals with active pulmonarytb and 35 healthy individuals in order to obtain an unbiased view of the mtb epitope pattern recognition pattern.
amod||evidence-2/NN||current-1/JJ	nsubj||suggests-3/VBZ||evidence-2/NN	root||ROOT-0/null||suggests-3/VBZ	det||role-6/NN||an-4/DT	amod||role-6/NN||analgesic-5/JJ	dobj||suggests-3/VBZ||role-6/NN	det||action-11/NN||the-8/DT	amod||action-11/NN||spinal-9/JJ	nn||action-11/NN||cord-10/NN	prep_for||role-6/NN||action-11/NN	amod||anesthetics-14/NNS||general-13/JJ	prep_of||action-11/NN||anesthetics-14/NNS	advmod||remain-31/VBP||however-16/RB	det||population-20/NN||the-18/DT	amod||population-20/NN||cellular-19/JJ	nsubj||remain-31/VBP||population-20/NN	nn||mechanisms-23/NNS||intracellular-22/NN	conj_and||population-20/NN||mechanisms-23/NNS	nsubj||remain-31/VBP||mechanisms-23/NNS	vmod||population-20/NN||underlying-24/VBG	amod||pain-26/NN||anti-visceral-25/JJ	dobj||underlying-24/VBG||pain-26/NN	amod||anesthetics-29/NNS||general-28/JJ	agent||underlying-24/VBG||anesthetics-29/NNS	advmod||remain-31/VBP||still-30/RB	parataxis||suggests-3/VBZ||remain-31/VBP	acomp||remain-31/VBP||unclear-32/JJ	pain-26||analgesic-5||no_rel||current evidence suggests an analgesic role for the spinal cord action of general anesthetics; however, the cellular population and intracellular mechanisms underlying anti-visceral pain by general anesthetics still remain unclear.
det||objective-2/NN||the-1/DT	nsubj||was-7/VBD||objective-2/NN	nsubj||compare-9/VB||objective-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||objective-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||compare-9/VB||to-8/TO	xcomp||was-7/VBD||compare-9/VB	amod||dilation-11/NN||endothelium-dependent-10/JJ	dobj||compare-9/VB||dilation-11/NN	prep_in||dilation-11/NN||patients-13/NNS	amod||type2diabetes-16/NNS||well-controlled-15/JJ	prep_with||compare-9/VB||type2diabetes-16/NNS	nsubj||are-18/VBP||type2diabetes-16/NNS	nsubj||using-22/VBG||type2diabetes-16/NNS	rcmod||type2diabetes-16/NNS||are-18/VBP	aux||using-22/VBG||are-20/VBP	neg||using-22/VBG||not-21/RB	rcmod||type2diabetes-16/NNS||using-22/VBG	conj_or||are-18/VBP||using-22/VBG	dobj||using-22/VBG||insulin-23/NN	prep_as||using-22/VBG||part-25/NN	poss||therapy-28/NN||their-27/PRP$	prep_of||part-25/NN||therapy-28/NN	type2diabetes-16||insulin-23||yes||the objective of the present study was to compare endothelium-dependent dilation in patients with well-controlled type2diabetes who are or are not using insulin as part of their therapy.
nsubj||hypothesized-2/VBN||we-1/PRP	root||ROOT-0/null||hypothesized-2/VBN	mark||protect-7/VB||that-3/IN	amod||consumption-5/NN||fishoil-4/JJ	nsubj||protect-7/VB||consumption-5/NN	aux||protect-7/VB||may-6/MD	ccomp||hypothesized-2/VBN||protect-7/VB	amod||vasculardisease-10/NN||atherosclerotic-9/JJ	prep_against||protect-7/VB||vasculardisease-10/NN	fishoil-4||vasculardisease-10||no_rel||we hypothesized that fishoil consumption may protect against atherosclerotic vasculardisease.
num||viruses-2/NNS||two-1/CD	nsubj||lethal-6/JJ||viruses-2/NNS	prep_with||viruses-2/NNS||g222-4/CD	cop||lethal-6/JJ||were-5/VBD	root||ROOT-0/null||lethal-6/JJ	mark||caused-15/VBD||while-7/IN	det||virus-10/NN||a-8/DT	amod||virus-10/NN||third-9/JJ	nsubj||caused-15/VBD||virus-10/NN	prep_with||virus-10/NN||g222-13/CD	advcl||lethal-6/JJ||caused-15/VBD	advmod||illness-18/NN||only-16/RB	amod||illness-18/NN||mild-17/JJ	dobj||caused-15/VBD||illness-18/NN	prep_in||caused-15/VBD||mice-20/NNS	amod||mice-20/NNS||similar-21/JJ	det||virus-25/NN||the-23/DT	amod||virus-25/NN||fourth-24/JJ	prep_to||similar-21/JJ||virus-25/NN	nsubj||contained-27/VBD||virus-25/NN	rcmod||virus-25/NN||contained-27/VBD	dobj||contained-27/VBD||d222-28/NNS	virus-25||viruses-2||no||two viruses with g222 were lethal while a third virus, with g222, caused only mild illness in mice similar to the fourth virus that contained d222.
advmod||found-12/VBN||moreover-1/RB	amod||neutralization-4/NN||antibody-mediated-3/JJ	nsubjpass||found-12/VBN||neutralization-4/NN	nsubj||increase-15/VB||neutralization-4/NN	det||chemokines-8/NNS||these-6/DT	nn||chemokines-8/NNS||cxc-7/NN	prep_of||neutralization-4/NN||chemokines-8/NNS	prep_in||chemokines-8/NNS||vivo-10/NN	auxpass||found-12/VBN||was-11/VBD	root||ROOT-0/null||found-12/VBN	aux||increase-15/VB||to-13/TO	advmod||increase-15/VB||significantly-14/RB	xcomp||found-12/VBN||increase-15/VB	nn||susceptibility-17/NN||host-16/NN	dobj||increase-15/VB||susceptibility-17/NN	amod||infection-21/NN||pulmonary-19/JJ	nn||infection-21/NN||b.anthracis-20/NNS	prep_to||increase-15/VB||infection-21/NN	det||model-25/NN||a-23/DT	amod||model-25/NN||murine-24/JJ	prep_in||infection-21/NN||model-25/NN	prep_of||model-25/NN||inhalationalanthrax-27/NN	nn||progression-30/NN||disease-29/NN	prep_with||increase-15/VB||progression-30/NN	vmod||progression-30/NN||characterized-31/VBN	amod||dissemination-35/NN||systemic-33/JJ	amod||dissemination-35/NN||bacterial-34/JJ	agent||characterized-31/VBN||dissemination-35/NN	agent||characterized-31/VBN||toxemia-37/NN	conj_and||dissemination-35/NN||toxemia-37/NN	nn||death-41/NN||host-40/NN	agent||characterized-31/VBN||death-41/NN	conj_and||dissemination-35/NN||death-41/NN	inhalationalanthrax-27||b.anthracis-20||no||moreover , antibody-mediated neutralization of these cxc chemokines in vivo was found to significantly increase host susceptibility to pulmonary b.anthracis infection in a murine model of inhalationalanthrax with disease progression characterized by systemic bacterial dissemination , toxemia , and host death .
nsubj||activate-5/VBP||thiazolidinediones-1/NNS	nsubj||used-16/JJ||thiazolidinediones-1/NNS	nsubj||help-19/VB||thiazolidinediones-1/NNS	appos||thiazolidinediones-1/NNS||tzds-3/NNS	root||ROOT-0/null||activate-5/VBP	amod||gamma-9/NN||peroxisome-6/JJ	amod||gamma-9/NN||proliferator-activated-7/JJ	nn||gamma-9/NN||receptor-8/NN	dobj||activate-5/VBP||gamma-9/NN	nn||³-12/NNP||pparî-11/NNP	appos||gamma-9/NN||³-12/NNP	cop||used-16/JJ||are-15/VBP	conj_and||activate-5/VBP||used-16/JJ	advmod||used-16/JJ||clinically-17/RB	aux||help-19/VB||to-18/TO	xcomp||used-16/JJ||help-19/VB	xcomp||help-19/VB||restore-20/VB	amod||sensitivity-23/NN||peripheral-21/JJ	nn||sensitivity-23/NN||insulin-22/NN	dobj||restore-20/VB||sensitivity-23/NN	prep_in||sensitivity-23/NN||type2diabetes-25/NNS	appos||type2diabetes-25/NNS||t2dm-27/NNP	type2diabetes-25||insulin-22||yes||thiazolidinediones (tzds) activate peroxisome proliferator-activated receptor gamma (pparî³) and are used clinically to help restore peripheral insulin sensitivity in type2diabetes (t2dm).
det||review-3/NN||this-2/DT	prep_in||explore-6/VB||review-3/NN	nsubj||explore-6/VB||we-5/PRP	root||ROOT-0/null||explore-6/VB	det||link-11/NN||a-7/DT	advmod||unrecognised-9/JJ||previously-8/RB	amod||link-11/NN||unrecognised-9/JJ	amod||link-11/NN||genetic-10/JJ	dobj||explore-6/VB||link-11/NN	prep_between||link-11/NN||ts-13/NN	det||series-17/NN||a-15/DT	amod||series-17/NN||competing-16/VBG	dobj||explore-6/VB||series-17/NN	conj_and||link-11/NN||series-17/NN	nsubj||links-56/VBZ||series-17/NN	amod||complexes-20/NNS||trans-synaptic-19/JJ	prep_of||series-17/NN||complexes-20/NNS	dep||series-17/NN||neurexins-22/NNS	appos||neurexins-22/NNS||nrxns-24/NNS	appos||neurexins-22/NNS||neuroligins-27/NNS	appos||neuroligins-27/NNS||nlgns-29/NNS	amod||proteins-35/NNS||leucine-rich-32/JJ	nn||proteins-35/NNS||repeat-33/NN	nn||proteins-35/NNS||transmembrane-34/NN	appos||neurexins-22/NNS||proteins-35/NNS	dep||proteins-35/NNS||lrrtms-37/VBZ	amod||neuronals-43/NNS||leucine-40/JJ	amod||neuronals-43/NNS||rich-41/JJ	nn||neuronals-43/NNS||repeat-42/NN	appos||neurexins-22/NNS||neuronals-43/NNS	appos||neuronals-43/NNS||lrrns-45/NNS	nn||precursor-49/NN||cerebellin-48/NN	dep||series-17/NN||precursor-49/NN	conj_and||neurexins-22/NNS||precursor-49/NN	dep||precursor-49/NN||2-50/CD	appos||2-50/CD||cbln2-52/NNP	rcmod||series-17/NN||links-56/VBZ	dobj||links-56/VBZ||it-57/PRP	nn||disorder-61/NN||autism-59/NN	nn||disorder-61/NN||spectrum-60/NN	prep_with||links-56/VBZ||disorder-61/NN	amod||pathways-64/NNS||neurodevelopmental-63/JJ	prep_through||disorder-61/NN||pathways-64/NNS	leucine-40||autism-59||no_rel||in this review, we explore a previously unrecognised genetic link between ts and a competing series of trans-synaptic complexes (neurexins (nrxns), neuroligins (nlgns), leucine-rich repeat transmembrane proteins (lrrtms), leucine rich repeat neuronals (lrrns) and cerebellin precursor 2 (cbln2)) that links it with autism spectrum disorder through neurodevelopmental pathways.
amod||enzyme-2/NN||insulin-degrading-1/JJ	nsubj||peptidase-10/NN||enzyme-2/NN	appos||enzyme-2/NN||ide-4/NN	cop||peptidase-10/NN||is-6/VBZ	det||peptidase-10/NN||a-7/DT	amod||sensitive-9/JJ||thiol-8/JJ	amod||peptidase-10/NN||sensitive-9/JJ	root||ROOT-0/null||peptidase-10/NN	nsubj||degrades-12/VBZ||peptidase-10/NN	nsubjpass||linked-22/VBN||peptidase-10/NN	rcmod||peptidase-10/NN||degrades-12/VBZ	nn||²-17/NNS||insulin-13/NN	conj_and||insulin-13/NN||amyloid-15/JJ	nn||²-17/NNS||amyloid-15/JJ	nn||²-17/NNS||î-16/NN	dobj||degrades-12/VBZ||²-17/NNS	aux||linked-22/VBN||has-20/VBZ	auxpass||linked-22/VBN||been-21/VBN	rcmod||peptidase-10/NN||linked-22/VBN	conj_and||degrades-12/VBZ||linked-22/VBN	nn||sdisease-28/NN||type2diabetesmellitus-24/NN	conj_and||type2diabetesmellitus-24/NN||alzheimer-26/NN	nn||sdisease-28/NN||alzheimer-26/NN	prep_to||linked-22/VBN||sdisease-28/NN	type2diabetesmellitus-24||insulin-13||yes||insulin-degrading enzyme (ide) is a thiol sensitive peptidase that degrades insulin and amyloid î², and has been linked to type2diabetesmellitus and alzheimer'sdisease.
prep_in||changed-11/VBN||2002-2/CD	det||treatment-6/NN||the-4/DT	amod||treatment-6/NN||first-line-5/JJ	nsubjpass||changed-11/VBN||treatment-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||treatment-6/NN||malaria-9/NN	auxpass||changed-11/VBN||was-10/VBD	root||ROOT-0/null||changed-11/VBN	prep_to||changed-11/VBN||artemether-lumefantrine-13/NN	nsubj||proved-19/VBN||artemether-lumefantrine-13/NN	nsubj||efficacious-23/JJ||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	aux||proved-19/VBN||has-18/VBZ	rcmod||artemether-lumefantrine-13/NN||proved-19/VBN	aux||efficacious-23/JJ||to-20/TO	cop||efficacious-23/JJ||be-21/VB	advmod||efficacious-23/JJ||highly-22/RB	xcomp||proved-19/VBN||efficacious-23/JJ	prepc_against||efficacious-23/JJ||multidrug-25/VBG	amod||falciparum-28/NN||resistant-26/JJ	nn||falciparum-28/NN||plasmodium-27/NN	dobj||multidrug-25/VBG||falciparum-28/NN	malaria-9||artemether--1||yes||in 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (al) that has proved to be highly efficacious against multidrug resistant plasmodium falciparum .
nn||supplementation-2/NN||oxygen-1/NN	nsubjpass||given-5/VBN||supplementation-2/NN	auxpass||given-5/VBN||is-3/VBZ	advmod||given-5/VBN||commonly-4/RB	root||ROOT-0/null||given-5/VBN	det||patients-8/NNS||the-7/DT	prep_to||given-5/VBN||patients-8/NNS	amod||pneumonia-11/NN||severe-10/JJ	prep_with||given-5/VBN||pneumonia-11/NN	nn||disease-14/NN||legionella-13/NN	prep_including||pneumonia-11/NN||disease-14/NN	pneumonia-11||oxygen-1||yes||oxygen supplementation is commonly given to the patients with severe pneumonia including legionella disease.
amod||gene-deficient-2/NN||il-10-1/JJ	nn||mice-9/NNS||gene-deficient-2/NN	dep||mice-9/NNS||il10-4/JJ	punct||il10-4/JJ||/-6/:	nsubj||develop-10/VBP||mice-9/NNS	nsubjpass||used-36/VBN||mice-9/NNS	root||ROOT-0/null||develop-10/VBP	amod||colitis-12/NNS||cd-like-11/JJ	dobj||develop-10/VBP||colitis-12/NNS	advmod||develop-10/VBP||mainly-13/RB	det||colon-16/NN||the-15/DT	prep_in||develop-10/VBP||colon-16/NN	prep_in||develop-10/VBP||part-19/NN	amod||responses-23/NNS||inappropriate-22/JJ	prep_due_to||part-19/NN||responses-23/NNS	amod||bacteria-27/NNS||normal-25/JJ	amod||bacteria-27/NNS||intestinal-26/JJ	prep_to||responses-23/NNS||bacteria-27/NNS	amod||strains-30/NNS||enterococcus-29/JJ	prep_including||bacteria-27/NNS||strains-30/NNS	aux||used-36/VBN||have-33/VBP	advmod||used-36/VBN||therefore-34/RB	auxpass||used-36/VBN||been-35/VBN	conj_and||develop-10/VBP||used-36/VBN	det||model-40/NN||an-38/DT	nn||model-40/NN||animal-39/NN	prep_as||used-36/VBN||model-40/NN	prep_of||model-40/NN||cd-42/NN	colitis-12||cd-42||no_rel||il-10 gene-deficient ( il10 -/- ) mice develop cd-like colitis mainly in the colon, in part due to inappropriate responses to normal intestinal bacteria including enterococcus strains, and have therefore been used as an animal model of cd.
amod||patients-3/NNS||chronic-1/JJ	nn||patients-3/NNS||hbv-2/NN	nsubjpass||treated-5/VBN||patients-3/NNS	nsubjpass||examined-9/VBN||patients-3/NNS	auxpass||treated-5/VBN||were-4/VBD	root||ROOT-0/null||treated-5/VBN	prep_with||treated-5/VBN||adefovirdipivoxil-7/NN	conj_and||treated-5/VBN||examined-9/VBN	nn||loads-14/NNS||serum-11/NN	nn||loads-14/NNS||hbv-12/NN	nn||loads-14/NNS||dna-13/NN	prep_for||examined-9/VBN||loads-14/NNS	appos||loads-14/NNS||cytokines-16/NNS	nn||helper-20/NN||t-19/NN	nsubj||cytokine-29/VBP||helper-20/NN	appos||helper-20/NN||th1-22/NNP	conj_and||helper-20/NN||2-25/CD	nsubj||cytokine-29/VBP||2-25/CD	appos||2-25/CD||th2-27/NNP	conj_and||treated-5/VBN||cytokine-29/VBP	xcomp||cytokine-29/VBP||producing-30/VBG	nn||cells-32/NNS||t-31/NN	dobj||producing-30/VBG||cells-32/NNS	num||weeks-35/NNS||104-34/CD	prep_during||producing-30/VBG||weeks-35/NNS	det||treatment-38/NN||the-37/DT	prep_of||weeks-35/NNS||treatment-38/NN	hbv-12||adefovirdipivoxil-7||yes||chronic hbv patients were treated with adefovirdipivoxil and examined for serum hbv dna loads, cytokines, and t helper (th1) and 2 (th2) cytokine producing t cells during 104 weeks of the treatment.
nsubjpass||recorded-19/VBN||rates-1/NNS	prep_of||rates-1/NNS||hypoglycaemia-3/NN	vmod||recorded-19/VBN||defined-5/VBN	nn||glucose-8/NN||plasma-7/NN	prep_as||defined-5/VBN||glucose-8/NN	number||3.1-10/CD||<-9/CD	num||mmol/l-11/NN||3.1-10/CD	dobj||defined-5/VBN||mmol/l-11/NN	dep||mg/dl-15/JJ||<-13/NNP	num||<-13/NNP||56-14/CD	dep||mmol/l-11/NN||mg/dl-15/JJ	auxpass||recorded-19/VBN||were-18/VBD	root||ROOT-0/null||recorded-19/VBN	hypoglycaemia-3||glucose-8||yes||rates of hypoglycaemia, defined as plasma glucose < 3.1 mmol/l (< 56 mg/dl), were recorded.
nsubj||protect-3/VB||h2s-1/NNS	aux||protect-3/VB||may-2/MD	root||ROOT-0/null||protect-3/VB	prep_against||protect-3/VB||atherosclerosis-5/NNS	prepc_by||protect-3/VB||preventing-7/VBG	amod||injury-10/NN||h2o2-8/JJ	amod||injury-10/NN||induced-9/JJ	dobj||preventing-7/VBG||injury-10/NN	amod||cells-13/NNS||endothelial-12/JJ	prep_to||preventing-7/VBG||cells-13/NNS	h2o2-8||atherosclerosis-5||no_rel||h2s may protect against atherosclerosis by preventing h2o2 induced injury to endothelial cells.
det||packing-3/NN||the-1/DT	nn||packing-3/NN||crystal-2/NN	nsubjpass||mediated-5/VBN||packing-3/NN	auxpass||mediated-5/VBN||is-4/VBZ	root||ROOT-0/null||mediated-5/VBN	det||network-9/NN||an-7/DT	amod||network-9/NN||extensive-8/JJ	agent||mediated-5/VBN||network-9/NN	amod||$-16/NNS||strong-11/JJ	advmod||directional-14/JJ||highly-13/RB	conj_and||strong-11/JJ||directional-14/JJ	amod||$-16/NNS||directional-14/JJ	nn||$-16/NNS||oâ-15/NN	prep_of||network-9/NN||$-16/NNS	amod||bonds-23/NNS||¯-20/JJ	nn||bonds-23/NNS||o-21/NN	nn||bonds-23/NNS||hydrogen-22/NN	prep_of||network-9/NN||bonds-23/NNS	conj_hâ||$-16/NNS||bonds-23/NNS	vmod||bonds-23/NNS||involving-24/VBG	det||molâecules-27/NNS||the-25/DT	nn||molâecules-27/NNS||water-26/NN	dobj||involving-24/VBG||molâecules-27/NNS	dep||$-16/NNS||coordinated-29/VBN	dep||$-16/NNS||uncoordinated-31/VBN	conj_and||coordinated-29/VBN||uncoordinated-31/VBN	det||network-46/NN||the-34/DT	amod||network-46/NN||functional-35/JJ	dep||functional-35/JJ||groups-36/NNS	prep_of||groups-36/NNS||pmida4âˆ-38/NNP	appos||groups-36/NNS||leading-41/VBG	det||supraâmolecular-45/NN||a-43/DT	amod||supraâmolecular-45/NN||three-dimensional-44/JJ	prep_to||leading-41/VBG||supraâmolecular-45/NN	prep_of||network-9/NN||network-46/NN	conj_and||$-16/NNS||network-46/NN	crystal-2||uncoordinated-31||no_rel||the crystal packing is mediated by an extensive network of strong and highly directional oâ€”hâ‹¯o hydrogen bonds involving the water molâ­ecules (coordinated and uncoordinated) and the functional groups of pmida4âˆ’, leading to a three-dimensional supraâ­molecular network.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||evaluate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	prep_in||evaluate-9/VB||patients-11/NNS	prep_with||patients-11/NNS||polycysticovarysyndrome-13/NN	appos||polycysticovarysyndrome-13/NN||pcos-15/NNS	mark||affects-20/VBZ||whether-17/IN	nn||administration-19/NN||metformin-18/NN	nsubj||affects-20/VBZ||administration-19/NN	ccomp||evaluate-9/VB||affects-20/VBZ	nn||levels-25/NNS||serum-21/NN	conj_and||serum-21/NN||follicular-23/NN	nn||levels-25/NNS||follicular-23/NN	nn||levels-25/NNS||amh-24/NN	dobj||affects-20/VBZ||levels-25/NNS	mark||related-31/VBN||whether-28/IN	nsubjpass||related-31/VBN||this-29/DT	nsubj||ovarian-33/VB||this-29/DT	auxpass||related-31/VBN||is-30/VBZ	ccomp||evaluate-9/VB||related-31/VBN	conj_and||affects-20/VBZ||related-31/VBN	aux||ovarian-33/VB||to-32/TO	xcomp||related-31/VBN||ovarian-33/VB	dobj||ovarian-33/VB||response-34/NN	det||treatment-37/NN||the-36/DT	prep_to||ovarian-33/VB||treatment-37/NN	pcos-15||metformin-18||no_rel||the aim of the present study was to evaluate in patients with polycysticovarysyndrome (pcos) whether metformin administration affects serum and follicular amh levels, and whether this is related to ovarian response to the treatment.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	prep_of||case-4/NN||entericfever-6/NN	vmod||entericfever-6/NN||caused-7/VBN	agent||caused-7/VBN||styphi-9/NNS	prep_in||resistant-15/JJ||styphi-9/NNS	det||isolate-13/NN||the-12/DT	nsubj||resistant-15/JJ||isolate-13/NN	nsubj||showed-21/VBD||isolate-13/NN	cop||resistant-15/JJ||was-14/VBD	rcmod||styphi-9/NNS||resistant-15/JJ	amod||acid-18/NN||nalidixic-17/JJ	prep_to||resistant-15/JJ||acid-18/NN	rcmod||styphi-9/NNS||showed-21/VBD	conj_but||resistant-15/JJ||showed-21/VBD	npadvmod||susceptibility-24/JJ||vitro-23/NN	prep_in||showed-21/VBD||susceptibility-24/JJ	prep_to||showed-21/VBD||ciprofloxacin-26/NN	entericfever-6||styphi-9||no||we report a case of entericfever caused by styphi in which the isolate was resistant to nalidixic acid, but showed in vitro susceptibility to ciprofloxacin.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
nn||diagnoses-2/NNS||differential-1/NN	nsubj||include-3/VBP||diagnoses-2/NNS	ccomp||discolouration-40/VBP||include-3/VBP	amod||forms-5/NNS||hypocalcified-4/JJ	dobj||include-3/VBP||forms-5/NNS	amod||imperfecta-8/NN||amelogenesis-7/JJ	prep_of||forms-5/NNS||imperfecta-8/NN	amod||porphyria-12/NN||congenital-10/JJ	amod||porphyria-12/NN||erythropoietic-11/JJ	appos||imperfecta-8/NN||porphyria-12/NN	appos||porphyria-12/NN||conditions-14/NNS	amod||conditions-14/NNS||leading-15/VBG	amod||loss-19/NN||early-17/JJ	nn||loss-19/NN||tooth-18/NN	prep_to||conditions-14/NNS||loss-19/NN	poss||disease-23/NN||kostmann-21/NN	nsubj||histiocytosis-31/VBZ||disease-23/NN	amod||neutropenia-26/NN||cyclic-25/JJ	appos||disease-23/NN||neutropenia-26/NN	nn||syndrome-29/NN||chediak-hegashi-28/NN	appos||disease-23/NN||syndrome-29/NN	dep||conditions-14/NNS||histiocytosis-31/VBZ	dobj||histiocytosis-31/VBZ||x-32/SYM	amod||syndrome-35/NN||papillon-lefevre-34/JJ	appos||x-32/SYM||syndrome-35/NN	amod||teeth-39/NNS||permanent-38/JJ	nsubj||discolouration-40/VBP||teeth-39/NNS	root||ROOT-0/null||discolouration-40/VBP	acomp||discolouration-40/VBP||due-41/JJ	nn||rickets-48/NNS||tetracyclines-43/NNS	conj_and||tetracyclines-43/NNS||vitamind-dependent-45/NN	nn||rickets-48/NNS||vitamind-dependent-45/NN	conj_and||tetracyclines-43/NNS||vitamind-resistant-47/NN	nn||rickets-48/NNS||vitamind-resistant-47/NN	prep_to||due-41/JJ||rickets-48/NNS	rickets-48||vitamind--1||yes||differential diagnoses include hypocalcified forms of amelogenesis imperfecta, congenital erythropoietic porphyria, conditions leading to early tooth loss (kostmann's disease, cyclic neutropenia, chediak-hegashi syndrome, histiocytosis x, papillon-lefevre syndrome), permanent teeth discolouration due to tetracyclines, vitamind-dependent and vitamind-resistant rickets.
nsubj||reviewed-2/VBN||we-1/PRP	root||ROOT-0/null||reviewed-2/VBN	det||case-4/NN||the-3/DT	dobj||reviewed-2/VBN||case-4/NN	det||male-8/NN||a-6/DT	amod||male-8/NN||26-year-old-7/JJ	prep_of||case-4/NN||male-8/NN	amod||palsy-11/NN||cerebral-10/JJ	prep_with||reviewed-2/VBN||palsy-11/NN	nsubj||had-13/VBD||palsy-11/NN	rcmod||palsy-11/NN||had-13/VBD	det||history-15/NN||a-14/DT	dobj||had-13/VBD||history-15/NN	nsubj||presented-21/VBN||history-15/NN	amod||constipation-19/NN||chronic-17/JJ	amod||constipation-19/NN||intermittent-18/JJ	prep_of||history-15/NN||constipation-19/NN	rcmod||history-15/NN||presented-21/VBN	det||department-25/NN||the-23/DT	nn||department-25/NN||emergency-24/NN	prep_to||presented-21/VBN||department-25/NN	appos||department-25/NN||ed-27/NN	prep_with||presented-21/VBN||signs-30/NNS	prep_of||signs-30/NNS||impaction-32/NN	amod||enemas-36/NNS||recurrent-34/JJ	nn||enemas-36/NNS||fleet-35/NN	prep_despite||presented-21/VBN||enemas-36/NNS	amod||polyethyleneglycol3350-39/NNS||oral-38/JJ	prep_despite||presented-21/VBN||polyethyleneglycol3350-39/NNS	conj_and||enemas-36/NNS||polyethyleneglycol3350-39/NNS	constipation-19||polyethyleneglycol3350-39||yes||we reviewed the case of a 26-year-old male with cerebral palsy who had a history of chronic intermittent constipation who presented to the emergency department (ed) with signs of impaction despite recurrent fleet enemas and oral polyethyleneglycol3350.
amod||effects-3/NNS||upper-1/JJ	nn||effects-3/NNS||gi-2/NN	nsubjpass||documented-18/VBN||effects-3/NNS	amod||treatment-7/NN||non-selective-5/JJ	amod||treatment-7/NN||nsaid-6/JJ	prep_of||effects-3/NNS||treatment-7/NN	vmod||documented-18/VBN||ranging-9/VBG	prep_from||ranging-9/VBG||abdominalpain-11/NN	prep_to||ranging-9/VBG||ulceration-13/NN	prep_to||ranging-9/VBG||bleeding-15/NN	conj_and||ulceration-13/NN||bleeding-15/NN	auxpass||documented-18/VBN||are-16/VBP	advmod||documented-18/VBN||extensively-17/RB	root||ROOT-0/null||documented-18/VBN	nsaid-6||bleeding-15||no_rel||upper gi effects of non-selective nsaid treatment, ranging from abdominalpain to ulceration and bleeding are extensively documented.
amod||domain-3/NN||bcr-abl-1/JJ	nn||domain-3/NN||kinase-2/NN	root||ROOT-0/null||domain-3/NN	appos||domain-3/NN||kd-5/NN	nsubj||mechanism-11/NN||mutation-7/NN	cop||mechanism-11/NN||is-8/VBZ	det||mechanism-11/NN||the-9/DT	amod||mechanism-11/NN||major-10/JJ	rcmod||domain-3/NN||mechanism-11/NN	vmod||mechanism-11/NN||contributing-12/VBG	aux||suboptimal-14/VB||to-13/TO	xcomp||contributing-12/VBG||suboptimal-14/VB	dobj||suboptimal-14/VB||response-15/NN	aux||tyrosine-17/VB||to-16/TO	vmod||suboptimal-14/VB||tyrosine-17/VB	amod||inhibitors-19/NNS||kinase-18/JJ	dobj||tyrosine-17/VB||inhibitors-19/NNS	appos||inhibitors-19/NNS||tki-21/NN	prep_in||inhibitors-19/NNS||bcr-abl-24/NN	amod||chronicmyeloidleukemia-27/NN||positive-26/JJ	dep||domain-3/NN||chronicmyeloidleukemia-27/NN	appos||chronicmyeloidleukemia-27/NN||cml-29/NN	dep||chronicmyeloidleukemia-27/NN||patients-31/NNS	cml-29||tyrosine-17||no_rel||bcr-abl kinase domain (kd) mutation is the major mechanism contributing to suboptimal response to tyrosine kinase inhibitors (tki) in bcr-abl -positive chronicmyeloidleukemia (cml) patients.
det||campaigns-3/NNS||the-1/DT	nn||campaigns-3/NNS||aids-2/NNS	nsubj||successful-6/JJ||campaigns-3/NNS	aux||successful-6/JJ||have-4/VBP	cop||successful-6/JJ||been-5/VBN	root||ROOT-0/null||successful-6/JJ	prepc_in||successful-6/JJ||making-8/VBG	predet||women-11/NNS||all-9/PDT	det||women-11/NNS||the-10/DT	nsubj||aware-12/JJ||women-11/NNS	xcomp||making-8/VBG||aware-12/JJ	prep_of||aware-12/JJ||hiv-14/NN	det||disease-19/NN||a-16/DT	advmod||disease-19/NN||sexually-17/RB	amod||disease-19/NN||transmitted-18/JJ	prep_as||successful-6/JJ||disease-19/NN	aids-2||hiv-14||no||the aids campaigns have been successful in making all the women aware of hiv as a sexually transmitted disease.
det||viruses-4/NNS||the-1/DT	amod||viruses-4/NNS||finnish-2/JJ	amod||viruses-4/NNS||pandemic-3/JJ	nsubj||related-8/JJ||viruses-4/NNS	cop||related-8/JJ||were-5/VBD	advmod||related-8/JJ||quite-6/RB	advmod||related-8/JJ||closely-7/RB	root||ROOT-0/null||related-8/JJ	amod||virus-14/NN||a/california/07-10/JJ	amod||virus-14/NN||/-11/JJ	num||virus-14/NN||2009-12/CD	nn||virus-14/NN||vaccine-13/NN	prep_to||related-8/JJ||virus-14/NN	virus-14||viruses-4||no||the finnish pandemic viruses were quite closely related to a/california/07/2009 vaccine virus.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	nn||rip-chip-4/NN||hur-3/NN	dobj||used-2/VBD||rip-chip-4/NN	det||method-10/NN||a-6/DT	amod||method-10/NN||comprehensive-7/JJ	conj_and||comprehensive-7/JJ||systematic-9/JJ	amod||method-10/NN||systematic-9/JJ	prep_as||used-2/VBD||method-10/NN	aux||survey-12/VB||to-11/TO	vmod||used-2/VBD||survey-12/VB	nn||genes-16/NNS||breast-13/NN	nn||genes-16/NNS||cancer-14/NN	nn||genes-16/NNS||target-15/NN	dobj||survey-12/VB||genes-16/NNS	det||lines-41/NNS||both-18/DT	amod||lines-41/NNS||mcf-7-19/JJ	nn||positive-23/NN||estrogen-21/NN	nn||positive-23/NN||receptor-22/NN	dep||mcf-7-19/JJ||positive-23/NN	nn||+-26/NNS||er-25/NN	appos||positive-23/NN||+-26/NNS	conj_and||mcf-7-19/JJ||mda-mb-231-29/JJ	amod||lines-41/NNS||mda-mb-231-29/JJ	num||receptor-32/NN||estrogen-31/CD	npadvmod||negative-33/JJ||receptor-32/NN	dep||er-35/NN||negative-33/JJ	dep||mda-mb-231-29/JJ||er-35/NN	nn||lines-41/NNS||breast-38/NN	nn||lines-41/NNS||cancer-39/NN	nn||lines-41/NNS||cell-40/NN	prep_in||genes-16/NNS||lines-41/NNS	cancer-39||estrogen-31||no_rel||we used hur rip-chip as a comprehensive and systematic method to survey breast cancer target genes in both mcf-7 (estrogen receptor positive, er+) and mda-mb-231 (estrogen receptor negative, er-) breast cancer cell lines.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||effect-5/NN||the-4/DT	dobj||examined-3/VBD||effect-5/NN	amod||consumption-8/NN||chronic-7/JJ	prep_of||effect-5/NN||consumption-8/NN	det||viscous-11/NNS||the-10/DT	prep_of||consumption-8/NN||viscous-11/NNS	amod||fiber-15/NN||non-fermentable-13/JJ	nn||fiber-15/NN||dietary-14/NN	appos||consumption-8/NN||fiber-15/NN	appos||consumption-8/NN||hydroxypropylmethylcellulose-17/NN	dep||hydroxypropylmethylcellulose-17/NN||hpmc-19/JJ	nn||lipids-29/NNS||glucose-23/NN	nn||lipids-29/NNS||control-24/NN	conj_and||control-24/NN||insulinresistance-26/NN	nn||lipids-29/NNS||insulinresistance-26/NN	conj_and||control-24/NN||liver-28/NN	nn||lipids-29/NNS||liver-28/NN	prep_on||examined-3/VBD||lipids-29/NNS	det||model-35/NN||an-31/DT	amod||model-35/NN||obese-32/JJ	amod||model-35/NN||diabetic-33/JJ	nn||model-35/NN||rat-34/NN	prep_in||lipids-29/NNS||model-35/NN	hydroxypropylmethylcellulose-17||obese-32||no_rel||this study examined the effect of chronic consumption of the viscous, non-fermentable dietary fiber, hydroxypropylmethylcellulose (hpmc), on glucose control, insulinresistance and liver lipids in an obese diabetic rat model.
nsubj||cause-13/NN||staphylococcusaureus-1/NNS	advmod||s.aureus-5/NNS||particularly-3/RB	amod||s.aureus-5/NNS||methicillin-resistant-4/JJ	appos||staphylococcusaureus-1/NNS||s.aureus-5/NNS	nn||-rrb--8/NNP||-lrb--6/NNP	nn||-rrb--8/NNP||mrsa-7/NNP	dep||s.aureus-5/NNS||-rrb--8/NNP	cop||cause-13/NN||is-10/VBZ	det||cause-13/NN||an-11/DT	amod||cause-13/NN||important-12/JJ	root||ROOT-0/null||cause-13/NN	amod||skin-16/NN||pyogenic-15/JJ	prep_of||cause-13/NN||skin-16/NN	nn||-rrb--21/NNS||softtissueinfections-18/NNS	nn||-rrb--21/NNS||-lrb--19/NN	nn||-rrb--21/NNS||sstis-20/NN	prep_of||cause-13/NN||-rrb--21/NNS	conj_and||skin-16/NN||-rrb--21/NNS	softtissueinfections-18||methicillin--1||yes||staphylococcusaureus , particularly methicillin-resistant s.aureus -lrb- mrsa -rrb- , is an important cause of pyogenic skin and softtissueinfections -lrb- sstis -rrb- .
aux||compare-2/VB||to-1/TO	csubj||doublet-12/VBP||compare-2/VB	det||activity-4/NN||the-3/DT	dobj||compare-2/VB||activity-4/NN	dobj||compare-2/VB||toxicity-6/NN	conj_and||activity-4/NN||toxicity-6/NN	prep_of||activity-4/NN||docetaxel/carboplatin-8/NN	appos||docetaxel/carboplatin-8/NN||dc-10/NN	root||ROOT-0/null||doublet-12/VBP	amod||agent-15/NN||vs-13/JJ	amod||agent-15/NN||single-14/JJ	nsubj||docetaxel-16/VB||agent-15/NN	ccomp||doublet-12/VBP||docetaxel-16/VB	dep||treatment-22/NN||d-18/LS	amod||treatment-22/NN||as-20/IN	amod||treatment-22/NN||second-line-21/JJ	dobj||docetaxel-16/VB||treatment-22/NN	prep_in||treatment-22/NN||patients-24/NNS	amod||non-smallcelllungcancer-27/NN||advanced-26/VBN	prep_with||patients-24/NNS||non-smallcelllungcancer-27/NN	dep||treatment-22/NN||nsclc-29/JJ	nsclc-29||docetaxel-16||yes||to compare the activity and toxicity of docetaxel/carboplatin (dc) doublet vs single agent docetaxel (d) as second-line treatment in patients with advanced non-smallcelllungcancer (nsclc).
nsubjpass||increased-22/VBN||hypertension-1/NN	conj_and||hypertension-1/NN||triglycerides-3/NN	nsubjpass||increased-22/VBN||triglycerides-3/NN	conj_and||hypertension-1/NN||insulinresistance-5/NN	nsubjpass||increased-22/VBN||insulinresistance-5/NN	dep||hypertension-1/NN||determined-7/VBN	amod||assessment-11/NN||homeostasis-9/JJ	nn||assessment-11/NN||model-10/NN	prep_by||determined-7/VBN||assessment-11/NN	prep_of||assessment-11/NN||insulinresistance-13/NN	amod||protein-17/NN||c-reactive-16/JJ	conj_and||hypertension-1/NN||protein-17/NN	nsubjpass||increased-22/VBN||protein-17/NN	dep||protein-17/NN||crp-19/VBN	auxpass||increased-22/VBN||were-21/VBD	root||ROOT-0/null||increased-22/VBN	prep_in||increased-22/VBN||sle-24/NN	parataxis||increased-22/VBN||p-26/VB	num||0.01-28/CD||<-27/CD	dobj||p-26/VB||0.01-28/CD	mark||differ-43/VB||while-30/IN	nn||lipoprotein-37/NN||smoking-31/NN	dep||lipoprotein-37/NN||ldl-33/NN	amod||lipoprotein-37/NN||high-35/JJ	nn||lipoprotein-37/NN||density-36/NN	nsubj||differ-43/VB||lipoprotein-37/NN	appos||lipoprotein-37/NN||hdl-39/NN	aux||differ-43/VB||did-41/VBD	neg||differ-43/VB||not-42/RB	advcl||increased-22/VBN||differ-43/VB	prep_between||differ-43/VB||groups-45/NNS	hypertension-1||triglycerides-3||no_rel||hypertension, triglycerides and insulinresistance (determined by homeostasis model assessment of insulinresistance) and c-reactive protein (crp) were increased in sle ( p < 0.01) while smoking, ldl, high density lipoprotein (hdl) did not differ between groups.
prep||recommend-9/VBP||given-1/VBN	det||results-3/NNS||the-2/DT	pobj||given-1/VBN||results-3/NNS	det||study-6/NN||this-5/DT	prep_from||results-3/NNS||study-6/NN	nsubj||recommend-9/VBP||we-8/PRP	root||ROOT-0/null||recommend-9/VBP	dep||vct-14/VBP||1-11/LS	nsubj||vct-14/VBP||making-13/NN	dep||recommend-9/VBP||vct-14/VBP	det||part-17/NN||a-15/DT	amod||part-17/NN||routine-16/JJ	dobj||vct-14/VBP||part-17/NN	nn||services-20/NNS||health-19/NN	prep_of||part-17/NN||services-20/NNS	advmod||vct-14/VBP||especially-22/RB	prep_in||vct-14/VBP||areas-24/NNS	advmod||live-29/VBP||where-25/WRB	amod||individuals-28/NNS||many-26/JJ	amod||individuals-28/NNS||high-risk-27/JJ	nsubj||live-29/VBP||individuals-28/NNS	rcmod||areas-24/NNS||live-29/VBP	prep_in||vct-14/VBP||2-32/CD	conj_and||areas-24/NNS||2-32/CD	dep||2-32/CD||improving-34/VBG	det||sources-37/NNS||the-35/DT	nn||sources-37/NNS||information-36/NN	dobj||improving-34/VBG||sources-37/NNS	dep||2-32/CD||increasing-39/VBG	conj_and||improving-34/VBG||increasing-39/VBG	det||understanding-41/NN||the-40/DT	dobj||increasing-39/VBG||understanding-41/NN	nn||individuals-46/NNS||hiv-43/NN	conj_and||hiv-43/NN||hiv-infected-45/JJ	nn||individuals-46/NNS||hiv-infected-45/JJ	prep_of||understanding-41/NN||individuals-46/NNS	dep||collaboration-53/NN||3-49/LS	amod||collaboration-53/NN||enhancing-51/JJ	amod||collaboration-53/NN||international-52/JJ	prep_in||vct-14/VBP||collaboration-53/NN	conj_and||areas-24/NNS||collaboration-53/NN	amod||planning-56/NN||strategic-55/JJ	prep_in||collaboration-53/NN||planning-56/NN	amod||assistance-59/NN||technical-58/JJ	prep_in||vct-14/VBP||assistance-59/NN	conj_and||areas-24/NNS||assistance-59/NN	prep_in||vct-14/VBP||protocols-62/NNS	conj_and||areas-24/NNS||protocols-62/NNS	aux||translate-64/VB||to-63/TO	vmod||protocols-62/NNS||translate-64/VB	dobj||translate-64/VB||policy-65/NN	amod||action-68/NN||effective-67/JJ	prep_into||translate-64/VB||action-68/NN	dep||chinese-74/VBP||4-71/LS	nsubj||chinese-74/VBP||supporting-73/JJ	parataxis||vct-14/VBP||chinese-74/VBP	amod||organizations-76/NNS||non-government-75/JJ	dobj||chinese-74/VBP||organizations-76/NNS	appos||organizations-76/NNS||ngos-78/NNS	prepc_in||chinese-74/VBP||playing-81/VBG	det||role-84/NN||a-82/DT	amod||role-84/NN||significant-83/JJ	dobj||playing-81/VBG||role-84/NN	det||battle-87/NN||the-86/DT	prep_in||playing-81/VBG||battle-87/NN	prep_against||battle-87/NN||aids-89/NNS	aids-89||hiv-43||no||given the results from this study, we recommend (1) making vct a routine part of health services, especially in areas where many high-risk individuals live; (2) improving the information sources and increasing the understanding of hiv and hiv-infected individuals; (3) enhancing international collaboration in strategic planning, technical assistance, and protocols to translate policy into effective action; (4) supporting chinese non-government organizations (ngos) in playing a significant role in the battle against aids.
num||investigations-3/NNS||five-1/CD	amod||investigations-3/NNS||main-2/JJ	nsubj||mantoux-5/VBZ||investigations-3/NNS	nsubjpass||carried-31/VBN||investigations-3/NNS	nsubj||diagnose-34/VB||investigations-3/NNS	advmod||mantoux-5/VBZ||namely-4/RB	root||ROOT-0/null||mantoux-5/VBZ	nn||rate-16/NN||test-6/NN	dep||rate-16/NN||bcg-8/NN	nn||rate-16/NN||test-9/NN	dep||rate-16/NN||chest-11/NN	nn||rate-16/NN||radiograph-12/NN	dep||rate-16/NN||erythrocyte-14/NN	nn||rate-16/NN||sedimentation-15/NN	dobj||mantoux-5/VBZ||rate-16/NN	appos||rate-16/NN||esr-18/NN	amod||cytology-24/NN||fine-21/JJ	nn||cytology-24/NN||needle-22/NN	nn||cytology-24/NN||aspiration-23/NN	dobj||mantoux-5/VBZ||cytology-24/NN	conj_and||rate-16/NN||cytology-24/NN	dep||cytology-24/NN||fnac-26/JJ	advmod||carried-31/VBN||biopsy-29/RB	auxpass||carried-31/VBN||were-30/VBD	conj_or||mantoux-5/VBZ||carried-31/VBN	prt||carried-31/VBN||out-32/RP	aux||diagnose-34/VB||to-33/TO	xcomp||carried-31/VBN||diagnose-34/VB	dobj||diagnose-34/VB||tb-35/NN	tb-35||bcg-8||yes||five main investigations namely mantoux test, bcg test, chest radiograph, erythrocyte sedimentation rate (esr) and fine needle aspiration cytology (fnac) or biopsy were carried out to diagnose tb.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||precedes-15/VBZ||that-3/IN	amod||activation-6/NN||altered-4/JJ	nn||activation-6/NN||insulin-5/NN	nsubj||precedes-15/VBZ||activation-6/NN	nsubj||contribute-18/VB||activation-6/NN	det||pi3k/akt-9/NN||the-8/DT	prep_of||activation-6/NN||pi3k/akt-9/NN	det||pathway-14/NN||the-12/DT	nn||pathway-14/NN||mapk-13/NN	prep_of||activation-6/NN||pathway-14/NN	conj_negcc||pi3k/akt-9/NN||pathway-14/NN	ccomp||conclude-2/VBP||precedes-15/VBZ	aux||contribute-18/VB||may-17/MD	ccomp||conclude-2/VBP||contribute-18/VB	conj_and||precedes-15/VBZ||contribute-18/VB	prep_to||contribute-18/VB||development-20/NN	amod||insulinresistance-23/NN||whole-body-22/JJ	prep_of||development-20/NN||insulinresistance-23/NN	prep_of||development-20/NN||type2diabetes-25/NNS	conj_and||insulinresistance-23/NN||type2diabetes-25/NNS	prep_in||contribute-18/VB||men-27/NNS	prep_with||men-27/NNS||lbw-29/NN	insulin-5||insulinresistance-23||no_rel||we conclude that altered insulin activation of the pi3k/akt but not the mapk pathway precedes and may contribute to development of whole-body insulinresistance and type2diabetes in men with lbw.
nsubj||analysed-2/VBD||we-1/PRP	root||ROOT-0/null||analysed-2/VBD	dobj||analysed-2/VBD||bc-3/NN	vmod||bc-3/NN||using-4/VBG	dep||using-4/VBG||air-5/NN	dep||using-4/VBG||air-5/NN	conj_and||air-5/NN||air-5/NN	amod||plethysmography-7/NN||displacement-6/JJ	dobj||air-5/NN||plethysmography-7/NN	dobj||air-5/NN||ms-9/NN	conj_and||plethysmography-7/NN||ms-9/NN	nn||dynamometry-13/NN||hand-11/NN	nn||dynamometry-13/NN||grip-12/NN	prep_by||air-5/NN||dynamometry-13/NN	num||t2d-16/NNS||40-15/CD	prep_in||dynamometry-13/NN||t2d-16/NNS	prep_after||air-5/NN||three-20/CD	prep_before||air-5/NN||three-20/CD	appos||three-20/CD||m3-22/NNP	num||months-26/NNS||six-25/CD	dep||using-4/VBG||months-26/NNS	conj_and||air-5/NN||months-26/NNS	appos||bc-3/NN||m6-28/NNP	nn||therapy-32/NN||insulin-31/NN	prep_of||bc-3/NN||therapy-32/NN	t2d-16||insulin-31||yes||we analysed bc using air displacement plethysmography and ms by hand grip dynamometry in 40 t2d before and after three (m3) and six months (m6) of insulin therapy.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	osteoarthritis-29||glucosamine-42||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
nsubjpass||raised-4/VBN||awareness-1/NN	aux||raised-4/VBN||should-2/MD	auxpass||raised-4/VBN||be-3/VB	root||ROOT-0/null||raised-4/VBN	prep_for||raised-4/VBN||consideration-6/NN	det||syndrome-11/NN||both-8/DT	amod||syndrome-11/NN||guillain-barrã-9/JJ	amod||syndrome-11/NN||©-10/JJ	prep_of||consideration-6/NN||syndrome-11/NN	poss||treatment-14/NN||its-13/PRP$	prep_of||consideration-6/NN||treatment-14/NN	conj_and||syndrome-11/NN||treatment-14/NN	nn||therapy-17/NN||intravenousimmuneglobulin-16/NN	prep_with||raised-4/VBN||therapy-17/NN	det||cause-20/NN||the-19/DT	prep_as||raised-4/VBN||cause-20/NN	prep_of||cause-20/NN||hyponatremia-22/NN	guillain-barrã©syndrome--1||intravenousimmuneglobulin-16||yes||awareness should be raised for consideration of both guillain-barrã©syndrome and its treatment with intravenousimmuneglobulin therapy as the cause of hyponatremia.
num||type-3/NN||ten-1/CD	amod||type-3/NN||obese-2/JJ	nsubj||-lrb--11/VBD||type-3/NN	num||patients-6/NNS||2-4/CD	amod||patients-6/NNS||diabetic-5/JJ	nsubjpass||infused-8/VBN||patients-6/NNS	auxpass||infused-8/VBN||were-7/VBD	rcmod||type-3/NN||infused-8/VBN	prep_with||infused-8/VBN||insulin-10/NN	root||ROOT-0/null||-lrb--11/VBD	num||units/h-13/NN||2-12/CD	nsubjpass||infused-34/VBN||units/h-13/NN	nsubjpass||served-51/VBN||units/h-13/NN	num||ml-16/NN||100-15/CD	prep_with||units/h-13/NN||ml-16/NN	number||%-19/NN||5-18/CD	amod||-rrb--21/NNS||%-19/NN	nn||-rrb--21/NNS||dextrose/h-20/NN	prep_of||ml-16/NN||-rrb--21/NNS	number||h.-24/CD||4-23/CD	num||8-26/CD||h.-24/CD	quantmod||8-26/CD||another-25/DT	prep_for||-rrb--21/NNS||8-26/CD	num||type-29/NN||6-28/CD	prep_of||ml-16/NN||type-29/NN	conj_and||-rrb--21/NNS||type-29/NN	num||patients-32/NNS||2-30/CD	amod||patients-32/NNS||diabetic-31/JJ	dep||type-29/NN||patients-32/NNS	auxpass||infused-34/VBN||were-33/VBD	ccomp||-lrb--11/VBD||infused-34/VBN	num||ml-37/NN||100-36/CD	prep_with||infused-34/VBN||ml-37/NN	number||%-40/NN||5-39/CD	amod||dextrose/h-41/NN||%-40/NN	prep_of||ml-37/NN||dextrose/h-41/NN	prep_of||ml-37/NN||saline-43/NN	conj_or||dextrose/h-41/NN||saline-43/NN	num||h-46/NN||4-45/CD	prep_for||ml-37/NN||h-46/NN	advmod||infused-34/VBN||respectively-48/RB	ccomp||-lrb--11/VBD||served-51/VBN	conj_and||infused-34/VBN||served-51/VBN	nn||subjects-54/NNS||control-53/NN	prep_as||served-51/VBN||subjects-54/NNS	dextrose--1||ten-1||no_rel||ten obese type 2 diabetic patients were infused with insulin -lrb- 2 units/h with 100 ml of 5 % dextrose/h -rrb- for 4 h. another 8 and 6 type 2 diabetic patients were infused with 100 ml of 5 % dextrose/h or saline for 4 h , respectively , and served as control subjects .
det||results-2/NNS||these-1/DT	nsubj||suggested-3/VBD||results-2/NNS	root||ROOT-0/null||suggested-3/VBD	mark||has-6/VBZ||that-4/IN	nsubj||has-6/VBZ||melatonin-5/NN	ccomp||suggested-3/VBD||has-6/VBZ	det||effect-9/NN||a-7/DT	amod||effect-9/NN||beneficial-8/JJ	dobj||has-6/VBZ||effect-9/NN	amod||lupus-12/NNS||pristane-induced-11/JJ	prep_on||has-6/VBZ||lupus-12/NNS	prepc_through||has-6/VBZ||regulating-14/VBG	det||disturbances-17/NNS||the-15/DT	amod||disturbances-17/NNS||cytokines-16/JJ	dobj||regulating-14/VBG||disturbances-17/NNS	melatonin-5||lupus-12||no_rel||these results suggested that melatonin has a beneficial effect on pristane-induced lupus through regulating the cytokines disturbances.
det||period-5/NN||the-2/DT	amod||period-5/NN||2-year-3/JJ	nn||period-5/NN||study-4/NN	prep_during||admitted-13/VBN||period-5/NN	num||hiv/aids-8/NNS||88-7/CD	npadvmod||critically-9/RB||hiv/aids-8/NNS	amod||patients-11/NNS||critically-9/RB	amod||patients-11/NNS||ill-10/JJ	nsubjpass||admitted-13/VBN||patients-11/NNS	auxpass||admitted-13/VBN||were-12/VBD	root||ROOT-0/null||admitted-13/VBN	det||icu-16/NN||the-15/DT	prep_to||admitted-13/VBN||icu-16/NN	aids--1||hiv--1||no||during the 2-year study period, 88 hiv/aids critically ill patients were admitted to the icu.
det||epidemic-3/NN||the-1/DT	nn||epidemic-3/NN||hiv/aids-2/NNS	nsubj||has-4/VBZ||epidemic-3/NN	root||ROOT-0/null||has-4/VBZ	amod||consequences-7/NNS||many-5/JJ	amod||consequences-7/NNS||serious-6/JJ	dobj||has-4/VBZ||consequences-7/NNS	prep_for||consequences-7/NNS||children-9/NNS	aids--1||hiv--1||no||the hiv/aids epidemic has many serious consequences for children.
amod||transmission-2/NN||mother-to-child-1/JJ	nsubj||accounts-8/VBZ||transmission-2/NN	prep_of||transmission-2/NN||hiv-4/NN	appos||transmission-2/NN||mtct-6/NN	root||ROOT-0/null||accounts-8/VBZ	dep||accounts-8/VBZ||for-9/IN	num||%-12/NN||95-11/CD	prep_over||accounts-8/VBZ||%-12/NN	det||hivinfections-16/NNS||all-14/DT	amod||hivinfections-16/NNS||paediatric-15/JJ	prep_of||%-12/NN||hivinfections-16/NNS	advmod||accounts-8/VBZ||worldwide-17/RB	hivinfections-16||hiv-4||no||mother-to-child transmission of hiv (mtct) accounts for over 95% of all paediatric hivinfections worldwide.
advmod||induced-9/VBN||furthermore-1/RB	amod||cd40-8/NNS||il-2-3/JJ	punct||±-6/NNP||/-4/:	nn||±-6/NNP||î-5/NNP	dep||cd40-8/NNS||±-6/NNP	nsubj||induced-9/VBN||cd40-8/NNS	root||ROOT-0/null||induced-9/VBN	det||â-13/NN||the-10/DT	amod||â-13/NN||ifn-î-11/JJ	amod||â-13/NN||³-12/JJ	dobj||induced-9/VBN||â-13/NN	dep||â-13/NN||$-14/$	npadvmod||decrease-18/RB||and-16/NNP	advmod||and-16/NNP||no-dependent-17/RB	dep||1-40/CD||decrease-18/RB	nn||metalloproteinase-21/NN||matrix-20/NN	prep_in||decrease-18/RB||metalloproteinase-21/NN	appos||metalloproteinase-21/NN||mmp-23/NN	dep||metalloproteinase-21/NN||expression-25/NN	dep||metalloproteinase-21/NN||activity-27/NN	conj_and||expression-25/NN||activity-27/NN	appos||expression-25/NN||concomitant-29/NN	prep_with||decrease-18/RB||increases-31/NNS	nn||inhibitor-34/NN||tissue-33/NN	prep_in||increases-31/NNS||inhibitor-34/NN	prep_of||inhibitor-34/NN||metalloproteinase-36/NN	appos||metalloproteinase-36/NN||timp-38/NN	num||$-14/$||1-40/CD	amod||expression-43/NN||e-cadherin-42/JJ	dobj||induced-9/VBN||expression-43/NN	conj_and||â-13/NN||expression-43/NN	prep_within||expression-43/NN||tumors-45/NNS	ifn--1||tumors-45||no_rel||furthermore, il-2/î±-cd40 induced the ifn-î³â€“ and no-dependent decrease in matrix metalloproteinase (mmp) expression and activity, concomitant with increases in tissue inhibitor of metalloproteinase (timp) 1 and e-cadherin expression within tumors.
nsubj||observed-4/VBN||we-1/PRP	aux||observed-4/VBN||have-2/VBP	advmod||observed-4/VBN||previously-3/RB	root||ROOT-0/null||observed-4/VBN	mark||improved-14/VBD||that-5/IN	prep_in||improved-14/VBD||vivo-7/NN	nsubj||improved-14/VBD||administration-8/NN	det||inhibitor-11/NN||an-10/DT	prep_of||administration-8/NN||inhibitor-11/NN	prep_of||inhibitor-11/NN||nitricoxide-13/NN	ccomp||observed-4/VBN||improved-14/VBD	det||response-16/NN||the-15/DT	dobj||improved-14/VBD||response-16/NN	prep_to||improved-14/VBD||bcg-18/NN	nn||mice-22/NNS||bladdertumor-20/NN	nn||mice-22/NNS||bearing-21/NN	prep_of||bcg-18/NN||mice-22/NNS	nitricoxide-13||bladdertumor-20||no_rel||we have previously observed that in vivo administration of an inhibitor of nitricoxide improved the response to bcg of bladdertumor bearing mice.
nsubj||agent-8/NN||orfvirus-1/NNS	appos||orfvirus-1/NNS||orfv-3/NNP	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||etiological-7/JJ	root||ROOT-0/null||agent-8/NN	prep_of||agent-8/NN||contagiouspustulardermatitis-10/NNS	cop||prototype-14/NN||is-12/VBZ	det||prototype-14/NN||the-13/DT	conj_and||agent-8/NN||prototype-14/NN	det||parapoxvirus-18/NNS||the-16/DT	amod||parapoxvirus-18/NNS||genus-17/JJ	prep_of||prototype-14/NN||parapoxvirus-18/NNS	appos||parapoxvirus-18/NNS||ppv-20/NN	contagiouspustulardermatitis-10||orfvirus-1||no||orfvirus (orfv) is the etiological agent of contagiouspustulardermatitis and is the prototype of the genus parapoxvirus (ppv).
nsubj||cause-5/NN||clostridiumdifficile-1/NN	nsubjpass||associated-10/VBN||clostridiumdifficile-1/NN	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||major-4/JJ	root||ROOT-0/null||cause-5/NN	prep_of||cause-5/NN||antibiotic-associatedcolitis-7/NNS	auxpass||associated-10/VBN||is-9/VBZ	conj_and||cause-5/NN||associated-10/VBN	amod||morbidity-13/NN||significant-12/JJ	prep_with||associated-10/VBN||morbidity-13/NN	prep_with||associated-10/VBN||mortality-15/NN	conj_and||morbidity-13/NN||mortality-15/NN	antibiotic-associatedcolitis-7||clostridiumdifficile-1||no||clostridiumdifficile is a major cause of antibiotic-associatedcolitis and is associated with significant morbidity and mortality.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	irondeficiency-11||iron-47||yes||we present data drawn from four different conditionsâ€”irondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâ€”both in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
det||test-4/NN||the-1/DT	amod||test-4/NN||xpert-2/JJ	nn||test-4/NN||mtb/rif-3/NN	nsubj||detect-15/VB||test-4/NN	dep||test-4/NN||cepheid-6/VBN	dobj||cepheid-6/VBN||sunnyvale-8/NN	dep||sunnyvale-8/NN||ca-10/MD	appos||sunnyvale-8/NN||usa-12/NN	aux||detect-15/VB||can-14/MD	root||ROOT-0/null||detect-15/VB	dobj||detect-15/VB||tuberculosis-16/NNP	poss||form-20/NN||its-18/PRP$	amod||form-20/NN||multidrug-resistant-19/JJ	dobj||detect-15/VB||form-20/NN	conj_and||tuberculosis-16/NNP||form-20/NN	advmod||high-23/JJ||very-22/RB	amod||sensitivity-24/NN||high-23/JJ	prep_with||detect-15/VB||sensitivity-24/NN	prep_with||detect-15/VB||specificity-26/NN	conj_and||sensitivity-24/NN||specificity-26/NN	amod||studies-29/NNS||controlled-28/JJ	prep_in||detect-15/VB||studies-29/NNS	neg||data-34/NNS||no-32/DT	nn||data-34/NNS||performance-33/NN	nsubj||exist-35/VBP||data-34/NNS	conj_but||detect-15/VB||exist-35/VBP	nn||facilities-41/NNS||district-37/NN	conj_and||district-37/NN||subdistrict-39/NN	nn||facilities-41/NNS||subdistrict-39/NN	nn||facilities-41/NNS||health-40/NN	prep_from||exist-35/VBP||facilities-41/NNS	amod||countries-44/NNS||tuberculosis-endemic-43/JJ	prep_in||exist-35/VBP||countries-44/NNS	tuberculosis-16||rif--1||yes||the xpert mtb/rif test (cepheid, sunnyvale, ca, usa) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries.
nsubjpass||defined-3/VBN||hypercholesterolemia-1/NN	auxpass||defined-3/VBN||is-2/VBZ	root||ROOT-0/null||defined-3/VBN	advmod||high-6/JJ||excessively-5/RB	amod||levels-9/NNS||high-6/JJ	amod||levels-9/NNS||plasma-7/JJ	nn||levels-9/NNS||cholesterol-8/NN	prep_as||defined-3/VBN||levels-9/NNS	cop||factor-16/NN||is-12/VBZ	det||factor-16/NN||a-13/DT	amod||factor-16/NN||strong-14/JJ	nn||factor-16/NN||risk-15/NN	conj_and||defined-3/VBN||factor-16/NN	amod||events-21/NNS||many-18/JJ	amod||events-21/NNS||negative-19/JJ	amod||events-21/NNS||cardiovascular-20/JJ	prep_for||factor-16/NN||events-21/NNS	hypercholesterolemia-1||cholesterol-8||no||hypercholesterolemia is defined as excessively high plasma cholesterol levels, and is a strong risk factor for many negative cardiovascular events.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effects-4/NNS||the-3/DT	dobj||investigated-2/VBD||effects-4/NNS	prep_on||effects-4/NNS||hemodynamics-6/NNS	nn||exchange-9/NN||gas-8/NN	prep_on||effects-4/NNS||exchange-9/NN	conj_and||hemodynamics-6/NNS||exchange-9/NN	det||emulsion-13/NN||a-11/DT	nn||emulsion-13/NN||lipid-12/NN	prep_of||effects-4/NNS||emulsion-13/NN	vmod||emulsion-13/NN||enriched-14/VBN	amod||fattyacids-17/NNS||omega-3-16/JJ	prep_with||enriched-14/VBN||fattyacids-17/NNS	prep_in||fattyacids-17/NNS||patients-19/NNS	prep_with||patients-19/NNS||ards-21/NNS	ards-21||gas-8||no_rel||we investigated the effects on hemodynamics and gas exchange of a lipid emulsion enriched with omega-3 fattyacids in patients with ards.
amod||management-3/NN||basic-1/JJ	nn||management-3/NN||lymphedema-2/NN	nsubj||feasible-5/JJ||management-3/NN	nsubj||effective-7/JJ||management-3/NN	cop||feasible-5/JJ||is-4/VBZ	root||ROOT-0/null||feasible-5/JJ	conj_and||feasible-5/JJ||effective-7/JJ	amod||areas-10/NNS||resource-limited-9/JJ	prep_in||feasible-5/JJ||areas-10/NNS	nsubj||endemic-13/JJ||areas-10/NNS	cop||endemic-13/JJ||are-12/VBP	rcmod||areas-10/NNS||endemic-13/JJ	prep_for||endemic-13/JJ||lymphaticfilariasis-15/NNS	lymphaticfilariasis-15||basic-1||no_rel||basic lymphedema management is feasible and effective in resource-limited areas that are endemic for lymphaticfilariasis.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||evaluate-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||efficacy-10/NN||the-9/DT	dobj||evaluate-8/VB||efficacy-10/NN	dobj||evaluate-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	amod||extended-release-16/NN||methylphenidatehcl-14/JJ	nn||extended-release-16/NN||oros-15/NNS	prep_of||efficacy-10/NN||extended-release-16/NN	appos||extended-release-16/NN||oros-mph-18/NN	prep_among||extended-release-16/NN||children-21/NNS	prep_with||children-21/NNS||attentiondeficithyperactivitydisorder-23/NN	nsubjpass||treated-31/VBN||attentiondeficithyperactivitydisorder-23/NN	dep||attentiondeficithyperactivitydisorder-23/NN||adhd-25/VBN	aux||treated-31/VBN||had-28/VBD	auxpass||treated-31/VBN||been-29/VBN	advmod||treated-31/VBN||previously-30/RB	rcmod||attentiondeficithyperactivitydisorder-23/NN||treated-31/VBN	amod||immediate-release-34/NN||methylphenidatehcl-33/JJ	prep_with||treated-31/VBN||immediate-release-34/NN	appos||extended-release-16/NN||mph-ir-36/NN	attentiondeficithyperactivitydisorder-23||methylphenidatehcl-33||yes||the objective of this study was to evaluate the efficacy and safety of methylphenidatehcl oros extended-release (oros-mph) among children with attentiondeficithyperactivitydisorder (adhd) who had been previously treated with methylphenidatehcl immediate-release (mph-ir).
root||ROOT-0/null||in-1/IN	pobj||in-1/IN||patients-2/NNS	vmod||patients-2/NNS||submitted-3/VBN	amod||resection-6/NN||ileal-5/JJ	prep_to||submitted-3/VBN||resection-6/NN	prep_for||resection-6/NN||crohn-8/NN	amod||non-invasive-11/JJ||sdisease-10/JJ	amod||crohn-8/NN||non-invasive-11/JJ	amod||ultrasonography-15/NN||small-12/JJ	nn||ultrasonography-15/NN||intestine-13/NN	nn||ultrasonography-15/NN||contrast-14/NN	dobj||submitted-3/VBN||ultrasonography-15/NN	num||ultrasonography-15/NN||1-16/CD	agent||submitted-3/VBN||assessing-19/VBG	nsubj||detects-25/VBZ||thickness-20/NN	nsubj||assessing-38/VBG||thickness-20/NN	amod||anastomosis-23/NNS||ileo-colonic-22/JJ	prep_of||thickness-20/NN||anastomosis-23/NNS	advmod||detects-25/VBZ||accurately-24/RB	advcl||assessing-19/VBG||detects-25/VBZ	amod||recurrence-32/NN||initial-26/JJ	amod||recurrence-32/NN||minimal-28/JJ	nn||recurrence-32/NN||crohn-29/NN	amod||recurrence-32/NN||sdisease-31/JJ	dobj||detects-25/VBZ||recurrence-32/NN	dep||assessing-38/VBG||2-35/LS	mark||assessing-38/VBG||by-37/IN	advcl||assessing-19/VBG||assessing-38/VBG	conj_and||detects-25/VBZ||assessing-38/VBG	det||thickness-40/NN||both-39/DT	dobj||assessing-38/VBG||thickness-40/NN	amod||anastomosis-43/NNS||ileo-colonic-42/JJ	prep_of||thickness-40/NN||anastomosis-43/NNS	dobj||assessing-38/VBG||extension-45/NN	conj_and||thickness-40/NN||extension-45/NN	amod||lesions-48/NNS||intramural-47/JJ	prep_of||extension-45/NN||lesions-48/NNS	amod||grades-52/NNS||neo-terminal-50/JJ	nn||grades-52/NNS||ileum-51/NN	prep_of||lesions-48/NNS||grades-52/NNS	det||severity-54/NN||the-53/DT	dep||assessing-38/VBG||severity-54/NN	det||recurrence-58/NN||the-56/DT	amod||recurrence-58/NN||post-surgical-57/JJ	prep_of||severity-54/NN||recurrence-58/NN	crohn'sdisease--1||contrast-14||no_rel||in patients submitted to ileal resection for crohn'sdisease non-invasive small intestine contrast ultrasonography 1) by assessing thickness of ileo-colonic anastomosis accurately detects initial, minimal crohn'sdisease recurrence, and 2) by assessing both thickness of ileo-colonic anastomosis and extension of intramural lesions of neo-terminal ileum grades the severity of the post-surgical recurrence.
advmod||characterized-8/VBN||recently-1/RB	det||microsatellite-6/NN||a-3/DT	nn||microsatellite-6/NN||gan-4/NN	amod||microsatellite-6/NN||polymorphic-5/JJ	nsubjpass||characterized-8/VBN||microsatellite-6/NN	auxpass||characterized-8/VBN||was-7/VBD	root||ROOT-0/null||characterized-8/VBN	det||promoter-13/NN||the-10/DT	nn||promoter-13/NN||mouse-11/NN	amod||promoter-13/NN||fli1-12/JJ	prep_in||characterized-8/VBN||promoter-13/NN	nsubj||modulates-15/VBZ||promoter-13/NN	nsubjpass||truncated-20/VBN||promoter-13/NN	rcmod||promoter-13/NN||modulates-15/VBZ	nn||activity-17/NN||promoter-16/NN	dobj||modulates-15/VBZ||activity-17/NN	auxpass||truncated-20/VBN||is-19/VBZ	rcmod||promoter-13/NN||truncated-20/VBN	conj_and||modulates-15/VBZ||truncated-20/VBN	num||models-25/NNS||two-22/CD	amod||models-25/NNS||lupus-23/JJ	nn||models-25/NNS||mouse-24/NN	prep_in||truncated-20/VBN||models-25/NNS	prepc_compared_to||models-25/NNS||to-27/TO	amod||prone-29/JJ||non-autoimmune-28/JJ	amod||mice-30/NNS||prone-29/JJ	pobj||models-25/NNS||mice-30/NNS	gan-4||lupus-23||no_rel||recently, a gan polymorphic microsatellite was characterized in the mouse fli1 promoter that modulates promoter activity and is truncated in two lupus mouse models compared to non-autoimmune prone mice.
amod||endpoints-3/NNS||secondary-1/JJ	nn||endpoints-3/NNS||efficacy-2/NN	nsubj||included-4/VBD||endpoints-3/NNS	root||ROOT-0/null||included-4/VBD	det||change-6/NN||the-5/DT	dobj||included-4/VBD||change-6/NN	prep_from||included-4/VBD||baseline-8/NN	amod||bp-13/NN||mean-10/JJ	amod||bp-13/NN||seated-11/VBN	amod||bp-13/NN||systolic-12/JJ	prep_in||included-4/VBD||bp-13/NN	appos||bp-13/NN||sbp-15/NN	prep_in||included-4/VBD||proportions-18/NNS	conj_and||bp-13/NN||proportions-18/NNS	prep_of||proportions-18/NNS||patients-20/NNS	vmod||patients-20/NNS||achieving-21/VBG	nn||goal-23/NN||bp-22/NN	dobj||achieving-21/VBG||goal-23/NN	number||140/90-26/CD||<-25/CD	num||â-27/NN||140/90-26/CD	dep||proportions-18/NNS||â-27/NN	num||$-31/$||$-28/$	number||mmâ-30/CD||‰-29/CD	num||$-28/$||mmâ-30/CD	nsubj||mmâ-40/VBP||$-31/$	number||hg-33/CD||‰-32/CD	num||$-31/$||hg-33/CD	number||130/80-36/CD||<-35/CD	num||â-37/NN||130/80-36/CD	conj_or||$-31/$||â-37/NN	nsubj||mmâ-40/VBP||â-37/NN	dep||â-37/NN||$-38/$	num||$-38/$||‰-39/CD	rcmod||â-27/NN||mmâ-40/VBP	dobj||mmâ-40/VBP||$-41/$	number||hg-43/CD||‰-42/CD	num||$-41/$||hg-43/CD	prep_in||$-41/$||patients-45/NNS	prep_with||â-27/NN||diabetes-47/NN	det||number-52/NN||the-51/DT	prep_in||included-4/VBD||number-52/NN	conj_and||bp-13/NN||number-52/NN	conj_and||bp-13/NN||percentage-54/NN	conj_and||number-52/NN||percentage-54/NN	prep_of||number-52/NN||patients-56/NNS	vmod||patients-56/NNS||achieving-57/VBG	det||range-59/NN||a-58/DT	dobj||achieving-57/VBG||range-59/NN	nn||targets-62/NNS||bp-61/NN	prep_of||range-59/NN||targets-62/NNS	hg-43||secondary-1||no_rel||secondary efficacy endpoints included the change from baseline in mean seated systolic bp (sbp), proportions of patients achieving bp goal (<140/90â€‰mmâ€‰hg or <130/80â€‰mmâ€‰hg in patients with diabetes), and the number and percentage of patients achieving a range of bp targets.
det||relationship-2/NN||the-1/DT	nsubjpass||investigated-21/VBN||relationship-2/NN	amod||hbp-5/NN||on-treatment-4/JJ	prep_between||relationship-2/NN||hbp-5/NN	vmod||relationship-2/NN||measured-7/VBN	advmod||measured-7/VBN||twice-8/RB	det||morning-11/NN||the-10/DT	prep_in||measured-7/VBN||morning-11/NN	prep_in||measured-7/VBN||twice-13/RB	advmod||morning-11/NN||twice-13/RB	conj_and||morning-11/NN||twice-13/RB	prep_at||measured-7/VBN||bedtime-15/JJ	nn||events-19/NNS||cv-18/NN	prep_at||measured-7/VBN||events-19/NNS	conj_and||bedtime-15/JJ||events-19/NNS	auxpass||investigated-21/VBN||was-20/VBD	root||ROOT-0/null||investigated-21/VBN	prt||investigated-21/VBN||in-22/RP	amod||patients-28/NNS||20â-24/JJ	num||patients-28/NNS||$-25/$	number||000-27/CD||‰-26/CD	num||$-25/$||000-27/CD	prep_over||investigated-21/VBN||patients-28/NNS	det||study-48/NN||the-30/DT	amod||study-48/NN||honest-31/JJ	nn||measurement-36/NN||home-33/NN	nn||measurement-36/NN||blood-34/NN	nn||measurement-36/NN||pressure-35/NN	dep||study-48/NN||measurement-36/NN	amod||naive-39/JJ||olmesartan-38/JJ	amod||patients-40/NNS||naive-39/JJ	prep_with||measurement-36/NN||patients-40/NNS	aux||establish-42/VB||to-41/TO	vmod||measurement-36/NN||establish-42/VB	amod||pressure-46/NN||standard-43/JJ	nn||pressure-46/NN||target-44/NN	nn||pressure-46/NN||blood-45/NN	dobj||establish-42/VB||pressure-46/NN	prep_in||investigated-21/VBN||study-48/NN	det||study-55/NN||a-50/DT	amod||study-55/NN||prospective-51/JJ	amod||study-55/NN||2-year-53/JJ	amod||study-55/NN||observational-54/JJ	appos||study-48/NN||study-55/NN	prep_of||study-55/NN||treatment-57/NN	det||blocker-62/NN||an-59/DT	nn||blocker-62/NN||angiotensin-60/NN	nn||blocker-62/NN||receptor-61/NN	prep_with||treatment-57/NN||blocker-62/NN	appos||study-48/NN||olmesartan-64/NN	appos||olmesartan-64/NN||olm-66/NN	amod||patients-72/NNS||olm-naive-70/JJ	nn||patients-72/NNS||hypertensive-71/NN	prep_in||olmesartan-64/NN||patients-72/NNS	hbp-5||olmesartan-64||yes||the relationship between on-treatment hbp, measured twice in the morning and twice at bedtime, and cv events was investigated in over 20â€‰000 patients in the honest (home blood pressure measurement with olmesartan naive patients to establish standard target blood pressure) study, a prospective, 2-year observational study of treatment with an angiotensin receptor blocker, olmesartan (olm), in olm-naive hypertensive patients.
nsubj||form-4/NN||neurosyphilis-1/NNS	cop||form-4/NN||is-2/VBZ	det||form-4/NN||a-3/DT	root||ROOT-0/null||form-4/NN	amod||infection-7/NN||tertiarysyphilis-6/JJ	prep_of||form-4/NN||infection-7/NN	vmod||infection-7/NN||caused-8/VBN	det||treponemapallidum-13/NN||the-10/DT	amod||treponemapallidum-13/NN||spirochete-11/JJ	nn||treponemapallidum-13/NN||bacterium-12/NN	agent||caused-8/VBN||treponemapallidum-13/NN	tertiarysyphilis-6||treponemapallidum-13||no||neurosyphilis is a form of tertiarysyphilis infection caused by the spirochete bacterium treponemapallidum.
det||strategy-4/NN||a-1/DT	amod||strategy-4/NN||nanoscale-2/JJ	nn||strategy-4/NN||modification-3/NN	nsubj||incorporate-7/VB||strategy-4/NN	nsubjpass||proposed-21/VBN||strategy-4/NN	nsubj||give-23/VB||strategy-4/NN	aux||incorporate-7/VB||can-6/MD	rcmod||strategy-4/NN||incorporate-7/VB	dobj||incorporate-7/VB||chondroitinsulfate-8/NN	appos||chondroitinsulfate-8/NN||cs-10/NN	det||materials-17/NNS||the-13/DT	amod||materials-17/NNS||cross-linked-14/JJ	amod||materials-17/NNS||porous-15/JJ	nn||materials-17/NNS||gelatin-16/NN	prep_into||incorporate-7/VB||materials-17/NNS	aux||proposed-21/VBN||has-18/VBZ	advmod||proposed-21/VBN||previously-19/RB	auxpass||proposed-21/VBN||been-20/VBN	root||ROOT-0/null||proposed-21/VBN	aux||give-23/VB||to-22/TO	xcomp||proposed-21/VBN||give-23/VB	amod||performance-25/NN||superior-24/JJ	dobj||give-23/VB||performance-25/NN	amod||scaffolds-30/NNS||designed-27/JJ	amod||scaffolds-30/NNS||corneal-28/JJ	nn||scaffolds-30/NNS||keratocyte-29/NN	prep_for||give-23/VB||scaffolds-30/NNS	cross--1||chondroitinsulfate-8||no_rel||a nanoscale modification strategy that can incorporate chondroitinsulfate (cs) into the cross-linked porous gelatin materials has previously been proposed to give superior performance for designed corneal keratocyte scaffolds.
prep||remain-13/VB||given-1/VBN	poss||cost-4/NN||its-2/PRP$	amod||cost-4/NN||low-3/JJ	pobj||given-1/VBN||cost-4/NN	amod||experience-8/NN||extensive-6/JJ	amod||experience-8/NN||clinical-7/JJ	pobj||given-1/VBN||experience-8/NN	conj_and||cost-4/NN||experience-8/NN	nsubj||remain-13/VB||allopurinol-10/NN	aux||remain-13/VB||will-11/MD	advmod||remain-13/VB||likely-12/RB	root||ROOT-0/null||remain-13/VB	det||drug-16/NN||the-14/DT	amod||drug-16/NN||first-line-15/JJ	xcomp||remain-13/VB||drug-16/NN	prep_for||remain-13/VB||management-18/NN	prep_of||management-18/NN||hyperuricemia-20/NN	prep_of||management-18/NN||gout-22/NN	conj_and||hyperuricemia-20/NN||gout-22/NN	gout-22||allopurinol-10||yes||given its low cost and extensive clinical experience, allopurinol will likely remain the first-line drug for management of hyperuricemia and gout.
det||survey-3/NN||a-1/DT	amod||survey-3/NN||cross-sectional-2/JJ	nsubjpass||conducted-5/VBN||survey-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	num||detentions-8/NNS||10-7/CD	prep_in||conducted-5/VBN||detentions-8/NNS	nn||province-11/NN||hunan-10/NN	prep_in||detentions-8/NNS||province-11/NN	appos||province-11/NN||china-13/NN	amod||information-17/NN||demographic-16/JJ	nsubjpass||collected-26/VBN||information-17/NN	prep_along_with||collected-26/VBN||knowledge-20/NN	conj_and||knowledge-20/NN||attitude-22/NN	prep_along_with||collected-26/VBN||attitude-22/NN	prep_of||knowledge-20/NN||hiv/aids-24/NNS	auxpass||collected-26/VBN||was-25/VBD	conj_and||conducted-5/VBN||collected-26/VBN	amod||interviews-29/NNS||standardized-28/JJ	prep_through||collected-26/VBN||interviews-29/NNS	aids--1||hiv--1||no||a cross-sectional survey was conducted in 10 detentions in hunan province, china, and demographic information along with knowledge and attitude of hiv/aids was collected through standardized interviews.
nsubj||utilize-2/VBD||we-1/PRP	root||ROOT-0/null||utilize-2/VBD	nn||data-4/NNS||program-3/NN	dobj||utilize-2/VBD||data-4/NNS	det||organization-9/NN||the-6/DT	nn||organization-9/NN||aids-7/NNS	nn||organization-9/NN||support-8/NN	prep_from||utilize-2/VBD||organization-9/NN	appos||organization-9/NN||taso-11/NNP	prep_in||organization-9/NN||uganda-14/NN	aux||compare-16/VB||to-15/TO	vmod||utilize-2/VBD||compare-16/VB	dobj||compare-16/VB||outcomes-17/NNS	nn||recipients-20/NNS||fa-19/NN	prep_among||outcomes-17/NNS||recipients-20/NNS	det||group-24/NN||a-22/DT	nn||group-24/NN||control-23/NN	prep_to||compare-16/VB||group-24/NN	xcomp||utilize-2/VBD||using-26/VBG	nn||methods-33/NNS||propensity-27/NN	nn||methods-33/NNS||score-28/NN	nn||methods-33/NNS||matching-29/NN	appos||methods-33/NNS||psm-31/NN	dobj||using-26/VBG||methods-33/NNS	num||clients-38/NNS||14,481-35/CD	amod||clients-38/NNS||hiv-infected-36/JJ	nn||clients-38/NNS||taso-37/NN	prep_among||using-26/VBG||clients-38/NNS	aids-7||hiv--1||no||we utilize program data from the aids support organization (taso) in uganda to compare outcomes among fa recipients to a control group, using propensity score matching (psm) methods among 14,481 hiv-infected taso clients.
nsubjpass||prescribed-7/VBN||acetaminophen-1/NN	appos||acetaminophen-1/NN||aap-3/NN	auxpass||prescribed-7/VBN||is-5/VBZ	advmod||prescribed-7/VBN||widely-6/RB	root||ROOT-0/null||prescribed-7/VBN	prep_for||prescribed-7/VBN||treatment-9/NN	amod||pain-12/NN||mild-11/JJ	prep_of||treatment-9/NN||pain-12/NN	prep_of||treatment-9/NN||fever-14/NN	conj_and||pain-12/NN||fever-14/NN	amod||countries-17/NNS||western-16/JJ	prep_in||prescribed-7/VBN||countries-17/NNS	pain-12||acetaminophen-1||yes||acetaminophen (aap) is widely prescribed for treatment of mild pain and fever in western countries.
advmod||promoted-13/VBD||overall-1/RB	num||%-4/NN||30-3/CD	nsubj||promoted-13/VBD||%-4/NN	amod||papulosis-7/NNS||bowenoid-6/JJ	prep_of||%-4/NN||papulosis-7/NNS	amod||hpv-11/NN||high-9/JJ	nn||hpv-11/NN||risk-10/NN	prep_with||papulosis-7/NNS||hpv-11/NN	advmod||promoted-13/VBD||strongly-12/RB	root||ROOT-0/null||promoted-13/VBD	dobj||promoted-13/VBD||iaps-14/NNS	amod||iaps-14/NNS||family-15/NN	amod||iaps-14/NNS||c-myc-17/JJ	conj_and||family-15/NN||c-myc-17/JJ	nsubj||activate-23/VB||condylomaacuminatum-19/NN	aux||activate-23/VB||did-20/VBD	neg||activate-23/VB||not-21/RB	advmod||activate-23/VB||significantly-22/RB	conj_but||promoted-13/VBD||activate-23/VB	det||genes-25/NNS||those-24/DT	dobj||activate-23/VB||genes-25/NNS	condylomaacuminatum-19||hpv-11||no||overall, 30% of bowenoid papulosis with high risk hpv strongly promoted iaps family and c-myc but condylomaacuminatum did not significantly activate those genes.
amod||prionprotein-2/NN||protease-resistant-1/JJ	nsubjpass||analysed-7/VBN||prionprotein-2/NN	appos||prionprotein-2/NN||prpres-4/NNS	auxpass||analysed-7/VBN||was-6/VBD	root||ROOT-0/null||analysed-7/VBN	amod||blot-10/NN||western-9/JJ	agent||analysed-7/VBN||blot-10/NN	det||spleen-13/NN||the-12/DT	prep_in||analysed-7/VBN||spleen-13/NN	amod||mice-16/NNS||transgenic-15/JJ	prep_of||spleen-13/NN||mice-16/NNS	nsubj||express-21/VBP||mice-16/NNS	appos||mice-16/NNS||tgovprp4-18/NNP	rcmod||mice-16/NNS||express-21/VBP	det||prionprotein-24/NN||the-22/DT	amod||prionprotein-24/NN||ovine-23/JJ	dobj||express-21/VBP||prionprotein-24/NN	det||control-27/NN||the-26/DT	prep_under||express-21/VBP||control-27/NN	det||promoter-32/NN||the-29/DT	amod||promoter-32/NN||neuron-specific-30/JJ	nn||promoter-32/NN||enolase-31/NN	prep_of||control-27/NN||promoter-32/NN	prep_after||express-21/VBP||infection-35/NN	amod||route-38/NN||intra-cerebral-37/JJ	prep_by||express-21/VBP||route-38/NN	det||variety-41/NN||a-40/DT	prep_with||express-21/VBP||variety-41/NN	prep_of||variety-41/NN||transmissiblespongiformencephalopathies-43/NNS	appos||transmissiblespongiformencephalopathies-43/NNS||tses-45/NNS	prep_from||express-21/VBP||cattle-48/NNS	amod||ruminants-51/NNS||small-50/JJ	prep_from||express-21/VBP||ruminants-51/NNS	conj_and||cattle-48/NNS||ruminants-51/NNS	transmissiblespongiformencephalopathies-43||prionprotein-24||no||protease-resistant prionprotein (prpres) was analysed by western blot in the spleen of transgenic mice (tgovprp4) that express the ovine prionprotein under the control of the neuron-specific enolase promoter, after infection by intra-cerebral route with a variety of transmissiblespongiformencephalopathies (tses) from cattle and small ruminants.
det||doses-3/NNS||the-2/DT	prep_at||lidocaine-13/JJ||doses-3/NNS	vmod||doses-3/NNS||used-4/VBN	nsubj||lidocaine-13/JJ||riluzole-6/NN	nsubj||effective-31/JJ||riluzole-6/NN	cop||lidocaine-13/JJ||was-7/VBD	advmod||lidocaine-13/JJ||at-8/IN	pobj||at-8/IN||least-9/JJS	prep_as||at-8/IN||effective-11/JJ	advmod||lidocaine-13/JJ||as-12/RB	root||ROOT-0/null||lidocaine-13/JJ	prepc_at||lidocaine-13/JJ||reducing-15/VBG	det||number-17/NN||the-16/DT	dobj||reducing-15/VBG||number-17/NN	prep_of||number-17/NN||episodes-19/NNS	amod||vt-22/NN||ischaemic-21/JJ	prep_of||episodes-19/NNS||vt-22/NN	prep_of||episodes-19/NNS||vf-24/NN	conj_or||vt-22/NN||vf-24/NN	prep_in||reducing-15/VBG||pigs-26/NNS	advmod||effective-31/JJ||much-29/RB	advmod||effective-31/JJ||more-30/RBR	conj_and||lidocaine-13/JJ||effective-31/JJ	prepc_at||effective-31/JJ||reducing-33/VBG	det||number-35/NN||the-34/DT	dobj||reducing-33/VBG||number-35/NN	prep_of||number-35/NN||pvcs-37/NNS	pvcs-37||lidocaine-13||yes||at the doses used, riluzole was at least as effective as lidocaine at reducing the number of episodes of ischaemic vt or vf in pigs, and much more effective at reducing the number of pvcs.
det||levels-3/NNS||the-1/DT	nn||levels-3/NNS||expression-2/NN	nsubjpass||downregulated-41/VBN||levels-3/NNS	amod||cells-9/NNS||gga-mir-26a-5/JJ	prep_in||gga-mir-26a-5/JJ||chicken-7/NN	nn||cells-9/NNS||lymphoma-8/NN	prep_of||levels-3/NNS||cells-9/NNS	vmod||cells-9/NNS||transformed-10/VBN	number||distinct-13/JJ||3-12/CD	amod||viruses-16/NNS||distinct-13/JJ	amod||viruses-16/NNS||avian-14/JJ	amod||viruses-16/NNS||oncogenic-15/JJ	agent||transformed-10/VBN||viruses-16/NNS	amod||mdv-24/NN||viz-18/JJ	nn||mdv-24/NN||marek-19/NN	nn||mdv-24/NN||sdisease-21/NN	nn||mdv-24/NN||virus-22/NN	agent||transformed-10/VBN||mdv-24/NN	conj_and||viruses-16/NNS||mdv-24/NN	nn||virus-29/NN||avian-27/NN	nn||virus-29/NN||leukosis-28/NN	agent||transformed-10/VBN||virus-29/NN	conj_and||viruses-16/NNS||virus-29/NN	appos||virus-29/NN||alv-31/NN	amod||virus-35/NN||reticuloendotheliosis-34/JJ	agent||transformed-10/VBN||virus-35/NN	conj_and||viruses-16/NNS||virus-35/NN	appos||virus-35/NN||rev-37/NN	auxpass||downregulated-41/VBN||were-39/VBD	advmod||downregulated-41/VBN||consistently-40/RB	root||ROOT-0/null||downregulated-41/VBN	prepc_compared_to||downregulated-41/VBN||to-43/TO	det||levels-45/NNS||the-44/DT	pobj||downregulated-41/VBN||levels-45/NNS	det||lymphocytes-49/NNS||the-47/DT	amod||lymphocytes-49/NNS||normal-48/JJ	prep_in||levels-45/NNS||lymphocytes-49/NNS	virus-35||viruses-16||no||the expression levels of gga-mir-26a in chicken lymphoma cells transformed by 3 distinct avian oncogenic viruses, viz marek'sdisease virus (mdv), avian leukosis virus (alv) and reticuloendotheliosis virus (rev) were consistently downregulated compared to the levels in the normal lymphocytes.
amod||men-2/NNS||fifty-nine-1/JJ	nsubjpass||studied-14/VBN||men-2/NNS	advmod||controlled-5/VBN||well-4/RB	amod||type2diabetes-6/NNS||controlled-5/VBN	prep_with||men-2/NNS||type2diabetes-6/NNS	num||men-12/NNS||18-8/CD	amod||men-12/NNS||age-matched-9/JJ	amod||men-12/NNS||healthy-10/JJ	amod||men-12/NNS||normoglycemic-11/JJ	prep_with||men-2/NNS||men-12/NNS	conj_and||type2diabetes-6/NNS||men-12/NNS	auxpass||studied-14/VBN||were-13/VBD	root||ROOT-0/null||studied-14/VBN	xcomp||studied-14/VBN||using-15/VBG	amod||tomography-18/NN||positron-16/JJ	nn||tomography-18/NN||emission-17/NN	dobj||using-15/VBG||tomography-18/NN	aux||assess-20/VB||to-19/TO	vmod||using-15/VBG||assess-20/VB	amod||perfusion-23/NN||hepatic-21/JJ	nn||perfusion-23/NN||tissue-22/NN	dobj||assess-20/VB||perfusion-23/NN	amod||glucose-26/NN||insulin-stimulated-25/JJ	dobj||assess-20/VB||glucose-26/NN	amod||metabolism-31/NN||fasting-29/JJ	amod||metabolism-31/NN||fattyacid-30/JJ	dobj||assess-20/VB||metabolism-31/NN	conj_and||glucose-26/NN||metabolism-31/NN	dobj||assess-20/VB||respectively-33/RB	advmod||glucose-26/NN||respectively-33/RB	conj_and||glucose-26/NN||respectively-33/RB	prep_in||assess-20/VB||relation-36/NN	amod||content-40/NN||hepatic-38/JJ	nn||content-40/NN||triglyceride-39/NN	prep_to||relation-36/NN||content-40/NN	vmod||content-40/NN||quantified-42/VBN	amod||spectroscopy-47/NN||proton-44/JJ	amod||spectroscopy-47/NN||magnetic-45/JJ	nn||spectroscopy-47/NN||resonance-46/NN	agent||quantified-42/VBN||spectroscopy-47/NN	type2diabetes-6||insulin--1||yes||fifty-nine men with well controlled type2diabetes and 18 age-matched healthy normoglycemic men were studied using positron emission tomography to assess hepatic tissue perfusion, insulin-stimulated glucose, and fasting fattyacid metabolism, respectively, in relation to hepatic triglyceride content, quantified by proton magnetic resonance spectroscopy.
nsubjpass||approved-9/VBN||bevacizumab-1/NN	prep_in||bevacizumab-1/NN||combination-3/NN	nn||alfa-6/NN||interferon-5/NN	prep_with||combination-3/NN||alfa-6/NN	auxpass||approved-9/VBN||is-7/VBZ	advmod||approved-9/VBN||now-8/RB	root||ROOT-0/null||approved-9/VBN	mark||ve-13/VBP||for-10/IN	nn||¯-12/NNP||treatment-naã-11/NNP	nsubj||ve-13/VBP||¯-12/NNP	advcl||approved-9/VBN||ve-13/VBP	amod||renalcellcarcinoma-15/NN||advanced-14/VBN	dobj||ve-13/VBP||renalcellcarcinoma-15/NN	appos||renalcellcarcinoma-15/NN||rcc-17/NN	preconj||us-22/PRP||both-20/PDT	det||us-22/PRP||the-21/DT	prep_in||renalcellcarcinoma-15/NN||us-22/PRP	prep_in||renalcellcarcinoma-15/NN||europe-24/NN	conj_and||us-22/PRP||europe-24/NN	interferon-5||rcc-17||no_rel||bevacizumab in combination with interferon alfa is now approved for treatment-naã¯ve advanced renalcellcarcinoma (rcc) in both the us and europe.
prepc_by||estimated-15/VBD||combining-2/VBG	dobj||combining-2/VBG||information-3/NN	nn||relations-6/NNS||risk-5/NN	prep_on||information-3/NN||relations-6/NNS	det||number-9/NN||a-8/DT	prep_from||combining-2/VBG||number-9/NN	amod||sources-12/NNS||published-11/VBN	prep_of||number-9/NN||sources-12/NNS	nsubj||estimated-15/VBD||we-14/PRP	root||ROOT-0/null||estimated-15/VBD	amod||fractions-17/NNS||alcohol-attributable-16/JJ	dobj||estimated-15/VBD||fractions-17/NNS	appos||fractions-17/NNS||aafs-19/NNS	prep_of||fractions-17/NNS||hiv/aids-22/NNS	det||procedure-26/NN||a-24/DT	amod||procedure-26/NN||stepwise-25/JJ	prep_in||estimated-15/VBD||procedure-26/NN	aids--1||hiv--1||no||by combining information on risk relations from a number of published sources, we estimated alcohol-attributable fractions (aafs) of hiv/aids in a stepwise procedure.
nsubjpass||approved-14/VBN||levofloxacin-1/NN	det||fluoroquinolone-4/NN||a-3/DT	appos||levofloxacin-1/NN||fluoroquinolone-4/NN	appos||levofloxacin-1/NN||l-isomer-6/NN	conj_and||fluoroquinolone-4/NN||l-isomer-6/NN	det||ofloxacin-10/NN||the-8/DT	amod||ofloxacin-10/NN||racemate-9/JJ	prep_of||fluoroquinolone-4/NN||ofloxacin-10/NN	aux||approved-14/VBN||has-12/VBZ	auxpass||approved-14/VBN||been-13/VBN	root||ROOT-0/null||approved-14/VBN	det||treatment-17/NN||the-16/DT	prep_for||approved-14/VBN||treatment-17/NN	amod||bacterialinfections-22/NNS||acute-19/JJ	conj_and||acute-19/JJ||chronic-21/JJ	amod||bacterialinfections-22/NNS||chronic-21/JJ	prep_of||treatment-17/NN||bacterialinfections-22/NNS	bacterialinfections-22||levofloxacin-1||yes||levofloxacin, a fluoroquinolone and l-isomer of the racemate ofloxacin, has been approved for the treatment of acute and chronic bacterialinfections.
det||combination-3/NN||the-1/DT	amod||combination-3/NN||budesonide/formoterol-2/JJ	nsubjpass||used-6/VBN||combination-3/NN	auxpass||used-6/VBN||is-4/VBZ	advmod||used-6/VBN||successfully-5/RB	root||ROOT-0/null||used-6/VBN	amod||relief-9/NN||fast-8/JJ	prep_for||used-6/VBN||relief-9/NN	nn||symptoms-12/NNS||asthma-11/NN	prep_of||relief-9/NN||symptoms-12/NNS	prep_in||symptoms-12/NNS||addition-14/NN	poss||use-17/NN||its-16/PRP$	prep_to||used-6/VBN||use-17/NN	nn||therapy-20/NN||maintenance-19/NN	prep_as||used-6/VBN||therapy-20/NN	asthma-11||budesonide--1||yes||the budesonide/formoterol combination is successfully used for fast relief of asthma symptoms in addition to its use as maintenance therapy.
nsubj||remain-11/VBP||diseases-1/NNS	vmod||diseases-1/NNS||linked-2/VBN	prep_to||linked-2/VBN||thiaminedeficiency-4/NN	dep||diseases-1/NNS||polyneuritis-6/NNS	amod||syndrome-9/NN||wernicke-korsakoff-8/JJ	appos||polyneuritis-6/NNS||syndrome-9/NN	root||ROOT-0/null||remain-11/VBP	acomp||remain-11/VBP||frequent-12/JJ	prep_among||remain-11/VBP||alcoholabusers-14/NNS	amod||populations-18/NNS||other-16/JJ	nn||populations-18/NNS||risk-17/NN	prep_among||remain-11/VBP||populations-18/NNS	conj_and||alcoholabusers-14/NNS||populations-18/NNS	alcohol--1||thiaminedeficiency-4||no_rel||diseases linked to thiaminedeficiency (polyneuritis, wernicke-korsakoff syndrome) remain frequent among alcoholabusers and other risk populations.
amod||studies-2/NNS||well-controlled-1/JJ	nsubj||confirm-23/VBP||studies-2/NNS	prep_in||studies-2/NNS||patients-4/NNS	amod||rhinitis-8/NNS||seasonal-6/JJ	amod||rhinitis-8/NNS||allergic-7/JJ	prep_with||patients-4/NNS||rhinitis-8/NNS	appos||rhinitis-8/NNS||sar-10/NN	amod||rhinitis-14/NNS||perennial-13/JJ	prep_with||patients-4/NNS||rhinitis-14/NNS	conj_or||rhinitis-8/NNS||rhinitis-14/NNS	appos||rhinitis-14/NNS||pr-16/NN	prep_with||patients-4/NNS||vasomotorrhinitis-19/NNS	conj_or||rhinitis-8/NNS||vasomotorrhinitis-19/NNS	appos||vasomotorrhinitis-19/NNS||vmr-21/NN	root||ROOT-0/null||confirm-23/VBP	mark||has-28/VBZ||that-24/IN	amod||spray-27/NN||azelastine-25/JJ	amod||spray-27/NN||nasal-26/JJ	nsubj||has-28/VBZ||spray-27/NN	nsubj||improves-36/VBZ||spray-27/NN	ccomp||confirm-23/VBP||has-28/VBZ	det||onset-31/NN||a-29/DT	amod||onset-31/NN||rapid-30/JJ	dobj||has-28/VBZ||onset-31/NN	prep_of||onset-31/NN||action-33/NN	ccomp||confirm-23/VBP||improves-36/VBZ	conj_and||has-28/VBZ||improves-36/VBZ	amod||symptoms-38/NNS||nasal-37/JJ	dobj||improves-36/VBZ||symptoms-38/NNS	vmod||symptoms-38/NNS||associated-39/VBN	prep_with||associated-39/VBN||rhinitis-41/NNS	amod||congestion-45/NN||nasal-44/JJ	prep_such_as||rhinitis-41/NNS||congestion-45/NN	amod||drip-48/NN||post-nasal-47/JJ	prep_such_as||rhinitis-41/NNS||drip-48/NN	conj_and||congestion-45/NN||drip-48/NN	vasomotorrhinitis-19||azelastine-25||yes||well-controlled studies in patients with seasonal allergic rhinitis (sar), perennial rhinitis (pr) or vasomotorrhinitis (vmr) confirm that azelastine nasal spray has a rapid onset of action, and improves nasal symptoms associated with rhinitis such as nasal congestion and post-nasal drip.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||now-2/RB	root||ROOT-0/null||show-3/VBP	det||treatment-5/NN||that-4/DT	dobj||show-3/VBP||treatment-5/NN	amod||mice-8/NNS||tumor-bearing-7/JJ	prep_of||treatment-5/NN||mice-8/NNS	amod||cd40-24/NNS||il-2-10/JJ	punct||±-13/NNP||/-11/:	nn||±-13/NNP||î-12/NNP	dep||cd40-24/NNS||±-13/NNP	amod||cd40-24/NNS||cd40-15/JJ	neg||il-2-19/JJ||not-18/RB	dep||cd40-24/NNS||il-2-19/JJ	advmod||±-22/JJ||î-21/RB	conj_or||il-2-19/JJ||±-22/JJ	dep||cd40-24/NNS||±-22/JJ	prep_with||treatment-5/NN||cd40-24/NNS	vmod||treatment-5/NN||induced-26/VBN	amod||synthase-29/NN||significant-27/JJ	nn||synthase-29/NN||nitricoxide-28/NN	nsubj||expression-34/NN||synthase-29/NN	appos||synthase-29/NN||nos-31/NN	num||expression-34/NN||2-33/CD	xcomp||induced-26/VBN||expression-34/NN	amod||macrophages-37/NNS||tumor-associated-36/JJ	prep_in||expression-34/NN||macrophages-37/NNS	tumor--1||il-2-19||no_rel||we now show that treatment of tumor-bearing mice with il-2/î±-cd40, but not il-2 or î±-cd40, induced significant nitricoxide synthase (nos) 2 expression in tumor-associated macrophages.
prep_at||made-16/VBN||6â-2/NNS	num||years-6/NNS||$-3/$	num||$-3/$||7-5/CD	npadvmod||6â-2/NNS||years-6/NNS	prep_of||6â-2/NNS||age-8/NN	det||comparison-11/NN||the-10/DT	nsubjpass||made-16/VBN||comparison-11/NN	amod||factors-14/NNS||various-13/JJ	prep_of||comparison-11/NN||factors-14/NNS	auxpass||made-16/VBN||was-15/VBD	root||ROOT-0/null||made-16/VBN	number||lga-19/NN||31-18/CD	amod||children-26/NNS||lga-19/NN	number||appropriate-for-gestational-age-22/NN||34-21/CD	conj_and||lga-19/NN||appropriate-for-gestational-age-22/NN	amod||children-26/NNS||appropriate-for-gestational-age-22/NN	discourse||children-26/NNS||aga-24/UH	prep_between||made-16/VBN||children-26/NNS	dobj||made-16/VBN||fibrinogen-27/NN	dobj||made-16/VBN||antithrombiniii-29/NNS	conj_and||fibrinogen-27/NN||antithrombiniii-29/NNS	nn||c-32/NN||protein-31/NN	dobj||made-16/VBN||c-32/NN	conj_and||fibrinogen-27/NN||c-32/NN	dobj||made-16/VBN||s-34/PRP	conj_and||fibrinogen-27/NN||s-34/PRP	amod||model-43/NN||fasting-36/VBG	nn||model-43/NN||insulin-37/NN	dep||model-43/NN||glucose-39/NN	dep||model-43/NN||homeostasis-41/NN	nn||model-43/NN||assessment-42/NN	dobj||made-16/VBN||model-43/NN	conj_and||fibrinogen-27/NN||model-43/NN	prep_of||model-43/NN||insulinresistance-45/NN	appos||model-43/NN||homa-ir-47/NN	nn||protein-60/NN||index-49/NN	dep||protein-60/NN||adiponectin-51/NN	dep||protein-60/NN||leptin-53/NN	dep||protein-60/NN||visfatin-55/NN	amod||protein-60/NN||igf-1-57/JJ	amod||protein-60/NN||igf-binding-59/JJ	dep||fibrinogen-27/NN||protein-60/NN	appos||protein-60/NN||igfbp-62/NN	nsubj||lipids-68/VBZ||-1-64/CD	amod||-1-64/CD||igfbp-3-66/JJ	rcmod||protein-60/NN||lipids-68/VBZ	det||factors-73/NNS||the-71/DT	amod||factors-73/NNS||genetic-72/JJ	poss||mutation-77/NN||factors-73/NNS	nn||mutation-77/NN||leiden-75/NN	amod||mutation-77/NN||g1691a-76/VBD	dobj||made-16/VBN||mutation-77/NN	conj_and||fibrinogen-27/NN||mutation-77/NN	amod||20210a/g-80/JJ||prothrombin-79/JJ	amod||polymorphism-81/NN||20210a/g-80/JJ	conj_and||fibrinogen-27/NN||polymorphism-81/NN	conj_and||mutation-77/NN||polymorphism-81/NN	conj_and||fibrinogen-27/NN||mutation-84/NN	conj_and||mutation-77/NN||mutation-84/NN	det||gene-89/NN||the-86/DT	amod||5,10-methylenetetrahydrofolate-reductase-88/JJ||enzyme-87/JJ	amod||gene-89/NN||5,10-methylenetetrahydrofolate-reductase-88/JJ	prep_in||mutation-84/NN||gene-89/NN	dep||gene-89/NN||mthfr-c677t-91/JJ	insulinresistance-45||glucose-39||no_rel||at 6â€“7 years of age, the comparison of various factors was made between 31 lga and 34 appropriate-for-gestational-age (aga) children fibrinogen, antithrombiniii, protein c and s, fasting insulin, glucose, homeostasis assessment model of insulinresistance (homa-ir) index, adiponectin, leptin, visfatin, igf-1, igf-binding protein (igfbp)-1, igfbp-3, lipids, and the genetic factors v leiden g1691a mutation, prothrombin 20210a/g polymorphism, and mutation in the enzyme 5,10-methylenetetrahydrofolate-reductase gene (mthfr-c677t).
prep_in||novel-31/JJ||conclusion-2/NN	det||demonstration-5/NN||the-4/DT	nsubj||novel-31/JJ||demonstration-5/NN	det||relationship-9/NN||an-7/DT	amod||relationship-9/NN||inverse-8/JJ	prep_of||demonstration-5/NN||relationship-9/NN	nn||time-12/NN||infusion-11/NN	prep_between||relationship-9/NN||time-12/NN	det||dose-18/NN||a-14/DT	amod||dose-18/NN||fixed-15/JJ	conj_and||fixed-15/JJ||convulsive-17/JJ	amod||dose-18/NN||convulsive-17/JJ	prep_of||time-12/NN||dose-18/NN	prep_of||dose-18/NN||bupropion-20/NN	det||risk-23/NN||the-22/DT	prep_of||time-12/NN||risk-23/NN	conj_and||dose-18/NN||risk-23/NN	prep_of||risk-23/NN||convulsions-25/NNS	det||study-29/NN||a-27/DT	amod||study-29/NN||prospective-28/JJ	prep_in||convulsions-25/NNS||study-29/NN	cop||novel-31/JJ||is-30/VBZ	root||ROOT-0/null||novel-31/JJ	convulsions-25||bupropion-20||no||in conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.
amod||efficacy-4/NN||limited-2/JJ	amod||efficacy-4/NN||clinical-3/JJ	prep_despite||remains-14/VBZ||efficacy-4/NN	nsubj||remains-14/VBZ||treatment-6/NN	prep_with||treatment-6/NN||dacarbazine-8/NN	prep_with||treatment-6/NN||temozolomide-10/NN	conj_or||dacarbazine-8/NN||temozolomide-10/NN	appos||treatment-6/NN||tmz-12/NN	root||ROOT-0/null||remains-14/VBZ	det||therapy-17/NN||the-15/DT	amod||therapy-17/NN||standard-16/JJ	xcomp||remains-14/VBZ||therapy-17/NN	amod||melanoma-20/NN||metastatic-19/JJ	prep_for||therapy-17/NN||melanoma-20/NN	melanoma-20||tmz-12||yes||despite limited clinical efficacy, treatment with dacarbazine or temozolomide (tmz) remains the standard therapy for metastatic melanoma.
amod||reactivation-2/NN||pharmacological-1/JJ	nsubjpass||suggested-23/VBN||reactivation-2/NN	nsubj||eradicate-28/VB||reactivation-2/NN	amod||expression-8/NN||humanimmunodeficiencyvirus-4/JJ	appos||expression-8/NN||hiv-6/NN	prep_of||reactivation-2/NN||expression-8/NN	nn||proviruses-11/NNS||latent-10/NN	prep_from||expression-8/NN||proviruses-11/NNS	vmod||proviruses-11/NNS||coupled-12/VBN	advmod||suppressive-15/JJ||fully-14/RB	amod||therapy-17/NN||suppressive-15/JJ	amod||therapy-17/NN||antiretroviral-16/JJ	prep_with||coupled-12/VBN||therapy-17/NN	appos||therapy-17/NN||art-19/NN	aux||suggested-23/VBN||has-21/VBZ	auxpass||suggested-23/VBN||been-22/VBN	root||ROOT-0/null||suggested-23/VBN	det||strategy-26/NN||a-25/DT	prep_as||suggested-23/VBN||strategy-26/NN	aux||eradicate-28/VB||to-27/TO	xcomp||suggested-23/VBN||eradicate-28/VB	dobj||eradicate-28/VB||hivinfection-29/NN	hivinfection-29||humanimmunodeficiencyvirus-4||no||pharmacological reactivation of humanimmunodeficiencyvirus (hiv) expression from latent proviruses coupled with fully suppressive antiretroviral therapy (art) has been suggested as a strategy to eradicate hivinfection.
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	hypertension-21||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
det||case-2/NN||the-1/DT	nsubj||describes-5/VBZ||case-2/NN	vmod||case-2/NN||presented-3/VBN	advmod||presented-3/VBN||here-4/RB	root||ROOT-0/null||describes-5/VBZ	det||effectiveness-7/NN||the-6/DT	dobj||describes-5/VBZ||effectiveness-7/NN	prep_of||effectiveness-7/NN||clozapine-9/NN	det||patient-14/NN||a-11/DT	amod||patient-14/NN||young-12/JJ	amod||patient-14/NN||female-13/JJ	prep_in||describes-5/VBZ||patient-14/NN	amod||bpd-17/NN||severe-16/JJ	prep_with||patient-14/NN||bpd-17/NN	nsubj||had-25/VBD||bpd-17/NN	nsubjpass||treated-35/VBN||bpd-17/NN	amod||features-21/NNS||psychotic-20/JJ	prep_without||bpd-17/NN||features-21/NNS	rcmod||bpd-17/NN||had-25/VBD	nn||periods-29/NNS||repeated-26/VBN	conj_and||repeated-26/VBN||prolonged-28/VBN	nn||periods-29/NNS||prolonged-28/VBN	dobj||had-25/VBD||periods-29/NNS	prep_of||periods-29/NNS||hospitalization-31/NN	auxpass||treated-35/VBN||was-33/VBD	advmod||treated-35/VBN||successfully-34/RB	rcmod||bpd-17/NN||treated-35/VBN	conj_and||had-25/VBD||treated-35/VBN	det||dose-39/NN||a-37/DT	amod||dose-39/NN||moderate-38/JJ	prep_with||treated-35/VBN||dose-39/NN	prep_of||dose-39/NN||clozapine-41/NN	det||failure-45/NN||a-44/DT	prep_following||describes-5/VBZ||failure-45/NN	aux||improve-47/VB||to-46/TO	vmod||failure-45/NN||improve-47/VB	amod||medications-51/NNS||other-49/JJ	amod||medications-51/NNS||psychotropic-50/JJ	prep_with||improve-47/VB||medications-51/NNS	psychotic-20||clozapine-41||yes||the case presented here describes the effectiveness of clozapine in a young female patient with severe bpd (without psychotic features), who had repeated and prolonged periods of hospitalization and was successfully treated with a moderate dose of clozapine, following a failure to improve with other psychotropic medications.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||analysis-6/NN||a-3/DT	amod||analysis-6/NN||molecular-4/JJ	amod||analysis-6/NN||epidemiologic-5/JJ	nsubj||isolates-13/VBZ||analysis-6/NN	num||mycobacteriumtuberculosis-9/NNS||356-8/CD	prep_of||analysis-6/NN||mycobacteriumtuberculosis-9/NNS	appos||mycobacteriumtuberculosis-9/NNS||mtb-11/NN	ccomp||conducted-2/VBD||isolates-13/VBZ	prep_from||isolates-13/VBZ||patients-15/NNS	vmod||patients-15/NNS||presenting-16/VBG	dobj||presenting-16/VBG||pulmonarytuberculosis-17/NNS	amod||taipei-20/NNS||metropolitan-19/JJ	prep_in||pulmonarytuberculosis-17/NNS||taipei-20/NNS	pulmonarytuberculosis-17||mtb-11||no||we conducted a molecular epidemiologic analysis of 356 mycobacteriumtuberculosis (mtb) isolates from patients presenting pulmonarytuberculosis in metropolitan taipei.
det||female-3/NN||a-1/DT	amod||female-3/NN||72-year-old-2/JJ	nsubj||treated-11/VBN||female-3/NN	det||male-7/NN||a-5/DT	amod||male-7/NN||57-year-old-6/JJ	conj_and||female-3/NN||male-7/NN	nsubj||treated-11/VBN||male-7/NN	prep_with||male-7/NN||chronichepatitisc-9/NN	aux||treated-11/VBN||were-10/VBD	root||ROOT-0/null||treated-11/VBN	det||therapy-15/NN||a-13/DT	nn||therapy-15/NN||combination-14/NN	prep_with||treated-11/VBN||therapy-15/NN	amod||-rrb--21/NNS||pegylated-17/JJ	nn||-rrb--21/NNS||interferon-18/NN	nn||-rrb--21/NNS||-lrb--19/NN	amod||-rrb--21/NNS||peg-ifn-20/JJ	prep_of||therapy-15/NN||-rrb--21/NNS	dep||treated-11/VBN||î-23/VBN	amod||s.c.-31/NN||±-24/JJ	amod||s.c.-31/NN||2a-25/JJ	number||180-27/CD||-lrb--26/CD	num||s.c.-31/NN||180-27/CD	nn||s.c.-31/NN||î-28/NN	num||s.c.-31/NN||1/4-29/CD	nn||s.c.-31/NN||g-30/NN	dobj||î-23/VBN||s.c.-31/NN	advmod||week-34/NN||once-32/RB	det||week-34/NN||a-33/DT	tmod||î-23/VBN||week-34/NN	nn||-rrb--43/NNS||-rrb--35/NNP	conj_and||-rrb--35/NNP||ribavirin-37/NNP	nn||-rrb--43/NNS||ribavirin-37/NNP	nn||-rrb--43/NNS||-lrb--38/NNP	num||-rrb--43/NNS||1,000-39/CD	amod||-rrb--43/NNS||mg-40/JJ	nn||-rrb--43/NNS||orally-41/NN	amod||-rrb--43/NNS||daily-42/JJ	dobj||treated-11/VBN||-rrb--43/NNS	chronichepatitisc-9||ifn--1||yes||a 72-year-old female and a 57-year-old male with chronichepatitisc were treated with a combination therapy of pegylated interferon -lrb- peg-ifn -rrb- - î ± 2a -lrb- 180 î 1/4 g s.c. once a week -rrb- and ribavirin -lrb- 1,000 mg orally daily -rrb- .
nsubj||induces-17/VBZ||bortezomib-1/NN	det||inhibitor-5/NN||a-3/DT	amod||inhibitor-5/NN||proteasome-4/JJ	appos||bortezomib-1/NN||inhibitor-5/NN	vmod||inhibitor-5/NN||approved-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||approved-6/VBN||treatment-9/NN	prep_of||treatment-9/NN||multiplemyeloma-11/NN	det||plasmacellneoplasm-14/NN||a-13/DT	appos||multiplemyeloma-11/NN||plasmacellneoplasm-14/NN	root||ROOT-0/null||induces-17/VBZ	nn||apoptosis-20/NNS||plasma-18/NN	nn||apoptosis-20/NNS||cell-19/NN	dobj||induces-17/VBZ||apoptosis-20/NNS	plasmacellneoplasm-14||bortezomib-1||yes||bortezomib, a proteasome inhibitor approved for the treatment of multiplemyeloma (a plasmacellneoplasm), induces plasma cell apoptosis.
advmod||reduces-4/VBZ||moreover-1/RB	nsubj||reduces-4/VBZ||raloxifene-3/NN	nsubj||improves-12/VBZ||raloxifene-3/NN	root||ROOT-0/null||reduces-4/VBZ	det||risk-6/NN||the-5/DT	dobj||reduces-4/VBZ||risk-6/NN	amod||cancer-10/NN||invasive-8/JJ	nn||cancer-10/NN||breast-9/NN	prep_of||risk-6/NN||cancer-10/NN	conj_and||reduces-4/VBZ||improves-12/VBZ	det||levels-14/NNS||the-13/DT	dobj||reduces-4/VBZ||levels-14/NNS	nn||lipoprotein-17/NN||serum-16/NN	prep_of||levels-14/NNS||lipoprotein-17/NN	det||risk-22/NN||an-20/DT	amod||risk-22/NN||increased-21/VBN	prep_with||reduces-4/VBZ||risk-22/NN	amod||thromboembolism-25/NN||venous-24/JJ	prep_of||risk-22/NN||thromboembolism-25/NN	amod||stroke-28/NN||fatal-27/JJ	prep_of||risk-22/NN||stroke-28/NN	conj_and||thromboembolism-25/NN||stroke-28/NN	dep||reduces-4/VBZ||without-30/IN	amod||change-32/NN||significant-31/JJ	pobj||without-30/IN||change-32/NN	det||incidence-35/NN||the-34/DT	prep_in||change-32/NN||incidence-35/NN	amod||events-38/NNS||coronary-37/JJ	prep_of||incidence-35/NN||events-38/NNS	thromboembolism-25||raloxifene-3||no||moreover, raloxifene reduces the risk of invasive breast cancer and improves the levels of serum lipoprotein but with an increased risk of venous thromboembolism and fatal stroke, without significant change in the incidence of coronary events.
prep_among||used-6/VBN||them-2/PRP	nsubjpass||used-6/VBN||doxycycline-4/NN	nsubjpass||used-6/VBN||doxycycline-4/NN	auxpass||used-6/VBN||is-5/VBZ	root||ROOT-0/null||used-6/VBN	conj_or||used-6/VBN||used-6/VBN	advmod||used-6/VBN||alone-7/RB	nn||chemoprophylaxis-10/NNS||malaria-9/NN	prep_for||used-6/VBN||chemoprophylaxis-10/NNS	prep_in||used-6/VBN||combination-13/NN	nn||derivatives-18/NNS||quinine-15/NN	conj_or||quinine-15/NN||artemisinin-17/NN	nn||derivatives-18/NNS||artemisinin-17/NN	prep_with||used-6/VBN||derivatives-18/NNS	nn||treatment-21/NN||malaria-20/NN	prep_for||derivatives-18/NNS||treatment-21/NN	malaria-20||quinine-15||yes||among them, doxycycline is used alone for malaria chemoprophylaxis or in combination with quinine or artemisinin derivatives for malaria treatment.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||interferon--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
advmod||angiomatosis-12/VBZ||bartonellahenselae-1/RB	det||agent-4/NN||the-3/DT	nsubj||angiomatosis-12/VBZ||agent-4/NN	nsubj||peliosis-14/VBZ||agent-4/NN	prep_of||agent-4/NN||catscratchdisease-6/NN	det||disorders-10/NNS||the-8/DT	amod||disorders-10/NNS||vasculoproliferative-9/JJ	prep_of||agent-4/NN||disorders-10/NNS	conj_and||catscratchdisease-6/NN||disorders-10/NNS	advmod||angiomatosis-12/VBZ||bacillary-11/RB	ccomp||contains-17/VBZ||angiomatosis-12/VBZ	conj_and||angiomatosis-12/VBZ||peliosis-14/VBZ	ccomp||contains-17/VBZ||peliosis-14/VBZ	dobj||angiomatosis-12/VBZ||hepatis-15/NNS	root||ROOT-0/null||contains-17/VBZ	prep_to||contains-17/VBZ||date-19/NN	num||groups-21/NNS||two-20/CD	nsubj||contains-17/VBZ||groups-21/NNS	nn||adhesins-26/NNS||described-23/NNP	amod||adhesins-26/NNS||pathogenicity-24/JJ	nn||adhesins-26/NNS||factors-25/NNS	prep_of||groups-21/NNS||adhesins-26/NNS	nn||systems-31/NNS||type-28/NN	nn||systems-31/NNS||iv-29/NN	nn||systems-31/NNS||secretion-30/NN	prep_of||groups-21/NNS||systems-31/NNS	conj_and||adhesins-26/NNS||systems-31/NNS	catscratchdisease-6||bartonellahenselae-1||no||bartonellahenselae , the agent of catscratchdisease and the vasculoproliferative disorders bacillary angiomatosis and peliosis hepatis, contains to date two groups of described pathogenicity factors adhesins and type iv secretion systems.
mark||upstream-5/JJ||because-1/IN	nsubj||upstream-5/JJ||cvl-2/NN	cop||upstream-5/JJ||is-3/VBZ	advmod||upstream-5/JJ||temporally-4/RB	advcl||consider-12/VB||upstream-5/JJ	amod||hivinfections-8/NNS||new-7/JJ	prep_of||upstream-5/JJ||hivinfections-8/NNS	nsubj||consider-12/VB||jurisdictions-10/NNS	aux||consider-12/VB||should-11/MD	root||ROOT-0/null||consider-12/VB	dep||consider-12/VB||adding-13/VBG	dobj||adding-13/VBG||cvl-14/NN	amod||surveillance-18/NN||routine-16/JJ	nn||surveillance-18/NN||hiv-17/NN	prep_to||adding-13/VBG||surveillance-18/NN	aux||track-20/VB||to-19/TO	vmod||adding-13/VBG||track-20/VB	det||epidemic-22/NN||the-21/DT	dobj||track-20/VB||epidemic-22/NN	dep||consider-12/VB||allocate-24/VB	ccomp||adding-13/VBG||allocate-24/VB	conj_and||adding-13/VBG||allocate-24/VB	dobj||allocate-24/VB||resources-25/NNS	aux||evaluate-29/VB||to-28/TO	dep||consider-12/VB||evaluate-29/VB	conj_and||adding-13/VBG||evaluate-29/VB	det||effectiveness-31/NN||the-30/DT	dobj||evaluate-29/VB||effectiveness-31/NN	nn||prevention-34/NN||hiv-33/NN	prep_of||effectiveness-31/NN||prevention-34/NN	nn||efforts-37/NNS||treatment-36/NN	prep_of||effectiveness-31/NN||efforts-37/NNS	conj_and||prevention-34/NN||efforts-37/NNS	hivinfections-8||hiv-33||no||because cvl is temporally upstream of new hivinfections, jurisdictions should consider adding cvl to routine hiv surveillance to track the epidemic, allocate resources, and to evaluate the effectiveness of hiv prevention and treatment efforts.
prep_in||desirable-29/JJ||view-2/NN	det||incidence-6/NN||the-4/DT	amod||incidence-6/NN||high-5/JJ	prep_of||view-2/NN||incidence-6/NN	prep_of||incidence-6/NN||hyperglycemia-8/NN	prep_of||incidence-6/NN||need-10/NN	conj_and||hyperglycemia-8/NN||need-10/NN	nn||treatment-13/NN||insulin-12/NN	prep_for||hyperglycemia-8/NN||treatment-13/NN	amod||studies-16/NNS||future-15/JJ	nsubj||desirable-29/JJ||studies-16/NNS	det||effect-19/NN||the-18/DT	prep_on||studies-16/NNS||effect-19/NN	prep_of||effect-19/NN||insulin-21/NN	amod||metabolism-24/NN||cerebral-23/JJ	prep_on||insulin-21/NN||metabolism-24/NN	nn||patients-27/NNS||sah-26/NN	prep_in||metabolism-24/NN||patients-27/NNS	cop||desirable-29/JJ||are-28/VBP	root||ROOT-0/null||desirable-29/JJ	hyperglycemia-8||insulin-21||yes||in view of the high incidence of hyperglycemia and need for insulin treatment, future studies on the effect of insulin on cerebral metabolism in sah patients are desirable.
nsubj||one-3/CD||mozambique-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||countries-6/NNS||the-5/DT	prep_of||one-3/CD||countries-6/NNS	det||burden-10/NN||the-8/DT	amod||burden-10/NN||highest-9/JJS	prep_with||countries-6/NNS||burden-10/NN	nn||tb-14/NN||tuberculosis-12/NNP	prep_of||burden-10/NN||tb-14/NN	amod||africa-18/NN||sub-saharan-17/JJ	prep_in||tb-14/NN||africa-18/NN	nsubj||important-33/JJ||information-21/NN	nsubj||understand-36/VB||information-21/NN	det||genotypes-25/NNS||the-23/DT	amod||genotypes-25/NNS||predominant-24/JJ	prep_on||information-21/NN||genotypes-25/NNS	prep_of||genotypes-25/NNS||mycobacteriumtuberculosis-27/NNS	vmod||mycobacteriumtuberculosis-27/NNS||circulating-28/VBG	det||country-31/NN||the-30/DT	prep_in||circulating-28/VBG||country-31/NN	cop||important-33/JJ||are-32/VBP	conj_and||one-3/CD||important-33/JJ	aux||understand-36/VB||to-34/TO	advmod||understand-36/VB||better-35/RBR	xcomp||important-33/JJ||understand-36/VB	det||epidemic-38/NN||the-37/DT	dobj||understand-36/VB||epidemic-38/NN	tb-14||mycobacteriumtuberculosis-27||no||mozambique is one of the countries with the highest burden of tuberculosis (tb) in sub-saharan africa, and information on the predominant genotypes of mycobacteriumtuberculosis circulating in the country are important to better understand the epidemic.
nsubj||enteropathology-5/NN||coeliacdisease-1/NN	cop||enteropathology-5/NN||is-2/VBZ	det||enteropathology-5/NN||an-3/DT	amod||enteropathology-5/NN||immune-mediated-4/JJ	root||ROOT-0/null||enteropathology-5/NN	vmod||enteropathology-5/NN||triggered-6/VBN	det||ingestion-9/NN||the-8/DT	agent||triggered-6/VBN||ingestion-9/NN	nn||proteins-13/NNS||cereal-11/NN	nn||proteins-13/NNS||gluten-12/NN	prep_of||ingestion-9/NN||proteins-13/NNS	coeliacdisease-1||gluten-12||no||coeliacdisease is an immune-mediated enteropathology triggered by the ingestion of cereal gluten proteins.
det||total-2/NN||a-1/DT	nsubjpass||included-23/VBN||total-2/NN	num||patients-5/NNS||11-4/CD	prep_of||total-2/NN||patients-5/NNS	prep_with||patients-5/NNS||brucellosis-7/NNS	nsubj||had-10/VBD||brucellosis-7/NNS	rcmod||brucellosis-7/NNS||had-10/VBD	amod||cultures-13/NNS||positive-11/JJ	nn||cultures-13/NNS||blood-12/NN	dobj||had-10/VBD||cultures-13/NNS	nn||species-16/NNS||brucella-15/NN	prep_for||cultures-13/NNS||species-16/NNS	num||patients-21/NNS||47-19/CD	amod||patients-21/NNS||suspected-20/VBN	conj_and||total-2/NN||patients-21/NNS	nsubjpass||included-23/VBN||patients-21/NNS	auxpass||included-23/VBN||were-22/VBD	root||ROOT-0/null||included-23/VBN	det||study-26/NN||this-25/DT	prep_in||included-23/VBN||study-26/NN	brucellosis-7||brucella-15||no||a total of 11 patients with brucellosis, who had positive blood cultures for brucella species, and 47 suspected patients were included in this study.
amod||viruses-3/NNS||classically-1/JJ	amod||viruses-3/NNS||attenuated-2/JJ	nsubj||proven-16/VBN||viruses-3/NNS	nsubj||means-21/NN||viruses-3/NNS	appos||viruses-3/NNS||those-5/DT	vmod||those-5/DT||created-6/VBN	agent||created-6/VBN||passaging-8/VBG	det||virus-10/NN||a-9/DT	dobj||passaging-8/VBG||virus-10/NN	amod||cells-13/NNS||cultured-12/JJ	prep_in||passaging-8/VBG||cells-13/NNS	aux||proven-16/VBN||have-15/VBP	root||ROOT-0/null||proven-16/VBN	aux||means-21/NN||to-17/TO	cop||means-21/NN||be-18/VB	det||means-21/NN||an-19/DT	amod||means-21/NN||effective-20/JJ	xcomp||proven-16/VBN||means-21/NN	prepc_for||means-21/NN||preventing-23/VBG	amod||viraldiseases-25/NNS||many-24/JJ	dobj||preventing-23/VBG||viraldiseases-25/NNS	prep_including||proven-16/VBN||smallpox-28/NN	prep_including||proven-16/VBN||polio-30/NNP	conj_and||smallpox-28/NN||polio-30/NNP	prep_including||proven-16/VBN||measles-32/NNS	conj_and||smallpox-28/NN||measles-32/NNS	prep_including||proven-16/VBN||mumps-34/NNS	conj_and||smallpox-28/NN||mumps-34/NNS	amod||fever-38/NN||yellow-37/JJ	prep_including||proven-16/VBN||fever-38/NN	conj_and||smallpox-28/NN||fever-38/NN	viraldiseases-25||viruses-3||no||classically attenuated viruses, those created by passaging a virus in cultured cells, have proven to be an effective means for preventing many viraldiseases, including smallpox, polio, measles, mumps, and yellow fever.
nsubj||searched-3/JJ||papers-1/NNS	nsubj||answer-5/VB||papers-1/NNS	cop||searched-3/JJ||were-2/VBD	root||ROOT-0/null||searched-3/JJ	aux||answer-5/VB||to-4/TO	xcomp||searched-3/JJ||answer-5/VB	dobj||answer-5/VB||questions-6/NNS	prep_about||answer-5/VB||efficacy-8/NN	prep_of||efficacy-8/NN||hes-10/NN	poss||impact-13/NN||its-12/PRP$	prep_about||answer-5/VB||impact-13/NN	conj_and||efficacy-8/NN||impact-13/NN	prep_on||impact-13/NN||coagulation-15/NN	prep_on||impact-13/NN||inflammation-17/NN	conj_and||coagulation-15/NN||inflammation-17/NN	poss||effects-20/NNS||its-19/PRP$	prep_about||answer-5/VB||effects-20/NNS	conj_and||efficacy-8/NN||effects-20/NNS	amod||mechanics-23/NNS||pulmonary-22/JJ	prep_on||effects-20/NNS||mechanics-23/NNS	amod||function-26/NN||renal-25/JJ	prep_on||effects-20/NNS||function-26/NN	conj_and||mechanics-23/NNS||function-26/NN	hes-10||inflammation-17||no_rel||papers were searched to answer questions about efficacy of hes, its impact on coagulation and inflammation and its effects on pulmonary mechanics and renal function.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effects-4/NNS||the-3/DT	dobj||investigated-2/VBD||effects-4/NNS	amod||lipoproteins-7/NNS||apob-containing-6/JJ	prep_of||effects-4/NNS||lipoproteins-7/NNS	amod||lipolysis-10/NNS||catecholamine-induced-9/JJ	prep_on||investigated-2/VBD||lipolysis-10/NNS	prep_in||lipolysis-10/NNS||adipocytes-12/NNS	amod||cells-16/NNS||subcutaneous-14/JJ	amod||cells-16/NNS||fat-15/JJ	prep_from||investigated-2/VBD||cells-16/NNS	amod||men-22/NNS||obese-18/JJ	advmod||healthy-21/JJ||otherwise-20/RB	conj_but||obese-18/JJ||healthy-21/JJ	amod||men-22/NNS||healthy-21/JJ	prep_of||cells-16/NNS||men-22/NNS	amod||pads-25/NNS||fat-24/JJ	appos||men-22/NNS||pads-25/NNS	prep_from||pads-25/NNS||mice-27/NNS	nn||lipoproteins-30/NNS||plasma-29/NN	prep_with||investigated-2/VBD||lipoproteins-30/NNS	vmod||lipoproteins-30/NNS||containing-31/VBG	amod||levels-35/NNS||high-32/JJ	conj_or||high-32/JJ||intermediate-34/JJ	amod||levels-35/NNS||intermediate-34/JJ	dobj||containing-31/VBG||levels-35/NNS	prep_of||levels-35/NNS||apob100-37/CD	neg||apob100-40/NN||no-39/DT	dobj||containing-31/VBG||apob100-40/NN	conj_or||levels-35/NNS||apob100-40/NN	amod||adipocytes-44/NNS||primary-42/JJ	amod||adipocytes-44/NNS||cultured-43/JJ	conj_or||levels-35/NNS||adipocytes-44/NNS	conj_and||apob100-40/NN||adipocytes-44/NNS	amod||cells-48/NNS||3t3-l1-47/JJ	conj_or||levels-35/NNS||cells-48/NNS	conj_and||apob100-40/NN||cells-48/NNS	obese-18||fat-24||no_rel||we investigated the effects of apob-containing lipoproteins on catecholamine-induced lipolysis in adipocytes from subcutaneous fat cells of obese but otherwise healthy men, fat pads from mice with plasma lipoproteins containing high or intermediate levels of apob100 or no apob100, primary cultured adipocytes, and 3t3-l1 cells.
det||stoichiometries-3/NNS||the-2/DT	nsubj||produce-8/VBP||stoichiometries-3/NNS	nsubj||consume-10/VBP||stoichiometries-3/NNS	prep_from||support-31/VBP||stoichiometries-3/NNS	amod||pathways-6/NNS||metabolic-5/JJ	prep_of||stoichiometries-3/NNS||pathways-6/NNS	rcmod||stoichiometries-3/NNS||produce-8/VBP	rcmod||stoichiometries-3/NNS||consume-10/VBP	conj_or||produce-8/VBP||consume-10/VBP	number||+-12/CD||h-11/CD	dobj||produce-8/VBP||+-12/CD	det||availability-17/NN||the-15/DT	amod||availability-17/NN||greater-16/JJR	dobj||produce-8/VBP||availability-17/NN	conj_and||+-12/CD||availability-17/NN	prep_of||availability-17/NN||glucose-19/NN	prepc_compared_to||produce-8/VBP||to-21/TO	pobj||produce-8/VBP||oxygen-22/NN	amod||parts-25/NNS||most-24/JJS	prep_in||oxygen-22/NN||parts-25/NNS	det||tumor-28/NN||a-27/DT	prep_of||parts-25/NNS||tumor-28/NN	nsubj||support-31/VBP||we-30/PRP	root||ROOT-0/null||support-31/VBP	det||view-34/NN||the-32/DT	amod||view-34/NN||classic-33/JJ	dobj||support-31/VBP||view-34/NN	mark||originates-45/VBZ||that-35/IN	nsubj||originates-45/VBZ||most-36/JJS	nsubj||add-59/VBP||most-36/JJS	det||efflux-41/NN||the-38/DT	amod||efflux-41/NN||net-39/JJ	nn||efflux-41/NN||proton-40/NN	prep_of||most-36/JJS||efflux-41/NN	amod||gliomas-44/NNS||c6-43/JJ	prep_from||efflux-41/NN||gliomas-44/NNS	ccomp||support-31/VBP||originates-45/VBZ	amod||formation-48/NN||glycolytic-47/JJ	prep_in||originates-45/VBZ||formation-48/NN	nn||+-53/NNS||lactate-50/NN	conj_and||lactate-50/NN||h-52/NN	nn||+-53/NNS||h-52/NN	prep_of||formation-48/NN||+-53/NNS	det||tumor-56/NN||the-55/DT	prep_inside||originates-45/VBZ||tumor-56/NN	ccomp||support-31/VBP||add-59/VBP	conj_but||originates-45/VBZ||add-59/VBP	mark||taken-64/VBN||that-60/IN	det||lactate-62/NN||some-61/DT	nsubjpass||taken-64/VBN||lactate-62/NN	auxpass||taken-64/VBN||is-63/VBZ	ccomp||add-59/VBP||taken-64/VBN	prt||taken-64/VBN||up-65/RP	prep_into||taken-64/VBN||cells-67/NNS	det||rim-70/NN||the-69/DT	prep_in||cells-67/NNS||rim-70/NN	prep_on||rim-70/NN||mct1-72/CD	det||lactate-76/NN||some-75/DT	nsubj||diffuses-77/VBZ||lactate-76/NN	ccomp||add-59/VBP||diffuses-77/VBZ	conj_and||taken-64/VBN||diffuses-77/VBZ	prt||diffuses-77/VBZ||away-78/RP	xcomp||diffuses-77/VBZ||leaving-80/VBG	poss||protons-83/NNS||its-81/PRP$	amod||protons-83/NNS||associated-82/JJ	dobj||leaving-80/VBG||protons-83/NNS	acomp||originates-45/VBZ||available-84/JJ	aux||re-enter-86/VB||to-85/TO	xcomp||available-84/JJ||re-enter-86/VB	dobj||re-enter-86/VB||cells-87/NNS	prep_for||cells-87/NNS||extrusion-89/NN	prep_on||re-enter-86/VB||nhe1-91/CD	tumor-56||add-59||no_rel||from the stoichiometries of metabolic pathways that produce or consume h+, and the greater availability of glucose compared to oxygen in most parts of a tumor, we support the classic view that most of the net proton efflux from c6 gliomas originates in glycolytic formation of lactate and h+ inside the tumor, but add that some lactate is taken up into cells in the rim on mct1, and some lactate diffuses away, leaving its associated protons available to re-enter cells for extrusion on nhe1.
advmod||demonstrated-4/VBD||previously-1/RB	nsubj||demonstrated-4/VBD||we-3/PRP	root||ROOT-0/null||demonstrated-4/VBD	mark||detected-10/VBD||that-5/IN	amod||antibodies-7/NNS||polyclonal-6/JJ	nsubj||detected-10/VBD||antibodies-7/NNS	prep_to||antibodies-7/NNS||proavp-9/NN	ccomp||demonstrated-4/VBD||detected-10/VBD	det||protein-12/NN||that-11/WDT	dobj||examined-18/VBD||protein-12/NN	det||breast-15/NN||all-14/DT	prep_in||protein-12/NN||breast-15/NN	nn||samples-17/NNS||cancer-16/NN	nsubj||examined-18/VBD||samples-17/NNS	ccomp||detected-10/VBD||examined-18/VBD	expl||was-22/VBD||there-21/EX	conj_but||demonstrated-4/VBD||was-22/VBD	neg||reaction-24/NN||no-23/DT	nsubj||was-22/VBD||reaction-24/NN	nn||tissue-27/NN||breast-26/NN	prep_with||reaction-24/NN||tissue-27/NN	vmod||tissue-27/NN||containing-28/VBG	dobj||containing-28/VBG||fibrocysticdisease-29/NN	fibrocysticdisease-29||antibodies-7||no_rel||previously, we demonstrated that polyclonal antibodies to proavp detected that protein in all breast cancer samples examined, but there was no reaction with breast tissue containing fibrocysticdisease.
nn||g-3/NN||paracetamol-1/NNP	num||g-3/NN||1-2/CD	nsubj||reduced-9/VBD||g-3/NN	vmod||g-3/NN||taken-4/VBN	advmod||taken-4/VBN||orally-5/RB	det||hours-8/NNS||every-6/DT	num||hours-8/NNS||6-7/CD	dobj||taken-4/VBN||hours-8/NNS	root||ROOT-0/null||reduced-9/VBD	amod||anglerecessionglaucoma-12/NN||openangleglaucoma-10/JJ	amod||anglerecessionglaucoma-12/NN||and/or-11/JJ	dobj||reduced-9/VBD||anglerecessionglaucoma-12/NN	det||groups-15/NNS||both-14/DT	prep_in||reduced-9/VBD||groups-15/NNS	prep_of||groups-15/NNS||patients-17/NNS	det||way-21/NN||a-20/DT	prep_in||reduced-9/VBD||way-21/NN	amod||way-21/NN||comparable-22/JJ	prep_with||comparable-22/JJ||that-24/DT	vmod||that-24/DT||achieved-25/VBN	det||beta-adrenergicreceptorantagonist-29/NN||a-27/DT	amod||beta-adrenergicreceptorantagonist-29/NN||topical-28/JJ	agent||achieved-25/VBN||beta-adrenergicreceptorantagonist-29/NN	openangleglaucoma-10||adrenergicreceptorantagonist--1||no_rel||paracetamol 1 g taken orally every 6 hours reduced openangleglaucoma and/or anglerecessionglaucoma in both groups of patients, in a way comparable with that achieved by a topical beta-adrenergicreceptorantagonist.
nsubj||revealed-2/VBD||they-1/PRP	root||ROOT-0/null||revealed-2/VBD	mark||proportional-33/JJ||that-3/IN	amod||times-6/NNS||relative-4/JJ	nn||times-6/NNS||divergence-5/NN	nsubj||proportional-33/JJ||times-6/NNS	det||wdv-10/NN||the-8/DT	amod||wdv-10/NN||viruses-9/JJ	prep_for||times-6/NNS||wdv-10/NN	nn||virus-14/NN||barley-12/NN	nn||virus-14/NN||dwarf-13/NN	appos||wdv-10/NN||virus-14/NN	appos||virus-14/NN||bdv-16/NN	nn||virus-21/NN||oat-19/NN	nn||virus-21/NN||dwarf-20/NN	appos||wdv-10/NN||virus-21/NN	conj_and||virus-14/NN||virus-21/NN	appos||virus-21/NN||odv-23/NN	amod||virus-28/NN||maize-26/JJ	nn||virus-28/NN||streak-27/NN	appos||wdv-10/NN||virus-28/NN	conj_and||virus-14/NN||virus-28/NN	appos||virus-28/NN||msv-30/NN	cop||proportional-33/JJ||are-32/VBP	ccomp||revealed-2/VBD||proportional-33/JJ	nn||times-36/NNS||divergence-35/NN	prep_to||proportional-33/JJ||times-36/NNS	poss||hosts-39/NNS||their-38/PRP$	prep_of||times-36/NNS||hosts-39/NNS	xcomp||proportional-33/JJ||suggesting-41/VBG	dobj||suggesting-41/VBG||codivergence-42/NN	virus-28||viruses-9||no||they revealed that relative divergence times for the viruses wdv, barley dwarf virus (bdv), oat dwarf virus (odv) and maize streak virus (msv) are proportional to divergence times of their hosts, suggesting codivergence.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	calcium-3||nephrocalcinosis-7||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||case-4/NN||a-3/DT	dobj||describe-2/VBP||case-4/NN	amod||bleeding-7/NN||severe-6/JJ	prep_of||case-4/NN||bleeding-7/NN	det||tongue-10/NN||the-9/DT	prep_from||bleeding-7/NN||tongue-10/NN	amod||acquired-13/JJ||secondary-11/JJ	dep||acquired-13/JJ||to-12/TO	amod||case-4/NN||acquired-13/JJ	vmod||case-4/NN||hemophiliaand-14/VBN	ccomp||hemophiliaand-14/VBN||discuss-15/VB	nn||options-17/NNS||treatment-16/NN	dobj||discuss-15/VB||options-17/NNS	amod||factorviii-23/NNS||aminocaproicacid-20/JJ	conj_and||aminocaproicacid-20/JJ||recombinant-22/JJ	amod||factorviii-23/NNS||recombinant-22/JJ	prep_including||hemophiliaand-14/VBN||factorviii-23/NNS	nsubjpass||reported-30/VBN||factorviii-23/NNS	aux||reported-30/VBN||have-26/VBP	neg||reported-30/VBN||not-27/RB	auxpass||reported-30/VBN||been-28/VBN	advmod||reported-30/VBN||widely-29/RB	rcmod||factorviii-23/NNS||reported-30/VBN	det||literature-33/NN||the-32/DT	prep_in||reported-30/VBN||literature-33/NN	det||management-36/NN||the-35/DT	prep_for||literature-33/NN||management-36/NN	amod||patients-39/NNS||such-38/JJ	prep_of||management-36/NN||patients-39/NNS	bleeding-7||aminocaproicacid-20||yes||we describe a case of severe bleeding from the tongue secondary to acquired hemophiliaand discuss treatment options, including aminocaproicacid and recombinant factorviii, which have not been widely reported in the literature for the management of such patients.
amod||titers-3/NNS||anti-tax-1/JJ	nn||titers-3/NNS||antibody-2/NN	nsubj||higher-6/JJR||titers-3/NNS	cop||higher-6/JJR||were-4/VBD	advmod||higher-6/JJR||also-5/RB	root||ROOT-0/null||higher-6/JJR	dep||higher-6/JJR||p-8/NNP	number||0.0005-10/CD||<-9/CD	num||p-8/NNP||0.0005-10/CD	det||ham/tsp-14/NN||the-13/DT	prep_in||higher-6/JJR||ham/tsp-14/NN	prepc_compared_to||higher-6/JJR||to-16/TO	det||carriers-20/NNS||the-17/DT	amod||carriers-20/NNS||asymptomatic-18/JJ	num||carriers-20/NNS||htlv-i-19/CD	pobj||higher-6/JJR||carriers-20/NNS	ham--1||htlv-i-19||no||anti-tax antibody titers were also higher ( p < 0.0005) in the ham/tsp compared to the asymptomatic htlv-i carriers.
det||risk-3/NN||an-1/DT	amod||risk-3/NN||increased-2/VBN	nsubjpass||described-18/VBN||risk-3/NN	amod||gastrointestinalbleeding-6/NN||upper-5/JJ	prep_for||risk-3/NN||gastrointestinalbleeding-6/NN	prep_with||gastrointestinalbleeding-6/NN||nsaids-8/NNS	advmod||gastrointestinalbleeding-6/NN||alone-9/RB	advmod||combined-12/JJ||when-11/WRB	advmod||gastrointestinalbleeding-6/NN||combined-12/JJ	conj_and||alone-9/RB||combined-12/JJ	amod||aspirin-15/NN||low-dose-14/JJ	prep_with||risk-3/NN||aspirin-15/NN	aux||described-18/VBN||has-16/VBZ	auxpass||described-18/VBN||been-17/VBN	root||ROOT-0/null||described-18/VBN	amod||studies-21/NNS||numerous-20/JJ	prep_in||described-18/VBN||studies-21/NNS	aspirin-15||gastrointestinalbleeding-6||no_rel||an increased risk for upper gastrointestinalbleeding with nsaids alone and when combined with low-dose aspirin has been described in numerous studies.
det||study-2/NN||this-1/DT	nsubj||assessed-3/VBD||study-2/NN	root||ROOT-0/null||assessed-3/VBD	det||kinetics-5/NNS||the-4/DT	dobj||assessed-3/VBD||kinetics-5/NNS	det||analog-10/NN||a-7/DT	amod||analog-10/NN||short-acting-8/JJ	nn||analog-10/NN||insulin-9/NN	prep_of||kinetics-5/NNS||analog-10/NN	amod||subjects-13/NNS||obese-12/JJ	prep_in||analog-10/NN||subjects-13/NNS	prep_with||assessed-3/VBD||type2diabetes-15/CD	type2diabetes-15||insulin-9||yes||this study assessed the kinetics of a short-acting insulin analog in obese subjects with type2diabetes.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	ifn--1||melanoma-54||no_rel||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
amod||fattyacids-3/NNS||oxidized-1/JJ	amod||fattyacids-3/NNS||unsaturated-2/JJ	nsubj||contribute-5/VB||fattyacids-3/NNS	aux||contribute-5/VB||may-4/MD	root||ROOT-0/null||contribute-5/VB	det||pathogenesis-8/NNS||the-7/DT	prep_to||contribute-5/VB||pathogenesis-8/NNS	prep_of||pathogenesis-8/NNS||atherosclerosis-10/NNS	atherosclerosis-10||fattyacids-3||no_rel||oxidized unsaturated fattyacids may contribute to the pathogenesis of atherosclerosis.
nsubjpass||diagnosed-4/VBN||she-1/PRP	auxpass||diagnosed-4/VBN||was-2/VBD	advmod||diagnosed-4/VBN||originally-3/RB	root||ROOT-0/null||diagnosed-4/VBN	prep_as||diagnosed-4/VBN||cmvretinitis-6/NNS	nsubj||failed-12/VBD||treatment-9/NN	nsubj||improve-14/VB||treatment-9/NN	prep_with||treatment-9/NN||ganciclovir-11/NN	conj_but||diagnosed-4/VBN||failed-12/VBD	aux||improve-14/VB||to-13/TO	xcomp||failed-12/VBD||improve-14/VB	poss||condition-17/NN||her-15/PRP$	nn||condition-17/NN||ocular-16/NN	dobj||improve-14/VB||condition-17/NN	cmvretinitis-6||ganciclovir-11||yes||she was originally diagnosed as cmvretinitis, but treatment with ganciclovir failed to improve her ocular condition.
vmod||important-26/JJ||considering-1/VBG	det||health-5/NN||the-2/DT	amod||health-5/NN||great-3/JJ	nn||health-5/NN||animal-4/NN	dobj||considering-1/VBG||health-5/NN	amod||impact-8/NN||economic-7/JJ	dobj||considering-1/VBG||impact-8/NN	conj_and||health-5/NN||impact-8/NN	prep_of||health-5/NN||ibv-10/NN	det||emergence-16/NN||the-14/DT	amod||emergence-16/NN||recent-15/JJ	dobj||considering-1/VBG||emergence-16/NN	conj_and||health-5/NN||emergence-16/NN	nn||coronaviruses-19/NNS||novel-18/NN	prep_of||emergence-16/NN||coronaviruses-19/NNS	prep_such_as||coronaviruses-19/NNS||sars-coronavirus-22/NNS	nsubj||important-26/JJ||it-24/PRP	nsubj||investigate-28/VB||it-24/PRP	cop||important-26/JJ||is-25/VBZ	root||ROOT-0/null||important-26/JJ	aux||investigate-28/VB||to-27/TO	xcomp||important-26/JJ||investigate-28/VB	det||role-30/NN||the-29/DT	dobj||investigate-28/VB||role-30/NN	nn||reservoirs-33/NNS||wildlife-32/NN	prep_of||role-30/NN||reservoirs-33/NNS	nn||biology-37/NN||cov-35/NN	nn||biology-37/NN||infection-36/NN	prep_in||investigate-28/VB||biology-37/NN	prep_in||investigate-28/VB||epidemiology-39/NN	conj_and||biology-37/NN||epidemiology-39/NN	sars--1||coronavirus--1||no||considering the great animal health and economic impact of ibv as well as the recent emergence of novel coronaviruses such as sars-coronavirus, it is important to investigate the role of wildlife reservoirs in cov infection biology and epidemiology.
nn||artesunate-2/NN||intramuscular-1/NN	nsubj||superior-5/JJ||artesunate-2/NN	nsubj||intramuscular-7/VB||artesunate-2/NN	aux||superior-5/JJ||may-3/MD	cop||superior-5/JJ||be-4/VB	root||ROOT-0/null||superior-5/JJ	aux||intramuscular-7/VB||to-6/TO	xcomp||superior-5/JJ||intramuscular-7/VB	dobj||intramuscular-7/VB||artemether-8/NN	det||treatment-11/NN||the-10/DT	prep_for||intramuscular-7/VB||treatment-11/NN	amod||malaria-14/NN||severe-13/JJ	prep_of||treatment-11/NN||malaria-14/NN	prep_in||malaria-14/NN||adults-16/NNS	malaria-14||artemether-8||yes||intramuscular artesunate may be superior to intramuscular artemether for the treatment of severe malaria in adults.
det||study-3/NN||this-2/DT	prep_in||emerged-8/VBD||study-3/NN	nsubj||emerged-8/VBD||treatment-5/NN	prep_with||treatment-5/NN||sulphadoxine-pyrimethamine-7/NN	root||ROOT-0/null||emerged-8/VBD	mark||followed-16/VBD||as-9/IN	det||efficacious-12/NNS||the-10/DT	amod||efficacious-12/NNS||most-11/JJS	nsubj||followed-16/VBD||efficacious-12/NNS	amod||falciparummalaria-15/NN||uncomplicated-14/JJ	prep_on||efficacious-12/NNS||falciparummalaria-15/NN	advcl||emerged-8/VBD||followed-16/VBD	prep_by||followed-16/VBD||amodiaquine-18/NN	falciparummalaria-15||sulphadoxine--1||yes||in this study, treatment with sulphadoxine-pyrimethamine emerged as the most efficacious on uncomplicated falciparummalaria followed by amodiaquine.
nsubj||control-57/VBP||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	iobj||compare-3/VB||approaches-6/NNS	amod||insulinglargine-9/NN||-lsb--7/JJ	amod||insulinglargine-9/NN||once-daily-8/JJ	dep||approaches-6/NNS||insulinglargine-9/NN	amod||approaches-6/NNS||plus-10/IN	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||‰-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	dep||approaches-6/NNS||+-19/NNS	nn||-rrb--21/NNP||l-20/NNP	dep||+-19/NNS||-rrb--21/NNP	nn||-rrb--28/NNP||insulinlispro-23/NN	nn||-rrb--28/NNP||mix-24/NN	nn||-rrb--28/NNP||50/50-25/NNP	nn||-rrb--28/NNP||-lrb--26/NNP	nn||-rrb--28/NNP||lm50/50-27/NNPS	prep_vs.||-rrb--21/NNP||-rrb--28/NNP	dep||-rrb--21/NNP||progression-29/VBN	advmod||up-31/RB||once-30/RB	advmod||progression-29/VBN||up-31/RB	aux||thrice-33/VB||to-32/TO	xcomp||progression-29/VBN||thrice-33/VB	amod||progression-37/NN||daily-34/JJ	amod||progression-37/NN||-lrb--35/JJ	nn||progression-37/NN||premix-36/NN	dobj||thrice-33/VB||progression-37/NN	nn||-rsb--41/NNP||pp-39/NNP	nn||-rsb--41/NNP||-rrb--40/NNP	appos||progression-37/NN||-rsb--41/NNP	prepc_of||-rsb--41/NNP||beginning-43/VBG	prepc_of||-rsb--41/NNP||advancing-45/VBG	conj_and||beginning-43/VBG||advancing-45/VBG	dobj||beginning-43/VBG||insulin-46/NN	prep_in||beginning-43/VBG||patients-48/NNS	amod||-rrb--53/NNS||type2diabetes-50/JJ	amod||-rrb--53/NNS||-lrb--51/JJ	amod||-rrb--53/NNS||t2d-52/JJ	prep_with||patients-48/NNS||-rrb--53/NNS	amod||glycaemic-56/JJ||inadequate-55/JJ	dep||-rrb--21/NNP||glycaemic-56/JJ	conj_and||progression-29/VBN||glycaemic-56/JJ	root||ROOT-0/null||control-57/VBP	amod||therapy-60/NN||oral-59/JJ	prep_on||control-57/VBP||therapy-60/NN	det||aim-64/NN||the-63/DT	prep_with||control-57/VBP||aim-64/NN	prepc_of||aim-64/NN||showing-66/VBG	dobj||showing-66/VBG||non-inferiority-67/NN	prep_of||non-inferiority-67/NN||pp-69/NN	prep_to||showing-66/VBG||g-71/NN	amod||l-73/NN||+-72/JJ	dobj||control-57/VBP||l-73/NN	type2diabetes-50||lispro-16||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â ‰ $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulinlispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
amod||fellows-2/NNS||enrolled-1/JJ	nsubjpass||attached-4/VBN||fellows-2/NNS	nsubjpass||placed-12/VBN||fellows-2/NNS	auxpass||attached-4/VBN||are-3/VBP	root||ROOT-0/null||attached-4/VBN	nn||institutions-7/NNS||host-6/NN	prep_to||attached-4/VBN||institutions-7/NNS	xcomp||attached-4/VBN||implementing-8/VBG	amod||programs-10/NNS||hiv/aids-9/JJ	dobj||implementing-8/VBG||programs-10/NNS	conj_and||attached-4/VBN||placed-12/VBN	det||supervision-15/NN||the-14/DT	prep_under||placed-12/VBN||supervision-15/NN	nn||institution-18/NN||host-17/NN	prep_of||supervision-15/NN||institution-18/NN	amod||mentors-21/NNS||academic-20/JJ	prep_of||supervision-15/NN||mentors-21/NNS	conj_and||institution-18/NN||mentors-21/NNS	aids--1||hiv--1||no||enrolled fellows are attached to host institutions implementing hiv/aids programs and placed under the supervision of host institution and academic mentors.
det||perspective-5/NN||a-2/DT	amod||perspective-5/NN||mexican-3/JJ	amod||perspective-5/NN||institutional-4/JJ	prep_from||celecoxib-31/JJ||perspective-5/NN	advmod||celecoxib-31/JJ||probably-7/RB	amod||institutions-12/NNS||other-9/JJ	amod||institutions-12/NNS||social-10/JJ	nn||institutions-12/NNS||security-11/NN	prep_in||celecoxib-31/JJ||institutions-12/NNS	amod||countries-16/NNS||similar-14/JJ	amod||countries-16/NNS||developing-15/VBG	prep_in||institutions-12/NNS||countries-16/NNS	det||option-21/NN||the-18/DT	advmod||cost-effective-20/JJ||most-19/RBS	amod||option-21/NN||cost-effective-20/JJ	nsubj||celecoxib-31/JJ||option-21/NN	nsubj||celecoxib-31/JJ||option-21/NN	prep_for||option-21/NN||treatment-23/NN	nn||oa-28/NN||knee-25/NN	num||oa-28/NN||and/or-26/CD	nn||oa-28/NN||hip-27/NN	prep_of||treatment-23/NN||oa-28/NN	aux||celecoxib-31/JJ||would-29/MD	cop||celecoxib-31/JJ||be-30/VB	root||ROOT-0/null||celecoxib-31/JJ	conj_and||celecoxib-31/JJ||celecoxib-31/JJ	oa-28||celecoxib-31||yes||from a mexican institutional perspective and probably in other social security institutions in similar developing countries, the most cost-effective option for treatment of knee and/or hip oa would be celecoxib.
prep_in||participated-6/VBD||2006-2/CD	det||rtrc-5/NN||the-4/DT	nsubj||participated-6/VBD||rtrc-5/NN	nsubj||contributed-17/VBD||rtrc-5/NN	root||ROOT-0/null||participated-6/VBD	det||workshop-10/NN||a-8/DT	amod||workshop-10/NN||materials-development-9/JJ	prep_in||participated-6/VBD||workshop-10/NN	prep_in||participated-6/VBD||kampala-12/NN	appos||kampala-12/NN||uganda-14/NN	conj_and||participated-6/VBD||contributed-17/VBD	det||development-20/NN||the-19/DT	prep_to||contributed-17/VBD||development-20/NN	amod||materials-27/NNS||comprehensive-22/JJ	nn||materials-27/NNS||hiv/aids-23/NN	amod||materials-27/NNS||pharmaceutical-24/JJ	nn||materials-27/NNS||management-25/NN	nn||materials-27/NNS||training-26/NN	prep_of||development-20/NN||materials-27/NNS	det||materials-30/NNS||these-29/DT	nsubj||available-34/JJ||materials-30/NNS	cop||available-34/JJ||are-31/VBP	advmod||available-34/JJ||now-32/RB	advmod||available-34/JJ||widely-33/RB	parataxis||participated-6/VBD||available-34/JJ	det||countries-38/NNS||all-36/DT	num||countries-38/NNS||four-37/CD	prep_in||available-34/JJ||countries-38/NNS	aids--1||hiv--1||no||in 2006, the rtrc participated in a materials-development workshop in kampala, uganda, and contributed to the development of comprehensive hiv/aids pharmaceutical management training materials; these materials are now widely available in all four countries.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	det||review-5/NN||this-4/DT	prep_of||aim-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||analyze-8/VB||to-7/TO	ccomp||is-6/VBZ||analyze-8/VB	det||results-10/NNS||the-9/DT	dobj||analyze-8/VB||results-10/NNS	dobj||analyze-8/VB||experiences-12/NNS	conj_and||results-10/NNS||experiences-12/NNS	amod||treatments-18/NNS||old-14/JJ	conj_and||old-14/JJ||new-16/JJ	amod||treatments-18/NNS||new-16/JJ	amod||treatments-18/NNS||medical-17/JJ	prep_with||analyze-8/VB||treatments-18/NNS	prep_of||treatments-18/NNS||cd-20/NN	aux||reevaluate-23/VB||to-22/TO	ccomp||is-6/VBZ||reevaluate-23/VB	conj_and||analyze-8/VB||reevaluate-23/VB	amod||therapies-25/NNS||medical-24/JJ	dobj||reevaluate-23/VB||therapies-25/NNS	prep_for||reevaluate-23/VB||complications-27/NNS	prep_of||complications-27/NNS||cd-29/NN	prep_of||complications-27/NNS||hypopituitarism-31/NN	conj_and||cd-29/NN||hypopituitarism-31/NN	prep_in||reevaluate-23/VB||patients-33/NNS	amod||cd-36/NN||cured-35/JJ	prep_with||patients-33/NNS||cd-36/NN	hypopituitarism-31||cd-36||no_rel||the aim of this review is to analyze the results and experiences with old and new medical treatments of cd and to reevaluate medical therapies for complications of cd and hypopituitarism in patients with cured cd.
det||vaccine-5/NN||the-1/DT	amod||vaccine-5/NN||only-2/JJ	advmod||available-4/JJ||currently-3/RB	amod||vaccine-5/NN||available-4/JJ	nsubj||calmette-guerin-14/NN||vaccine-5/NN	prep_against||vaccine-5/NN||tuberculosis-7/NNP	appos||vaccine-5/NN||tb-9/NN	cop||calmette-guerin-14/NN||is-11/VBZ	amod||bacille-13/JJ||mycobacteriumbovis-12/JJ	amod||calmette-guerin-14/NN||bacille-13/JJ	root||ROOT-0/null||calmette-guerin-14/NN	nsubj||inconsistent-21/JJ||calmette-guerin-14/NN	nsubj||protect-24/VB||calmette-guerin-14/NN	appos||calmette-guerin-14/NN||bcg-16/NN	aux||inconsistent-21/JJ||has-20/VBZ	rcmod||calmette-guerin-14/NN||inconsistent-21/JJ	advmod||inconsistent-21/JJ||efficacy-22/RB	aux||protect-24/VB||to-23/TO	xcomp||inconsistent-21/JJ||protect-24/VB	det||disease-27/NN||the-26/DT	prep_against||protect-24/VB||disease-27/NN	prep_in||inconsistent-21/JJ||adults-29/NNS	tuberculosis-7||bcg-16||no||the only currently available vaccine against tuberculosis (tb) is mycobacteriumbovis bacille calmette-guerin (bcg), which has inconsistent efficacy to protect against the disease in adults.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||determine-8/VB||aim-2/NN	nsubj||prednisone-22/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	mark||pharmacokinetics-14/VBZ||whether-9/IN	nsubj||pharmacokinetics-14/VBZ||mycophenolatemofetil-10/NN	appos||mycophenolatemofetil-10/NN||mmf-12/NN	ccomp||determine-8/VB||pharmacokinetics-14/VBZ	dep||pharmacokinetics-14/VBZ||pk-16/NN	amod||mmf-20/NN||combined-19/VBN	prep_under||pharmacokinetics-14/VBZ||mmf-20/NN	xcomp||was-6/VBD||prednisone-22/VB	conj_and||determine-8/VB||prednisone-22/VB	amod||therapy-24/NN||remission-maintenance-23/JJ	nsubj||predict-26/VB||therapy-24/NN	aux||predict-26/VB||can-25/MD	ccomp||prednisone-22/VB||predict-26/VB	amod||lupuserythematosus-28/NNS||systemic-27/JJ	dobj||predict-26/VB||lupuserythematosus-28/NNS	appos||lupuserythematosus-28/NNS||sle-30/NN	amod||flares-33/NNS||clinical-32/JJ	dobj||determine-8/VB||flares-33/NNS	prednisone-22||sle-30||no_rel||the aim of this study was to determine whether mycophenolatemofetil (mmf) pharmacokinetics (pk) under combined mmf and prednisone remission-maintenance therapy can predict systemic lupuserythematosus (sle) clinical flares.
det||combination-2/NN||the-1/DT	nsubj||effective-8/JJ||combination-2/NN	prep_of||combination-2/NN||remifentanil-4/NN	prep_of||combination-2/NN||lidocaine-6/NN	conj_and||remifentanil-4/NN||lidocaine-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	prepc_in||effective-8/JJ||alleviating-10/VBG	dobj||alleviating-10/VBG||pain-11/NN	vmod||pain-11/NN||associated-12/VBN	det||injection-17/NN||a-14/DT	amod||injection-17/NN||microemulsion-15/JJ	amod||injection-17/NN||propofol-16/JJ	prep_with||associated-12/VBN||injection-17/NN	prepc_compared_with||associated-12/VBN||with-19/IN	advmod||lidocaine-21/NN||just-20/RB	pobj||associated-12/VBN||lidocaine-21/NN	pain-11||propofol-16||yes||the combination of remifentanil and lidocaine is effective in alleviating pain associated with a microemulsion propofol injection compared with just lidocaine.
det||mechanism-4/NN||the-1/DT	amod||mechanism-4/NN||possible-2/JJ	amod||mechanism-4/NN||molecular-3/JJ	nsubjpass||explored-12/VBN||mechanism-4/NN	nsubj||indoleamine-18/VB||mechanism-4/NN	vmod||mechanism-4/NN||mediating-5/VBG	det||effect-8/NN||this-6/DT	amod||effect-8/NN||immunosuppressive-7/JJ	dobj||mediating-5/VBG||effect-8/NN	prep_of||effect-8/NN||uc-mscs-10/NNS	auxpass||explored-12/VBN||was-11/VBD	root||ROOT-0/null||explored-12/VBN	agent||explored-12/VBN||addition-14/NN	prep_of||addition-14/NN||inhibitors-16/NNS	aux||indoleamine-18/VB||to-17/TO	xcomp||explored-12/VBN||indoleamine-18/VB	amod||ido-21/NN||2,3-dioxygenase-19/JJ	dobj||indoleamine-18/VB||ido-21/NN	appos||ido-21/NN||nitricoxide-24/NN	discourse||nitricoxide-24/NN||no-26/UH	appos||ido-21/NN||prostaglandine2-29/NNS	conj_and||nitricoxide-24/NN||prostaglandine2-29/NNS	appos||prostaglandine2-29/NNS||pge2-31/NNP	amod||î-37/NN||transforming-34/JJ	nn||î-37/NN||growth-35/NN	nn||î-37/NN||factor-36/NN	appos||ido-21/NN||î-37/NN	conj_and||nitricoxide-24/NN||î-37/NN	number||1-39/CD||²-38/CD	amod||î-37/NN||1-39/CD	dep||1-39/CD||tgf-î-41/NNP	number||1-43/CD||²-42/CD	num||tgf-î-41/NNP||1-43/CD	appos||ido-21/NN||interleukin-46/NN	conj_and||nitricoxide-24/NN||interleukin-46/NN	num||interleukin-46/NN||10-47/CD	dep||interleukin-46/NN||il-10-49/JJ	immunosuppressive-7||uc--1||no_rel||the possible molecular mechanism mediating this immunosuppressive effect of uc-mscs was explored by addition of inhibitors to indoleamine 2,3-dioxygenase (ido), nitricoxide (no), prostaglandine2 (pge2), transforming growth factor î²1 (tgf-î²1) and interleukin 10 (il-10).
amod||rats-4/NNS||forty-two-1/JJ	amod||rats-4/NNS||male-2/JJ	amod||rats-4/NNS||sprague-dawley-3/JJ	nsubjpass||divided-7/VBN||rats-4/NNS	auxpass||divided-7/VBN||were-5/VBD	advmod||divided-7/VBN||equally-6/RB	root||ROOT-0/null||divided-7/VBN	num||groups-10/NNS||six-9/CD	prep_into||divided-7/VBN||groups-10/NNS	nn||i-12/NNS||group-11/NN	dep||groups-10/NNS||i-12/NNS	appos||i-12/NNS||control-14/NN	amod||chow-19/NN||normal-17/JJ	nn||chow-19/NN||rat-18/NN	dep||groups-10/NNS||chow-19/NN	nn||ii-22/NN||group-21/NN	appos||chow-19/NN||ii-22/NN	amod||oil-26/NN||fresh-24/JJ	nn||oil-26/NN||soy-25/NN	dep||groups-10/NNS||oil-26/NN	nn||iii-29/NN||group-28/NN	appos||oil-26/NN||iii-29/NN	nn||oil-32/NN||soy-31/NN	dep||groups-10/NNS||oil-32/NN	amod||oil-32/NN||heated-33/JJ	dep||heated-33/JJ||once-34/RB	nn||iv-37/NN||group-36/NN	appos||once-34/RB||iv-37/NN	nn||oil-40/NN||soy-39/NN	dep||groups-10/NNS||oil-40/NN	amod||twice-42/JJ||heated-41/JJ	amod||oil-40/NN||twice-42/JJ	nn||v-45/NN||group-44/NN	appos||oil-40/NN||v-45/NN	nn||oil-48/NN||soy-47/NN	dep||groups-10/NNS||oil-48/NN	amod||oil-48/NN||heated-49/JJ	num||times-51/NNS||five-50/CD	dep||heated-49/JJ||times-51/NNS	nn||vi-54/NN||group-53/NN	appos||times-51/NNS||vi-54/NN	nn||oil-57/NN||soy-56/NN	dep||groups-10/NNS||oil-57/NN	amod||oil-57/NN||heated-58/JJ	num||times-60/NNS||ten-59/CD	dep||groups-10/NNS||times-60/NNS	oil-57||ten-59||no_rel||forty-two male sprague-dawley rats were equally divided into six groups group i (control) - normal rat chow, group ii - fresh soy oil, group iii - soy oil heated once, group iv - soy oil heated twice, group v - soy oil heated five times, group vi - soy oil heated ten times.
advmod||macaques-5/VBZ||thus-1/RB	amod||rhesus-4/NNS||chinese-origin-3/JJ	nsubj||macaques-5/VBZ||rhesus-4/NNS	root||ROOT-0/null||macaques-5/VBZ	xcomp||macaques-5/VBZ||serve-6/VB	advmod||useful-8/JJ||as-7/RB	amod||models-9/NNS||useful-8/JJ	dobj||serve-6/VB||models-9/NNS	prepc_in||serve-6/VB||studying-11/VBG	amod||pathogenesis-13/NNS||y.pestis-12/JJ	dobj||studying-11/VBG||pathogenesis-13/NNS	nn||response-16/NN||host-15/NN	dobj||studying-11/VBG||response-16/NN	conj_and||pathogenesis-13/NNS||response-16/NN	det||efficacy-19/NN||the-18/DT	dobj||studying-11/VBG||efficacy-19/NN	conj_and||pathogenesis-13/NNS||efficacy-19/NN	amod||countermeasures-23/NNS||new-21/JJ	amod||countermeasures-23/NNS||medical-22/JJ	prep_of||efficacy-19/NN||countermeasures-23/NNS	prep_against||countermeasures-23/NNS||plague-25/NNP	plague-25||y.pestis-12||no||thus , chinese-origin rhesus macaques serve as useful models in studying y.pestis pathogenesis , host response and the efficacy of new medical countermeasures against plague .
nsubj||arthropod-6/NN||dengue-1/NN	cop||arthropod-6/NN||is-2/VBZ	det||arthropod-6/NN||the-3/DT	advmod||important-5/JJ||most-4/RBS	amod||arthropod-6/NN||important-5/JJ	root||ROOT-0/null||arthropod-6/NN	dep||arthropod-6/NN||borne-7/VBN	amod||disease-9/NN||viral-8/JJ	dobj||borne-7/VBN||disease-9/NN	advmod||borne-7/VBN||worldwide-10/RB	prep_in||borne-7/VBN||terms-12/NNS	prep_of||terms-12/NNS||morbidity-14/NN	prep_of||terms-12/NNS||mortality-16/NN	conj_and||morbidity-14/NN||mortality-16/NN	auxpass||caused-19/VBN||is-18/VBZ	dep||arthropod-6/NN||caused-19/VBN	conj_and||borne-7/VBN||caused-19/VBN	agent||caused-19/VBN||any-21/DT	det||serotypes-25/NNS||the-23/DT	num||serotypes-25/NNS||four-24/CD	prep_of||any-21/DT||serotypes-25/NNS	prep_of||serotypes-25/NNS||denguevirus-27/NNS	dep||denguevirus-27/NNS||denv-1-29/JJ	prep_to||denv-1-29/JJ||4-31/CD	dengue-1||denguevirus-27||no||dengue is the most important arthropod borne viral disease worldwide in terms of morbidity and mortality and is caused by any of the four serotypes of denguevirus (denv-1 to 4).
det||role-2/NN||the-1/DT	nsubjpass||evaluated-17/VBN||role-2/NN	nsubj||has-19/VBZ||role-2/NN	prep_of||role-2/NN||oestrogen-4/NN	det||anti-oxidant-8/NN||an-6/DT	amod||anti-oxidant-8/NN||endogenous-7/JJ	appos||oestrogen-4/NN||anti-oxidant-8/NN	prep_on||anti-oxidant-8/NN||recovery-10/NN	amod||injury-13/NN||ischemia-reperfusion-12/JJ	prep_from||recovery-10/NN||injury-13/NN	aux||evaluated-17/VBN||has-14/VBZ	neg||evaluated-17/VBN||not-15/RB	auxpass||evaluated-17/VBN||been-16/VBN	root||ROOT-0/null||evaluated-17/VBN	conj_nor||evaluated-17/VBN||has-19/VBZ	det||impact-21/NN||the-20/DT	dobj||has-19/VBZ||impact-21/NN	amod||flow-25/NN||prolonged-23/VBN	amod||flow-25/NN||low-24/JJ	prep_of||impact-21/NN||flow-25/NN	nn||function-28/NN||vascular-27/NN	prep_on||flow-25/NN||function-28/NN	auxpass||established-30/VBN||been-29/VBN	vmod||function-28/NN||established-30/VBN	oestrogen-4||ischemia--1||no_rel||the role of oestrogen, an endogenous anti-oxidant on recovery from ischemia-reperfusion injury has not been evaluated nor has the impact of prolonged low flow on vascular function been established.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||population-2/NN||the-1/DT	nsubj||comprised-3/VBN||population-2/NN	nsubj||receiving-13/VBG||population-2/NN	root||ROOT-0/null||comprised-3/VBN	dobj||comprised-3/VBN||patients-4/NNS	det||diagnosis-8/NN||a-6/DT	amod||diagnosis-8/NN||first-7/JJ	prep_with||comprised-3/VBN||diagnosis-8/NN	amod||depressivedisorder-11/NN||major-10/JJ	prep_of||diagnosis-8/NN||depressivedisorder-11/NN	conj_and||comprised-3/VBN||receiving-13/VBG	det||one-18/NN||the-15/DT	amod||one-18/NN||first-16/JJ	nn||one-18/NN||time-17/NN	prep_for||receiving-13/VBG||one-18/NN	det||escitalopram-23/NN||the-20/DT	amod||escitalopram-23/NN||following-21/JJ	nn||escitalopram-23/NN||ssris-22/NNS	prep_of||one-18/NN||escitalopram-23/NN	appos||escitalopram-23/NN||sertraline-25/NN	appos||escitalopram-23/NN||paroxetine-27/NN	conj_and||sertraline-25/NN||paroxetine-27/NN	appos||escitalopram-23/NN||citalopram-30/NN	conj_and||sertraline-25/NN||citalopram-30/NN	depressivedisorder-11||sertraline-25||yes||the population comprised patients with a first diagnosis of major depressivedisorder and receiving for the first time one of the following ssris escitalopram, sertraline, paroxetine, and citalopram.
nsubj||control-57/VBP||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	iobj||compare-3/VB||approaches-6/NNS	amod||insulinglargine-9/NN||-lsb--7/JJ	amod||insulinglargine-9/NN||once-daily-8/JJ	dep||approaches-6/NNS||insulinglargine-9/NN	amod||approaches-6/NNS||plus-10/IN	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||‰-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	dep||approaches-6/NNS||+-19/NNS	nn||-rrb--21/NNP||l-20/NNP	dep||+-19/NNS||-rrb--21/NNP	nn||-rrb--28/NNP||insulinlispro-23/NN	nn||-rrb--28/NNP||mix-24/NN	nn||-rrb--28/NNP||50/50-25/NNP	nn||-rrb--28/NNP||-lrb--26/NNP	nn||-rrb--28/NNP||lm50/50-27/NNPS	prep_vs.||-rrb--21/NNP||-rrb--28/NNP	dep||-rrb--21/NNP||progression-29/VBN	advmod||up-31/RB||once-30/RB	advmod||progression-29/VBN||up-31/RB	aux||thrice-33/VB||to-32/TO	xcomp||progression-29/VBN||thrice-33/VB	amod||progression-37/NN||daily-34/JJ	amod||progression-37/NN||-lrb--35/JJ	nn||progression-37/NN||premix-36/NN	dobj||thrice-33/VB||progression-37/NN	nn||-rsb--41/NNP||pp-39/NNP	nn||-rsb--41/NNP||-rrb--40/NNP	appos||progression-37/NN||-rsb--41/NNP	prepc_of||-rsb--41/NNP||beginning-43/VBG	prepc_of||-rsb--41/NNP||advancing-45/VBG	conj_and||beginning-43/VBG||advancing-45/VBG	dobj||beginning-43/VBG||insulin-46/NN	prep_in||beginning-43/VBG||patients-48/NNS	amod||-rrb--53/NNS||type2diabetes-50/JJ	amod||-rrb--53/NNS||-lrb--51/JJ	amod||-rrb--53/NNS||t2d-52/JJ	prep_with||patients-48/NNS||-rrb--53/NNS	amod||glycaemic-56/JJ||inadequate-55/JJ	dep||-rrb--21/NNP||glycaemic-56/JJ	conj_and||progression-29/VBN||glycaemic-56/JJ	root||ROOT-0/null||control-57/VBP	amod||therapy-60/NN||oral-59/JJ	prep_on||control-57/VBP||therapy-60/NN	det||aim-64/NN||the-63/DT	prep_with||control-57/VBP||aim-64/NN	prepc_of||aim-64/NN||showing-66/VBG	dobj||showing-66/VBG||non-inferiority-67/NN	prep_of||non-inferiority-67/NN||pp-69/NN	prep_to||showing-66/VBG||g-71/NN	amod||l-73/NN||+-72/JJ	dobj||control-57/VBP||l-73/NN	type2diabetes-50||insulinlispro-23||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â ‰ $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulinlispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
det||cohort-3/NN||the-1/DT	amod||cohort-3/NN||medalist-2/JJ	nsubj||has-29/VBZ||cohort-3/NN	det||±-9/NN||a-6/DT	amod||±-9/NN||mean-7/JJ	nn||±-9/NN||â-8/NN	prep_with||cohort-3/NN||±-9/NN	vmod||±-9/NN||sd-10/VBN	nn||duration-12/NN||disease-11/NN	nn||â-22/NN||duration-12/NN	conj_and||duration-12/NN||age-14/NN	nn||â-22/NN||age-14/NN	num||â-17/NN||56.2-16/CD	prep_of||duration-12/NN||â-17/NN	amod||â-22/NN||±-18/JJ	dep||±-18/JJ||5.8-19/CD	dep||±-18/JJ||67.2-21/CD	conj_and||5.8-19/CD||67.2-21/CD	dobj||sd-10/VBN||â-22/NN	number||7.5-24/CD||±-23/CD	num||years-25/NNS||7.5-24/CD	tmod||sd-10/VBN||years-25/NNS	advmod||sd-10/VBN||respectively-27/RB	dep||mean-39/VBP||has-29/VBZ	det||phenotype-32/NN||a-30/DT	amod||phenotype-32/NN||clinical-31/JJ	dobj||has-29/VBZ||phenotype-32/NN	amod||type1diabetes-35/JJ||similar-33/JJ	dep||type1diabetes-35/JJ||to-34/TO	amod||phenotype-32/NN||type1diabetes-35/JJ	appos||phenotype-32/NN||type1diabetes-37/NNP	root||ROOT-0/null||mean-39/VBP	nn||onset-43/NN||â-40/NN	num||onset-43/NN||±-41/CD	nn||onset-43/NN||sd-42/NN	dobj||mean-39/VBP||onset-43/NN	num||±-47/NNS||11.0-45/CD	nn||±-47/NNS||â-46/NN	prep_at||onset-43/NN||±-47/NNS	num||years-49/NNS||6.4-48/CD	nsubj||mean-39/VBP||years-49/NNS	appos||years-49/NNS||bmi-51/NN	num||â-54/NN||26.0-53/CD	prep_at||bmi-51/NN||â-54/NN	number||5.1-56/CD||±-55/CD	num||kg/m2-57/NNS||5.1-56/CD	dep||â-54/NN||kg/m2-57/NNS	nn||dose-60/NN||insulin-59/NN	prep_at||bmi-51/NN||dose-60/NN	conj_and||â-54/NN||dose-60/NN	num||±-64/NNS||0.46-62/CD	nn||±-64/NNS||â-63/NN	prep_of||dose-60/NN||±-64/NNS	number||u/kg-66/JJ||0.2-65/CD	amod||±-64/NNS||u/kg-66/JJ	number||1/4-69/CD||âˆ-68/CD	prep_at||bmi-51/NN||1/4-69/CD	conj_and||â-54/NN||1/4-69/CD	num||%-71/NN||94-70/CD	npadvmod||positive-72/JJ||%-71/NN	amod||1/4-69/CD||positive-72/JJ	amod||dr4-76/NNS||dr3-74/JJ	amod||dr4-76/NNS||and/or-75/JJ	prep_for||1/4-69/CD||dr4-76/NNS	num||%-80/NN||29.5-79/CD	prep_at||bmi-51/NN||%-80/NN	conj_and||â-54/NN||%-80/NN	amod||autoantibodies-91/NNS||positive-81/JJ	det||decarboxylase-87/NN||either-83/DT	amod||decarboxylase-87/NN||ia2-84/JJ	conj_or||ia2-84/JJ||glutamicacid-86/JJ	amod||decarboxylase-87/NN||glutamicacid-86/JJ	prep_for||positive-81/JJ||decarboxylase-87/NN	appos||decarboxylase-87/NN||gad-89/NN	dep||%-80/NN||autoantibodies-91/NNS	type1diabetes-37||insulin-59||yes||the medalist cohort, with a mean â± sd disease duration and age of 56.2 â± 5.8 and 67.2 â± 7.5 years, respectively, has a clinical phenotype similar to type1diabetes (type1diabetes) mean â± sd onset at 11.0 â± 6.4 years, bmi at 26.0 â± 5.1 kg/m2, insulin dose of 0.46 â± 0.2 u/kg, âˆ¼94% positive for dr3 and/or dr4, and 29.5% positive for either ia2 or glutamicacid decarboxylase (gad) autoantibodies.
nn||bats-2/NNS||asian-1/NN	nsubjpass||identified-5/VBN||bats-2/NNS	aux||identified-5/VBN||have-3/VBP	auxpass||identified-5/VBN||been-4/VBN	root||ROOT-0/null||identified-5/VBN	amod||hosts-9/NNS||potential-7/JJ	nn||hosts-9/NNS||reservoir-8/NN	prep_as||identified-5/VBN||hosts-9/NNS	prep_of||hosts-9/NNS||coronaviruses-11/NNS	vmod||coronaviruses-11/NNS||associated-12/VBN	prep_with||associated-12/VBN||severeacuterespiratorysyndrome-14/NN	appos||severeacuterespiratorysyndrome-14/NN||sars-cov-16/NNP	severeacuterespiratorysyndrome-14||sars-cov-16||no||asian bats have been identified as potential reservoir hosts of coronaviruses associated with severeacuterespiratorysyndrome (sars-cov).
prep_to||associated-14/VBN||date-2/NN	det||number-5/NN||a-4/DT	nsubjpass||associated-14/VBN||number-5/NN	prep_of||number-5/NN||genes-7/NNS	vmod||genes-7/NNS||involved-8/VBN	nn||signalling-11/NN||interferon-10/NN	prep_in||involved-8/VBN||signalling-11/NN	aux||associated-14/VBN||have-12/VBP	auxpass||associated-14/VBN||been-13/VBN	root||ROOT-0/null||associated-14/VBN	amod||autoimmunediseases-17/NNS||various-16/JJ	prep_with||associated-14/VBN||autoimmunediseases-17/NNS	autoimmunediseases-17||interferon-10||no||to date, a number of genes involved in interferon signalling have been associated with various autoimmunediseases.
nsubj||recovered-8/VBD||similarity-1/NN	det||flora-5/NNS||the-3/DT	amod||flora-5/NNS||oral-4/JJ	prep_between||similarity-1/NN||flora-5/NNS	prep_between||similarity-1/NN||organisms-7/NNS	conj_and||flora-5/NNS||organisms-7/NNS	root||ROOT-0/null||recovered-8/VBD	amod||urethritis-11/NNS||nongonococcal-10/JJ	prep_from||recovered-8/VBD||urethritis-11/NNS	prep_from||recovered-8/VBD||prostatitis-13/NNS	conj_and||urethritis-11/NNS||prostatitis-13/NNS	dobj||recovered-8/VBD||points-15/NNS	nsubj||retrograde-17/VB||points-15/NNS	aux||retrograde-17/VB||to-16/TO	xcomp||recovered-8/VBD||retrograde-17/VB	dobj||retrograde-17/VB||entry-18/NN	prep_of||entry-18/NN||bacteria-20/NNS	amod||cavity-23/NN||oral-22/JJ	prep_from||bacteria-20/NNS||cavity-23/NN	det||urethra-26/NN||the-25/DT	prep_into||retrograde-17/VB||urethra-26/NN	amod||intercourse-30/NN||insertive-28/JJ	amod||intercourse-30/NN||oral-29/JJ	prep_following||urethra-26/NN||intercourse-30/NN	cavity-23||bacteria-20||no||similarity between the oral flora and organisms recovered from nongonococcal urethritis and prostatitis, points to retrograde entry of bacteria from oral cavity into the urethra following insertive oral intercourse.
amod||levels-4/NNS||mean-1/JJ	amod||levels-4/NNS||serum-2/JJ	amod||levels-4/NNS||timp-2-3/JJ	nsubj||differ-7/VB||levels-4/NNS	nsubj||hc-14/VBP||levels-4/NNS	aux||differ-7/VB||did-5/VBD	neg||differ-7/VB||not-6/RB	root||ROOT-0/null||differ-7/VB	nn||patients-12/NNS||uc-9/NN	conj_and||uc-9/NN||cd-11/NN	nn||patients-12/NNS||cd-11/NN	prep_between||differ-7/VB||patients-12/NNS	conj_or||differ-7/VB||hc-14/VBP	parataxis||hc-14/VBP||p-16/VB	num||0.05-18/CD||>-17/CD	dobj||p-16/VB||0.05-18/CD	det||cases-21/NNS||all-20/DT	prep_in||p-16/VB||cases-21/NNS	uc-9||hc-14||yes||mean serum timp-2 levels did not differ between uc and cd patients or hc (p > 0.05 in all cases).
det||media-3/NNS||this-1/DT	amod||media-3/NNS||conditioned-2/JJ	nsubjpass||applied-6/VBN||media-3/NNS	auxpass||applied-6/VBN||was-4/VBD	advmod||applied-6/VBN||then-5/RB	root||ROOT-0/null||applied-6/VBN	amod||myotubes-11/NNS||primary-8/JJ	amod||myotubes-11/NNS||human-9/JJ	amod||myotubes-11/NNS||skeletal-10/JJ	prep_to||applied-6/VBN||myotubes-11/NNS	vmod||myotubes-11/NNS||derived-12/VBN	amod||biopsies-16/NNS||vastus-14/JJ	nn||biopsies-16/NNS||lateralis-15/NNS	prep_from||derived-12/VBN||biopsies-16/NNS	vmod||biopsies-16/NNS||taken-17/VBN	prep_from||taken-17/VBN||patients-19/NNS	prep_with||patients-19/NNS||type2diabetes-21/CD	aux||examine-23/VB||to-22/TO	xcomp||taken-17/VBN||examine-23/VB	amod||uptake-26/NN||insulin-stimulated-24/JJ	nn||uptake-26/NN||glucose-25/NN	dobj||examine-23/VB||uptake-26/NN	type2diabetes-21||insulin--1||yes||this conditioned media was then applied to primary human skeletal myotubes derived from vastus lateralis biopsies taken from patients with type2diabetes to examine insulin-stimulated glucose uptake.
amod||reservoirs-2/NNS||long-lived-1/JJ	nsubj||infected-9/VBD||reservoirs-2/NNS	prep_of||reservoirs-2/NNS||humanimmunodeficiencyvirus-4/NNS	appos||humanimmunodeficiencyvirus-4/NNS||hiv-6/NN	advmod||infected-9/VBD||latently-8/RB	root||ROOT-0/null||infected-9/VBD	nsubj||present-11/VB||cells-10/NNS	ccomp||infected-9/VBD||present-11/VB	det||barrier-14/NN||the-12/DT	amod||barrier-14/NN||main-13/JJ	dobj||present-11/VB||barrier-14/NN	det||cure-17/NN||a-16/DT	prep_to||present-11/VB||cure-17/NN	prep_for||cure-17/NN||hivinfection-19/NN	hivinfection-19||hiv-6||no||long-lived reservoirs of humanimmunodeficiencyvirus (hiv) latently infected cells present the main barrier to a cure for hivinfection.
det||interaction-3/NN||the-1/DT	amod||interaction-3/NN||symbiotic-2/JJ	nsubj||involves-9/VBZ||interaction-3/NN	amod||plants-6/NNS||leguminous-5/JJ	prep_between||interaction-3/NN||plants-6/NNS	prep_between||interaction-3/NN||rhizobia-8/NN	conj_and||plants-6/NNS||rhizobia-8/NN	root||ROOT-0/null||involves-9/VBZ	num||processes-11/NNS||two-10/CD	npadvmod||bacterialinfection-12/JJ||processes-11/NNS	acomp||involves-9/VBZ||bacterialinfection-12/JJ	xcomp||involves-9/VBZ||resulting-14/VBG	det||penetration-17/NN||the-16/DT	prep_in||resulting-14/VBG||penetration-17/NN	prep_of||penetration-17/NN||bacteria-19/NNS	amod||cells-24/NNS||epidermal-21/JJ	conj_and||epidermal-21/JJ||cortical-23/JJ	amod||cells-24/NNS||cortical-23/JJ	prep_in||bacteria-19/NNS||cells-24/NNS	nn||nodule-28/NN||root-27/NN	nsubj||organogenesis-29/VBZ||nodule-28/NN	conj_and||involves-9/VBZ||organogenesis-29/VBZ	bacterialinfection-12||bacteria-19||no||the symbiotic interaction between leguminous plants and rhizobia involves two processes bacterialinfection, resulting in the penetration of bacteria in epidermal and cortical cells, and root nodule organogenesis.
det||concepts-3/NNS||the-1/DT	amod||concepts-3/NNS||basic-2/JJ	nsubj||differ-10/VBP||concepts-3/NNS	nsubjpass||understood-20/VBN||concepts-3/NNS	prep_of||concepts-3/NNS||balance-5/NN	prep_of||concepts-3/NNS||harmony-7/NN	conj_and||balance-5/NN||harmony-7/NN	rcmod||concepts-3/NNS||differ-10/VBP	amod||groups-16/NNS||low-12/JJ	conj_and||low-12/JJ||high-14/JJ	amod||groups-16/NNS||high-14/JJ	nn||groups-16/NNS||ses-15/NN	prep_between||differ-10/VBP||groups-16/NNS	aux||understood-20/VBN||must-18/MD	auxpass||understood-20/VBN||be-19/VB	root||ROOT-0/null||understood-20/VBN	advmod||reduce-26/VB||when-21/WRB	amod||interventions-24/NNS||tailoring-22/VBG	nn||interventions-24/NNS||community-23/NN	nsubj||reduce-26/VB||interventions-24/NNS	aux||reduce-26/VB||to-25/TO	dep||understood-20/VBN||reduce-26/VB	nn||factors-29/NNS||cvd-27/NN	nn||factors-29/NNS||risk-28/NN	dobj||reduce-26/VB||factors-29/NNS	cvd-27||basic-2||no_rel||the basic concepts of balance and harmony, which differ between low and high ses groups, must be understood when tailoring community interventions to reduce cvd risk factors.
nsubj||one-3/CD||species-specificity-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||characteristics-7/NNS||the-5/DT	amod||characteristics-7/NNS||major-6/JJ	prep_of||one-3/CD||characteristics-7/NNS	prep_of||characteristics-7/NNS||cytomegaloviruses-9/NNS	appos||cytomegaloviruses-9/NNS||cmvs-11/NNS	cop||reason-17/NN||is-14/VBZ	det||reason-17/NN||the-15/DT	amod||reason-17/NN||primary-16/JJ	conj_and||one-3/CD||reason-17/NN	det||lack-20/NN||the-19/DT	prep_for||reason-17/NN||lack-20/NN	det||model-24/NN||a-22/DT	nn||model-24/NN||mouse-23/NN	prep_of||lack-20/NN||model-24/NN	det||infection-28/NN||the-26/DT	amod||infection-28/NN||direct-27/JJ	prep_for||model-24/NN||infection-28/NN	amod||cmv-31/NN||human-30/JJ	prep_of||infection-28/NN||cmv-31/NN	appos||cmv-31/NN||hcmv-33/NNP	cmv-31||hcmv-33||no||species-specificity is one of the major characteristics of cytomegaloviruses (cmvs) and is the primary reason for the lack of a mouse model for the direct infection of human cmv (hcmv).
vmod||determined-26/VBD||based-1/VBN	advmod||successful-4/JJ||highly-3/RB	amod||demonstrations-5/NNS||successful-4/JJ	prep_on||based-1/VBN||demonstrations-5/NNS	prep_in||based-1/VBN||israel-7/NN	mark||decimate-18/VB||that-8/IN	amod||bait-12/NN||attractive-9/JJ	amod||bait-12/NN||toxic-10/JJ	nn||bait-12/NN||sugar-11/NN	nn||methods-16/NNS||bait-12/NN	appos||methods-16/NNS||atsb-14/NN	nsubj||decimate-18/VB||methods-16/NNS	aux||decimate-18/VB||can-17/MD	ccomp||based-1/VBN||decimate-18/VB	amod||populations-20/NNS||local-19/JJ	dobj||decimate-18/VB||populations-20/NNS	prep_of||populations-20/NNS||mosquitoes-22/NNS	det||study-25/NN||this-24/DT	nsubj||determined-26/VBD||study-25/NN	root||ROOT-0/null||determined-26/VBD	det||effectiveness-28/NN||the-27/DT	dobj||determined-26/VBD||effectiveness-28/NN	amod||methods-31/NNS||atsb-30/JJ	prep_of||effectiveness-28/NN||methods-31/NNS	nn||control-35/NN||malaria-33/NN	nn||control-35/NN||vector-34/NN	prep_for||determined-26/VBD||control-35/NN	det||district-40/NN||the-37/DT	amod||district-40/NN||semi-arid-38/JJ	nn||district-40/NN||bandiagara-39/NN	prep_in||control-35/NN||district-40/NN	prep_of||district-40/NN||mali-42/NNS	amod||africa-45/NN||west-44/JJ	appos||mali-42/NNS||africa-45/NN	sugar-11||malaria-33||no_rel||based on highly successful demonstrations in israel that attractive toxic sugar bait (atsb) methods can decimate local populations of mosquitoes, this study determined the effectiveness of atsb methods for malaria vector control in the semi-arid bandiagara district of mali, west africa.
amod||understanding-2/NN||greater-1/JJR	nsubj||help-20/VB||understanding-2/NN	det||interplay-5/NN||the-4/DT	prep_of||understanding-2/NN||interplay-5/NN	det||factors-9/NNS||the-7/DT	amod||factors-9/NNS||key-8/JJ	prep_between||interplay-5/NN||factors-9/NNS	vmod||factors-9/NNS||involved-10/VBN	det||regulation-13/NN||the-12/DT	prep_in||involved-10/VBN||regulation-13/NN	nn||metabolism-16/NN||iron-15/NN	prep_of||regulation-13/NN||metabolism-16/NN	prep_of||regulation-13/NN||erythropoiesis-18/NNS	conj_and||metabolism-16/NN||erythropoiesis-18/NNS	aux||help-20/VB||will-19/MD	root||ROOT-0/null||help-20/VB	xcomp||help-20/VB||develop-21/VB	advmod||effective-23/JJ||more-22/RBR	amod||therapies-24/NNS||effective-23/JJ	dobj||develop-21/VB||therapies-24/NNS	prep_for||develop-21/VB||disorders-26/NNS	nn||irondeficiency-30/NN||ironoverload-28/NN	prep_of||disorders-26/NNS||irondeficiency-30/NN	nn||synthesis-34/NN||hemoglobin-33/NN	prep_of||disorders-26/NNS||synthesis-34/NN	conj_and||irondeficiency-30/NN||synthesis-34/NN	ironoverload-28||iron-15||no||greater understanding of the interplay between the key factors involved in the regulation of iron metabolism and erythropoiesis will help develop more effective therapies for disorders of ironoverload, irondeficiency, and hemoglobin synthesis.
det||substitution-3/NN||a-1/DT	amod||substitution-3/NN||partial-2/JJ	nsubj||offers-11/VBZ||substitution-3/NN	nn||vaccines-6/NNS||injection-5/NN	prep_of||substitution-3/NN||vaccines-6/NNS	amod||formulations-9/NNS||oral-8/JJ	prep_with||vaccines-6/NNS||formulations-9/NNS	advmod||offers-11/VBZ||still-10/RB	root||ROOT-0/null||offers-11/VBZ	amod||prospects-13/NNS||good-12/JJ	dobj||offers-11/VBZ||prospects-13/NNS	advmod||viable-16/JJ||economically-15/RB	amod||vaccines-21/NNS||viable-16/JJ	amod||anti-hbv-19/JJ||efficacious-18/JJ	conj_and||viable-16/JJ||anti-hbv-19/JJ	amod||vaccines-21/NNS||anti-hbv-19/JJ	amod||vaccines-21/NNS||plant-based-20/JJ	prep_for||prospects-13/NNS||vaccines-21/NNS	hbv--1||vaccines-21||no_rel||a partial substitution of injection vaccines with oral formulations still offers good prospects for economically viable and efficacious anti-hbv plant-based vaccines.
prep||occurred-18/VBD||except-1/IN	pcomp||except-1/IN||in-2/IN	num||cadets-4/NNS||two-3/CD	pobj||in-2/IN||cadets-4/NNS	advmod||ill-6/JJ||already-5/RB	amod||cadets-4/NNS||ill-6/JJ	amod||bleeding-9/NN||first-8/JJ	prep_on||cadets-4/NNS||bleeding-9/NN	neg||evidence-11/NN||no-10/DT	nsubj||occurred-18/VBD||evidence-11/NN	amod||infectiousmononucleosis-14/NNS||clinical-13/JJ	prep_of||evidence-11/NN||infectiousmononucleosis-14/NNS	appos||evidence-11/NN||i.m.-16/NNP	root||ROOT-0/null||occurred-18/VBD	det||period-23/NN||the-20/DT	num||period-23/NN||4-21/CD	nn||period-23/NN||yr-22/NN	prep_over||occurred-18/VBD||period-23/NN	det||cadets-27/NNS||the-25/DT	num||cadets-27/NNS||890-26/CD	prep_in||occurred-18/VBD||cadets-27/NNS	xcomp||occurred-18/VBD||entering-28/VBG	det||academy-30/NN||the-29/DT	dobj||entering-28/VBG||academy-30/NN	nn||antibody-33/NN||ebv-32/NN	prep_with||entering-28/VBG||antibody-33/NN	infectiousmononucleosis-14||ebv-32||no||except in two cadets already ill on first bleeding no evidence of clinical infectiousmononucleosis (i.m.) occurred over the 4 yr period in the 890 cadets entering the academy with ebv antibody.
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||patients-7/NNS||one-4/CD	num||patients-7/NNS||hundred-5/CD	amod||patients-7/NNS||eighty-6/JJ	dobj||included-3/VBD||patients-7/NNS	dep||patients-7/NNS||divided-8/VBN	det||diabetic-13/NN||the-10/DT	amod||diabetic-13/NN||following-11/JJ	nn||diabetic-13/NN||groups-12/NNS	prep_in||divided-8/VBN||diabetic-13/NN	amod||disorders-17/NNS||ischemic-15/JJ	amod||disorders-17/NNS||cardiopathy-related-16/JJ	prep_without||diabetic-13/NN||disorders-17/NNS	appos||diabetic-13/NN||dm-19/NN	amod||disorders-35/NNS||diabetic-22/JJ	prep_with||diabetic-22/JJ||clinical-24/JJ	prep_with||diabetic-22/JJ||off-clinical-26/JJ	conj_or||clinical-24/JJ||off-clinical-26/JJ	dep||diabetic-22/JJ||electrocardiogram-28/NN	amod||ultrasound-31/NN||cardiac-30/JJ	appos||electrocardiogram-28/NN||ultrasound-31/NN	amod||disorders-35/NNS||ischemic-33/JJ	amod||disorders-35/NNS||cardiopathy-related-34/JJ	appos||diabetic-13/NN||disorders-35/NNS	amod||ic-39/NN||dm-37/JJ	amod||ic-39/NN||+-38/JJ	appos||disorders-35/NNS||ic-39/NN	dep||patients-7/NNS||nondiabetic-43/JJ	conj_and||divided-8/VBN||nondiabetic-43/JJ	amod||disorders-47/NNS||ischemic-45/JJ	amod||disorders-47/NNS||cardiopathy-related-46/JJ	prep_with||nondiabetic-43/JJ||disorders-47/NNS	appos||disorders-47/NNS||ic-49/NN	cardiopathy--1||dm-37||no_rel||the study included one hundred eighty patients divided in the following groups diabetic without ischemic cardiopathy-related disorders (dm), diabetic with clinical or off-clinical (electrocardiogram, cardiac ultrasound) ischemic cardiopathy-related disorders (dm + ic), and nondiabetic with ischemic cardiopathy-related disorders (ic).
amod||size-3/NN||adipose-1/JJ	nn||size-3/NN||cell-2/NN	nsubjpass||measured-5/VBN||size-3/NN	auxpass||measured-5/VBN||was-4/VBD	ccomp||ai-26/VBP||measured-5/VBN	prep_in||measured-5/VBN||biopsies-7/NNS	det||tissue-12/NN||the-9/DT	amod||tissue-12/NN||abdominal-10/JJ	nn||tissue-12/NN||adipose-11/NN	prep_from||measured-5/VBN||tissue-12/NN	nn||-rrb--21/NNS||insulin-16/NN	nn||-rrb--21/NNS||sensitivity-17/NN	amod||-rrb--21/NNS||-lrb--18/JJ	nn||-rrb--21/NNS||homa-19/NN	nn||-rrb--21/NNS||index-20/NN	prep_from||measured-5/VBN||-rrb--21/NNS	conj_and||tissue-12/NN||-rrb--21/NNS	nsubj||ai-26/VBP||hdl-cholesterol-23/NN	nsubj||apo-28/VBP||hdl-cholesterol-23/NN	conj_and||hdl-cholesterol-23/NN||apo-25/NN	nsubj||ai-26/VBP||apo-25/NN	root||ROOT-0/null||ai-26/VBP	conj_and||ai-26/VBP||apo-28/VBP	number||166-30/CD||b.-29/CD	num||individuals-33/NNS||166-30/CD	amod||individuals-33/NNS||additional-31/JJ	amod||individuals-33/NNS||non-obese-32/JJ	nsubj||underwent-40/VBD||individuals-33/NNS	det||predisposition-37/NN||a-35/DT	amod||predisposition-37/NN||genetic-36/JJ	prep_with||individuals-33/NNS||predisposition-37/NN	prep_for||predisposition-37/NN||type2diabetes-39/CD	ccomp||apo-28/VBP||underwent-40/VBD	det||clamp-44/NN||a-41/DT	amod||clamp-44/NN||euglycemic-42/JJ	amod||clamp-44/NN||hyperinsulinemic-43/JJ	dobj||underwent-40/VBD||clamp-44/NN	aux||measure-46/VB||to-45/TO	vmod||underwent-40/VBD||measure-46/VB	nn||sensitivity-48/NN||insulin-47/NN	dobj||measure-46/VB||sensitivity-48/NN	type2diabetes-39||insulin-47||yes||adipose cell size was measured in biopsies from the abdominal adipose tissue as well as insulin sensitivity -lrb- homa index -rrb- , hdl-cholesterol and apo ai and apo b. 166 additional non-obese individuals with a genetic predisposition for type2diabetes underwent a euglycemic hyperinsulinemic clamp to measure insulin sensitivity .
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||benefit-5/NN||the-3/DT	amod||benefit-5/NN||relative-4/JJ	iobj||examined-2/VBD||benefit-5/NN	prepc_of||benefit-5/NN||introducing-7/VBG	amod||maintenance-12/NN||budesonide/formoterol-8/JJ	appos||maintenance-12/NN||bud/form-10/NNP	dobj||introducing-7/VBG||maintenance-12/NN	nn||therapy-15/NN||reliever-14/NN	dobj||introducing-7/VBG||therapy-15/NN	conj_and||maintenance-12/NN||therapy-15/NN	amod||®-21/NNP||symbicort-17/JJ	nn||®-21/NNP||smartâ-18/NNP	nn||®-21/NNP||®-19/NNP	nn||®-21/NNP||turbuhalerâ-20/NNP	appos||therapy-15/NN||®-21/NNP	prep_in||introducing-7/VBG||patients-24/NNS	advmod||prescribed-26/VBN||previously-25/RB	vmod||patients-24/NNS||prescribed-26/VBN	dobj||prescribed-26/VBN||treatments-27/NNS	amod||initiative-30/NN||global-29/JJ	prep_from||prescribed-26/VBN||initiative-30/NN	amod||steps-36/NNS||asthma-32/JJ	appos||steps-36/NNS||gina-34/NNP	prep_for||prescribed-26/VBN||steps-36/NNS	dobj||examined-2/VBD||2-37/CD	num||2-37/CD||3-39/CD	dobj||examined-2/VBD||4-41/CD	conj_or||2-37/CD||4-41/CD	asthma-32||formoterol--1||yes||we examined the relative benefit of introducing budesonide/formoterol (bud/form) maintenance and reliever therapy (symbicort smartâ® turbuhalerâ®) in patients previously prescribed treatments from global initiative for asthma (gina) steps 2, 3 or 4.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	prep_of||role-4/NN||variation-6/NN	amod||genes-10/NNS||putative-8/JJ	nn||genes-10/NNS||psychosis-9/NNS	prep_in||variation-6/NN||genes-10/NNS	vmod||variation-6/NN||coding-11/VBG	prep_for||coding-11/VBG||elements-13/NNS	det||system-18/NN||the-15/DT	amod||system-18/NN||white-16/JJ	nn||system-18/NN||matter-17/NN	prep_of||elements-13/NNS||system-18/NN	agent||coding-11/VBG||examining-20/VBG	det||contribution-22/NN||the-21/DT	dobj||examining-20/VBG||contribution-22/NN	amod||variation-25/NN||genotypic-24/JJ	prep_of||contribution-22/NN||variation-25/NN	num||polymorphisms-29/NNS||three-27/CD	amod||polymorphisms-29/NNS||single-nucleotide-28/JJ	prep_in||variation-6/NN||polymorphisms-29/NNS	dep||variation-6/NN||snps-31/NNS	dep||variation-6/NN||neuregulin-33/NN	num||neuregulin-33/NN||1-34/CD	appos||neuregulin-33/NN||nrg1-36/NNP	amod||rs2857766-46/NNS||snp8nrg221533-38/JJ	amod||oligodendrocytes-41/JJ||myelin-40/JJ	amod||rs2857766-46/NNS||oligodendrocytes-41/JJ	nn||rs2857766-46/NNS||glycoprotein-42/NN	appos||rs2857766-46/NNS||mog-44/NN	dep||variation-6/NN||rs2857766-46/NNS	prep_of||role-4/NN||cnp-48/NN	conj_and||variation-6/NN||cnp-48/NN	appos||cnp-48/NN||rs2070106-50/NNP	num||ice-56/NN||one-53/CD	amod||ice-56/NN||haplotype-54/JJ	nn||ice-56/NN||hap-55/NN	conj_and||variation-6/NN||ice-56/NN	conj_and||cnp-48/NN||ice-56/NN	appos||ice-56/NN||decode-58/NN	amod||volume-63/NN||white-61/JJ	nn||volume-63/NN||matter-62/NN	prep_to||investigated-2/VBD||volume-63/NN	prep_in||volume-63/NN||patients-65/NNS	prep_with||investigated-2/VBD||psychoticdisorder-67/NN	poss||relatives-71/NNS||their-69/PRP$	amod||relatives-71/NNS||unaffected-70/JJ	prep_with||investigated-2/VBD||relatives-71/NNS	conj_and||psychoticdisorder-67/NN||relatives-71/NNS	psychoticdisorder-67||ice-56||no_rel||we investigated the role of variation in putative psychosis genes coding for elements of the white matter system by examining the contribution of genotypic variation in three single-nucleotide polymorphisms (snps) neuregulin 1 ( nrg1 ) snp8nrg221533, myelin oligodendrocytes glycoprotein (mog) rs2857766 and cnp (rs2070106) and one haplotype hap ice (decode) to white matter volume in patients with psychoticdisorder and their unaffected relatives.
det||mixture-5/NN||the-1/DT	amod||mixture-5/NN||lidocaine-2/JJ	conj_and||lidocaine-2/JJ||propofol-4/JJ	amod||mixture-5/NN||propofol-4/JJ	nsubj||effective-7/JJ||mixture-5/NN	cop||effective-7/JJ||is-6/VBZ	root||ROOT-0/null||effective-7/JJ	prepc_in||effective-7/JJ||alleviating-9/VBG	dobj||alleviating-9/VBG||pain-10/NN	vmod||pain-10/NN||associated-11/VBN	amod||injection-15/NN||microemulsion-13/JJ	amod||injection-15/NN||propofol-14/JJ	prep_with||associated-11/VBN||injection-15/NN	pain-10||propofol-14||yes||the lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion propofol injection.
amod||years-3/NNS||recent-2/JJ	prep_in||discussed-21/VBN||years-3/NNS	det||ways-6/NNS||the-5/DT	prep_in||interact-11/VBP||ways-6/NNS	nsubjpass||discussed-21/VBN||ways-6/NNS	amod||programs-10/NNS||hiv/aids-focused-9/JJ	nsubj||interact-11/VBP||programs-10/NNS	rcmod||ways-6/NNS||interact-11/VBP	det||delivery-14/NN||the-13/DT	prep_with||interact-11/VBP||delivery-14/NN	amod||services-18/NNS||other-16/JJ	nn||services-18/NNS||health-17/NN	prep_of||delivery-14/NN||services-18/NNS	auxpass||discussed-21/VBN||is-19/VBZ	advmod||discussed-21/VBN||often-20/RB	root||ROOT-0/null||discussed-21/VBN	det||evidence-25/NN||the-24/DT	nsubj||limited-38/JJ||evidence-25/NN	mark||strengthen-31/VBP||whether-28/IN	nn||programs-30/NNS||hiv/aids-29/NNS	nsubj||strengthen-31/VBP||programs-30/NNS	nsubj||distort-33/VBP||programs-30/NNS	prepc_as_to||evidence-25/NN||strengthen-31/VBP	prepc_as_to||evidence-25/NN||distort-33/VBP	conj_or||strengthen-31/VBP||distort-33/VBP	amod||services-36/NNS||overall-34/JJ	nn||services-36/NNS||health-35/NN	dobj||strengthen-31/VBP||services-36/NNS	cop||limited-38/JJ||is-37/VBZ	conj_but||discussed-21/VBN||limited-38/JJ	aids--1||hiv--1||no||in recent years, the ways in which hiv/aids-focused programs interact with the delivery of other health services is often discussed, but the evidence as to whether hiv/aids programs strengthen or distort overall health services is limited.
nsubj||agent-5/NN||itraconazole-1/NN	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||an-3/DT	amod||agent-5/NN||anti-fungal-4/JJ	root||ROOT-0/null||agent-5/NN	advmod||used-7/VBN||widely-6/RB	vmod||agent-5/NN||used-7/VBN	aux||treat-9/VB||to-8/TO	xcomp||used-7/VBN||treat-9/VB	amod||forms-11/NNS||various-10/JJ	dobj||treat-9/VB||forms-11/NNS	prep_of||forms-11/NNS||mycosis-13/NNS	mycosis-13||itraconazole-1||yes||itraconazole is an anti-fungal agent widely used to treat various forms of mycosis.
aux||examine-2/VB||to-1/TO	root||ROOT-0/null||examine-2/VB	det||efficacy-4/NN||the-3/DT	dobj||examine-2/VB||efficacy-4/NN	dobj||examine-2/VB||safety-6/NN	conj_and||efficacy-4/NN||safety-6/NN	dobj||examine-2/VB||tolerability-9/NN	conj_and||efficacy-4/NN||tolerability-9/NN	amod||chloride-15/NN||travoprost-11/JJ	num||%-13/NN||0.004-12/CD	dep||travoprost-11/JJ||%-13/NN	nn||chloride-15/NN||benzalkonium-14/NN	prep_of||efficacy-4/NN||chloride-15/NN	appos||chloride-15/NN||bak-17/NN	amod||living-32/NN||free-20/JJ	prepc_compared_with||free-20/JJ||with-22/IN	amod||use-24/NN||previous-23/JJ	pobj||free-20/JJ||use-24/NN	number||0.005-27/CD||latanoprost-26/CD	num||%-28/NN||0.005-27/CD	prep_of||use-24/NN||%-28/NN	amod||patients-31/NNS||japanese-30/JJ	prep_in||%-28/NN||patients-31/NNS	dep||examine-2/VB||living-32/NN	det||us-35/PRP||the-34/DT	prep_in||living-32/NN||us-35/PRP	nsubj||had-37/VBD||us-35/PRP	rcmod||us-35/PRP||had-37/VBD	amod||open-angleglaucoma-39/NN||primary-38/JJ	dobj||had-37/VBD||open-angleglaucoma-39/NN	dobj||had-37/VBD||ocularhypertension-41/NN	conj_or||open-angleglaucoma-39/NN||ocularhypertension-41/NN	open-angleglaucoma-39||latanoprost-26||yes||to examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (bak)-free compared with previous use of latanoprost 0.005% in japanese patients living in the us who had primary open-angleglaucoma or ocularhypertension.
det||hepatitisbvirus-2/NNS||the-1/DT	nsubj||factor-10/NN||hepatitisbvirus-2/NNS	appos||hepatitisbvirus-2/NNS||hbv-4/NN	cop||factor-10/NN||is-6/VBZ	det||factor-10/NN||a-7/DT	amod||factor-10/NN||major-8/JJ	amod||factor-10/NN||etiological-9/JJ	root||ROOT-0/null||factor-10/NN	prep_of||factor-10/NN||inflammation-12/NN	prep_of||factor-10/NN||damage-14/NN	conj_and||inflammation-12/NN||damage-14/NN	det||liver-17/NN||the-16/DT	prep_to||factor-10/NN||liver-17/NN	vmod||liver-17/NN||resulting-18/VBG	nn||carcinoma-21/NN||hepatocellular-20/NN	prep_in||resulting-18/VBG||carcinoma-21/NN	hbv-4||hepatitisbvirus-2||no||the hepatitisbvirus (hbv) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
det||model-2/NN||the-1/DT	nsubj||estimates-3/VBZ||model-2/NN	root||ROOT-0/null||estimates-3/VBZ	mark||reduce-22/VB||that-4/IN	det||introduction-6/NN||the-5/DT	nsubj||reduce-22/VB||introduction-6/NN	det||programme-12/NN||a-8/DT	amod||programme-12/NN||universal-9/JJ	nn||programme-12/NN||rotavirus-10/NNS	nn||programme-12/NN||vaccination-11/NN	prep_of||introduction-6/NN||programme-12/NN	prep_with||programme-12/NN||rotateq-14/NNP	num||%-17/NN||90-16/CD	dep||introduction-6/NN||%-17/NN	nn||rate-19/NN||coverage-18/NN	dep||%-17/NN||rate-19/NN	aux||reduce-22/VB||would-21/MD	ccomp||estimates-3/VBZ||reduce-22/VB	det||burden-28/NN||the-23/DT	nn||burden-28/NN||rotavirusgastroenteritis-24/NN	appos||burden-28/NN||rvge-26/NN	dobj||reduce-22/VB||burden-28/NN	num||%-31/NN||75-30/CD	prep_by||reduce-22/VB||%-31/NN	prep_in||%-31/NN||spain-33/NN	num||cases-38/NNS||53,692-35/CD	nn||cases-38/NNS||home-36/NN	nn||cases-38/NNS||care-37/NN	nsubjpass||avoided-57/VBN||cases-38/NNS	num||visits-42/NNS||35,187-40/CD	nn||visits-42/NNS||gp/paediatrician-41/NN	conj_and||cases-38/NNS||visits-42/NNS	nsubjpass||avoided-57/VBN||visits-42/NNS	num||visits-47/NNS||34,287-44/CD	nn||visits-47/NNS||emergency-45/NN	nn||visits-47/NNS||department-46/NN	conj_and||cases-38/NNS||visits-47/NNS	nsubjpass||avoided-57/VBN||visits-47/NNS	num||hospitalisations-50/NNS||10,987-49/CD	conj_and||cases-38/NNS||hospitalisations-50/NNS	nsubjpass||avoided-57/VBN||hospitalisations-50/NNS	num||infections-54/NNS||2,053-52/CD	amod||infections-54/NNS||nosocomial-53/JJ	conj_and||cases-38/NNS||infections-54/NNS	nsubjpass||avoided-57/VBN||infections-54/NNS	aux||avoided-57/VBN||would-55/MD	auxpass||avoided-57/VBN||be-56/VB	parataxis||estimates-3/VBZ||avoided-57/VBN	rotavirusgastroenteritis-24||rotavirus-10||no||the model estimates that the introduction of a universal rotavirus vaccination programme with rotateq (90% coverage rate) would reduce the rotavirusgastroenteritis (rvge) burden by 75% in spain; 53,692 home care cases, 35,187 gp/paediatrician visits, 34,287 emergency department visits, 10,987 hospitalisations and 2,053 nosocomial infections would be avoided.
det||results-2/NNS||these-1/DT	nsubj||indicated-3/VBD||results-2/NNS	root||ROOT-0/null||indicated-3/VBD	mark||offers-6/VBZ||that-4/IN	nsubj||offers-6/VBZ||ea-5/NN	ccomp||indicated-3/VBD||offers-6/VBZ	det||effect-9/NN||a-7/DT	amod||effect-9/NN||beneficial-8/JJ	dobj||offers-6/VBZ||effect-9/NN	prep_on||offers-6/VBZ||insulinresistance-11/NN	amod||mice-17/NNS||obese-13/JJ	conj_and||obese-13/JJ||diabetic-15/JJ	amod||mice-17/NNS||diabetic-15/JJ	nn||mice-17/NNS||db/db-16/NN	prep_in||insulinresistance-11/NN||mice-17/NNS	dep||mice-17/NNS||at-19/IN	pobj||at-19/IN||least-20/JJS	dep||at-19/IN||partly-21/RB	prep_via||insulinresistance-11/NN||stimulation-24/NN	amod||±-29/NNS||sirt1/pgc-26/JJ	amod||±-29/NNS||-1-27/JJ	nn||±-29/NNS||î-28/NN	prep_of||stimulation-24/NN||±-29/NNS	advmod||resulting-32/VBG||thus-31/RB	vmod||offers-6/VBZ||resulting-32/VBG	amod||signal-36/NN||improved-34/VBN	nn||signal-36/NN||insulin-35/NN	prep_in||resulting-32/VBG||signal-36/NN	insulin-35||obese-13||no_rel||these results indicated that ea offers a beneficial effect on insulinresistance in obese and diabetic db/db mice, at least partly, via stimulation of sirt1/pgc-1 î± , thus resulting in improved insulin signal.
amod||procedures-3/NNS||invasive-1/JJ	amod||procedures-3/NNS||medical-2/JJ	nsubjpass||associated-27/VBN||procedures-3/NNS	nn||contact-6/NN||household-5/NN	appos||procedures-3/NNS||contact-6/NN	amod||carriers-12/NNS||hepatitisbvirus-8/JJ	appos||carriers-12/NNS||hbv-10/NN	prep_with||contact-6/NN||carriers-12/NNS	nn||care-15/NN||body-14/NN	conj_and||procedures-3/NNS||care-15/NN	nsubjpass||associated-27/VBN||care-15/NN	nn||treatments-18/NNS||beauty-17/NN	conj_and||procedures-3/NNS||treatments-18/NNS	conj_and||care-15/NN||treatments-18/NNS	conj_and||procedures-3/NNS||lack-21/NN	nsubjpass||associated-27/VBN||lack-21/NN	nn||vaccination-24/NN||hbv-23/NN	prep_of||lack-21/NN||vaccination-24/NN	auxpass||associated-27/VBN||were-25/VBD	advmod||associated-27/VBN||independently-26/RB	root||ROOT-0/null||associated-27/VBN	prep_with||associated-27/VBN||ahb-29/NN	hbv-23||hepatitisbvirus-8||no||invasive medical procedures, household contact with hepatitisbvirus (hbv) carriers, body care and beauty treatments, and lack of hbv vaccination were independently associated with ahb.
amod||asthma-2/NN||aspirin-intolerant-1/JJ	nsubj||condition-9/NN||asthma-2/NN	appos||asthma-2/NN||aia-4/NN	cop||condition-9/NN||is-6/VBZ	det||condition-9/NN||a-7/DT	amod||condition-9/NN||rare-8/JJ	root||ROOT-0/null||condition-9/NN	nsubjpass||characterized-12/VBN||condition-9/NN	auxpass||characterized-12/VBN||is-11/VBZ	rcmod||condition-9/NN||characterized-12/VBN	det||development-15/NN||the-14/DT	agent||characterized-12/VBN||development-15/NN	prep_of||development-15/NN||bronchoconstriction-17/NN	amod||patients-20/NNS||asthmatic-19/JJ	prep_in||bronchoconstriction-17/NN||patients-20/NNS	prep_after||characterized-12/VBN||ingestion-22/NN	amod||anti-inflammatorydrugs-25/NNS||non-steroidal-24/JJ	prep_of||ingestion-22/NN||anti-inflammatorydrugs-25/NNS	prep_including||anti-inflammatorydrugs-25/NNS||aspirin-27/NN	asthma-2||aspirin-27||no||aspirin-intolerant asthma (aia) is a rare condition that is characterized by the development of bronchoconstriction in asthmatic patients after ingestion of non-steroidal anti-inflammatorydrugs including aspirin.
nsubj||condition-7/NN||sicklecellanaemia-1/NN	cop||condition-7/NN||is-2/VBZ	det||condition-7/NN||an-3/DT	amod||condition-7/NN||autosomal-4/JJ	amod||condition-7/NN||recessive-5/JJ	amod||condition-7/NN||genetic-6/JJ	root||ROOT-0/null||condition-7/NN	vmod||condition-7/NN||producing-8/VBG	amod||molecules-12/NNS||abnormal-9/JJ	nn||molecules-12/NNS||haemoglobin-10/NN	nn||molecules-12/NNS||hbs-11/NN	dobj||producing-8/VBG||molecules-12/NNS	nsubj||result-14/VBP||molecules-12/NNS	rcmod||molecules-12/NNS||result-14/VBP	amod||cells-21/NNS||stiff-16/JJ	conj_and||stiff-16/JJ||sticky-18/JJ	amod||cells-21/NNS||sticky-18/JJ	amod||cells-21/NNS||red-19/JJ	nn||cells-21/NNS||blood-20/NN	prep_in||result-14/VBP||cells-21/NNS	vmod||cells-21/NNS||leading-22/VBG	amod||episodes-25/NNS||unpredictable-24/JJ	prep_to||leading-22/VBG||episodes-25/NNS	nn||occlusions-28/NNS||microvascular-27/NN	prep_of||episodes-25/NNS||occlusions-28/NNS	sicklecellanaemia-1||hbs-11||no||sicklecellanaemia is an autosomal recessive genetic condition producing abnormal haemoglobin hbs molecules that result in stiff and sticky red blood cells leading to unpredictable episodes of microvascular occlusions.
det||subjects-5/NNS||the-3/DT	num||subjects-5/NNS||513-4/CD	prep_among||associated-20/VBN||subjects-5/NNS	nn||pain-8/NN||knee-7/NN	prep_with||subjects-5/NNS||pain-8/NN	det||presence-12/NN||the-10/DT	amod||presence-12/NN||additional-11/JJ	nsubjpass||associated-20/VBN||presence-12/NN	nsubjpass||associated-20/VBN||presence-12/NN	amod||evidence-15/NN||radiographic-14/JJ	prep_of||presence-12/NN||evidence-15/NN	prep_of||evidence-15/NN||oa-17/NN	auxpass||associated-20/VBN||was-18/VBD	advmod||associated-20/VBN||significantly-19/RB	root||ROOT-0/null||associated-20/VBN	conj_and||associated-20/VBN||associated-20/VBN	amod||occasions-23/NNS||more-22/JJR	prep_with||associated-20/VBN||occasions-23/NNS	prep_of||occasions-23/NNS||unbearable-27/NN	dep||occasions-23/NNS||pain-30/NN	num||%-33/NN||59-32/CD	dep||pain-30/NN||%-33/NN	num||%-36/NN||36-35/CD	dep||pain-30/NN||%-36/NN	conj_versus||%-33/NN||%-36/NN	amod||activity-40/NN||restricted-39/VBN	dep||occasions-23/NNS||activity-40/NN	conj_and||pain-30/NN||activity-40/NN	num||%-43/NN||64-42/CD	dep||activity-40/NN||%-43/NN	num||%-46/NN||39-45/CD	dep||activity-40/NN||%-46/NN	conj_versus||%-43/NN||%-46/NN	amod||use-53/NN||increased-52/VBN	npadvmod||associated-20/VBN||use-53/NN	prep_of||use-53/NN||nonsteroidalantiinflammatorydrugs-55/NNS	appos||nonsteroidalantiinflammatorydrugs-55/NNS||nsaids-57/NNS	num||%-61/NN||88-60/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-61/NN	num||%-64/NN||78-63/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-64/NN	conj_versus||%-61/NN||%-64/NN	det||number-69/NN||the-67/DT	amod||number-69/NN||reported-68/VBN	npadvmod||associated-20/VBN||number-69/NN	conj_and||use-53/NN||number-69/NN	nn||visits-72/NNS||doctor-71/NN	prep_of||number-69/NN||visits-72/NNS	num||%-75/NN||59-74/CD	dep||visits-72/NNS||%-75/NN	num||%-78/NN||33-77/CD	dep||visits-72/NNS||%-78/NN	conj_versus||%-75/NN||%-78/NN	det||year-83/NN||the-81/DT	amod||year-83/NN||past-82/JJ	prep_in||associated-20/VBN||year-83/NN	nonsteroidalantiinflammatorydrugs-55||oa-17||no_rel||" among the 513 subjects with knee pain, the additional presence of radiographic evidence of oa was significantly associated with more occasions of ""unbearable"" pain (59% versus 36%) and restricted activity (64% versus 39%), as well as increased use of nonsteroidalantiinflammatorydrugs (nsaids) (88% versus 78%) and the reported number of doctor visits (59% versus 33%) in the past year."
nsubj||increases-2/VBZ||iugr-1/NN	root||ROOT-0/null||increases-2/VBZ	det||risk-4/NN||the-3/DT	dobj||increases-2/VBZ||risk-4/NN	amod||sensitivity-18/NN||type2diabetesmellitus-6/JJ	appos||sensitivity-18/NN||t2dm-8/NNP	amod||life-12/NN||later-11/JJ	prep_in||sensitivity-18/NN||life-12/NN	amod||insulin-17/NN||reduced-16/VBN	prep_due_to||sensitivity-18/NN||insulin-17/NN	prep_of||risk-4/NN||sensitivity-18/NN	amod||adaptation-21/NN||impaired-20/VBN	prep_of||risk-4/NN||adaptation-21/NN	conj_and||sensitivity-18/NN||adaptation-21/NN	nn||secretion-24/NN||insulin-23/NN	prep_of||adaptation-21/NN||secretion-24/NN	type2diabetesmellitus-6||insulin-23||yes||iugr increases the risk of type2diabetesmellitus (t2dm) in later life, due to reduced insulin sensitivity and impaired adaptation of insulin secretion.
det||hormone-4/NN||the-1/DT	amod||hormone-4/NN||pineal-2/JJ	nn||hormone-4/NN||gland-3/NN	nsubjpass||shown-10/VBN||hormone-4/NN	nsubj||inhibit-15/VB||hormone-4/NN	appos||hormone-4/NN||melatonin-6/NN	aux||shown-10/VBN||has-8/VBZ	auxpass||shown-10/VBN||been-9/VBN	root||ROOT-0/null||shown-10/VBN	amod||studies-13/NNS||numerous-12/JJ	agent||shown-10/VBN||studies-13/NNS	aux||inhibit-15/VB||to-14/TO	xcomp||shown-10/VBN||inhibit-15/VB	det||proliferation-17/NN||the-16/DT	dobj||inhibit-15/VB||proliferation-17/NN	amod||±-22/NNS||estrogen-19/JJ	nn||±-22/NNS||receptor-20/NN	nn||±-22/NNS||î-21/NN	prep_of||proliferation-17/NN||±-22/NNS	nn||±-25/NNP||erî-24/NNP	appos||±-22/NNS||±-25/NNP	amod||lines-32/NNS||positive-28/JJ	nn||lines-32/NNS||breast-29/NN	nn||lines-32/NNS||cancer-30/NN	nn||lines-32/NNS||cell-31/NN	dep||±-22/NNS||lines-32/NNS	cancer-30||melatonin-6||no_rel||the pineal gland hormone, melatonin, has been shown by numerous studies to inhibit the proliferation of estrogen receptor î± (erî±)-positive breast cancer cell lines.
nn||scores-2/NNS||pain-1/NN	nsubjpass||assessed-6/VBN||scores-2/NNS	auxpass||assessed-6/VBN||were-3/VBD	advmod||commonly-5/RB||most-4/RBS	advmod||assessed-6/VBN||commonly-5/RB	root||ROOT-0/null||assessed-6/VBN	prep_in||assessed-6/VBN||studies-8/NNS	prep_including||studies-8/NNS||pregabalin-10/NN	nsubj||reported-19/VBD||trials-12/NNS	prep_of||trials-12/NNS||pregabalin-14/NN	det||plaster-18/NN||the-16/DT	amod||plaster-18/NN||lidocaine-17/JJ	prep_of||trials-12/NNS||plaster-18/NN	conj_and||pregabalin-14/NN||plaster-18/NN	parataxis||assessed-6/VBN||reported-19/VBD	det||proportion-21/NN||the-20/DT	dobj||reported-19/VBD||proportion-21/NN	prep_of||proportion-21/NN||responders-23/NNS	pain-1||lidocaine-17||yes||pain scores were most commonly assessed in studies including pregabalin; trials of pregabalin and the lidocaine plaster reported the proportion of responders.
det||protection-3/NN||the-1/DT	amod||protection-3/NN||acute-2/JJ	nsubj||supports-19/VBZ||protection-3/NN	amod||stimuli-7/NNS||subsequent-5/JJ	nn||stimuli-7/NNS||bronchoconstrictor-6/NN	prep_against||protection-3/NN||stimuli-7/NNS	amod||amp-11/NN||inhaled-10/JJ	prep_such_as||stimuli-7/NNS||amp-11/NN	det||reversal-15/NN||the-13/DT	amod||reversal-15/NN||rapid-14/JJ	prep_such_as||stimuli-7/NNS||reversal-15/NN	conj_and||amp-11/NN||reversal-15/NN	amod||obstruction-18/NN||airway-17/JJ	prep_of||reversal-15/NN||obstruction-18/NN	root||ROOT-0/null||supports-19/VBZ	det||use-21/NN||the-20/DT	dobj||supports-19/VBZ||use-21/NN	prep_of||use-21/NN||budesonide/formoterol-23/NN	preconj||relief-26/NN||both-25/DT	prep_for||supports-19/VBZ||relief-26/NN	prep_for||supports-19/VBZ||prevention-28/NN	conj_and||relief-26/NN||prevention-28/NN	det||treatment-31/NN||the-30/DT	prep_in||relief-26/NN||treatment-31/NN	prep_of||treatment-31/NN||asthma-33/NN	asthma-33||formoterol--1||yes||the acute protection against subsequent bronchoconstrictor stimuli such as inhaled amp and the rapid reversal of airway obstruction supports the use of budesonide/formoterol for both relief and prevention in the treatment of asthma.
det||bisphosphonate-3/NN||the-1/DT	amod||bisphosphonate-3/NN||oral-2/JJ	nsubj||appears-24/VBZ||bisphosphonate-3/NN	nsubj||mitigate-26/VB||bisphosphonate-3/NN	appos||bisphosphonate-3/NN||risedronate-5/NN	vmod||bisphosphonate-3/NN||dosed-7/VBN	det||food-11/NN||the-9/DT	nn||food-11/NN||us-10/PRP	prep_as||dosed-7/VBN||food-11/NN	nn||administration-14/NN||drug-13/NN	prep_as||dosed-7/VBN||administration-14/NN	conj_and||food-11/NN||administration-14/NN	vmod||administration-14/NN||approved-15/VBN	det||treatment-18/NN||the-17/DT	prep_for||approved-15/VBN||treatment-18/NN	prep_for||approved-15/VBN||prevention-20/NN	conj_or||treatment-18/NN||prevention-20/NN	prep_of||treatment-18/NN||postmenopausalosteoporosis-22/NNS	root||ROOT-0/null||appears-24/VBZ	aux||mitigate-26/VB||to-25/TO	xcomp||appears-24/VBZ||mitigate-26/VB	nn||loss-28/NN||bone-27/NN	dobj||mitigate-26/VB||loss-28/NN	vmod||loss-28/NN||associated-29/VBN	num||years-32/NNS||2-31/CD	prep_with||associated-29/VBN||years-32/NNS	amod||anastrozole-35/NN||adjuvant-34/JJ	prep_of||years-32/NNS||anastrozole-35/NN	prep_in||associated-29/VBN||women-37/NNS	amod||cancer-41/NN||early-stage-39/JJ	nn||cancer-41/NN||breast-40/NN	prep_with||women-37/NNS||cancer-41/NN	postmenopausalosteoporosis-22||risedronate-5||yes||the oral bisphosphonate, risedronate - dosed as the us food and drug administration approved for the treatment or prevention of postmenopausalosteoporosis - appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer.
advmod||improve-43/VB||however-1/RB	det||options-6/NNS||some-3/DT	amod||options-6/NNS||hypercholesterolemia-4/JJ	nn||options-6/NNS||treatment-5/NN	nsubj||become-9/VBN||options-6/NNS	nsubj||improve-43/VB||options-6/NNS	aux||become-9/VBN||have-8/VBP	rcmod||options-6/NNS||become-9/VBN	advmod||used-11/VBN||widely-10/RB	dep||become-9/VBN||used-11/VBN	amod||therapies-15/NNS||pharmaceutical-14/JJ	prep_including||become-9/VBN||therapies-15/NNS	nsubj||decrease-18/VB||therapies-15/NNS	aux||decrease-18/VB||can-17/MD	rcmod||therapies-15/NNS||decrease-18/VB	xcomp||decrease-18/VB||circulating-19/VBG	dobj||circulating-19/VBG||cholesterol-20/NN	prepc_by||circulating-19/VBG||preventing-22/VBG	preconj||formation-25/NN||either-23/CC	poss||formation-25/NN||its-24/PRP$	dobj||preventing-22/VBG||formation-25/NN	det||liver-28/NN||the-27/DT	prep_in||formation-25/NN||liver-28/NN	poss||absorption-31/NN||its-30/PRP$	dobj||preventing-22/VBG||absorption-31/NN	conj_or||formation-25/NN||absorption-31/NN	det||intestine-34/NN||the-33/DT	prep_in||absorption-31/NN||intestine-34/NN	advmod||have-37/VB||also-36/RB	dep||decrease-18/VB||have-37/VB	amod||effects-39/NNS||pleiotropic-38/JJ	dobj||have-37/VB||effects-39/NNS	prep||have-37/VB||with-40/IN	aux||improve-43/VB||can-41/MD	advmod||improve-43/VB||directly-42/RB	root||ROOT-0/null||improve-43/VB	amod||outcomes-46/NNS||peripheral-44/JJ	nn||outcomes-46/NNS||vascular-45/NN	dobj||improve-43/VB||outcomes-46/NNS	hypercholesterolemia-4||cholesterol-20||no||however, some hypercholesterolemia treatment options that have become widely used, including pharmaceutical therapies which can decrease circulating cholesterol by preventing either its formation in the liver or its absorption in the intestine, also have pleiotropic effects with can directly improve peripheral vascular outcomes.
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	cancer-55||gold-14||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
nsubj||trial-9/NN||this-1/DT	cop||trial-9/NN||is-2/VBZ	det||trial-9/NN||a-3/DT	amod||trial-9/NN||randomized-4/JJ	amod||trial-9/NN||double-blind-6/JJ	amod||trial-9/NN||clinical-8/JJ	root||ROOT-0/null||trial-9/NN	vmod||trial-9/NN||comparing-11/VBG	det||association-13/NN||the-12/DT	dobj||comparing-11/VBG||association-13/NN	prep_of||association-13/NN||chlorthalidone-15/NN	prep_of||association-13/NN||amiloride-17/NN	conj_and||chlorthalidone-15/NN||amiloride-17/NN	prep_with||comparing-11/VBG||losartan-19/NN	amod||option-23/NN||first-21/JJ	nn||option-23/NN||drug-22/NN	prep_as||comparing-11/VBG||option-23/NN	prep_in||option-23/NN||patients-25/NNS	vmod||patients-25/NNS||aged-26/VBN	number||70-29/CD||30-27/CD	dep||70-29/CD||to-28/TO	num||years-30/NNS||70-29/CD	tmod||aged-26/VBN||years-30/NNS	nn||hypertension-35/NN||stage-33/NN	nn||hypertension-35/NN||i-34/NN	prep_with||aged-26/VBN||hypertension-35/NN	hypertension-35||chlorthalidone-15||yes||this is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage i hypertension.
amod||patients-4/NNS||type-1/NN	number||type-1/NN||2-2/CD	amod||patients-4/NNS||diabetic-3/JJ	nsubjpass||randomized-8/VBN||patients-4/NNS	prep_after||patients-4/NNS||acutemyocardialinfarction-6/NN	auxpass||randomized-8/VBN||were-7/VBD	root||ROOT-0/null||randomized-8/VBN	det||strategy-13/NN||an-10/DT	nn||strategy-13/NN||insulin-11/NN	nn||strategy-13/NN||treatment-12/NN	prep_to||randomized-8/VBN||strategy-13/NN	vmod||strategy-13/NN||targeting-14/VBG	dobj||targeting-14/VBG||postprandial-15/NN	dep||postprandial-15/NN||prandial-17/NN	nn||557-21/NNP||n-19/NNP	nn||557-21/NNP||=-20/NNP	dep||prandial-17/NN||557-21/NNP	amod||hyperglycemia-32/NN||fasting/interprandial-24/JJ	dep||hyperglycemia-32/NN||basal-26/NN	nn||558-30/NNP||n-28/NNP	nn||558-30/NNP||=-29/NNP	dep||basal-26/NN||558-30/NNP	dobj||targeting-14/VBG||hyperglycemia-32/NN	conj_or||postprandial-15/NN||hyperglycemia-32/NN	hyperglycemia-32||insulin-11||yes||type 2 diabetic patients after acutemyocardialinfarction were randomized to an insulin treatment strategy targeting postprandial (prandial; n = 557) or fasting/interprandial (basal; n = 558) hyperglycemia.
aux||gain-2/VB||to-1/TO	advcl||undertook-20/VBD||gain-2/VB	dobj||gain-2/VB||insight-3/NN	nn||signatures-7/NNS||gene-5/NN	nn||signatures-7/NNS||expression-6/NN	prep_into||gain-2/VB||signatures-7/NNS	nsubj||distinguish-10/VB||signatures-7/NNS	aux||distinguish-10/VB||can-9/MD	rcmod||signatures-7/NNS||distinguish-10/VB	dobj||distinguish-10/VB||atopicdermatitis-11/NNS	amod||controls-14/NNS||non-atopic-13/JJ	prep_from||distinguish-10/VB||controls-14/NNS	nn||biopsies-17/NNS||skin-16/NN	prep_without||distinguish-10/VB||biopsies-17/NNS	nsubj||undertook-20/VBD||we-19/PRP	root||ROOT-0/null||undertook-20/VBD	det||study-23/NN||a-21/DT	amod||study-23/NN||comparative-22/JJ	dobj||undertook-20/VBD||study-23/NN	nn||expression-26/NN||gene-25/NN	prep_of||study-23/NN||expression-26/NN	prep_in||undertook-20/VBD||fdks-28/NNS	amod||donors-31/NNS||adult-30/JJ	prep_from||fdks-28/NNS||donors-31/NNS	prep_with||undertook-20/VBD||atopicdermatitis-33/NNS	amod||donors-36/NNS||non-atopic-35/JJ	prep_with||undertook-20/VBD||donors-36/NNS	conj_and||atopicdermatitis-33/NNS||donors-36/NNS	atopicdermatitis-33||atopic--1||no||to gain insight into gene expression signatures that can distinguish atopicdermatitis from non-atopic controls without skin biopsies, we undertook a comparative study of gene expression in fdks from adult donors with atopicdermatitis and non-atopic donors.
amod||advances-2/NNS||recent-1/JJ	nsubj||employ-9/VBP||advances-2/NNS	det||therapy-6/NN||an-4/DT	amod||therapy-6/NN||effective-5/JJ	prep_toward||advances-2/NNS||therapy-6/NN	prep_for||therapy-6/NN||priondiseases-8/NNS	root||ROOT-0/null||employ-9/VBP	nn||interference-11/NN||rna-10/NN	dobj||employ-9/VBP||interference-11/NN	nsubj||suppress-13/VB||interference-11/NN	aux||suppress-13/VB||to-12/TO	xcomp||employ-9/VBP||suppress-13/VB	amod||expression-15/NN||prpc-14/JJ	dobj||suppress-13/VB||expression-15/NN	amod||neuropathology-19/NN||subsequent-17/JJ	nn||neuropathology-19/NN||prion-18/NN	dobj||suppress-13/VB||neuropathology-19/NN	conj_and||expression-15/NN||neuropathology-19/NN	vmod||suppress-13/VB||exploiting-21/VBG	det||phenomenon-23/NN||the-22/DT	dobj||exploiting-21/VBG||phenomenon-23/NN	det||disease-25/NN||phenomenon-23/NN	nsubj||correlate-29/VBP||disease-25/NN	dep||disease-25/NN||severity-26/NN	dep||disease-25/NN||progression-28/NN	conj_and||severity-26/NN||progression-28/NN	rcmod||phenomenon-23/NN||correlate-29/VBP	nn||levels-34/NNS||host-31/NN	amod||levels-34/NNS||prpc-32/JJ	nn||levels-34/NNS||expression-33/NN	prep_with||correlate-29/VBP||levels-34/NNS	priondiseases-8||prion-18||no||recent advances toward an effective therapy for priondiseases employ rna interference to suppress prpc expression and subsequent prion neuropathology, exploiting the phenomenon that disease severity and progression correlate with host prpc expression levels.
amod||feâˆ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâˆ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâˆ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâˆ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	irondeficiency-40||iron-31||yes||defective feâˆ’s cluster synthesis not only affects activities of many ironâˆ’sulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	nsubj||explore-21/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||level-12/NN||the-9/DT	amod||level-12/NN||cd127-10/JJ	nn||level-12/NN||expression-11/NN	dobj||investigate-8/VB||level-12/NN	amod||subsets-15/NNS||different-14/JJ	prep_on||investigate-8/VB||subsets-15/NNS	amod||cell-19/NN||cd8-17/JJ	nn||cell-19/NN||t-18/NN	prep_of||subsets-15/NNS||cell-19/NN	xcomp||was-6/VBD||explore-21/VB	conj_and||investigate-8/VB||explore-21/VB	det||relationship-23/NN||the-22/DT	dobj||explore-21/VB||relationship-23/NN	iobj||explore-21/VB||relationship-23/NN	amod||expression-26/NN||cd127-25/JJ	prep_between||relationship-23/NN||expression-26/NN	amod||cells-31/NNS||cd8-28/JJ	nn||cells-31/NNS||memory-29/NN	nn||cells-31/NNS||t-30/NN	prep_on||expression-26/NN||cells-31/NNS	prep_on||expression-26/NN||serumhepatitisbvirus-33/NNS	conj_and||cells-31/NNS||serumhepatitisbvirus-33/NNS	appos||relationship-23/NN||hbv-35/NN	amod||levels-45/NNS||dna-37/JJ	conj_and||dna-37/JJ||hepatitisb-39/JJ	amod||levels-45/NNS||hepatitisb-39/JJ	amod||levels-45/NNS||e-40/JJ	nn||levels-45/NNS||antigen-41/NN	appos||levels-45/NNS||hbeag-43/NN	dep||relationship-23/NN||levels-45/NNS	prep_in||levels-45/NNS||patients-47/NNS	prep_with||patients-47/NNS||chronichepatitisb-49/NN	dep||patients-47/NNS||chb-51/VBN	chronichepatitisb-49||hepatitisbvirus--1||no||the aim of this study was to investigate the cd127 expression level on different subsets of cd8 t cell and explore the relationship between cd127 expression on cd8 memory t cells and serumhepatitisbvirus (hbv) dna and hepatitisb e antigen (hbeag) levels in patients with chronichepatitisb (chb).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||test-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||test-8/VB||to-7/TO	xcomp||was-6/VBD||test-8/VB	mark||decreases-22/VBZ||whether-9/IN	det||extract-18/NN||an-10/DT	amod||low-12/JJ||aqueous-11/JJ	amod||extract-18/NN||low-12/JJ	amod||extract-18/NN||molecular-13/JJ	nn||extract-18/NN||weight-14/NN	appos||extract-18/NN||lmw-16/NN	nsubj||decreases-22/VBZ||extract-18/NN	nn||muscle-21/NN||cod-20/NN	prep_from||extract-18/NN||muscle-21/NN	ccomp||test-8/VB||decreases-22/VBZ	amod||mortality-24/NN||acute-23/JJ	dobj||decreases-22/VBZ||mortality-24/NN	det||model-28/NN||the-26/DT	nn||model-28/NN||mouse-27/NN	prep_in||decreases-22/VBZ||model-28/NN	amod||chf-31/NN||acute-30/JJ	prep_of||model-28/NN||chf-31/NN	vmod||chf-31/NN||caused-32/VBN	agent||caused-32/VBN||dox-34/NN	chf-31||dox-34||no||the aim of this study was to test whether an aqueous low molecular weight (lmw) extract from cod muscle decreases acute mortality in the mouse model of acute chf caused by dox.
advmod||increased-16/VBN||however-1/RB	det||prevalence-4/NN||the-3/DT	nsubj||increased-16/VBN||prevalence-4/NN	nn||resistance-7/NN||mupirocin-6/NN	prep_of||prevalence-4/NN||resistance-7/NN	prep_in||resistance-7/NN||s.aureus-9/NNS	advmod||in-12/IN||particularly-11/RB	rcmod||prevalence-4/NN||in-12/IN	pobj||in-12/IN||mrsa-13/NN	aux||increased-16/VBN||has-15/VBZ	root||ROOT-0/null||increased-16/VBN	det||use-22/NN||the-18/DT	amod||use-22/NN||extensive-19/JJ	conj_and||extensive-19/JJ||widespread-21/JJ	amod||use-22/NN||widespread-21/JJ	prep_with||increased-16/VBN||use-22/NN	det||agent-25/NN||this-24/DT	prep_of||use-22/NN||agent-25/NN	nn||settings-28/NNS||hospital-27/NN	prep_in||agent-25/NN||settings-28/NNS	mrsa-13||s.aureus-9||no||however , the prevalence of mupirocin resistance in s.aureus , particularly in mrsa , has increased with the extensive and widespread use of this agent in hospital settings .
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||identify-9/VB||aim-2/NN	nsubj||identify-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||current-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||identify-9/VB||to-8/TO	xcomp||was-7/VBD||identify-9/VB	xcomp||was-7/VBD||identify-9/VB	conj_and||identify-9/VB||identify-9/VB	amod||clusters-13/NNS||simultaneous-10/JJ	amod||clusters-13/NNS||local-11/JJ	amod||clusters-13/NNS||space-time-12/JJ	dobj||identify-9/VB||clusters-13/NNS	det||year-15/NN||each-14/DT	dep||clusters-13/NNS||year-15/NN	num||2007-19/CD||2002-17/CD	dep||2007-19/CD||to-18/TO	prep_from||identify-9/VB||2007-19/CD	amod||cases-22/NNS||human-21/JJ	prep_for||2007-19/CD||cases-22/NNS	prep_of||cases-22/NNS||campylobacteriosis-24/NNS	nn||flocks-28/NNS||broiler-27/NN	prep_for||identify-9/VB||flocks-28/NNS	vmod||flocks-28/NNS||testing-29/VBG	acomp||testing-29/VBG||positive-30/JJ	nn||spp-33/NN||campylobacter-32/NN	prep_for||positive-30/JJ||spp-33/NN	campylobacteriosis-24||campylobacter-32||no||the aim of the current study was to identify simultaneous local space-time clusters each year from 2002 to 2007 for human cases of campylobacteriosis and for broiler flocks testing positive for campylobacter spp.
nsubj||have-11/VBP||adults-1/NNS	amod||origin-5/NN||south-3/JJ	nn||origin-5/NN||asian-4/NN	prep_of||adults-1/NNS||origin-5/NN	vmod||origin-5/NN||living-6/VBG	det||kingdom-10/NN||the-8/DT	amod||kingdom-10/NN||united-9/VBN	prep_in||living-6/VBG||kingdom-10/NN	root||ROOT-0/null||have-11/VBP	amod||risks-13/NNS||high-12/JJ	nsubj||raised-20/VBD||risks-13/NNS	amod||obesity-18/NN||type2diabetes-15/JJ	conj_and||type2diabetes-15/JJ||central-17/JJ	amod||obesity-18/NN||central-17/JJ	prep_of||risks-13/NNS||obesity-18/NN	ccomp||have-11/VBP||raised-20/VBD	xcomp||raised-20/VBD||circulating-21/VBG	dobj||circulating-21/VBG||insulin-22/NN	dobj||circulating-21/VBG||triglyceride-24/NN	conj_and||insulin-22/NN||triglyceride-24/NN	amod||concentrations-29/NNS||c-reactive-27/JJ	nn||concentrations-29/NNS||protein-28/NN	dobj||circulating-21/VBG||concentrations-29/NNS	conj_and||insulin-22/NN||concentrations-29/NNS	amod||hdl-cholesterol-33/NN||low-32/JJ	dobj||circulating-21/VBG||hdl-cholesterol-33/NN	conj_and||insulin-22/NN||hdl-cholesterol-33/NN	dep||circulating-21/VBG||when-34/WRB	prepc_compared_with||raised-20/VBD||with-36/IN	amod||europeans-38/NNS||white-37/JJ	pobj||raised-20/VBD||europeans-38/NNS	insulin-22||obesity-18||no_rel||adults of south asian origin living in the united kingdom have high risks of type2diabetes and central obesity; raised circulating insulin, triglyceride, and c-reactive protein concentrations; and low hdl-cholesterol when compared with white europeans.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	num||cases-4/NNS||7-3/CD	dobj||report-2/VBP||cases-4/NNS	prep_of||cases-4/NNS||melanonychia-6/NN	vmod||melanonychia-6/NN||associated-7/VBN	det||use-10/NN||the-9/DT	prep_with||associated-7/VBN||use-10/NN	prep_of||use-10/NN||hydroxycarbamide-12/NN	prep_for||hydroxycarbamide-12/NN||essentialthrombocythemia-14/NN	essentialthrombocythemia-14||hydroxycarbamide-12||yes||we report 7 cases of melanonychia associated with the use of hydroxycarbamide for essentialthrombocythemia.
prep||are-9/VBP||given-1/VBN	det||impairment-3/NN||the-2/DT	pobj||given-1/VBN||impairment-3/NN	nn||secretion-6/NN||insulin-5/NN	prep_in||impairment-3/NN||secretion-6/NN	nsubj||are-9/VBP||they-8/PRP	root||ROOT-0/null||are-9/VBP	amod||risk-12/NN||high-11/JJ	prep_at||are-9/VBP||risk-12/NN	prep_for||risk-12/NN||progression-14/NN	prep_to||are-9/VBP||type2diabetes-16/CD	type2diabetes-16||insulin-5||yes||given the impairment in insulin secretion, they are at high risk for progression to type2diabetes.
det||combination-2/NN||a-1/DT	nsubj||reduced-9/VBD||combination-2/NN	nn||exercise-7/NN||cr-4/NN	conj_and||cr-4/NN||endurance-6/JJ	nn||exercise-7/NN||endurance-6/JJ	prep_of||combination-2/NN||exercise-7/NN	advmod||reduced-9/VBD||further-8/RB	root||ROOT-0/null||reduced-9/VBD	acomp||reduced-9/VBD||obesity-10/JJ	acomp||reduced-9/VBD||insulinresistance-12/JJ	conj_and||obesity-10/JJ||insulinresistance-12/JJ	det||condition-15/NN||the-14/DT	prep_under||reduced-9/VBD||condition-15/NN	amod||diet-18/NN||high-fat-17/JJ	prep_of||condition-15/NN||diet-18/NN	fat--1||insulinresistance-12||no_rel||a combination of cr and endurance exercise further reduced obesity and insulinresistance under the condition of high-fat diet.
det||survey-8/NN||an-1/DT	amod||survey-8/NN||island-2/JJ	amod||survey-8/NN||wide-3/JJ	amod||survey-8/NN||cross-sectional-5/JJ	amod||survey-8/NN||community-based-7/JJ	nsubjpass||done-17/VBN||survey-8/NN	nn||symptoms-13/NNS||asthma-10/NN	prep_of||survey-8/NN||asthma-12/NN	conj_and||symptoms-13/NNS||asthma-12/NN	prep_of||survey-8/NN||symptoms-13/NNS	prep_of||survey-8/NN||allergies-15/NNS	conj_and||symptoms-13/NNS||allergies-15/NNS	auxpass||done-17/VBN||was-16/VBD	root||ROOT-0/null||done-17/VBN	prep_among||done-17/VBN||adults-19/NNS	prep_among||done-17/VBN||children-21/NNS	conj_and||adults-19/NNS||children-21/NNS	xcomp||done-17/VBN||using-22/VBG	det||questionnaire-29/NN||the-23/DT	nn||questionnaire-29/NN||european-24/NN	nn||questionnaire-29/NN||community-25/NN	nn||questionnaire-29/NN||respiratory-26/NN	nn||questionnaire-29/NN||health-27/NN	nn||questionnaire-29/NN||survey-28/NN	dobj||using-22/VBG||questionnaire-29/NN	prep_for||questionnaire-29/NN||adults-31/NNS	det||study-35/NN||the-33/DT	amod||study-35/NN||international-34/JJ	dobj||using-22/VBG||study-35/NN	conj_and||questionnaire-29/NN||study-35/NN	prep_of||study-35/NN||asthma-37/NN	prep_of||study-35/NN||allergies-39/NNS	conj_and||asthma-37/NN||allergies-39/NNS	prep_in||using-22/VBG||children-41/NNS	allergies-39||allergies-39||no||an island wide, cross-sectional, community-based survey of asthma, asthma symptoms and allergies was done among adults and children using the european community respiratory health survey questionnaire for adults and the international study of asthma and allergies in children.
advmod||active-2/JJ||highly-1/RB	amod||therapy-4/NN||active-2/JJ	amod||therapy-4/NN||antiretroviral-3/JJ	nsubj||changed-9/VBN||therapy-4/NN	appos||therapy-4/NN||haart-6/NN	aux||changed-9/VBN||has-8/VBZ	root||ROOT-0/null||changed-9/VBN	det||face-11/NN||the-10/DT	dobj||changed-9/VBN||face-11/NN	amod||acquiredimmunedeficiencysyndrome-17/NN||humanimmunodeficiencyvirus-13/JJ	appos||acquiredimmunedeficiencysyndrome-17/NN||hiv-15/NN	prep_of||face-11/NN||acquiredimmunedeficiencysyndrome-17/NN	appos||acquiredimmunedeficiencysyndrome-17/NN||aids-19/NNS	prepc_by||changed-9/VBN||leading-22/VBG	amod||decreases-25/NNS||dramatic-24/JJ	prep_to||leading-22/VBG||decreases-25/NNS	amod||morbidity-28/NN||hiv-related-27/JJ	prep_in||decreases-25/NNS||morbidity-28/NN	prep_in||decreases-25/NNS||mortality-30/NN	conj_and||morbidity-28/NN||mortality-30/NN	det||developed-33/JJ||the-32/DT	prep_in||leading-22/VBG||developed-33/JJ	prepc_by||changed-9/VBN||developing-37/VBG	conj_and||leading-22/VBG||developing-37/VBG	dobj||developing-37/VBG||world-38/NN	acquiredimmunedeficiencysyndrome-17||hiv-15||no||highly active antiretroviral therapy (haart) has changed the face of humanimmunodeficiencyvirus (hiv) acquiredimmunedeficiencysyndrome (aids) by leading to dramatic decreases in hiv-related morbidity and mortality in the developed as well as developing world.
nsubj||requires-5/VBZ||treatment-1/NN	prep_for||treatment-1/NN||oa-3/NN	advmod||requires-5/VBZ||often-4/RB	root||ROOT-0/null||requires-5/VBZ	amod||use-7/NN||chronic-6/JJ	dobj||requires-5/VBZ||use-7/NN	nsubjpass||associated-21/VBN||use-7/NN	amod||anti-inflammatorydrugs-13/NNS||selective-9/JJ	conj_or||selective-9/JJ||nonselective-11/JJ	amod||anti-inflammatorydrugs-13/NNS||nonselective-11/JJ	amod||anti-inflammatorydrugs-13/NNS||nonsteroidal-12/JJ	prep_of||use-7/NN||anti-inflammatorydrugs-13/NNS	appos||anti-inflammatorydrugs-13/NNS||nsaids-15/NNS	aux||associated-21/VBN||have-19/VBP	auxpass||associated-21/VBN||been-20/VBN	rcmod||use-7/NN||associated-21/VBN	amod||complications-26/NNS||gastrointestinal-23/JJ	conj_and||gastrointestinal-23/JJ||cardiovascular-25/JJ	amod||complications-26/NNS||cardiovascular-25/JJ	prep_with||associated-21/VBN||complications-26/NNS	nsaids-15||oa-3||no_rel||treatment for oa often requires chronic use of selective or nonselective nonsteroidal anti-inflammatorydrugs (nsaids), which have been associated with gastrointestinal and cardiovascular complications.
det||study-3/NN||this-2/DT	prep_in||used-5/VBD||study-3/NN	nsubj||used-5/VBD||we-4/PRP	root||ROOT-0/null||used-5/VBD	num||assays-8/NNS||two-6/CD	nn||assays-8/NNS||pcr-7/NN	dobj||used-5/VBD||assays-8/NNS	nsubj||screen-14/VB||assays-8/NNS	num||assay-12/NN||one-10/CD	nn||assay-12/NN||antibody-11/NN	dobj||used-5/VBD||assay-12/NN	conj_and||assays-8/NNS||assay-12/NN	nsubj||screen-14/VB||assay-12/NN	aux||screen-14/VB||to-13/TO	xcomp||used-5/VBD||screen-14/VB	num||samples-17/NNS||25-15/CD	nn||samples-17/NNS||blood-16/NN	dobj||screen-14/VB||samples-17/NNS	amod||children-20/NNS||autistic-19/JJ	prep_from||screen-14/VB||children-20/NNS	vmod||children-20/NNS||born-21/VBN	vmod||children-20/NNS||born-21/VBN	conj_and||born-21/VBN||born-21/VBN	prep_to||born-21/VBN||mothers-23/NNS	prep_with||mothers-23/NNS||cfs-25/NN	num||controls-30/NNS||20-28/CD	amod||controls-30/NNS||mixed-29/VBN	prep_from||born-21/VBN||controls-30/NNS	nn||members-33/NNS||family-32/NN	prep_including||controls-30/NNS||members-33/NNS	det||assayed-37/NN||the-35/DT	nn||assayed-37/NN||children-36/NNS	prep_of||members-33/NNS||assayed-37/NN	prep_including||controls-30/NNS||people-39/NNS	conj_and||members-33/NNS||people-39/NNS	prep_with||people-39/NNS||fibromyalgia-41/NNP	prep_including||controls-30/NNS||people-43/NNS	conj_and||members-33/NNS||people-43/NNS	amod||lymedisease-46/NN||chronic-45/JJ	prep_with||people-43/NNS||lymedisease-46/NN	lymedisease-46||antibody-11||no_rel||in this study we used two pcr assays and one antibody assay to screen 25 blood samples from autistic children born to mothers with cfs and from 20 mixed controls including family members of the children assayed, people with fibromyalgia and people with chronic lymedisease.
mark||strong-2/JJ||if-1/IN	advcl||reduce-19/VB||strong-2/JJ	advmod||strong-2/JJ||enough-3/RB	conj_and||strong-2/JJ||with-6/IN	advcl||reduce-19/VB||with-6/IN	amod||access-8/NN||sufficient-7/JJ	pobj||with-6/IN||access-8/NN	nn||services-11/NNS||quality-10/NN	prep_to||access-8/NN||services-11/NNS	pobj||with-6/IN||support-13/NN	conj_and||access-8/NN||support-13/NN	prep_from||support-13/NN||communities-15/NNS	nsubj||reduce-19/VB||families-17/NNS	aux||reduce-19/VB||can-18/MD	root||ROOT-0/null||reduce-19/VB	det||impacts-21/NNS||the-20/DT	dobj||reduce-19/VB||impacts-21/NNS	prep_of||impacts-21/NNS||hiv/aids-23/NNS	prep_on||hiv/aids-23/NNS||children-25/NNS	amod||levels-28/NNS||negligible-27/JJ	prep_to||reduce-19/VB||levels-28/NNS	amod||areas-31/NNS||most-30/JJS	prep_in||reduce-19/VB||areas-31/NNS	prep_of||areas-31/NNS||impact-33/NN	aids--1||hiv--1||no||if strong enough, and with sufficient access to quality services and support from communities, families can reduce the impacts of hiv/aids on children to negligible levels in most areas of impact.
nn||cisplatin-3/NN||background-1/NN	nn||cisplatin-3/NN||liposomal-2/NN	nsubj||formulation-7/NN||cisplatin-3/NN	cop||formulation-7/NN||is-4/VBZ	det||formulation-7/NN||a-5/DT	amod||formulation-7/NN||new-6/JJ	root||ROOT-0/null||formulation-7/NN	vmod||formulation-7/NN||developed-8/VBN	aux||reduce-10/VB||to-9/TO	xcomp||developed-8/VBN||reduce-10/VB	det||toxicity-13/NN||the-11/DT	amod||toxicity-13/NN||systemic-12/JJ	dobj||reduce-10/VB||toxicity-13/NN	prep_of||toxicity-13/NN||cisplatin-15/NN	mark||improving-18/VBG||while-16/IN	advmod||improving-18/VBG||simultaneously-17/RB	advcl||reduce-10/VB||improving-18/VBG	det||targeting-20/NN||the-19/DT	dobj||improving-18/VBG||targeting-20/NN	det||drug-23/NN||the-22/DT	prep_of||targeting-20/NN||drug-23/NN	det||tumor-27/NN||the-25/DT	amod||tumor-27/NN||primary-26/JJ	prep_to||improving-18/VBG||tumor-27/NN	prep_to||improving-18/VBG||metastases-30/NNS	conj_and||tumor-27/NN||metastases-30/NNS	amod||time-34/NN||increasing-32/VBG	nn||time-34/NN||circulation-33/NN	prep_by||improving-18/VBG||time-34/NN	det||fluids-38/NNS||the-36/DT	nn||fluids-38/NNS||body-37/NN	prep_in||time-34/NN||fluids-38/NNS	prep_in||time-34/NN||tissues-40/NNS	conj_and||fluids-38/NNS||tissues-40/NNS	metastases-30||cisplatin-15||no_rel||background liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation time in the body fluids and tissues.
num||weeks-2/NNS||six-1/CD	npadvmod||challenged-10/VBN||weeks-2/NNS	det||vaccination-5/NN||the-4/DT	prep_after||challenged-10/VBN||vaccination-5/NN	det||mice-8/NNS||the-7/DT	nsubjpass||challenged-10/VBN||mice-8/NNS	auxpass||challenged-10/VBN||were-9/VBD	root||ROOT-0/null||challenged-10/VBN	det||dose-14/NN||a-12/DT	amod||dose-14/NN||lethal-13/JJ	prep_with||challenged-10/VBN||dose-14/NN	amod||influenzavirus-17/NNS||h5n1-16/JJ	prep_of||dose-14/NN||influenzavirus-17/NNS	h5n1-16||influenzavirus-17||no||six weeks after the vaccination, the mice were challenged with a lethal dose of h5n1 influenzavirus.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	cjd-28||prions-29||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
nsubjpass||used-4/VBN||nitrofurantoin-1/NN	aux||used-4/VBN||could-2/MD	auxpass||used-4/VBN||be-3/VB	root||ROOT-0/null||used-4/VBN	amod||cystitis-7/NNS||simple-6/JJ	prep_for||used-4/VBN||cystitis-7/NNS	dep||cystitis-7/NNS||aminoglycosides-9/NNS	amod||uti-12/NN||uncomplicated-11/JJ	prep_for||aminoglycosides-9/NNS||uti-12/NN	prep_in||uti-12/NN||inpatients-14/NNS	uti-12||nitrofurantoin-1||yes||nitrofurantoin could be used for simple cystitis; aminoglycosides for uncomplicated uti in inpatients.
det||patients-3/NNS||these-2/DT	nsubj||receiving-4/VBG||patients-3/NNS	prepc_in||dizziness-14/NN||receiving-4/VBG	nn||therapy-7/NN||combination-5/NN	nn||therapy-7/NN||anticonvulsant-6/NN	dobj||receiving-4/VBG||therapy-7/NN	det||aes-12/NN||the-9/DT	advmod||aes-12/NN||most-10/RBS	amod||aes-12/NN||common-11/JJ	nsubj||dizziness-14/NN||aes-12/NN	cop||dizziness-14/NN||were-13/VBD	root||ROOT-0/null||dizziness-14/NN	conj_and||dizziness-14/NN||nausea-16/NN	conj_and||dizziness-14/NN||vomiting-18/NN	conj_and||dizziness-14/NN||somnolence-20/NN	conj_and||dizziness-14/NN||diplopia-23/NN	nausea-16||anticonvulsant-6||no_rel||in these patients receiving combination anticonvulsant therapy, the most common aes were dizziness, nausea and vomiting, somnolence, and diplopia.
det||values-3/NNS||the-1/DT	amod||values-3/NNS||median-2/JJ	nsubj||68.2-9/NN||values-3/NNS	amod||levels-7/NNS||serum-5/JJ	amod||levels-7/NNS||s100a12-6/JJ	prep_of||values-3/NNS||levels-7/NNS	aux||68.2-9/NN||were-8/VBD	root||ROOT-0/null||68.2-9/NN	dobj||68.2-9/NN||ng/ml-10/NN	parataxis||68.2-9/NN||range-12/VB	num||.4-14/CD||43.4-147-13/CD	dobj||range-12/VB||.4-14/CD	prep_in||68.2-9/NN||uc-17/NN	num||ng/ml-20/NN||70-19/CD	prep_in||68.2-9/NN||ng/ml-20/NN	conj_and||uc-17/NN||ng/ml-20/NN	number||.8-23/CD||41.4-169-22/CD	dep||ng/ml-20/NN||.8-23/CD	prep_in||ng/ml-20/NN||cd-26/NN	num||ng/ml-29/NN||43.4-28/CD	prep_in||68.2-9/NN||ng/ml-29/NN	conj_and||uc-17/NN||ng/ml-29/NN	number||.4-32/CD||34.4-74-31/CD	dep||ng/ml-29/NN||.4-32/CD	nn||patients-36/NNS||ibs-35/NN	prep_in||ng/ml-29/NN||patients-36/NNS	cd-26||ibs-35||no_rel||the median values of serum s100a12 levels were 68.2 ng/ml (range 43.4-147.4) in uc, 70 ng/ml (41.4-169.8) in cd and 43.4 ng/ml (34.4-74.4) in ibs patients.
nsubjpass||used-28/VBN||time-1/NN	vmod||time-1/NN||spent-2/VBN	det||range-8/NN||the-4/DT	amod||range-8/NN||predefined-5/JJ	amod||range-8/NN||bloodglucose-6/JJ	nn||range-8/NN||level-7/NN	prep_in||spent-2/VBN||range-8/NN	appos||range-8/NN||time-10/NN	vmod||time-10/NN||needed-11/VBN	aux||reach-13/VB||to-12/TO	xcomp||needed-11/VBN||reach-13/VB	det||target-18/NN||the-14/DT	amod||target-18/NN||defined-15/JJ	amod||target-18/NN||bloodglucose-16/JJ	nn||target-18/NN||level-17/NN	dobj||reach-13/VB||target-18/NN	amod||indicators-21/NNS||hyperglycaemia-related-20/JJ	dobj||reach-13/VB||indicators-21/NNS	conj_and||target-18/NN||indicators-21/NNS	amod||indicators-24/NNS||protocol-related-23/JJ	dobj||reach-13/VB||indicators-24/NNS	conj_and||target-18/NN||indicators-24/NNS	auxpass||used-28/VBN||were-25/VBD	advmod||used-28/VBN||other-26/JJ	advmod||used-28/VBN||frequently-27/RB	root||ROOT-0/null||used-28/VBN	dobj||used-28/VBN||indicators-29/NNS	hyperglycaemia--1||glucose--1||no||time spent in the predefined bloodglucose level range, time needed to reach the defined bloodglucose level target, hyperglycaemia-related indicators and protocol-related indicators were other frequently used indicators.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||rif-19||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
nsubj||remains-2/VBZ||hiv/aids-1/NNS	root||ROOT-0/null||remains-2/VBZ	cop||disease-5/NN||being-3/VBG	det||disease-5/NN||a-4/DT	xcomp||remains-2/VBZ||disease-5/NN	amod||worldwide-11/NNS||great-7/JJ	amod||worldwide-11/NNS||public-8/JJ	nn||worldwide-11/NNS||health-9/NN	nn||worldwide-11/NNS||concern-10/NN	prep_of||disease-5/NN||worldwide-11/NNS	aids--1||hiv--1||no||hiv/aids remains being a disease of great public health concern worldwide.
det||review-2/NN||this-1/DT	nsubj||comprises-3/VBZ||review-2/NN	root||ROOT-0/null||comprises-3/VBZ	det||approach-6/NN||a-4/DT	amod||approach-6/NN||broad-5/JJ	dobj||comprises-3/VBZ||approach-6/NN	nn||disorders-10/NNS||alcohol-8/NN	nn||disorders-10/NNS||use-9/NN	prep_of||approach-6/NN||disorders-10/NNS	det||assessment-16/NN||a-13/DT	advmod||specific-15/JJ||more-14/RBR	amod||assessment-16/NN||specific-15/JJ	dobj||comprises-3/VBZ||assessment-16/NN	conj_and||approach-6/NN||assessment-16/NN	det||basis-21/NN||the-18/DT	amod||basis-21/NN||pathophysiologic-19/JJ	amod||basis-21/NN||molecular-20/JJ	prep_of||assessment-16/NN||basis-21/NN	conj_and||approach-6/NN||genetics-24/NNS	conj_and||assessment-16/NN||genetics-24/NNS	amod||presentation-30/NN||clinical-29/JJ	dobj||comprises-3/VBZ||presentation-30/NN	conj_and||approach-6/NN||presentation-30/NN	amod||modalities-33/NNS||current-32/JJ	conj_and||approach-6/NN||modalities-33/NNS	conj_and||presentation-30/NN||modalities-33/NNS	prep_of||presentation-30/NN||treatment-35/NN	prep_for||treatment-35/NN||alcoholicliverdisease-37/NN	alcoholicliverdisease-37||alcohol-8||no||this review comprises a broad approach of alcohol use disorders, and a more specific assessment of the pathophysiologic molecular basis, and genetics, as well as clinical presentation and current modalities of treatment for alcoholicliverdisease.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	neg||differences-4/NNS||no-3/DT	nsubj||were-2/VBD||differences-4/NNS	amod||mortality-7/NN||in-hospital-6/JJ	prep_in||differences-4/NNS||mortality-7/NN	prep_in||differences-4/NNS||reinfarction-9/NN	conj_or||mortality-7/NN||reinfarction-9/NN	amod||revascularization-14/NN||urgent-11/JJ	nn||revascularization-14/NN||target-12/NN	nn||revascularization-14/NN||vessel-13/NN	prep_in||differences-4/NNS||revascularization-14/NN	conj_or||mortality-7/NN||revascularization-14/NN	prep_in||differences-4/NNS||stroke-16/NN	conj_or||mortality-7/NN||stroke-16/NN	amod||thrombosis-22/NNS||acute-18/JJ	conj_or||acute-18/JJ||subacute-20/JJ	amod||thrombosis-22/NNS||subacute-20/JJ	nn||thrombosis-22/NNS||stent-21/NN	prep_in||differences-4/NNS||thrombosis-22/NNS	conj_or||mortality-7/NN||thrombosis-22/NNS	mark||showed-28/VBD||while-24/IN	nsubj||showed-28/VBD||group-25/NN	num||patients-27/NNS||1-26/CD	dep||group-25/NN||patients-27/NNS	advcl||were-2/VBD||showed-28/VBD	det||incidence-31/NN||a-29/DT	amod||incidence-31/NN||lower-30/JJR	nsubj||-rrb--49/NN||incidence-31/NN	amod||complications-35/NNS||major-33/JJ	amod||complications-35/NNS||bleeding-34/VBG	prep_of||incidence-31/NN||complications-35/NNS	vmod||complications-35/NNS||-lrb--36/VBG	nn||scale-38/NN||acuity-37/NN	dobj||-lrb--36/VBG||scale-38/NN	num||scale-38/NN||1.1-39/CD	prep||-lrb--36/VBG||vs.-40/FW	num||%-42/NN||4.0-41/CD	pobj||vs.-40/FW||%-42/NN	nn||â-45/NN||p-44/NN	appos||%-42/NN||â-45/NN	dep||-rrb--49/NN||=-46/SYM	nn||-rrb--49/NN||â-47/NN	num||-rrb--49/NN||0.035-48/CD	ccomp||showed-28/VBD||-rrb--49/NN	det||length-53/NN||a-51/DT	amod||length-53/NN||shorter-52/JJR	nsubj||stay-56/VBP||length-53/NN	prep_of||length-53/NN||hospital-55/NN	advcl||were-2/VBD||stay-56/VBP	conj_and||showed-28/VBD||stay-56/VBP	number||3.5-58/CD||-lrb--57/CD	num||â-62/NN||3.5-58/CD	nn||â-62/NN||â-59/NN	nn||â-62/NN||â-60/NN	num||â-62/NN||±-61/CD	dobj||stay-56/VBP||â-62/NN	dobj||â-77/NN||1.7-63/CD	prep||1.7-63/CD||vs.-64/FW	amod||â-67/NN||4.0-65/JJ	nn||â-67/NN||â-66/NN	pobj||vs.-64/FW||â-67/NN	amod||â-75/NN||±-68/JJ	nn||â-75/NN||â-69/NN	num||â-75/NN||1.6-70/CD	nn||â-75/NN||â-71/NN	nn||â-75/NN||days-72/NNS	dep||â-75/NN||p-74/NN	nsubj||â-77/NN||â-75/NN	dep||â-77/NN||=-76/SYM	rcmod||â-62/NN||â-77/NN	num||-rrb--79/NNS||0.002-78/CD	npadvmod||as-80/RB||-rrb--79/NNS	advmod||stay-56/VBP||as-80/RB	prepc_compared_with||stay-56/VBP||with-82/IN	pobj||stay-56/VBP||heparin-83/NN	vmod||heparin-83/NN||treated-84/VBN	dobj||treated-84/VBN||patients-85/NNS	stroke-16||heparin-83||no_rel||there were no differences in in-hospital mortality , reinfarction , urgent target vessel revascularization , stroke or acute or subacute stent thrombosis , while group 1 patients showed a lower incidence of major bleeding complications -lrb- acuity scale 1.1 vs. 4.0 % , p â = â 0.035 -rrb- and a shorter length of hospital stay -lrb- 3.5 â â ± â 1.7 vs. 4.0 â â ± â 1.6 â days , p â = â 0.002 -rrb- as compared with heparin treated patients .
nsubj||shares-2/VBZ||rks4594-1/NNS	root||ROOT-0/null||shares-2/VBZ	advmod||as-5/IN||as-3/RB	advmod||as-5/IN||many-4/JJ	quantmod||4346-6/CD||as-5/IN	dobj||shares-2/VBZ||4346-6/CD	det||genes-10/NNS||the-8/DT	num||genes-10/NNS||4,640-9/CD	prep_of||4346-6/CD||genes-10/NNS	det||strain-13/NN||a-12/DT	prep_with||shares-2/VBZ||strain-13/NN	nn||choleraesuis-16/NNS||s.-15/NN	prep_of||strain-13/NN||choleraesuis-16/NNS	nsubj||pathogen-23/NN||choleraesuis-16/NNS	cop||pathogen-23/NN||is-19/VBZ	advmod||pathogen-23/NN||primarily-20/RB	det||pathogen-23/NN||a-21/DT	amod||pathogen-23/NN||swine-22/JJ	rcmod||choleraesuis-16/NNS||pathogen-23/NN	num||genes-28/NNS||4008-27/CD	rcmod||choleraesuis-16/NNS||genes-28/NNS	conj_but||pathogen-23/NN||genes-28/NNS	det||agent-33/NN||another-30/DT	amod||agent-33/NN||human-adapted-31/JJ	amod||agent-33/NN||typhoid-32/JJ	prep_with||genes-28/NNS||agent-33/NN	appos||agent-33/NN||s.typhi-35/NNS	typhoid-32||s.typhi-35||no||rks4594 shares as many as 4346 of the 4,640 genes with a strain of s. choleraesuis , which is primarily a swine pathogen , but only 4008 genes with another human-adapted typhoid agent , s.typhi .
advmod||effective-5/JJ||where-1/WRB	nn||controls-3/NNS||bovinetuberculosis-2/NNS	nsubj||effective-5/JJ||controls-3/NNS	cop||effective-5/JJ||are-4/VBP	advcl||uncommon-19/JJ||effective-5/JJ	amod||tb-9/NN||human-7/JJ	amod||tb-9/NN||zoonotic-8/JJ	nsubj||uncommon-19/JJ||tb-9/NN	prep_due_to||tb-9/NN||mycobacteriumbovis-13/NNS	nn||caprae-16/NN||m.-15/NN	prep_due_to||tb-9/NN||caprae-16/NN	conj_or||mycobacteriumbovis-13/NNS||caprae-16/NN	cop||uncommon-19/JJ||is-18/VBZ	root||ROOT-0/null||uncommon-19/JJ	amod||cases-22/NNS||clinical-21/JJ	nsubj||infrequent-24/JJ||cases-22/NNS	cop||infrequent-24/JJ||are-23/VBP	conj_and||uncommon-19/JJ||infrequent-24/JJ	prep_in||infrequent-24/JJ||cattle-26/NNS	bovinetuberculosis-2||mycobacteriumbovis-13||no||where bovinetuberculosis controls are effective , human zoonotic tb , due to mycobacteriumbovis or m. caprae , is uncommon and clinical cases are infrequent in cattle .
amod||studies-2/NNS||recent-1/JJ	nsubj||reported-4/VBN||studies-2/NNS	aux||reported-4/VBN||have-3/VBP	root||ROOT-0/null||reported-4/VBN	mark||involves-13/VBZ||that-5/IN	det||mechanism-7/NN||the-6/DT	nsubj||involves-13/VBZ||mechanism-7/NN	vmod||mechanism-7/NN||underlying-8/VBG	det||priming-10/NN||the-9/DT	dobj||underlying-8/VBG||priming-10/NN	prep_of||priming-10/NN||pulmonaryinflammation-12/NN	ccomp||reported-4/VBN||involves-13/VBZ	det||cross-talk-16/NN||the-14/DT	amod||cross-talk-16/NN||complicated-15/VBN	dobj||involves-13/VBZ||cross-talk-16/NN	amod||receptors-19/NNS||toll-like-18/JJ	prep_between||cross-talk-16/NN||receptors-19/NNS	dep||cross-talk-16/NN||tlrs-21/VBZ	dobj||involves-13/VBZ||interactions-24/NNS	conj_and||cross-talk-16/NN||interactions-24/NNS	prep_between||interactions-24/NNS||neutrophils-26/NNS	appos||neutrophils-26/NNS||pmns-28/NNS	nn||macrophages-32/NNS||alveolar-31/NN	prep_between||interactions-24/NNS||macrophages-32/NNS	conj_and||neutrophils-26/NNS||macrophages-32/NNS	advmod||•-36/NN||am-34/RB	amod||•-36/NN||ï-35/JJ	appos||neutrophils-26/NNS||•-36/NN	amod||cells-42/NNS||endothelial-41/JJ	conj_and||cross-talk-16/NN||cells-42/NNS	conj_and||interactions-24/NNS||cells-42/NNS	prep_in||mediator-58/NN||cells-42/NNS	appos||cells-42/NNS||ecs-44/NN	amod||species-51/NNS||reactive-49/JJ	nn||species-51/NNS||oxygen-50/NN	nsubj||mediator-58/NN||species-51/NNS	appos||species-51/NNS||ros-53/NN	cop||mediator-58/NN||are-55/VBP	det||mediator-58/NN||the-56/DT	amod||mediator-58/NN||key-57/JJ	rcmod||cells-42/NNS||mediator-58/NN	oxygen-50||pulmonaryinflammation-12||no_rel||recent studies have reported that the mechanism underlying the priming of pulmonaryinflammation involves the complicated cross-talk between toll-like receptors (tlrs) and interactions between neutrophils (pmns) and alveolar macrophages (am ï• ) as well as endothelial cells (ecs), in which reactive oxygen species (ros) are the key mediator.
amod||management-2/NN||optimal-1/JJ	nsubjpass||defined-16/VBN||management-2/NN	conj_and||management-2/NN||outcome-4/NN	nsubjpass||defined-16/VBN||outcome-4/NN	amod||lymphoma-8/NN||primary-6/JJ	amod||lymphoma-8/NN||gastric-7/JJ	prep_of||management-2/NN||lymphoma-8/NN	appos||management-2/NN||pgl-10/NN	aux||defined-16/VBN||have-12/VBP	neg||defined-16/VBN||not-13/RB	auxpass||defined-16/VBN||been-14/VBN	advmod||defined-16/VBN||well-15/RB	root||ROOT-0/null||defined-16/VBN	det||era-20/NN||the-18/DT	amod||era-20/NN||rituximab-19/JJ	prep_in||defined-16/VBN||era-20/NN	lymphoma-8||rituximab-19||no_rel||optimal management and outcome of primary gastric lymphoma (pgl) have not been well defined in the rituximab era.
det||approach-3/NN||a-1/DT	amod||approach-3/NN||similar-2/JJ	nsubj||helpful-6/JJ||approach-3/NN	nsubj||identify-8/VB||approach-3/NN	aux||helpful-6/JJ||can-4/MD	cop||helpful-6/JJ||be-5/VB	root||ROOT-0/null||helpful-6/JJ	aux||identify-8/VB||to-7/TO	xcomp||helpful-6/JJ||identify-8/VB	advmod||relevant-10/JJ||biologically-9/RB	amod||targets-14/NNS||relevant-10/JJ	advmod||meaningful-13/JJ||clinically-12/RB	conj_and||relevant-10/JJ||meaningful-13/JJ	amod||targets-14/NNS||meaningful-13/JJ	dobj||identify-8/VB||targets-14/NNS	amod||infection-20/NN||m.tuberculosis-16/JJ	appos||infection-20/NN||mtb-18/NN	prep_in||identify-8/VB||infection-20/NN	nn||development-26/NN||diagnosis-22/NN	conj_or||diagnosis-22/NN||tb-24/NN	nn||development-26/NN||tb-24/NN	nn||development-26/NN||vaccine-25/NN	prep_for||infection-20/NN||development-26/NN	advmod||defined-30/JJ||clinically-28/RB	advmod||defined-30/JJ||well-29/RB	amod||populations-31/NNS||defined-30/JJ	prep_in||identify-8/VB||populations-31/NNS	tb-24||mtb-18||no||a similar approach can be helpful to identify biologically relevant and clinically meaningful targets in m.tuberculosis (mtb) infection for diagnosis or tb vaccine development in clinically well defined populations.
nsubjpass||known-3/VBN||little-1/RB	auxpass||known-3/VBN||is-2/VBZ	root||ROOT-0/null||known-3/VBN	prep||known-3/VBN||regarding-4/VBG	det||types-6/NNS||the-5/DT	npadvmod||with-15/IN||types-6/NNS	nn||american-10/NN||information-8/NN	nn||american-10/NN||african-9/NN	prep_of||types-6/NNS||american-10/NN	amod||patients-14/NNS||non-african-12/JJ	nn||patients-14/NNS||american-13/NN	prep_of||types-6/NNS||patients-14/NNS	conj_and||american-10/NN||patients-14/NNS	pcomp||regarding-4/VBG||with-15/IN	amod||kidneydisease-17/NN||chronic-16/JJ	pobj||with-15/IN||kidneydisease-17/NN	appos||kidneydisease-17/NN||ckd-19/NN	poss||families-23/NNS||their-22/PRP$	nsubj||need-24/VBP||families-23/NNS	nsubj||inform-26/VB||families-23/NNS	conj_and||known-3/VBN||need-24/VBP	aux||inform-26/VB||to-25/TO	xcomp||need-24/VBP||inform-26/VB	nn||decisions-33/NNS||renal-27/NN	nn||decisions-33/NNS||replacement-28/NN	nn||decisions-33/NNS||therapy-29/NN	appos||decisions-33/NNS||rrt-31/NN	dobj||inform-26/VB||decisions-33/NNS	inform-26||kidneydisease-17||no_rel||little is known regarding the types of information african american and non-african american patients with chronic kidneydisease (ckd) and their families need to inform renal replacement therapy (rrt) decisions.
nsubj||suggests-2/VBZ||this-1/DT	root||ROOT-0/null||suggests-2/VBZ	mark||complicate-9/VB||that-3/IN	amod||necrosis-6/NNS||pituitary-4/JJ	nn||necrosis-6/NNS||gland-5/NN	nsubj||complicate-9/VB||necrosis-6/NNS	aux||complicate-9/VB||may-7/MD	advmod||complicate-9/VB||also-8/RB	ccomp||suggests-2/VBZ||complicate-9/VB	nn||pregnancy-11/NN||gdm-10/NN	dobj||complicate-9/VB||pregnancy-11/NN	advmod||uncontrolled-16/JJ||when-12/WRB	nn||levels-14/NNS||glucose-13/NN	nsubj||uncontrolled-16/JJ||levels-14/NNS	cop||uncontrolled-16/JJ||are-15/VBP	advcl||complicate-9/VB||uncontrolled-16/JJ	pituitary-4||glucose-13||no_rel||this suggests that pituitary gland necrosis may also complicate gdm pregnancy when glucose levels are uncontrolled.
amod||drugs-3/NNS||other-1/JJ	amod||drugs-3/NNS||anti-tuberculous-2/JJ	nsubjpass||added-16/VBN||drugs-3/NNS	amod||ethambutol-7/JJ||pyrazinamide-5/JJ	dep||drugs-3/NNS||ethambutol-7/JJ	det||steroid-11/NN||a-10/DT	conj_and||drugs-3/NNS||steroid-11/NN	nsubjpass||added-16/VBN||steroid-11/NN	appos||steroid-11/NN||dexamethasone-13/NN	auxpass||added-16/VBN||were-15/VBD	root||ROOT-0/null||added-16/VBN	tuberculous--1||pyrazinamide-5||yes||other anti-tuberculous drugs (pyrazinamide, ethambutol) and a steroid (dexamethasone) were added.
amod||immunomodulators-2/NNS||concomitant-1/JJ	nsubj||reduced-10/VBD||immunomodulators-2/NNS	det||form-5/NN||the-4/DT	prep_in||immunomodulators-2/NNS||form-5/NN	prep_of||form-5/NN||methotrexate-7/NN	prep_of||form-5/NN||azathioprine-9/NN	conj_or||methotrexate-7/NN||azathioprine-9/NN	root||ROOT-0/null||reduced-10/VBD	det||immunogenicity-12/NN||the-11/DT	dobj||reduced-10/VBD||immunogenicity-12/NN	amod||antibodies-15/NNS||therapeutic-14/JJ	prep_of||immunogenicity-12/NN||antibodies-15/NNS	prep_in||reduced-10/VBD||rheumatoidarthritis-17/NNS	prep_in||reduced-10/VBD||crohndisease-19/NN	conj_and||rheumatoidarthritis-17/NNS||crohndisease-19/NN	prep_in||reduced-10/VBD||juvenileidiopathicarthritis-22/NNS	conj_and||rheumatoidarthritis-17/NNS||juvenileidiopathicarthritis-22/NNS	juvenileidiopathicarthritis-22||methotrexate-7||yes||concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoidarthritis, crohndisease, and juvenileidiopathicarthritis.
nn||cancer-2/NN||breast-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	advmod||cancer-8/NN||frequently-4/RB	det||cancer-8/NN||a-5/DT	advmod||dependent-7/JJ||hormonally-6/RB	amod||cancer-8/NN||dependent-7/JJ	root||ROOT-0/null||cancer-8/NN	nsubjpass||established-24/VBN||associations-11/NNS	prepc_of||associations-11/NNS||circulating-13/VBG	dobj||circulating-13/VBG||estrogens-14/NNS	dobj||circulating-13/VBG||androgens-16/NNS	conj_and||estrogens-14/NNS||androgens-16/NNS	amod||risk-21/NN||subsequent-18/JJ	nn||risk-21/NN||breast-19/NN	nn||risk-21/NN||cancer-20/NN	prep_with||circulating-13/VBG||risk-21/NN	auxpass||established-24/VBN||are-22/VBP	advmod||established-24/VBN||well-23/RB	conj_and||cancer-8/NN||established-24/VBN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||established-24/VBN||women-27/NNS	estrogens-14||cancer-20||no_rel||breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women.
nsubj||bioequivalent-3/JJ||fosaprepitant-1/NN	nsubj||aprepitant-5/VB||fosaprepitant-1/NN	nsubj||offer-9/VB||fosaprepitant-1/NN	cop||bioequivalent-3/JJ||is-2/VBZ	root||ROOT-0/null||bioequivalent-3/JJ	aux||aprepitant-5/VB||to-4/TO	xcomp||bioequivalent-3/JJ||aprepitant-5/VB	aux||offer-9/VB||could-8/MD	conj_and||bioequivalent-3/JJ||offer-9/VB	amod||benefits-11/NNS||potential-10/JJ	dobj||offer-9/VB||benefits-11/NNS	prep_for||offer-9/VB||patients-13/NNS	nsubj||unable-17/JJ||patients-13/NNS	nsubj||tolerate-19/VB||patients-13/NNS	aux||unable-17/JJ||may-15/MD	cop||unable-17/JJ||be-16/VB	rcmod||patients-13/NNS||unable-17/JJ	aux||tolerate-19/VB||to-18/TO	xcomp||unable-17/JJ||tolerate-19/VB	amod||administration-21/NN||oral-20/JJ	dobj||tolerate-19/VB||administration-21/NN	prep_of||administration-21/NN||antiemetics-23/NNS	det||episode-26/NN||an-25/DT	prep_during||tolerate-19/VB||episode-26/NN	prep_of||episode-26/NN||nausea-28/NN	prep_of||episode-26/NN||vomiting-30/NN	conj_or||nausea-28/NN||vomiting-30/NN	nausea-28||aprepitant-5||yes||fosaprepitant is bioequivalent to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting.
amod||mosquitoes-2/NNS||insecticide-resistant-1/JJ	nsubj||compromising-4/VBG||mosquitoes-2/NNS	aux||compromising-4/VBG||are-3/VBP	root||ROOT-0/null||compromising-4/VBG	det||ability-6/NN||the-5/DT	dobj||compromising-4/VBG||ability-6/NN	amod||tools-11/NNS||current-8/JJ	nn||tools-11/NNS||mosquito-9/NN	nn||tools-11/NNS||control-10/NN	prep_of||ability-6/NN||tools-11/NNS	aux||control-13/VB||to-12/TO	vmod||compromising-4/VBG||control-13/VB	nn||vectors-15/NNS||malaria-14/NN	dobj||control-13/VB||vectors-15/NNS	insecticide--1||malaria-14||no_rel||insecticide-resistant mosquitoes are compromising the ability of current mosquito control tools to control malaria vectors.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||evidence-4/NN||weak-3/JJ	nsubj||is-2/VBZ||evidence-4/NN	mark||have-12/VB||that-5/IN	nsubj||have-12/VB||children-6/NNS	prep_with||children-6/NNS||fasd-8/NN	prep_with||children-6/NNS||adhd-10/NN	conj_and||fasd-8/NN||adhd-10/NN	aux||have-12/VB||may-11/MD	ccomp||is-2/VBZ||have-12/VB	det||response-15/NN||a-13/DT	amod||response-15/NN||better-14/JJR	dobj||have-12/VB||response-15/NN	aux||dexamphetamine-17/VB||to-16/TO	vmod||response-15/NN||dexamphetamine-17/VB	prep_than||dexamphetamine-17/VB||methylphenidate-19/NN	adhd-10||dexamphetamine-17||yes||there is weak evidence that children with fasd and adhd may have a better response to dexamphetamine than methylphenidate.
mark||associated-15/VBN||while-1/IN	amod||plasminogenactivator-4/NN||increased-2/VBN	amod||plasminogenactivator-4/NN||urokinase-type-3/JJ	nsubjpass||associated-15/VBN||plasminogenactivator-4/NN	appos||plasminogenactivator-4/NN||upa-6/NN	vmod||plasminogenactivator-4/NN||expression-8/VBG	nn||tissue-12/NN||breast-10/NN	nn||tissue-12/NN||cancer-11/NN	prep_in||expression-8/VBG||tissue-12/NN	auxpass||associated-15/VBN||is-13/VBZ	advmod||associated-15/VBN||directly-14/RB	advcl||suggests-22/VBZ||associated-15/VBN	amod||prognosis-18/NN||poor-17/JJ	prep_with||associated-15/VBN||prognosis-18/NN	amod||evidence-21/NN||recent-20/JJ	nsubj||suggests-22/VBZ||evidence-21/NN	root||ROOT-0/null||suggests-22/VBZ	mark||suppress-27/VB||that-23/IN	nn||overexpression-25/NN||upa-24/NN	nsubj||suppress-27/VB||overexpression-25/NN	nsubj||prolong-31/VB||overexpression-25/NN	aux||suppress-27/VB||may-26/MD	ccomp||suggests-22/VBZ||suppress-27/VB	nn||growth-29/NN||tumor-28/NN	dobj||suppress-27/VB||growth-29/NN	ccomp||suggests-22/VBZ||prolong-31/VB	conj_and||suppress-27/VB||prolong-31/VB	dobj||prolong-31/VB||survival-32/NN	upa-24||tumor-28||no_rel||while increased urokinase-type plasminogenactivator (upa) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that upa overexpression may suppress tumor growth and prolong survival.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||possibility-10/NN||the-9/DT	dobj||investigate-8/VB||possibility-10/NN	mark||causes-17/VBZ||that-11/IN	det||synthesis-16/NN||a-12/DT	amod||synthesis-16/NN||decreased-13/VBN	amod||synthesis-16/NN||mitochondrial-14/JJ	nn||synthesis-16/NN||atp-15/NN	nsubj||causes-17/VBZ||synthesis-16/NN	nsubj||plays-23/VBZ||synthesis-16/NN	ccomp||investigate-8/VB||causes-17/VBZ	amod||fatigue-21/NN||muscular-18/JJ	conj_and||muscular-18/JJ||mental-20/JJ	amod||fatigue-21/NN||mental-20/JJ	dobj||causes-17/VBZ||fatigue-21/NN	ccomp||investigate-8/VB||plays-23/VBZ	conj_and||causes-17/VBZ||plays-23/VBZ	det||role-25/NN||a-24/DT	dobj||plays-23/VBZ||role-25/NN	det||pathophysiology-28/NN||the-27/DT	prep_in||plays-23/VBZ||pathophysiology-28/NN	det||syndrome-33/NN||the-30/DT	amod||syndrome-33/NN||chronic-31/JJ	nn||syndrome-33/NN||fatigue-32/NN	prep_of||pathophysiology-28/NN||syndrome-33/NN	appos||syndrome-33/NN||cfs/me-35/NN	cfs--1||atp-15||no_rel||the aim of this study was to investigate the possibility that a decreased mitochondrial atp synthesis causes muscular and mental fatigue and plays a role in the pathophysiology of the chronic fatigue syndrome (cfs/me).
aux||examine-2/VB||to-1/TO	root||ROOT-0/null||examine-2/VB	det||effect-4/NN||the-3/DT	dobj||examine-2/VB||effect-4/NN	amod||iron-7/NN||intravenous-6/JJ	prep_of||effect-4/NN||iron-7/NN	nn||agents-10/NNS||erythropoietin-stimulating-9/NN	prep_of||effect-4/NN||agents-10/NNS	conj_and||iron-7/NN||agents-10/NNS	appos||iron-7/NN||esas-12/NNS	amod||control-16/NN||glycemic-15/JJ	prep_on||examine-2/VB||control-16/NN	prep_on||examine-2/VB||a1c-18/NNS	conj_and||control-16/NN||a1c-18/NNS	prep_of||control-16/NN||patients-20/NNS	nn||kidneydisease-25/NN||diabetes-22/NN	conj_and||diabetes-22/NN||chronic-24/JJ	nn||kidneydisease-25/NN||chronic-24/JJ	prep_with||patients-20/NNS||kidneydisease-25/NN	appos||kidneydisease-25/NN||ckd-27/NN	erythropoietin--1||kidneydisease-25||no_rel||to examine the effect of intravenous iron and erythropoietin-stimulating agents (esas) on glycemic control and a1c of patients with diabetes and chronic kidneydisease (ckd).
poss||series-4/NN||our-1/PRP$	advmod||large-3/JJ||relatively-2/RB	amod||series-4/NN||large-3/JJ	nsubj||suggested-5/VBD||series-4/NN	nsubj||responsive-79/JJ||series-4/NN	nsubj||pyridoxine-81/VB||series-4/NN	root||ROOT-0/null||suggested-5/VBD	mark||challenging-15/JJ||that-6/IN	amod||diagnosis-8/NN||clinical-7/JJ	nsubj||challenging-15/JJ||diagnosis-8/NN	amod||dependent-11/JJ||pyridoxine-10/JJ	amod||epilepsy-12/NN||dependent-11/JJ	prep_of||diagnosis-8/NN||epilepsy-12/NN	aux||challenging-15/JJ||can-13/MD	cop||challenging-15/JJ||be-14/VB	ccomp||suggested-5/VBD||challenging-15/JJ	mark||response-24/NN||because-16/IN	dep||response-24/NN||i-18/NNP	expl||response-24/NN||there-20/EX	aux||response-24/NN||may-21/MD	cop||response-24/NN||be-22/VB	det||response-24/NN||some-23/DT	ccomp||challenging-15/JJ||response-24/NN	amod||drugs-27/NNS||antiepileptic-26/JJ	prep_to||response-24/NN||drugs-27/NNS	nsubj||instant-45/JJ||ii-30/NN	nsubj||obvious-47/JJ||ii-30/NN	prep_in||ii-30/NN||infants-33/NNS	nn||pathology-36/NN||multisystem-35/NN	prep_with||infants-33/NNS||pathology-36/NN	det||response-39/NN||the-38/DT	appos||pathology-36/NN||response-39/NN	aux||pyridoxine-41/VB||to-40/TO	vmod||response-39/NN||pyridoxine-41/VB	aux||instant-45/JJ||may-42/MD	neg||instant-45/JJ||not-43/RB	cop||instant-45/JJ||be-44/VB	parataxis||response-24/NN||instant-45/JJ	parataxis||response-24/NN||obvious-47/JJ	conj_and||instant-45/JJ||obvious-47/JJ	dep||challenging-15/JJ||iii-51/NN	amod||abnormalities-55/NNS||structural-53/JJ	nn||abnormalities-55/NNS||brain-54/NN	nsubj||co-exist-57/VB||abnormalities-55/NNS	nsubjpass||considered-60/VBN||abnormalities-55/NNS	aux||co-exist-57/VB||may-56/MD	ccomp||suggested-5/VBD||co-exist-57/VB	conj_and||challenging-15/JJ||co-exist-57/VB	auxpass||considered-60/VBN||be-59/VB	conj_and||challenging-15/JJ||considered-60/VBN	conj_and||co-exist-57/VB||considered-60/VBN	amod||cause-62/NN||sufficient-61/JJ	dobj||considered-60/VBN||cause-62/NN	prep_of||cause-62/NN||epilepsy-64/NN	mark||consequence-72/NN||whereas-66/IN	det||fits-68/NNS||the-67/DT	nsubj||consequence-72/NN||fits-68/NNS	aux||consequence-72/NN||may-69/MD	cop||consequence-72/NN||be-70/VB	det||consequence-72/NN||a-71/DT	advcl||considered-60/VBN||consequence-72/NN	nn||deficiency-75/NN||antiquitin-74/NN	prep_of||consequence-72/NN||deficiency-75/NN	cop||responsive-79/JJ||are-77/VBP	advmod||responsive-79/JJ||then-78/RB	conj_and||suggested-5/VBD||responsive-79/JJ	aux||pyridoxine-81/VB||to-80/TO	xcomp||responsive-79/JJ||pyridoxine-81/VB	fits-68||pyridoxine-81||yes||our relatively large series suggested that clinical diagnosis of pyridoxine dependent epilepsy can be challenging because (i) there may be some response to antiepileptic drugs; (ii) in infants with multisystem pathology, the response to pyridoxine may not be instant and obvious; and (iii) structural brain abnormalities may co-exist and be considered sufficient cause of epilepsy, whereas the fits may be a consequence of antiquitin deficiency and are then responsive to pyridoxine.
prep_with||prevented-20/VBN||use-2/NN	det||scheme-6/NN||a-4/DT	amod||scheme-6/NN||voting-5/VBG	prep_of||use-2/NN||scheme-6/NN	nsubj||required-8/VBD||scheme-6/NN	rcmod||scheme-6/NN||required-8/VBD	num||algorithms-10/NNS||three-9/CD	dobj||required-8/VBD||algorithms-10/NNS	nsubj||trigger-12/VB||algorithms-10/NNS	aux||trigger-12/VB||to-11/TO	xcomp||required-8/VBD||trigger-12/VB	nn||suspension-15/NN||insulin-13/NN	nn||suspension-15/NN||pump-14/NN	dobj||trigger-12/VB||suspension-15/NN	amod||hypoglycemia-18/NN||nocturnal-17/JJ	nsubjpass||prevented-20/VBN||hypoglycemia-18/NN	auxpass||prevented-20/VBN||was-19/VBD	root||ROOT-0/null||prevented-20/VBN	prep_during||prevented-20/VBN||6-22/CD	num||%-25/NN||60-24/CD	appos||6-22/CD||%-25/NN	num||nights-29/NNS||10-28/CD	prep_of||6-22/CD||nights-29/NNS	insulin-13||hypoglycemia-18||no_rel||with use of a voting scheme that required three algorithms to trigger insulin pump suspension, nocturnal hypoglycemia was prevented during 6 (60%) of 10 nights.
amod||factors-5/NNS||socio-demographic-1/JJ	conj_and||socio-demographic-1/JJ||behavioural-3/JJ	amod||factors-5/NNS||behavioural-3/JJ	nn||factors-5/NNS||risk-4/NN	nsubjpass||ascertained-7/VBN||factors-5/NNS	auxpass||ascertained-7/VBN||were-6/VBD	root||ROOT-0/null||ascertained-7/VBN	amod||interview-10/NN||personal-9/JJ	prep_through||ascertained-7/VBN||interview-10/NN	nsubjpass||determined-20/VBN||infection-13/NN	amod||viruses-18/NNS||hepatitisb-15/JJ	conj_and||hepatitisb-15/JJ||c-17/SYM	amod||viruses-18/NNS||c-17/SYM	prep_with||infection-13/NN||viruses-18/NNS	auxpass||determined-20/VBN||was-19/VBD	conj_and||ascertained-7/VBN||determined-20/VBN	poss||markers-24/NNS||their-22/PRP$	amod||markers-24/NNS||serologic-23/JJ	agent||determined-20/VBN||markers-24/NNS	hepatitisb-15||viruses-18||no||socio-demographic and behavioural risk factors were ascertained through personal interview, and infection with hepatitisb and c viruses was determined by their serologic markers.
amod||individuals-2/NNS||healthy-1/JJ	nsubjpass||selected-4/VBN||individuals-2/NNS	auxpass||selected-4/VBN||were-3/VBD	root||ROOT-0/null||selected-4/VBN	amod||characteristics-9/NNS||demographic-6/JJ	conj_and||demographic-6/JJ||behavioural-8/JJ	amod||characteristics-9/NNS||behavioural-8/JJ	prep_for||selected-4/VBN||characteristics-9/NNS	amod||sampling-13/NN||stratified-11/JJ	nn||sampling-13/NN||cluster-12/NN	agent||selected-4/VBN||sampling-13/NN	agent||selected-4/VBN||blood-15/NN	conj_and||sampling-13/NN||blood-15/NN	vmod||sampling-13/NN||tested-16/VBN	prep_for||tested-16/VBN||hepatitisbsurfaceantigen-18/NN	dep||sampling-13/NN||hbsag-20/VBG	agent||selected-4/VBN||antibody-23/NN	conj_and||sampling-13/NN||antibody-23/NN	aux||hbv-25/VB||to-24/TO	vmod||antibody-23/NN||hbv-25/VB	amod||antigen-27/NN||core-26/JJ	dobj||hbv-25/VB||antigen-27/NN	dep||antibody-23/NN||anti-hbc-29/JJ	amod||antibodies-34/NNS||anti-hcv-33/VBG	agent||selected-4/VBN||antibodies-34/NNS	conj_and||sampling-13/NN||antibodies-34/NNS	appos||antibodies-34/NNS||anti-hcv-36/NNP	hbv-25||hepatitisbsurfaceantigen-18||yes||healthy individuals were selected for demographic and behavioural characteristics by stratified cluster sampling and blood tested for hepatitisbsurfaceantigen (hbsag), antibody to hbv core antigen (anti-hbc), and anti-hcv antibodies (anti-hcv).
aux||determine-2/VB||to-1/TO	advcl||studied-29/VBN||determine-2/VB	det||prevalence-4/NN||the-3/DT	dobj||determine-2/VB||prevalence-4/NN	amod||dysfunction-7/NN||pulmonary-6/JJ	prep_of||prevalence-4/NN||dysfunction-7/NN	prep_in||determine-2/VB||lupuserythematosus-9/NNS	num||patients-12/NNS||24-11/CD	nsubjpass||studied-29/VBN||patients-12/NNS	amod||lupuserythematosus-15/NNS||systemic-14/JJ	prep_with||patients-12/NNS||lupuserythematosus-15/NNS	appos||lupuserythematosus-15/NNS||sle-17/NN	num||patients-21/NNS||5-20/CD	prep_with||patients-12/NNS||patients-21/NNS	conj_and||lupuserythematosus-15/NNS||patients-21/NNS	amod||lupuserythematosus-24/NNS||discoid-23/JJ	prep_with||patients-21/NNS||lupuserythematosus-24/NNS	appos||patients-12/NNS||dle-26/NN	auxpass||studied-29/VBN||were-28/VBD	root||ROOT-0/null||studied-29/VBN	dle-26||lupuserythematosus-24||no||to determine the prevalence of pulmonary dysfunction in lupuserythematosus, 24 patients with systemic lupuserythematosus (sle) and 5 patients with discoid lupuserythematosus (dle) were studied.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	advmod||studied-2/VBD||prospectively-3/RB	num||groups-5/NNS||three-4/CD	dobj||studied-2/VBD||groups-5/NNS	iobj||studied-2/VBD||groups-5/NNS	prep_of||groups-5/NNS||patients-7/NNS	appos||groups-5/NNS||1-9/CD	num||group-12/NN||one-11/CD	dep||groups-5/NNS||group-12/NN	num||patients-15/NNS||35-14/CD	prep_of||group-12/NN||patients-15/NNS	prep_with||patients-15/NNS||fibroticdisorders-17/NNS	prep_of||group-12/NN||16-19/CD	conj_and||patients-15/NNS||16-19/CD	amod||pulmonaryfibrosis-22/NNS||idiopathic-21/JJ	prep_with||16-19/CD||pulmonaryfibrosis-22/NNS	appos||pulmonaryfibrosis-22/NNS||ipf-24/NN	prep_of||group-12/NN||19-27/CD	conj_and||patients-15/NNS||19-27/CD	amod||pneumonias-31/NNS||fibrotic-29/JJ	amod||pneumonias-31/NNS||interstitial-30/JJ	prep_with||19-27/CD||pneumonias-31/NNS	vmod||group-12/NN||associated-32/VBN	nn||disorders-36/NNS||collagen-34/NN	nn||disorders-36/NNS||tissue-35/NN	prep_with||associated-32/VBN||disorders-36/NNS	dep||group-12/NN||ctd-ips-38/NNS	dep||group-45/NN||2-42/LS	num||group-45/NN||one-44/CD	dep||group-12/NN||group-45/NN	num||patients-48/NNS||14-47/CD	prep_of||group-45/NN||patients-48/NNS	prep_with||patients-48/NNS||pulmonarysarcoidosis-50/NNS	appos||patients-48/NNS||3-54/CD	num||subjects-58/NNS||11-56/CD	amod||subjects-58/NNS||normal-57/JJ	prep_of||group-45/NN||subjects-58/NNS	conj_and||patients-48/NNS||subjects-58/NNS	collagen-34||pulmonaryfibrosis-22||no_rel||we studied prospectively three groups of patients (1) one group of 35 patients with fibroticdisorders, 16 with idiopathic pulmonaryfibrosis (ipf) and 19 with fibrotic interstitial pneumonias associated with collagen tissue disorders (ctd-ips); (2) one group of 14 patients with pulmonarysarcoidosis; and (3) 11 normal subjects.
poss||work-3/NN||our-1/PRP$	amod||work-3/NN||recent-2/JJ	nsubj||shows-5/VBZ||work-3/NN	advmod||shows-5/VBZ||also-4/RB	root||ROOT-0/null||shows-5/VBZ	mark||exhibits-8/VBZ||that-6/IN	nsubj||exhibits-8/VBZ||iptakalim-7/NN	ccomp||shows-5/VBZ||exhibits-8/VBZ	det||profile-13/NN||a-9/DT	amod||profile-13/NN||clozapine-like-10/JJ	amod||profile-13/NN||atypical-11/JJ	amod||profile-13/NN||antipsychotic-12/JJ	dobj||exhibits-8/VBZ||profile-13/NN	vmod||exhibits-8/VBZ||indicating-15/VBG	mark||possess-19/VB||that-16/IN	nsubj||possess-19/VB||iptakalim-17/NN	aux||possess-19/VB||may-18/MD	ccomp||indicating-15/VBG||possess-19/VB	det||action-22/NN||a-20/DT	amod||action-22/NN||dual-21/JJ	dobj||possess-19/VB||action-22/NN	prep_against||action-22/NN||nicotineaddiction-24/NN	prep_against||action-22/NN||schizophrenia-26/NN	conj_and||nicotineaddiction-24/NN||schizophrenia-26/NN	schizophrenia-26||clozapine--1||yes||our recent work also shows that iptakalim exhibits a clozapine-like atypical antipsychotic profile, indicating that iptakalim may possess a dual action against nicotineaddiction and schizophrenia.
nsubjpass||mentioned-4/VBN||it-1/PRP	nsubjpass||divided-23/VBN||it-1/PRP	auxpass||mentioned-4/VBN||was-2/VBD	advmod||mentioned-4/VBN||first-3/RB	root||ROOT-0/null||mentioned-4/VBN	agent||mentioned-4/VBN||maurice-6/NN	vmod||maurice-6/NN||raynaud-7/VBN	prep_in||raynaud-7/VBN||1862-9/CD	xcomp||raynaud-7/VBN||describing-10/VBG	quantmod||$-12/$||â-11/RB	num||asphyxia-15/FW||$-12/$	num||$-12/$||œa-13/CD	amod||asphyxia-15/FW||local-14/JJ	dobj||describing-10/VBG||asphyxia-15/FW	det||$-19/NN||the-17/DT	amod||$-19/NN||extremitiesâ-18/JJ	prep_of||asphyxia-15/FW||$-19/NN	auxpass||divided-23/VBN||was-21/VBD	advmod||divided-23/VBN||further-22/RBR	conj_and||mentioned-4/VBN||divided-23/VBN	amod||raynaudâ-26/NNS||primary-25/JJ	prep_into||divided-23/VBN||raynaudâ-26/NNS	nsubjpass||related-42/VBN||raynaudâ-26/NNS	num||disease-30/NN||$-27/$	number||s-29/CD||™-28/CD	num||$-27/$||s-29/CD	nsubj||phenomenon-37/NN||disease-30/NN	amod||raynaudâ-33/NNS||secondary-32/JJ	conj_and||disease-30/NN||raynaudâ-33/NNS	nsubj||phenomenon-37/NN||raynaudâ-33/NNS	amod||disease-30/NN||$-34/$	number||$-34/$||™-35/CD	cop||phenomenon-37/NN||s-36/VBZ	rcmod||raynaudâ-26/NNS||phenomenon-37/NN	auxpass||related-42/VBN||is-40/VBZ	advmod||related-42/VBN||often-41/RB	rcmod||phenomenon-37/NN||related-42/VBN	prep_to||related-42/VBN||connectivetissuediseases-44/NNS	amod||strain-51/NN||physical-48/NN	conj_or||physical-48/NN||chemical-50/NN	amod||strain-51/NN||chemical-50/NN	rcmod||raynaudâ-26/NNS||strain-51/NN	conj_and||phenomenon-37/NN||strain-51/NN	chemical-50||connectivetissuediseases-44||no_rel||it was first mentioned by maurice raynaud in 1862 describing â€œa local asphyxia of the extremitiesâ€? and was further divided into primary raynaudâ€™s disease and secondary raynaudâ€™s phenomenon, which is often related to connectivetissuediseases, but also physical or chemical strain.
amod||cytotoxicity-2/NN||cellular-1/JJ	nsubjpass||investigated-11/VBN||cytotoxicity-2/NN	conj_and||cytotoxicity-2/NN||proliferation-4/NN	nsubjpass||investigated-11/VBN||proliferation-4/NN	conj_and||cytotoxicity-2/NN||apoptosis-6/NNS	nsubjpass||investigated-11/VBN||apoptosis-6/NNS	conj_and||cytotoxicity-2/NN||differentiation-8/NNS	nsubjpass||investigated-11/VBN||differentiation-8/NNS	auxpass||investigated-11/VBN||were-9/VBD	advmod||investigated-11/VBN||comprehensively-10/RB	root||ROOT-0/null||investigated-11/VBN	amod||lines-15/NNS||realgar-treated-13/JJ	nn||lines-15/NNS||cell-14/NN	prep_in||investigated-11/VBN||lines-15/NNS	vmod||lines-15/NNS||derived-16/VBN	nn||patient-22/NN||pml-rarî-18/NNP	nn||patient-22/NN||±-19/NNP	nn||patient-22/NN||+-20/NNP	nn||patient-22/NN||apl-21/NN	prep_from||derived-16/VBN||patient-22/NN	det||atra-28/NN||the-25/DT	amod||atra-28/NN||all-transretinoicacid-26/JJ	prep_including||derived-16/VBN||atra-28/NN	amod||nb4-32/JJ||sensitive-31/JJ	dobj||derived-16/VBN||nb4-32/JJ	parataxis||derived-16/VBN||nb4-32/JJ	amod||lines-37/NNS||atra-resistant-34/JJ	amod||lines-37/NNS||mr2-35/JJ	nn||lines-37/NNS||cell-36/NN	dobj||derived-16/VBN||lines-37/NNS	parataxis||derived-16/VBN||lines-37/NNS	conj_and||nb4-32/JJ||lines-37/NNS	apl-21||all-transretinoicacid-26||yes||cellular cytotoxicity, proliferation, apoptosis and differentiation were comprehensively investigated in realgar-treated cell lines derived from pml-rarî±+ apl patient, including the all-transretinoicacid (atra)-sensitive nb4 and atra-resistant mr2 cell lines.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	calcitonin-52||eia-72||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
vmod||determined-7/VBD||using-1/VBG	det||protocol-4/NN||the-2/DT	amod||protocol-4/NN||assay-3/JJ	dobj||using-1/VBG||protocol-4/NN	nsubj||determined-7/VBD||we-6/PRP	root||ROOT-0/null||determined-7/VBD	amod||levels-10/NNS||serum-8/JJ	amod||levels-10/NNS||vldl-tg-9/JJ	dobj||determined-7/VBD||levels-10/NNS	num||patients-14/NNS||69-12/CD	amod||patients-14/NNS||fasting-13/JJ	prep_in||determined-7/VBD||patients-14/NNS	amod||liverdisease-19/NN||biopsy-proven-16/JJ	amod||liverdisease-19/NN||hcv-related-17/JJ	amod||liverdisease-19/NN||chronic-18/JJ	prep_with||determined-7/VBD||liverdisease-19/NN	num||subjects-23/NNS||50-21/CD	amod||subjects-23/NNS||healthy-22/JJ	prep_with||determined-7/VBD||subjects-23/NNS	conj_and||liverdisease-19/NN||subjects-23/NNS	tg--1||liverdisease-19||no_rel||using the assay protocol, we determined serum vldl-tg levels in 69 fasting patients with biopsy-proven hcv-related chronic liverdisease and 50 healthy subjects.
det||gene-3/NN||the-1/DT	amod||gene-3/NN||p32-2/JJ	nsubj||identical-14/JJ||gene-3/NN	det||$-7/$||the-5/DT	amod||$-7/$||2006â-6/JJ	prep_of||gene-3/NN||$-7/$	advmod||mongolian-10/RB||2007-9/RB	dep||sheeppoxvirus-11/CD||mongolian-10/RB	num||$-7/$||sheeppoxvirus-11/CD	dep||$-7/$||strain-12/NN	cop||identical-14/JJ||was-13/VBD	root||ROOT-0/null||identical-14/JJ	advmod||published-17/VBN||previously-16/RB	amod||strains-19/NNS||published-17/VBN	amod||strains-19/NNS||sheeppox-18/JJ	prep_to||identical-14/JJ||strains-19/NNS	sheeppox-18||sheeppoxvirus-11||no||the p32 gene of the 2006â€“2007 mongolian sheeppoxvirus strain was identical to previously published sheeppox strains.
det||agent-2/NN||this-1/DT	nsubjpass||approved-5/VBN||agent-2/NN	auxpass||approved-5/VBN||was-3/VBD	advmod||approved-5/VBN||recently-4/RB	root||ROOT-0/null||approved-5/VBN	det||treatment-8/NN||the-7/DT	prep_for||approved-5/VBN||treatment-8/NN	nsubj||failed-15/VBN||treatment-8/NN	amod||patients-12/NNS||relapsed/refractory-10/JJ	nn||patients-12/NNS||cll-11/NN	prep_of||treatment-8/NN||patients-12/NNS	aux||failed-15/VBN||have-14/VBP	rcmod||treatment-8/NN||failed-15/VBN	acomp||failed-15/VBN||fludarabine-16/JJ	acomp||failed-15/VBN||alemtuzumab-18/JJ	conj_and||fludarabine-16/JJ||alemtuzumab-18/JJ	cll-11||alemtuzumab-18||yes||this agent was recently approved for the treatment of relapsed/refractory cll patients who have failed fludarabine and alemtuzumab.
advmod||examine-3/VBP||moreover-1/RB	nsubj||examine-3/VBP||we-2/PRP	root||ROOT-0/null||examine-3/VBP	det||role-5/NN||the-4/DT	dobj||examine-3/VBP||role-5/NN	det||antibody-9/NN||a-7/DT	amod||antibody-9/NN||monoclonal-8/JJ	prep_of||role-5/NN||antibody-9/NN	appos||antibody-9/NN||mab-11/NN	amod||4c5-17/NNS||hsp90-14/JJ	amod||4c5-17/NNS||mab-16/JJ	prep_against||antibody-9/NN||4c5-17/NNS	det||interactions-21/NNS||these-20/DT	prep_regarding||antibody-9/NN||interactions-21/NNS	poss||value-24/NN||its-23/PRP$	prep_regarding||antibody-9/NN||value-24/NN	conj_and||interactions-21/NNS||value-24/NN	det||inhibitor-28/NN||a-26/DT	amod||inhibitor-28/NN||potential-27/JJ	prep_as||value-24/NN||inhibitor-28/NN	amod||invasion-34/NN||human-30/JJ	nn||invasion-34/NN||breast-31/NN	nn||invasion-34/NN||cancer-32/NN	nn||invasion-34/NN||cell-33/NN	prep_of||inhibitor-28/NN||invasion-34/NN	prep_of||inhibitor-28/NN||metastasis-36/NNS	conj_and||invasion-34/NN||metastasis-36/NNS	antibody-9||metastasis-36||no_rel||moreover we examine the role of a monoclonal antibody (mab) against hsp90, mab 4c5, regarding these interactions and its value as a potential inhibitor of human breast cancer cell invasion and metastasis.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-33/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-23/VBZ||levels-10/NNS	prep_of||levels-10/NNS||n-3fattyacids-12/JJ	appos||n-3fattyacids-12/JJ||fa-14/NN	possessive||fa-14/NN||'s-15/POS	amod||levels-19/NNS||higher-18/JJR	prep_of||levels-10/NNS||levels-19/NNS	conj_and||n-3fattyacids-12/JJ||levels-19/NNS	amod||fa-22/NN||n-6-21/JJ	prep_of||levels-19/NNS||fa-22/NN	ccomp||contained-8/VBD||'s-23/VBZ	det||diet-27/NN||the-25/DT	nn||diet-27/NN||control-26/NN	prep_than||'s-23/VBZ||diet-27/NN	appos||diet-27/NN||ctr-29/NN	nsubj||found-33/VBD||we-32/PRP	root||ROOT-0/null||found-33/VBD	amod||decreases-35/NNS||significant-34/JJ	nsubj||'s-46/VBZ||decreases-35/NNS	amod||acid-38/NN||docosahexaenoic-37/JJ	prep_in||decreases-35/NNS||acid-38/NN	appos||acid-38/NN||dha-40/NN	amod||fa-45/NN||total-43/JJ	amod||fa-45/NN||n-3-44/JJ	prep_in||decreases-35/NNS||fa-45/NN	conj_and||acid-38/NN||fa-45/NN	ccomp||found-33/VBD||'s-46/VBZ	nn||maternal-49/NN||hfd-48/NN	prep_in||'s-46/VBZ||maternal-49/NN	amod||plasma-52/NN||fetal-51/JJ	prep_in||'s-46/VBZ||plasma-52/NN	conj_and||maternal-49/NN||plasma-52/NN	n-3fattyacids-12||fa-45||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
nn||abnormalities-2/NNS||glucose-1/NN	nsubjpass||documented-4/VBN||abnormalities-2/NNS	auxpass||documented-4/VBN||were-3/VBD	root||ROOT-0/null||documented-4/VBN	num||%-7/NN||71-6/CD	prep_in||documented-4/VBN||%-7/NN	nn||type2diabetes-10/NNS||patients-9/NNS	prep_of||%-7/NN||type2diabetes-10/NNS	num||%-13/NN||29-12/CD	prep_in||documented-4/VBN||%-13/NN	amod||glucose-17/NN||impaired-15/VBN	amod||glucose-17/NN||fasting-16/JJ	appos||%-13/NN||glucose-17/NN	appos||glucose-17/NN||ifg-19/NN	num||%-23/NN||58-22/CD	prep_in||glucose-17/NN||%-23/NN	prep_in||glucose-17/NN||impairedglucosetolerance-26/NN	conj_and||%-23/NN||impairedglucosetolerance-26/NN	appos||%-23/NN||igt-28/NN	num||%-32/NN||37.5-31/CD	prep_in||glucose-17/NN||%-32/NN	impairedglucosetolerance-26||glucose-17||no_rel||glucose abnormalities were documented in 71% of patients type2diabetes in 29%, impaired fasting glucose (ifg) in 58%, and impairedglucosetolerance (igt) in 37.5%.
amod||regimens-2/NNS||bortezomib-based-1/JJ	nsubj||have-3/VBP||regimens-2/NNS	root||ROOT-0/null||have-3/VBP	amod||activities-5/NNS||significant-4/JJ	dobj||have-3/VBP||activities-5/NNS	prep_in||activities-5/NNS||multiplemyeloma-7/NN	dep||have-3/VBP||mm-9/NN	multiplemyeloma-7||bortezomib--1||yes||bortezomib-based regimens have significant activities in multiplemyeloma (mm).
mark||seems-5/VBZ||as-1/IN	amod||signalling-4/NN||a2b-2/JJ	nn||signalling-4/NN||ar-3/NN	nsubj||seems-5/VBZ||signalling-4/NN	nsubjpass||associated-8/VBN||signalling-4/NN	advcl||represent-19/VB||seems-5/VBZ	aux||associated-8/VBN||to-6/TO	auxpass||associated-8/VBN||be-7/VB	xcomp||seems-5/VBZ||associated-8/VBN	prepc_with||associated-8/VBN||pre/postconditioning-10/VBG	amod||mechanisms-14/NNS||cardioprotective-11/JJ	conj_and||cardioprotective-11/JJ||anti-inflammatory-13/JJ	amod||mechanisms-14/NNS||anti-inflammatory-13/JJ	dobj||pre/postconditioning-10/VBG||mechanisms-14/NNS	amod||agonists-17/NNS||selective-16/JJ	nsubj||represent-19/VB||agonists-17/NNS	aux||represent-19/VB||may-18/MD	root||ROOT-0/null||represent-19/VB	det||group-23/NN||a-20/DT	amod||group-23/NN||new-21/JJ	amod||group-23/NN||therapeutic-22/JJ	dobj||represent-19/VB||group-23/NN	prep_for||represent-19/VB||patients-25/NNS	vmod||patients-25/NNS||suffering-26/VBG	prep_from||suffering-26/VBG||coronaryarterydisease-28/NN	anti-inflammatory-13||ar-3||no_rel||as a2b ar signalling seems to be associated with pre/postconditioning cardioprotective and anti-inflammatory mechanisms, selective agonists may represent a new therapeutic group for patients suffering from coronaryarterydisease.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||examine-8/VB||goal-2/NN	det||study-5/NN||this-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||was-6/VBD||examine-8/VB	amod||disparities-10/NNS||racial-9/JJ	dobj||examine-8/VB||disparities-10/NNS	det||treatment-13/NN||the-12/DT	prep_in||examine-8/VB||treatment-13/NN	prep_of||treatment-13/NN||depression-15/NN	amod||medication-18/NN||antidepressant-17/JJ	prep_with||examine-8/VB||medication-18/NN	det||u.s.-22/NN||the-20/DT	amod||u.s.-22/NN||southeastern-21/JJ	prep_in||medication-18/NN||u.s.-22/NN	amod||data-24/NNS||cross-sectional-23/JJ	nsubjpass||collected-26/VBN||data-24/NNS	auxpass||collected-26/VBN||were-25/VBD	rcmod||u.s.-22/NN||collected-26/VBN	prep_at||collected-26/VBN||baseline-28/NN	num||participants-31/NNS||69,068-30/CD	prep_from||collected-26/VBN||participants-31/NNS	number||71-33/CD||-lrb--32/CD	num||%-34/NN||71-33/CD	dep||u.s.-22/NN||%-34/NN	nn||american-36/NN||african-35/NN	dep||u.s.-22/NN||american-36/NN	number||%-39/NN||60-38/CD	amod||female-40/NN||%-39/NN	appos||american-36/NN||female-40/NN	num||%-44/NN||82-43/CD	prep_in||medication-18/NN||%-44/NN	conj_and||u.s.-22/NN||%-44/NN	prep_with||%-44/NN||incomes-46/NNS	vmod||incomes-46/NNS||<-47/VBG	dobj||<-47/VBG||$-48/$	number||-rrb--50/CD||25,000-49/CD	num||$-48/$||-rrb--50/CD	dep||$-48/$||recruited-51/VBN	nn||centers-55/NNS||community-53/NN	nn||centers-55/NNS||health-54/NN	prep_from||recruited-51/VBN||centers-55/NNS	dep||$-48/$||enrolled-57/VBN	conj_and||recruited-51/VBN||enrolled-57/VBN	det||study-63/NN||the-59/DT	amod||study-63/NN||southern-60/JJ	amod||study-63/NN||cohort-61/JJ	nn||study-63/NN||community-62/NN	prep_in||enrolled-57/VBN||study-63/NN	num||sccs-65/NNS||-lrb--64/CD	npadvmod||-rrb--66/JJ||sccs-65/NNS	amod||study-63/NN||-rrb--66/JJ	antidepressant-17||cross--1||no_rel||the goal of this study was to examine racial disparities in the treatment of depression with antidepressant medication in the southeastern u.s. cross-sectional data were collected at baseline from 69,068 participants -lrb- 71 % african american , 60 % female , and 82 % with incomes < $ 25,000 -rrb- recruited from community health centers and enrolled in the southern cohort community study -lrb- sccs -rrb- .
det||effect-3/NN||the-1/DT	amod||effect-3/NN||limited-2/JJ	nsubj||led-11/VBD||effect-3/NN	amod||abscess-7/NNS||percutaneous-5/JJ	amod||abscess-7/NNS||transhepatic-6/JJ	prep_of||effect-3/NN||abscess-7/NNS	amod||abscess-7/NNS||drainage-8/JJ	amod||abscess-7/NNS||antibiotics-10/JJ	conj_and||drainage-8/JJ||antibiotics-10/JJ	root||ROOT-0/null||led-11/VBD	dobj||led-11/VBD||us-12/PRP	nsubj||perform-14/VB||us-12/PRP	aux||perform-14/VB||to-13/TO	xcomp||led-11/VBD||perform-14/VB	amod||resection-16/NN||radical-15/JJ	dobj||perform-14/VB||resection-16/NN	det||abscess-19/NNS||the-18/DT	prep_of||resection-16/NN||abscess-19/NNS	abscess-19||antibiotics-10||no_rel||the limited effect of percutaneous transhepatic abscess drainage and antibiotics led us to perform radical resection of the abscess.
num||calves-2/NNS||four-1/CD	root||ROOT-0/null||calves-2/NNS	auxpass||inoculated-5/VBN||were-3/VBD	advmod||inoculated-5/VBN||experimentally-4/RB	rcmod||calves-2/NNS||inoculated-5/VBN	advmod||pathogenic-8/JJ||highly-7/RB	amod||avianinfluenzavirus-9/NNS||pathogenic-8/JJ	prep_with||inoculated-5/VBN||avianinfluenzavirus-9/NNS	advmod||inoculated-5/VBN||a/cat/germany-10/RB	punct||calves-2/NNS||/-11/:	nsubj||isolated-16/VBD||r606/2006-12/NNS	appos||r606/2006-12/NNS||h5n1-14/NNP	dep||calves-2/NNS||isolated-16/VBD	det||cat-19/NN||a-18/DT	prep_from||isolated-16/VBD||cat-19/NN	prep_in||isolated-16/VBD||2006-21/CD	h5n1-14||avianinfluenzavirus-9||no||four calves were experimentally inoculated with highly pathogenic avianinfluenzavirus a/cat/germany/r606/2006 (h5n1) isolated from a cat in 2006.
nsubjpass||triggered-14/VBN||events-1/NNS	amod||events-1/NNS||similar-2/JJ	prep_to||similar-2/JJ||those-4/DT	vmod||those-4/DT||occurring-5/VBG	prep_in||occurring-5/VBG||er-7/NN	amod||events-12/NNS||stress-induced-10/JJ	nn||events-12/NNS||mh-11/NN	prep_in||occurring-5/VBG||events-12/NNS	conj_and||er-7/NN||events-12/NNS	auxpass||triggered-14/VBN||are-13/VBP	root||ROOT-0/null||triggered-14/VBN	prep_after||triggered-14/VBN||exposure-16/NN	prep_to||triggered-14/VBN||anestheticagents-18/NNS	amod||patients-24/NNS||mh-susceptible-20/JJ	appos||patients-24/NNS||mhs-22/NN	prep_in||anestheticagents-18/NNS||patients-24/NNS	mhs-22||anestheticagents-18||no||events similar to those occurring in er and in stress-induced mh events are triggered after exposure to anestheticagents in mh-susceptible (mhs) patients.
det||review-3/NN||this-2/DT	prep_in||summarise-6/VBP||review-3/NN	nsubj||summarise-6/VBP||we-5/PRP	root||ROOT-0/null||summarise-6/VBP	cc||critically-8/RB||and-7/CC	dep||summarise-6/VBP||critically-8/RB	ccomp||critically-8/RB||evaluate-9/VB	det||data-12/NNS||the-10/DT	amod||data-12/NNS||existing-11/VBG	dobj||evaluate-9/VB||data-12/NNS	det||link-16/NN||the-14/DT	amod||link-16/NN||possible-15/JJ	prep_on||data-12/NNS||link-16/NN	prep_between||link-16/NN||vitamind-18/NN	prep_between||link-16/NN||multiplesclerosis-20/NNS	conj_and||vitamind-18/NN||multiplesclerosis-20/NNS	prep_in||data-12/NNS||light-22/NN	det||question-26/NN||the-24/DT	amod||question-26/NN||crucial-25/JJ	prep_of||light-22/NN||question-26/NN	mark||impact-33/VB||whether-27/IN	nsubj||impact-33/VB||optimization-28/NN	amod||status-31/NN||vitamind-30/JJ	prep_of||optimization-28/NN||status-31/NN	aux||impact-33/VB||may-32/MD	ccomp||summarise-6/VBP||impact-33/VB	det||risk-35/NN||the-34/DT	dobj||impact-33/VB||risk-35/NN	vmod||risk-35/NN||and/or-36/VBG	det||course-38/NN||the-37/DT	dobj||and/or-36/VBG||course-38/NN	prep_of||course-38/NN||multiplesclerosis-40/NNS	vitamind-30||multiplesclerosis-40||no_rel||in this review, we summarise and critically evaluate the existing data on the possible link between vitamind and multiplesclerosis in light of the crucial question whether optimization of vitamind status may impact the risk and/or the course of multiplesclerosis.
det||review-2/NN||this-1/DT	nsubj||seeks-3/VBZ||review-2/NN	nsubj||synthesise-5/VB||review-2/NN	root||ROOT-0/null||seeks-3/VBZ	aux||synthesise-5/VB||to-4/TO	xcomp||seeks-3/VBZ||synthesise-5/VB	poss||data-8/NNS||our-6/PRP$	amod||data-8/NNS||new-7/JJ	dobj||synthesise-5/VB||data-8/NNS	amod||nanotubes-12/NNS||multi-walled-10/JJ	nn||nanotubes-12/NNS||carbon-11/NN	prep_with||synthesise-5/VB||nanotubes-12/NNS	appos||nanotubes-12/NNS||cnt-14/NN	det||hypothesis-18/NNS||that-17/DT	prep_with||synthesise-5/VB||hypothesis-18/NNS	det||behaviour-21/NN||the-20/DT	prep_for||hypothesis-18/NNS||behaviour-21/NN	amod||fibres-24/NNS||long-23/JJ	prep_of||behaviour-21/NN||fibres-24/NNS	det||lung-27/NN||the-26/DT	prep_in||fibres-24/NNS||lung-27/NN	poss||retention-30/NN||their-29/PRP$	prep_with||synthesise-5/VB||retention-30/NN	conj_and||hypothesis-18/NNS||retention-30/NN	det||pleura-34/NN||the-32/DT	amod||pleura-34/NN||parietal-33/JJ	prep_in||retention-30/NN||pleura-34/NN	vmod||retention-30/NN||leading-35/VBG	det||initiation-38/NN||the-37/DT	prep_to||leading-35/VBG||initiation-38/NN	nn||pathology-43/NN||inflammation-40/NN	conj_and||inflammation-40/NN||pleural-42/NN	nn||pathology-43/NN||pleural-42/NN	prep_of||initiation-38/NN||pathology-43/NN	prep_such_as||retention-30/NN||mesothelioma-46/NN	mesothelioma-46||fibres-24||no_rel||this review seeks to synthesise our new data with multi-walled carbon nanotubes (cnt) with that hypothesis for the behaviour of long fibres in the lung and their retention in the parietal pleura leading to the initiation of inflammation and pleural pathology such as mesothelioma.
det||projects-2/NNS||these-1/DT	nsubj||played-4/VBN||projects-2/NNS	aux||played-4/VBN||have-3/VBP	root||ROOT-0/null||played-4/VBN	det||role-7/NN||an-5/DT	amod||role-7/NN||important-6/JJ	dobj||played-4/VBN||role-7/NN	prepc_by||played-4/VBN||complementing-9/VBG	amod||efforts-11/NNS||national-10/JJ	dobj||complementing-9/VBG||efforts-11/NNS	det||fight-14/NN||the-13/DT	prep_in||complementing-9/VBG||fight-14/NN	prep_against||fight-14/NN||hiv/aids-16/NNS	prep_in||hiv/aids-16/NNS||china-18/NN	aids--1||hiv--1||no||these projects have played an important role by complementing national efforts in the fight against hiv/aids in china.
poss||science-3/NN||today-1/NN	nsubj||demonstrated-5/VBN||science-3/NN	aux||demonstrated-5/VBN||has-4/VBZ	root||ROOT-0/null||demonstrated-5/VBN	mark||caused-9/VBN||that-6/IN	nsubjpass||caused-9/VBN||caries-7/NNS	auxpass||caused-9/VBN||is-8/VBZ	ccomp||demonstrated-5/VBN||caused-9/VBN	amod||microorganisms-13/NNS||indigenous-11/JJ	amod||microorganisms-13/NNS||oral-12/JJ	agent||caused-9/VBN||microorganisms-13/NNS	vmod||microorganisms-13/NNS||becoming-14/VBG	det||biofilm-17/NN||a-15/DT	amod||biofilm-17/NN||dynamic-16/JJ	xcomp||becoming-14/VBG||biofilm-17/NN	nsubj||produce-26/VBP||biofilm-17/NN	det||presence-22/NN||the-21/DT	prep_in||produce-26/VBP||presence-22/NN	amod||sugars-25/NNS||fermentable-24/JJ	prep_of||presence-22/NN||sugars-25/NNS	rcmod||biofilm-17/NN||produce-26/VBP	amod||acids-28/NNS||organic-27/JJ	nsubj||capable-29/JJ||acids-28/NNS	xcomp||produce-26/VBP||capable-29/JJ	prepc_of||capable-29/JJ||dissolving-31/VBG	amod||enamel-33/NN||inorganic-32/JJ	dobj||dissolving-31/VBG||enamel-33/NN	dobj||dissolving-31/VBG||dentin-35/NN	conj_and||enamel-33/NN||dentin-35/NN	prepc_followed_by||dissolving-31/VBG||by-37/IN	det||destruction-40/NN||the-38/DT	amod||destruction-40/NN||proteolytic-39/JJ	nsubj||leaving-43/VBG||destruction-40/NN	prep_of||destruction-40/NN||collagen-42/NN	pcomp||dissolving-31/VBG||leaving-43/VBG	amod||dentin-46/NN||soft-44/JJ	amod||dentin-46/NN||infected-45/JJ	dobj||leaving-43/VBG||dentin-46/NN	collagen-42||caries-7||no_rel||today's science has demonstrated that caries is caused by indigenous oral microorganisms becoming a dynamic biofilm, that in the presence of fermentable sugars produce organic acids capable of dissolving inorganic enamel and dentin followed by the proteolytic destruction of collagen leaving soft infected dentin.
det||palsa-2/NN||the-1/DT	nsubj||provides-5/VBZ||palsa-2/NN	prep||palsa-2/NN||plus-3/CC	pobj||plus-3/CC||programme-4/NN	root||ROOT-0/null||provides-5/VBZ	dobj||provides-5/VBZ||guidelines-6/NNS	dobj||provides-5/VBZ||training-8/NN	conj_and||guidelines-6/NNS||training-8/NN	amod||nurses-16/NNS||primary-10/JJ	nn||nurses-16/NNS||health-11/NN	nn||nurses-16/NNS||care-12/NN	appos||nurses-16/NNS||phc-14/NN	prep_for||provides-5/VBZ||nurses-16/NNS	det||management-19/NN||the-18/DT	prep_in||nurses-16/NNS||management-19/NN	amod||lungdiseases-22/NNS||adult-21/JJ	prep_of||management-19/NN||lungdiseases-22/NNS	prep_of||management-19/NN||hiv/aids-24/NNS	conj_and||lungdiseases-22/NNS||hiv/aids-24/NNS	prep_including||nurses-16/NNS||art-27/NN	aids--1||hiv--1||no||the palsa plus programme provides guidelines and training for primary health care (phc) nurses in the management of adult lungdiseases and hiv/aids, including art.
root||ROOT-0/null||conclusions-1/NNS	vmod||conclusions-1/NNS||â-2/VBN	dobj||â-2/VBN||$-3/$	mark||linked-19/VBN||$-3/$	poss||conclusions-6/NNS||our-5/PRP$	nsubj||are-7/VBP||conclusions-6/NNS	rcmod||$-3/$||are-7/VBP	dep||need-12/NN||1-9/LS	det||need-12/NN||the-11/DT	nsubjpass||linked-19/VBN||need-12/NN	nn||treatment-15/NN||insulin-14/NN	prep_for||need-12/NN||treatment-15/NN	prep_in||need-12/NN||lada-17/NN	auxpass||linked-19/VBN||is-18/VBZ	ccomp||are-7/VBP||linked-19/VBN	det||degree-22/NN||the-21/DT	prep_to||linked-19/VBN||degree-22/NN	prep_of||degree-22/NN||autoimmunity-24/NN	prep_of||degree-22/NN||î-26/NN	conj_and||autoimmunity-24/NN||î-26/NN	punct||autoimmunity-24/NN||²-27/''	nn||failure-30/NN||cell-29/NN	prep_of||degree-22/NN||failure-30/NN	conj_and||autoimmunity-24/NN||failure-30/NN	dep||subjects-34/NNS||2-32/LS	appos||failure-30/NN||subjects-34/NNS	nsubj||similar-47/JJ||lada-36/NN	conj_and||lada-36/NN||type2diabetes-38/NNS	nsubj||similar-47/JJ||type2diabetes-38/NNS	det||need-41/NN||the-40/DT	prep_without||lada-36/NN||need-41/NN	nn||treatment-44/NN||insulin-43/NN	prep_for||need-41/NN||treatment-44/NN	cop||similar-47/JJ||are-45/VBP	advmod||similar-47/JJ||phenotypically-46/RB	prepc_with||subjects-34/NNS||similar-47/JJ	dep||treatment-53/NN||3-50/LS	nn||treatment-53/NN||insulin-52/NN	prep_of||degree-22/NN||treatment-53/NN	conj_and||autoimmunity-24/NN||treatment-53/NN	prep_in||treatment-53/NN||type-55/NN	num||patients-58/NNS||2-56/CD	amod||patients-58/NNS||diabetic-57/JJ	nsubjpass||associated-60/VBN||patients-58/NNS	auxpass||associated-60/VBN||is-59/VBZ	rcmod||type-55/NN||associated-60/VBN	preconj||insulinresistance-63/NN||both-62/DT	prep_with||associated-60/VBN||insulinresistance-63/NN	prep_with||associated-60/VBN||î-65/NN	conj_and||insulinresistance-63/NN||î-65/NN	dep||insufficiency-69/NN||²-66/SYM	nn||insufficiency-69/NN||cell-68/NN	dep||conclusions-1/NNS||insufficiency-69/NN	type2diabetes-38||insulin-52||yes||conclusions â€”our conclusions are that 1 ) the need for insulin treatment in lada is linked to the degree of autoimmunity and î²-cell failure, 2 ) subjects with lada and type2diabetes without the need for insulin treatment are phenotypically similar, and 3 ) insulin treatment in type 2 diabetic patients is associated with both insulinresistance and î²-cell insufficiency.
prep_in||important-39/JJ||light-2/NN	det||effectiveness-6/NN||the-4/DT	amod||effectiveness-6/NN||suboptimal-5/JJ	prep_of||light-2/NN||effectiveness-6/NN	nn||methods-11/NNS||vaccines-8/NNS	dep||methods-11/NNS||barrier-10/NN	prep_of||effectiveness-6/NN||methods-11/NNS	nn||strategies-15/NNS||behavior-13/NN	nn||strategies-15/NNS||change-14/NN	prep_of||effectiveness-6/NN||strategies-15/NNS	conj_and||methods-11/NNS||strategies-15/NNS	prep_for||effectiveness-6/NN||prevention-17/NN	prep_of||prevention-17/NN||hivinfection-19/NN	det||effects-25/NNS||the-21/DT	nn||effects-25/NNS||cost-22/NN	conj_and||cost-22/NN||side-24/NN	nn||effects-25/NNS||side-24/NN	prep_of||light-2/NN||effects-25/NNS	conj_and||effectiveness-6/NN||effects-25/NNS	amod||therapy-28/NN||antiretroviral-27/JJ	prep_of||effects-25/NNS||therapy-28/NN	appos||therapy-28/NN||art-30/NN	poss||treatment-34/NN||its-33/PRP$	prep_for||therapy-28/NN||treatment-34/NN	nsubj||important-39/JJ||it-36/PRP	nsubj||urgent-41/JJ||it-36/PRP	nsubj||develop-43/VB||it-36/PRP	nsubj||implement-45/VB||it-36/PRP	cop||important-39/JJ||is-37/VBZ	preconj||important-39/JJ||both-38/DT	root||ROOT-0/null||important-39/JJ	conj_and||important-39/JJ||urgent-41/JJ	aux||develop-43/VB||to-42/TO	xcomp||important-39/JJ||develop-43/VB	xcomp||important-39/JJ||implement-45/VB	conj_and||develop-43/VB||implement-45/VB	det||agenda-49/NN||a-46/DT	amod||agenda-49/NN||rigorous-47/JJ	nn||agenda-49/NN||research-48/NN	dobj||develop-43/VB||agenda-49/NN	aux||investigate-51/VB||to-50/TO	dep||develop-43/VB||investigate-51/VB	det||risks-54/NNS||the-52/DT	amod||risks-54/NNS||potential-53/JJ	dobj||investigate-51/VB||risks-54/NNS	dobj||investigate-51/VB||benefits-56/NNS	conj_and||risks-54/NNS||benefits-56/NNS	prep_of||risks-54/NNS||timh-58/NN	aux||identify-61/VB||to-60/TO	dep||develop-43/VB||identify-61/VB	conj_and||investigate-51/VB||identify-61/VB	poss||role-63/NN||its-62/PRP$	dobj||identify-61/VB||role-63/NN	det||management-66/NN||the-65/DT	prep_in||identify-61/VB||management-66/NN	prep_of||management-66/NN||hiv/aids-68/NNS	conj_and||investigate-51/VB||associated-70/JJ	conj_and||identify-61/VB||associated-70/JJ	dobj||associated-70/JJ||illnesses-71/NNS	prep_in||associated-70/JJ||india-73/NN	aids--1||hiv--1||no||in light of the suboptimal effectiveness of vaccines, barrier methods and behavior change strategies for prevention of hivinfection and the cost and side effects of antiretroviral therapy (art) for its treatment, it is both important and urgent to develop and implement a rigorous research agenda to investigate the potential risks and benefits of timh and to identify its role in the management of hiv/aids and associated illnesses in india.
mark||associated-5/VBN||since-1/IN	amod||inflammation-3/NN||chronic-2/JJ	nsubjpass||associated-5/VBN||inflammation-3/NN	auxpass||associated-5/VBN||is-4/VBZ	advcl||evaluated-16/VBD||associated-5/VBN	nn||remodeling-8/NN||tissue-7/NN	prep_with||associated-5/VBN||remodeling-8/NN	prep_in||remodeling-8/NN||inflammatoryboweldisease-10/NN	appos||inflammatoryboweldisease-10/NN||ibd-12/NN	nsubj||evaluated-16/VBD||we-15/PRP	root||ROOT-0/null||evaluated-16/VBD	npadvmod||timp-1-18/JJ||serum-17/NN	dobj||evaluated-16/VBD||timp-1-18/JJ	amod||levels-21/NNS||timp-4-20/JJ	dobj||evaluated-16/VBD||levels-21/NNS	conj_and||timp-1-18/JJ||levels-21/NNS	nn||patients-24/NNS||ibd-23/NN	prep_in||evaluated-16/VBD||patients-24/NNS	prep_in||evaluated-16/VBD||comparison-27/NN	amod||controls-30/NNS||healthy-29/JJ	prep_with||comparison-27/NN||controls-30/NNS	appos||controls-30/NNS||hc-32/NN	inflammation-3||hc-32||yes||since chronic inflammation is associated with tissue remodeling in inflammatoryboweldisease (ibd), we evaluated serum timp-1 and timp-4 levels in ibd patients, in comparison with healthy controls (hc).
nsubj||heparin-6/NN||enoxaparin-1/NN	cop||heparin-6/NN||is-2/VBZ	det||heparin-6/NN||the-3/DT	advmod||heparin-6/NN||only-4/RB	amod||heparin-6/NN||low-molecular-weight-5/JJ	root||ROOT-0/null||heparin-6/NN	nsubjpass||licensed-9/VBN||heparin-6/NN	auxpass||licensed-9/VBN||is-8/VBZ	rcmod||heparin-6/NN||licensed-9/VBN	det||prophylaxis-14/NNS||both-11/DT	amod||prophylaxis-14/NNS||venous-12/JJ	nn||prophylaxis-14/NNS||thromboembolism-13/NN	prep_for||licensed-9/VBN||prophylaxis-14/NNS	prep_for||licensed-9/VBN||treatment-16/NN	conj_and||prophylaxis-14/NNS||treatment-16/NN	thromboembolism-13||enoxaparin-1||yes||enoxaparin is the only low-molecular-weight heparin that is licensed for both venous thromboembolism prophylaxis and treatment.
amod||surveillance-3/NN||continued-1/VBN	amod||surveillance-3/NN||laboratory-based-2/JJ	nsubj||viruses-22/VBZ||surveillance-3/NN	det||influenza-8/NN||the-5/DT	num||influenza-8/NN||2009-6/CD	amod||influenza-8/NN||pandemic-7/JJ	prep_of||surveillance-3/NN||influenza-8/NN	det||h1n1-11/NNS||a-9/DT	nsubj||important-14/JJ||h1n1-11/NNS	cop||important-14/JJ||is-13/VBZ	parataxis||viruses-22/VBZ||important-14/JJ	mark||identify-19/VB||in-15/IN	dep||identify-19/VB||order-16/NN	aux||identify-19/VB||to-17/TO	advmod||identify-19/VB||rapidly-18/RB	advcl||important-14/JJ||identify-19/VB	nsubj||resistant-21/JJ||drug-20/NN	xcomp||identify-19/VB||resistant-21/JJ	root||ROOT-0/null||viruses-22/VBZ	amod||variants-25/NNS||and/or-23/JJ	nn||variants-25/NNS||virus-24/NN	dobj||viruses-22/VBZ||variants-25/NNS	amod||ability-28/NN||potential-27/JJ	prep_with||viruses-22/VBZ||ability-28/NN	aux||cause-30/VB||to-29/TO	vmod||viruses-22/VBZ||cause-30/VB	amod||forms-32/NNS||severe-31/JJ	dobj||cause-30/VB||forms-32/NNS	prep_of||forms-32/NNS||infection-34/NN	det||ability-37/NN||an-36/DT	prep_of||forms-32/NNS||ability-37/NN	conj_and||infection-34/NN||ability-37/NN	aux||circumvent-39/VB||to-38/TO	vmod||cause-30/VB||circumvent-39/VB	amod||immunity-41/NN||vaccine-induced-40/JJ	dobj||circumvent-39/VB||immunity-41/NN	virus-24||viruses-22||no||continued laboratory-based surveillance of the 2009 pandemic influenza a(h1n1) is important in order to rapidly identify drug resistant viruses and/or virus variants with potential ability to cause severe forms of infection and an ability to circumvent vaccine-induced immunity.
num||patients-2/NNS||twelve-1/CD	nsubj||received-6/VBD||patients-2/NNS	amod||cancers-5/NNS||gynecological-4/JJ	prep_with||patients-2/NNS||cancers-5/NNS	root||ROOT-0/null||received-6/VBD	amod||pegfilgrastim-11/NN||carboplatin/paclitaxel-7/JJ	amod||pegfilgrastim-11/NN||chemotherapy-8/JJ	conj_and||chemotherapy-8/JJ||single-dose-10/JJ	amod||pegfilgrastim-11/NN||single-dose-10/JJ	dobj||received-6/VBD||pegfilgrastim-11/NN	prep_as||received-6/VBD||prophylaxis-13/NNS	amod||neutropenia-16/NN||febrile-15/JJ	prep_of||prophylaxis-13/NNS||neutropenia-16/NN	neutropenia-16||pegfilgrastim-11||yes||twelve patients with gynecological cancers received carboplatin/paclitaxel chemotherapy and single-dose pegfilgrastim as prophylaxis of febrile neutropenia.
nsubjpass||collected-16/VBN||data-1/NNS	det||incidence-4/NN||the-3/DT	prep_on||data-1/NNS||incidence-4/NN	nn||infection-7/NN||vzv-6/NN	prep_of||incidence-4/NN||infection-7/NN	appos||infection-7/NN||chickenpox-9/NN	poss||period-14/NN||their-12/PRP$	amod||period-14/NN||undergraduate-13/JJ	prep_during||infection-7/NN||period-14/NN	auxpass||collected-16/VBN||was-15/VBD	root||ROOT-0/null||collected-16/VBN	xcomp||collected-16/VBN||using-17/VBG	det||questionnaire-21/NN||a-18/DT	amod||questionnaire-21/NN||self-administered-19/JJ	amod||questionnaire-21/NN||structured-20/JJ	dobj||using-17/VBG||questionnaire-21/NN	chickenpox-9||vzv-6||yes||data on the incidence of vzv infection (chickenpox) during their undergraduate period was collected using a self-administered structured questionnaire.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	det||study-9/NN||this-8/DT	nsubjpass||based-11/VBN||study-9/NN	auxpass||based-11/VBN||was-10/VBD	rcmod||$-6/$||based-11/VBN	det||cohort-14/NN||a-13/DT	prep_on||based-11/VBN||cohort-14/NN	num||patients-17/NNS||33,067-16/CD	prep_of||cohort-14/NN||patients-17/NNS	prep_with||based-11/VBN||type2diabetes-19/NNS	vmod||type2diabetes-19/NNS||identified-20/VBN	det||record-27/NN||the-22/DT	amod||record-27/NN||cleveland-23/JJ	nn||record-27/NN||clinic-24/NN	amod||record-27/NN||electronic-25/JJ	nn||record-27/NN||health-26/NN	prep_in||identified-20/VBN||record-27/NN	nsubjpass||prescribed-34/VBN||record-27/NN	discourse||record-27/NN||ehr-29/UH	auxpass||prescribed-34/VBN||were-32/VBD	advmod||prescribed-34/VBN||initially-33/RB	rcmod||record-27/NN||prescribed-34/VBN	det||oralhypoglycemicagent-37/NN||a-35/DT	amod||oralhypoglycemicagent-37/NN||single-36/JJ	dobj||prescribed-34/VBN||oralhypoglycemicagent-37/NN	prep_between||oralhypoglycemicagent-37/NN||1998-39/CD	prep_between||oralhypoglycemicagent-37/NN||2006-41/CD	conj_and||1998-39/CD||2006-41/CD	oralhypoglycemicagent-37||type2diabetes-19||no_rel||research design and methods â€”this study was based on a cohort of 33,067 patients with type2diabetes identified in the cleveland clinic electronic health record (ehr) who were initially prescribed a single oralhypoglycemicagent between 1998 and 2006.
aux||test-2/VB||to-1/TO	advcl||performed-21/VBN||test-2/VB	det||idea-4/NN||this-3/DT	dobj||test-2/VB||idea-4/NN	det||analysis-8/NN||a-6/DT	amod||analysis-8/NN||temporal-7/JJ	nsubjpass||performed-21/VBN||analysis-8/NN	nn||dynamics-13/NNS||embolism-10/NN	conj_and||embolism-10/NN||refilling-12/NN	nn||dynamics-13/NNS||refilling-12/NN	prep_of||analysis-8/NN||dynamics-13/NNS	nn||rate-16/NN||transpiration-15/NN	prep_of||analysis-8/NN||rate-16/NN	conj_and||dynamics-13/NNS||rate-16/NN	nn||content-19/NN||starch-18/NN	prep_of||analysis-8/NN||content-19/NN	conj_and||dynamics-13/NNS||content-19/NN	auxpass||performed-21/VBN||was-20/VBD	root||ROOT-0/null||performed-21/VBN	amod||plants-26/NNS||aba-deficient-23/JJ	amod||plants-26/NNS||mutant-24/JJ	nn||plants-26/NNS||tomato-25/NN	prep_on||performed-21/VBN||plants-26/NNS	starch-18||embolism-10||no_rel||to test this idea, a temporal analysis of embolism and refilling dynamics, transpiration rate and starch content was performed on aba-deficient mutant tomato plants.
nsubj||evolved-14/VBN||resistance-1/NN	det||falciparum-7/NN||the-3/DT	nn||falciparum-7/NN||malaria-4/NN	nn||falciparum-7/NN||parasite-5/NN	nn||falciparum-7/NN||plasmodium-6/NN	prep_of||resistance-1/NN||falciparum-7/NN	prep_to||falciparum-7/NN||sulfadoxine-pyrimethamine-9/NN	appos||resistance-1/NN||sp-11/NN	aux||evolved-14/VBN||has-13/VBZ	root||ROOT-0/null||evolved-14/VBN	advmod||evolved-14/VBN||worldwide-15/RB	malaria-4||pyrimethamine--1||yes||resistance of the malaria parasite plasmodium falciparum to sulfadoxine-pyrimethamine (sp) has evolved worldwide.
amod||type1diabetes-2/NNS||insulin-dependent-1/JJ	nsubj||autoimmunedisease-9/NN||type1diabetes-2/NNS	appos||type1diabetes-2/NNS||t1d-4/NNP	cop||autoimmunedisease-9/NN||is-6/VBZ	det||autoimmunedisease-9/NN||a-7/DT	amod||autoimmunedisease-9/NN||devastating-8/JJ	root||ROOT-0/null||autoimmunedisease-9/NN	nsubj||destroys-11/VBZ||autoimmunedisease-9/NN	nsubj||afflicts-19/VBZ||autoimmunedisease-9/NN	rcmod||autoimmunedisease-9/NN||destroys-11/VBZ	amod||cells-13/NNS||beta-12/JJ	dobj||destroys-11/VBZ||cells-13/NNS	det||islets-17/NNS||the-15/DT	amod||islets-17/NNS||pancreatic-16/JJ	prep_within||destroys-11/VBZ||islets-17/NNS	rcmod||autoimmunedisease-9/NN||afflicts-19/VBZ	conj_and||destroys-11/VBZ||afflicts-19/VBZ	number||million-22/CD||10-21/CD	num||people-23/NNS||million-22/CD	prep_over||afflicts-19/VBZ||people-23/NNS	advmod||afflicts-19/VBZ||worldwide-24/RB	type1diabetes-2||insulin--1||yes||insulin-dependent type1diabetes (t1d) is a devastating autoimmunedisease that destroys beta cells within the pancreatic islets and afflicts over 10 million people worldwide.
ccomp||herpesvirus-27/VBZ||marek-1/VB	amod||md-5/NN||sdisease-3/JJ	nsubj||disease-12/NN||md-5/NN	cop||disease-12/NN||is-7/VBZ	det||disease-12/NN||an-8/DT	advmod||important-10/JJ||economically-9/RB	amod||disease-12/NN||important-10/JJ	amod||disease-12/NN||viral-11/JJ	ccomp||marek-1/VB||disease-12/NN	prep_of||disease-12/NN||chickens-14/NNS	vmod||chickens-14/NNS||caused-15/VBN	agent||caused-15/VBN||marek-17/NN	amod||virus-20/NN||sdisease-19/JJ	dep||marek-17/NN||virus-20/NN	appos||marek-17/NN||mdv-22/NN	det||oncogenic-26/NN||an-25/DT	nsubj||herpesvirus-27/VBZ||oncogenic-26/NN	root||ROOT-0/null||herpesvirus-27/VBZ	marek'sdisease--1||herpesvirus-27||no||marek'sdisease (md) is an economically important viral disease of chickens caused by marek'sdisease virus (mdv), an oncogenic herpesvirus.
nsubj||characterize-5/VBP||perturbations-1/NNS	nn||metabolism-4/NN||lipid-3/NN	prep_in||perturbations-1/NNS||metabolism-4/NN	root||ROOT-0/null||characterize-5/VBP	dobj||characterize-5/VBP||many-6/JJ	det||diseases-10/NNS||the-8/DT	amod||diseases-10/NNS||chronic-9/JJ	prep_of||many-6/JJ||diseases-10/NNS	advmod||plaguing-12/VBG||currently-11/RB	vmod||diseases-10/NNS||plaguing-12/VBG	poss||society-14/NN||our-13/PRP$	dobj||plaguing-12/VBG||society-14/NN	prep_such_as||many-6/JJ||obesity-18/NN	prep_such_as||many-6/JJ||diabetes-20/NN	conj_and||obesity-18/NN||diabetes-20/NN	prep_such_as||many-6/JJ||cardiovasculardisease-23/NN	conj_and||obesity-18/NN||cardiovasculardisease-23/NN	obesity-18||lipid-3||no_rel||perturbations in lipid metabolism characterize many of the chronic diseases currently plaguing our society, such as obesity, diabetes, and cardiovasculardisease.
vmod||present-16/VBP||using-1/VBG	det||$-10/FW||the-2/DT	nn||$-10/FW||caenorhabditis-3/FW	nn||$-10/FW||elegans-4/FW	nn||$-10/FW||â-5/FW	nn||$-10/FW||$-6/FW	nn||$-10/FW||pseudomonasaeruginosa-8/FW	nn||$-10/FW||hostâ-9/FW	dobj||using-1/VBG||$-10/FW	iobj||using-1/VBG||$-10/FW	nn||system-13/NN||pathogen-12/NN	dep||$-10/FW||system-13/NN	nsubj||present-16/VBP||we-15/PRP	root||ROOT-0/null||present-16/VBP	amod||evidence-18/NN||genetic-17/JJ	dobj||present-16/VBP||evidence-18/NN	mark||required-72/VBN||that-19/IN	det||fat-3-24/NNS||a-20/DT	nn||fat-3-24/NNS||î-21/NN	amod||fat-3-24/NNS||6-desaturase-23/JJ	nsubjpass||required-72/VBN||fat-3-24/NNS	poss||productsâ-30/NNS||its-27/PRP$	num||productsâ-30/NNS||two-28/CD	amod||productsâ-30/NNS||18-carbon-29/JJ	prep_through||fat-3-24/NNS||productsâ-30/NNS	dep||fat-3-24/NNS||$-31/$	num||$-31/$||gamma-linolenicacid-33/CD	dep||$-31/$||gla-35/NN	appos||gla-35/NN||183n6-37/NNS	amod||acid-41/NN||stearidonic-40/JJ	dep||fat-3-24/NNS||acid-41/NN	conj_and||$-31/$||acid-41/NN	dep||acid-41/NN||sda-43/NN	appos||sda-43/NN||184n3-45/NNS	det||acid-54/NN||the-50/DT	num||pufas-52/NNS||20-carbon-51/CD	npadvmod||arachidonic-53/JJ||pufas-52/NNS	amod||acid-54/NN||arachidonic-53/JJ	dep||fat-3-24/NNS||acid-54/NN	conj_negcc||$-31/$||acid-54/NN	dep||acid-54/NN||aa-56/NN	appos||aa-56/NN||204n6-58/NNS	amod||$-69/NNS||eicosapentaenoic-61/JJ	amod||$-69/NNS||acid-62/JJ	dep||$-69/NNS||epa-64/NN	appos||epa-64/NN||205n3-66/NNS	nn||$-69/NNS||â-68/NN	conj_negcc||$-31/$||$-69/NNS	conj_and||acid-54/NN||$-69/NNS	auxpass||required-72/VBN||is-71/VBZ	ccomp||present-16/VBP||required-72/VBN	amod||immunity-76/NN||basal-74/JJ	nn||immunity-76/NN||innate-75/NN	prep_for||required-72/VBN||immunity-76/NN	prep_in||immunity-76/NN||vivo-78/NN	sda-43||carbon--1||no_rel||using the caenorhabditis elegans â€“ pseudomonasaeruginosa hostâ€“pathogen system, we present genetic evidence that a î”6-desaturase fat-3, through its two 18-carbon productsâ€”gamma-linolenicacid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)â€”is required for basal innate immunity in vivo.
amod||mesalamine-2/NN||extended-release-1/JJ	nsubj||mesalamineproduct-8/NN||mesalamine-2/NN	cop||mesalamineproduct-8/NN||is-3/VBZ	det||mesalamineproduct-8/NN||the-4/DT	amod||mesalamineproduct-8/NN||first-5/JJ	advmod||daily-7/JJ||once-6/RB	amod||mesalamineproduct-8/NN||daily-7/JJ	root||ROOT-0/null||mesalamineproduct-8/NN	vmod||mesalamineproduct-8/NN||approved-9/VBN	det||administration-15/NN||the-11/DT	nn||administration-15/NN||food-12/NN	conj_and||food-12/NN||drug-14/NN	nn||administration-15/NN||drug-14/NN	agent||approved-9/VBN||administration-15/NN	det||maintenance-18/NN||the-17/DT	prep_for||administration-15/NN||maintenance-18/NN	nn||remission-21/NN||uc-20/NN	prep_of||maintenance-18/NN||remission-21/NN	uc-20||mesalamineproduct-8||yes||extended-release mesalamine is the first once daily mesalamineproduct approved by the food and drug administration for the maintenance of uc remission.
nsubj||reported-6/VBD||none-1/NN	det||other-4/JJ||the-3/DT	prep_of||none-1/NN||other-4/JJ	advmod||reported-6/VBD||previously-5/RB	root||ROOT-0/null||reported-6/VBD	nsubjpass||associated-9/VBN||snps-7/NNS	auxpass||associated-9/VBN||were-8/VBD	ccomp||reported-6/VBD||associated-9/VBN	prep_with||associated-9/VBN||type2diabetes-11/CD	advmod||found-17/VBN||however-13/RB	nsubjpass||found-17/VBN||associations-15/NNS	auxpass||found-17/VBN||were-16/VBD	parataxis||reported-6/VBD||found-17/VBN	amod||variants-22/NNS||cdkal1-19/JJ	conj_and||cdkal1-19/JJ||hhex-21/JJ	amod||variants-22/NNS||hhex-21/JJ	prep_between||found-17/VBN||variants-22/NNS	amod||response-26/NN||acute-24/JJ	nn||response-26/NN||insulin-25/NN	prep_between||found-17/VBN||response-26/NN	conj_and||variants-22/NNS||response-26/NN	appos||response-26/NN||air-28/NN	advmod||associated-39/VBN||where-31/WRB	det||alleles-35/NNS||the-32/DT	amod||alleles-35/NNS||caucasian-33/JJ	nn||alleles-35/NNS||risk-34/NN	nsubjpass||associated-39/VBN||alleles-35/NNS	prep_for||alleles-35/NNS||type2diabetes-37/CD	auxpass||associated-39/VBN||were-38/VBD	rcmod||response-26/NN||associated-39/VBN	amod||secretion-43/NN||reduced-41/VBN	nn||secretion-43/NN||insulin-42/NN	prep_with||associated-39/VBN||secretion-43/NN	amod||indians-47/NNS||normoglycemic-45/JJ	nn||indians-47/NNS||pima-46/NN	prep_in||secretion-43/NN||indians-47/NNS	type2diabetes-37||insulin-42||yes||none of the other previously reported snps were associated with type2diabetes; however, associations were found between cdkal1 and hhex variants and acute insulin response (air), where the caucasian risk alleles for type2diabetes were associated with reduced insulin secretion in normoglycemic pima indians.
det||people-5/NNS||an-1/DT	amod||people-5/NNS||estimated-2/VBN	number||million-4/CD||150-200-3/CD	num||people-5/NNS||million-4/CD	nsubjpass||infected-8/VBN||people-5/NNS	advmod||infected-8/VBN||worldwide-6/RB	auxpass||infected-8/VBN||are-7/VBP	root||ROOT-0/null||infected-8/VBN	prep_with||infected-8/VBN||hepatitisc-10/NNP	advmod||information-14/NN||only-12/RB	amod||information-14/NN||limited-13/JJ	nsubj||hcv-22/VBP||information-14/NN	det||epidemiology-17/NN||the-16/DT	prep_about||information-14/NN||epidemiology-17/NN	amod||-lrb--21/NNS||hepatitisc-19/JJ	nn||-lrb--21/NNS||virus-20/NN	prep_of||epidemiology-17/NN||-lrb--21/NNS	rcmod||hepatitisc-10/NNP||hcv-22/VBP	amod||infection-24/NN||-rrb--23/JJ	nsubj||available-26/JJ||infection-24/NN	cop||available-26/JJ||is-25/VBZ	ccomp||hcv-22/VBP||available-26/JJ	hepatitisc-19||hepatitiscvirus--1||no||an estimated 150-200 million people worldwide are infected with hepatitisc. only limited information about the epidemiology of hepatitisc virus -lrb- hcv -rrb- infection is available .
amod||dependent-2/JJ||vitamind-1/JJ	amod||i-5/NNS||dependent-2/JJ	amod||i-5/NNS||rickets-3/JJ	nn||i-5/NNS||type-4/NN	nsubj||disorder-29/NN||i-5/NNS	appos||i-5/NNS||vddr-i-7/NNP	advmod||referred-11/VBN||also-10/RB	vmod||i-5/NNS||referred-11/VBN	advmod||vitamind-14/JJ||as-13/RB	amod||±-16/NNS||vitamind-14/JJ	amod||±-16/NNS||1î-15/JJ	prep_to||referred-11/VBN||±-16/NNS	amod||deficiency-19/NN||hydroxylase-18/JJ	dep||±-16/NNS||deficiency-19/NN	amod||rickets-23/NNS||pseudovitamind-21/JJ	nn||rickets-23/NNS||deficiency-22/NN	dep||±-16/NNS||rickets-23/NNS	conj_or||deficiency-19/NN||rickets-23/NNS	cop||disorder-29/NN||is-25/VBZ	det||disorder-29/NN||an-26/DT	amod||disorder-29/NN||autosomal-27/JJ	nn||disorder-29/NN||recessive-28/NN	root||ROOT-0/null||disorder-29/NN	vmod||disorder-29/NN||characterized-30/VBN	dep||characterized-30/VBN||clinically-31/RB	prep_by||clinically-31/RB||hypotonia-33/NN	nn||weakness-36/NN||muscle-35/NN	conj_and||disorder-29/NN||weakness-36/NN	nn||failure-39/NN||growth-38/NN	appos||weakness-36/NN||failure-39/NN	amod||seizures-42/NNS||hypocalcemic-41/JJ	conj_and||disorder-29/NN||seizures-42/NNS	amod||infancy-45/NN||early-44/JJ	prep_in||seizures-42/NNS||infancy-45/NN	amod||findings-49/NNS||radiographic-48/JJ	conj_and||disorder-29/NN||findings-49/NNS	prep_of||findings-49/NNS||rickets-51/NNS	rickets-51||vitamind-14||yes||vitamind dependent rickets type i (vddr-i), also referred to as vitamind 1î±-hydroxylase deficiency or pseudovitamind deficiency rickets, is an autosomal recessive disorder characterized clinically by hypotonia, muscle weakness, growth failure, hypocalcemic seizures in early infancy, and radiographic findings of rickets.
det||attempt-3/NN||a-1/DT	amod||attempt-3/NN||vigorous-2/JJ	nsubj||improve-20/VB||attempt-3/NN	vmod||attempt-3/NN||aiming-4/VBG	nn||clearance-7/NN||tumor-6/NN	prep_at||aiming-4/VBG||clearance-7/NN	vmod||clearance-7/NN||followed-8/VBN	amod||therapy-12/NN||adjuvant-10/JJ	amod||therapy-12/NN||multimodality-11/JJ	agent||followed-8/VBN||therapy-12/NN	det||program-18/NN||a-15/DT	nn||program-18/NN||tumor-16/NN	nn||program-18/NN||surveillance-17/NN	prep_along_with||improve-20/VB||program-18/NN	aux||improve-20/VB||may-19/MD	root||ROOT-0/null||improve-20/VB	dobj||improve-20/VB||survival-21/NN	tumor-16||adjuvant-10||no_rel||a vigorous attempt aiming at tumor clearance followed by adjuvant multimodality therapy along with a tumor surveillance program may improve survival.
nsubj||ptsd-3/VBD||considerations-1/NNS	advmod||ptsd-3/VBD||about-2/RB	root||ROOT-0/null||ptsd-3/VBD	mark||unjustified-11/VBN||as-4/IN	det||contraindication-6/NN||a-5/DT	nsubjpass||unjustified-11/VBN||contraindication-6/NN	nn||treatment-9/NN||interferon-8/NN	prep_for||contraindication-6/NN||treatment-9/NN	auxpass||unjustified-11/VBN||are-10/VBP	advcl||ptsd-3/VBD||unjustified-11/VBN	interferon-8||ptsd-3||no_rel||considerations about ptsd as a contraindication for interferon treatment are unjustified.
advmod||investigated-4/VBD||specifically-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	dep||changes-9/NNS||a-7/DT	dobj||investigated-4/VBD||changes-9/NNS	nn||flux-12/NN||glucose-11/NN	prep_in||changes-9/NNS||flux-12/NN	amod||ar-15/NN||cardiac-14/JJ	prep_via||flux-12/NN||ar-15/NN	dobj||investigated-4/VBD||sdh-17/NN	conj_and||changes-9/NNS||sdh-17/NN	det||function-20/NN||a-19/DT	prep_as||sdh-17/NN||function-20/NN	nn||duration-23/NN||diabetes-22/NN	prep_of||function-20/NN||duration-23/NN	dep||injury-29/NN||b-26/NN	amod||injury-29/NN||ischemic-28/JJ	dobj||investigated-4/VBD||injury-29/NN	conj_and||changes-9/NNS||injury-29/NN	conj_and||changes-9/NNS||function-31/NN	conj_and||injury-29/NN||function-31/NN	prep_after||injury-29/NN||ir-33/NN	dep||effect-39/NN||c-36/NN	det||effect-39/NN||the-38/DT	dobj||investigated-4/VBD||effect-39/NN	conj_and||changes-9/NNS||effect-39/NN	prep_of||effect-39/NN||inhibition-41/NN	prep_of||inhibition-41/NN||ar-43/NN	dobj||investigated-4/VBD||sdh-45/NN	conj_or||changes-9/NNS||sdh-45/NN	amod||injury-48/NN||ischemic-47/JJ	prep_on||sdh-45/NN||injury-48/NN	prep_on||sdh-45/NN||function-50/NN	conj_and||injury-48/NN||function-50/NN	glucose-11||ar-43||no_rel||specifically, we investigated, (a) changes in glucose flux via cardiac ar and sdh as a function of diabetes duration, (b) ischemic injury and function after ir, (c) the effect of inhibition of ar or sdh on ischemic injury and function.
det||increase-2/NN||an-1/DT	nsubjpass||associated-12/VBN||increase-2/NN	nsubjpass||associated-12/VBN||increase-2/NN	amod||adiposity-9/NN||total-4/JJ	conj_and||total-4/JJ||visceral-8/JJ	amod||adiposity-9/NN||visceral-8/JJ	prep_in||increase-2/NN||adiposity-9/NN	auxpass||associated-12/VBN||is-10/VBZ	advmod||associated-12/VBN||probably-11/RB	root||ROOT-0/null||associated-12/VBN	conj_negcc||associated-12/VBN||associated-12/VBN	det||decrease-15/NN||a-14/DT	prep_with||associated-12/VBN||decrease-15/NN	nn||distensibility-18/NN||vascular-17/NN	prep_in||decrease-15/NN||distensibility-18/NN	det||boys-24/NNS||the-20/DT	nn||boys-24/NNS||gujarati-21/NN	nn||boys-24/NNS||indian-22/NN	amod||boys-24/NNS||adolescent-23/JJ	prep_in||distensibility-18/NN||boys-24/NNS	prep_in||associated-12/VBN||girls-28/NNS	advmod||indicating-31/VBG||thus-30/RB	xcomp||associated-12/VBN||indicating-31/VBG	det||role-34/NN||a-32/DT	amod||role-34/NN||protective-33/JJ	dobj||indicating-31/VBG||role-34/NN	amod||estrogen-38/NN||female-36/JJ	nn||estrogen-38/NN||sexhormone-37/NN	prep_of||role-34/NN||estrogen-38/NN	nsubjpass||shown-42/VBN||estrogen-38/NN	nsubj||protect-45/VB||estrogen-38/NN	aux||shown-42/VBN||has-40/VBZ	auxpass||shown-42/VBN||been-41/VBN	rcmod||estrogen-38/NN||shown-42/VBN	advmod||shown-42/VBN||earlier-43/RBR	aux||protect-45/VB||to-44/TO	xcomp||shown-42/VBN||protect-45/VB	det||vasculature-47/NN||the-46/DT	dobj||protect-45/VB||vasculature-47/NN	prep_from||protect-45/VB||atherosclerosis-49/NNS	amod||dysfunction-52/NN||endothelial-51/JJ	appos||atherosclerosis-49/NNS||dysfunction-52/NN	nsubj||occurs-54/VBZ||dysfunction-52/NN	rcmod||dysfunction-52/NN||occurs-54/VBZ	prep_with||occurs-54/VBZ||increase-56/NN	prep_in||increase-56/NN||adiposity-58/NN	atherosclerosis-49||estrogen-38||no_rel||an increase in total as well as visceral adiposity is probably associated with a decrease in vascular distensibility in the gujarati indian adolescent boys but not in girls, thus indicating a protective role of female sexhormone estrogen which has been shown earlier to protect the vasculature from atherosclerosis, endothelial dysfunction which occurs with increase in adiposity.
advmod||recognised-9/VBN||of-1/IN	advmod||of-1/IN||late-2/RB	amod||staphylococcusaureus-5/NNS||meticillin-resistant-4/JJ	nsubjpass||recognised-9/VBN||staphylococcusaureus-5/NNS	aux||recognised-9/VBN||is-6/VBZ	advmod||recognised-9/VBN||increasingly-7/RB	auxpass||recognised-9/VBN||being-8/VBG	root||ROOT-0/null||recognised-9/VBN	det||cause-12/NN||a-11/DT	prep_as||recognised-9/VBN||cause-12/NN	amod||skin-15/NN||community-acquired-14/JJ	prep_of||cause-12/NN||skin-15/NN	prep_of||cause-12/NN||softtissueinfections-17/NNS	conj_and||skin-15/NN||softtissueinfections-17/NNS	softtissueinfections-17||meticillin--1||yes||of late, meticillin-resistant staphylococcusaureus is increasingly being recognised as a cause of community-acquired skin and softtissueinfections.
num||others-2/NNS||ten-1/CD	nsubjpass||infused-4/VBN||others-2/NNS	nsubj||maintain-29/VB||others-2/NNS	auxpass||infused-4/VBN||were-3/VBD	root||ROOT-0/null||infused-4/VBN	prep_with||infused-4/VBN||insulin-6/NN	num||units/h-9/NN||2-8/CD	appos||insulin-6/NN||units/h-9/NN	num||h-13/NN||6-12/CD	prep_for||insulin-6/NN||h-13/NN	prep_in||h-13/NN||addition-15/NN	det||injection-19/NN||the-17/DT	nn||injection-19/NN||lps-18/NN	prep_to||infused-4/VBN||injection-19/NN	num||ml/h-23/NN||100-22/CD	prep_along_with||injection-19/NN||ml/h-23/NN	number||%-26/NN||5-25/CD	amod||dextrose-27/NN||%-26/NN	prep_of||ml/h-23/NN||dextrose-27/NN	aux||maintain-29/VB||to-28/TO	xcomp||infused-4/VBN||maintain-29/VB	dobj||maintain-29/VB||normoglycemia-30/NN	dextrose-27||ten-1||no_rel||ten others were infused with insulin (2 units/h) for 6 h in addition to the lps injection along with 100 ml/h of 5% dextrose to maintain normoglycemia.
nsubj||neoplasia-11/NN||softtissuesarcoma-1/NN	appos||softtissuesarcoma-1/NN||sts-3/NN	cop||neoplasia-11/NN||is-5/VBZ	det||neoplasia-11/NN||an-6/DT	amod||neoplasia-11/NN||anatomically-7/JJ	conj_and||anatomically-7/JJ||histologically-9/JJ	amod||neoplasia-11/NN||histologically-9/JJ	amod||neoplasia-11/NN||heterogeneous-10/JJ	root||ROOT-0/null||neoplasia-11/NN	nsubj||shares-13/VBZ||neoplasia-11/NN	rcmod||neoplasia-11/NN||shares-13/VBZ	det||origin-18/NN||a-14/DT	amod||origin-18/NN||putative-15/JJ	amod||origin-18/NN||mesenchymal-16/JJ	nn||origin-18/NN||cell-17/NN	dobj||shares-13/VBZ||origin-18/NN	neoplasia-11||sts-3||no||softtissuesarcoma (sts) is an anatomically and histologically heterogeneous neoplasia that shares a putative mesenchymal cell origin.
det||mechanisms-2/NNS||the-1/DT	prep_by||modify-8/VB||mechanisms-2/NNS	nsubjpass||examined-17/VBN||mechanisms-2/NNS	nsubj||involve-20/VB||mechanisms-2/NNS	nn||intervention-6/NN||lifestyle-5/NN	nsubj||modify-8/VB||intervention-6/NN	aux||modify-8/VB||may-7/MD	rcmod||mechanisms-2/NNS||modify-8/VB	nn||secretion-10/NN||insulin-9/NN	dobj||modify-8/VB||secretion-10/NN	prep_in||modify-8/VB||type2diabetes-12/CD	aux||examined-17/VBN||have-13/VBP	advmod||examined-17/VBN||also-14/RB	neg||examined-17/VBN||not-15/RB	auxpass||examined-17/VBN||been-16/VBN	root||ROOT-0/null||examined-17/VBN	aux||involve-20/VB||may-19/MD	conj_but||examined-17/VBN||involve-20/VB	det||axis-23/NNS||the-21/DT	nn||axis-23/NNS||incretin-22/NN	dobj||involve-20/VB||axis-23/NNS	type2diabetes-12||insulin-9||yes||the mechanisms by which lifestyle intervention may modify insulin secretion in type2diabetes have also not been examined but may involve the incretin axis.
advmod||found-6/VBN||recently-1/RB	nsubjpass||found-6/VBN||dexamethasone-3/NN	nsubj||have-8/VB||dexamethasone-3/NN	aux||found-6/VBN||has-4/VBZ	auxpass||found-6/VBN||been-5/VBN	root||ROOT-0/null||found-6/VBN	aux||have-8/VB||to-7/TO	xcomp||found-6/VBN||have-8/VB	det||effect-11/NN||a-9/DT	amod||effect-11/NN||prophylactic-10/JJ	dobj||have-8/VB||effect-11/NN	amod||vomiting-14/NN||postoperative-13/JJ	prep_on||effect-11/NN||vomiting-14/NN	prep_on||effect-11/NN||pain-16/NN	conj_and||vomiting-14/NN||pain-16/NN	prep_in||effect-11/NN||children-18/NNS	vmod||children-18/NNS||undergoing-19/VBG	advmod||undergoing-19/VBG||tonsillectomy-20/RB	vomiting-14||dexamethasone-3||yes||recently, dexamethasone has been found to have a prophylactic effect on postoperative vomiting and pain in children undergoing tonsillectomy.
det||wake-3/NN||the-2/DT	prep_in||value-15/NN||wake-3/NN	det||epidemic-7/NN||the-5/DT	nn||epidemic-7/NN||hiv-6/NN	prep_of||wake-3/NN||epidemic-7/NN	amod||views-10/NNS||traditional-9/JJ	nsubj||value-15/NN||views-10/NNS	prep_of||views-10/NNS||children-12/NNS	cop||value-15/NN||'s-13/VBZ	amod||value-15/NN||social-14/JJ	root||ROOT-0/null||value-15/NN	amod||â-18/NN||domestic-17/JJ	prep_as||value-15/NN||â-18/NN	dep||value-15/NN||$-19/$	num||$-19/$||œhelpersâ-20/CD	amod||$-19/$||$-21/$	dep||$-21/$||have-22/JJ	vmod||$-19/$||evolved-23/VBN	nsubjpass||regarded-27/VBN||them-25/PRP	auxpass||regarded-27/VBN||being-26/VBG	prepc_into||evolved-23/VBN||regarded-27/VBN	amod||actors-32/NNS||capable-29/JJ	conj_and||capable-29/JJ||competent-31/JJ	amod||actors-32/NNS||competent-31/JJ	prep_as||regarded-27/VBN||actors-32/NNS	det||care-35/NN||the-34/DT	prep_in||regarded-27/VBN||care-35/NN	prep_in||regarded-27/VBN||support-37/NN	conj_and||care-35/NN||support-37/NN	prep_of||care-35/NN||people-39/NNS	vmod||people-39/NNS||living-40/VBG	prep_with||living-40/VBG||hiv-42/NN	prep_with||living-40/VBG||aids-44/NNS	conj_or||hiv-42/NN||aids-44/NNS	advmod||integral-48/JJ||as-47/RB	dep||value-15/NN||integral-48/JJ	conj_and||$-19/$||integral-48/JJ	nn||survival-51/NN||household-50/NN	prep_to||integral-48/JJ||survival-51/NN	aids-44||hiv-42||no||in the wake of the hiv epidemic, traditional views of children's social value as domestic â€œhelpersâ€? have evolved into them being regarded as capable and competent actors in the care and support of people living with hiv or aids, and as integral to household survival.
nsubj||resulted-4/VBD||treatment-1/NN	prep_with||treatment-1/NN||phenobarbital-3/NN	root||ROOT-0/null||resulted-4/VBD	amod||improvement-7/NN||substantial-6/JJ	prep_in||resulted-4/VBD||improvement-7/NN	det||number-10/NN||the-9/DT	prep_in||resulted-4/VBD||number-10/NN	nn||episodes-13/NNS||seizure-12/NN	prep_of||number-10/NN||episodes-13/NNS	advmod||continued-19/VBD||however-15/RB	amod||movement-18/NN||fine-16/JJ	amod||movement-18/NN||seizure-like-17/JJ	nsubj||continued-19/VBD||movement-18/NN	nsubj||continued-19/VBD||movement-18/NN	parataxis||resulted-4/VBD||continued-19/VBD	parataxis||resulted-4/VBD||continued-19/VBD	conj_and||continued-19/VBD||continued-19/VBD	prt||continued-19/VBD||in-20/RP	preconj||continued-19/VBD||both-21/DT	det||hands-24/NNS||the-23/DT	prep_of||continued-19/VBD||hands-24/NNS	appos||hands-24/NNS||feet-26/NNS	det||tongue-30/NN||the-29/DT	prep_in||continued-19/VBD||tongue-30/NN	det||follow-up-34/NN||the-32/DT	amod||follow-up-34/NN||five-month-33/JJ	prep_until||continued-19/VBD||follow-up-34/NN	seizure-12||phenobarbital-3||no_rel||treatment with phenobarbital resulted in substantial improvement in the number of seizure episodes, however fine seizure-like movement continued in both of the hands, feet and in the tongue until the five-month follow-up.
det||outcome-3/NN||the-1/DT	amod||outcome-3/NN||primary-2/JJ	nsubj||percentage-6/NN||outcome-3/NN	cop||percentage-6/NN||was-4/VBD	det||percentage-6/NN||the-5/DT	root||ROOT-0/null||percentage-6/NN	prep_of||percentage-6/NN||patients-8/NNS	prep_with||patients-8/NNS||vomiting-10/NN	amod||31â-17/NNS||0â-12/JJ	amod||31â-17/NNS||$-13/$	num||$-13/$||30-15/CD	prep_at||vomiting-10/NN||31â-17/NNS	dep||vomiting-10/NN||$-18/$	num||$-18/$||60-20/CD	dep||vomiting-10/NN||61â-23/NNS	conj_and||$-18/$||61â-23/NNS	num||minutes-27/NNS||$-24/$	num||$-24/$||120-26/CD	dep||61â-23/NNS||minutes-27/NNS	det||administration-30/NN||the-29/DT	prep_after||percentage-6/NN||administration-30/NN	prep_of||administration-30/NN||ondansetron-32/NN	prep_of||administration-30/NN||prochlorperazine-34/NN	conj_or||ondansetron-32/NN||prochlorperazine-34/NN	vomiting-10||prochlorperazine-34||yes||the primary outcome was the percentage of patients with vomiting at 0â€“30, 31â€“60, and 61â€“120 minutes after the administration of ondansetron or prochlorperazine.
amod||tomography-4/NN||near-infrared-1/JJ	amod||tomography-4/NN||three-dimensional-2/JJ	amod||tomography-4/NN||fluorescent-mediated-3/JJ	nsubjpass||used-6/VBN||tomography-4/NN	nsubj||image-8/VB||tomography-4/NN	nsubj||collect-14/VB||tomography-4/NN	nsubj||calculate-20/VB||tomography-4/NN	auxpass||used-6/VBN||was-5/VBD	root||ROOT-0/null||used-6/VBN	aux||image-8/VB||to-7/TO	xcomp||used-6/VBN||image-8/VB	det||model-12/NN||the-9/DT	amod||model-12/NN||ls174t-10/JJ	nn||model-12/NN||tumor-11/NN	dobj||image-8/VB||model-12/NN	xcomp||used-6/VBN||collect-14/VB	conj_and||image-8/VB||collect-14/VB	amod||data-17/NNS||antibody-alone-15/JJ	nn||data-17/NNS||pk-16/NN	dobj||collect-14/VB||data-17/NNS	xcomp||used-6/VBN||calculate-20/VB	conj_and||image-8/VB||calculate-20/VB	det||number-22/NN||the-21/DT	dobj||calculate-20/VB||number-22/NN	prep_of||number-22/NN||copies-24/NNS	amod||epitope-27/NN||ve-cad-26/JJ	prep_of||copies-24/NNS||epitope-27/NN	prep_per||epitope-27/NN||cell-29/NN	tumor-11||antibody--1||no_rel||near-infrared three-dimensional fluorescent-mediated tomography was used to image the ls174t tumor model, collect antibody-alone pk data, and calculate the number of copies of ve-cad epitope per cell.
nsubjpass||confirmed-3/VBN||tuberculosis-1/NNP	auxpass||confirmed-3/VBN||was-2/VBD	root||ROOT-0/null||confirmed-3/VBN	det||biopsy-7/NN||an-5/DT	amod||biopsy-7/NN||open-6/JJ	prep_through||confirmed-3/VBN||biopsy-7/NN	det||patient-10/NN||the-9/DT	nsubjpass||treated-12/VBN||patient-10/NN	auxpass||treated-12/VBN||was-11/VBD	conj_and||confirmed-3/VBN||treated-12/VBN	advmod||treated-12/VBN||successfully-13/RB	nn||chemotherapy-16/NN||antitubercular-15/NN	prep_with||treated-12/VBN||chemotherapy-16/NN	tuberculosis-1||antitubercular-15||yes||tuberculosis was confirmed through an open biopsy and the patient was treated successfully with antitubercular chemotherapy.
dep||mechanism-9/NN||relevant-1/JJ	det||work-4/NN||the-3/DT	prep_to||relevant-1/JJ||work-4/NN	vmod||work-4/NN||reported-5/VBN	advmod||reported-5/VBN||here-6/RB	cop||mechanism-9/NN||is-7/VBZ	det||mechanism-9/NN||the-8/DT	root||ROOT-0/null||mechanism-9/NN	det||threonine/serine-13/NN||the-11/DT	amod||threonine/serine-13/NN||plp-dependent-12/JJ	prep_of||mechanism-9/NN||threonine/serine-13/NN	nsubj||mechanism-9/NN||dehydratases-14/NNS	nsubj||generate-17/VBP||dehydratases-14/NNS	rcmod||dehydratases-14/NNS||generate-17/VBP	amod||intermediates-20/NNS||reactive-18/JJ	nn||intermediates-20/NNS||enamine/imine-19/NN	dobj||generate-17/VBP||intermediates-20/NNS	nsubjpass||converted-23/VBN||intermediates-20/NNS	auxpass||converted-23/VBN||are-22/VBP	rcmod||intermediates-20/NNS||converted-23/VBN	nn||acids-26/NNS||keto-25/NN	prep_to||converted-23/VBN||acids-26/NNS	agent||converted-23/VBN||members-28/NNS	det||family-32/NN||the-30/DT	nn||family-32/NN||rida-31/NN	prep_of||members-28/NNS||family-32/NN	prep_of||family-32/NN||enzymes-34/NNS	enzymes-34||rida-31||no_rel||relevant to the work reported here is the mechanism of the plp-dependent threonine/serine dehydratases, which generate reactive enamine/imine intermediates that are converted to keto acids by members of the rida family of enzymes.
prep_in||helpful-16/JJ||patients-2/NNS	prep_with||patients-2/NNS||bradyarrhythmia-4/NN	amod||atropine-10/NN||intravenous-6/JJ	appos||atropine-10/NN||iv-8/NN	nsubj||helpful-16/JJ||atropine-10/NN	nsubj||lead-28/VB||atropine-10/NN	num||mg-13/NNS||1-3-12/CD	appos||atropine-10/NN||mg-13/NNS	cop||helpful-16/JJ||is-15/VBZ	root||ROOT-0/null||helpful-16/JJ	number||%-22/NN||70-18/CD	dep||%-22/NN||%-19/NN	dep||%-22/NN||to-20/TO	number||%-22/NN||80-21/CD	prep_in||helpful-16/JJ||%-22/NN	nn||patients-25/NNS||acs-24/NN	prep_of||%-22/NN||patients-25/NNS	aux||lead-28/VB||will-27/MD	conj_and||helpful-16/JJ||lead-28/VB	det||increasedheartrate-31/NN||an-30/DT	prep_to||lead-28/VB||increasedheartrate-31/NN	increasedheartrate-31||atropine-10||no||in patients with bradyarrhythmia, intravenous (iv) atropine (1-3 mg) is helpful in 70% to 80% of acs patients and will lead to an increasedheartrate.
nsubj||suggests-2/VBZ||evidence-1/NN	root||ROOT-0/null||suggests-2/VBZ	mark||characterized-9/VBN||that-3/IN	det||epidemic-7/NN||the-4/DT	nn||epidemic-7/NN||mozambican-5/NN	nn||epidemic-7/NN||hiv-6/NN	nsubjpass||characterized-9/VBN||epidemic-7/NN	nsubj||hiv-41/VB||epidemic-7/NN	auxpass||characterized-9/VBN||is-8/VBZ	ccomp||suggests-2/VBZ||characterized-9/VBN	det||preponderance-12/NN||a-11/DT	agent||characterized-9/VBN||preponderance-12/NN	amod||infections-15/NNS||heterosexual-14/JJ	prep_of||preponderance-12/NN||infections-15/NNS	det||world-19/NN||the-18/DT	poss||shortages-25/NNS||world-19/NN	advmod||severe-22/JJ||most-21/RBS	amod||shortages-25/NNS||severe-22/JJ	nn||shortages-25/NNS||health-23/NN	nn||shortages-25/NNS||worker-24/NN	prep_among||preponderance-12/NN||shortages-25/NNS	advmod||poor-28/JJ||relatively-27/RB	amod||knowledge-29/NN||poor-28/JJ	prep_among||preponderance-12/NN||knowledge-29/NN	conj_and||shortages-25/NNS||knowledge-29/NN	prep_of||knowledge-29/NN||hiv/aids-31/NNS	det||population-35/NN||the-33/DT	amod||population-35/NN||general-34/JJ	prep_in||hiv/aids-31/NNS||population-35/NN	amod||access-39/NN||lagging-38/VBG	prep_among||preponderance-12/NN||access-39/NN	conj_and||shortages-25/NNS||access-39/NN	aux||hiv-41/VB||to-40/TO	xcomp||characterized-9/VBN||hiv-41/VB	amod||services-45/NNS||preventive-42/JJ	conj_and||preventive-42/JJ||therapeutic-44/JJ	amod||services-45/NNS||therapeutic-44/JJ	dobj||hiv-41/VB||services-45/NNS	prepc_compared_to||hiv-41/VB||to-47/TO	nn||nations-49/NNS||counterpart-48/NN	pobj||hiv-41/VB||nations-49/NNS	amod||africa-52/NN||southern-51/JJ	prep_in||nations-49/NNS||africa-52/NN	aids--1||hiv-41||no||evidence suggests that the mozambican hiv epidemic is characterized by a preponderance of heterosexual infections, among the world's most severe health worker shortages, relatively poor knowledge of hiv/aids in the general population, and lagging access to hiv preventive and therapeutic services compared to counterpart nations in southern africa.
nn||studies-3/NNS||virus-1/NN	nn||studies-3/NNS||neutralization-2/NN	nsubjpass||carried-5/VBN||studies-3/NNS	auxpass||carried-5/VBN||were-4/VBD	root||ROOT-0/null||carried-5/VBN	prt||carried-5/VBN||out-6/RP	num||assays-10/NNS||two-8/CD	amod||assays-10/NNS||different-9/JJ	prep_with||carried-5/VBN||assays-10/NNS	num||panels-14/NNS||two-12/CD	amod||panels-14/NNS||different-13/JJ	prep_with||carried-5/VBN||panels-14/NNS	conj_and||assays-10/NNS||panels-14/NNS	amod||viruses-18/NNS||clade-16/JJ	nn||viruses-18/NNS||c-17/NN	prep_of||panels-14/NNS||viruses-18/NNS	virus-1||viruses-18||no||virus neutralization studies were carried out with two different assays and two different panels of clade c viruses.
nsubj||study-6/NN||this-1/DT	cop||study-6/NN||is-2/VBZ	det||study-6/NN||the-3/DT	amod||study-6/NN||first-4/JJ	nn||study-6/NN||field-5/NN	root||ROOT-0/null||study-6/NN	vmod||study-6/NN||showing-7/VBG	det||role-9/NN||the-8/DT	dobj||showing-7/VBG||role-9/NN	det||albopictus-16/NN||the-11/DT	advmod||arrived-13/JJ||recently-12/RB	amod||albopictus-16/NN||arrived-13/JJ	nn||albopictus-16/NN||species-14/NN	nn||albopictus-16/NN||aedes-15/NNS	prep_of||role-9/NN||albopictus-16/NN	amod||transmission-19/NN||chikungunyavirus-18/JJ	prep_in||albopictus-16/NN||transmission-19/NN	amod||africa-22/NN||central-21/JJ	prep_in||transmission-19/NN||africa-22/NN	nsubj||demonstrates-26/VBZ||it-25/PRP	conj_and||study-6/NN||demonstrates-26/VBZ	det||species-28/NN||this-27/DT	poss||role-30/NN||species-28/NN	dobj||demonstrates-26/VBZ||role-30/NN	prepc_in||demonstrates-26/VBZ||modifying-32/VBG	det||presentation-35/NN||the-33/DT	amod||presentation-35/NN||epidemiological-34/JJ	dobj||modifying-32/VBG||presentation-35/NN	prep_of||presentation-35/NN||chikungunya-37/NN	prep_in||modifying-32/VBG||gabon-39/NN	chikungunya-37||chikungunyavirus-18||no||this is the first field study showing the role of the recently arrived species aedes albopictus in chikungunyavirus transmission in central africa, and it demonstrates this species' role in modifying the epidemiological presentation of chikungunya in gabon.
amod||patients-5/NNS||atrialfibrillation-1/JJ	amod||patients-5/NNS||af-3/JJ	nsubj||anticoagulation-14/NN||patients-5/NNS	det||risk-9/NN||a-7/DT	amod||risk-9/NN||high-8/JJ	prep_with||patients-5/NNS||risk-9/NN	prep_of||risk-9/NN||stroke-11/NN	cop||anticoagulation-14/NN||are-12/VBP	amod||anticoagulation-14/NN||recommended-13/VBN	root||ROOT-0/null||anticoagulation-14/NN	prep_with||anticoagulation-14/NN||warfarin-16/NN	stroke-11||warfarin-16||yes||atrialfibrillation (af) patients with a high risk of stroke are recommended anticoagulation with warfarin.
det||sites-2/NNS||all-1/DT	nsubj||demonstrated-3/VBD||sites-2/NNS	root||ROOT-0/null||demonstrated-3/VBD	det||fungus-6/NN||a-4/DT	amod||fungus-6/NN||zygomycete-5/JJ	dobj||demonstrated-3/VBD||fungus-6/NN	vmod||fungus-6/NN||surrounded-7/VBN	amod||material-11/NN||eosinophilic-9/JJ	nn||material-11/NN||splendori-hoeppli-10/NN	agent||surrounded-7/VBN||material-11/NN	amod||material-11/NN||consistent-12/JJ	prep_with||consistent-12/JJ||basidiobolomycosis-14/NNS	basidiobolomycosis-14||fungus-6||no||all sites demonstrated a zygomycete fungus surrounded by eosinophilic splendori-hoeppli material consistent with basidiobolomycosis.
det||status-3/NN||the-1/DT	nn||status-3/NN||methylation-2/NN	nsubjpass||evaluated-11/VBN||status-3/NN	nsubjpass||matched-34/VBN||status-3/NN	amod||m-9/NN||cst6-5/JJ	nn||m-9/NN||gene-6/NN	amod||m-9/NN||encoding-7/VBG	nn||m-9/NN||cystatin-8/NN	prep_of||status-3/NN||m-9/NN	auxpass||evaluated-11/VBN||was-10/VBD	root||ROOT-0/null||evaluated-11/VBN	ccomp||evaluated-11/VBN||using-12/VBG	amod||reaction-16/NN||methylation-specific-13/JJ	nn||reaction-16/NN||polymerase-14/NN	nn||reaction-16/NN||chain-15/NN	dobj||using-12/VBG||reaction-16/NN	appos||reaction-16/NN||pcr-18/NN	amod||tissues-23/NNS||formalin-fixed-21/JJ	amod||tissues-23/NNS||paraffin-embedded-22/JJ	prep_in||reaction-16/NN||tissues-23/NNS	amod||participants-26/NNS||292-25/JJ	prep_from||using-12/VBG||participants-26/NNS	ccomp||evaluated-11/VBN||using-28/VBG	conj_and||using-12/VBG||using-28/VBG	vmod||using-28/VBG||pyrosequencing-29/VBG	amod||tumor-32/NN||fresh-frozen-31/JJ	prep_in||pyrosequencing-29/VBG||tumor-32/NN	conj_and||evaluated-11/VBN||matched-34/VBN	amod||tissues-36/NNS||normal-35/JJ	dobj||matched-34/VBN||tissues-36/NNS	num||patients-40/NNS||51-38/CD	nn||patients-40/NNS||ibc-39/NN	prep_from||matched-34/VBN||patients-40/NNS	formalin--1||tumor-32||no_rel||the methylation status of cst6 gene encoding cystatin m was evaluated using methylation-specific polymerase chain reaction (pcr) in formalin-fixed paraffin-embedded tissues from 292 participants and using pyrosequencing in fresh-frozen tumor and matched normal tissues from 51 ibc patients.
det||results-2/NNS||the-1/DT	nsubj||showed-3/VBD||results-2/NNS	root||ROOT-0/null||showed-3/VBD	det||administration-6/NN||that-4/DT	nn||administration-6/NN||ip-5/NN	dobj||showed-3/VBD||administration-6/NN	amod||120-9/CD||bupropionhcl-8/JJ	prep_of||administration-6/NN||120-9/CD	xcomp||showed-3/VBD||mg/kg-10/VBG	amod||injection-13/NN||bolus-12/JJ	prep_by||mg/kg-10/VBG||injection-13/NN	vmod||injection-13/NN||induced-14/VBN	dobj||induced-14/VBN||convulsions-15/NNS	prep_in||induced-14/VBN||6-17/CD	num||mice-21/NNS||10-20/CD	prep_out_of||6-17/CD||mice-21/NNS	num||%-24/NN||60-23/CD	dep||mice-21/NNS||%-24/NN	amod||mice-27/NNS||convulsing-26/VBG	prep_of||%-24/NN||mice-27/NNS	prep_in||showed-3/VBD||group-30/NN	num||group-30/NN||1-31/CD	convulsions-15||bupropionhcl-8||no||the results showed that ip administration of bupropionhcl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.
nsubj||shows-2/VBZ||it-1/PRP	root||ROOT-0/null||shows-2/VBZ	mark||likely-17/JJ||that-3/IN	prep||likely-17/JJ||given-5/VBN	det||epidemiology-8/NN||the-6/DT	amod||epidemiology-8/NN||local-7/JJ	pobj||given-5/VBN||epidemiology-8/NN	det||viruses-12/NNS||the-10/DT	num||viruses-12/NNS||two-11/CD	prep_of||epidemiology-8/NN||viruses-12/NNS	amod||patients-15/NNS||co-infected-14/JJ	nsubj||likely-17/JJ||patients-15/NNS	nsubj||have-19/VB||patients-15/NNS	cop||likely-17/JJ||are-16/VBP	ccomp||shows-2/VBZ||likely-17/JJ	aux||have-19/VB||to-18/TO	xcomp||likely-17/JJ||have-19/VB	amod||levels-22/NNS||low-20/JJ	nn||levels-22/NNS||replication-21/NN	dobj||have-19/VB||levels-22/NNS	prep_of||levels-22/NNS||hbv-24/NN	vmod||hbv-24/NN||suggesting-25/VBG	det||effect-28/NN||a-26/DT	amod||effect-28/NN||suppressive-27/JJ	dobj||suggesting-25/VBG||effect-28/NN	prep_of||effect-28/NN||hcv-30/NN	prep_on||suggesting-25/VBG||hbv-32/NN	hbv-32||viruses-12||no||it shows that, given the local epidemiology of the two viruses, co-infected patients are likely to have low replication levels of hbv suggesting a suppressive effect of hcv on hbv.
amod||models-4/NNS||multiple-1/JJ	amod||models-4/NNS||logistic-2/JJ	nn||models-4/NNS||regression-3/NN	nsubjpass||used-6/VBN||models-4/NNS	nsubj||determine-8/VB||models-4/NNS	auxpass||used-6/VBN||were-5/VBD	root||ROOT-0/null||used-6/VBN	aux||determine-8/VB||to-7/TO	xcomp||used-6/VBN||determine-8/VB	nn||factors-10/NNS||risk-9/NN	dobj||determine-8/VB||factors-10/NNS	amod||stress-13/NN||psychosocial-12/JJ	prep_for||determine-8/VB||stress-13/NN	appos||stress-13/NN||demoralization-15/NN	nn||consumption-18/NN||tobacco-17/NN	appos||demoralization-15/NN||consumption-18/NN	nn||¹-22/NNP||â-20/NNP	nn||¹-22/NNP||‰-21/NNP	dep||consumption-18/NN||¹-22/NNP	num||items/day-24/NN||10-23/CD	dep||¹-22/NNP||items/day-24/NN	amod||consumption-29/NN||high-risk-27/JJ	nn||consumption-29/NN||alcohol-28/NN	appos||consumption-18/NN||consumption-29/NN	dep||consumption-29/NN||men-31/NNS	number||20-33/CD||>-32/CD	dep||men-31/NNS||20-33/CD	nn||alcohol/day-36/NN||g-34/NN	amod||alcohol/day-36/NN||pure-35/JJ	dep||20-33/CD||alcohol/day-36/NN	dep||men-31/NNS||women-38/NNS	number||10-40/CD||>-39/CD	dep||women-38/NNS||10-40/CD	nn||alcohol/day-43/NN||g-41/NN	amod||alcohol/day-43/NN||pure-42/JJ	dep||10-40/CD||alcohol/day-43/NN	appos||consumption-18/NN||binge-46/NN	vmod||binge-46/NN||drinking-47/VBG	vmod||consumption-18/NN||problemdrinking-49/VBG	prepc_according_to||problemdrinking-49/VBG||to-51/TO	pobj||problemdrinking-49/VBG||cage-52/NN	amod||intake-57/NN||regular-54/JJ	amod||intake-57/NN||medical-55/JJ	nn||intake-57/NN||drug-56/NN	pobj||problemdrinking-49/VBG||intake-57/NN	conj_and||cage-52/NN||intake-57/NN	quantmod||weekly-61/CD||at-59/IN	mwe||at-59/IN||least-60/JJS	pobj||at-59/IN||least-60/JJS	dep||consumption-18/NN||weekly-61/CD	problemdrinking-49||alcohol-28||no||multiple logistic regression models were used to determine risk factors for psychosocial stress, demoralization, tobacco consumption (â‰¹ 10 items/day), high-risk alcohol consumption (men > 20 g pure alcohol/day, women > 10 g pure alcohol/day), binge drinking, problemdrinking according to cage and regular medical drug intake (at least weekly).
root||ROOT-0/null||abreviations-1/NNS	vmod||abreviations-1/NNS||ae-2/VBN	dep||effect-5/NN||=-3/SYM	amod||effect-5/NN||adverse-4/JJ	ccomp||ae-2/VBN||effect-5/NN	dep||abreviations-1/NNS||ami-7/VBN	dep||acutemyocardialinfarction-9/NN||=-8/SYM	ccomp||ami-7/VBN||acutemyocardialinfarction-9/NN	aux||=-12/VB||ca-11/MD	parataxis||ami-7/VBN||=-12/VB	nn||antagonists-14/NNS||calcium-13/NN	dobj||=-12/VB||antagonists-14/NNS	parataxis||ami-7/VBN||chd-16/VBN	dep||coronaryheartdisease-18/NN||=-17/SYM	ccomp||chd-16/VBN||coronaryheartdisease-18/NN	parataxis||ami-7/VBN||coi-20/VBN	dep||infection-24/NN||=-21/SYM	amod||infection-24/NN||chronic-22/JJ	amod||infection-24/NN||oral-23/JJ	ccomp||coi-20/VBN||infection-24/NN	parataxis||ami-7/VBN||csa-26/VBN	dep||cyclosporine-28/NN||=-27/SYM	ccomp||csa-26/VBN||cyclosporine-28/NN	dep||cyclosporine-28/NN||a-29/DT	parataxis||ami-7/VBN||cvd-31/VBN	dep||cardio-vasculardiseases-33/NNS||=-32/SYM	ccomp||cvd-31/VBN||cardio-vasculardiseases-33/NNS	parataxis||ami-7/VBN||dm-35/VBN	dep||diabetesmellitus-37/NNS||=-36/SYM	ccomp||dm-35/VBN||diabetesmellitus-37/NNS	parataxis||ami-7/VBN||dna-39/VBN	dep||acid-42/NN||=-40/SYM	amod||acid-42/NN||deoxyribonucleic-41/JJ	ccomp||dna-39/VBN||acid-42/NN	parataxis||ami-7/VBN||gh-44/VBN	dep||hypertrophy-47/NN||=-45/SYM	amod||hypertrophy-47/NN||gingival-46/JJ	ccomp||gh-44/VBN||hypertrophy-47/NN	parataxis||ami-7/VBN||go-49/VB	dep||overgrowth-52/NN||=-50/SYM	amod||overgrowth-52/NN||gingival-51/JJ	ccomp||go-49/VB||overgrowth-52/NN	parataxis||ami-7/VBN||hs-crp-54/VBN	dep||protein-59/NN||=-55/SYM	amod||protein-59/NN||high-sensitivity-56/JJ	nn||protein-59/NN||c-57/NN	nn||protein-59/NN||reactive-58/NN	ccomp||hs-crp-54/VBN||protein-59/NN	parataxis||ami-7/VBN||il-61/VBN	dep||interleukine-63/NN||=-62/SYM	ccomp||il-61/VBN||interleukine-63/NN	parataxis||ami-7/VBN||icam-65/VB	amod||molecule-69/NN||=-66/JJ	nn||molecule-69/NN||intracellular-67/NN	nn||molecule-69/NN||adhesion-68/NN	dobj||icam-65/VB||molecule-69/NN	nsubj||organization-162/NN||molecule-69/NN	nn||â-72/NN||je/mcp-71/NN	dep||molecule-69/NN||â-72/NN	dep||â-72/NN||$-73/$	num||protein-79/NNS||1-75/CD	nn||protein-79/NNS||=-76/NNP	amod||protein-79/NNS||macrophage-77/JJ	amod||protein-79/NNS||chemotactic-78/JJ	npadvmod||forming-155/RB||protein-79/NNS	dep||protein-79/NNS||lpsâ-81/NNP	dep||lpsâ-81/NNP||$-82/$	npadvmod||of-149/RB||lipopolisaccharides-84/NNS	dep||lipopolisaccharides-84/NNS||mipâ-86/NNP	dep||mipâ-86/NNP||$-87/$	number||=-90/NN||2-89/CD	amod||macrophage-91/NNS||=-90/NN	npadvmod||inflammatory-92/RB||macrophage-91/NNS	dep||proteinâ-93/CD||inflammatory-92/RB	num||$-87/$||proteinâ-93/CD	dep||$-87/$||$-94/$	num||metalloproteinases-101/NNS||2-96/CD	dep||metalloproteinases-101/NNS||mmp-98/NNP	nn||metalloproteinases-101/NNS||=-99/NNP	nn||metalloproteinases-101/NNS||matrix-100/NN	npadvmod||=-104/RB||metalloproteinases-101/NNS	dep||metalloproteinases-101/NNS||mrna-103/NNP	dep||messengerâ-105/CD||=-104/RB	num||$-94/$||messengerâ-105/CD	dep||$-87/$||$-106/$	amod||acid-109/NN||ribonucleic-108/JJ	npadvmod||=-112/RB||acid-109/NN	dep||acid-109/NN||nos-111/NN	dep||nitricoxide-113/CD||=-112/RB	num||$-106/$||nitricoxide-113/CD	dep||$-106/$||synthase-114/NN	dep||$-106/$||paiâ-116/NNP	dep||paiâ-116/NNP||$-117/$	num||plasminogenactivator-121/NN||1-119/CD	nn||plasminogenactivator-121/NN||=-120/NNP	npadvmod||of-136/RB||plasminogenactivator-121/NN	dep||$-123/$||inhibitorâ-122/RB	dep||plasminogenactivator-121/NN||$-123/$	num||diseases-130/NNS||1-125/CD	dep||diseases-130/NNS||pd-127/NNP	nn||diseases-130/NNS||=-128/NNP	amod||diseases-130/NNS||periodontal-129/JJ	npadvmod||tissue-134/RB||diseases-130/NNS	dep||diseases-130/NNS||timp-132/NN	num||timp-132/NN||=-133/CD	dep||inhibitor-135/CD||tissue-134/RB	num||$-123/$||inhibitor-135/CD	dep||metalloproteinase-137/CD||of-136/RB	num||$-117/$||metalloproteinase-137/CD	dep||$-106/$||tnf-139/NN	dep||factor-143/NN||=-140/SYM	nn||factor-143/NN||tumor-141/NN	nn||factor-143/NN||necrosis-142/NNS	rcmod||tnf-139/NN||factor-143/NN	dep||$-106/$||usa-145/NN	dep||states-148/NNS||=-146/SYM	amod||states-148/NNS||united-147/JJ	rcmod||usa-145/NN||states-148/NNS	dep||america-150/CD||of-149/RB	num||$-82/$||america-150/CD	dep||$-82/$||ufc-152/NN	dep||units-154/NNS||=-153/SYM	rcmod||ufc-152/NN||units-154/NNS	dep||cultures-156/CD||forming-155/RB	num||$-73/$||cultures-156/CD	dep||organization-162/NN||=-159/SYM	nn||organization-162/NN||world-160/NN	nn||organization-162/NN||health-161/NN	rcmod||molecule-69/NN||organization-162/NN	tumor-141||dm-35||yes||abreviations ae = adverse effect; ami = acutemyocardialinfarction; ca = calcium antagonists; chd = coronaryheartdisease; coi = chronic oral infection; csa = cyclosporine a; cvd = cardio-vasculardiseases; dm = diabetesmellitus; dna = deoxyribonucleic acid; gh = gingival hypertrophy; go = gingival overgrowth; hs-crp = high-sensitivity c reactive protein; il = interleukine; icam = intracellular adhesion molecule; je/mcpâ€“1 = macrophage chemotactic protein; lpsâ€“ lipopolisaccharides; mipâ€“2 = macrophage inflammatory proteinâ€“2; mmp = matrix metalloproteinases; mrna = messengerâ€“ribonucleic acid; nos = nitricoxide synthase; paiâ€“1 = plasminogenactivator inhibitorâ€“1; pd = periodontal diseases; timp = tissue inhibitor of metalloproteinase; tnf = tumor necrosis factor; usa = united states of america; ufc = units forming cultures; who= world health organization.
nsubj||were-9/VBD||patients-1/NNS	vmod||patients-1/NNS||enrolled-2/VBN	det||trial-8/NN||the-4/DT	nn||trial-8/NN||asthma-5/NN	nn||trial-8/NN||intervention-6/NN	nn||trial-8/NN||research-7/NN	prep_in||enrolled-2/VBN||trial-8/NN	root||ROOT-0/null||were-9/VBD	amod||corticosteroids-12/NNS||inhaled-11/JJ	prep_on||were-9/VBD||corticosteroids-12/NNS	dep||corticosteroids-12/NNS||â-13/VBN	xcomp||â-13/VBN||‰-14/VBG	number||200-16/CD||¥-15/CD	num||+-23/NNS||200-16/CD	nn||+-23/NNS||î-17/NNP	num||+-23/NNS||1/4-18/CD	amod||+-23/NNS||g-19/JJ	amod||+-23/NNS||beclomethasone-20/JJ	conj_or||beclomethasone-20/JJ||equivalent-22/JJ	amod||+-23/NNS||equivalent-22/JJ	nsubj||long-acting-beta2-agonists-24/JJ||+-23/NNS	xcomp||‰-14/VBG||long-acting-beta2-agonists-24/JJ	dep||corticosteroids-12/NNS||demonstrated-26/VBN	conj_and||â-13/VBN||demonstrated-26/VBN	dobj||demonstrated-26/VBN||worsening-27/VBG	prep_of||worsening-27/VBG||asthma-29/NN	nn||withdrawal-34/NN||long-acting-î-31/NNP	nn||withdrawal-34/NN||²-32/NNP	amod||withdrawal-34/NN||2-agonist-33/JJ	prep_on||asthma-29/NN||withdrawal-34/NN	asthma-29||beclomethasone-20||yes||patients enrolled in the asthma intervention research trial were on inhaled corticosteroids â‰¥200 î¼g beclomethasone or equivalent + long-acting-beta2-agonists and demonstrated worsening of asthma on long-acting-î²2-agonist withdrawal.
det||pathways-3/NNS||the-1/DT	amod||pathways-3/NNS||cellular-2/JJ	nsubjpass||known-25/VBN||pathways-3/NNS	vmod||pathways-3/NNS||activated-4/VBN	amod||prionprotein-7/NN||mutant-6/JJ	agent||activated-4/VBN||prionprotein-7/NN	appos||prionprotein-7/NN||prp-9/NN	amod||priondiseases-13/NNS||genetic-12/JJ	prep_in||prionprotein-7/NN||priondiseases-13/NNS	advmod||leading-16/VBG||ultimately-15/RB	vmod||pathways-3/NNS||leading-16/VBG	amod||dysfunction-19/NN||neuronal-18/JJ	prep_to||leading-16/VBG||dysfunction-19/NN	prep_to||leading-16/VBG||degeneration-21/NN	conj_and||dysfunction-19/NN||degeneration-21/NN	auxpass||known-25/VBN||are-23/VBP	neg||known-25/VBN||not-24/RB	root||ROOT-0/null||known-25/VBN	priondiseases-13||prionprotein-7||no||the cellular pathways activated by mutant prionprotein (prp) in genetic priondiseases, ultimately leading to neuronal dysfunction and degeneration, are not known.
det||rate-6/NN||the-1/DT	amod||rate-6/NN||minimum-2/JJ	amod||rate-6/NN||estimated-3/JJ	nn||rate-6/NN||population-4/NN	nn||rate-6/NN||mortality-5/NN	nsubj||8.63-12/CD||rate-6/NN	prep_from||rate-6/NN||melioidosis-8/NNS	prep_in||melioidosis-8/NNS||2006-10/CD	cop||8.63-12/CD||was-11/VBD	root||ROOT-0/null||8.63-12/CD	num||people-15/NNS||100,000-14/CD	prep_per||8.63-12/CD||people-15/NNS	num||%-18/NN||95-17/CD	dep||people-15/NNS||%-18/NN	nn||â-22/FW||ci-19/FW	nn||â-22/FW||=-20/FW	nn||â-22/FW||7.33-21/FW	dep||%-18/NN||â-22/FW	dep||â-22/FW||$-23/$	num||$-23/$||10.11-25/CD	det||cause-32/NN||the-28/DT	amod||cause-32/NN||third-29/JJ	advmod||common-31/JJ||most-30/RBS	amod||cause-32/NN||common-31/JJ	appos||people-15/NNS||cause-32/NN	prep_of||cause-32/NN||death-34/NN	amod||diseases-37/NNS||infectious-36/JJ	prep_from||death-34/NN||diseases-37/NNS	prep_in||diseases-37/NNS||northeast-39/NN	vmod||northeast-39/NN||thailand-40/VBN	prep_after||thailand-40/VBN||humanimmunodeficiencyvirus-42/NNS	discourse||humanimmunodeficiencyvirus-42/NNS||hiv-44/UH	punct||aids-49/NNS||/-46/:	amod||aids-49/NNS||acquiredimmunodeficiencysyndrome-47/JJ	dep||humanimmunodeficiencyvirus-42/NNS||aids-49/NNS	dep||humanimmunodeficiencyvirus-42/NNS||tuberculosis-52/NNP	conj_and||aids-49/NNS||tuberculosis-52/NNP	aids-49||hiv-44||no||the minimum estimated population mortality rate from melioidosis in 2006 was 8.63 per 100,000 people (95% ci = 7.33â€“10.11), the third most common cause of death from infectious diseases in northeast thailand after humanimmunodeficiencyvirus (hiv)/acquiredimmunodeficiencysyndrome (aids) and tuberculosis.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||aripiprazole-66||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
prepc_in||vital-9/JJ||developing-2/VBG	amod||programmes-5/NNS||home-based-3/JJ	nn||programmes-5/NNS||care-4/NN	dobj||developing-2/VBG||programmes-5/NNS	nsubj||vital-9/JJ||it-7/PRP	nsubj||consider-11/VB||it-7/PRP	cop||vital-9/JJ||is-8/VBZ	root||ROOT-0/null||vital-9/JJ	aux||consider-11/VB||to-10/TO	xcomp||vital-9/JJ||consider-11/VB	det||needs-14/NNS||the-12/DT	amod||needs-14/NNS||perceived-13/VBN	dobj||consider-11/VB||needs-14/NNS	prep_of||needs-14/NNS||persons-16/NNS	vmod||persons-16/NNS||living-17/VBG	prep_with||living-17/VBG||hiv/aids-19/NNS	poss||caregivers-24/NNS||their-21/PRP$	amod||caregivers-24/NNS||direct-22/JJ	amod||caregivers-24/NNS||informal-23/JJ	prep_with||living-17/VBG||caregivers-24/NNS	conj_and||hiv/aids-19/NNS||caregivers-24/NNS	aids--1||hiv--1||no||in developing home-based care programmes, it is vital to consider the perceived needs of persons living with hiv/aids and their direct informal caregivers.
amod||studies-2/NNS||immunogenicity-1/JJ	nsubj||revealed-3/VBD||studies-2/NNS	root||ROOT-0/null||revealed-3/VBD	mark||mediated-23/VBD||that-4/IN	det||viruses-7/NNS||both-5/DT	amod||viruses-7/NNS||recombinant-6/JJ	nsubj||mediated-23/VBD||viruses-7/NNS	dep||viruses-7/NNS||elicited-8/VBN	xcomp||elicited-8/VBN||neutralizing-9/VBG	dobj||neutralizing-9/VBG||antibodies-10/NNS	det||virus-14/NN||the-12/DT	nn||virus-14/NN||yf-13/NN	prep_to||neutralizing-9/VBG||virus-14/NN	dep||viruses-7/NNS||generated-18/VBN	conj_and||elicited-8/VBN||generated-18/VBN	det||interferon-22/NN||an-19/DT	amod||interferon-22/NN||antigen-specific-20/JJ	nn||interferon-22/NN||gamma-21/NN	dobj||elicited-8/VBN||interferon-22/NN	ccomp||revealed-3/VBD||mediated-23/VBD	amod||response-25/NN||t-cell-24/JJ	dobj||mediated-23/VBD||response-25/NN	amod||mice-28/NNS||immunized-27/JJ	prep_in||mediated-23/VBD||mice-28/NNS	virus-14||viruses-7||no||immunogenicity studies revealed that both recombinant viruses elicited neutralizing antibodies to the yf virus as well as generated an antigen-specific gamma interferon mediated t-cell response in immunized mice.
nsubj||binds-5/VBZ||hemagglutinin-1/NN	prep_of||hemagglutinin-1/NN||avianinfluenzaviruses-3/NNS	advmod||binds-5/VBZ||preferentially-4/RB	root||ROOT-0/null||binds-5/VBZ	amod||acids-8/NNS||sialic-7/JJ	prep_to||binds-5/VBZ||acids-8/NNS	vmod||acids-8/NNS||linked-9/VBN	aux||galactose-11/VB||to-10/TO	xcomp||linked-9/VBN||galactose-11/VB	det||linkage-17/NN||an-13/DT	nn||linkage-17/NN||î-14/NNP	nn||linkage-17/NN||±-15/NNP	amod||linkage-17/NN||-2,3-16/JJ	prep_by||galactose-11/VB||linkage-17/NN	mark||binds-22/VBZ||whereas-18/IN	nsubj||binds-22/VBZ||hemagglutinin-19/NN	prep_of||hemagglutinin-19/NN||humaninfluenzaviruses-21/NNS	advcl||galactose-11/VB||binds-22/VBZ	amod||acids-25/NNS||sialic-24/JJ	prep_to||binds-22/VBZ||acids-25/NNS	det||linkage-31/NN||an-27/DT	nn||linkage-31/NN||î-28/NNP	nn||linkage-31/NN||±-29/NNP	amod||linkage-31/NN||-2,6-30/JJ	prep_with||binds-22/VBZ||linkage-31/NN	avianinfluenza--1||influenzaviruses--1||no||hemagglutinin of avianinfluenzaviruses preferentially binds to sialic acids linked to galactose by an î±-2,3 linkage whereas hemagglutinin of humaninfluenzaviruses binds to sialic acids with an î±-2,6 linkage.
dep||identified-18/VBD||correlating-1/VBG	amod||imaging-5/NN||high-speed-2/JJ	amod||imaging-5/NN||x-ray-3/JJ	amod||imaging-5/NN||cinematographic-4/JJ	dobj||correlating-1/VBG||imaging-5/NN	prepc_of||imaging-5/NN||singing-7/VBG	nn||finches-9/NNS||zebra-8/NN	dobj||singing-7/VBG||finches-9/NNS	nn||guttata-12/NN||taeniopygia-11/NN	appos||finches-9/NNS||guttata-12/NN	nn||structures-16/NNS||song-15/NN	prep_to||singing-7/VBG||structures-16/NNS	nsubj||identified-18/VBD||we-17/PRP	root||ROOT-0/null||identified-18/VBD	nn||gape-20/NN||beak-19/NN	dobj||identified-18/VBD||gape-20/NN	det||expansion-23/NN||the-22/DT	dobj||identified-18/VBD||expansion-23/NN	conj_and||gape-20/NN||expansion-23/NN	det||cavity-27/NN||the-25/DT	amod||cavity-27/NN||oropharyngeal-esophageal-26/JJ	prep_of||expansion-23/NN||cavity-27/NN	appos||cavity-27/NN||oec-29/NN	amod||articulators-33/NNS||potential-32/JJ	prep_as||identified-18/VBD||articulators-33/NNS	speed--1||cavity-27||no_rel||correlating high-speed x-ray cinematographic imaging of singing zebra finches ( taeniopygia guttata ) to song structures we identified beak gape and the expansion of the oropharyngeal-esophageal cavity (oec) as potential articulators.
det||protein-17/NN||the-1/DT	amod||gp160-7/NNS||humanimmunodeficiencyvirus-2/JJ	amod||gp160-7/NNS||type-1-3/JJ	amod||gp160-7/NNS||hiv-1-5/JJ	nn||protein-17/NN||gp160-7/NNS	amod||complex-10/NN||gp120-gp41-9/JJ	appos||gp160-7/NNS||complex-10/NN	amod||protein-17/NN||trimer-12/JJ	nn||protein-17/NN||envelope-13/FW	appos||protein-17/NN||env-15/NN	nsubj||candidate-22/NN||protein-17/NN	cop||candidate-22/NN||is-18/VBZ	det||candidate-22/NN||a-19/DT	amod||candidate-22/NN||potential-20/JJ	nn||candidate-22/NN||vaccine-21/NN	root||ROOT-0/null||candidate-22/NN	prep_for||candidate-22/NN||hiv/aids-24/NNS	aids--1||humanimmunodeficiencyvirus-2||no||the humanimmunodeficiencyvirus type-1 (hiv-1) gp160 (gp120-gp41 complex) trimer envelope (env) protein is a potential vaccine candidate for hiv/aids.
det||standard-3/NN||the-1/DT	amod||standard-3/NN||current-2/JJ	nsubj||chemotherapy-12/NN||standard-3/NN	prep_of||standard-3/NN||care-5/NN	amod||carcinoma-9/NN||metastatic-7/JJ	amod||carcinoma-9/NN||urothelial-8/JJ	prep_for||care-5/NN||carcinoma-9/NN	cop||chemotherapy-12/NN||is-10/VBZ	amod||chemotherapy-12/NN||cisplatin-based-11/JJ	root||ROOT-0/null||chemotherapy-12/NN	nsubj||curative-18/JJ||treatment-14/NN	cop||curative-18/JJ||is-15/VBZ	advmod||curative-18/JJ||generally-16/RB	neg||curative-18/JJ||not-17/RB	conj_but||chemotherapy-12/NN||curative-18/JJ	carcinoma-9||cisplatin--1||no_rel||the current standard of care for metastatic urothelial carcinoma is cisplatin-based chemotherapy but treatment is generally not curative.
amod||women-2/NNS||pregnant-1/JJ	nsubjpass||asked-29/VBN||women-2/NNS	nsubj||participate-31/VB||women-2/NNS	vmod||women-2/NNS||aged-3/VBN	npadvmod||aged-3/VBN||18-4/CD	npadvmod||aged-3/VBN||over-6/IN	conj_and||18-4/CD||over-6/IN	preconj||diabetesmellitustype1-9/CD||either-8/CC	prep_with||aged-3/VBN||diabetesmellitustype1-9/CD	prep_with||aged-3/VBN||2-11/CD	conj_or||diabetesmellitustype1-9/CD||2-11/CD	nn||therapy-14/NN||insulin-13/NN	prep_on||diabetesmellitustype1-9/CD||therapy-14/NN	amod||diabetes-18/NN||gestational-17/JJ	prep_with||aged-3/VBN||diabetes-18/NN	conj_or||diabetesmellitustype1-9/CD||diabetes-18/NN	vmod||diabetes-18/NN||requiring-19/VBG	nn||therapy-21/NN||insulin-20/NN	dobj||requiring-19/VBG||therapy-21/NN	num||weeks-24/NNS||30-23/CD	prep_before||requiring-19/VBG||weeks-24/NNS	prep_of||weeks-24/NNS||gestation-26/NN	aux||asked-29/VBN||will-27/MD	auxpass||asked-29/VBN||be-28/VB	root||ROOT-0/null||asked-29/VBN	aux||participate-31/VB||to-30/TO	xcomp||asked-29/VBN||participate-31/VB	diabetesmellitustype1-9||insulin-20||yes||pregnant women aged 18 and over with either diabetesmellitustype1 or 2 on insulin therapy or with gestational diabetes requiring insulin therapy before 30 weeks of gestation will be asked to participate.
nsubj||â-9/VBP||chikungunyafever-1/NN	vmod||chikungunyafever-1/NN||caused-3/VBN	agent||caused-3/VBN||â-5/NN	amod||â-5/NN||$-6/$	dep||$-6/$||œchikungunyavirus-7/JJ	root||ROOT-0/null||â-9/VBP	nsubj||disease-14/NN||$-10/NNP	cop||disease-14/NN||is-11/VBZ	det||disease-14/NN||an-12/DT	amod||disease-14/NN||arbovirus-13/JJ	ccomp||â-9/VBP||disease-14/NN	vmod||disease-14/NN||transmitted-15/VBN	det||bite-18/NN||the-17/DT	agent||transmitted-15/VBN||bite-18/NN	amod||mosquitoes-21/NNS||infected-20/JJ	prep_of||bite-18/NN||mosquitoes-21/NNS	vmod||mosquitoes-21/NNS||belonging-22/VBG	det||aedes-26/NNS||the-24/DT	amod||aedes-26/NNS||genus-25/JJ	prep_to||belonging-22/VBG||aedes-26/NNS	chikungunyafever-1||chikungunyavirus--1||no||chikungunyafever, caused by â€œchikungunyavirus,â€? is an arbovirus disease transmitted by the bite of infected mosquitoes belonging to the genus aedes .
amod||titres-3/NNS||bcg-specific-1/JJ	nn||titres-3/NNS||igg-2/NN	nsubj||high-6/JJ||titres-3/NNS	cop||high-6/JJ||were-4/VBD	advmod||high-6/JJ||particularly-5/RB	root||ROOT-0/null||high-6/JJ	prep_among||high-6/JJ||patients-8/NNS	vmod||patients-8/NNS||coinfected-9/VBN	prep_with||coinfected-9/VBN||tb-11/FW	prep_with||coinfected-9/VBN||hiv-13/FW	conj_and||tb-11/FW||hiv-13/FW	amod||$-16/NNS||cd4â-15/JJ	prep_with||coinfected-9/VBN||$-16/NNS	amod||counts-19/NNS||t-cell-18/JJ	nsubj||<-20/VBP||counts-19/NNS	parataxis||high-6/JJ||<-20/VBP	amod||cells/ml-24/NN||200â-21/JJ	amod||cells/ml-24/NN||$-22/$	dobj||<-20/VBP||cells/ml-24/NN	nsubj||produced-26/VBD||cells/ml-24/NN	rcmod||cells/ml-24/NN||produced-26/VBD	amod||levels-28/NNS||low-27/JJ	dobj||produced-26/VBD||levels-28/NNS	prep_of||levels-28/NNS||mycobacteriumtuberculosis-30/NNS	amod||ifnî-33/NNS||specific-32/JJ	dep||mycobacteriumtuberculosis-30/NNS||ifnî-33/NNS	punct||mycobacteriumtuberculosis-30/NNS||³-34/''	prep_in||produced-26/VBD||vitro-36/NN	tb-11||mycobacteriumtuberculosis-30||no||bcg-specific igg titres were particularly high among patients coinfected with tb and hiv with cd4â€…t-cell counts <200â€…cells/ml who produced low levels of mycobacteriumtuberculosis -specific ifnî³ in vitro.
det||community-3/NN||the-1/DT	amod||community-3/NN||international-2/JJ	nsubj||agrees-4/VBZ||community-3/NN	root||ROOT-0/null||agrees-4/VBZ	mark||achieved-13/VBN||that-5/IN	det||goals-9/NNS||the-6/DT	amod||goals-9/NNS||millennium-7/JJ	nn||goals-9/NNS||development-8/NN	nsubjpass||achieved-13/VBN||goals-9/NNS	nsubj||hiv/aids-29/VBZ||goals-9/NNS	aux||achieved-13/VBN||will-10/MD	neg||achieved-13/VBN||not-11/RB	auxpass||achieved-13/VBN||be-12/VB	ccomp||agrees-4/VBZ||achieved-13/VBN	prepc_without||achieved-13/VBN||ensuring-15/VBG	amod||access-17/NN||universal-16/JJ	dobj||ensuring-15/VBG||access-17/NN	preconj||sexual-20/JJ||both-19/DT	prep_to||ensuring-15/VBG||sexual-20/JJ	amod||services-27/NNS||reproductive-22/JJ	nn||services-27/NNS||health-23/NN	nn||services-27/NNS||srh-25/NN	prep_to||ensuring-15/VBG||services-27/NNS	conj_and||sexual-20/JJ||services-27/NNS	ccomp||agrees-4/VBZ||hiv/aids-29/VBZ	conj_and||achieved-13/VBN||hiv/aids-29/VBZ	dobj||hiv/aids-29/VBZ||prevention-30/NN	dobj||hiv/aids-29/VBZ||treatment-32/NN	conj_and||prevention-30/NN||treatment-32/NN	dobj||hiv/aids-29/VBZ||care-34/NN	conj_and||prevention-30/NN||care-34/NN	dobj||hiv/aids-29/VBZ||support-36/NN	conj_and||prevention-30/NN||support-36/NN	aids--1||hiv--1||no||the international community agrees that the millennium development goals will not be achieved without ensuring universal access to both sexual and reproductive health (srh) services and hiv/aids prevention, treatment, care and support.
vmod||reduce-21/VBP||known-1/VBN	nn||virus-4/NN||ovineprogressivepneumonia-3/NN	prep_as||known-1/VBN||virus-4/NN	appos||virus-4/NN||oppv-6/NNP	det||u.s.-10/NN||the-9/DT	prep_in||known-1/VBN||u.s.-10/NN	prep_in||known-1/VBN||visna/maedivirus-13/NNS	conj_and||u.s.-10/NN||visna/maedivirus-13/NNS	appos||u.s.-10/NN||vmv-15/NN	advmod||known-1/VBN||elsewhere-17/RB	det||viruses-20/NNS||these-19/DT	nsubj||reduce-21/VBP||viruses-20/NNS	root||ROOT-0/null||reduce-21/VBP	det||$-24/$||an-22/DT	amod||$-24/$||animalâ-23/JJ	nsubj||health-27/NN||$-24/$	num||$-24/$||™-25/CD	cop||health-27/NN||s-26/VBZ	ccomp||reduce-21/VBP||health-27/NN	ccomp||reduce-21/VBP||productivity-29/NN	conj_and||health-27/NN||productivity-29/NN	ccomp||reduce-21/VBP||lifespan-32/NN	conj_and||health-27/NN||lifespan-32/NN	ovineprogressivepneumonia-3||visna/maedivirus-13||no||known as ovineprogressivepneumonia virus (oppv) in the u.s., and visna/maedivirus (vmv) elsewhere, these viruses reduce an animalâ€™s health, productivity, and lifespan.
det||53-2/CD||a-1/DT	dep||developed-12/VBD||53-2/CD	amod||lady-5/NN||year-old-4/JJ	nsubj||developed-12/VBD||lady-5/NN	prep_on||lady-5/NN||chloroquine-7/NN	prep_for||chloroquine-7/NN||treatment-9/NN	prep_of||treatment-9/NN||rheumatoidarthritis-11/NNS	root||ROOT-0/null||developed-12/VBD	dobj||developed-12/VBD||decrease-13/NN	prep_in||developed-12/VBD||vision-15/NN	num||months-17/NNS||36-16/CD	dep||vision-15/NN||months-17/NNS	prep_after||developed-12/VBD||initiation-19/NN	det||treatment-22/NN||the-21/DT	prep_of||initiation-19/NN||treatment-22/NN	rheumatoidarthritis-11||chloroquine-7||yes||a 53- year-old lady on chloroquine for treatment of rheumatoidarthritis developed decrease in vision 36 months after initiation of the treatment.
det||trial-6/NN||a-2/DT	amod||trial-6/NN||randomized-3/JJ	amod||trial-6/NN||double-blind-5/JJ	prep_in||collected-10/VBN||trial-6/NN	nsubjpass||collected-10/VBN||faeces-8/NNS	nsubj||irritablebowelsyndrome-27/JJ||faeces-8/NNS	auxpass||collected-10/VBN||were-9/VBD	root||ROOT-0/null||collected-10/VBN	amod||volunteers-13/NNS||healthy-12/JJ	prep_from||collected-10/VBN||volunteers-13/NNS	prep_from||collected-10/VBN||patients-17/NNS	conj_and||volunteers-13/NNS||patients-17/NNS	amod||cd-20/NN||active-19/JJ	prep_with||patients-17/NNS||cd-20/NN	appos||cd-20/NN||ulcerativecolitis-22/NNS	appos||ulcerativecolitis-22/NNS||uc-24/NN	conj_and||collected-10/VBN||irritablebowelsyndrome-27/JJ	conj_and||collected-10/VBN||irritablebowelsyndrome-27/JJ	conj_and||irritablebowelsyndrome-27/JJ||irritablebowelsyndrome-27/JJ	prep_after||irritablebowelsyndrome-27/JJ||treatment-31/NN	prep_before||irritablebowelsyndrome-27/JJ||treatment-31/NN	uc-24||cd-20||no_rel||in a randomized, double-blind trial, faeces were collected from healthy volunteers, and from patients with active cd, ulcerativecolitis (uc) and irritablebowelsyndrome before and after treatment.
nsubjpass||presented-3/VBN||evidence-1/NN	auxpass||presented-3/VBN||is-2/VBZ	root||ROOT-0/null||presented-3/VBN	mark||involves-7/VBZ||that-4/IN	amod||stress-6/NN||oxidative-5/JJ	nsubj||involves-7/VBZ||stress-6/NN	ccomp||presented-3/VBN||involves-7/VBZ	det||development-9/NN||the-8/DT	dobj||involves-7/VBZ||development-9/NN	det||subset-13/NN||an-11/DT	amod||subset-13/NN||aggressive-12/JJ	prep_of||development-9/NN||subset-13/NN	amod||breasttumours-18/NNS||primary-15/JJ	amod||breasttumours-18/NNS||oestrogen-16/JJ	amod||breasttumours-18/NNS||receptor-positive-17/JJ	prep_of||subset-13/NN||breasttumours-18/NNS	breasttumours-18||oestrogen-16||no||evidence is presented that oxidative stress involves the development of an aggressive subset of primary oestrogen receptor-positive breasttumours.
nsubjpass||used-10/VBN||ampicillin-1/NN	conj_and||ampicillin-1/NN||co-trimoxazole-3/NN	nsubjpass||used-10/VBN||co-trimoxazole-3/NN	conj_and||ampicillin-1/NN||ciprofloxacin-6/NN	nsubjpass||used-10/VBN||ciprofloxacin-6/NN	aux||used-10/VBN||should-7/MD	neg||used-10/VBN||not-8/RB	auxpass||used-10/VBN||be-9/VB	root||ROOT-0/null||used-10/VBN	amod||treatment-13/NN||empiric-12/JJ	prep_as||used-10/VBN||treatment-13/NN	prep_for||treatment-13/NN||uti-15/NN	det||context-18/NN||this-17/DT	prep_in||used-10/VBN||context-18/NN	uti-15||ampicillin-1||yes||ampicillin, co-trimoxazole, and ciprofloxacin should not be used as empiric treatment for uti in this context.
poss||results-2/NNS||our-1/PRP$	nsubj||demonstrated-3/VBD||results-2/NNS	root||ROOT-0/null||demonstrated-3/VBD	mark||required-7/VBN||that-4/IN	nsubjpass||required-7/VBN||tpx-5/NN	auxpass||required-7/VBN||is-6/VBZ	ccomp||demonstrated-3/VBD||required-7/VBN	prep_for||required-7/VBN||m.tuberculosis-9/NNS	aux||deal-11/VB||to-10/TO	ccomp||required-7/VBN||deal-11/VB	amod||stresses-16/NNS||oxidative-13/JJ	conj_and||oxidative-13/JJ||nitrosative-15/JJ	amod||stresses-16/NNS||nitrosative-15/JJ	prep_with||deal-11/VB||stresses-16/NNS	aux||survive-19/VB||to-18/TO	ccomp||required-7/VBN||survive-19/VB	conj_and||deal-11/VB||survive-19/VB	prep_in||survive-19/VB||macrophages-21/NNS	aux||establish-24/VB||to-23/TO	ccomp||required-7/VBN||establish-24/VB	conj_and||deal-11/VB||establish-24/VB	amod||infections-28/NNS||acute-25/JJ	conj_and||acute-25/JJ||persistent-27/JJ	amod||infections-28/NNS||persistent-27/JJ	dobj||establish-24/VB||infections-28/NNS	nn||models-32/NNS||animal-30/NN	nn||models-32/NNS||tuberculosis-31/NN	prep_in||infections-28/NNS||models-32/NNS	tuberculosis-31||m.tuberculosis-9||no||our results demonstrated that tpx is required for m.tuberculosis to deal with oxidative and nitrosative stresses , to survive in macrophages and to establish acute and persistent infections in animal tuberculosis models .
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||safety-4/NN||the-3/DT	dobj||compare-2/VB||safety-4/NN	dobj||compare-2/VB||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	amod||ointment-10/NN||loteprednoletabonate-8/JJ	amod||ointment-10/NN||ophthalmic-9/JJ	prep_of||safety-4/NN||ointment-10/NN	number||%-12/NN||0.5-11/CD	amod||ointment-10/NN||%-12/NN	amod||ointment-15/NN||le-14/JJ	appos||ointment-10/NN||ointment-15/NN	det||formulation-22/NN||a-18/DT	amod||formulation-22/NN||new-19/JJ	amod||formulation-22/NN||topical-20/JJ	nn||formulation-22/NN||ointment-21/NN	appos||ointment-10/NN||formulation-22/NN	prep_with||compare-2/VB||vehicle-25/NN	det||treatment-28/NN||the-27/DT	prep_for||vehicle-25/NN||treatment-28/NN	prep_of||treatment-28/NN||inflammation-30/NN	prep_of||treatment-28/NN||pain-32/NN	conj_and||inflammation-30/NN||pain-32/NN	nn||surgery-35/NN||cataract-34/NN	prep_following||vehicle-25/NN||surgery-35/NN	vehicle-25||inflammation-30||no_rel||to compare the safety and efficacy of loteprednoletabonate ophthalmic ointment 0.5% (le ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.
nsubjpass||affected-5/VBN||cows-1/NNS	nsubjpass||hypothyroid-12/VBN||cows-1/NNS	auxpass||affected-5/VBN||were-4/VBD	rcmod||cows-1/NNS||affected-5/VBN	amod||liver-9/NN||severe-7/JJ	amod||liver-9/NN||fatty-8/JJ	prep_with||affected-5/VBN||liver-9/NN	auxpass||hypothyroid-12/VBN||were-11/VBD	root||ROOT-0/null||hypothyroid-12/VBN	prep_prior_to||hypothyroid-12/VBN||development-15/NN	det||condition-18/NN||the-17/DT	prep_of||development-15/NN||condition-18/NN	acomp||hypothyroid-12/VBN||due-19/JJ	amod||concentrations-23/NNS||lower-21/JJR	amod||concentrations-23/NNS||t4-22/JJ	prep_to||due-19/JJ||concentrations-23/NNS	acomp||hypothyroid-12/VBN||had-26/VBD	conj_and||due-19/JJ||had-26/VBD	advmod||lower-28/JJR||significantly-27/RB	amod||concentration-29/NN||lower-28/JJR	dobj||had-26/VBD||concentration-29/NN	prep_of||concentration-29/NN||t3-31/NNS	amod||ratios-35/NNS||higher-33/JJR	amod||ratios-35/NNS||t3/t4-34/JJ	prep_of||concentration-29/NN||ratios-35/NNS	conj_and||t3-31/NNS||ratios-35/NNS	prep_than||had-26/VBD||cows-37/NNS	amod||liver-43/NN||mild-39/JJ	conj_and||mild-39/JJ||moderate-41/JJ	amod||liver-43/NN||moderate-41/JJ	nn||liver-43/NN||fatty-42/NN	prep_with||cows-37/NNS||liver-43/NN	hypothyroid-12||t3-31||yes||cows, that were affected with severe fatty liver, were hypothyroid prior to development of the condition due to lower t4 concentrations, and had significantly lower concentration of t3 and higher t3/t4 ratios than cows with mild and moderate fatty liver.
expl||discussion-5/NN||there-1/EX	aux||discussion-5/NN||has-2/VBZ	cop||discussion-5/NN||been-3/VBN	amod||discussion-5/NN||little-4/JJ	root||ROOT-0/null||discussion-5/NN	det||importance-8/NN||the-7/DT	prep_about||discussion-5/NN||importance-8/NN	amod||management-11/NN||oral-10/JJ	prep_of||importance-8/NN||management-11/NN	amod||therapy-17/NN||interferon-13/JJ	appos||therapy-17/NN||ifn-15/NN	prep_about||discussion-5/NN||therapy-17/NN	conj_and||importance-8/NN||therapy-17/NN	mark||documented-31/VBN||although-19/IN	nsubjpass||documented-31/VBN||management-20/NN	det||effects-24/NNS||the-22/DT	nn||effects-24/NNS||side-23/NN	prep_of||management-20/NN||effects-24/NNS	prep_of||effects-24/NNS||therapy-26/NN	prep_for||therapy-26/NN||chronichepatitisc-28/NN	aux||documented-31/VBN||has-29/VBZ	auxpass||documented-31/VBN||been-30/VBN	advcl||discussion-5/NN||documented-31/VBN	chronichepatitisc-28||interferon-13||yes||there has been little discussion about the importance of oral management and interferon (ifn) therapy, although management of the side effects of therapy for chronichepatitisc has been documented.
det||findings-2/NNS||these-1/DT	nsubj||include-5/VB||findings-2/NNS	aux||include-5/VB||do-3/VBP	neg||include-5/VB||not-4/RB	root||ROOT-0/null||include-5/VB	amod||arc-8/NN||aids-relatedcomplex-6/JJ	dobj||include-5/VB||arc-8/NN	amod||manifestations-12/NNS||other-11/JJ	dobj||include-5/VB||manifestations-12/NNS	conj_or||arc-8/NN||manifestations-12/NNS	nn||infection-18/NN||humanimmunodeficiencyvirus-14/NNP	appos||infection-18/NN||hiv-16/NN	prep_of||manifestations-12/NNS||infection-18/NN	arc-8||humanimmunodeficiencyvirus-14||no||these findings do not include aids-relatedcomplex (arc) or other manifestations of humanimmunodeficiencyvirus (hiv) infection.
nsubj||active-9/JJ||combinations-1/NNS	prep_of||combinations-1/NNS||capecitabine-3/NN	det||taxane-6/NN||a-5/DT	prep_of||combinations-1/NNS||taxane-6/NN	conj_and||capecitabine-3/NN||taxane-6/NN	cop||active-9/JJ||are-7/VBP	advmod||active-9/JJ||highly-8/RB	root||ROOT-0/null||active-9/JJ	amod||cancer-13/NN||metastatic-11/JJ	nn||cancer-13/NN||breast-12/NN	prep_in||active-9/JJ||cancer-13/NN	nsubjpass||demonstrated-24/VBN||synergy-16/NN	prep_between||synergy-16/NN||capecitabine-18/NN	prep_between||synergy-16/NN||docetaxel-20/NN	conj_and||capecitabine-18/NN||docetaxel-20/NN	aux||demonstrated-24/VBN||has-21/VBZ	advmod||demonstrated-24/VBN||also-22/RB	auxpass||demonstrated-24/VBN||been-23/VBN	conj_and||active-9/JJ||demonstrated-24/VBN	cancer-13||capecitabine-18||no_rel||combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between capecitabine and docetaxel has also been demonstrated.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||study-15/NN||this-8/DT	cop||study-15/NN||was-9/VBD	det||study-15/NN||a-10/DT	amod||study-15/NN||randomized-11/VBN	amod||study-15/NN||double-blind-12/JJ	nn||study-15/NN||crossover-13/NN	nn||study-15/NN||pilot-14/NN	rcmod||$-6/$||study-15/NN	dep||study-15/NN||placebo-17/NN	num||terbutaline-21/NN||2.5-19/CD	nn||terbutaline-21/NN||mg-20/NN	dep||study-15/NN||terbutaline-21/NN	conj_and||placebo-17/NN||terbutaline-21/NN	num||terbutaline-26/NN||5.0-24/CD	nn||terbutaline-26/NN||mg-25/NN	dep||study-15/NN||terbutaline-26/NN	conj_and||placebo-17/NN||terbutaline-26/NN	num||patients-30/NNS||15-29/CD	prep_in||study-15/NN||patients-30/NNS	prep_with||patients-30/NNS||type1diabetes-32/CD	terbutaline-26||type1diabetes-32||no_rel||research design and methods â€”this was a randomized double-blind crossover pilot study (placebo, 2.5 mg terbutaline, and 5.0 mg terbutaline) in 15 patients with type1diabetes.
prep_conclusionsâ||demonstrated-7/VBN||$-2/$	det||study-5/NN||this-4/DT	nsubj||demonstrated-7/VBN||study-5/NN	aux||demonstrated-7/VBN||has-6/VBZ	root||ROOT-0/null||demonstrated-7/VBN	mark||amplify-16/VB||that-8/IN	amod||administration-10/NN||6-week-9/JJ	nsubj||amplify-16/VB||administration-10/NN	det||fluoxetine-14/NN||the-12/DT	amod||fluoxetine-14/NN||ssri-13/JJ	prep_of||administration-10/NN||fluoxetine-14/NN	aux||amplify-16/VB||can-15/MD	ccomp||demonstrated-7/VBN||amplify-16/VB	nn||mechanisms-21/NNS||ans-17/NN	conj_and||ans-17/NN||metabolic-19/JJ	nn||mechanisms-21/NNS||metabolic-19/JJ	nn||mechanisms-21/NNS||counterregulatory-20/NN	dobj||amplify-16/VB||mechanisms-21/NNS	amod||hypoglycemia-24/NN||moderate-23/JJ	prep_during||amplify-16/VB||hypoglycemia-24/NN	prep_in||hypoglycemia-24/NN||patients-26/NNS	prep_with||patients-26/NNS||type1diabetes-28/CD	ssri-13||hypoglycemia-24||no_rel||conclusionsâ€” this study has demonstrated that 6-week administration of the ssri fluoxetine can amplify ans and metabolic counterregulatory mechanisms during moderate hypoglycemia in patients with type1diabetes.
aux||determine-2/VB||to-1/TO	advcl||fed-25/VBN||determine-2/VB	dobj||determine-2/VB||effects-3/NNS	prep_of||effects-3/NNS||irondeficiency-5/NN	nn||activation-8/NN||ampk-7/NN	prep_on||irondeficiency-5/NN||activation-8/NN	prep_on||irondeficiency-5/NN||signaling-10/NN	conj_and||activation-8/NN||signaling-10/NN	det||composition-18/NN||the-15/DT	nn||composition-18/NN||ampk-16/NN	nn||composition-18/NN||subunit-17/NN	prep_of||effects-3/NNS||composition-18/NN	conj_and||irondeficiency-5/NN||composition-18/NN	amod||muscle-21/NN||skeletal-20/JJ	prep_in||composition-18/NN||muscle-21/NN	nsubjpass||fed-25/VBN||rats-23/NNS	auxpass||fed-25/VBN||were-24/VBD	root||ROOT-0/null||fed-25/VBN	det||control-27/NN||a-26/DT	dobj||fed-25/VBN||control-27/NN	iobj||fed-25/VBN||control-27/NN	dep||control-27/NN||c-29/SYM	dep||fe-33/FW||=-30/SYM	amod||fe-33/FW||50-58-31/JJ	nn||fe-33/FW||mg/kg-32/FW	rcmod||c-29/SYM||fe-33/FW	nn||deficient-37/NN||iron-36/NN	dobj||fed-25/VBN||deficient-37/NN	iobj||fed-25/VBN||deficient-37/NN	conj_or||control-27/NN||deficient-37/NN	dep||control-27/NN||id-39/VBN	dep||fe-43/FW||=-40/SYM	amod||fe-43/FW||2-6-41/JJ	nn||fe-43/FW||mg/kg-42/FW	ccomp||id-39/VBN||fe-43/FW	dep||control-27/NN||diet-45/NN	amod||wks-51/NN||6â-47/JJ	amod||wks-51/NN||$-48/$	num||$-48/$||8-50/CD	prep_for||diet-45/NN||wks-51/NN	irondeficiency-5||fe-43||yes||to determine effects of irondeficiency on ampk activation and signaling, as well as the ampk subunit composition in skeletal muscle, rats were fed a control (c=50-58 mg/kg fe) or iron deficient (id=2-6 mg/kg fe) diet for 6â€“8 wks.
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	diabeticretinopathy-40||speed-30||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
amod||trials-2/NNS||many-1/JJ	nsubjpass||performed-5/VBN||trials-2/NNS	aux||performed-5/VBN||have-3/VBP	auxpass||performed-5/VBN||been-4/VBN	root||ROOT-0/null||performed-5/VBN	det||decade-9/NN||the-7/DT	amod||decade-9/NN||last-8/JJ	prep_over||performed-5/VBN||decade-9/NN	ccomp||performed-5/VBN||using-10/VBG	dobj||using-10/VBG||bendamustine-11/NN	neg||only-13/RB||not-12/RB	dep||using-10/VBG||only-13/RB	dep||only-13/RB||as-14/IN	conj||using-10/VBG||monotherapy-15/VBG	cc||in-19/IN||but-17/CC	dep||in-19/IN||also-18/RB	dep||monotherapy-15/VBG||in-19/IN	pobj||in-19/IN||combination-20/NN	amod||agents-23/NNS||other-22/JJ	prep_with||combination-20/NN||agents-23/NNS	amod||fludarabine-31/JJ||rituximab-25/JJ	amod||fludarabine-31/JJ||vincristine-27/JJ	amod||fludarabine-31/JJ||mitoxantrone-29/JJ	prep_including||agents-23/NNS||fludarabine-31/JJ	amod||agents-35/NNS||other-34/JJ	prep_including||agents-23/NNS||agents-35/NNS	conj_and||fludarabine-31/JJ||agents-35/NNS	prep_as||agents-35/NNS||therapy-37/NN	prep_for||therapy-37/NN||patients-39/NNS	amod||non-hodgkinâ-42/NNS||relapsed-41/JJ	prep_with||patients-39/NNS||non-hodgkinâ-42/NNS	dobj||monotherapy-15/VBG||$-43/$	num||$-43/$||™-44/CD	nsubj||lymphomas-46/VBZ||s-45/PRP	nsubjpass||approved-51/VBN||s-45/PRP	rcmod||$-43/$||lymphomas-46/VBZ	advmod||approved-51/VBN||recently-49/RB	auxpass||approved-51/VBN||was-50/VBD	rcmod||$-43/$||approved-51/VBN	conj_and||lymphomas-46/VBZ||approved-51/VBN	prep_for||approved-51/VBN||use-53/NN	prep_in||use-53/NN||therapy-55/NN	prep_of||therapy-55/NN||patients-57/NNS	amod||lymphomas-61/NNS||relapsed-59/JJ	nn||lymphomas-61/NNS||indolent-60/NN	prep_with||approved-51/VBN||lymphomas-61/NNS	vmod||lymphomas-61/NNS||considered-62/VBN	dobj||considered-62/VBN||refractory-63/JJ	amod||therapy-66/NN||rituximab-65/JJ	prep_to||considered-62/VBN||therapy-66/NN	hodgkin--1||vincristine-27||yes||many trials have been performed over the last decade using bendamustine not only as monotherapy, but also in combination with other agents including rituximab, vincristine, mitoxantrone, fludarabine, and other agents as therapy for patients with relapsed non-hodgkinâ€™s lymphomas, and recently was approved for use in therapy of patients with relapsed indolent lymphomas considered refractory to rituximab therapy.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	dobj||used-2/VBD||2000â-3/NNS	prep||2000â-3/NNS||$-4/$	advmod||data-7/NNS||2004-6/RB	dep||¥-28/CD||data-7/NNS	det||supplement-10/NN||the-9/DT	prep_from||data-7/NNS||supplement-10/NN	nn||project-17/NN||hiv/aids-12/NNS	nn||project-17/NN||surveillance-13/NN	nn||project-17/NN||shas-15/NN	prep_to||data-7/NNS||project-17/NN	det||project-22/NN||a-19/DT	amod||project-22/NN||cross-sectional-20/JJ	nn||project-22/NN||interview-21/NN	appos||project-17/NN||project-22/NN	amod||‰-27/NNS||hiv-infected-24/JJ	nn||‰-27/NNS||persons-25/NNS	nn||‰-27/NNS||â-26/NN	prep_of||project-22/NN||‰-27/NNS	num||$-4/$||¥-28/CD	num||years-30/NNS||18-29/CD	dep||$-4/$||years-30/NNS	vmod||years-30/NNS||conducted-31/VBN	num||states-34/NNS||18-33/CD	prep_in||conducted-31/VBN||states-34/NNS	aids--1||hiv--1||no||we used 2000â€“2004 data from the supplement to hiv/aids surveillance (shas) project, a cross-sectional interview project of hiv-infected persons â‰¥18 years conducted in 18 states.
nsubj||sought-3/VBD||we-1/PRP	nsubj||evaluate-6/VB||we-1/PRP	advmod||sought-3/VBD||therefore-2/RB	root||ROOT-0/null||sought-3/VBD	aux||evaluate-6/VB||to-4/TO	advmod||evaluate-6/VB||retrospectively-5/RB	xcomp||sought-3/VBD||evaluate-6/VB	poss||influence-8/NN||their-7/PRP$	dobj||evaluate-6/VB||influence-8/NN	prep_on||evaluate-6/VB||outcomes-10/NNS	amod||patients-16/NNS||relapsed-12/JJ	amod||patients-16/NNS||and/or-13/JJ	amod||patients-16/NNS||refractory-14/JJ	nn||patients-16/NNS||myeloma-15/NN	prep_in||evaluate-6/VB||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	prep_with||treated-17/VBN||bortezomib-19/NN	prep_with||treated-17/VBN||bortezomib-21/NN	conj_or||bortezomib-19/NN||bortezomib-21/NN	amod||doxorubicin-25/NN||pegylated-23/JJ	amod||doxorubicin-25/NN||liposomal-24/JJ	prep_with||treated-17/VBN||doxorubicin-25/NN	appos||doxorubicin-25/NN||pld-27/NN	myeloma-15||bortezomib-21||yes||we therefore sought to retrospectively evaluate their influence on outcomes in relapsed and/or refractory myeloma patients treated with bortezomib or bortezomib with pegylated liposomal doxorubicin (pld).
nsubjpass||effective-3/JJ||leflunomide-1/NN	nsubjpass||tolerated-6/VBN||leflunomide-1/NN	auxpass||effective-3/JJ||is-2/VBZ	cop||effective-3/JJ||is-2/VBZ	ccomp||scarce-26/JJ||effective-3/JJ	advmod||tolerated-6/VBN||well-5/RB	conj_and||effective-3/JJ||tolerated-6/VBN	ccomp||scarce-26/JJ||tolerated-6/VBN	det||treatment-9/NN||the-8/DT	prep_in||tolerated-6/VBN||treatment-9/NN	prep_of||treatment-9/NN||rheumatoidarthritis-11/NNS	appos||rheumatoidarthritis-11/NNS||ra-13/NN	advmod||effective-3/JJ||however-16/RB	nsubj||scarce-26/JJ||data-18/NNS	poss||use-21/NN||its-20/PRP$	prep_on||data-18/NNS||use-21/NN	amod||ra-24/NN||early-23/JJ	prep_in||use-21/NN||ra-24/NN	cop||scarce-26/JJ||are-25/VBP	root||ROOT-0/null||scarce-26/JJ	rheumatoidarthritis-11||leflunomide-1||yes||leflunomide is effective and well tolerated in the treatment of rheumatoidarthritis (ra), however, data on its use in early ra are scarce.
advmod||gained-5/VBN||also-1/RB	nsubj||gained-5/VBN||nicotinicacid-3/NN	aux||gained-5/VBN||has-4/VBZ	root||ROOT-0/null||gained-5/VBN	amod||interest-7/NN||more-6/JJR	dobj||gained-5/VBN||interest-7/NN	advmod||gained-5/VBN||partly-8/RB	mark||demonstrated-13/VBN||because-9/IN	amod||studies-11/NNS||recent-10/JJ	nsubj||demonstrated-13/VBN||studies-11/NNS	aux||demonstrated-13/VBN||have-12/VBP	advcl||gained-5/VBN||demonstrated-13/VBN	amod||effects-15/NNS||positive-14/JJ	dobj||demonstrated-13/VBN||effects-15/NNS	amod||development-18/NN||atherosclerosis-17/JJ	prep_on||demonstrated-13/VBN||development-18/NN	advmod||seems-27/VBZ||partly-20/RB	mark||seems-27/VBZ||because-21/IN	det||effect-24/NN||the-22/DT	nn||effect-24/NN||side-23/NN	nsubj||seems-27/VBZ||effect-24/NN	nsubj||avoidable-31/JJ||effect-24/NN	prep_of||effect-24/NN||flushing-26/NN	advcl||gained-5/VBN||seems-27/VBZ	conj_and||demonstrated-13/VBN||seems-27/VBZ	aux||avoidable-31/JJ||to-28/TO	cop||avoidable-31/JJ||be-29/VB	advmod||avoidable-31/JJ||partially-30/RB	xcomp||seems-27/VBZ||avoidable-31/JJ	det||administration-35/NN||the-33/DT	amod||administration-35/NN||concomitant-34/JJ	prep_with||avoidable-31/JJ||administration-35/NN	prep_of||administration-35/NN||laropiprant-37/NN	atherosclerosis-17||nicotinicacid-3||yes||also, nicotinicacid has gained more interest partly because recent studies have demonstrated positive effects on atherosclerosis development and partly because the side effect of flushing seems to be partially avoidable with the concomitant administration of laropiprant.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type2diabetes-52||insulin-46||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
nsubj||accounted-23/VBD||questions-1/NNS	vmod||questions-1/NNS||related-2/VBN	prep_to||related-2/VBN||co-morbidities-4/NNS	prep_in||co-morbidities-4/NNS||hiv/aids-6/NNS	amod||cancers-10/NNS||non-aids-8/JJ	amod||cancers-10/NNS||related-9/JJ	dep||hiv/aids-6/NNS||cancers-10/NNS	amod||diseases-13/NNS||systemic-12/JJ	dep||hiv/aids-6/NNS||diseases-13/NNS	conj_and||cancers-10/NNS||diseases-13/NNS	amod||toxicities-19/NNS||chronic-16/JJ	amod||toxicities-19/NNS||antiretroviral-17/JJ	nn||toxicities-19/NNS||treatment-18/NN	prep_in||co-morbidities-4/NNS||toxicities-19/NNS	conj_and||hiv/aids-6/NNS||toxicities-19/NNS	dep||hiv/aids-6/NNS||metabolicdisorders-21/NNS	root||ROOT-0/null||accounted-23/VBD	advmod||lower-26/JJR||significantly-25/RB	amod||scores-27/NNS||lower-26/JJR	prep_for||accounted-23/VBD||scores-27/NNS	dep||scores-27/NNS||mean-29/NN	num||%-32/NN||41.7-31/CD	appos||mean-29/NN||%-32/NN	num||%-35/NN||95-34/CD	npadvmod||ci-36/RB||%-35/NN	advmod||mean-29/NN||ci-36/RB	num||%-38/NN||39.3-37/CD	dep||mean-29/NN||%-38/NN	quantmod||$-40/$||â-39/RB	num||%-43/NN||$-40/$	num||$-40/$||44-42/CD	dep||%-38/NN||%-43/NN	prepc_compared_to||accounted-23/VBD||to-46/TO	nn||epidemiology-48/NN||hiv/aids-47/NNS	pobj||accounted-23/VBD||epidemiology-48/NN	pobj||accounted-23/VBD||prevention-50/NN	conj_and||epidemiology-48/NN||prevention-50/NN	dep||epidemiology-48/NN||mean-52/VB	num||%-55/NN||65.7-54/CD	nsubj||$-63/VBG||%-55/NN	number||%-58/NN||95-57/CD	amod||ci-59/NN||%-58/NN	appos||%-55/NN||ci-59/NN	num||%-61/NN||63.7-60/CD	npadvmod||â-62/RB||%-61/NN	advmod||$-63/VBG||â-62/RB	ccomp||mean-52/VB||$-63/VBG	num||%-66/NN||67.7-65/CD	dobj||$-63/VBG||%-66/NN	aids--1||hiv--1||no||questions related to co-morbidities in hiv/aids (non-aids related cancers and systemic diseases) and chronic antiretroviral treatment toxicities (metabolicdisorders) accounted for significantly lower scores (mean, 41.7%, 95% ci 39.3%â€“44%) compared to hiv/aids epidemiology and prevention (mean, 65.7%, 95% ci 63.7%â€“67.7%).
vmod||identified-20/VBN||guided-1/VBN	nn||analysis-6/NN||gene-3/NN	nn||analysis-6/NN||expression-4/NN	nn||analysis-6/NN||array-5/NN	nsubj||interrogating-11/VBG||analysis-6/NN	det||screen-10/NN||a-8/DT	amod||screen-10/NN||phenotypic-9/JJ	conj_and||analysis-6/NN||screen-10/NN	nsubj||interrogating-11/VBG||screen-10/NN	agent||guided-1/VBN||interrogating-11/VBG	det||collection-13/NN||a-12/DT	dobj||interrogating-11/VBG||collection-13/NN	amod||derivatives-16/NNS||3,7-diamino-phenothiazinium-15/JJ	prep_of||collection-13/NN||derivatives-16/NNS	nsubj||identified-20/VBN||we-18/PRP	aux||identified-20/VBN||have-19/VBP	root||ROOT-0/null||identified-20/VBN	det||methyleneblue-23/NN||the-21/DT	amod||methyleneblue-23/NN||redox-drug-22/JJ	dobj||identified-20/VBN||methyleneblue-23/NN	appos||methyleneblue-23/NN||mb-25/NN	vmod||methyleneblue-23/NN||used-28/VBN	dep||used-28/VBN||clinically-29/RB	det||treatment-33/NN||the-31/DT	amod||treatment-33/NN||infusional-32/JJ	prep_for||clinically-29/RB||treatment-33/NN	prep_of||treatment-33/NN||methemoglobinemia-35/NN	det||modulator-40/NN||a-38/DT	amod||modulator-40/NN||negative-39/JJ	prep_as||identified-20/VBN||modulator-40/NN	nn||expression-46/NN||heat-42/NN	nn||expression-46/NN||shock-43/NN	nn||expression-46/NN||response-44/NN	nn||expression-46/NN||gene-45/NN	prep_of||modulator-40/NN||expression-46/NN	amod||cells-51/NNS||human-48/JJ	amod||cells-51/NNS||metastatic-49/JJ	nn||cells-51/NNS||melanoma-50/NN	prep_in||expression-46/NN||cells-51/NNS	methemoglobinemia-35||methyleneblue-23||no||guided by gene expression array analysis and a phenotypic screen interrogating a collection of 3,7-diamino-phenothiazinium derivatives, we have identified the redox-drug methyleneblue (mb), used clinically for the infusional treatment of methemoglobinemia, as a negative modulator of heat shock response gene expression in human metastatic melanoma cells.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||produce-18/VB||whether-3/IN	ccomp||investigate-2/VB||not-5/RB	conj_or||produce-18/VB||not-5/RB	nsubj||produce-18/VB||coadministration-6/NN	prep_of||coadministration-6/NN||tacrolimus-8/NNS	appos||tacrolimus-8/NNS||tac-10/NN	prep_with||tacrolimus-8/NNS||prednisolone-13/NN	appos||prednisolone-13/NN||psl-15/NN	aux||produce-18/VB||can-17/MD	ccomp||investigate-2/VB||produce-18/VB	det||effect-21/NN||a-19/DT	amod||effect-21/NN||beneficial-20/JJ	dobj||produce-18/VB||effect-21/NN	det||treatment-24/NN||the-23/DT	prep_in||produce-18/VB||treatment-24/NN	amod||dermatomyositis-28/NNS||polymyositis-26/JJ	amod||dermatomyositis-28/NNS||/-27/JJ	prep_of||treatment-24/NN||dermatomyositis-28/NNS	appos||dermatomyositis-28/NNS||pm/dm-30/NNP	tacrolimus-8||polymyositis-26||no_rel||to investigate whether or not coadministration of tacrolimus (tac) with prednisolone (psl) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (pm/dm).
mark||lowered-6/VBD||as-1/IN	amod||over-expression-3/NN||hepatic-2/JJ	nsubj||lowered-6/VBD||over-expression-3/NN	prep_of||over-expression-3/NN||cry-5/NN	advcl||suggest-21/VBP||lowered-6/VBD	amod||concentrations-8/NNS||bloodglucose-7/JJ	dobj||lowered-6/VBD||concentrations-8/NNS	amod||sensitivity-12/NN||improved-10/VBN	nn||sensitivity-12/NN||insulin-11/NN	dobj||lowered-6/VBD||sensitivity-12/NN	conj_and||concentrations-8/NNS||sensitivity-12/NN	nn||mice-17/NNS||insulin-14/NN	amod||mice-17/NNS||resistant-15/JJ	nn||mice-17/NNS||db/db-16/NN	prep_in||sensitivity-12/NN||mice-17/NNS	poss||results-20/NNS||our-19/PRP$	nsubj||suggest-21/VBP||results-20/NNS	root||ROOT-0/null||suggest-21/VBP	mark||provide-29/VB||that-22/IN	nsubj||enhance-25/VB||compounds-23/NNS	nsubj||provide-29/VB||compounds-23/NNS	rcmod||compounds-23/NNS||enhance-25/VB	nn||activity-27/NN||cry-26/NN	dobj||enhance-25/VB||activity-27/NN	aux||provide-29/VB||may-28/MD	ccomp||suggest-21/VBP||provide-29/VB	amod||benefit-31/NN||therapeutic-30/JJ	dobj||provide-29/VB||benefit-31/NN	prep_to||provide-29/VB||individuals-33/NNS	prep_with||individuals-33/NNS||typeiidiabetes-35/NNS	typeiidiabetes-35||insulin-14||yes||as hepatic over-expression of cry lowered bloodglucose concentrations and improved insulin sensitivity in insulin resistant db/db mice, our results suggest that compounds which enhance cry activity may provide therapeutic benefit to individuals with typeiidiabetes.
det||themes-2/NNS||the-1/DT	nsubj||included-11/VBD||themes-2/NNS	vmod||themes-2/NNS||emerging-3/VBG	det||discussions-8/NNS||the-5/DT	nn||discussions-8/NNS||focus-6/NN	nn||discussions-8/NNS||group-7/NN	prep_from||emerging-3/VBG||discussions-8/NNS	prep_from||emerging-3/VBG||interviews-10/NNS	conj_and||discussions-8/NNS||interviews-10/NNS	root||ROOT-0/null||included-11/VBD	num||factors-16/NNS||four-12/CD	amod||factors-16/NNS||main-13/JJ	amod||factors-16/NNS||suggested-14/JJ	nn||factors-16/NNS||barrier-15/NN	dobj||included-11/VBD||factors-16/NNS	dep||fears-20/NNS||1-18/LS	dep||factors-16/NNS||fears-20/NNS	prep_of||fears-20/NNS||hiv/aids-22/NNS	amod||coinfection-25/NN||tb-hiv-24/JJ	prep_of||fears-20/NNS||coinfection-25/NN	conj_and||hiv/aids-22/NNS||coinfection-25/NN	prep_of||fears-20/NNS||death-27/NN	conj_and||hiv/aids-22/NNS||death-27/NN	prep_of||fears-20/NNS||stigma-30/NN	conj_and||hiv/aids-22/NNS||stigma-30/NN	dep||lack-36/NN||2-33/LS	amod||lack-36/NN||perceived-35/VBN	dobj||included-11/VBD||lack-36/NN	conj_and||factors-16/NNS||lack-36/NN	prep_of||lack-36/NN||confidentiality-38/NN	nn||results-42/NNS||hiv-40/NN	nn||results-42/NNS||test-41/NN	prep_of||confidentiality-38/NN||results-42/NNS	dep||shortages-48/NNS||3-45/LS	nn||shortages-48/NNS||staff-47/NN	dobj||included-11/VBD||shortages-48/NNS	conj_and||factors-16/NNS||shortages-48/NNS	prep||shortages-48/NNS||and-49/CC	amod||workload-51/NN||high-50/JJ	pobj||and-49/CC||workload-51/NN	dep||infrastructure-58/NN||4-55/LS	amod||infrastructure-58/NN||poor-57/VBN	dobj||included-11/VBD||infrastructure-58/NN	conj_and||factors-16/NNS||infrastructure-58/NN	aux||encourage-60/VB||to-59/TO	vmod||included-11/VBD||encourage-60/VB	vmod||included-11/VBD||monitor-62/VB	conj_and||encourage-60/VB||monitor-62/VB	vmod||included-11/VBD||deliver-65/VB	conj_and||encourage-60/VB||deliver-65/VB	dobj||encourage-60/VB||hct-66/NN	aids--1||hiv-40||no||the themes emerging from the focus group discussions and interviews included four main suggested barrier factors (1) fears of hiv/aids, tb-hiv coinfection, death, and stigma; (2) perceived lack of confidentiality of hiv test results; (3) staff shortages and high workload; and (4) poor infrastructure to encourage, monitor, and deliver hct.
amod||survival-2/NN||clonogenic-1/JJ	nsubj||reveal-16/VBP||survival-2/NN	nn||viability-assays-5/NNS||live/dead-4/NN	conj_and||survival-2/NN||viability-assays-5/NNS	nsubj||reveal-16/VBP||viability-assays-5/NNS	advmod||with-8/IN||together-7/RB	rcmod||survival-2/NN||with-8/IN	amod||activity-10/NN||enzymatic-9/JJ	pobj||with-8/IN||activity-10/NN	nn||assays-14/NNS||cell-12/NN	nn||assays-14/NNS||proliferation-13/NN	pobj||with-8/IN||assays-14/NNS	conj_and||activity-10/NN||assays-14/NNS	root||ROOT-0/null||reveal-16/VBP	mark||correlate-28/VBP||that-17/IN	det||levels-19/NNS||the-18/DT	nsubj||correlate-28/VBP||levels-19/NNS	amod||activity-24/NN||paclitaxel-induced-21/JJ	amod||activity-24/NN||caspase-3-22/JJ	amod||activity-24/NN||enzymatic-23/JJ	prep_of||levels-19/NNS||activity-24/NN	nn||cells-27/NNS||tumor-26/NN	prep_in||activity-24/NN||cells-27/NNS	ccomp||reveal-16/VBP||correlate-28/VBP	advmod||correlate-28/VBP||directly-29/RB	nn||sensitivity-32/NN||tumor-31/NN	prep_with||correlate-28/VBP||sensitivity-32/NN	det||drug.we-35/NN||the-34/DT	prep_to||correlate-28/VBP||drug.we-35/NN	rcmod||drug.we-35/NN||observed-36/VBD	det||increase-39/NN||a-37/DT	amod||increase-39/NN||2-fold-38/JJ	dobj||observed-36/VBD||increase-39/NN	amod||activity-42/NN||caspase-3-41/JJ	prep_in||increase-39/NN||activity-42/NN	amod||cells-46/NNS||4t1-luc-44/JJ	nn||cells-46/NNS||breasttumor-45/NN	prep_in||activity-42/NN||cells-46/NNS	det||decrease-53/NN||a-49/DT	amod||decrease-53/NN||3-fold-50/JJ	conj_and||3-fold-50/JJ||4-fold-52/JJ	amod||decrease-53/NN||4-fold-52/JJ	dobj||observed-36/VBD||decrease-53/NN	conj_but||increase-39/NN||decrease-53/NN	amod||lines-60/NNS||a549-55/JJ	conj_and||a549-55/JJ||a427-57/JJ	amod||lines-60/NNS||a427-57/JJ	nn||lines-60/NNS||lungtumor-58/NN	nn||lines-60/NNS||cell-59/NN	prep_in||decrease-53/NN||lines-60/NNS	advmod||observed-36/VBD||respectively-62/RB	lungtumor-58||paclitaxel--1||yes||clonogenic survival and live/dead viability-assays, together with enzymatic activity and cell proliferation assays, reveal that the levels of paclitaxel-induced caspase-3 enzymatic activity in tumor cells correlate directly with tumor sensitivity to the drug.we observed a 2-fold increase in caspase-3 activity in 4t1-luc breasttumor cells, but a 3-fold and 4-fold decrease in a549 and a427 lungtumor cell lines, respectively.
det||score-3/NN||the-1/DT	nn||score-3/NN||pain-2/NN	nsubjpass||assessed-5/VBN||score-3/NN	nsubjpass||assessed-5/VBN||score-3/NN	auxpass||assessed-5/VBN||was-4/VBD	root||ROOT-0/null||assessed-5/VBN	conj_and||assessed-5/VBN||assessed-5/VBN	det||scale-11/NN||a-7/DT	amod||scale-11/NN||4-point-8/JJ	amod||scale-11/NN||verbal-9/JJ	nn||scale-11/NN||rating-10/NN	agent||assessed-5/VBN||scale-11/NN	appos||scale-11/NN||vrs-13/NN	num||seconds-17/NNS||10-16/CD	prep_at||scale-11/NN||seconds-17/NNS	prep_after||assessed-5/VBN||injection-19/NN	amod||mg-24/NN||microemulsion-21/JJ	nn||mg-24/NN||propofol-22/NN	num||mg-24/NN||30-23/CD	prep_of||injection-19/NN||mg-24/NN	det||injection-28/NN||the-27/DT	prep_during||assessed-5/VBN||injection-28/NN	det||dose-33/NN||the-30/DT	amod||dose-33/NN||remaining-31/VBG	nn||dose-33/NN||total-32/NN	prep_of||injection-28/NN||dose-33/NN	pain-2||propofol-22||yes||the pain score was assessed by a 4-point verbal rating scale (vrs) at 10 seconds after injection of microemulsion propofol 30 mg and during the injection of the remaining total dose.
nsubj||disease-4/NN||anthrax-1/NN	cop||disease-4/NN||is-2/VBZ	det||disease-4/NN||a-3/DT	root||ROOT-0/null||disease-4/NN	amod||beings-7/NNS||human-6/JJ	prep_of||disease-4/NN||beings-7/NNS	prep_of||disease-4/NN||animals-9/NNS	conj_and||beings-7/NNS||animals-9/NNS	vmod||beings-7/NNS||caused-10/VBN	det||encapsulated-13/NN||the-12/DT	agent||caused-10/VBN||encapsulated-13/NN	appos||encapsulated-13/NN||spore-forming-15/NN	appos||spore-forming-15/NN||bacillusanthracis-17/NNS	anthrax-1||bacillusanthracis-17||no||anthrax is a disease of human beings and animals caused by the encapsulated, spore-forming, bacillusanthracis .
det||study-4/NN||this-1/DT	nn||study-4/NN||phase-2/NN	nn||study-4/NN||iii-3/NN	nsubj||evaluated-5/VBN||study-4/NN	root||ROOT-0/null||evaluated-5/VBN	det||efficacy-7/NN||the-6/DT	dobj||evaluated-5/VBN||efficacy-7/NN	dobj||evaluated-5/VBN||safety-9/NN	conj_and||efficacy-7/NN||safety-9/NN	prep_of||efficacy-7/NN||rituximab-11/NN	dobj||evaluated-5/VBN||methotrexate-13/NN	conj_plus||efficacy-7/NN||methotrexate-13/NN	appos||methotrexate-13/NN||mtx-15/NN	prep_in||methotrexate-13/NN||patients-18/NNS	amod||rheumatoidarthritis-21/NNS||active-20/JJ	prep_with||evaluated-5/VBN||rheumatoidarthritis-21/NNS	nsubj||had-26/VBD||rheumatoidarthritis-21/NNS	appos||rheumatoidarthritis-21/NNS||ra-23/NN	rcmod||rheumatoidarthritis-21/NNS||had-26/VBD	det||response-29/NN||an-27/DT	amod||response-29/NN||inadequate-28/JJ	dobj||had-26/VBD||response-29/NN	prep_to||response-29/NN||mtx-31/NN	nsubjpass||naã-35/VBN||who-33/WP	auxpass||naã-35/VBN||were-34/VBD	rcmod||rheumatoidarthritis-21/NNS||naã-35/VBN	conj_and||had-26/VBD||naã-35/VBN	amod||ve-37/NN||¯-36/JJ	dobj||naã-35/VBN||ve-37/NN	amod||treatment-41/NN||prior-39/JJ	amod||treatment-41/NN||biological-40/JJ	prep_to||naã-35/VBN||treatment-41/NN	rheumatoidarthritis-21||mtx-31||yes||this phase iii study evaluated the efficacy and safety of rituximab plus methotrexate (mtx) in patients with active rheumatoidarthritis (ra) who had an inadequate response to mtx and who were naã¯ve to prior biological treatment.
nn||levels-2/NNS||epidemic-1/NN	nsubj||compound-11/VB||levels-2/NNS	prep_of||levels-2/NNS||hiv/aids-4/NNS	det||parts-7/NNS||some-6/DT	prep_in||hiv/aids-4/NNS||parts-7/NNS	amod||africa-10/NN||sub-saharan-9/JJ	prep_of||parts-7/NNS||africa-10/NN	root||ROOT-0/null||compound-11/VB	det||portrait-13/NN||this-12/DT	dobj||compound-11/VB||portrait-13/NN	prep_of||portrait-13/NN||hopelessness-15/NNS	aids--1||hiv--1||no||epidemic levels of hiv/aids in some parts of sub-saharan africa compound this portrait of hopelessness.
amod||korea-3/NN||south-2/JJ	prep_in||isolated-49/VBN||korea-3/NN	advmod||avianinfluenzavirus-6/VBZ||where-5/WRB	advcl||isolated-49/VBN||avianinfluenzavirus-6/VBZ	nsubj||circulate-16/VBP||subtypes-7/NNS	nsubjpass||detected-20/VBN||subtypes-7/NNS	num||subtypes-7/NNS||h3n2-8/CD	num||subtypes-7/NNS||h5n1-10/CD	num||subtypes-7/NNS||h6n1-12/CD	conj_and||subtypes-7/NNS||h9n2-15/CD	nsubj||circulate-16/VBP||h9n2-15/CD	ccomp||avianinfluenzavirus-6/VBZ||circulate-16/VBP	aux||detected-20/VBN||have-18/VBP	auxpass||detected-20/VBN||been-19/VBN	ccomp||avianinfluenzavirus-6/VBZ||detected-20/VBN	conj_or||circulate-16/VBP||detected-20/VBN	num||influenzavirus-26/NNS||3-22/CD	advmod||similar-24/JJ||genetically-23/RB	amod||influenzavirus-26/NNS||similar-24/JJ	nn||influenzavirus-26/NNS||canine-25/NN	nsubjpass||isolated-49/VBN||influenzavirus-26/NNS	dep||isolated-49/VBN||h3n2-28/NNP	nsubjpass||isolated-49/VBN||strains-30/NNS	nn||origin-33/NN||avian-32/NN	prep_of||strains-30/NNS||origin-33/NN	dep||strains-30/NNS||a/canine/korea-35/NN	punct||01/2007-37/CD||/-36/:	dep||a/canine/korea-35/NN||01/2007-37/CD	dep||a/canine/korea-35/NN||a/canine/korea-39/NN	conj_and||01/2007-37/CD||a/canine/korea-39/NN	number||02/2007-41/CD||/-40/CD	dep||a/canine/korea-39/NN||02/2007-41/CD	dep||a/canine/korea-35/NN||a/canine/korea-44/NN	conj_and||01/2007-37/CD||a/canine/korea-44/NN	punct||01/2007-37/CD||/-45/:	dep||a/canine/korea-35/NN||03/2007-46/CD	auxpass||isolated-49/VBN||were-48/VBD	root||ROOT-0/null||isolated-49/VBN	prep_from||isolated-49/VBN||dogs-51/NNS	vmod||dogs-51/NNS||exhibiting-52/VBG	amod||respiratorydisease-54/NN||severe-53/JJ	dobj||exhibiting-52/VBG||respiratorydisease-54/NN	h5n1-10||influenzavirus-26||no||in south korea, where avianinfluenzavirus subtypes h3n2, h5n1, h6n1, and h9n2 circulate or have been detected, 3 genetically similar canine influenzavirus (h3n2) strains of avian origin (a/canine/korea/01/2007, a/canine/korea/02/2007, and a/canine/korea/03/2007) were isolated from dogs exhibiting severe respiratorydisease.
prep_in||alanine-11/VBP||mice-2/NNS	vmod||mice-2/NNS||treated-3/VBN	prep_with||treated-3/VBN||aminoguanidine-5/NN	amod||increases-8/NNS||ischemia/reperfusion-induced-7/JJ	nsubj||alanine-11/VBP||increases-8/NNS	prep_in||increases-8/NNS||serum-10/NN	root||ROOT-0/null||alanine-11/VBP	amod||levels-13/NNS||aminotransferase-12/JJ	nsubjpass||reduced-18/VBN||levels-13/NNS	conj_and||levels-13/NNS||apoptosis-15/NNS	nsubjpass||reduced-18/VBN||apoptosis-15/NNS	auxpass||reduced-18/VBN||were-16/VBD	advmod||reduced-18/VBN||significantly-17/RB	ccomp||alanine-11/VBP||reduced-18/VBN	amod||liver-21/NN||steatotic-20/JJ	prep_in||reduced-18/VBN||liver-21/NN	prepc_compared_with||reduced-18/VBN||with-23/IN	pobj||reduced-18/VBN||mice-24/NNS	vmod||mice-24/NNS||treated-25/VBN	amod||saline-29/NN||phosphate-27/JJ	amod||saline-29/NN||buffered-28/JJ	prep_with||treated-25/VBN||saline-29/NN	ischemia--1||alanine-11||no_rel||in mice treated with aminoguanidine, ischemia/reperfusion-induced increases in serum alanine aminotransferase levels and apoptosis were significantly reduced in steatotic liver compared with mice treated with phosphate buffered saline.
amod||prophylaxis-3/NNS||post-transplant-1/JJ	nn||prophylaxis-3/NNS||hbv-2/NN	nsubj||effective-31/JJ||prophylaxis-3/NNS	prep_with||prophylaxis-3/NNS||lamivudine-5/NN	prep_with||prophylaxis-3/NNS||intramuscular-7/NN	conj_and||lamivudine-5/NN||intramuscular-7/NN	vmod||prophylaxis-3/NNS||hbig-8/VBG	amod||dosage-11/NN||appropriate-10/JJ	prep_with||hbig-8/VBG||dosage-11/NN	aux||keep-13/VB||to-12/TO	xcomp||hbig-8/VBG||keep-13/VB	amod||titer-16/NN||anti-hbs-14/JJ	nn||titer-16/NN||antibody-15/NN	dobj||keep-13/VB||titer-16/NN	num||iu/l-19/NN||300-18/CD	prep_above||keep-13/VB||iu/l-19/NN	det||months-24/NNS||the-21/DT	amod||months-24/NNS||first-22/JJ	num||months-24/NNS||six-23/CD	prep_in||iu/l-19/NN||months-24/NNS	num||iu/l-28/NN||100-27/CD	prep_above||keep-13/VB||iu/l-28/NN	conj_and||iu/l-19/NN||iu/l-28/NN	dep||keep-13/VB||afterwards-29/RB	cop||effective-31/JJ||is-30/VBZ	root||ROOT-0/null||effective-31/JJ	prep_for||effective-31/JJ||prevention-33/NN	nn||recurrence-36/NN||hbv-35/NN	prep_of||prevention-33/NN||recurrence-36/NN	prep_after||effective-31/JJ||lt.-38/NN	hbv-35||hbig-8||yes||post-transplant hbv prophylaxis with lamivudine and intramuscular hbig with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l in the first six months and above 100 iu/l afterwards is effective for prevention of hbv recurrence after lt.
amod||adjuvant-2/NN||current-1/JJ	nsubj||pharmacological-3/VBP||adjuvant-2/NN	root||ROOT-0/null||pharmacological-3/VBP	dobj||pharmacological-3/VBP||therapy-4/NN	amod||unfractionatedheparin-12/NN||ami-6/JJ	prep_with||ami-6/JJ||aspirin-8/NN	appos||aspirin-8/NN||clopidogrel-10/NN	prep_of||therapy-4/NN||unfractionatedheparin-12/NN	discourse||unfractionatedheparin-12/NN||uh-14/UH	amod||inhibitors-21/NNS||platelet-18/JJ	nn||inhibitors-21/NNS||gp-19/NN	nn||inhibitors-21/NNS||iib/iiia-20/NN	nsubj||provides-22/VBZ||inhibitors-21/NNS	conj_and||pharmacological-3/VBP||provides-22/VBZ	amod||benefits-25/NNS||useful-23/JJ	amod||benefits-25/NNS||therapeutic-24/JJ	dobj||provides-22/VBZ||benefits-25/NNS	ami-6||clopidogrel-10||yes||current adjuvant pharmacological therapy of ami with aspirin, clopidogrel, unfractionatedheparin (uh), and platelet gp iib/iiia inhibitors provides useful therapeutic benefits.
det||patients-2/NNS||the-1/DT	nsubj||received-19/VBD||patients-2/NNS	det||group-9/NN||the-4/DT	amod||preemptive-6/JJ||multimodal-5/JJ	amod||group-9/NN||preemptive-6/JJ	nn||group-9/NN||pain-7/NN	nn||group-9/NN||relief-8/NN	prep_in||patients-2/NNS||group-9/NN	det||group-13/NN||the-11/DT	nn||group-13/NN||study-12/NN	dep||group-9/NN||group-13/NN	nn||121-17/NNP||n-15/NNP	nn||121-17/NNP||=-16/NNP	appos||group-13/NN||121-17/NNP	root||ROOT-0/null||received-19/VBD	amod||blockade-22/NN||regional-20/JJ	nn||blockade-22/NN||nerve-21/NN	dobj||received-19/VBD||blockade-22/NN	number||%-25/NN||0.25-24/CD	amod||bupivacaine-26/NN||%-25/NN	prep_with||received-19/VBD||bupivacaine-26/NN	prep||received-19/VBD||combined-27/VBN	pcomp||combined-27/VBN||with-28/IN	amod||mg/kg-34/NN||preoperative-29/JJ	advmod||administered-31/JJ||rectally-30/RB	amod||mg/kg-34/NN||administered-31/JJ	nn||mg/kg-34/NN||paracetamol-32/NN	num||mg/kg-34/NN||45-33/CD	pobj||with-28/IN||mg/kg-34/NN	amod||min-40/NN||diclofenac-36/JJ	num||min-40/NN||1-37/CD	amod||min-40/NN||mg/kg-38/JJ	dep||mg/kg-38/JJ||60-39/CD	pobj||with-28/IN||min-40/NN	conj_or||mg/kg-34/NN||min-40/NN	prep_before||mg/kg-34/NN||surgery-42/NN	prep_for||surgery-42/NN||cases-44/NNS	nsubj||were-46/VBD||cases-44/NNS	nsubj||undergo-48/VB||cases-44/NNS	rcmod||cases-44/NNS||were-46/VBD	aux||undergo-48/VB||to-47/TO	xcomp||were-46/VBD||undergo-48/VB	amod||surgery-51/NN||lower-49/JJR	nn||surgery-51/NN||abdominal-50/NN	dobj||undergo-48/VB||surgery-51/NN	pain-7||bupivacaine-26||yes||the patients in the multimodal preemptive pain relief group (the study group, n = 121) received regional nerve blockade with 0.25% bupivacaine combined with preoperative rectally administered paracetamol 45 mg/kg or diclofenac 1 mg/kg 60 min before surgery for cases that were to undergo lower abdominal surgery.
poss||data-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	det||basis-6/NN||the-4/DT	amod||basis-6/NN||mechanistic-5/JJ	nsubj||hold-30/VB||basis-6/NN	amod||cd40â-13/NN||il-2-8/JJ	punct||±-11/NNP||/-9/:	nn||±-11/NNP||î-10/NNP	dep||cd40â-13/NN||±-11/NNP	prep_for||basis-6/NN||cd40â-13/NN	dep||cd40â-13/NN||$-14/$	amod||control-17/NN||mediated-16/JJ	npadvmod||that-22/IN||control-17/NN	prep_of||control-17/NN||metastases-19/NNS	prep_of||control-17/NN||suggest-21/NNS	conj_and||metastases-19/NNS||suggest-21/NNS	advmod||application-25/NN||that-22/IN	det||application-25/NN||the-23/DT	nn||application-25/NN||context-dependent-24/NN	npadvmod||of-26/IN||application-25/NN	dep||donors-28/CD||of-26/IN	neg||of-26/IN||no-27/RB	num||$-14/$||donors-28/CD	aux||hold-30/VB||may-29/MD	ccomp||demonstrate-3/VBP||hold-30/VB	dobj||hold-30/VB||promise-31/NN	prep_for||hold-30/VB||prevention-33/NN	amod||disease-36/NN||metastatic-35/JJ	prep_of||prevention-33/NN||disease-36/NN	il-2-8||metastases-19||no_rel||our data demonstrate the mechanistic basis for il-2/î±-cd40â€“mediated control of metastases and suggest that the context-dependent application of no donors may hold promise for prevention of metastatic disease.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||budesonide--1||yes||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
advmod||outline-3/VBZ||here-1/RB	nsubj||outline-3/VBZ||we-2/PRP	nsubj||discuss-47/VB||we-2/PRP	root||ROOT-0/null||outline-3/VBZ	det||ecology-6/NN||the-4/DT	amod||ecology-6/NN||known-5/JJ	dobj||outline-3/VBZ||ecology-6/NN	det||viruses-12/NNS||the-8/DT	amod||viruses-12/NNS||mosquito-borne-9/JJ	amod||viruses-12/NNS||equine-10/JJ	nn||viruses-12/NNS||encephalitis-11/NN	prep_of||ecology-6/NN||viruses-12/NNS	dep||viruses-12/NNS||weev-14/NNP	dep||viruses-12/NNS||eeev-16/NNP	conj_and||weev-14/NNP||eeev-16/NNP	dep||viruses-12/NNS||veev-19/NNP	conj_and||weev-14/NNP||veev-19/NNP	dobj||outline-3/VBZ||wnv-22/NN	conj_and||ecology-6/NN||wnv-22/NN	conj_and||ecology-6/NN||usuv-24/NNP	conj_and||wnv-22/NN||usuv-24/NNP	conj_and||ecology-6/NN||rvfv-26/NNP	conj_and||wnv-22/NN||rvfv-26/NNP	amod||virus-30/NN||japaneseencephalitis-29/JJ	conj_and||ecology-6/NN||virus-30/NN	conj_and||wnv-22/NN||virus-30/NN	amod||virus-36/NN||tick-borneencephalitis-35/JJ	dobj||outline-3/VBZ||virus-36/NN	conj_and||ecology-6/NN||virus-36/NN	poss||virus-43/NN||its-38/PRP$	nn||virus-43/NN||north-39/NN	num||virus-43/NN||american-40/CD	nn||virus-43/NN||counterpart-41/NN	nn||virus-43/NN||powassan-42/NN	conj_and||ecology-6/NN||virus-43/NN	conj_and||virus-36/NN||virus-43/NN	aux||discuss-47/VB||will-46/MD	conj_and||outline-3/VBZ||discuss-47/VB	det||mode-51/NN||the-48/DT	advmod||likely-50/JJ||most-49/RBS	amod||mode-51/NN||likely-50/JJ	dobj||discuss-47/VB||mode-51/NN	mark||expand-56/VB||that-52/IN	det||viruses-54/NNS||these-53/DT	nsubj||expand-56/VB||viruses-54/NNS	aux||expand-56/VB||could-55/MD	ccomp||discuss-47/VB||expand-56/VB	poss||range-60/NN||their-57/PRP$	amod||range-60/NN||respective-58/JJ	amod||range-60/NN||geographical-59/JJ	dobj||expand-56/VB||range-60/NN	tick-borneencephalitis-35||viruses-54||no||here we outline the known ecology of the mosquito-borne equine encephalitis viruses (weev, eeev, and veev), wnv, usuv, rvfv, and japaneseencephalitis virus, as well as tick-borneencephalitis virus and its north american counterpart powassan virus, and will discuss the most likely mode that these viruses could expand their respective geographical range.
det||individuals-5/NNS||all-1/DT	advmod||diagnosed-3/VBN||newly-2/RB	amod||individuals-5/NNS||diagnosed-3/VBN	nn||individuals-5/NNS||hiv/aids-4/NNS	nsubjpass||evaluated-9/VBN||individuals-5/NNS	aux||evaluated-9/VBN||should-6/MD	auxpass||evaluated-9/VBN||be-7/VB	advmod||evaluated-9/VBN||routinely-8/RB	root||ROOT-0/null||evaluated-9/VBN	prep_for||evaluated-9/VBN||hyperglycemia-11/NN	aids--1||hiv--1||no||all newly diagnosed hiv/aids individuals should be routinely evaluated for hyperglycemia.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||benefit-5/NN||the-3/DT	amod||benefit-5/NN||relative-4/JJ	iobj||examined-2/VBD||benefit-5/NN	prepc_of||benefit-5/NN||introducing-7/VBG	amod||maintenance-12/NN||budesonide/formoterol-8/JJ	appos||maintenance-12/NN||bud/form-10/NNP	dobj||introducing-7/VBG||maintenance-12/NN	nn||therapy-15/NN||reliever-14/NN	dobj||introducing-7/VBG||therapy-15/NN	conj_and||maintenance-12/NN||therapy-15/NN	amod||®-21/NNP||symbicort-17/JJ	nn||®-21/NNP||smartâ-18/NNP	nn||®-21/NNP||®-19/NNP	nn||®-21/NNP||turbuhalerâ-20/NNP	appos||therapy-15/NN||®-21/NNP	prep_in||introducing-7/VBG||patients-24/NNS	advmod||prescribed-26/VBN||previously-25/RB	vmod||patients-24/NNS||prescribed-26/VBN	dobj||prescribed-26/VBN||treatments-27/NNS	amod||initiative-30/NN||global-29/JJ	prep_from||prescribed-26/VBN||initiative-30/NN	amod||steps-36/NNS||asthma-32/JJ	appos||steps-36/NNS||gina-34/NNP	prep_for||prescribed-26/VBN||steps-36/NNS	dobj||examined-2/VBD||2-37/CD	num||2-37/CD||3-39/CD	dobj||examined-2/VBD||4-41/CD	conj_or||2-37/CD||4-41/CD	asthma-32||budesonide--1||yes||we examined the relative benefit of introducing budesonide/formoterol (bud/form) maintenance and reliever therapy (symbicort smartâ® turbuhalerâ®) in patients previously prescribed treatments from global initiative for asthma (gina) steps 2, 3 or 4.
dep||spirochete-6/NN||brachyspirahyodysenteriae-1/JJ	cop||spirochete-6/NN||is-2/VBZ	det||spirochete-6/NN||an-3/DT	amod||spirochete-6/NN||anaerobic-4/JJ	amod||spirochete-6/NN||intestinal-5/JJ	root||ROOT-0/null||spirochete-6/NN	nsubj||colonizes-8/VBZ||spirochete-6/NN	rcmod||spirochete-6/NN||colonizes-8/VBZ	det||intestine-11/NN||the-9/DT	amod||intestine-11/NN||large-10/JJ	dobj||colonizes-8/VBZ||intestine-11/NN	prep_of||intestine-11/NN||pigs-13/NNS	prep_of||intestine-11/NN||causes-15/NNS	conj_and||pigs-13/NNS||causes-15/NNS	nsubj||spirochete-6/NN||swinedysentery-16/NN	det||disease-19/NN||a-18/DT	appos||swinedysentery-16/NN||disease-19/NN	amod||importance-23/NN||significant-21/JJ	amod||importance-23/NN||economic-22/JJ	prep_of||disease-19/NN||importance-23/NN	swinedysentery-16||brachyspirahyodysenteriae-1||no||brachyspirahyodysenteriae is an anaerobic intestinal spirochete that colonizes the large intestine of pigs and causes swinedysentery, a disease of significant economic importance.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||lumefantrine--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
amod||susceptibility-2/NN||decreased-1/VBN	nsubj||become-6/VBN||susceptibility-2/NN	prep_to||susceptibility-2/NN||fluoroquinolones-4/NNS	aux||become-6/VBN||has-5/VBZ	root||ROOT-0/null||become-6/VBN	det||problem-9/NN||a-7/DT	amod||problem-9/NN||major-8/JJ	xcomp||become-6/VBN||problem-9/NN	det||therapy-13/NN||the-11/DT	amod||therapy-13/NN||successful-12/JJ	prep_for||become-6/VBN||therapy-13/NN	amod||infections-16/NNS||human-15/JJ	prep_of||therapy-13/NN||infections-16/NNS	vmod||infections-16/NNS||caused-17/VBN	agent||caused-17/VBN||salmonellaenterica-19/NN	advmod||salmonellaenterica-19/NN||especially-21/RB	det||typhoidandparatyphoidfevers-24/NNS||the-22/DT	amod||typhoidandparatyphoidfevers-24/NNS||life-threatening-23/JJ	dep||salmonellaenterica-19/NN||typhoidandparatyphoidfevers-24/NNS	typhoidandparatyphoidfevers-24||salmonellaenterica-19||no||decreased susceptibility to fluoroquinolones has become a major problem for the successful therapy of human infections caused by salmonellaenterica , especially the life-threatening typhoidandparatyphoidfevers.
prep_above||noted-7/VBN||all-2/DT	nsubjpass||noted-7/VBN||it-4/PRP	aux||noted-7/VBN||should-5/MD	auxpass||noted-7/VBN||be-6/VB	root||ROOT-0/null||noted-7/VBN	det||ability-9/NN||the-8/DT	dobj||noted-7/VBN||ability-9/NN	amod||assay-13/NN||r5-enzyme-linked-11/JJ	nn||assay-13/NN||immunosorbent-12/NN	prep_of||ability-9/NN||assay-13/NN	amod||methods-17/NNS||other-16/JJ	prep_of||ability-9/NN||methods-17/NNS	conj_and||assay-13/NN||methods-17/NNS	aux||measure-20/VB||to-19/TO	vmod||noted-7/VBN||measure-20/VB	poss||toxicity-23/NN||gluten-21/NN	nsubj||validated-29/JJ||toxicity-23/NN	amod||patients-26/NNS||celiacdisease-25/JJ	prep_toward||toxicity-23/NN||patients-26/NNS	cop||validated-29/JJ||is-27/VBZ	neg||validated-29/JJ||not-28/RB	ccomp||measure-20/VB||validated-29/JJ	advmod||validated-29/JJ||clinically-30/RB	enzyme--1||celiacdisease-25||no_rel||above all, it should be noted the ability of r5-enzyme-linked immunosorbent assay, and other methods, to measure gluten's toxicity toward celiacdisease patients is not validated clinically.
prepc_compared_with||lower-10/JJR||with-2/IN	pobj||lower-10/JJR||adolescents-3/NNS	prep_with||adolescents-3/NNS||ngt-5/NN	amod||insulin-8/NN||first-phase-7/JJ	nsubj||lower-10/JJR||insulin-8/NN	cop||lower-10/JJR||was-9/VBD	root||ROOT-0/null||lower-10/JJR	det||function-38/NN||those-12/DT	prep_with||igt-16/JJ||ifg-14/NN	amod||function-38/NN||igt-16/JJ	conj_and||igt-16/JJ||ifg/igt-19/JJ	amod||function-38/NN||ifg/igt-19/JJ	amod||deterioration-22/NN||further-21/JJ	prep_with||ifg/igt-19/JJ||deterioration-22/NN	prep_in||deterioration-22/NN||those-24/DT	prep_with||those-24/DT||type2diabetes-26/CD	dep||ifg/igt-19/JJ||p-28/NNP	number||0.001-30/CD||<-29/CD	num||p-28/NNP||0.001-30/CD	advmod||²-35/JJ||î-34/RB	conj_and||igt-16/JJ||²-35/JJ	amod||function-38/NN||²-35/JJ	nn||function-38/NN||cell-37/NN	prep_in||lower-10/JJR||function-38/NN	advmod||function-38/NN||relative-39/JJ	nn||sensitivity-42/NN||insulin-41/NN	prep_to||relative-39/JJ||sensitivity-42/NN	nn||-RSB--49/NNP||glucose-44/NN	nn||-RSB--49/NNP||disposition-45/NN	nn||-RSB--49/NNP||index-46/NN	nn||-RSB--49/NNP||-LSB--47/NNP	nn||-RSB--49/NNP||gdi-48/NNP	nsubj||lower-53/JJR||-RSB--49/NNP	cop||lower-53/JJR||was-51/VBD	advmod||lower-53/JJR||also-52/RB	rcmod||sensitivity-42/NN||lower-53/JJR	prep_in||lower-53/JJR||those-55/DT	prep_with||those-55/DT||ifg-57/NN	prep_with||those-55/DT||igt-59/NN	conj_and||ifg-57/NN||igt-59/NN	prep_with||those-55/DT||ifg/igt-62/NN	conj_and||ifg-57/NN||ifg/igt-62/NN	dep||ifg-57/NN||40-64/CD	dep||ifg-57/NN||47-66/CD	conj_and||40-64/CD||47-66/CD	num||%-70/NN||47-69/CD	dep||ifg-57/NN||%-70/NN	conj_and||40-64/CD||%-70/NN	advmod||%-70/NN||respectively-72/RB	det||decrease-78/NN||a-76/DT	amod||decrease-78/NN||further-77/JJ	prep_with||lower-10/JJR||decrease-78/NN	num||%-81/NN||80-80/CD	appos||decrease-78/NN||%-81/NN	prep_in||decrease-78/NN||those-84/DT	prep_with||those-84/DT||type2diabetes-86/NNS	appos||type2diabetes-86/NNS||p-88/NNP	number||0.001-90/CD||<-89/CD	num||p-88/NNP||0.001-90/CD	type2diabetes-86||insulin-41||yes||compared with adolescents with ngt, first-phase insulin was lower in those with ifg, igt, and ifg/igt with further deterioration in those with type2diabetes ( p < 0.001), and î²-cell function relative to insulin sensitivity (glucose disposition index [gdi]) was also lower in those with ifg, igt, and ifg/igt (40, 47, and 47%, respectively), with a further decrease (80%) in those with type2diabetes ( p < 0.001).
amod||investigation-2/NN||epidemiologic-1/JJ	nsubj||showed-3/VBD||investigation-2/NN	root||ROOT-0/null||showed-3/VBD	dobj||showed-3/VBD||that-4/DT	nsubj||provided-9/VBD||that-4/DT	amod||persons-7/NNS||789-6/JJ	prep_of||that-4/DT||persons-7/NNS	rcmod||that-4/DT||provided-9/VBD	nn||samples-11/NNS||blood-10/NN	dobj||provided-9/VBD||samples-11/NNS	nsubj||seropositive-19/JJ||195-13/CD	num||%-16/NN||25-15/CD	appos||195-13/CD||%-16/NN	cop||seropositive-19/JJ||were-18/VBD	ccomp||showed-3/VBD||seropositive-19/JJ	conj_and||showed-3/VBD||seropositive-19/JJ	nsubj||immunoglobulin-27/VBN||33-21/CD	num||%-24/NN||4-23/CD	appos||33-21/CD||%-24/NN	aux||immunoglobulin-27/VBN||had-26/VBD	ccomp||showed-3/VBD||immunoglobulin-27/VBN	conj_and||showed-3/VBD||immunoglobulin-27/VBN	amod||levels-32/NNS||-LSB--28/JJ	nn||levels-32/NNS||ig-29/NN	amod||levels-32/NNS||-RSB--30/JJ	nn||levels-32/NNS||m-31/NN	nsubj||consistent-33/JJ||levels-32/NNS	xcomp||immunoglobulin-27/VBN||consistent-33/JJ	amod||acuteinfection-36/NN||recent-35/JJ	prep_with||consistent-33/JJ||acuteinfection-36/NN	nsubj||symptomatic-43/JJ||11-38/CD	det||persons-41/NNS||these-40/DT	prep_of||11-38/CD||persons-41/NNS	cop||symptomatic-43/JJ||were-42/VBD	dep||acuteinfection-36/NN||symptomatic-43/JJ	nsubj||igg-53/VBN||162-47/CD	num||%-50/NN||21-49/CD	appos||162-47/CD||%-50/NN	aux||igg-53/VBN||had-52/VBD	conj_and||showed-3/VBD||igg-53/VBN	dep||igg-53/VBN||only-54/RB	acomp||igg-53/VBN||consistent-56/JJ	amod||infection-59/NN||past-58/JJ	prep_with||consistent-56/JJ||infection-59/NN	immunoglobulin-27||acuteinfection-36||no_rel||epidemiologic investigation showed that of 789 persons who provided blood samples, 195 (25%) were seropositive, 33 (4%) had immunoglobulin [ig] m levels consistent with recent acuteinfection (11 of these persons were symptomatic), and 162 (21%) had igg only, consistent with past infection.
det||therapy-3/NN||the-1/DT	amod||therapy-3/NN||antibiotic-2/JJ	nsubjpass||based-5/VBN||therapy-3/NN	auxpass||based-5/VBN||was-4/VBD	root||ROOT-0/null||based-5/VBN	advmod||bronchial-8/JJ||susceptibility-7/RB	amod||baumannii-12/NNS||bronchial-8/JJ	amod||baumannii-12/NNS||secretions-9/JJ	amod||baumannii-12/NNS||isolated-10/VBN	nn||baumannii-12/NNS||acinetobacter-11/NN	prep_on||based-5/VBN||baumannii-12/NNS	nn||pneumoniae-15/NN||klebsiella-14/NN	prep_on||based-5/VBN||pneumoniae-15/NN	conj_and||baumannii-12/NNS||pneumoniae-15/NN	det||pathogens-18/NNS||these-17/DT	nsubjpass||isolated-21/VBN||pathogens-18/NNS	auxpass||isolated-21/VBN||were-19/VBD	advmod||isolated-21/VBN||also-20/RB	parataxis||based-5/VBN||isolated-21/VBN	det||abscess-25/NNS||the-23/DT	amod||abscess-25/NNS||drained-24/JJ	prep_from||isolated-21/VBN||abscess-25/NNS	abscess-25||antibiotic-2||no_rel||the antibiotic therapy was based on susceptibility bronchial secretions isolated acinetobacter baumannii and klebsiella pneumoniae; these pathogens were also isolated from the drained abscess.
nsubj||included-9/VBD||factors-1/NNS	vmod||factors-1/NNS||related-2/VBN	prep_to||related-2/VBN||participation-4/NN	nn||programs-8/NNS||hiv-6/NN	nn||programs-8/NNS||prevention-7/NN	prep_in||participation-4/NN||programs-8/NNS	root||ROOT-0/null||included-9/VBD	nn||perception-18/NN||age-10/NN	dep||perception-18/NN||ethnicity-12/NN	dep||perception-18/NN||income-14/NN	amod||perception-18/NN||hiv-16/JJ	nn||perception-18/NN||risk-17/NN	dobj||included-9/VBD||perception-18/NN	dep||included-9/VBD||living-20/VBG	prep_with||living-20/VBG||boyfriend-22/NN	dep||included-9/VBD||living-24/VBG	conj_and||living-20/VBG||living-24/VBG	amod||area-27/NN||urban-26/JJ	nsubj||talked-36/VBN||area-27/NN	appos||area-27/NN||size-29/NN	amod||network-33/NN||msm-31/JJ	amod||network-33/NN||social-32/JJ	prep_of||size-29/NN||network-33/NN	aux||talked-36/VBN||having-35/VBG	prepc_in||living-24/VBG||talked-36/VBN	nn||status-39/NN||hiv-38/NN	prep_about||talked-36/VBN||status-39/NN	prep_with||talked-36/VBN||partners-41/NNS	dep||included-9/VBD||knowing-44/VBG	conj_and||living-20/VBG||knowing-44/VBG	dobj||knowing-44/VBG||someone-45/NN	nsubj||hivpositive-48/JJ||someone-45/NN	cop||hivpositive-48/JJ||is-47/VBZ	rcmod||someone-45/NN||hivpositive-48/JJ	hivpositive-48||hiv-38||no||factors related to participation in hiv prevention programs included age, ethnicity, income, hiv risk perception, living with boyfriend, living in urban area, size of msm social network, having talked about hiv status with partners, and knowing someone who is hivpositive.
nsubj||cause-10/NN||humancytomegalovirus-1/NNS	appos||humancytomegalovirus-1/NNS||cmv-3/NN	advmod||cause-10/NN||infection-5/RB	cop||cause-10/NN||is-6/VBZ	det||cause-10/NN||the-7/DT	advmod||common-9/JJ||most-8/RBS	amod||cause-10/NN||common-9/JJ	root||ROOT-0/null||cause-10/NN	amod||viralinfection-13/NN||perinatal-12/JJ	prep_of||cause-10/NN||viralinfection-13/NN	det||world-17/NN||the-15/DT	amod||world-17/NN||developed-16/JJ	prep_in||viralinfection-13/NN||world-17/NN	vmod||cause-10/NN||resulting-19/VBG	quantmod||40,000-22/CD||approximately-21/RB	num||infants-25/NNS||40,000-22/CD	amod||infants-25/NNS||congenitally-23/JJ	amod||infants-25/NNS||infected-24/JJ	prep_in||resulting-19/VBG||infants-25/NNS	det||states-29/NNS||the-27/DT	amod||states-29/NNS||united-28/VBN	prep_in||infants-25/NNS||states-29/NNS	det||year-31/NN||each-30/DT	tmod||resulting-19/VBG||year-31/NN	cmv-3||humancytomegalovirus-1||no||humancytomegalovirus (cmv) infection is the most common cause of perinatal viralinfection in the developed world, resulting in approximately 40,000 congenitally infected infants in the united states each year.
det||study-4/NN||this-1/DT	amod||study-4/NN||prospective-2/JJ	nn||study-4/NN||cohort-3/NN	nsubj||conducted-5/VBD||study-4/NN	root||ROOT-0/null||conducted-5/VBD	prep_in||conducted-5/VBD||zambia-7/NN	vmod||zambia-7/NN||evaluated-8/VBN	det||safety-10/NN||the-9/DT	dobj||evaluated-8/VBN||safety-10/NN	prep_of||safety-10/NN||artemether-lumefantrine-12/NN	appos||artemether-lumefantrine-12/NN||al-14/NNP	amod||women-18/NNS||pregnant-17/JJ	prep_in||evaluated-8/VBN||women-18/NNS	prep_with||evaluated-8/VBN||malaria-20/NN	malaria-20||artemether--1||yes||this prospective cohort study conducted in zambia evaluated the safety of artemether-lumefantrine (al) in pregnant women with malaria.
nsubj||appears-3/VBZ||hypersensitivity-1/NN	advmod||appears-3/VBZ||usually-2/RB	root||ROOT-0/null||appears-3/VBZ	amod||infusions-6/NNS||multiple-5/JJ	prep_after||appears-3/VBZ||infusions-6/NNS	xcomp||appears-3/VBZ||suggesting-8/VBG	nn||allergicreactions-11/NNS||type-9/NN	nn||allergicreactions-11/NNS||i-10/NN	dobj||suggesting-8/VBG||allergicreactions-11/NNS	advmod||seem-20/VBP||however-13/RB	amod||types-16/NNS||other-15/JJ	nsubj||seem-20/VBP||types-16/NNS	nsubjpass||implicated-23/VBN||types-16/NNS	prep_of||types-16/NNS||hypersensitivity-18/NN	advmod||seem-20/VBP||also-19/RB	parataxis||appears-3/VBZ||seem-20/VBP	aux||implicated-23/VBN||to-21/TO	auxpass||implicated-23/VBN||be-22/VB	xcomp||seem-20/VBP||implicated-23/VBN	hypersensitivity-18||hypersensitivity-18||no||hypersensitivity usually appears after multiple infusions, suggesting type i allergicreactions; however, other types of hypersensitivity also seem to be implicated.
det||vulnerability-3/NN||this-1/DT	amod||vulnerability-3/NN||increased-2/VBN	nsubj||due-6/JJ||vulnerability-3/NN	aux||due-6/JJ||may-4/MD	cop||due-6/JJ||be-5/VB	root||ROOT-0/null||due-6/JJ	amod||symptom-9/NN||more-8/JJR	prep_to||due-6/JJ||symptom-9/NN	vmod||symptom-9/NN||â-10/VBN	dobj||â-10/VBN||$-11/$	num||$-11/$||œnoiseâ-12/CD	dep||$-11/$||$-13/$	quantmod||euglycemia-18/CD||more-15/JJR	quantmod||euglycemia-18/CD||symptoms-16/IN	quantmod||euglycemia-18/CD||during-17/IN	npadvmod||more-37/JJR||euglycemia-18/CD	appos||euglycemia-18/CD||making-21/NN	npadvmod||harder-23/JJR||it-22/PRP	amod||making-21/NN||harder-23/JJR	amod||driving-28/NN||detect-25/JJ	nn||driving-28/NN||hypoglycemia-26/NN	nn||driving-28/NN||while-27/NN	prep_to||harder-23/JJR||driving-28/NN	advmod||driving-28/NN||possibly-30/RB	amod||utilization-33/NN||greater-31/JJR	nn||utilization-33/NN||carbohydrate-32/NN	dep||driving-28/NN||utilization-33/NN	prep_rendering||euglycemia-18/CD||them-36/PRP	dep||hypoglycemia-41/CD||more-37/JJR	dep||more-37/JJR||vulnerable-38/CD	prep_to||more-37/JJR||experiencing-40/NNP	num||$-13/$||hypoglycemia-41/CD	amod||counterregulation-45/NN||less-43/JJR	amod||counterregulation-45/NN||hormonal-44/JJ	dobj||â-10/VBN||counterregulation-45/NN	conj_and||$-11/$||counterregulation-45/NN	appos||counterregulation-45/NN||leading-47/VBG	amod||hypoglycemia-51/NN||more-49/JJR	amod||hypoglycemia-51/NN||profound-50/JJ	prep_to||leading-47/VBG||hypoglycemia-51/NN	amod||neuroglycopenia-55/NN||more-54/JJR	dobj||â-10/VBN||neuroglycopenia-55/NN	conj_and||$-11/$||neuroglycopenia-55/NN	vmod||â-10/VBN||rendering-57/VBG	nsubj||driving-63/VBG||them-58/PRP	advmod||vulnerable-60/JJ||more-59/RBR	dep||driving-63/VBG||vulnerable-60/JJ	prep_to||vulnerable-60/JJ||impaired-62/JJ	xcomp||rendering-57/VBG||driving-63/VBG	hypoglycemia-51||carbohydrate-32||no_rel||this increased vulnerability may be due to more symptom â€œnoiseâ€? (more symptoms during euglycemia), making it harder to detect hypoglycemia while driving; possibly greater carbohydrate utilization, rendering them more vulnerable to experiencing hypoglycemia; less hormonal counterregulation, leading to more profound hypoglycemia; and more neuroglycopenia, rendering them more vulnerable to impaired driving.
prep_objectiveâ||demonstrated-7/VBN||$-2/$	amod||work-5/NN||previous-4/JJ	nsubj||demonstrated-7/VBN||work-5/NN	aux||demonstrated-7/VBN||has-6/VBZ	root||ROOT-0/null||demonstrated-7/VBN	mark||augments-20/VBZ||that-8/IN	amod||administration-10/NN||chronic-9/JJ	nsubj||augments-20/VBZ||administration-10/NN	det||fluoxetine-19/NN||the-12/DT	amod||reuptake-14/JJ||serotonin-13/JJ	amod||fluoxetine-19/NN||reuptake-14/JJ	nn||fluoxetine-19/NN||inhibitor-15/NN	appos||fluoxetine-19/NN||ssri-17/NNP	prep_of||administration-10/NN||fluoxetine-19/NN	ccomp||demonstrated-7/VBN||augments-20/VBZ	amod||responses-22/NNS||counterregulatory-21/JJ	dobj||augments-20/VBZ||responses-22/NNS	prep_to||augments-20/VBZ||hypoglycemia-24/NN	amod||humans-27/NNS||healthy-26/JJ	prep_in||hypoglycemia-24/NN||humans-27/NNS	serotonin-13||hypoglycemia-24||no_rel||objectiveâ€” previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (ssri) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	hypocalcemia-26||crystal-4||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
amod||mites-2/NNS||hominis-1/JJ	nsubj||show-11/VBP||mites-2/NNS	vmod||mites-2/NNS||collected-3/VBN	amod||communities-7/NNS||scabies-5/JJ	amod||communities-7/NNS||endemic-6/JJ	prep_from||collected-3/VBN||communities-7/NNS	amod||australia-10/NN||northern-9/JJ	prep_in||communities-7/NNS||australia-10/NN	root||ROOT-0/null||show-11/VBP	xcomp||show-11/VBP||increasing-12/VBG	dobj||increasing-12/VBG||tolerance-13/NN	number||%-16/NN||5-15/CD	amod||permethrin-17/NN||%-16/NN	prep_to||increasing-12/VBG||permethrin-17/NN	amod||ivermectin-20/NN||oral-19/JJ	prep_to||increasing-12/VBG||ivermectin-20/NN	conj_and||permethrin-17/NN||ivermectin-20/NN	scabies-5||permethrin-17||yes||hominis mites collected from scabies endemic communities in northern australia show increasing tolerance to 5% permethrin and oral ivermectin.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	mark||cause-21/VB||that-3/IN	poss||dysregulation-5/NN||their-4/PRP$	nsubj||cause-21/VB||dysregulation-5/NN	det||novo-13/NN||either-7/DT	prep_due_to||novo-13/NN||inborn-10/CD	conj_or||inborn-10/CD||de-12/IN	prep_due_to||novo-13/NN||de-12/IN	dep||dysregulation-5/NN||novo-13/NN	amod||mutations-15/NNS||genomic-14/JJ	nsubj||selected-16/VBD||mutations-15/NNS	rcmod||novo-13/NN||selected-16/VBD	prep_by||novo-13/NN||treatment-18/NN	aux||cause-21/VB||could-20/MD	ccomp||propose-2/VBP||cause-21/VB	det||relapse-23/NN||a-22/DT	dobj||cause-21/VB||relapse-23/NN	amod||patients-28/NNS||apparent-25/JJ	nn||patients-28/NNS||cr-26/NN	nn||patients-28/NNS||aml-27/NN	prep_in||relapse-23/NN||patients-28/NNS	cr-26||aml-27||no_rel||we propose that their dysregulation (either due to inborn or de novo genomic mutations selected by treatment) could cause a relapse in apparent cr aml patients.
nsubj||occurred-7/VBD||normalization-1/NN	nn||acidosis-6/NNS||hyperchloremia-3/NN	conj_and||hyperchloremia-3/NN||metabolic-5/NN	nn||acidosis-6/NNS||metabolic-5/NN	prep_of||normalization-1/NN||acidosis-6/NNS	root||ROOT-0/null||occurred-7/VBD	advmod||occurred-7/VBD||faster-8/RBR	det||patients-11/NNS||the-10/DT	prep_in||occurred-7/VBD||patients-11/NNS	nsubj||received-13/VBD||patients-11/NNS	rcmod||patients-11/NNS||received-13/VBD	acomp||received-13/VBD||sodiumacetate-14/JJ	acidosis-6||sodiumacetate-14||yes||normalization of hyperchloremia and metabolic acidosis occurred faster in the patients who received sodiumacetate.
nsubj||disorder-8/NN||celiacdisease-1/NN	appos||celiacdisease-1/NN||cd-3/NN	cop||disorder-8/NN||is-5/VBZ	det||disorder-8/NN||a-6/DT	amod||disorder-8/NN||chronic-7/JJ	root||ROOT-0/null||disorder-8/NN	prep_in||precipitated-21/VBN||disorder-8/NN	advmod||predisposed-11/JJ||genetically-10/RB	amod||individuals-12/NNS||predisposed-11/JJ	prep_in||disorder-8/NN||individuals-12/NNS	det||enteropathy-19/NN||a-15/DT	amod||enteropathy-19/NN||small-16/JJ	amod||enteropathy-19/NN||intestinal-17/JJ	amod||enteropathy-19/NN||immune-mediated-18/JJ	nsubjpass||precipitated-21/VBN||enteropathy-19/NN	auxpass||precipitated-21/VBN||is-20/VBZ	rcmod||disorder-8/NN||precipitated-21/VBN	amod||gluten-24/NN||dietary-23/JJ	agent||precipitated-21/VBN||gluten-24/NN	celiacdisease-1||gluten-24||no||celiacdisease (cd) is a chronic disorder in genetically predisposed individuals in which a small intestinal immune-mediated enteropathy is precipitated by dietary gluten.
nsubj||some-10/DT||smoking-1/NN	nn||carcinogens-4/NNS||chemical-3/NN	appos||smoking-1/NN||carcinogens-4/NNS	prep_like||carcinogens-4/NNS||asbestos-6/NN	prep_like||carcinogens-4/NNS||organicsolvents-8/NNS	conj_or||asbestos-6/NN||organicsolvents-8/NNS	cop||some-10/DT||are-9/VBP	root||ROOT-0/null||some-10/DT	det||factors-13/NNS||these-12/DT	prep_of||some-10/DT||factors-13/NNS	nsubj||increase-15/VBP||factors-13/NNS	rcmod||factors-13/NNS||increase-15/VBP	det||risk-17/NN||the-16/DT	dobj||increase-15/VBP||risk-17/NN	det||rcc-20/NN||the-19/DT	prep_of||risk-17/NN||rcc-20/NN	asbestos-6||rcc-20||no_rel||smoking, chemical carcinogens like asbestos or organicsolvents are some of these factors that increase the risk of the rcc.
prep||represent-28/VB||given-1/VBN	det||paucity-3/NN||a-2/DT	pobj||given-1/VBN||paucity-3/NN	prep_of||paucity-3/NN||studies-5/NNS	vmod||studies-5/NNS||characterizing-6/VBG	det||effects-8/NNS||the-7/DT	dobj||characterizing-6/VBG||effects-8/NNS	amod||continence-20/NN||htlv-1-10/JJ	det||system-15/NN||the-12/DT	amod||nervous-14/JJ||autonomic-13/JJ	amod||system-15/NN||nervous-14/JJ	prep_on||htlv-1-10/JJ||system-15/NN	advmod||system-15/NN||particularly-17/RB	dep||system-15/NN||aspects-18/NNS	amod||aspects-18/NNS||controlling-19/VBG	prep_of||effects-8/NNS||continence-20/NN	det||patient-23/NN||this-22/DT	poss||course-26/NN||patient-23/NN	amod||course-26/NN||clinical-25/JJ	nsubj||represent-28/VB||course-26/NN	aux||represent-28/VB||may-27/MD	root||ROOT-0/null||represent-28/VB	num||type-30/NN||one-29/CD	dobj||represent-28/VB||type-30/NN	nn||point-33/NN||end-32/NN	prep_of||type-30/NN||point-33/NN	prep_for||represent-28/VB||patients-35/NNS	nn||bladder-40/NN||ham/tsp-37/NN	conj_and||ham/tsp-37/NN||neurogenic-39/JJ	nn||bladder-40/NN||neurogenic-39/JJ	prep_with||patients-35/NNS||bladder-40/NN	ham--1||htlv-1-10||no||given a paucity of studies characterizing the effects of htlv-1 on the autonomic nervous system, particularly aspects controlling continence, this patient's clinical course may represent one type of end point for patients with ham/tsp and neurogenic bladder.
det||prevalence-2/NN||the-1/DT	nsubjpass||determined-13/VBN||prevalence-2/NN	amod||virus-5/NN||tick-borneencephalitis-4/JJ	prep_of||prevalence-2/NN||virus-5/NN	appos||virus-5/NN||tbev-7/NNP	amod||korea-11/NN||southern-10/JJ	prep_in||virus-5/NN||korea-11/NN	auxpass||determined-13/VBN||was-12/VBD	root||ROOT-0/null||determined-13/VBN	agent||determined-13/VBN||collecting-15/VBG	dobj||collecting-15/VBG||ticks-16/NNS	vmod||collecting-15/VBG||using-17/VBG	nn||drags-19/NNS||tick-18/NN	dobj||using-17/VBG||drags-19/NNS	tick-borneencephalitis-4||tbev-7||no||the prevalence of tick-borneencephalitis virus (tbev) in southern korea was determined by collecting ticks using tick drags.
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||entecavir-1||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||prevalence-4/NN||the-3/DT	dobj||examined-2/VBD||prevalence-4/NN	det||âˆ-8/NN||the-6/DT	amod||âˆ-8/NN||mcp-1-7/JJ	poss||g-13/NN||âˆ-8/NN	num||g-13/NN||2518-10/CD	det||g-13/NN||a-11/DT	amod||g-13/NN||>-12/JJ	prep_of||prevalence-4/NN||g-13/NN	dep||g-13/NN||polymorphism-14/VBP	nn||patients-17/NNS||sle-16/NN	prep_in||polymorphism-14/VBP||patients-17/NNS	dep||patients-17/NNS||n-19/VBN	dep||199-21/CD||=-20/SYM	ccomp||n-19/VBN||199-21/CD	prep_of||prevalence-4/NN||controls-24/NNS	conj_and||g-13/NN||controls-24/NNS	dep||prevalence-4/NN||n-26/VBN	dep||250-28/CD||=-27/SYM	ccomp||n-26/VBN||250-28/CD	prep_in||examined-2/VBD||poland-31/NN	mcp--1||sle-16||no_rel||we examined the prevalence of the mcp-1 âˆ’2518 a>g polymorphism in sle patients ( n = 199) and controls ( n = 250) in poland.
det||case-2/NN||this-1/DT	nsubj||illustrates-3/VBZ||case-2/NN	root||ROOT-0/null||illustrates-3/VBZ	det||features-8/NNS||the-4/DT	advmod||well-known-6/JJ||less-5/RBR	amod||features-8/NNS||well-known-6/JJ	amod||features-8/NNS||clinical-7/JJ	dobj||illustrates-3/VBZ||features-8/NNS	amod||poisoning-12/NN||delayed-10/VBN	amod||poisoning-12/NN||ethyleneglycol-11/JJ	prep_of||features-8/NNS||poisoning-12/NN	amod||cranial-16/NN||multiple-15/JJ	prep_including||poisoning-12/NN||cranial-16/NN	prep_including||poisoning-12/NN||peripheralneuropathies-18/NNS	conj_and||cranial-16/NN||peripheralneuropathies-18/NNS	det||findings-23/NNS||the-21/DT	amod||findings-23/NNS||clinical-22/JJ	prep_of||features-8/NNS||findings-23/NNS	conj_and||poisoning-12/NN||findings-23/NNS	nsubj||point-26/VB||findings-23/NNS	aux||point-26/VB||may-25/MD	rcmod||findings-23/NNS||point-26/VB	det||diagnosis-29/NN||this-28/DT	prep_towards||point-26/VB||diagnosis-29/NN	det||absence-32/NN||the-31/DT	prep_in||diagnosis-29/NN||absence-32/NN	det||history-35/NN||a-34/DT	prep_of||absence-32/NN||history-35/NN	prep_of||history-35/NN||ingestion-37/NN	ethyleneglycol-11||peripheralneuropathies-18||no_rel||this case illustrates the less well-known clinical features of delayed ethyleneglycol poisoning, including multiple cranial and peripheralneuropathies, and the clinical findings which may point towards this diagnosis in the absence of a history of ingestion.
amod||enzymes-2/NNS||deubiquitylating-1/JJ	nsubj||hydrolyze-7/VB||enzymes-2/NNS	appos||enzymes-2/NNS||dubs-4/NNP	aux||hydrolyze-7/VB||can-6/MD	root||ROOT-0/null||hydrolyze-7/VB	det||bond-16/NN||a-8/DT	amod||bond-16/NN||peptide-9/JJ	conj_or||peptide-9/JJ||amide-11/JJ	amod||bond-16/NN||amide-11/JJ	conj_or||peptide-9/JJ||ester-13/JJ	amod||bond-16/NN||ester-13/JJ	conj_or||peptide-9/JJ||thiolester-15/JJ	amod||bond-16/NN||thiolester-15/JJ	dobj||hydrolyze-7/VB||bond-16/NN	det||c-terminus-19/NNS||the-18/DT	prep_at||hydrolyze-7/VB||c-terminus-19/NNS	prep_of||c-terminus-19/NNS||ubiq-21/NNP	appos||ubiq-21/NNP||ubiquitin-23/NN	det||post-translationally-28/NN||the-27/DT	prep_including||hydrolyze-7/VB||post-translationally-28/NN	vmod||post-translationally-28/NN||formed-29/VBN	amod||bonds-32/NNS||branched-30/JJ	nn||bonds-32/NNS||peptide-31/NN	dobj||formed-29/VBN||bonds-32/NNS	prep_in||formed-29/VBN||mono-34/NN	amod||conjugates-38/NNS||multi-ubiquitylated-37/JJ	prep_in||formed-29/VBN||conjugates-38/NNS	conj_or||mono-34/NN||conjugates-38/NNS	mono-34||amide-11||no_rel||deubiquitylating enzymes (dubs) can hydrolyze a peptide, amide, ester or thiolester bond at the c-terminus of ubiq (ubiquitin), including the post-translationally formed branched peptide bonds in mono- or multi-ubiquitylated conjugates.
aux||investigate-2/VB||to-1/TO	csubj||synthase-11/VBD||investigate-2/VB	csubj||synthase-11/VBD||investigate-2/VB	det||expression-4/NN||the-3/DT	dobj||investigate-2/VB||expression-4/NN	amod||prostaglandine-7/NN||microsomal-6/JJ	prep_of||expression-4/NN||prostaglandine-7/NN	appos||prostaglandine-7/NN||pge-9/NN	root||ROOT-0/null||synthase-11/VBD	conj_and||synthase-11/VBD||synthase-11/VBD	dobj||synthase-11/VBD||1-12/CD	dep||1-12/CD||mpges-1-14/JJ	dobj||synthase-11/VBD||cyclooxygenase-17/NN	conj_and||1-12/CD||cyclooxygenase-17/NN	appos||cyclooxygenase-17/NN||cox-19/NN	nn||biopsies-23/NNS||muscle-22/NN	prep_in||cyclooxygenase-17/NN||biopsies-23/NNS	prep_from||synthase-11/VBD||patients-25/NNS	prep_with||patients-25/NNS||polymyositis-27/NNS	prep_with||patients-25/NNS||dermatomyositis-29/NNS	conj_or||polymyositis-27/NNS||dermatomyositis-29/NNS	amod||treatment-35/NN||conventional-33/JJ	nn||treatment-35/NN||immunosuppressive-34/NN	prep_after||synthase-11/VBD||treatment-35/NN	prep_before||synthase-11/VBD||treatment-35/NN	dermatomyositis-29||pge-9||no_rel||to investigate the expression of microsomal prostaglandine (pge) synthase 1 (mpges-1) and cyclooxygenase (cox) in muscle biopsies from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
amod||practice-3/NN||everyday-2/JJ	prep_in||experienced-16/VBD||practice-3/NN	nsubj||experienced-16/VBD||patients-5/NNS	prep_with||patients-5/NNS||type-7/NN	num||type-7/NN||1-8/CD	amod||insulins-15/NNS||type2diabetes-10/JJ	advmod||controlled-12/JJ||inadequately-11/RB	amod||insulins-15/NNS||controlled-12/JJ	prep_by||controlled-12/JJ||premix-14/NN	conj_or||patients-5/NNS||insulins-15/NNS	nsubj||experienced-16/VBD||insulins-15/NNS	root||ROOT-0/null||experienced-16/VBD	amod||improvement-18/NN||significant-17/JJ	dobj||experienced-16/VBD||improvement-18/NN	amod||control-21/NN||glycaemic-20/JJ	prep_in||experienced-16/VBD||control-21/NN	num||months-24/NNS||12-23/CD	prep_over||control-21/NN||months-24/NNS	prepc_after||experienced-16/VBD||switching-26/VBG	det||regimen-31/NN||a-28/DT	amod||regimen-31/NN||glargine-based-29/JJ	nn||regimen-31/NN||insulin-30/NN	prep_to||switching-26/VBG||regimen-31/NN	type2diabetes-10||insulins-15||yes||in everyday practice, patients with type 1 or type2diabetes inadequately controlled by premix insulins experienced significant improvement in glycaemic control over 12 months after switching to a glargine-based insulin regimen.
det||antibody-3/NN||the-1/DT	amod||antibody-3/NN||e4g10-2/JJ	nsubj||targeted-5/VBD||antibody-3/NN	advmod||targeted-5/VBD||specifically-4/RB	root||ROOT-0/null||targeted-5/VBD	det||endothelial-cadherin-9/NN||the-6/DT	amod||endothelial-cadherin-9/NN||monomeric-7/JJ	nn||endothelial-cadherin-9/NN||vascular-8/NN	nsubj||expressed-14/VBD||endothelial-cadherin-9/NN	dep||endothelial-cadherin-9/NN||ve-cad-11/JJ	advmod||expressed-14/VBD||epitope-13/RB	ccomp||targeted-5/VBD||expressed-14/VBD	det||vessels-19/NNS||the-16/DT	nn||vessels-19/NNS||tumor-17/NN	amod||vessels-19/NNS||angiogenic-18/JJ	prep_in||expressed-14/VBD||vessels-19/NNS	antibody-3||tumor-17||no_rel||the e4g10 antibody specifically targeted the monomeric vascular endothelial-cadherin (ve-cad) epitope expressed in the tumor angiogenic vessels.
det||products-4/NNS||these-1/DT	amod||products-4/NNS||toxic-2/JJ	nn||products-4/NNS||oxygen-3/NN	nsubj||results-7/NNS||products-4/NNS	cop||results-7/NNS||are-5/VBP	det||results-7/NNS||the-6/DT	root||ROOT-0/null||results-7/NNS	prep_of||results-7/NNS||re-oxygenation-9/NN	det||collapsedlung-12/NN||a-11/DT	prep_of||re-oxygenation-9/NN||collapsedlung-12/NN	collapsedlung-12||oxygen-3||no_rel||these toxic oxygen products are the results of re-oxygenation of a collapsedlung.
nsubj||reduced-3/VBN||uganda-1/NN	aux||reduced-3/VBN||has-2/VBZ	root||ROOT-0/null||reduced-3/VBN	poss||prevalence-5/NN||its-4/PRP$	dobj||reduced-3/VBN||prevalence-5/NN	prep_of||prevalence-5/NN||hiv/aids-7/NNS	number||6.5-11/CD||18-9/CD	dep||6.5-11/CD||to-10/TO	num||%-12/NN||6.5-11/CD	prep_from||reduced-3/VBN||%-12/NN	det||decade-15/NN||a-14/DT	prep_within||%-12/NN||decade-15/NN	aids--1||hiv--1||no||uganda has reduced its prevalence of hiv/aids from 18 to 6.5% within a decade.
aux||determine-2/VB||to-1/TO	advcl||tested-36/VBN||determine-2/VB	det||role-4/NN||the-3/DT	dobj||determine-2/VB||role-4/NN	amod||degradation-7/NN||metabolic-6/JJ	prep_of||role-4/NN||degradation-7/NN	det||mechanism-10/NN||a-9/DT	prep_as||determine-2/VB||mechanism-10/NN	amod||resistance-13/NN||acaricide-12/JJ	prep_for||mechanism-10/NN||resistance-13/NN	amod||mites-16/NNS||scabies-15/JJ	prep_in||determine-2/VB||mites-16/NNS	nsubjpass||tested-36/VBN||pbo-18/NN	appos||pbo-18/NN||piperonylbutoxide-20/NN	conj_and||pbo-18/NN||def-23/NN	nsubjpass||tested-36/VBN||def-23/NN	amod||phosphorotrithioate-26/NN||s,s,s-tributyl-25/JJ	appos||def-23/NN||phosphorotrithioate-26/NN	conj_and||pbo-18/NN||dem-29/NNP	nsubjpass||tested-36/VBN||dem-29/NNP	amod||maleate-32/NN||diethyl-31/JJ	appos||pbo-18/NN||maleate-32/NN	auxpass||tested-36/VBN||were-34/VBD	advmod||tested-36/VBN||first-35/RB	root||ROOT-0/null||tested-36/VBN	amod||activity-39/NN||synergistic-38/JJ	prep_for||tested-36/VBN||activity-39/NN	prep_with||tested-36/VBN||permethrin-41/NN	det||bioassay-44/NN||a-43/DT	prep_in||permethrin-41/NN||bioassay-44/NN	nn||killing-47/NN||mite-46/NN	prep_of||bioassay-44/NN||killing-47/NN	scabies-15||permethrin-41||yes||to determine the role of metabolic degradation as a mechanism for acaricide resistance in scabies mites, pbo (piperonylbutoxide), def (s,s,s-tributyl phosphorotrithioate) and dem (diethyl maleate) were first tested for synergistic activity with permethrin in a bioassay of mite killing.
det||standard-3/NN||the-1/DT	amod||standard-3/NN||current-2/JJ	nsubj||eradicates-14/VBZ||standard-3/NN	prep_of||standard-3/NN||care-5/NN	nn||treatment-8/NN||combination-7/NN	appos||standard-3/NN||treatment-8/NN	prep_with||treatment-8/NN||interferon-10/NN	prep_with||treatment-8/NN||ribavirin-12/NN	conj_and||interferon-10/NN||ribavirin-12/NN	root||ROOT-0/null||eradicates-14/VBZ	det||virus-16/NN||the-15/DT	dobj||eradicates-14/VBZ||virus-16/NN	quantmod||50-20/CD||only-18/RB	quantmod||50-20/CD||about-19/RB	num||%-21/NN||50-20/CD	prep_in||virus-16/NN||%-21/NN	advmod||patients-25/NNS||chronically-23/RB	amod||patients-25/NNS||infected-24/JJ	prep_of||%-21/NN||patients-25/NNS	virus-16||ribavirin-12||yes||the current standard of care, combination treatment with interferon and ribavirin, eradicates the virus in only about 50% of chronically infected patients.
amod||-rrb--4/NNS||vibriocholerae-1/JJ	amod||-rrb--4/NNS||-lrb--2/JJ	nn||-rrb--4/NNS||v.cholerae-3/NN	nsubj||causes-5/VBZ||-rrb--4/NNS	root||ROOT-0/null||causes-5/VBZ	det||disease-9/NN||a-6/DT	advmod||lethal-8/JJ||potentially-7/RB	amod||disease-9/NN||lethal-8/JJ	dobj||causes-5/VBZ||disease-9/NN	vmod||disease-9/NN||named-10/VBN	dobj||named-10/VBN||cholera-11/NN	vibriocholerae-1||v.cholerae-3||no||vibriocholerae -lrb- v.cholerae -rrb- causes a potentially lethal disease named cholera .
det||ability-2/NN||the-1/DT	nsubj||important-10/JJ||ability-2/NN	aux||give-4/VB||to-3/TO	vmod||ability-2/NN||give-4/VB	amod||doses-6/NNS||high-5/JJ	dobj||give-4/VB||doses-6/NNS	prep_of||doses-6/NNS||iron-8/NN	cop||important-10/JJ||is-9/VBZ	root||ROOT-0/null||important-10/JJ	det||context-13/NN||the-12/DT	prep_in||important-10/JJ||context-13/NN	amod||irondeficiencyanemia-16/NN||managing-15/VBG	prep_of||context-13/NN||irondeficiencyanemia-16/NN	det||number-19/NN||a-18/DT	prep_in||irondeficiencyanemia-16/NN||number-19/NN	amod||conditions-22/NNS||clinical-21/JJ	prep_of||number-19/NN||conditions-22/NNS	advmod||high-28/JJ||where-23/WRB	nsubj||high-28/JJ||demands-24/NNS	prep_for||demands-24/NNS||iron-26/NN	cop||high-28/JJ||are-27/VBP	rcmod||irondeficiencyanemia-16/NN||high-28/JJ	dep||important-10/JJ||including-30/VBG	amod||bloodloss-32/NNS||chronic-31/JJ	pobj||including-30/VBG||bloodloss-32/NNS	vmod||bloodloss-32/NNS||associated-33/VBN	nn||menorrhagia-37/NN||inflammatoryboweldisease-35/NN	prep_with||associated-33/VBN||menorrhagia-37/NN	nn||kidneydisease-41/NN||chronic-40/NN	prep_with||associated-33/VBN||kidneydisease-41/NN	conj_and||menorrhagia-37/NN||kidneydisease-41/NN	irondeficiencyanemia-16||iron-26||yes||the ability to give high doses of iron is important in the context of managing irondeficiencyanemia in a number of clinical conditions where demands for iron are high (including chronic bloodloss associated with inflammatoryboweldisease, menorrhagia, and chronic kidneydisease).
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	glucose-11||obesity-32||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
amod||forms-4/NNS||attractive-1/JJ	conj_and||attractive-1/JJ||novel-3/JJ	amod||forms-4/NNS||novel-3/JJ	nsubj||include-7/VBP||forms-4/NNS	prep_of||forms-4/NNS||therapy-6/NN	root||ROOT-0/null||include-7/VBP	dobj||include-7/VBP||strategies-8/NNS	aux||eliminate-10/VB||to-9/TO	vmod||strategies-8/NNS||eliminate-10/VB	amod||peptides-13/NNS||detrimental-11/JJ	nn||peptides-13/NNS||gluten-12/NN	dobj||eliminate-10/VB||peptides-13/NNS	det||diet-17/NN||the-15/DT	amod||diet-17/NN||celiac-16/JJ	prep_from||eliminate-10/VB||diet-17/NN	advmod||neutralized-29/VBN||so-18/RB	mark||neutralized-29/VBN||that-19/IN	det||effect-22/NN||the-20/DT	amod||effect-22/NN||immunogenic-21/JJ	nsubjpass||neutralized-29/VBN||effect-22/NN	det||epitopes-26/NNS||the-24/DT	nn||epitopes-26/NNS||gluten-25/NN	prep_of||effect-22/NN||epitopes-26/NNS	aux||neutralized-29/VBN||can-27/MD	auxpass||neutralized-29/VBN||be-28/VB	advcl||eliminate-10/VB||neutralized-29/VBN	dobj||include-7/VBP||strategies-34/NNS	conj_and||strategies-8/NNS||strategies-34/NNS	aux||block-36/VB||to-35/TO	vmod||strategies-34/NNS||block-36/VB	det||response-40/NN||the-37/DT	amod||response-40/NN||gluten-induced-38/JJ	amod||response-40/NN||inflammatory-39/JJ	dobj||block-36/VB||response-40/NN	celiac-16||gluten-25||no||attractive and novel forms of therapy include strategies to eliminate detrimental gluten peptides from the celiac diet so that the immunogenic effect of the gluten epitopes can be neutralized, as well as strategies to block the gluten-induced inflammatory response.
nsubj||classified-9/VBD||two-thirds-1/NNS	det||plhiv-4/NN||the-3/DT	prep_of||two-thirds-1/NNS||plhiv-4/NN	num||%-7/NN||66-6/CD	appos||plhiv-4/NN||%-7/NN	root||ROOT-0/null||classified-9/VBD	dobj||classified-9/VBD||themselves-10/PRP	auxpass||given-13/VBN||being-12/VBG	prepc_with||classified-9/VBD||given-13/VBN	det||aids-15/NNS||an-14/DT	iobj||given-13/VBN||aids-15/NNS	amod||stage-18/NN||advanced-17/JJ	dep||aids-15/NNS||stage-18/NN	prep_of||stage-18/NN||hiv-20/NN	dobj||given-13/VBN||diagnosis-22/NN	num||%-25/NN||48-24/CD	nsubj||were-26/VBD||%-25/NN	ccomp||classified-9/VBD||were-26/VBD	conj_and||classified-9/VBD||were-26/VBD	advmod||were-26/VBD||currently-27/RB	prep_on||were-26/VBD||art-29/NN	num||%-32/NN||35-31/CD	nsubj||were-33/VBD||%-32/NN	conj_and||classified-9/VBD||were-33/VBD	advmod||were-33/VBD||currently-34/RB	det||grant-38/NN||a-36/DT	nn||grant-38/NN||disability-37/NN	prep_on||were-33/VBD||grant-38/NN	prep_for||grant-38/NN||hiv/aids-40/NNS	num||%-44/NN||13-43/CD	prep_for||stopped-50/VBN||%-44/NN	det||grant-47/NN||the-45/DT	nn||grant-47/NN||disability-46/NN	nsubjpass||stopped-50/VBN||grant-47/NN	aux||stopped-50/VBN||had-48/VBD	auxpass||stopped-50/VBN||been-49/VBN	conj_and||classified-9/VBD||stopped-50/VBN	aids-15||hiv-20||no||two-thirds of the plhiv (66%) classified themselves with being given an aids (advanced stage of hiv) diagnosis, 48% were currently on art, 35% were currently on a disability grant for hiv/aids and for 13% the disability grant had been stopped.
nsubj||indicate-2/VBP||results-1/NNS	root||ROOT-0/null||indicate-2/VBP	mark||associated-9/JJ||that-3/IN	amod||stigma-6/NN||shame-related-4/JJ	nn||stigma-6/NN||hiv-5/NN	nsubj||associated-9/JJ||stigma-6/NN	aux||associated-9/JJ||is-7/VBZ	advmod||associated-9/JJ||strongly-8/RB	ccomp||indicate-2/VBP||associated-9/JJ	amod||beliefs-12/NNS||religious-11/JJ	prep_with||associated-9/JJ||beliefs-12/NNS	det||belief-16/NN||the-15/DT	prep_such_as||beliefs-12/NNS||belief-16/NN	mark||punishment-21/NN||that-17/IN	nsubj||punishment-21/NN||hiv-18/NN	cop||punishment-21/NN||is-19/VBZ	det||punishment-21/NN||a-20/DT	ccomp||associated-9/JJ||punishment-21/NN	prep_from||punishment-21/NN||god-23/NN	nn||0.01-27/NNP||p-25/NNP	nn||0.01-27/NNP||<-26/NNP	appos||god-23/NN||0.01-27/NNP	mark||followed-40/VBN||that-30/IN	nsubj||followed-40/VBN||people-31/NNS	vmod||people-31/NNS||living-32/VBG	prep_with||living-32/VBG||hiv/aids-34/NNS	appos||hiv/aids-34/NNS||plwha-36/NNP	aux||followed-40/VBN||have-38/VBP	neg||followed-40/VBN||not-39/RB	ccomp||associated-9/JJ||followed-40/VBN	conj_or||punishment-21/NN||followed-40/VBN	det||word-42/NN||the-41/DT	dobj||followed-40/VBN||word-42/NN	prep_of||word-42/NN||god-44/NN	appos||god-44/NN||p-46/NNP	number||0.001-48/CD||<-47/CD	num||p-46/NNP||0.001-48/CD	aids--1||hiv-18||no||results indicate that shame-related hiv stigma is strongly associated with religious beliefs such as the belief that hiv is a punishment from god (p < 0.01) or that people living with hiv/aids (plwha) have not followed the word of god (p < 0.001).
nsubj||shown-3/VBN||we-1/PRP	aux||shown-3/VBN||have-2/VBP	root||ROOT-0/null||shown-3/VBN	mark||boosts-6/VBZ||that-4/IN	nsubj||boosts-6/VBZ||semen-5/NN	nsubj||contains-10/VBZ||semen-5/NN	ccomp||shown-3/VBN||boosts-6/VBZ	amod||infection-8/NN||hiv-1-7/JJ	dobj||boosts-6/VBZ||infection-8/NN	ccomp||shown-3/VBN||contains-10/VBZ	conj_and||boosts-6/VBZ||contains-10/VBZ	dobj||contains-10/VBZ||fragments-11/NNS	amod||phosphatase-15/NN||prostatic-13/JJ	amod||phosphatase-15/NN||acid-14/JJ	prep_of||fragments-11/NNS||phosphatase-15/NN	appos||phosphatase-15/NN||pap-17/NN	xcomp||contains-10/VBZ||forming-19/VBG	amod||aggregates-21/NNS||amyloid-20/JJ	nsubj||termed-22/VBD||aggregates-21/NNS	ccomp||forming-19/VBG||termed-22/VBD	dobj||termed-22/VBD||sevi-23/NNS	nsubj||promote-31/VB||sevi-23/NNS	amod||enhancer-26/NN||semen-derived-25/JJ	dep||sevi-23/NNS||enhancer-26/NN	prep_of||enhancer-26/NN||viralinfection-28/NN	rcmod||sevi-23/NNS||promote-31/VB	nn||attachment-33/NN||virion-32/NN	dobj||promote-31/VB||attachment-33/NN	nn||cells-36/NNS||target-35/NN	prep_to||promote-31/VB||cells-36/NNS	viralinfection-28||pap-17||no_rel||we have shown that semen boosts hiv-1 infection and contains fragments of prostatic acid phosphatase (pap) forming amyloid aggregates termed sevi (semen-derived enhancer of viralinfection) that promote virion attachment to target cells.
det||study-2/NN||this-1/DT	root||ROOT-0/null||study-2/NN	vmod||study-2/NN||using-3/VBG	amod||research-5/NN||participatory-4/JJ	dobj||using-3/VBG||research-5/NN	nsubj||abusing-42/VBG||research-5/NN	nn||methods-11/NNS||action-7/NN	appos||methods-11/NNS||pra-9/NN	dobj||using-3/VBG||methods-11/NNS	conj_and||research-5/NN||methods-11/NNS	nsubj||abusing-42/VBG||methods-11/NNS	vmod||research-5/NN||sought-12/VBN	aux||understand-14/VB||to-13/TO	ccomp||sought-12/VBN||understand-14/VB	dobj||understand-14/VB||factors-15/NNS	advmod||understand-14/VB||related-16/VBN	prep_to||related-16/VBN||alcoholabuse-18/NN	prep_to||related-16/VBN||non-adherence-20/NN	conj_and||alcoholabuse-18/NN||non-adherence-20/NN	aux||formulate-23/VB||to-22/TO	ccomp||sought-12/VBN||formulate-23/VB	conj_and||understand-14/VB||formulate-23/VB	amod||interventions-25/NNS||appropriate-24/JJ	dobj||formulate-23/VB||interventions-25/NNS	det||sample-28/NN||a-27/DT	prep_in||formulate-23/VB||sample-28/NN	prep_of||sample-28/NN||people-30/NNS	vmod||people-30/NNS||living-31/VBG	prep_with||living-31/VBG||hiv-33/NN	prep_with||living-31/VBG||aids-35/NNS	conj_and||hiv-33/NN||aids-35/NNS	appos||research-5/NN||plwha-37/NNP	aux||abusing-42/VBG||were-40/VBD	advmod||abusing-42/VBG||also-41/RB	rcmod||research-5/NN||abusing-42/VBG	dobj||abusing-42/VBG||alcohol-43/NN	prep_at||using-3/VBG||kariobangi-46/NNS	prep_in||kariobangi-46/NNS||nairobi-48/NNS	appos||nairobi-48/NNS||kenya-50/NN	alcoholabuse-18||alcohol-43||no||this study using participatory research and action (pra) methods sought to understand factors related to alcoholabuse and non-adherence and to formulate appropriate interventions in a sample of people living with hiv and aids (plwha) who were also abusing alcohol, at kariobangi in nairobi, kenya.
amod||programmes-3/NNS||selective-1/JJ	nn||programmes-3/NNS||breeding-2/NN	nsubjpass||introduced-15/VBN||programmes-3/NNS	nsubj||reduce-21/VB||programmes-3/NNS	vmod||programmes-3/NNS||based-5/VBN	nn||genotype-11/NN||prionprotein-7/NNP	appos||genotype-11/NN||prp-9/NN	prep_on||based-5/VBN||genotype-11/NN	aux||introduced-15/VBN||have-13/VBP	auxpass||introduced-15/VBN||been-14/VBN	root||ROOT-0/null||introduced-15/VBN	det||union-19/NN||the-17/DT	nn||union-19/NN||european-18/NN	prep_throughout||introduced-15/VBN||union-19/NN	aux||reduce-21/VB||to-20/TO	xcomp||introduced-15/VBN||reduce-21/VB	det||risk-23/NN||the-22/DT	dobj||reduce-21/VB||risk-23/NN	nn||transmissiblespongiformencephalopathies-26/NNS||sheep-25/NN	prep_of||risk-23/NN||transmissiblespongiformencephalopathies-26/NNS	appos||transmissiblespongiformencephalopathies-26/NNS||tses-28/NNS	transmissiblespongiformencephalopathies-26||prionprotein-7||no||selective breeding programmes, based on prionprotein (prp) genotype, have been introduced throughout the european union to reduce the risk of sheep transmissiblespongiformencephalopathies (tses).
det||study-2/NN||this-1/DT	nsubj||focused-3/VBD||study-2/NN	root||ROOT-0/null||focused-3/VBD	det||determination-6/NN||the-5/DT	prep_upon||focused-3/VBD||determination-6/NN	amod||properties-11/NNS||physicochemical-8/JJ	conj_and||physicochemical-8/JJ||microbial-10/JJ	amod||properties-11/NNS||microbial-10/JJ	prep_of||determination-6/NN||properties-11/NNS	prep_including||focused-3/VBD||metals-14/NNS	amod||anions-17/NNS||selected-16/VBN	prep_including||focused-3/VBD||anions-17/NNS	conj_and||metals-14/NNS||anions-17/NNS	nn||bacteria-20/NNS||coliform-19/NN	prep_including||focused-3/VBD||bacteria-20/NNS	conj_and||metals-14/NNS||bacteria-20/NNS	prepc_in||bacteria-20/NNS||drinking-22/VBG	nn||samples-24/NNS||water-23/NN	dobj||drinking-22/VBG||samples-24/NNS	amod||wells-27/NNS||hand-dug-26/JJ	prep_from||drinking-22/VBG||wells-27/NNS	det||metropolis-31/NNS||the-29/DT	amod||metropolis-31/NNS||kumasi-30/JJ	prep_in||wells-27/NNS||metropolis-31/NNS	det||republic-34/NN||the-33/DT	prep_of||metropolis-31/NNS||republic-34/NN	prep_of||republic-34/NN||ghana-36/NN	wells-27||bacteria-20||no||this study focused upon the determination of physicochemical and microbial properties, including metals, selected anions and coliform bacteria in drinking water samples from hand-dug wells in the kumasi metropolis of the republic of ghana.
det||issue-4/NN||the-2/DT	amod||issue-4/NN||previous-3/JJ	prep_in||used-12/VBD||issue-4/NN	amod||care-7/NN||critical-6/JJ	prep_of||issue-4/NN||care-7/NN	nsubj||used-12/VBD||otto-9/NN	nsubj||explore-17/VB||otto-9/NN	conj_and||otto-9/NN||colleagues-11/NNS	nsubj||used-12/VBD||colleagues-11/NNS	nsubj||explore-17/VB||colleagues-11/NNS	root||ROOT-0/null||used-12/VBD	amod||studies-15/NNS||vitro-14/JJ	prep_in||used-12/VBD||studies-15/NNS	aux||explore-17/VB||to-16/TO	xcomp||used-12/VBD||explore-17/VB	det||theory-19/NN||the-18/DT	dobj||explore-17/VB||theory-19/NN	mark||factor-32/NN||that-20/IN	nsubj||factor-32/NN||immunomodulation-21/NN	prep_by||immunomodulation-21/NN||correction-24/NN	prep_of||correction-24/NN||hyperglycemia-26/NN	aux||factor-32/NN||may-28/MD	cop||factor-32/NN||be-29/VB	det||factor-32/NN||a-30/DT	amod||factor-32/NN||contributing-31/JJ	ccomp||explore-17/VB||factor-32/NN	det||efficacy-36/NN||the-34/DT	amod||efficacy-36/NN||reported-35/VBN	prep_to||factor-32/NN||efficacy-36/NN	amod||therapy-40/NN||intensive-38/JJ	nn||therapy-40/NN||insulin-39/NN	prep_of||efficacy-36/NN||therapy-40/NN	appos||therapy-40/NN||iit-42/NN	advmod||ill-46/JJ||critically-45/RB	amod||patients-47/NNS||ill-46/JJ	prep_in||therapy-40/NN||patients-47/NNS	hyperglycemia-26||insulin-39||yes||in the previous issue of critical care , otto and colleagues used in vitro studies to explore the theory that immunomodulation, by correction of hyperglycemia, may be a contributing factor to the reported efficacy of intensive insulin therapy (iit) in critically ill patients.
amod||vaccines-6/NNS||novel-1/JJ	nn||vaccines-6/NNS||tuberculosis-2/NNP	appos||vaccines-6/NNS||tb-4/NN	nsubjpass||designed-13/VBN||vaccines-6/NNS	nsubj||boost-15/VB||vaccines-6/NNS	advmod||tested-8/VBN||recently-7/RB	vmod||vaccines-6/NNS||tested-8/VBN	prep_in||tested-8/VBN||humans-10/NNS	aux||designed-13/VBN||have-11/VBP	auxpass||designed-13/VBN||been-12/VBN	ccomp||mycobacteriumbovis-23/VBZ||designed-13/VBN	aux||boost-15/VB||to-14/TO	xcomp||designed-13/VBN||boost-15/VB	dobj||boost-15/VB||immunity-16/NN	vmod||immunity-16/NN||induced-17/VBN	det||vaccine-21/NN||the-19/DT	amod||vaccine-21/NN||current-20/JJ	agent||induced-17/VBN||vaccine-21/NN	root||ROOT-0/null||mycobacteriumbovis-23/VBZ	amod||rin-27/NN||bacille-24/JJ	amod||rin-27/NN||calmette-guã-25/JJ	nn||rin-27/NN||©-26/NN	nsubj||mycobacteriumbovis-23/VBZ||rin-27/NN	appos||rin-27/NN||bcg-29/NN	tuberculosis-2||bcg-29||no||novel tuberculosis (tb) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, mycobacteriumbovis bacille calmette-guã©rin (bcg).
amod||care-4/NN||benzodiazepines-1/JJ	conj_and||benzodiazepines-1/JJ||supportive-3/JJ	amod||care-4/NN||supportive-3/JJ	nsubjpass||used-11/VBN||care-4/NN	nsubj||treat-13/VB||care-4/NN	amod||nutritional-7/JJ||vitaminand-6/JJ	amod||support-8/NN||nutritional-7/JJ	prep_including||care-4/NN||support-8/NN	auxpass||used-11/VBN||are-9/VBP	advmod||used-11/VBN||mainly-10/RB	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	dobj||treat-13/VB||alcoholwithdrawal-14/NN	prep_in||treat-13/VB||korea-16/NN	vitamin--1||alcoholwithdrawal-14||no_rel||benzodiazepines and supportive care including vitaminand nutritional support are mainly used to treat alcoholwithdrawal in korea.
amod||hyperglycemia-3/NN||intermittent-2/JJ	prep_for||exchanged-12/VBN||hyperglycemia-3/NN	det||medium-6/NN||the-5/DT	nsubjpass||exchanged-12/VBN||medium-6/NN	vmod||medium-6/NN||containing-7/VBG	num||glucose-10/NN||11-8/CD	nn||glucose-10/NN||mm-9/NN	dobj||containing-7/VBG||glucose-10/NN	auxpass||exchanged-12/VBN||was-11/VBD	root||ROOT-0/null||exchanged-12/VBN	det||medium-15/NN||the-14/DT	prep_with||exchanged-12/VBN||medium-15/NN	vmod||medium-15/NN||containing-16/VBG	num||glucose-19/NN||33-17/CD	nn||glucose-19/NN||mm-18/NN	iobj||containing-16/VBG||glucose-19/NN	det||hours-22/NNS||every-20/DT	num||hours-22/NNS||12-21/CD	dobj||containing-16/VBG||hours-22/NNS	hyperglycemia-3||glucose-19||no||for intermittent hyperglycemia, the medium containing 11 mm glucose was exchanged with the medium containing 33 mm glucose every 12 hours.
prep_in||conducted-6/VBD||2007/2008-2/CD	det||authors-5/NNS||the-4/DT	nsubj||conducted-6/VBD||authors-5/NNS	root||ROOT-0/null||conducted-6/VBD	det||trial-17/NN||an-7/DT	amod||trial-17/NN||investigator-initiated-8/JJ	amod||trial-17/NN||non-commercial-10/JJ	amod||trial-17/NN||double-blind-12/JJ	amod||trial-17/NN||randomised-14/JJ	amod||trial-17/NN||controlled-15/JJ	nn||trial-17/NN||pilot-16/NN	dobj||conducted-6/VBD||trial-17/NN	dep||trial-17/NN||hwi-01-19/JJ	aux||assess-22/VB||to-21/TO	vmod||conducted-6/VBD||assess-22/VB	det||equivalence-25/NN||the-23/DT	amod||equivalence-25/NN||clinical-24/JJ	dobj||assess-22/VB||equivalence-25/NN	prep_of||equivalence-25/NN||ibuprofen-27/NN	prep_of||equivalence-25/NN||ciprofloxacin-29/NN	conj_and||ibuprofen-27/NN||ciprofloxacin-29/NN	det||treatment-32/NN||the-31/DT	prep_in||assess-22/VB||treatment-32/NN	amod||urinarytractinfection-35/NN||uncomplicated-34/JJ	prep_of||treatment-32/NN||urinarytractinfection-35/NN	appos||urinarytractinfection-35/NN||uti-37/NN	uti-37||ciprofloxacin-29||yes||in 2007/2008, the authors conducted an investigator-initiated, non-commercial, double-blind, randomised controlled pilot trial (hwi-01) to assess the clinical equivalence of ibuprofen and ciprofloxacin in the treatment of uncomplicated urinarytractinfection (uti).
nn||binding-2/NN||virus-1/NN	nsubjpass||conducted-7/VBN||binding-2/NN	nsubj||determine-9/VB||binding-2/NN	nn||experiments-5/NNS||infection-4/NN	conj_and||binding-2/NN||experiments-5/NNS	nsubjpass||conducted-7/VBN||experiments-5/NNS	nsubj||determine-9/VB||experiments-5/NNS	auxpass||conducted-7/VBN||were-6/VBD	root||ROOT-0/null||conducted-7/VBN	aux||determine-9/VB||to-8/TO	xcomp||conducted-7/VBN||determine-9/VB	advmod||important-11/JJ||functionally-10/RB	amod||glycans-12/NNS||important-11/JJ	dobj||determine-9/VB||glycans-12/NNS	prep_for||determine-9/VB||influenzavirusinfection-14/NN	det||focus-18/NN||a-17/DT	prep_with||determine-9/VB||focus-18/NN	advmod||emerged-21/VBN||recently-20/RB	amod||viruses-23/NNS||emerged-21/VBN	amod||viruses-23/NNS||swine-22/JJ	prep_on||focus-18/NN||viruses-23/NNS	virus-1||viruses-23||no||virus binding and infection experiments were conducted to determine functionally important glycans for influenzavirusinfection, with a focus on recently emerged swine viruses.
num||types-3/NNS||seven-1/CD	amod||types-3/NNS||different-2/JJ	nsubjpass||examined-7/VBN||types-3/NNS	prep_of||types-3/NNS||evidence-5/NN	auxpass||examined-7/VBN||were-6/VBD	root||ROOT-0/null||examined-7/VBN	dep||models-11/NNS||1-9/LS	dobj||examined-7/VBN||models-11/NNS	nn||prevalence-14/NN||hiv-13/NN	prep_of||models-11/NNS||prevalence-14/NN	prep_of||models-11/NNS||incidence-16/NN	conj_and||prevalence-14/NN||incidence-16/NN	prep_in||prevalence-14/NN||kampala-18/NN	amod||sites-22/NNS||other-20/JJ	amod||sites-22/NNS||sentinel-21/JJ	dobj||examined-7/VBN||sites-22/NNS	conj_and||models-11/NNS||sites-22/NNS	prep_in||sites-22/NNS||uganda-24/NN	dep||reports-29/NNS||2-27/LS	dep||sites-22/NNS||reports-29/NNS	nn||change-32/NN||behaviour-31/NN	prep_of||reports-29/NNS||change-32/NN	det||newspaper-36/NN||the-34/DT	amod||newspaper-36/NN||primary-35/JJ	prep_in||change-32/NN||newspaper-36/NN	prep_in||newspaper-36/NN||uganda-38/NN	dep||surveys-43/NNS||3-41/LS	dep||sites-22/NNS||surveys-43/NNS	prep_with||surveys-43/NNS||questions-45/NNS	prep_about||questions-45/NNS||perceptions-47/NNS	amod||change-51/NN||personal-49/JJ	nn||change-51/NN||behaviour-50/NN	prep_of||perceptions-47/NNS||change-51/NN	appos||demographic-57/NN||4-54/CD	amod||demographic-57/NN||large-56/JJ	dep||sites-22/NNS||demographic-57/NN	nn||surveys-60/NNS||health-59/NN	dep||sites-22/NNS||surveys-60/NNS	conj_and||demographic-57/NN||surveys-60/NNS	appos||surveys-60/NNS||dhs-62/NN	vmod||sites-22/NNS||collected-64/VBN	prep_in||collected-64/VBN||1988/9-66/CD	prep_in||collected-64/VBN||1995-68/CD	conj_and||1988/9-66/CD||1995-68/CD	amod||program-72/NN||large-70/JJ	amod||program-72/NN||global-71/JJ	nsubj||surveys-78/VBZ||program-72/NN	prep_on||program-72/NN||aids-74/NNS	appos||aids-74/NNS||gpa-76/NN	conj_and||examined-7/VBN||surveys-78/VBZ	prep_in||surveys-78/VBZ||1989-80/CD	prep_in||surveys-78/VBZ||1995-82/CD	conj_and||1989-80/CD||1995-82/CD	prep_with||surveys-78/VBZ||questions-84/NNS	amod||behaviour-88/NN||reported-86/VBN	amod||behaviour-88/NN||sexual-87/JJ	prep_about||questions-84/NNS||behaviour-88/NN	dep||smaller-93/JJR||5-91/CD	parataxis||surveys-78/VBZ||smaller-93/JJR	prep||smaller-93/JJR||less-94/CC	amod||surveys-96/NNS||representative-95/JJ	pobj||less-94/CC||surveys-96/NNS	amod||behaviour-100/NN||reported-98/VBN	amod||behaviour-100/NN||sexual-99/JJ	prep_of||surveys-96/NNS||behaviour-100/NN	vmod||behaviour-100/NN||collected-101/VBN	amod||years-104/NNS||other-103/JJ	prep_in||collected-101/VBN||years-104/NNS	appos||reports-109/NNS||6-107/CD	dep||behaviour-100/NN||reports-109/NNS	prep_of||reports-109/NNS||numbers-111/NNS	prep_of||numbers-111/NNS||condoms-113/NNS	vmod||condoms-113/NNS||shipped-114/VBN	prep_to||shipped-114/VBN||uganda-116/NN	appos||uganda-116/NN||7-120/CD	amod||documents-123/NNS||historical-122/JJ	prep_to||shipped-114/VBN||documents-123/NNS	conj_and||uganda-116/NN||documents-123/NNS	xcomp||shipped-114/VBN||describing-124/VBG	det||implementation-126/NN||the-125/DT	dobj||describing-124/VBG||implementation-126/NN	nn||programmes-130/NNS||hiv-128/NN	nn||programmes-130/NNS||prevention-129/NN	prep_of||implementation-126/NN||programmes-130/NNS	prep_in||describing-124/VBG||uganda-132/NN	aids-74||hiv-128||no||seven different types of evidence were examined (1) models of hiv prevalence and incidence in kampala and other sentinel sites in uganda; (2) reports of behaviour change in the primary newspaper in uganda; (3) surveys with questions about perceptions of personal behaviour change; (4) large demographic and health surveys (dhs) collected in 1988/9 and 1995 and large global program on aids (gpa) surveys in 1989 and 1995 with questions about reported sexual behaviour; (5) smaller less representative surveys of reported sexual behaviour collected in other years; (6) reports of numbers of condoms shipped to uganda; and (7) historical documents describing the implementation of hiv prevention programmes in uganda.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	neg||correlation-4/NN||no-3/DT	dobj||found-2/VBD||correlation-4/NN	amod||rates-8/NNS||high-6/JJ	nn||rates-8/NNS||mdr-7/NN	prep_between||correlation-4/NN||rates-8/NNS	nn||incidence-11/NN||tb-10/NN	dobj||found-2/VBD||incidence-11/NN	conj_and||correlation-4/NN||incidence-11/NN	amod||rates-15/NNS||hiv/tb-13/JJ	amod||rates-15/NNS||co-infection-14/JJ	appos||incidence-11/NN||rates-15/NNS	dobj||found-2/VBD||year-18/NN	conj_or||correlation-4/NN||year-18/NN	prep_of||year-18/NN||introduction-20/NN	prep_of||introduction-20/NN||rifampin-22/NN	tb-10||rifampin-22||yes||we found no correlation between high mdr rates and tb incidence, hiv/tb co-infection rates, or year of introduction of rifampin.
nn||design-2/NN||research-1/NN	nsubj||pumpâ-10/VBD||design-2/NN	poss||insulin-9/NN||methods-4/NNS	nn||insulin-9/NN||$-6/NNP	num||insulin-9/NN||seventeen-8/CD	conj_and||design-2/NN||insulin-9/NN	nsubj||pumpâ-10/VBD||insulin-9/NN	root||ROOT-0/null||pumpâ-10/VBD	num||adolescents-14/NNS||$-11/$	num||$-11/$||treated-13/CD	nsubj||underwent-17/VBD||adolescents-14/NNS	prep_with||adolescents-14/NNS||type1diabetes-16/CD	ccomp||pumpâ-10/VBD||underwent-17/VBD	num||procedures-21/NNS||two-18/CD	amod||procedures-21/NNS||euglycemic-19/JJ	nn||procedures-21/NNS||clamp-20/NN	dobj||underwent-17/VBD||procedures-21/NNS	det||bolus-26/NNS||a-23/DT	num||bolus-26/NNS||0.2-24/CD	amod||bolus-26/NNS||unit/kg-25/VBG	prep_after||underwent-17/VBD||bolus-26/NNS	preconj||insulinaspart-29/NN||either-28/DT	prep_of||bolus-26/NNS||insulinaspart-29/NN	prep_of||bolus-26/NNS||lispro-31/NN	conj_or||insulinaspart-29/NN||lispro-31/NN	prep_on||insulinaspart-29/NN||day-33/NN	num||day-33/NN||1-34/CD	prep_of||bolus-26/NNS||day-36/NN	conj_and||insulinaspart-29/NN||day-36/NN	num||day-36/NN||4-37/CD	nn||insertion-42/NN||insulin-39/NN	nn||insertion-42/NN||pump-40/NN	nn||insertion-42/NN||site-41/NN	prep_of||day-36/NN||insertion-42/NN	type1diabetes-16||insulin-39||yes||research design and methods â€”seventeen insulin pumpâ€“treated adolescents with type1diabetes underwent two euglycemic clamp procedures after a 0.2 unit/kg bolus of either insulinaspart or lispro on day 1 and day 4 of insulin pump site insertion.
det||model-5/NN||a-2/DT	nn||model-5/NN||rat-3/NN	nn||model-5/NN||candidaalbicansvaginitis-4/NNS	prep_in||inhibited-12/VBD||model-5/NN	nsubj||inhibited-12/VBD||ckpv-8/NNP	nsubj||macrophages-17/VBZ||ckpv-8/NNP	npadvmod||significantly-11/RB||2-10/CD	advmod||inhibited-12/VBD||significantly-11/RB	root||ROOT-0/null||inhibited-12/VBD	amod||survival-15/NN||vaginal-13/JJ	nn||survival-15/NN||candidaalbicans-14/NNS	dobj||inhibited-12/VBD||survival-15/NN	conj_and||inhibited-12/VBD||macrophages-17/VBZ	amod||infiltration-20/NN||sub-epithelial-18/JJ	nn||infiltration-20/NN||mucosa-19/NN	dobj||macrophages-17/VBZ||infiltration-20/NN	candidaalbicansvaginitis-4||candidaalbicans-14||no||in a rat candidaalbicansvaginitis model, (ckpv)2 significantly inhibited vaginal candidaalbicans survival and macrophages sub-epithelial mucosa infiltration.
nsubj||tried-6/VBN||youth-2/NN	nsubj||lose-8/VB||youth-2/NN	prep_among||common-35/JJ||youth-2/NN	aux||tried-6/VBN||had-4/VBD	advmod||tried-6/VBN||ever-5/RB	rcmod||youth-2/NN||tried-6/VBN	aux||lose-8/VB||to-7/TO	xcomp||tried-6/VBN||lose-8/VB	dobj||lose-8/VB||weight-9/NN	dep||youth-2/NN||n-11/VBN	dep||1,646-13/CD||=-12/SYM	ccomp||n-11/VBN||1,646-13/CD	amod||practices-18/NNS||healthy-16/JJ	amod||practices-18/NNS||weight-loss-17/JJ	nsubj||common-35/JJ||practices-18/NNS	dep||practices-18/NNS||diet-20/NN	number||76.5-22/CD||-LSB--21/CD	num||%-23/NN||76.5-22/CD	nsubj||-RSB--24/VBZ||%-23/NN	nsubj||exercise-26/VBP||%-23/NN	rcmod||diet-20/NN||-RSB--24/VBZ	rcmod||diet-20/NN||exercise-26/VBP	conj_and||-RSB--24/VBZ||exercise-26/VBP	number||94.8-28/CD||-LSB--27/CD	dep||%-29/NN||94.8-28/CD	dep||-RSB--30/NNS||%-29/NN	dobj||exercise-26/VBP||-RSB--30/NNS	cop||common-35/JJ||were-32/VBD	det||common-35/JJ||the-33/DT	advmod||common-35/JJ||most-34/RBS	root||ROOT-0/null||common-35/JJ	mark||common-75/JJ||whereas-37/IN	amod||practices-39/NNS||unhealthy-38/JJ	nsubj||common-75/JJ||practices-39/NNS	dep||practices-39/NNS||fasting-41/VBG	ccomp||fasting-41/VBG||-LSB--42/VBG	num||%-44/NN||8.6-43/CD	dobj||-LSB--42/VBG||%-44/NN	advmod||-LSB--42/VBG||-RSB--45/RB	ccomp||fasting-41/VBG||using-47/VBG	conj_and||-LSB--42/VBG||using-47/VBG	nn||aids-49/NNS||diet-48/NN	dobj||using-47/VBG||aids-49/NNS	vmod||aids-49/NNS||-LSB--50/VBN	number||%-52/NN||7.5-51/CD	amod||-RSB--62/NN||%-52/NN	nn||-RSB--62/NN||-RSB--53/JJ	conj_or||-RSB--53/JJ||vomiting-55/NN	nn||-RSB--62/NN||vomiting-55/NN	conj_or||-RSB--53/JJ||laxative-57/NN	nn||-RSB--62/NN||laxative-57/NN	nn||-RSB--62/NN||use-58/NN	num||-RSB--62/NN||-LSB--59/CD	number||%-61/NN||2.3-60/CD	amod||-RSB--62/NN||%-61/NN	dep||-LSB--50/VBN||-RSB--62/NN	ccomp||fasting-41/VBG||skipping-65/VBG	conj_and||-LSB--42/VBG||skipping-65/VBG	nn||doses-67/NNS||insulin-66/NN	dobj||skipping-65/VBG||doses-67/NNS	vmod||skipping-65/VBG||-LSB--68/VBG	number||%-70/NN||4.2-69/CD	amod||-RSB--71/NNS||%-70/NN	dobj||-LSB--68/VBG||-RSB--71/NNS	cop||common-75/JJ||were-73/VBD	advmod||common-75/JJ||less-74/RBR	advcl||common-35/JJ||common-75/JJ	aids-49||laxative-57||no_rel||among youth who had ever tried to lose weight ( n = 1,646), healthy weight-loss practices (diet [76.5%] and exercise [94.8%]) were the most common, whereas unhealthy practices (fasting [8.6%], using diet aids [7.5%], vomiting or laxative use [2.3%], and skipping insulin doses [4.2%]) were less common.
mark||understand-5/VB||in-1/IN	dep||understand-5/VB||order-2/NN	aux||understand-5/VB||to-3/TO	advmod||understand-5/VB||well-4/RB	advcl||conducted-15/VBN||understand-5/VB	det||knowledge-8/NN||the-6/DT	amod||knowledge-8/NN||hiv/aids-7/JJ	dobj||understand-5/VB||knowledge-8/NN	prep_among||knowledge-8/NN||detainees-10/NNS	det||survey-13/NN||a-12/DT	nsubjpass||conducted-15/VBN||survey-13/NN	auxpass||conducted-15/VBN||was-14/VBD	root||ROOT-0/null||conducted-15/VBN	amod||settings-19/NNS||different-17/JJ	nn||settings-19/NNS||detention-18/NN	prep_in||conducted-15/VBN||settings-19/NNS	nn||province-22/NN||hunan-21/NN	prep_in||settings-19/NNS||province-22/NN	prep_in||province-22/NN||2008-24/CD	aux||assess-26/VB||to-25/TO	ccomp||conducted-15/VBN||assess-26/VB	dobj||assess-26/VB||knowledge-27/NN	dobj||assess-26/VB||attitudes-29/NNS	conj_and||knowledge-27/NN||attitudes-29/NNS	prep_about||assess-26/VB||hiv-31/NN	prep_among||hiv-31/NN||detainees-33/NNS	aux||provide-36/VB||to-35/TO	ccomp||conducted-15/VBN||provide-36/VB	conj_and||assess-26/VB||provide-36/VB	amod||information-38/NN||useful-37/JJ	dobj||provide-36/VB||information-38/NN	nn||prevention-41/NN||hiv-40/NN	prep_for||information-38/NN||prevention-41/NN	nn||strategies-44/NNS||intervention-43/NN	prep_for||information-38/NN||strategies-44/NNS	conj_and||prevention-41/NN||strategies-44/NNS	nn||centers-47/NNS||detention-46/NN	prep_in||provide-36/VB||centers-47/NNS	aids--1||hiv-40||no||in order to well understand the hiv/aids knowledge among detainees, a survey was conducted in different detention settings in hunan province in 2008 to assess knowledge and attitudes about hiv among detainees and to provide useful information for hiv prevention and intervention strategies in detention centers.
advmod||show-4/VBP||here-1/RB	nsubj||show-4/VBP||we-3/PRP	root||ROOT-0/null||show-4/VBP	mark||²-10/VBZ||that-5/IN	det||loss-7/NN||the-6/DT	nsubj||²-10/VBZ||loss-7/NN	prep_of||loss-7/NN||î-9/NN	ccomp||show-4/VBP||²-10/VBZ	num||integrin-12/NN||3-11/CD	dobj||²-10/VBZ||integrin-12/NN	amod||results-15/NNS||fibroblasts-14/JJ	prep_in||integrin-12/NN||results-15/NNS	amod||turnover-20/NN||enhanced-17/JJ	amod||turnover-20/NN||focal-18/JJ	nn||turnover-20/NN||adhesion-19/NN	prep_in||results-15/NNS||turnover-20/NN	nn||speed-23/NN||migration-22/NN	prep_in||results-15/NNS||speed-23/NN	conj_and||turnover-20/NN||speed-23/NN	amod||motility-27/NN||impaired-25/VBN	amod||motility-27/NN||directional-26/JJ	dobj||²-10/VBZ||motility-27/NN	conj_but||integrin-12/NN||motility-27/NN	det||matrices-33/NNS||both-29/DT	amod||matrices-33/NNS||2d-30/JJ	conj_and||2d-30/JJ||3d-32/JJ	amod||matrices-33/NNS||3d-32/JJ	prep_on||motility-27/NN||matrices-33/NNS	speed-23||adhesion-19||no_rel||here, we show that the loss of î²3 integrin in fibroblasts results in enhanced focal adhesion turnover and migration speed but impaired directional motility on both 2d and 3d matrices.
amod||feeding-3/NN||alternate-1/JJ	amod||feeding-3/NN||hc-con-2/JJ	nsubj||reproduced-4/VBD||feeding-3/NN	root||ROOT-0/null||reproduced-4/VBD	dobj||reproduced-4/VBD||most-5/JJS	det||effects-9/NNS||the-7/DT	amod||effects-9/NNS||beneficial-8/JJ	prep_of||most-5/JJS||effects-9/NNS	amod||diet-13/NN||daily-11/JJ	amod||diet-13/NN||cholesterol-free-12/JJ	prep_of||effects-9/NNS||diet-13/NN	advmod||diminished-17/VBN||strongly-16/RB	amod||hepatic-18/NN||diminished-17/VBN	prep_including||reproduced-4/VBD||hepatic-18/NN	appos||hepatic-18/NN||vascular-20/NN	amod||activation-23/NN||renal-22/JJ	appos||hepatic-18/NN||activation-23/NN	conj_and||vascular-20/NN||activation-23/NN	conj_and||vascular-20/NN||inflammation-25/NN	conj_and||activation-23/NN||inflammation-25/NN	advmod||reduced-30/VBN||also-27/RB	nsubjpass||reduced-30/VBN||atherosclerosis-28/NNS	auxpass||reduced-30/VBN||was-29/VBD	parataxis||reproduced-4/VBD||reduced-30/VBN	agent||reduced-30/VBN||half-32/NN	advmod||half-32/NN||as-33/RB	prep||reduced-30/VBN||compared-34/VBN	pcomp||compared-34/VBN||to-35/TO	pobj||to-35/TO||hc-36/NN	dep||higher-40/JJR||albeit-38/IN	dep||higher-40/JJR||still-39/RB	dep||hc-36/NN||higher-40/JJR	prepc_compared_to||hc-36/NN||to-42/TO	det||group-45/NN||the-43/DT	amod||group-45/NN||con-44/JJ	pobj||hc-36/NN||group-45/NN	inflammation-25||hc-36||yes||alternate hc-con feeding reproduced most of the beneficial effects of daily cholesterol-free diet, including strongly diminished hepatic, vascular and renal activation and inflammation; also atherosclerosis was reduced by half as compared to hc, albeit still higher compared to the con group.
det||method-2/NN||a-1/DT	nsubjpass||developed-17/VBN||method-2/NN	prepc_of||method-2/NN||employing-4/VBG	amod||spectrometry-7/NN||high-resolution-5/JJ	amod||spectrometry-7/NN||mass-6/JJ	dobj||employing-4/VBG||spectrometry-7/NN	prep_in||spectrometry-7/NN||combination-9/NN	dep||employing-4/VBG||with-10/IN	nn||deuterium-14/NN||vivo-12/NN	nn||deuterium-14/NN||metabolite-13/NN	prep_in||employing-4/VBG||deuterium-14/NN	vmod||deuterium-14/NN||labeling-15/VBG	auxpass||developed-17/VBN||was-16/VBD	root||ROOT-0/null||developed-17/VBN	det||study-20/NN||this-19/DT	prep_in||developed-17/VBN||study-20/NN	aux||investigate-22/VB||to-21/TO	vmod||study-20/NN||investigate-22/VB	det||effects-24/NNS||the-23/DT	dobj||investigate-22/VB||effects-24/NNS	nn||exposure-27/NN||alcohol-26/NN	prep_of||effects-24/NNS||exposure-27/NN	nn||homeostasis-30/NNS||lipid-29/NN	prep_on||investigate-22/VB||homeostasis-30/NNS	det||tissue-35/NN||the-32/DT	amod||tissue-35/NN||white-33/JJ	nn||tissue-35/NN||adipose-34/NN	prep_at||investigate-22/VB||tissue-35/NN	appos||study-20/NN||wat-37/NN	nn||axis-41/NNS||liver-40/NN	dep||study-20/NN||axis-41/NNS	det||model-45/NN||a-43/DT	nn||model-45/NN||mouse-44/NN	prep_in||axis-41/NNS||model-45/NN	prep_of||model-45/NN||alcoholicfattyliver-47/NN	alcoholicfattyliver-47||alcohol-26||no||a method of employing high-resolution mass spectrometry in combination with in vivo metabolite deuterium labeling was developed in this study to investigate the effects of alcohol exposure on lipid homeostasis at the white adipose tissue (wat)-liver axis in a mouse model of alcoholicfattyliver.
vmod||has-8/VBZ||approved-1/VBN	prep_for||approved-1/VBN||treatment-3/NN	prep_of||treatment-3/NN||rheumatoidarthritis-5/NNS	nsubj||has-8/VBZ||anakinra-7/NN	root||ROOT-0/null||has-8/VBZ	det||record-12/NN||a-9/DT	amod||record-12/NN||remarkable-10/JJ	nn||record-12/NN||safety-11/NN	dobj||has-8/VBZ||record-12/NN	rheumatoidarthritis-5||anakinra-7||yes||approved for treatment of rheumatoidarthritis, anakinra has a remarkable safety record.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||treatment-12/NN||that-3/IN	amod||calcitonin-6/NN||synthetic-4/JJ	amod||calcitonin-6/NN||human-5/JJ	nsubj||treatment-12/NN||calcitonin-6/NN	cop||treatment-12/NN||is-7/VBZ	det||treatment-12/NN||a-8/DT	amod||treatment-12/NN||safe-9/JJ	conj_and||safe-9/JJ||effective-11/JJ	amod||treatment-12/NN||effective-11/JJ	ccomp||conclude-2/VBP||treatment-12/NN	nn||sdiseaseofbone-16/NN||paget-14/NN	prep_for||treatment-12/NN||sdiseaseofbone-16/NN	paget'sdiseaseofbone--1||calcitonin-6||yes||we conclude that synthetic human calcitonin is a safe and effective treatment for paget'sdiseaseofbone.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	immunoglobulin-9||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
nn||studies-2/NNS||outcome-1/NN	nsubjpass||needed-4/VBN||studies-2/NNS	nsubj||determine-6/VB||studies-2/NNS	auxpass||needed-4/VBN||are-3/VBP	root||ROOT-0/null||needed-4/VBN	aux||determine-6/VB||to-5/TO	xcomp||needed-4/VBN||determine-6/VB	mark||had-10/VBD||whether-7/IN	nsubj||had-10/VBD||sb-8/NN	num||sb-8/NN||1159-9/CD	ccomp||determine-6/VB||had-10/VBD	det||impact-13/NN||the-11/DT	amod||impact-13/NN||desired-12/VBN	dobj||had-10/VBD||impact-13/NN	prepc_on||impact-13/NN||increasing-15/VBG	nn||access-17/NN||syringe-16/NN	dobj||increasing-15/VBG||access-17/NN	prepc_on||impact-13/NN||reducing-19/VBG	conj_and||increasing-15/VBG||reducing-19/VBG	amod||risk-22/NN||blood-borne-20/JJ	nn||risk-22/NN||viralinfection-21/NN	dobj||reducing-19/VBG||risk-22/NN	nn||idus-25/NNS||california-24/NN	prep_among||reducing-19/VBG||idus-25/NNS	viralinfection-21||idus-25||yes||outcome studies are needed to determine whether sb 1159 had the desired impact on increasing syringe access and reducing blood-borne viralinfection risk among california idus.
amod||levels-4/NNS||mean-1/JJ	amod||levels-4/NNS||serum-2/JJ	amod||levels-4/NNS||timp-4-3/JJ	nsubj||pg/ml-10/NN||levels-4/NNS	cop||pg/ml-10/NN||were-5/VBD	num||pg/ml-10/NN||1761.2-6/CD	nn||pg/ml-10/NN||â-7/NNP	nn||pg/ml-10/NN||±-8/NNP	num||pg/ml-10/NN||67.7-9/CD	root||ROOT-0/null||pg/ml-10/NN	nn||patients-13/NNS||uc-12/NN	prep_in||pg/ml-10/NN||patients-13/NNS	number||â-16/CD||1708.1-15/CD	num||pg/ml-28/NN||â-16/CD	nn||pg/ml-28/NN||±-17/NNP	num||pg/ml-28/NN||73.4-18/CD	amod||pg/ml-28/NN||pg/ml-19/JJ	nn||patients-22/NNS||cd-21/NN	prep_in||pg/ml-19/JJ||patients-22/NNS	num||±-26/NNS||5573.4-24/CD	nn||±-26/NNS||â-25/NN	prep_in||pg/ml-19/JJ||±-26/NNS	conj_and||patients-22/NNS||±-26/NNS	dep||pg/ml-19/JJ||1246.3-27/CD	dep||pg/ml-10/NN||pg/ml-28/NN	prep_in||pg/ml-28/NN||hc-30/NN	uc-12||hc-30||yes||mean serum timp-4 levels were 1761.2 â± 67.7 pg/ml in uc patients, 1708.1 â± 73.4 pg/ml in cd patients and 5573.4 â± 1246.3 pg/ml in hc.
amod||countries-3/NNS||many-1/JJ	amod||countries-3/NNS||resource-constrained-2/JJ	nsubj||train-5/VBP||countries-3/NNS	advmod||train-5/VBP||now-4/RB	root||ROOT-0/null||train-5/VBP	amod||clinicians-7/NNS||non-physician-6/JJ	dobj||train-5/VBP||clinicians-7/NNS	amod||care-10/NN||hiv/aids-9/JJ	prep_in||train-5/VBP||care-10/NN	det||strategy-13/NN||a-12/DT	appos||care-10/NN||strategy-13/NN	vmod||strategy-13/NN||known-14/VBN	prep_as||known-14/VBN||task-shifting-17/JJ	aids--1||hiv--1||no||many resource-constrained countries now train non-physician clinicians in hiv/aids care, a strategy known as 'task-shifting.'
nsubj||reemerging-6/VBG||venezuelanequineencephalitis-1/NNS	appos||venezuelanequineencephalitis-1/NNS||vee-3/NN	aux||reemerging-6/VBG||is-5/VBZ	root||ROOT-0/null||reemerging-6/VBG	prep_in||reemerging-6/VBG||peru-8/NN	venezuelanequineencephalitis-1||vee-3||no||venezuelanequineencephalitis (vee) is reemerging in peru.
det||patients-4/NNS||the-2/DT	amod||patients-4/NNS||137-3/JJ	prep_among||identified-23/VBD||patients-4/NNS	prep_with||patients-4/NNS||acuteqfever-6/NN	appos||acuteqfever-6/NN||89-8/CD	num||%-11/NN||65.0-10/CD	dep||89-8/CD||%-11/NN	prep_with||patients-4/NNS||scrubtyphus-14/NNS	conj_or||acuteqfever-6/NN||scrubtyphus-14/NNS	appos||acuteqfever-6/NN||43-16/CD	num||%-19/NN||31.4-18/CD	dep||43-16/CD||%-19/NN	nsubj||identified-23/VBD||we-22/PRP	root||ROOT-0/null||identified-23/VBD	num||patients-25/NNS||5-24/CD	dobj||identified-23/VBD||patients-25/NNS	nsubjpass||co-infected-32/VBN||patients-25/NNS	num||%-28/NN||3.6-27/CD	appos||patients-25/NNS||%-28/NN	auxpass||co-infected-32/VBN||were-31/VBD	rcmod||patients-25/NNS||co-infected-32/VBN	prep_with||co-infected-32/VBN||coxiellaburnetii-34/NNS	prep_with||co-infected-32/VBN||orientiatsutsugamushi-36/NNS	conj_and||coxiellaburnetii-34/NNS||orientiatsutsugamushi-36/NNS	scrubtyphus-14||orientiatsutsugamushi-36||no||among the 137 patients with acuteqfever (89, 65.0%) or scrubtyphus (43, 31.4%), we identified 5 patients (3.6%) who were co-infected with coxiellaburnetii and orientiatsutsugamushi .
amod||classification-2/NN||international-1/JJ	nsubjpass||used-15/VBN||classification-2/NN	nsubj||identify-17/VB||classification-2/NN	prep_of||classification-2/NN||disease-4/NN	dep||disease-4/NN||icd-9-6/JJ	nn||042â-10/NNS||diagnosis-8/NN	nn||042â-10/NNS||code-9/NN	dep||disease-4/NN||042â-10/NNS	dep||042â-10/NNS||$-11/$	num||$-11/$||044-13/CD	auxpass||used-15/VBN||was-14/VBD	root||ROOT-0/null||used-15/VBN	aux||identify-17/VB||to-16/TO	xcomp||used-15/VBN||identify-17/VB	amod||admissions-19/NNS||hiv/aids-18/JJ	dobj||identify-17/VB||admissions-19/NNS	aids--1||hiv--1||no||international classification of disease (icd-9) diagnosis code 042â€“044 was used to identify hiv/aids admissions.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effectiveness-4/NN||the-3/DT	dobj||evaluated-2/VBN||effectiveness-4/NN	prep_of||effectiveness-4/NN||insulinglargine-6/NN	appos||insulinglargine-6/NN||glargine-8/NN	prep||insulinglargine-6/NN||based-11/VBN	npadvmod||with-15/IN||regimens-12/NNS	prep_in||regimens-12/NNS||patients-14/NNS	pcomp||based-11/VBN||with-15/IN	pobj||with-15/IN||type2diabetesmellitus-16/NNS	appos||type2diabetesmellitus-16/NNS||t2dm-18/NNP	amod||practice-22/NN||clinical-21/JJ	prep_in||insulinglargine-6/NN||practice-22/NN	prep_in||practice-22/NN||spain-24/NN	type2diabetesmellitus-16||glargine-8||yes||we evaluated the effectiveness of insulinglargine (glargine)-based regimens in patients with type2diabetesmellitus (t2dm) in clinical practice in spain.
det||phenotype-2/NN||the-1/DT	nsubjpass||extended-12/VBN||phenotype-2/NN	nsubj||include-14/VB||phenotype-2/NN	vmod||phenotype-2/NN||associated-3/VBN	amod||mutations-8/NNS||heterozygous-5/JJ	amod||mutations-8/NNS||hnf4a-6/JJ	nn||mutations-8/NNS||gene-7/NN	prep_with||associated-3/VBN||mutations-8/NNS	aux||extended-12/VBN||has-9/VBZ	advmod||extended-12/VBN||recently-10/RB	auxpass||extended-12/VBN||been-11/VBN	root||ROOT-0/null||extended-12/VBN	aux||include-14/VB||to-13/TO	xcomp||extended-12/VBN||include-14/VB	amod||responsive-16/JJ||diazoxide-15/JJ	amod||hypoglycemia-18/NN||responsive-16/JJ	amod||hypoglycemia-18/NN||neonatal-17/JJ	dobj||include-14/VB||hypoglycemia-18/NN	prep_in||include-14/VB||addition-20/NN	amod||diabetes-23/NN||maturity-onset-22/JJ	prep_to||include-14/VB||diabetes-23/NN	det||mody-28/NN||the-25/DT	amod||mody-28/NN||young-26/JJ	prep_of||diabetes-23/NN||mody-28/NN	hypoglycemia-18||diazoxide-15||yes||the phenotype associated with heterozygous hnf4a gene mutations has recently been extended to include diazoxide responsive neonatal hypoglycemia in addition to maturity-onset diabetes of the young (mody).
aux||inform-2/VB||to-1/TO	advcl||characterized-13/VBD||inform-2/VB	dobj||inform-2/VB||development-3/NN	prep_of||development-3/NN||tuberculosis-5/NNP	parataxis||inform-2/VB||tb-7/VB	nn||strategies-10/NNS||control-9/NN	dobj||inform-2/VB||strategies-10/NNS	nsubj||characterized-13/VBD||we-12/PRP	root||ROOT-0/null||characterized-13/VBD	det||total-15/NN||a-14/DT	nsubj||isolates-19/VBZ||total-15/NN	num||mycobacteriumtuberculosiscomplex-18/NN||2,261-17/CD	prep_of||total-15/NN||mycobacteriumtuberculosiscomplex-18/NN	ccomp||characterized-13/VBD||isolates-19/VBZ	prepc_by||isolates-19/VBZ||using-21/VBG	amod||phenotypic-23/JJ||multiple-22/JJ	dobj||using-21/VBG||phenotypic-23/JJ	amod||markers-26/NNS||molecular-25/JJ	dobj||using-21/VBG||markers-26/NNS	conj_and||phenotypic-23/JJ||markers-26/NNS	prep_including||isolates-19/VBZ||polymorphisms-29/NNS	amod||sequences-32/NNS||repetitive-31/JJ	prep_in||polymorphisms-29/NNS||sequences-32/NNS	nn||repeats-38/NNS||spoligotyping-34/NN	conj_and||spoligotyping-34/NN||variable-number-36/JJ	nn||repeats-38/NNS||variable-number-36/JJ	nn||repeats-38/NNS||tandem-37/NN	dep||-RSB--41/JJ||repeats-38/NNS	num||vntrs-40/NNS||-LSB--39/CD	npadvmod||-RSB--41/JJ||vntrs-40/NNS	dep||sequences-32/NNS||-RSB--41/JJ	amod||sequence-45/NN||large-44/JJ	prep_including||isolates-19/VBZ||sequence-45/NN	conj_and||polymorphisms-29/NNS||sequence-45/NN	amod||polymorphisms-48/NNS||single-nucleotide-47/JJ	conj_and||polymorphisms-29/NNS||polymorphisms-48/NNS	conj_and||sequence-45/NN||polymorphisms-48/NNS	tb-7||mycobacteriumtuberculosiscomplex-18||no||to inform development of tuberculosis (tb) control strategies, we characterized a total of 2,261 mycobacteriumtuberculosiscomplex isolates by using multiple phenotypic and molecular markers, including polymorphisms in repetitive sequences (spoligotyping and variable-number tandem repeats [vntrs]) and large sequence and single-nucleotide polymorphisms.
amod||softtissuesarcoma-5/NN||non-gastrointestinal-2/JJ	amod||softtissuesarcoma-5/NN||stromal-3/JJ	nn||softtissuesarcoma-5/NN||tumor-4/NN	prep_in||surgery-13/NN||softtissuesarcoma-5/NN	amod||sts-8/NN||non-gist-7/JJ	appos||softtissuesarcoma-5/NN||sts-8/NN	amod||treatment-11/NN||optimal-10/JJ	nsubj||surgery-13/NN||treatment-11/NN	cop||surgery-13/NN||is-12/VBZ	root||ROOT-0/null||surgery-13/NN	amod||margins-17/NNS||wide-15/JJ	nn||margins-17/NNS||resection-16/NN	prep_with||surgery-13/NN||margins-17/NNS	tumor-4||sts-8||no||in non-gastrointestinal stromal tumor softtissuesarcoma (non-gist sts) optimal treatment is surgery with wide resection margins.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	cd-29||pituitary-23||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nsubj||has-2/VBZ||clozapine-1/NN	root||ROOT-0/null||has-2/VBZ	amod||efficacy-4/NN||therapeutic-3/JJ	dobj||has-2/VBZ||efficacy-4/NN	prep_in||efficacy-4/NN||some-6/DT	det||patients-11/NNS||all-9/DT	amod||patients-11/NNS||treatment-resistant-10/JJ	dobj||has-2/VBZ||patients-11/NNS	conj_negcc||efficacy-4/NN||patients-11/NNS	prep_with||patients-11/NNS||schizophrenia-13/NN	schizophrenia-13||clozapine-1||yes||clozapine has therapeutic efficacy in some but not all treatment-resistant patients with schizophrenia.
det||trial-6/NN||the-2/DT	nn||trial-6/NN||phase-3/NN	nn||trial-6/NN||ii-4/NN	amod||trial-6/NN||disperse-2-5/JJ	prep_in||showed-29/VBD||trial-6/NN	num||patients-9/NNS||990-8/CD	prep_of||trial-6/NN||patients-9/NNS	amod||acute-12/JJ||non-st-elevation-11/JJ	amod||syndromes-14/NNS||acute-12/JJ	amod||syndromes-14/NNS||coronary-13/JJ	prep_with||patients-9/NNS||syndromes-14/NNS	appos||syndromes-14/NNS||acs-16/NN	nn||treatment-20/NN||ticagrelor-19/NN	nsubj||showed-29/VBD||treatment-20/NN	num||mg-23/NN||90-22/CD	prep_with||treatment-20/NN||mg-23/NN	num||mg-26/NN||180-25/CD	prep_with||treatment-20/NN||mg-26/NN	conj_and||mg-23/NN||mg-26/NN	advmod||mg-26/NN||twice-27/RB	advmod||showed-29/VBD||daily-28/RB	root||ROOT-0/null||showed-29/VBD	amod||rates-31/NNS||comparable-30/JJ	nsubj||mg-41/VBP||rates-31/NNS	amod||bleeding-36/NN||major-33/JJ	conj_and||major-33/JJ||minor-35/JJ	amod||bleeding-36/NN||minor-35/JJ	prep_of||rates-31/NNS||bleeding-36/NN	prepc_compared_with||bleeding-36/NN||with-38/IN	amod||75-40/CD||clopidogrel-39/JJ	pobj||bleeding-36/NN||75-40/CD	ccomp||showed-29/VBD||mg-41/VBP	mark||were-44/VBD||while-42/IN	expl||were-44/VBD||there-43/EX	advcl||mg-41/VBP||were-44/VBD	advmod||fewer-46/JJR||numerically-45/RB	amod||myocardialinfarctions-47/NNS||fewer-46/JJR	nsubj||were-44/VBD||myocardialinfarctions-47/NNS	bleeding-36||clopidogrel-39||no||in the phase ii disperse-2 trial of 990 patients with non-st-elevation acute coronary syndromes (acs), ticagrelor treatment with 90 mg and 180 mg twice daily showed comparable rates of major and minor bleeding compared with clopidogrel 75 mg while there were numerically fewer myocardialinfarctions.
amod||sepsis-2/NN||severe-1/JJ	nsubj||emerged-4/VBN||sepsis-2/NN	aux||emerged-4/VBN||has-3/VBZ	root||ROOT-0/null||emerged-4/VBN	det||cause-8/NN||a-6/DT	amod||cause-8/NN||major-7/JJ	prep_as||emerged-4/VBN||cause-8/NN	prep_of||cause-8/NN||admission-10/NN	prep_of||cause-8/NN||mortality-12/NN	conj_and||admission-10/NN||mortality-12/NN	amod||patients-16/NNS||hospitalized-14/JJ	nn||patients-16/NNS||hiv/aids-15/NNS	prep_for||admission-10/NN||patients-16/NNS	advmod||affecting-19/VBG||significantly-18/RB	xcomp||emerged-4/VBN||affecting-19/VBG	amod||survival-24/NN||short-20/JJ	conj_and||short-20/JJ||longer-term-23/JJ	amod||survival-24/NN||longer-term-23/JJ	dobj||affecting-19/VBG||survival-24/NN	advmod||ill-27/JJ||critically-26/RB	amod||patients-29/NNS||ill-27/JJ	nn||patients-29/NNS||hiv/aids-28/NN	prep_of||survival-24/NN||patients-29/NNS	aids--1||hiv--1||no||severe sepsis has emerged as a major cause of admission and mortality for hospitalized hiv/aids patients, significantly affecting short- and longer-term survival of critically ill hiv/aids patients.
amod||nsaids-2/NNS||non-selective-1/JJ	nsubjpass||prescribed-9/VBN||nsaids-2/NNS	nsubj||reduce-11/VB||nsaids-2/NNS	nsubj||alleviate-14/VB||nsaids-2/NNS	amod||inhibitors-6/NNS||cox-2-4/JJ	amod||inhibitors-6/NNS||selective-5/JJ	conj_or||nsaids-2/NNS||inhibitors-6/NNS	nsubjpass||prescribed-9/VBN||inhibitors-6/NNS	nsubj||reduce-11/VB||inhibitors-6/NNS	auxpass||prescribed-9/VBN||are-7/VBP	advmod||prescribed-9/VBN||widely-8/RB	root||ROOT-0/null||prescribed-9/VBN	aux||reduce-11/VB||to-10/TO	xcomp||prescribed-9/VBN||reduce-11/VB	dobj||reduce-11/VB||inflammation-12/NN	xcomp||prescribed-9/VBN||alleviate-14/VB	conj_and||reduce-11/VB||alleviate-14/VB	dobj||alleviate-14/VB||pain-15/NN	advmod||used-22/VBN||however-17/RB	nsubjpass||used-22/VBN||they-19/PRP	aux||used-22/VBN||must-20/MD	auxpass||used-22/VBN||be-21/VB	parataxis||prescribed-9/VBN||used-22/VBN	prep_with||used-22/VBN||caution-24/NN	prep_in||used-22/VBN||individuals-26/NNS	det||risk-38/NN||an-28/DT	amod||risk-38/NN||increased-29/JJ	amod||risk-38/NN||cardiovascular-30/JJ	conj_or||cardiovascular-30/JJ||renal-32/JJ	amod||risk-38/NN||renal-32/JJ	conj_or||cardiovascular-30/JJ||gastrointestinal-34/JJ	amod||risk-38/NN||gastrointestinal-34/JJ	nn||risk-38/NN||gi-36/NNP	prep_with||individuals-26/NNS||risk-38/NN	nsaids-2||inflammation-12||no_rel||non-selective nsaids or cox-2 selective inhibitors are widely prescribed to reduce inflammation and alleviate pain; however, they must be used with caution in individuals with an increased cardiovascular, renal or gastrointestinal (gi) risk.
advmod||associated-9/VBN||even-1/RB	mark||associated-9/VBN||though-2/IN	nsubjpass||associated-9/VBN||coronavirusinfection-3/NN	prep_of||coronavirusinfection-3/NN||humans-5/NNS	auxpass||associated-9/VBN||is-6/VBZ	neg||associated-9/VBN||not-7/RB	advmod||associated-9/VBN||normally-8/RB	advcl||showed-25/VBD||associated-9/VBN	amod||diseases-12/NNS||severe-11/JJ	prep_with||associated-9/VBN||diseases-12/NNS	det||identification-15/NN||the-14/DT	nsubj||showed-25/VBD||identification-15/NN	det||coronavirus-18/NNS||the-17/DT	prep_of||identification-15/NN||coronavirus-18/NNS	amod||coronavirus-18/NNS||responsible-19/JJ	det||outbreak-22/NN||the-21/DT	prep_for||responsible-19/JJ||outbreak-22/NN	prep_of||outbreak-22/NN||severeacuterespiratorysyndrome-24/NN	root||ROOT-0/null||showed-25/VBD	mark||enter-31/VB||that-26/IN	advmod||pathogenic-28/JJ||highly-27/RB	amod||coronaviruses-29/NNS||pathogenic-28/JJ	nsubj||enter-31/VB||coronaviruses-29/NNS	aux||enter-31/VB||can-30/MD	ccomp||showed-25/VBD||enter-31/VB	det||population-34/NN||the-32/DT	amod||population-34/NN||human-33/JJ	dobj||enter-31/VB||population-34/NN	severeacuterespiratorysyndrome-24||coronavirus-18||no||even though coronavirusinfection of humans is not normally associated with severe diseases, the identification of the coronavirus responsible for the outbreak of severeacuterespiratorysyndrome showed that highly pathogenic coronaviruses can enter the human population.
amod||treatment-2/NN||pam3cys-1/JJ	nsubj||followed-13/VBD||treatment-2/NN	vmod||treatment-2/NN||induced-3/VBN	det||aggravation-8/NN||an-4/DT	amod||aggravation-8/NN||acute-5/JJ	conj_but||acute-5/JJ||transient-7/JJ	amod||aggravation-8/NN||transient-7/JJ	dobj||induced-3/VBN||aggravation-8/NN	nn||manifestations-11/NNS||asthma-10/NN	prep_of||aggravation-8/NN||manifestations-11/NNS	root||ROOT-0/null||followed-13/VBD	det||reduction-16/NN||a-15/DT	prep_by||followed-13/VBD||reduction-16/NN	prep_by||followed-13/VBD||loss-18/NN	conj_or||reduction-16/NN||loss-18/NN	prep_of||reduction-16/NN||ahr-20/NN	prep_to||followed-13/VBD||methacholine-22/NN	prepc_depending_on||followed-13/VBD||on-25/IN	det||time-27/NN||the-26/DT	pobj||followed-13/VBD||time-27/NN	amod||treatment-30/NN||pam3cys-29/JJ	prep_between||time-27/NN||treatment-30/NN	nn||challenges-33/NNS||ova-32/NN	prep_between||time-27/NN||challenges-33/NNS	conj_and||treatment-30/NN||challenges-33/NNS	asthma-10||methacholine-22||no_rel||pam3cys treatment induced an acute but transient aggravation of asthma manifestations, followed by a reduction or loss of ahr to methacholine, depending on the time between pam3cys treatment and ova challenges.
nn||onset-3/NN||schizophrenia-2/NN	prep_after||treated-7/VBN||onset-3/NN	nsubjpass||treated-7/VBN||he-5/PRP	auxpass||treated-7/VBN||was-6/VBD	root||ROOT-0/null||treated-7/VBN	prep_in||treated-7/VBN||sequence-10/NN	prep_with||treated-7/VBN||olanzapine-13/NN	prep_with||treated-7/VBN||amisulpride-15/NN	conj_and||olanzapine-13/NN||amisulpride-15/NN	prep_with||treated-7/VBN||aripiprazole-17/NN	conj_and||olanzapine-13/NN||aripiprazole-17/NN	schizophrenia-2||olanzapine-13||yes||after schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and aripiprazole.
det||study-3/NN||this-2/DT	prep_in||found-6/VBD||study-3/NN	nsubj||found-6/VBD||we-5/PRP	root||ROOT-0/null||found-6/VBD	mark||isolates-11/VBZ||that-7/IN	amod||s.aureus-10/NNS||many-8/JJ	amod||s.aureus-10/NNS||bovine-9/JJ	nsubj||isolates-11/VBZ||s.aureus-10/NNS	ccomp||found-6/VBD||isolates-11/VBZ	dep||isolates-11/VBZ||including-13/VBG	det||strain-16/NN||the-14/DT	amod||strain-16/NN||rf122-15/JJ	pobj||including-13/VBG||strain-16/NN	dep||isolates-11/VBZ||generate-18/VB	amod||amounts-20/NNS||dramatic-19/JJ	dobj||generate-18/VB||amounts-20/NNS	nn||±-23/NNS||î-22/NN	prep_of||amounts-20/NNS||±-23/NNS	dep||amounts-20/NNS||toxin-25/NN	prep_in||toxin-25/NN||vitro-27/NNP	prepc_compared_with||generate-18/VB||with-29/IN	amod||s.aureus-32/NNS||human-30/JJ	amod||s.aureus-32/NNS||clinical-31/JJ	pobj||generate-18/VB||s.aureus-32/NNS	dep||s.aureus-32/NNS||isolates-33/VBZ	nn||wcuh29-37/NNS||mrsa-36/NN	prep_including||s.aureus-32/NNS||wcuh29-37/NNS	nn||usa300-40/NNS||mrsa-39/NN	prep_including||s.aureus-32/NNS||usa300-40/NNS	conj_and||wcuh29-37/NNS||usa300-40/NNS	mrsa-39||s.aureus-32||no||in this study , we found that many bovine s.aureus isolates , including the rf122 strain , generate dramatic amounts of î ± - toxin in vitro compared with human clinical s.aureus isolates , including mrsa wcuh29 and mrsa usa300 .
nsubj||inoculated-5/VBD||chickens-1/NNS	conj_and||chickens-1/NNS||blackbirds-3/NNS	nsubj||inoculated-5/VBD||blackbirds-3/NNS	advmod||inoculated-5/VBD||directly-4/RB	root||ROOT-0/null||inoculated-5/VBD	mark||shed-9/VBD||with-6/IN	det||viruses-8/NNS||these-7/DT	nsubj||shed-9/VBD||viruses-8/NNS	nsubj||seroconverted-15/VBD||viruses-8/NNS	advcl||inoculated-5/VBD||shed-9/VBD	amod||amounts-11/NNS||significant-10/JJ	dobj||shed-9/VBD||amounts-11/NNS	prep_of||amounts-11/NNS||virus-13/NN	advcl||inoculated-5/VBD||seroconverted-15/VBD	conj_and||shed-9/VBD||seroconverted-15/VBD	nsubj||developed-20/VBD||rats-17/NNS	conj_and||rats-17/NNS||pigeons-19/NNS	nsubj||developed-20/VBD||pigeons-19/NNS	parataxis||inoculated-5/VBD||developed-20/VBD	amod||antibodies-22/NNS||antiviral-21/JJ	dobj||developed-20/VBD||antibodies-22/NNS	cc||failed-31/VBD||but-24/CC	prepc_except_for||failed-31/VBD||for-27/IN	num||pigeon-29/NN||one-28/CD	pobj||failed-31/VBD||pigeon-29/NN	parataxis||inoculated-5/VBD||failed-31/VBD	aux||shed-33/VB||to-32/TO	xcomp||failed-31/VBD||shed-33/VB	dobj||shed-33/VB||virus-34/NN	virus-34||viruses-8||no||chickens and blackbirds directly inoculated with these viruses shed significant amounts of virus and seroconverted; rats and pigeons developed antiviral antibodies, but, except for one pigeon, failed to shed virus.
amod||transcranial-2/JJ||repetitive-1/JJ	amod||stimulation-4/NN||transcranial-2/JJ	amod||stimulation-4/NN||magnetic-3/JJ	nsubj||able-9/JJ||stimulation-4/NN	nsubj||modulate-11/VB||stimulation-4/NN	appos||stimulation-4/NN||rtms-6/NNS	cop||able-9/JJ||is-8/VBZ	root||ROOT-0/null||able-9/JJ	aux||modulate-11/VB||to-10/TO	xcomp||able-9/JJ||modulate-11/VB	nn||response-13/NN||pain-12/NN	dobj||modulate-11/VB||response-13/NN	prep_to||modulate-11/VB||capsaicin-15/NN	pain-12||capsaicin-15||yes||repetitive transcranial magnetic stimulation (rtms) is able to modulate pain response to capsaicin.
nn||pylori-2/NNS||helicobacter-1/NN	nsubj||-lrb--3/VBD||pylori-2/NNS	root||ROOT-0/null||-lrb--3/VBD	nn||pylori-5/NNS||h.-4/NN	dobj||-lrb--3/VBD||pylori-5/NNS	amod||infection-7/NN||-rrb--6/JJ	nsubj||appears-8/VBZ||infection-7/NN	nsubj||subvert-10/VB||infection-7/NN	nsubj||upregulates-18/VBZ||infection-7/NN	rcmod||pylori-5/NNS||appears-8/VBZ	aux||subvert-10/VB||to-9/TO	xcomp||appears-8/VBZ||subvert-10/VB	det||mechanism-15/NN||the-11/DT	amod||mechanism-15/NN||human-12/JJ	nn||mechanism-15/NN||iron-13/NN	amod||mechanism-15/NN||regulatory-14/JJ	dobj||subvert-10/VB||mechanism-15/NN	advmod||upregulates-18/VBZ||thus-17/RB	rcmod||pylori-5/NNS||upregulates-18/VBZ	conj_and||appears-8/VBZ||upregulates-18/VBZ	dobj||upregulates-18/VBZ||hepcidin-19/NN	vmod||-lrb--3/VBD||resulting-21/VBG	amod||-rrb--27/NNS||unexplained-23/JJ	amod||-rrb--27/NNS||iron-deficiencyanemia-24/JJ	nn||-rrb--27/NNS||-lrb--25/NN	nn||-rrb--27/NNS||ida-26/NN	prep_in||resulting-21/VBG||-rrb--27/NNS	iron-deficiencyanemia-24||iron-13||yes||helicobacter pylori -lrb- h. pylori -rrb- infection appears to subvert the human iron regulatory mechanism and thus upregulates hepcidin , resulting in unexplained iron-deficiencyanemia -lrb- ida -rrb- .
nsubjpass||used-5/VBN||cisplatin-1/NN	nsubj||treat-7/VB||cisplatin-1/NN	nsubjpass||regulated-25/VBN||cisplatin-1/NN	auxpass||used-5/VBN||is-2/VBZ	advmod||often-4/RB||more-3/RBR	advmod||used-5/VBN||often-4/RB	root||ROOT-0/null||used-5/VBN	aux||treat-7/VB||to-6/TO	xcomp||used-5/VBN||treat-7/VB	nn||cancer-9/NN||ovarian-8/NN	dobj||treat-7/VB||cancer-9/NN	nsubj||provides-15/VBZ||cancer-9/NN	prep_due_to||provides-15/VBZ||cancer-9/NN	appos||cancer-9/NN||ovca-11/NNP	rcmod||cancer-9/NN||provides-15/VBZ	amod||advantage-18/NN||modest-16/JJ	nn||advantage-18/NN||survival-17/NN	dobj||provides-15/VBZ||advantage-18/NN	advmod||provides-15/VBZ||primarily-19/RB	pobj||provides-15/VBZ||chemo-resistance-22/NN	advmod||regulated-25/VBN||up-24/RB	conj_and||used-5/VBN||regulated-25/VBN	amod||machineries-27/NNS||anti-apoptotic-26/JJ	dobj||regulated-25/VBN||machineries-27/NNS	nn||cells-30/NNS||ovca-29/NN	prep_in||regulated-25/VBN||cells-30/NNS	cancer-9||cisplatin-1||no_rel||cisplatin is more often used to treat ovarian cancer (ovca), which provides modest survival advantage primarily due to chemo-resistance and up regulated anti-apoptotic machineries in ovca cells.
nsubj||replicate-6/VB||bovineherpesvirustype1-1/NNS	nsubj||cause-11/VB||bovineherpesvirustype1-1/NNS	dep||bovineherpesvirustype1-1/NNS||bohv-1-3/JJ	aux||replicate-6/VB||may-5/MD	root||ROOT-0/null||replicate-6/VB	det||sites-9/NNS||both-8/DT	prep_at||replicate-6/VB||sites-9/NNS	conj_and||replicate-6/VB||cause-11/VB	num||entities-15/NNS||two-12/CD	amod||entities-15/NNS||major-13/JJ	amod||entities-15/NNS||clinical-14/JJ	dobj||cause-11/VB||entities-15/NNS	vmod||entities-15/NNS||designated-16/VBN	amod||rhinotracheitis-20/NNS||infectious-18/JJ	amod||rhinotracheitis-20/NNS||bovine-19/JJ	prep_as||designated-16/VBN||rhinotracheitis-20/NNS	appos||rhinotracheitis-20/NNS||ibr-22/NN	prep_as||designated-16/VBN||infectiouspustularvulvovaginitis/balanoposthitis-25/NNS	conj_and||rhinotracheitis-20/NNS||infectiouspustularvulvovaginitis/balanoposthitis-25/NNS	appos||rhinotracheitis-20/NNS||ipv/ipb-27/NN	prep_in||designated-16/VBN||cattle-30/NNS	ipv--1||bovineherpesvirustype1-1||no||bovineherpesvirustype1 (bohv-1) may replicate at both sites and cause two major clinical entities designated as infectious bovine rhinotracheitis (ibr) and infectiouspustularvulvovaginitis/balanoposthitis (ipv/ipb) in cattle.
det||issue-4/NN||a-2/DT	amod||issue-4/NN||recent-3/JJ	prep_in||examine-13/VBP||issue-4/NN	prep_of||issue-4/NN||globalization-6/NN	prep_of||issue-4/NN||health-8/NN	conj_and||globalization-6/NN||health-8/NN	nsubj||examine-13/VBP||yu-10/NNP	conj_et||yu-10/NNP||al.-12/NNP	nsubj||examine-13/VBP||al.-12/NNP	root||ROOT-0/null||examine-13/VBP	det||impact-15/NN||the-14/DT	dobj||examine-13/VBP||impact-15/NN	amod||programs-18/NNS||hiv/aids-17/JJ	prep_of||impact-15/NN||programs-18/NNS	nn||systems-22/NNS||health-20/NN	nn||systems-22/NNS||care-21/NN	prep_on||programs-18/NNS||systems-22/NNS	aids--1||hiv--1||no||in a recent issue of globalization and health , yu et al. examine the impact of hiv/aids programs on health care systems .
root||ROOT-0/null||ensuring-1/VBG	amod||deliveries-3/NNS||institutional-2/JJ	dobj||ensuring-1/VBG||deliveries-3/NNS	conj_and||ensuring-1/VBG||encouraging-5/VBG	dobj||encouraging-5/VBG||self-disclosure-6/NN	nn||results-9/NNS||hiv-8/NN	prep_of||self-disclosure-6/NN||results-9/NNS	det||mothers-12/NNS||the-11/DT	prep_by||encouraging-5/VBG||mothers-12/NNS	poss||partners-15/NNS||their-14/PRP$	prep_to||mothers-12/NNS||partners-15/NNS	conj_and||ensuring-1/VBG||giving-17/VBG	amod||mothers-19/NNS||hivpositive-18/JJ	iobj||giving-17/VBG||mothers-19/NNS	amod||doses-21/NNS||nevirapine-20/JJ	dobj||giving-17/VBG||doses-21/NNS	aux||take-23/VB||to-22/TO	vmod||giving-17/VBG||take-23/VB	dobj||take-23/VB||home-24/NN	advmod||home-24/NN||early-25/RB	prep_in||home-24/NN||pregnancy-27/NN	advmod||take-23/VB||all-28/RB	dep||take-23/VB||play-29/VB	amod||roles-31/NNS||significant-30/JJ	dobj||take-23/VB||roles-31/NNS	prepc_in||giving-17/VBG||improving-33/VBG	dobj||improving-33/VBG||adherence-34/NN	amod||prophylaxis-37/NNS||pmtct-36/JJ	prep_to||improving-33/VBG||prophylaxis-37/NNS	hivpositive-18||hiv-8||no||ensuring institutional deliveries, encouraging self-disclosure of hiv results by the mothers to their partners and giving hivpositive mothers nevirapine doses to take home early in pregnancy all play significant roles in improving adherence to pmtct prophylaxis.
nsubj||vaccinated-13/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||incidence-5/NN||the-4/DT	dobj||compare-3/VB||incidence-5/NN	prep_of||incidence-5/NN||tuberculosis-7/NNP	num||years-10/NNS||two-9/CD	prep_over||compare-3/VB||years-10/NNS	prep_in||years-10/NNS||infants-12/NNS	root||ROOT-0/null||vaccinated-13/VBD	prep_at||vaccinated-13/VBD||birth-15/NN	amod||bcg-18/NN||intradermal-17/JJ	prep_with||vaccinated-13/VBD||bcg-18/NN	amod||bcg-22/NN||percutaneous-21/JJ	prep_with||vaccinated-13/VBD||bcg-22/NN	conj_or||bcg-18/NN||bcg-22/NN	tuberculosis-7||bcg-22||yes||objective to compare the incidence of tuberculosis over two years in infants vaccinated at birth with intradermal bcg or with percutaneous bcg.
det||study-4/NN||a-1/DT	amod||cohort-3/JJ||retrospective-2/JJ	amod||study-4/NN||cohort-3/JJ	nsubjpass||conducted-6/VBN||study-4/NN	nsubj||identify-8/VB||study-4/NN	auxpass||conducted-6/VBN||was-5/VBD	root||ROOT-0/null||conducted-6/VBN	aux||identify-8/VB||to-7/TO	xcomp||conducted-6/VBN||identify-8/VB	nn||factors-10/NNS||risk-9/NN	dobj||identify-8/VB||factors-10/NNS	prep_for||identify-8/VB||transmission-12/NN	prep_of||transmission-12/NN||sars-cov-14/NNP	prep_during||identify-8/VB||intubation-16/NN	prep_from||intubation-16/NN||laboratory-18/NN	vmod||laboratory-18/NN||confirmed-19/VBN	amod||patients-21/NNS||sars-20/JJ	dobj||confirmed-19/VBN||patients-21/NNS	prep_to||confirmed-19/VBN||hcws-23/NNS	vmod||hcws-23/NNS||involved-24/VBN	poss||care-27/NN||their-26/PRP$	prep_in||involved-24/VBN||care-27/NN	sars-20||sars-cov-14||no||a retrospective cohort study was conducted to identify risk factors for transmission of sars-cov during intubation from laboratory confirmed sars patients to hcws involved in their care.
det||infection-2/NN||the-1/DT	nsubjpass||associated-9/VBN||infection-2/NN	prep_of||infection-2/NN||cells-4/NNS	nn||viruses-7/NNS||rna-6/NN	prep_by||cells-4/NNS||viruses-7/NNS	auxpass||associated-9/VBN||is-8/VBZ	root||ROOT-0/null||associated-9/VBN	det||recognition-12/NN||the-11/DT	prep_with||associated-9/VBN||recognition-12/NN	nn||pamps-15/NNS||virus-14/NN	prep_of||recognition-12/NN||pamps-15/NNS	amod||patterns-19/NNS||pathogen-associated-17/JJ	amod||patterns-19/NNS||molecular-18/JJ	appos||pamps-15/NNS||patterns-19/NNS	det||production-23/NN||the-22/DT	prep_with||associated-9/VBN||production-23/NN	conj_and||recognition-12/NN||production-23/NN	nn||interferon-27/NN||type-25/FW	nn||interferon-27/NN||i-26/FW	prep_of||production-23/NN||interferon-27/NN	appos||interferon-27/NN||ifn-29/NN	ifn-29||virus-14||no_rel||the infection of cells by rna viruses is associated with the recognition of virus pamps (pathogen-associated molecular patterns) and the production of type i interferon (ifn).
mark||relieved-5/VBN||if-1/IN	nsubjpass||relieved-5/VBN||pain-2/NN	auxpass||relieved-5/VBN||was-3/VBD	neg||relieved-5/VBN||not-4/RB	advcl||received-8/VBD||relieved-5/VBN	nsubj||received-8/VBD||patients-7/NNS	root||ROOT-0/null||received-8/VBD	det||bolus-11/NNS||an-9/DT	nn||bolus-11/NNS||iv-10/NN	dobj||received-8/VBD||bolus-11/NNS	amod||mg-15/NN||pethidinehydrochloride-13/JJ	dep||pethidinehydrochloride-13/JJ||25-14/CD	prep_of||bolus-11/NNS||mg-15/NN	pain-2||pethidinehydrochloride-13||yes||if pain was not relieved, patients received an iv bolus of pethidinehydrochloride 25 mg.
aux||investigate-2/VB||to-1/TO	advcl||compared-14/VBD||investigate-2/VB	det||impact-4/NN||the-3/DT	dobj||investigate-2/VB||impact-4/NN	prep_of||impact-4/NN||irondeficiency-6/NN	amod||pathways-9/NNS||bioenergetic-8/JJ	prep_on||investigate-2/VB||pathways-9/NNS	prep_in||pathways-9/NNS||chlamydomonas-11/NNS	nsubj||compared-14/VBD||we-13/PRP	root||ROOT-0/null||compared-14/VBD	nn||rates-16/NNS||growth-15/NN	dobj||compared-14/VBD||rates-16/NNS	nn||content-19/NN||iron-18/NN	dobj||compared-14/VBD||content-19/NN	conj_and||rates-16/NNS||content-19/NN	amod||parameters-23/NNS||photosynthetic-22/JJ	dobj||compared-14/VBD||parameters-23/NNS	conj_and||rates-16/NNS||parameters-23/NNS	advmod||compared-14/VBD||systematically-24/RB	prep_in||compared-14/VBD||acetate-26/NN	amod||cells-29/NNS||co2-grown-28/JJ	prep_versus||acetate-26/NN||cells-29/NNS	irondeficiency-6||iron-18||yes||to investigate the impact of irondeficiency on bioenergetic pathways in chlamydomonas, we compared growth rates, iron content, and photosynthetic parameters systematically in acetate versus co2-grown cells.
det||risk-2/NN||this-1/DT	nsubj||higher-5/JJR||risk-2/NN	cop||higher-5/JJR||was-3/VBD	advmod||higher-5/JJR||statistically-4/RB	root||ROOT-0/null||higher-5/JJR	nn||patients-8/NNS||hiv-7/NN	prep_among||higher-5/JJR||patients-8/NNS	det||phase-12/NN||the-10/DT	nn||phase-12/NN||continuation-11/NN	prep_during||higher-5/JJR||phase-12/NN	dep||phase-12/NN||p-14/VBN	dep||0.0003-16/CD||=-15/SYM	ccomp||p-14/VBN||0.0003-16/CD	mark||hivpositive-22/VBP||as-19/IN	det||result-21/NN||a-20/DT	nsubj||hivpositive-22/VBP||result-21/NN	advcl||higher-5/JJR||hivpositive-22/VBP	nn||patients-24/NNS||tb-23/NN	nsubj||had-25/VBD||patients-24/NNS	ccomp||hivpositive-22/VBP||had-25/VBD	amod||survival-27/NN||shorter-26/JJR	dobj||had-25/VBD||survival-27/NN	dep||survival-27/NN||log-29/VB	amod||test-31/NN||rank-30/JJ	nsubj||6.90-33/CD||test-31/NN	dep||6.90-33/CD||=-32/SYM	ccomp||log-29/VB||6.90-33/CD	dep||log-29/VB||df-35/VB	dep||2-37/CD||=-36/SYM	ccomp||df-35/VB||2-37/CD	dep||log-29/VB||p-39/VB	dep||0.008-41/CD||=-40/SYM	ccomp||p-39/VB||0.008-41/CD	hivpositive-22||hiv-7||no||this risk was statistically higher among hiv patients during the continuation phase (p=0.0003), as a result hivpositive tb patients had shorter survival (log rank test= 6.90, df= 2, p= 0.008).
amod||retinopathy-2/NN||oxygen-induced-1/JJ	nsubj||model-10/NN||retinopathy-2/NN	appos||retinopathy-2/NN||oir-4/NN	cop||model-10/NN||is-6/VBZ	det||model-10/NN||a-7/DT	amod||model-10/NN||robust-8/JJ	nn||model-10/NN||animal-9/NN	root||ROOT-0/null||model-10/NN	nsubj||allows-16/VBZ||model-10/NN	amod||retinopathyofprematurity-13/NN||human-12/JJ	prep_of||model-10/NN||retinopathyofprematurity-13/NN	advmod||allows-16/VBZ||readily-15/RB	rcmod||model-10/NN||allows-16/VBZ	dobj||allows-16/VBZ||changes-17/NNS	nsubjpass||studied-36/VBN||changes-17/NNS	amod||gene-20/NN||retinal-19/JJ	prep_in||changes-17/NNS||gene-20/NN	amod||expression-26/NN||microrna-22/JJ	appos||expression-26/NN||mirna-24/NNP	dobj||allows-16/VBZ||expression-26/NN	conj_and||changes-17/NNS||expression-26/NN	nsubjpass||studied-36/VBN||expression-26/NN	prep_in||expression-26/NN||response-28/NN	prep_to||allows-16/VBZ||fluctuations-30/NNS	nn||levels-33/NNS||oxygen-32/NN	prep_in||fluctuations-30/NNS||levels-33/NNS	aux||studied-36/VBN||to-34/TO	auxpass||studied-36/VBN||be-35/VB	xcomp||allows-16/VBZ||studied-36/VBN	retinopathyofprematurity-13||oxygen-32||no||oxygen-induced retinopathy (oir) is a robust animal model of human retinopathyofprematurity that readily allows changes in retinal gene and microrna (mirna) expression in response to fluctuations in oxygen levels to be studied.
number||two-2/CD||ninety-1/CD	nsubj||had-17/VBD||two-2/CD	num||%-5/NN||18.3-4/CD	appos||two-2/CD||%-5/NN	amod||children-10/NNS||502-9/JJ	prep_out_of||two-2/CD||children-10/NNS	num||years-13/NNS||five-12/CD	prep_below||children-10/NNS||years-13/NNS	amod||years-13/NNS||old-14/JJ	prep_with||old-14/JJ||falciparummalaria-16/NN	root||ROOT-0/null||had-17/VBD	dobj||had-17/VBD||hypoglycaemia-18/NN	dep||hypoglycaemia-18/NN||bloodglucose-20/JJ	num||mmol/l-23/NN||2.6-22/CD	prep_below||bloodglucose-20/JJ||mmol/l-23/NN	num||mg/dl-26/NN||50-25/CD	prep_below||bloodglucose-20/JJ||mg/dl-26/NN	conj_or||mmol/l-23/NN||mg/dl-26/NN	det||point-30/NN||the-29/DT	prep_at||had-17/VBD||point-30/NN	nn||admission-33/NN||hospital-32/NN	prep_of||point-30/NN||admission-33/NN	hypoglycaemia-18||glucose--1||yes||ninety two (18.3%) out of 502 children below five years old with falciparummalaria had hypoglycaemia ( bloodglucose below 2.6 mmol/l or 50 mg/dl) at the point of hospital admission.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	exenatide-5||type2diabetes-33||no_rel||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
nn||telaprevir-2/NN||background-1/NN	nsubj||advancement-12/NN||telaprevir-2/NN	prep_in||telaprevir-2/NN||combination-4/NN	prep_with||combination-4/NN||peginterferon-6/NN	prep_with||combination-4/NN||ribavirin-8/NN	conj_and||peginterferon-6/NN||ribavirin-8/NN	cop||advancement-12/NN||is-9/VBZ	det||advancement-12/NN||a-10/DT	amod||advancement-12/NN||promising-11/JJ	root||ROOT-0/null||advancement-12/NN	amod||treatment-15/NN||chronichepatitisc-14/JJ	prep_in||advancement-12/NN||treatment-15/NN	chronichepatitisc-14||ribavirin-8||yes||background telaprevir in combination with peginterferon and ribavirin is a promising advancement in chronichepatitisc treatment.
det||prevalences-2/NNS||the-1/DT	nsubj||33.1-27/NNP||prevalences-2/NNS	amod||antibody-6/NN||anti-hbv-4/JJ	nn||antibody-6/NN||core-5/NN	prep_of||prevalences-2/NNS||antibody-6/NN	dep||antibody-6/NN||anti-hbc-8/JJ	amod||antigen-14/NN||hepatitisb-11/JJ	nn||antigen-14/NN||virus-12/NN	nn||antigen-14/NN||surface-13/NN	prep_of||prevalences-2/NNS||antigen-14/NN	conj_and||antibody-6/NN||antigen-14/NN	appos||antigen-14/NN||hbsag-16/NN	amod||antibody-22/NN||anti-hbv-20/JJ	nn||antibody-22/NN||surface-21/NN	prep_of||prevalences-2/NNS||antibody-22/NN	conj_and||antibody-6/NN||antibody-22/NN	appos||antibody-22/NN||anti-hbs-24/NNS	cop||33.1-27/NNP||were-26/VBD	root||ROOT-0/null||33.1-27/NNP	conj_and||33.1-27/NNP||10.4-29/CD	num||%-33/NN||56.1-32/CD	conj_and||33.1-27/NNP||%-33/NN	advmod||33.1-27/NNP||respectively-35/RB	hbv--1||hbsag-16||yes||the prevalences of anti-hbv core antibody (anti-hbc), hepatitisb virus surface antigen (hbsag), and anti-hbv surface antibody (anti-hbs) were 33.1, 10.4, and 56.1%, respectively.
amod||feâˆ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâˆ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâˆ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâˆ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	irondeficiency-40||iron-31||yes||defective feâˆ’s cluster synthesis not only affects activities of many ironâˆ’sulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
amod||determinants-2/NNS||relevant-1/JJ	nsubjpass||discussed-12/VBN||determinants-2/NNS	det||spread-6/NN||the-4/DT	amod||spread-6/NN||future-5/JJ	prep_of||determinants-2/NNS||spread-6/NN	prep_of||spread-6/NN||hiv-8/NN	prep_among||hiv-8/NN||ivdu-10/NN	auxpass||discussed-12/VBN||are-11/VBP	root||ROOT-0/null||discussed-12/VBN	det||factors-18/NNS||the-15/DT	amod||factors-18/NNS||major-16/JJ	nn||factors-18/NNS||risk-17/NN	prep_including||discussed-12/VBN||factors-18/NNS	prep_for||factors-18/NNS||hivseropositivity-20/NN	det||modes-23/NNS||the-22/DT	prep_including||discussed-12/VBN||modes-23/NNS	conj_and||factors-18/NNS||modes-23/NNS	nn||transmission-26/NN||hiv-25/NN	prep_of||modes-23/NNS||transmission-26/NN	prep_including||discussed-12/VBN||aspects-29/NNS	conj_and||factors-18/NNS||aspects-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||aspects-29/NNS||history-33/NN	prep_of||history-33/NN||hivinfection-35/NN	prep_in||hivinfection-35/NN||ivdu-37/NN	hivinfection-35||hiv-25||no||relevant determinants of the future spread of hiv among ivdu are discussed, including the major risk factors for hivseropositivity, the modes of hiv transmission, and aspects of the natural history of hivinfection in ivdu.
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||one-12/CD||tb-3/NN	vmod||tb-3/NN||caused-5/VBN	agent||caused-5/VBN||mycobacteriumtuberculosis-7/NNS	appos||tb-3/NN||mtb-9/NN	cop||one-12/CD||is-11/VBZ	root||ROOT-0/null||one-12/CD	det||causes-18/NNS||the-14/DT	amod||causes-18/NNS||leading-15/VBG	amod||causes-18/NNS||infectious-16/JJ	nn||causes-18/NNS||disease-17/NN	prep_of||one-12/CD||causes-18/NNS	nn||worldwide-23/NNS||morbidity-20/NN	conj_and||morbidity-20/NN||mortality-22/NN	nn||worldwide-23/NNS||mortality-22/NN	prep_of||causes-18/NNS||worldwide-23/NNS	tuberculosis-1||mycobacteriumtuberculosis-7||no||tuberculosis (tb) caused by mycobacteriumtuberculosis ( mtb ) is one of the leading infectious disease causes of morbidity and mortality worldwide.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	tamoxifen-25||cancer-14||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
det||treatment-3/NN||the-1/DT	amod||treatment-3/NN||best-2/JJS	nsubjpass||known-15/VBN||treatment-3/NN	prep_for||treatment-3/NN||bone-5/NN	prep_for||treatment-3/NN||jointinfection-7/NN	conj_and||bone-5/NN||jointinfection-7/NN	amod||pneumococci-12/NNS||antibiotic-10/JJ	amod||pneumococci-12/NNS||resistant-11/JJ	prep_due_to||bone-5/NN||pneumococci-12/NNS	auxpass||known-15/VBN||is-13/VBZ	neg||known-15/VBN||not-14/RB	root||ROOT-0/null||known-15/VBN	advmod||known-15/VBN||especially-17/RB	amod||children-20/NNS||immunocompromised-19/JJ	prep_in||known-15/VBN||children-20/NNS	jointinfection-7||antibiotic-10||no_rel||the best treatment for bone and jointinfection due to antibiotic resistant pneumococci is not known, especially in immunocompromised children.
prep_in||showed-7/VBD||summary-2/NN	amod||peroxides-6/NNS||several-4/JJ	nn||peroxides-6/NNS||norsesterterpene-5/NN	nsubj||showed-7/VBD||peroxides-6/NNS	root||ROOT-0/null||showed-7/VBD	amod||activities-10/NNS||novel-8/JJ	amod||activities-10/NNS||biological-9/JJ	dobj||showed-7/VBD||activities-10/NNS	prep_of||activities-10/NNS||inhibition-12/NN	neg||production-15/NN||no-14/DT	prep_in||showed-7/VBD||production-15/NN	vmod||showed-7/VBD||suggesting-17/VBG	mark||provide-21/VB||that-18/IN	nsubj||provide-21/VB||these-19/DT	aux||provide-21/VB||might-20/MD	ccomp||suggesting-17/VBG||provide-21/VB	dobj||provide-21/VB||leads-22/NNS	nn||agents-28/NNS||anti-inflammatory-24/NN	conj_or||anti-inflammatory-24/NN||cancer-26/NN	nn||agents-28/NNS||cancer-26/NN	nn||agents-28/NNS||chemopreventive-27/NN	prep_for||leads-22/NNS||agents-28/NNS	anti-inflammatory-24||cancer-26||no_rel||in summary, several norsesterterpene peroxides showed novel biological activities of inhibition in no production, suggesting that these might provide leads for anti-inflammatory or cancer chemopreventive agents.
nsubjpass||caused-8/VBN||hand-1/NN	appos||hand-1/NN||footandmouthdisease-3/NN	dep||hand-1/NN||hfmd-5/VBN	auxpass||caused-8/VBN||is-7/VBZ	root||ROOT-0/null||caused-8/VBN	agent||caused-8/VBN||members-10/NNS	det||picornaviridae-14/NN||the-12/DT	nn||picornaviridae-14/NN||family-13/NN	prep_of||members-10/NNS||picornaviridae-14/NN	det||enterovirus-18/NNS||the-16/DT	amod||enterovirus-18/NNS||genus-17/JJ	prep_in||picornaviridae-14/NN||enterovirus-18/NNS	hand-1||footandmouthdisease-3||no||hand, footandmouthdisease (hfmd) is caused by members of the family picornaviridae in the genus enterovirus .
nsubj||%-8/NN||agreement-1/NN	prep_between||agreement-1/NN||oic-hiv-3/FW	prep_between||agreement-1/NN||wb-5/FW	conj_and||oic-hiv-3/FW||wb-5/FW	cop||%-8/NN||was-6/VBD	num||%-8/NN||99.1-7/CD	root||ROOT-0/null||%-8/NN	num||%-11/NN||95-10/CD	npadvmod||ci-12/RB||%-11/NN	prep||%-8/NN||ci-12/RB	pobj||ci-12/RB||96.9-13/CD	advmod||ci-12/RB||â-14/RB	num||%-18/NN||$-15/$	num||$-15/$||99.9-17/CD	pobj||ci-12/RB||%-18/NN	neg||oic-hivpositives-23/NNS||no-21/DT	amod||oic-hivpositives-23/NNS||false-22/JJ	prep_with||%-8/NN||oic-hivpositives-23/NNS	mark||used-32/VBN||if-24/IN	amod||criteria-26/NNS||stringent-25/JJ	nsubjpass||used-32/VBN||criteria-26/NNS	amod||diagnoses-30/NNS||positive-28/JJ	amod||diagnoses-30/NNS||oic-hiv-29/JJ	prep_for||criteria-26/NNS||diagnoses-30/NNS	auxpass||used-32/VBN||were-31/VBD	advcl||%-8/NN||used-32/VBN	hivpositives--1||hiv--1||no||agreement between oic-hiv and wb was 99.1% (95%ci 96.9â€“99.9%) with no false oic-hivpositives if stringent criteria for positive oic-hiv diagnoses were used.
nsubjpass||categorized-3/VBN||women-1/NNS	auxpass||categorized-3/VBN||were-2/VBD	dep||recommended-8/VBD||categorized-3/VBN	prepc_according_to||categorized-3/VBN||to-5/TO	nn||levels-7/NNS||bp-6/NN	pobj||categorized-3/VBN||levels-7/NNS	root||ROOT-0/null||recommended-8/VBD	det||outside-14/NN||the-10/DT	amod||outside-14/NN||american-11/JJ	nn||outside-14/NN||heart-12/NN	nn||outside-14/NN||association-13/NN	prep_by||recommended-8/VBD||outside-14/NN	nn||<-17/NNS||pregnancy-16/NN	prep_of||outside-14/NN||<-17/NNS	num||mmhg-19/NN||120/80-18/CD	nsubj||recommended-8/VBD||mmhg-19/NN	dep||mmhg-19/NN||normal-21/JJ	appos||mmhg-19/NN||120â-24/NNS	dep||120â-24/NNS||$-25/$	npadvmod||90-46/RB||139/80-27/NNP	dep||$-29/$||â-28/RB	dep||139/80-27/NNP||$-29/$	num||mmhg-32/NN||89-31/CD	npadvmod||140-41/RB||mmhg-32/NN	appos||mmhg-32/NN||prehypertension-34/NN	cc||¥-40/NNP||and-37/CC	dep||¥-40/NNP||â-38/RB	nn||¥-40/NNP||‰-39/NNP	dep||mmhg-32/NN||¥-40/NNP	dep||and/or-42/CD||140-41/RB	num||$-29/$||and/or-42/CD	dep||¥-45/NNP||â-43/RB	advmod||¥-45/NNP||‰-44/RB	dep||139/80-27/NNP||¥-45/NNP	dep||mmhg-47/CD||90-46/RB	num||$-25/$||mmhg-47/CD	appos||mmhg-19/NN||use-49/NN	conj_or||120â-24/NNS||use-49/NN	amod||medications-52/NNS||antihypertensive-51/JJ	prep_of||use-49/NN||medications-52/NNS	appos||medications-52/NNS||hypertension-54/NN	antihypertensive-51||hypertension-54||no_rel||women were categorized according to bp levels recommended by the american heart association outside of pregnancy <120/80 mmhg (normal), 120â€“139/80â€“89 mmhg (prehypertension), and â‰¥140 and/or â‰¥90 mmhg or use of antihypertensive medications (hypertension).
advmod||attenuated-2/JJ||more-1/RBR	amod||response-4/NN||attenuated-2/JJ	amod||response-4/NN||flush-3/JJ	nsubjpass||shown-9/VBN||response-4/NN	amod||niacin-7/NN||topical-6/JJ	prep_to||response-4/NN||niacin-7/NN	auxpass||shown-9/VBN||was-8/VBD	root||ROOT-0/null||shown-9/VBN	nn||probands-12/NNS||schizophrenia-11/NN	prep_in||shown-9/VBN||probands-12/NNS	poss||relatives-15/NNS||their-14/PRP$	prep_in||shown-9/VBN||relatives-15/NNS	conj_and||probands-12/NNS||relatives-15/NNS	nn||families-18/NNS||multiplex-17/NN	prep_from||shown-9/VBN||families-18/NNS	dep||shown-9/VBN||than-19/IN	poss||counterparts-22/NNS||their-21/PRP$	prep_in||shown-9/VBN||counterparts-22/NNS	nn||families-25/NNS||simplex-24/NN	prep_from||counterparts-22/NNS||families-25/NNS	det||differentiation-29/NN||the-28/DT	nsubjpass||revealed-32/VBN||differentiation-29/NN	auxpass||revealed-32/VBN||was-30/VBD	advmod||revealed-32/VBN||better-31/RBR	conj_and||shown-9/VBN||revealed-32/VBN	xcomp||revealed-32/VBN||using-33/VBG	num||concentration-36/NN||0.1-34/CD	nn||concentration-36/NN||m-35/NN	dobj||using-33/VBG||concentration-36/NN	prep_of||concentration-36/NN||niacin-38/NN	num||m-41/NN||0.01-40/CD	prep_than||using-33/VBG||m-41/NN	num||m.-44/NN||0.001-43/CD	prep_than||using-33/VBG||m.-44/NN	conj_or||m-41/NN||m.-44/NN	det||concentration-48/NN||the-46/DT	amod||concentration-48/NN||highest-47/JJS	prep_for||using-33/VBG||concentration-48/NN	num||m-51/NN||0.1-50/CD	prep_of||concentration-48/NN||m-51/NN	det||lag-56/NN||the-53/DT	amod||lag-56/NN||longest-54/JJS	nn||lag-56/NN||time-55/NN	prep_for||using-33/VBG||lag-56/NN	conj_and||concentration-48/NN||lag-56/NN	num||minutes-59/NNS||15-58/CD	prep_of||lag-56/NN||minutes-59/NNS	det||subgroup-62/NN||a-61/DT	nsubj||-lrb--65/VBZ||subgroup-62/NN	prep_of||subgroup-62/NN||probands-64/NNS	ccomp||shown-9/VBN||-lrb--65/VBZ	conj_and||shown-9/VBN||-lrb--65/VBZ	num||%-67/NN||23-66/CD	dobj||-lrb--65/VBZ||%-67/NN	advmod||-lrb--65/VBZ||-rrb--68/RB	nsubj||-lrb--71/VBZ||parents-70/NNS	ccomp||shown-9/VBN||-lrb--71/VBZ	conj_and||shown-9/VBN||-lrb--71/VBZ	num||%-73/NN||27-72/CD	dobj||-lrb--71/VBZ||%-73/NN	advmod||-lrb--71/VBZ||-rrb--74/RB	nsubj||-lrb--78/VBZ||siblings-77/NNS	conj_and||shown-9/VBN||-lrb--78/VBZ	number||%-80/NN||19-79/CD	amod||response-85/NN||%-80/NN	amod||response-85/NN||-rrb--81/JJ	advmod||exhibited-83/JJ||still-82/RB	amod||response-85/NN||exhibited-83/JJ	nn||response-85/NN||nonflush-84/NN	dobj||-lrb--78/VBZ||response-85/NN	flush-3||niacin-38||no||more attenuated flush response to topical niacin was shown in schizophrenia probands and their relatives from multiplex families than in their counterparts from simplex families , and the differentiation was better revealed using 0.1 m concentration of niacin than 0.01 m or 0.001 m. for the highest concentration of 0.1 m and the longest time lag of 15 minutes , a subgroup of probands -lrb- 23 % -rrb- , parents -lrb- 27 % -rrb- , and siblings -lrb- 19 % -rrb- still exhibited nonflush response .
advmod||awaiting-2/VBG||eagerly-1/RB	vmod||become-42/VBN||awaiting-2/VBG	det||results-4/NNS||the-3/DT	dobj||awaiting-2/VBG||results-4/NNS	det||management-7/NN||the-6/DT	prep_of||results-4/NNS||management-7/NN	amod||study-10/NN||myelomeningocele-9/JJ	prep_of||management-7/NN||study-10/NN	dep||management-7/NN||moms-12/VBZ	prep_of||results-4/NNS||with-15/IN	conj_and||management-7/NN||with-15/IN	det||interest-18/NN||an-16/DT	amod||interest-18/NN||increasing-17/VBG	pobj||with-15/IN||interest-18/NN	prepc_in||interest-18/NN||setting-20/VBG	prt||setting-20/VBG||up-21/RP	amod||repair-24/NN||intrauterine-22/JJ	nn||repair-24/NN||myelomeningocele-23/NN	dobj||setting-20/VBG||repair-24/NN	appos||repair-24/NN||iumr-26/NN	det||management-31/NN||the-29/DT	amod||management-31/NN||optimal-30/JJ	nsubj||become-42/VBN||management-31/NN	prep_of||management-31/NN||patients-33/NNS	vmod||patients-33/NNS||suffering-34/VBG	amod||myelomeningocele-37/NN||congenital-36/JJ	prep_from||suffering-34/VBG||myelomeningocele-37/NN	appos||myelomeningocele-37/NN||mmc-39/NN	aux||become-42/VBN||has-41/VBZ	root||ROOT-0/null||become-42/VBN	det||matter-44/NN||a-43/DT	xcomp||become-42/VBN||matter-44/NN	prep_of||matter-44/NN||debate-46/NN	advmod||become-42/VBN||again-47/RB	myelomeningocele-37||mmc-39||no_rel||eagerly awaiting the results of the management of myelomeningocele study (moms) and with an increasing interest in setting up intrauterine myelomeningocele repair (iumr), the optimal management of patients suffering from congenital myelomeningocele (mmc) has become a matter of debate again.
amod||cancer-2/NN||endometrial-1/JJ	nsubj||cancer-9/NN||cancer-2/NN	appos||cancer-2/NN||ec-4/NN	cop||cancer-9/NN||is-6/VBZ	det||cancer-9/NN||a-7/DT	amod||cancer-9/NN||hormone-dependent-8/JJ	root||ROOT-0/null||cancer-9/NN	nsubj||represents-12/VBZ||cancer-9/NN	advmod||represents-12/VBZ||currently-11/RB	rcmod||cancer-9/NN||represents-12/VBZ	det||malignancy-16/NN||the-13/DT	advmod||frequent-15/JJ||most-14/RBS	amod||malignancy-16/NN||frequent-15/JJ	dobj||represents-12/VBZ||malignancy-16/NN	det||tract-21/NN||the-18/DT	amod||tract-21/NN||female-19/JJ	amod||tract-21/NN||reproductive-20/JJ	prep_of||malignancy-16/NN||tract-21/NN	cancer-9||hormone--1||no_rel||endometrial cancer (ec) is a hormone-dependent cancer that currently represents the most frequent malignancy of the female reproductive tract.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||ifn--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
nsubj||tried-6/VBN||youth-2/NN	nsubj||lose-8/VB||youth-2/NN	prep_among||common-35/JJ||youth-2/NN	aux||tried-6/VBN||had-4/VBD	advmod||tried-6/VBN||ever-5/RB	rcmod||youth-2/NN||tried-6/VBN	aux||lose-8/VB||to-7/TO	xcomp||tried-6/VBN||lose-8/VB	dobj||lose-8/VB||weight-9/NN	dep||youth-2/NN||n-11/VBN	dep||1,646-13/CD||=-12/SYM	ccomp||n-11/VBN||1,646-13/CD	amod||practices-18/NNS||healthy-16/JJ	amod||practices-18/NNS||weight-loss-17/JJ	nsubj||common-35/JJ||practices-18/NNS	dep||practices-18/NNS||diet-20/NN	number||76.5-22/CD||-LSB--21/CD	num||%-23/NN||76.5-22/CD	nsubj||-RSB--24/VBZ||%-23/NN	nsubj||exercise-26/VBP||%-23/NN	rcmod||diet-20/NN||-RSB--24/VBZ	rcmod||diet-20/NN||exercise-26/VBP	conj_and||-RSB--24/VBZ||exercise-26/VBP	number||94.8-28/CD||-LSB--27/CD	dep||%-29/NN||94.8-28/CD	dep||-RSB--30/NNS||%-29/NN	dobj||exercise-26/VBP||-RSB--30/NNS	cop||common-35/JJ||were-32/VBD	det||common-35/JJ||the-33/DT	advmod||common-35/JJ||most-34/RBS	root||ROOT-0/null||common-35/JJ	mark||common-75/JJ||whereas-37/IN	amod||practices-39/NNS||unhealthy-38/JJ	nsubj||common-75/JJ||practices-39/NNS	dep||practices-39/NNS||fasting-41/VBG	ccomp||fasting-41/VBG||-LSB--42/VBG	num||%-44/NN||8.6-43/CD	dobj||-LSB--42/VBG||%-44/NN	advmod||-LSB--42/VBG||-RSB--45/RB	ccomp||fasting-41/VBG||using-47/VBG	conj_and||-LSB--42/VBG||using-47/VBG	nn||aids-49/NNS||diet-48/NN	dobj||using-47/VBG||aids-49/NNS	vmod||aids-49/NNS||-LSB--50/VBN	number||%-52/NN||7.5-51/CD	amod||-RSB--62/NN||%-52/NN	nn||-RSB--62/NN||-RSB--53/JJ	conj_or||-RSB--53/JJ||vomiting-55/NN	nn||-RSB--62/NN||vomiting-55/NN	conj_or||-RSB--53/JJ||laxative-57/NN	nn||-RSB--62/NN||laxative-57/NN	nn||-RSB--62/NN||use-58/NN	num||-RSB--62/NN||-LSB--59/CD	number||%-61/NN||2.3-60/CD	amod||-RSB--62/NN||%-61/NN	dep||-LSB--50/VBN||-RSB--62/NN	ccomp||fasting-41/VBG||skipping-65/VBG	conj_and||-LSB--42/VBG||skipping-65/VBG	nn||doses-67/NNS||insulin-66/NN	dobj||skipping-65/VBG||doses-67/NNS	vmod||skipping-65/VBG||-LSB--68/VBG	number||%-70/NN||4.2-69/CD	amod||-RSB--71/NNS||%-70/NN	dobj||-LSB--68/VBG||-RSB--71/NNS	cop||common-75/JJ||were-73/VBD	advmod||common-75/JJ||less-74/RBR	advcl||common-35/JJ||common-75/JJ	insulin-66||vomiting-55||no_rel||among youth who had ever tried to lose weight ( n = 1,646), healthy weight-loss practices (diet [76.5%] and exercise [94.8%]) were the most common, whereas unhealthy practices (fasting [8.6%], using diet aids [7.5%], vomiting or laxative use [2.3%], and skipping insulin doses [4.2%]) were less common.
amod||studies-2/NNS||recent-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||limited-14/VBN||that-5/IN	det||effects-7/NNS||the-6/DT	nsubjpass||limited-14/VBN||effects-7/NNS	prep_of||effects-7/NNS||bisphosphonates-9/NNS	prep_on||bisphosphonates-9/NNS||breasttumours-11/NNS	auxpass||limited-14/VBN||are-12/VBP	neg||limited-14/VBN||not-13/RB	ccomp||shown-4/VBN||limited-14/VBN	prep_to||limited-14/VBN||bone-16/NN	mark||achieved-25/VBN||that-19/IN	amod||effects-22/NNS||prolonged-20/JJ	amod||effects-22/NNS||anti-tumour-21/JJ	nsubjpass||achieved-25/VBN||effects-22/NNS	aux||achieved-25/VBN||may-23/MD	auxpass||achieved-25/VBN||be-24/VB	ccomp||shown-4/VBN||achieved-25/VBN	conj_and||limited-14/VBN||achieved-25/VBN	poss||inclusion-28/NN||their-27/PRP$	prep_following||achieved-25/VBN||inclusion-28/NN	nn||therapy-31/NN||combination-30/NN	prep_in||inclusion-28/NN||therapy-31/NN	breasttumours-11||bisphosphonates-9||no_rel||recent studies have shown that the effects of bisphosphonates on breasttumours are not limited to bone, and that prolonged anti-tumour effects may be achieved following their inclusion in combination therapy.
det||combination-2/NN||the-1/DT	nsubj||effective-8/JJ||combination-2/NN	prep_of||combination-2/NN||remifentanil-4/NN	prep_of||combination-2/NN||lidocaine-6/NN	conj_and||remifentanil-4/NN||lidocaine-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	prepc_in||effective-8/JJ||alleviating-10/VBG	dobj||alleviating-10/VBG||pain-11/NN	vmod||pain-11/NN||associated-12/VBN	det||injection-17/NN||a-14/DT	amod||injection-17/NN||microemulsion-15/JJ	amod||injection-17/NN||propofol-16/JJ	prep_with||associated-12/VBN||injection-17/NN	prepc_compared_with||associated-12/VBN||with-19/IN	advmod||lidocaine-21/NN||just-20/RB	pobj||associated-12/VBN||lidocaine-21/NN	pain-11||remifentanil-4||yes||the combination of remifentanil and lidocaine is effective in alleviating pain associated with a microemulsion propofol injection compared with just lidocaine.
det||review-3/NN||this-2/DT	prep_in||focus-6/VBP||review-3/NN	nsubj||focus-6/VBP||we-5/PRP	root||ROOT-0/null||focus-6/VBP	prep_on||focus-6/VBP||processes-8/NNS	prep_on||focus-6/VBP||organs-10/NNS	conj_and||processes-8/NNS||organs-10/NNS	prep_on||focus-6/VBP||systems-12/NNS	conj_and||processes-8/NNS||systems-12/NNS	vmod||processes-8/NNS||targeted-13/VBN	det||yessotoxin-17/NN||the-15/DT	amod||yessotoxin-17/NN||marinetoxins-16/JJ	agent||targeted-13/VBN||yessotoxin-17/NN	appos||yessotoxin-17/NN||ytx-19/NN	agent||targeted-13/VBN||okadaicacid-22/NN	conj_and||yessotoxin-17/NN||okadaicacid-22/NN	appos||okadaicacid-22/NN||oa-24/NN	agent||targeted-13/VBN||palytoxin-27/NN	conj_and||yessotoxin-17/NN||palytoxin-27/NN	appos||palytoxin-27/NN||ptx-29/NN	oa-24||ptx-29||no_rel||in this review, we focus on processes, organs and systems targeted by the marinetoxins yessotoxin (ytx), okadaicacid (oa) and palytoxin (ptx).
amod||modeling-2/NN||such-1/JJ	nsubj||provide-4/VB||modeling-2/NN	nsubj||care-28/VB||modeling-2/NN	nsubj||prevent-36/VB||modeling-2/NN	aux||provide-4/VB||may-3/MD	root||ROOT-0/null||provide-4/VB	amod||recommendations-7/NNS||intelligent/directed-5/JJ	nn||recommendations-7/NNS||therapy-6/NN	dobj||provide-4/VB||recommendations-7/NNS	amod||recommendations-7/NNS||guidance-9/NN	advmod||automation-13/JJ||ultimately-12/RB	amod||recommendations-7/NNS||automation-13/JJ	conj_and||guidance-9/NN||automation-13/JJ	det||future-18/NN||the-16/DT	amod||future-18/NN||near-17/JJ	prep_in||recommendations-7/NNS||future-18/NN	det||means-21/NN||a-20/DT	prep_as||future-18/NN||means-21/NN	prepc_of||means-21/NN||providing-23/VBG	amod||safety-26/NN||optimal-24/JJ	nn||safety-26/NN||patient-25/NN	dobj||providing-23/VBG||safety-26/NN	conj_and||provide-4/VB||care-28/VB	det||provision-31/NN||the-30/DT	prep_in||care-28/VB||provision-31/NN	nn||drips-34/NNS||insulin-33/NN	prep_of||provision-31/NN||drips-34/NNS	aux||prevent-36/VB||to-35/TO	xcomp||care-28/VB||prevent-36/VB	dobj||prevent-36/VB||hyperglycemia-37/NN	dobj||prevent-36/VB||hypoglycemia-39/NN	conj_and||hyperglycemia-37/NN||hypoglycemia-39/NN	hyperglycemia-37||insulin-33||yes||such modeling may provide intelligent/directed therapy recommendations, guidance, and ultimately automation, in the near future as a means of providing optimal patient safety and care in the provision of insulin drips to prevent hyperglycemia and hypoglycemia.
nsubj||extracted-2/VBD||we-1/PRP	nsubj||compared-4/VBD||we-1/PRP	root||ROOT-0/null||extracted-2/VBD	conj_and||extracted-2/VBD||compared-4/VBD	det||markers-9/NN||the-5/DT	amod||markers-9/NN||following-6/VBG	amod||markers-9/NN||parameters-7/JJ	nn||markers-9/NN||biochemical-8/NN	dobj||extracted-2/VBD||markers-9/NN	nn||markers-12/NNS||hbv-11/NN	dobj||extracted-2/VBD||markers-12/NNS	conj_and||markers-9/NN||markers-12/NNS	nn||antigen-15/NN||surface-14/NN	dep||markers-12/NNS||antigen-15/NN	amod||antibody-18/NN||core-17/JJ	dep||antigen-15/NN||antibody-18/NN	nn||antibody-21/NN||surface-20/NN	dep||antigen-15/NN||antibody-21/NN	conj_and||antibody-18/NN||antibody-21/NN	nn||antibody-25/NN||hcv-24/NN	dobj||extracted-2/VBD||antibody-25/NN	conj_and||markers-9/NN||antibody-25/NN	amod||studies-28/NNS||radiological-27/JJ	dobj||extracted-2/VBD||studies-28/NNS	conj_and||markers-9/NN||studies-28/NNS	dobj||extracted-2/VBD||length-31/NN	conj_and||markers-9/NN||length-31/NN	prep_of||length-31/NN||stay-33/NN	appos||stay-33/NN||los-35/NN	hbv-11||antibody-25||no_rel||we extracted and compared the following parameters biochemical markers, hbv markers (surface antigen, core antibody and surface antibody), hcv antibody, radiological studies, and length of stay (los).
advmod||offered-11/VBN||however-1/RB	prep_in||offered-11/VBN||malaysia-4/NN	nn||screening-8/NN||rubella-6/NN	nn||screening-8/NN||antibody-7/NN	nsubjpass||offered-11/VBN||screening-8/NN	auxpass||offered-11/VBN||is-9/VBZ	neg||offered-11/VBN||not-10/RB	root||ROOT-0/null||offered-11/VBN	advmod||offered-11/VBN||routinely-12/RB	amod||women-15/NNS||pregnant-14/JJ	prep_to||offered-11/VBN||women-15/NNS	dep||funded-18/VBN||public-17/NN	amod||clinics-20/NNS||funded-18/VBN	nn||clinics-20/NNS||health-19/NN	prep_in||offered-11/VBN||clinics-20/NNS	nn||constraint-24/NN||cost-23/NN	prep_due_to||clinics-20/NNS||constraint-24/NN	rubella-6||antibody-7||no_rel||however, in malaysia, rubella antibody screening is not offered routinely to pregnant women in public funded health clinics due to cost constraint.
nsubjpass||determined-66/VBN||levels-1/NNS	amod||factor-7/NN||angiopoietin-2-3/JJ	nn||factor-7/NN||von-5/NNP	amod||factor-7/NN||willebrand-6/JJ	prep_of||levels-1/NNS||factor-7/NN	appos||factor-7/NN||vwf-9/NN	nn||propeptide-13/NN||vwf-12/NN	appos||levels-1/NNS||propeptide-13/NN	amod||molecule-1-21/NN||soluble-15/JJ	amod||molecule-1-21/NN||p-selectin-16/JJ	amod||molecule-1-21/NN||soluble-18/JJ	nn||molecule-1-21/NN||intercellular-19/NN	nn||molecule-1-21/NN||adhesion-20/NN	appos||levels-1/NNS||molecule-1-21/NN	dep||molecule-1-21/NN||icam-1-23/JJ	amod||kinase-1-32/NN||soluble-26/JJ	amod||kinase-1-32/NN||endoglin-27/JJ	amod||kinase-1-32/NN||soluble-29/JJ	amod||kinase-1-32/NN||fms-like-30/JJ	nn||kinase-1-32/NN||tyrosine-31/NN	appos||molecule-1-21/NN||kinase-1-32/NN	dep||kinase-1-32/NN||flt-1-34/JJ	amod||protein-41/NN||soluble-37/JJ	amod||protein-41/NN||tie-2-38/JJ	amod||protein-41/NN||c-reactive-40/JJ	appos||molecule-1-21/NN||protein-41/NN	appos||protein-41/NN||procalcitonin-43/NN	num||protein-49/NN||10-45/CD	amod||protein-49/NN||kda-46/JJ	amod||protein-49/NN||interferon-47/JJ	amod||protein-49/NN||gamma-induced-48/JJ	appos||molecule-1-21/NN||protein-49/NN	dep||protein-49/NN||ip-10-51/JJ	amod||receptor-57/NN||soluble-55/JJ	amod||receptor-57/NN||triggering-56/VBG	appos||molecule-1-21/NN||receptor-57/NN	conj_and||protein-49/NN||receptor-57/NN	vmod||receptor-57/NN||expressed-58/VBN	amod||cells-1-61/NN||myeloid-60/JJ	prep_on||expressed-58/VBN||cells-1-61/NN	dep||protein-49/NN||trem-1-63/JJ	auxpass||determined-66/VBN||were-65/VBD	root||ROOT-0/null||determined-66/VBN	agent||determined-66/VBN||elisa-68/NN	adhesion-20||tyrosine-31||no_rel||levels of angiopoietin-2, von willebrand factor (vwf), vwf propeptide, soluble p-selectin, soluble intercellular adhesion molecule-1 (icam-1), soluble endoglin, soluble fms-like tyrosine kinase-1 (flt-1), soluble tie-2, c-reactive protein, procalcitonin, 10 kda interferon gamma-induced protein (ip-10), and soluble triggering receptor expressed on myeloid cells-1 (trem-1) were determined by elisa.
amod||infection-5/NNS||humantcelllymphotropicvirustype1-1/JJ	dep||infection-5/NNS||htlv-1-3/JJ	nsubj||lead-7/VB||infection-5/NNS	aux||lead-7/VB||can-6/MD	root||ROOT-0/null||lead-7/VB	prep_to||lead-7/VB||development-9/NN	amod||leukemia/lymphoma-14/NN||adult-11/JJ	nn||leukemia/lymphoma-14/NN||t-12/NN	nn||leukemia/lymphoma-14/NN||cell-13/NN	prep_of||development-9/NN||leukemia/lymphoma-14/NN	appos||leukemia/lymphoma-14/NN||atl-16/NN	amod||tropicalspasticparaparesis-21/NNS||htlv-1-associatedmyelopathy-19/JJ	amod||tropicalspasticparaparesis-21/NNS||/-20/JJ	prep_of||development-9/NN||tropicalspasticparaparesis-21/NNS	conj_or||leukemia/lymphoma-14/NN||tropicalspasticparaparesis-21/NNS	appos||leukemia/lymphoma-14/NN||ham/tsp-23/NN	det||subset-27/NN||a-26/DT	prep_in||lead-7/VB||subset-27/NN	amod||subjects-30/NNS||infected-29/JJ	prep_of||subset-27/NN||subjects-30/NNS	ham--1||htlv-1-3||no||humantcelllymphotropicvirustype1 (htlv-1) infection can lead to development of adult t cell leukemia/lymphoma (atl) or htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) in a subset of infected subjects.
poss||study-3/NN||our-1/PRP$	amod||study-3/NN||previous-2/JJ	nsubj||showed-4/VBD||study-3/NN	root||ROOT-0/null||showed-4/VBD	mark||increased-14/VBN||that-5/IN	nsubjpass||increased-14/VBN||expression-6/NN	prep_of||expression-6/NN||c-met-8/NN	nn||cells-12/NNS||prostate-10/NN	nn||cells-12/NNS||cancer-11/NN	prep_in||c-met-8/NN||cells-12/NNS	auxpass||increased-14/VBN||was-13/VBD	ccomp||showed-4/VBD||increased-14/VBN	prep_after||increased-14/VBN||attenuation-16/NN	nn||receptor-19/NN||androgen-18/NN	prep_of||attenuation-16/NN||receptor-19/NN	appos||receptor-19/NN||ar-21/NN	vmod||receptor-19/NN||signalling-23/VBG	androgen-18||ar-21||no_rel||our previous study showed that expression of c-met in prostate cancer cells was increased after attenuation of androgen receptor (ar) signalling.
amod||i-6/NNS||human-1/JJ	amod||i-6/NNS||t-cell-2/JJ	nn||i-6/NNS||leukemia-3/NN	nn||i-6/NNS||virus-4/NN	nn||i-6/NNS||type-5/NN	nsubj||cause-11/VB||i-6/NNS	dep||i-6/NNS||htlv-1-8/JJ	aux||cause-11/VB||can-10/MD	root||ROOT-0/null||cause-11/VB	det||malignancy-14/NN||an-12/DT	amod||malignancy-14/NN||aggressive-13/JJ	dobj||cause-11/VB||malignancy-14/NN	vmod||malignancy-14/NN||known-15/VBN	amod||leukemia/lymphoma-19/NN||adult-17/JJ	amod||leukemia/lymphoma-19/NN||t-cell-18/JJ	prep_as||known-15/VBN||leukemia/lymphoma-19/NN	appos||leukemia/lymphoma-19/NN||atl-21/NN	dobj||cause-11/VB||inflammatorydiseases-26/NNS	conj_and||malignancy-14/NN||inflammatorydiseases-26/NNS	amod||tropicalspasticparaparesis-31/NNS||htlv-1-associatedmyelopathy-29/JJ	amod||tropicalspasticparaparesis-31/NNS||/-30/JJ	prep_such_as||inflammatorydiseases-26/NNS||tropicalspasticparaparesis-31/NNS	appos||tropicalspasticparaparesis-31/NNS||ham/tsp-33/NN	htlv-1-associatedmyelopathy-29||htlv-1-8||no||human t-cell leukemia virus type i (htlv-1) can cause an aggressive malignancy known as adult t-cell leukemia/lymphoma (atl) as well as inflammatorydiseases such as htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
aux||examine-2/VB||to-1/TO	root||ROOT-0/null||examine-2/VB	det||significance-4/NN||the-3/DT	dobj||examine-2/VB||significance-4/NN	amod||immunoassay-11/NN||vzv-igg-6/JJ	nn||immunoassay-11/NN||igg-8/NN	amod||immunoassay-11/NN||enzyme-10/JJ	prep_of||significance-4/NN||immunoassay-11/NN	appos||immunoassay-11/NN||eia-13/NN	det||determination-17/NN||the-16/DT	nsubj||counts-22/VBZ||determination-17/NN	amod||lymphocyte-21/NN||peripheral-19/JJ	nn||lymphocyte-21/NN||blood-20/NN	prep_of||determination-17/NN||lymphocyte-21/NN	conj_and||examine-2/VB||counts-22/VBZ	det||diagnosis-25/NN||the-24/DT	prep_in||counts-22/VBZ||diagnosis-25/NN	nn||herpete-29/NN||ophthalmiczoster-27/NN	nn||herpete-29/NN||sine-28/NN	prep_of||diagnosis-25/NN||herpete-29/NN	amod||zsh-32/NN||ophthalmic-31/JJ	appos||herpete-29/NN||zsh-32/NN	ophthalmiczoster-27||vzv--1||no||to examine the significance of vzv-igg (igg) enzyme immunoassay (eia) and the determination of peripheral blood lymphocyte counts in the diagnosis of ophthalmiczoster sine herpete (ophthalmic zsh).
nsubjpass||carried-9/VBN||analysis-1/NN	det||spectrum-5/NN||the-3/DT	amod||spectrum-5/NN||different-4/JJ	prep_of||analysis-1/NN||spectrum-5/NN	prep_of||spectrum-5/NN||ois/co-infections-7/NNS	auxpass||carried-9/VBN||were-8/VBD	root||ROOT-0/null||carried-9/VBN	prt||carried-9/VBN||out-10/RP	num||hiv-13/NN||204-12/CD	prep_with||carried-9/VBN||hiv-13/NN	amod||patients-15/NNS||sero-positive-14/JJ	dobj||carried-9/VBN||patients-15/NNS	nsubj||visited-24/VBD||patients-15/NNS	num||males-18/NNS||142-17/CD	dep||patients-15/NNS||males-18/NNS	num||females-21/NNS||62-20/CD	dep||patients-15/NNS||females-21/NNS	conj_and||males-18/NNS||females-21/NNS	rcmod||patients-15/NNS||visited-24/VBD	det||clinic-28/NN||the-25/DT	amod||clinic-28/NN||hiv/aids-26/JJ	nn||clinic-28/NN||apex-27/NN	dobj||visited-24/VBD||clinic-28/NN	det||hospital-33/NN||a-30/DT	amod||hospital-33/NN||tertiary-31/JJ	nn||hospital-33/NN||care-32/NN	prep_in||visited-24/VBD||hospital-33/NN	prep_from||visited-24/VBD||march-35/NN	num||march-35/NN||2006-36/CD	aux||march-38/VB||to-37/TO	vmod||carried-9/VBN||march-38/VB	dobj||march-38/VB||2009-39/CD	aids--1||hiv-13||no||analysis of the different spectrum of ois/co-infections were carried out with 204 hiv sero-positive patients (142 males and 62 females) who visited the hiv/aids apex clinic in a tertiary care hospital from march 2006 to march 2009.
mark||offers-12/VBZ||while-1/IN	det||introduction-4/NN||the-2/DT	amod||introduction-4/NN||recent-3/JJ	nsubj||offers-12/VBZ||introduction-4/NN	amod||vaccines-7/NNS||prophylactic-6/JJ	prep_of||introduction-4/NN||vaccines-7/NNS	amod||types-11/NNS||specific-9/JJ	nn||types-11/NNS||hpv-10/NN	prep_against||vaccines-7/NNS||types-11/NNS	advcl||remains-22/VBZ||offers-12/VBZ	amod||promise-14/NN||great-13/JJ	dobj||offers-12/VBZ||promise-14/NN	prep_for||offers-12/VBZ||prevention-16/NN	amod||cancer-19/NN||cervical-18/JJ	prep_of||prevention-16/NN||cancer-19/NN	expl||remains-22/VBZ||there-21/EX	root||ROOT-0/null||remains-22/VBZ	det||need-24/NN||a-23/DT	nsubj||remains-22/VBZ||need-24/NN	xcomp||remains-22/VBZ||need-24/NN	prep_for||need-24/NN||therapeutics-26/NNS	cancer-19||vaccines-7||no_rel||while the recent introduction of prophylactic vaccines against specific hpv types offers great promise for prevention of cervical cancer, there remains a need for therapeutics.
nn||factors-2/NNS||risk-1/NN	nsubj||significant-42/JJ||factors-2/NNS	prep_such_as||factors-2/NNS||age-5/NN	nn||status-8/NN||smoking-7/NN	prep_such_as||factors-2/NNS||status-8/NN	conj_and||age-5/NN||status-8/NN	amod||cholesterol-11/NN||total-10/JJ	prep_such_as||factors-2/NNS||cholesterol-11/NN	conj_and||age-5/NN||cholesterol-11/NN	amod||levels-17/NNS||high-13/JJ	nn||levels-17/NNS||density-14/NN	nn||levels-17/NNS||lipoprotein-15/NN	nn||levels-17/NNS||cholesterol-16/NN	prep_such_as||factors-2/NNS||levels-17/NNS	conj_and||age-5/NN||levels-17/NNS	vmod||significant-42/JJ||qualifying-19/VBG	dobj||qualifying-19/VBG||event-20/NN	det||syndrome-25/NN||the-22/DT	amod||syndrome-25/NN||acute-23/JJ	amod||syndrome-25/NN||coronary-24/JJ	prep_for||qualifying-19/VBG||syndrome-25/NN	appos||syndrome-25/NN||revascularization-27/NN	appos||revascularization-27/NN||history-29/NN	prep_of||history-29/NN||stroke-31/NN	prep_of||history-29/NN||diabetes-33/NN	conj_or||stroke-31/NN||diabetes-33/NN	nn||grade-36/NN||angina-35/NN	nsubj||significant-42/JJ||grade-36/NN	conj_and||grade-36/NN||treatment-38/NN	nsubj||significant-42/JJ||treatment-38/NN	prep_with||grade-36/NN||pravastatin-40/NN	cop||significant-42/JJ||were-41/VBD	root||ROOT-0/null||significant-42/JJ	prep_for||significant-42/JJ||development-44/NN	preconj||first-47/JJ||both-46/DT	prep_of||development-44/NN||first-47/JJ	amod||events-51/NNS||subsequent-49/JJ	nn||events-51/NNS||mi-50/NN	prep_of||development-44/NN||events-51/NNS	conj_and||first-47/JJ||events-51/NNS	cholesterol-16||stroke-31||no_rel||risk factors such as age, smoking status, total cholesterol and high density lipoprotein cholesterol levels, qualifying event for the acute coronary syndrome, revascularization, history of stroke or diabetes, angina grade and treatment with pravastatin were significant for development of both first and subsequent mi events.
det||study-4/NN||this-1/DT	amod||study-4/NN||prospective-2/JJ	nn||study-4/NN||cohort-3/NN	nsubj||conducted-5/VBD||study-4/NN	root||ROOT-0/null||conducted-5/VBD	prep_in||conducted-5/VBD||zambia-7/NN	vmod||zambia-7/NN||evaluated-8/VBN	det||safety-10/NN||the-9/DT	dobj||evaluated-8/VBN||safety-10/NN	prep_of||safety-10/NN||artemether-lumefantrine-12/NN	appos||artemether-lumefantrine-12/NN||al-14/NNP	amod||women-18/NNS||pregnant-17/JJ	prep_in||evaluated-8/VBN||women-18/NNS	prep_with||evaluated-8/VBN||malaria-20/NN	malaria-20||artemether--1||yes||this prospective cohort study conducted in zambia evaluated the safety of artemether-lumefantrine (al) in pregnant women with malaria.
amod||subjects-2/NNS||adult-1/JJ	nsubj||underwent-5/VBD||subjects-2/NNS	prep_with||subjects-2/NNS||type1diabetes-4/CD	root||ROOT-0/null||underwent-5/VBD	num||study-8/NN||one-6/CD	amod||study-8/NN||closed-loop-7/JJ	dobj||underwent-5/VBD||study-8/NN	prep_with||study-8/NN||insulin-10/NN	dobj||underwent-5/VBD||placebo-12/NN	conj_plus||study-8/NN||placebo-12/NN	num||study-15/NN||one-14/CD	conj_plus||study-8/NN||study-15/NN	conj_and||placebo-12/NN||study-15/NN	prep_with||underwent-5/VBD||insulin-17/NN	prep||insulin-17/NN||plus-18/CC	pobj||plus-18/CC||glucagon-19/NN	prep||underwent-5/VBD||given-21/VBN	pcomp||given-21/VBN||at-22/IN	pobj||at-22/IN||times-23/NNS	amod||hypoglycemia-26/NN||impending-25/JJ	prep_of||times-23/NNS||hypoglycemia-26/NN	hypoglycemia-26||glucagon-19||yes||adult subjects with type1diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia.
nn||alpha-2/NNS||interferon-1/NN	nsubjpass||used-9/VBN||alpha-2/NNS	nn||±-5/NNP||ifn-î-4/NNP	appos||alpha-2/NNS||±-5/NNP	aux||used-9/VBN||has-7/VBZ	auxpass||used-9/VBN||been-8/VBN	root||ROOT-0/null||used-9/VBN	det||therapy-13/NN||a-11/DT	nn||therapy-13/NN||maintenance-12/NN	prep_as||used-9/VBN||therapy-13/NN	mark||stem-16/VBP||after-14/IN	nsubj||stem-16/VBP||autologous-15/NNS	advcl||used-9/VBN||stem-16/VBP	nn||transplantation-18/NN||cell-17/NN	dobj||stem-16/VBP||transplantation-18/NN	appos||transplantation-18/NN||asct-20/NN	amod||patients-27/NNS||multiplemyeloma-23/JJ	appos||patients-27/NNS||mm-25/NN	prep_for||transplantation-18/NN||patients-27/NNS	multiplemyeloma-23||ifn--1||yes||interferon alpha (ifn-î±) has been used as a maintenance therapy after autologous stem cell transplantation (asct) for multiplemyeloma (mm) patients.
nsubj||increased-12/VBN||breasttumors-1/NNS	vmod||breasttumors-1/NNS||lacking-2/VBG	det||±-6/NN||the-3/DT	amod||±-6/NN||estrogen-4/JJ	amod||±-6/NN||receptor-î-5/JJ	dobj||lacking-2/VBG||±-6/NN	nn||±-9/NNP||er-î-8/NNP	appos||±-6/NN||±-9/NNP	aux||increased-12/VBN||have-11/VBP	root||ROOT-0/null||increased-12/VBN	dobj||increased-12/VBN||incidence-13/NN	prep_of||incidence-13/NN||resistance-15/NN	prep_to||increased-12/VBN||therapy-17/NN	amod||prognosis-21/NN||poorer-19/JJR	amod||prognosis-21/NN||clinical-20/JJ	prep_to||increased-12/VBN||prognosis-21/NN	conj_and||therapy-17/NN||prognosis-21/NN	breasttumors-1||estrogen-4||yes||breasttumors lacking the estrogen receptor-î± (er-î±) have increased incidence of resistance to therapy and poorer clinical prognosis.
aux||characterize-2/VB||to-1/TO	csubj||randomized-38/VBD||characterize-2/VB	det||amount-4/NN||the-3/DT	dobj||characterize-2/VB||amount-4/NN	amod||hypoglycemia-7/NN||nocturnal-6/JJ	prep_of||amount-4/NN||hypoglycemia-7/NN	conj_and||characterize-2/VB||evaluate-9/VB	csubj||randomized-38/VBD||evaluate-9/VB	dobj||evaluate-9/VB||factors-10/NNS	vmod||factors-10/NNS||associated-11/VBN	amod||hypoglycemia-14/NN||nocturnal-13/JJ	prep_with||associated-11/VBN||hypoglycemia-14/NN	vmod||hypoglycemia-14/NN||assessed-15/VBN	amod||monitoring-19/NN||continuous-17/JJ	nn||monitoring-19/NN||glucose-18/NN	prep_with||assessed-15/VBN||monitoring-19/NN	appos||monitoring-19/NN||cgm-21/NN	prep_in||monitoring-19/NN||adults-24/NNS	prep_in||monitoring-19/NN||children-26/NNS	conj_and||adults-24/NNS||children-26/NNS	prep_with||assessed-15/VBN||type1diabetes-28/NNS	nsubj||participated-30/VBD||type1diabetes-28/NNS	rcmod||type1diabetes-28/NNS||participated-30/VBD	det||cgm-37/NN||the-32/DT	amod||cgm-37/NN||juvenile-33/JJ	nn||cgm-37/NN||diabetes-34/NN	nn||cgm-37/NN||research-35/NN	nn||cgm-37/NN||foundation-36/NN	prep_in||participated-30/VBD||cgm-37/NN	root||ROOT-0/null||randomized-38/VBD	amod||trial-40/NN||clinical-39/JJ	dobj||randomized-38/VBD||trial-40/NN	glucose-18||hypoglycemia-14||no_rel||to characterize the amount of nocturnal hypoglycemia and evaluate factors associated with nocturnal hypoglycemia assessed with continuous glucose monitoring (cgm) in adults and children with type1diabetes who participated in the juvenile diabetes research foundation cgm randomized clinical trial.
nsubj||important-3/JJ||it-1/PRP	nsubj||consider-5/VB||it-1/PRP	cop||important-3/JJ||is-2/VBZ	root||ROOT-0/null||important-3/JJ	aux||consider-5/VB||to-4/TO	xcomp||important-3/JJ||consider-5/VB	dobj||consider-5/VB||pulmonaryembolism-6/NN	det||differential-9/NN||the-8/DT	prep_in||consider-5/VB||differential-9/NN	nn||patients-12/NNS||hiv-11/NN	prep_of||differential-9/NN||patients-12/NNS	nn||cough-16/NN||fever-14/NN	prep_with||consider-5/VB||cough-16/NN	prep_with||consider-5/VB||dyspnea-19/NN	conj_and||cough-16/NN||dyspnea-19/NN	advmod||cough-16/NN||particularly-21/RB	prep_in||cough-16/NN||those-23/DT	amod||hivinfection-26/NN||well-controlled-25/JJ	prep_with||those-23/DT||hivinfection-26/NN	hivinfection-26||hiv-11||no||it is important to consider pulmonaryembolism in the differential of hiv patients with fever, cough, and dyspnea, particularly in those with well-controlled hivinfection.
aux||investigate-2/VB||to-1/TO	csubj||synthase-11/VBD||investigate-2/VB	csubj||synthase-11/VBD||investigate-2/VB	det||expression-4/NN||the-3/DT	dobj||investigate-2/VB||expression-4/NN	amod||prostaglandine-7/NN||microsomal-6/JJ	prep_of||expression-4/NN||prostaglandine-7/NN	appos||prostaglandine-7/NN||pge-9/NN	root||ROOT-0/null||synthase-11/VBD	conj_and||synthase-11/VBD||synthase-11/VBD	dobj||synthase-11/VBD||1-12/CD	dep||1-12/CD||mpges-1-14/JJ	dobj||synthase-11/VBD||cyclooxygenase-17/NN	conj_and||1-12/CD||cyclooxygenase-17/NN	appos||cyclooxygenase-17/NN||cox-19/NN	nn||biopsies-23/NNS||muscle-22/NN	prep_in||cyclooxygenase-17/NN||biopsies-23/NNS	prep_from||synthase-11/VBD||patients-25/NNS	prep_with||patients-25/NNS||polymyositis-27/NNS	prep_with||patients-25/NNS||dermatomyositis-29/NNS	conj_or||polymyositis-27/NNS||dermatomyositis-29/NNS	amod||treatment-35/NN||conventional-33/JJ	nn||treatment-35/NN||immunosuppressive-34/NN	prep_after||synthase-11/VBD||treatment-35/NN	prep_before||synthase-11/VBD||treatment-35/NN	prostaglandine-7||polymyositis-27||no_rel||to investigate the expression of microsomal prostaglandine (pge) synthase 1 (mpges-1) and cyclooxygenase (cox) in muscle biopsies from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
nsubjpass||evaluated-3/VBN||subjects-1/NNS	auxpass||evaluated-3/VBN||were-2/VBD	root||ROOT-0/null||evaluated-3/VBN	prep_for||evaluated-3/VBN||diabeticnephropathy-5/NN	amod||rate-11/NN||24-h-7/JJ	nn||rate-11/NN||urinary-8/NN	nn||rate-11/NN||albumin-9/NN	nn||rate-11/NN||excretion-10/NN	dep||diabeticnephropathy-5/NN||rate-11/NN	prep_for||evaluated-3/VBN||diabeticretinopathy-14/NN	conj_and||diabeticnephropathy-5/NN||diabeticretinopathy-14/NN	dep||diabeticretinopathy-14/NN||classified-16/VBN	prepc_according_to||classified-16/VBN||to-18/TO	det||group-22/NN||the-19/DT	amod||group-22/NN||global-20/JJ	nn||group-22/NN||diabeticretinopathy-21/NN	pobj||classified-16/VBN||group-22/NN	diabeticnephropathy-5||albumin-9||no_rel||subjects were evaluated for diabeticnephropathy (24-h urinary albumin excretion rate) and diabeticretinopathy (classified according to the global diabeticretinopathy group).
nsubj||drug-9/NN||chondroitinsulfate-1/NN	appos||chondroitinsulfate-1/NN||cs-3/NN	cop||drug-9/NN||is-5/VBZ	det||drug-9/NN||a-6/DT	amod||drug-9/NN||symptomatic-7/JJ	amod||drug-9/NN||slow-acting-8/JJ	root||ROOT-0/null||drug-9/NN	prep_for||drug-9/NN||osteoarthritis-11/NNS	appos||osteoarthritis-11/NNS||oa-13/NN	advmod||used-16/VBN||widely-15/RB	vmod||osteoarthritis-11/NNS||used-16/VBN	det||clinic-19/NN||the-18/DT	prep_in||used-16/VBN||clinic-19/NN	osteoarthritis-11||chondroitinsulfate-1||yes||chondroitinsulfate (cs) is a symptomatic slow-acting drug for osteoarthritis (oa) widely used in the clinic.
mark||assess-4/VB||in-1/IN	dep||assess-4/VB||order-2/NN	aux||assess-4/VB||to-3/TO	advcl||study-13/VBP||assess-4/VB	amod||value-7/NN||combined-5/VBN	amod||value-7/NN||diagnostic-6/JJ	dobj||assess-4/VB||value-7/NN	det||tests-10/NNS||these-9/DT	prep_of||value-7/NN||tests-10/NNS	nsubj||study-13/VBP||we-12/PRP	root||ROOT-0/null||study-13/VBP	det||profiles-16/NNS||the-14/DT	amod||profiles-16/NNS||kinetic-15/JJ	dobj||study-13/VBP||profiles-16/NNS	prepc_of||profiles-16/NNS||circulating-18/VBG	amod||igm-22/NN||ns1-19/JJ	amod||igm-22/NN||dengue-21/JJ	dobj||circulating-18/VBG||igm-22/NN	nn||antibodies-25/NNS||igg-24/NN	dobj||circulating-18/VBG||antibodies-25/NNS	conj_and||igm-22/NN||antibodies-25/NNS	det||course-28/NN||the-27/DT	prep_over||igm-22/NN||course-28/NN	det||disease-31/NN||the-30/DT	prep_of||course-28/NN||disease-31/NN	prepc_by||circulating-18/VBG||using-33/VBG	det||denv1-40/NN||an-34/DT	amod||denv1-40/NN||in-house-35/JJ	amod||denv1-40/NN||dengue-36/JJ	nn||denv1-40/NN||type-37/NN	num||denv1-40/NN||1-38/CD	dobj||using-33/VBG||denv1-40/NN	amod||elisa-45/NN||specific-42/JJ	amod||elisa-45/NN||ns1-43/JJ	nn||elisa-45/NN||capture-44/NN	dep||denv1-40/NN||elisa-45/NN	det||igm-51/NN||the-47/DT	amod||igm-51/NN||commercial-48/JJ	nn||igm-51/NN||panbio-49/NN	nn||igm-51/NN||dengue-50/NN	dobj||using-33/VBG||igm-51/NN	conj_and||denv1-40/NN||igm-51/NN	nn||elisas-55/NNS||igg-53/NN	nn||elisas-55/NNS||capture-54/NN	conj_and||denv1-40/NN||elisas-55/NNS	conj_and||igm-51/NN||elisas-55/NNS	dengue-50||antibodies-25||no_rel||in order to assess combined diagnostic value of these tests, we study the kinetic profiles of circulating ns1, dengue igm and igg antibodies over the course of the disease by using an in-house dengue type 1 (denv1) specific ns1 capture elisa and the commercial panbio dengue igm and igg capture elisas.
root||ROOT-0/null||insulin-1/NN	amod||²-5/NNS||pancreatic-3/JJ	nn||²-5/NNS||î-4/NN	prep_in||insulin-1/NN||²-5/NNS	nsubj||target-10/NN||cells-7/NNS	cop||target-10/NN||is-8/VBZ	det||target-10/NN||a-9/DT	dep||insulin-1/NN||target-10/NN	prep_of||target-10/NN||autoimmunity-12/NN	prep_in||autoimmunity-12/NN||type1diabetes-14/CD	type1diabetes-14||insulin-1||yes||insulin in pancreatic î²-cells is a target of autoimmunity in type1diabetes.
advmod||superior-9/JJ||furthermore-1/RB	det||response-6/NN||the-3/DT	amod||response-6/NN||anti-liposome-4/JJ	nn||response-6/NN||igg-5/NN	nsubj||superior-9/JJ||response-6/NN	cop||superior-9/JJ||was-7/VBD	advmod||superior-9/JJ||significantly-8/RB	root||ROOT-0/null||superior-9/JJ	prep_in||superior-9/JJ||sera-11/NN	amod||patients-14/NNS||pulmonarytb-13/JJ	prep_from||superior-9/JJ||patients-14/NNS	prepc_compared_to||superior-9/JJ||to-16/TO	nn||+-18/NN||ppd-17/NN	pobj||superior-9/JJ||+-18/NN	pobj||superior-9/JJ||ppd-20/NN	conj_and||+-18/NN||ppd-20/NN	amod||subjects-23/NNS||healthy-22/JJ	nsubj||suggesting-29/VBG||subjects-23/NNS	appos||subjects-23/NNS||p-25/NNP	number||0.001-27/CD||<-26/CD	num||p-25/NNP||0.001-27/CD	parataxis||superior-9/JJ||suggesting-29/VBG	det||expression-31/NN||the-30/DT	dobj||suggesting-29/VBG||expression-31/NN	det||antigens-34/NNS||these-33/DT	prep_of||expression-31/NN||antigens-34/NNS	prep_in||antigens-34/NNS||vivo-36/NN	amod||infection-40/NN||active-38/JJ	nn||infection-40/NN||mtb-39/NN	prep_during||suggesting-29/VBG||infection-40/NN	pulmonarytb-13||mtb-39||no||furthermore, the anti-liposome igg response was significantly superior in sera from pulmonarytb patients compared to ppd+ and ppd- healthy subjects (p<0.001) suggesting the expression of these antigens in vivo during active mtb infection.
nn||g-3/NN||paracetamol-1/NNP	num||g-3/NN||1-2/CD	nsubj||reduced-9/VBD||g-3/NN	vmod||g-3/NN||taken-4/VBN	advmod||taken-4/VBN||orally-5/RB	det||hours-8/NNS||every-6/DT	num||hours-8/NNS||6-7/CD	dobj||taken-4/VBN||hours-8/NNS	root||ROOT-0/null||reduced-9/VBD	amod||anglerecessionglaucoma-12/NN||openangleglaucoma-10/JJ	amod||anglerecessionglaucoma-12/NN||and/or-11/JJ	dobj||reduced-9/VBD||anglerecessionglaucoma-12/NN	det||groups-15/NNS||both-14/DT	prep_in||reduced-9/VBD||groups-15/NNS	prep_of||groups-15/NNS||patients-17/NNS	det||way-21/NN||a-20/DT	prep_in||reduced-9/VBD||way-21/NN	amod||way-21/NN||comparable-22/JJ	prep_with||comparable-22/JJ||that-24/DT	vmod||that-24/DT||achieved-25/VBN	det||beta-adrenergicreceptorantagonist-29/NN||a-27/DT	amod||beta-adrenergicreceptorantagonist-29/NN||topical-28/JJ	agent||achieved-25/VBN||beta-adrenergicreceptorantagonist-29/NN	paracetamol-1||anglerecessionglaucoma-12||no_rel||paracetamol 1 g taken orally every 6 hours reduced openangleglaucoma and/or anglerecessionglaucoma in both groups of patients, in a way comparable with that achieved by a topical beta-adrenergicreceptorantagonist.
amod||macaques-2/NNS||pig-tailed-1/JJ	nsubj||show-10/VB||macaques-2/NNS	nsubj||observed-16/JJ||macaques-2/NNS	vmod||macaques-2/NNS||infected-3/VBN	amod||203gg-7/NNS||pbj-nef202-5/JJ	amod||203gg-7/NNS||/-6/JJ	prep_with||infected-3/VBN||203gg-7/NNS	aux||show-10/VB||did-8/VBD	neg||show-10/VB||not-9/RB	root||ROOT-0/null||show-10/VB	amod||complications-12/NNS||enteropathic-11/JJ	dobj||show-10/VB||complications-12/NNS	advmod||observed-16/JJ||lethality-14/RB	advmod||observed-16/JJ||as-15/RB	conj_and||show-10/VB||observed-16/JJ	amod||virus-20/NN||wild-type-18/JJ	nn||virus-20/NN||pbj-19/NN	prep_with||observed-16/JJ||virus-20/NN	amod||replication-24/NN||efficient-23/JJ	prep_despite||observed-16/JJ||replication-24/NN	det||viruses-27/NNS||both-26/DT	prep_of||replication-24/NN||viruses-27/NNS	prep_in||observed-16/JJ||vivo-29/NN	virus-20||viruses-27||no||pig-tailed macaques infected with pbj-nef202/203gg did not show enteropathic complications and lethality as observed with wild-type pbj virus, despite efficient replication of both viruses in vivo .
nsubjpass||caused-3/VBN||type2diabetes-1/NNS	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	agent||caused-3/VBN||defects-5/NNS	preconj||signaling-9/NN||both-7/DT	nn||signaling-9/NN||insulin-8/NN	prep_in||defects-5/NNS||signaling-9/NN	nn||secretion-12/NN||insulin-11/NN	prep_in||defects-5/NNS||secretion-12/NN	conj_and||signaling-9/NN||secretion-12/NN	insulin-11||type2diabetes-1||no_rel||type2diabetes is caused by defects in both insulin signaling and insulin secretion.
det||case-4/NN||the-2/DT	amod||case-4/NN||present-3/JJ	prep_in||had-8/VBD||case-4/NN	det||patient-7/NN||the-6/DT	nsubj||had-8/VBD||patient-7/NN	root||ROOT-0/null||had-8/VBD	dobj||had-8/VBD||chroniclymphocyticleukemia-9/NN	nsubjpass||treated-14/VBN||chroniclymphocyticleukemia-9/NN	aux||treated-14/VBN||was-12/VBD	auxpass||treated-14/VBN||being-13/VBG	rcmod||chroniclymphocyticleukemia-9/NN||treated-14/VBN	det||agent-18/NN||an-16/DT	amod||agent-18/NN||alkylating-17/VBG	prep_with||treated-14/VBN||agent-18/NN	tmod||developed-25/VBD||agent-18/NN	dep||agent-18/NN||chlorambucil-20/JJ	advmod||developed-25/VBD||when-22/WRB	det||patient-24/NN||the-23/DT	nsubj||developed-25/VBD||patient-24/NN	rcmod||agent-18/NN||developed-25/VBD	nn||metastasis-27/NNS||skin-26/NN	dobj||developed-25/VBD||metastasis-27/NNS	nn||adenocarcinoma-30/NN||gallbladder-29/NN	prep_from||developed-25/VBD||adenocarcinoma-30/NN	prep_during||developed-25/VBD||post-32/NN	advmod||follow-up-35/VBN||cholecystectomy-34/RB	amod||post-32/NN||follow-up-35/VBN	chroniclymphocyticleukemia-9||chlorambucil-20||yes||in the present case, the patient had chroniclymphocyticleukemia, which was being treated with an alkylating agent (chlorambucil) when the patient developed skin metastasis from gallbladder adenocarcinoma during post- cholecystectomy follow-up.
det||research-3/NN||this-2/DT	prep_in||designed-5/VBD||research-3/NN	nsubj||designed-5/VBD||we-4/PRP	nsubj||implemented-7/VBD||we-4/PRP	root||ROOT-0/null||designed-5/VBD	conj_and||designed-5/VBD||implemented-7/VBD	det||oidr-9/NN||the-8/DT	dobj||implemented-7/VBD||oidr-9/NN	advmod||implemented-7/VBD||reflectometry-10/RB	xcomp||implemented-7/VBD||measuring-11/VBG	dobj||measuring-11/VBG||system-12/NN	det||source-21/NN||a-14/DT	amod||source-21/NN||650â-15/JJ	amod||source-21/NN||$-16/$	number||nm-18/CD||‰-17/CD	num||$-16/$||nm-18/CD	nn||source-21/NN||diode-19/NN	nn||source-21/NN||laser-20/NN	prep_with||measuring-11/VBG||source-21/NN	nn||physicians-24/NNS||aid-23/NN	prep_to||source-21/NN||physicians-24/NNS	prepc_in||measuring-11/VBG||diagnosing-26/VBG	det||squamouscellcarcinomas-28/NNS||both-27/DT	dobj||diagnosing-26/VBG||squamouscellcarcinomas-28/NNS	appos||squamouscellcarcinomas-28/NNS||scc-30/NN	dobj||diagnosing-26/VBG||basalcellcarcinomas-33/NNS	conj_and||squamouscellcarcinomas-28/NNS||basalcellcarcinomas-33/NNS	appos||basalcellcarcinomas-33/NNS||bcc-35/NN	squamouscellcarcinomas-28||nm-18||no_rel||in this research we designed and implemented the oidr reflectometry measuring system with a 650â€‰ nm diode laser source to aid physicians in diagnosing both squamouscellcarcinomas (scc) and basalcellcarcinomas(bcc).
nsubj||asked-2/VBD||we-1/PRP	root||ROOT-0/null||asked-2/VBD	mark||able-8/JJ||whether-3/IN	amod||stimulation-6/NN||cb1-4/JJ	nn||stimulation-6/NN||receptor-5/NN	nsubj||able-8/JJ||stimulation-6/NN	nsubj||decrease-10/VB||stimulation-6/NN	cop||able-8/JJ||was-7/VBD	ccomp||asked-2/VBD||able-8/JJ	aux||decrease-10/VB||to-9/TO	xcomp||able-8/JJ||decrease-10/VB	amod||biogenesis-12/NNS||mitochondrial-11/JJ	dobj||decrease-10/VB||biogenesis-12/NNS	amod||tissues-17/NNS||different-14/JJ	advmod||active-16/JJ||metabolically-15/RB	amod||tissues-17/NNS||active-16/JJ	prep_in||decrease-10/VB||tissues-17/NNS	amod||diet-21/NN||obese-19/JJ	amod||diet-21/NN||high-fat-20/JJ	prep_of||tissues-17/NNS||diet-21/NN	appos||diet-21/NN||hfd-23/NN	nn||mice-27/NNS||fed-26/NN	dep||diet-21/NN||mice-27/NNS	fat--1||obese-19||no_rel||we asked whether cb1 receptor stimulation was able to decrease mitochondrial biogenesis in different metabolically active tissues of obese high-fat diet (hfd)-fed mice.
prep_in||secondary-23/VBZ||countries-2/NNS	advmod||employed-8/VBN||where-3/WRB	amod||rehydration-5/NN||intravenous-4/JJ	nsubjpass||employed-8/VBN||rehydration-5/NN	auxpass||employed-8/VBN||is-6/VBZ	advmod||employed-8/VBN||often-7/RB	rcmod||countries-2/NNS||employed-8/VBN	det||administration-13/NN||the-10/DT	nn||administration-13/NN||emergency-11/NN	nn||administration-13/NN||department-12/NN	nsubj||secondary-23/VBZ||administration-13/NN	nsubj||gastroenteritis-25/VB||administration-13/NN	amod||ondansetron-16/NN||oral-15/JJ	prep_of||administration-13/NN||ondansetron-16/NN	prep_to||ondansetron-16/NN||children-18/NNS	prep_with||children-18/NNS||dehydration-20/NN	prep_with||children-18/NNS||vomiting-22/NN	conj_and||dehydration-20/NN||vomiting-22/NN	root||ROOT-0/null||secondary-23/VBZ	aux||gastroenteritis-25/VB||to-24/TO	xcomp||secondary-23/VBZ||gastroenteritis-25/VB	dobj||gastroenteritis-25/VB||results-26/NNS	amod||savings-30/NNS||significant-28/JJ	amod||savings-30/NNS||monetary-29/JJ	prep_in||results-26/NNS||savings-30/NNS	prepc_compared_to||gastroenteritis-25/VB||to-32/TO	det||policy-35/NN||a-33/DT	amod||policy-35/NN||no-ondansetron-34/JJ	pobj||gastroenteritis-25/VB||policy-35/NN	vomiting-22||ondansetron-16||yes||in countries where intravenous rehydration is often employed, the emergency department administration of oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis results in significant monetary savings compared to a no-ondansetron policy.
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	paliperidone-6||tachycardia-14||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||trial-8/NN||a-4/DT	amod||trial-8/NN||prospective-5/JJ	nn||trial-8/NN||phase-6/NN	nn||trial-8/NN||ii-7/NN	prep_on||report-2/VBP||trial-8/NN	num||patients-11/NNS||32-10/CD	prep_of||trial-8/NN||patients-11/NNS	nsubj||underwent-13/VBD||patients-11/NNS	rcmod||patients-11/NNS||underwent-13/VBD	amod||transplantation-18/NN||unrelated-14/JJ	nn||transplantation-18/NN||donor-15/NN	nn||transplantation-18/NN||hematopoietic-16/NN	nn||transplantation-18/NN||cell-17/NN	dobj||underwent-13/VBD||transplantation-18/NN	det||sirolimus-24/NNS||a-21/DT	nn||sirolimus-24/NNS||tacrolimus-22/NNS	prep_with||underwent-13/VBD||sirolimus-24/NNS	nn||globulin-28/NN||rabbit-26/NN	amod||globulin-28/NN||anti-thymoctye-27/JJ	prep_with||underwent-13/VBD||globulin-28/NN	conj_and||sirolimus-24/NNS||globulin-28/NN	vmod||sirolimus-24/NNS||gvhd-29/VBN	amod||regimen-31/NN||prophylactic-30/JJ	dobj||gvhd-29/VBN||regimen-31/NN	gvhd-29||sirolimus-24||yes||we report on a prospective phase ii trial of 32 patients who underwent unrelated donor hematopoietic cell transplantation, with a tacrolimus, sirolimus and rabbit anti-thymoctye globulin gvhd prophylactic regimen.
amod||prednisolone-2/NN||oral-1/JJ	nsubj||yielded-9/VBD||prednisolone-2/NN	advmod||yielded-9/VBD||up-3/RB	prep_to||up-3/RB||5mg/kg/day-5/NNS	num||weeks-8/NNS||four-7/CD	prep_for||5mg/kg/day-5/NNS||weeks-8/NNS	root||ROOT-0/null||yielded-9/VBD	neg||effect-11/NN||no-10/DT	dobj||yielded-9/VBD||effect-11/NN	prep_on||yielded-9/VBD||thrombocytopenia-13/NN	prep_on||yielded-9/VBD||regression-15/NN	conj_or||thrombocytopenia-13/NN||regression-15/NN	nn||size-18/NN||tumor-17/NN	prep_of||thrombocytopenia-13/NN||size-18/NN	tumor-17||prednisolone-2||yes||oral prednisolone up to 5mg/kg/day for four weeks yielded no effect on thrombocytopenia or regression of tumor size.
mark||reduces-4/VBZ||while-1/IN	nsubj||reduces-4/VBZ||warfarin-2/NN	advmod||reduces-4/VBZ||significantly-3/RB	advcl||limit-16/VBP||reduces-4/VBZ	det||risk-6/NN||the-5/DT	dobj||reduces-4/VBZ||risk-6/NN	amod||stroke-9/NN||af-related-8/JJ	prep_of||risk-6/NN||stroke-9/NN	amod||risks-13/NNS||perceived-11/VBN	amod||risks-13/NNS||bleeding-12/VBG	nsubj||limit-16/VBP||risks-13/NNS	conj_and||risks-13/NNS||compliance-15/NN	nsubj||limit-16/VBP||compliance-15/NN	root||ROOT-0/null||limit-16/VBP	poss||use-19/NN||its-17/PRP$	amod||use-19/NN||widespread-18/JJ	dobj||limit-16/VBP||use-19/NN	det||population-24/NN||the-21/DT	amod||population-24/NN||high-risk-22/JJ	nn||population-24/NN||af-23/NN	prep_in||limit-16/VBP||population-24/NN	stroke-9||warfarin-2||yes||while warfarin significantly reduces the risk of af-related stroke, perceived bleeding risks and compliance limit its widespread use in the high-risk af population.
nsubj||undergoing-3/VBG||patients-2/NNS	prepc_among||safe-21/JJ||undergoing-3/VBG	amod||stenting-5/NN||primary-4/JJ	dobj||undergoing-3/VBG||stenting-5/NN	amod||administration-8/NN||abciximab-7/JJ	prep_with||undergoing-3/VBG||administration-8/NN	amod||reversal-12/NN||immediate-10/JJ	nn||reversal-12/NN||post-pci-11/NN	nsubjpass||safe-21/JJ||reversal-12/NN	nsubjpass||associated-23/VBN||reversal-12/NN	vmod||reversal-12/NN||anticoagulation-13/VBN	agent||anticoagulation-13/VBN||protamine-15/NN	amod||infusion-19/NN||associated-17/VBN	nn||infusion-19/NN||heparin-18/NN	prep_without||anticoagulation-13/VBN||infusion-19/NN	auxpass||safe-21/JJ||is-20/VBZ	cop||safe-21/JJ||is-20/VBZ	root||ROOT-0/null||safe-21/JJ	conj_and||safe-21/JJ||associated-23/VBN	det||reduction-27/NN||a-25/DT	amod||reduction-27/NN||significant-26/JJ	prep_with||associated-23/VBN||reduction-27/NN	amod||complications-31/NNS||major-29/JJ	amod||complications-31/NNS||bleeding-30/VBG	prep_in||reduction-27/NN||complications-31/NNS	bleeding-30||protamine-15||no_rel||among patients undergoing primary stenting with abciximab administration, immediate post-pci reversal anticoagulation by protamine without associated heparin infusion is safe and associated with a significant reduction in major bleeding complications.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mycobacteriumtuberculosis-22||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
amod||patients-3/NNS||chronic-1/JJ	nn||patients-3/NNS||hbv-2/NN	nsubjpass||treated-5/VBN||patients-3/NNS	nsubjpass||examined-9/VBN||patients-3/NNS	auxpass||treated-5/VBN||were-4/VBD	root||ROOT-0/null||treated-5/VBN	prep_with||treated-5/VBN||adefovirdipivoxil-7/NN	conj_and||treated-5/VBN||examined-9/VBN	nn||loads-14/NNS||serum-11/NN	nn||loads-14/NNS||hbv-12/NN	nn||loads-14/NNS||dna-13/NN	prep_for||examined-9/VBN||loads-14/NNS	appos||loads-14/NNS||cytokines-16/NNS	nn||helper-20/NN||t-19/NN	nsubj||cytokine-29/VBP||helper-20/NN	appos||helper-20/NN||th1-22/NNP	conj_and||helper-20/NN||2-25/CD	nsubj||cytokine-29/VBP||2-25/CD	appos||2-25/CD||th2-27/NNP	conj_and||treated-5/VBN||cytokine-29/VBP	xcomp||cytokine-29/VBP||producing-30/VBG	nn||cells-32/NNS||t-31/NN	dobj||producing-30/VBG||cells-32/NNS	num||weeks-35/NNS||104-34/CD	prep_during||producing-30/VBG||weeks-35/NNS	det||treatment-38/NN||the-37/DT	prep_of||weeks-35/NNS||treatment-38/NN	hbv-12||adefovirdipivoxil-7||yes||chronic hbv patients were treated with adefovirdipivoxil and examined for serum hbv dna loads, cytokines, and t helper (th1) and 2 (th2) cytokine producing t cells during 104 weeks of the treatment.
prep_in||improves-7/VBZ||particular-2/JJ	amod||lh/hcg-6/NN||in-4/IN	nn||lh/hcg-6/NN||ec-5/NN	nsubj||improves-7/VBZ||lh/hcg-6/NN	root||ROOT-0/null||improves-7/VBZ	nn||invasiveness-9/NNS||cell-8/NN	dobj||improves-7/VBZ||invasiveness-9/NNS	det||mechanism-13/NN||a-12/DT	prep_through||improves-7/VBZ||mechanism-13/NN	nsubj||involves-15/VBZ||mechanism-13/NN	rcmod||mechanism-13/NN||involves-15/VBZ	det||lh/hcg-r-17/NN||the-16/DT	dobj||involves-15/VBZ||lh/hcg-r-17/NN	nsubj||activate-22/VBP||lh/hcg-r-17/NN	nsubj||modulate-27/VBP||lh/hcg-r-17/NN	prep_in||activate-22/VBP||turn-21/NN	rcmod||lh/hcg-r-17/NN||activate-22/VBP	dobj||activate-22/VBP||protein-23/NN	amod||protein-23/NN||kinase-24/JJ	dep||kinase-24/JJ||a-25/DT	rcmod||lh/hcg-r-17/NN||modulate-27/VBP	conj_and||activate-22/VBP||modulate-27/VBP	amod||receptors-30/NNS||integrin-28/JJ	nn||receptors-30/NNS||adhesion-29/NN	dobj||modulate-27/VBP||receptors-30/NNS	adhesion-29||hcg--1||no_rel||in particular, in ec lh/hcg improves cell invasiveness, through a mechanism which involves the lh/hcg-r, which in turn activate protein kinase a and modulate integrin adhesion receptors.
nsubj||labelled-5/VBD||signalling-1/NN	amod||18f-4/NNS||radioisotope-3/JJ	prep_of||signalling-1/NN||18f-4/NNS	root||ROOT-0/null||labelled-5/VBD	nsubj||injected-10/VBD||fluorodeoxyglucose-6/NN	dep||fluorodeoxyglucose-6/NN||18f-fdg-8/JJ	ccomp||labelled-5/VBD||injected-10/VBD	prep_in||injected-10/VBD||mice-12/NNS	amod||isomerase-15/NN||glucose-6-phosphate-14/JJ	prep_with||injected-10/VBD||isomerase-15/NN	appos||isomerase-15/NN||g6pi-17/NNP	amod||arthritis-21/NN||induced-20/JJ	nsubjpass||analysed-23/VBN||arthritis-21/NN	auxpass||analysed-23/VBN||was-22/VBD	parataxis||labelled-5/VBD||analysed-23/VBN	agent||analysed-23/VBN||pet/ct-25/NN	arthritis-21||radioisotope-3||no_rel||signalling of radioisotope 18f labelled fluorodeoxyglucose (18f-fdg) injected in mice with glucose-6-phosphate isomerase (g6pi)-induced arthritis was analysed by pet/ct.
nsubj||have-11/VBP||adults-1/NNS	amod||origin-5/NN||south-3/JJ	nn||origin-5/NN||asian-4/NN	prep_of||adults-1/NNS||origin-5/NN	vmod||origin-5/NN||living-6/VBG	det||kingdom-10/NN||the-8/DT	amod||kingdom-10/NN||united-9/VBN	prep_in||living-6/VBG||kingdom-10/NN	root||ROOT-0/null||have-11/VBP	amod||risks-13/NNS||high-12/JJ	nsubj||raised-20/VBD||risks-13/NNS	amod||obesity-18/NN||type2diabetes-15/JJ	conj_and||type2diabetes-15/JJ||central-17/JJ	amod||obesity-18/NN||central-17/JJ	prep_of||risks-13/NNS||obesity-18/NN	ccomp||have-11/VBP||raised-20/VBD	xcomp||raised-20/VBD||circulating-21/VBG	dobj||circulating-21/VBG||insulin-22/NN	dobj||circulating-21/VBG||triglyceride-24/NN	conj_and||insulin-22/NN||triglyceride-24/NN	amod||concentrations-29/NNS||c-reactive-27/JJ	nn||concentrations-29/NNS||protein-28/NN	dobj||circulating-21/VBG||concentrations-29/NNS	conj_and||insulin-22/NN||concentrations-29/NNS	amod||hdl-cholesterol-33/NN||low-32/JJ	dobj||circulating-21/VBG||hdl-cholesterol-33/NN	conj_and||insulin-22/NN||hdl-cholesterol-33/NN	dep||circulating-21/VBG||when-34/WRB	prepc_compared_with||raised-20/VBD||with-36/IN	amod||europeans-38/NNS||white-37/JJ	pobj||raised-20/VBD||europeans-38/NNS	cholesterol--1||type2diabetes-15||no_rel||adults of south asian origin living in the united kingdom have high risks of type2diabetes and central obesity; raised circulating insulin, triglyceride, and c-reactive protein concentrations; and low hdl-cholesterol when compared with white europeans.
mark||caused-6/VBD||although-1/IN	amod||treatment-3/NN||standard-2/JJ	nsubj||caused-6/VBD||treatment-3/NN	prep_for||treatment-3/NN||obsessive-compulsivedisorder-5/NN	advcl||improves-21/VBZ||caused-6/VBD	nn||swings-8/NNS||mood-7/NN	dobj||caused-6/VBD||swings-8/NNS	det||combination-11/NN||the-10/DT	nsubj||improves-21/VBZ||combination-11/NN	nn||mg/day-15/NN||fluvoxamine-13/NN	num||mg/day-15/NN||300-14/CD	prep_of||combination-11/NN||mg/day-15/NN	nn||mg/day-19/NN||olanzapine-17/NN	num||mg/day-19/NN||15-18/CD	prep_of||combination-11/NN||mg/day-19/NN	conj_and||mg/day-15/NN||mg/day-19/NN	advmod||improves-21/VBZ||significantly-20/RB	root||ROOT-0/null||improves-21/VBZ	det||picture-24/NN||the-22/DT	amod||picture-24/NN||clinical-23/JJ	dobj||improves-21/VBZ||picture-24/NN	obsessive-compulsivedisorder-5||fluvoxamine-13||yes||although standard treatment for obsessive-compulsivedisorder caused mood swings, the combination of fluvoxamine 300 mg/day and olanzapine 15 mg/day significantly improves the clinical picture.
nsubj||occurs-8/VBZ||transmission-1/NN	prep_of||transmission-1/NN||s.aureus-3/NNS	prep_including||transmission-1/NN||mrsa-6/NN	root||ROOT-0/null||occurs-8/VBZ	advmod||occurs-8/VBZ||principally-9/RB	amod||contact-14/NN||direct-11/JJ	amod||contact-14/NN||human-to-human-12/JJ	nn||contact-14/NN||skin-13/NN	prep_by||occurs-8/VBZ||contact-14/NN	mrsa-6||s.aureus-3||no||transmission of s.aureus , including mrsa , occurs principally by direct human-to-human skin contact .
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	amod||regulators-7/NNS||negative-6/JJ	prep_of||role-4/NN||regulators-7/NNS	prep_of||regulators-7/NNS||interferon-9/NN	vmod||interferon-9/NN||signaling-10/VBG	dep||signaling-10/VBG||known-11/VBN	nsubj||signaling-16/VBG||suppressors-13/NNS	prep_of||suppressors-13/NNS||cytokine-15/NN	prepc_as||known-11/VBN||signaling-16/VBG	dobj||signaling-16/VBG||socs-18/NNS	prepc_in||signaling-16/VBG||mediating-21/VBG	dobj||mediating-21/VBG||interferon-resistance-22/NN	amod||cells-26/NNS||human-24/JJ	nn||cells-26/NNS||melanoma-25/NN	prep_in||mediating-21/VBG||cells-26/NNS	melanoma-25||interferon-9||yes||we investigated the role of negative regulators of interferon signaling known as suppressors of cytokine signaling (socs) in mediating interferon-resistance in human melanoma cells.
nsubj||appears-2/VBZ||ldx-1/NN	nsubj||used-16/VBN||ldx-1/NN	nsubj||reduced-22/VBD||ldx-1/NN	root||ROOT-0/null||appears-2/VBZ	aux||used-16/VBN||to-3/TO	aux||used-16/VBN||have-4/VB	det||profile-9/NN||an-5/DT	amod||profile-9/NN||efficacy-6/JJ	conj_and||efficacy-6/JJ||tolerability-8/JJ	amod||profile-9/NN||tolerability-8/JJ	dobj||used-16/VBN||profile-9/NN	nsubj||treat-18/VB||profile-9/NN	amod||profile-9/NN||comparable-10/JJ	amod||formulations-15/NNS||other-12/JJ	amod||formulations-15/NNS||extended-release-13/JJ	nn||formulations-15/NNS||stimulant-14/NN	prep_to||comparable-10/JJ||formulations-15/NNS	xcomp||appears-2/VBZ||used-16/VBN	aux||treat-18/VB||to-17/TO	xcomp||used-16/VBN||treat-18/VB	acomp||treat-18/VB||adhd-19/JJ	conj_but||appears-2/VBZ||reduced-22/VBD	dobj||reduced-22/VBD||potential-23/NN	amod||effects-27/NNS||abuse-related-25/JJ	nn||effects-27/NNS||liking-26/NN	prep_for||reduced-22/VBD||effects-27/NNS	advmod||compared-29/VBN||when-28/WRB	advcl||reduced-22/VBD||compared-29/VBN	nn||amounts-32/NNS||equivalent-31/NN	prep_to||compared-29/VBN||amounts-32/NNS	amod||d-amphetamine-35/NN||immediate-release-34/JJ	prep_of||amounts-32/NNS||d-amphetamine-35/NN	adhd-19||d-amphetamine-35||yes||ldx appears to have an efficacy and tolerability profile comparable to other extended-release stimulant formulations used to treat adhd, but reduced potential for abuse-related liking effects when compared to equivalent amounts of immediate-release d-amphetamine.
det||objective-3/NN||the-1/DT	amod||objective-3/NN||principal-2/JJ	nsubj||was-25/VBD||objective-3/NN	nsubj||develop-27/VB||objective-3/NN	nsubj||implement-29/VB||objective-3/NN	det||studies-7/NNS||these-5/DT	amod||studies-7/NNS||multisite-6/JJ	prep_of||objective-3/NN||studies-7/NNS	dep||studies-7/NNS||florida-9/NN	amod||york-12/NN||new-11/JJ	appos||florida-9/NN||york-12/NN	amod||epicenters-16/NNS||new-14/JJ	nn||epicenters-16/NNS||jersey-15/NN	dep||florida-9/NN||epicenters-16/NNS	amod||-RSB--21/NNS||humanimmunodeficiencyvirus-18/JJ	amod||-RSB--21/NNS||-LSB--19/JJ	nn||-RSB--21/NNS||hiv-20/NN	prep_for||epicenters-16/NNS||-RSB--21/NNS	prep_among||-RSB--21/NNS||women-23/NNS	root||ROOT-0/null||was-25/VBD	aux||develop-27/VB||to-26/TO	xcomp||was-25/VBD||develop-27/VB	xcomp||was-25/VBD||implement-29/VB	conj_and||develop-27/VB||implement-29/VB	amod||combinations-31/NNS||effective-30/JJ	dobj||develop-27/VB||combinations-31/NNS	amod||interventions-34/NNS||behavioral-33/JJ	prep_of||combinations-31/NNS||interventions-34/NNS	aux||optimize-36/VB||to-35/TO	vmod||develop-27/VB||optimize-36/VB	det||status-39/NN||the-37/DT	nn||status-39/NN||health-38/NN	dobj||optimize-36/VB||status-39/NN	det||population-46/NN||the-41/DT	advmod||neglected-43/JJ||most-42/RBS	amod||population-46/NN||neglected-43/JJ	conj_and||neglected-43/JJ||understudied-45/JJ	amod||population-46/NN||understudied-45/JJ	prep_of||status-39/NN||population-46/NN	vmod||population-46/NN||affected-47/VBN	det||epidemic-54/NN||the-49/DT	amod||epidemic-54/NN||acquiredimmunodeficiencysyndrome-50/JJ	appos||epidemic-54/NN||aids-52/NNS	agent||affected-47/VBN||epidemic-54/NN	det||states-58/NNS||the-56/DT	amod||states-58/NNS||united-57/VBN	prep_in||affected-47/VBN||states-58/NNS	amod||women-60/NNS||poor-59/JJ	dep||was-25/VBD||women-60/NNS	prep_of||women-60/NNS||color-62/NN	vmod||color-62/NN||living-63/VBG	prep_with||living-63/VBG||hiv-65/NN	acquiredimmunodeficiencysyndrome-50||humanimmunodeficiencyvirus-18||no||the principal objective of these multisite studies (florida, new york, new jersey epicenters for humanimmunodeficiencyvirus [hiv] among women) was to develop and implement effective combinations of behavioral interventions to optimize the health status of the most neglected and understudied population affected by the acquiredimmunodeficiencysyndrome (aids) epidemic in the united states poor women of color living with hiv.
det||study-3/NN||this-2/DT	prep_in||translated-6/VBN||study-3/NN	nsubj||translated-6/VBN||we-5/PRP	root||ROOT-0/null||translated-6/VBN	advmod||adapted-9/VBN||culturally-8/RB	dep||translated-6/VBN||adapted-9/VBN	dep||translated-6/VBN||tested-11/VBN	conj_and||adapted-9/VBN||tested-11/VBN	det||reliability-13/NN||the-12/DT	dobj||adapted-9/VBN||reliability-13/NN	dobj||adapted-9/VBN||validity-15/NN	conj_and||reliability-13/NN||validity-15/NN	num||quality-20/NN||two-17/CD	amod||quality-20/NN||widely-used-18/JJ	amod||quality-20/NN||health-related-19/JJ	prep_of||validity-15/NN||quality-20/NN	nn||questionnaires-23/NNS||life-22/NN	prep_of||quality-20/NN||questionnaires-23/NNS	det||survey-28/NN||the-25/DT	amod||survey-28/NN||mos-hiv-26/JJ	nn||survey-28/NN||health-27/NN	dobj||adapted-9/VBN||survey-28/NN	conj_and||reliability-13/NN||survey-28/NN	det||sf-12-31/NN||the-30/DT	conj_and||reliability-13/NN||sf-12-31/NN	conj_and||survey-28/NN||sf-12-31/NN	dobj||adapted-9/VBN||in-33/IN	conj_and||reliability-13/NN||in-33/IN	prep_in||reliability-13/NN||people-34/NNS	xcomp||translated-6/VBN||living-35/VBG	prep_with||living-35/VBG||hiv/aids-37/NNS	amod||thailand-40/NN||northern-39/JJ	prep_in||hiv/aids-37/NNS||thailand-40/NN	aids--1||hiv--1||no||in this study, we translated, culturally adapted and tested the reliability and validity of two widely-used health-related quality of life questionnaires - the mos-hiv health survey and the sf-12 - in people living with hiv/aids in northern thailand.
nsubjpass||associated-4/VBN||perniciousanaemia-1/NN	auxpass||associated-4/VBN||is-2/VBZ	advmod||associated-4/VBN||undeniably-3/RB	root||ROOT-0/null||associated-4/VBN	amod||deficiency-7/NN||vitaminb12-6/JJ	prep_with||associated-4/VBN||deficiency-7/NN	det||association-11/NN||the-10/DT	nsubj||unclear-22/JJ||association-11/NN	amod||concentrations-15/NNS||subnormal-13/JJ	amod||concentrations-15/NNS||vitaminb12-14/JJ	prep_between||association-11/NN||concentrations-15/NNS	conj_and||association-11/NN||anaemia-17/NN	nsubj||unclear-22/JJ||anaemia-17/NN	amod||people-20/NNS||older-19/JJR	prep_in||anaemia-17/NN||people-20/NNS	cop||unclear-22/JJ||is-21/VBZ	conj_but||associated-4/VBN||unclear-22/JJ	perniciousanaemia-1||vitaminb12-14||yes||perniciousanaemia is undeniably associated with vitaminb12 deficiency, but the association between subnormal vitaminb12 concentrations and anaemia in older people is unclear.
prep_after||administered-29/VBN||detoxification-2/NN	nn||use-5/NN||alcohol-4/NN	nsubjpass||administered-29/VBN||use-5/NN	nn||test-8/NN||detection-6/NN	nn||test-8/NN||inventory-7/NN	dep||use-5/NN||test-8/NN	conj_and||use-5/NN||severity-10/NN	nsubjpass||administered-29/VBN||severity-10/NN	amod||questionnaire-13/NN||alcoholdependence-12/JJ	prep_of||severity-10/NN||questionnaire-13/NN	conj_and||use-5/NN||schedule-15/NN	nsubjpass||administered-29/VBN||schedule-15/NN	amod||assessment-18/NN||clinical-17/JJ	prep_for||schedule-15/NN||assessment-18/NN	prep_in||assessment-18/NN||neuropsychiatry-20/NN	nn||interview-24/NN||family-23/NN	conj_and||use-5/NN||interview-24/NN	nsubjpass||administered-29/VBN||interview-24/NN	amod||studies-27/NNS||genetic-26/JJ	prep_for||interview-24/NN||studies-27/NNS	auxpass||administered-29/VBN||were-28/VBD	root||ROOT-0/null||administered-29/VBN	alcoholdependence-12||alcohol-4||no||after detoxification, alcohol use detection inventory test, severity of alcoholdependence questionnaire, schedule for clinical assessment in neuropsychiatry, and family interview for genetic studies were administered.
det||vaccine-2/NN||a-1/DT	nsubj||protects-4/VBZ||vaccine-2/NN	nsubj||advance-27/NN||vaccine-2/NN	rcmod||vaccine-2/NN||protects-4/VBZ	amod||influenzaviruses-7/NNS||different-6/JJ	prep_against||protects-4/VBZ||influenzaviruses-7/NNS	vmod||influenzaviruses-7/NNS||belonging-8/VBG	prep||belonging-8/VBG||to-9/TO	det||subtype-12/NN||the-10/DT	amod||subtype-12/NN||same-11/JJ	pobj||to-9/TO||subtype-12/NN	prep||belonging-8/VBG||even-14/RB	conj_or||to-9/TO||even-14/RB	dep||to-9/TO||against-15/IN	pobj||against-15/IN||viruses-16/NNS	vmod||viruses-16/NNS||belonging-17/VBG	mwe||than-20/IN||more-19/JJR	quantmod||one-21/CD||than-20/IN	num||subtype-22/NN||one-21/CD	prep_to||belonging-17/VBG||subtype-22/NN	aux||advance-27/NN||would-23/MD	cop||advance-27/NN||be-24/VB	det||advance-27/NN||a-25/DT	amod||advance-27/NN||major-26/JJ	root||ROOT-0/null||advance-27/NN	poss||battle-30/NN||our-29/PRP$	prep_in||advance-27/NN||battle-30/NN	prep_against||battle-30/NN||influenza-32/NN	influenza-32||influenzaviruses-7||no||a vaccine that protects against different influenzaviruses belonging to the same subtype or even against viruses belonging to more than one subtype would be a major advance in our battle against influenza.
det||response-4/NN||an-1/DT	amod||response-4/NN||early-2/JJ	amod||response-4/NN||virological-3/JJ	nsubj||leads-19/VBZ||response-4/NN	appos||response-4/NN||evr-6/NN	det||start-10/NN||the-9/DT	prep_after||response-4/NN||start-10/NN	amod||treatment-16/NN||interferon-12/JJ	appos||treatment-16/NN||ifn-14/NN	prep_of||start-10/NN||treatment-16/NN	prep_for||treatment-16/NN||chronichepatitisc-18/NN	root||ROOT-0/null||leads-19/VBZ	det||outcome-24/NN||a-21/DT	amod||outcome-24/NN||successful-22/JJ	amod||outcome-24/NN||virological-23/JJ	prep_to||leads-19/VBZ||outcome-24/NN	chronichepatitisc-18||ifn-14||yes||an early virological response (evr) after the start of interferon (ifn) treatment for chronichepatitisc leads to a successful virological outcome.
det||analysis-2/NN||this-1/DT	nsubj||illustrates-14/VBZ||analysis-2/NN	nn||patterns-5/NNS||workforce-4/NN	prep_of||analysis-2/NN||patterns-5/NNS	num||facilities-8/NNS||30-7/CD	prep_across||patterns-5/NNS||facilities-8/NNS	num||districts-11/NNS||three-10/CD	prep_in||facilities-8/NNS||districts-11/NNS	prep_of||districts-11/NNS||zambia-13/NN	root||ROOT-0/null||illustrates-14/VBZ	mark||been-25/VBN||that-15/IN	det||achievements-18/NNS||the-16/DT	amod||achievements-18/NNS||remarkable-17/JJ	nsubj||been-25/VBN||achievements-18/NNS	amod||delivery-23/NN||scaling-up-20/JJ	nn||delivery-23/NN||hiv/aids-21/NN	nn||delivery-23/NN||service-22/NN	prep_in||achievements-18/NNS||delivery-23/NN	aux||been-25/VBN||has-24/VBZ	ccomp||illustrates-14/VBZ||been-25/VBN	det||back-28/NN||the-27/DT	prep_on||been-25/VBN||back-28/NN	amod||levels-33/NNS||sustained-30/JJ	amod||levels-33/NNS||non-hiv-31/JJ	nn||levels-33/NNS||workload-32/NN	prep_of||back-28/NN||levels-33/NNS	amod||workload-37/NN||increasing-35/VBG	nn||workload-37/NN||hiv-36/NN	prep_of||back-28/NN||workload-37/NN	conj_and||levels-33/NNS||workload-37/NN	amod||numbers-42/NNS||stagnant-39/JJ	nn||numbers-42/NNS||health-40/NN	nn||numbers-42/NNS||worker-41/NN	prep_of||back-28/NN||numbers-42/NNS	conj_and||levels-33/NNS||numbers-42/NNS	aids--1||hiv-36||no||this analysis of workforce patterns across 30 facilities in three districts of zambia illustrates that the remarkable achievements in scaling-up hiv/aids service delivery has been on the back of sustained non-hiv workload levels, increasing hiv workload and stagnant health worker numbers.
amod||i-6/NNS||human-1/JJ	amod||i-6/NNS||t-cell-2/JJ	nn||i-6/NNS||leukemia-3/NN	nn||i-6/NNS||virus-4/NN	nn||i-6/NNS||type-5/NN	nsubj||cause-11/VB||i-6/NNS	dep||i-6/NNS||htlv-1-8/JJ	aux||cause-11/VB||can-10/MD	root||ROOT-0/null||cause-11/VB	det||malignancy-14/NN||an-12/DT	amod||malignancy-14/NN||aggressive-13/JJ	dobj||cause-11/VB||malignancy-14/NN	vmod||malignancy-14/NN||known-15/VBN	amod||leukemia/lymphoma-19/NN||adult-17/JJ	amod||leukemia/lymphoma-19/NN||t-cell-18/JJ	prep_as||known-15/VBN||leukemia/lymphoma-19/NN	appos||leukemia/lymphoma-19/NN||atl-21/NN	dobj||cause-11/VB||inflammatorydiseases-26/NNS	conj_and||malignancy-14/NN||inflammatorydiseases-26/NNS	amod||tropicalspasticparaparesis-31/NNS||htlv-1-associatedmyelopathy-29/JJ	amod||tropicalspasticparaparesis-31/NNS||/-30/JJ	prep_such_as||inflammatorydiseases-26/NNS||tropicalspasticparaparesis-31/NNS	appos||tropicalspasticparaparesis-31/NNS||ham/tsp-33/NN	tropicalspasticparaparesis-31||htlv-1-8||no||human t-cell leukemia virus type i (htlv-1) can cause an aggressive malignancy known as adult t-cell leukemia/lymphoma (atl) as well as inflammatorydiseases such as htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nn||tissue-2/NN||lymphoreticular-1/NN	nsubj||showed-3/VBD||tissue-2/NN	root||ROOT-0/null||showed-3/VBD	neg||evidence-5/NN||no-4/DT	dobj||showed-3/VBD||evidence-5/NN	nn||colonization-8/NN||prion-7/NN	prep_of||evidence-5/NN||colonization-8/NN	vmod||showed-3/VBD||suggesting-10/VBG	mark||similar-18/JJ||that-11/IN	det||pathogenesis-14/NNS||the-12/DT	amod||pathogenesis-14/NNS||peripheral-13/JJ	nsubj||similar-18/JJ||pathogenesis-14/NNS	prep_of||pathogenesis-14/NNS||kuru-16/NN	cop||similar-18/JJ||is-17/VBZ	ccomp||suggesting-10/VBG||similar-18/JJ	prep_to||similar-18/JJ||that-20/DT	vmod||that-20/DT||seen-21/VBN	amod||cjd-24/NN||classical-23/JJ	prep_in||seen-21/VBN||cjd-24/NN	prep_in||seen-21/VBN||vcjd-27/NN	conj_negcc||cjd-24/NN||vcjd-27/NN	cjd-24||prion-7||no_rel||lymphoreticular tissue showed no evidence of prion colonization, suggesting that the peripheral pathogenesis of kuru is similar to that seen in classical cjd rather than vcjd.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||tested-7/VBD||study-4/NN	nsubj||tested-7/VBD||we-6/PRP	root||ROOT-0/null||tested-7/VBD	det||uniformity-9/NN||the-8/DT	dobj||tested-7/VBD||uniformity-9/NN	amod||effect-12/NN||vitamine-11/JJ	prep_of||uniformity-9/NN||effect-12/NN	det||risk-15/NN||the-14/DT	prep_on||effect-12/NN||risk-15/NN	amod||pneumonia-18/NN||hospital-treated-17/JJ	prep_of||risk-15/NN||pneumonia-18/NN	num||cases-21/NNS||898-20/CD	appos||pneumonia-18/NN||cases-21/NNS	prepc_by||tested-7/VBD||adding-24/VBG	det||variable-27/NN||a-25/DT	amod||variable-27/NN||dummy-26/JJ	dobj||adding-24/VBG||variable-27/NN	aux||allow-29/VB||to-28/TO	vmod||adding-24/VBG||allow-29/VB	det||subgroup-31/NN||each-30/DT	iobj||allow-29/VB||subgroup-31/NN	poss||effect-35/NN||its-32/PRP$	amod||effect-35/NN||own-33/JJ	amod||effect-35/NN||vitamine-34/JJ	dobj||allow-29/VB||effect-35/NN	det||model-39/NN||a-37/DT	nn||model-39/NN||cox-38/NN	prep_in||effect-35/NN||model-39/NN	vmod||model-39/NN||covering-40/VBG	det||participants-42/NNS||all-41/DT	dobj||covering-40/VBG||participants-42/NNS	pneumonia-18||vitamine-34||no_rel||in the present study, we tested the uniformity of vitamine effect on the risk of hospital-treated pneumonia (898 cases) by adding a dummy variable to allow each subgroup its own vitamine effect in a cox model covering all participants.
det||development-2/NN||the-1/DT	nsubj||proven-8/VBN||development-2/NN	nsubj||elusive-11/JJ||development-2/NN	det||vaccine-6/NN||an-4/DT	amod||vaccine-6/NN||hiv/aids-5/JJ	prep_of||development-2/NN||vaccine-6/NN	aux||proven-8/VBN||has-7/VBZ	root||ROOT-0/null||proven-8/VBN	aux||elusive-11/JJ||to-9/TO	cop||elusive-11/JJ||be-10/VB	xcomp||proven-8/VBN||elusive-11/JJ	aids--1||hiv--1||no||the development of an hiv/aids vaccine has proven to be elusive.
advmod||examined-16/VBN||however-1/RB	det||effects-4/NNS||the-3/DT	nsubjpass||examined-16/VBN||effects-4/NNS	prep_of||effects-4/NNS||rosiglitazone-6/NN	prep_on||rosiglitazone-6/NN||inflammation-8/NN	amod||muscle-11/NN||skeletal-10/JJ	prep_of||inflammation-8/NN||muscle-11/NN	aux||examined-16/VBN||have-12/VBP	neg||examined-16/VBN||not-13/RB	auxpass||examined-16/VBN||been-14/VBN	advmod||examined-16/VBN||fully-15/RB	root||ROOT-0/null||examined-16/VBN	prep_in||examined-16/VBN||type2diabetes-18/CD	type2diabetes-18||rosiglitazone-6||yes||however, the effects of rosiglitazone on inflammation of skeletal muscle have not been fully examined in type2diabetes.
num||patients-3/NNS||48-2/CD	nsubj||undergoing-19/VBG||patients-3/NNS	prep_with||patients-3/NNS||pdac-5/NN	num||resectable-8/NN||40-7/CD	dep||pdac-5/NN||resectable-8/NN	num||unresectable-11/NN||8-10/CD	appos||resectable-8/NN||unresectable-11/NN	num||patients-15/NNS||10-14/CD	prep_with||patients-3/NNS||patients-15/NNS	conj_and||pdac-5/NN||patients-15/NNS	amod||pancreatitis-18/NNS||chronic-17/JJ	prep_with||patients-15/NNS||pancreatitis-18/NNS	prepc_from||drawn-27/VBN||undergoing-19/VBG	advmod||undergoing-19/VBG||pancreatectomy-20/RB	num||ml-22/NN||10-21/CD	dobj||undergoing-19/VBG||ml-22/NN	amod||blood-25/NN||venous-24/JJ	prep_of||ml-22/NN||blood-25/NN	auxpass||drawn-27/VBN||was-26/VBD	root||ROOT-0/null||drawn-27/VBN	dobj||drawn-27/VBN||preoperatively-28/NN	appos||preoperatively-28/NN||pb-30/NN	amod||day-37/NN||postoperatively-33/JJ	nn||day-37/NN||pob-35/NN	dobj||drawn-27/VBN||day-37/NN	conj_and||preoperatively-28/NN||day-37/NN	nsubjpass||drawn-27/VBN||1-38/CD	appos||1-38/CD||d1b-40/NNP	appos||1-38/CD||day-43/NN	num||day-43/NN||7-44/CD	appos||day-43/NN||d7b-46/NNP	amod||weeks-51/NNS||after-49/IN	num||weeks-51/NNS||6-50/CD	appos||1-38/CD||weeks-51/NNS	conj_and||day-43/NN||weeks-51/NNS	appos||weeks-51/NNS||6wb-53/NNP	pb-30||pancreatitis-18||no_rel||from 48 patients with pdac (40 resectable, 8 unresectable) and 10 patients with chronic pancreatitis undergoing pancreatectomy 10 ml of venous blood was drawn preoperatively (pb) and postoperatively (pob, day 1 (d1b), day 7 (d7b) and after 6 weeks (6wb).
nsubj||amplify-13/VB||hyperglycaemia-1/NN	vmod||hyperglycaemia-1/NN||induced-2/VBN	det||supply-7/NN||an-4/DT	amod||supply-7/NN||exogenous-5/JJ	nn||supply-7/NN||glucose-6/NN	agent||induced-2/VBN||supply-7/NN	aux||amplify-13/VB||may-8/MD	prep_in||amplify-13/VB||turn-11/NN	root||ROOT-0/null||amplify-13/VB	det||response-16/NN||the-14/DT	amod||response-16/NN||inflammatory-15/JJ	dobj||amplify-13/VB||response-16/NN	prep||amplify-13/VB||such-17/JJ	mark||becomes-20/VBZ||that-18/IN	nsubj||becomes-20/VBZ||it-19/PRP	ccomp||amplify-13/VB||becomes-20/VBZ	det||response-23/NN||a-21/DT	amod||response-23/NN||disproportionate-22/JJ	xcomp||becomes-20/VBZ||response-23/NN	hyperglycaemia-1||glucose-6||no||hyperglycaemia induced by an exogenous glucose supply may, in turn, amplify the inflammatory response such that it becomes a disproportionate response.
det||range-2/NN||a-1/DT	nsubjpass||used-8/VBN||range-2/NN	nsubj||investigate-10/VB||range-2/NN	nsubj||investigate-10/VB||range-2/NN	nn||systems-5/NNS||model-4/NN	prep_of||range-2/NN||systems-5/NNS	aux||used-8/VBN||have-6/VBP	auxpass||used-8/VBN||been-7/VBN	root||ROOT-0/null||used-8/VBN	aux||investigate-10/VB||to-9/TO	xcomp||used-8/VBN||investigate-10/VB	xcomp||used-8/VBN||investigate-10/VB	conj_and||investigate-10/VB||investigate-10/VB	det||effects-12/NNS||the-11/DT	dobj||investigate-10/VB||effects-12/NNS	amod||bisphosphonates-15/NNS||different-14/JJ	prep_of||effects-12/NNS||bisphosphonates-15/NNS	nn||growth-18/NN||tumour-17/NN	prep_on||investigate-10/VB||growth-18/NN	preconj||investigate-10/VB||both-20/DT	prep_in||investigate-10/VB||bone-22/NN	amod||sites-26/NNS||peripheral-25/JJ	prep_at||investigate-10/VB||sites-26/NNS	tumour-17||bisphosphonates-15||no_rel||a range of model systems have been used to investigate the effects of different bisphosphonates on tumour growth, both in bone and at peripheral sites.
mark||high-6/JJ||although-1/IN	det||rate-4/NN||the-2/DT	nn||rate-4/NN||discontinuation-3/NN	nsubj||high-6/JJ||rate-4/NN	cop||high-6/JJ||was-5/VBD	advcl||found-10/VBN||high-6/JJ	nsubjpass||found-10/VBN||aripiprazole-8/NN	nsubj||effective-13/JJ||aripiprazole-8/NN	nsubj||safe-15/JJ||aripiprazole-8/NN	nsubj||tolerated-18/JJ||aripiprazole-8/NN	auxpass||found-10/VBN||was-9/VBD	root||ROOT-0/null||found-10/VBN	aux||effective-13/JJ||to-11/TO	cop||effective-13/JJ||be-12/VB	xcomp||found-10/VBN||effective-13/JJ	xcomp||found-10/VBN||safe-15/JJ	conj_and||effective-13/JJ||safe-15/JJ	advmod||tolerated-18/JJ||well-17/RB	xcomp||found-10/VBN||tolerated-18/JJ	conj_and||effective-13/JJ||tolerated-18/JJ	det||treatment-22/NN||the-20/DT	amod||treatment-22/NN||long-term-21/JJ	prep_in||effective-13/JJ||treatment-22/NN	amod||patients-25/NNS||taiwanese-24/JJ	prep_of||treatment-22/NN||patients-25/NNS	prep_with||effective-13/JJ||schizophrenia-27/NN	nsubj||continued-29/VBD||schizophrenia-27/NN	nsubj||receive-31/VB||schizophrenia-27/NN	rcmod||schizophrenia-27/NN||continued-29/VBD	aux||receive-31/VB||to-30/TO	xcomp||continued-29/VBD||receive-31/VB	dobj||receive-31/VB||treatment-32/NN	num||weeks-35/NNS||64-34/CD	prep_for||receive-31/VB||weeks-35/NNS	schizophrenia-27||aripiprazole-8||yes||although the discontinuation rate was high, aripiprazole was found to be effective, safe and well tolerated in the long-term treatment of taiwanese patients with schizophrenia who continued to receive treatment for 64 weeks.
nsubj||endemic-9/NN||bartonellosis-1/NNS	prep_due_to||bartonellosis-1/NNS||bartonellabacilliformis-4/NNS	cop||endemic-9/NN||is-5/VBZ	det||endemic-9/NN||a-6/DT	advmod||lethal-8/JJ||highly-7/RB	amod||endemic-9/NN||lethal-8/JJ	root||ROOT-0/null||endemic-9/NN	advmod||disease-14/NN||sometimes-11/RB	nn||disease-14/NN||epidemic-12/NN	amod||disease-14/NN||infectious-13/JJ	conj_and||endemic-9/NN||disease-14/NN	amod||america-17/NN||south-16/JJ	prep_in||disease-14/NN||america-17/NN	det||concern-24/NN||a-20/DT	amod||concern-24/NN||serious-21/JJ	amod||concern-24/NN||public-22/JJ	nn||concern-24/NN||health-23/NN	conj_and||endemic-9/NN||concern-24/NN	conj_and||disease-14/NN||concern-24/NN	prep_in||concern-24/NN||perãº-26/NNP	bartonellosis-1||bartonellabacilliformis-4||no||bartonellosis due to bartonellabacilliformis is a highly lethal endemic and sometimes epidemic infectious disease in south america, and a serious public health concern in perãº.
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	anemia-6||irondeficiency-5||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
det||bowel-3/NN||the-1/DT	amod||bowel-3/NN||neonatal-2/JJ	nsubj||takes-4/VBZ||bowel-3/NN	root||ROOT-0/null||takes-4/VBZ	amod||hours-6/NNS||several-5/JJ	dobj||takes-4/VBZ||hours-6/NNS	nsubj||fill-8/VB||hours-6/NNS	aux||fill-8/VB||to-7/TO	xcomp||takes-4/VBZ||fill-8/VB	prep_with||fill-8/VB||gas-10/NN	advmod||obscuring-13/VBG||potentially-12/RB	xcomp||fill-8/VB||obscuring-13/VBG	dobj||obscuring-13/VBG||one-14/CD	det||signs-18/NNS||the-16/DT	amod||signs-18/NNS||radiological-17/JJ	prep_of||one-14/CD||signs-18/NNS	prep_of||signs-18/NNS||bowelperforation-20/NN	det||neonate-23/NN||the-22/DT	prep_in||obscuring-13/VBG||neonate-23/NN	bowelperforation-20||gas-10||no_rel||the neonatal bowel takes several hours to fill with gas, potentially obscuring one of the radiological signs of bowelperforation in the neonate.
mark||detect-4/VB||in-1/IN	dep||detect-4/VB||order-2/NN	aux||detect-4/VB||to-3/TO	advcl||developed-17/VBD||detect-4/VB	amod||igm-6/NN||anti-hav-5/JJ	dobj||detect-4/VB||igm-6/NN	det||serum-9/NN||the-8/DT	prep_in||detect-4/VB||serum-9/NN	prep_of||serum-9/NN||patients-11/NNS	vmod||patients-11/NNS||infected-12/VBN	prep_with||infected-12/VBN||hav-14/NN	nsubj||developed-17/VBD||we-16/PRP	root||ROOT-0/null||developed-17/VBD	det||assay-20/NN||a-18/DT	amod||assay-20/NN||rapid-19/JJ	dobj||developed-17/VBD||assay-20/NN	prep_based_on||assay-20/NN||immunochromatography-23/NN	appos||immunochromatography-23/NN||ica-25/NN	dobj||developed-17/VBD||evaluated-28/VBN	conj_and||assay-20/NN||evaluated-28/VBN	det||sensitivity-30/NN||the-29/DT	dobj||evaluated-28/VBN||sensitivity-30/NN	det||immunoassay-42/NN||this-32/DT	amod||immunoassay-42/NN||assay-33/JJ	prepc_by||assay-33/JJ||comparing-35/VBG	dobj||comparing-35/VBG||it-36/PRP	det||microparticle-40/NN||a-38/DT	amod||microparticle-40/NN||commercial-39/JJ	prep_with||comparing-35/VBG||microparticle-40/NN	amod||immunoassay-42/NN||enzyme-41/JJ	prep_of||sensitivity-30/NN||immunoassay-42/NN	appos||immunoassay-42/NN||meia-44/NNP	nsubjpass||used-49/VBN||that-46/WDT	auxpass||used-49/VBN||is-47/VBZ	advmod||used-49/VBN||widely-48/RB	ccomp||immunoassay-42/NN||used-49/VBN	amod||diagnosis-52/NN||serological-51/JJ	prep_for||used-49/VBN||diagnosis-52/NN	anti-hav-5||hav-14||no_rel||in order to detect anti-hav igm in the serum of patients infected with hav, we developed a rapid assay based on immunochromatography (ica) and evaluated the sensitivity of this assay by comparing it with a commercial microparticle enzyme immunoassay (meia) that is widely used for serological diagnosis.
vmod||demonstrated-7/VBD||using-1/VBG	nn||chromatography-mass-3/NNS||gas-2/NN	dobj||using-1/VBG||chromatography-mass-3/NNS	advmod||using-1/VBG||spectrometry-4/RB	nsubj||demonstrated-7/VBD||we-6/PRP	root||ROOT-0/null||demonstrated-7/VBD	mark||present-11/JJ||that-8/IN	nsubj||present-11/JJ||naa-9/NN	cop||present-11/JJ||was-10/VBD	ccomp||demonstrated-7/VBD||present-11/JJ	det||concentration-16/NN||a-13/DT	amod||concentration-16/NN||high-14/JJ	nn||concentration-16/NN||micromolar-15/NN	prep_in||present-11/JJ||concentration-16/NN	prep_in||present-11/JJ||ocf-18/NN	amod||ovariantumors-21/NNS||epithelial-20/JJ	prep_of||ocf-18/NN||ovariantumors-21/NNS	appos||ovariantumors-21/NNS||eots-23/NNS	amod||histology-27/NN||serous-26/JJ	prep_of||ovariantumors-21/NNS||histology-27/NN	advmod||present-11/JJ||sometimes-29/RB	det||range-33/NN||the-31/DT	amod||range-33/NN||same-32/JJ	prep_in||present-11/JJ||range-33/NN	mark||found-35/VBD||as-34/IN	advcl||present-11/JJ||found-35/VBD	det||space-39/NN||the-37/DT	nn||space-39/NN||extracellular-38/NN	prep_in||found-35/VBD||space-39/NN	det||brain-43/NN||the-41/DT	amod||brain-43/NN||human-42/JJ	prep_of||space-39/NN||brain-43/NN	ovariantumors-21||gas-2||no_rel||using gas chromatography-mass spectrometry, we demonstrated that naa was present in a high micromolar concentration in ocf of epithelial ovariantumors (eots) of serous histology, sometimes in the same range as found in the extracellular space of the human brain.
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||budesonide--1||yes||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
prepc_based_on||reported-24/VBN||on-2/IN	pobj||reported-24/VBN||data-3/NNS	det||sample-7/NN||a-5/DT	amod||sample-7/NN||representative-6/JJ	prep_from||data-3/NNS||sample-7/NN	num||programs-13/NNS||128-9/CD	amod||programs-13/NNS||public-funded-10/JJ	nn||programs-13/NNS||hiv-11/NN	nn||programs-13/NNS||prevention-12/NN	prep_of||sample-7/NN||programs-13/NNS	num||types-16/NNS||14-15/CD	prep_of||programs-13/NNS||types-16/NNS	nn||pradesh-19/NN||andhra-18/NN	prep_in||types-16/NNS||pradesh-19/NN	nsubj||reported-24/VBN||we-21/PRP	aux||reported-24/VBN||have-22/VBP	advmod||reported-24/VBN||recently-23/RB	root||ROOT-0/null||reported-24/VBN	det||number-26/NN||the-25/DT	dobj||reported-24/VBN||number-26/NN	prep_of||number-26/NN||hivinfections-28/NNS	vmod||hivinfections-28/NNS||averted-29/VBN	det||type-32/NN||each-31/DT	agent||averted-29/VBN||type-32/NN	nn||intervention-36/NN||hiv-34/NN	nn||intervention-36/NN||prevention-35/NN	prep_of||type-32/NN||intervention-36/NN	poss||cost-39/NN||their-38/PRP$	prep_of||type-32/NN||cost-39/NN	conj_and||intervention-36/NN||cost-39/NN	hivinfections-28||hiv-34||no||based on data from a representative sample of 128 public-funded hiv prevention programs of 14 types in andhra pradesh, we have recently reported the number of hivinfections averted by each type of hiv prevention intervention and their cost.
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	prep_such_as||disorders-27/NNS||disseminatedintravascularcoagulation-30/NN	appos||disseminatedintravascularcoagulation-30/NN||dic-32/NN	prep_such_as||disorders-27/NNS||shock-35/NN	conj_and||disseminatedintravascularcoagulation-30/NN||shock-35/NN	prep_such_as||disorders-27/NNS||pancreatitis-38/NNS	conj_and||disseminatedintravascularcoagulation-30/NN||pancreatitis-38/NNS	disseminatedintravascularcoagulation-30||trypsin-2||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminatedintravascularcoagulation (dic), shock, and pancreatitis.
ccomp||were-15/VBD||results-1/VBZ	det||end-4/NN||the-3/DT	prep_at||results-1/VBZ||end-4/NN	prep_of||end-4/NN||2003-6/CD	dobj||results-1/VBZ||2005-8/CD	num||2005-8/CD||2007-10/CD	dobj||results-1/VBZ||2009-12/CD	conj_and||2005-8/CD||2009-12/CD	expl||were-15/VBD||there-14/EX	root||ROOT-0/null||were-15/VBD	det||people-26/NNS||an-16/DT	amod||people-26/NNS||estimated-17/JJ	num||0.65-20/NNS||0.84-18/CD	nn||people-26/NNS||0.65-20/NNS	num||0.65-20/NNS||0.70-22/CD	conj_and||0.65-20/NNS||0.74-24/CD	nn||people-26/NNS||0.74-24/CD	num||people-26/NNS||million-25/CD	nsubj||were-15/VBD||people-26/NNS	vmod||people-26/NNS||living-27/VBG	prep_with||living-27/VBG||hiv/aids-29/NNS	prep_in||hiv/aids-29/NNS||china-31/NN	advmod||living-27/VBG||respectively-33/RB	det||prevalence-39/NN||an-36/DT	amod||prevalence-39/NN||overall-37/JJ	nn||prevalence-39/NN||hiv-38/NN	prep_with||living-27/VBG||prevalence-39/NN	num||â-42/NN||0.05-41/CD	prep_of||prevalence-39/NN||â-42/NN	dep||%-46/NN||$-43/$	num||$-43/$||0.06-45/CD	amod||â-42/NN||%-46/NN	aids--1||hiv-38||no||results at the end of 2003, 2005, 2007 and 2009, there were an estimated 0.84, 0.65, 0.70 and 0.74 million people living with hiv/aids in china, respectively, with an overall hiv prevalence of 0.05â€“0.06%.
poss||findings-2/NNS||our-1/PRP$	nsubj||imply-3/VBP||findings-2/NNS	root||ROOT-0/null||imply-3/VBP	mark||gene-10/NN||that-4/IN	nsubj||gene-10/NN||cep68-5/NNS	aux||gene-10/NN||could-6/MD	cop||gene-10/NN||be-7/VB	det||gene-10/NN||a-8/DT	amod||gene-10/NN||susceptible-9/JJ	ccomp||imply-3/VBP||gene-10/NN	nn||intolerance-13/NN||aspirin-12/NN	prep_for||gene-10/NN||intolerance-13/NN	prep_in||intolerance-13/NN||asthmatics-15/NNS	vmod||gene-10/NN||suggesting-17/VBG	mark||affect-23/VB||that-18/IN	det||gly74ser-21/NNS||the-19/DT	amod||gly74ser-21/NNS||nonsynonymous-20/JJ	nsubj||affect-23/VB||gly74ser-21/NNS	aux||affect-23/VB||could-22/MD	ccomp||suggesting-17/VBG||affect-23/VB	det||polarity-25/NN||the-24/DT	dobj||affect-23/VB||polarity-25/NN	det||structure-29/NN||the-27/DT	nn||structure-29/NN||protein-28/NN	prep_of||polarity-25/NN||structure-29/NN	asthmatics-15||aspirin-12||no||our findings imply that cep68 could be a susceptible gene for aspirin intolerance in asthmatics, suggesting that the nonsynonymous gly74ser could affect the polarity of the protein structure.
amod||subjects-3/NNS||obese-2/JJ	prep_in||fattyacid-13/VBD||subjects-3/NNS	advmod||fattyacid-13/VBD||however-5/RB	nsubj||fattyacid-13/VBD||sc-7/NN	dep||sc-7/NN||cav-1-9/JJ	prep_with||associated-11/VBN||cav-1-9/JJ	auxpass||associated-11/VBN||was-10/VBD	rcmod||cav-1-9/JJ||associated-11/VBN	root||ROOT-0/null||fattyacid-13/VBD	acomp||fattyacid-13/VBD||synthase-14/JJ	nsubj||p-22/VBP||fas-16/NN	appos||fas-16/NN||r-18/SYM	dep||0.36-20/CD||=-19/SYM	rcmod||r-18/SYM||0.36-20/CD	dep||synthase-14/JJ||p-22/VBP	dep||0.02-24/CD||=-23/SYM	ccomp||p-22/VBP||0.02-24/CD	amod||element-29/NN||sterol-27/JJ	amod||element-29/NN||regulatory-28/JJ	npadvmod||protein-1c-31/JJ||element-29/NN	amod||element-29/NN||binding-30/JJ	dep||synthase-14/JJ||protein-1c-31/JJ	nsubj||p-50/VBP||srebp-1c-33/JJ	dep||srebp-1c-33/JJ||r-35/SYM	dep||0.58-37/CD||=-36/SYM	rcmod||r-35/SYM||0.58-37/CD	advmod||<-40/NNP||p-39/RB	appos||r-35/SYM||<-40/NNP	dep||<-40/NNP||0.0001-41/CD	appos||srebp-1c-33/JJ||acaca-44/NN	dep||acaca-44/NN||r-46/SYM	dep||0.33-48/CD||=-47/SYM	rcmod||r-46/SYM||0.33-48/CD	dep||synthase-14/JJ||p-50/VBP	dep||0.03-52/CD||=-51/SYM	ccomp||p-50/VBP||0.03-52/CD	dep||synthase-14/JJ||spot-14-55/JJ	dep||synthase-14/JJ||r-57/VBN	dep||0.36-59/CD||=-58/SYM	ccomp||r-57/VBN||0.36-59/CD	ccomp||r-57/VBN||p-61/VB	dep||0.02-63/CD||=-62/SYM	ccomp||p-61/VB||0.02-63/CD	advmod||co-activator-1-68/JJ||ppar-î-66/RB	advmod||co-activator-1-68/JJ||³-67/RB	dep||synthase-14/JJ||co-activator-1-68/JJ	nsubj||n-76/VBP||pgc-1-70/JJ	appos||pgc-1-70/JJ||r-72/SYM	dep||0.88-74/CD||=-73/SYM	rcmod||r-72/SYM||0.88-74/CD	dep||synthase-14/JJ||n-76/VBP	dep||19-78/CD||=-77/SYM	ccomp||n-76/VBP||19-78/CD	obese-2||fattyacid-13||no_rel||in obese subjects, however, sc- cav-1 was associated with fattyacid synthase ( fas , r = 0.36, p = 0.02), sterol regulatory element binding protein-1c ( srebp-1c (r = 0.58, p < 0.0001), acaca (r = 0.33, p = 0.03), spot-14 (r = 0.36, p = 0.02), ppar-î³ co-activator-1 ( pgc-1 , r = 0.88, n = 19).
nsubjpass||recognised-5/VBN||hantaviruses-1/NNS	nsubj||cause-7/VB||hantaviruses-1/NNS	aux||recognised-5/VBN||have-2/VBP	advmod||recognised-5/VBN||previously-3/RB	auxpass||recognised-5/VBN||been-4/VBN	root||ROOT-0/null||recognised-5/VBN	aux||cause-7/VB||to-6/TO	xcomp||recognised-5/VBN||cause-7/VB	num||syndromes-10/NNS||two-8/CD	amod||syndromes-10/NNS||separate-9/JJ	dobj||cause-7/VB||syndromes-10/NNS	amod||syndromes-10/NNS||hemorrhagicfeverwithrenalsyndrome-11/JJ	prep_in||hemorrhagicfeverwithrenalsyndrome-11/JJ||eurasia-13/NN	amod||syndromes-10/NNS||hantaviruspulmonarysyndrome-16/JJ	conj_and||hemorrhagicfeverwithrenalsyndrome-11/JJ||hantaviruspulmonarysyndrome-16/JJ	appos||syndromes-10/NNS||hps-18/NN	det||americas-22/NNS||the-21/DT	prep_in||cause-7/VB||americas-22/NNS	hantaviruspulmonarysyndrome-16||hantaviruses-1||no||hantaviruses have previously been recognised to cause two separate syndromes hemorrhagicfeverwithrenalsyndrome in eurasia, and hantaviruspulmonarysyndrome (hps) in the americas.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||organization-5/NN||the-3/DT	amod||organization-5/NN||nuclear-4/JJ	dobj||investigated-2/VBD||organization-5/NN	nn||genes-15/NNS||estrogen-7/NN	dep||alpha-9/NN||receptor-8/JJ	amod||genes-15/NNS||alpha-9/NN	number||±-12/CD||erî-11/CD	dep||alpha-9/NN||±-12/CD	nn||genes-15/NNS||target-14/NN	prep_of||organization-5/NN||genes-15/NNS	amod||epithelial-19/NN||human-17/JJ	nn||epithelial-19/NN||breast-18/NN	prep_in||investigated-2/VBD||epithelial-19/NN	nn||lines-23/NNS||cancer-21/NN	nn||lines-23/NNS||cell-22/NN	prep_in||investigated-2/VBD||lines-23/NNS	conj_and||epithelial-19/NN||lines-23/NNS	prep||investigated-2/VBD||before-25/IN	prep||investigated-2/VBD||after-27/IN	conj_and||before-25/IN||after-27/IN	amod||activation-29/NN||transcriptional-28/JJ	pobj||after-27/IN||activation-29/NN	vmod||activation-29/NN||induced-30/VBN	prep_with||induced-30/VBN||estradiol-32/NN	cancer-21||estradiol-32||no_rel||we investigated the nuclear organization of estrogen receptor alpha (erî±) target genes in human breast epithelial and cancer cell lines, before and after transcriptional activation induced with estradiol.
nsubjpass||shown-8/VBN||sitagliptin-1/NN	nsubj||improve-10/VB||sitagliptin-1/NN	aux||shown-8/VBN||has-2/VBZ	amod||studies-6/NNS||several-4/JJ	amod||studies-6/NNS||clinical-5/JJ	prep_in||shown-8/VBN||studies-6/NNS	auxpass||shown-8/VBN||been-7/VBN	root||ROOT-0/null||shown-8/VBN	aux||improve-10/VB||to-9/TO	xcomp||shown-8/VBN||improve-10/VB	amod||control-12/NN||metabolic-11/JJ	dobj||improve-10/VB||control-12/NN	prep_in||improve-10/VB||type2diabetes-14/NNS	appos||type2diabetes-14/NNS||both-16/DT	advmod||used-18/VBN||when-17/WRB	advcl||improve-10/VB||used-18/VBN	prep_as||used-18/VBN||monotherapy-20/NN	advmod||used-23/VBN||when-22/WRB	advcl||improve-10/VB||used-23/VBN	conj_and||used-18/VBN||used-23/VBN	prep_in||used-23/VBN||combination-25/NN	prep_with||used-23/VBN||metformin-27/NN	prep_with||used-23/VBN||sulfonylurea-29/NN	conj_or||metformin-27/NN||sulfonylurea-29/NN	prep_with||used-23/VBN||thiazolidinediones-31/NNS	conj_or||metformin-27/NN||thiazolidinediones-31/NNS	prep_with||used-23/VBN||insulin-33/NN	conj_or||metformin-27/NN||insulin-33/NN	type2diabetes-14||insulin-33||yes||sitagliptin has in several clinical studies been shown to improve metabolic control in type2diabetes, both when used as monotherapy and when used in combination with metformin, sulfonylurea, thiazolidinediones or insulin.
nsubjpass||eradicated-12/VBN||brucellosis-1/NNS	nsubj||remains-25/VBZ||brucellosis-1/NNS	det||zoonosis-4/NNS||a-3/DT	appos||brucellosis-1/NNS||zoonosis-4/NNS	vmod||zoonosis-4/NNS||caused-5/VBN	det||genusbrucella-8/NN||the-7/DT	agent||caused-5/VBN||genusbrucella-8/NN	aux||eradicated-12/VBN||has-10/VBZ	auxpass||eradicated-12/VBN||been-11/VBN	root||ROOT-0/null||eradicated-12/VBN	amod||europe-15/NN||northern-14/JJ	prep_in||eradicated-12/VBN||europe-15/NN	prep_in||eradicated-12/VBN||australia-17/NN	conj_and||europe-15/NN||australia-17/NN	det||usa-20/NN||the-19/DT	prep_in||eradicated-12/VBN||usa-20/NN	conj_and||europe-15/NN||usa-20/NN	prep_in||eradicated-12/VBN||canada-22/NN	conj_and||europe-15/NN||canada-22/NN	conj_but||eradicated-12/VBN||remains-25/VBZ	acomp||remains-25/VBZ||endemic-26/JJ	amod||areas-29/NNS||most-28/JJS	prep_in||remains-25/VBZ||areas-29/NNS	det||world-32/NN||the-31/DT	prep_of||areas-29/NNS||world-32/NN	brucellosis-1||genusbrucella-8||no||brucellosis, a zoonosis caused by the genusbrucella , has been eradicated in northern europe, australia, the usa and canada, but remains endemic in most areas of the world.
aux||compare-2/VB||to-1/TO	advcl||conducted-30/VBD||compare-2/VB	dobj||compare-2/VB||types-3/NNS	prep_of||types-3/NNS||infections-5/NNS	amod||outcomes-8/NNS||clinical-7/JJ	dobj||compare-2/VB||outcomes-8/NNS	conj_and||types-3/NNS||outcomes-8/NNS	nn||factors-12/NNS||risk-11/NN	dobj||compare-2/VB||factors-12/NNS	conj_and||types-3/NNS||factors-12/NNS	vmod||factors-12/NNS||associated-13/VBN	amod||infections-27/NNS||mrsa-15/NN	prep_in||mrsa-15/NN||dogs-17/NNS	prep_with||mrsa-15/NN||those-19/DT	vmod||those-19/DT||associated-20/VBN	amod||staphylococcusaureus-23/NNS||methicillin-susceptible-22/JJ	prep_with||associated-20/VBN||staphylococcusaureus-23/NNS	appos||staphylococcusaureus-23/NNS||mssa-25/NNP	prep_with||associated-13/VBN||infections-27/NNS	nsubj||conducted-30/VBD||we-29/PRP	root||ROOT-0/null||conducted-30/VBD	det||study-36/NN||a-31/DT	amod||study-36/NN||caseâ-32/JJ	amod||study-36/NN||$-33/$	nn||study-36/NN||control-35/NN	dobj||conducted-30/VBD||study-36/NN	num||hospitals-41/NNS||3-38/CD	amod||hospitals-41/NNS||veterinary-39/JJ	nn||hospitals-41/NNS||referral-40/NN	prep_at||conducted-30/VBD||hospitals-41/NNS	det||states-45/NNS||the-43/DT	amod||states-45/NNS||united-44/VBN	prep_in||hospitals-41/NNS||states-45/NNS	prep_in||hospitals-41/NNS||canada-47/NNS	conj_and||states-45/NNS||canada-47/NNS	amod||$-50/NNS||2001â-49/JJ	prep_during||conducted-30/VBD||$-50/NNS	dep||$-50/NNS||2007-52/CD	mrsa-15||staphylococcusaureus-23||no||to compare types of infections, clinical outcomes, and risk factors associated with mrsa in dogs with those associated with methicillin-susceptible staphylococcusaureus (mssa) infections, we conducted a caseâ€“control study at 3 veterinary referral hospitals in the united states and canada during 2001â€“2007.
amod||information-2/NN||extensive-1/JJ	nsubj||available-6/JJ||information-2/NN	prep_on||information-2/NN||safety-4/NN	cop||available-6/JJ||is-5/VBZ	root||ROOT-0/null||available-6/JJ	mark||used-11/VBN||as-7/IN	nsubjpass||used-11/VBN||etanercept-8/NN	nsubj||first-26/JJ||etanercept-8/NN	aux||used-11/VBN||has-9/VBZ	auxpass||used-11/VBN||been-10/VBN	advcl||available-6/JJ||used-11/VBN	amod||years-14/NNS||many-13/JJ	prep_for||used-11/VBN||years-14/NNS	amod||indications-17/NNS||other-16/JJ	prep_for||years-14/NNS||indications-17/NNS	prep_such_as||indications-17/NNS||rheumatoidarthritis-20/NNS	prep_such_as||indications-17/NNS||psoriaticarthritis-22/NNS	conj_and||rheumatoidarthritis-20/NNS||psoriaticarthritis-22/NNS	cop||first-26/JJ||is-24/VBZ	det||first-26/JJ||the-25/DT	advcl||available-6/JJ||first-26/JJ	conj_and||used-11/VBN||first-26/JJ	det||tumor-29/NN||the-28/DT	prep_of||first-26/JJ||tumor-29/NN	rcmod||tumor-29/NN||necrosis-30/VBZ	nn||antagonists-32/NNS||factor-31/NN	dobj||necrosis-30/VBZ||antagonists-32/NNS	nsubj||gain-34/VB||antagonists-32/NNS	aux||gain-34/VB||to-33/TO	xcomp||necrosis-30/VBZ||gain-34/VB	dobj||gain-34/VB||approval-35/NN	prep_in||gain-34/VB||psoriasis-37/NNS	rheumatoidarthritis-20||etanercept-8||yes||extensive information on safety is available as etanercept has been used for many years for other indications such as rheumatoidarthritis and psoriaticarthritis and is the first of the tumor necrosis factor antagonists to gain approval in psoriasis.
amod||children-2/NNS||thirty-four-1/JJ	nsubjpass||screened-25/VBN||children-2/NNS	num||males-5/NNS||25-4/CD	dep||children-2/NNS||males-5/NNS	amod||age-8/NN||median-7/JJ	dep||males-5/NNS||age-8/NN	number||â-10/CD||10.8-9/CD	num||yrs-13/NN||â-10/CD	nn||yrs-13/NN||±-11/NNP	num||yrs-13/NN||3.4-12/CD	dep||age-8/NN||yrs-13/NN	amod||obesity-17/NN||severe-16/JJ	prep_with||children-2/NNS||obesity-17/NN	dep||children-2/NNS||bmi-19/VBN	xcomp||bmi-19/VBN||>-20/VBG	num||%-22/NN||95-21/CD	dobj||>-20/VBG||%-22/NN	auxpass||screened-25/VBN||were-24/VBD	root||ROOT-0/null||screened-25/VBN	prep_for||screened-25/VBN||diabetes-27/NN	amod||test-32/NN||oral-29/JJ	nn||test-32/NN||glucose-30/NN	nn||test-32/NN||tolerance-31/NN	prep_with||diabetes-27/NN||test-32/NN	appos||test-32/NN||ogtt-34/NN	amod||inflammation-38/NN||systemic-37/JJ	prep_for||screened-25/VBN||inflammation-38/NN	conj_and||diabetes-27/NN||inflammation-38/NN	amod||protein-41/NN||c-reactive-40/JJ	prep_with||inflammation-38/NN||protein-41/NN	appos||protein-41/NN||crp-43/NN	nn||inflammation-47/NN||gut-46/NN	prep_for||screened-25/VBN||inflammation-47/NN	conj_and||diabetes-27/NN||inflammation-47/NN	amod||nitricoxide-50/NN||rectal-49/JJ	prep_with||inflammation-47/NN||nitricoxide-50/NN	discourse||nitricoxide-50/NN||no-52/UH	amod||calprotectin-56/NN||faecal-55/JJ	prep_with||inflammation-47/NN||calprotectin-56/NN	conj_and||nitricoxide-50/NN||calprotectin-56/NN	nitricoxide-50||inflammation-47||no_rel||thirty-four children (25 males; median age 10.8 â± 3.4 yrs) with severe obesity (bmi >95%) were screened for diabetes with oral glucose tolerance test (ogtt), systemic inflammation with c-reactive protein (crp) and gut inflammation with rectal nitricoxide (no) and faecal calprotectin.
nsubj||been-3/VBN||he-1/PRP	aux||been-3/VBN||has-2/VBZ	root||ROOT-0/null||been-3/VBN	amod||drugs-6/NNS||anti-tuberculous-5/JJ	prep_on||been-3/VBN||drugs-6/NNS	dep||drugs-6/NNS||isoniazid-8/NN	appos||isoniazid-8/NN||rifampin-10/NN	num||year-14/NN||1-13/CD	prep_for||been-3/VBN||year-14/NN	poss||encephalitis-18/NN||his-16/PRP$	amod||encephalitis-18/NN||tuberculous-17/JJ	prep_for||year-14/NN||encephalitis-18/NN	tuberculous-17||rifampin-10||yes||he has been on anti-tuberculous drugs (isoniazid, rifampin) for 1 year for his tuberculous encephalitis.
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	di--1||adenosine--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
nsubj||combined-25/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||costs-6/NNS||the-4/DT	nn||costs-6/NNS||treatment-5/NN	dobj||compare-3/VB||costs-6/NNS	prep_of||costs-6/NNS||insulinglargine-8/NN	dep||insulinglargine-8/NN||ig-10/NN	nn||®-13/NNP||lantusâ-12/NNP	dep||ig-10/NN||®-13/NNP	aux||detemir-16/VB||to-15/TO	vmod||insulinglargine-8/NN||detemir-16/VB	dep||combined-25/VBD||id-18/NN	nn||®-21/NNP||levemirâ-20/NNP	dep||id-18/NN||®-21/NNP	nsubj||combined-25/VBD||both-24/DT	root||ROOT-0/null||combined-25/VBD	amod||insulinaspart-28/NN||bolus-27/JJ	prep_with||combined-25/VBD||insulinaspart-28/NN	nn||®-31/NNP||novorapidâ-30/NNP	appos||insulinaspart-28/NN||®-31/NNP	amod||t2d-36/NNS||type2diabetes-34/JJ	prep_in||combined-25/VBD||t2d-36/NNS	prep_in||t2d-36/NNS||germany-39/NN	type2diabetes-34||insulinglargine-8||yes||objective to compare the treatment costs of insulinglargine (ig; lantusâ®) to detemir (id; levemirâ®), both combined with bolus insulinaspart (novorapidâ®) in type2diabetes (t2d) in germany.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||the-3/DT	dobj||report-2/VBP||case-4/NN	det||woman-9/NN||a-6/DT	amod||woman-9/NN||34-year-old-7/JJ	amod||woman-9/NN||caucasian-8/JJ	prep_of||case-4/NN||woman-9/NN	det||history-12/NN||a-11/DT	prep_with||report-2/VBP||history-12/NN	prep_of||history-12/NN||bcelllymphoma-14/NN	amod||aih-17/NN||concurrent-16/JJ	prep_with||report-2/VBP||aih-17/NN	conj_and||history-12/NN||aih-17/NN	vmod||aih-17/NN||treated-18/VBN	prep_with||treated-18/VBN||rituximab-20/NN	bcelllymphoma-14||rituximab-20||yes||we report the case of a 34-year-old caucasian woman with a history of bcelllymphoma and concurrent aih treated with rituximab.
nsubjpass||associated-8/VBN||irondeficiencyanaemia-1/NN	amod||supplementation-5/NN||oral-3/JJ	nn||supplementation-5/NN||iron-4/NN	conj_and||irondeficiencyanaemia-1/NN||supplementation-5/NN	nsubjpass||associated-8/VBN||supplementation-5/NN	aux||associated-8/VBN||have-6/VBP	auxpass||associated-8/VBN||been-7/VBN	root||ROOT-0/null||associated-8/VBN	advmod||associated-8/VBN||negatively-9/RB	prep_with||associated-8/VBN||quality-11/NN	prep_of||quality-11/NN||life-13/NN	amod||effects-18/NNS||adverse-17/JJ	prep_with||associated-8/VBN||effects-18/NNS	conj_and||quality-11/NN||effects-18/NNS	advmod||associated-8/VBN||respectively-20/RB	prep_in||associated-8/VBN||subjects-23/NNS	prep_with||subjects-23/NNS||inflammatoryboweldisease-25/NN	appos||inflammatoryboweldisease-25/NN||ibd-27/NN	irondeficiencyanaemia-1||iron-4||yes||irondeficiencyanaemia and oral iron supplementation have been associated negatively with quality of life, and with adverse effects, respectively, in subjects with inflammatoryboweldisease (ibd).
prep_objectiveâ||demonstrated-7/VBN||$-2/$	amod||work-5/NN||previous-4/JJ	nsubj||demonstrated-7/VBN||work-5/NN	aux||demonstrated-7/VBN||has-6/VBZ	root||ROOT-0/null||demonstrated-7/VBN	mark||augments-20/VBZ||that-8/IN	amod||administration-10/NN||chronic-9/JJ	nsubj||augments-20/VBZ||administration-10/NN	det||fluoxetine-19/NN||the-12/DT	amod||reuptake-14/JJ||serotonin-13/JJ	amod||fluoxetine-19/NN||reuptake-14/JJ	nn||fluoxetine-19/NN||inhibitor-15/NN	appos||fluoxetine-19/NN||ssri-17/NNP	prep_of||administration-10/NN||fluoxetine-19/NN	ccomp||demonstrated-7/VBN||augments-20/VBZ	amod||responses-22/NNS||counterregulatory-21/JJ	dobj||augments-20/VBZ||responses-22/NNS	prep_to||augments-20/VBZ||hypoglycemia-24/NN	amod||humans-27/NNS||healthy-26/JJ	prep_in||hypoglycemia-24/NN||humans-27/NNS	hypoglycemia-24||fluoxetine-19||no_rel||objectiveâ€” previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (ssri) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans.
advmod||produce-10/VBP||curiously-1/RB	amod||queens-4/NNS||mated-fertile-3/JJ	nsubj||produce-10/VBP||queens-4/NNS	det||tuberculatum-9/NN||the-6/DT	nn||tuberculatum-9/NN||ant-7/NN	nn||tuberculatum-9/NN||ectatomma-8/NN	prep_of||queens-4/NNS||tuberculatum-9/NN	root||ROOT-0/null||produce-10/VBP	det||coat-14/NN||an-11/DT	amod||coat-14/NN||uncommon-12/JJ	amod||coat-14/NN||extra-wax-13/JJ	dobj||produce-10/VBP||coat-14/NN	cc||produce-10/VBP||and-15/CC	advmod||coat-34/NN||consequently-17/RB	nsubj||coat-34/NN||queens-18/NNS	amod||females-21/NNS||mated-fertile-20/JJ	appos||queens-18/NNS||females-21/NNS	cop||coat-34/NN||are-23/VBP	amod||coat-34/NN||matte-24/JJ	amod||cuticular-29/NN||such-27/JJ	amod||cuticular-29/NN||extra-28/JJ	prep_due_to||coat-34/NN||cuticular-29/NN	nn||coat-34/NN||hydrocarbon-30/NN	appos||coat-34/NN||chc-32/NN	dep||produce-10/VBP||coat-34/NN	nsubj||covers-36/VBZ||coat-34/NN	rcmod||coat-34/NN||covers-36/VBZ	det||cuticle-38/NN||the-37/DT	nsubj||brightness-42/NNS||cuticle-38/NN	conj_and||cuticle-38/NN||masks-40/NNS	nsubj||brightness-42/NNS||masks-40/NNS	det||brightness-42/NNS||the-41/DT	xcomp||covers-36/VBZ||brightness-42/NNS	det||queens-45/NNS||the-44/DT	poss||cuticle-47/NN||queens-45/NNS	prep_of||brightness-42/NNS||cuticle-47/NN	mark||shiny-55/JJ||while-48/IN	nsubj||shiny-55/JJ||gynes-49/NNS	amod||queens-52/NNS||virgin-infertile-51/JJ	appos||gynes-49/NNS||queens-52/NNS	cop||shiny-55/JJ||are-54/VBP	advcl||covers-36/VBZ||shiny-55/JJ	infertile--1||hydrocarbon-30||no_rel||curiously, mated-fertile queens of the ant ectatomma tuberculatum produce an uncommon extra-wax coat and, consequently queens (mated-fertile females) are matte due to such extra cuticular hydrocarbon (chc) coat that covers the cuticle and masks the brightness of the queens' cuticle while gynes (virgin-infertile queens) are shiny.
nsubjpass||prepared-22/VBN||objective-1/NN	nsubjpass||evaluated-31/VBN||objective-1/NN	det||attempt-4/NN||an-3/DT	prep_in||objective-1/NN||attempt-4/NN	amod||treatment-7/NN||better-6/JJR	prep_for||attempt-4/NN||treatment-7/NN	prep_of||treatment-7/NN||bacterialinfections-9/NNS	nn||wounds-12/NNS||burn-11/NN	prep_of||treatment-7/NN||wounds-12/NNS	conj_and||bacterialinfections-9/NNS||wounds-12/NNS	nn||formulations-15/NNS||plaster-14/NN	appos||bacterialinfections-9/NNS||formulations-15/NNS	vmod||formulations-15/NNS||containing-16/VBG	amod||concentrations-18/NNS||different-17/JJ	dobj||containing-16/VBG||concentrations-18/NNS	prep_of||concentrations-18/NNS||norfloxacin-20/NN	auxpass||prepared-22/VBN||were-21/VBD	root||ROOT-0/null||prepared-22/VBN	xcomp||prepared-22/VBN||using-23/VBG	dobj||using-23/VBG||polymers-24/NNS	nn||alcohol-29/NN||polyvinylpyrrolidone-26/NN	conj_and||polyvinylpyrrolidone-26/NN||polyvinyl-28/NN	nn||alcohol-29/NN||polyvinyl-28/NN	prep_like||using-23/VBG||alcohol-29/NN	conj_and||prepared-22/VBN||evaluated-31/VBN	amod||parameters-34/NNS||physicochemical-33/JJ	prep_for||evaluated-31/VBN||parameters-34/NNS	amod||release-39/NN||vitro-37/JJ	nn||release-39/NN||drug-38/NN	prep_in||evaluated-31/VBN||release-39/NN	amod||activity-42/NN||antimicrobial-41/JJ	appos||release-39/NN||activity-42/NN	amod||properties-48/NNS||burn-45/JJ	amod||properties-48/NNS||wound-46/VBN	nn||properties-48/NNS||healing-47/NN	prep_in||evaluated-31/VBN||properties-48/NNS	conj_and||release-39/NN||properties-48/NNS	bacterialinfections-9||norfloxacin-20||yes||objective in an attempt for better treatment of bacterialinfections and burn wounds, plaster formulations containing different concentrations of norfloxacin were prepared using polymers like polyvinylpyrrolidone and polyvinyl alcohol and evaluated for physicochemical parameters, in vitro drug release, antimicrobial activity, and burn wound healing properties.
det||cohort-6/NN||a-1/DT	amod||cohort-6/NN||12-matched-2/JJ	amod||cohort-6/NN||new-3/JJ	nn||cohort-6/NN||insulin-4/NN	nn||cohort-6/NN||user-5/NN	nsubjpass||selected-31/VBN||cohort-6/NN	prep_on||cohort-6/NN||age-8/NN	nn||±-11/NNS||â-10/NN	dep||age-8/NN||±-11/NNS	num||years-13/NNS||3-12/CD	dep||±-11/NNS||years-13/NNS	amod||status-17/NN||smoking-16/VBG	prep_on||cohort-6/NN||status-17/NN	conj_and||age-8/NN||status-17/NN	prep_on||cohort-6/NN||likelihood-20/NN	conj_and||age-8/NN||likelihood-20/NN	prepc_of||likelihood-20/NN||initiating-22/VBG	nn||therapy-24/NN||insulin-23/NN	dobj||initiating-22/VBG||therapy-24/NN	dep||selected-31/VBN||â-26/VB	num||0.05-28/CD||±-27/CD	dobj||â-26/VB||0.05-28/CD	auxpass||selected-31/VBN||was-30/VBD	root||ROOT-0/null||selected-31/VBN	det||cohort-34/NN||a-33/DT	prep_from||selected-31/VBN||cohort-34/NN	num||patients-38/NNS||4,623-36/CD	amod||patients-38/NNS||chinese-37/JJ	prep_of||cohort-34/NN||patients-38/NNS	prep_with||selected-31/VBN||type2diabetes-40/JJ	prep_with||selected-31/VBN||free-42/JJ	conj_and||type2diabetes-40/JJ||free-42/JJ	prep_of||free-42/JJ||cancer-44/NN	prep_with||selected-31/VBN||naive-47/JJ	conj_and||type2diabetes-40/JJ||naive-47/JJ	prep_to||naive-47/JJ||insulin-49/NN	prep_at||insulin-49/NN||enrollment-51/NN	type2diabetes-40||insulin-49||yes||a 12-matched new insulin user cohort on age (â±3 years), smoking status, and likelihood of initiating insulin therapy (â±0.05) was selected from a cohort of 4,623 chinese patients with type2diabetes, free of cancer, and naive to insulin at enrollment.
aux||determine-2/VB||to-1/TO	advcl||fed-25/VBN||determine-2/VB	dobj||determine-2/VB||effects-3/NNS	prep_of||effects-3/NNS||irondeficiency-5/NN	nn||activation-8/NN||ampk-7/NN	prep_on||irondeficiency-5/NN||activation-8/NN	prep_on||irondeficiency-5/NN||signaling-10/NN	conj_and||activation-8/NN||signaling-10/NN	det||composition-18/NN||the-15/DT	nn||composition-18/NN||ampk-16/NN	nn||composition-18/NN||subunit-17/NN	prep_of||effects-3/NNS||composition-18/NN	conj_and||irondeficiency-5/NN||composition-18/NN	amod||muscle-21/NN||skeletal-20/JJ	prep_in||composition-18/NN||muscle-21/NN	nsubjpass||fed-25/VBN||rats-23/NNS	auxpass||fed-25/VBN||were-24/VBD	root||ROOT-0/null||fed-25/VBN	det||control-27/NN||a-26/DT	dobj||fed-25/VBN||control-27/NN	iobj||fed-25/VBN||control-27/NN	dep||control-27/NN||c-29/SYM	dep||fe-33/FW||=-30/SYM	amod||fe-33/FW||50-58-31/JJ	nn||fe-33/FW||mg/kg-32/FW	rcmod||c-29/SYM||fe-33/FW	nn||deficient-37/NN||iron-36/NN	dobj||fed-25/VBN||deficient-37/NN	iobj||fed-25/VBN||deficient-37/NN	conj_or||control-27/NN||deficient-37/NN	dep||control-27/NN||id-39/VBN	dep||fe-43/FW||=-40/SYM	amod||fe-43/FW||2-6-41/JJ	nn||fe-43/FW||mg/kg-42/FW	ccomp||id-39/VBN||fe-43/FW	dep||control-27/NN||diet-45/NN	amod||wks-51/NN||6â-47/JJ	amod||wks-51/NN||$-48/$	num||$-48/$||8-50/CD	prep_for||diet-45/NN||wks-51/NN	irondeficiency-5||iron-36||yes||to determine effects of irondeficiency on ampk activation and signaling, as well as the ampk subunit composition in skeletal muscle, rats were fed a control (c=50-58 mg/kg fe) or iron deficient (id=2-6 mg/kg fe) diet for 6â€“8 wks.
nsubj||belong-15/VBP||endostatin-1/NN	conj_and||endostatin-1/NN||anastellin-3/NN	nsubj||belong-15/VBP||anastellin-3/NN	appos||endostatin-1/NN||fragments-5/NNS	nn||xviii-9/NNS||collagen-7/NN	nn||xviii-9/NNS||type-8/NN	prep_of||fragments-5/NNS||xviii-9/NNS	appos||endostatin-1/NN||fibronectin-11/NN	conj_and||fragments-5/NNS||fibronectin-11/NN	advmod||fibronectin-11/NN||respectively-13/RB	root||ROOT-0/null||belong-15/VBP	det||family-18/NN||a-17/DT	prep_to||belong-15/VBP||family-18/NN	amod||inhibitors-21/NNS||endogenous-20/JJ	prep_of||family-18/NN||inhibitors-21/NNS	prep_of||inhibitors-21/NNS||angiogenesis-23/NNS	nsubj||inhibit-25/VBP||angiogenesis-23/NNS	rcmod||angiogenesis-23/NNS||inhibit-25/VBP	nn||growth-27/NN||tumor-26/NN	dobj||inhibit-25/VBP||growth-27/NN	dobj||inhibit-25/VBP||metastasis-29/NNS	conj_and||growth-27/NN||metastasis-29/NNS	det||number-32/NN||a-31/DT	prep_in||growth-27/NN||number-32/NN	nn||models-35/NNS||mouse-34/NN	prep_of||number-32/NN||models-35/NNS	amod||cancer-38/NN||human-37/JJ	prep_of||models-35/NNS||cancer-38/NN	collagen-7||tumor-26||no_rel||endostatin and anastellin, fragments of collagen type xviii and fibronectin, respectively, belong to a family of endogenous inhibitors of angiogenesis which inhibit tumor growth and metastasis in a number of mouse models of human cancer.
nsubj||mycosis-5/NNS||tineanigra-1/NN	cop||mycosis-5/NNS||is-2/VBZ	det||mycosis-5/NNS||a-3/DT	amod||mycosis-5/NNS||superficial-4/JJ	root||ROOT-0/null||mycosis-5/NNS	vmod||mycosis-5/NNS||caused-6/VBN	agent||caused-6/VBN||hortaeawerneckii-8/NNS	tineanigra-1||hortaeawerneckii-8||no||tineanigra is a superficial mycosis caused by hortaeawerneckii .
prep_in||enhanced-7/VBD||summary-2/NN	nsubj||enhanced-7/VBD||c-4/SYM	conj_and||c-4/SYM||ecg-6/NN	nsubj||enhanced-7/VBD||ecg-6/NN	root||ROOT-0/null||enhanced-7/VBD	det||effect-10/NN||the-8/DT	amod||effect-10/NN||antibacterial-9/JJ	dobj||enhanced-7/VBD||effect-10/NN	nn||²-13/NNS||î-12/NN	prep_of||effect-10/NN||²-13/NNS	dep||effect-10/NN||lactamantibiotics-15/NNS	prep_against||lactamantibiotics-15/NNS||mrsa-17/NN	prep_in||enhanced-7/VBD||vitro-19/NN	prep_in||enhanced-7/VBD||in-21/IN	conj_and||vitro-19/NN||in-21/IN	pobj||in-21/IN||vivo-22/NN	nsubjpass||related-27/VBN||vivo-22/NN	aux||related-27/VBN||might-25/MD	auxpass||related-27/VBN||be-26/VB	rcmod||vivo-22/NN||related-27/VBN	det||accumulation-31/NN||the-29/DT	amod||accumulation-31/NN||increased-30/VBN	prep_to||related-27/VBN||accumulation-31/NN	prep_of||accumulation-31/NN||antibiotics-33/NNS	prep_within||antibiotics-33/NNS||mrsa-35/NN	prep_via||mrsa-35/NN||suppression-37/NN	amod||pumpsâ-41/NNS||important-39/JJ	nn||pumpsâ-41/NNS||efflux-40/NN	nn||expression-45/NN||pumpsâ-41/NNS	amod||expression-45/NN||$-42/$	dep||$-42/$||™-43/JJ	nn||expression-45/NN||gene-44/NN	prep_of||suppression-37/NN||expression-45/NN	mrsa-35||antibiotics-33||no_rel||in summary, c and ecg enhanced the antibacterial effect of î²-lactamantibiotics against mrsa in vitro and in vivo , which might be related to the increased accumulation of antibiotics within mrsa via suppression of important efflux pumpsâ€™ gene expression.
amod||patients-2/NNS||eighty-1/JJ	nsubjpass||included-16/VBN||patients-2/NNS	nsubj||evaluate-21/VB||patients-2/NNS	vmod||patients-2/NNS||fulfilling-3/VBG	det||criteria-6/NNS||the-4/DT	amod||criteria-6/NNS||icd-10-5/JJ	dobj||fulfilling-3/VBG||criteria-6/NNS	prep_for||criteria-6/NNS||schizophrenia-8/NN	dep||with-11/IN||predominantly-10/RB	dep||included-16/VBN||with-11/IN	amod||symptoms-13/NNS||negative-12/JJ	pobj||with-11/IN||symptoms-13/NNS	auxpass||included-16/VBN||were-15/VBD	root||ROOT-0/null||included-16/VBN	det||study-19/NN||this-18/DT	prep_in||included-16/VBN||study-19/NN	aux||evaluate-21/VB||to-20/TO	xcomp||included-16/VBN||evaluate-21/VB	nn||gain-23/NN||weight-22/NN	dobj||evaluate-21/VB||gain-23/NN	det||effect-27/NN||an-25/DT	amod||effect-27/NN||adverse-26/JJ	prep_as||evaluate-21/VB||effect-27/NN	prep_of||effect-27/NN||treatment-29/NN	amod||index-43/NN||olanzapine-31/JJ	prep_in||olanzapine-31/JJ||relation-33/NN	prep_to||olanzapine-31/JJ||age-35/NN	prep_to||olanzapine-31/JJ||gender-37/NN	conj_and||age-35/NN||gender-37/NN	prep_to||olanzapine-31/JJ||dose-39/NN	conj_and||age-35/NN||dose-39/NN	prep_to||olanzapine-31/JJ||body-41/NN	conj_and||age-35/NN||body-41/NN	amod||index-43/NN||mass-42/JJ	prep_with||evaluate-21/VB||index-43/NN	appos||index-43/NN||bmi-45/NN	schizophrenia-8||olanzapine-31||yes||eighty patients fulfilling the icd-10 criteria for schizophrenia, predominantly with negative symptoms, were included in this study to evaluate weight gain as an adverse effect of treatment with olanzapine in relation to age, gender, dose and body mass index (bmi).
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||ketamine-21||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
nsubj||showed-5/VBD||sera-1/NN	amod||animals-4/NNS||immunized-3/JJ	prep_of||sera-1/NN||animals-4/NNS	root||ROOT-0/null||showed-5/VBD	amod||response-8/NN||high-6/JJ	nn||response-8/NN||igg-7/NN	nsubj||showed-17/VBD||response-8/NN	amod||cross-reactivity-11/NN||strong-10/JJ	conj_and||response-8/NN||cross-reactivity-11/NN	nsubj||showed-17/VBD||cross-reactivity-11/NN	amod||results-16/NNS||different-13/JJ	nn||results-16/NNS||mtb-14/NN	nn||results-16/NNS||antigens.these-15/NN	prep_against||response-8/NN||results-16/NNS	ccomp||showed-5/VBD||showed-17/VBD	mark||candidates-25/NNS||that-18/IN	nn||pls-20/NN||bcg-19/NN	nsubj||candidates-25/NNS||pls-20/NN	aux||candidates-25/NNS||could-21/MD	cop||candidates-25/NNS||be-22/VB	amod||candidates-25/NNS||potential-23/JJ	nn||candidates-25/NNS||vaccine-24/NN	ccomp||showed-17/VBD||candidates-25/NNS	prep_against||candidates-25/NNS||tb-27/NN	tb-27||bcg-19||no||sera of immunized animals showed high igg response and strong cross-reactivity against different mtb antigens.these results showed that bcg pls could be potential vaccine candidates against tb.
det||structure-3/NN||the-1/DT	nn||structure-3/NN||crystal-2/NN	nsubj||consists-16/VBZ||structure-3/NN	nsubj||consists-16/VBZ||structure-3/NN	det||compound-7/NN||the-5/DT	nn||compound-7/NN||title-6/NN	prep_of||structure-3/NN||compound-7/NN	nn||-RSB--14/NNP||-LSB--9/NNP	nn||-RSB--14/NNP||zncl2-10/NNP	appos||-RSB--14/NNP||c10h8n2s-12/NNP	appos||structure-3/NN||-RSB--14/NNP	root||ROOT-0/null||consists-16/VBZ	conj_and||consists-16/VBZ||consists-16/VBZ	det||ring-21/NN||a-18/DT	amod||ring-21/NN||six-membered-19/JJ	nn||ring-21/NN||chelate-20/NN	prep_of||consists-16/VBZ||ring-21/NN	prep_in||tetraâhedrally-29/JJ||ring-21/NN	det||atom-26/NN||the-24/DT	nn||atom-26/NN||zn-25/NN	nsubj||tetraâhedrally-29/JJ||atom-26/NN	cop||tetraâhedrally-29/JJ||is-27/VBZ	advmod||tetraâhedrally-29/JJ||approximately-28/RB	rcmod||ring-21/NN||tetraâhedrally-29/JJ	dep||tetraâhedrally-29/JJ||coordinated-30/VBN	num||ions-34/NNS||two-32/CD	nn||ions-34/NNS||chloride-33/NN	prep_by||coordinated-30/VBN||ions-34/NNS	det||atoms-41/NNS||the-37/DT	num||atoms-41/NNS||two-38/CD	amod||atoms-41/NNS||pyridyl-39/JJ	nn||atoms-41/NNS||n-40/NN	prep_by||consists-16/VBZ||atoms-41/NNS	det||sulfide-46/NN||a-43/DT	amod||sulfide-46/NN||single-44/JJ	amod||sulfide-46/NN||di-2-pyridyl-45/JJ	prep_of||atoms-41/NNS||sulfide-46/NN	vmod||sulfide-46/NN||ligand-47/VBN	zn-25||di--1||no_rel||the crystal structure of the title compound, [zncl2(c10h8n2s)], consists of a six-membered chelate ring in which the zn atom is approximately tetraâ­hedrally coordinated by two chloride ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	amod||3-13/CD||whether-9/IN	det||3-13/CD||the-10/DT	amod||3-13/CD||vkorc1-11/JJ	number||3-13/CD||*-12/CD	dobj||investigate-8/VB||3-13/CD	nsubj||gâ-16/VBP||rs7294/9041-15/NNS	dep||3-13/CD||gâ-16/VBP	num||â-20/NN||$-17/$	number||>-19/CD||‰-18/CD	num||$-17/$||>-19/CD	dobj||gâ-16/VBP||â-20/NN	dep||â-20/NN||$-21/$	num||$-21/$||‰-22/CD	dep||â-20/NN||a-23/SYM	num||*-27/NNP||vkorc1-26/CD	dobj||investigate-8/VB||*-27/NNP	conj_and||3-13/CD||*-27/NNP	num||*-27/NNP||4-28/CD	amod||câ-31/NN||rs17708472/6009-30/JJ	dep||*-27/NNP||câ-31/NN	dep||â-35/NN||$-32/$	num||â-35/NN||‰-33/CD	amod||â-35/NN||>-34/JJ	dep||câ-31/NN||â-35/NN	dep||â-35/NN||$-36/$	number||t-38/CD||‰-37/CD	num||$-36/$||t-38/CD	dobj||investigate-8/VB||cyp4f2-42/NNS	conj_and||3-13/CD||cyp4f2-42/NNS	amod||câ-45/NN||rs2108622/1347-44/JJ	dep||cyp4f2-42/NNS||câ-45/NN	dep||â-49/NN||$-46/$	num||â-49/NN||‰-47/CD	amod||â-49/NN||>-48/JJ	dep||câ-45/NN||â-49/NN	dep||â-49/NN||$-50/$	number||t-52/CD||‰-51/CD	num||$-50/$||t-52/CD	nsubjpass||associated-56/VBN||polymorphisms-54/NNS	auxpass||associated-56/VBN||were-55/VBD	rcmod||cyp4f2-42/NNS||associated-56/VBN	amod||requirements-62/NNS||elevated-58/JJ	nn||requirements-62/NNS||warfarin-59/NN	nn||requirements-62/NNS||maintenance-60/NN	nn||requirements-62/NNS||dose-61/NN	prep_with||associated-56/VBN||requirements-62/NNS	prep_in||requirements-62/NNS||patients-64/NNS	prep_with||patients-64/NNS||myocardialinfarction-66/NN	dep||3-13/CD||n-68/VBN	dep||105-70/CD||=-69/SYM	ccomp||n-68/VBN||105-70/CD	det||study-77/NN||the-73/DT	amod||study-77/NN||warfarin-74/JJ	nn||study-77/NN||aspirin-75/NN	nn||study-77/NN||reinfarction-76/NN	prep_from||investigate-8/VB||study-77/NN	appos||study-77/NN||waris-ii-79/NNP	myocardialinfarction-66||warfarin-74||yes||the aim of this study was to investigate whether the vkorc1*3 (rs7294/9041 gâ€‰>â€‰a), vkorc1*4 (rs17708472/6009 câ€‰>â€‰t), and cyp4f2 (rs2108622/1347 câ€‰>â€‰t) polymorphisms were associated with elevated warfarin maintenance dose requirements in patients with myocardialinfarction ( n = 105) from the warfarin aspirin reinfarction study (waris-ii).
det||intensity-3/NN||the-1/DT	nn||intensity-3/NN||pain-2/NN	nsubjpass||decreased-25/VBN||intensity-3/NN	det||children-6/NNS||the-5/DT	prep_of||intensity-3/NN||children-6/NNS	nsubjpass||treated-9/VBN||children-6/NNS	auxpass||treated-9/VBN||were-8/VBD	rcmod||children-6/NNS||treated-9/VBN	advmod||administered-12/VBN||rectally-11/RB	amod||paracetamol-13/NNP||administered-12/VBN	prep_with||treated-9/VBN||paracetamol-13/NNP	prep_with||treated-9/VBN||diclofenac-15/NN	conj_or||paracetamol-13/NNP||diclofenac-15/NN	vmod||diclofenac-15/NN||combined-16/VBN	amod||block-20/NN||regional-18/JJ	nn||block-20/NN||nerve-19/NN	prep_with||combined-16/VBN||block-20/NN	prep_before||combined-16/VBN||surgery-22/NN	auxpass||decreased-25/VBN||was-23/VBD	advmod||decreased-25/VBN||significantly-24/RB	root||ROOT-0/null||decreased-25/VBN	prep||decreased-25/VBN||as-26/IN	prepc_compared_to||decreased-25/VBN||to-28/TO	pobj||decreased-25/VBN||that-29/DT	det||children-32/NNS||the-31/DT	prep_of||that-29/DT||children-32/NNS	nsubjpass||treated-35/VBN||children-32/NNS	auxpass||treated-35/VBN||were-34/VBD	rcmod||children-32/NNS||treated-35/VBN	det||method-39/NN||the-37/DT	amod||method-39/NN||traditional-38/JJ	prep_with||treated-35/VBN||method-39/NN	pain-2||paracetamol-13||yes||the pain intensity of the children who were treated with rectally administered paracetamol or diclofenac combined with regional nerve block before surgery was significantly decreased as compared to that of the children who were treated with the traditional method.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	num||recipients-5/NNS||124-3/CD	nn||recipients-5/NNS||rifampicin-4/NN	dobj||studied-2/VBD||recipients-5/NNS	amod||coinfection-11/NN||concurrent-7/JJ	amod||coinfection-11/NN||hiv-1-8/JJ	amod||coinfection-11/NN||/-9/JJ	nn||coinfection-11/NN||tb-10/NN	prep_with||studied-2/VBD||coinfection-11/NN	vmod||studied-2/VBD||receiving-13/VBG	dobj||receiving-13/VBG||efavirenz-14/NN	num||mg/day-17/NN||600-16/CD	appos||efavirenz-14/NN||mg/day-17/NN	dep||efavirenz-14/NN||n-20/VBN	dep||65-22/CD||=-21/SYM	ccomp||n-20/VBN||65-22/CD	dobj||receiving-13/VBG||nevirapine-25/NN	conj_or||efavirenz-14/NN||nevirapine-25/NN	num||mg/day-28/NN||400-27/CD	appos||nevirapine-25/NN||mg/day-28/NN	dep||nevirapine-25/NN||n-31/VBN	dep||59-33/CD||=-32/SYM	ccomp||n-31/VBN||59-33/CD	vmod||nevirapine-25/NN||based-35/VBN	amod||therapy-37/NN||antiretroviral-36/JJ	dobj||based-35/VBN||therapy-37/NN	appos||nevirapine-25/NN||art-39/NN	tb-10||rifampicin-4||yes||we studied 124 rifampicin recipients with concurrent hiv-1/tb coinfection, receiving efavirenz (600 mg/day) (n = 65) or nevirapine (400 mg/day) (n = 59) based antiretroviral therapy (art).
det||contribution-3/NN||the-1/DT	amod||contribution-3/NN||relative-2/JJ	nsubj||unclear-16/JJ||contribution-3/NN	det||components-9/NNS||the-5/DT	amod||components-9/NNS||budesonide-6/JJ	conj_and||budesonide-6/JJ||formoterol-8/JJ	amod||components-9/NNS||formoterol-8/JJ	prep_of||contribution-3/NN||components-9/NNS	det||control-14/NN||the-11/DT	amod||control-14/NN||improved-12/JJ	nn||control-14/NN||asthma-13/NN	prep_to||components-9/NNS||control-14/NN	cop||unclear-16/JJ||is-15/VBZ	root||ROOT-0/null||unclear-16/JJ	asthma-13||budesonide-6||no||the relative contribution of the budesonide and formoterol components to the improved asthma control is unclear.
nsubjpass||used-4/VBN||mesalamine-1/NN	aux||used-4/VBN||has-2/VBZ	auxpass||used-4/VBN||been-3/VBN	root||ROOT-0/null||used-4/VBN	det||medication-8/NN||the-6/DT	amod||medication-8/NN||first-line-7/JJ	prep_as||used-4/VBN||medication-8/NN	det||treatment-11/NN||the-10/DT	prep_for||medication-8/NN||treatment-11/NN	prep_of||treatment-11/NN||ulcerativecolitis-13/NNS	appos||ulcerativecolitis-13/NNS||uc-15/NN	ulcerativecolitis-13||mesalamine-1||yes||mesalamine has been used as the first-line medication for the treatment of ulcerativecolitis (uc).
amod||experiments-2/NNS||previous-1/JJ	nsubj||showed-3/VBD||experiments-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||reduced-10/VBD||that-4/IN	amod||heparin-6/NN||ultra-low-molecular-weight-5/JJ	nsubj||reduced-10/VBD||heparin-6/NN	appos||heparin-6/NN||ulmwh-8/NN	ccomp||showed-3/VBD||reduced-10/VBD	det||deficit-15/NN||the-11/DT	amod||deficit-15/NN||infarct-12/JJ	conj_and||infarct-12/JJ||neurologic-14/JJ	amod||deficit-15/NN||neurologic-14/JJ	dobj||reduced-10/VBD||deficit-15/NN	prep_in||reduced-10/VBD||rats-17/NNS	vmod||rats-17/NNS||followed-18/VBN	amod||cerebralischemia-21/NN||transient-20/JJ	agent||followed-18/VBN||cerebralischemia-21/NN	det||mechanisms-25/NNS||the-24/DT	nsubj||unclear-31/JJ||mechanisms-25/NNS	poss||effect-29/NN||its-27/PRP$	amod||effect-29/NN||neuroprotective-28/JJ	prep_of||mechanisms-25/NNS||effect-29/NN	cop||unclear-31/JJ||are-30/VBP	conj_but||showed-3/VBD||unclear-31/JJ	heparin-6||infarct-12||no_rel||previous experiments showed that ultra-low-molecular-weight heparin (ulmwh) reduced the infarct and neurologic deficit in rats followed by transient cerebralischemia, but the mechanisms of its neuroprotective effect are unclear.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||formoterol-41||yes||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
det||medication-2/NN||the-1/DT	nsubjpass||registered-12/VBN||medication-2/NN	vmod||medication-2/NN||used-3/VBN	prep_for||used-3/VBN||diabetes-5/NN	prep_for||used-3/VBN||arterialhypertension-7/NN	conj_and||diabetes-5/NN||arterialhypertension-7/NN	prep_for||used-3/VBN||hyperlipidemia-9/NN	conj_and||diabetes-5/NN||hyperlipidemia-9/NN	aux||registered-12/VBN||will-10/MD	auxpass||registered-12/VBN||be-11/VB	root||ROOT-0/null||registered-12/VBN	prep_together_with||registered-12/VBN||antiplateletdrugs-16/NNS	antiplateletdrugs-16||hyperlipidemia-9||no_rel||the medication used for diabetes, arterialhypertension and hyperlipidemia will be registered, together with antiplateletdrugs.
nsubj||induced-6/VBN||statusepilepticus-1/NNS	appos||statusepilepticus-1/NNS||se-3/NNP	aux||induced-6/VBN||was-5/VBD	root||ROOT-0/null||induced-6/VBN	amod||adenosine5-38/NNS||pilocarpine-8/JJ	prep_in||pilocarpine-8/JJ||rats-10/NNS	nsubjpass||infused-14/VBN||rats-10/NNS	auxpass||infused-14/VBN||were-12/VBD	advmod||infused-14/VBN||intracerebroventricularly-13/RB	rcmod||rats-10/NNS||infused-14/VBN	det||saline-17/NN||either-16/DT	prep_with||infused-14/VBN||saline-17/NN	appos||saline-17/NN||2-19/CD	poss||adenosine5-30/NN||,3-21/CD	dep||adenosine5-30/NN||o-24/NN	appos||o-24/NN||4-benzoylbenzoyl-27/NN	dep||2-19/CD||adenosine5-30/NN	dep||adenosine5-30/NN||triphosphate-33/NN	appos||triphosphate-33/NN||bzatp-35/NN	prep_by||induced-6/VBN||adenosine5-38/NNS	dep||induced-6/VBN||triphosphate-2-41/VBN	dobj||triphosphate-2-41/VBN||,3-43/CD	dep||induced-6/VBN||dialdehyde-46/JJ	dep||dialdehyde-46/JJ||oxatp-48/VB	dep||induced-6/VBN||il-1ra-52/JJ	conj_or||dialdehyde-46/JJ||il-1ra-52/JJ	dep||dialdehyde-46/JJ||interleukin-54/VB	num||antagonist-57/NN||1-55/CD	nn||antagonist-57/NN||receptor-56/NN	dobj||interleukin-54/VB||antagonist-57/NN	amod||induction-62/NN||se-61/JJ	prep_prior_to||dialdehyde-46/JJ||induction-62/NN	pilocarpine-8||statusepilepticus-1||no_rel||statusepilepticus (se) was induced by pilocarpine in rats that were intracerebroventricularly infused with either saline, 2',3'-o-(4-benzoylbenzoyl)-adenosine5'-triphosphate (bzatp), adenosine5'-triphosphate-2',3'-dialdehyde (oxatp), or il-1ra (interleukin 1 receptor antagonist) prior to se induction.
amod||mice-4/NNS||resultsâ-1/JJ	amod||mice-4/NNS||$-2/$	nsubj||resistant-8/JJ||mice-4/NNS	nsubj||high-fat-10/VB||mice-4/NNS	amod||pref-1-6/JJ||overexpressing-5/JJ	amod||mice-4/NNS||pref-1-6/JJ	cop||resistant-8/JJ||were-7/VBD	root||ROOT-0/null||resistant-8/JJ	aux||high-fat-10/VB||to-9/TO	xcomp||resistant-8/JJ||high-fat-10/VB	nn||$-12/NNP||dietâ-11/NNP	dobj||high-fat-10/VB||$-12/NNP	vmod||$-12/NNP||induced-14/VBN	advmod||induced-14/VBN||obesity-15/RB	mark||reflected-18/VBD||as-17/IN	advcl||induced-14/VBN||reflected-18/VBD	det||reduction-22/NN||a-20/DT	amod||reduction-22/NN||marked-21/JJ	prep_by||reflected-18/VBD||reduction-22/NN	amod||mass-26/NN||adipose-24/JJ	nn||mass-26/NN||tissue-25/NN	prep_in||reflected-18/VBD||mass-26/NN	obesity-15||fat--1||no_rel||resultsâ€” mice overexpressing pref-1 were resistant to high-fat dietâ€“induced obesity, as reflected by a marked reduction in adipose tissue mass.
nsubj||causes-7/VBZ||aquafol-1/NN	det||propofol-5/NN||a-3/DT	nn||propofol-5/NN||microemulsion-4/NN	appos||aquafol-1/NN||propofol-5/NN	root||ROOT-0/null||causes-7/VBZ	advmod||severe-9/JJ||more-8/RBR	amod||pain-12/NN||severe-9/JJ	conj_and||severe-9/JJ||frequent-11/JJ	amod||pain-12/NN||frequent-11/JJ	dobj||causes-7/VBZ||pain-12/NN	prep_on||causes-7/VBZ||injection-14/NN	prep_than||injection-14/NN||propofol-16/NN	pain-12||propofol-16||yes||aquafol, a microemulsion propofol, causes more severe and frequent pain on injection than propofol.
amod||vv-2/NN||recombinant-1/JJ	nsubjpass||identified-4/VBN||vv-2/NN	auxpass||identified-4/VBN||was-3/VBD	root||ROOT-0/null||identified-4/VBN	agent||identified-4/VBN||plaquing-6/VBG	det||mixture-8/NN||the-7/DT	dobj||plaquing-6/VBG||mixture-8/NN	nn||non-permissive-11/NN||cells-10/NNS	prep_on||plaquing-6/VBG||non-permissive-11/NN	prep_for||non-permissive-11/NN||fpv-13/NN	prep_for||non-permissive-11/NN||selection-15/NN	conj_and||fpv-13/NN||selection-15/NN	dep||positive-21/JJ||green-17/NN	number||positive-21/JJ||fluorescent-18/CD	conj_or||positive-21/JJ||lacz-20/JJ	amod||plaques-24/NNS||lacz-20/JJ	amod||plaques-24/NNS||positive-21/JJ	amod||plaques-24/NNS||recombinant-22/JJ	nn||plaques-24/NNS||vaccinia-23/NN	prep_of||fpv-13/NN||plaques-24/NNS	vaccinia-23||vv-2||no||recombinant vv was identified by plaquing the mixture on cells non-permissive for fpv and selection of green fluorescent or lacz positive recombinant vaccinia plaques.
nsubjpass||adopted-7/VBN||artemether/lumefantrine-1/NN	appos||artemether/lumefantrine-1/NN||al-3/NNP	aux||adopted-7/VBN||has-5/VBZ	auxpass||adopted-7/VBN||been-6/VBN	root||ROOT-0/null||adopted-7/VBN	det||treatment-10/NN||the-9/DT	prep_as||adopted-7/VBN||treatment-10/NN	prep_of||treatment-10/NN||choice-12/NN	amod||malaria-15/NN||uncomplicated-14/JJ	prep_for||adopted-7/VBN||malaria-15/NN	prep_in||malaria-15/NN||kenya-17/NN	amod||countries-20/NNS||other-19/JJ	prep_for||adopted-7/VBN||countries-20/NNS	conj_and||malaria-15/NN||countries-20/NNS	det||region-23/NN||the-22/DT	prep_in||countries-20/NNS||region-23/NN	malaria-15||lumefantrine--1||yes||artemether/lumefantrine (al) has been adopted as the treatment of choice for uncomplicated malaria in kenya and other countries in the region.
amod||models-3/NNS||linear-1/JJ	nn||models-3/NNS||regression-2/NN	nsubj||examined-4/VBD||models-3/NNS	root||ROOT-0/null||examined-4/VBD	dobj||examined-4/VBD||impact-5/NN	amod||factors-9/NNS||prior-7/JJ	nn||factors-9/NNS||treatment-8/NN	prep_of||impact-5/NN||factors-9/NNS	dep||factors-9/NNS||age-11/NN	appos||age-11/NN||gender-13/NN	dep||age-11/NN||duration-15/NN	prep_of||duration-15/NN||diabetes-17/NN	dep||age-11/NN||type-19/NN	conj_and||duration-15/NN||type-19/NN	amod||treatment-22/NN||prior-21/JJ	prep_of||type-19/NN||treatment-22/NN	amod||comorbidities-25/NNS||diabetes-related-24/JJ	dep||age-11/NN||comorbidities-25/NNS	conj_and||duration-15/NN||comorbidities-25/NNS	amod||factors-30/NNS||current-28/JJ	nn||factors-30/NNS||treatment-29/NN	prep_of||impact-5/NN||factors-30/NNS	conj_and||factors-9/NNS||factors-30/NNS	nn||gain-33/NN||weight-32/NN	dep||factors-9/NNS||gain-33/NN	amod||events-36/NNS||hypoglycemic-35/JJ	appos||gain-33/NN||events-36/NNS	amod||goal-40/NN||reaching-38/JJ	amod||goal-40/NN||therapeutic-39/JJ	appos||gain-33/NN||goal-40/NN	prep_on||examined-4/VBD||ts-43/NN	hypoglycemic-35||ts-43||no_rel||linear regression models examined impact of prior treatment factors (age, gender, duration of diabetes, type of prior treatment and diabetes-related comorbidities) and current treatment factors (weight gain, hypoglycemic events, reaching therapeutic goal) on ts.
det||trial-6/NN||the-2/DT	nn||trial-6/NN||phase-3/NN	nn||trial-6/NN||ii-4/NN	amod||trial-6/NN||disperse-2-5/JJ	prep_in||showed-29/VBD||trial-6/NN	num||patients-9/NNS||990-8/CD	prep_of||trial-6/NN||patients-9/NNS	amod||acute-12/JJ||non-st-elevation-11/JJ	amod||syndromes-14/NNS||acute-12/JJ	amod||syndromes-14/NNS||coronary-13/JJ	prep_with||patients-9/NNS||syndromes-14/NNS	appos||syndromes-14/NNS||acs-16/NN	nn||treatment-20/NN||ticagrelor-19/NN	nsubj||showed-29/VBD||treatment-20/NN	num||mg-23/NN||90-22/CD	prep_with||treatment-20/NN||mg-23/NN	num||mg-26/NN||180-25/CD	prep_with||treatment-20/NN||mg-26/NN	conj_and||mg-23/NN||mg-26/NN	advmod||mg-26/NN||twice-27/RB	advmod||showed-29/VBD||daily-28/RB	root||ROOT-0/null||showed-29/VBD	amod||rates-31/NNS||comparable-30/JJ	nsubj||mg-41/VBP||rates-31/NNS	amod||bleeding-36/NN||major-33/JJ	conj_and||major-33/JJ||minor-35/JJ	amod||bleeding-36/NN||minor-35/JJ	prep_of||rates-31/NNS||bleeding-36/NN	prepc_compared_with||bleeding-36/NN||with-38/IN	amod||75-40/CD||clopidogrel-39/JJ	pobj||bleeding-36/NN||75-40/CD	ccomp||showed-29/VBD||mg-41/VBP	mark||were-44/VBD||while-42/IN	expl||were-44/VBD||there-43/EX	advcl||mg-41/VBP||were-44/VBD	advmod||fewer-46/JJR||numerically-45/RB	amod||myocardialinfarctions-47/NNS||fewer-46/JJR	nsubj||were-44/VBD||myocardialinfarctions-47/NNS	myocardialinfarctions-47||clopidogrel-39||yes||in the phase ii disperse-2 trial of 990 patients with non-st-elevation acute coronary syndromes (acs), ticagrelor treatment with 90 mg and 180 mg twice daily showed comparable rates of major and minor bleeding compared with clopidogrel 75 mg while there were numerically fewer myocardialinfarctions.
poss||results-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||results-2/NNS	nsubj||suggest-16/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	det||sensitivity-5/NN||the-4/DT	dobj||demonstrate-3/VBP||sensitivity-5/NN	nn||degradation-8/NN||insulin-7/NN	prep_of||sensitivity-5/NN||degradation-8/NN	prep_by||demonstrate-3/VBP||ide-10/NN	det||environment-14/NN||the-12/DT	nn||environment-14/NN||redox-13/NN	prep_to||ide-10/NN||environment-14/NN	conj_and||demonstrate-3/VBP||suggest-16/VBP	det||mechanism-18/NN||another-17/DT	dobj||suggest-16/VBP||mechanism-18/NN	dobj||contribute-27/VB||which-20/WDT	det||cell-22/NN||the-21/DT	poss||state-25/NN||cell-22/NN	nn||state-25/NN||oxidation-24/NN	nsubj||contribute-27/VB||state-25/NN	aux||contribute-27/VB||may-26/MD	prepc_by||suggest-16/VBP||contribute-27/VB	det||development-30/NN||the-29/DT	prep_to||contribute-27/VB||development-30/NN	prep||development-30/NN||of-31/IN	det||link-35/NN||the-34/DT	npadvmod||between-36/IN||link-35/NN	advmod||demonstrate-3/VBP||between-36/IN	conj_and||demonstrate-3/VBP||between-36/IN	dep||sdisease-42/JJ||type2diabetes-38/NNS	conj_and||type2diabetes-38/NNS||alzheimer-40/NN	dep||sdisease-42/JJ||alzheimer-40/NN	dep||demonstrate-3/VBP||sdisease-42/JJ	type2diabetes-38||insulin-7||yes||our results demonstrate the sensitivity of insulin degradation by ide to the redox environment and suggest another mechanism by which the cell's oxidation state may contribute to the development of, and the link between, type2diabetes and alzheimer'sdisease.
det||paper-4/NN||a-2/DT	amod||paper-4/NN||recent-3/JJ	prep_in||considered-41/VBN||paper-4/NN	vmod||paper-4/NN||written-5/VBN	agent||written-5/VBN||hilbe-7/NNP	agent||written-5/VBN||al-9/NNP	conj_et||hilbe-7/NNP||al-9/NNP	nn||res-13/NN||bmc-11/NN	nn||res-13/NN||vet-12/NN	dep||hilbe-7/NNP||res-13/NN	amod||res-13/NN||2009-15/CD	det||nature-19/NN||the-18/DT	nsubjpass||considered-41/VBN||nature-19/NN	conj_and||nature-19/NN||specificity-21/NN	nsubjpass||considered-41/VBN||specificity-21/NN	det||deposition-25/NN||the-23/DT	nn||deposition-25/NN||prionprotein-24/NN	prep_of||nature-19/NN||deposition-25/NN	det||kidney-28/NN||the-27/DT	prep_in||deposition-25/NN||kidney-28/NN	amod||species-31/NNS||feline-30/JJ	prep_of||kidney-28/NN||species-31/NNS	vmod||species-31/NNS||affected-32/VBN	amod||spongiformencephalopathy-35/NN||feline-34/JJ	prep_with||affected-32/VBN||spongiformencephalopathy-35/NN	appos||spongiformencephalopathy-35/NN||fse-37/NN	auxpass||considered-41/VBN||were-39/VBD	advmod||considered-41/VBN||clearly-40/RB	root||ROOT-0/null||considered-41/VBN	xcomp||considered-41/VBN||doubtful-42/JJ	spongiformencephalopathy-35||prionprotein-24||no||in a recent paper written by hilbe et al (bmc vet res, 2009), the nature and specificity of the prionprotein deposition in the kidney of feline species affected with feline spongiformencephalopathy (fse) were clearly considered doubtful.
advmod||developed-7/VBD||furthermore-1/RB	nsubj||developed-7/VBD||mice-3/NNS	vmod||mice-3/NNS||vaccinated-4/VBN	prep_with||vaccinated-4/VBN||flu-na-diii-6/NN	root||ROOT-0/null||developed-7/VBD	amod||titers-11/NNS||protective-8/JJ	amod||titers-11/NNS||influenzavirus-specific-9/JJ	nn||titers-11/NNS||antibody-10/NN	dobj||developed-7/VBD||titers-11/NNS	flu--1||influenzavirus--1||no||furthermore, mice vaccinated with flu-na-diii developed protective influenzavirus-specific antibody titers.
aux||examine-2/VB||to-1/TO	advcl||performed-10/VBN||examine-2/VB	det||question-4/NN||this-3/DT	dobj||examine-2/VB||question-4/NN	amod||clamps-8/NNS||euglycemic-6/JJ	nn||clamps-8/NNS||glucose-7/NN	nsubjpass||performed-10/VBN||clamps-8/NNS	auxpass||performed-10/VBN||were-9/VBD	root||ROOT-0/null||performed-10/VBN	advmod||performed-10/VBN||twice-11/RB	amod||order-15/NN||random-14/JJ	prep_in||performed-10/VBN||order-15/NN	num||youth-19/NN||11-18/CD	prep_in||performed-10/VBN||youth-19/NN	prep_with||youth-19/NN||type1diabetes-21/CD	nn||15.1-24/NNS||age-23/NN	nsubj||â-25/VBP||15.1-24/NNS	dep||youth-19/NN||â-25/VBP	number||3-27/CD||±-26/CD	num||years-28/NNS||3-27/CD	tmod||â-25/VBP||years-28/NNS	amod||â-32/NN||a1c-30/JJ	num||â-32/NN||7.6-31/CD	nsubj||±-33/VBG||â-32/NN	vmod||â-25/VBP||±-33/VBG	num||%-35/NN||0.6-34/CD	dobj||±-33/VBG||%-35/NN	num||lispro-40/NN||0.2-38/CD	amod||lispro-40/NN||units/kg-39/VBG	prep_with||youth-19/NN||lispro-40/NN	num||glargine-44/NN||0.4-42/CD	amod||glargine-44/NN||units/kg-43/VBG	prep_with||youth-19/NN||glargine-44/NN	conj_and||lispro-40/NN||glargine-44/NN	vmod||lispro-40/NN||given-46/VBN	preconj||given-46/VBN||either-47/CC	prep_as||given-46/VBN||separate-49/JJ	det||injection-55/NN||a-52/DT	amod||injection-55/NN||single-53/JJ	amod||injection-55/NN||mixed-54/JJ	prep_as||given-46/VBN||injection-55/NN	conj_or||separate-49/JJ||injection-55/NN	type1diabetes-21||glucose-7||no_rel||to examine this question, euglycemic glucose clamps were performed twice, in random order, in 11 youth with type1diabetes (age 15.1 â± 3 years, a1c 7.6 â± 0.6%) with 0.2 units/kg lispro and 0.4 units/kg glargine, given either as separate or as a single mixed injection.
amod||characterization-4/NN||phenotypic-1/JJ	conj_and||phenotypic-1/JJ||genotypic-3/JJ	amod||characterization-4/NN||genotypic-3/JJ	nsubjpass||performed-19/VBN||characterization-4/NN	number||isolates-7/CD||133-6/CD	prep_of||characterization-4/NN||isolates-7/CD	prep_of||isolates-7/CD||neisseriameningitidis-9/NNS	vmod||neisseriameningitidis-9/NNS||obtained-10/VBN	amod||cases-13/NNS||meningococcaldisease-12/JJ	prep_from||obtained-10/VBN||cases-13/NNS	prep_in||cases-13/NNS||argentina-15/NN	prep_during||obtained-10/VBN||2010-17/CD	auxpass||performed-19/VBN||were-18/VBD	root||ROOT-0/null||performed-19/VBN	det||laboratory-24/NN||the-21/DT	amod||laboratory-24/NN||national-22/JJ	nn||laboratory-24/NN||reference-23/NN	agent||performed-19/VBN||laboratory-24/NN	prep_as||performed-19/VBN||part-26/NN	det||project-29/NN||a-28/DT	prep_of||part-26/NN||project-29/NN	vmod||project-29/NN||coordinated-30/VBN	det||paho-33/NN||the-32/DT	agent||coordinated-30/VBN||paho-33/NN	det||network-38/NN||the-35/DT	nn||network-38/NN||sireva-36/NN	nn||network-38/NN||ii-37/NN	prep_within||paho-33/NN||network-38/NN	meningococcaldisease-12||neisseriameningitidis-9||no||phenotypic and genotypic characterization of 133 isolates of neisseriameningitidis obtained from meningococcaldisease cases in argentina during 2010 were performed by the national reference laboratory as part of a project coordinated by the paho within the sireva ii network.
poss||study-2/NN||our-1/PRP$	nsubj||showed-3/VBD||study-2/NN	root||ROOT-0/null||showed-3/VBD	mark||effective-19/JJ||that-4/IN	number||%-6/NN||1-5/CD	amod||tropicamide-7/NN||%-6/NN	nsubj||effective-19/JJ||tropicamide-7/NN	poss||mechanism-13/NN||its-10/PRP$	amod||mechanism-13/NN||parasympathetic-11/JJ	amod||mechanism-13/NN||antagonistic-12/JJ	prep_with||tropicamide-7/NN||mechanism-13/NN	prep_of||mechanism-13/NN||action-15/NN	cop||effective-19/JJ||was-17/VBD	advmod||effective-19/JJ||more-18/RBR	ccomp||showed-3/VBD||effective-19/JJ	prepc_at||effective-19/JJ||inducing-21/VBG	dobj||inducing-21/VBG||pupillarydilation-22/NN	number||%-25/NN||2.5-24/CD	amod||phenylephrine-26/NN||%-25/NN	prep_than||inducing-21/VBG||phenylephrine-26/NN	det||combination-30/NN||the-29/DT	nsubj||effective-41/JJ||combination-30/NN	number||%-33/NN||1-32/CD	amod||tropicamide-34/NN||%-33/NN	prep_of||combination-30/NN||tropicamide-34/NN	number||%-37/NN||2.5-36/CD	amod||phenylephrine-38/NN||%-37/NN	prep_of||combination-30/NN||phenylephrine-38/NN	conj_and||tropicamide-34/NN||phenylephrine-38/NN	cop||effective-41/JJ||was-39/VBD	advmod||effective-41/JJ||more-40/RBR	conj_and||showed-3/VBD||effective-41/JJ	amod||drops-44/NNS||multiple-43/JJ	prep_than||effective-41/JJ||drops-44/NNS	amod||drops-48/NNS||single-46/JJ	nn||drops-48/NNS||eye-47/NN	prep_of||drops-44/NNS||drops-48/NNS	pupillarydilation-22||phenylephrine-38||no||our study showed that 1% tropicamide, with its parasympathetic antagonistic mechanism of action, was more effective at inducing pupillarydilation than 2.5% phenylephrine, and the combination of 1% tropicamide and 2.5% phenylephrine was more effective than multiple drops of single eye drops.
nsubj||threat-5/NN||tuberculosis-1/NNP	cop||threat-5/NN||is-2/VBZ	det||threat-5/NN||a-3/DT	amod||threat-5/NN||worldwide-4/JJ	root||ROOT-0/null||threat-5/NN	nsubj||requires-13/VBZ||development-8/NN	det||vaccine-12/NN||an-10/DT	amod||vaccine-12/NN||effective-11/JJ	prep_of||development-8/NN||vaccine-12/NN	conj_and||threat-5/NN||requires-13/VBZ	mark||dissected-25/VBN||that-14/IN	det||response-18/NN||the-15/DT	amod||response-18/NN||protective-16/JJ	amod||response-18/NN||immune-17/JJ	nsubjpass||dissected-25/VBN||response-18/NN	prep_to||response-18/NN||mycobacteriumtuberculosis-20/NNS	appos||mycobacteriumtuberculosis-20/NNS||mtb-22/NN	auxpass||dissected-25/VBN||be-24/VB	ccomp||requires-13/VBZ||dissected-25/VBN	det||response-30/NN||the-27/DT	amod||response-30/NN||pathological-28/JJ	amod||response-30/NN||immune-29/JJ	prep_from||dissected-25/VBN||response-30/NN	tuberculosis-1||mtb-22||no||tuberculosis is a worldwide threat, and development of an effective vaccine requires that the protective immune response to mycobacteriumtuberculosis (mtb) be dissected from the pathological immune response.
prepc_in_addition_to||represent-17/VBP||facilitating-4/VBG	det||understanding-7/NN||an-5/DT	amod||understanding-7/NN||improved-6/VBN	dobj||facilitating-4/VBG||understanding-7/NN	det||mechanisms-11/NNS||the-9/DT	amod||mechanisms-11/NNS||basic-10/JJ	prep_of||understanding-7/NN||mechanisms-11/NNS	prep_of||mechanisms-11/NNS||aging-13/VBG	amod||genes-16/NNS||such-15/JJ	nsubj||represent-17/VBP||genes-16/NNS	root||ROOT-0/null||represent-17/VBP	amod||targets-19/NNS||potential-18/JJ	dobj||represent-17/VBP||targets-19/NNS	amod||intervention-22/NN||therapeutic-21/JJ	prep_for||targets-19/NNS||intervention-22/NN	amod||diseases-26/NNS||multiple-24/JJ	amod||diseases-26/NNS||age-associated-25/JJ	prep_in||intervention-22/NN||diseases-26/NNS	prep_including||represent-17/VBP||cancer-29/NN	nn||disease-32/NN||heart-31/NN	prep_including||represent-17/VBP||disease-32/NN	conj_and||cancer-29/NN||disease-32/NN	prep_including||represent-17/VBP||diabetes-34/NN	conj_and||cancer-29/NN||diabetes-34/NN	amod||disorders-38/NNS||neurodegenerative-37/JJ	prep_including||represent-17/VBP||disorders-38/NNS	conj_and||cancer-29/NN||disorders-38/NNS	cancer-29||basic-10||no_rel||in addition to facilitating an improved understanding of the basic mechanisms of aging, such genes represent potential targets for therapeutic intervention in multiple age-associated diseases, including cancer, heart disease, diabetes, and neurodegenerative disorders.
det||elisa-3/NN||a-1/DT	amod||elisa-3/NN||bcg-specific-2/JJ	nsubjpass||used-8/VBN||elisa-3/NN	nsubj||quantify-10/VB||elisa-3/NN	nn||cytometry-6/NN||flow-5/NN	conj_and||elisa-3/NN||cytometry-6/NN	nsubjpass||used-8/VBN||cytometry-6/NN	nsubj||quantify-10/VB||cytometry-6/NN	auxpass||used-8/VBN||were-7/VBD	root||ROOT-0/null||used-8/VBN	aux||quantify-10/VB||to-9/TO	xcomp||used-8/VBN||quantify-10/VB	prt||quantify-10/VB||in-11/RP	amod||plasmablasts-14/NNS||vivo-12/JJ	amod||plasmablasts-14/NNS||activated-13/VBN	dobj||quantify-10/VB||plasmablasts-14/NNS	nn||samples-17/NNS||blood-16/NN	prep_in||quantify-10/VB||samples-17/NNS	nsubj||negative-24/JJ||samples-17/NNS	nsubj||hivpositive-26/JJ||samples-17/NNS	nn||subjects-20/NNS||ethiopian-19/NN	prep_from||samples-17/NNS||subjects-20/NNS	cop||negative-24/JJ||were-22/VBD	advmod||negative-24/JJ||hiv-23/RB	rcmod||samples-17/NNS||negative-24/JJ	rcmod||samples-17/NNS||hivpositive-26/JJ	conj_or||negative-24/JJ||hivpositive-26/JJ	hivpositive-26||hiv-23||no||a bcg-specific elisa and flow cytometry were used to quantify in vivo activated plasmablasts in blood samples from ethiopian subjects who were hiv negative or hivpositive.
det||msm-2/NN||the-1/DT	nsubj||likely-32/JJ||msm-2/NN	nsubj||receive-34/VB||msm-2/NN	vmod||msm-2/NN||sampled-3/VBN	amod||pride-6/NN||gay-5/JJ	prep_at||sampled-3/VBN||pride-6/NN	nsubj||reported-8/VBD||pride-6/NN	rcmod||pride-6/NN||reported-8/VBD	ccomp||reported-8/VBD||engaging-9/VBG	prep_in||engaging-9/VBG||uai-11/NN	aux||used-14/VBN||having-13/VBG	ccomp||reported-8/VBD||used-14/VBN	conj_or||engaging-9/VBG||used-14/VBN	det||stimulant-16/NN||any-15/DT	dobj||used-14/VBN||stimulant-16/NN	dep||stimulant-16/NN||cocaine-18/NN	dep||stimulant-16/NN||crack-cocaine-20/NN	conj_or||cocaine-18/NN||crack-cocaine-20/NN	dep||stimulant-16/NN||methamphetamine-23/NN	conj_or||cocaine-18/NN||methamphetamine-23/NN	det||months-29/NNS||the-26/DT	amod||months-29/NNS||last-27/JJ	num||months-29/NNS||12â-28/CD	prep_in||used-14/VBN||months-29/NNS	cop||likely-32/JJ||were-30/VBD	advmod||likely-32/JJ||more-31/RBR	root||ROOT-0/null||likely-32/JJ	aux||receive-34/VB||to-33/TO	xcomp||likely-32/JJ||receive-34/VB	nn||vaccination-36/NN||hepatitis-35/NN	dobj||receive-34/VB||vaccination-36/NN	advmod||receive-34/VB||on-site-37/JJ	hepatitis-35||methamphetamine-23||no_rel||the msm sampled at gay pride who reported engaging in uai or having used any stimulant (cocaine, crack-cocaine, or methamphetamine) in the last 12â months were more likely to receive hepatitis vaccination on-site.
amod||a2-3/NNS||pregnancy-associated-1/JJ	nn||a2-3/NNS||plasmaprotein-2/NN	nsubj||factor-11/NN||a2-3/NNS	appos||a2-3/NNS||pappa2-5/NNP	cop||factor-11/NN||is-7/VBZ	det||factor-11/NN||an-8/DT	amod||factor-11/NN||insulin-like-9/JJ	nn||factor-11/NN||growth-10/NN	root||ROOT-0/null||factor-11/NN	amod||protein-13/NN||binding-12/JJ	nsubj||protease-17/VBP||protein-13/NN	appos||protein-13/NN||igfbp-15/NN	rcmod||factor-11/NN||protease-17/VBP	ccomp||protease-17/VBP||expressed-18/VBN	det||placenta-21/NN||the-20/DT	prep_in||expressed-18/VBN||placenta-21/NN	ccomp||protease-17/VBP||upregulated-23/VBN	conj_and||expressed-18/VBN||upregulated-23/VBN	prep_in||upregulated-23/VBN||pregnancies-25/NNS	vmod||pregnancies-25/NNS||complicated-26/VBN	agent||complicated-26/VBN||pre-eclampsia-28/NN	insulin--1||pre-eclampsia-28||no_rel||pregnancy-associated plasmaprotein a2 (pappa2) is an insulin-like growth factor binding protein (igfbp) protease expressed in the placenta and upregulated in pregnancies complicated by pre-eclampsia.
nsubj||enzyme-7/NN||katg-1/NN	cop||enzyme-7/NN||is-2/VBZ	advmod||enzyme-7/NN||also-3/RB	det||enzyme-7/NN||the-4/DT	amod||enzyme-7/NN||key-5/JJ	amod||enzyme-7/NN||mycobacterial-6/JJ	root||ROOT-0/null||enzyme-7/NN	amod||enzyme-7/NN||responsible-8/JJ	det||activation-11/NN||the-10/DT	prep_for||responsible-8/JJ||activation-11/NN	det||isoniazid-17/NN||the-13/DT	amod||isoniazid-17/NN||first-line-14/JJ	nn||isoniazid-17/NN||tuberculosis-15/NNP	nn||isoniazid-17/NN||drug-16/NN	prep_of||activation-11/NN||isoniazid-17/NN	tuberculosis-15||isoniazid-17||yes||katg is also the key mycobacterial enzyme responsible for the activation of the first-line tuberculosis drug isoniazid.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||measured-9/VBD||we-8/PRP	rcmod||$-6/$||measured-9/VBD	amod||circumference-11/NN||waist-10/JJ	dobj||measured-9/VBD||circumference-11/NN	nn||pressure-14/NN||blood-13/NN	dobj||measured-9/VBD||pressure-14/NN	conj_and||circumference-11/NN||pressure-14/NN	nn||concentrations-21/NNS||glucose-16/NN	conj_and||glucose-16/NN||insulin-18/NN	nn||concentrations-21/NNS||insulin-18/NN	conj_and||glucose-16/NN||lipid-20/NN	nn||concentrations-21/NNS||lipid-20/NN	dobj||measured-9/VBD||concentrations-21/NNS	conj_and||circumference-11/NN||concentrations-21/NNS	det||prevalence-25/NN||the-24/DT	dobj||measured-9/VBD||prevalence-25/NN	conj_and||circumference-11/NN||prevalence-25/NN	amod||syndrome-28/NN||metabolic-27/JJ	prep_of||prevalence-25/NN||syndrome-28/NN	amod||panel-36/NN||national-30/JJ	nn||panel-36/NN||cholesterol-31/NN	nn||panel-36/NN||education-32/NN	nn||panel-36/NN||program-33/NN	nn||panel-36/NN||adult-34/NN	nn||panel-36/NN||treatment-35/NN	dep||syndrome-28/NN||panel-36/NN	dep||syndrome-28/NN||definition-38/NN	conj_iii||panel-36/NN||definition-38/NN	num||men-42/NNS||1,492-41/CD	prep_in||measured-9/VBD||men-42/NNS	prep_in||measured-9/VBD||women-44/NNS	conj_and||men-42/NNS||women-44/NNS	vmod||men-42/NNS||aged-45/VBN	dobj||aged-45/VBN||26â-46/NNS	num||years-50/NNS||$-47/$	num||$-47/$||32-49/CD	npadvmod||aged-45/VBN||years-50/NNS	prep_in||aged-45/VBN||delhi-52/NNS	poss||weight-57/NN||delhi-52/NNS	appos||delhi-52/NNS||india-54/NN	nsubjpass||recorded-61/VBN||weight-57/NN	conj_and||weight-57/NN||height-59/NN	nsubjpass||recorded-61/VBN||height-59/NN	auxpass||recorded-61/VBN||were-60/VBD	rcmod||delhi-52/NNS||recorded-61/VBN	det||months-64/NNS||every-62/DT	num||months-64/NNS||6-63/CD	tmod||recorded-61/VBN||months-64/NNS	prep_throughout||recorded-61/VBN||infancy-66/NN	dep||infancy-66/NN||0â-68/NNS	num||years-72/NNS||$-69/$	num||$-69/$||2-71/CD	dep||0â-68/NNS||years-72/NNS	prep_throughout||recorded-61/VBN||childhood-75/NN	conj_and||infancy-66/NN||childhood-75/NN	dep||childhood-75/NN||2â-77/NNS	num||years-81/NNS||$-78/$	num||$-78/$||11-80/CD	dep||2â-77/NNS||years-81/NNS	prep_throughout||recorded-61/VBN||adolescence-85/NN	conj_and||infancy-66/NN||adolescence-85/NN	num||yearsâ-88/NNS||11-87/CD	dep||adolescence-85/NN||yearsâ-88/NNS	dep||yearsâ-88/NNS||$-89/$	dep||$-89/$||adult-91/NN	cholesterol-31||delhi-52||no_rel||research design and methods â€”we measured waist circumference, blood pressure, glucose, insulin and lipid concentrations, and the prevalence of metabolic syndrome (national cholesterol education program adult treatment panel iii definition) in 1,492 men and women aged 26â€“32 years in delhi, india, whose weight and height were recorded every 6 months throughout infancy (0â€“2 years), childhood (2â€“11 years), and adolescence (11 yearsâ€“adult).
det||response-5/NN||the-1/DT	amod||response-5/NN||unprecedented-2/JJ	amod||response-5/NN||global-4/JJ	nsubj||responsible-15/JJ||response-5/NN	det||disease-9/NN||a-7/DT	amod||disease-9/NN||single-8/JJ	prep_to||response-5/NN||disease-9/NN	appos||disease-9/NN||hiv/aids-11/NNS	aux||responsible-15/JJ||has-13/VBZ	cop||responsible-15/JJ||been-14/VBN	root||ROOT-0/null||responsible-15/JJ	det||portion-19/NN||a-17/DT	amod||portion-19/NN||substantial-18/JJ	prep_for||responsible-15/JJ||portion-19/NN	det||boon-22/NN||this-21/DT	prep_of||portion-19/NN||boon-22/NN	aids--1||hiv--1||no||the unprecedented, global response to a single disease, hiv/aids, has been responsible for a substantial portion of this boon.
advmod||$-5/VBZ||thus-1/RB	det||bradycardiaâ-4/NN||the-3/DT	nsubj||$-5/VBZ||bradycardiaâ-4/NN	root||ROOT-0/null||$-5/VBZ	amod||signals-8/NNS||propranolol-7/JJ	nsubj||significant-15/JJ||signals-8/NNS	vmod||signals-8/NNS||calculated-9/VBN	det||study-12/NN||this-11/DT	prep_in||calculated-9/VBN||study-12/NN	cop||significant-15/JJ||were-13/VBD	neg||significant-15/JJ||not-14/RB	ccomp||$-5/VBZ||significant-15/JJ	bradycardia--1||propranolol-7||no||thus, the bradycardiaâ€“propranolol signals calculated in this study were not significant.
det||rats-4/NNS||the-1/DT	nn||rats-4/NNS||asthma-2/NN	nn||rats-4/NNS||model-3/NN	nsubjpass||treated-6/VBN||rats-4/NNS	auxpass||treated-6/VBN||were-5/VBD	root||ROOT-0/null||treated-6/VBN	prep_with||treated-6/VBN||rn-8/NN	amod||rn-8/NN||saline-10/JJ	amod||rn-8/NN||dexamethasone-13/JJ	conj_and||saline-10/JJ||dexamethasone-13/JJ	dep||rn-8/NN||dxm-16/RB	vmod||rn-8/NN||treated-19/VBN	dobj||treated-19/VBN||rats-20/NNS	vmod||rats-20/NNS||served-21/VBN	amod||controls-26/NNS||normal-23/JJ	conj_and||normal-23/JJ||model-25/JJ	amod||controls-26/NNS||model-25/JJ	prep_as||served-21/VBN||controls-26/NNS	asthma-2||dexamethasone-13||yes||the asthma model rats were treated with rn; saline- and dexamethasone- (dxm-) treated rats served as normal and model controls.
prepc_based_on||reported-24/VBN||on-2/IN	pobj||reported-24/VBN||data-3/NNS	det||sample-7/NN||a-5/DT	amod||sample-7/NN||representative-6/JJ	prep_from||data-3/NNS||sample-7/NN	num||programs-13/NNS||128-9/CD	amod||programs-13/NNS||public-funded-10/JJ	nn||programs-13/NNS||hiv-11/NN	nn||programs-13/NNS||prevention-12/NN	prep_of||sample-7/NN||programs-13/NNS	num||types-16/NNS||14-15/CD	prep_of||programs-13/NNS||types-16/NNS	nn||pradesh-19/NN||andhra-18/NN	prep_in||types-16/NNS||pradesh-19/NN	nsubj||reported-24/VBN||we-21/PRP	aux||reported-24/VBN||have-22/VBP	advmod||reported-24/VBN||recently-23/RB	root||ROOT-0/null||reported-24/VBN	det||number-26/NN||the-25/DT	dobj||reported-24/VBN||number-26/NN	prep_of||number-26/NN||hivinfections-28/NNS	vmod||hivinfections-28/NNS||averted-29/VBN	det||type-32/NN||each-31/DT	agent||averted-29/VBN||type-32/NN	nn||intervention-36/NN||hiv-34/NN	nn||intervention-36/NN||prevention-35/NN	prep_of||type-32/NN||intervention-36/NN	poss||cost-39/NN||their-38/PRP$	prep_of||type-32/NN||cost-39/NN	conj_and||intervention-36/NN||cost-39/NN	hivinfections-28||hiv-34||no||based on data from a representative sample of 128 public-funded hiv prevention programs of 14 types in andhra pradesh, we have recently reported the number of hivinfections averted by each type of hiv prevention intervention and their cost.
amod||factor-2/NN||regulatory-1/JJ	nsubj||interact-9/VB||factor-2/NN	nsubj||histone-18/VB||factor-2/NN	number||1-4/CD||x-box-3/CD	dep||factor-2/NN||1-4/CD	appos||factor-2/NN||rfx1-6/NNP	aux||interact-9/VB||can-8/MD	root||ROOT-0/null||interact-9/VB	prep_with||interact-9/VB||dna-11/NN	amod||dna-11/NN||methyltransferase-12/JJ	dep||methyltransferase-12/JJ||1-13/CD	appos||dna-11/NN||dnmt1-15/NNP	conj_and||interact-9/VB||histone-18/VB	dobj||histone-18/VB||deacetylase-19/NN	num||deacetylase-19/NN||1-20/CD	appos||deacetylase-19/NN||hdac1-22/NNP	amod||down-regulation-27/NN||rfx1-26/JJ	nsubj||contributes-28/VBZ||down-regulation-27/NN	nsubj||dna-30/VB||down-regulation-27/NN	conj_and||interact-9/VB||contributes-28/VBZ	aux||dna-30/VB||to-29/TO	xcomp||contributes-28/VBZ||dna-30/VB	amod||hyperacetylation-35/NN||hypomethylation-31/JJ	conj_and||hypomethylation-31/JJ||histone-33/JJ	amod||hyperacetylation-35/NN||histone-33/JJ	amod||hyperacetylation-35/NN||h3-34/JJ	dobj||dna-30/VB||hyperacetylation-35/NN	det||cluster-38/NN||the-37/DT	prep_at||dna-30/VB||cluster-38/NN	amod||11a-44/NNS||differentiation-40/JJ	appos||11a-44/NNS||cd-42/NN	prep_of||cluster-38/NN||11a-44/NNS	amod||promoters-47/NNS||cd70-46/JJ	prep_at||dna-30/VB||promoters-47/NNS	conj_and||cluster-38/NN||promoters-47/NNS	amod||cells-52/NNS||cd4-49/JJ	amod||cells-52/NNS||+-50/JJ	nn||cells-52/NNS||t-51/NN	prep_in||promoters-47/NNS||cells-52/NNS	prep_of||cells-52/NNS||patients-54/NNS	prep_with||dna-30/VB||systemiclupuserythematosus-56/NNS	appos||systemiclupuserythematosus-56/NNS||sle-58/NN	systemiclupuserythematosus-56||cd-42||no_rel||regulatory factor x-box 1 (rfx1) can interact with dna methyltransferase 1 (dnmt1) and histone deacetylase 1 (hdac1), and rfx1 down-regulation contributes to dna hypomethylation and histone h3 hyperacetylation at the cluster of differentiation (cd) 11a and cd70 promoters in cd4+ t cells of patients with systemiclupuserythematosus (sle).
det||plurality-2/NN||a-1/DT	nsubjpass||treated-8/VBN||plurality-2/NN	prep_of||plurality-2/NN||patients-4/NNS	prep_with||patients-4/NNS||schizophrenia-6/NN	auxpass||treated-8/VBN||was-7/VBD	root||ROOT-0/null||treated-8/VBN	prep_with||treated-8/VBN||clozapine-10/NN	num||%-13/NN||39-12/CD	appos||clozapine-10/NN||%-13/NN	nsubjpass||followed-18/VBN||this-16/DT	auxpass||followed-18/VBN||was-17/VBD	parataxis||treated-8/VBN||followed-18/VBN	agent||followed-18/VBN||risperidone-20/JJ	agent||followed-18/VBN||sulpride-22/JJ	conj_and||risperidone-20/JJ||sulpride-22/JJ	agent||followed-18/VBN||chlorpromazine-24/JJ	conj_and||risperidone-20/JJ||chlorpromazine-24/JJ	agent||followed-18/VBN||perphenazine-26/JJ	conj_and||risperidone-20/JJ||perphenazine-26/JJ	agent||followed-18/VBN||haloperidol-29/JJ	conj_and||risperidone-20/JJ||haloperidol-29/JJ	schizophrenia-6||chlorpromazine-24||yes||a plurality of patients with schizophrenia was treated with clozapine (39%); this was followed by risperidone, sulpride, chlorpromazine, perphenazine, and haloperidol.
nsubj||cause-18/NN||tularemia-1/NN	vmod||tularemia-1/NN||caused-3/VBN	det||francisellatularensis-7/NNS||the-5/DT	nn||francisellatularensis-7/NNS||bacterium-6/NN	agent||caused-3/VBN||francisellatularensis-7/NNS	advmod||subspecies-12/VBZ||where-9/WRB	nn||tularensis-11/NNS||f.-10/NN	nsubj||subspecies-12/VBZ||tularensis-11/NNS	rcmod||francisellatularensis-7/NNS||subspecies-12/VBZ	dobj||subspecies-12/VBZ||holarctica-13/NN	aux||cause-18/NN||has-14/VBZ	advmod||cause-18/NN||long-15/RB	cop||cause-18/NN||been-16/VBN	det||cause-18/NN||the-17/DT	root||ROOT-0/null||cause-18/NN	amod||disease-21/NN||endemic-20/JJ	prep_of||cause-18/NN||disease-21/NN	prep_in||cause-18/NN||parts-23/NNS	amod||sweden-26/NN||northern-25/JJ	prep_of||parts-23/NNS||sweden-26/NN	tularemia-1||francisellatularensis-7||no||tularemia , caused by the bacterium francisellatularensis , where f. tularensis subspecies holarctica has long been the cause of endemic disease in parts of northern sweden .
amod||survival-2/NN||cumulative-1/JJ	nsubjpass||analyzed-12/VBN||survival-2/NN	nsubjpass||analyzed-12/VBN||survival-2/NN	amod||rates-10/NNS||hepatocellular-4/JJ	amod||rates-10/NNS||carcinoma-5/JJ	appos||rates-10/NNS||hcc-7/NN	nn||rates-10/NNS||development-9/NN	conj_and||survival-2/NN||rates-10/NNS	nsubjpass||analyzed-12/VBN||rates-10/NNS	auxpass||analyzed-12/VBN||were-11/VBD	root||ROOT-0/null||analyzed-12/VBN	conj_or||analyzed-12/VBN||analyzed-12/VBN	nn||abusive-15/NNS||alcohol-14/NN	prep_in||analyzed-12/VBN||abusive-15/NNS	amod||patients-18/NNS||cirrhotic-17/JJ	appos||abusive-15/NNS||patients-18/NNS	nn||virusinfection-23/NN||hepatitis-22/NN	prep_with||analyzed-12/VBN||virusinfection-23/NN	prep_without||analyzed-12/VBN||virusinfection-23/NN	alcohol-14||hepatitis-22||no_rel||cumulative survival and hepatocellular carcinoma (hcc) development rates were analyzed in alcohol abusive, cirrhotic patients with or without hepatitis virusinfection.
det||study-2/NN||this-1/DT	nsubj||established-4/VBN||study-2/NN	aux||established-4/VBN||has-3/VBZ	root||ROOT-0/null||established-4/VBN	amod||correlation-6/NN||inverse-5/JJ	dobj||established-4/VBN||correlation-6/NN	det||increase-9/NN||the-8/DT	prep_of||correlation-6/NN||increase-9/NN	amod||immunity-12/NN||th1/th2-11/JJ	prep_of||increase-9/NN||immunity-12/NN	det||decline-15/NN||the-14/DT	prep_of||correlation-6/NN||decline-15/NN	conj_and||increase-9/NN||decline-15/NN	nn||load-19/NN||hbv-17/NN	nn||load-19/NN||dna-18/NN	prep_of||decline-15/NN||load-19/NN	amod||patients-23/NNS||chronic-21/JJ	nn||patients-23/NNS||hbv-22/NN	prep_in||load-19/NN||patients-23/NNS	amod||treatment-26/NN||adefovirdipivoxil-25/JJ	prep_during||established-4/VBN||treatment-26/NN	hbv-22||adefovirdipivoxil-25||yes||this study has established inverse correlation of the increase of th1/th2 immunity and the decline of hbv dna load in chronic hbv patients during adefovirdipivoxil treatment.
det||study-3/NN||this-2/DT	prep_in||used-13/VBN||study-3/NN	nsubjpass||used-13/VBN||assessment-5/NN	nsubj||identify-15/VB||assessment-5/NN	amod||plasmablasts-10/NNS||bcg-specific-7/JJ	amod||plasmablasts-10/NNS||igg-secreting-8/JJ	amod||plasmablasts-10/NNS||peripheral-9/JJ	prep_of||assessment-5/NN||plasmablasts-10/NNS	auxpass||used-13/VBN||was-12/VBD	root||ROOT-0/null||used-13/VBN	aux||identify-15/VB||to-14/TO	xcomp||used-13/VBN||identify-15/VB	amod||tb-17/NN||active-16/JJ	dobj||identify-15/VB||tb-17/NN	det||groups-21/NNS||these-19/DT	amod||groups-21/NNS||high-risk-20/JJ	prep_in||identify-15/VB||groups-21/NNS	tb-17||bcg--1||yes||in this study, assessment of bcg-specific igg-secreting peripheral plasmablasts, was used to identify active tb in these high-risk groups.
det||study-2/NN||the-1/DT	nsubj||investigated-3/VBD||study-2/NN	root||ROOT-0/null||investigated-3/VBD	det||possibility-5/NN||the-4/DT	dobj||investigated-3/VBD||possibility-5/NN	prepc_of||possibility-5/NN||identifying-7/VBG	det||speed-9/NN||the-8/DT	dobj||identifying-7/VBG||speed-9/NN	det||movement-13/NN||an-11/DT	amod||movement-13/NN||imagined-12/JJ	prep_of||speed-9/NN||movement-13/NN	nn||recordings-16/NNS||eeg-15/NN	prep_from||identifying-7/VBG||recordings-16/NNS	amod||patients-22/NNS||amyotrophiclateralsclerosis-18/JJ	appos||patients-22/NNS||als-20/NN	prep_in||recordings-16/NNS||patients-22/NNS	speed-9||als-20||no_rel||the study investigated the possibility of identifying the speed of an imagined movement from eeg recordings in amyotrophiclateralsclerosis (als) patients.
det||study-3/NN||this-2/DT	prep_in||attempted-6/VBD||study-3/NN	nsubj||attempted-6/VBD||we-5/PRP	nsubj||assess-8/VB||we-5/PRP	root||ROOT-0/null||attempted-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||attempted-6/VBD||assess-8/VB	dobj||assess-8/VB||simvastatin-9/NN	dobj||assess-8/VB||simvastatin-9/NN	conj_and||simvastatin-9/NN||simvastatin-9/NN	advmod||used-12/VBN||widely-11/RB	vmod||simvastatin-9/NN||used-12/VBN	det||drug-16/NN||a-14/DT	amod||drug-16/NN||cholesterol-lowering-15/JJ	prep_as||used-12/VBN||drug-16/NN	preconj||simvastatin-9/NN||both-18/DT	det||agent-22/NN||a-20/DT	amod||agent-22/NN||single-21/JJ	prep_as||simvastatin-9/NN||agent-22/NN	nsubj||$-29/VBG||combination-25/NN	amod||analogsâ-28/NNS||purine-27/JJ	prep_with||combination-25/NN||analogsâ-28/NNS	prepc_in||simvastatin-9/NN||$-29/VBG	nn||$-34/NNS||fludarabine-31/NN	conj_and||fludarabine-31/NN||cladribineâ-33/NN	nn||$-34/NNS||cladribineâ-33/NN	dobj||$-29/VBG||$-34/NNS	prep_in||$-29/VBG||terms-37/NNS	poss||effect-40/NN||its-39/PRP$	prep_of||terms-37/NNS||effect-40/NN	prep_on||effect-40/NN||apoptosis-42/NNS	nn||damage-45/NN||dna-44/NN	prep_on||effect-40/NN||damage-45/NN	conj_and||apoptosis-42/NNS||damage-45/NN	nn||cells-48/NNS||cll-47/NN	prep_of||effect-40/NN||cells-48/NNS	cll-47||cladribine--1||yes||in this study, we attempted to assess simvastatin, widely used as a cholesterol-lowering drug, both as a single agent and in combination with purine analogsâ€”fludarabine and cladribineâ€”in terms of its effect on apoptosis and dna damage of cll cells.
nsubj||agent-10/NN||denguevirus-1/NNS	det||flavivirus-5/NNS||a-3/DT	amod||flavivirus-5/NNS||mosquito-borne-4/JJ	appos||denguevirus-1/NNS||flavivirus-5/NNS	cop||agent-10/NN||is-7/VBZ	det||agent-10/NN||the-8/DT	amod||agent-10/NN||etiological-9/JJ	root||ROOT-0/null||agent-10/NN	prep_of||agent-10/NN||denguefever-12/NN	prep_of||agent-10/NN||denguehemorrhagicfever-14/NN	conj_and||denguefever-12/NN||denguehemorrhagicfever-14/NN	prep_of||agent-10/NN||dengueshocksyndrome-17/NN	conj_and||denguefever-12/NN||dengueshocksyndrome-17/NN	dengueshocksyndrome-17||denguevirus-1||no||denguevirus, a mosquito-borne flavivirus, is the etiological agent of denguefever, denguehemorrhagicfever, and dengueshocksyndrome.
det||effects-2/NNS||these-1/DT	nsubjpass||analyzed-4/VBN||effects-2/NNS	auxpass||analyzed-4/VBN||were-3/VBD	root||ROOT-0/null||analyzed-4/VBN	prep_in||analyzed-4/VBN||individuals-6/NNS	amod||diabetesmellitustype2-10/NNS||non-insulin-8/JJ	amod||diabetesmellitustype2-10/NNS||depended-9/VBG	prep_with||analyzed-4/VBN||diabetesmellitustype2-10/NNS	appos||diabetesmellitustype2-10/NNS||niddm2-12/NNP	amod||glucose-17/NN||impaired-15/VBN	amod||glucose-17/NN||fasting-16/JJ	prep_with||analyzed-4/VBN||glucose-17/NN	conj_and||diabetesmellitustype2-10/NNS||glucose-17/NN	appos||glucose-17/NN||ifg-19/NN	diabetesmellitustype2-10||insulin--1||yes||these effects were analyzed in individuals with non-insulin depended diabetesmellitustype2 (niddm2) and impaired fasting glucose (ifg).
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||modulate-8/VB||that-4/IN	nsubj||modulate-8/VB||pde5inhibitors-5/NNS	nsubj||enhance-13/VB||pde5inhibitors-5/NNS	aux||modulate-8/VB||may-6/MD	advmod||modulate-8/VB||effectively-7/RB	ccomp||suggest-3/VBP||modulate-8/VB	dobj||modulate-8/VB||btb-9/NN	advmod||modulate-8/VB||permeability-10/RB	ccomp||suggest-3/VBP||enhance-13/VB	conj_and||modulate-8/VB||enhance-13/VB	nn||efficacy-17/NN||delivery-14/NN	conj_and||delivery-14/NN||therapeutic-16/JJ	nn||efficacy-17/NN||therapeutic-16/JJ	dobj||enhance-13/VB||efficacy-17/NN	amod||antibodies-20/NNS||monoclonal-19/JJ	prep_of||efficacy-17/NN||antibodies-20/NNS	amod||metastases-24/NNS||hard-to-treat-22/JJ	nn||metastases-24/NNS||brain-23/NN	prep_in||antibodies-20/NNS||metastases-24/NNS	amod||tumors-28/NNS||different-26/JJ	amod||tumors-28/NNS||primary-27/JJ	prep_from||enhance-13/VB||tumors-28/NNS	nsubj||metastasized-31/VBN||tumors-28/NNS	aux||metastasized-31/VBN||had-30/VBD	rcmod||tumors-28/NNS||metastasized-31/VBN	det||brain-34/NN||the-33/DT	prep_to||metastasized-31/VBN||brain-34/NN	antibodies-20||metastases-24||no_rel||these findings suggest that pde5inhibitors may effectively modulate btb permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain.
nn||lipoproteins-2/NNS||plasma-1/NN	nsubj||mechanism-8/NN||lipoproteins-2/NNS	cop||mechanism-8/NN||are-3/VBP	det||mechanism-8/NN||a-4/DT	amod||mechanism-8/NN||potent-5/JJ	nn||mechanism-8/NN||host-6/NN	nn||mechanism-8/NN||defense-7/NN	root||ROOT-0/null||mechanism-8/NN	amod||salmonellainfection-11/NN||invasive-10/JJ	prep_against||mechanism-8/NN||salmonellainfection-11/NN	prepc_by||mechanism-8/NN||blocking-14/VBG	dobj||blocking-14/VBG||adhesion-15/NN	prep_of||adhesion-15/NN||salmonella-17/NN	det||cells-21/NNS||the-19/DT	nn||cells-21/NNS||host-20/NN	prep_to||blocking-14/VBG||cells-21/NNS	amod||invasion-25/NN||subsequent-23/JJ	nn||invasion-25/NN||tissue-24/NN	prep_to||blocking-14/VBG||invasion-25/NN	conj_and||cells-21/NNS||invasion-25/NN	salmonellainfection-11||salmonella-17||no||plasma lipoproteins are a potent host defense mechanism against invasive salmonellainfection, by blocking adhesion of salmonella to the host cells and subsequent tissue invasion.
nsubj||compensated-10/VBN||patients-1/NNS	nsubj||overt-12/VB||patients-1/NNS	det||syndrome-4/NN||the-3/DT	prep_with||patients-1/NNS||syndrome-4/NN	nn||unresponsiveness-7/NNS||tsh-6/NN	prep_of||syndrome-4/NN||unresponsiveness-7/NNS	aux||compensated-10/VBN||may-8/MD	aux||compensated-10/VBN||have-9/VB	root||ROOT-0/null||compensated-10/VBN	conj_or||compensated-10/VBN||overt-12/VB	dobj||overt-12/VB||hypothyroidism-13/NN	det||spectrum-17/NN||a-15/DT	amod||spectrum-17/NN||wide-16/JJ	prep_with||overt-12/VB||spectrum-17/NN	amod||alterations-22/NNS||clinical-19/JJ	conj_and||clinical-19/JJ||morphological-21/JJ	amod||alterations-22/NNS||morphological-21/JJ	prep_of||spectrum-17/NN||alterations-22/NNS	prepc_depending_on||overt-12/VB||on-24/IN	det||degree-26/NN||the-25/DT	pobj||overt-12/VB||degree-26/NN	prep_of||degree-26/NN||impairment-28/NN	nn||function-34/NN||tsh-receptor-30/NNP	appos||function-34/NN||tsh-r-32/NN	prep_of||impairment-28/NN||function-34/NN	hypothyroidism-13||tsh-6||no_rel||patients with the syndrome of tsh unresponsiveness may have compensated or overt hypothyroidism with a wide spectrum of clinical and morphological alterations depending on the degree of impairment of tsh-receptor (tsh-r) function.
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tb--1||isoniazid-27||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
num||cycles-3/NNS||twelve-2/CD	prep_after||revealed-11/VBD||cycles-3/NNS	amod||chemotherapy-6/NN||oxaliplatin-capecitabine-5/JJ	prep_of||cycles-3/NNS||chemotherapy-6/NN	amod||tomography-10/NN||abdominopelvic-8/JJ	amod||tomography-10/NN||computed-9/JJ	nsubj||revealed-11/VBD||tomography-10/NN	root||ROOT-0/null||revealed-11/VBD	amod||shrinkage-13/NN||marked-12/JJ	nsubj||showed-22/VBD||shrinkage-13/NN	det||metastases-17/NNS||the-15/DT	nn||metastases-17/NNS||liver-16/NN	prep_of||shrinkage-13/NN||metastases-17/NNS	nn||tomography-21/NN||positron-19/NN	nn||tomography-21/NN||emission-20/NN	prep_of||shrinkage-13/NN||tomography-21/NN	conj_and||metastases-17/NNS||tomography-21/NN	ccomp||revealed-11/VBD||showed-22/VBD	neg||uptake-24/NN||no-23/DT	dobj||showed-22/VBD||uptake-24/NN	amod||fdg-28/NN||18f-fluoro-deoxy-glucose-26/JJ	prep_of||uptake-24/NN||fdg-28/NN	advmod||fdg-28/NN||either-30/RB	det||liver-33/NN||the-32/DT	prep_in||showed-22/VBD||liver-33/NN	prep_in||showed-22/VBD||peritoneum-35/NN	conj_or||liver-33/NN||peritoneum-35/NN	amod||uptake-38/NN||localized-37/VBN	prep_except||liver-33/NN||uptake-38/NN	det||colon-42/NN||the-40/DT	amod||colon-42/NN||sigmoid-41/JJ	prep_in||uptake-38/NN||colon-42/NN	metastases-17||capecitabine--1||no_rel||after twelve cycles of oxaliplatin-capecitabine chemotherapy, abdominopelvic computed tomography revealed marked shrinkage of the liver metastases and positron emission tomography showed no uptake of 18f-fluoro-deoxy-glucose (fdg) either in the liver or peritoneum except localized uptake in the sigmoid colon.
nsubj||study-5/NN||this-1/DT	cop||study-5/NN||was-2/VBD	det||study-5/NN||a-3/DT	amod||study-5/NN||prospective-4/JJ	root||ROOT-0/null||study-5/NN	prep_of||study-5/NN||patients-7/NNS	nn||iiib-13/NN||type2diabetes-9/NN	conj_and||type2diabetes-9/NN||ckd-11/NN	nn||iiib-13/NN||ckd-11/NN	nn||iiib-13/NN||stage-12/NN	prep_with||patients-7/NNS||iiib-13/NN	prep_of||study-5/NN||iv-15/NN	conj_or||patients-7/NNS||iv-15/NN	vmod||iv-15/NN||undergoing-16/VBG	amod||iron-18/NN||intravenous-17/JJ	dobj||undergoing-16/VBG||iron-18/NN	dep||iron-18/NN||group-20/NN	dep||group-20/NN||a-21/DT	vmod||iron-18/NN||and/or-23/VBG	dobj||and/or-23/VBG||esa-24/NN	appos||iron-18/NN||groupb-26/NN	iron-18||type2diabetes-9||no_rel||this was a prospective study of patients with type2diabetes and ckd stage iiib or iv undergoing intravenous iron (group a) and/or esa (groupb).
agent||formed-32/VBN||conjugating-2/VBG	amod||antibodies-4/NNS||anti-h5n1-3/JJ	dobj||conjugating-2/VBG||antibodies-4/NNS	det||chemistry-19/NN||the-6/DT	amod||chemistry-19/NN||ps@pdav-7/JJ	prep_via||ps@pdav-7/JJ||n-9/NN	dep||n-9/NN||hydroxysuccinimide-11/JJ	dep||n-9/NN||1-ethyl3-13/JJ	conj_and||hydroxysuccinimide-11/JJ||1-ethyl3-13/JJ	dep||n-9/NN||3-dimethylaminopropyl-16/JJ	nn||chemistry-19/NN||carbodiimide-18/NN	prep_to||conjugating-2/VBG||chemistry-19/NN	det||microsphere-27/NN||a-21/DT	amod||microsphere-27/NN||stable-22/JJ	amod||microsphere-27/NN||blue-23/JJ	amod||microsphere-27/NN||complex-24/JJ	amod||microsphere-27/NN||anti-h5n1-26/JJ	nsubjpass||formed-32/VBN||microsphere-27/NN	dep||microsphere-27/NN||ps@pdav-anti-h5n1-29/JJ	auxpass||formed-32/VBN||was-31/VBD	root||ROOT-0/null||formed-32/VBN	antibodies-4||h5n1--1||no_rel||by conjugating anti-h5n1 antibodies to the ps@pdav via n -hydroxysuccinimide and 1-ethyl3-(3-dimethylaminopropyl) carbodiimide chemistry, a stable blue complex, anti-h5n1 microsphere (ps@pdav-anti-h5n1) was formed.
det||cancer-2/NN||the-1/DT	nsubj||stem-3/VBP||cancer-2/NN	root||ROOT-0/null||stem-3/VBP	nn||theory-5/NN||cell-4/NN	nsubj||suggests-6/VBZ||theory-5/NN	ccomp||stem-3/VBP||suggests-6/VBZ	nsubj||persist-8/VB||cscs-7/NNS	nsubj||cause-16/VB||cscs-7/NNS	ccomp||suggests-6/VBZ||persist-8/VB	prep_in||persist-8/VB||tumors-10/NNS	det||population-14/NN||a-12/DT	amod||population-14/NN||distinct-13/JJ	prep_as||tumors-10/NNS||population-14/NN	ccomp||suggests-6/VBZ||cause-16/VB	conj_and||persist-8/VB||cause-16/VB	dobj||cause-16/VB||relapse-17/NN	dobj||cause-16/VB||metastasis-19/NNS	conj_and||relapse-17/NN||metastasis-19/NNS	prepc_by||cause-16/VB||giving-21/VBG	dobj||giving-21/VBG||rise-22/NN	amod||tumors-25/NNS||new-24/JJ	prep_to||giving-21/VBG||tumors-25/NNS	rise-22||tumors-25||no_rel||the cancer stem cell theory suggests cscs persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors.
det||use-2/NN||the-1/DT	nsubj||favoured-17/VBN||use-2/NN	nsubj||mitoxantrone-49/JJ||use-2/NN	cc||abuse-5/CD||or-4/CC	dep||use-2/NN||abuse-5/CD	amod||points-10/NNS||surrogate-8/JJ	nn||points-10/NNS||end-9/NN	prep_of||use-2/NN||points-10/NNS	prep_of||points-10/NNS||quality-12/NN	prep_of||quality-12/NN||life-14/NN	aux||favoured-17/VBN||has-15/VBZ	advmod||favoured-17/VBN||recently-16/RB	root||ROOT-0/null||favoured-17/VBN	det||decisions-20/NNS||some-18/DT	amod||decisions-20/NNS||questionable-19/JJ	dobj||favoured-17/VBN||decisions-20/NNS	det||organs-25/NNS||the-22/DT	amod||organs-25/NNS||main-23/JJ	nn||organs-25/NNS||regulator-24/NN	prep_of||decisions-20/NNS||organs-25/NNS	det||approval-30/NN||the-29/DT	prep_such_as||organs-25/NNS||approval-30/NN	det||administration-36/NN||the-32/DT	nn||administration-36/NN||food-33/NN	conj_and||food-33/NN||drugs-35/NNS	nn||administration-36/NN||drugs-35/NNS	prep_by||approval-30/NN||administration-36/NN	det||use-39/NN||the-38/DT	prep_of||administration-36/NN||use-39/NN	prep_of||use-39/NN||gemcitabine-41/NN	amod||cancer-46/NN||advanced-43/VBN	amod||cancer-46/NN||chemotherapy-naive-44/JJ	amod||cancer-46/NN||pancreatic-45/JJ	prep_in||gemcitabine-41/NN||cancer-46/NN	conj_or||favoured-17/VBN||mitoxantrone-49/JJ	det||treatment-53/NN||the-51/DT	amod||treatment-53/NN||palliative-52/JJ	prep_in||mitoxantrone-49/JJ||treatment-53/NN	amod||cancer-57/NN||hormone-resistant-55/JJ	amod||cancer-57/NN||pancreatic-56/JJ	prep_of||treatment-53/NN||cancer-57/NN	prepc_based_on||favoured-17/VBN||on-60/IN	det||improvement-62/NN||the-61/DT	pobj||favoured-17/VBN||improvement-62/NN	amod||benefit-65/NN||clinical-64/JJ	prep_in||improvement-62/NN||benefit-65/NN	det||instrument-69/NN||a-67/DT	amod||instrument-69/NN||non-validated-68/JJ	dep||improvement-62/NN||instrument-69/NN	aux||evaluate-71/VB||to-70/TO	vmod||instrument-69/NN||evaluate-71/VB	det||outcome-73/NN||the-72/DT	dobj||evaluate-71/VB||outcome-73/NN	amod||chemotherapy-76/NN||palliative-75/JJ	prep_of||outcome-73/NN||chemotherapy-76/NN	det||survival-84/NN||a-79/DT	amod||survival-84/NN||minimal-80/JJ	conj_and||minimal-80/JJ||questionable-82/JJ	amod||survival-84/NN||questionable-82/JJ	amod||survival-84/NN||overall-83/JJ	prep_besides||improvement-62/NN||survival-84/NN	nn||control-88/NN||pain-87/NN	pobj||favoured-17/VBN||control-88/NN	conj_or||improvement-62/NN||control-88/NN	dep||control-88/NN||evaluated-90/VBN	det||instrument-94/NN||a-92/DT	amod||instrument-94/NN||non-validated-93/JJ	prep_with||evaluated-90/VBN||instrument-94/NN	pain-87||mitoxantrone-49||yes||the use (or abuse) of surrogate end points of quality of life has recently favoured some questionable decisions of the main regulator organs, such as the approval by the food and drugs administration of the use of gemcitabine in advanced chemotherapy-naive pancreatic cancer, or mitoxantrone in the palliative treatment of hormone-resistant pancreatic cancer, based on the improvement in clinical benefit (a non-validated instrument to evaluate the outcome of palliative chemotherapy) besides a minimal and questionable overall survival, or pain control (evaluated with a non-validated instrument).
nsubj||threaten-12/VB||influenzaviruses-1/NNS	advmod||pathogenic-5/JJ||highly-4/RB	amod||avianinfluenzavirus-6/NNS||pathogenic-5/JJ	prep_including||influenzaviruses-1/NNS||avianinfluenzavirus-6/NNS	appos||avianinfluenzavirus-6/NNS||h5n1-8/NNP	aux||threaten-12/VB||could-11/MD	root||ROOT-0/null||threaten-12/VB	nn||safety-14/NN||blood-13/NN	dobj||threaten-12/VB||safety-14/NN	h5n1-8||influenzaviruses-1||no||influenzaviruses, including highly pathogenic avianinfluenzavirus (h5n1), could threaten blood safety.
num||types-3/NNS||seven-1/CD	amod||types-3/NNS||different-2/JJ	nsubjpass||examined-7/VBN||types-3/NNS	prep_of||types-3/NNS||evidence-5/NN	auxpass||examined-7/VBN||were-6/VBD	root||ROOT-0/null||examined-7/VBN	dep||models-11/NNS||1-9/LS	dobj||examined-7/VBN||models-11/NNS	nn||prevalence-14/NN||hiv-13/NN	prep_of||models-11/NNS||prevalence-14/NN	prep_of||models-11/NNS||incidence-16/NN	conj_and||prevalence-14/NN||incidence-16/NN	prep_in||prevalence-14/NN||kampala-18/NN	amod||sites-22/NNS||other-20/JJ	amod||sites-22/NNS||sentinel-21/JJ	dobj||examined-7/VBN||sites-22/NNS	conj_and||models-11/NNS||sites-22/NNS	prep_in||sites-22/NNS||uganda-24/NN	dep||reports-29/NNS||2-27/LS	dep||sites-22/NNS||reports-29/NNS	nn||change-32/NN||behaviour-31/NN	prep_of||reports-29/NNS||change-32/NN	det||newspaper-36/NN||the-34/DT	amod||newspaper-36/NN||primary-35/JJ	prep_in||change-32/NN||newspaper-36/NN	prep_in||newspaper-36/NN||uganda-38/NN	dep||surveys-43/NNS||3-41/LS	dep||sites-22/NNS||surveys-43/NNS	prep_with||surveys-43/NNS||questions-45/NNS	prep_about||questions-45/NNS||perceptions-47/NNS	amod||change-51/NN||personal-49/JJ	nn||change-51/NN||behaviour-50/NN	prep_of||perceptions-47/NNS||change-51/NN	appos||demographic-57/NN||4-54/CD	amod||demographic-57/NN||large-56/JJ	dep||sites-22/NNS||demographic-57/NN	nn||surveys-60/NNS||health-59/NN	dep||sites-22/NNS||surveys-60/NNS	conj_and||demographic-57/NN||surveys-60/NNS	appos||surveys-60/NNS||dhs-62/NN	vmod||sites-22/NNS||collected-64/VBN	prep_in||collected-64/VBN||1988/9-66/CD	prep_in||collected-64/VBN||1995-68/CD	conj_and||1988/9-66/CD||1995-68/CD	amod||program-72/NN||large-70/JJ	amod||program-72/NN||global-71/JJ	nsubj||surveys-78/VBZ||program-72/NN	prep_on||program-72/NN||aids-74/NNS	appos||aids-74/NNS||gpa-76/NN	conj_and||examined-7/VBN||surveys-78/VBZ	prep_in||surveys-78/VBZ||1989-80/CD	prep_in||surveys-78/VBZ||1995-82/CD	conj_and||1989-80/CD||1995-82/CD	prep_with||surveys-78/VBZ||questions-84/NNS	amod||behaviour-88/NN||reported-86/VBN	amod||behaviour-88/NN||sexual-87/JJ	prep_about||questions-84/NNS||behaviour-88/NN	dep||smaller-93/JJR||5-91/CD	parataxis||surveys-78/VBZ||smaller-93/JJR	prep||smaller-93/JJR||less-94/CC	amod||surveys-96/NNS||representative-95/JJ	pobj||less-94/CC||surveys-96/NNS	amod||behaviour-100/NN||reported-98/VBN	amod||behaviour-100/NN||sexual-99/JJ	prep_of||surveys-96/NNS||behaviour-100/NN	vmod||behaviour-100/NN||collected-101/VBN	amod||years-104/NNS||other-103/JJ	prep_in||collected-101/VBN||years-104/NNS	appos||reports-109/NNS||6-107/CD	dep||behaviour-100/NN||reports-109/NNS	prep_of||reports-109/NNS||numbers-111/NNS	prep_of||numbers-111/NNS||condoms-113/NNS	vmod||condoms-113/NNS||shipped-114/VBN	prep_to||shipped-114/VBN||uganda-116/NN	appos||uganda-116/NN||7-120/CD	amod||documents-123/NNS||historical-122/JJ	prep_to||shipped-114/VBN||documents-123/NNS	conj_and||uganda-116/NN||documents-123/NNS	xcomp||shipped-114/VBN||describing-124/VBG	det||implementation-126/NN||the-125/DT	dobj||describing-124/VBG||implementation-126/NN	nn||programmes-130/NNS||hiv-128/NN	nn||programmes-130/NNS||prevention-129/NN	prep_of||implementation-126/NN||programmes-130/NNS	prep_in||describing-124/VBG||uganda-132/NN	aids-74||hiv-128||no||seven different types of evidence were examined (1) models of hiv prevalence and incidence in kampala and other sentinel sites in uganda; (2) reports of behaviour change in the primary newspaper in uganda; (3) surveys with questions about perceptions of personal behaviour change; (4) large demographic and health surveys (dhs) collected in 1988/9 and 1995 and large global program on aids (gpa) surveys in 1989 and 1995 with questions about reported sexual behaviour; (5) smaller less representative surveys of reported sexual behaviour collected in other years; (6) reports of numbers of condoms shipped to uganda; and (7) historical documents describing the implementation of hiv prevention programmes in uganda.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||decrease-7/VB||if-3/IN	amod||analogs-6/NNS||long-acting-4/JJ	nn||analogs-6/NNS||insulin-5/NN	nsubj||decrease-7/VB||analogs-6/NNS	advcl||investigate-2/VB||decrease-7/VB	det||risk-9/NN||the-8/DT	dobj||decrease-7/VB||risk-9/NN	prep_of||risk-9/NN||diabeticketoacidosis-11/NNS	appos||diabeticketoacidosis-11/NNS||dka-13/NN	amod||individuals-17/NNS||young-16/JJ	prep_in||diabeticketoacidosis-11/NNS||individuals-17/NNS	prep_with||individuals-17/NNS||type1diabetes-19/CD	insulin-5||type1diabetes-19||no_rel||to investigate if long-acting insulin analogs decrease the risk of diabeticketoacidosis (dka) in young individuals with type1diabetes.
amod||association-2/NN||significant-1/JJ	nsubjpass||found-6/VBN||association-2/NN	prep_with||association-2/NN||acuteinfection-4/NN	auxpass||found-6/VBN||was-5/VBD	root||ROOT-0/null||found-6/VBN	cop||male-9/JJ||being-8/VBG	prepc_for||found-6/VBN||male-9/JJ	prepc_for||found-6/VBN||drinking-11/VBG	conj_and||male-9/JJ||drinking-11/VBG	dobj||drinking-11/VBG||alcohol-12/NN	prepc_for||found-6/VBN||consuming-15/VBG	conj_and||male-9/JJ||consuming-15/VBG	amod||while-17/NN||shellfish-16/JJ	dobj||consuming-15/VBG||while-17/NN	prep_on||consuming-15/VBG||board-19/NN	dep||board-19/NN||odds-21/NNS	nn||4.27-23/NNS||ratio-22/NN	nsubj||p-35/VBP||4.27-23/NNS	number||%-26/NN||95-25/CD	amod||â-30/NNS||%-26/NN	nn||â-30/NNS||confidence-27/NN	amod||â-30/NNS||interval-28/JJ	num||â-30/NNS||1.23-29/CD	appos||4.27-23/NNS||â-30/NNS	num||â-30/NNS||$-31/$	num||$-31/$||26.94-33/CD	rcmod||odds-21/NNS||p-35/VBP	dep||0.019-37/CD||=-36/SYM	ccomp||p-35/VBP||0.019-37/CD	alcohol-12||acuteinfection-4||no_rel||significant association with acuteinfection was found for being male, drinking alcohol, and consuming shellfish while on board (odds ratio 4.27, 95% confidence interval 1.23â€“26.94, p = 0.019).
det||studies-4/NNS||the-1/DT	advmod||significant-3/JJ||most-2/RBS	amod||studies-4/NNS||significant-3/JJ	nsubjpass||reviewed-19/VBN||studies-4/NNS	vmod||studies-4/NNS||published-5/VBN	prep_to||published-5/VBN||date-7/NN	det||use-11/NN||the-10/DT	prep_on||studies-4/NNS||use-11/NN	amod||pamoate-14/NN||olanzapine-13/JJ	prep_of||use-11/NN||pamoate-14/NN	prep_in||pamoate-14/NN||schizophrenia-16/NN	auxpass||reviewed-19/VBN||are-18/VBP	root||ROOT-0/null||reviewed-19/VBN	det||article-22/NN||this-21/DT	prep_in||reviewed-19/VBN||article-22/NN	schizophrenia-16||olanzapine-13||yes||the most significant studies published to date, on the use of olanzapine pamoate in schizophrenia, are reviewed in this article.
det||tissues-2/NNS||the-1/DT	nsubj||had-10/VBD||tissues-2/NNS	prep_from||tissues-2/NNS||patients-4/NNS	vmod||patients-4/NNS||revised-5/VBN	amod||wear-9/NN||suspected-7/VBN	amod||wear-9/NN||high-8/JJ	prep_for||revised-5/VBN||wear-9/NN	root||ROOT-0/null||had-10/VBD	det||score-14/NN||a-11/DT	amod||score-14/NN||lower-12/JJR	nn||score-14/NN||alval-13/NN	dobj||had-10/VBD||score-14/NN	amod||lymphocytes-17/NNS||fewer-16/JJR	appos||score-14/NN||lymphocytes-17/NNS	amod||macrophages-21/NN||more-20/JJR	dobj||had-10/VBD||macrophages-21/NN	conj_but||score-14/NN||macrophages-21/NN	nn||particles-24/NNS||metal-23/NN	conj_but||score-14/NN||particles-24/NNS	conj_and||macrophages-21/NN||particles-24/NNS	det||tissues-27/NNS||those-26/DT	prep_than||macrophages-21/NN||tissues-27/NNS	prep_from||had-10/VBD||hips-29/NNS	vmod||hips-29/NNS||revised-30/VBN	prep_for||revised-30/VBN||pain-32/NN	amod||hypersensitivity-36/NN||suspected-34/VBN	nn||hypersensitivity-36/NN||metal-35/NN	prep_for||revised-30/VBN||hypersensitivity-36/NN	conj_and||pain-32/NN||hypersensitivity-36/NN	pain-32||metal-35||no_rel||the tissues from patients revised for suspected high wear had a lower alval score, fewer lymphocytes, but more macrophages and metal particles than those tissues from hips revised for pain and suspected metal hypersensitivity.
poss||results-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||considered-8/VBN||that-4/IN	nsubjpass||considered-8/VBN||lamivudine-5/NN	nsubj||prevent-19/VB||lamivudine-5/NN	aux||considered-8/VBN||should-6/MD	auxpass||considered-8/VBN||be-7/VB	ccomp||demonstrate-3/VBP||considered-8/VBN	advmod||considered-8/VBN||preemptively-9/RB	det||chemotherapy-12/NN||the-11/DT	prep_before||considered-8/VBN||chemotherapy-12/NN	det||patients-17/NNS||all-14/DT	amod||patients-17/NNS||hbsag-positive-15/JJ	nn||patients-17/NNS||nhl-16/NN	prep_for||chemotherapy-12/NN||patients-17/NNS	aux||prevent-19/VB||to-18/TO	xcomp||considered-8/VBN||prevent-19/VB	nn||reactivation-21/NN||hbv-20/NN	dobj||prevent-19/VB||reactivation-21/NN	prep_regardless_of||hbeag-26/VBG||pre-chemotherapy-25/NN	xcomp||considered-8/VBN||hbeag-26/VBG	dobj||hbeag-26/VBG||status-27/NN	hbv-20||lamivudine-5||yes||our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all hbsag-positive nhl patients to prevent hbv reactivation, regardless of pre-chemotherapy hbeag status.
nsubj||shows-8/VBZ||aripiprazole-1/NN	det||stabilizer-6/NN||a-3/DT	amod||stabilizer-6/NN||dopamine-4/JJ	nn||stabilizer-6/NN||system-5/NN	appos||aripiprazole-1/NN||stabilizer-6/NN	root||ROOT-0/null||shows-8/VBZ	advmod||shows-8/VBZ||efficacy-9/RB	det||symptoms-13/NNS||both-11/DT	amod||symptoms-13/NNS||negative-12/JJ	prep_against||shows-8/VBZ||symptoms-13/NNS	amod||symptoms-16/NNS||positive-15/JJ	prep_against||shows-8/VBZ||symptoms-16/NNS	conj_and||symptoms-13/NNS||symptoms-16/NNS	prep_in||shows-8/VBZ||patients-18/NNS	prep_with||patients-18/NNS||schizophrenia-20/NN	schizophrenia-20||aripiprazole-1||yes||aripiprazole, a dopamine system stabilizer, shows efficacy against both negative symptoms and positive symptoms in patients with schizophrenia.
aux||elucidate-2/VB||to-1/TO	advcl||investigated-25/VBD||elucidate-2/VB	nn||mechanisms-4/NNS||novel-3/NN	dobj||elucidate-2/VB||mechanisms-4/NNS	vmod||mechanisms-4/NNS||contributing-5/VBG	det||complex-10/NN||the-7/DT	amod||complex-10/NN||htlv-1-8/JJ	amod||complex-10/NN||neurological-9/JJ	prep_to||contributing-5/VBG||complex-10/NN	poss||presentation-15/NN||its-12/PRP$	amod||presentation-15/NN||classic-13/JJ	amod||presentation-15/NN||neurological-14/JJ	prep_to||contributing-5/VBG||presentation-15/NN	conj_and||complex-10/NN||presentation-15/NN	vmod||presentation-15/NN||called-16/VBN	dobj||called-16/VBN||ham/tsp-17/NN	amod||myelopathy/tropicalspasticparaparesis-21/NNS||htlv-1-19/JJ	amod||myelopathy/tropicalspasticparaparesis-21/NNS||associated-20/JJ	appos||ham/tsp-17/NN||myelopathy/tropicalspasticparaparesis-21/NNS	nsubj||investigated-25/VBD||we-24/PRP	root||ROOT-0/null||investigated-25/VBD	det||expression-27/NN||the-26/DT	dobj||investigated-25/VBD||expression-27/NN	det||receptor-31/NN||the-29/DT	amod||receptor-31/NN||tim-3-30/JJ	prep_of||expression-27/NN||receptor-31/NN	amod||cells-36/NNS||cd8-33/JJ	amod||cells-36/NNS||+-34/JJ	nn||cells-36/NNS||t-35/NN	prep_on||receptor-31/NN||cells-36/NNS	det||cohort-39/NN||a-38/DT	prep_from||investigated-25/VBD||cohort-39/NN	amod||patients-46/NNS||htlv-1-41/JJ	amod||patients-46/NNS||seropositive-42/JJ	amod||patients-46/NNS||asymptomatic-43/JJ	conj_and||asymptomatic-43/JJ||symptomatic-45/JJ	amod||patients-46/NNS||symptomatic-45/JJ	prep_of||cohort-39/NN||patients-46/NNS	ham--1||htlv-1-41||no||to elucidate novel mechanisms contributing to the htlv-1 neurological complex and its classic neurological presentation called ham/tsp (htlv-1 associated myelopathy/tropicalspasticparaparesis), we investigated the expression of the tim-3 receptor on cd8+ t cells from a cohort of htlv-1 seropositive asymptomatic and symptomatic patients.
det||case-2/NN||the-1/DT	nsubjpass||presented-26/VBN||case-2/NN	det||suffering-7/NN||an-4/DT	amod||suffering-7/NN||18-year-old-5/JJ	amod||suffering-7/NN||female-6/JJ	prep_of||case-2/NN||suffering-7/NN	prep_from||suffering-7/NN||bipolaraffectivedisorder-9/NN	nsubjpass||treated-16/VBN||bipolaraffectivedisorder-9/NN	appos||bipolaraffectivedisorder-9/NN||mania-11/NN	aux||treated-16/VBN||was-14/VBD	auxpass||treated-16/VBN||being-15/VBG	rcmod||bipolaraffectivedisorder-9/NN||treated-16/VBN	prep_with||treated-16/VBN||carbamazepine-18/NN	prep_with||treated-16/VBN||lithium-20/NN	conj_and||carbamazepine-18/NN||lithium-20/NN	prep_with||treated-16/VBN||chlorpromazine-22/NN	conj_and||carbamazepine-18/NN||chlorpromazine-22/NN	prep_with||treated-16/VBN||benzhexol-24/NN	conj_and||carbamazepine-18/NN||benzhexol-24/NN	auxpass||presented-26/VBN||is-25/VBZ	root||ROOT-0/null||presented-26/VBN	bipolaraffectivedisorder-9||carbamazepine-18||yes||the case of an 18-year-old female suffering from bipolaraffectivedisorder (mania) who was being treated with carbamazepine, lithium, chlorpromazine and benzhexol is presented.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||based-10/VBN||that-3/IN	det||plasticity-7/NN||the-4/DT	amod||plasticity-7/NN||experience-dependent-5/JJ	amod||plasticity-7/NN||behavioral-6/JJ	nsubjpass||based-10/VBN||plasticity-7/NN	auxpass||based-10/VBN||was-8/VBD	advmod||based-10/VBN||partly-9/RB	ccomp||conclude-2/VBP||based-10/VBN	det||sensitivity-14/NN||the-12/DT	amod||sensitivity-14/NN||reduced-13/VBN	prep_on||based-10/VBN||sensitivity-14/NN	nn||neurons-18/NNS||taste-16/NN	nn||neurons-18/NNS||receptor-17/NN	prep_of||sensitivity-14/NN||neurons-18/NNS	mark||contributed-27/VBD||that-20/IN	det||desensitization-22/NN||the-21/DT	nsubj||contributed-27/VBD||desensitization-22/NN	nn||neurons-26/NNS||taste-24/NN	nn||neurons-26/NNS||receptor-25/NN	prep_of||desensitization-22/NN||neurons-26/NNS	ccomp||conclude-2/VBP||contributed-27/VBD	conj_and||based-10/VBN||contributed-27/VBD	det||cross-habituation-30/NN||the-29/DT	prep_to||contributed-27/VBD||cross-habituation-30/NN	det||chemicals-34/NNS||the-32/DT	num||chemicals-34/NNS||two-33/CD	prep_to||contributed-27/VBD||chemicals-34/NNS	cross--1||chemicals-34||no_rel||we conclude that the experience-dependent behavioral plasticity was partly based on the reduced sensitivity of taste receptor neurons and that the desensitization of taste receptor neurons contributed to the cross-habituation to the two chemicals.
nsubj||aim-2/VBP||we-1/PRP	nsubj||study-4/VB||we-1/PRP	root||ROOT-0/null||aim-2/VBP	aux||study-4/VB||to-3/TO	xcomp||aim-2/VBP||study-4/VB	det||modulation-6/NN||the-5/DT	dobj||study-4/VB||modulation-6/NN	det||promoter-9/NN||this-8/DT	prep_of||modulation-6/NN||promoter-9/NN	prep_by||study-4/VB||cisplatin-11/NN	xcomp||study-4/VB||using-12/VBG	det||reporter-16/NN||an-13/DT	amod||reporter-16/NN||improved-14/VBN	nn||reporter-16/NN||fusion-15/NN	dobj||using-12/VBG||reporter-16/NN	amod||cells-20/NNS||ovarian-18/JJ	nn||cells-20/NNS||cancer-19/NN	prep_in||using-12/VBG||cells-20/NNS	nn||xenografts-23/NNS||tumor-22/NN	prep_in||using-12/VBG||xenografts-23/NNS	conj_and||cells-20/NNS||xenografts-23/NNS	amod||approach-27/NN||non-invasive-25/JJ	nn||approach-27/NN||imaging-26/NN	prep_by||using-12/VBG||approach-27/NN	cancer-19||cisplatin-11||no_rel||we aim to study the modulation of this promoter by cisplatin using an improved fusion reporter in ovarian cancer cells and tumor xenografts by non-invasive imaging approach.
nn||volume-2/NN||infarct-1/NN	nsubj||greater-4/JJR||volume-2/NN	cop||greater-4/JJR||was-3/VBD	root||ROOT-0/null||greater-4/JJR	nn||±-7/NNP||tnfî-6/NNP	prep_in||greater-4/JJR||±-7/NNP	nn||rats-10/NNS||tg-9/NN	dep||±-7/NNP||rats-10/NNS	dep||greater-4/JJR||than-11/IN	amod||controls-14/NNS||non-tg-13/JJ	prep_in||greater-4/JJR||controls-14/NNS	num||hours-17/NNS||24-16/CD	prep_at||controls-14/NNS||hours-17/NNS	nn||‰-21/NNS||p-19/NN	nn||‰-21/NNS||â-20/NN	dep||hours-17/NNS||‰-21/NNS	dep||‰-21/NNS||$-22/$	num||$-22/$||0.05-23/CD	num||days-27/NNS||7-26/CD	prep_at||controls-14/NNS||days-27/NNS	conj_and||hours-17/NNS||days-27/NNS	nn||‰-31/NNS||p-29/NN	nn||‰-31/NNS||â-30/NN	dep||days-27/NNS||‰-31/NNS	dep||‰-31/NNS||$-32/$	num||$-32/$||0.01-33/CD	tg-9||infarct-1||no_rel||infarct volume was greater in tnfî±-tg rats than in non-tg controls at 24 hours (p â‰¤ 0.05) and 7 days (p â‰¤ 0.01).
amod||studies-2/NNS||mechanistic-1/JJ	nsubj||showed-3/VBD||studies-2/NNS	dep||mediated-17/VBD||showed-3/VBD	mark||formed-6/VBD||that-4/IN	nsubj||formed-6/VBD||conjugates-5/NNS	ccomp||showed-3/VBD||formed-6/VBD	det||porphyrin-13/NN||the-8/DT	amod||porphyrin-13/NN||mono-9/JJ	conj_and||mono-9/JJ||tri-cationic-12/JJ	amod||porphyrin-13/NN||tri-cationic-12/JJ	prep_from||formed-6/VBD||porphyrin-13/NN	amod||antibody-16/NN||anti-cd104-15/JJ	prep_from||formed-6/VBD||antibody-16/NN	conj_and||porphyrin-13/NN||antibody-16/NN	root||ROOT-0/null||mediated-17/VBD	nn||irradiation-20/NN||apoptosis-18/NNS	amod||irradiation-20/NN||following-19/VBG	dobj||mediated-17/VBD||irradiation-20/NN	amod||light-24/NN||non-thermal-22/JJ	amod||light-24/NN||red-23/JJ	prep_with||mediated-17/VBD||light-24/NN	number||â-27/CD||630-26/CD	num||±-28/NNS||â-27/CD	prep_of||light-24/NN||±-28/NNS	num||wavelength-31/NN||15-29/CD	nn||wavelength-31/NN||nm-30/NN	nsubj||mediated-17/VBD||wavelength-31/NN	mono-9||nm-30||no_rel||mechanistic studies showed that conjugates formed from the mono- and tri-cationic porphyrin and anti-cd104 antibody mediated apoptosis following irradiation with non-thermal red light of 630 â± 15 nm wavelength.
nsubjpass||analyzed-30/VBN||frequency-1/NN	conj_and||frequency-1/NN||intensity-3/NN	nsubjpass||analyzed-30/VBN||intensity-3/NN	amod||production-7/NN||intrathecal-5/JJ	nn||production-7/NN||antibody-6/NN	prep_of||frequency-1/NN||production-7/NN	prep_against||production-7/NN||ebv-9/NN	advmod||ebv-9/NN||as-10/RB	prepc_compared_to||ebv-9/NN||to-12/TO	nn||zoster-18/NN||measles-13/NN	dep||zoster-18/NN||rubella-15/NN	amod||zoster-18/NN||varicella-17/JJ	pobj||ebv-9/NN||zoster-18/NN	appos||zoster-18/NN||vzv-20/NN	amod||virus-25/NN||herpes-23/JJ	nn||virus-25/NN||simplex-24/NN	pobj||ebv-9/NN||virus-25/NN	conj_and||zoster-18/NN||virus-25/NN	appos||zoster-18/NN||hsv-27/NN	auxpass||analyzed-30/VBN||were-29/VBD	root||ROOT-0/null||analyzed-30/VBN	agent||analyzed-30/VBN||determination-32/NN	amod||indices-37/NNS||virus-specific-34/JJ	amod||indices-37/NNS||csf-to-serum-35/JJ	nn||indices-37/NNS||antibody-36/NN	prep_of||determination-32/NN||indices-37/NNS	appos||indices-37/NNS||ai-39/NNP	varicella-17||vzv-20||no||frequency and intensity of intrathecal antibody production against ebv as compared to measles, rubella, varicella zoster (vzv) and herpes simplex virus (hsv) were analyzed by determination of virus-specific csf-to-serum antibody indices (ai).
mark||therapy-8/NN||although-1/IN	nsubj||therapy-8/NN||fludarabine-2/NN	cop||therapy-8/NN||is-3/VBZ	det||therapy-8/NN||the-4/DT	amod||therapy-8/NN||standard-5/JJ	amod||therapy-8/NN||first-6/JJ	nn||therapy-8/NN||line-7/NN	advcl||available-17/JJ||therapy-8/NN	aux||treat-10/VB||to-9/TO	vmod||therapy-8/NN||treat-10/VB	dobj||treat-10/VB||cll-11/NN	advmod||data-15/NNS||only-13/RB	amod||data-15/NNS||few-14/JJ	nsubj||available-17/JJ||data-15/NNS	cop||available-17/JJ||are-16/VBP	root||ROOT-0/null||available-17/JJ	det||resistance-20/NN||the-19/DT	prep_about||available-17/JJ||resistance-20/NN	amod||cells-23/NNS||b-22/JJ	prep_of||resistance-20/NN||cells-23/NNS	det||analog-28/NN||this-25/DT	amod||analog-28/NN||purine-26/JJ	nn||analog-28/NN||nucleoside-27/NN	prep_to||available-17/JJ||analog-28/NN	prep_in||analog-28/NN||vivo-30/NN	cll-11||fludarabine-2||yes||although fludarabine is the standard first line therapy to treat cll, only few data are available about the resistance of b cells to this purine nucleoside analog in vivo .
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	quantmod||6-4/CD||only-3/RB	num||prescriptions-5/NNS||6-4/CD	dobj||found-2/VBD||prescriptions-5/NNS	vmod||prescriptions-5/NNS||having-6/VBG	det||treatment-9/NN||the-7/DT	amod||treatment-9/NN||recommended-8/VBN	dobj||having-6/VBG||treatment-9/NN	nsubjpass||ors-12/VBN||treatment-9/NN	auxpass||ors-12/VBN||is-11/VBZ	rcmod||treatment-9/NN||ors-12/VBN	prep_along_with||ors-12/VBN||zinc-15/NN	neg||probiotics-20/NNS||no-18/DT	amod||probiotics-20/NNS||additional-19/JJ	prep_with||ors-12/VBN||probiotics-20/NNS	prep_with||ors-12/VBN||antibiotics-22/NN	conj_or||probiotics-20/NNS||antibiotics-22/NN	prep_with||ors-12/VBN||racecadotril-24/NN	conj_or||probiotics-20/NNS||racecadotril-24/NN	prep_with||ors-12/VBN||antiemetics-26/NNS	conj_or||probiotics-20/NNS||antiemetics-26/NNS	prep_except||prescriptions-5/NNS||domperidone-29/NN	prep_for||domperidone-29/NN||vomiting-31/NN	zinc-15||vomiting-31||no_rel||we found only 6 prescriptions having the recommended treatment that is ors along with zinc, with no additional probiotics, antibiotics, racecadotril or antiemetics (except domperidone for vomiting).
num||transplantation-5/NN||one-2/CD	nn||transplantation-5/NN||year-3/NN	nn||transplantation-5/NN||following-4/NN	prep_at||normal-9/JJ||transplantation-5/NN	advmod||normal-9/JJ||alt-7/RB	cop||normal-9/JJ||was-8/VBD	root||ROOT-0/null||normal-9/JJ	prep_in||normal-9/JJ||27-11/CD	num||%-14/NN||77-13/CD	appos||27-11/CD||%-14/NN	nsubj||normal-9/JJ||cases-16/NNS	amod||undetectable-19/NN||hbv-dna-18/JJ	appos||cases-16/NNS||undetectable-19/NN	prep_in||undetectable-19/NN||16-21/CD	num||%-24/NN||45.7-23/CD	appos||16-21/CD||%-24/NN	vmod||normal-9/JJ||hbeag-27/VBG	vmod||normal-9/JJ||hbsag-29/VBG	conj_and||hbeag-27/VBG||hbsag-29/VBG	dobj||hbeag-27/VBG||seroconversion-30/NN	prep_in||seroconversion-30/NN||8-32/CD	num||%-35/NN||22.8-34/CD	appos||8-32/CD||%-35/NN	prep_in||seroconversion-30/NN||3-39/CD	conj_and||8-32/CD||3-39/CD	num||%-42/NN||8.6-41/CD	appos||3-39/CD||%-42/NN	dep||3-39/CD||cases-44/NNS	prep_in||seroconversion-30/NN||respectively-46/RB	advmod||8-32/CD||respectively-46/RB	conj_and||8-32/CD||respectively-46/RB	hbv--1||hbsag-29||yes||at one year following transplantation, alt was normal in 27 (77%) cases, hbv-dna undetectable in 16 (45.7%), hbeag and hbsag seroconversion in 8 (22.8%), and 3 (8.6%) cases, respectively.
nsubj||agent-5/NN||mycobacteriumulcerans-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	ccomp||found-16/VBD||agent-5/NN	prep_of||agent-5/NN||buruliulcer-7/NN	appos||buruliulcer-7/NN||bu-9/NN	det||disease-15/NN||a-12/DT	amod||disease-15/NN||destructive-13/JJ	nn||disease-15/NN||skin-14/NN	nsubj||found-16/VBD||disease-15/NN	root||ROOT-0/null||found-16/VBD	advmod||found-16/VBD||predominantly-17/RB	amod||africa-20/NN||sub-saharan-19/JJ	prep_in||found-16/VBD||africa-20/NN	amod||australia-23/NN||south-eastern-22/JJ	prep_in||found-16/VBD||australia-23/NN	conj_and||africa-20/NN||australia-23/NN	buruliulcer-7||mycobacteriumulcerans-1||no||mycobacteriumulcerans is the causative agent of buruliulcer (bu), a destructive skin disease found predominantly in sub-saharan africa and south-eastern australia.
nn||phenidate-2/NN||methyl-1/NN	nsubj||drugs-10/NNS||phenidate-2/NN	amod||phenidate-2/NN||megestrol-4/JJ	amod||phenidate-2/NN||modafinil-7/JJ	conj_and||megestrol-4/JJ||modafinil-7/JJ	cop||drugs-10/NNS||are-8/VBP	det||drugs-10/NNS||some-9/DT	root||ROOT-0/null||drugs-10/NNS	amod||effect-13/NN||promising-12/JJ	prep_with||drugs-10/NNS||effect-13/NN	aux||treat-15/VB||to-14/TO	vmod||drugs-10/NNS||treat-15/VB	acomp||treat-15/VB||fatigue-16/JJ	mark||are-21/VBP||though-18/IN	amod||studies-20/NNS||confirmatory-19/JJ	nsubj||are-21/VBP||studies-20/NNS	nsubjpass||established-25/VBN||studies-20/NNS	advcl||treat-15/VB||are-21/VBP	advmod||are-21/VBP||yet-22/RB	aux||established-25/VBN||to-23/TO	auxpass||established-25/VBN||be-24/VB	xcomp||are-21/VBP||established-25/VBN	fatigue-16||modafinil-7||yes||methyl phenidate, megestrol, and modafinil are some drugs with promising effect to treat fatigue, though confirmatory studies are yet to be established.
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||problem-18/NN||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	appos||tuberculosis-2/NNS||resistance-7/NN	aux||isoniazid-11/VB||to-8/TO	advmod||isoniazid-11/VB||at-9/IN	pobj||at-9/IN||least-10/JJS	vmod||resistance-7/NN||isoniazid-11/VB	vmod||resistance-7/NN||rifampin-13/VB	conj_and||isoniazid-11/VB||rifampin-13/VB	cop||problem-18/NN||is-15/VBZ	det||problem-18/NN||a-16/DT	amod||problem-18/NN||worldwide-17/JJ	root||ROOT-0/null||problem-18/NN	tb--1||rifampin-13||yes||multidrug-resistant tuberculosis (mdr-tb), resistance to at least isoniazid and rifampin, is a worldwide problem.
csubj||humanimmunodeficiencyvirus-8/VBZ||aged-1/VBN	csubj||remained-39/VBD||aged-1/VBN	dep||old-6/JJ||>-3/RB	num||years-5/NNS||50â-4/CD	npadvmod||old-6/JJ||years-5/NNS	dep||humanimmunodeficiencyvirus-8/VBZ||old-6/JJ	root||ROOT-0/null||humanimmunodeficiencyvirus-8/VBZ	dobj||humanimmunodeficiencyvirus-8/VBZ||hiv-10/NN	nsubj||segment-16/NN||patients-12/NNS	cop||segment-16/NN||are-13/VBP	det||segment-16/NN||the-14/DT	amod||segment-16/NN||fastest-growing-15/JJ	rcmod||hiv-10/NN||segment-16/NN	det||population-20/NN||the-18/DT	amod||population-20/NN||hiv-infected-19/JJ	prep_of||segment-16/NN||population-20/NN	det||usa-23/NN||the-22/DT	prep_in||population-20/NN||usa-23/NN	amod||therapy-27/NN||antiretroviral-26/JJ	prep_despite||increased-37/VBN||therapy-27/NN	amod||disorder-31/NN||hiv-associated-29/JJ	nn||disorder-31/NN||neurocognitive-30/NN	nsubj||increased-37/VBN||disorder-31/NN	appos||disorder-31/NN||hand-33/NN	advmod||increased-37/VBN||prevalence-35/RB	aux||increased-37/VBN||has-36/VBZ	rcmod||hiv-10/NN||increased-37/VBN	conj_and||segment-16/NN||increased-37/VBN	conj_or||humanimmunodeficiencyvirus-8/VBZ||remained-39/VBD	det||same-41/JJ||the-40/DT	xcomp||remained-39/VBD||same-41/JJ	det||group-44/NN||this-43/DT	prep_among||remained-39/VBD||group-44/NN	hiv)--1||humanimmunodeficiencyvirus-8||no||aged (>50â years old) humanimmunodeficiencyvirus (hiv) patients are the fastest-growing segment of the hiv-infected population in the usa and despite antiretroviral therapy, hiv-associated neurocognitive disorder (hand) prevalence has increased or remained the same among this group.
det||questionnaire-2/NN||the-1/DT	nsubj||consisted-3/VBD||questionnaire-2/NN	nsubj||questions-21/VBZ||questionnaire-2/NN	nsubj||assess-23/VB||questionnaire-2/NN	root||ROOT-0/null||consisted-3/VBD	num||questions-6/NNS||24-5/CD	prep_of||consisted-3/VBD||questions-6/NNS	prep_regarding||questions-6/NNS||awareness-8/NN	det||modes-11/NNS||the-10/DT	prep_of||awareness-8/NN||modes-11/NNS	prep_of||modes-11/NNS||transmission-13/NN	prep_of||transmission-13/NN||hiv/aids-15/NNS	num||questions-18/NNS||nine-17/CD	appos||hiv/aids-15/NNS||questions-18/NNS	conj_and||consisted-3/VBD||questions-21/VBZ	aux||assess-23/VB||to-22/TO	xcomp||questions-21/VBZ||assess-23/VB	det||attitude-25/NN||the-24/DT	dobj||assess-23/VB||attitude-25/NN	prep_toward||assess-23/VB||people-27/NNS	vmod||people-27/NNS||living-28/VBG	prep_with||living-28/VBG||hiv/aids-30/NNS	appos||hiv/aids-30/NNS||plwha-32/NNP	num||questions-36/NNS||15-35/CD	appos||hiv/aids-30/NNS||questions-36/NNS	aids--1||hiv--1||no||the questionnaire consisted of 24 questions regarding awareness of the modes of transmission of hiv/aids (nine questions) and questions to assess the attitude toward people living with hiv/aids (plwha) (15 questions).
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
poss||understanding-2/NN||our-1/PRP$	nsubjpass||revolutionized-10/VBN||understanding-2/NN	det||treatment-5/NN||the-4/DT	prep_of||understanding-2/NN||treatment-5/NN	nn||cancer-8/NN||ovarian-7/NN	prep_of||treatment-5/NN||cancer-8/NN	auxpass||revolutionized-10/VBN||was-9/VBD	root||ROOT-0/null||revolutionized-10/VBN	det||discovery-13/NN||the-12/DT	prep_with||revolutionized-10/VBN||discovery-13/NN	amod||regimens-21/NNS||platinum-15/JJ	conj_and||platinum-15/JJ||taxane-based-18/JJ	amod||regimens-21/NNS||taxane-based-18/JJ	amod||regimens-21/NNS||adjuvant-19/JJ	nn||regimens-21/NNS||chemotherapy-20/NN	prep_of||discovery-13/NN||regimens-21/NNS	cancer-8||platinum-15||no_rel||our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant chemotherapy regimens.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||tested-7/VBD||study-4/NN	nsubj||tested-7/VBD||we-6/PRP	root||ROOT-0/null||tested-7/VBD	det||uniformity-9/NN||the-8/DT	dobj||tested-7/VBD||uniformity-9/NN	amod||effect-12/NN||vitamine-11/JJ	prep_of||uniformity-9/NN||effect-12/NN	det||risk-15/NN||the-14/DT	prep_on||effect-12/NN||risk-15/NN	amod||pneumonia-18/NN||hospital-treated-17/JJ	prep_of||risk-15/NN||pneumonia-18/NN	num||cases-21/NNS||898-20/CD	appos||pneumonia-18/NN||cases-21/NNS	prepc_by||tested-7/VBD||adding-24/VBG	det||variable-27/NN||a-25/DT	amod||variable-27/NN||dummy-26/JJ	dobj||adding-24/VBG||variable-27/NN	aux||allow-29/VB||to-28/TO	vmod||adding-24/VBG||allow-29/VB	det||subgroup-31/NN||each-30/DT	iobj||allow-29/VB||subgroup-31/NN	poss||effect-35/NN||its-32/PRP$	amod||effect-35/NN||own-33/JJ	amod||effect-35/NN||vitamine-34/JJ	dobj||allow-29/VB||effect-35/NN	det||model-39/NN||a-37/DT	nn||model-39/NN||cox-38/NN	prep_in||effect-35/NN||model-39/NN	vmod||model-39/NN||covering-40/VBG	det||participants-42/NNS||all-41/DT	dobj||covering-40/VBG||participants-42/NNS	pneumonia-18||vitamine-34||no_rel||in the present study, we tested the uniformity of vitamine effect on the risk of hospital-treated pneumonia (898 cases) by adding a dummy variable to allow each subgroup its own vitamine effect in a cox model covering all participants.
nsubjpass||recognized-4/VBN||non-vibriocholera-1/NN	aux||recognized-4/VBN||has-2/VBZ	auxpass||recognized-4/VBN||been-3/VBN	root||ROOT-0/null||recognized-4/VBN	mark||known-15/VBN||as-5/IN	det||entity-8/NN||a-6/DT	amod||entity-8/NN||clinical-7/JJ	nsubjpass||known-15/VBN||entity-8/NN	nsubjpass||caused-18/VBN||entity-8/NN	advmod||as-12/IN||as-10/RB	advmod||as-12/IN||long-11/JJ	quantmod||cholera-13/CD||as-12/IN	prep_for||entity-8/NN||cholera-13/CD	auxpass||known-15/VBN||was-14/VBD	advcl||recognized-4/VBN||known-15/VBN	aux||caused-18/VBN||to-16/TO	auxpass||caused-18/VBN||be-17/VB	xcomp||known-15/VBN||caused-18/VBN	agent||caused-18/VBN||vibriocholerae-20/NN	vibriocholerae-20||vibriocholera--1||no||non-vibriocholera has been recognized as a clinical entity for as long as cholera was known to be caused by vibriocholerae .
det||period-3/NN||the-1/DT	amod||period-3/NN||latency-2/JJ	nsubjpass||diagnosed-23/VBN||period-3/NN	det||time-6/NN||the-5/DT	dep||period-3/NN||time-6/NN	amod||exposure-9/NN||initial-8/JJ	prep_between||time-6/NN||exposure-9/NN	nn||imaging-12/NN||radiological-11/NN	prep_between||time-6/NN||imaging-12/NN	conj_and||exposure-9/NN||imaging-12/NN	conj_and||period-3/NN||duration-15/NN	nsubjpass||diagnosed-23/VBN||duration-15/NN	nn||exposure-18/NN||silica-17/NN	prep_of||duration-15/NN||exposure-18/NN	auxpass||diagnosed-23/VBN||was-19/VBD	advmod||diagnosed-23/VBN||longer-20/RB	prep_in||longer-20/RB||patients-22/NNS	root||ROOT-0/null||diagnosed-23/VBN	prep_with||diagnosed-23/VBN||silicosis-25/NNS	dep||diagnosed-23/VBN||than-26/IN	prep_in||diagnosed-23/VBN||those-28/DT	prep_without||those-28/DT||silicosis-30/NNS	dep||silicosis-30/NNS||p-32/VBN	num||0.05-34/CD||<-33/CD	dobj||p-32/VBN||0.05-34/CD	silicosis-30||silica-17||no||the latency period (the time between initial exposure and radiological imaging) and duration of silica exposure was longer in patients diagnosed with silicosis than in those without silicosis (p < 0.05).
nsubj||improved-16/VBN||rituximab-1/NN	nsubj||weakened-28/VBN||rituximab-1/NN	prep||rituximab-1/NN||plus-2/CC	nn||vincristine-7/NN||cyclophosphamide-3/NN	dep||vincristine-7/NN||doxorubicin-5/NN	pobj||plus-2/CC||vincristine-7/NN	nn||chemotherapy-11/NN||prednisone-10/NN	pobj||plus-2/CC||chemotherapy-11/NN	conj_and||vincristine-7/NN||chemotherapy-11/NN	appos||rituximab-1/NN||r-chop-13/NN	aux||improved-16/VBN||has-15/VBZ	root||ROOT-0/null||improved-16/VBN	dobj||improved-16/VBN||survival-17/NN	prep_in||improved-16/VBN||patients-19/NNS	amod||b-celllymphoma-23/NN||diffuse-21/JJ	amod||b-celllymphoma-23/NN||large-22/JJ	prep_with||patients-19/NNS||b-celllymphoma-23/NN	dep||improved-16/VBN||dlbcl-25/JJ	conj_and||improved-16/VBN||weakened-28/VBN	det||power-31/NN||the-29/DT	amod||power-31/NN||prognostic-30/JJ	dobj||weakened-28/VBN||power-31/NN	det||index-36/NN||the-33/DT	amod||index-36/NN||international-34/JJ	amod||index-36/NN||prognostic-35/JJ	prep_of||power-31/NN||index-36/NN	appos||index-36/NN||ipi-38/NN	b-celllymphoma-23||rituximab-1||yes||rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (r-chop) has improved survival in patients with diffuse large b-celllymphoma (dlbcl) and weakened the prognostic power of the international prognostic index (ipi).
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||trial-6/NN||a-3/DT	amod||trial-6/NN||16-week-4/JJ	nn||trial-6/NN||intervention-5/NN	dobj||performed-2/VBD||trial-6/NN	det||diet-12/NN||a-8/DT	amod||diet-12/NN||hypocaloric-9/JJ	amod||diet-12/NN||low-fat-11/JJ	prep_of||trial-6/NN||diet-12/NN	dobj||performed-2/VBD||10-14/CD	conj_plus||trial-6/NN||10-14/CD	advmod||ezetimibe-16/JJ||mg/day-15/RB	amod||10-14/CD||ezetimibe-16/JJ	dep||10-14/CD||n-18/VBN	dep||15-20/CD||=-19/SYM	ccomp||n-18/VBN||15-20/CD	det||diet-27/NN||a-23/DT	amod||diet-27/NN||hypocaloric-24/JJ	amod||diet-27/NN||low-fat-26/JJ	conj_plus||trial-6/NN||diet-27/NN	conj_versus||10-14/CD||diet-27/NN	amod||diet-27/NN||alone-28/RB	dep||trial-6/NN||n-30/VBN	dep||10-32/CD||=-31/SYM	ccomp||n-30/VBN||10-32/CD	amod||triglyceride-36/NN||intrahepatic-35/JJ	prep_on||performed-2/VBD||triglyceride-36/NN	appos||triglyceride-36/NN||ihtg-38/NN	amod||triglyceride-36/NN||content-40/JJ	vmod||triglyceride-36/NN||plasma-42/VBN	amod||subjects-67/NNS||high-43/JJ	dep||$-45/$||sensitivityâ-44/RB	dep||subjects-67/NNS||$-45/$	npadvmod||in-65/RB||c-reactive-47/NN	advmod||c-reactive-47/NN||protein-48/RB	pobj||protein-48/RB||hs-crp-50/NN	appos||hs-crp-50/NN||adipocytokines-53/NNS	amod||concentrations-57/NNS||fetuin-a-56/JJ	pobj||protein-48/RB||concentrations-57/NNS	conj_and||hs-crp-50/NN||concentrations-57/NNS	conj_and||hs-crp-50/NN||apolipoprotein-59/NNS	conj_and||concentrations-57/NNS||apolipoprotein-59/NNS	appos||concentrations-57/NNS||apo-61/NN	amod||kinetics-64/NNS||b-100-63/JJ	dep||concentrations-57/NNS||kinetics-64/NNS	dep||obese-66/CD||in-65/RB	num||$-45/$||obese-66/CD	dobj||plasma-42/VBN||subjects-67/NNS	ezetimibe-16||obese-66||no_rel||we performed a 16-week intervention trial of a hypocaloric, low-fat diet plus 10 mg/day ezetimibe ( n = 15) versus a hypocaloric, low-fat diet alone ( n = 10) on intrahepatic triglyceride (ihtg) content, plasma high sensitivityâ€“c-reactive protein (hs-crp), adipocytokines, and fetuin-a concentrations and apolipoprotein (apo)b-100 kinetics in obese subjects.
det||combination-2/NN||the-1/DT	nsubj||effective-8/JJ||combination-2/NN	prep_of||combination-2/NN||remifentanil-4/NN	prep_of||combination-2/NN||lidocaine-6/NN	conj_and||remifentanil-4/NN||lidocaine-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	prepc_in||effective-8/JJ||alleviating-10/VBG	dobj||alleviating-10/VBG||pain-11/NN	vmod||pain-11/NN||associated-12/VBN	det||injection-17/NN||a-14/DT	amod||injection-17/NN||microemulsion-15/JJ	amod||injection-17/NN||propofol-16/JJ	prep_with||associated-12/VBN||injection-17/NN	prepc_compared_with||associated-12/VBN||with-19/IN	advmod||lidocaine-21/NN||just-20/RB	pobj||associated-12/VBN||lidocaine-21/NN	pain-11||lidocaine-21||yes||the combination of remifentanil and lidocaine is effective in alleviating pain associated with a microemulsion propofol injection compared with just lidocaine.
advmod||-lrb--8/VBZ||when-1/WRB	csubj||-lrb--8/VBZ||tested-2/VBN	num||specimens-7/NNS||30-4/CD	amod||specimens-7/NNS||spiked-5/JJ	nn||specimens-7/NNS||blood-6/NN	prep_on||tested-2/VBN||specimens-7/NNS	advcl||comparable-29/JJ||-lrb--8/VBZ	num||mrsa-10/NN||21-9/CD	dobj||-lrb--8/VBZ||mrsa-10/NN	num||non-13/NN||eight-12/CD	appos||mrsa-10/NN||non-13/NN	dep||mrsa-10/NN||s.aureus-15/NNS	num||-rrb--20/NNS||one-17/CD	amod||-rrb--20/NNS||negative-18/JJ	nn||-rrb--20/NNS||control-19/NN	dep||mrsa-10/NN||-rrb--20/NNS	conj_and||s.aureus-15/NNS||-rrb--20/NNS	det||performance-23/NN||the-22/DT	nsubj||comparable-29/JJ||performance-23/NN	nsubj||sensitive-36/JJ||performance-23/NN	nsubj||ppv-40/JJ||performance-23/NN	nsubj||npv-45/JJ||performance-23/NN	prep_of||performance-23/NN||lamp-25/NN	prep_of||performance-23/NN||pcr-27/NN	conj_and||lamp-25/NN||pcr-27/NN	cop||comparable-29/JJ||was-28/VBD	root||ROOT-0/null||comparable-29/JJ	num||%-31/NN||100-30/CD	npadvmod||specific-32/JJ||%-31/NN	dep||comparable-29/JJ||specific-32/JJ	num||%-35/NN||100-34/CD	npadvmod||sensitive-36/JJ||%-35/NN	conj_and||comparable-29/JJ||sensitive-36/JJ	num||%-39/NN||100-38/CD	npadvmod||ppv-40/JJ||%-39/NN	conj_and||comparable-29/JJ||ppv-40/JJ	num||%-44/NN||100-43/CD	npadvmod||npv-45/JJ||%-44/NN	conj_and||comparable-29/JJ||npv-45/JJ	mrsa-10||s.aureus-15||no||when tested on 30 spiked blood specimens -lrb- 21 mrsa , eight non - s.aureus and one negative control -rrb- , the performance of lamp and pcr was comparable 100 % specific , 100 % sensitive , 100 % ppv , and 100 % npv .
poss||results-2/NNS||our-1/PRP$	nsubj||show-3/VBP||results-2/NNS	nsubj||complement-33/VB||results-2/NNS	root||ROOT-0/null||show-3/VBP	mark||stably-20/VB||that-4/IN	det||tip-6/NN||a-5/DT	nsubj||stably-20/VB||tip-6/NN	vmod||tip-6/NN||engineered-8/VBN	prep_with||engineered-8/VBN||properties-10/NNS	vmod||properties-10/NNS||based-11/VBN	det||trial-17/NN||a-13/DT	amod||trial-17/NN||recent-14/JJ	nn||trial-17/NN||hiv-15/NN	nn||trial-17/NN||gene-therapy-16/NN	prep_on||based-11/VBN||trial-17/NN	aux||stably-20/VB||could-19/MD	ccomp||show-3/VBP||stably-20/VB	amod||prevalence-23/NN||lower-21/JJR	nn||prevalence-23/NN||hiv/aids-22/NN	dobj||stably-20/VB||prevalence-23/NN	prep_by||stably-20/VB||âˆ-25/NN	num||âˆ-25/NN||1/4-26/CD	amod||âˆ-25/NN||30-fold-27/JJ	amod||âˆ-25/NN||within-28/IN	num||years-30/NNS||50-29/CD	dep||âˆ-25/NN||years-30/NNS	aux||complement-33/VB||could-32/MD	conj_and||show-3/VBP||complement-33/VB	amod||therapies-35/NNS||current-34/JJ	dobj||complement-33/VB||therapies-35/NNS	aids--1||hiv-15||no||our results show that a tip, engineered with properties based on a recent hiv gene-therapy trial, could stably lower hiv/aids prevalence by âˆ¼30-fold within 50 years and could complement current therapies.
det||ulcer-2/NN||the-1/DT	nsubj||improved-3/VBD||ulcer-2/NN	root||ROOT-0/null||improved-3/VBD	advmod||slightly-5/RB||only-4/RB	dobj||improved-3/VBD||slightly-5/RB	num||months-8/NNS||2-7/CD	prep_after||improved-3/VBD||months-8/NNS	amod||ointment-12/NN||povidone-iodine-10/JJ	nn||ointment-12/NN||sugar-11/NN	prep_with||improved-3/VBD||ointment-12/NN	amod||nausea-16/NN||severe-15/JJ	prep_because_of||ointment-12/NN||nausea-16/NN	prep_because_of||ointment-12/NN||anorexia-18/NN	conj_and||nausea-16/NN||anorexia-18/NN	sugar-11||nausea-16||no_rel||the ulcer improved only slightly after 2 months with povidone-iodine sugar ointment because of severe nausea and anorexia.
nsubj||hypothesized-2/VBN||we-1/PRP	nsubj||increased-18/VBN||we-1/PRP	root||ROOT-0/null||hypothesized-2/VBN	mark||leads-7/VBZ||that-3/IN	amod||mutation-6/NN||murine-4/JJ	amod||mutation-6/NN||pparg-p465l-5/JJ	nsubj||leads-7/VBZ||mutation-6/NN	ccomp||hypothesized-2/VBN||leads-7/VBZ	amod||insulinresistance-10/NN||covert-9/JJ	prep_to||leads-7/VBZ||insulinresistance-10/NN	nsubjpass||masked-14/VBN||insulinresistance-10/NN	auxpass||masked-14/VBN||is-13/VBZ	rcmod||insulinresistance-10/NN||masked-14/VBN	agent||masked-14/VBN||hyperinsulinemia-16/NN	conj_and||hypothesized-2/VBN||increased-18/VBN	amod||mass-21/NN||pancreatic-19/JJ	nn||mass-21/NN||islet-20/NN	dobj||increased-18/VBN||mass-21/NN	aux||retain-24/VB||to-23/TO	vmod||increased-18/VBN||retain-24/VB	amod||glucose-27/NN||normal-25/JJ	nn||glucose-27/NN||plasma-26/NN	dobj||retain-24/VB||glucose-27/NN	insulinresistance-10||glucose-27||no_rel||we hypothesized that murine pparg-p465l mutation leads to covert insulinresistance, which is masked by hyperinsulinemia and increased pancreatic islet mass, to retain normal plasma glucose.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||examine-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||was-6/VBD||examine-8/VB	det||effect-10/NN||the-9/DT	dobj||examine-8/VB||effect-10/NN	det||program-15/NN||a-12/DT	amod||program-15/NN||pepfar-funded-13/JJ	nn||program-15/NN||hiv/aids-14/NNS	prep_of||effect-10/NN||program-15/NN	num||clinics-20/NNS||six-17/CD	amod||clinics-20/NNS||government-run-18/JJ	amod||clinics-20/NNS||general-19/JJ	prep_on||examine-8/VB||clinics-20/NNS	prep_in||clinics-20/NNS||kampala-22/NN	aids--1||hiv--1||no||the aim of this study was to examine the effect of a pepfar-funded hiv/aids program on six government-run general clinics in kampala.
amod||drugs-3/NNS||several-1/JJ	amod||drugs-3/NNS||new-2/JJ	nsubj||available-7/JJ||drugs-3/NNS	prep_for||drugs-3/NNS||rheumatoidarthritis-5/NNS	cop||available-7/JJ||are-6/VBP	root||ROOT-0/null||available-7/JJ	prep_including||available-7/JJ||leflunomide-9/NN	rheumatoidarthritis-5||leflunomide-9||yes||several new drugs for rheumatoidarthritis are available including leflunomide.
nsubj||provides-2/VBZ||clozapine-1/NN	root||ROOT-0/null||provides-2/VBZ	amod||treatments-4/NNS||effective-3/JJ	dobj||provides-2/VBZ||treatments-4/NNS	prep_for||treatments-4/NNS||schizophrenia-6/NN	poss||usage-9/NN||its-8/PRP$	nsubj||agranulocytosis-15/NNS||usage-9/NN	cop||agranulocytosis-15/NNS||is-10/VBZ	amod||agranulocytosis-15/NNS||limited-11/JJ	prep_because_of||limited-11/JJ||life-threatening-14/JJ	conj_but||provides-2/VBZ||agranulocytosis-15/NNS	schizophrenia-6||clozapine-1||yes||clozapine provides effective treatments for schizophrenia but its usage is limited because of life-threatening agranulocytosis.
nsubj||stabilizes-9/VBZ||reduction-1/NN	nsubj||lowers-11/VBZ||reduction-1/NN	amod||carbohydrates-4/NNS||dietary-3/JJ	prep_of||reduction-1/NN||carbohydrates-4/NNS	amod||doses-8/NNS||corresponding-6/JJ	nn||doses-8/NNS||insulin-7/NN	prep_of||reduction-1/NN||doses-8/NNS	conj_and||carbohydrates-4/NNS||doses-8/NNS	root||ROOT-0/null||stabilizes-9/VBZ	conj_and||stabilizes-9/VBZ||lowers-11/VBZ	amod||bloodglucose-13/NN||mean-12/JJ	dobj||stabilizes-9/VBZ||bloodglucose-13/NN	prep_in||stabilizes-9/VBZ||individuals-15/NNS	prep_with||individuals-15/NNS||type1diabetes-17/NNS	prep_within||type1diabetes-17/NNS||days-19/NNS	type1diabetes-17||insulin-7||yes||reduction of dietary carbohydrates and corresponding insulin doses stabilizes and lowers mean bloodglucose in individuals with type1diabetes within days.
det||structure-3/NN||the-1/DT	nn||structure-3/NN||crystal-2/NN	nsubj||consists-16/VBZ||structure-3/NN	nsubj||consists-16/VBZ||structure-3/NN	det||compound-7/NN||the-5/DT	nn||compound-7/NN||title-6/NN	prep_of||structure-3/NN||compound-7/NN	nn||-RSB--14/NNP||-LSB--9/NNP	nn||-RSB--14/NNP||zncl2-10/NNP	appos||-RSB--14/NNP||c10h8n2s-12/NNP	appos||structure-3/NN||-RSB--14/NNP	root||ROOT-0/null||consists-16/VBZ	conj_and||consists-16/VBZ||consists-16/VBZ	det||ring-21/NN||a-18/DT	amod||ring-21/NN||six-membered-19/JJ	nn||ring-21/NN||chelate-20/NN	prep_of||consists-16/VBZ||ring-21/NN	prep_in||tetraâhedrally-29/JJ||ring-21/NN	det||atom-26/NN||the-24/DT	nn||atom-26/NN||zn-25/NN	nsubj||tetraâhedrally-29/JJ||atom-26/NN	cop||tetraâhedrally-29/JJ||is-27/VBZ	advmod||tetraâhedrally-29/JJ||approximately-28/RB	rcmod||ring-21/NN||tetraâhedrally-29/JJ	dep||tetraâhedrally-29/JJ||coordinated-30/VBN	num||ions-34/NNS||two-32/CD	nn||ions-34/NNS||chloride-33/NN	prep_by||coordinated-30/VBN||ions-34/NNS	det||atoms-41/NNS||the-37/DT	num||atoms-41/NNS||two-38/CD	amod||atoms-41/NNS||pyridyl-39/JJ	nn||atoms-41/NNS||n-40/NN	prep_by||consists-16/VBZ||atoms-41/NNS	det||sulfide-46/NN||a-43/DT	amod||sulfide-46/NN||single-44/JJ	amod||sulfide-46/NN||di-2-pyridyl-45/JJ	prep_of||atoms-41/NNS||sulfide-46/NN	vmod||sulfide-46/NN||ligand-47/VBN	tetra--1||di--1||no_rel||the crystal structure of the title compound, [zncl2(c10h8n2s)], consists of a six-membered chelate ring in which the zn atom is approximately tetraâ­hedrally coordinated by two chloride ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand.
amod||mrna-2/NN||nk-1r-1/JJ	nsubj||ratâ-11/VBD||mrna-2/NN	nn||expression-5/NN||protein-4/NN	conj_and||mrna-2/NN||expression-5/NN	nsubj||ratâ-11/VBD||expression-5/NN	det||group-10/NN||the-7/DT	amod||group-10/NN||budesonide-8/JJ	nn||group-10/NN||treatment-9/NN	prep_in||mrna-2/NN||group-10/NN	root||ROOT-0/null||ratâ-11/VBD	num||lung-15/NN||$-12/$	number||s-14/CD||™-13/CD	num||$-12/$||s-14/CD	nsubj||less-19/JJR||lung-15/NN	conj_and||lung-15/NN||asmcs-17/NNS	nsubj||less-19/JJR||asmcs-17/NNS	cop||less-19/JJR||were-18/VBD	ccomp||ratâ-11/VBD||less-19/JJR	prep_than||less-19/JJR||that-21/DT	det||groupbut-25/NN||the-23/DT	amod||groupbut-25/NN||asthmatic-24/JJ	prep_in||that-21/DT||groupbut-25/NN	dep||less-19/JJR||greater-26/JJR	prep_than||less-19/JJR||that-28/DT	det||group-32/NN||the-30/DT	nn||group-32/NN||control-31/NN	prep_in||that-28/DT||group-32/NN	asthmatic-24||budesonide-8||no||nk-1r mrna and protein expression in the budesonide treatment group ratâ€™s lung and asmcs were less than that in the asthmatic groupbut greater than that in the control group.
det||induction-2/NN||the-1/DT	nsubjpass||prevented-17/VBN||induction-2/NN	prep_of||induction-2/NN||obesity-4/NN	prep_of||induction-2/NN||dyslipidemia-6/NN	conj_and||obesity-4/NN||dyslipidemia-6/NN	prep_of||induction-2/NN||insulinresistance-9/NN	conj_and||obesity-4/NN||insulinresistance-9/NN	amod||diet-12/NN||high-fat-11/JJ	prep_by||obesity-4/NN||diet-12/NN	prep_in||diet-12/NN||rodents-14/NNS	aux||prevented-17/VBN||can-15/MD	auxpass||prevented-17/VBN||be-16/VB	root||ROOT-0/null||prevented-17/VBN	amod||fattyacids-22/NNS||n-3-19/JJ	amod||fattyacids-22/NNS||long-chain-20/JJ	amod||fattyacids-22/NNS||polyunsaturated-21/JJ	agent||prevented-17/VBN||fattyacids-22/NNS	appos||fattyacids-22/NNS||lc-pufas-24/NNS	obesity-4||fat--1||no_rel||the induction of obesity, dyslipidemia, and insulinresistance by high-fat diet in rodents can be prevented by n-3 long-chain polyunsaturated fattyacids (lc-pufas).
nsubj||efficacious-8/JJ||incb13739-1/NNS	nsubj||tolerated-11/JJ||incb13739-1/NNS	vmod||incb13739-1/NNS||added-2/VBN	amod||therapy-6/NN||ongoing-4/JJ	nn||therapy-6/NN||metformin-5/NN	prep_to||added-2/VBN||therapy-6/NN	cop||efficacious-8/JJ||was-7/VBD	root||ROOT-0/null||efficacious-8/JJ	advmod||tolerated-11/JJ||well-10/RB	conj_and||efficacious-8/JJ||tolerated-11/JJ	prep_in||efficacious-8/JJ||patients-13/NNS	prep_with||patients-13/NNS||type2diabetes-15/NNS	nsubj||had-17/VBD||type2diabetes-15/NNS	rcmod||type2diabetes-15/NNS||had-17/VBD	amod||glycemic-19/JJ||inadequate-18/JJ	amod||control-20/NN||glycemic-19/JJ	dobj||had-17/VBD||control-20/NN	prep_with||had-17/VBD||metformin-22/NN	advmod||had-17/VBD||alone-23/RB	type2diabetes-15||metformin-22||yes||incb13739 added to ongoing metformin therapy was efficacious and well tolerated in patients with type2diabetes who had inadequate glycemic control with metformin alone.
aux||report-2/VB||to-1/TO	root||ROOT-0/null||report-2/VB	det||trend-5/NN||the-4/DT	prep_on||report-2/VB||trend-5/NN	amod||mortality-8/NN||all-cause-7/JJ	prep_in||trend-5/NN||mortality-8/NN	det||district-12/NN||a-10/DT	amod||district-12/NN||rural-11/JJ	prep_in||report-2/VB||district-12/NN	prep_of||district-12/NN||malawi-14/NNS	nsubj||has-16/VBZ||malawi-14/NNS	rcmod||malawi-14/NNS||has-16/VBZ	advmod||has-16/VBZ||successfully-17/RB	amod||care-20/NN||scaled-up-18/JJ	nn||care-20/NN||hiv/aids-19/NNS	dobj||has-16/VBZ||care-20/NN	amod||treatment-23/NN||antiretroviral-22/JJ	prep_including||care-20/NN||treatment-23/NN	appos||treatment-23/NN||art-25/NN	poss||population-29/NN||its-28/PRP$	prep_to||treatment-23/NN||population-29/NN	amod||evidence-33/NN||corroborative-32/JJ	prep_through||treatment-23/NN||evidence-33/NN	dep||deaths-38/NNS||a-35/LS	amod||deaths-38/NNS||registered-37/JJ	prep_from||evidence-33/NN||deaths-38/NNS	amod||authorities-41/NNS||traditional-40/JJ	prep_at||deaths-38/NNS||authorities-41/NNS	appos||deaths-38/NNS||tas-43/NN	appos||deaths-38/NNS||b-46/SYM	nn||sales-49/NNS||coffin-48/NN	dep||treatment-23/NN||sales-49/NNS	dep||funerals-54/VBZ||c-51/LS	nsubj||funerals-54/VBZ||church-53/NN	conj_and||report-2/VB||funerals-54/VBZ	aids--1||hiv--1||no||to report on the trend in all-cause mortality in a rural district of malawi that has successfully scaled-up hiv/aids care including antiretroviral treatment (art) to its population, through corroborative evidence from a) registered deaths at traditional authorities (tas), b) coffin sales and c) church funerals.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	root||ROOT-0/null||study-3/NN	vmod||study-3/NN||aimed-4/VBN	aux||determine-6/VB||to-5/TO	xcomp||aimed-4/VBN||determine-6/VB	det||effect-8/NN||the-7/DT	dobj||determine-6/VB||effect-8/NN	prep_of||effect-8/NN||acupressure-10/NN	det||point-14/NN||the-12/DT	amod||point-14/NN||sanyinjiao-13/JJ	prep_at||determine-6/VB||point-14/NN	dep||point-14/NN||sp-6-16/JJ	prep_on||determine-6/VB||severity-19/NN	amod||symptoms-22/NNS||menstrual-21/JJ	prep_of||severity-19/NN||symptoms-22/NNS	amod||outcome-25/NN||primary-24/JJ	appos||symptoms-22/NNS||outcome-25/NN	det||duration-29/NN||the-28/DT	prep_on||determine-6/VB||duration-29/NN	conj_and||severity-19/NN||duration-29/NN	amod||time-32/NN||resting-31/JJ	prep_of||duration-29/NN||time-32/NN	det||number-37/NN||the-36/DT	conj_and||study-3/NN||number-37/NN	nn||consumption-40/NN||ibuprofen-39/NN	prep_of||number-37/NN||consumption-40/NN	amod||outcome-43/NN||secondary-42/JJ	appos||consumption-40/NN||outcome-43/NN	det||types-48/NNS||the-46/DT	num||types-48/NNS||two-47/CD	prep_in||consumption-40/NN||types-48/NNS	amod||dysmenorrhea-51/NN||primary-50/JJ	prep_of||types-48/NNS||dysmenorrhea-51/NN	dysmenorrhea-51||ibuprofen-39||yes||the present study aimed to determine the effect of acupressure at the sanyinjiao point (sp-6) on severity of menstrual symptoms (primary outcome) and the duration of resting time as well as the number of ibuprofen consumption (secondary outcome) in the two types of primary dysmenorrhea.
nsubj||are-11/VBP||studies-1/NNS	aux||explore-3/VB||to-2/TO	vmod||studies-1/NNS||explore-3/VB	det||effect-5/NN||the-4/DT	dobj||explore-3/VB||effect-5/NN	prep_of||effect-5/NN||anticoagulants-7/NNS	nn||survival-10/NN||cancer-9/NN	prep_on||anticoagulants-7/NNS||survival-10/NN	root||ROOT-0/null||are-11/VBP	advmod||are-11/VBP||underway-12/RB	amod||malignancies-15/NNS||other-14/JJ	prep_in||are-11/VBP||malignancies-15/NNS	nn||breast-24/NN||lung-18/NN	dep||breast-24/NN||pancreas-20/NN	dep||breast-24/NN||ovary-22/NN	prep_such_as||malignancies-15/NNS||breast-24/NN	nn||cancer-28/NN||stomach-27/NN	prep_such_as||malignancies-15/NNS||cancer-28/NN	conj_and||breast-24/NN||cancer-28/NN	cancer-28||anticoagulants-7||no_rel||studies to explore the effect of anticoagulants on cancer survival are underway in other malignancies such as lung, pancreas, ovary, breast, and stomach cancer.
nsubj||inhibitor-7/NN||lapatinib-1/NN	cop||inhibitor-7/NN||is-2/VBZ	det||inhibitor-7/NN||a-3/DT	amod||inhibitor-7/NN||small-molecule-4/JJ	amod||inhibitor-7/NN||tyrosine-5/JJ	nn||inhibitor-7/NN||kinase-6/NN	root||ROOT-0/null||inhibitor-7/NN	nsubj||blocks-9/VBZ||inhibitor-7/NN	rcmod||inhibitor-7/NN||blocks-9/VBZ	dobj||blocks-9/VBZ||phosphorylation-10/NN	det||receptor-16/NN||the-12/DT	amod||receptor-16/NN||epidermal-13/JJ	nn||receptor-16/NN||growth-14/NN	nn||receptor-16/NN||factor-15/NN	prep_of||phosphorylation-10/NN||receptor-16/NN	dobj||blocks-9/VBZ||her2-18/NNS	conj_and||phosphorylation-10/NN||her2-18/NNS	nn||cells-22/NNS||breast-20/NN	nn||cells-22/NNS||cancer-21/NN	prep_in||her2-18/NNS||cells-22/NNS	vmod||blocks-9/VBZ||resulting-24/VBG	prep_in||resulting-24/VBG||apoptosis-26/NNS	cancer-21||tyrosine-5||no_rel||lapatinib is a small-molecule tyrosine kinase inhibitor that blocks phosphorylation of the epidermal growth factor receptor and her2 in breast cancer cells, resulting in apoptosis.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	dobj||examined-2/VBD||correlates-3/NNS	amod||rna-7/NN||genital-5/JJ	amod||rna-7/NN||hiv-1-6/JJ	prep_of||correlates-3/NNS||rna-7/NN	prep_in||rna-7/NN||women-9/NNS	nsubj||seropositive-12/JJ||who-10/WP	cop||seropositive-12/JJ||were-11/VBD	dep||examined-2/VBD||seropositive-12/JJ	det||-rrb--20/NNP||both-14/DT	amod||-rrb--20/NNP||herpes-15/JJ	nn||-rrb--20/NNP||simplex-16/NN	nn||-rrb--20/NNP||virus-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||hsv-19/NNP	prep_for||seropositive-12/JJ||-rrb--20/NNP	dep||seropositive-12/JJ||-2-21/CD	dep||seropositive-12/JJ||hiv-1-23/CD	conj_and||-2-21/CD||hiv-1-23/CD	dep||enrolled-27/VBN||who-25/WP	auxpass||enrolled-27/VBN||were-26/VBD	dep||examined-2/VBD||enrolled-27/VBN	conj_and||seropositive-12/JJ||enrolled-27/VBN	det||trial-32/NN||a-29/DT	amod||trial-32/NN||randomised-30/JJ	amod||trial-32/NN||controlled-31/JJ	prep_in||enrolled-27/VBN||trial-32/NN	nn||therapy-36/NN||hsv-34/NN	nn||therapy-36/NN||suppressive-35/NN	prep_of||trial-32/NN||therapy-36/NN	num||aciclovir-38/NN||-lrb--37/CD	nsubjpass||enrolled-27/VBN||aciclovir-38/NN	num||-rrb--44/NN||400-39/CD	amod||-rrb--44/NN||mg-40/JJ	amod||-rrb--44/NN||b.i.d-41/JJ	nn||-rrb--44/NN||vs.-42/FW	nn||-rrb--44/NN||placebo-43/FW	dep||enrolled-27/VBN||-rrb--44/NN	prep_in||enrolled-27/VBN||tanzania-46/NN	hsv-34||aciclovir-38||yes||we examined correlates of genital hiv-1 rna in women who were seropositive for both herpes simplex virus -lrb- hsv -rrb- -2 and hiv-1 and who were enrolled in a randomised controlled trial of hsv suppressive therapy -lrb- aciclovir 400 mg b.i.d vs. placebo -rrb- in tanzania .
amod||analysis-2/NN||phylogenetic-1/JJ	nsubj||contributed-9/VBN||analysis-2/NN	nsubj||played-15/VBD||analysis-2/NN	amod||sequences-5/NNS||partial-4/JJ	prep_of||analysis-2/NN||sequences-5/NNS	prep_of||sequences-5/NNS||rubellaviruses-7/NNS	aux||contributed-9/VBN||has-8/VBZ	root||ROOT-0/null||contributed-9/VBN	nn||efforts-13/NNS||virus-11/NN	nn||efforts-13/NNS||surveillance-12/NN	prep_to||contributed-9/VBN||efforts-13/NNS	conj_and||contributed-9/VBN||played-15/VBD	det||role-18/NN||an-16/DT	amod||role-18/NN||important-17/JJ	dobj||played-15/VBD||role-18/NN	prepc_in||played-15/VBD||demonstrating-20/VBG	mark||eliminated-26/VBN||that-21/IN	nn||rubellaviruses-23/NNS||indigenous-22/NNS	nsubjpass||eliminated-26/VBN||rubellaviruses-23/NNS	aux||eliminated-26/VBN||have-24/VBP	auxpass||eliminated-26/VBN||been-25/VBN	ccomp||demonstrating-20/VBG||eliminated-26/VBN	det||states-30/NNS||the-28/DT	amod||states-30/NNS||united-29/VBN	prep_in||eliminated-26/VBN||states-30/NNS	virus-11||viruses--1||no||phylogenetic analysis of partial sequences of rubellaviruses has contributed to virus surveillance efforts and played an important role in demonstrating that indigenous rubellaviruses have been eliminated in the united states.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	det||study-5/NN||the-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	ccomp||was-6/VBD||investigate-8/VB	det||ä-13/NN||the-9/DT	nn||ä-13/NN||regä-10/NNP	nn||ä-13/NN||±-11/NNP	amod||ä-13/NN||onal-12/JJ	nsubj||±-17/VBG||ä-13/NN	num||ntravenous-15/NNS||±-14/CD	npadvmod||anesthesä-16/JJ||ntravenous-15/NNS	dep||±-17/VBG||anesthesä-16/JJ	xcomp||investigate-8/VB||±-17/VBG	det||procedure-19/NN||a-18/DT	dobj||±-17/VBG||procedure-19/NN	nn||arthroscopy-22/NN||knee-21/NN	prep_in||±-17/VBG||arthroscopy-22/NN	aux||evaluate-25/VB||to-24/TO	ccomp||was-6/VBD||evaluate-25/VB	conj_and||investigate-8/VB||evaluate-25/VB	det||effects-27/NNS||the-26/DT	dobj||evaluate-25/VB||effects-27/NNS	prepc_of||effects-27/NNS||adding-29/VBG	dobj||adding-29/VBG||ketamine-30/NN	det||charactery-35/NN||the-32/DT	nn||charactery-35/NN||anesthesia-33/NN	nn||charactery-35/NN||block-34/NN	prep_over||adding-29/VBG||charactery-35/NN	nn||pain-38/NN||tourniquet-37/NN	prep_over||adding-29/VBG||pain-38/NN	conj_and||charactery-35/NN||pain-38/NN	pain-38||ketamine-30||yes||the goal of the study was to investigate the regä±onal ä±ntravenous anesthesä±a procedure in knee arthroscopy and to evaluate the effects of adding ketamine over the anesthesia block charactery and tourniquet pain.
nsubjpass||evaluated-5/VBN||severity-1/NN	prep_of||severity-1/NN||aws-3/NN	auxpass||evaluated-5/VBN||was-4/VBD	root||ROOT-0/null||evaluated-5/VBN	det||assessment-11/NN||the-7/DT	amod||assessment-11/NN||clinical-8/JJ	nn||assessment-11/NN||institute-9/NN	nn||assessment-11/NN||withdrawal-10/NN	agent||evaluated-5/VBN||assessment-11/NN	nn||scale-14/NN||alcohol-13/NN	prep_of||assessment-11/NN||scale-14/NN	appos||scale-14/NN||ciwa-ar-16/NN	agent||evaluated-5/VBN||that-19/DT	conj_and||assessment-11/NN||that-19/DT	prep_of||that-19/DT||alcoholdependence-21/NN	prep_of||that-19/DT||craving-23/NN	conj_and||alcoholdependence-21/NN||craving-23/NN	det||questionnaire-42/NN||the-25/DT	amod||compulsive-27/JJ||obsessive-26/JJ	amod||questionnaire-42/NN||compulsive-27/JJ	nn||questionnaire-42/NN||drinking-28/NN	nn||questionnaire-42/NN||scale-29/NN	num||ocds-31/NNS||-LSB--30/CD	npadvmod||-RSB--32/JJ||ocds-31/NNS	amod||questionnaire-42/NN||-RSB--32/JJ	det||severity-35/NN||the-34/DT	conj_and||-RSB--32/JJ||severity-35/NN	amod||questionnaire-42/NN||severity-35/NN	amod||data-38/NNS||alcoholdependence-37/JJ	prep_of||severity-35/NN||data-38/NNS	dep||data-38/NNS||sadd-40/JJ	agent||evaluated-5/VBN||questionnaire-42/NN	alcoholdependence-37||alcohol-13||no||severity of aws was evaluated by the clinical institute withdrawal assessment of alcohol scale (ciwa-ar) and that of alcoholdependence and craving by the obsessive compulsive drinking scale [ocds] and the severity of alcoholdependence data (sadd) questionnaire.
amod||samples-2/NNS||faecal-1/JJ	nsubjpass||collected-4/VBN||samples-2/NNS	nsubjpass||examined-6/VBN||samples-2/NNS	auxpass||collected-4/VBN||were-3/VBD	root||ROOT-0/null||collected-4/VBN	conj_and||collected-4/VBN||examined-6/VBN	agent||collected-4/VBN||using-8/VBG	amod||katz-13/NN||formalin-ether-9/JJ	nn||katz-13/NN||sedimentation-10/NN	dep||katz-13/NN||kato-12/NN	dobj||using-8/VBG||katz-13/NN	nn||techniques-17/NNS||harada-15/NN	nn||techniques-17/NNS||mori-16/NN	dobj||using-8/VBG||techniques-17/NNS	conj_and||katz-13/NN||techniques-17/NNS	formalin--1||harada-15||no_rel||faecal samples were collected and examined by using formalin-ether sedimentation, kato katz and harada mori techniques.
advmod||differed-11/VBD||however-1/RB	det||expression-7/NN||the-3/DT	amod||expression-7/NN||serological-4/JJ	conj_and||serological-4/JJ||molecular-6/JJ	amod||expression-7/NN||molecular-6/JJ	nsubj||differed-11/VBD||expression-7/NN	nn||infection-10/NN||hbv-9/NN	prep_of||expression-7/NN||infection-10/NN	root||ROOT-0/null||differed-11/VBD	det||groups-15/NNS||the-13/DT	num||groups-15/NNS||two-14/CD	prep_in||differed-11/VBD||groups-15/NNS	det||group-17/NN||the-16/DT	nsubj||included-20/VBD||group-17/NN	prep_of||group-17/NN||patients-19/NNS	rcmod||groups-15/NNS||included-20/VBD	amod||individuals-22/NNS||more-21/JJR	dobj||included-20/VBD||individuals-22/NNS	amod||infection-26/NN||ongoing-24/JJ	nn||infection-26/NN||hbv-25/NN	prep_with||included-20/VBD||infection-26/NN	mark||defined-29/VBN||as-28/IN	advcl||included-20/VBD||defined-29/VBN	det||presence-32/NN||the-31/DT	prep_by||defined-29/VBN||presence-32/NN	amod||hbsag-35/NN||detectable-34/JJ	prep_of||presence-32/NN||hbsag-35/NN	prep_in||differed-11/VBD||or-37/CC	conj_or||groups-15/NNS||or-37/CC	nn||dna-39/NN||hbv-38/NN	prep_in||differed-11/VBD||dna-39/NN	conj_or||groups-15/NNS||dna-39/NN	num||%-42/NN||17-41/CD	dep||dna-39/NN||%-42/NN	num||%-45/NN||12-44/CD	dep||dna-39/NN||%-45/NN	conj_and||%-42/NN||%-45/NN	advmod||%-42/NN||respectively-47/RB	hbv-38||hbsag-35||yes||however, the serological and molecular expression of hbv infection differed in the two groups the group of patients included more individuals with ongoing hbv infection, as defined by the presence of detectable hbsag and or hbv dna (17% and 12%, respectively).
nsubj||aed-9/NN||lamotrigine-1/NN	appos||lamotrigine-1/NN||ltg-3/NN	cop||aed-9/NN||is-5/VBZ	det||aed-9/NN||a-6/DT	amod||aed-9/NN||broad-7/JJ	nn||aed-9/NN||spectrum-8/NN	root||ROOT-0/null||aed-9/NN	prep_with||aed-9/NN||efficacy-11/NN	amod||syndromes-17/NNS||partial-13/JJ	conj_and||partial-13/JJ||generalized-15/JJ	amod||syndromes-17/NNS||generalized-15/JJ	nn||syndromes-17/NNS||epilepsy-16/NN	prep_in||efficacy-11/NN||syndromes-17/NNS	amod||tolerability-20/NN||good-19/JJ	prep_in||efficacy-11/NN||tolerability-20/NN	conj_and||syndromes-17/NNS||tolerability-20/NN	epilepsy-16||lamotrigine-1||yes||lamotrigine (ltg) is a broad spectrum aed with efficacy in partial and generalized epilepsy syndromes and good tolerability.
det||report-2/NN||this-1/DT	nsubj||discusses-3/VBZ||report-2/NN	root||ROOT-0/null||discusses-3/VBZ	det||case-5/NN||a-4/DT	dobj||discusses-3/VBZ||case-5/NN	amod||psychosis-8/NNS||acute-7/JJ	prep_of||case-5/NN||psychosis-8/NNS	prep_of||case-5/NN||enuresis-10/NNS	conj_and||psychosis-8/NNS||enuresis-10/NNS	det||alcohol-19/NN||a-12/DT	amod||alcohol-19/NN||patient-13/JJ	prep_on||patient-13/JJ||disulfiram-15/NN	nsubj||ingested-18/VBN||disulfiram-15/NN	aux||ingested-18/VBN||had-17/VBD	rcmod||disulfiram-15/NN||ingested-18/VBN	prep_in||case-5/NN||alcohol-19/NN	alcohol-19||psychosis-8||no_rel||this report discusses a case of acute psychosis and enuresis in a patient on disulfiram who had ingested alcohol.
det||effects-2/NNS||the-1/DT	nsubjpass||truncated-8/VBN||effects-2/NNS	amod||treatment-6/NN||anti-cd25-4/JJ	nn||treatment-6/NN||mab-5/NN	prep_of||effects-2/NNS||treatment-6/NN	auxpass||truncated-8/VBN||are-7/VBP	root||ROOT-0/null||truncated-8/VBN	prep_in||truncated-8/VBN||cats-10/NNS	advmod||infected-12/VBN||acutely-11/RB	vmod||cats-10/NNS||infected-12/VBN	amod||post-fivinfection-44/NN||fiv-c36-14/JJ	mark||included-37/VBD||as-15/IN	prepc_compared_to||included-37/VBD||to-17/TO	advmod||cats-25/NNS||chronically-18/RB	amod||cats-25/NNS||infected-19/JJ	nn||cats-25/NNS||cats-20/NNS	conj_or||cats-20/NNS||fiv-naã-22/JJ	nn||cats-25/NNS||fiv-naã-22/JJ	amod||cats-25/NNS||¯-23/JJ	nn||cats-25/NNS||ve-24/NN	pobj||included-37/VBD||cats-25/NNS	mark||heightened-32/VBN||as-27/IN	amod||levels-30/NNS||treg-28/VBG	nn||levels-30/NNS||cell-29/NN	nsubjpass||heightened-32/VBN||levels-30/NNS	auxpass||heightened-32/VBN||were-31/VBD	dep||cats-25/NNS||heightened-32/VBN	det||treatment-35/NN||all-34/DT	prep_in||heightened-32/VBN||treatment-35/NN	nsubj||included-37/VBD||groups-36/NNS	dep||fiv-c36-14/JJ||included-37/VBD	det||study-40/NN||the-39/DT	prep_in||included-37/VBD||study-40/NN	num||weeks-43/NNS||two-42/CD	prep_within||included-37/VBD||weeks-43/NNS	prep_with||infected-12/VBN||post-fivinfection-44/NN	fivinfection--1||fiv--1||no||the effects of anti-cd25 mab treatment are truncated in cats acutely infected with fiv-c36 as compared to chronically infected cats or fiv-naã¯ve cats, as treg cell levels were heightened in all treatment groups included in the study within two weeks post-fivinfection.
mark||known-14/VBN||although-1/IN	det||mechanism-3/NN||the-2/DT	nsubjpass||known-14/VBN||mechanism-3/NN	amod||respiratorydisease-8/NN||virus-induced-5/JJ	amod||respiratorydisease-8/NN||aspirin-exacerbated-7/JJ	prep_of||mechanism-3/NN||respiratorydisease-8/NN	dep||respiratorydisease-8/NN||aerd-10/VBN	auxpass||known-14/VBN||is-12/VBZ	neg||known-14/VBN||not-13/RB	advcl||suggested-31/VBN||known-14/VBN	advmod||known-14/VBN||fully-15/RB	amod||activation-18/NN||direct-17/JJ	nsubjpass||suggested-31/VBN||activation-18/NN	amod||components-21/NNS||viral-20/JJ	prep_of||activation-18/NN||components-21/NNS	amod||receptor-24/NN||toll-like-23/JJ	prep_through||components-21/NNS||receptor-24/NN	num||receptor-24/NN||3-25/CD	appos||receptor-24/NN||tlr3-27/NNP	aux||suggested-31/VBN||has-29/VBZ	auxpass||suggested-31/VBN||been-30/VBN	root||ROOT-0/null||suggested-31/VBN	virus--1||aspirin--1||no||although the mechanism of virus-induced, aspirin-exacerbated respiratorydisease (aerd) is not known fully, direct activation of viral components through toll-like receptor 3 (tlr3) has been suggested.
nsubj||contributes-6/VBZ||calcineurininhibitor-1/NN	appos||calcineurininhibitor-1/NN||cni-3/NN	advmod||contributes-6/VBZ||toxicity-5/RB	root||ROOT-0/null||contributes-6/VBZ	amod||nephropathy-10/NN||chronic-8/JJ	nn||nephropathy-10/NN||allograft-9/NN	prep_to||contributes-6/VBZ||nephropathy-10/NN	appos||nephropathy-10/NN||can-12/NN	nephropathy-10||calcineurininhibitor-1||no_rel||calcineurininhibitor (cni) toxicity contributes to chronic allograft nephropathy (can).
det||activity-2/NN||the-1/DT	nsubjpass||thought-18/VBN||activity-2/NN	nsubj||determinant-23/NN||activity-2/NN	amod||dehydrogenase-5/NN||dihydropyrimidine-4/JJ	prep_of||activity-2/NN||dehydrogenase-5/NN	appos||dehydrogenase-5/NN||dpd-7/NN	det||enzyme-12/NN||the-10/DT	amod||enzyme-12/NN||key-11/JJ	appos||activity-2/NN||enzyme-12/NN	amod||catabolism-15/NN||pyrimidine-14/JJ	prep_of||enzyme-12/NN||catabolism-15/NN	auxpass||thought-18/VBN||is-17/VBZ	root||ROOT-0/null||thought-18/VBN	aux||determinant-23/NN||to-19/TO	cop||determinant-23/NN||be-20/VB	det||determinant-23/NN||an-21/DT	amod||determinant-23/NN||important-22/JJ	xcomp||thought-18/VBN||determinant-23/NN	det||occurrence-26/NN||the-25/DT	prep_for||determinant-23/NN||occurrence-26/NN	amod||reactions-30/NNS||severe-28/JJ	amod||reactions-30/NNS||toxic-29/JJ	prep_of||occurrence-26/NN||reactions-30/NNS	prep_to||reactions-30/NNS||5-fluorouracil-32/NN	nsubj||one-39/CD||5-fluorouracil-32/NN	dep||5-fluorouracil-32/NN||5-fu-34/JJ	cop||one-39/CD||is-38/VBZ	rcmod||5-fluorouracil-32/NN||one-39/CD	det||chemotherapeuticagents-45/NNS||the-41/DT	advmod||prescribed-44/VBN||most-42/RBS	advmod||prescribed-44/VBN||commonly-43/RB	amod||chemotherapeuticagents-45/NNS||prescribed-44/VBN	prep_of||one-39/CD||chemotherapeuticagents-45/NNS	det||treatment-48/NN||the-47/DT	prep_for||chemotherapeuticagents-45/NNS||treatment-48/NN	amod||cancers-51/NNS||solid-50/JJ	prep_of||treatment-48/NN||cancers-51/NNS	cancers-51||chemotherapeuticagents-45||no_rel||the activity of dihydropyrimidine dehydrogenase (dpd), the key enzyme of pyrimidine catabolism, is thought to be an important determinant for the occurrence of severe toxic reactions to 5-fluorouracil (5-fu), which is one of the most commonly prescribed chemotherapeuticagents for the treatment of solid cancers.
nn||centre-2/NN||art-1/NN	dep||centre-19/NN||centre-2/NN	amod||john-5/NN||st.-4/JJ	poss||hospital-9/NN||john-5/NN	amod||hospital-9/NN||medical-7/JJ	nn||hospital-9/NN||college-8/NN	prep_at||centre-2/NN||hospital-9/NN	appos||hospital-9/NN||bangalore-11/NN	appos||hospital-9/NN||snehadan-13/NN	conj_and||bangalore-11/NN||snehadan-13/NN	det||supportive-16/NN||a-15/DT	dep||centre-19/NN||supportive-16/NN	conj_and||supportive-16/NN||care-18/NN	dep||centre-19/NN||care-18/NN	dep||aids-23/VBZ||centre-19/NN	prep_for||centre-19/NN||hiv-21/NN	punct||aids-23/VBZ||/-22/:	root||ROOT-0/null||aids-23/VBZ	dobj||aids-23/VBZ||patients-24/NNS	prep_at||aids-23/VBZ||bangalore-26/NN	aids-23||hiv-21||no||art centre at st. john 's medical college hospital , bangalore and snehadan , a supportive and care centre for hiv / aids patients at bangalore .
poss||profiling-3/NN||our-1/PRP$	amod||profiling-3/NN||systematic-2/JJ	nsubj||advanced-14/VBD||profiling-3/NN	nsubj||identified-29/VBD||profiling-3/NN	nn||changes-6/NNS||phosphorylation-5/NN	prep_of||profiling-3/NN||changes-6/NNS	prep_in||changes-6/NNS||response-8/NN	amod||treatment-11/NN||bortezomib-10/JJ	prep_to||response-8/NN||treatment-11/NN	neg||only-13/JJ||not-12/RB	preconj||advanced-14/VBD||only-13/JJ	root||ROOT-0/null||advanced-14/VBD	det||understanding-18/NN||the-15/DT	amod||understanding-18/NN||global-16/JJ	amod||understanding-18/NN||mechanistic-17/JJ	dobj||advanced-14/VBD||understanding-18/NN	det||action-21/NN||the-20/DT	prep_of||understanding-18/NN||action-21/NN	prep_of||action-21/NN||bortezomib-23/NN	nn||cells-26/NNS||myeloma-25/NN	prep_on||advanced-14/VBD||cells-26/NNS	advmod||identified-29/VBD||also-28/RB	conj_but||advanced-14/VBD||identified-29/VBD	advmod||uncharacterized-31/JJ||previously-30/RB	acomp||signaling-32/VBG||uncharacterized-31/JJ	ccomp||identified-29/VBD||signaling-32/VBG	xcomp||identified-29/VBD||signaling-32/VBG	dobj||signaling-32/VBG||proteins-33/NNS	nn||cells-36/NNS||myeloma-35/NN	prep_in||signaling-32/VBG||cells-36/NNS	myeloma-35||bortezomib-23||yes||our systematic profiling of phosphorylation changes in response to bortezomib treatment not only advanced the global mechanistic understanding of the action of bortezomib on myeloma cells but also identified previously uncharacterized signaling proteins in myeloma cells.
dep||murine-8/VB||vaccination-1/JJ	prep_by||vaccination-1/JJ||bcg-3/NN	amod||bcg-3/NN||prime-4/JJ	amod||+-7/NNS||ighsp65-6/JJ	prep_with||bcg-3/NN||+-7/NNS	dep||boost-12/NN||murine-8/VB	acomp||murine-8/VB||il-12-9/JJ	punct||boost-12/NN||/-10/:	amod||boost-12/NN||hvj-envelope-11/JJ	root||ROOT-0/null||boost-12/NN	vmod||boost-12/NN||resulted-13/VBN	amod||efficacy-17/NN||significant-15/JJ	amod||efficacy-17/NN||protective-16/JJ	prep_in||resulted-13/VBN||efficacy-17/NN	dep||efficacy-17/NN||>-19/NNP	num||>-19/NNP||10-20/CD	num||>-19/NNP||â-22/CD	npadvmod||000-fold-25/JJ||$-23/$	num||$-23/$||‰-24/CD	amod||>-19/NNP||000-fold-25/JJ	prep_versus||>-19/NNP||bcg-27/NN	advmod||bcg-27/NN||alone-28/RB	nn||infection-32/NN||tb-31/NN	prep_against||efficacy-17/NN||infection-32/NN	det||lungs-35/NNS||the-34/DT	prep_in||resulted-13/VBN||lungs-35/NNS	prep_of||lungs-35/NNS||mice-37/NNS	tb-31||bcg-27||yes||vaccination by bcg prime with ighsp65+murine il-12/hvj-envelope boost resulted in significant protective efficacy (>10,â€‰000-fold versus bcg alone) against tb infection in the lungs of mice.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||effect-5/NN||the-4/DT	dobj||examined-3/VBD||effect-5/NN	amod||consumption-8/NN||chronic-7/JJ	prep_of||effect-5/NN||consumption-8/NN	det||viscous-11/NNS||the-10/DT	prep_of||consumption-8/NN||viscous-11/NNS	amod||fiber-15/NN||non-fermentable-13/JJ	nn||fiber-15/NN||dietary-14/NN	appos||consumption-8/NN||fiber-15/NN	appos||consumption-8/NN||hydroxypropylmethylcellulose-17/NN	dep||hydroxypropylmethylcellulose-17/NN||hpmc-19/JJ	nn||lipids-29/NNS||glucose-23/NN	nn||lipids-29/NNS||control-24/NN	conj_and||control-24/NN||insulinresistance-26/NN	nn||lipids-29/NNS||insulinresistance-26/NN	conj_and||control-24/NN||liver-28/NN	nn||lipids-29/NNS||liver-28/NN	prep_on||examined-3/VBD||lipids-29/NNS	det||model-35/NN||an-31/DT	amod||model-35/NN||obese-32/JJ	amod||model-35/NN||diabetic-33/JJ	nn||model-35/NN||rat-34/NN	prep_in||lipids-29/NNS||model-35/NN	lipids-29||insulinresistance-26||no_rel||this study examined the effect of chronic consumption of the viscous, non-fermentable dietary fiber, hydroxypropylmethylcellulose (hpmc), on glucose control, insulinresistance and liver lipids in an obese diabetic rat model.
poss||findings-2/NNS||its-1/PRP$	nsubj||contribute-4/VB||findings-2/NNS	aux||contribute-4/VB||may-3/MD	root||ROOT-0/null||contribute-4/VB	det||identification-7/NN||the-6/DT	prep_in||contribute-4/VB||identification-7/NN	amod||individuals-11/NNS||higher-9/JJR	nn||individuals-11/NNS||risk-10/NN	prep_of||identification-7/NN||individuals-11/NNS	prep_for||individuals-11/NNS||diabetes-13/NN	prep_for||individuals-11/NNS||cardiovasculardisease-15/NN	conj_and||diabetes-13/NN||cardiovasculardisease-15/NN	det||comprehension-19/NN||a-17/DT	amod||comprehension-19/NN||better-18/JJR	prep_with||contribute-4/VB||comprehension-19/NN	det||intercorrelation-23/NN||the-21/DT	amod||intercorrelation-23/NN||complex-22/JJ	prep_about||comprehension-19/NN||intercorrelation-23/NN	nn||metabolism-28/NN||adiposity-25/NN	prep_between||intercorrelation-23/NN||glucose-27/NN	conj_and||metabolism-28/NN||glucose-27/NN	prep_between||intercorrelation-23/NN||metabolism-28/NN	prep_between||intercorrelation-23/NN||vasculardisease-30/NN	conj_and||metabolism-28/NN||vasculardisease-30/NN	adiposity-25||glucose-27||no_rel||its findings may contribute in the identification of higher risk individuals for diabetes and cardiovasculardisease with a better comprehension about the complex intercorrelation between adiposity, glucose metabolism and vasculardisease.
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	nn||schizoaffectivedisorder-14/NN||schizophrenia-12/NN	prep_with||patients-10/NNS||schizoaffectivedisorder-14/NN	nn||disorder-18/NN||schizophreniform-17/NN	prep_with||patients-10/NNS||disorder-18/NN	conj_or||schizoaffectivedisorder-14/NN||disorder-18/NN	dep||patients-10/NNS||diagnosed-19/VBN	prepc_according_to||diagnosed-19/VBN||to-21/TO	det||manual-26/NN||the-22/DT	amod||manual-26/NN||diagnostic-23/JJ	conj_and||diagnostic-23/JJ||statistical-25/JJ	amod||manual-26/NN||statistical-25/JJ	pobj||diagnosed-19/VBN||manual-26/NN	amod||disorders-29/NNS||mental-28/JJ	npadvmod||4th-30/JJ||disorders-29/NNS	amod||edition-31/NN||4th-30/JJ	prep_of||manual-26/NN||edition-31/NN	advmod||assigned-34/VBN||randomly-33/RB	dep||patients-10/NNS||assigned-34/VBN	conj_and||diagnosed-19/VBN||assigned-34/VBN	prep_to||assigned-34/VBN||treatment-36/NN	poss||mg/day-43/NN||olanzapine-38/PRP$	amod||mg/day-43/NN||5â-39/JJ	amod||mg/day-43/NN||$-40/$	num||$-40/$||20-42/CD	prep_with||assigned-34/VBN||mg/day-43/NN	det||antipsychotic-46/NN||another-45/DT	prep_with||assigned-34/VBN||antipsychotic-46/NN	conj_or||mg/day-43/NN||antipsychotic-46/NN	amod||2â-49/NNS||haloperidol-48/JJ	dep||antipsychotic-46/NN||2â-49/NNS	num||mg/day-53/NN||$-50/$	num||$-50/$||20-52/CD	dep||2â-49/NNS||mg/day-53/NN	poss||mg/day-60/NN||risperidone-55/PRP$	amod||mg/day-60/NN||2â-56/JJ	amod||mg/day-60/NN||$-57/$	num||$-57/$||10-59/CD	dep||2â-49/NNS||mg/day-60/NN	conj_or||mg/day-53/NN||mg/day-60/NN	poss||mg/day-68/NN||ziprasidone-63/PRP$	amod||mg/day-68/NN||80â-64/JJ	amod||mg/day-68/NN||$-65/$	num||$-65/$||160-67/CD	dep||2â-49/NNS||mg/day-68/NN	conj_or||mg/day-53/NN||mg/day-68/NN	ziprasidone-63||schizophrenia-12||no_rel||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffectivedisorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â€“20 mg/day or another antipsychotic (haloperidol 2â€“20 mg/day, risperidone 2â€“10 mg/day, or ziprasidone 80â€“160 mg/day).
det||program-3/NN||the-1/DT	nn||program-3/NN||fellowship-2/NN	nsubj||offers-4/VBZ||program-3/NN	root||ROOT-0/null||offers-4/VBZ	det||opportunity-7/NN||a-5/DT	amod||opportunity-7/NN||unique-6/JJ	dobj||offers-4/VBZ||opportunity-7/NN	amod||training-10/NN||hands-on-9/JJ	prep_for||opportunity-7/NN||training-10/NN	nn||leadership-14/NN||hiv/aids-12/NNS	nn||leadership-14/NN||program-13/NN	prep_in||offers-4/VBZ||leadership-14/NN	prep_in||offers-4/VBZ||management-16/NN	conj_and||leadership-14/NN||management-16/NN	preconj||fellows-19/NNS||both-18/DT	prep_for||leadership-14/NN||fellows-19/NNS	nn||institutions-22/NNS||host-21/NN	prep_for||leadership-14/NN||institutions-22/NNS	conj_and||fellows-19/NNS||institutions-22/NNS	aids--1||hiv--1||no||the fellowship program offers a unique opportunity for hands-on training in hiv/aids program leadership and management for both fellows and host institutions.
nsubjpass||related-7/VBN||seropositivity-1/NN	prep_for||seropositivity-1/NN||hepatitisbvirussurfaceantigen-3/NN	auxpass||related-7/VBN||was-4/VBD	neg||related-7/VBN||not-5/RB	advmod||related-7/VBN||significantly-6/RB	root||ROOT-0/null||related-7/VBN	amod||cancer-10/NN||pancreatic-9/JJ	prep_to||related-7/VBN||cancer-10/NN	dep||related-7/VBN||either-12/CC	conj||related-7/VBN||in-13/IN	pobj||in-13/IN||univariate-14/NN	dep||univariate-14/NN||odds-16/NNS	dep||odds-16/NNS||ratio-17/NN	num||ratio-17/NN||1.03-18/CD	number||%-21/NN||95-20/CD	amod||ci-22/NN||%-21/NN	dep||odds-16/NNS||ci-22/NN	num||.53-25/CD||0.69-1-24/CD	appos||ci-22/NN||.53-25/CD	dep||odds-16/NNS||p-27/NN	dep||0.91-29/CD||=-28/SYM	rcmod||p-27/NN||0.91-29/CD	amod||analysis-33/NN||multivariate-32/JJ	pobj||in-13/IN||analysis-33/NN	conj_or||univariate-14/NN||analysis-33/NN	dep||analysis-33/NN||aor-35/NN	amod||aor-35/NN||1.02-37/CD	number||%-40/NN||95-39/CD	amod||ci-41/NN||%-40/NN	dep||aor-35/NN||ci-41/NN	num||.56-44/CD||0.67-1-43/CD	appos||ci-41/NN||.56-44/CD	dep||aor-35/NN||p-46/NN	dep||0.93-48/CD||=-47/SYM	rcmod||p-46/NN||0.93-48/CD	cancer-10||hepatitisbvirussurfaceantigen-3||no_rel||seropositivity for hepatitisbvirussurfaceantigen was not significantly related to pancreatic cancer, either in univariate (odds ratio 1.03; 95% ci, 0.69-1.53; p = 0.91) or multivariate analysis (aor, 1.02; 95% ci, 0.67-1.56; p = 0.93).
amod||syphilis-2/NNS||venereal-1/JJ	nsubj||multi-stage-5/NN||syphilis-2/NNS	cop||multi-stage-5/NN||is-3/VBZ	det||multi-stage-5/NN||a-4/DT	root||ROOT-0/null||multi-stage-5/NN	advmod||disease-9/NN||sexually-7/RB	amod||disease-9/NN||transmitted-8/JJ	appos||multi-stage-5/NN||disease-9/NN	vmod||disease-9/NN||caused-10/VBN	det||treponemapallidum-15/NN||the-12/DT	amod||treponemapallidum-15/NN||spirochetal-13/JJ	nn||treponemapallidum-15/NN||bacterium-14/NN	agent||caused-10/VBN||treponemapallidum-15/NN	appos||treponemapallidum-15/NN||tp-17/NN	syphilis-2||bacterium-14||no||venereal syphilis is a multi-stage, sexually transmitted disease caused by the spirochetal bacterium treponemapallidum (tp) .
nsubj||led-9/VBD||over-expression-1/NN	amod||proteins-4/NNS||socs-3/JJ	prep_of||over-expression-1/NN||proteins-4/NNS	nn||lines-8/NNS||melanoma-6/NN	nn||lines-8/NNS||cell-7/NN	prep_in||proteins-4/NNS||lines-8/NNS	root||ROOT-0/null||led-9/VBD	amod||inhibition-12/NN||significant-11/JJ	prep_to||led-9/VBD||inhibition-12/NN	amod||stat1-15/NNS||tyr701-phosphorylated-14/JJ	prep_of||inhibition-12/NN||stat1-15/NNS	dep||stat1-15/NNS||p-stat1-17/JJ	nn||expression-21/NN||gene-20/NN	prep_to||led-9/VBD||expression-21/NN	conj_and||inhibition-12/NN||expression-21/NN	prep_following||expression-21/NN||stimulation-23/NN	nn||±-26/NNP||ifn-î-25/NNP	prep_with||stimulation-23/NN||±-26/NNP	dep||±-26/NNP||ifit2-28/NNP	dep||ifit2-28/NNP||oas-1-30/JJ	dep||ifit2-28/NNP||isg-15-32/JJ	nn||³-36/NNP||ifn-î-35/NNP	prep_with||stimulation-23/NN||³-36/NNP	conj_or||±-26/NNP||³-36/NNP	appos||±-26/NNP||irf1-38/NNP	ifn--1||oas--1||no_rel||over-expression of socs proteins in melanoma cell lines led to significant inhibition of tyr701-phosphorylated stat1 (p-stat1) and gene expression following stimulation with ifn-î± (ifit2, oas-1, isg-15) or ifn-î³ (irf1).
nsubj||led-4/VBD||treatment-1/NN	prep_with||treatment-1/NN||haloperidol-3/NN	root||ROOT-0/null||led-4/VBD	prep_to||led-4/VBD||improvement-6/NN	det||tics-10/NN||the-8/DT	amod||tics-10/NN||characteristic-9/JJ	prep_in||improvement-6/NN||tics-10/NN	nn||sdisorder-14/NN||tourette-12/NN	prep_of||tics-10/NN||sdisorder-14/NN	prep_to||led-4/VBD||improvement-19/NN	conj_and||improvement-6/NN||improvement-19/NN	det||behaviors-24/NNS||these-21/DT	num||behaviors-24/NNS||three-22/CD	amod||behaviors-24/NNS||complex-associated-23/JJ	prep_in||led-4/VBD||behaviors-24/NNS	tourette'sdisorder--1||haloperidol-3||yes||treatment with haloperidol led to improvement in the characteristic tics of tourette'sdisorder as well as to improvement in these three complex-associated behaviors.
det||tissues-2/NNS||the-1/DT	nsubj||had-10/VBD||tissues-2/NNS	prep_from||tissues-2/NNS||patients-4/NNS	vmod||patients-4/NNS||revised-5/VBN	amod||wear-9/NN||suspected-7/VBN	amod||wear-9/NN||high-8/JJ	prep_for||revised-5/VBN||wear-9/NN	root||ROOT-0/null||had-10/VBD	det||score-14/NN||a-11/DT	amod||score-14/NN||lower-12/JJR	nn||score-14/NN||alval-13/NN	dobj||had-10/VBD||score-14/NN	amod||lymphocytes-17/NNS||fewer-16/JJR	appos||score-14/NN||lymphocytes-17/NNS	amod||macrophages-21/NN||more-20/JJR	dobj||had-10/VBD||macrophages-21/NN	conj_but||score-14/NN||macrophages-21/NN	nn||particles-24/NNS||metal-23/NN	conj_but||score-14/NN||particles-24/NNS	conj_and||macrophages-21/NN||particles-24/NNS	det||tissues-27/NNS||those-26/DT	prep_than||macrophages-21/NN||tissues-27/NNS	prep_from||had-10/VBD||hips-29/NNS	vmod||hips-29/NNS||revised-30/VBN	prep_for||revised-30/VBN||pain-32/NN	amod||hypersensitivity-36/NN||suspected-34/VBN	nn||hypersensitivity-36/NN||metal-35/NN	prep_for||revised-30/VBN||hypersensitivity-36/NN	conj_and||pain-32/NN||hypersensitivity-36/NN	pain-32||metal-35||no_rel||the tissues from patients revised for suspected high wear had a lower alval score, fewer lymphocytes, but more macrophages and metal particles than those tissues from hips revised for pain and suspected metal hypersensitivity.
det||profiling-3/NN||the-1/DT	amod||profiling-3/NN||global-2/JJ	nsubj||gives-8/VBZ||profiling-3/NN	det||genome-7/NN||the-5/DT	nn||genome-7/NN||vzv-6/NN	prep_of||profiling-3/NN||genome-7/NN	root||ROOT-0/null||gives-8/VBZ	amod||insights-10/NNS||further-9/JJ	dobj||gives-8/VBZ||insights-10/NNS	det||replication-13/NN||the-12/DT	prep_into||gives-8/VBZ||replication-13/NN	prep_into||gives-8/VBZ||pathogenesis-15/NNS	conj_and||replication-13/NN||pathogenesis-15/NNS	det||virus-18/NN||this-17/DT	prep_of||replication-13/NN||virus-18/NN	nsubj||lead-22/VB||virus-18/NN	aux||lead-22/VB||can-21/MD	rcmod||virus-18/NN||lead-22/VB	amod||prevention-25/NN||improved-24/VBN	prep_to||lead-22/VB||prevention-25/NN	prep_to||lead-22/VB||therapy-27/NN	conj_and||prevention-25/NN||therapy-27/NN	prep_of||prevention-25/NN||chickenpox-29/NN	prep_of||prevention-25/NN||shingles-31/NNS	conj_and||chickenpox-29/NN||shingles-31/NNS	chickenpox-29||vzv-6||no||the global profiling of the vzv genome gives further insights into the replication and pathogenesis of this virus, which can lead to improved prevention and therapy of chickenpox and shingles.
det||data-2/NNS||these-1/DT	nsubj||able-9/JJ||data-2/NNS	nsubj||explain-11/VB||data-2/NNS	aux||able-9/JJ||may-3/MD	prep_in||able-9/JJ||part-6/NN	cop||able-9/JJ||be-8/VB	root||ROOT-0/null||able-9/JJ	aux||explain-11/VB||to-10/TO	xcomp||able-9/JJ||explain-11/VB	det||use-14/NN||the-12/DT	amod||use-14/NN||traditional-13/JJ	dobj||explain-11/VB||use-14/NN	amod||plants-18/NNS||tannin-containing-16/JJ	amod||plants-18/NNS||medicinal-17/JJ	prep_of||use-14/NN||plants-18/NNS	det||treatment-21/NN||the-20/DT	prep_for||explain-11/VB||treatment-21/NN	det||variety-24/NN||a-23/DT	prep_of||treatment-21/NN||variety-24/NN	prep_of||variety-24/NN||inflammatorydiseases-26/NNS	prep_including||explain-11/VB||inflammatoryboweldisease-29/NN	prep_including||explain-11/VB||celiacdisease-31/NN	conj_and||inflammatoryboweldisease-29/NN||celiacdisease-31/NN	prep_including||explain-11/VB||rheumatoidarthritis-34/NNS	conj_and||inflammatoryboweldisease-29/NN||rheumatoidarthritis-34/NNS	tannin--1||rheumatoidarthritis-34||no_rel||these data may, in part, be able to explain the traditional use of tannin-containing medicinal plants for the treatment of a variety of inflammatorydiseases, including inflammatoryboweldisease, celiacdisease, and rheumatoidarthritis.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-33/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-23/VBZ||levels-10/NNS	prep_of||levels-10/NNS||n-3fattyacids-12/JJ	appos||n-3fattyacids-12/JJ||fa-14/NN	possessive||fa-14/NN||'s-15/POS	amod||levels-19/NNS||higher-18/JJR	prep_of||levels-10/NNS||levels-19/NNS	conj_and||n-3fattyacids-12/JJ||levels-19/NNS	amod||fa-22/NN||n-6-21/JJ	prep_of||levels-19/NNS||fa-22/NN	ccomp||contained-8/VBD||'s-23/VBZ	det||diet-27/NN||the-25/DT	nn||diet-27/NN||control-26/NN	prep_than||'s-23/VBZ||diet-27/NN	appos||diet-27/NN||ctr-29/NN	nsubj||found-33/VBD||we-32/PRP	root||ROOT-0/null||found-33/VBD	amod||decreases-35/NNS||significant-34/JJ	nsubj||'s-46/VBZ||decreases-35/NNS	amod||acid-38/NN||docosahexaenoic-37/JJ	prep_in||decreases-35/NNS||acid-38/NN	appos||acid-38/NN||dha-40/NN	amod||fa-45/NN||total-43/JJ	amod||fa-45/NN||n-3-44/JJ	prep_in||decreases-35/NNS||fa-45/NN	conj_and||acid-38/NN||fa-45/NN	ccomp||found-33/VBD||'s-46/VBZ	nn||maternal-49/NN||hfd-48/NN	prep_in||'s-46/VBZ||maternal-49/NN	amod||plasma-52/NN||fetal-51/JJ	prep_in||'s-46/VBZ||plasma-52/NN	conj_and||maternal-49/NN||plasma-52/NN	n-3fattyacids-12||fa-45||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
nn||administration-2/NN||vitamink-1/NN	nsubj||mainstay-5/NN||administration-2/NN	cop||mainstay-5/NN||is-3/VBZ	det||mainstay-5/NN||the-4/DT	root||ROOT-0/null||mainstay-5/NN	prep_of||mainstay-5/NN||therapy-7/NN	prep_in||therapy-7/NN||vkcfd-9/NN	prep_with||mainstay-5/NN||plasma-12/NN	vmod||plasma-12/NN||supplementation-13/VBN	nn||episodes-19/NNS||surgery-15/NN	conj_or||surgery-15/NN||severe-17/JJ	nn||episodes-19/NNS||severe-17/JJ	nn||episodes-19/NNS||bleeding-18/NN	prep_during||supplementation-13/VBN||episodes-19/NNS	bleeding-18||vitamink-1||no_rel||vitamink administration is the mainstay of therapy in vkcfd, with plasma supplementation during surgery or severe bleeding episodes.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||case-4/NN||a-3/DT	dobj||describe-2/VBP||case-4/NN	amod||necrotizingfasciitis-7/NNS||groupastreptococcus-6/JJ	prep_of||case-4/NN||necrotizingfasciitis-7/NNS	amod||ligation-11/NN||saphenofemoral-9/JJ	nn||ligation-11/NN||junction-10/NN	prep_following||necrotizingfasciitis-7/NNS||ligation-11/NN	nn||stripping-14/NNS||vein-13/NN	prep_following||necrotizingfasciitis-7/NNS||stripping-14/NNS	conj_and||ligation-11/NN||stripping-14/NNS	necrotizingfasciitis-7||groupastreptococcus-6||no||we describe a case of groupastreptococcus necrotizingfasciitis following saphenofemoral junction ligation and vein stripping.
det||factors-5/NNS||the-1/DT	num||factors-5/NNS||two-2/CD	advmod||consistent-4/JJ||most-3/RBS	amod||factors-5/NNS||consistent-4/JJ	nsubj||having-14/VBG||factors-5/NNS	vmod||factors-5/NNS||associated-6/VBN	nn||testing-9/NN||hiv-8/NN	prep_with||associated-6/VBN||testing-9/NN	det||countries-12/NNS||the-11/DT	prep_across||associated-6/VBN||countries-12/NNS	aux||having-14/VBG||were-13/VBD	root||ROOT-0/null||having-14/VBG	dep||having-14/VBG||heard-15/VBN	prep_about||heard-15/VBN||hiv/aids-17/NNS	det||centre-23/NN||a-19/DT	nn||centre-23/NN||clinic-20/NN	conj_or||clinic-20/NN||health-22/NN	nn||centre-23/NN||health-22/NN	prep_from||hiv/aids-17/NNS||centre-23/NN	aux||talked-27/VBN||having-26/VBG	dep||having-14/VBG||talked-27/VBN	conj_and||heard-15/VBN||talked-27/VBN	prep_to||talked-27/VBN||someone-29/NN	prep_about||someone-29/NN||hiv-31/NN	prep_about||someone-29/NN||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||the two most consistent factors associated with hiv testing across the countries were having heard about hiv/aids from a clinic or health centre, and having talked to someone about hiv and aids.
prep_on||developed-5/VBD||admission-2/NN	nsubj||developed-5/VBD||he-4/PRP	root||ROOT-0/null||developed-5/VBD	amod||oedema-7/NN||pulmonary-6/JJ	dobj||developed-5/VBD||oedema-7/NN	amod||hypertension-10/NN||systolic-9/JJ	prep_from||developed-5/VBD||hypertension-10/NN	nsubjpass||controlled-13/VBN||hypertension-10/NN	auxpass||controlled-13/VBN||was-12/VBD	rcmod||hypertension-10/NN||controlled-13/VBN	amod||support-16/NN||ventilatory-15/JJ	agent||controlled-13/VBN||support-16/NN	agent||controlled-13/VBN||nitroglycerine-18/NN	conj_and||support-16/NN||nitroglycerine-18/NN	agent||controlled-13/VBN||furosemide-20/NN	conj_and||support-16/NN||furosemide-20/NN	hypertension-10||furosemide-20||yes||on admission, he developed pulmonary oedema from systolic hypertension which was controlled by ventilatory support, nitroglycerine and furosemide.
nsubj||enteropathy-8/NN||celiacdisease-1/NN	appos||celiacdisease-1/NN||cd-3/NN	cop||enteropathy-8/NN||is-5/VBZ	det||enteropathy-8/NN||an-6/DT	amod||enteropathy-8/NN||autoimmune-7/JJ	root||ROOT-0/null||enteropathy-8/NN	vmod||enteropathy-8/NN||triggered-9/VBN	det||ingestion-12/NN||the-11/DT	agent||triggered-9/VBN||ingestion-12/NN	prep_of||ingestion-12/NN||gluten-14/NN	celiacdisease-1||gluten-14||no||celiacdisease (cd) is an autoimmune enteropathy triggered by the ingestion of gluten.
nn||department-2/NN||emergency-1/NN	nsubjpass||treated-15/VBN||department-2/NN	dep||treated-15/VBN||ed-4/NN	nsubjpass||treated-15/VBN||patients-6/NNS	amod||thromboembolism-9/NN||venous-8/JJ	prep_with||patients-6/NNS||thromboembolism-9/NN	appos||patients-6/NNS||vte-11/NN	auxpass||treated-15/VBN||are-13/VBP	advmod||treated-15/VBN||eventually-14/RB	root||ROOT-0/null||treated-15/VBN	det||dose-19/NN||a-17/DT	amod||dose-19/NN||standard-18/JJ	prep_with||treated-15/VBN||dose-19/NN	prep_of||dose-19/NN||warfarin-21/NN	det||fact-24/NN||the-23/DT	prep_despite||treated-15/VBN||fact-24/NN	mark||known-31/VBN||that-25/IN	det||number-27/NN||a-26/DT	nsubjpass||known-31/VBN||number-27/NN	nsubj||sensitive-34/JJ||number-27/NN	nsubj||warfarin-36/VB||number-27/NN	nsubj||experience-39/VB||number-27/NN	prep_of||number-27/NN||patients-29/NNS	auxpass||known-31/VBN||are-30/VBP	ccomp||treated-15/VBN||known-31/VBN	aux||sensitive-34/JJ||to-32/TO	cop||sensitive-34/JJ||be-33/VB	xcomp||known-31/VBN||sensitive-34/JJ	aux||warfarin-36/VB||to-35/TO	xcomp||sensitive-34/JJ||warfarin-36/VB	aux||experience-39/VB||may-38/MD	ccomp||treated-15/VBN||experience-39/VB	conj_and||known-31/VBN||experience-39/VB	amod||inrs-41/NNS||supra-therapeutic-40/JJ	dobj||experience-39/VB||inrs-41/NNS	amod||events-45/NNS||adverse-43/JJ	amod||events-45/NNS||bleeding-44/VBG	dobj||experience-39/VB||events-45/NNS	conj_and||inrs-41/NNS||events-45/NNS	thromboembolism-9||warfarin-36||yes||emergency department (ed) patients with venous thromboembolism (vte) are eventually treated with a standard dose of warfarin despite the fact that a number of patients are known to be sensitive to warfarin and may experience supra-therapeutic inrs and adverse bleeding events.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||determine-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||determine-6/VB||to-5/TO	xcomp||conducted-4/VBN||determine-6/VB	det||prevalence-8/NN||the-7/DT	dobj||determine-6/VB||prevalence-8/NN	amod||parasitosis-11/NNS||intestinal-10/JJ	prep_of||prevalence-8/NN||parasitosis-11/NNS	amod||patients-14/NNS||hiv/aids-13/JJ	prep_in||parasitosis-11/NNS||patients-14/NNS	prep_in||patients-14/NNS||dschang-16/NN	dep||prevalence-8/NN||cameroon-18/NN	aids--1||hiv--1||no||this study was conducted to determine the prevalence of intestinal parasitosis in hiv/aids patients in dschang -cameroon.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	tick-borneencephalitis-50||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
nsubj||treated-2/VBD||we-1/PRP	root||ROOT-0/null||treated-2/VBD	det||level-5/NN||a-3/DT	amod||level-5/NN||long-4/JJ	nsubj||epiduralabscess-9/VBZ||level-5/NN	dep||level-5/NN||t4-l1-7/JJ	ccomp||treated-2/VBD||epiduralabscess-9/VBZ	det||patient-13/NN||a-11/DT	amod||patient-13/NN||diabetic-12/JJ	prep_in||epiduralabscess-9/VBZ||patient-13/NN	nsubj||had-15/VBD||patient-13/NN	nsubj||undergo-17/VB||patient-13/NN	nsubj||drainage-23/VB||patient-13/NN	rcmod||patient-13/NN||had-15/VBD	aux||undergo-17/VB||to-16/TO	xcomp||had-15/VBD||undergo-17/VB	amod||decompression-21/NNS||emergent-18/JJ	amod||decompression-21/NNS||long-19/JJ	nn||decompression-21/NNS||level-20/NN	dobj||undergo-17/VB||decompression-21/NNS	xcomp||had-15/VBD||drainage-23/VB	conj_and||undergo-17/VB||drainage-23/VB	acomp||drainage-23/VB||due-24/JJ	aux||complete-26/VB||to-25/TO	xcomp||due-24/JJ||complete-26/VB	dobj||complete-26/VB||paralysis-27/NN	det||extremities-31/NNS||the-29/DT	amod||extremities-31/NNS||lower-30/JJR	prep_of||paralysis-27/NN||extremities-31/NNS	dobj||complete-26/VB||progression-33/NN	conj_and||paralysis-27/NN||progression-33/NN	amod||deficit-36/NN||neurologic-35/JJ	prep_of||progression-33/NN||deficit-36/NN	det||level-41/NN||the-38/DT	amod||level-41/NN||upper-39/JJ	amod||level-41/NN||thoracic-40/JJ	prep_toward||complete-26/VB||level-41/NN	t4--1||epiduralabscess-9||no_rel||we treated a long level (t4-l1) epiduralabscess in a diabetic patient who had to undergo emergent long level decompression and drainage due to complete paralysis of the lower extremities and progression of neurologic deficit toward the upper thoracic level.
det||objective-3/NN||the-1/DT	amod||objective-3/NN||main-2/JJ	nsubj||is-8/VBZ||objective-3/NN	nsubj||monitor-10/VB||objective-3/NN	det||study-7/NN||the-5/DT	amod||study-7/NN||current-6/JJ	prep_of||objective-3/NN||study-7/NN	ccomp||â-36/VBP||is-8/VBZ	aux||monitor-10/VB||to-9/TO	xcomp||is-8/VBZ||monitor-10/VB	det||status-13/NN||the-11/DT	amod||status-13/NN||auditory-12/JJ	dobj||monitor-10/VB||status-13/NN	det||group-16/NN||a-15/DT	prep_in||status-13/NN||group-16/NN	prep_of||group-16/NN||adults-18/NNS	prep_with||monitor-10/VB||aids-20/NNS	vmod||monitor-10/VB||receiving-22/VBG	advmod||active-24/JJ||highly-23/RB	amod||therapy-26/NN||active-24/JJ	amod||therapy-26/NN||antiretroviral-25/JJ	dobj||receiving-22/VBG||therapy-26/NN	appos||therapy-26/NN||haart-28/NN	dep||therapy-26/NN||3tc-31/NNP	dep||3tc-31/NNP||lamivudine-33/NN	nsubj||â-36/VBP||d4t-35/NNS	root||ROOT-0/null||â-36/VBP	dobj||â-36/VBP||$-37/$	npadvmod||outpatient-47/JJ||stavudine-39/NN	conj_and||stavudine-39/NN||efavirenz-42/NN	npadvmod||outpatient-47/JJ||efavirenz-42/NN	quantmod||hospital-46/NN||in-44/IN	quantmod||hospital-46/NN||a-45/DT	num||stavudine-39/NN||hospital-46/NN	amod||clinic-48/NNS||outpatient-47/JJ	npadvmod||in-49/RB||clinic-48/NNS	dep||gauteng-50/CD||in-49/RB	num||$-37/$||gauteng-50/CD	aids-20||3tc-31||yes||the main objective of the current study is to monitor the auditory status in a group of adults with aids, receiving highly active antiretroviral therapy (haart) (3tc -lamivudine, d4t â€“ stavudine, and efavirenz) in a hospital outpatient clinic in gauteng.
nsubj||showed-5/VBD||sera-1/NN	amod||animals-4/NNS||immunized-3/JJ	prep_of||sera-1/NN||animals-4/NNS	root||ROOT-0/null||showed-5/VBD	amod||response-8/NN||high-6/JJ	nn||response-8/NN||igg-7/NN	nsubj||showed-17/VBD||response-8/NN	amod||cross-reactivity-11/NN||strong-10/JJ	conj_and||response-8/NN||cross-reactivity-11/NN	nsubj||showed-17/VBD||cross-reactivity-11/NN	amod||results-16/NNS||different-13/JJ	nn||results-16/NNS||mtb-14/NN	nn||results-16/NNS||antigens.these-15/NN	prep_against||response-8/NN||results-16/NNS	ccomp||showed-5/VBD||showed-17/VBD	mark||candidates-25/NNS||that-18/IN	nn||pls-20/NN||bcg-19/NN	nsubj||candidates-25/NNS||pls-20/NN	aux||candidates-25/NNS||could-21/MD	cop||candidates-25/NNS||be-22/VB	amod||candidates-25/NNS||potential-23/JJ	nn||candidates-25/NNS||vaccine-24/NN	ccomp||showed-17/VBD||candidates-25/NNS	prep_against||candidates-25/NNS||tb-27/NN	tb-27||bcg-19||yes||sera of immunized animals showed high igg response and strong cross-reactivity against different mtb antigens.these results showed that bcg pls could be potential vaccine candidates against tb.
nsubj||shown-14/VBN||bevacizumab-1/NN	det||antibody-5/NN||a-3/DT	amod||antibody-5/NN||monoclonal-4/JJ	appos||bevacizumab-1/NN||antibody-5/NN	vmod||antibody-5/NN||directed-6/VBN	det||ligand-9/NN||the-8/DT	prep_against||directed-6/VBN||ligand-9/NN	appos||ligand-9/NN||vegf-11/NN	aux||shown-14/VBN||has-13/VBZ	root||ROOT-0/null||shown-14/VBN	dobj||shown-14/VBN||activity-15/NN	prep_against||activity-15/NN||rcc-17/NN	det||agent-21/NN||a-19/DT	amod||agent-21/NN||single-20/JJ	prep_as||shown-14/VBN||agent-21/NN	prep_in||agent-21/NN||patients-23/NNS	nsubj||failed-26/VBN||patients-23/NNS	aux||failed-26/VBN||had-25/VBD	rcmod||patients-23/NNS||failed-26/VBN	amod||therapy-29/NN||prior-27/JJ	nn||therapy-29/NN||cytokine-28/NN	dobj||failed-26/VBN||therapy-29/NN	dobj||failed-26/VBN||as-31/RB	advmod||therapy-29/NN||as-31/RB	conj_and||therapy-29/NN||as-31/RB	amod||therapy-34/NN||first-32/JJ	nn||therapy-34/NN||line-33/NN	dep||therapy-29/NN||therapy-34/NN	prep_in||therapy-34/NN||combination-36/NN	prep_with||failed-26/VBN||interferon-38/NN	antibody-5||rcc-17||no_rel||bevacizumab, a monoclonal antibody directed against the ligand, vegf, has shown activity against rcc as a single agent in patients who had failed prior cytokine therapy and as first line therapy in combination with interferon.
det||expression-2/NN||the-1/DT	nsubjpass||analyzed-11/VBN||expression-2/NN	conj_and||expression-2/NN||localization-4/NN	nsubjpass||analyzed-11/VBN||localization-4/NN	prep_of||expression-2/NN||synoviolin-6/NN	det||liver-9/NN||the-8/DT	prep_in||synoviolin-6/NN||liver-9/NN	auxpass||analyzed-11/VBN||were-10/VBD	root||ROOT-0/null||analyzed-11/VBN	amod||models-16/NNS||ccl4-induced-13/JJ	amod||models-16/NNS||hepatic-14/JJ	nn||models-16/NNS||injury-15/NN	prep_in||analyzed-11/VBN||models-16/NNS	amod||tissues-20/NNS||human-18/JJ	nn||tissues-20/NNS||cirrhosis-19/NNS	prep_in||analyzed-11/VBN||tissues-20/NNS	conj_and||models-16/NNS||tissues-20/NNS	ccl4--1||cirrhosis-19||no_rel||the expression and localization of synoviolin in the liver were analyzed in ccl4-induced hepatic injury models and human cirrhosis tissues.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||evaluate-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||efficacy-10/NN||the-9/DT	dobj||evaluate-8/VB||efficacy-10/NN	dobj||evaluate-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	amod||extended-release-16/NN||methylphenidatehcl-14/JJ	nn||extended-release-16/NN||oros-15/NNS	prep_of||efficacy-10/NN||extended-release-16/NN	appos||extended-release-16/NN||oros-mph-18/NN	prep_among||extended-release-16/NN||children-21/NNS	nn||hyperactivitydisorder-25/NN||attention-23/NN	nn||hyperactivitydisorder-25/NN||deficit-24/NN	prep_with||children-21/NNS||hyperactivitydisorder-25/NN	nsubjpass||treated-33/VBN||hyperactivitydisorder-25/NN	dep||hyperactivitydisorder-25/NN||adhd-27/VBN	aux||treated-33/VBN||had-30/VBD	auxpass||treated-33/VBN||been-31/VBN	advmod||treated-33/VBN||previously-32/RB	rcmod||hyperactivitydisorder-25/NN||treated-33/VBN	amod||immediate-release-36/NN||methylphenidatehcl-35/JJ	prep_with||treated-33/VBN||immediate-release-36/NN	appos||extended-release-16/NN||mph-ir-38/NN	adhd-27||methylphenidatehcl-35||yes||the objective of this study was to evaluate the efficacy and safety of methylphenidatehcl oros extended-release (oros-mph) among children with attention deficit hyperactivitydisorder (adhd) who had been previously treated with methylphenidatehcl immediate-release (mph-ir).
aux||assess-2/VB||to-1/TO	advcl||increase-13/VBP||assess-2/VB	amod||agents-5/NNS||biological-4/JJ	prep_if||assess-2/VB||agents-5/NNS	nsubj||increase-13/VBP||ie-7/NN	amod||ie-7/NN||rituximab-8/JJ	amod||ie-7/NN||abatacept-10/JJ	conj_and||rituximab-8/JJ||abatacept-10/JJ	amod||ie-7/NN||anakinra-12/JJ	conj_and||rituximab-8/JJ||anakinra-12/JJ	root||ROOT-0/null||increase-13/VBP	det||risk-15/NN||the-14/DT	dobj||increase-13/VBP||risk-15/NN	amod||infections-18/NNS||serious-17/JJ	prep_of||risk-15/NN||infections-18/NNS	prep_in||increase-13/VBP||patients-20/NNS	prep_with||patients-20/NNS||rheumatoidarthritis-22/NNS	amod||trials-27/NNS||published-24/VBN	amod||trials-27/NNS||randomised-25/JJ	amod||trials-27/NNS||controlled-26/VBN	prep_in||rheumatoidarthritis-22/NNS||trials-27/NNS	rheumatoidarthritis-22||anakinra-12||yes||to assess if biological agents, ie rituximab, abatacept and anakinra increase the risk of serious infections in patients with rheumatoidarthritis in published randomised controlled trials.
amod||cultures-2/NNS||secondary-1/JJ	nsubjpass||performed-4/VBN||cultures-2/NNS	auxpass||performed-4/VBN||was-3/VBD	root||ROOT-0/null||performed-4/VBN	xcomp||performed-4/VBN||using-5/VBG	amod||cells-8/NNS||cd34-6/JJ	amod||cells-8/NNS||+-7/JJ	dobj||using-5/VBG||cells-8/NNS	dep||cells-8/NNS||isolated-9/VBN	num||days-12/NNS||35-11/CD	prep_at||isolated-9/VBN||days-12/NNS	amod||cultures-15/NNS||primary-14/JJ	prep_from||days-12/NNS||cultures-15/NNS	advmod||cultured-18/VBN||further-17/RBR	dep||cells-8/NNS||cultured-18/VBN	conj_and||isolated-9/VBN||cultured-18/VBN	nn||medium-24/NN||stemspanâ-20/NNP	nn||medium-24/NN||„-21/NNP	nn||medium-24/NN||cents-22/NNS	nn||medium-24/NN||sfem-23/NN	prep_in||cultured-18/VBN||medium-24/NN	det||days-28/NNS||another-26/DT	num||days-28/NNS||14-27/CD	prep_for||cultured-18/VBN||days-28/NNS	aux||confirm-30/VB||to-29/TO	xcomp||cultured-18/VBN||confirm-30/VB	det||effect-34/NN||the-31/DT	amod||effect-34/NN||long-32/JJ	nn||effect-34/NN||term-33/NN	dobj||confirm-30/VB||effect-34/NN	prep_of||effect-34/NN||alemtuzumab-36/NN	amod||cultures-39/NNS||liquid-38/JJ	prep_in||confirm-30/VB||cultures-39/NNS	secondary-1||alemtuzumab-36||no_rel||secondary cultures was performed using cd34+ cells isolated at 35 days from primary cultures and further cultured in stemspanâ„¢ sfem medium for another 14 days to confirm the long term effect of alemtuzumab in liquid cultures.
nn||therapies-3/NNS||nicotine-1/NN	nn||therapies-3/NNS||replacement-2/NN	nsubj||tools-9/NNS||therapies-3/NNS	appos||therapies-3/NNS||nrt-5/NN	cop||tools-9/NNS||are-7/VBP	amod||tools-9/NNS||powerful-8/JJ	root||ROOT-0/null||tools-9/NNS	det||treatment-13/NN||the-11/DT	amod||treatment-13/NN||successful-12/JJ	prep_for||tools-9/NNS||treatment-13/NN	nn||use-18/NN||nicotineaddiction-15/NN	conj_and||nicotineaddiction-15/NN||tobacco-17/NN	nn||use-18/NN||tobacco-17/NN	prep_of||treatment-13/NN||use-18/NN	nicotineaddiction-15||nicotine-1||no||nicotine replacement therapies (nrt) are powerful tools for the successful treatment of nicotineaddiction and tobacco use.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	type2diabetes-33||insulin-27||yes||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
prepc_after||have-11/VBP||failing-2/VBG	det||blocker-8/NN||a-3/DT	amod||blocker-8/NN||first-4/JJ	nn||blocker-8/NN||tumor-5/NN	nn||blocker-8/NN||necrosis-6/NN	nn||blocker-8/NN||factor-7/NN	dobj||failing-2/VBG||blocker-8/NN	nsubj||have-11/VBP||patients-10/NNS	root||ROOT-0/null||have-11/VBP	amod||options-14/NNS||several-12/JJ	nn||options-14/NNS||treatment-13/NN	dobj||have-11/VBP||options-14/NNS	csubj||necrosis-20/VBZ||starting-16/VBG	det||tumor-19/NN||a-17/DT	amod||tumor-19/NN||second-18/JJ	dobj||starting-16/VBG||tumor-19/NN	conj_but||have-11/VBP||necrosis-20/VBZ	nn||blocker-22/NN||factor-21/NN	dobj||necrosis-20/VBZ||blocker-22/NN	dobj||necrosis-20/VBZ||rituximab-25/JJ	conj_or||blocker-22/NN||rituximab-25/JJ	conj_or||blocker-22/NN||abatacept-27/JJ	conj_or||rituximab-25/JJ||abatacept-27/JJ	neg||studies-33/NNS||no-30/DT	amod||studies-33/NNS||formal-31/JJ	amod||studies-33/NNS||randomized-32/JJ	nsubj||available-35/JJ||studies-33/NNS	nsubj||indicate-37/VB||studies-33/NNS	cop||available-35/JJ||are-34/VBP	conj_but||have-11/VBP||available-35/JJ	aux||indicate-37/VB||to-36/TO	xcomp||available-35/JJ||indicate-37/VB	nsubj||strategy-42/NN||what-38/WP	cop||strategy-42/NN||is-39/VBZ	det||strategy-42/NN||the-40/DT	amod||strategy-42/NN||optimal-41/JJ	ccomp||indicate-37/VB||strategy-42/NN	tumor-19||rituximab-25||no_rel||after failing a first tumor necrosis factor blocker, patients have several treatment options - starting a second tumor necrosis factor blocker, or rituximab or abatacept - but no formal randomized studies are available to indicate what is the optimal strategy.
nsubjpass||measured-19/VBN||markers-1/NNS	nn||control-4/NN||glucose-3/NN	prep_of||markers-1/NNS||control-4/NN	amod||test-10/NN||oral-7/JJ	nn||test-10/NN||glucose-8/NN	nn||test-10/NN||tolerance-9/NN	prep_including||markers-1/NNS||test-10/NN	amod||hemoglobin-13/NN||glycated-12/JJ	prep_including||markers-1/NNS||hemoglobin-13/NN	conj_and||test-10/NN||hemoglobin-13/NN	amod||glucose-16/NN||urinary-15/JJ	prep_including||markers-1/NNS||glucose-16/NN	conj_and||test-10/NN||glucose-16/NN	auxpass||measured-19/VBN||were-18/VBD	root||ROOT-0/null||measured-19/VBN	dobj||measured-19/VBN||adiposity-23/NN	det||accumulation-26/NN||the-25/DT	dobj||measured-19/VBN||accumulation-26/NN	conj_and||adiposity-23/NN||accumulation-26/NN	nn||lipids-29/NNS||liver-28/NN	prep_of||accumulation-26/NN||lipids-29/NNS	adiposity-23||lipids-29||no_rel||markers of glucose control, including oral glucose tolerance test, glycated hemoglobin and urinary glucose, were measured as well as adiposity and the accumulation of liver lipids.
amod||level-2/NN||pd-1-1/JJ	nsubj||correlated-10/JJ||level-2/NN	amod||tem/temra-7/NN||peripheral-4/JJ	amod||tem/temra-7/NN||cd8-5/JJ	amod||tem/temra-7/NN||+-6/JJ	prep_on||level-2/NN||tem/temra-7/NN	cop||correlated-10/JJ||was-8/VBD	advmod||correlated-10/JJ||highly-9/RB	root||ROOT-0/null||correlated-10/JJ	nn||load-14/NN||hcv-12/NN	amod||load-14/NN||viral-13/JJ	prep_with||correlated-10/JJ||load-14/NN	amod||patients-18/NNS||chronic-16/JJ	amod||patients-18/NNS||hcv-infected-17/JJ	prep_in||load-14/NN||patients-18/NNS	nsubj||made-21/VBD||patients-18/NNS	rcmod||patients-18/NNS||made-21/VBD	amod||indicator-25/NN||pd-1-22/JJ	det||indicator-25/NN||a-23/DT	nn||indicator-25/NN||novel-24/NN	dobj||made-21/VBD||indicator-25/NN	aux||evaluate-27/VB||to-26/TO	vmod||made-21/VBD||evaluate-27/VB	nn||replication-29/NN||hcv-28/NN	dobj||evaluate-27/VB||replication-29/NN	nn||progression-32/NN||disease-31/NN	dobj||evaluate-27/VB||progression-32/NN	conj_and||replication-29/NN||progression-32/NN	amod||patients-35/NNS||chronichepatitisc-34/JJ	prep_in||replication-29/NN||patients-35/NNS	chronichepatitisc-34||hcv-28||no||pd-1 level on peripheral cd8+ tem/temra was highly correlated with hcv viral load in chronic hcv-infected patients, which made pd-1 a novel indicator to evaluate hcv replication and disease progression in chronichepatitisc patients.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||yes||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
nn||cisplatin-3/NN||background-1/NN	nn||cisplatin-3/NN||liposomal-2/NN	nsubj||formulation-7/NN||cisplatin-3/NN	cop||formulation-7/NN||is-4/VBZ	det||formulation-7/NN||a-5/DT	amod||formulation-7/NN||new-6/JJ	root||ROOT-0/null||formulation-7/NN	vmod||formulation-7/NN||developed-8/VBN	aux||reduce-10/VB||to-9/TO	xcomp||developed-8/VBN||reduce-10/VB	det||toxicity-13/NN||the-11/DT	amod||toxicity-13/NN||systemic-12/JJ	dobj||reduce-10/VB||toxicity-13/NN	prep_of||toxicity-13/NN||cisplatin-15/NN	mark||improving-18/VBG||while-16/IN	advmod||improving-18/VBG||simultaneously-17/RB	advcl||reduce-10/VB||improving-18/VBG	det||targeting-20/NN||the-19/DT	dobj||improving-18/VBG||targeting-20/NN	det||drug-23/NN||the-22/DT	prep_of||targeting-20/NN||drug-23/NN	det||tumor-27/NN||the-25/DT	amod||tumor-27/NN||primary-26/JJ	prep_to||improving-18/VBG||tumor-27/NN	prep_to||improving-18/VBG||metastases-30/NNS	conj_and||tumor-27/NN||metastases-30/NNS	amod||time-34/NN||increasing-32/VBG	nn||time-34/NN||circulation-33/NN	prep_by||improving-18/VBG||time-34/NN	det||fluids-38/NNS||the-36/DT	nn||fluids-38/NNS||body-37/NN	prep_in||time-34/NN||fluids-38/NNS	prep_in||time-34/NN||tissues-40/NNS	conj_and||fluids-38/NNS||tissues-40/NNS	tumor-27||cisplatin-15||no_rel||background liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation time in the body fluids and tissues.
amod||effects-3/NNS||upper-1/JJ	nn||effects-3/NNS||gi-2/NN	nsubjpass||documented-18/VBN||effects-3/NNS	amod||treatment-7/NN||non-selective-5/JJ	amod||treatment-7/NN||nsaid-6/JJ	prep_of||effects-3/NNS||treatment-7/NN	vmod||documented-18/VBN||ranging-9/VBG	prep_from||ranging-9/VBG||abdominalpain-11/NN	prep_to||ranging-9/VBG||ulceration-13/NN	prep_to||ranging-9/VBG||bleeding-15/NN	conj_and||ulceration-13/NN||bleeding-15/NN	auxpass||documented-18/VBN||are-16/VBP	advmod||documented-18/VBN||extensively-17/RB	root||ROOT-0/null||documented-18/VBN	abdominalpain-11||nsaid-6||no_rel||upper gi effects of non-selective nsaid treatment, ranging from abdominalpain to ulceration and bleeding are extensively documented.
amod||cells-4/NNS||cultured-2/JJ	nn||cells-4/NNS||melanoma-3/NN	prep_in||dots-10/VBZ||cells-4/NNS	amod||co-localizes-7/NNS||fmnl2-6/JJ	nsubj||dots-10/VBZ||co-localizes-7/NNS	prep_with||co-localizes-7/NNS||f-actin-9/NN	root||ROOT-0/null||dots-10/VBZ	det||tips-13/NNS||the-12/DT	prep_at||dots-10/VBZ||tips-13/NNS	amod||protrusions-16/NNS||cellular-15/JJ	prep_of||tips-13/NNS||protrusions-16/NNS	melanoma-3||f---1||no_rel||in cultured melanoma cells, fmnl2 co-localizes with f-actin dots at the tips of cellular protrusions.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||show-20/VB||that-5/IN	nsubj||show-20/VB||extracts-6/NNS	amod||plants-10/NNS||haudenosaunee-8/JJ	amod||plants-10/NNS||medicinal-9/JJ	prep_from||extracts-6/NNS||plants-10/NNS	vmod||plants-10/NNS||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	dobj||treat-13/VB||symptoms-14/NNS	advmod||caused-16/VBN||often-15/RB	vmod||symptoms-14/NNS||caused-16/VBN	agent||caused-16/VBN||bacterialinfection-18/NN	aux||show-20/VB||would-19/MD	ccomp||tested-2/VBD||show-20/VB	amod||properties-22/NNS||antibacterial-21/JJ	dobj||show-20/VB||properties-22/NNS	nn||assays-25/NNS||laboratory-24/NN	prep_in||show-20/VB||assays-25/NNS	mark||effective-34/JJ||that-28/IN	det||extracts-30/NNS||these-29/DT	nsubj||effective-34/JJ||extracts-30/NNS	aux||effective-34/JJ||would-31/MD	cop||effective-34/JJ||be-32/VB	advmod||effective-34/JJ||more-33/RBR	ccomp||tested-2/VBD||effective-34/JJ	conj_and||show-20/VB||effective-34/JJ	advmod||virulent-37/JJ||moderately-36/RB	amod||bacteria-38/NNS||virulent-37/JJ	prep_against||effective-34/JJ||bacteria-38/NNS	amod||bacteria-42/NNS||less-40/JJR	nn||bacteria-42/NNS||virulent-41/NN	prep_than||effective-34/JJ||bacteria-42/NNS	bacterialinfection-18||bacteria-42||no||we tested the hypothesis that extracts from haudenosaunee medicinal plants used to treat symptoms often caused by bacterialinfection would show antibacterial properties in laboratory assays, and that these extracts would be more effective against moderately virulent bacteria than less virulent bacteria.
nsubjpass||assigned-20/VBN||outpatients-2/NNS	advmod||assigned-20/VBN||with-3/RB	nsubj||maintained-7/VBN||schizophrenia-4/NN	nsubjpass||assigned-20/VBN||schizophrenia-4/NN	aux||maintained-7/VBN||had-6/VBD	rcmod||schizophrenia-4/NN||maintained-7/VBN	dobj||maintained-7/VBN||stability-8/NN	amod||olanzapine-12/NN||open-label-10/JJ	amod||olanzapine-12/NN||oral-11/JJ	prep_on||maintained-7/VBN||olanzapine-12/NN	number||8-16/CD||4-14/CD	dep||8-16/CD||to-15/TO	num||weeks-17/NNS||8-16/CD	prep_for||olanzapine-12/NN||weeks-17/NNS	auxpass||assigned-20/VBN||were-18/VBD	advmod||assigned-20/VBN||randomly-19/RB	root||ROOT-0/null||assigned-20/VBN	prep_to||assigned-20/VBN||low-24/NN	num||weeks-30/NNS||150-28/CD	amod||weeks-30/NNS||mg/2-29/JJ	dep||low-24/NN||weeks-30/NNS	dep||weeks-30/NNS||n-32/NN	dep||140-34/CD||=-33/SYM	rcmod||n-32/NN||140-34/CD	dep||low-24/NN||medium-39/NN	num||weeks-45/NNS||405-43/CD	amod||weeks-45/NNS||mg/4-44/JJ	dep||medium-39/NN||weeks-45/NNS	nn||318-49/NNP||n-47/NNP	nn||318-49/NNP||=-48/NNP	dep||weeks-45/NNS||318-49/NNP	advmod||medium-39/NN||or-52/CC	nsubj||lai-70/VBP||high-55/NN	num||weeks-61/NNS||300-59/CD	amod||weeks-61/NNS||mg/2-60/JJ	dep||high-55/NN||weeks-61/NNS	dep||weeks-61/NNS||n-63/NN	dep||141-65/CD||=-64/SYM	rcmod||n-63/NN||141-65/CD	advmod||high-55/NN||dosages-67/RB	prep_of||high-55/NN||olanzapine-69/JJ	ccomp||assigned-20/VBN||lai-70/VBP	num||weeks-73/NNS||24-72/CD	prep_for||lai-70/VBP||weeks-73/NNS	schizophrenia-4||olanzapine-69||yes||" outpatients with schizophrenia who had maintained stability on open-label oral olanzapine for 4 to 8 weeks were randomly assigned to ""low"" (150 mg/2 weeks; n = 140), ""medium"" (405 mg/4 weeks; n = 318), or ""high"" (300 mg/2 weeks; n = 141) dosages of olanzapine lai for 24 weeks."
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	xcomp||â-5/VBP||$-6/VBG	quantmod||total-9/NN||a-8/DT	num||participants-18/NNS||total-9/NN	quantmod||total-9/NN||of-10/IN	number||total-9/NN||3,188-11/CD	nn||participants-18/NNS||diabetes-12/NN	nn||participants-18/NNS||prevention-13/NN	nn||participants-18/NNS||program-14/NN	discourse||participants-18/NNS||dpp-16/UH	dobj||$-6/VBG||participants-18/NNS	det||bmi-22/NN||a-20/DT	amod||bmi-22/NN||mean-21/JJ	prep_with||$-6/VBG||bmi-22/NN	num||kg/m2-25/NNS||34-24/CD	prep_of||bmi-22/NN||kg/m2-25/NNS	amod||glucose-29/NN||elevated-27/JJ	amod||glucose-29/NN||fasting-28/VBG	prep_with||$-6/VBG||glucose-29/NN	conj_and||bmi-22/NN||glucose-29/NN	appos||glucose-29/NN||impairedglucosetolerance-31/NN	amod||measurements-38/NNS||baseline-34/JJ	amod||measurements-38/NNS||urinary-35/JJ	nn||measurements-38/NNS||albumin-36/NN	nn||measurements-38/NNS||excretion-37/NN	nsubjpass||followed-40/VBN||measurements-38/NNS	auxpass||followed-40/VBN||were-39/VBD	conj_and||â-5/VBP||followed-40/VBN	nn||diabetes-43/NN||incident-42/NN	prep_for||followed-40/VBN||diabetes-43/NN	det||mean-46/NN||a-45/DT	prep_over||followed-40/VBN||mean-46/NN	num||years-49/NNS||3.2-48/CD	prep_of||mean-46/NN||years-49/NNS	impairedglucosetolerance-31||albumin-36||no_rel||research design and methods â€”a total of 3,188 diabetes prevention program (dpp) participants with a mean bmi of 34 kg/m2 and elevated fasting glucose, impairedglucosetolerance, and baseline urinary albumin excretion measurements were followed for incident diabetes over a mean of 3.2 years.
nsubj||anthracycline-8/VBP||all-1/DT	dep||all-1/DT||transretinoicacid-3/VBN	dep||transretinoicacid-3/VBN||atra-5/NNP	punct||transretinoicacid-3/VBN||/-7/:	root||ROOT-0/null||anthracycline-8/VBP	nsubj||beneficial-11/JJ||chemotherapy-9/NN	cop||beneficial-11/JJ||is-10/VBZ	ccomp||anthracycline-8/VBP||beneficial-11/JJ	advmod||diagnosed-14/JJ||newly-13/RB	amod||acutepromyelocyticleukemia-15/NN||diagnosed-14/JJ	prep_in||beneficial-11/JJ||acutepromyelocyticleukemia-15/NN	appos||acutepromyelocyticleukemia-15/NN||apl-17/NN	advmod||important-24/JJ||however-20/RB	nsubj||important-24/JJ||it-22/PRP	nsubj||identify-26/VB||it-22/PRP	cop||important-24/JJ||is-23/VBZ	parataxis||anthracycline-8/VBP||important-24/JJ	aux||identify-26/VB||to-25/TO	xcomp||important-24/JJ||identify-26/VB	dobj||identify-26/VB||patients-27/NNS	amod||disease-30/NN||high-risk-29/JJ	prep_with||patients-27/NNS||disease-30/NN	aux||increase-32/VB||to-31/TO	vmod||identify-26/VB||increase-32/VB	det||rate-35/NN||the-33/DT	nn||rate-35/NN||cure-34/NN	dobj||increase-32/VB||rate-35/NN	apl-17||transretinoicacid-3||yes||all- transretinoicacid (atra)/anthracycline chemotherapy is beneficial in newly diagnosed acutepromyelocyticleukemia (apl); however, it is important to identify patients with high-risk disease to increase the cure rate.
det||standard-3/NN||the-1/DT	amod||standard-3/NN||gold-2/JJ	nsubj||biopsy-10/NN||standard-3/NN	prepc_of||standard-3/NN||assessing-5/VBG	nn||fibrosis-7/NN||liver-6/NN	dobj||assessing-5/VBG||fibrosis-7/NN	cop||biopsy-10/NN||is-8/VBZ	nn||biopsy-10/NN||liver-9/NN	root||ROOT-0/null||biopsy-10/NN	nsubj||invasive-14/JJ||biopsy-10/NN	cop||invasive-14/JJ||is-13/VBZ	rcmod||biopsy-10/NN||invasive-14/JJ	rcmod||biopsy-10/NN||not-16/RB	conj_and||invasive-14/JJ||not-16/RB	neg||invasive-14/JJ||not-16/RB	prep_without||invasive-14/JJ||risk-18/NN	gold-2||fibrosis-7||no_rel||the gold standard of assessing liver fibrosis is liver biopsy, which is invasive and not without risk.
nsubj||complication-6/NN||diabeticretinopathy-1/NN	cop||complication-6/NN||is-2/VBZ	det||complication-6/NN||a-3/DT	amod||complication-6/NN||serious-4/JJ	amod||complication-6/NN||long-term-5/JJ	root||ROOT-0/null||complication-6/NN	prep_of||complication-6/NN||diabetesmellitus-8/NNS	diabeticretinopathy-1||diabetesmellitus-8||no||diabeticretinopathy is a serious long-term complication of diabetesmellitus.
det||cyld-4/NN||the-1/DT	nn||cyld-4/NN||tumor-2/NN	nn||cyld-4/NN||suppressor-3/NN	nsubj||enzyme-8/NN||cyld-4/NN	cop||enzyme-8/NN||is-5/VBZ	det||enzyme-8/NN||a-6/DT	amod||enzyme-8/NN||deubiquitinating-7/VBG	root||ROOT-0/null||enzyme-8/NN	nsubj||inhibits-10/VBZ||enzyme-8/NN	rcmod||enzyme-8/NN||inhibits-10/VBZ	dobj||inhibits-10/VBZ||activation-11/NN	nsubj||has-20/VBZ||activation-11/NN	det||îº-16/NN||the-13/DT	nn||îº-16/NN||nf-14/NN	prep_of||activation-11/NN||îº-16/NN	dep||activation-11/NN||b-17/SYM	rcmod||activation-11/NN||has-20/VBZ	amod||roles-22/NNS||key-21/JJ	dobj||has-20/VBZ||roles-22/NNS	prep_in||roles-22/NNS||inflammation-24/NN	prep_in||roles-22/NNS||apoptosis-26/NNS	conj_and||inflammation-24/NN||apoptosis-26/NNS	inflammation-24||enzyme-8||no_rel||the tumor suppressor cyld is a deubiquitinating enzyme that inhibits activation of the nf- îº b, which has key roles in inflammation and apoptosis.
nsubj||agent-5/NN||itraconazole-1/NN	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||an-3/DT	amod||agent-5/NN||anti-fungal-4/JJ	root||ROOT-0/null||agent-5/NN	advmod||used-7/VBN||widely-6/RB	vmod||agent-5/NN||used-7/VBN	aux||treat-9/VB||to-8/TO	xcomp||used-7/VBN||treat-9/VB	amod||forms-11/NNS||various-10/JJ	dobj||treat-9/VB||forms-11/NNS	prep_of||forms-11/NNS||mycosis-13/NNS	mycosis-13||itraconazole-1||yes||itraconazole is an anti-fungal agent widely used to treat various forms of mycosis.
prep_in||found-14/VBD||addition-2/NN	vmod||found-14/VBD||using-4/VBG	det||cox-6/NN||a-5/DT	poss||model-11/NN||cox-6/NN	amod||model-11/NN||proportional-8/JJ	nn||model-11/NN||hazards-9/NNS	nn||model-11/NN||regression-10/NN	dobj||using-4/VBG||model-11/NN	nsubj||found-14/VBD||we-13/PRP	root||ROOT-0/null||found-14/VBD	mark||factor-33/NN||that-15/IN	det||level-20/NN||an-16/DT	amod||level-20/NN||elevated-17/JJ	nn||level-20/NN||opn-18/NN	nn||level-20/NN||protein-19/NN	nsubj||factor-33/NN||level-20/NN	det||serum-23/NN||the-22/DT	prep_in||level-20/NN||serum-23/NN	nn||extracts-27/NNS||tumor-25/NN	nn||extracts-27/NNS||tissue-26/NN	prep_in||level-20/NN||extracts-27/NNS	conj_and||serum-23/NN||extracts-27/NNS	cop||factor-33/NN||is-28/VBZ	det||factor-33/NN||a-29/DT	amod||factor-33/NN||significant-30/JJ	amod||factor-33/NN||negative-31/JJ	amod||factor-33/NN||prognostic-32/JJ	ccomp||found-14/VBD||factor-33/NN	prep_for||factor-33/NN||patients-35/NNS	prep_with||patients-35/NNS||sts-37/NN	sts-37||tumor-25||no_rel||in addition, using a cox's proportional hazards regression model, we found that an elevated opn protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with sts.
amod||control-2/NN||efficient-1/JJ	nsubj||requires-8/VBZ||control-2/NN	prep_of||control-2/NN||tuberculosis-4/NNP	appos||tuberculosis-4/NNP||tb-6/NN	dep||mycobacteriumbovis-20/VBZ||requires-8/VBZ	dobj||requires-8/VBZ||development-9/NN	prep_of||development-9/NN||strategies-11/NNS	nsubj||enhance-14/VB||strategies-11/NNS	aux||enhance-14/VB||can-13/MD	rcmod||strategies-11/NNS||enhance-14/VB	dobj||enhance-14/VB||efficacy-15/NN	det||vaccine-19/NN||the-17/DT	amod||vaccine-19/NN||existing-18/VBG	prep_of||efficacy-15/NN||vaccine-19/NN	root||ROOT-0/null||mycobacteriumbovis-20/VBZ	amod||guerin-23/NN||bacille-21/JJ	nn||guerin-23/NN||calmette-22/NN	nsubj||mycobacteriumbovis-20/VBZ||guerin-23/NN	appos||guerin-23/NN||bcg-25/NN	tb-6||bcg-25||no||efficient control of tuberculosis (tb) requires development of strategies that can enhance efficacy of the existing vaccine mycobacteriumbovis bacille calmette guerin (bcg).
nsubj||has-2/VBZ||azathioprine-1/NN	root||ROOT-0/null||has-2/VBZ	acomp||has-2/VBZ||equivalent-3/JJ	advmod||equivalent-3/JJ||efficacy-4/RB	det||agent-8/NN||a-6/DT	nn||agent-8/NN||maintenance-7/NN	prep_as||equivalent-3/JJ||agent-8/NN	aux||cyclophosphamide-10/VB||to-9/TO	xcomp||equivalent-3/JJ||cyclophosphamide-10/VB	amod||episodes-13/NNS||fewer-12/JJR	prep_with||cyclophosphamide-10/VB||episodes-13/NNS	prep_of||episodes-13/NNS||leukopenia-15/NN	leukopenia-15||azathioprine-1||no_rel||azathioprine has equivalent efficacy as a maintenance agent to cyclophosphamide with fewer episodes of leukopenia.
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
nsubjpass||studied-17/VBN||associations-1/NNS	nn||estrogens-4/NNS||serum-3/NN	prep_of||associations-1/NNS||estrogens-4/NNS	prep_of||associations-1/NNS||androgens-6/NNS	conj_and||estrogens-4/NNS||androgens-6/NNS	nn||risk-10/NN||breast-8/NN	nn||risk-10/NN||cancer-9/NN	prep_with||estrogens-4/NNS||risk-10/NN	amod||women-13/NNS||premenopausal-12/JJ	prep_in||risk-10/NN||women-13/NNS	auxpass||studied-17/VBN||are-14/VBP	advmod||well-16/RB||less-15/RBR	advmod||studied-17/VBN||well-16/RB	root||ROOT-0/null||studied-17/VBN	cancer-9||estrogens-4||no_rel||associations of serum estrogens and androgens with breast cancer risk in premenopausal women are less well studied.
det||4-3/CD||the-1/DT	amod||4-3/CD||mdg-2/JJ	nsubj||call-6/VBP||4-3/CD	conj_and||4-3/CD||6-5/CD	nsubj||call-6/VBP||6-5/CD	root||ROOT-0/null||call-6/VBP	det||reduction-9/NN||a-8/DT	prep_for||call-6/VBP||reduction-9/NN	nn||mortality-12/NN||child-11/NN	prep_of||reduction-9/NN||mortality-12/NN	prep_by||call-6/VBP||two-thirds-14/NNS	amod||malaria-17/NN||combating-16/JJ	prep_by||call-6/VBP||malaria-17/NN	conj_and||two-thirds-14/NNS||malaria-17/NN	prep_by||call-6/VBP||hiv/aids-19/NNS	conj_and||two-thirds-14/NNS||hiv/aids-19/NNS	prep_by||call-6/VBP||tb-21/NN	conj_and||two-thirds-14/NNS||tb-21/NN	amod||diseases-25/NNS||other-24/JJ	prep_by||call-6/VBP||diseases-25/NNS	conj_and||two-thirds-14/NNS||diseases-25/NNS	advmod||call-6/VBP||respectively-27/RB	aids--1||hiv--1||no||the mdg 4 and 6 call for a reduction of child mortality by two-thirds and combating malaria, hiv/aids, tb, and other diseases, respectively.
advmod||showed-6/VBD||moreover-1/RB	poss||study-4/NN||our-3/PRP$	nsubj||showed-6/VBD||study-4/NN	advmod||showed-6/VBD||also-5/RB	root||ROOT-0/null||showed-6/VBD	mark||cooperated-11/VBD||that-7/IN	det||sirna-10/NN||the-8/DT	amod||sirna-10/NN||p53-targeting-9/JJ	nsubj||cooperated-11/VBD||sirna-10/NN	ccomp||showed-6/VBD||cooperated-11/VBD	prep_with||cooperated-11/VBD||cisplatin-13/NN	det||inhibition-16/NN||the-15/DT	prep_in||cooperated-11/VBD||inhibition-16/NN	nn||cells-20/NNS||bladder-18/NN	nn||cells-20/NNS||cancer-19/NN	prep_of||inhibition-16/NN||cells-20/NNS	cancer-19||cisplatin-13||no_rel||moreover, our study also showed that the p53-targeting sirna cooperated with cisplatin in the inhibition of bladder cancer cells.
prep_in||demonstrates-6/VBZ||summary-2/NN	poss||study-5/NN||our-4/PRP$	nsubj||demonstrates-6/VBZ||study-5/NN	root||ROOT-0/null||demonstrates-6/VBZ	mark||parameters-22/NNS||that-7/IN	nn||use-9/NN||statin-8/NN	nsubj||parameters-22/NNS||use-9/NN	nn||fraction-12/NN||ejection-11/NN	conj_and||use-9/NN||fraction-12/NN	nsubj||parameters-22/NNS||fraction-12/NN	nn||duration-16/NN||transplant-15/NN	conj_and||use-9/NN||duration-16/NN	nsubj||parameters-22/NNS||duration-16/NN	amod||angiography-19/NN||coronary-18/JJ	prep_before||duration-16/NN||angiography-19/NN	cop||parameters-22/NNS||are-20/VBP	amod||parameters-22/NNS||independent-21/JJ	ccomp||demonstrates-6/VBZ||parameters-22/NNS	vmod||parameters-22/NNS||associated-23/VBN	det||severity-26/NN||the-25/DT	prep_with||associated-23/VBN||severity-26/NN	prep_of||severity-26/NN||coronaryatherosclerosis-28/NNS	amod||patients-33/NNS||long-term-30/JJ	nn||patients-33/NNS||kidney-31/NN	nn||patients-33/NNS||transplant-32/NN	prep_in||coronaryatherosclerosis-28/NNS||patients-33/NNS	statin-8||coronaryatherosclerosis-28||no_rel||in summary, our study demonstrates that statin use, ejection fraction, and transplant duration before coronary angiography are independent parameters associated with the severity of coronaryatherosclerosis in long-term kidney transplant patients.
advmod||dissatisfied-10/VBN||however-1/RB	quantmod||10-4/CD||approximately-3/RB	num||%-5/NN||10-4/CD	nsubjpass||dissatisfied-10/VBN||%-5/NN	amod||patients-8/NNS||hypothyroid-7/JJ	prep_of||%-5/NN||patients-8/NNS	auxpass||dissatisfied-10/VBN||are-9/VBP	root||ROOT-0/null||dissatisfied-10/VBN	det||outcome-13/NN||the-12/DT	prep_with||dissatisfied-10/VBN||outcome-13/NN	amod||monotherapy-16/NN||levothyroxine-15/JJ	prep_of||outcome-13/NN||monotherapy-16/NN	nsubj||continue-20/VBP||physicians-19/NNS	nsubj||report-22/VB||physicians-19/NNS	conj_and||dissatisfied-10/VBN||continue-20/VBP	aux||report-22/VB||to-21/TO	xcomp||continue-20/VBP||report-22/VB	dobj||report-22/VB||benefits-23/NNS	amod||therapy-27/NN||combined-25/VBN	amod||therapy-27/NN||levothyroxine-triidothyronine-26/JJ	prep_from||report-22/VB||therapy-27/NN	det||patients-31/NNS||some-29/DT	amod||patients-31/NNS||hypothyroid-30/JJ	prep_for||therapy-27/NN||patients-31/NNS	hypothyroid-30||levothyroxine-15||yes||however, approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients.
mark||kv2-5/VBD||since-1/IN	det||encoding-4/NN||the-2/DT	amod||encoding-4/NN||kcnb1-3/JJ	nsubj||kv2-5/VBD||encoding-4/NN	advcl||postulated-24/VBD||kv2-5/VBD	num||accounts-8/NNS||.1-6/CD	nn||accounts-8/NNS||channel-7/NN	dobj||kv2-5/VBD||accounts-8/NNS	det||majority-11/NN||the-10/DT	prep_for||kv2-5/VBD||majority-11/NN	nn||currents-14/NNS||kv-13/NN	prep_of||majority-11/NN||currents-14/NNS	xcomp||kv2-5/VBD||modulating-15/VBG	nn||secretion-17/NN||insulin-16/NN	dobj||modulating-15/VBG||secretion-17/NN	amod||beta-cells-21/NNS||pancreatic-19/JJ	nn||beta-cells-21/NNS||islet-20/NN	prep_by||modulating-15/VBG||beta-cells-21/NNS	nsubj||postulated-24/VBD||we-23/PRP	root||ROOT-0/null||postulated-24/VBD	mark||gene-31/NN||that-25/IN	nsubj||gene-31/NN||kcnb1-26/NNS	cop||gene-31/NN||is-27/VBZ	det||gene-31/NN||a-28/DT	amod||gene-31/NN||plausible-29/JJ	nn||gene-31/NN||candidate-30/NN	ccomp||postulated-24/VBD||gene-31/NN	amod||variation-34/NN||genetic-33/JJ	prep_for||gene-31/NN||variation-34/NN	vmod||variation-34/NN||contributing-35/VBG	det||function-41/NN||the-37/DT	amod||function-41/NN||variable-38/JJ	amod||secretory-40/JJ||compensatory-39/JJ	amod||function-41/NN||secretory-40/JJ	prep_to||contributing-35/VBG||function-41/NN	prep_of||function-41/NN||beta-cells-43/NNS	amod||diabetes-46/NN||type-2-45/JJ	prep_in||beta-cells-43/NNS||diabetes-46/NN	appos||diabetes-46/NN||t2d-48/NNP	t2d-48||insulin-16||yes||since the kcnb1 encoding kv2.1 channel accounts for the majority of kv currents modulating insulin secretion by pancreatic islet beta-cells, we postulated that kcnb1 is a plausible candidate gene for genetic variation contributing to the variable compensatory secretory function of beta-cells in type-2 diabetes (t2d).
amod||combinations-4/NNS||docetaxel-1/JJ	conj_and||docetaxel-1/JJ||gemcitabine-3/JJ	amod||combinations-4/NNS||gemcitabine-3/JJ	nsubj||proven-6/VBN||combinations-4/NNS	aux||proven-6/VBN||have-5/VBP	root||ROOT-0/null||proven-6/VBN	acomp||proven-6/VBN||active-7/JJ	det||treatment-10/NN||the-9/DT	prep_for||proven-6/VBN||treatment-10/NN	prep_of||treatment-10/NN||non-smallcelllungcancer-12/NN	dep||non-smallcelllungcancer-12/NN||nsclc-14/JJ	gemcitabine-3||non-smallcelllungcancer-12||no_rel||docetaxel and gemcitabine combinations have proven active for the treatment of non-smallcelllungcancer (nsclc).
det||study-2/NN||this-1/DT	nsubj||provided-4/VBN||study-2/NN	aux||provided-4/VBN||has-3/VBZ	root||ROOT-0/null||provided-4/VBN	amod||insights-6/NNS||new-5/JJ	dobj||provided-4/VBN||insights-6/NNS	det||disposition-10/NN||the-8/DT	nn||disposition-10/NN||intracellular-9/NN	prep_into||provided-4/VBN||disposition-10/NN	prep_of||disposition-10/NN||mtx-12/NN	nn||cells-15/NNS||leukemia-14/NN	prep_in||mtx-12/NN||cells-15/NNS	advmod||affects-19/VBZ||how-17/WRB	nsubj||affects-19/VBZ||it-18/PRP	prep_into||provided-4/VBN||affects-19/VBZ	conj_and||disposition-10/NN||affects-19/VBZ	dobj||affects-19/VBZ||treatment-20/NN	advmod||affects-19/VBZ||efficacy-21/RB	leukemia-14||mtx-12||yes||this study has provided new insights into the intracellular disposition of mtx in leukemia cells and how it affects treatment efficacy.
det||adults-3/NNS||these-2/DT	prep_of||had-10/VBD||adults-3/NNS	nsubj||hiv-infected-7/JJ||56-5/CD	cop||hiv-infected-7/JJ||were-6/VBD	dep||had-10/VBD||hiv-infected-7/JJ	nsubj||had-10/VBD||120-9/CD	root||ROOT-0/null||had-10/VBD	det||member-13/NN||a-11/DT	nn||member-13/NN||family-12/NN	dobj||had-10/VBD||member-13/NN	prep_with||member-13/NN||hiv/aids-15/NNS	nsubj||were-19/VBD||146-18/CD	conj_and||had-10/VBD||were-19/VBD	prep_in||were-19/VBD||households-21/NNS	amod||members-24/NNS||hiv-infected-23/JJ	prep_without||were-19/VBD||members-24/NNS	aids--1||hiv--1||no||of these adults, 56 were hiv-infected, 120 had a family member with hiv/aids, and 146 were in households without hiv-infected members.
det||work-5/NN||the-3/DT	amod||work-5/NN||pioneering-4/JJ	prep_due_to||possible-23/JJ||work-5/NN	prep_of||work-5/NN||cushing-7/JJ	prep_of||work-5/NN||hirsch-9/JJ	conj_and||cushing-7/JJ||hirsch-9/JJ	prep_of||work-5/NN||yasargil-11/JJ	conj_and||cushing-7/JJ||yasargil-11/JJ	prep_of||work-5/NN||krause-13/JJ	conj_and||cushing-7/JJ||krause-13/JJ	prep_of||work-5/NN||dandy-15/JJ	conj_and||cushing-7/JJ||dandy-15/JJ	prep_of||work-5/NN||other-17/JJ	conj_and||cushing-7/JJ||other-17/JJ	vmod||work-5/NN||dedicated-18/VBN	dobj||dedicated-18/VBN||neurosurgeons-19/NNS	nsubj||possible-23/JJ||it-21/PRP	nsubj||address-25/VB||it-21/PRP	cop||possible-23/JJ||is-22/VBZ	root||ROOT-0/null||possible-23/JJ	aux||address-25/VB||to-24/TO	xcomp||possible-23/JJ||address-25/VB	det||tumor-27/NN||the-26/DT	dobj||address-25/VB||tumor-27/NN	amod||lesions-30/NNS||other-29/JJ	dobj||address-25/VB||lesions-30/NNS	conj_and||tumor-27/NN||lesions-30/NNS	det||anterior-33/NN||the-32/DT	prep_in||address-25/VB||anterior-33/NN	det||mid-line-36/NN||the-35/DT	prep_in||address-25/VB||mid-line-36/NN	conj_and||anterior-33/NN||mid-line-36/NN	det||base-41/NN||the-38/DT	nn||base-41/NN||posterior-39/NN	nn||base-41/NN||cranial-40/NN	prep_in||address-25/VB||base-41/NN	conj_and||anterior-33/NN||base-41/NN	base-41||tumor-27||no_rel||due to the pioneering work of cushing, hirsch, yasargil, krause, dandy and other dedicated neurosurgeons, it is possible to address the tumor and other lesions in the anterior, the mid-line and the posterior cranial base.
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tb--1||pyrazinamide-29||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
nsubj||disease-18/NN||newcastledisease-1/NN	appos||newcastledisease-1/NN||nd-3/NN	vmod||newcastledisease-1/NN||caused-6/VBN	amod||virus-9/NN||newcastledisease-8/JJ	agent||caused-6/VBN||virus-9/NN	appos||virus-9/NN||ndv-11/NN	cop||disease-18/NN||is-14/VBZ	det||disease-18/NN||a-15/DT	advmod||contagious-17/JJ||highly-16/RB	amod||disease-18/NN||contagious-17/JJ	root||ROOT-0/null||disease-18/NN	prep_of||disease-18/NN||birds-20/NNS	aux||one-24/CD||has-22/VBZ	cop||one-24/CD||been-23/VBN	conj_and||disease-18/NN||one-24/CD	det||causes-28/NNS||the-26/DT	amod||causes-28/NNS||major-27/JJ	prep_of||one-24/CD||causes-28/NNS	amod||losses-31/NNS||economic-30/JJ	prep_of||causes-28/NNS||losses-31/NNS	det||industry-35/NN||the-33/DT	nn||industry-35/NN||poultry-34/NN	prep_in||one-24/CD||industry-35/NN	newcastledisease-8||ndv-11||no||newcastledisease (nd), caused by newcastledisease virus (ndv), is a highly contagious disease of birds and has been one of the major causes of economic losses in the poultry industry.
nsubj||drug-8/NN||ablc-1/NN	cop||drug-8/NN||is-2/VBZ	det||drug-8/NN||a-3/DT	amod||drug-8/NN||safe-4/JJ	conj_and||safe-4/JJ||effective-6/JJ	amod||drug-8/NN||effective-6/JJ	amod||drug-8/NN||broad-spectrum-7/JJ	root||ROOT-0/null||drug-8/NN	det||treatment-11/NN||the-10/DT	prep_in||drug-8/NN||treatment-11/NN	amod||fungalinfections-14/NNS||invasive-13/JJ	prep_of||treatment-11/NN||fungalinfections-14/NNS	prep_in||fungalinfections-14/NNS||patients-16/NNS	nn||refractory-19/NNS||infection-18/NN	prep_with||patients-16/NNS||refractory-19/NNS	prep_with||patients-16/NNS||refractory-19/NNS	conj_or||refractory-19/NNS||refractory-19/NNS	nn||deoxycholate-22/NN||amb-21/NN	prep_to||refractory-19/NNS||deoxycholate-22/NN	nn||intolerant-26/NN||patients-25/NNS	prep_in||refractory-19/NNS||intolerant-26/NN	det||formulation-30/NN||the-28/DT	amod||formulation-30/NN||same-29/JJ	prep_of||intolerant-26/NN||formulation-30/NN	fungalinfections-14||ablc-1||yes||ablc is a safe and effective broad-spectrum drug in the treatment of invasive fungalinfections in patients with infection refractory to amb deoxycholate or in patients intolerant of the same formulation.
det||withdrawal-4/NN||the-1/DT	amod||withdrawal-4/NN||recent-2/JJ	amod||withdrawal-4/NN||worldwide-3/JJ	nsubj||changed-13/VBN||withdrawal-4/NN	nn||rejection-9/NN||sibutramine-6/NN	conj_and||sibutramine-6/NN||fda-8/NN	nn||rejection-9/NN||fda-8/NN	prep_of||withdrawal-4/NN||rejection-9/NN	prep_of||rejection-9/NN||lorcaserin-11/NN	aux||changed-13/VBN||has-12/VBZ	root||ROOT-0/null||changed-13/VBN	det||landscape-15/NN||the-14/DT	dobj||changed-13/VBN||landscape-15/NN	neg||only-17/JJ||not-16/RB	preconj||changed-13/VBN||only-17/JJ	amod||therapeutics-20/NNS||serotonin-based-19/JJ	prep_for||changed-13/VBN||therapeutics-20/NNS	advmod||changed-13/VBN||specifically-21/RB	amod||pharmacotherapy-26/NN||obesity-25/JJ	prep_for||changed-13/VBN||pharmacotherapy-26/NN	conj_but||therapeutics-20/NNS||pharmacotherapy-26/NN	prep_in||pharmacotherapy-26/NN||general-28/NN	obesity-25||sibutramine-6||yes||the recent worldwide withdrawal of sibutramine and fda rejection of lorcaserin has changed the landscape not only for serotonin-based therapeutics specifically, but for obesity pharmacotherapy in general.
nsubj||involved-5/VBN||subtypes-1/NNS	amod||receptors-4/NNS||purinergic-3/JJ	prep_of||subtypes-1/NNS||receptors-4/NNS	root||ROOT-0/null||involved-5/VBN	prep_in||involved-5/VBN||modulation-7/NN	amod||concentration-12/NN||cytoplasmic-9/JJ	nn||concentration-12/NN||calcium-10/NN	nn||concentration-12/NN||ion-11/NN	prep_of||modulation-7/NN||concentration-12/NN	nn||i-18/NNP||-LSB--14/NNP	nn||i-18/NNP||ca2-15/NNP	nn||i-18/NNP||+-16/NNP	nn||i-18/NNP||-RSB--17/NNP	appos||concentration-12/NN||i-18/NNP	nn||release-22/NN||insulin-21/NN	prep_in||involved-5/VBN||release-22/NN	conj_and||modulation-7/NN||release-22/NN	nn||²-27/NNS||mouse-24/NN	amod||²-27/NNS||pancreatic-25/JJ	nn||²-27/NNS||î-26/NN	prep_in||release-22/NN||²-27/NNS	nsubjpass||examined-31/VBN||cells-29/NNS	auxpass||examined-31/VBN||were-30/VBD	parataxis||involved-5/VBN||examined-31/VBN	num||systems-34/NNS||two-33/CD	prep_in||examined-31/VBN||systems-34/NNS	amod||islets-37/NNS||pancreatic-36/JJ	appos||systems-34/NNS||islets-37/NNS	amod||culture-40/NN||primary-39/JJ	prep_in||islets-37/NNS||culture-40/NN	amod||cells-44/NNS||beta-tc6-42/JJ	nn||cells-44/NNS||insulinoma-43/NN	prep_in||islets-37/NNS||cells-44/NNS	conj_and||culture-40/NN||cells-44/NNS	ion-11||insulinoma-43||no_rel||subtypes of purinergic receptors involved in modulation of cytoplasmic calcium ion concentration ([ca2+]i) and insulin release in mouse pancreatic î²-cells were examined in two systems, pancreatic islets in primary culture and beta-tc6 insulinoma cells.
prepc_by||pin-pointed-18/VBN||utilizing-2/VBG	amod||testing-4/NN||in-silico-3/JJ	dobj||utilizing-2/VBG||testing-4/NN	det||library-9/NN||a-6/DT	amod||library-9/NN||transmembrane-7/JJ	nn||library-9/NN||sequence-8/NN	prep_of||testing-4/NN||library-9/NN	vmod||library-9/NN||derived-10/VBN	nn||sequences-14/NNS||virus-12/NN	nn||sequences-14/NNS||protein-13/NN	prep_from||derived-10/VBN||sequences-14/NNS	nsubj||pin-pointed-18/VBN||we-16/PRP	aux||pin-pointed-18/VBN||have-17/VBP	root||ROOT-0/null||pin-pointed-18/VBN	det||motif-22/NN||a-19/DT	num||motif-22/NN||nine-20/CD	amod||motif-22/NN||amino-acid-21/JJ	dobj||pin-pointed-18/VBN||motif-22/NN	vmod||motif-22/NN||shared-23/VBN	det||group-26/NN||a-25/DT	agent||shared-23/VBN||group-26/NN	amod||viruses-29/NNS||different-28/JJ	prep_of||group-26/NN||viruses-29/NNS	det||motif-32/NN||this-31/DT	nsubj||resembles-33/VBZ||motif-32/NN	parataxis||pin-pointed-18/VBN||resembles-33/VBZ	det||domain-36/NN||the-34/DT	amod||domain-36/NN||transmembrane-35/JJ	xcomp||resembles-33/VBZ||domain-36/NN	det||±-40/NN||the-38/DT	nn||±-40/NN||î-39/NN	prep_of||domain-36/NN||±-40/NN	dep||domain-36/NN||subunit-42/NN	det||receptor-46/NN||the-44/DT	amod||receptor-46/NN||t-cell-45/JJ	prep_of||subunit-42/NN||receptor-46/NN	nn||±-49/NNP||tcrî-48/NNP	appos||receptor-46/NN||±-49/NNP	virus-12||viruses-29||no||by utilizing in-silico testing of a transmembrane sequence library derived from virus protein sequences, we have pin-pointed a nine amino-acid motif shared by a group of different viruses; this motif resembles the transmembrane domain of the î±-subunit of the t-cell receptor (tcrî±).
amod||isotretinoin-2/NN||oral-1/JJ	nsubj||drug-5/NN||isotretinoin-2/NN	cop||drug-5/NN||is-3/VBZ	det||drug-5/NN||the-4/DT	root||ROOT-0/null||drug-5/NN	prep_of||drug-5/NN||choice-7/NN	amod||acnevulgaris-10/NNS||severe-9/JJ	prep_for||choice-7/NN||acnevulgaris-10/NNS	poss||use-14/NN||its-13/PRP$	nsubj||controversial-17/JJ||use-14/NN	cop||controversial-17/JJ||is-15/VBZ	advmod||controversial-17/JJ||still-16/RB	conj_but||drug-5/NN||controversial-17/JJ	prepc_in||controversial-17/JJ||preventing-19/VBG	prepc_in||controversial-17/JJ||treating-21/VBG	conj_or||preventing-19/VBG||treating-21/VBG	prepc_in||controversial-17/JJ||stopping-23/VBG	conj_or||preventing-19/VBG||stopping-23/VBG	det||progression-25/NN||the-24/DT	dobj||preventing-19/VBG||progression-25/NN	iobj||preventing-19/VBG||progression-25/NN	det||neoplasia-30/NN||the-27/DT	amod||neoplasia-30/NN||cervical-28/JJ	amod||neoplasia-30/NN||intraepithelial-29/JJ	prep_of||progression-25/NN||neoplasia-30/NN	dep||progression-25/NN||-LSB--31/NNP	num||-LSB--31/NNP||6-32/CD	num||-LSB--31/NNP||7-34/CD	num||-RSB--37/NNS||8-36/CD	appos||-LSB--31/NNP||-RSB--37/NNS	acnevulgaris-10||isotretinoin-2||yes||oral isotretinoin is the drug of choice for severe acnevulgaris, but its use is still controversial in preventing, treating or stopping the progression of the cervical intraepithelial neoplasia [ 6 , 7 , 8 ].
nsubjpass||affected-5/VBN||cows-1/NNS	nsubjpass||hypothyroid-12/VBN||cows-1/NNS	auxpass||affected-5/VBN||were-4/VBD	rcmod||cows-1/NNS||affected-5/VBN	amod||liver-9/NN||severe-7/JJ	amod||liver-9/NN||fatty-8/JJ	prep_with||affected-5/VBN||liver-9/NN	auxpass||hypothyroid-12/VBN||were-11/VBD	root||ROOT-0/null||hypothyroid-12/VBN	prep_prior_to||hypothyroid-12/VBN||development-15/NN	det||condition-18/NN||the-17/DT	prep_of||development-15/NN||condition-18/NN	acomp||hypothyroid-12/VBN||due-19/JJ	amod||concentrations-23/NNS||lower-21/JJR	amod||concentrations-23/NNS||t4-22/JJ	prep_to||due-19/JJ||concentrations-23/NNS	acomp||hypothyroid-12/VBN||had-26/VBD	conj_and||due-19/JJ||had-26/VBD	advmod||lower-28/JJR||significantly-27/RB	amod||concentration-29/NN||lower-28/JJR	dobj||had-26/VBD||concentration-29/NN	prep_of||concentration-29/NN||t3-31/NNS	amod||ratios-35/NNS||higher-33/JJR	amod||ratios-35/NNS||t3/t4-34/JJ	prep_of||concentration-29/NN||ratios-35/NNS	conj_and||t3-31/NNS||ratios-35/NNS	prep_than||had-26/VBD||cows-37/NNS	amod||liver-43/NN||mild-39/JJ	conj_and||mild-39/JJ||moderate-41/JJ	amod||liver-43/NN||moderate-41/JJ	nn||liver-43/NN||fatty-42/NN	prep_with||cows-37/NNS||liver-43/NN	hypothyroid-12||t3-31||yes||cows, that were affected with severe fatty liver, were hypothyroid prior to development of the condition due to lower t4 concentrations, and had significantly lower concentration of t3 and higher t3/t4 ratios than cows with mild and moderate fatty liver.
nsubj||correlated-3/VBD||we-1/PRP	advmod||correlated-3/VBD||subsequently-2/RB	root||ROOT-0/null||correlated-3/VBD	det||levels-6/NNS||the-4/DT	nn||levels-6/NNS||ros-5/NN	dobj||correlated-3/VBD||levels-6/NNS	det||mechanisms-10/NNS||the-8/DT	amod||mechanisms-10/NNS||anticancer-9/JJ	prep_to||correlated-3/VBD||mechanisms-10/NNS	prep_of||mechanisms-10/NNS||epi-12/NN	prep_of||mechanisms-10/NNS||8hd-14/NNS	conj_and||epi-12/NN||8hd-14/NNS	amod||cells-20/NNS||human-16/JJ	nn||cells-20/NNS||colon-17/NN	nn||cells-20/NNS||adenocarcinoma-18/NN	amod||cells-20/NNS||caco-2-19/JJ	prep_in||correlated-3/VBD||cells-20/NNS	epi-12||adenocarcinoma-18||no_rel||we subsequently correlated the ros levels to the anticancer mechanisms of epi and 8hd in human colon adenocarcinoma caco-2 cells.
det||questionnaire-2/NN||the-1/DT	nsubj||consisted-3/VBD||questionnaire-2/NN	nsubj||questions-21/VBZ||questionnaire-2/NN	nsubj||assess-23/VB||questionnaire-2/NN	root||ROOT-0/null||consisted-3/VBD	num||questions-6/NNS||24-5/CD	prep_of||consisted-3/VBD||questions-6/NNS	prep_regarding||questions-6/NNS||awareness-8/NN	det||modes-11/NNS||the-10/DT	prep_of||awareness-8/NN||modes-11/NNS	prep_of||modes-11/NNS||transmission-13/NN	prep_of||transmission-13/NN||hiv/aids-15/NNS	num||questions-18/NNS||nine-17/CD	appos||hiv/aids-15/NNS||questions-18/NNS	conj_and||consisted-3/VBD||questions-21/VBZ	aux||assess-23/VB||to-22/TO	xcomp||questions-21/VBZ||assess-23/VB	det||attitude-25/NN||the-24/DT	dobj||assess-23/VB||attitude-25/NN	prep_toward||assess-23/VB||people-27/NNS	vmod||people-27/NNS||living-28/VBG	prep_with||living-28/VBG||hiv/aids-30/NNS	appos||hiv/aids-30/NNS||plwha-32/NNP	num||questions-36/NNS||15-35/CD	appos||hiv/aids-30/NNS||questions-36/NNS	aids--1||hiv--1||no||the questionnaire consisted of 24 questions regarding awareness of the modes of transmission of hiv/aids (nine questions) and questions to assess the attitude toward people living with hiv/aids (plwha) (15 questions).
amod||washing-5/NNS||deep-1/JJ	conj_and||deep-1/JJ||thorough-3/JJ	amod||washing-5/NNS||thorough-3/JJ	nn||washing-5/NNS||biliary-4/NN	nsubj||covered-18/VBD||washing-5/NNS	conj_and||washing-5/NNS||stenting-8/VBG	nsubj||covered-18/VBD||stenting-8/VBG	det||polytetrafluoroethylene-13/NN||a-10/DT	amod||polytetrafluoroethylene-13/NN||new-11/JJ	amod||polytetrafluoroethylene-13/NN||removable-12/JJ	prep_with||stenting-8/VBG||polytetrafluoroethylene-13/NN	appos||polytetrafluoroethylene-13/NN||ptfe-15/NN	root||ROOT-0/null||covered-18/VBD	amod||stent-20/NN||flared-type-19/JJ	nsubj||led-21/VBD||stent-20/NN	nsubj||complete-23/VB||stent-20/NN	ccomp||covered-18/VBD||led-21/VBD	aux||complete-23/VB||to-22/TO	xcomp||led-21/VBD||complete-23/VB	dobj||complete-23/VB||resolution-24/NN	det||jaundice-28/NN||the-26/DT	amod||jaundice-28/NN||obstructive-27/JJ	prep_of||resolution-24/NN||jaundice-28/NN	ptfe-15||jaundice-28||no_rel||deep and thorough biliary washing, and stenting with a new removable polytetrafluoroethylene (ptfe)-covered flared-type stent led to complete resolution of the obstructive jaundice.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	num||patients-4/NNS||4-3/CD	dobj||report-2/VBP||patients-4/NNS	prep_with||report-2/VBP||mycosisfungoides-6/NNS	nsubj||developed-8/VBD||mycosisfungoides-6/NNS	rcmod||mycosisfungoides-6/NNS||developed-8/VBD	amod||ulceration-10/NN||cutaneous-9/JJ	dobj||developed-8/VBD||ulceration-10/NN	det||manifestation-14/NN||an-12/DT	amod||manifestation-14/NN||initial-13/JJ	prep_as||developed-8/VBD||manifestation-14/NN	amod||toxicity-17/NN||methotrexate-16/JJ	prep_of||manifestation-14/NN||toxicity-17/NN	mycosisfungoides-6||methotrexate-16||yes||we report 4 patients with mycosisfungoides who developed cutaneous ulceration as an initial manifestation of methotrexate toxicity.
amod||outbreaks-2/NNS||recurrent-1/JJ	nsubj||pose-8/VBP||outbreaks-2/NNS	advmod||pathogenic-5/JJ||highly-4/RB	amod||avianinfluenzavirus-7/NNS||pathogenic-5/JJ	amod||avianinfluenzavirus-7/NNS||h5n1-6/JJ	prep_of||outbreaks-2/NNS||avianinfluenzavirus-7/NNS	root||ROOT-0/null||pose-8/VBP	det||threat-10/NN||a-9/DT	dobj||pose-8/VBP||threat-10/NN	advmod||causing-13/VBG||eventually-12/RB	prepc_of||threat-10/NN||causing-13/VBG	det||pandemic-15/NN||a-14/DT	dobj||causing-13/VBG||pandemic-15/NN	h5n1-6||avianinfluenzavirus-7||no||recurrent outbreaks of highly pathogenic h5n1 avianinfluenzavirus pose a threat of eventually causing a pandemic.
aux||provide-2/VB||to-1/TO	ccomp||studied-36/VBD||provide-2/VB	amod||evidence-6/NN||molecular-3/JJ	conj_and||molecular-3/JJ||virologic-5/JJ	amod||evidence-6/NN||virologic-5/JJ	dobj||provide-2/VB||evidence-6/NN	mark||enzootic-14/JJ||that-7/IN	amod||rabies-10/NNS||domestic-8/JJ	nn||rabies-10/NNS||dog-9/NN	nsubj||enzootic-14/JJ||rabies-10/NNS	cop||enzootic-14/JJ||is-11/VBZ	neg||longer-13/RBR||no-12/RB	advmod||enzootic-14/JJ||longer-13/RBR	ccomp||provide-2/VB||enzootic-14/JJ	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_to||enzootic-14/JJ||states-18/NNS	aux||identify-21/VB||to-20/TO	conj_and||provide-2/VB||identify-21/VB	ccomp||studied-36/VBD||identify-21/VB	amod||relatives-23/NNS||putative-22/JJ	dobj||identify-21/VB||relatives-23/NNS	amod||rabiesviruses-26/NNS||dog-related-25/JJ	prep_of||relatives-23/NNS||rabiesviruses-26/NNS	appos||rabiesviruses-26/NNS||rvs-28/NN	vmod||rabiesviruses-26/NNS||circulating-30/VBG	amod||carnivores-33/NNS||other-32/JJ	prep_in||circulating-30/VBG||carnivores-33/NNS	nsubj||studied-36/VBD||we-35/PRP	root||ROOT-0/null||studied-36/VBD	dobj||studied-36/VBD||rvs-37/NN	vmod||rvs-37/NN||associated-38/VBN	amod||enzootics-45/NNS||recent-40/JJ	conj_and||recent-40/JJ||historic-42/JJ	amod||enzootics-45/NNS||historic-42/JJ	nn||enzootics-45/NNS||dog-43/NN	nn||enzootics-45/NNS||rabies-44/NN	prep_with||associated-38/VBN||enzootics-45/NNS	advmod||associated-38/VBN||worldwide-46/RB	rabies-44||rabiesviruses-26||no||to provide molecular and virologic evidence that domestic dog rabies is no longer enzootic to the united states and to identify putative relatives of dog-related rabiesviruses (rvs) circulating in other carnivores, we studied rvs associated with recent and historic dog rabies enzootics worldwide.
nsubj||bacterium-6/NN||francisellatularensis-1/NNS	cop||bacterium-6/NN||is-2/VBZ	det||bacterium-6/NN||a-3/DT	advmod||bacterium-6/NN||highly-4/RB	amod||bacterium-6/NN||infectious-5/JJ	root||ROOT-0/null||bacterium-6/NN	vmod||bacterium-6/NN||causing-7/VBG	det||tularemia-11/NN||the-8/DT	amod||tularemia-11/NN||zoonotic-9/JJ	nn||tularemia-11/NN||disease-10/NN	dobj||causing-7/VBG||tularemia-11/NN	tularemia-11||francisellatularensis-1||no||francisellatularensis is a highly infectious bacterium causing the zoonotic disease tularemia.
amod||lines-2/NNS||several-1/JJ	nsubj||support-5/VBP||lines-2/NNS	prep_of||lines-2/NNS||evidence-4/NN	root||ROOT-0/null||support-5/VBP	det||notion-7/NN||the-6/DT	dobj||support-5/VBP||notion-7/NN	mark||predispose-13/VB||that-8/IN	amod||viscosity-11/NN||elevated-9/JJ	nn||viscosity-11/NN||blood-10/NN	nsubj||predispose-13/VB||viscosity-11/NN	aux||predispose-13/VB||may-12/MD	ccomp||support-5/VBP||predispose-13/VB	prep_to||predispose-13/VB||insulinresistance-15/NN	prep_to||predispose-13/VB||type2diabetesmellitus-17/NNS	conj_and||insulinresistance-15/NN||type2diabetesmellitus-17/NNS	prepc_by||predispose-13/VB||limiting-19/VBG	dobj||limiting-19/VBG||delivery-20/NN	prep_of||delivery-20/NN||glucose-22/NN	prep_of||delivery-20/NN||insulin-24/NN	conj_and||glucose-22/NN||insulin-24/NN	prep_of||delivery-20/NN||oxygen-27/NN	conj_and||glucose-22/NN||oxygen-27/NN	advmod||active-30/JJ||metabolically-29/RB	amod||tissues-31/NNS||active-30/JJ	prep_to||glucose-22/NN||tissues-31/NNS	glucose-22||type2diabetesmellitus-17||no_rel||several lines of evidence support the notion that elevated blood viscosity may predispose to insulinresistance and type2diabetesmellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues.
det||asthma-3/NN||the-1/DT	nn||asthma-3/NN||jamaica-2/NN	nsubj||population-12/NN||asthma-3/NN	amod||survey-8/NN||allergies-5/JJ	amod||survey-8/NN||national-6/JJ	nn||survey-8/NN||prevalence-7/NN	conj_and||asthma-3/NN||survey-8/NN	nsubj||population-12/NN||survey-8/NN	cop||population-12/NN||is-9/VBZ	det||population-12/NN||the-10/DT	amod||population-12/NN||first-11/JJ	root||ROOT-0/null||population-12/NN	prep||population-12/NN||based-14/VBN	pobj||based-14/VBN||survey-15/NN	det||caribbean-18/NN||the-17/DT	prep_in||survey-15/NN||caribbean-18/NN	aux||determine-20/VB||to-19/TO	vmod||caribbean-18/NN||determine-20/VB	det||prevalence-22/NN||the-21/DT	dobj||determine-20/VB||prevalence-22/NN	prep_of||prevalence-22/NN||asthma-24/NN	prep_of||prevalence-22/NN||allergies-26/NNS	conj_and||asthma-24/NN||allergies-26/NNS	dep||determine-20/VB||both-27/DT	prep_in||determine-20/VB||adults-29/NNS	prep_in||determine-20/VB||children-31/NNS	conj_and||adults-29/NNS||children-31/NNS	vmod||adults-29/NNS||using-32/VBG	amod||methods-34/NNS||standardized-33/JJ	dobj||using-32/VBG||methods-34/NNS	allergies-26||allergies-26||no||the jamaica asthma and allergies national prevalence survey is the first population- based survey in the caribbean to determine the prevalence of asthma and allergies both in adults and children using standardized methods.
det||study-8/NN||a-2/DT	amod||study-8/NN||multicenter-3/JJ	amod||study-8/NN||double-blind-5/JJ	amod||study-8/NN||randomized-7/JJ	prep_in||assigned-16/VBN||study-8/NN	num||patients-11/NNS||131-10/CD	nsubjpass||assigned-16/VBN||patients-11/NNS	amod||uc-14/NN||quiescent-13/JJ	prep_with||patients-11/NNS||uc-14/NN	auxpass||assigned-16/VBN||were-15/VBD	root||ROOT-0/null||assigned-16/VBN	num||groups-19/NNS||two-18/CD	prep_to||assigned-16/VBN||groups-19/NNS	dobj||assigned-16/VBN||65-20/CD	aux||receive-22/VB||to-21/TO	vmod||65-20/CD||receive-22/VB	det||formulation-26/NN||a-23/DT	amod||formulation-26/NN||ph-dependent-24/JJ	nn||formulation-26/NN||release-25/NN	dobj||receive-22/VB||formulation-26/NN	prep_of||formulation-26/NN||mesalamine-28/NN	num||g/day-31/NN||2.4-30/CD	prep_at||receive-22/VB||g/day-31/NN	dep||65-20/CD||ph-2-33/JJ	number||g-35/CD||.4-34/CD	dep||ph-2-33/JJ||g-35/CD	dobj||assigned-16/VBN||66-38/CD	conj_and||65-20/CD||66-38/CD	aux||receive-40/VB||to-39/TO	vmod||66-38/CD||receive-40/VB	det||formulation-44/NN||a-41/DT	amod||formulation-44/NN||time-dependent-42/JJ	nn||formulation-44/NN||release-43/NN	dobj||receive-40/VB||formulation-44/NN	prep_of||formulation-44/NN||mesalamine-46/NN	num||g/day-49/NN||2.25-48/CD	prep_at||receive-40/VB||g/day-49/NN	dep||66-38/CD||time-2-51/JJ	number||g-53/CD||.25-52/CD	dep||time-2-51/JJ||g-53/CD	uc-14||mesalamine-46||yes||in a multicenter, double-blind, randomized study, 131 patients with quiescent uc were assigned to two groups 65 to receive a ph-dependent release formulation of mesalamine at 2.4 g/day (ph-2.4 g) and 66 to receive a time-dependent release formulation of mesalamine at 2.25 g/day (time-2.25 g).
amod||studies-2/NNS||more-1/JJR	nsubj||large-7/JJ||studies-2/NNS	cop||large-7/JJ||are-3/VBP	amod||large-7/JJ||necessary-4/JJ	advmod||large-7/JJ||preferentially-6/RB	root||ROOT-0/null||large-7/JJ	amod||trials-11/NNS||prospective-8/JJ	amod||trials-11/NNS||randomized-9/JJ	amod||trials-11/NNS||clinical-10/JJ	nsubj||obtain-13/VB||trials-11/NNS	aux||obtain-13/VB||to-12/TO	ccomp||large-7/JJ||obtain-13/VB	amod||information-15/NN||more-14/JJR	dobj||obtain-13/VB||information-15/NN	det||impact-18/NN||the-17/DT	prep_on||obtain-13/VB||impact-18/NN	det||rituximab-21/NN||the-20/DT	prep_of||impact-18/NN||rituximab-21/NN	det||b-celllymphoma-26/NN||the-23/DT	amod||b-celllymphoma-26/NN||primary-24/JJ	amod||b-celllymphoma-26/NN||gastric-25/JJ	prep_in||rituximab-21/NN||b-celllymphoma-26/NN	b-celllymphoma-26||rituximab-21||yes||more studies are necessary, preferentially large prospective randomized clinical trials to obtain more information on the impact of the rituximab in the primary gastric b-celllymphoma.
nn||profiling-3/NN||gene-1/NN	nn||profiling-3/NN||expression-2/NN	nsubjpass||evaluated-12/VBN||profiling-3/NN	det||set-7/NN||the-5/DT	amod||set-7/NN||same-6/JJ	prep_of||profiling-3/NN||set-7/NN	prep_of||set-7/NN||tumors-9/NNS	auxpass||evaluated-12/VBN||was-10/VBD	advmod||evaluated-12/VBN||also-11/RB	root||ROOT-0/null||evaluated-12/VBN	xcomp||evaluated-12/VBN||using-13/VBG	nn||hg-u133-15/NN||affymetrix-14/NN	dobj||using-13/VBG||hg-u133-15/NN	prep||hg-u133-15/NN||plus-16/CC	amod||arrays-18/NNS||2.0-17/JJ	pobj||plus-16/CC||arrays-18/NNS	hg--1||tumors-9||no_rel||gene expression profiling of the same set of tumors was also evaluated using affymetrix hg-u133 plus 2.0 arrays.
nsubj||live-3/VB||plha-1/NN	nsubjpass||associated-165/VBN||plha-1/NN	rcmod||plha-1/NN||live-3/VB	poss||-LSB--7/NN||their-5/PRP$	nn||-LSB--7/NN||families-6/NNS	prep_with||live-3/VB||-LSB--7/NN	prep_with||live-3/VB||=-9/NNP	conj_or||-LSB--7/NN||=-9/NNP	num||=-9/NNP||3.29-10/CD	num||%-13/NN||95-12/CD	dobj||live-3/VB||%-13/NN	vmod||%-13/NN||ci-14/VBN	num||-RSB--18/NNS||1.28-8-15/CD	nn||-RSB--18/NNS||.45-16/CD	dobj||ci-14/VBN||-RSB--18/NNS	dobj||ci-14/VBN||lived-20/VBN	conj_or||-RSB--18/NNS||lived-20/VBN	vmod||-RSB--18/NNS||lived-20/VBN	det||-LSB--25/NN||a-22/DT	amod||-LSB--25/NN||rented-23/VBN	nn||-LSB--25/NN||house-24/NN	prep_in||lived-20/VBN||-LSB--25/NN	number||2.52-28/CD||=-27/CD	num||-RSB--35/NN||2.52-28/CD	number||%-31/NN||95-30/CD	amod||-RSB--35/NN||%-31/NN	amod||-RSB--35/NN||ci-32/JJ	nn||-RSB--35/NN||1.09-5-33/NN	num||-RSB--35/NN||.79-34/CD	prep_in||lived-20/VBN||-RSB--35/NN	conj_or||-LSB--25/NN||-RSB--35/NN	dobj||have-54/VBP||-RSB--35/NN	amod||women-38/NNS||non-pregnant-37/JJ	appos||-RSB--35/NN||women-38/NNS	num||women-38/NNS||-LSB--39/CD	num||9.3-42/CD||=-41/CD	num||women-38/NNS||9.3-42/CD	conj_or||-LSB--39/CD||9.3-42/CD	number||%-45/NN||95-44/CD	amod||ci-46/NN||%-45/NN	appos||-RSB--35/NN||ci-46/NN	num||-RSB--49/NNS||1.93-44-47/CD	num||-RSB--49/NNS||.82-48/CD	dep||ci-46/NN||-RSB--49/NNS	amod||art-53/NN||perceived-52/VBN	nsubj||have-54/VBP||art-53/NN	rcmod||-RSB--35/NN||have-54/VBP	amod||effects-57/NNS||many-55/JJ	nn||effects-57/NNS||side-56/NN	dobj||have-54/VBP||effects-57/NNS	vmod||effects-57/NNS||-LSB--58/VBN	dep||6.23-61/CD||=-60/SYM	dobj||have-54/VBP||6.23-61/CD	conj_or||effects-57/NNS||6.23-61/CD	num||%-64/NN||95-63/CD	prep_in||lived-20/VBN||%-64/NN	conj_or||-LSB--25/NN||%-64/NN	num||-RSB--68/NNS||ci1-65/CD	nn||-RSB--68/NNS||.63,23.82-66/CD	dep||%-64/NN||-RSB--68/NNS	nsubj||perceived-71/VBD||who-70/WP	prep_in||lived-20/VBN||perceived-71/VBD	conj_or||-LSB--25/NN||perceived-71/VBD	amod||-LSB--92/NNS||hiv-72/JJ	prepc_as||hiv-72/JJ||stigmatizing-74/VBG	nn||-LSB--76/NNS||disease-75/NN	iobj||stigmatizing-74/VBG||-LSB--76/NNS	number||3.1-79/CD||=-78/CD	num||ci-83/NN||3.1-79/CD	number||%-82/NN||95-81/CD	amod||ci-83/NN||%-82/NN	iobj||stigmatizing-74/VBG||ci-83/NN	conj_or||-LSB--76/NNS||ci-83/NN	num||-RSB--86/NNS||1.09-8-84/CD	num||-RSB--86/NNS||.76-85/CD	dobj||stigmatizing-74/VBG||-RSB--86/NNS	nsubj||tested-89/VBN||-RSB--86/NNS	rcmod||-RSB--86/NNS||tested-89/VBN	prep_with||tested-89/VBN||sickness/symptoms-91/NNS	dobj||perceived-71/VBD||-LSB--92/NNS	dep||2.62-95/CD||=-94/SYM	dobj||perceived-71/VBD||2.62-95/CD	conj_or||-LSB--92/NNS||2.62-95/CD	number||%-98/NN||95-97/CD	amod||-RSB--102/NNS||%-98/NN	nn||-RSB--102/NNS||ci-99/NN	amod||-RSB--102/NNS||1.26-5-100/JJ	num||-RSB--102/NNS||.44-101/CD	dobj||ci-14/VBN||-RSB--102/NNS	conj_or||-RSB--18/NNS||-RSB--102/NNS	nsubj||disclose-107/VB||-RSB--102/NNS	aux||disclose-107/VB||did-105/VBD	neg||disclose-107/VB||not-106/RB	rcmod||-RSB--102/NNS||disclose-107/VB	poss||status-110/NN||their-108/PRP$	nn||status-110/NN||hiv-109/NN	dobj||disclose-107/VB||status-110/NN	poss||-LSB--114/NN||their-112/PRP$	nn||-LSB--114/NN||partner-113/NN	prep_for||disclose-107/VB||-LSB--114/NN	number||2.78-117/CD||=-116/CD	num||ci-121/NN||2.78-117/CD	number||%-120/NN||95-119/CD	amod||ci-121/NN||%-120/NN	dobj||ci-14/VBN||ci-121/NN	conj_or||-RSB--18/NNS||ci-121/NN	num||-LSB--129/NNS||1.02-7-122/CD	num||-LSB--129/NNS||.56-123/CD	nn||-LSB--129/NNS||-RSB--124/NNP	amod||-LSB--129/NNS||frequent-126/JJ	nn||-LSB--129/NNS||alcohol-127/NN	nn||-LSB--129/NNS||users-128/NNS	dep||ci-121/NN||-LSB--129/NNS	dep||3.55-132/CD||=-131/SYM	dobj||live-3/VB||3.55-132/CD	conj_or||%-13/NN||3.55-132/CD	number||%-135/NN||95-134/CD	amod||-LSB--152/NN||%-135/NN	amod||-LSB--152/NN||ci-136/JJ	amod||-LSB--152/NN||1.63-7-137/JJ	num||-RSB--139/NNS||.71-138/CD	nn||-LSB--152/NN||-RSB--139/NNS	nsubj||spent-142/VBD||who-141/WP	conj_and||-RSB--139/NNS||spent-142/VBD	nn||-LSB--152/NN||spent-142/VBD	mwe||than-144/IN||more-143/JJR	quantmod||120-145/CD||than-144/IN	num||months-146/NNS||120-145/CD	tmod||spent-142/VBD||months-146/NNS	prep_with||spent-142/VBD||partner-148/NN	nn||diagnosis-151/NN||hiv-150/NN	prep_at||spent-142/VBD||diagnosis-151/NN	dobj||live-3/VB||-LSB--152/NN	dep||5.86-155/CD||=-154/SYM	dobj||live-3/VB||5.86-155/CD	conj_or||-LSB--152/NN||5.86-155/CD	number||%-158/NN||95-157/CD	amod||-RSB--162/NNS||%-158/NN	amod||-RSB--162/NNS||ci-159/JJ	number||.41-161/CD||1.35-25-160/CD	num||-RSB--162/NNS||.41-161/CD	dobj||live-3/VB||-RSB--162/NNS	auxpass||associated-165/VBN||were-163/VBD	advmod||associated-165/VBN||significantly-164/RB	root||ROOT-0/null||associated-165/VBN	amod||presentation-168/NN||late-167/JJ	prep_with||associated-165/VBN||presentation-168/NN	amod||care-171/NN||hiv/aids-170/JJ	prep_to||associated-165/VBN||care-171/NN	aids--1||hiv-150||no||plha who live with their families [or = 3.29, 95%ci 1.28-8.45)], lived in a rented house [or = 2.52, 95%ci 1.09-5.79], non-pregnant women [or = 9.3, 95% ci 1.93-44.82], who perceived art have many side effects [or = 6.23, 95%ci1.63,23.82)], who perceived hiv as stigmatizing disease [or = 3.1, 95% ci 1.09-8.76], who tested with sickness/symptoms [or = 2.62, 95% ci 1.26-5.44], who did not disclose their hiv status for their partner [or = 2.78, 95% ci 1.02-7.56], frequent alcohol users [or = 3.55, 95% ci 1.63-7.71] and who spent more than 120 months with partner at hiv diagnosis[or = 5.86, 95% ci 1.35-25.41] were significantly associated with late presentation to hiv/aids care.
amod||m.tb-2/NN||rifampin-resistant-1/JJ	nsubjpass||found-37/VBN||m.tb-2/NN	dep||m.tb-2/NN||nâ-4/NN	num||â-8/NN||$-5/$	number||=-7/CD||š-6/CD	num||$-5/$||=-7/CD	dep||nâ-4/NN||â-8/NN	dep||â-8/NN||$-9/$	num||$-9/$||š41-10/CD	conj_and||m.tb-2/NN||tb-iris-13/NNS	nsubjpass||found-37/VBN||tb-iris-13/NNS	dep||tb-iris-13/NNS||nâ-15/NN	num||â-19/NN||$-16/$	number||=-18/CD||š-17/CD	num||$-16/$||=-18/CD	dep||nâ-15/NN||â-19/NN	dep||â-19/NN||$-20/$	num||$-20/$||š51-21/CD	npadvmod||resistant-25/JJ||drug-24/NN	amod||bacterialinfections-26/NNS||resistant-25/JJ	conj_and||m.tb-2/NN||bacterialinfections-26/NNS	nsubjpass||found-37/VBN||bacterialinfections-26/NNS	dep||m.tb-2/NN||nâ-28/NN	num||â-32/NN||$-29/$	number||=-31/CD||š-30/CD	num||$-29/$||=-31/CD	dep||nâ-28/NN||â-32/NN	dep||â-32/NN||$-33/$	num||$-33/$||š12-34/CD	auxpass||found-37/VBN||were-36/VBD	root||ROOT-0/null||found-37/VBN	num||%-40/NN||12-39/CD	prep_in||found-37/VBN||%-40/NN	num||%-43/NN||14-42/CD	prep_in||found-37/VBN||%-43/NN	conj_and||%-40/NN||%-43/NN	num||%-46/NN||3.4-45/CD	prep_in||found-37/VBN||%-46/NN	conj_and||%-40/NN||%-46/NN	det||cases-50/NNS||the-48/DT	amod||cases-50/NNS||352-49/JJ	prep_of||%-46/NN||cases-50/NNS	advmod||found-37/VBN||respectively-52/RB	tb--1||rifampin--1||yes||rifampin-resistant m.tb (nâ€š=â€š41), tb-iris (nâ€š=â€š51) and drug resistant bacterialinfections (nâ€š=â€š12) were found in 12%, 14% and 3.4% of the 352 cases, respectively.
root||ROOT-0/null||hiv-1-1/JJ	dep||hiv-1-1/JJ||humanimmunodeficiencyvirus-3/NNS	npadvmod||env-9/JJ||type-4/NN	number||env-9/JJ||1-5/CD	amod||env-9/JJ||aids-acquiredimmunodeficiencysyndrome-7/JJ	amod||humanimmunodeficiencyvirus-3/NNS||env-9/JJ	dep||hiv-1-1/JJ||envelope-11/NN	appos||envelope-11/NN||gp160-13/NNS	num||glycoprotein-17/NN||160,000-15/CD	amod||glycoprotein-17/NN||d-16/JJ	dep||hiv-1-1/JJ||glycoprotein-17/NN	appos||glycoprotein-17/NN||gp120-19/NNS	num||glycoprotein-23/NN||120,000-21/CD	amod||glycoprotein-23/NN||d-22/JJ	dep||hiv-1-1/JJ||glycoprotein-23/NN	appos||glycoprotein-23/NN||gp41-25/NNS	num||glycoprotein-29/NN||41,000-27/CD	amod||glycoprotein-29/NN||d-28/JJ	dep||hiv-1-1/JJ||glycoprotein-29/NN	appos||glycoprotein-29/NN||lanl-31/NN	nn||alamos-34/NNS||los-33/NN	dep||hiv-1-1/JJ||alamos-34/NNS	amod||laboratories-36/NNS||national-35/JJ	dep||alamos-34/NNS||laboratories-36/NNS	advmod||alamos-34/NNS||pdb-38/RB	nn||bank-42/NN||protein-40/NN	nn||bank-42/NN||data-41/NN	dep||hiv-1-1/JJ||bank-42/NN	appos||bank-42/NN||hvtn-44/NN	nn||trial-49/NN||step-46/NN	nn||trial-49/NN||hiv-47/NN	nn||trial-49/NN||vaccine-48/NN	dep||hiv-1-1/JJ||trial-49/NN	appos||trial-49/NN||aa-51/NN	dep||hiv-1-1/JJ||aminoacids-53/NNS	appos||aminoacids-53/NNS||msa-55/NN	amod||alignment-59/NN||multiple-57/JJ	nn||alignment-59/NN||sequence-58/NN	dep||hiv-1-1/JJ||alignment-59/NN	appos||alignment-59/NN||asa-61/NN	amod||area-65/NN||accessible-63/JJ	nn||area-65/NN||surface-64/NN	dep||hiv-1-1/JJ||area-65/NN	appos||area-65/NN||snps-67/NNS	amod||polymorphisms-71/NNS||single-69/JJ	nn||polymorphisms-71/NNS||nucleotide-70/NN	dep||hiv-1-1/JJ||polymorphisms-71/NNS	appos||polymorphisms-71/NNS||haart-73/NN	advmod||active-76/JJ||highly-75/RB	amod||therapy-78/NN||active-76/JJ	amod||therapy-78/NN||antiretroviral-77/JJ	dep||hiv-1-1/JJ||therapy-78/NN	appos||therapy-78/NN||ccr5-80/NNS	amod||type-85/NN||c-c-82/JJ	amod||type-85/NN||chemokine-83/JJ	nn||type-85/NN||receptor-84/NN	dep||hiv-1-1/JJ||type-85/NN	dep||type-85/NN||5-86/CD	advmod||type-85/NN||cns-88/RB	amod||system-92/NN||central-90/JJ	amod||system-92/NN||nervous-91/JJ	dep||hiv-1-1/JJ||system-92/NN	appos||system-92/NN||hive-94/NN	dep||hiv-1-1/JJ||hivencephalitis-96/NNS	appos||hivencephalitis-96/NNS||p-98/NN	dep||hiv-1-1/JJ||polarity-100/NN	appos||polarity-100/NN||np-102/NN	dep||hiv-1-1/JJ||non-polarity-104/NN	appos||non-polarity-104/NN||ctl-106/NN	amod||t-109/NN||cytotoxic-108/JJ	dep||hiv-1-1/JJ||t-109/NN	amod||niaid-112/JJ||lymphocyte-110/JJ	amod||t-109/NN||niaid-112/JJ	amod||institute-115/NN||national-114/JJ	dep||hiv-1-1/JJ||institute-115/NN	nn||diseases-120/NNS||allergy-117/NN	conj_and||allergy-117/NN||infectious-119/JJ	nn||diseases-120/NNS||infectious-119/JJ	prep_of||institute-115/NN||diseases-120/NNS	aids-acquiredimmunodeficiencysyndrome-7||hiv-47||no||hiv-1 - humanimmunodeficiencyvirus type 1, aids-acquiredimmunodeficiencysyndrome, env - envelope, gp160 - 160,000d glycoprotein, gp120 - 120,000d glycoprotein, gp41 - 41,000d glycoprotein, lanl - los alamos national laboratories, pdb - protein data bank, hvtn - step hiv vaccine trial, aa - aminoacids, msa - multiple sequence alignment, asa - accessible surface area, snps- single nucleotide polymorphisms, haart - highly active antiretroviral therapy, ccr5 - c-c chemokine receptor type 5, cns - central nervous system, hive - hivencephalitis, p - polarity, np - non-polarity, ctl - cytotoxic t lymphocyte, niaid - national institute of allergy and infectious diseases.
det||patients-4/NNS||the-1/DT	amod||patients-4/NNS||479-2/JJ	amod||patients-4/NNS||evaluable-3/JJ	nsubj||had-11/VBD||patients-4/NNS	prep_with||patients-4/NNS||metastaticcancer-6/NN	amod||sites-10/NNS||other-8/JJ	nn||sites-10/NNS||primarycancer-9/NN	prep_from||metastaticcancer-6/NN||sites-10/NNS	root||ROOT-0/null||had-11/VBD	dobj||had-11/VBD||cr-12/NN	dobj||had-11/VBD||pr-14/NN	conj_and||cr-12/NN||pr-14/NN	amod||rates-20/NNS||cr-17/JJ	amod||rates-20/NNS||+-18/JJ	nn||rates-20/NNS||pr-19/NN	dobj||had-11/VBD||rates-20/NNS	conj_and||cr-12/NN||rates-20/NNS	num||%-23/NN||25-22/CD	prep_of||rates-20/NNS||%-23/NN	num||%-26/NN||27-25/CD	prep_of||rates-20/NNS||%-26/NN	conj_and||%-23/NN||%-26/NN	num||%-30/NN||51-29/CD	prep_of||rates-20/NNS||%-30/NN	conj_and||%-23/NN||%-30/NN	num||weeks-33/NNS||4-32/CD	prep_at||%-30/NN||weeks-33/NNS	num||%-36/NN||26-35/CD	prep_of||rates-20/NNS||%-36/NN	conj_and||%-23/NN||%-36/NN	num||%-39/NN||22-38/CD	prep_of||rates-20/NNS||%-39/NN	conj_and||%-23/NN||%-39/NN	num||%-43/NN||48-42/CD	prep_of||rates-20/NNS||%-43/NN	conj_and||%-23/NN||%-43/NN	num||weeks-46/NNS||8-45/CD	prep_at||%-43/NN||weeks-46/NNS	num||%-50/NN||22-49/CD	prep_of||rates-20/NNS||%-50/NN	conj_and||%-23/NN||%-50/NN	num||%-53/NN||29-52/CD	prep_of||rates-20/NNS||%-53/NN	conj_and||%-23/NN||%-53/NN	num||%-57/NN||51-56/CD	prep_of||rates-20/NNS||%-57/NN	conj_and||%-23/NN||%-57/NN	num||weeks-60/NNS||12-59/CD	prep_at||had-11/VBD||weeks-60/NNS	cr-17||primarycancer-9||no_rel||the 479 evaluable patients with metastaticcancer from other primarycancer sites had cr , pr , and cr + pr rates of 25%, 27%, and 51% at 4 weeks; 26%, 22%, and 48% at 8 weeks; and 22%, 29%, and 51% at 12 weeks.
advmod||tested-11/VBD||here-1/RB	vmod||tested-11/VBD||using-3/VBG	amod||herpesvirus-4-5/NN||murid-4/JJ	dobj||using-3/VBG||herpesvirus-4-5/NN	dep||herpesvirus-4-5/NN||muhv-4-7/JJ	nsubj||tested-11/VBD||we-10/PRP	root||ROOT-0/null||tested-11/VBD	det||impact-13/NN||the-12/DT	nsubj||transferred-16/VBD||impact-13/NN	prep_of||impact-13/NN||adoptively-15/NN	ccomp||tested-11/VBD||transferred-16/VBD	dobj||transferred-16/VBD||antibody-17/NN	amod||gamma-herpesvirusinfection-20/NN||early-19/JJ	prep_on||transferred-16/VBD||gamma-herpesvirusinfection-20/NN	herpesvirusinfection--1||herpesvirus--1||no||here, using murid herpesvirus-4 (muhv-4), we tested the impact of adoptively transferred antibody on early gamma-herpesvirusinfection.
nsubj||calmetteâ-7/VBD||data-1/NNS	amod||exposure-4/NN||tuberculosis-3/JJ	prep_on||data-1/NNS||exposure-4/NN	prep_on||data-1/NNS||bacillus-6/NNS	conj_and||exposure-4/NN||bacillus-6/NNS	root||ROOT-0/null||calmetteâ-7/VBD	nsubjpass||obtained-18/VBN||$-8/NN	nn||$-8/NN||guã-10/FW	nn||$-8/NN||©-11/FW	dep||$-8/NN||rin-12/FW	discourse||$-8/NN||bcg-14/UH	advmod||obtained-18/VBN||vaccination-16/RB	auxpass||obtained-18/VBN||were-17/VBD	ccomp||calmetteâ-7/VBD||obtained-18/VBN	tuberculosis-3||bcg-14||yes||data on tuberculosis exposure and bacillus calmetteâ€“guã©rin (bcg) vaccination were obtained.
det||algorithm-5/NN||this-1/DT	amod||algorithm-5/NN||real-time-2/JJ	nn||algorithm-5/NN||hypoglycemia-3/NN	nn||algorithm-5/NN||prediction-4/NN	nsubj||combines-9/VBZ||algorithm-5/NN	appos||algorithm-5/NN||hpa-7/NN	root||ROOT-0/null||combines-9/VBZ	num||algorithms-12/NNS||five-10/CD	amod||algorithms-12/NNS||individual-11/JJ	dobj||combines-9/VBZ||algorithms-12/NNS	appos||algorithms-12/NNS||all-14/DT	vmod||all-14/DT||based-15/VBN	amod||data-21/NNS||continuous-17/JJ	nn||data-21/NNS||glucose-18/NN	nn||data-21/NNS||monitoring-19/NN	amod||data-21/NNS||1-min-20/JJ	prep_on||based-15/VBN||data-21/NNS	hypoglycemia-3||glucose-18||yes||this real-time hypoglycemia prediction algorithm (hpa) combines five individual algorithms, all based on continuous glucose monitoring 1-min data.
det||bacillusanthracis-5/NNS||the-2/DT	amod||bacillusanthracis-5/NNS||pathogenic-3/JJ	nn||bacillusanthracis-5/NNS||bacterium-4/NN	prep_in||requires-8/VBZ||bacillusanthracis-5/NNS	nsubj||requires-8/VBZ||virulence-7/NN	root||ROOT-0/null||requires-8/VBZ	amod||expression-10/NN||induced-9/JJ	dobj||requires-8/VBZ||expression-10/NN	det||toxin-14/NN||the-12/DT	nn||toxin-14/NN||anthrax-13/NN	prep_of||expression-10/NN||toxin-14/NN	amod||genes-17/NNS||capsule-16/JJ	prep_of||expression-10/NN||genes-17/NNS	conj_and||toxin-14/NN||genes-17/NNS	anthrax-13||bacillusanthracis-5||no||in the pathogenic bacterium bacillusanthracis , virulence requires induced expression of the anthrax toxin and capsule genes.
amod||infection-5/NN||humancytomegalovirus-1/JJ	appos||infection-5/NN||cmv-3/NN	nsubj||causes-7/VBZ||infection-5/NN	advmod||infection-5/NN||still-6/RB	root||ROOT-0/null||causes-7/VBZ	amod||morbidity-9/NN||significant-8/JJ	dobj||causes-7/VBZ||morbidity-9/NN	dobj||causes-7/VBZ||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	amod||transplantation-17/NN||allogeneic-13/JJ	amod||transplantation-17/NN||hematopoietic-14/JJ	nn||transplantation-17/NN||stem-15/NN	nn||transplantation-17/NN||cell-16/NN	prep_after||causes-7/VBZ||transplantation-17/NN	appos||transplantation-17/NN||hsct-19/NN	cmv-3||humancytomegalovirus-1||no||humancytomegalovirus (cmv) infection still causes significant morbidity and mortality after allogeneic hematopoietic stem cell transplantation (hsct).
nn||analyses-2/NNS||ihc-1/NN	nsubjpass||performed-4/VBN||analyses-2/NNS	auxpass||performed-4/VBN||were-3/VBD	root||ROOT-0/null||performed-4/VBN	det||block-8/NN||each-6/DT	nn||block-8/NN||cell-7/NN	prep_on||performed-4/VBN||block-8/NN	prep_with||block-8/NN||antibodies-10/NNS	nn||receptor-13/NN||estrogen-12/NN	prep_to||performed-4/VBN||receptor-13/NN	appos||receptor-13/NN||er-15/NN	amod||receptor-19/NN||progesterone-18/JJ	appos||receptor-13/NN||receptor-19/NN	appos||receptor-19/NN||pr-21/NN	amod||receptor-33/NN||her2-24/JJ	conj_and||her2-24/JJ||egfr-26/JJ	amod||receptor-33/NN||egfr-26/JJ	conj_and||her2-24/JJ||ck5/6-28/JJ	amod||receptor-33/NN||ck5/6-28/JJ	conj_and||her2-24/JJ||ki-67-30/JJ	amod||receptor-33/NN||ki-67-30/JJ	conj_and||her2-24/JJ||androgen-32/JJ	amod||receptor-33/NN||androgen-32/JJ	appos||receptor-13/NN||receptor-33/NN	appos||receptor-13/NN||ar-35/NN	ar-35||antibodies-10||no_rel||ihc analyses were performed on each cell block with antibodies to estrogen receptor (er), progesterone receptor (pr), her2, egfr, ck5/6, ki-67 and androgen receptor (ar).
amod||data-2/NNS||comparable-1/JJ	nsubjpass||used-7/VBN||data-2/NNS	amod||countries-5/NNS||individual-4/JJ	prep_from||data-2/NNS||countries-5/NNS	auxpass||used-7/VBN||was-6/VBD	root||ROOT-0/null||used-7/VBN	agent||used-7/VBN||applying-9/VBG	det||definition-12/NN||a-10/DT	amod||definition-12/NN||consistent-11/JJ	dobj||applying-9/VBG||definition-12/NN	nn||expenditures-15/NNS||hiv-14/NN	prep_for||definition-12/NN||expenditures-15/NNS	amod||expenditures-19/NNS||total-17/JJ	nn||expenditures-19/NNS||health-18/NN	prep_for||definition-12/NN||expenditures-19/NNS	conj_and||expenditures-15/NNS||expenditures-19/NNS	amod||reports-29/NNS||nhas-21/JJ	aux||align-23/VB||to-22/TO	xcomp||nhas-21/JJ||align-23/VB	dobj||align-23/VB||them-24/PRP	amod||aids-27/NNS||national-26/JJ	prep_with||align-23/VB||aids-27/NNS	nn||reports-29/NNS||assessment-28/NN	prep_from||applying-9/VBG||reports-29/NNS	aids-27||hiv-14||no||comparable data from individual countries was used by applying a consistent definition for hiv expenditures and total health expenditures from nhas to align them with national aids assessment reports.
nsubj||plays-5/VBZ||sulfotransferase-1/NN	appos||sulfotransferase-1/NN||sult-3/NN	root||ROOT-0/null||plays-5/VBZ	det||role-8/NN||an-6/DT	amod||role-8/NN||important-7/JJ	dobj||plays-5/VBZ||role-8/NN	nsubj||conferred-17/VBG||role-8/NN	det||formation-11/NN||the-10/DT	prep_in||role-8/NN||formation-11/NN	prep_of||formation-11/NN||estrogen-13/NN	aux||conferred-17/VBG||is-15/VBZ	advmod||conferred-17/VBG||usually-16/RB	rcmod||role-8/NN||conferred-17/VBG	det||factor-21/NN||a-19/DT	nn||factor-21/NN||risk-20/NN	prep_as||conferred-17/VBG||factor-21/NN	nn||cancer-24/NN||breast-23/NN	prep_for||factor-21/NN||cancer-24/NN	cancer-24||estrogen-13||no_rel||sulfotransferase (sult) plays an important role in the formation of estrogen which is usually conferred as a risk factor for breast cancer.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||m.tuberculosis-36||no||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
amod||production-3/NN||diabetes-induced-1/JJ	nn||production-3/NN||superoxide-2/NN	nsubj||inhibited-9/JJ||production-3/NN	amod||fibrosis-6/NN||cardiac-5/JJ	conj_and||production-3/NN||fibrosis-6/NN	nsubj||inhibited-9/JJ||fibrosis-6/NN	cop||inhibited-9/JJ||were-7/VBD	advmod||inhibited-9/JJ||partially-8/RB	root||ROOT-0/null||inhibited-9/JJ	prep_by||inhibited-9/JJ||candesartan-11/NN	prep_by||inhibited-9/JJ||benazepril-13/NN	conj_and||candesartan-11/NN||benazepril-13/NN	mark||produced-17/VBD||whereas-15/IN	nsubj||produced-17/VBD||aliskiren-16/NN	advcl||inhibited-9/JJ||produced-17/VBD	amod||inhibition-19/NN||complete-18/JJ	dobj||produced-17/VBD||inhibition-19/NN	fibrosis-6||benazepril-13||no_rel||diabetes-induced superoxide production and cardiac fibrosis were partially inhibited by candesartan and benazepril, whereas aliskiren produced complete inhibition.
nn||thailandensis-2/NNS||burkholderia-1/NN	nsubj||saprophyte-7/NN||thailandensis-2/NNS	cop||saprophyte-7/NN||is-3/VBZ	det||saprophyte-7/NN||a-4/DT	amod||saprophyte-7/NN||non-pathogenic-5/JJ	amod||saprophyte-7/NN||environmental-6/JJ	root||ROOT-0/null||saprophyte-7/NN	advmod||related-9/VBN||closely-8/RB	amod||saprophyte-7/NN||related-9/VBN	prep_to||related-9/VBN||burkholderiapseudomallei-11/NNS	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	appos||burkholderiapseudomallei-11/NNS||agent-15/NN	det||animal-20/NN||the-17/DT	advmod||fatal-19/JJ||often-18/RB	amod||animal-20/NN||fatal-19/JJ	prep_of||agent-15/NN||animal-20/NN	amod||melioidosis-24/NNS||human-22/JJ	nn||melioidosis-24/NNS||disease-23/NN	prep_of||agent-15/NN||melioidosis-24/NNS	conj_and||animal-20/NN||melioidosis-24/NNS	melioidosis-24||burkholderiapseudomallei-11||no||burkholderia thailandensis is a non-pathogenic environmental saprophyte closely related to burkholderiapseudomallei , the causative agent of the often fatal animal and human disease melioidosis.
nsubj||received-16/VBN||janumettm-1/NN	nsubj||received-16/VBN||janumettm-1/NN	nsubj||received-16/VBN||janumettm-1/NN	det||combination-6/NN||a-3/DT	amod||combination-6/NN||fixed-4/VBN	nn||combination-6/NN||dose-5/NN	appos||janumettm-1/NN||combination-6/NN	nn||hcl-9/NN||sitagliptin/metformin-8/NN	prep_of||combination-6/NN||hcl-9/NN	vmod||combination-6/NN||manufactured-10/VBN	nn||pharmaceuticals-13/NNS||merck-12/NN	agent||manufactured-10/VBN||pharmaceuticals-13/NNS	aux||received-16/VBN||has-15/VBZ	root||ROOT-0/null||received-16/VBN	conj_or||received-16/VBN||received-16/VBN	conj_or||received-16/VBN||received-16/VBN	nsubj||approval-22/NN||us-17/PRP	nn||approval-22/NN||food-18/NN	conj_and||food-18/NN||drug-20/NN	nn||approval-22/NN||drug-20/NN	nn||approval-22/NN||administration-21/NN	xcomp||received-16/VBN||approval-22/NN	prep_for||approval-22/NN||treatment-24/NN	prep_of||treatment-24/NN||patients-26/NNS	prep_with||received-16/VBN||type2diabetes-28/NNS	nsubjpass||controlled-33/VBN||type2diabetes-28/NNS	auxpass||controlled-33/VBN||are-31/VBP	advmod||controlled-33/VBN||inadequately-32/RB	rcmod||type2diabetes-28/NNS||controlled-33/VBN	preconj||received-16/VBN||either-35/CC	prep_by||received-16/VBN||sitagliptin-37/NN	prep_by||received-16/VBN||metformin-39/NN	conj_or||sitagliptin-37/NN||metformin-39/NN	advmod||received-16/VBN||alone-40/RB	advmod||received-16/VBN||together-42/RB	amod||form-46/NN||free-dose-44/JJ	nn||form-46/NN||combination-45/NN	prep_in||received-16/VBN||form-46/NN	type2diabetes-28||metformin-39||yes||janumettm, a fixed dose combination of sitagliptin/metformin hcl manufactured by merck pharmaceuticals, has received us food and drug administration approval for treatment of patients with type2diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form.
dep||strategy-10/NN||conclusion-1/NN	mark||strategy-10/NN||though-2/IN	nn||education-4/NN||outreach-3/NN	nsubj||strategy-10/NN||education-4/NN	cop||strategy-10/NN||is-5/VBZ	det||strategy-10/NN||an-6/DT	amod||strategy-10/NN||effective-7/JJ	conj_and||effective-7/JJ||feasible-9/JJ	amod||strategy-10/NN||feasible-9/JJ	advcl||is-24/VBZ||strategy-10/NN	prepc_for||strategy-10/NN||improving-12/VBG	dobj||improving-12/VBG||comprehensiveness-13/NN	prep_of||comprehensiveness-13/NN||care-15/NN	prepc_for||strategy-10/NN||wellbeing-17/VBG	conj_and||improving-12/VBG||wellbeing-17/VBG	prep_of||wellbeing-17/VBG||patients-19/NNS	prep_with||patients-19/NNS||hiv/aids-21/NNS	expl||is-24/VBZ||there-23/EX	root||ROOT-0/null||is-24/VBZ	neg||evidence-26/NN||no-25/DT	nsubj||is-24/VBZ||evidence-26/NN	mark||increases-29/VBZ||that-27/IN	nsubj||increases-29/VBZ||it-28/PRP	ccomp||is-24/VBZ||increases-29/VBZ	dobj||increases-29/VBZ||access-30/NN	det||programme-34/NN||the-32/DT	nn||programme-34/NN||art-33/NN	prep_to||increases-29/VBZ||programme-34/NN	aids--1||hiv--1||no||conclusion though outreach education is an effective and feasible strategy for improving comprehensiveness of care and wellbeing of patients with hiv/aids, there is no evidence that it increases access to the art programme.
nsubj||immunomodulator-5/NN||tacrolimus-1/NNS	cop||immunomodulator-5/NN||is-2/VBZ	det||immunomodulator-5/NN||a-3/DT	amod||immunomodulator-5/NN||potent-4/JJ	root||ROOT-0/null||immunomodulator-5/NN	nsubj||effective-8/JJ||immunomodulator-5/NN	cop||effective-8/JJ||is-7/VBZ	rcmod||immunomodulator-5/NN||effective-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||effective-8/JJ||treatment-11/NN	prep_of||treatment-11/NN||inflammatoryboweldisease-13/NN	appos||inflammatoryboweldisease-13/NN||ibd-15/NN	tacrolimus-1||ibd-15||no_rel||tacrolimus is a potent immunomodulator that is effective in the treatment of inflammatoryboweldisease (ibd).
nsubj||drug-9/NN||levetiracetam-1/NN	appos||levetiracetam-1/NN||lev-3/NN	cop||drug-9/NN||is-5/VBZ	det||drug-9/NN||a-6/DT	amod||drug-9/NN||novel-7/JJ	amod||drug-9/NN||antiepileptic-8/JJ	root||ROOT-0/null||drug-9/NN	nsubjpass||approved-17/VBN||drug-9/NN	appos||drug-9/NN||aed-11/NN	aux||approved-17/VBN||has-14/VBZ	advmod||approved-17/VBN||recently-15/RB	auxpass||approved-17/VBN||been-16/VBN	rcmod||drug-9/NN||approved-17/VBN	amod||treatment-20/NN||add-on-19/JJ	prep_as||approved-17/VBN||treatment-20/NN	amod||types-24/NNS||various-22/JJ	nn||types-24/NNS||seizure-23/NN	prep_for||treatment-20/NN||types-24/NNS	nn||populations-27/NNS||epilepsy-26/NN	prep_in||approved-17/VBN||populations-27/NNS	nsubj||include-29/VBP||populations-27/NNS	rcmod||populations-27/NNS||include-29/VBP	dobj||include-29/VBP||children-30/NNS	amod||seizures-34/NNS||refractory-32/JJ	amod||seizures-34/NNS||partial-33/JJ	prep_for||children-30/NNS||seizures-34/NNS	nn||¥-40/NNP||epilepsy-36/NN	nn||¥-40/NNP||patients-37/NNS	nn||¥-40/NNP||â-38/NN	nn||¥-40/NNP||‰-39/NNP	prep_in||include-29/VBP||¥-40/NNP	num||years-42/NNS||4-41/CD	npadvmod||old-43/JJ||years-42/NNS	amod||¥-40/NNP||old-43/JJ	amod||seizures-47/NNS||myoclonic-46/JJ	prep_for||¥-40/NNP||seizures-47/NNS	amod||myoclonic-50/JJ||juvenile-49/JJ	amod||patients-70/NNS||myoclonic-50/JJ	nn||patients-70/NNS||epilepsy-51/NN	nn||patients-70/NNS||patients-52/NNS	nn||patients-70/NNS||â-53/NN	amod||patients-70/NNS||‰-54/JJ	number||12-56/CD||¥-55/CD	num||years-57/NNS||12-56/CD	npadvmod||old-58/JJ||years-57/NNS	amod||patients-70/NNS||old-58/JJ	conj_and||old-58/JJ||for-61/IN	amod||patients-70/NNS||for-61/IN	amod||seizures-65/NNS||primary-62/JJ	amod||seizures-65/NNS||generalized-63/JJ	amod||seizures-65/NNS||tonic-clonic-64/JJ	pobj||for-61/IN||seizures-65/NNS	prep_in||seizures-65/NNS||idiopathic-67/NN	amod||patients-70/NNS||generalized-68/JJ	nn||patients-70/NNS||epilepsy-69/NN	prep_in||seizures-47/NNS||patients-70/NNS	dep||patients-70/NNS||â-72/VBN	nn||¥-74/NNP||‰-73/NNP	dobj||â-72/VBN||¥-74/NNP	num||years-76/NNS||6-75/CD	npadvmod||old-77/JJ||years-76/NNS	amod||¥-74/NNP||old-77/JJ	nn||approval-80/NN||fda-79/NN	prep_with||â-72/VBN||approval-80/NN	nn||¥-84/NNP||â-82/NNP	nn||¥-84/NNP||‰-83/NNP	dep||approval-80/NN||¥-84/NNP	num||years-86/NNS||12-85/CD	npadvmod||old-87/JJ||years-86/NNS	amod||¥-84/NNP||old-87/JJ	nn||approval-90/NN||emea-89/NN	prep_with||â-72/VBN||approval-90/NN	epilepsy-69||levetiracetam-1||yes||levetiracetam (lev) is a novel antiepileptic drug (aed) that has recently been approved as add-on treatment for various seizure types in epilepsy populations that include children for refractory partial seizures in epilepsy patients â‰¥4 years old, for myoclonic seizures in juvenile myoclonic epilepsy patients â‰¥12 years old, and for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy patients (â‰¥6 years old with fda approval; â‰¥12 years old with emea approval).
advmod||recently-2/RB||more-1/RBR	advmod||emerging-13/VBG||recently-2/RB	nsubj||emerging-13/VBG||gonadotropins-4/NNS	cc||lh/hcg-10/NN||and-6/CC	dep||lh/hcg-10/NN||in-8/RB	amod||lh/hcg-10/NN||particular-9/JJ	dep||gonadotropins-4/NNS||lh/hcg-10/NN	aux||emerging-13/VBG||are-12/VBP	root||ROOT-0/null||emerging-13/VBG	nn||regulators-16/NNS||novel-15/NN	prep_as||emerging-13/VBG||regulators-16/NNS	nn||progression-19/NN||tumor-18/NN	prep_of||regulators-16/NNS||progression-19/NN	tumor-18||hcg--1||no_rel||more recently, gonadotropins, and, in particular lh/hcg, are emerging as novel regulators of tumor progression.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	quantmod||6-4/CD||only-3/RB	num||prescriptions-5/NNS||6-4/CD	dobj||found-2/VBD||prescriptions-5/NNS	vmod||prescriptions-5/NNS||having-6/VBG	det||treatment-9/NN||the-7/DT	amod||treatment-9/NN||recommended-8/VBN	dobj||having-6/VBG||treatment-9/NN	nsubjpass||ors-12/VBN||treatment-9/NN	auxpass||ors-12/VBN||is-11/VBZ	rcmod||treatment-9/NN||ors-12/VBN	prep_along_with||ors-12/VBN||zinc-15/NN	neg||probiotics-20/NNS||no-18/DT	amod||probiotics-20/NNS||additional-19/JJ	prep_with||ors-12/VBN||probiotics-20/NNS	prep_with||ors-12/VBN||antibiotics-22/NN	conj_or||probiotics-20/NNS||antibiotics-22/NN	prep_with||ors-12/VBN||racecadotril-24/NN	conj_or||probiotics-20/NNS||racecadotril-24/NN	prep_with||ors-12/VBN||antiemetics-26/NNS	conj_or||probiotics-20/NNS||antiemetics-26/NNS	prep_except||prescriptions-5/NNS||domperidone-29/NN	prep_for||domperidone-29/NN||vomiting-31/NN	domperidone-29||vomiting-31||no_rel||we found only 6 prescriptions having the recommended treatment that is ors along with zinc, with no additional probiotics, antibiotics, racecadotril or antiemetics (except domperidone for vomiting).
nsubjpass||treated-3/VBN||osteomyelitis-1/NNS	auxpass||treated-3/VBN||was-2/VBD	root||ROOT-0/null||treated-3/VBN	amod||teicoplanin-6/NN||parenteral-5/JJ	prep_with||treated-3/VBN||teicoplanin-6/NN	amod||rifampicin-9/NN||oral-8/JJ	prep_with||treated-3/VBN||rifampicin-9/NN	conj_and||teicoplanin-6/NN||rifampicin-9/NN	prep_with||treated-3/VBN||azithromycin-11/NN	conj_and||teicoplanin-6/NN||azithromycin-11/NN	teicoplanin-6||osteomyelitis-1||no_rel||osteomyelitis was treated with parenteral teicoplanin, oral rifampicin and azithromycin.
nsubjpass||speculated-4/VBN||it-1/PRP	aux||speculated-4/VBN||has-2/VBZ	auxpass||speculated-4/VBN||been-3/VBN	root||ROOT-0/null||speculated-4/VBN	mark||associated-14/VBN||that-5/IN	amod||antigen-8/NN||human-6/JJ	nn||antigen-8/NN||leukocyte-7/NN	nn||alleles-12/NNS||antigen-8/NN	appos||alleles-12/NNS||hla-10/NN	nsubjpass||associated-14/VBN||alleles-12/NNS	auxpass||associated-14/VBN||are-13/VBP	ccomp||speculated-4/VBN||associated-14/VBN	det||outcome-17/NN||the-16/DT	prep_with||associated-14/VBN||outcome-17/NN	nn||infection-23/NN||hepatitisbvirus-19/NNP	appos||infection-23/NN||hbv-21/NN	prep_of||outcome-17/NN||infection-23/NN	mark||shown-32/VBN||although-24/IN	det||data-26/NNS||the-25/DT	nsubj||shown-32/VBN||data-26/NNS	vmod||data-26/NNS||obtained-27/VBN	amod||populations-30/NNS||various-29/JJ	prep_from||obtained-27/VBN||populations-30/NNS	aux||shown-32/VBN||have-31/VBP	advcl||associated-14/VBN||shown-32/VBN	det||inconsistencies-34/NNS||some-33/DT	dobj||shown-32/VBN||inconsistencies-34/NNS	hbv-21||hepatitisbvirus-19||no||it has been speculated that human leukocyte antigen (hla) alleles are associated with the outcome of hepatitisbvirus (hbv) infection although the data obtained from various populations have shown some inconsistencies.
nsubj||determined-3/VBD||we-1/PRP	advmod||determined-3/VBD||therefore-2/RB	root||ROOT-0/null||determined-3/VBD	det||frequency-5/NN||the-4/DT	dobj||determined-3/VBD||frequency-5/NN	nn||seropositivity-8/NN||igg-7/NN	prep_of||frequency-5/NN||seropositivity-8/NN	prep_against||determined-3/VBD||scrubtyphus-10/NNS	appos||scrubtyphus-10/NNS||orientiatsutsugamushi-12/NNP	prep_against||determined-3/VBD||murinetyphus-15/NNS	conj_and||scrubtyphus-10/NNS||murinetyphus-15/NNS	appos||scrubtyphus-10/NNS||rickettsiatyphi-17/NNP	prep_as||determined-3/VBD||indices-21/NNS	amod||exposure-24/NN||prior-23/JJ	prep_of||indices-21/NNS||exposure-24/NN	det||pathogens-27/NNS||these-26/DT	prep_to||determined-3/VBD||pathogens-27/NNS	advmod||adults-32/NNS||randomly-30/RB	amod||adults-32/NNS||selected-31/VBN	prep_in||determined-3/VBD||adults-32/NNS	prep_in||adults-32/NNS||urban-34/JJ	amod||city-38/NN||peri-urban-36/JJ	nn||city-38/NN||vientiane-37/NN	prep_in||adults-32/NNS||city-38/NN	conj_and||urban-34/JJ||city-38/NN	dep||adults-32/NNS||nâ-40/VBN	num||â-44/NN||$-41/$	number||=-43/CD||š-42/CD	num||$-41/$||=-43/CD	dobj||nâ-40/VBN||â-44/NN	amod||â-44/NN||$-45/$	number||,002-47/CD||š2-46/CD	num||$-45/$||,002-47/CD	advmod||‰-50/JJ||â-49/RB	dep||$-45/$||‰-50/JJ	number||35-52/CD||¥-51/CD	num||years-53/NNS||35-52/CD	tmod||nâ-40/VBN||years-53/NNS	murinetyphus-15||rickettsiatyphi-17||no||we therefore determined the frequency of igg seropositivity against scrubtyphus ( orientiatsutsugamushi ) and murinetyphus ( rickettsiatyphi ), as indices of prior exposure to these pathogens, in randomly selected adults in urban and peri-urban vientiane city (nâ€š=â€š2,002, â‰¥35 years).
det||point-3/NN||this-2/DT	prep_at||demonstrates-9/VBZ||point-3/NN	det||evidence-7/NN||the-5/DT	amod||evidence-7/NN||best-6/JJS	nsubj||demonstrates-9/VBZ||evidence-7/NN	advmod||demonstrates-9/VBZ||powerfully-8/RB	root||ROOT-0/null||demonstrates-9/VBZ	nn||patients-13/NNS||stroke-10/NN	conj_and||stroke-10/NN||tia-12/NN	nn||patients-13/NNS||tia-12/NN	nsubjpass||prescribed-16/VBN||patients-13/NNS	aux||prescribed-16/VBN||should-14/MD	auxpass||prescribed-16/VBN||be-15/VB	ccomp||demonstrates-9/VBZ||prescribed-16/VBN	amod||therapy-20/NN||high-17/JJ	nn||therapy-20/NN||dose-18/NN	nn||therapy-20/NN||statin-19/NN	dobj||prescribed-16/VBN||therapy-20/NN	amod||prevention-24/NN||secondary-22/JJ	nn||prevention-24/NN||stroke-23/NN	prep_for||therapy-20/NN||prevention-24/NN	tia-12||statin-19||no_rel||at this point, the best evidence powerfully demonstrates stroke and tia patients should be prescribed high dose statin therapy for secondary stroke prevention.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	prep_into||enrolled-3/VBN||one-5/CD	num||groups-8/NNS||four-7/CD	prep_of||one-5/CD||groups-8/NNS	det||basis-11/NN||the-10/DT	prep_on||groups-8/NNS||basis-11/NN	nn||status-16/NN||hiv-13/NN	conj_and||hiv-13/NN||ks-15/NN	nn||status-16/NN||ks-15/NN	prep_of||basis-11/NN||status-16/NN	nsubj||negative/ks-19/VBZ||hiv-18/NN	dep||groups-8/NNS||negative/ks-19/VBZ	acomp||negative/ks-19/VBZ||negative-20/JJ	amod||negative-23/JJ||hivpositive/ks-22/JJ	acomp||negative/ks-19/VBZ||negative-23/JJ	conj_and||negative-20/JJ||negative-23/JJ	num||negative/ks-26/NNS||hiv-25/CD	npadvmod||positive-27/JJ||negative/ks-26/NNS	acomp||negative/ks-19/VBZ||positive-27/JJ	conj_and||negative-20/JJ||positive-27/JJ	amod||positive-31/JJ||hivpositive/ks-30/JJ	acomp||negative/ks-19/VBZ||positive-31/JJ	conj_and||negative-20/JJ||positive-31/JJ	hivpositive--1||hiv-25||no||participants were enrolled into one of four groups on the basis of hiv and ks status (hiv negative/ks negative, hivpositive/ks negative, hiv negative/ks positive, and hivpositive/ks positive).
nsubj||reduced-6/VBD||use-1/NN	det||test-5/NN||the-3/DT	nn||test-5/NN||mtb/rif-4/NN	prep_of||use-1/NN||test-5/NN	root||ROOT-0/null||reduced-6/VBD	amod||time-8/NN||median-7/JJ	dobj||reduced-6/VBD||time-8/NN	prep_to||reduced-6/VBD||treatment-10/NN	amod||tuberculosis-13/NNP||smear-negative-12/JJ	prep_for||treatment-10/NN||tuberculosis-13/NNP	num||days-16/NNS||56-15/CD	prep_from||reduced-6/VBD||days-16/NNS	appos||days-16/NNS||39â-18/NNP	num||39â-18/NNP||$-19/$	num||$-19/$||81-21/CD	dep||days-16/NNS||to-23/TO	num||days-25/NNS||5-24/CD	dep||days-16/NNS||days-25/NNS	appos||days-25/NNS||2â-27/NNP	num||2â-27/NNP||$-28/$	num||$-28/$||8-30/CD	tuberculosis-13||mtb--1||no||use of the mtb/rif test reduced median time to treatment for smear-negative tuberculosis from 56 days (39â€“81) to 5 days (2â€“8).
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||variable-2/JJ	nsubj||necessitates-28/VBZ||efficacy-3/NN	quantmod||$-6/$||0â-5/RB	num||%-9/NN||$-6/$	num||$-6/$||80-8/CD	appos||efficacy-3/NN||%-9/NN	nn||©-16/FW||mycobacteriumbovis-12/FW	nn||©-16/FW||bacille-13/FW	nn||©-16/FW||calmette-14/FW	nn||©-16/FW||gurã-15/FW	prep_of||efficacy-3/NN||©-16/FW	discourse||vaccine-21/NN||bcg-19/UH	prep_in||©-16/FW||vaccine-21/NN	amod||tuberculosis-24/NNP||adult-23/JJ	prep_against||efficacy-3/NN||tuberculosis-24/NNP	discourse||efficacy-3/NN||tb-26/UH	root||ROOT-0/null||necessitates-28/VBZ	dobj||necessitates-28/VBZ||development-29/NN	amod||candidates-33/NNS||alternative-31/JJ	nn||candidates-33/NNS||vaccine-32/NN	prep_of||development-29/NN||candidates-33/NNS	tb-26||bcg-19||yes||the variable efficacy (0â€“80%) of mycobacteriumbovis bacille calmette gurã©in (bcg) vaccine against adult tuberculosis (tb) necessitates development of alternative vaccine candidates.
nsubj||observed-2/VBD||we-1/PRP	root||ROOT-0/null||observed-2/VBD	amod||levels-5/NNS||normal-3/JJ	nn||levels-5/NNS||glucose-4/NN	dobj||observed-2/VBD||levels-5/NNS	iobj||observed-2/VBD||levels-5/NNS	prep_in||levels-5/NNS||101-7/CD	num||%-10/NN||81.5-9/CD	appos||101-7/CD||%-10/NN	dep||101-7/CD||patients-12/NNS	prep_in||levels-5/NNS||hyperglycemia-14/NN	conj_and||101-7/CD||hyperglycemia-14/NN	prep_in||hyperglycemia-14/NN||23-16/CD	num||%-19/NN||18.5-18/CD	appos||levels-5/NNS||%-19/NN	dep||levels-5/NNS||patients-21/NNS	nsubj||different-26/JJ||patients-21/NNS	cop||different-26/JJ||is-24/VBZ	advmod||different-26/JJ||significantly-25/RB	rcmod||patients-21/NNS||different-26/JJ	dep||different-26/JJ||p-28/NNP	number||0.0001-30/CD||<-29/CD	num||p-28/NNP||0.0001-30/CD	prepc_compared_to||different-26/JJ||to-33/TO	det||prevalence-36/NN||the-34/DT	amod||prevalence-36/NN||diabetesmellitus-35/JJ	pobj||different-26/JJ||prevalence-36/NN	num||%-39/NN||7.6-38/CD	appos||prevalence-36/NN||%-39/NN	det||population-44/NN||the-42/DT	nn||population-44/NN||brazilian-43/NN	prep_in||prevalence-36/NN||population-44/NN	hyperglycemia-14||glucose-4||no||we observed normal glucose levels in 101 (81.5%) patients and hyperglycemia in 23 (18.5%) patients, which is significantly different (p < 0.0001) compared to the diabetesmellitus prevalence (7.6%) in the brazilian population.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||âˆ-14/VB	num||±-17/NN||’14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||âˆ-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||âˆ-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||âˆ-37/NN	num||±-40/NN||’14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||âˆ-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||âˆ-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||âˆ-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	insulin-82||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (âˆ’14 â± 3 pg/ml [âˆ’4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (âˆ’14 â± 2 pg/ml [âˆ’4.0 â± 0.6 pmol/l]) but increased to âˆ’3 â± 3 pg/ml (âˆ’0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||factors-5/NNS||the-3/DT	amod||factors-5/NNS||clinical-4/JJ	dobj||evaluated-2/VBN||factors-5/NNS	nsubj||affect-7/VBP||factors-5/NNS	rcmod||factors-5/NNS||affect-7/VBP	det||pain-9/NN||the-8/DT	dobj||affect-7/VBP||pain-9/NN	prep_on||affect-7/VBP||injection-11/NN	prep_of||injection-11/NN||propofol-13/NN	aux||develop-15/VB||to-14/TO	vmod||evaluated-2/VBN||develop-15/VB	det||strategy-17/NN||a-16/DT	dobj||develop-15/VB||strategy-17/NN	aux||prevent-19/VB||to-18/TO	vmod||strategy-17/NN||prevent-19/VB	vmod||strategy-17/NN||reduce-21/VB	conj_or||prevent-19/VB||reduce-21/VB	dobj||prevent-19/VB||pain-22/NN	pain-22||propofol-13||yes||we evaluated the clinical factors that affect the pain on injection of propofol to develop a strategy to prevent or reduce pain.
prep_in||potent-7/JJ||conclusion-2/NN	nsubj||potent-7/JJ||clevudine-4/NN	nsubj||lower-12/JJR||clevudine-4/NN	cop||potent-7/JJ||is-5/VBZ	advmod||potent-7/JJ||more-6/RBR	root||ROOT-0/null||potent-7/JJ	amod||suppression-10/NN||viral-9/JJ	prep_for||potent-7/JJ||suppression-10/NN	conj_and||potent-7/JJ||lower-12/JJR	amod||resistance-15/NN||antiviral-14/JJ	prep_for||lower-12/JJR||resistance-15/NN	prep_at||resistance-15/NN||week-17/NN	num||week-17/NN||48-18/CD	mark||¯-25/VBZ||than-19/IN	nsubj||¯-25/VBZ||lamivudine-20/NN	prep_in||lamivudine-20/NN||treatment-22/NN	prep_of||treatment-22/NN||naã-24/NN	advcl||potent-7/JJ||¯-25/VBZ	nn||patients-27/NNS||ve-26/NN	dobj||¯-25/VBZ||patients-27/NNS	prepc_with||¯-25/VBZ||hbeag-29/VBG	amod||chronichepatitisb-31/NN||positive-30/JJ	dobj||hbeag-29/VBG||chronichepatitisb-31/NN	antiviral-14||chronichepatitisb-31||no_rel||in conclusion, clevudine is more potent for viral suppression and lower for antiviral resistance at week 48 than lamivudine in treatment of naã¯ve patients with hbeag positive chronichepatitisb.
amod||objectives-2/NNS||secondary-1/JJ	nsubj||effectiveness-5/NN||objectives-2/NNS	cop||effectiveness-5/NN||were-3/VBD	det||effectiveness-5/NN||the-4/DT	root||ROOT-0/null||effectiveness-5/NN	prep_of||effectiveness-5/NN||ondansetron-7/NN	prep_of||effectiveness-5/NN||prochlorperazine-9/NN	conj_and||ondansetron-7/NN||prochlorperazine-9/NN	aux||treat-11/VB||to-10/TO	vmod||effectiveness-5/NN||treat-11/VB	dobj||treat-11/VB||nausea-12/NN	poss||tolerability-15/NN||their-14/PRP$	dobj||treat-11/VB||tolerability-15/NN	conj_and||nausea-12/NN||tolerability-15/NN	nausea-12||ondansetron-7||yes||secondary objectives were the effectiveness of ondansetron and prochlorperazine to treat nausea and their tolerability.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||examine-8/VB||objective-2/NN	det||analysis-5/NN||this-4/DT	prep_of||objective-2/NN||analysis-5/NN	ccomp||approved-21/VBD||was-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||was-6/VBD||examine-8/VB	advmod||examine-8/VB||retrospectively-9/RB	det||safety-12/NN||the-10/DT	nn||safety-12/NN||cv-11/NN	dobj||examine-8/VB||safety-12/NN	amod||bid-15/NN||exenatide-14/JJ	prep_of||safety-12/NN||bid-15/NN	det||agonist-20/NN||a-17/DT	amod||agonist-20/NN||glp-1-18/JJ	nn||agonist-20/NN||receptor-19/NN	nsubj||approved-21/VBD||agonist-20/NN	root||ROOT-0/null||approved-21/VBD	prepc_for||approved-21/VBD||treating-23/VBG	dobj||treating-23/VBG||hyperglycemia-24/NN	prep_in||hyperglycemia-24/NN||patients-26/NNS	prep_with||treating-23/VBG||type2diabetes-28/NNS	neg||controlled-31/VBN||not-29/RB	advmod||controlled-31/VBN||adequately-30/RB	vmod||type2diabetes-28/NNS||controlled-31/VBN	prep_with||controlled-31/VBN||diet-33/NN	prep_with||controlled-31/VBN||exercise-35/NN	conj_and||diet-33/NN||exercise-35/NN	type2diabetes-28||exenatide-14||yes||the objective of this analysis was to examine retrospectively the cv safety of exenatide bid, a glp-1 receptor agonist approved for treating hyperglycemia in patients with type2diabetes not adequately controlled with diet and exercise.
nsubj||include-12/VBP||risks-1/NNS	det||spread-4/NN||the-3/DT	prep_for||risks-1/NNS||spread-4/NN	prep_of||spread-4/NN||hiv/aids-6/NNS	amod||people-9/NNS||young-8/JJ	prep_among||hiv/aids-6/NNS||people-9/NNS	prep_in||people-9/NNS||kazakhstan-11/NN	root||ROOT-0/null||include-12/VBP	dobj||include-12/VBP||prostitution-13/NN	dobj||include-12/VBP||prostitution-13/NN	conj_and||prostitution-13/NN||prostitution-13/NN	cc||prostitution-13/NN||well-15/RB	prep_as||prostitution-13/NN||stigmatization-17/NN	det||hivpositive-20/NN||the-19/DT	prep_of||stigmatization-17/NN||hivpositive-20/NN	prep_of||prostitution-13/NN||homosexuals-23/NNS	hivpositive-20||hiv--1||no||risks for the spread of hiv/aids among young people in kazakhstan include prostitution as well as stigmatization of the hivpositive and of homosexuals.
advmod||eligible-2/JJ||forty-1/RB	amod||patients-3/NNS||eligible-2/JJ	nsubjpass||randomized-14/VBN||patients-3/NNS	nsubj||receive-16/VB||patients-3/NNS	nsubj||levofloxacin-32/VB||patients-3/NNS	amod||exacerbation-6/NN||acute-5/JJ	prep_with||patients-3/NNS||exacerbation-6/NN	amod||bronchitis-9/NNS||chronic-8/JJ	prep_of||exacerbation-6/NN||bronchitis-9/NNS	appos||patients-3/NNS||aecb-11/NN	auxpass||randomized-14/VBN||were-13/VBD	root||ROOT-0/null||randomized-14/VBN	aux||receive-16/VB||to-15/TO	xcomp||randomized-14/VBN||receive-16/VB	nn||mg-19/NN||cefditoren-17/NN	num||mg-19/NN||200-18/CD	dobj||receive-16/VB||mg-19/NN	advmod||day-22/NN||twice-20/RB	det||day-22/NN||a-21/DT	npadvmod||receive-16/VB||day-22/NN	num||days-25/NNS||5-24/CD	prep_for||receive-16/VB||days-25/NNS	dep||days-25/NNS||n-27/VBN	dep||20-29/CD||=-28/SYM	ccomp||n-27/VBN||20-29/CD	xcomp||randomized-14/VBN||levofloxacin-32/VB	conj_or||receive-16/VB||levofloxacin-32/VB	num||mg-34/NN||500-33/CD	dobj||levofloxacin-32/VB||mg-34/NN	advmod||daily-36/JJ||once-35/RB	advmod||levofloxacin-32/VB||daily-36/JJ	num||days-39/NNS||7-38/CD	prep_for||daily-36/JJ||days-39/NNS	dep||days-39/NNS||n-41/VBN	dep||20-43/CD||=-42/SYM	ccomp||n-41/VBN||20-43/CD	bronchitis-9||cefditoren-17||yes||forty eligible patients with acute exacerbation of chronic bronchitis (aecb) were randomized to receive cefditoren 200 mg twice a day for 5 days (n = 20) or levofloxacin 500 mg once daily for 7 days (n = 20).
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	fat--1||cvd-36||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
nsubj||precedes-6/VBZ||impairedglucosetolerance-1/NN	nsubjpass||associated-15/VBN||impairedglucosetolerance-1/NN	appos||impairedglucosetolerance-1/NN||igt-3/NN	rcmod||impairedglucosetolerance-1/NN||precedes-6/VBZ	amod||type2diabetes-8/NNS||overt-7/JJ	dobj||precedes-6/VBZ||type2diabetes-8/NNS	appos||type2diabetes-8/NNS||t2dm-10/NNP	prep_for||type2diabetes-8/NNS||decades-13/NNS	auxpass||associated-15/VBN||is-14/VBZ	root||ROOT-0/null||associated-15/VBN	amod||alterations-19/NNS||multiple-17/JJ	amod||alterations-19/NNS||metabolic-18/JJ	prep_with||associated-15/VBN||alterations-19/NNS	nn||tissues-23/NNS||insulin-21/NN	amod||tissues-23/NNS||sensitive-22/JJ	prep_in||alterations-19/NNS||tissues-23/NNS	type2diabetes-8||insulin-21||yes||impairedglucosetolerance (igt) which precedes overt type2diabetes (t2dm) for decades is associated with multiple metabolic alterations in insulin sensitive tissues.
amod||studies-5/NNS||short-1/JJ	conj_and||short-1/JJ||long-term-4/JJ	amod||studies-5/NNS||long-term-4/JJ	nsubj||demonstrated-7/VBN||studies-5/NNS	nsubj||tolerated-25/VBN||studies-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||efficacious-22/NNS||that-8/IN	amod||risperidone-10/NN||long-acting-9/JJ	nsubj||efficacious-22/NNS||risperidone-10/NN	dep||risperidone-10/NN||25-12/CD	dep||risperidone-10/NN||37.5-14/CD	conj_or||25-12/CD||37.5-14/CD	num||mg-18/NN||50-17/CD	dep||risperidone-10/NN||mg-18/NN	conj_or||25-12/CD||mg-18/NN	cop||efficacious-22/NNS||is-20/VBZ	det||efficacious-22/NNS||both-21/DT	ccomp||demonstrated-7/VBN||efficacious-22/NNS	advmod||tolerated-25/VBN||well-24/RB	conj_and||demonstrated-7/VBN||tolerated-25/VBN	det||variety-29/NN||a-27/DT	amod||variety-29/NN||wide-28/JJ	prep_in||tolerated-25/VBN||variety-29/NN	prep_of||variety-29/NN||patients-31/NNS	prep_with||demonstrated-7/VBN||schizophrenia-33/NN	amod||psychoses-36/NNS||related-35/VBN	prep_with||demonstrated-7/VBN||psychoses-36/NNS	conj_and||schizophrenia-33/NN||psychoses-36/NNS	schizophrenia-33||risperidone-10||yes||short- and long-term studies have demonstrated that long-acting risperidone (25, 37.5, or 50 mg) is both efficacious and well tolerated in a wide variety of patients with schizophrenia and related psychoses.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||œsix-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nvp-23||yes||we assessed nvp-resistance in indian infants enrolled in the â€œsix-week extended-dose nevirapineâ€? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
amod||crt-2/NN||concurrent-1/JJ	nsubjpass||found-8/VBN||crt-2/NN	nsubj||well-tolerated-11/JJ||crt-2/NN	nsubj||effective-13/JJ||crt-2/NN	prep_with||crt-2/NN||capecitabine-4/NN	prep_with||crt-2/NN||cisplatin-6/NN	conj_and||capecitabine-4/NN||cisplatin-6/NN	auxpass||found-8/VBN||was-7/VBD	root||ROOT-0/null||found-8/VBN	aux||well-tolerated-11/JJ||to-9/TO	cop||well-tolerated-11/JJ||be-10/VB	xcomp||found-8/VBN||well-tolerated-11/JJ	xcomp||found-8/VBN||effective-13/JJ	conj_and||well-tolerated-11/JJ||effective-13/JJ	prep_in||well-tolerated-11/JJ||patients-15/NNS	prep_with||patients-15/NNS||esophagealcancer-17/NN	esophagealcancer-17||cisplatin-6||yes||concurrent crt with capecitabine and cisplatin was found to be well-tolerated and effective in patients with esophagealcancer.
nsubjpass||reported-5/VBN||actinomycosis-1/NNS	aux||reported-5/VBN||has-2/VBZ	auxpass||reported-5/VBN||been-3/VBN	advmod||reported-5/VBN||rarely-4/RB	root||ROOT-0/null||reported-5/VBN	prep_in||reported-5/VBN||patients-7/NNS	prep_with||patients-7/NNS||hiv/aids-9/NNS	prep_in||hiv/aids-9/NNS||contrast-11/NN	amod||pathogens-17/NNS||other-13/JJ	amod||pathogens-17/NNS||opportunistic-14/JJ	conj_and||opportunistic-14/JJ||common-16/JJ	amod||pathogens-17/NNS||common-16/JJ	prep_to||reported-5/VBN||pathogens-17/NNS	aids--1||hiv--1||no||actinomycosis has been rarely reported in patients with hiv/aids in contrast to other opportunistic and common pathogens.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||determine-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	mark||collected-16/VBD||whether-9/IN	amod||levels-13/NNS||estradiol-10/JJ	conj_and||estradiol-10/JJ||testosterone-12/JJ	amod||levels-13/NNS||testosterone-12/JJ	nsubj||collected-16/VBD||levels-13/NNS	prep_in||levels-13/NNS||serum-15/NN	ccomp||determine-8/VB||collected-16/VBD	mark||associated-20/VBN||before-17/IN	nsubjpass||associated-20/VBN||menopause-18/NN	auxpass||associated-20/VBN||are-19/VBP	advcl||collected-16/VBD||associated-20/VBN	amod||risk-25/NN||subsequent-22/JJ	nn||risk-25/NN||breast-23/NN	nn||risk-25/NN||cancer-24/NN	prep_with||associated-20/VBN||risk-25/NN	estradiol-10||cancer-24||no_rel||the objective of this study was to determine whether estradiol and testosterone levels in serum collected before menopause are associated with subsequent breast cancer risk.
amod||vaccines-9/NNS||immunization-1/JJ	amod||swine-6/NNS||1918-like-3/JJ	conj_and||1918-like-3/JJ||classical-5/JJ	amod||swine-6/NNS||classical-5/JJ	prep_with||immunization-1/JJ||swine-6/NNS	amod||vaccines-9/NNS||h1n1-7/JJ	nn||vaccines-9/NNS||virus-8/NN	nsubj||results-10/VBZ||vaccines-9/NNS	root||ROOT-0/null||results-10/VBZ	amod||antibodies-13/NNS||cross-protective-12/JJ	prep_in||results-10/VBZ||antibodies-13/NNS	det||influenza-19/NN||the-15/DT	num||h1n1-17/NNS||2009-16/CD	npadvmod||pandemic-18/JJ||h1n1-17/NNS	amod||influenza-19/NN||pandemic-18/JJ	prep_against||antibodies-13/NNS||influenza-19/NN	xcomp||results-10/VBZ||indicating-21/VBG	amod||similarities-23/NNS||antigenic-22/JJ	dobj||indicating-21/VBG||similarities-23/NNS	det||viruses-26/NNS||these-25/DT	prep_among||indicating-21/VBG||viruses-26/NNS	cross--1||vaccines-9||no_rel||immunization with 1918-like and classical swine h1n1 virus vaccines results in cross-protective antibodies against the 2009 h1n1 pandemic influenza, indicating antigenic similarities among these viruses.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||inh-14||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
amod||mice-4/NNS||liver-1/JJ	amod||mice-4/NNS||ct26-2/JJ	amod||mice-4/NNS||tumor-bearing-3/JJ	nsubjpass||injected-7/VBN||mice-4/NNS	auxpass||injected-7/VBN||were-5/VBD	advmod||injected-7/VBN||hydrodynamically-6/RB	root||ROOT-0/null||injected-7/VBN	amod||doses-10/NNS||different-9/JJ	prep_with||injected-7/VBN||doses-10/NNS	det||plasmid-13/NN||a-12/DT	prep_of||doses-10/NNS||plasmid-13/NN	xcomp||injected-7/VBN||containing-14/VBG	det||transposon-16/NN||a-15/DT	dobj||containing-14/VBG||transposon-16/NN	vmod||transposon-16/NN||encoding-17/VBG	det||gene-21/NN||an-18/DT	amod||gene-21/NN||angiostatin-endostatin-19/JJ	nn||gene-21/NN||fusion-20/NN	dobj||encoding-17/VBG||gene-21/NN	nn||ae-24/NN||statin-23/NN	appos||gene-21/NN||ae-24/NN	amod||amounts-29/NNS||varying-28/VBG	prep_along_with||gene-21/NN||amounts-29/NNS	amod||plasmid-33/NN||sb-31/JJ	amod||plasmid-33/NN||transposase-encoding-32/JJ	prep_of||amounts-29/NNS||plasmid-33/NN	tumor--1||sb-31||no_rel||liver ct26 tumor-bearing mice were hydrodynamically injected with different doses of a plasmid containing a transposon encoding an angiostatin-endostatin fusion gene (statin ae) along with varying amounts of sb transposase-encoding plasmid.
nn||chlamydialinfection-2/NN||ocular-1/NN	nsubjpass||monitored-10/VBN||chlamydialinfection-2/NN	nsubjpass||monitored-10/VBN||chlamydialinfection-2/NN	prep_in||chlamydialinfection-2/NN||1-4/CD	amod||children-8/NNS||5-year-old-7/JJ	prep_to||chlamydialinfection-2/NN||children-8/NNS	auxpass||monitored-10/VBN||was-9/VBD	root||ROOT-0/null||monitored-10/VBN	conj_and||monitored-10/VBN||monitored-10/VBN	num||distributions-15/NNS||four-12/CD	amod||distributions-15/NNS||biannual-13/JJ	nn||distributions-15/NNS||azithromycin-14/NN	prep_over||monitored-10/VBN||distributions-15/NNS	num||months-19/NNS||24-18/CD	prep_for||monitored-10/VBN||months-19/NNS	det||treatment-23/NN||the-21/DT	amod||treatment-23/NN||last-22/JJ	prep_after||monitored-10/VBN||treatment-23/NN	chlamydialinfection-2||azithromycin-14||yes||ocular chlamydialinfection in 1- to 5-year-old children was monitored over four biannual azithromycin distributions and for 24 months after the last treatment.
det||lack-2/NN||the-1/DT	nsubj||hindered-12/VBN||lack-2/NN	amod||trials-7/NNS||adequate-4/JJ	amod||trials-7/NNS||randomized-5/JJ	amod||trials-7/NNS||clinical-6/JJ	prep_of||lack-2/NN||trials-7/NNS	appos||trials-7/NNS||rct-9/NN	aux||hindered-12/VBN||has-11/VBZ	root||ROOT-0/null||hindered-12/VBN	dobj||hindered-12/VBN||identification-13/NN	nsubj||safe-19/JJ||identification-13/NN	nsubj||effective-21/JJ||identification-13/NN	amod||therapies-16/NNS||new-15/JJ	prep_of||identification-13/NN||therapies-16/NNS	cop||safe-19/JJ||are-18/VBP	rcmod||identification-13/NN||safe-19/JJ	rcmod||identification-13/NN||effective-21/JJ	conj_and||safe-19/JJ||effective-21/JJ	prep_for||safe-19/JJ||patients-23/NNS	amod||focalsegmentalglomerulosclerosis-26/NNS||primary-25/JJ	prep_with||patients-23/NNS||focalsegmentalglomerulosclerosis-26/NNS	appos||focalsegmentalglomerulosclerosis-26/NNS||fsgs-28/NNS	dep||safe-19/JJ||especially-31/RB	prep_in||safe-19/JJ||patients-33/NNS	nsubj||fail-35/VBP||patients-33/NNS	nsubj||respond-37/VB||patients-33/NNS	rcmod||patients-33/NNS||fail-35/VBP	aux||respond-37/VB||to-36/TO	xcomp||fail-35/VBP||respond-37/VB	prep_to||respond-37/VB||corticosteroids-39/NNS	nn||therapies-42/NNS||immunosuppressive-41/NN	prep_to||respond-37/VB||therapies-42/NNS	conj_and||corticosteroids-39/NNS||therapies-42/NNS	corticosteroids-39||fsgs-28||no_rel||the lack of adequate randomized clinical trials (rct) has hindered identification of new therapies that are safe and effective for patients with primary focalsegmentalglomerulosclerosis (fsgs), especially in patients who fail to respond to corticosteroids and immunosuppressive therapies.
det||patient-2/NN||the-1/DT	nsubj||reported-4/VBD||patient-2/NN	advmod||reported-4/VBD||also-3/RB	root||ROOT-0/null||reported-4/VBD	det||history-6/NN||a-5/DT	dobj||reported-4/VBD||history-6/NN	prep_of||history-6/NN||allergy-8/NN	prep_to||reported-4/VBD||humanalbuminsolution-10/NN	nn||®-13/NNP||plamasterilâ-12/NNP	dep||humanalbuminsolution-10/NN||®-13/NNP	dep||®-13/NNP||abbott-15/NN	num||years-18/NNS||15-17/CD	npadvmod||before-19/IN||years-18/NNS	advmod||humanalbuminsolution-10/NN||before-19/IN	nn||surgery-23/NN||bypass-22/NN	prep_during||reported-4/VBD||surgery-23/NN	humanalbuminsolution-10||allergy-8||no_rel||the patient also reported a history of allergy to humanalbuminsolution (plamasterilâ®; abbott) 15 years before, during bypass surgery.
nsubj||receiving-3/VBG||patients-2/NNS	prepc_in||had-17/VBD||receiving-3/VBG	dobj||receiving-3/VBG||dacarbazine-4/NN	amod||chemotherapy-7/NN||first-line-6/JJ	prep_as||receiving-3/VBG||chemotherapy-7/NN	amod||melanoma-10/NN||metastatic-9/JJ	prep_for||chemotherapy-7/NN||melanoma-10/NN	det||addition-13/NN||the-12/DT	nsubj||had-17/VBD||addition-13/NN	amod||bosentan-16/NN||high-dose-15/JJ	prep_of||addition-13/NN||bosentan-16/NN	root||ROOT-0/null||had-17/VBD	neg||effect-19/NN||no-18/DT	dobj||had-17/VBD||effect-19/NN	prep_on||effect-19/NN||time-21/NN	nn||progression-24/NN||tumor-23/NN	prep_to||had-17/VBD||progression-24/NN	amod||parameters-28/NNS||other-26/JJ	nn||parameters-28/NNS||efficacy-27/NN	prep_to||had-17/VBD||parameters-28/NNS	conj_or||progression-24/NN||parameters-28/NNS	dacarbazine-4||melanoma-10||no_rel||in patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters.
det||spread-2/NN||the-1/DT	nsubj||suggests-23/VBZ||spread-2/NN	det||h1n1influenzavirus-6/NNS||the-4/DT	num||h1n1influenzavirus-6/NNS||2009-5/CD	prep_of||spread-2/NN||h1n1influenzavirus-6/NNS	det||population-9/NN||the-8/DT	prep_in||h1n1influenzavirus-6/NNS||population-9/NN	advmod||population-9/NN||worldwide-10/RB	det||number-17/NN||the-15/DT	amod||number-17/NN||large-16/JJ	prep_in_addition_to||spread-2/NN||number-17/NN	prep_of||number-17/NN||individuals-19/NNS	advmod||vaccinated-21/VBN||already-20/RB	vmod||individuals-19/NNS||vaccinated-21/VBN	root||ROOT-0/null||suggests-23/VBZ	mark||have-32/VBP||that-24/IN	det||proportion-27/NN||a-25/DT	amod||proportion-27/NN||large-26/JJ	nsubj||have-32/VBP||proportion-27/NN	det||population-30/NN||the-29/DT	prep_of||proportion-27/NN||population-30/NN	advmod||have-32/VBP||now-31/RB	ccomp||suggests-23/VBZ||have-32/VBP	amod||antibodies-34/NNS||cross-protective-33/JJ	dobj||have-32/VBP||antibodies-34/NNS	det||virus-38/NN||the-36/DT	num||virus-38/NN||1918-37/CD	prep_against||antibodies-34/NNS||virus-38/NN	advmod||alleviating-41/VBG||greatly-40/RB	vmod||antibodies-34/NNS||alleviating-41/VBG	dobj||alleviating-41/VBG||concerns-42/NNS	dobj||alleviating-41/VBG||fears-44/NNS	conj_and||concerns-42/NNS||fears-44/NNS	det||exposure/release-48/NN||the-46/DT	amod||exposure/release-48/NN||accidental-47/JJ	prep_regarding||concerns-42/NNS||exposure/release-48/NN	det||virus-52/NN||the-50/DT	num||virus-52/NN||1918-51/CD	prep_of||exposure/release-48/NN||virus-52/NN	det||laboratory-55/NN||the-54/DT	prep_from||virus-52/NN||laboratory-55/NN	det||use-58/NN||the-57/DT	prep_of||exposure/release-48/NN||use-58/NN	conj_and||virus-52/NN||use-58/NN	det||virus-61/NN||the-60/DT	prep_of||use-58/NN||virus-61/NN	det||agent-65/NN||a-63/DT	amod||agent-65/NN||bioterrorist-64/JJ	prep_as||virus-61/NN||agent-65/NN	h1n1influenza--1||antibodies-34||no_rel||the spread of the 2009 h1n1influenzavirus in the population worldwide, in addition to the large number of individuals already vaccinated, suggests that a large proportion of the population now have cross-protective antibodies against the 1918 virus, greatly alleviating concerns and fears regarding the accidental exposure/release of the 1918 virus from the laboratory and the use of the virus as a bioterrorist agent.
nsubj||showed-24/VBD||antisera-1/NN	vmod||antisera-1/NN||raised-2/VBN	det||virus-6/NN||the-4/DT	amod||virus-6/NN||parental-5/JJ	prep_against||raised-2/VBN||virus-6/NN	vmod||virus-6/NN||reacted-7/VBN	advmod||reacted-7/VBN||equally-8/RB	preconj||homologous-11/JJ||both-10/DT	amod||viruses-14/NNS||homologous-11/JJ	conj_and||homologous-11/JJ||heterlogous-13/JJ	amod||viruses-14/NNS||heterlogous-13/JJ	prep_to||reacted-7/VBN||viruses-14/NNS	advmod||showed-24/VBD||however-16/RB	nsubj||showed-24/VBD||antisera-18/NN	vmod||antisera-18/NN||raised-19/VBN	det||virus-23/NN||the-21/DT	amod||virus-23/NN||mutant-22/JJ	prep_against||raised-19/VBN||virus-23/NN	root||ROOT-0/null||showed-24/VBD	num||folds-26/NNS||4-8-25/CD	npadvmod||lower-27/JJR||folds-26/NNS	amod||reactivity-28/NN||lower-27/JJR	dobj||showed-24/VBD||reactivity-28/NN	det||virus-32/NN||the-30/DT	amod||virus-32/NN||parental-31/JJ	prep_to||showed-24/VBD||virus-32/NN	virus-32||viruses-14||no||antisera raised against the parental virus reacted equally to both homologous and heterlogous viruses, however, antisera raised against the mutant virus showed 4-8 folds lower reactivity to the parental virus.
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	hypertension-21||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	dep||examined-12/VBD||understand-3/VB	det||role-5/NN||the-4/DT	dobj||understand-3/VB||role-5/NN	prep_of||role-5/NN||pd-1-7/JJ	amod||immunity-10/NN||antiviral-9/JJ	prep_in||pd-1-7/JJ||immunity-10/NN	nsubj||examined-12/VBD||we-11/PRP	root||ROOT-0/null||examined-12/VBD	det||expression-14/NN||the-13/DT	dobj||examined-12/VBD||expression-14/NN	amod||cells-26/NNS||pd-1-16/JJ	amod||+-24/NNS||epstein-barrvirus-18/JJ	appos||+-24/NNS||ebv-20/NN	amod||+-24/NNS||epitope-specific-22/JJ	num||+-24/NNS||cd8-23/CD	prep_on||pd-1-16/JJ||+-24/NNS	nn||cells-26/NNS||t-25/NN	prep_of||expression-14/NN||cells-26/NNS	amod||infectiousmononucleosis-29/NNS||acute-28/JJ	prep_during||examined-12/VBD||infectiousmononucleosis-29/NNS	appos||infectiousmononucleosis-29/NNS||aim-31/NN	prep_during||examined-12/VBD||convalescence-34/NN	conj_and||infectiousmononucleosis-29/NNS||convalescence-34/NN	infectiousmononucleosis-29||ebv-20||no||to better understand the role of pd-1 in antiviral immunity we examined the expression of pd-1 on epstein-barrvirus (ebv) epitope-specific cd8+ t cells during acute infectiousmononucleosis (aim) and convalescence.
nn||bats-2/NNS||asian-1/NN	nsubjpass||identified-5/VBN||bats-2/NNS	aux||identified-5/VBN||have-3/VBP	auxpass||identified-5/VBN||been-4/VBN	root||ROOT-0/null||identified-5/VBN	amod||hosts-9/NNS||potential-7/JJ	nn||hosts-9/NNS||reservoir-8/NN	prep_as||identified-5/VBN||hosts-9/NNS	prep_of||hosts-9/NNS||coronaviruses-11/NNS	vmod||coronaviruses-11/NNS||associated-12/VBN	prep_with||associated-12/VBN||severeacuterespiratorysyndrome-14/NN	appos||severeacuterespiratorysyndrome-14/NN||sars-cov-16/NNP	severeacuterespiratorysyndrome-14||coronaviruses-11||no||asian bats have been identified as potential reservoir hosts of coronaviruses associated with severeacuterespiratorysyndrome (sars-cov).
det||study-2/NN||this-1/DT	nsubj||demonstrates-3/VBZ||study-2/NN	root||ROOT-0/null||demonstrates-3/VBZ	det||mechanism-5/NN||the-4/DT	dobj||demonstrates-3/VBZ||mechanism-5/NN	amod||toxicity-8/NN||enhanced-7/JJ	prep_of||mechanism-5/NN||toxicity-8/NN	amod||neurons-11/NNS||human-10/JJ	prep_in||demonstrates-3/VBZ||neurons-11/NNS	vmod||neurons-11/NNS||subjected-12/VBN	prep_to||subjected-12/VBN||co-exposure-14/NN	nn||tat-18/NN||hiv-16/NN	nn||tat-18/NN||protein-17/NN	prep_of||co-exposure-14/NN||tat-18/NN	prep_of||co-exposure-14/NN||morphine-20/NN	conj_and||tat-18/NN||morphine-20/NN	advmod||implying-23/VBG||thus-22/RB	xcomp||subjected-12/VBN||implying-23/VBG	poss||importance-25/NN||its-24/PRP$	dobj||implying-23/VBG||importance-25/NN	amod||abusers-29/NNS||hivpositive-27/JJ	nn||abusers-29/NNS||drug-28/NN	prep_in||implying-23/VBG||abusers-29/NNS	advmod||reported-37/VBN||where-31/WRB	nsubjpass||reported-37/VBN||damage-32/NN	nsubj||severe-41/JJ||damage-32/NN	det||brain-35/NN||the-34/DT	prep_to||damage-32/NN||brain-35/NN	auxpass||reported-37/VBN||is-36/VBZ	advcl||demonstrates-3/VBZ||reported-37/VBN	aux||severe-41/JJ||to-38/TO	cop||severe-41/JJ||be-39/VB	advmod||severe-41/JJ||more-40/RBR	xcomp||reported-37/VBN||severe-41/JJ	amod||abusers-44/NNS||non-drug-43/JJ	prep_than||severe-41/JJ||abusers-44/NNS	hivpositive-27||hiv-16||no||this study demonstrates the mechanism of enhanced toxicity in human neurons subjected to co-exposure of hiv protein tat and morphine, thus implying its importance in hivpositive drug abusers, where damage to the brain is reported to be more severe than non-drug abusers.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||difference-5/NN||no-3/DT	amod||difference-5/NN||significant-4/JJ	nsubj||was-2/VBD||difference-5/NN	det||groups-9/NNS||the-7/DT	num||groups-9/NNS||two-8/CD	prep_between||difference-5/NN||groups-9/NNS	prep_with||was-2/VBD||regard-11/NN	det||incidence-14/NN||the-13/DT	prep_to||was-2/VBD||incidence-14/NN	prep_of||incidence-14/NN||complications-16/NNS	det||incidence-21/NN||an-19/DT	amod||incidence-21/NN||increased-20/VBN	prep_except_for||was-2/VBD||incidence-21/NN	nsubj||necessitated-28/VBD||incidence-21/NN	nn||pain-24/NN||breakthrough-23/NN	prep_of||incidence-21/NN||pain-24/NN	prep_of||incidence-21/NN||discomfort-26/NN	conj_and||pain-24/NN||discomfort-26/NN	rcmod||incidence-21/NN||necessitated-28/VBD	det||use-30/NN||the-29/DT	dobj||necessitated-28/VBD||use-30/NN	prep_of||use-30/NN||fentanyl-32/NN	mark||p-41/VBP||as-33/IN	det||treatment-36/NN||a-34/DT	nn||treatment-36/NN||rescue-35/NN	nsubj||p-41/VBP||treatment-36/NN	det||group-40/NN||the-38/DT	amod||group-40/NN||propofol-39/JJ	prep_in||treatment-36/NN||group-40/NN	advcl||necessitated-28/VBD||p-41/VBP	number||0.001-43/CD||<-42/CD	dobj||p-41/VBP||0.001-43/CD	pain-24||propofol-39||yes||there was no significant difference between the two groups with regard to the incidence of complications except for an increased incidence of breakthrough pain and discomfort which necessitated the use of fentanyl as a rescue treatment in the propofol group p <0.001.
det||stress-3/NN||the-1/DT	amod||stress-3/NN||oxidative-2/JJ	nsubj||accompanies-5/VBZ||stress-3/NN	nsubj||attributed-30/VBD||stress-3/NN	nsubj||obesity-32/VB||stress-3/NN	rcmod||stress-3/NN||accompanies-5/VBZ	nsubj||contribute-27/VB||feeding-6/NN	advmod||when-9/WRB||particularly-8/RB	advmod||is-11/VBZ||when-9/WRB	expl||is-11/VBZ||there-10/EX	rcmod||feeding-6/NN||is-11/VBZ	amod||ingestion-13/NN||excessive-12/JJ	nsubj||is-11/VBZ||ingestion-13/NN	amod||macronutrients-18/NNS||fat-15/JJ	amod||macronutrients-18/NNS||and/or-16/JJ	amod||macronutrients-18/NNS||other-17/JJ	prep_of||ingestion-13/NN||macronutrients-18/NNS	amod||ingestion-21/NN||concomitant-20/JJ	prep_without||macronutrients-18/NNS||ingestion-21/NN	amod||foods/beverages-24/NNS||antioxidant-rich-23/JJ	prep_of||ingestion-21/NN||foods/beverages-24/NNS	aux||contribute-27/VB||may-26/MD	ccomp||accompanies-5/VBZ||contribute-27/VB	prep_to||contribute-27/VB||inflammation-29/NN	root||ROOT-0/null||attributed-30/VBD	aux||obesity-32/VB||to-31/TO	xcomp||attributed-30/VBD||obesity-32/VB	obesity-32||fat-15||no_rel||the oxidative stress which accompanies feeding, particularly when there is excessive ingestion of fat and/or other macronutrients without concomitant ingestion of antioxidant-rich foods/beverages, may contribute to inflammation attributed to obesity.
nn||primates-2/NNS||nonhuman-1/NN	nsubj||reflect-10/VBP||primates-2/NNS	appos||primates-2/NNS||nhps-4/NNS	vmod||primates-2/NNS||infected-6/VBN	prep_with||infected-6/VBN||mtb-8/NN	advmod||reflect-10/VBP||accurately-9/RB	root||ROOT-0/null||reflect-10/VBP	amod||tb-12/NN||human-11/JJ	dobj||reflect-10/VBP||tb-12/NN	amod||contexts-17/NNS||clinical-14/JJ	conj_and||clinical-14/JJ||pathological-16/JJ	amod||contexts-17/NNS||pathological-16/JJ	prep_in||tb-12/NN||contexts-17/NNS	tb-12||mtb-8||no||nonhuman primates (nhps) infected with mtb accurately reflect human tb in clinical and pathological contexts.
det||objective-3/NN||the-1/DT	amod||objective-3/NN||principal-2/JJ	nsubj||was-25/VBD||objective-3/NN	nsubj||develop-27/VB||objective-3/NN	nsubj||implement-29/VB||objective-3/NN	det||studies-7/NNS||these-5/DT	amod||studies-7/NNS||multisite-6/JJ	prep_of||objective-3/NN||studies-7/NNS	dep||studies-7/NNS||florida-9/NN	amod||york-12/NN||new-11/JJ	appos||florida-9/NN||york-12/NN	amod||epicenters-16/NNS||new-14/JJ	nn||epicenters-16/NNS||jersey-15/NN	dep||florida-9/NN||epicenters-16/NNS	amod||-RSB--21/NNS||humanimmunodeficiencyvirus-18/JJ	amod||-RSB--21/NNS||-LSB--19/JJ	nn||-RSB--21/NNS||hiv-20/NN	prep_for||epicenters-16/NNS||-RSB--21/NNS	prep_among||-RSB--21/NNS||women-23/NNS	root||ROOT-0/null||was-25/VBD	aux||develop-27/VB||to-26/TO	xcomp||was-25/VBD||develop-27/VB	xcomp||was-25/VBD||implement-29/VB	conj_and||develop-27/VB||implement-29/VB	amod||combinations-31/NNS||effective-30/JJ	dobj||develop-27/VB||combinations-31/NNS	amod||interventions-34/NNS||behavioral-33/JJ	prep_of||combinations-31/NNS||interventions-34/NNS	aux||optimize-36/VB||to-35/TO	vmod||develop-27/VB||optimize-36/VB	det||status-39/NN||the-37/DT	nn||status-39/NN||health-38/NN	dobj||optimize-36/VB||status-39/NN	det||population-46/NN||the-41/DT	advmod||neglected-43/JJ||most-42/RBS	amod||population-46/NN||neglected-43/JJ	conj_and||neglected-43/JJ||understudied-45/JJ	amod||population-46/NN||understudied-45/JJ	prep_of||status-39/NN||population-46/NN	vmod||population-46/NN||affected-47/VBN	det||epidemic-54/NN||the-49/DT	amod||epidemic-54/NN||acquiredimmunodeficiencysyndrome-50/JJ	appos||epidemic-54/NN||aids-52/NNS	agent||affected-47/VBN||epidemic-54/NN	det||states-58/NNS||the-56/DT	amod||states-58/NNS||united-57/VBN	prep_in||affected-47/VBN||states-58/NNS	amod||women-60/NNS||poor-59/JJ	dep||was-25/VBD||women-60/NNS	prep_of||women-60/NNS||color-62/NN	vmod||color-62/NN||living-63/VBG	prep_with||living-63/VBG||hiv-65/NN	hiv.--1||humanimmunodeficiencyvirus-18||no||the principal objective of these multisite studies (florida, new york, new jersey epicenters for humanimmunodeficiencyvirus [hiv] among women) was to develop and implement effective combinations of behavioral interventions to optimize the health status of the most neglected and understudied population affected by the acquiredimmunodeficiencysyndrome (aids) epidemic in the united states poor women of color living with hiv.
nn||accumulation-2/NN||iron-1/NN	nsubj||result-7/NN||accumulation-2/NN	prep_in||accumulation-2/NN||aceruloplasminemia-4/NN	cop||result-7/NN||is-5/VBZ	det||result-7/NN||a-6/DT	root||ROOT-0/null||result-7/NN	amod||export-12/NN||defective-9/JJ	amod||export-12/NN||cellular-10/JJ	nn||export-12/NN||iron-11/NN	prep_of||result-7/NN||export-12/NN	advmod||appropriate-18/JJ||where-14/WRB	nn||regulation-16/NN||hepcidin-15/NN	nsubj||appropriate-18/JJ||regulation-16/NN	cop||appropriate-18/JJ||is-17/VBZ	rcmod||export-12/NN||appropriate-18/JJ	det||degree-21/NN||the-20/DT	prep_for||appropriate-18/JJ||degree-21/NN	prep_of||degree-21/NN||ironoverload-23/NN	ironoverload-23||iron-11||no||iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of ironoverload.
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
aux||use-2/VB||to-1/TO	advcl||necessary-16/JJ||use-2/VB	dobj||use-2/VB||pyrimethamine-3/NN	det||drug-8/NN||an-5/DT	amod||drug-8/NN||alternative-6/JJ	amod||drug-8/NN||anti-malarial-7/JJ	prep_as||use-2/VB||drug-8/NN	amod||parasites-12/NNS||chloroquine-resistant-10/JJ	nn||parasites-12/NNS||malaria-11/NN	prep_for||drug-8/NN||parasites-12/NNS	nsubj||necessary-16/JJ||it-14/PRP	nsubj||determine-18/VB||it-14/PRP	cop||necessary-16/JJ||was-15/VBD	root||ROOT-0/null||necessary-16/JJ	aux||determine-18/VB||to-17/TO	xcomp||necessary-16/JJ||determine-18/VB	det||enzyme-20/NN||the-19/DT	poss||variation-23/NN||enzyme-20/NN	amod||variation-23/NN||genetic-22/JJ	dobj||determine-18/VB||variation-23/NN	amod||syntase-27/NN||dihydrofolate-25/JJ	amod||syntase-27/NN||reductase-thymidylate-26/JJ	prep_in||variation-23/NN||syntase-27/NN	appos||syntase-27/NN||dhfr-ts-29/NNS	nn||strains-33/NNS||korean-32/NN	prep_among||determine-18/VB||strains-33/NNS	malaria-11||pyrimethamine-3||yes||to use pyrimethamine as an alternative anti-malarial drug for chloroquine-resistant malaria parasites, it was necessary to determine the enzyme's genetic variation in dihydrofolate reductase-thymidylate syntase (dhfr-ts) among korean strains.
det||study-3/NN||this-2/DT	prep_in||demonstrate-5/VBP||study-3/NN	nsubj||demonstrate-5/VBP||we-4/PRP	root||ROOT-0/null||demonstrate-5/VBP	mark||inhibits-27/VBZ||that-6/IN	det||combination-8/NN||the-7/DT	nsubj||inhibits-27/VBZ||combination-8/NN	amod||+-11/NN||zn2-10/JJ	prep_of||combination-8/NN||+-11/NN	prep_of||combination-8/NN||pt-13/NN	conj_and||+-11/NN||pt-13/NN	amod||concentrations-16/NNS||low-15/JJ	prep_at||+-11/NN||concentrations-16/NNS	num||+-21/NNS||2-18/CD	amod||+-21/NNS||âµm-19/JJ	amod||+-21/NNS||zn2-20/JJ	dep||concentrations-16/NNS||+-21/NNS	num||pt-25/NN||2-23/CD	nn||pt-25/NN||âµm-24/NN	dep||concentrations-16/NNS||pt-25/NN	conj_and||+-21/NNS||pt-25/NN	ccomp||demonstrate-5/VBP||inhibits-27/VBZ	det||replication-29/NN||the-28/DT	dobj||inhibits-27/VBZ||replication-29/NN	prep_of||replication-29/NN||sars-coronavirus-31/NNS	appos||sars-coronavirus-31/NNS||sars-cov-33/NNP	amod||virus-38/NN||equine-36/JJ	nn||virus-38/NN||arteritis-37/NNS	prep_of||replication-29/NN||virus-38/NN	conj_and||sars-coronavirus-31/NNS||virus-38/NN	appos||sars-coronavirus-31/NNS||eav-40/NN	nn||culture-44/NN||cell-43/NN	prep_in||inhibits-27/VBZ||culture-44/NN	sars--1||coronavirus--1||no||in this study we demonstrate that the combination of zn2+ and pt at low concentrations (2 âµm zn2+ and 2 âµm pt) inhibits the replication of sars-coronavirus (sars-cov) and equine arteritis virus (eav) in cell culture.
nsubj||impacts-3/VBZ||hiv/aids-1/NNS	advmod||impacts-3/VBZ||negatively-2/RB	root||ROOT-0/null||impacts-3/VBZ	nn||alleviation-5/NN||poverty-4/NN	dobj||impacts-3/VBZ||alleviation-5/NN	nsubj||hinder-12/VB||alleviation-5/NN	nn||security-8/NN||food-7/NN	dobj||impacts-3/VBZ||security-8/NN	conj_and||alleviation-5/NN||security-8/NN	nsubj||hinder-12/VB||security-8/NN	advmod||hinder-12/VB||reciprocally-11/RB	rcmod||alleviation-5/NN||hinder-12/VB	det||scale-15/NN||the-13/DT	amod||scale-15/NN||rapid-14/JJ	dobj||hinder-12/VB||scale-15/NN	prt||hinder-12/VB||up-16/RP	dobj||impacts-3/VBZ||effectiveness-18/NN	conj_and||alleviation-5/NN||effectiveness-18/NN	nsubj||hinder-12/VB||effectiveness-18/NN	nn||programs-22/NNS||hiv-20/NN	nn||programs-22/NNS||care-21/NN	prep_of||effectiveness-18/NN||programs-22/NNS	aids--1||hiv-20||no||hiv/aids negatively impacts poverty alleviation and food security, which reciprocally hinder the rapid scale up and effectiveness of hiv care programs.
det||divergence-5/NN||the-3/DT	nn||divergence-5/NN||sequence-4/NN	prep_due_to||have-19/VBP||divergence-5/NN	det||virus-9/NN||this-7/DT	amod||virus-9/NN||new-8/JJ	prep_of||divergence-5/NN||virus-9/NN	amod||virus-9/NN||relative-10/JJ	det||ebolaviruses-15/NNS||all-12/DT	advmod||recognized-14/VBN||previously-13/RB	amod||ebolaviruses-15/NNS||recognized-14/VBN	prep_to||relative-10/JJ||ebolaviruses-15/NNS	det||findings-18/NNS||these-17/DT	nsubj||have-19/VBP||findings-18/NNS	root||ROOT-0/null||have-19/VBP	amod||implications-21/NNS||important-20/JJ	dobj||have-19/VBP||implications-21/NNS	prep_for||implications-21/NNS||design-23/NN	amod||assays-27/NNS||future-25/JJ	amod||assays-27/NNS||diagnostic-26/JJ	prep_of||design-23/NN||assays-27/NNS	aux||monitor-29/VB||to-28/TO	vmod||implications-21/NNS||monitor-29/VB	nn||disease-32/NN||ebola-30/NN	nn||disease-32/NN||hf-31/NN	dobj||monitor-29/VB||disease-32/NN	prep_in||disease-32/NN||humans-34/NNS	prep_in||disease-32/NN||animals-36/NNS	conj_and||humans-34/NNS||animals-36/NNS	amod||efforts-40/NNS||ongoing-39/JJ	dobj||have-19/VBP||efforts-40/NNS	conj_and||implications-21/NNS||efforts-40/NNS	aux||develop-42/VB||to-41/TO	vmod||efforts-40/NNS||develop-42/VB	amod||antivirals-44/NNS||effective-43/JJ	dobj||develop-42/VB||antivirals-44/NNS	dobj||develop-42/VB||vaccines-46/NNS	conj_and||antivirals-44/NNS||vaccines-46/NNS	antivirals-44||virus-9||no_rel||due to the sequence divergence of this new virus relative to all previously recognized ebolaviruses, these findings have important implications for design of future diagnostic assays to monitor ebola hf disease in humans and animals, and ongoing efforts to develop effective antivirals and vaccines.
nsubjpass||reported-6/VBN||cryptosporidiosis-1/NNS	nsubjpass||associated-9/VBN||cryptosporidiosis-1/NNS	conj_and||cryptosporidiosis-1/NNS||strongyloidiasis-3/NNS	nsubjpass||reported-6/VBN||strongyloidiasis-3/NNS	nsubjpass||associated-9/VBN||strongyloidiasis-3/NNS	aux||reported-6/VBN||have-4/VBP	auxpass||reported-6/VBN||been-5/VBN	root||ROOT-0/null||reported-6/VBN	aux||associated-9/VBN||to-7/TO	auxpass||associated-9/VBN||be-8/VB	xcomp||reported-6/VBN||associated-9/VBN	prep_with||associated-9/VBN||hiv/aids-11/NNS	aids--1||hiv--1||no||cryptosporidiosis and strongyloidiasis have been reported to be associated with hiv/aids.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	ccomp||assigned-21/VBN||â-5/VBP	dobj||â-5/VBP||$-6/$	det||study-13/NN||this-9/DT	amod||study-13/NN||open-label-10/JJ	amod||study-13/NN||7-month-12/JJ	prep_in||$-6/$||study-13/NN	num||patients-16/NNS||520-15/CD	nsubjpass||assigned-21/VBN||patients-16/NNS	nsubj||receive-23/VB||patients-16/NNS	prep_with||patients-16/NNS||type1diabetes-18/CD	auxpass||assigned-21/VBN||were-19/VBD	advmod||assigned-21/VBN||randomly-20/RB	root||ROOT-0/null||assigned-21/VBN	aux||receive-23/VB||to-22/TO	xcomp||assigned-21/VBN||receive-23/VB	dobj||receive-23/VB||detemir-24/NN	advmod||daily-26/JJ||once-25/RB	advmod||receive-23/VB||daily-26/JJ	advmod||daily-29/JJ||twice-28/RB	advmod||receive-23/VB||daily-29/JJ	conj_or||daily-26/JJ||daily-29/JJ	amod||insulinaspart-32/NN||mealtime-31/JJ	prep_with||receive-23/VB||insulinaspart-32/NN	type1diabetes-18||insulinaspart-32||yes||research design and methods â€”in this open-label, 7-month study, 520 patients with type1diabetes were randomly assigned to receive detemir once daily or twice daily with mealtime insulinaspart.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	vincristine-30||cytomegalovirus-6||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
amod||levels-3/NNS||total-1/JJ	nn||levels-3/NNS||cholesterol-2/NN	nsubj||lower-5/JJR||levels-3/NNS	cop||lower-5/JJR||were-4/VBD	root||ROOT-0/null||lower-5/JJR	nsubj||prevalent-10/JJ||hypercholesterolemia-7/NN	cop||prevalent-10/JJ||was-8/VBD	advmod||prevalent-10/JJ||less-9/RBR	conj_and||lower-5/JJR||prevalent-10/JJ	det||moroccan-13/NN||the-12/DT	prep_among||prevalent-10/JJ||moroccan-13/NN	prep_among||prevalent-10/JJ||turkish-15/NN	conj_and||moroccan-13/NN||turkish-15/NN	det||population-20/NN||the-17/DT	amod||population-20/NN||dutch-18/JJ	amod||population-20/NN||ethnic-19/JJ	prep_than||moroccan-13/NN||population-20/NN	hypercholesterolemia-7||cholesterol-2||no||total cholesterol levels were lower and hypercholesterolemia was less prevalent among the moroccan and turkish than the dutch ethnic population.
nsubj||becoming-16/VBG||hypersensitivity-1/NN	prep_to||hypersensitivity-1/NN||bloodworms-3/NNS	dep||bloodworms-3/NNS||chironomid-5/VBN	acomp||chironomid-5/VBN||larvae-6/JJ	vmod||bloodworms-3/NNS||leading-8/VBG	nn||allergicdisorders-14/NNS||asthma-10/NN	conj_and||asthma-10/NN||other-12/JJ	nn||allergicdisorders-14/NNS||other-12/JJ	amod||allergicdisorders-14/NNS||related-13/JJ	prep_to||leading-8/VBG||allergicdisorders-14/NNS	aux||becoming-16/VBG||is-15/VBZ	root||ROOT-0/null||becoming-16/VBG	xcomp||becoming-16/VBG||common-17/JJ	prep_in||common-17/JJ||individuals-19/NNS	nsubj||keep-21/VBP||individuals-19/NNS	nsubj||work-23/VBP||individuals-19/NNS	rcmod||individuals-19/NNS||keep-21/VBP	rcmod||individuals-19/NNS||work-23/VBP	conj_or||keep-21/VBP||work-23/VBP	prep_with||keep-21/VBP||fish-25/NN	det||use-30/NN||the-28/DT	amod||use-30/NN||increased-29/VBN	prep_due_to||keep-21/VBP||use-30/NN	prep_of||use-30/NN||bloodworms-32/NNS	nn||food-35/NN||fish-34/NN	prep_as||bloodworms-32/NNS||food-35/NN	prep_as||bloodworms-32/NNS||bait-37/NN	conj_or||food-35/NN||bait-37/NN	allergicdisorders-14||hypersensitivity-1||no||hypersensitivity to bloodworms (chironomid larvae) leading to asthma and other related allergicdisorders is becoming common in individuals who keep or work with fish due to the increased use of bloodworms as fish food or bait.
amod||vaccines-6/NNS||novel-1/JJ	nn||vaccines-6/NNS||tuberculosis-2/NNP	appos||vaccines-6/NNS||tb-4/NN	nsubjpass||designed-13/VBN||vaccines-6/NNS	nsubj||boost-15/VB||vaccines-6/NNS	advmod||tested-8/VBN||recently-7/RB	vmod||vaccines-6/NNS||tested-8/VBN	prep_in||tested-8/VBN||humans-10/NNS	aux||designed-13/VBN||have-11/VBP	auxpass||designed-13/VBN||been-12/VBN	ccomp||mycobacteriumbovis-23/VBZ||designed-13/VBN	aux||boost-15/VB||to-14/TO	xcomp||designed-13/VBN||boost-15/VB	dobj||boost-15/VB||immunity-16/NN	vmod||immunity-16/NN||induced-17/VBN	det||vaccine-21/NN||the-19/DT	amod||vaccine-21/NN||current-20/JJ	agent||induced-17/VBN||vaccine-21/NN	root||ROOT-0/null||mycobacteriumbovis-23/VBZ	amod||rin-27/NN||bacille-24/JJ	amod||rin-27/NN||calmette-guã-25/JJ	nn||rin-27/NN||©-26/NN	nsubj||mycobacteriumbovis-23/VBZ||rin-27/NN	appos||rin-27/NN||bcg-29/NN	tuberculosis-2||bcg-29||yes||novel tuberculosis (tb) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, mycobacteriumbovis bacille calmette-guã©rin (bcg).
amod||finding-2/NN||histological-1/JJ	nsubj||observed-3/VBD||finding-2/NN	root||ROOT-0/null||observed-3/VBD	amod||inflammation-6/NN||mild-4/JJ	amod||inflammation-6/NN||chronic-5/JJ	dobj||observed-3/VBD||inflammation-6/NN	vmod||inflammation-6/NN||surrounding-7/VBG	det||deposition-9/NN||the-8/DT	dobj||surrounding-7/VBG||deposition-9/NN	det||particles-13/NNS||the-11/DT	nn||particles-13/NNS||metal-12/NN	prep_of||deposition-9/NN||particles-13/NNS	det||macrophages-20/NNS||the-15/DT	amod||macrophages-20/NNS||anti-16/JJ	amod||macrophages-20/NNS||cotrel-dubousset-17/JJ	num||macrophages-20/NNS||68-18/CD	amod||macrophages-20/NNS||positive-19/JJ	nsubjpass||observed-22/VBN||macrophages-20/NNS	auxpass||observed-22/VBN||were-21/VBD	conj_and||observed-3/VBD||observed-22/VBN	prep_at||observed-22/VBN||tissue-24/NN	amod||tissue-24/NN||adjacent-25/JJ	det||particles-29/NNS||the-27/DT	nn||particles-29/NNS||metal-28/NN	prep_to||adjacent-25/JJ||particles-29/NNS	num||patients-32/NNS||5-31/CD	prep_in||particles-29/NNS||patients-32/NNS	inflammation-6||metal-28||no_rel||histological finding observed mild chronic inflammation surrounding the deposition of the metal particles and the anti cotrel-dubousset 68 positive macrophages were observed at tissue adjacent to the metal particles in 5 patients.
nn||patients-2/NNS||emf-1/NN	nsubj||showed-3/VBD||patients-2/NNS	root||ROOT-0/null||showed-3/VBD	amod||frequency-5/NN||greater-4/JJR	dobj||showed-3/VBD||frequency-5/NN	dobj||showed-3/VBD||reactivity-7/NN	conj_and||frequency-5/NN||reactivity-7/NN	nn||antibodies-10/NNS||igg-9/NN	prep_of||frequency-5/NN||antibodies-10/NNS	amod||proteins-13/NNS||myocardial-12/JJ	prep_against||showed-3/VBD||proteins-13/NNS	amod||weights-16/NNS||molecular-15/JJ	prep_of||proteins-13/NNS||weights-16/NNS	num||kd-18/NN||35-17/CD	dobj||showed-3/VBD||kd-18/NN	num||kd-21/NN||42-20/CD	appos||kd-18/NN||kd-21/NN	num||kd-24/NN||70-23/CD	appos||kd-18/NN||kd-24/NN	conj_and||kd-21/NN||kd-24/NN	nn||values-27/NNS||p-26/NN	nsubj||<-28/VBZ||values-27/NNS	dep||kd-21/NN||<-28/VBZ	dobj||<-28/VBZ||0.01-29/CD	dobj||<-28/VBZ||<-31/NNP	conj_and||0.01-29/CD||<-31/NNP	num||<-31/NNP||0.01-32/CD	dobj||<-28/VBZ||<-34/NNP	conj_and||0.01-29/CD||<-34/NNP	num||<-34/NNP||0.05-35/CD	advmod||<-28/VBZ||respectively-36/RB	kd-24||antibodies-10||no_rel||emf patients showed greater frequency and reactivity of igg antibodies against myocardial proteins of molecular weights 35 kd, 42 kd and 70 kd ( p values <0.01, <0.01 and <0.05 respectively).
det||course-3/NN||the-2/DT	prep_in||increases-19/VBZ||course-3/NN	amod||kidneydisease-6/NN||chronic-5/JJ	prep_of||course-3/NN||kidneydisease-6/NN	appos||kidneydisease-6/NN||ckd-8/NN	det||level-18/NN||the-10/DT	amod||erythrocyte-12/JJ||intracellular-11/JJ	amod||level-18/NN||erythrocyte-12/JJ	nn||level-18/NN||calcium-13/NN	num||+-16/NNS||cai2-15/CD	appos||level-18/NN||+-16/NNS	nsubj||increases-19/VBZ||level-18/NN	root||ROOT-0/null||increases-19/VBZ	det||progression-23/NN||the-22/DT	prep_along_with||increases-19/VBZ||progression-23/NN	det||disease-26/NN||the-25/DT	prep_of||progression-23/NN||disease-26/NN	kidneydisease-6||calcium-13||no_rel||in the course of chronic kidneydisease (ckd) the intracellular erythrocyte calcium (cai2+) level increases along with the progression of the disease.
amod||subjects-2/NNS||hiv-infected-1/JJ	nsubj||â-16/VBP||subjects-2/NNS	amod||calmette-5/JJ||bacille-4/JJ	amod||scars-12/NNS||calmette-5/JJ	nn||scars-12/NNS||guã-6/NN	nn||scars-12/NNS||©-7/NNS	nn||scars-12/NNS||rin-8/NN	appos||scars-12/NNS||bcg-10/NN	prep_with||subjects-2/NNS||scars-12/NNS	amod||counts-15/NNS||cd4-14/JJ	prep_with||subjects-2/NNS||counts-15/NNS	conj_and||scars-12/NNS||counts-15/NNS	ccomp||release-58/VBP||â-16/VBP	xcomp||â-16/VBP||‰-17/VBG	number||200-19/CD||¥-18/CD	num||cells/mm3-20/NNS||200-19/CD	dobj||‰-17/VBG||cells/mm3-20/NNS	vmod||cells/mm3-20/NNS||entering-21/VBG	det||trial-26/NN||a-22/DT	nn||trial-26/NN||tb-23/NN	nn||trial-26/NN||booster-24/NN	nn||trial-26/NN||vaccine-25/NN	dobj||entering-21/VBG||trial-26/NN	prep_in||entering-21/VBG||tanzania-28/NN	vmod||tanzania-28/NN||had-29/VBN	dobj||had-29/VBN||baseline-30/NN	prep_in||baseline-30/NN||vivo-32/NN	npadvmod||immune-36/JJ||vitro-35/NN	amod||tests-37/NNS||immune-36/JJ	prep_in||entering-21/VBG||tests-37/NNS	conj_and||tanzania-28/NN||tests-37/NNS	vmod||tests-37/NNS||performed-38/VBN	amod||tests-41/NNS||tuberculin-39/JJ	nn||tests-41/NNS||skin-40/NN	dobj||performed-38/VBN||tests-41/NNS	appos||cells/mm3-20/NNS||tst-43/NN	nn||assays-50/NNS||lpa-46/NN	conj_and||lpa-46/NN||five-48/CD	nn||assays-50/NNS||five-48/CD	nn||assays-50/NNS||day-49/NN	nsubj||release-58/VBP||assays-50/NNS	nn||gamma-53/NN||interferon-52/NN	prep_of||assays-50/NNS||gamma-53/NN	nn||³-56/NNP||ifn-î-55/NNP	appos||gamma-53/NN||³-56/NNP	root||ROOT-0/null||release-58/VBP	tb-23||bcg-10||yes||hiv-infected subjects with bacille calmette guã©rin (bcg) scars and cd4 counts â‰¥ 200 cells/mm3 entering a tb booster vaccine trial in tanzania had baseline in vivo and in vitro immune tests performed tuberculin skin tests (tst), lpa and five day assays of interferon gamma (ifn-î³) release.
poss||laboratory-3/NN||our-2/PRP$	prep_in||address-6/VBP||laboratory-3/NN	nsubj||address-6/VBP||we-5/PRP	root||ROOT-0/null||address-6/VBP	advmod||unsettled-8/VBN||still-7/RB	amod||questions-9/NNS||unsettled-8/VBN	nsubj||ellipticine-47/VBP||questions-9/NNS	nsubj||mechanism-51/NN||questions-9/NNS	prep_of||ellipticine-47/VBP||mechanisms-13/NNS	prep_of||mechanisms-13/NNS||action-15/NN	amod||drugs-18/NNS||dna-damaging-17/JJ	prep_of||action-15/NN||drugs-18/NNS	nsubj||use-21/VBP||both-19/DT	advmod||use-21/VBP||currently-20/RB	rcmod||mechanisms-13/NNS||use-21/VBP	prep_for||use-21/VBP||treatment-23/NN	amod||neuroblastomas-26/NNS||human-25/JJ	prep_of||treatment-23/NN||neuroblastomas-26/NNS	dep||mechanisms-13/NNS||doxorubicin-28/NN	dep||mechanisms-13/NNS||cis-platin-30/NN	conj_and||doxorubicin-28/NN||cis-platin-30/NN	dep||mechanisms-13/NNS||cyclophosphamide-32/NN	conj_and||doxorubicin-28/NN||cyclophosphamide-32/NN	dep||mechanisms-13/NNS||etoposide-34/NN	conj_and||doxorubicin-28/NN||etoposide-34/NN	det||growth-41/NN||another-37/DT	amod||growth-41/NN||anticancer-38/JJ	nn||growth-41/NN||agent-39/NN	amod||growth-41/NN||decreasing-40/VBG	conj_and||mechanisms-13/NNS||growth-41/NN	prep_of||ellipticine-47/VBP||growth-41/NN	prep_of||growth-41/NN||neuroblastomas-43/NNS	prep_in||neuroblastomas-43/NNS||vitro-45/NNP	rcmod||questions-9/NNS||ellipticine-47/VBP	cop||mechanism-51/NN||are-49/VBP	amod||mechanism-51/NN||predominant-50/JJ	ccomp||address-6/VBP||mechanism-51/NN	dep||mechanism-51/NN||s-53/PRP	amod||mechanism-51/NN||responsible-55/JJ	poss||action-59/NN||their-57/PRP$	nn||action-59/NN||antitumor-58/NN	prep_for||responsible-55/JJ||action-59/NN	nn||lines-63/NNS||neuroblastoma-61/NN	nn||lines-63/NNS||cell-62/NN	prep_in||mechanism-51/NN||lines-63/NNS	prep_in||mechanism-51/NN||vitro-65/NN	neuroblastomas-43||etoposide-34||yes||in our laboratory, we address still unsettled questions, which of mechanisms of action of dna-damaging drugs both currently use for treatment of human neuroblastomas (doxorubicin, cis-platin, cyclophosphamide and etoposide) and another anticancer agent decreasing growth of neuroblastomas in vitro , ellipticine, are predominant mechanism(s) responsible for their antitumor action in neuroblastoma cell lines in vitro .
nsubj||genotypes-9/NNS||hpv-1/NN	num||hpv-1/NN||18-2/CD	conj_and||hpv-1/NN||hpv-4/NN	nsubj||genotypes-9/NNS||hpv-4/NN	num||hpv-4/NN||16-5/CD	cop||genotypes-9/NNS||were-6/VBD	det||genotypes-9/NNS||the-7/DT	amod||genotypes-9/NNS||predominant-8/JJ	root||ROOT-0/null||genotypes-9/NNS	amod||subjects-15/NNS||hivpositive-11/JJ	conj_and||hivpositive-11/JJ||hiv-13/JJ	amod||subjects-15/NNS||hiv-13/JJ	amod||subjects-15/NNS||negative-14/JJ	prep_among||genotypes-9/NNS||subjects-15/NNS	advmod||genotypes-9/NNS||respectively-16/RB	hivpositive-11||hiv-13||no||hpv 18 and hpv 16 were the predominant genotypes among hivpositive and hiv negative subjects respectively.
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||is-6/VBZ||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	root||ROOT-0/null||is-6/VBZ	dep||resistant-9/NN||vitro-8/NN	prep_in||is-6/VBZ||resistant-9/NN	prep_to||is-6/VBZ||isoniazid-11/NN	appos||isoniazid-11/NN||h-13/NN	prep_to||is-6/VBZ||rifampicin-16/NN	conj_and||isoniazid-11/NN||rifampicin-16/NN	appos||isoniazid-11/NN||r-18/NN	tb--1||rifampicin-16||yes||multidrug-resistant tuberculosis (mdr-tb) is in vitro resistant to isoniazid (h) and rifampicin (r).
det||treatments-3/NNS||both-2/DT	prep_under||experienced-9/VBD||treatments-3/NNS	quantmod||many-7/JJ||twice-5/RB	quantmod||many-7/JJ||as-6/RB	num||patients-8/NNS||many-7/JJ	nsubj||experienced-9/VBD||patients-8/NNS	root||ROOT-0/null||experienced-9/VBD	neg||pain-11/NN||no-10/DT	dobj||experienced-9/VBD||pain-11/NN	parataxis||experienced-9/VBD||score-13/VBP	dep||0-15/CD||=-14/SYM	ccomp||score-13/VBP||0-15/CD	det||day-21/NN||the-18/DT	amod||day-21/NN||first-19/JJ	nn||day-21/NN||postoperative-20/NN	prep_on||experienced-9/VBD||day-21/NN	prepc_compared_to||day-21/NN||to-23/TO	det||day-25/NN||the-24/DT	pobj||day-21/NN||day-25/NN	prep_of||day-25/NN||surgery-27/NN	num||%-30/NN||35.9-29/CD	dep||day-25/NN||%-30/NN	number||16.4-32/CD||vs-31/CD	num||%-33/NN||16.4-32/CD	nsubj||vs-39/VBP||%-33/NN	prep_for||%-33/NN||tramadol/paracetamol-35/NN	num||%-38/NN||36.7-37/CD	prep_for||%-33/NN||%-38/NN	conj_and||tramadol/paracetamol-35/NN||%-38/NN	rcmod||%-30/NN||vs-39/VBP	num||%-41/NN||18-40/CD	dobj||vs-39/VBP||%-41/NN	amod||treatment-44/NN||tramadol-43/JJ	prep_for||vs-39/VBP||treatment-44/NN	pain-11||paracetamol--1||yes||under both treatments, twice as many patients experienced no pain (score = 0) on the first postoperative day compared to the day of surgery (35.9% vs 16.4% for tramadol/paracetamol and 36.7% vs 18% for tramadol treatment).
nsubj||trial-9/NN||this-1/DT	cop||trial-9/NN||is-2/VBZ	det||trial-9/NN||a-3/DT	amod||trial-9/NN||randomized-4/JJ	amod||trial-9/NN||double-blind-6/JJ	amod||trial-9/NN||clinical-8/JJ	root||ROOT-0/null||trial-9/NN	vmod||trial-9/NN||comparing-11/VBG	det||association-13/NN||the-12/DT	dobj||comparing-11/VBG||association-13/NN	prep_of||association-13/NN||chlorthalidone-15/NN	prep_of||association-13/NN||amiloride-17/NN	conj_and||chlorthalidone-15/NN||amiloride-17/NN	prep_with||comparing-11/VBG||losartan-19/NN	amod||option-23/NN||first-21/JJ	nn||option-23/NN||drug-22/NN	prep_as||comparing-11/VBG||option-23/NN	prep_in||option-23/NN||patients-25/NNS	vmod||patients-25/NNS||aged-26/VBN	number||70-29/CD||30-27/CD	dep||70-29/CD||to-28/TO	num||years-30/NNS||70-29/CD	tmod||aged-26/VBN||years-30/NNS	nn||hypertension-35/NN||stage-33/NN	nn||hypertension-35/NN||i-34/NN	prep_with||aged-26/VBN||hypertension-35/NN	hypertension-35||amiloride-17||yes||this is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage i hypertension.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBD||woman-16/NN	rcmod||woman-16/NN||presented-18/VBD	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBD||syndrome-22/NN	det||sorethroat-25/NN||a-24/DT	prep_with||syndrome-22/NN||sorethroat-25/NN	prep_with||syndrome-22/NN||mouthulcers-27/NNS	conj_and||sorethroat-25/NN||mouthulcers-27/NNS	prep_with||syndrome-22/NN||otalgia-29/NN	conj_and||sorethroat-25/NN||otalgia-29/NN	amod||months-32/NNS||several-31/JJ	prep_after||presented-18/VBD||months-32/NNS	amod||symptoms-35/NNS||constitutional-34/JJ	prep_of||months-32/NNS||symptoms-35/NNS	hydralazine--1||sorethroat-25||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sorethroat, mouthulcers and otalgia after several months of constitutional symptoms.
amod||analysis-3/NN||multivariate-2/JJ	prep_on||have-22/VBP||analysis-3/NN	det||weight-6/NN||the-4/DT	amod||weight-6/NN||normal-5/JJ	prep_to||likely-20/JJ||weight-6/NN	nsubj||have-22/VBP||weight-6/NN	advmod||obese-8/JJ||centrally-7/RB	amod||children-9/NNS||obese-8/JJ	nsubj||1.66-11/CD||children-9/NNS	nsubj||likely-20/JJ||children-9/NNS	cop||1.66-11/CD||were-10/VBD	rcmod||weight-6/NN||1.66-11/CD	rcmod||weight-6/NN||2.01-13/CD	conj_and||1.66-11/CD||2.01-13/CD	rcmod||weight-6/NN||1.47-15/CD	conj_and||1.66-11/CD||1.47-15/CD	num||times-18/NNS||2.05-17/CD	npadvmod||more-19/RBR||times-18/NNS	advmod||likely-20/JJ||more-19/RBR	rcmod||weight-6/NN||likely-20/JJ	conj_and||1.66-11/CD||likely-20/JJ	root||ROOT-0/null||have-22/VBP	amod||levels-25/NNS||significant-23/JJ	amod||levels-25/NNS||adverse-24/JJ	dobj||have-22/VBP||levels-25/NNS	nn||cholesterol-28/NN||ldl-27/NN	prep_of||levels-25/NNS||cholesterol-28/NN	nn||cholesterol-31/NN||hdl-30/NN	prep_of||levels-25/NNS||cholesterol-31/NN	conj_and||cholesterol-28/NN||cholesterol-31/NN	prep_of||levels-25/NNS||triglycerides-33/NNPS	conj_and||cholesterol-28/NN||triglycerides-33/NNPS	prep_of||levels-25/NNS||insulin-35/NN	conj_and||cholesterol-28/NN||insulin-35/NN	advmod||have-22/VBP||respectively-37/RB	cholesterol-31||obese-8||no_rel||on multivariate analysis the normal weight centrally obese children were 1.66, 2.01, 1.47 and 2.05 times more likely to have significant adverse levels of ldl cholesterol, hdl cholesterol, triglycerides and insulin, respectively.
det||eclampsia-5/NN||a-1/DT	amod||eclampsia-5/NN||late-2/JJ	nn||eclampsia-5/NN||onset-3/NN	nn||eclampsia-5/NN||postpartum-4/NN	nsubjpass||considered-13/VBN||eclampsia-5/NN	advmod||eclampsia-5/NN||even-6/RB	amod||weeks-8/NNS||several-7/JJ	pobj||even-6/RB||weeks-8/NNS	prep_after||even-6/RB||delivery-10/NN	aux||considered-13/VBN||should-11/MD	auxpass||considered-13/VBN||be-12/VB	root||ROOT-0/null||considered-13/VBN	amod||diagnosis-16/NN||possible-15/JJ	prep_as||considered-13/VBN||diagnosis-16/NN	mark||prevents-27/VBZ||since-18/IN	amod||initiation-21/NN||early-19/JJ	nn||initiation-21/NN||treatment-20/NN	nsubj||prevents-27/VBZ||initiation-21/NN	nsubj||reduces-31/VBZ||initiation-21/NN	amod||medication-26/NN||magnesiumsulphate-23/JJ	conj_and||magnesiumsulphate-23/JJ||antihypertensive-25/JJ	amod||medication-26/NN||antihypertensive-25/JJ	prep_with||initiation-21/NN||medication-26/NN	advcl||considered-13/VBN||prevents-27/VBZ	amod||complications-29/NNS||severe-28/JJ	dobj||prevents-27/VBZ||complications-29/NNS	advcl||considered-13/VBN||reduces-31/VBZ	conj_and||prevents-27/VBZ||reduces-31/VBZ	dobj||reduces-31/VBZ||mortality-32/NN	eclampsia-5||magnesiumsulphate-23||yes||a late onset postpartum eclampsia even several weeks after delivery should be considered as possible diagnosis, since early treatment initiation with magnesiumsulphate and antihypertensive medication prevents severe complications and reduces mortality.
det||study-2/NN||this-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||patients-5/NNS||46-4/CD	dobj||included-3/VBD||patients-5/NNS	num||eyes-8/NNS||46-7/CD	appos||patients-5/NNS||eyes-8/NNS	amod||open-angleglaucoma-12/NN||primary-11/JJ	prep_with||included-3/VBD||open-angleglaucoma-12/NN	nsubjpass||treated-16/VBN||open-angleglaucoma-12/NN	aux||treated-16/VBN||had-14/VBD	auxpass||treated-16/VBN||been-15/VBN	rcmod||open-angleglaucoma-12/NN||treated-16/VBN	prep_with||treated-16/VBN||latanoprost-18/NN	open-angleglaucoma-12||latanoprost-18||yes||this study included 46 patients (46 eyes) with primary open-angleglaucoma who had been treated with latanoprost.
advmod||î-7/VBP||furthermore-1/RB	nn||/-6/NNP||ppar-3/NN	nn||/-6/NNP||î-4/NN	nn||/-6/NNP||²-5/NNP	nsubj||î-7/VBP||/-6/NNP	root||ROOT-0/null||î-7/VBP	amod||ligands-9/NNS||´-8/JJ	nsubj||prevent-10/VB||ligands-9/NNS	nsubj||avoid-18/VB||ligands-9/NNS	nsubj||suppress-26/VB||ligands-9/NNS	ccomp||î-7/VBP||prevent-10/VB	amod||inflammation-12/NN||fattyacid-induced-11/JJ	dobj||prevent-10/VB||inflammation-12/NN	amod||cells-16/NNS||skeletal-14/JJ	nn||cells-16/NNS||muscle-15/NN	prep_in||prevent-10/VB||cells-16/NNS	ccomp||î-7/VBP||avoid-18/VB	conj_and||prevent-10/VB||avoid-18/VB	det||development-20/NN||the-19/DT	dobj||avoid-18/VB||development-20/NN	amod||hypertrophy-23/NN||cardiac-22/JJ	prep_of||development-20/NN||hypertrophy-23/NN	ccomp||î-7/VBP||suppress-26/VB	conj_and||prevent-10/VB||suppress-26/VB	amod||inflammation-28/NN||macrophage-derived-27/JJ	dobj||suppress-26/VB||inflammation-28/NN	prep_in||suppress-26/VB||atherosclerosis-30/NNS	inflammation-28||fattyacid--1||no_rel||furthermore, ppar î² / î´ ligands prevent fattyacid-induced inflammation in skeletal muscle cells, avoid the development of cardiac hypertrophy, and suppress macrophage-derived inflammation in atherosclerosis.
aux||inform-2/VB||to-1/TO	advcl||conducted-24/VBN||inform-2/VB	amod||efforts-5/NNS||future-3/JJ	nn||efforts-5/NNS||elimination-4/NN	dobj||inform-2/VB||efforts-5/NNS	nsubjpass||conducted-24/VBN||mass-7/NN	vmod||mass-7/NN||screening-8/VBG	det||areas-12/NNS||the-10/DT	amod||areas-12/NNS||focal-11/JJ	prep_from||screening-8/VBG||areas-12/NNS	aux||measure-14/VB||to-13/TO	xcomp||screening-8/VBG||measure-14/VB	dobj||measure-14/VB||prevalence-15/NN	prep_of||prevalence-15/NN||malaria-17/NN	preconj||microscopy-20/NN||both-19/DT	prep_with||measure-14/VB||microscopy-20/NN	prep_with||measure-14/VB||pcr-22/NN	conj_and||microscopy-20/NN||pcr-22/NN	auxpass||conducted-24/VBN||was-23/VBD	root||ROOT-0/null||conducted-24/VBN	malaria-17||inform-2||no_rel||to inform future elimination efforts, mass screening from the focal areas to measure prevalence of malaria with both microscopy and pcr was conducted.
quantmod||10.6-2/CD||only-1/RB	num||%-3/NN||10.6-2/CD	nsubj||completed-15/VBD||%-3/NN	num||%-6/NN||95-5/CD	dep||%-3/NN||%-6/NN	vmod||%-6/NN||ci-7/VBN	num||.2-9/CD||9.9-11-8/CD	dobj||ci-7/VBN||.2-9/CD	det||women-14/NNS||the-12/DT	amod||women-14/NNS||hivpositive-13/JJ	prep_of||%-3/NN||women-14/NNS	root||ROOT-0/null||completed-15/VBD	nsubj||follow-17/VB||their-16/PRP$	ccomp||completed-15/VBD||follow-17/VB	prt||follow-17/VB||up-18/RP	amod||testing-22/NN||infant-20/JJ	nn||testing-22/NN||hiv-21/NN	prep_to||follow-17/VB||testing-22/NN	hivpositive-13||hiv-21||no||only 10.6% (95% ci 9.9-11.2) of the hivpositive women completed their follow up to infant hiv testing.
det||rationale-2/NN||the-1/DT	nsubj||starts-12/VBZ||rationale-2/NN	amod||humanpapillomavirus-6/NNS||current-4/JJ	amod||humanpapillomavirus-6/NNS||worldwide-5/JJ	prep_behind||rationale-2/NN||humanpapillomavirus-6/NNS	dep||rationale-2/NN||hpv-8/VBN	nn||programs-11/NNS||vaccination-10/NN	dep||rationale-2/NN||programs-11/NNS	root||ROOT-0/null||starts-12/VBZ	num||premises-16/NNS||two-14/CD	amod||premises-16/NNS||basic-15/JJ	prep_from||starts-12/VBZ||premises-16/NNS	dep||have-33/VBP||1-18/LS	mark||prevent-23/VB||that-20/IN	nsubj||prevent-23/VB||hpvvaccines-21/NNS	nsubj||save-27/VB||hpvvaccines-21/NNS	aux||prevent-23/VB||will-22/MD	advcl||have-33/VBP||prevent-23/VB	amod||cancers-25/NNS||cervical-24/JJ	dobj||prevent-23/VB||cancers-25/NNS	conj_and||prevent-23/VB||save-27/VB	advcl||have-33/VBP||save-27/VB	iobj||save-27/VB||lives-28/NNS	dobj||save-27/VB||and-29/NNP	nsubj||have-33/VBP||2-31/CD	parataxis||starts-12/VBZ||have-33/VBP	neg||risk-35/NN||no-34/DT	dobj||have-33/VBP||risk-35/NN	amod||effects-39/NNS||serious-37/JJ	nn||effects-39/NNS||side-38/NN	prep_of||risk-35/NN||effects-39/NNS	hpvvaccines-21||cancers-25||no_rel||the rationale behind current worldwide humanpapillomavirus (hpv) vaccination programs starts from two basic premises, 1) that hpvvaccines will prevent cervical cancers and save lives and, 2) have no risk of serious side effects.
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	mrsa-33||vancomycin--1||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
nn||csos-2/NNS||conclusion-1/NN	nsubj||increased-5/VBN||csos-2/NNS	aux||increased-5/VBN||have-3/VBP	advmod||increased-5/VBN||significantly-4/RB	root||ROOT-0/null||increased-5/VBN	poss||participation-7/NN||their-6/PRP$	dobj||increased-5/VBN||participation-7/NN	dobj||increased-5/VBN||contribution-9/NN	conj_and||participation-7/NN||contribution-9/NN	amod||programmes-12/NNS||hiv/aids-11/JJ	prep_to||increased-5/VBN||programmes-12/NNS	prep_in||programmes-12/NNS||china-14/NN	aids--1||hiv--1||no||conclusion csos have significantly increased their participation and contribution to hiv/aids programmes in china.
amod||peripheralneuropathy-2/NN||bortezomib-associated-1/JJ	nsubjpass||reported-10/VBN||peripheralneuropathy-2/NN	nsubj||appears-12/VBZ||peripheralneuropathy-2/NN	nsubj||resolve-14/VB||peripheralneuropathy-2/NN	prep_in||peripheralneuropathy-2/NN||patients-4/NNS	prep_with||patients-4/NNS||multiplemyeloma-6/NN	aux||reported-10/VBN||has-7/VBZ	auxpass||reported-10/VBN||been-8/VBN	advmod||reported-10/VBN||commonly-9/RB	root||ROOT-0/null||reported-10/VBN	conj_but||reported-10/VBN||appears-12/VBZ	aux||resolve-14/VB||to-13/TO	xcomp||appears-12/VBZ||resolve-14/VB	det||majority-17/NN||a-16/DT	prep_in||resolve-14/VB||majority-17/NN	det||patients-20/NNS||these-19/DT	prep_of||majority-17/NN||patients-20/NNS	nn||reduction-23/NN||dose-22/NN	prep_after||resolve-14/VB||reduction-23/NN	prep_after||resolve-14/VB||discontinuation-25/NN	conj_or||reduction-23/NN||discontinuation-25/NN	peripheralneuropathy-2||bortezomib--1||no_rel||bortezomib-associated peripheralneuropathy in patients with multiplemyeloma has been commonly reported but appears to resolve in a majority of these patients after dose reduction or discontinuation.
nsubjpass||induced-3/VBN||hyperglycemia-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	amod||injections-6/NNS||intraperitoneal-5/JJ	agent||induced-3/VBN||injections-6/NNS	prep_of||injections-6/NNS||2-8/CD	xcomp||induced-3/VBN||g/kg-9/VBG	amod||solution-11/NN||dextrose-10/JJ	dobj||g/kg-9/VBG||solution-11/NN	advmod||day-15/NN||twice-13/RB	det||day-15/NN||a-14/DT	tmod||g/kg-9/VBG||day-15/NN	num||weeks-19/NNS||2-18/CD	prep_for||g/kg-9/VBG||weeks-19/NNS	hyperglycemia-1||dextrose-10||no||hyperglycemia was induced by intraperitoneal injections of 2 g/kg dextrose solution, twice a day, for 2 weeks.
amod||syndrome-3/NN||guillain-barrã-1/JJ	amod||syndrome-3/NN||©-2/JJ	nsubj||polyneuropathy-7/NN||syndrome-3/NN	cop||polyneuropathy-7/NN||is-4/VBZ	det||polyneuropathy-7/NN||an-5/DT	amod||polyneuropathy-7/NN||immune-mediated-6/JJ	root||ROOT-0/null||polyneuropathy-7/NN	nsubjpass||treated-12/VBN||polyneuropathy-7/NN	auxpass||treated-12/VBN||is-9/VBZ	advmod||treated-12/VBN||routinely-10/RB	advmod||treated-12/VBN||initially-11/RB	rcmod||polyneuropathy-7/NN||treated-12/VBN	det||intravenousimmunoglobulin-15/NN||either-14/DT	prep_with||treated-12/VBN||intravenousimmunoglobulin-15/NN	prep_with||treated-12/VBN||plasmapheresis-17/NNS	conj_or||intravenousimmunoglobulin-15/NN||plasmapheresis-17/NNS	guillain-barrã©syndrome--1||intravenousimmunoglobulin-15||yes||guillain-barrã©syndrome is an immune-mediated polyneuropathy that is routinely initially treated with either intravenousimmunoglobulin or plasmapheresis.
amod||patients-2/NNS||asymptomatic-1/JJ	nsubjpass||enrolled-64/VBN||patients-2/NNS	appos||patients-2/NNS||n-4/NNP	number||485-6/CD||=-5/CD	num||n-4/NNP||485-6/CD	vmod||patients-2/NNS||aged-8/VBN	nn||‰-10/NNS||â-9/NN	dobj||aged-8/VBN||‰-10/NNS	number||50-12/CD||¥-11/CD	num||years-13/NNS||50-12/CD	npadvmod||aged-8/VBN||years-13/NNS	advmod||thickness-21/NN||either-15/RB	det||thickness-21/NN||a-16/DT	amod||carotid-18/JJ||maximal-17/JJ	amod||thickness-21/NN||carotid-18/JJ	nn||thickness-21/NN||artery-19/NN	nn||thickness-21/NN||intima-media-20/NN	prep_with||aged-8/VBN||thickness-21/NN	nn||‰-24/NNS||â-23/NN	prep_of||thickness-21/NN||‰-24/NNS	amod||thickness-21/NN||¥-25/JJ	num||mm-27/NNS||1.1-26/CD	dep||¥-25/JJ||mm-27/NNS	det||creatinine-38/NN||a-30/DT	advmod||albumin-32/JJ||urinary-31/RB	amod||creatinine-38/NN||albumin-32/JJ	nn||creatinine-38/NN||â-33/NNP	nn||creatinine-38/NN||‰-34/NNP	nn||creatinine-38/NN||¥-35/NNP	num||creatinine-38/NN||30-36/CD	nn||creatinine-38/NN||mg/g-37/NN	prep_with||aged-8/VBN||creatinine-38/NN	conj_or||thickness-21/NN||creatinine-38/NN	nsubj||had-41/VBD||who-40/WP	prep_with||aged-8/VBN||had-41/VBD	conj_or||thickness-21/NN||had-41/VBD	quantmod||two-44/CD||at-42/IN	mwe||at-42/IN||least-43/JJS	pobj||at-42/IN||least-43/JJS	dobj||had-41/VBD||two-44/CD	det||obesity-50/NN||the-46/DT	amod||obesity-50/NN||following-47/JJ	amod||obesity-50/NN||abdominal-49/JJ	prep_of||two-44/CD||obesity-50/NN	amod||cholesterol-54/NN||low-52/JJ	nn||cholesterol-54/NN||hdl-53/NN	prep_of||two-44/CD||cholesterol-54/NN	conj_and||obesity-50/NN||cholesterol-54/NN	amod||levels-58/NNS||high-56/JJ	nn||levels-58/NNS||triglyceride-57/NN	prep_of||two-44/CD||levels-58/NNS	conj_and||obesity-50/NN||levels-58/NNS	prep_of||two-44/CD||hypertension-61/NN	conj_and||obesity-50/NN||hypertension-61/NN	auxpass||enrolled-64/VBN||were-63/VBD	root||ROOT-0/null||enrolled-64/VBN	num||institutions-67/NNS||50-66/CD	prep_at||enrolled-64/VBN||institutions-67/NNS	cholesterol-54||hypertension-61||no_rel||asymptomatic patients ( n = 485) aged â‰¥50 years with either a maximal carotid artery intima-media thickness of â‰¥1.1 mm, or a urinary albumin â‰¥30 mg/g creatinine or who had at least two of the following, abdominal obesity, low hdl cholesterol, high triglyceride levels, and hypertension, were enrolled at 50 institutions.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||pyrimethamine--1||no||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-33/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-23/VBZ||levels-10/NNS	prep_of||levels-10/NNS||n-3fattyacids-12/JJ	appos||n-3fattyacids-12/JJ||fa-14/NN	possessive||fa-14/NN||'s-15/POS	amod||levels-19/NNS||higher-18/JJR	prep_of||levels-10/NNS||levels-19/NNS	conj_and||n-3fattyacids-12/JJ||levels-19/NNS	amod||fa-22/NN||n-6-21/JJ	prep_of||levels-19/NNS||fa-22/NN	ccomp||contained-8/VBD||'s-23/VBZ	det||diet-27/NN||the-25/DT	nn||diet-27/NN||control-26/NN	prep_than||'s-23/VBZ||diet-27/NN	appos||diet-27/NN||ctr-29/NN	nsubj||found-33/VBD||we-32/PRP	root||ROOT-0/null||found-33/VBD	amod||decreases-35/NNS||significant-34/JJ	nsubj||'s-46/VBZ||decreases-35/NNS	amod||acid-38/NN||docosahexaenoic-37/JJ	prep_in||decreases-35/NNS||acid-38/NN	appos||acid-38/NN||dha-40/NN	amod||fa-45/NN||total-43/JJ	amod||fa-45/NN||n-3-44/JJ	prep_in||decreases-35/NNS||fa-45/NN	conj_and||acid-38/NN||fa-45/NN	ccomp||found-33/VBD||'s-46/VBZ	nn||maternal-49/NN||hfd-48/NN	prep_in||'s-46/VBZ||maternal-49/NN	amod||plasma-52/NN||fetal-51/JJ	prep_in||'s-46/VBZ||plasma-52/NN	conj_and||maternal-49/NN||plasma-52/NN	n-3fattyacids-12||fa-45||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
advmod||accessible-10/JJ||unfortunately-1/RB	amod||rabiesvaccines-4/NNS||life-saving-3/JJ	nsubj||accessible-10/JJ||rabiesvaccines-4/NNS	nsubj||accessible-10/JJ||rabiesvaccines-4/NNS	nsubj||affordable-12/JJ||rabiesvaccines-4/NNS	conj_and||rabiesvaccines-4/NNS||biologicals-6/NNS	nsubj||accessible-10/JJ||biologicals-6/NNS	cop||accessible-10/JJ||are-7/VBP	advmod||accessible-10/JJ||often-8/RB	preconj||accessible-10/JJ||neither-9/DT	root||ROOT-0/null||accessible-10/JJ	conj_and||accessible-10/JJ||accessible-10/JJ	conj_nor||accessible-10/JJ||affordable-12/JJ	advmod||accessible-10/JJ||particularly-14/RB	det||sectors-18/NNS||the-16/DT	amod||sectors-18/NNS||poorest-17/JJS	prep_to||accessible-10/JJ||sectors-18/NNS	nsubj||are-22/VBP||sectors-18/NNS	prep_of||sectors-18/NNS||society-20/NN	rcmod||sectors-18/NNS||are-22/VBP	advmod||are-22/VBP||most-23/RBS	prep_at||are-22/VBP||risk-25/NN	dobj||falls-34/VBZ||whom-28/WP	det||burden-31/NN||the-29/DT	amod||burden-31/NN||largest-30/JJS	nsubj||falls-34/VBZ||burden-31/NN	prep_of||burden-31/NN||rabies-33/NNP	prepc_upon||accessible-10/JJ||falls-34/VBZ	rabies-33||rabiesvaccines-4||yes||unfortunately, life-saving rabiesvaccines and biologicals are often neither accessible nor affordable, particularly to the poorest sectors of society who are most at risk and upon whom the largest burden of rabies falls.
nn||bovis-2/NNS||m.-1/NN	nsubj||bacille-3/VBP||bovis-2/NNS	root||ROOT-0/null||bacille-3/VBP	nn||-rrb--9/NNP||calmette-guã-4/NNP	nn||-rrb--9/NNP||©-5/NNP	nn||-rrb--9/NNP||rin-6/NNP	nn||-rrb--9/NNP||-lrb--7/NNP	nn||-rrb--9/NNP||bcg-8/NNP	nsubj||fails-22/VBZ||-rrb--9/NNP	nsubj||protect-25/VB||-rrb--9/NNP	advmod||vaccine-15/NN||currently-11/RB	det||vaccine-15/NN||the-12/DT	advmod||available-14/JJ||only-13/RB	amod||vaccine-15/NN||available-14/JJ	appos||-rrb--9/NNP||vaccine-15/NN	nn||-rrb--20/NNP||tuberculosis-17/NNP	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||tb-19/NNP	prep_against||vaccine-15/NN||-rrb--20/NNP	ccomp||bacille-3/VBP||fails-22/VBZ	aux||protect-25/VB||to-23/TO	advmod||protect-25/VB||adequately-24/RB	xcomp||fails-22/VBZ||protect-25/VB	dobj||protect-25/VB||individuals-26/NNS	amod||infection-32/NN||active-28/JJ	conj_and||active-28/JJ||latent-30/JJ	amod||infection-32/NN||latent-30/JJ	nn||infection-32/NN||tb-31/NN	prep_from||protect-25/VB||infection-32/NN	tb-31||bcg-8||no||m. bovis bacille calmette-guã © rin -lrb- bcg -rrb- , currently the only available vaccine against tuberculosis -lrb- tb -rrb- , fails to adequately protect individuals from active and latent tb infection .
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effects-4/NNS||the-3/DT	dobj||investigated-2/VBD||effects-4/NNS	amod||hyperglycemia-7/NN||neonatal-6/JJ	prep_of||effects-4/NNS||hyperglycemia-7/NN	amod||‰-11/NNS||bloodglucose-9/JJ	nn||‰-11/NNS||â-10/NN	nsubj||¥-12/VBZ||‰-11/NNS	dep||hyperglycemia-7/NN||¥-12/VBZ	num||mmol/l-14/NN||10-13/CD	dobj||¥-12/VBZ||mmol/l-14/NN	vmod||mmol/l-14/NN||treated-16/VBN	prep_with||treated-16/VBN||insulin-18/NN	nn||¥-22/NNP||â-20/NNP	nn||¥-22/NNP||‰-21/NNP	prep_for||insulin-18/NN||¥-22/NNP	num||hours-24/NNS||12-23/CD	dep||insulin-18/NN||hours-24/NNS	nn||outcome-30/NN||growth-27/NN	conj_and||growth-27/NN||neurobehavioral-29/NN	nn||outcome-30/NN||neurobehavioral-29/NN	prep_on||investigated-2/VBD||outcome-30/NN	num||years-33/NNS||2-32/CD	prep_at||investigated-2/VBD||years-33/NNS	prep_of||years-33/NNS||age-35/NN	hyperglycemia-7||insulin-18||yes||we investigated the effects of neonatal hyperglycemia (bloodglucose â‰¥ 10 mmol/l, treated with insulin for â‰¥ 12 hours) on growth and neurobehavioral outcome at 2 years of age.
amod||patients-2/NNS||sixty-1/JJ	nsubjpass||divided-12/VBN||patients-2/NNS	prep_with||patients-2/NNS||psychoticdisorder-4/NN	nsubjpass||assigned-7/VBN||psychoticdisorder-4/NN	auxpass||assigned-7/VBN||were-6/VBD	rcmod||psychoticdisorder-4/NN||assigned-7/VBN	amod||treatment-10/NN||6-month-9/JJ	prep_to||assigned-7/VBN||treatment-10/NN	auxpass||divided-12/VBN||were-11/VBD	root||ROOT-0/null||divided-12/VBN	num||groups-15/NNS||two-14/CD	prep_in||divided-12/VBN||groups-15/NNS	num||haloperidol-18/NN||30-16/CD	amod||haloperidol-18/NN||received-17/VBN	dobj||divided-12/VBN||haloperidol-18/NN	amod||antipsychotic-22/NN||first-20/JJ	nn||antipsychotic-22/NN||generation-21/NN	appos||haloperidol-18/NN||antipsychotic-22/NN	num||olanzapine-27/NN||30-25/CD	amod||olanzapine-27/NN||received-26/VBN	dobj||divided-12/VBN||olanzapine-27/NN	conj_and||haloperidol-18/NN||olanzapine-27/NN	amod||antipsychotic-31/NN||second-29/JJ	nn||antipsychotic-31/NN||generation-30/NN	appos||olanzapine-27/NN||antipsychotic-31/NN	olanzapine-27||psychoticdisorder-4||no_rel||sixty patients with psychoticdisorder who were assigned to 6-month treatment were divided in two groups 30 received haloperidol (first generation antipsychotic) and 30 received olanzapine (second generation antipsychotic).
nsubj||showed-2/VBD||m252-1/NNS	ccomp||challenge-14/VBP||showed-2/VBD	amod||protection-4/NN||better-3/JJR	dobj||showed-2/VBD||protection-4/NN	prep_than||showed-2/VBD||m253-6/NNS	prep_than||showed-2/VBD||m254-8/NNS	conj_and||m253-6/NNS||m254-8/NNS	det||y-11/NN||a-10/DT	prep_against||showed-2/VBD||y-11/NN	nsubj||challenge-14/VBP||pestis-13/NNS	root||ROOT-0/null||challenge-14/VBP	det||model-19/NN||a-16/DT	amod||model-19/NN||plague-17/JJ	nn||model-19/NN||mouse-18/NN	prep_in||challenge-14/VBP||model-19/NN	plague-17||y-11||no||m252 showed better protection than m253 and m254 against a y, pestis challenge in a plague mouse model.
det||ability-2/NN||the-1/DT	nsubj||suggests-20/VBZ||ability-2/NN	prep_of||ability-2/NN||ride-4/NN	aux||enhance-6/VB||to-5/TO	vmod||ride-4/NN||enhance-6/VB	dobj||enhance-6/VB||infectivity-7/NN	amod||vzv-10/NN||cell-free-9/JJ	prep_of||infectivity-7/NN||vzv-10/NN	det||range-14/NN||a-12/DT	amod||range-14/NN||wide-13/JJ	prep_over||enhance-6/VB||range-14/NN	nn||times-17/NNS||incubation-16/NN	prep_of||range-14/NN||times-17/NNS	prep_of||range-14/NN||temperatures-19/NNS	conj_and||times-17/NNS||temperatures-19/NNS	root||ROOT-0/null||suggests-20/VBZ	mark||useful-25/JJ||that-21/IN	nsubj||useful-25/JJ||ride-22/NN	aux||useful-25/JJ||may-23/MD	cop||useful-25/JJ||be-24/VB	ccomp||suggests-20/VBZ||useful-25/JJ	prepc_for||useful-25/JJ||increasing-27/VBG	det||stability-29/NN||the-28/DT	dobj||increasing-27/VBG||stability-29/NN	nn||vaccines-34/NNS||varicella-31/NN	conj_or||varicella-31/NN||zoster-33/NN	nn||vaccines-34/NNS||zoster-33/NN	prep_of||stability-29/NN||vaccines-34/NNS	varicella-31||vzv-10||no||the ability of ride to enhance infectivity of cell-free vzv over a wide range of incubation times and temperatures suggests that ride may be useful for increasing the stability of varicella or zoster vaccines.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	prep_into||enrolled-3/VBN||one-5/CD	num||groups-8/NNS||four-7/CD	prep_of||one-5/CD||groups-8/NNS	det||basis-11/NN||the-10/DT	prep_on||groups-8/NNS||basis-11/NN	nn||status-16/NN||hiv-13/NN	conj_and||hiv-13/NN||ks-15/NN	nn||status-16/NN||ks-15/NN	prep_of||basis-11/NN||status-16/NN	nsubj||negative/ks-19/VBZ||hiv-18/NN	dep||groups-8/NNS||negative/ks-19/VBZ	acomp||negative/ks-19/VBZ||negative-20/JJ	amod||negative-23/JJ||hivpositive/ks-22/JJ	acomp||negative/ks-19/VBZ||negative-23/JJ	conj_and||negative-20/JJ||negative-23/JJ	num||negative/ks-26/NNS||hiv-25/CD	npadvmod||positive-27/JJ||negative/ks-26/NNS	acomp||negative/ks-19/VBZ||positive-27/JJ	conj_and||negative-20/JJ||positive-27/JJ	amod||positive-31/JJ||hivpositive/ks-30/JJ	acomp||negative/ks-19/VBZ||positive-31/JJ	conj_and||negative-20/JJ||positive-31/JJ	hivpositive--1||hiv-25||no||participants were enrolled into one of four groups on the basis of hiv and ks status (hiv negative/ks negative, hivpositive/ks negative, hiv negative/ks positive, and hivpositive/ks positive).
nn||items-3/NNS||rating-1/NN	nn||items-3/NNS||scale-2/NN	nsubj||nonresponsive-20/VBP||items-3/NNS	nsubj||â-22/VB||items-3/NNS	det||trial-8/NN||a-5/DT	amod||trial-8/NN||6-week-6/JJ	amod||trial-8/NN||clinical-7/JJ	prep_in||items-3/NNS||trial-8/NN	prep_of||trial-8/NN||olanzapine-10/NN	nn||augmentation-13/NN||placebo-12/NN	prep_versus||olanzapine-10/NN||augmentation-13/NN	prep_in||augmentation-13/NN||patients-15/NNS	amod||bipolardisorder-18/NN||mixed-17/JJ	prep_with||patients-15/NNS||bipolardisorder-18/NN	advmod||nonresponsive-20/VBP||partially-19/RB	root||ROOT-0/null||nonresponsive-20/VBP	aux||â-22/VB||to-21/TO	xcomp||nonresponsive-20/VBP||â-22/VB	nn||¥-24/NNP||‰-23/NNP	dobj||â-22/VB||¥-24/NNP	num||days-26/NNS||14-25/CD	nsubjpass||analyzed-31/VBN||days-26/NNS	nsubj||characterize-33/VB||days-26/NNS	nn||monotherapy-29/NN||divalproex-28/NN	prep_of||days-26/NNS||monotherapy-29/NN	auxpass||analyzed-31/VBN||were-30/VBD	rcmod||¥-24/NNP||analyzed-31/VBN	aux||characterize-33/VB||to-32/TO	xcomp||analyzed-31/VBN||characterize-33/VB	nn||patterns-35/NNS||symptom-34/NN	dobj||characterize-33/VB||patterns-35/NNS	nsubj||predict-38/VB||patterns-35/NNS	aux||predict-38/VB||could-37/MD	rcmod||patterns-35/NNS||predict-38/VB	dobj||predict-38/VB||remission-39/NN	bipolardisorder-18||olanzapine-10||yes||rating scale items in a 6-week clinical trial of olanzapine versus placebo augmentation in patients with mixed bipolardisorder partially nonresponsive to â‰¥14 days of divalproex monotherapy were analyzed to characterize symptom patterns that could predict remission.
aux||identify-2/VB||to-1/TO	dep||meet-8/VBP||identify-2/VB	conj_and||identify-2/VB||implement-4/VB	dep||meet-8/VBP||implement-4/VB	dobj||identify-2/VB||strategies-5/NNS	det||help-7/NN||that-6/DT	nsubj||meet-8/VBP||help-7/NN	root||ROOT-0/null||meet-8/VBP	nn||requirements-11/NNS||safety-9/NN	nn||requirements-11/NNS||monitoring-10/NN	dobj||meet-8/VBP||requirements-11/NNS	det||context-14/NN||the-13/DT	prep_in||requirements-11/NNS||context-14/NN	det||study-18/NN||an-16/DT	amod||study-18/NN||observational-17/JJ	prep_of||context-14/NN||study-18/NN	amod||treatment-27/NN||artemether-lumefantrine-20/JJ	appos||treatment-27/NN||al-22/NNP	amod||treatment-27/NN||administered-24/VBN	prep_as||administered-24/VBN||first-line-26/NN	prep_for||meet-8/VBP||treatment-27/NN	amod||malaria-30/NN||uncomplicated-29/JJ	prep_for||treatment-27/NN||malaria-30/NN	amod||tanzania-33/NN||rural-32/JJ	prep_in||malaria-30/NN||tanzania-33/NN	malaria-30||artemether--1||yes||to identify and implement strategies that help meet safety monitoring requirements in the context of an observational study for artemether-lumefantrine (al) administered as first-line treatment for uncomplicated malaria in rural tanzania.
det||composition-3/NN||the-1/DT	nn||composition-3/NN||lipid-2/NN	nsubjpass||altered-7/VBN||composition-3/NN	prep_of||composition-3/NN||rafts-5/NNS	auxpass||altered-7/VBN||is-6/VBZ	root||ROOT-0/null||altered-7/VBN	nn||models-10/NNS||cell-9/NN	prep_in||altered-7/VBN||models-10/NNS	nsubj||responsible-16/JJ||models-10/NNS	prep_of||models-10/NNS||gaucherdisease-12/NN	aux||responsible-16/JJ||may-14/MD	cop||responsible-16/JJ||be-15/VB	rcmod||models-10/NNS||responsible-16/JJ	amod||lipid-19/NN||impaired-18/VBN	prep_for||responsible-16/JJ||lipid-19/NN	nn||observed-23/NN||protein-21/NN	amod||observed-23/NN||sorting-22/VBG	prep_for||responsible-16/JJ||observed-23/NN	conj_and||lipid-19/NN||observed-23/NN	det||disorder-26/NN||this-25/DT	prep_in||lipid-19/NN||disorder-26/NN	conj_and||altered-7/VBN||consequently-29/RB	dep||consequently-29/RB||pathology-30/RB	gaucherdisease-12||lipid-19||no_rel||the lipid composition of rafts is altered in cell models of gaucherdisease which may be responsible for impaired lipid and protein sorting observed in this disorder, and consequently pathology.
nsubj||remains-5/VBZ||lysis-1/NNS	amod||bacteriophages-4/NNS||specific-3/JJ	prep_by||lysis-1/NNS||bacteriophages-4/NNS	root||ROOT-0/null||remains-5/VBZ	det||method-8/NN||an-6/DT	amod||method-8/NN||essential-7/JJ	xcomp||remains-5/VBZ||method-8/NN	amod||detection-11/NN||y.pestis-10/JJ	prep_of||method-8/NN||detection-11/NN	nn||diagnostics-14/NNS||plague-13/NN	prep_of||method-8/NN||diagnostics-14/NNS	conj_and||detection-11/NN||diagnostics-14/NNS	plague-13||y.pestis-10||no||lysis by specific bacteriophages remains an essential method of y.pestis detection and plague diagnostics .
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||identified-6/VBD||study-4/NN	nsubj||identified-6/VBD||we-5/PRP	root||ROOT-0/null||identified-6/VBD	dobj||identified-6/VBD||genes-7/NNS	nsubj||predict-12/VB||genes-7/NNS	dobj||identified-6/VBD||mirnas-9/NNS	conj_and||genes-7/NNS||mirnas-9/NNS	nsubj||predict-12/VB||mirnas-9/NNS	aux||predict-12/VB||may-11/MD	rcmod||genes-7/NNS||predict-12/VB	amod||resistance-14/NN||clinical-13/JJ	dobj||predict-12/VB||resistance-14/NN	prep_of||resistance-14/NN||cll-16/NN	aux||fludarabine-18/VB||to-17/TO	vmod||predict-12/VB||fludarabine-18/VB	vmod||predict-12/VB||describe-21/VB	conj_and||fludarabine-18/VB||describe-21/VB	det||mechanism-25/NN||an-22/DT	amod||mechanism-25/NN||interesting-23/JJ	amod||mechanism-25/NN||oncogenic-24/JJ	dobj||fludarabine-18/VB||mechanism-25/NN	nn||patients-28/NNS||cll-27/NN	prep_in||fludarabine-18/VB||patients-28/NNS	amod||patients-28/NNS||resistant-29/JJ	aux||fludarabine-31/VB||to-30/TO	xcomp||resistant-29/JJ||fludarabine-31/VB	dobj||altered-42/VBN||which-33/WDT	det||myc-36/NN||the-34/DT	amod||myc-36/NN||complete-35/JJ	nsubjpass||altered-42/VBN||myc-36/NN	amod||network-40/NN||specific-38/JJ	amod||network-40/NN||regulatory-39/JJ	dep||myc-36/NN||network-40/NN	auxpass||altered-42/VBN||was-41/VBD	prepc_by||fludarabine-31/VB||altered-42/VBN	dep||fludarabine-18/VB||dna-44/NN	dep||fludarabine-18/VB||rna-46/NN	conj_and||dna-44/NN||rna-46/NN	dep||dna-44/NN||levels-47/NNS	amod||targets-51/NNS||transcriptional-50/JJ	dep||fludarabine-18/VB||targets-51/NNS	conj_and||dna-44/NN||targets-51/NNS	cll-27||fludarabine-31||yes||in the present study we identified genes and mirnas that may predict clinical resistance of cll to fludarabine, and describe an interesting oncogenic mechanism in cll patients resistant to fludarabine by which the complete myc -specific regulatory network was altered (dna and rna levels, and transcriptional targets).
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||provides-11/VBZ||that-4/IN	det||combination-6/NN||the-5/DT	nsubj||provides-11/VBZ||combination-6/NN	amod||olmesartanmedoxomil-10/NN||amlodipine-8/JJ	amod||olmesartanmedoxomil-10/NN||+-9/JJ	prep_of||combination-6/NN||olmesartanmedoxomil-10/NN	ccomp||suggest-3/VBP||provides-11/VBZ	det||option-16/NN||a-12/DT	amod||option-16/NN||safe-13/JJ	conj_and||safe-13/JJ||effective-15/JJ	amod||option-16/NN||effective-15/JJ	dobj||provides-11/VBZ||option-16/NN	det||treatment-19/NN||the-18/DT	prep_for||option-16/NN||treatment-19/NN	prep_of||treatment-19/NN||hypertension-21/NN	prepc_in||provides-11/VBZ||challenging-23/VBG	amod||populations-25/NNS||patient-24/JJ	dobj||challenging-23/VBG||populations-25/NNS	amlodipine-8||hypertension-21||no_rel||these results suggest that the combination of amlodipine+olmesartanmedoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations.
nsubjpass||used-4/VBN||tegaserod-1/NN	aux||used-4/VBN||has-2/VBZ	auxpass||used-4/VBN||been-3/VBN	root||ROOT-0/null||used-4/VBN	prep_for||used-4/VBN||treatment-6/NN	prep_of||treatment-6/NN||irritablebowelsyndrome-8/NN	appos||irritablebowelsyndrome-8/NN||ibs-10/NN	expl||is-14/VBZ||there-13/EX	conj_but||used-4/VBN||is-14/VBZ	neg||data-16/NNS||no-15/DT	nsubj||is-14/VBZ||data-16/NNS	poss||effect-19/NN||its-18/PRP$	prep_regarding||data-16/NNS||effect-19/NN	nn||patients-22/NNS||korean-21/NN	prep_on||effect-19/NN||patients-22/NNS	irritablebowelsyndrome-8||tegaserod-1||yes||tegaserod has been used for treatment of irritablebowelsyndrome (ibs) but there is no data regarding its effect on korean patients.
advmod||achieved-25/VBN||moreover-1/RB	advmod||added-6/VBN||when-3/WRB	nsubjpass||added-6/VBN||thioridazine-4/NN	auxpass||added-6/VBN||was-5/VBD	advcl||achieved-25/VBN||added-6/VBN	det||regimen-9/NN||a-8/DT	prep_to||added-6/VBN||regimen-9/NN	vmod||regimen-9/NN||containing-10/VBG	dobj||containing-10/VBG||rifampicin-11/NN	dobj||containing-10/VBG||isoniazid-13/NN	conj_and||rifampicin-11/NN||isoniazid-13/NN	dobj||containing-10/VBG||pyrazinamide-15/NN	conj_and||rifampicin-11/NN||pyrazinamide-15/NN	nn||tuberculosis-18/NNP||susceptible-17/NNP	prep_for||containing-10/VBG||tuberculosis-18/NNP	det||effect-23/NN||a-20/DT	amod||effect-23/NN||significant-21/JJ	amod||effect-23/NN||synergistic-22/JJ	nsubjpass||achieved-25/VBN||effect-23/NN	auxpass||achieved-25/VBN||was-24/VBD	root||ROOT-0/null||achieved-25/VBN	poss||âˆ-31/NNP||âˆ-27/NNP	nn||âˆ-31/NNP||6.2-29/NNP	nn||âˆ-31/NNP||vs-30/NNP	poss||cfu-35/NN||âˆ-31/NNP	number||log-34/CD||5.9-33/CD	num||cfu-35/NN||log-34/CD	dep||achieved-25/VBN||cfu-35/NN	nn||0.01-39/NNP||p-37/NNP	nn||0.01-39/NNP||<-38/NNP	appos||cfu-35/NN||0.01-39/NNP	tuberculosis-18||isoniazid-13||yes||moreover, when thioridazine was added to a regimen containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved (âˆ’6.2 vs âˆ’5.9 log cfu, p<0.01).
nn||fibre-2/NN||conclusion-1/NN	nsubj||effective-11/JJ||fibre-2/NN	conj_and||fibre-2/NN||antispasmodics-4/NNS	nsubj||effective-11/JJ||antispasmodics-4/NNS	conj_and||fibre-2/NN||peppermintoil-7/NN	nsubj||effective-11/JJ||peppermintoil-7/NN	cop||effective-11/JJ||were-8/VBD	det||effective-11/JJ||all-9/DT	advmod||effective-11/JJ||more-10/RBR	root||ROOT-0/null||effective-11/JJ	prep_than||effective-11/JJ||placebo-13/NN	det||treatment-16/NN||the-15/DT	prep_in||effective-11/JJ||treatment-16/NN	prep_of||treatment-16/NN||irritablebowelsyndrome-18/NN	antispasmodics-4||irritablebowelsyndrome-18||no_rel||conclusion fibre, antispasmodics, and peppermintoil were all more effective than placebo in the treatment of irritablebowelsyndrome.
nsubj||include-2/VBP||these-1/DT	root||ROOT-0/null||include-2/VBP	det||definition-7/NN||an-3/DT	amod||definition-7/NN||untenable-4/JJ	conj_and||untenable-4/JJ||idiosyncratic-6/JJ	amod||definition-7/NN||idiosyncratic-6/JJ	dobj||include-2/VBP||definition-7/NN	prep_of||definition-7/NN||addiction-9/NN	prep_of||definition-7/NN||use-11/NN	conj_or||addiction-9/NN||use-11/NN	amod||items-14/NNS||single-13/JJ	prep_of||use-11/NN||items-14/NNS	prep_of||definition-7/NN||of-16/IN	conj_or||addiction-9/NN||of-16/IN	advmod||lenient-18/JJ||very-17/RB	amod||criteria-19/NNS||lenient-18/JJ	pobj||of-16/IN||criteria-19/NNS	prepc_for||addiction-9/NN||diagnosing-21/VBG	dobj||diagnosing-21/VBG||nicotinedependence-22/NN	appos||nicotinedependence-22/NN||reliance-24/NN	poss||attributions-29/NNS||responders-26/NNS	amod||attributions-29/NNS||causal-28/JJ	prep_on||reliance-24/NN||attributions-29/NNS	prepc_in||diagnosing-21/VBG||determining-31/VBG	amod||addiction-35/NN||physical-32/NN	conj_and||physical-32/NN||mental-34/JJ	amod||addiction-35/NN||mental-34/JJ	dobj||determining-31/VBG||addiction-35/NN	prep_to||determining-31/VBG||nicotine-37/NN	prepc_for||addiction-9/NN||biased-39/VBG	conj_and||diagnosing-21/VBG||biased-39/VBG	dobj||biased-39/VBG||coding-40/NN	dobj||biased-39/VBG||interpretation-42/NN	conj_and||coding-40/NN||interpretation-42/NN	det||data-45/NNS||the-44/DT	prep_of||coding-40/NN||data-45/NNS	nicotinedependence-22||nicotine-37||no||these include an untenable and idiosyncratic definition of addiction, use of single items or of very lenient criteria for diagnosing nicotinedependence, reliance on responders' causal attributions in determining physical and mental addiction to nicotine and biased coding and interpretation of the data.
ccomp||evoked-15/VBD||short-2/JJ	number||ms-5/CD||60-4/CD	dep||short-2/JJ||ms-5/CD	amod||pulses-11/NNS||high-8/JJ	nn||pulses-11/NNS||intensity-9/NN	nn||pulses-11/NNS||laser-10/NN	nsubj||evoked-15/VBD||pulses-11/NNS	appos||pulses-11/NNS||sp-13/NN	ccomp||evoked-40/VBD||evoked-15/VBD	xcomp||evoked-15/VBD||monomodal-16/VB	dobj||monomodal-16/VB||pricking-19/NN	dep||pricking-19/NN||pain-22/NN	nsubjpass||enhanced-26/VBN||pain-22/NN	auxpass||enhanced-26/VBN||was-24/VBD	neg||enhanced-26/VBN||not-25/RB	rcmod||pain-22/NN||enhanced-26/VBN	amod||capsaicin-29/NN||topical-28/JJ	agent||enhanced-26/VBN||capsaicin-29/NN	advmod||longer-32/JJR||whereas-31/RB	amod||pricking-19/NN||longer-32/JJR	amod||pulses-36/NNS||lower-34/JJR	nn||pulses-36/NNS||power-35/NN	nsubj||evoked-40/VBD||pulses-36/NNS	appos||pulses-36/NNS||lp-38/NN	root||ROOT-0/null||evoked-40/VBD	xcomp||evoked-40/VBD||monomodal-41/VB	dobj||monomodal-41/VB||burning-44/NN	iobj||monomodal-41/VB||burning-44/NN	dep||burning-44/NN||pain-47/NN	nsubjpass||enhanced-50/VBN||pain-47/NN	auxpass||enhanced-50/VBN||was-49/VBD	rcmod||pain-47/NN||enhanced-50/VBN	amod||capsaicin-53/NN||topical-52/JJ	agent||enhanced-50/VBN||capsaicin-53/NN	pain-47||capsaicin-53||yes||" short (60 ms), high intensity laser pulses (sp) evoked monomodal ""pricking"" pain which was not enhanced by topical capsaicin, whereas longer, lower power pulses (lp) evoked monomodal ""burning"" pain which was enhanced by topical capsaicin."
det||beginning-4/NN||the-3/DT	prep_as_of||includes-16/VBZ||beginning-4/NN	prep_of||beginning-4/NN||2013-6/CD	poss||â-9/NN||our-8/PRP$	appos||2013-6/CD||â-9/NN	amod||â-9/NN||$-10/$	dep||$-10/$||œantibodies-11/JJ	aux||watchâ-13/VB||to-12/TO	vmod||beginning-4/NN||watchâ-13/VB	dobj||watchâ-13/VB||$-14/$	num||$-14/$||list-15/CD	root||ROOT-0/null||includes-16/VBZ	num||mabs-19/NNS||28-17/CD	amod||mabs-19/NNS||single-18/JJ	dobj||includes-16/VBZ||mabs-19/NNS	num||mixture-23/NN||one-21/CD	nn||mixture-23/NN||mab-22/NN	dobj||includes-16/VBZ||mixture-23/NN	conj_and||mabs-19/NNS||mixture-23/NN	nsubj||undergoing-26/VBG||mixture-23/NN	aux||undergoing-26/VBG||are-25/VBP	rcmod||mixture-23/NN||undergoing-26/VBG	dobj||undergoing-26/VBG||evaluation-27/NN	prep_in||evaluation-27/NN||phase-29/NN	num||studies-31/NNS||3-30/CD	nsubj||includes-16/VBZ||studies-31/NNS	amod||disorders-36/NNS||inflammatory-33/JJ	conj_or||inflammatory-33/JJ||immunological-35/JJ	amod||disorders-36/NNS||immunological-35/JJ	prep_for||studies-31/NNS||disorders-36/NNS	prep_for||studies-31/NNS||cancers-38/NNS	conj_and||disorders-36/NNS||cancers-38/NNS	amod||cholesterol-41/NN||high-40/JJ	prep_for||studies-31/NNS||cholesterol-41/NN	conj_and||disorders-36/NNS||cholesterol-41/NN	prep_for||studies-31/NNS||osteoporosis-43/NNS	conj_and||disorders-36/NNS||osteoporosis-43/NNS	prep_for||studies-31/NNS||alzheimerdisease-45/NN	conj_and||disorders-36/NNS||alzheimerdisease-45/NN	amod||disease-48/NN||infectious-47/JJ	prep_for||studies-31/NNS||disease-48/NN	conj_and||disorders-36/NNS||disease-48/NN	alzheimerdisease-45||antibodies--1||no_rel||as of the beginning of 2013, our â€œantibodies to watchâ€? list includes 28 single mabs and one mab mixture that are undergoing evaluation in phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, alzheimerdisease and infectious disease.
nsubj||reported-4/VBN||we-1/PRP	nsubj||aminoacid-32/VBN||we-1/PRP	aux||reported-4/VBN||have-2/VBP	advmod||reported-4/VBN||previously-3/RB	root||ROOT-0/null||reported-4/VBN	amod||strains-9/NNS||g10p-5/JJ	amod||strains-9/NNS||-LSB--6/JJ	num||strains-9/NNS||11-7/CD	amod||strains-9/NNS||-RSB--8/JJ	nsubj||associated-10/VBN||strains-9/NNS	dep||reported-4/VBN||associated-10/VBN	det||gastrointestinaldisease-16/NN||both-12/DT	amod||gastrointestinaldisease-16/NN||asymptomaticinfections-13/JJ	conj_and||asymptomaticinfections-13/JJ||severe-15/JJ	amod||gastrointestinaldisease-16/NN||severe-15/JJ	prep_with||associated-10/VBN||gastrointestinaldisease-16/NN	prep_in||gastrointestinaldisease-16/NN||neonates-18/NNS	prep_from||associated-10/VBN||vellore-20/NN	amod||india-23/NN||southern-22/JJ	prep_in||vellore-20/NN||india-23/NN	prepc_with||associated-10/VBN||>-26/VBG	number||%-28/NN||90-27/CD	amod||nucleotide-30/NN||%-28/NN	amod||nucleotide-30/NN||partial-29/JJ	dobj||>-26/VBG||nucleotide-30/NN	conj_and||reported-4/VBN||aminoacid-32/VBN	dobj||aminoacid-32/VBN||identity-33/NN	det||genes-43/NNS||the-35/DT	amod||genes-43/NNS||vp4-36/JJ	conj_and||vp4-36/JJ||vp6-38/JJ	amod||genes-43/NNS||vp6-38/JJ	conj_and||vp4-36/JJ||vp7-40/JJ	amod||genes-43/NNS||vp7-40/JJ	conj_and||vp4-36/JJ||nsp4-42/JJ	amod||genes-43/NNS||nsp4-42/JJ	prep_to||aminoacid-32/VBN||genes-43/NNS	det||-LSB--49/NN||the-45/DT	advmod||asymptomatic-47/JJ||exclusively-46/RB	amod||-LSB--49/NN||asymptomatic-47/JJ	amod||-LSB--49/NN||g10p-48/JJ	prep_of||genes-43/NNS||-LSB--49/NN	num||i321-53/NNS||11-50/CD	amod||i321-53/NNS||-RSB--51/JJ	nn||i321-53/NNS||strain-52/NN	dobj||reported-4/VBN||i321-53/NNS	asymptomaticinfections-13||aminoacid-32||no_rel||we have previously reported g10p[11] strains associated with both asymptomaticinfections and severe gastrointestinaldisease in neonates from vellore in southern india, with >90% partial nucleotide and aminoacid identity to the vp4, vp6, vp7 and nsp4 genes of the exclusively asymptomatic g10p[11] strain i321.
det||objective-3/NN||the-1/DT	nn||objective-3/NN||study-2/NN	nsubj||was-4/VBD||objective-3/NN	nsubj||investigate-6/VB||objective-3/NN	root||ROOT-0/null||was-4/VBD	aux||investigate-6/VB||to-5/TO	xcomp||was-4/VBD||investigate-6/VB	det||safety-8/NN||the-7/DT	dobj||investigate-6/VB||safety-8/NN	dobj||investigate-6/VB||tolerability-10/NN	conj_and||safety-8/NN||tolerability-10/NN	prep_of||safety-8/NN||up-titration-12/NN	amod||doses-15/NNS||high-14/JJ	prep_to||investigate-6/VB||doses-15/NNS	prep_of||doses-15/NNS||taspoglutide-17/NN	det||analogue-24/NN||a-19/DT	amod||analogue-24/NN||once-weekly-20/JJ	amod||analogue-24/NN||human-21/JJ	amod||analogue-24/NN||glucagon-like-22/JJ	amod||analogue-24/NN||peptide-1-23/JJ	appos||taspoglutide-17/NN||analogue-24/NN	prep_in||investigate-6/VB||subjects-27/NNS	prep_with||subjects-27/NNS||type2diabetes-29/NNS	advmod||controlled-31/VBN||inadequately-30/RB	amod||type2diabetes-29/NNS||controlled-31/VBN	prep_on||investigate-6/VB||metformin-33/NN	advmod||investigate-6/VB||alone-34/RB	type2diabetes-29||metformin-33||yes||the study objective was to investigate the safety and tolerability of up-titration to high doses of taspoglutide, a once-weekly human glucagon-like peptide-1 analogue, in subjects with type2diabetes inadequately controlled on metformin alone.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatics-61||acetylsalicylicacid-9||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
aux||elucidate-2/VB||to-1/TO	advcl||investigated-25/VBD||elucidate-2/VB	nn||mechanisms-4/NNS||novel-3/NN	dobj||elucidate-2/VB||mechanisms-4/NNS	vmod||mechanisms-4/NNS||contributing-5/VBG	det||complex-10/NN||the-7/DT	amod||complex-10/NN||htlv-1-8/JJ	amod||complex-10/NN||neurological-9/JJ	prep_to||contributing-5/VBG||complex-10/NN	poss||presentation-15/NN||its-12/PRP$	amod||presentation-15/NN||classic-13/JJ	amod||presentation-15/NN||neurological-14/JJ	prep_to||contributing-5/VBG||presentation-15/NN	conj_and||complex-10/NN||presentation-15/NN	vmod||presentation-15/NN||called-16/VBN	dobj||called-16/VBN||ham/tsp-17/NN	amod||myelopathy/tropicalspasticparaparesis-21/NNS||htlv-1-19/JJ	amod||myelopathy/tropicalspasticparaparesis-21/NNS||associated-20/JJ	appos||ham/tsp-17/NN||myelopathy/tropicalspasticparaparesis-21/NNS	nsubj||investigated-25/VBD||we-24/PRP	root||ROOT-0/null||investigated-25/VBD	det||expression-27/NN||the-26/DT	dobj||investigated-25/VBD||expression-27/NN	det||receptor-31/NN||the-29/DT	amod||receptor-31/NN||tim-3-30/JJ	prep_of||expression-27/NN||receptor-31/NN	amod||cells-36/NNS||cd8-33/JJ	amod||cells-36/NNS||+-34/JJ	nn||cells-36/NNS||t-35/NN	prep_on||receptor-31/NN||cells-36/NNS	det||cohort-39/NN||a-38/DT	prep_from||investigated-25/VBD||cohort-39/NN	amod||patients-46/NNS||htlv-1-41/JJ	amod||patients-46/NNS||seropositive-42/JJ	amod||patients-46/NNS||asymptomatic-43/JJ	conj_and||asymptomatic-43/JJ||symptomatic-45/JJ	amod||patients-46/NNS||symptomatic-45/JJ	prep_of||cohort-39/NN||patients-46/NNS	tropicalspasticparaparesis--1||htlv-1-41||no||to elucidate novel mechanisms contributing to the htlv-1 neurological complex and its classic neurological presentation called ham/tsp (htlv-1 associated myelopathy/tropicalspasticparaparesis), we investigated the expression of the tim-3 receptor on cd8+ t cells from a cohort of htlv-1 seropositive asymptomatic and symptomatic patients.
det||context-3/NN||this-2/DT	prep_in||assessed-24/VBN||context-3/NN	det||efficacy-6/NN||the-5/DT	nsubjpass||assessed-24/VBN||efficacy-6/NN	conj_and||efficacy-6/NN||tolerance-8/NN	nsubjpass||assessed-24/VBN||tolerance-8/NN	amod||injection-12/NN||risperidone-10/JJ	amod||injection-12/NN||long-acting-11/JJ	prep_of||efficacy-6/NN||injection-12/NN	appos||injection-12/NN||rlai-14/NNP	nn||treatment-18/NN||maintenance-17/NN	prep_for||injection-12/NN||treatment-18/NN	prep_in||treatment-18/NN||patients-20/NNS	prep_with||patients-20/NNS||bipolardisorder-22/NN	auxpass||assessed-24/VBN||is-23/VBZ	root||ROOT-0/null||assessed-24/VBN	bipolardisorder-22||risperidone-10||yes||in this context, the efficacy and tolerance of risperidone long-acting injection (rlai) for maintenance treatment in patients with bipolardisorder is assessed.
nsubjpass||proposed-4/VBN||it-1/PRP	aux||proposed-4/VBN||has-2/VBZ	auxpass||proposed-4/VBN||been-3/VBN	root||ROOT-0/null||proposed-4/VBN	mark||used-15/VBN||that-5/IN	nsubjpass||used-15/VBN||doses-6/NNS	prep_of||doses-6/NNS||amikacin-8/NN	number||15-11/CD||>-10/CD	num||mg/kg-12/NN||15-11/CD	prep_of||amikacin-8/NN||mg/kg-12/NN	aux||used-15/VBN||should-13/MD	auxpass||used-15/VBN||be-14/VB	ccomp||proposed-4/VBN||used-15/VBN	prep_in||used-15/VBN||conditions-17/NNS	vmod||conditions-17/NNS||associated-18/VBN	det||volume-22/NN||an-20/DT	amod||volume-22/NN||increased-21/VBN	prep_with||associated-18/VBN||volume-22/NN	prep_of||volume-22/NN||distribution-24/NN	appos||volume-22/NN||vd-26/NN	amod||sepsis-32/NN||severe-31/JJ	prep_such_as||volume-22/NN||sepsis-32/NN	prep_such_as||volume-22/NN||septicshock-34/NN	conj_and||sepsis-32/NN||septicshock-34/NN	sepsis-32||amikacin-8||yes||it has been proposed that doses of amikacin of >15 mg/kg should be used in conditions associated with an increased volume of distribution (vd), such as severe sepsis and septicshock.
nsubj||tread-9/VBN||advances-1/NNS	det||field-4/NN||the-3/DT	prep_in||advances-1/NNS||field-4/NN	nn||analgesia-7/NN||labour-6/NN	prep_of||field-4/NN||analgesia-7/NN	aux||tread-9/VBN||have-8/VBP	root||ROOT-0/null||tread-9/VBN	det||journey-12/NN||a-10/DT	amod||journey-12/NN||long-11/JJ	dobj||tread-9/VBN||journey-12/NN	det||days-15/NNS||the-14/DT	prep_from||tread-9/VBN||days-15/NNS	prep_of||days-15/NNS||ether-17/NN	prep_of||days-15/NNS||chloroform-19/NN	conj_and||ether-17/NN||chloroform-19/NN	prep_in||tread-9/VBN||1847-21/CD	det||practice-26/NN||the-23/DT	amod||practice-26/NN||present-24/JJ	nn||practice-26/NN||day-25/NN	prep_to||tread-9/VBN||practice-26/NN	amod||programme-29/NN||comprehensive-28/JJ	prep_of||practice-26/NN||programme-29/NN	nn||management-33/NN||labour-31/NN	nn||management-33/NN||pain-32/NN	prep_of||programme-29/NN||management-33/NN	vmod||management-33/NN||using-34/VBG	amod||medicine-36/NN||evidence-based-35/JJ	dobj||using-34/VBG||medicine-36/NN	pain-32||ether-17||yes||advances in the field of labour analgesia have tread a long journey from the days of ether and chloroform in 1847 to the present day practice of comprehensive programme of labour pain management using evidence-based medicine.
amod||asthma-2/NN||aspirin-intolerant-1/JJ	nsubj||occurs-6/VBZ||asthma-2/NN	appos||asthma-2/NN||aia-4/NN	root||ROOT-0/null||occurs-6/VBZ	det||lower-9/JJR||the-8/DT	prep_in||occurs-6/VBZ||lower-9/JJR	amod||airways-12/NNS||upper-11/JJ	prep_in||occurs-6/VBZ||airways-12/NNS	conj_and||lower-9/JJR||airways-12/NNS	amod||production-15/NN||excessive-14/JJ	prep_through||occurs-6/VBZ||production-15/NN	prep_of||production-15/NN||leukotrienes-17/NNS	prep_upon||leukotrienes-17/NNS||administration-19/NN	amod||anti-inflammatorydrugs-22/NNS||non-steroidal-21/JJ	prep_of||administration-19/NN||anti-inflammatorydrugs-22/NNS	appos||anti-inflammatorydrugs-22/NNS||nsaids-24/NNS	asthma-2||aspirin--1||no||aspirin-intolerant asthma (aia) occurs in the lower and upper airways through excessive production of leukotrienes upon administration of non-steroidal anti-inflammatorydrugs (nsaids).
nsubj||stimulate-2/VB||gkas-1/NNS	root||ROOT-0/null||stimulate-2/VB	nn||release-4/NN||insulin-3/NN	dobj||stimulate-2/VB||release-4/NN	nn||metabolism-7/NN||glucose-6/NN	dobj||stimulate-2/VB||metabolism-7/NN	conj_and||release-4/NN||metabolism-7/NN	det||liver-10/NN||the-9/DT	prep_in||release-4/NN||liver-10/NN	advmod||lowering-12/VBG||thereby-11/RB	vmod||liver-10/NN||lowering-12/VBG	nn||sugar-14/NN||blood-13/NN	dobj||lowering-12/VBG||sugar-14/NN	amod||trials-18/NNS||promising-17/JJ	nsubj||demonstrate-21/VBP||trials-18/NNS	prep_in||trials-18/NNS||humans-20/NNS	conj_and||stimulate-2/VB||demonstrate-21/VBP	mark||effective-26/JJ||that-22/IN	nsubj||effective-26/JJ||they-23/PRP	cop||effective-26/JJ||are-24/VBP	advmod||effective-26/JJ||highly-25/RB	ccomp||demonstrate-21/VBP||effective-26/JJ	prep_in||effective-26/JJ||patients-28/NNS	prep_with||patients-28/NNS||type2diabetesmellitus-30/CD	type2diabetesmellitus-30||insulin-3||yes||gkas stimulate insulin release and glucose metabolism in the liver thereby lowering blood sugar, and promising trials in humans demonstrate that they are highly effective in patients with type2diabetesmellitus.
advmod||examine-3/VBP||moreover-1/RB	nsubj||examine-3/VBP||we-2/PRP	root||ROOT-0/null||examine-3/VBP	det||role-5/NN||the-4/DT	dobj||examine-3/VBP||role-5/NN	det||antibody-9/NN||a-7/DT	amod||antibody-9/NN||monoclonal-8/JJ	prep_of||role-5/NN||antibody-9/NN	appos||antibody-9/NN||mab-11/NN	amod||4c5-17/NNS||hsp90-14/JJ	amod||4c5-17/NNS||mab-16/JJ	prep_against||antibody-9/NN||4c5-17/NNS	det||interactions-21/NNS||these-20/DT	prep_regarding||antibody-9/NN||interactions-21/NNS	poss||value-24/NN||its-23/PRP$	prep_regarding||antibody-9/NN||value-24/NN	conj_and||interactions-21/NNS||value-24/NN	det||inhibitor-28/NN||a-26/DT	amod||inhibitor-28/NN||potential-27/JJ	prep_as||value-24/NN||inhibitor-28/NN	amod||invasion-34/NN||human-30/JJ	nn||invasion-34/NN||breast-31/NN	nn||invasion-34/NN||cancer-32/NN	nn||invasion-34/NN||cell-33/NN	prep_of||inhibitor-28/NN||invasion-34/NN	prep_of||inhibitor-28/NN||metastasis-36/NNS	conj_and||invasion-34/NN||metastasis-36/NNS	cancer-32||antibody-9||no_rel||moreover we examine the role of a monoclonal antibody (mab) against hsp90, mab 4c5, regarding these interactions and its value as a potential inhibitor of human breast cancer cell invasion and metastasis.
nsubjpass||analyzed-30/VBN||frequency-1/NN	conj_and||frequency-1/NN||intensity-3/NN	nsubjpass||analyzed-30/VBN||intensity-3/NN	amod||production-7/NN||intrathecal-5/JJ	nn||production-7/NN||antibody-6/NN	prep_of||frequency-1/NN||production-7/NN	prep_against||production-7/NN||ebv-9/NN	advmod||ebv-9/NN||as-10/RB	prepc_compared_to||ebv-9/NN||to-12/TO	nn||zoster-18/NN||measles-13/NN	dep||zoster-18/NN||rubella-15/NN	amod||zoster-18/NN||varicella-17/JJ	pobj||ebv-9/NN||zoster-18/NN	appos||zoster-18/NN||vzv-20/NN	amod||virus-25/NN||herpes-23/JJ	nn||virus-25/NN||simplex-24/NN	pobj||ebv-9/NN||virus-25/NN	conj_and||zoster-18/NN||virus-25/NN	appos||zoster-18/NN||hsv-27/NN	auxpass||analyzed-30/VBN||were-29/VBD	root||ROOT-0/null||analyzed-30/VBN	agent||analyzed-30/VBN||determination-32/NN	amod||indices-37/NNS||virus-specific-34/JJ	amod||indices-37/NNS||csf-to-serum-35/JJ	nn||indices-37/NNS||antibody-36/NN	prep_of||determination-32/NN||indices-37/NNS	appos||indices-37/NNS||ai-39/NNP	zoster-18||vzv-20||no||frequency and intensity of intrathecal antibody production against ebv as compared to measles, rubella, varicella zoster (vzv) and herpes simplex virus (hsv) were analyzed by determination of virus-specific csf-to-serum antibody indices (ai).
aux||discuss-2/VB||to-1/TO	root||ROOT-0/null||discuss-2/VB	det||features-5/NNS||the-3/DT	amod||features-5/NNS||clinical-4/JJ	dobj||discuss-2/VB||features-5/NNS	dobj||discuss-2/VB||management-7/NN	conj_and||features-5/NNS||management-7/NN	prep_of||discuss-2/VB||patients-9/NNS	nsubj||presented-11/VBD||patients-9/NNS	nsubj||had-15/VBD||patients-9/NNS	rcmod||patients-9/NNS||presented-11/VBD	prep_with||presented-11/VBD||opticdiscedema-13/NN	rcmod||patients-9/NNS||had-15/VBD	conj_and||presented-11/VBD||had-15/VBD	dobj||had-15/VBD||features-16/NNS	amod||intracranialhypertension-20/NN||presumed-18/VBN	amod||intracranialhypertension-20/NN||idiopathic-19/JJ	prep_of||features-16/NNS||intracranialhypertension-20/NN	appos||intracranialhypertension-20/NN||iih-22/NN	opticdiscedema-13||intracranialhypertension-20||no||to discuss the clinical features and management of patients who presented with opticdiscedema and had features of presumed idiopathic intracranialhypertension (iih).
nsubjpass||known-4/VBN||it-1/PRP	auxpass||known-4/VBN||is-2/VBZ	neg||known-4/VBN||not-3/RB	root||ROOT-0/null||known-4/VBN	mark||is-7/VBZ||if-5/IN	expl||is-7/VBZ||there-6/EX	advcl||known-4/VBN||is-7/VBZ	det||relationship-9/NN||a-8/DT	nsubj||is-7/VBZ||relationship-9/NN	nn||rate-12/NN||input-11/NN	prep_between||relationship-9/NN||rate-12/NN	prep_between||relationship-9/NN||incidence-14/NN	conj_and||rate-12/NN||incidence-14/NN	amod||seizures-17/NNS||bupropion-induced-16/JJ	prep_of||relationship-9/NN||seizures-17/NNS	seizures-17||bupropion--1||no||it is not known if there is a relationship between input rate and incidence of bupropion-induced seizures.
amod||therapy-2/NN||lamivudine-1/JJ	nsubj||had-3/VBD||therapy-2/NN	root||ROOT-0/null||had-3/VBD	det||effect-6/NN||a-4/DT	amod||effect-6/NN||significant-5/JJ	dobj||had-3/VBD||effect-6/NN	amod||seroconversion-9/NN||hbeag-8/JJ	prep_on||effect-6/NN||seroconversion-9/NN	nn||disappearance-12/NN||hbv-dna-11/NN	prep_on||effect-6/NN||disappearance-12/NN	conj_and||seroconversion-9/NN||disappearance-12/NN	nn||normalization-16/NN||alt-15/NN	dobj||had-3/VBD||normalization-16/NN	conj_and||effect-6/NN||normalization-16/NN	nn||children-19/NNS||korean-18/NN	prep_for||normalization-16/NN||children-19/NNS	prep_with||had-3/VBD||chronichepatitisb-21/NN	hbv--1||lamivudine-1||yes||lamivudine therapy had a significant effect on hbeag seroconversion and hbv-dna disappearance, and alt normalization for korean children with chronichepatitisb.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||efficacy-4/NN||the-3/DT	dobj||evaluated-2/VBN||efficacy-4/NN	prep_of||efficacy-4/NN||glimepiride-6/NN	prep_of||efficacy-4/NN||metformin-8/NN	conj_and||glimepiride-6/NN||metformin-8/NN	prep_of||efficacy-4/NN||rosiglitazone-11/NN	conj_and||glimepiride-6/NN||rosiglitazone-11/NN	amod||treatment-14/NN||initial-13/JJ	prep_as||glimepiride-6/NN||treatment-14/NN	amod||patients-20/NNS||drug-naã-16/JJ	nn||patients-20/NNS||¯-17/NN	nn||patients-20/NNS||ve-18/NN	amod||patients-20/NNS||type2diabetesmellitus-19/JJ	prep_for||treatment-14/NN||patients-20/NNS	det||study-29/NN||a-22/DT	amod||study-29/NN||48-week-23/JJ	amod||study-29/NN||double-blind-25/JJ	amod||study-29/NN||randomized-27/JJ	amod||study-29/NN||controlled-28/JJ	prep_in||evaluated-2/VBN||study-29/NN	nsubj||included-31/VBD||study-29/NN	rcmod||study-29/NN||included-31/VBD	num||patients-34/NNS||349-32/CD	nn||patients-34/NNS||korean-33/NN	dobj||included-31/VBD||patients-34/NNS	type2diabetesmellitus-19||glimepiride-6||yes||we evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naã¯ve type2diabetesmellitus patients in a 48-week, double-blind, randomized controlled study that included 349 korean patients.
amod||objectives-2/NNS||secondary-1/JJ	nsubj||effectiveness-5/NN||objectives-2/NNS	cop||effectiveness-5/NN||were-3/VBD	det||effectiveness-5/NN||the-4/DT	root||ROOT-0/null||effectiveness-5/NN	prep_of||effectiveness-5/NN||ondansetron-7/NN	prep_of||effectiveness-5/NN||prochlorperazine-9/NN	conj_and||ondansetron-7/NN||prochlorperazine-9/NN	aux||treat-11/VB||to-10/TO	vmod||effectiveness-5/NN||treat-11/VB	dobj||treat-11/VB||nausea-12/NN	poss||tolerability-15/NN||their-14/PRP$	dobj||treat-11/VB||tolerability-15/NN	conj_and||nausea-12/NN||tolerability-15/NN	nausea-12||prochlorperazine-9||yes||secondary objectives were the effectiveness of ondansetron and prochlorperazine to treat nausea and their tolerability.
det||critically-3/NN||this-1/DT	nn||critically-3/NN||commentary-2/NN	nsubj||examines-4/VBZ||critically-3/NN	root||ROOT-0/null||examines-4/VBZ	det||paper-7/NN||a-5/DT	amod||paper-7/NN||specially-written-6/JJ	dobj||examines-4/VBZ||paper-7/NN	nsubj||describes-19/VBZ||paper-7/NN	dep||paper-7/NN||published-9/VBN	det||issue-13/NN||the-11/DT	amod||issue-13/NN||same-12/JJ	prep_in||published-9/VBN||issue-13/NN	det||journal-16/NN||this-15/DT	prep_of||issue-13/NN||journal-16/NN	rcmod||paper-7/NN||describes-19/VBZ	det||rct-26/NN||a-20/DT	amod||rct-26/NN||fictitious-21/JJ	amod||rct-26/NN||industry-driven-23/JJ	amod||rct-26/NN||multicentre-25/JJ	dobj||describes-19/VBZ||rct-26/NN	xcomp||describes-19/VBZ||comparing-27/VBG	det||placeboxetine-31/NN||the-28/DT	amod||placeboxetine-31/NN||fictitious-29/JJ	nn||placeboxetine-31/NN||antidepressant-30/NN	dobj||comparing-27/VBG||placeboxetine-31/NN	prep_with||comparing-27/VBG||sertraline-33/NN	nn||patients-36/NNS||indian-35/NN	prep_in||sertraline-33/NN||patients-36/NNS	amod||depressivedisorder-39/NN||major-38/JJ	prep_with||comparing-27/VBG||depressivedisorder-39/NN	depressivedisorder-39||sertraline-33||yes||this commentary critically examines a specially-written paper (published in the same issue of this journal) that describes a fictitious, industry-driven, multicentre rct comparing the fictitious antidepressant placeboxetine with sertraline in indian patients with major depressivedisorder.
det||eradication-2/NN||the-1/DT	nsubj||appears-6/VBZ||eradication-2/NN	nsubj||way-12/NN||eradication-2/NN	amod||avianinfluenzaviruses-5/NNS||pathogenic-4/JJ	prep_of||eradication-2/NN||avianinfluenzaviruses-5/NNS	root||ROOT-0/null||appears-6/VBZ	aux||way-12/NN||to-7/TO	cop||way-12/NN||be-8/VB	det||way-12/NN||the-9/DT	advmod||effective-11/JJ||most-10/RBS	amod||way-12/NN||effective-11/JJ	xcomp||appears-6/VBZ||way-12/NN	aux||prevent-14/VB||to-13/TO	vmod||way-12/NN||prevent-14/VB	det||pandemic-17/NN||an-15/DT	nn||pandemic-17/NN||influenza-16/NN	dobj||prevent-14/VB||pandemic-17/NN	influenza-16||influenzaviruses--1||no||the eradication of pathogenic avianinfluenzaviruses appears to be the most effective way to prevent an influenza pandemic.
amod||characteristics-4/NNS||residentsâ-1/JJ	amod||characteristics-4/NNS||$-2/$	dep||$-2/$||™-3/JJ	nsubj||sex-12/NN||characteristics-4/NNS	vmod||characteristics-4/NNS||associated-5/VBN	amod||use-9/NN||psychotropic-7/JJ	nn||use-9/NN||medication-8/NN	prep_with||associated-5/VBN||use-9/NN	cop||sex-12/NN||were-10/VBD	amod||sex-12/NN||female-11/JJ	root||ROOT-0/null||sex-12/NN	nn||-LSB--16/NN||odds-14/NNS	nn||-LSB--16/NN||ratio-15/NN	dep||sex-12/NN||-LSB--16/NN	dep||sex-12/NN||-RSB--18/NN	conj_or||-LSB--16/NN||-RSB--18/NN	appos||-LSB--16/NN||1.36-20/CD	num||-RSB--28/NNS||95-22/CD	nn||-RSB--28/NNS||%-23/NN	nn||-RSB--28/NNS||confidence-24/NN	amod||-RSB--28/NNS||interval-25/JJ	amod||-RSB--28/NNS||-LSB--26/JJ	nn||-RSB--28/NNS||ci-27/NN	dep||1.36-20/CD||-RSB--28/NNS	num||.80-31/CD||1.03-1-30/CD	appos||-RSB--28/NNS||.80-31/CD	appos||-LSB--16/NN||age-34/NN	conj_and||1.36-20/CD||age-34/NN	cc||restlessness-49/NNS||or-36/CC	dep||restlessness-49/NNS||0.97-38/CD	num||%-41/NN||95-40/CD	dep||0.97-38/CD||%-41/NN	dep||%-41/NN||ci-42/NN	num||.98-45/CD||0.95-0-44/CD	appos||%-41/NN||.98-45/CD	amod||restlessness-49/NNS||permanent-48/JJ	dep||age-34/NN||restlessness-49/NNS	cc||2.54-53/NNP||or-51/CC	dep||restlessness-49/NNS||2.54-53/NNP	num||%-56/NN||95-55/CD	npadvmod||ci-57/JJ||%-56/NN	amod||restlessness-49/NNS||ci-57/JJ	num||.78-60/CD||1.71-3-59/CD	appos||restlessness-49/NNS||.78-60/CD	appos||-LSB--16/NN||dementia-63/NN	conj_and||1.36-20/CD||dementia-63/NN	cc||1.76-67/CD||or-65/CC	dep||dementia-63/NN||1.76-67/CD	number||%-70/NN||95-69/CD	amod||ci-71/NN||%-70/NN	dep||dementia-63/NN||ci-71/NN	num||.34-74/CD||1.33-2-73/CD	appos||dementia-63/NN||.34-74/CD	appos||-LSB--16/NN||depression-77/NN	conj_and||1.36-20/CD||depression-77/NN	cc||5.51-81/CD||or-79/CC	dep||depression-77/NN||5.51-81/CD	number||%-84/NN||95-83/CD	amod||ci-85/NN||%-84/NN	dep||depression-77/NN||ci-85/NN	num||.58-88/CD||3.50-7-87/CD	appos||depression-77/NN||.58-88/CD	det||number-93/NN||the-92/DT	appos||-LSB--16/NN||number-93/NN	conj_and||1.36-20/CD||number-93/NN	amod||medications-96/NNS||prescribed-95/JJ	prep_of||number-93/NN||medications-96/NNS	cc||1.29-100/CD||or-98/CC	dep||medications-96/NNS||1.29-100/CD	number||%-103/NN||95-102/CD	amod||ci-104/NN||%-103/NN	dep||medications-96/NNS||ci-104/NN	num||.35-107/CD||1.23-1-106/CD	appos||-LSB--16/NN||.35-107/CD	restlessness-49||psychotropic-7||no_rel||residentsâ€™ characteristics associated with psychotropic medication use were female sex (odds ratio [or], 1.36; 95% confidence interval [ci], 1.03-1.80), age (or, 0.97; 95% ci, 0.95-0.98), permanent restlessness (or, 2.54; 95% ci, 1.71-3.78), dementia (or, 1.76; 95% ci, 1.33-2.34), depression (or, 5.51; 95% ci, 3.50-7.58), and the number of prescribed medications (or, 1.29; 95% ci, 1.23-1.35).
nsubj||predict-3/VB||atp-cra-1/NN	aux||predict-3/VB||could-2/MD	root||ROOT-0/null||predict-3/VB	amod||response-5/NN||clinical-4/JJ	dobj||predict-3/VB||response-5/NN	nn||chemotherapy-10/NN||paclitaxel-7/NN	conj_and||paclitaxel-7/NN||cisplatin-9/NN	nn||chemotherapy-10/NN||cisplatin-9/NN	prep_to||predict-3/VB||chemotherapy-10/NN	amod||accuracy-13/NN||high-12/JJ	prep_with||predict-3/VB||accuracy-13/NN	amod||patients-18/NNS||advanced-15/JJ	amod||patients-18/NNS||gastric-16/JJ	nn||patients-18/NNS||cancer-17/NN	prep_in||accuracy-13/NN||patients-18/NNS	cancer-17||paclitaxel-7||no_rel||atp-cra could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients.
det||system-3/NN||the-1/DT	amod||system-3/NN||immune-2/JJ	poss||role-5/NN||system-3/NN	nsubj||complex-11/JJ||role-5/NN	amod||patients-9/NNS||hiv-7/JJ	amod||patients-9/NNS||infected-8/JJ	prep_in||role-5/NN||patients-9/NNS	cop||complex-11/JJ||is-10/VBZ	root||ROOT-0/null||complex-11/JJ	amod||expression-14/NN||cytokine-13/JJ	prep_with||complex-11/JJ||expression-14/NN	advmod||influencing-16/VBG||strongly-15/RB	xcomp||complex-11/JJ||influencing-16/VBG	dobj||influencing-16/VBG||hivinfection-17/NN	dobj||influencing-16/VBG||replication-19/NN	conj_and||hivinfection-17/NN||replication-19/NN	hivinfection-17||hiv-7||no||the immune system's role in hiv infected patients is complex with cytokine expression strongly influencing hivinfection and replication.
nsubj||dependent-4/JJ||women-1/NNS	nsubj||unlikely-33/JJ||women-1/NNS	nsubj||come-35/VB||women-1/NNS	cop||dependent-4/JJ||are-3/VBP	rcmod||women-1/NNS||dependent-4/JJ	amod||drugs-7/NNS||non-injecting-6/JJ	prep_on||dependent-4/JJ||drugs-7/NNS	prep_on||dependent-4/JJ||alcohol-9/NN	conj_and||drugs-7/NNS||alcohol-9/NN	cop||likely-12/JJ||are-10/VBP	advmod||likely-12/JJ||also-11/RB	advcl||dependent-4/JJ||likely-12/JJ	aux||increased-15/VBN||to-13/TO	aux||increased-15/VBN||have-14/VB	xcomp||likely-12/JJ||increased-15/VBN	dobj||increased-15/VBN||vulnerability-16/NN	prep_to||increased-15/VBN||hivinfection-18/NN	mark||inject-24/VB||until-21/IN	nsubj||inject-24/VB||they-22/PRP	nsubj||engage-27/VB||they-22/PRP	advmod||inject-24/VB||actually-23/RB	advcl||dependent-4/JJ||inject-24/VB	conj_but||likely-12/JJ||inject-24/VB	dobj||inject-24/VB||drugs-25/NNS	conj_but||likely-12/JJ||engage-27/VB	conj_or||inject-24/VB||engage-27/VB	nn||work-30/NN||sex-29/NN	prep_in||engage-27/VB||work-30/NN	cop||unlikely-33/JJ||are-32/VBP	root||ROOT-0/null||unlikely-33/JJ	aux||come-35/VB||to-34/TO	xcomp||unlikely-33/JJ||come-35/VB	det||attention-38/NN||the-37/DT	prep_to||come-35/VB||attention-38/NN	nn||programs-42/NNS||hiv-40/NN	nn||programs-42/NNS||prevention-41/NN	prep_of||attention-38/NN||programs-42/NNS	alcohol-9||hivinfection-18||no_rel||women who are dependent on non-injecting drugs and alcohol are also likely to have increased vulnerability to hivinfection, but until they actually inject drugs or engage in sex work, are unlikely to come to the attention of hiv prevention programs.
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||recently-2/RB	root||ROOT-0/null||reported-3/VBD	det||association-6/NN||a-4/DT	amod||association-6/NN||negative-5/JJ	dobj||reported-3/VBD||association-6/NN	amod||igm-antibodies-9/NNS||natural-8/JJ	prep_between||association-6/NN||igm-antibodies-9/NNS	prep_against||igm-antibodies-9/NNS||phosphorylcholine-11/NN	dep||phosphorylcholine-11/NN||anti-pc-13/JJ	det||population-18/NN||the-16/DT	amod||population-18/NN||general-17/JJ	prep_in||reported-3/VBD||population-18/NN	amod||levels-22/NNS||high-20/JJ	amod||levels-22/NNS||anti-pc-21/JJ	prep_in||reported-3/VBD||levels-22/NNS	conj_and||population-18/NN||levels-22/NNS	vmod||levels-22/NNS||leading-23/VBG	amod||development-27/NN||decreased-25/VBN	nn||development-27/NN||atherosclerosis-26/NNS	prep_to||leading-23/VBG||development-27/NN	amod||levels-30/NNS||low-29/JJ	prep_in||reported-3/VBD||levels-30/NNS	conj_and||population-18/NN||levels-30/NNS	amod||risk-33/NN||increased-32/VBN	prep_to||levels-30/NNS||risk-33/NN	prep_of||risk-33/NN||cvd-35/NN	cvd-35||antibodies--1||no_rel||we recently reported a negative association between natural igm-antibodies against phosphorylcholine (anti-pc) in the general population, high anti-pc levels leading to decreased atherosclerosis development and low levels to increased risk of cvd.
nsubj||inhibited-2/VBD||5-fu-1/JJ	root||ROOT-0/null||inhibited-2/VBD	det||activity-5/NN||the-3/DT	amod||activity-5/NN||proliferative-4/JJ	dobj||inhibited-2/VBD||activity-5/NN	amod||cells-8/NNS||ht-29-7/JJ	prep_of||activity-5/NN||cells-8/NNS	nsubj||dependent-13/JJ||cells-8/NNS	cop||dependent-13/JJ||was-11/VBD	advmod||dependent-13/JJ||mostly-12/RB	rcmod||cells-8/NNS||dependent-13/JJ	det||arrest-16/NN||the-15/DT	prep_on||dependent-13/JJ||arrest-16/NN	det||cells-19/NNS||the-18/DT	prep_of||arrest-16/NN||cells-19/NNS	det||induction-28/NN||the-21/DT	amod||induction-28/NN||g0/g1-phase-22/JJ	cc||on-26/IN||but-23/CC	dep||on-26/IN||also-24/RB	advmod||on-26/IN||partially-25/RB	dep||g0/g1-phase-22/JJ||on-26/IN	pobj||on-26/IN||apoptosis-27/NNS	prep_to||dependent-13/JJ||induction-28/NN	det||effect-32/NN||the-31/DT	nsubjpass||potentiated-34/VBN||effect-32/NN	auxpass||potentiated-34/VBN||was-33/VBD	conj_and||inhibited-2/VBD||potentiated-34/VBN	nn||pre-treatment-37/NN||cq-36/NN	agent||potentiated-34/VBN||pre-treatment-37/NN	arrest-16||5-fu-1||no_rel||5-fu inhibited the proliferative activity of ht-29 cells, which was mostly dependent on the arrest of the cells to the g0/g1-phase but also partially on apoptosis induction, and the effect was potentiated by cq pre-treatment.
prep_in||provide-19/VB||patients-2/NNS	prep_with||patients-2/NNS||gastroparesis-4/NNS	amod||gastroparesis-4/NNS||recalcitrant-5/JJ	amod||therapies-9/NNS||first-7/JJ	nn||therapies-9/NNS||line-8/NN	prep_to||recalcitrant-5/JJ||therapies-9/NNS	prep_such_as||therapies-9/NNS||metoclopramide-12/NN	amod||use-15/NN||off-label-14/JJ	nsubj||provide-19/VB||use-15/NN	prep_of||use-15/NN||mirtazapine-17/NN	aux||provide-19/VB||may-18/MD	root||ROOT-0/null||provide-19/VB	amod||non-invasive-21/JJ||adequate-20/JJ	amod||management-22/NN||non-invasive-21/JJ	dobj||provide-19/VB||management-22/NN	amod||symptoms-25/NNS||gastroparetic-24/JJ	prep_of||management-22/NN||symptoms-25/NNS	gastroparesis-4||metoclopramide-12||yes||in patients with gastroparesis recalcitrant to first line therapies such as metoclopramide, off-label use of mirtazapine may provide adequate non-invasive management of gastroparetic symptoms.
advmod||correlated-6/VBN||moreover-1/RB	nsubjpass||correlated-6/VBN||socs1-3/NNS	auxpass||correlated-6/VBN||was-4/VBD	advmod||correlated-6/VBN||positively-5/RB	root||ROOT-0/null||correlated-6/VBN	det||expression-9/NN||the-8/DT	prep_with||correlated-6/VBN||expression-9/NN	amod||mrna-12/NN||htlv-1-11/JJ	prep_of||expression-9/NN||mrna-12/NN	nn||samples-16/NNS||ham/tsp-14/NN	nn||samples-16/NNS||patient-15/NN	prep_in||mrna-12/NN||samples-16/NNS	ham--1||htlv-1-11||no||moreover, socs1 was positively correlated with the expression of htlv-1 mrna in ham/tsp patient samples.
mark||associated-15/VBN||while-1/IN	amod||plasminogenactivator-4/NN||increased-2/VBN	amod||plasminogenactivator-4/NN||urokinase-type-3/JJ	nsubjpass||associated-15/VBN||plasminogenactivator-4/NN	appos||plasminogenactivator-4/NN||upa-6/NN	vmod||plasminogenactivator-4/NN||expression-8/VBG	nn||tissue-12/NN||breast-10/NN	nn||tissue-12/NN||cancer-11/NN	prep_in||expression-8/VBG||tissue-12/NN	auxpass||associated-15/VBN||is-13/VBZ	advmod||associated-15/VBN||directly-14/RB	advcl||suggests-22/VBZ||associated-15/VBN	amod||prognosis-18/NN||poor-17/JJ	prep_with||associated-15/VBN||prognosis-18/NN	amod||evidence-21/NN||recent-20/JJ	nsubj||suggests-22/VBZ||evidence-21/NN	root||ROOT-0/null||suggests-22/VBZ	mark||suppress-27/VB||that-23/IN	nn||overexpression-25/NN||upa-24/NN	nsubj||suppress-27/VB||overexpression-25/NN	nsubj||prolong-31/VB||overexpression-25/NN	aux||suppress-27/VB||may-26/MD	ccomp||suggests-22/VBZ||suppress-27/VB	nn||growth-29/NN||tumor-28/NN	dobj||suppress-27/VB||growth-29/NN	ccomp||suggests-22/VBZ||prolong-31/VB	conj_and||suppress-27/VB||prolong-31/VB	dobj||prolong-31/VB||survival-32/NN	upa-24||tumor-28||no_rel||while increased urokinase-type plasminogenactivator (upa) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that upa overexpression may suppress tumor growth and prolong survival.
amod||evidence-2/NN||mounting-1/VBG	nsubj||suggested-4/VBN||evidence-2/NN	aux||suggested-4/VBN||has-3/VBZ	root||ROOT-0/null||suggested-4/VBN	mark||candidate-13/NN||that-5/IN	nn||inhibitor-1-7/NN||plasminogenactivator-6/NN	nsubj||candidate-13/NN||inhibitor-1-7/NN	dep||inhibitor-1-7/NN||pai-1-9/JJ	cop||candidate-13/NN||is-11/VBZ	det||candidate-13/NN||a-12/DT	ccomp||suggested-4/VBN||candidate-13/NN	amod||risk-16/NN||increased-15/VBN	prep_for||candidate-13/NN||risk-16/NN	prep_of||risk-16/NN||diabeticretinopathy-18/NN	diabeticretinopathy-18||plasminogenactivator-6||no_rel||mounting evidence has suggested that plasminogenactivator inhibitor-1 (pai-1) is a candidate for increased risk of diabeticretinopathy.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||measure-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||measure-8/VB||to-7/TO	xcomp||was-6/VBD||measure-8/VB	det||impact-10/NN||the-9/DT	dobj||measure-8/VB||impact-10/NN	det||intervention-14/NN||an-12/DT	amod||intervention-14/NN||educational-13/JJ	prep_of||impact-10/NN||intervention-14/NN	prep_on||measure-8/VB||parents-16/NNS	prep_of||parents-16/NNS||children-18/NNS	vmod||children-18/NNS||taking-19/VBG	dobj||taking-19/VBG||methotrexate-20/NN	appos||methotrexate-20/NN||mtx-22/NN	prep_for||methotrexate-20/NN||juvenileidiopathicarthritis-25/NNS	appos||juvenileidiopathicarthritis-25/NNS||jia-27/NN	jia-27||mtx-22||yes||the purpose of this study was to measure the impact of an educational intervention on parents of children taking methotrexate (mtx) for juvenileidiopathicarthritis (jia).
nn||pylori-2/NNS||helicobacter-1/NN	nsubj||-lrb--3/VBD||pylori-2/NNS	root||ROOT-0/null||-lrb--3/VBD	nn||pylori-5/NNS||h.-4/NN	dobj||-lrb--3/VBD||pylori-5/NNS	amod||infection-7/NN||-rrb--6/JJ	nsubj||appears-8/VBZ||infection-7/NN	nsubj||subvert-10/VB||infection-7/NN	nsubj||upregulates-18/VBZ||infection-7/NN	rcmod||pylori-5/NNS||appears-8/VBZ	aux||subvert-10/VB||to-9/TO	xcomp||appears-8/VBZ||subvert-10/VB	det||mechanism-15/NN||the-11/DT	amod||mechanism-15/NN||human-12/JJ	nn||mechanism-15/NN||iron-13/NN	amod||mechanism-15/NN||regulatory-14/JJ	dobj||subvert-10/VB||mechanism-15/NN	advmod||upregulates-18/VBZ||thus-17/RB	rcmod||pylori-5/NNS||upregulates-18/VBZ	conj_and||appears-8/VBZ||upregulates-18/VBZ	dobj||upregulates-18/VBZ||hepcidin-19/NN	vmod||-lrb--3/VBD||resulting-21/VBG	amod||-rrb--27/NNS||unexplained-23/JJ	amod||-rrb--27/NNS||iron-deficiencyanemia-24/JJ	nn||-rrb--27/NNS||-lrb--25/NN	nn||-rrb--27/NNS||ida-26/NN	prep_in||resulting-21/VBG||-rrb--27/NNS	iron-deficiencyanemia-24||iron-13||yes||helicobacter pylori -lrb- h. pylori -rrb- infection appears to subvert the human iron regulatory mechanism and thus upregulates hepcidin , resulting in unexplained iron-deficiencyanemia -lrb- ida -rrb- .
nsubj||inhibitor-12/NN||sitagliptin-1/NN	cop||inhibitor-12/NN||is-2/VBZ	det||inhibitor-12/NN||a-3/DT	amod||peptidase-4-5/JJ||dipeptidyl-4/JJ	amod||inhibitor-12/NN||peptidase-4-5/JJ	nn||iv-8/NN||dpp-7/NN	dep||inhibitor-12/NN||iv-8/NN	appos||iv-8/NN||cd26-10/NNS	root||ROOT-0/null||inhibitor-12/NN	vmod||inhibitor-12/NN||indicated-13/VBN	prep_for||indicated-13/VBN||treatment-15/NN	prep_of||treatment-15/NN||typeiidiabetes-17/NNS	det||therapy-22/NN||a-19/DT	amod||therapy-22/NN||second-20/JJ	nn||therapy-22/NN||line-21/NN	prep_as||typeiidiabetes-17/NNS||therapy-22/NN	prep_after||indicated-13/VBN||metformin-24/NN	typeiidiabetes-17||sitagliptin-1||yes||sitagliptin is a dipeptidyl peptidase-4 (dpp iv, cd26) inhibitor indicated for treatment of typeiidiabetes as a second line therapy after metformin.
amod||lato-3/NN||borreliaburgdorferi-1/JJ	amod||lato-3/NN||sensu-2/JJ	nsubj||agent-7/NN||lato-3/NN	cop||agent-7/NN||is-4/VBZ	det||agent-7/NN||the-5/DT	amod||agent-7/NN||causative-6/JJ	root||ROOT-0/null||agent-7/NN	prep_of||agent-7/NN||lymeborreliosis-9/NNS	prep_in||lymeborreliosis-9/NNS||humans-11/NNS	lymeborreliosis-9||borreliaburgdorferi-1||no||borreliaburgdorferi sensu lato is the causative agent of lymeborreliosis in humans.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||concern-4/NN||worldwide-3/JJ	nsubj||is-2/VBZ||concern-4/NN	det||possibility-7/NN||the-6/DT	prep_over||concern-4/NN||possibility-7/NN	det||pandemic-12/NN||a-9/DT	amod||pandemic-12/NN||new-10/JJ	nn||pandemic-12/NN||influenza-11/NN	prep_of||possibility-7/NN||pandemic-12/NN	vmod||pandemic-12/NN||originating-13/VBG	det||influenzaviruses-20/NNS||the-15/DT	advmod||pathogenic-17/JJ||highly-16/RB	amod||influenzaviruses-20/NNS||pathogenic-17/JJ	amod||influenzaviruses-20/NNS||avian-18/JJ	amod||influenzaviruses-20/NNS||h5n1-19/JJ	prep_from||originating-13/VBG||influenzaviruses-20/NNS	h5n1-19||influenzaviruses-20||no||there is worldwide concern over the possibility of a new influenza pandemic originating from the highly pathogenic avian h5n1 influenzaviruses.
nsubj||pathogen-9/NN||denguevirus-1/NNS	appos||denguevirus-1/NNS||denv-3/NNP	cop||pathogen-9/NN||is-5/VBZ	det||pathogen-9/NN||a-6/DT	amod||pathogen-9/NN||serious-7/JJ	amod||pathogen-9/NN||mosquito-borne-8/JJ	root||ROOT-0/null||pathogen-9/NN	vmod||pathogen-9/NN||causing-10/VBG	vmod||pathogen-9/NN||causing-10/VBG	conj_or||causing-10/VBG||causing-10/VBG	amod||burden-14/NN||significant-11/JJ	amod||burden-14/NN||global-12/JJ	nn||burden-14/NN||disease-13/NN	dobj||causing-10/VBG||burden-14/NN	preconj||causing-10/VBG||either-16/CC	amod||denguefever-19/NN||classic-18/JJ	prep_as||causing-10/VBG||denguefever-19/NN	appos||denguefever-19/NN||df-21/NN	poss||denguehemorrhagicfever-29/NN||its-25/PRP$	advmod||severe-27/JJ||most-26/RBS	amod||denguehemorrhagicfever-29/NN||severe-27/JJ	amod||denguehemorrhagicfever-29/NN||manifestation-28/JJ	prep_in||causing-10/VBG||denguehemorrhagicfever-29/NN	appos||denguehemorrhagicfever-29/NN||dhf-31/NN	denguefever-19||denguevirus-1||no||denguevirus (denv) is a serious mosquito-borne pathogen causing significant global disease burden, either as classic denguefever (df) or in its most severe manifestation denguehemorrhagicfever (dhf).
det||contrary-3/NN||the-2/DT	prep_on||tgf-î-40/VBZ||contrary-3/NN	amod||injections-7/NNS||triple-5/JJ	nn||injections-7/NNS||i.p.-6/NN	nsubj||tgf-î-40/VBZ||injections-7/NNS	num||hours-10/NNS||24-9/CD	npadvmod||apart-11/RB||hours-10/NNS	advmod||injections-7/NNS||apart-11/RB	num||î-15/NN||10-14/CD	prep_of||injections-7/NNS||î-15/NN	num||ejhe-18/NN||1/4-16/CD	nn||ejhe-18/NN||g-17/NN	nsubj||increased-19/VBD||ejhe-18/NN	rcmod||î-15/NN||increased-19/VBD	advmod||ifn-î-21/JJ||significantly-20/RB	amod||production-23/NN||ifn-î-21/JJ	amod||production-23/NN||³-22/JJ	dobj||increased-19/VBD||production-23/NN	det||p-28/NN||the-25/DT	amod||p-28/NN||spleen-26/JJ	amod||p-28/NN||-lrb--27/JJ	prep_in||increased-19/VBD||p-28/NN	vmod||p-28/NN||<-29/VBG	num||-rrb--31/NNS||0.02-30/CD	dobj||<-29/VBG||-rrb--31/NNS	mark||increased-35/VBD||while-32/IN	advmod||ejhe-wr-34/NN||only-33/RB	nsubj||increased-35/VBD||ejhe-wr-34/NN	advcl||<-29/VBG||increased-35/VBD	advmod||ifn-î-37/JJ||significantly-36/RB	amod||³-38/NNS||ifn-î-37/JJ	dobj||increased-35/VBD||³-38/NNS	root||ROOT-0/null||tgf-î-40/VBZ	number||1-42/CD||²-41/CD	dobj||tgf-î-40/VBZ||1-42/CD	amod||<-47/NNS||il-17-44/JJ	amod||<-47/NNS||-lrb--45/JJ	nn||<-47/NNS||p-46/NN	dobj||tgf-î-40/VBZ||<-47/NNS	conj_and||1-42/CD||<-47/NNS	dep||<-47/NNS||0.03-48/CD	num||production-52/NN||0.005-50/CD	amod||production-52/NN||-rrb--51/JJ	dep||<-47/NNS||production-52/NN	det||microenvironment-56/NN||the-54/DT	nn||microenvironment-56/NN||tumor-55/NN	prep_within||production-52/NN||microenvironment-56/NN	amod||fibrosarcoma-59/NN||meth-a-58/JJ	prep_of||microenvironment-56/NN||fibrosarcoma-59/NN	ifn--1||tumor-55||no_rel||on the contrary , triple i.p. injections , 24 hours apart ; of 10 î 1/4 g ejhe increased significantly ifn-î ³ production in the spleen -lrb- p < 0.02 -rrb- while only ejhe-wr increased significantly ifn-î ³ , tgf-î ² 1 and il-17 -lrb- p < 0.03 - 0.005 -rrb- production within the tumor microenvironment of meth-a fibrosarcoma .
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	infectiousmononucleosis-12||epstein-barrvirus-4||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
amod||agents-3/NNS||transfusion-transmissible-1/JJ	amod||agents-3/NNS||infectious-2/JJ	nsubj||are-23/VBP||agents-3/NNS	prep_such_as||agents-3/NNS||humanimmunodeficiencyvirus-6/NNS	appos||humanimmunodeficiencyvirus-6/NNS||hiv-8/NN	prep_such_as||agents-3/NNS||hepatitisbvirus-11/NNS	conj_and||humanimmunodeficiencyvirus-6/NNS||hepatitisbvirus-11/NNS	appos||hepatitisbvirus-11/NNS||hbv-13/NN	amod||virus-17/NN||hepatitisc-16/JJ	prep_such_as||agents-3/NNS||virus-17/NN	conj_and||humanimmunodeficiencyvirus-6/NNS||virus-17/NN	appos||virus-17/NN||hcv-19/NN	prep_such_as||agents-3/NNS||syphilis-22/NNS	conj_and||humanimmunodeficiencyvirus-6/NNS||syphilis-22/NNS	root||ROOT-0/null||are-23/VBP	det||threats-27/NNS||the-25/DT	amod||threats-27/NNS||greatest-26/JJS	prep_among||are-23/VBP||threats-27/NNS	nn||safety-30/NN||blood-29/NN	prep_to||threats-27/NNS||safety-30/NN	det||recipient-33/JJ||the-32/DT	prep_for||safety-30/NN||recipient-33/JJ	hbv-13||hepatitisbvirus-11||no||transfusion-transmissible infectious agents such as humanimmunodeficiencyvirus (hiv), hepatitisbvirus (hbv), hepatitisc virus (hcv) and syphilis are among the greatest threats to blood safety for the recipient.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||implemented-11/VBN||treatment-3/NN	prep_with||treatment-3/NN||sulphadoxine-pyrimethamine-5/NN	appos||treatment-3/NN||iptp-sp-7/NN	aux||implemented-11/VBN||is-9/VBZ	auxpass||implemented-11/VBN||being-10/VBG	root||ROOT-0/null||implemented-11/VBN	advmod||malaria-14/JJ||most-13/RBS	amod||countries-16/NNS||malaria-14/JJ	amod||countries-16/NNS||endemic-15/JJ	prep_in||implemented-11/VBN||countries-16/NNS	det||regimen-21/NN||a-18/DT	amod||regimen-21/NN||standard-19/JJ	amod||regimen-21/NN||two-doses-20/JJ	prep_as||countries-16/NNS||regimen-21/NN	mark||reduces-24/VBZ||as-22/IN	nsubj||reduces-24/VBZ||it-23/PRP	advcl||implemented-11/VBN||reduces-24/VBZ	det||risk-26/NN||the-25/DT	dobj||reduces-24/VBZ||risk-26/NN	amod||weight-30/NN||low-28/JJ	nn||weight-30/NN||birth-29/NN	prep_of||risk-26/NN||weight-30/NN	appos||weight-30/NN||lbw-32/NN	det||prevalence-36/NN||the-35/DT	dobj||reduces-24/VBZ||prevalence-36/NN	conj_and||risk-26/NN||prevalence-36/NN	amod||anaemia-39/NN||maternal-38/JJ	prep_of||prevalence-36/NN||anaemia-39/NN	malaria-14||pyrimethamine--1||yes||intermittent preventive treatment with sulphadoxine-pyrimethamine (iptp-sp) is being implemented in most malaria endemic countries as a standard two-doses regimen as it reduces the risk of low birth weight (lbw) and the prevalence of maternal anaemia.
auxpass||studied-2/VBN||was-1/VBD	root||ROOT-0/null||studied-2/VBN	amod||constipation-5/NN||loperamide-induced-4/JJ	prep_against||studied-2/VBN||constipation-5/NN	nn||rats-8/NNS||wistar-7/NN	prep_in||constipation-5/NN||rats-8/NNS	constipation-5||loperamide--1||no||was studied against loperamide-induced constipation in wistar rats.
det||data-2/NNS||these-1/DT	nsubj||suggest-3/VBP||data-2/NNS	nsubj||are-25/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||derive-9/VB||that-4/IN	amod||patients-7/NNS||normal-weight-5/JJ	amod||patients-7/NNS||type2diabetes-6/JJ	nsubj||derive-9/VB||patients-7/NNS	aux||derive-9/VB||would-8/MD	ccomp||suggest-3/VBP||derive-9/VB	det||benefits-12/NNS||the-10/DT	amod||benefits-12/NNS||same-11/JJ	dobj||derive-9/VB||benefits-12/NNS	amod||treatment-15/NN||first-line-14/JJ	prep_from||benefits-12/NNS||treatment-15/NN	prep_with||derive-9/VB||metformin-17/NN	nn||patients-22/NNS||overweight-19/NN	conj_and||overweight-19/NN||obese-21/NN	nn||patients-22/NNS||obese-21/NN	prep_as||derive-9/VB||patients-22/NNS	conj_and||suggest-3/VBP||are-25/VBP	neg||are-25/VBP||not-26/RB	amod||risk-29/NN||increased-28/VBN	prep_at||not-26/RB||risk-29/NN	amod||loss-33/NN||excess-31/JJ	nn||loss-33/NN||weight-32/NN	prep_of||risk-29/NN||loss-33/NN	type2diabetes-6||metformin-17||yes||these data suggest that normal-weight type2diabetes patients would derive the same benefits from first-line treatment with metformin as overweight and obese patients, and are not at increased risk of excess weight loss.
amod||a-16-2/NN||coxsackievirus-1/JJ	nsubj||agent-8/NN||a-16-2/NN	dep||a-16-2/NN||cva-16-4/JJ	cop||agent-8/NN||is-6/VBZ	det||agent-8/NN||the-7/DT	root||ROOT-0/null||agent-8/NN	nn||foot-12/NN||hand-10/NN	prep_of||agent-8/NN||foot-12/NN	nn||disease-16/NN||mouth-15/NN	prep_of||agent-8/NN||disease-16/NN	conj_and||foot-12/NN||disease-16/NN	prep_in||agent-8/NN||children-18/NNS	hand-10||foot-12||no||coxsackievirus a-16 (cva-16) is the agent of hand, foot, and mouth disease in children.
nsubj||believe-2/VBP||we-1/PRP	root||ROOT-0/null||believe-2/VBP	mark||have-20/VB||that-3/IN	poss||results-5/NNS||our-4/PRP$	nsubj||have-20/VB||results-5/NNS	nsubj||demonstrate-33/VB||results-5/NNS	prepc_besides||results-5/NNS||shedding-8/VBG	dobj||shedding-8/VBG||light-9/NN	det||mechanism-12/NN||the-11/DT	prep_on||shedding-8/VBG||mechanism-12/NN	amod||resistance-15/NN||chloroquine-14/JJ	prep_of||mechanism-12/NN||resistance-15/NN	nn||falciparum-18/NN||p.-17/NN	prep_in||resistance-15/NN||falciparum-18/NN	ccomp||believe-2/VBP||have-20/VB	dobj||have-20/VB||implications-21/NNS	det||development-24/NN||the-23/DT	prep_for||implications-21/NNS||development-24/NN	nn||therapies-27/NNS||novel-26/NN	prep_of||development-24/NN||therapies-27/NNS	amod||strains-31/NNS||resistant-29/JJ	nn||strains-31/NNS||malaria-30/NN	prep_against||therapies-27/NNS||strains-31/NNS	ccomp||believe-2/VBP||demonstrate-33/VB	conj_and||have-20/VB||demonstrate-33/VB	det||usefulness-35/NN||the-34/DT	dobj||demonstrate-33/VB||usefulness-35/NN	det||approach-38/NN||an-37/DT	prep_of||usefulness-35/NN||approach-38/NN	vmod||approach-38/NN||combining-39/VBG	dobj||combining-39/VBG||systems-40/NNS	nn||strategies-42/NNS||biology-41/NN	dobj||have-20/VB||strategies-42/NNS	amod||bioinformatics-45/NNS||structural-44/JJ	prep_with||have-20/VB||bioinformatics-45/NNS	amod||data-48/NNS||experimental-47/JJ	prep_with||have-20/VB||data-48/NNS	conj_and||bioinformatics-45/NNS||data-48/NNS	malaria-30||chloroquine-14||yes||we believe that our results , besides shedding light on the mechanism of chloroquine resistance in p. falciparum , have implications for the development of novel therapies against resistant malaria strains and demonstrate the usefulness of an approach combining systems biology strategies with structural bioinformatics and experimental data .
prep_as||taken-20/VBN||part-2/NN	det||study-7/NN||a-4/DT	nn||study-7/NN||household-5/NN	nn||study-7/NN||contact-6/NN	prep_of||part-2/NN||study-7/NN	nn||infection-10/NN||mtb-9/NN	prep_of||study-7/NN||infection-10/NN	prep_of||study-7/NN||disease-12/NN	conj_and||infection-10/NN||disease-12/NN	prep_in||study-7/NN||kampala-14/NN	appos||kampala-14/NN||uganda-16/NN	nsubj||taken-20/VBN||we-18/PRP	aux||taken-20/VBN||have-19/VBP	root||ROOT-0/null||taken-20/VBN	det||approach-23/NN||a-21/DT	amod||approach-23/NN||unique-22/JJ	dobj||taken-20/VBN||approach-23/NN	det||study-26/NN||the-25/DT	prep_to||taken-20/VBN||study-26/NN	amod||susceptibility-29/NN||genetic-28/JJ	prep_of||study-26/NN||susceptibility-29/NN	prep_to||taken-20/VBN||tb-31/NN	prepc_by||taken-20/VBN||studying-34/VBG	num||phenotypes-36/NNS||three-35/CD	dobj||studying-34/VBG||phenotypes-36/NNS	tb-31||mtb-9||no||as part of a household contact study of mtb infection and disease in kampala, uganda, we have taken a unique approach to the study of genetic susceptibility to tb, by studying three phenotypes.
mark||expressed-8/VBD||while-1/IN	det||lines-7/NNS||the-2/DT	num||lines-7/NNS||three-3/CD	amod||lines-7/NNS||cervical-4/JJ	nn||lines-7/NNS||cancer-5/NN	nn||lines-7/NNS||cell-6/NN	nsubj||expressed-8/VBD||lines-7/NNS	advcl||enzymes-24/NNS||expressed-8/VBD	num||mmps-11/NNS||10-14-9/CD	amod||mmps-11/NNS||different-10/JJ	dobj||expressed-8/VBD||mmps-11/NNS	det||expression-15/NN||the-13/DT	amod||expression-15/NN||median-14/JJ	nsubj||enzymes-24/NNS||expression-15/NN	nn||cells-20/NNS||endometrial-17/NN	conj_and||endometrial-17/NN||choriocarcinoma-19/NN	nn||cells-20/NNS||choriocarcinoma-19/NN	prep_in||expression-15/NN||cells-20/NNS	cop||enzymes-24/NNS||was-21/VBD	num||enzymes-24/NNS||7-22/CD	amod||enzymes-24/NNS||different-23/JJ	root||ROOT-0/null||enzymes-24/NNS	enzymes-24||cancer-5||no_rel||while the three cervical cancer cell lines expressed 10-14 different mmps, the median expression in endometrial and choriocarcinoma cells was 7 different enzymes.
advmod||indicator-12/NN||thus-1/RB	amod||state-4/NN||hypothyroid-3/JJ	nsubj||indicator-12/NN||state-4/NN	nsubj||provoke-19/VB||state-4/NN	amod||period-7/NN||mid-dry-6/JJ	prep_during||state-4/NN||period-7/NN	aux||indicator-12/NN||may-8/MD	cop||indicator-12/NN||be-9/VB	det||indicator-12/NN||an-10/DT	amod||indicator-12/NN||early-11/JJ	root||ROOT-0/null||indicator-12/NN	amod||liver-16/NN||postpartal-14/JJ	amod||liver-16/NN||fatty-15/JJ	prep_of||indicator-12/NN||liver-16/NN	aux||provoke-19/VB||may-18/MD	conj_and||indicator-12/NN||provoke-19/VB	amod||increase-22/NN||t3/t4-20/JJ	nn||increase-22/NN||ratio-21/NN	dobj||provoke-19/VB||increase-22/NN	det||group-25/NN||this-24/DT	prep_in||provoke-19/VB||group-25/NN	prep_of||group-25/NN||cows-27/NNS	hypothyroid-3||t3--1||yes||thus, hypothyroid state during mid-dry period may be an early indicator of postpartal fatty liver and may provoke t3/t4 ratio increase in this group of cows.
advmod||©-2/VBG||â-1/RB	root||ROOT-0/null||©-2/VBG	num||wiley-5/NN||2010-3/CD	nn||wiley-5/NN||john-4/NN	dobj||©-2/VBG||wiley-5/NN	dobj||©-2/VBG||sons-7/NNS	conj_and||wiley-5/NN||sons-7/NNS	dep||©-2/VBG||a/s-8/VBP	aux||elucidate-10/VB||to-9/TO	xcomp||a/s-8/VBP||elucidate-10/VB	det||mechanisms-12/NNS||the-11/DT	dobj||elucidate-10/VB||mechanisms-12/NNS	amod||bronchialasthma-16/NN||intractable-14/JJ	amod||bronchialasthma-16/NN||pediatric-15/JJ	prep_of||mechanisms-12/NNS||bronchialasthma-16/NN	det||indication-19/NN||the-18/DT	dobj||elucidate-10/VB||indication-19/NN	conj_and||mechanisms-12/NNS||indication-19/NN	amod||erythromycin-22/NN||low-dose-21/JJ	prep_of||indication-19/NN||erythromycin-22/NN	dep||©-2/VBG||em-24/NN	dep||©-2/VBG||therapy-26/NN	det||serum-29/NN||the-28/DT	npadvmod||chemokine-30/JJ||serum-29/NN	amod||levels-31/NNS||chemokine-30/JJ	appos||therapy-26/NN||levels-31/NNS	nsubjpass||treated-56/VBN||levels-31/NNS	cc||evaluated-38/VBN||and-33/CC	det||factor-36/NN||the-34/DT	amod||factor-36/NN||angiogenic-35/JJ	nsubjpass||evaluated-38/VBN||factor-36/NN	auxpass||evaluated-38/VBN||were-37/VBD	dep||levels-31/NNS||evaluated-38/VBN	num||patients-42/NNS||55-40/CD	amod||patients-42/NNS||pediatric-41/JJ	prep_in||evaluated-38/VBN||patients-42/NNS	prep_with||patients-42/NNS||bronchialasthma-44/NN	num||â-47/NN||7.4-46/CD	dep||patients-42/NNS||â-47/NN	prep_of||levels-31/NNS||±-48/NNP	num||±-48/NNP||3.5-49/CD	advmod||old-51/JJ||yr-50/RB	amod||levels-31/NNS||old-51/JJ	aux||treated-56/VBN||had-54/VBD	auxpass||treated-56/VBN||been-55/VBN	rcmod||levels-31/NNS||treated-56/VBN	amod||steroid-59/NN||inhaled-58/JJ	prep_with||treated-56/VBN||steroid-59/NN	amod||antagonist-63/NN||leukotriene-61/JJ	nn||antagonist-63/NN||receptor-62/NN	prep_with||treated-56/VBN||antagonist-63/NN	conj_and||steroid-59/NN||antagonist-63/NN	prep_with||treated-56/VBN||theophylline-65/NN	conj_and||steroid-59/NN||theophylline-65/NN	prep_with||treated-56/VBN||others-67/NNS	conj_and||steroid-59/NN||others-67/NNS	mwe||than-70/IN||more-69/JJR	quantmod||a-71/DT||than-70/IN	prep_for||treated-56/VBN||a-71/DT	tmod||treated-56/VBN||year-72/NN	bronchialasthma-44||theophylline-65||yes||â© 2010 john wiley & sons a/s to elucidate the mechanisms of intractable pediatric bronchialasthma and the indication of low-dose erythromycin (em) therapy, the serum chemokine levels of and the angiogenic factor were evaluated in 55 pediatric patients with bronchialasthma; 7.4 â± 3.5 yr old, who had been treated with inhaled steroid, leukotriene receptor antagonist, theophylline and others for more than a year.
nsubj||drug-5/NN||chloroquine-1/NN	aux||drug-5/NN||has-2/VBZ	cop||drug-5/NN||been-3/VBN	det||drug-5/NN||the-4/DT	root||ROOT-0/null||drug-5/NN	prep_of||drug-5/NN||choice-7/NN	det||treatment-10/NN||the-9/DT	prep_for||drug-5/NN||treatment-10/NN	prep_of||treatment-10/NN||malaria-12/NN	amod||decades-15/NNS||many-14/JJ	prep_for||malaria-12/NN||decades-15/NNS	malaria-12||chloroquine-1||yes||chloroquine has been the drug of choice for the treatment of malaria for many decades.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	acomp||reviews-3/VBZ||available-4/JJ	amod||data-8/NNS||preclinical-5/JJ	conj_and||preclinical-5/JJ||clinical-7/JJ	amod||data-8/NNS||clinical-7/JJ	dep||available-4/JJ||data-8/NNS	prep_of||data-8/NNS||posaconazole-10/NN	xcomp||reviews-3/VBZ||focusing-12/VBG	poss||role-15/NN||its-14/PRP$	prep_on||focusing-12/VBG||role-15/NN	det||teatment-18/NN||the-17/DT	prep_in||role-15/NN||teatment-18/NN	amod||fungalinfections-22/NNS||refractory-20/JJ	nn||fungalinfections-22/NNS||invasive-21/NN	prep_of||teatment-18/NN||fungalinfections-22/NNS	fungalinfections-22||posaconazole-10||yes||this article reviews available preclinical and clinical data of posaconazole, focusing on its role in the teatment of refractory invasive fungalinfections.
prepc_based_on||used-14/VBN||on-2/IN	det||study-4/NN||this-3/DT	pobj||used-14/VBN||study-4/NN	nsubjpass||used-14/VBN||ceftriaxone-6/NN	conj_and||ceftriaxone-6/NN||cefixime-8/NN	nsubjpass||used-14/VBN||cefixime-8/NN	conj_and||ceftriaxone-6/NN||spectinomycin-11/NN	nsubjpass||used-14/VBN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	root||ROOT-0/null||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	nn||pakistan-25/NN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||pakistan-25/NN||bhutan-28/NN	mark||be-43/VB||whereas-30/IN	nsubj||be-43/VB||ciprofloxacin-31/NN	appos||ciprofloxacin-31/NN||penicilling-33/NN	appos||ciprofloxacin-31/NN||tetracycline-35/NN	conj_and||penicilling-33/NN||tetracycline-35/NN	appos||ciprofloxacin-31/NN||erythromycin-37/NN	conj_and||penicilling-33/NN||erythromycin-37/NN	appos||ciprofloxacin-31/NN||azithromycin-40/NN	conj_and||penicilling-33/NN||azithromycin-40/NN	aux||be-43/VB||should-41/MD	neg||be-43/VB||not-42/RB	rcmod||pakistan-25/NN||be-43/VB	gonorrhoea-21||erythromycin-37||yes||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicilling, tetracycline, erythromycin, and azithromycin should not be.
advmod||represent-8/VB||overall-1/RB	det||line-6/NN||the-3/DT	nn||line-6/NN||hab-4/NN	nn||line-6/NN||mouse-5/NN	nsubj||represent-8/VB||line-6/NN	aux||represent-8/VB||may-7/MD	root||ROOT-0/null||represent-8/VB	det||model-11/NN||an-9/DT	amod||model-11/NN||interesting-10/JJ	dobj||represent-8/VB||model-11/NN	appos||model-11/NN||i-13/NNP	prepc_for||represent-8/VB||identifying-16/VBG	amod||factors-18/NNS||biological-17/JJ	dobj||identifying-16/VBG||factors-18/NNS	vmod||factors-18/NNS||underlying-19/VBG	amod||responses-23/NNS||misguided-20/JJ	amod||responses-23/NNS||conditioned-21/JJ	nn||responses-23/NNS||fear-22/NN	dobj||underlying-19/VBG||responses-23/NNS	dobj||underlying-19/VBG||ii-26/NN	conj_and||responses-23/NNS||ii-26/NN	prepc_for||underlying-19/VBG||studying-29/VBG	amod||pharmacotherapies-32/NNS||novel-30/JJ	amod||pharmacotherapies-32/NNS||anxiolytic-31/JJ	dobj||studying-29/VBG||pharmacotherapies-32/NNS	prep_for||studying-29/VBG||patients-34/NNS	amod||disorders-37/NNS||fear-associated-36/JJ	prep_with||patients-34/NNS||disorders-37/NNS	amod||disorder-42/NN||post-traumatic-40/JJ	nn||disorder-42/NN||stress-41/NN	prep_including||represent-8/VB||disorder-42/NN	prep_including||represent-8/VB||phobias-44/NNP	conj_and||disorder-42/NN||phobias-44/NNP	phobias-44||anxiolytic-31||no_rel||overall, the hab mouse line may represent an interesting model (i) for identifying biological factors underlying misguided conditioned fear responses and (ii) for studying novel anxiolytic pharmacotherapies for patients with fear-associated disorders, including post-traumatic stress disorder and phobias.
nsubj||opened-3/VBN||this-1/DT	aux||opened-3/VBN||has-2/VBZ	root||ROOT-0/null||opened-3/VBN	det||field-5/NN||the-4/DT	dobj||opened-3/VBN||field-5/NN	det||strand-9/NN||a-7/DT	amod||strand-9/NN||new-8/JJ	prep_to||opened-3/VBN||strand-9/NN	amod||research-12/NN||bisphosphonate-11/JJ	prep_of||strand-9/NN||research-12/NN	vmod||strand-9/NN||focussed-14/VBN	prepc_on||focussed-14/VBN||elucidating-16/VBG	poss||effects-18/NNS||their-17/PRP$	dobj||elucidating-16/VBG||effects-18/NNS	prep_on||elucidating-16/VBG||cells-20/NNS	prep_on||elucidating-16/VBG||components-22/NNS	conj_and||cells-20/NNS||components-22/NNS	det||microenvironment-31/NN||the-24/DT	amod||microenvironment-31/NN||local-25/JJ	conj_and||local-25/JJ||regional-27/JJ	amod||microenvironment-31/NN||regional-27/JJ	conj_and||local-25/JJ||distal-29/JJ	amod||microenvironment-31/NN||distal-29/JJ	nn||microenvironment-31/NN||tumour-30/NN	prep_of||cells-20/NNS||microenvironment-31/NN	bisphosphonate-11||tumour-30||no_rel||this has opened the field to a new strand of bisphosphonate research, focussed on elucidating their effects on cells and components of the local, regional and distal tumour microenvironment.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthma-15||asa-27||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
amod||laboratories-2/NNS||most-1/JJS	nsubj||able-4/JJ||laboratories-2/NNS	nsubj||detect-7/VB||laboratories-2/NNS	cop||able-4/JJ||were-3/VBD	root||ROOT-0/null||able-4/JJ	aux||detect-7/VB||to-5/TO	advmod||detect-7/VB||correctly-6/RB	xcomp||able-4/JJ||detect-7/VB	advmod||relevant-9/JJ||clinically-8/RB	amod||amounts-10/NNS||relevant-9/JJ	dobj||detect-7/VB||amounts-10/NNS	prep_of||amounts-10/NNS||influenzavirus-12/NNS	appos||influenzavirus-12/NNS||h5n1-14/NNP	nsubj||improved-19/VBD||results-18/NNS	conj_and||able-4/JJ||improved-19/VBD	mark||tested-25/VBN||as-20/IN	det||panel-23/NN||each-21/DT	amod||panel-23/NN||subsequent-22/JJ	nsubjpass||tested-25/VBN||panel-23/NN	auxpass||tested-25/VBN||was-24/VBD	advcl||improved-19/VBD||tested-25/VBN	h5n1-14||influenzavirus-12||no||most laboratories were able to correctly detect clinically relevant amounts of influenzavirus (h5n1), and results improved as each subsequent panel was tested.
nsubjpass||known-3/VBN||little-1/RB	auxpass||known-3/VBN||is-2/VBZ	root||ROOT-0/null||known-3/VBN	advmod||improve-7/VB||how-5/WRB	aux||improve-7/VB||to-6/TO	prepc_about||known-3/VBN||improve-7/VB	nn||adherence-9/NN||art-8/NN	dobj||improve-7/VB||adherence-9/NN	amod||countries-13/NNS||many-11/JJ	amod||countries-13/NNS||hiv/aids-affected-12/JJ	prep_in||adherence-9/NN||countries-13/NNS	prep_including||adherence-9/NN||china-16/NN	aids--1||hiv--1||no||little is known about how to improve art adherence in many hiv/aids-affected countries, including china.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||association-4/NN||the-3/DT	dobj||investigated-2/VBD||association-4/NN	det||variant-8/NN||the-6/DT	amod||variant-8/NN||c1858t-7/JJ	prep_of||association-4/NN||variant-8/NN	amod||function-12/NN||residual-10/JJ	amod||function-12/NN||beta-cell-11/JJ	prep_with||investigated-2/VBD||function-12/NN	advmod||assessed-15/JJ||as-14/RB	dep||function-12/NN||assessed-15/JJ	amod||hba1c-24/NNS||stimulated-17/JJ	nn||hba1c-24/NNS||c-peptide-18/NN	conj_and||c-peptide-18/NN||proinsulin-20/NN	nn||hba1c-24/NNS||proinsulin-20/NN	conj_and||c-peptide-18/NN||insulin-22/NN	nn||hba1c-24/NNS||insulin-22/NN	nn||hba1c-24/NNS||dose-adjusted-23/NN	prep_by||assessed-15/JJ||hba1c-24/NNS	amod||control-28/NN||glycemic-27/JJ	prep_with||investigated-2/VBD||control-28/NN	conj_and||function-12/NN||control-28/NN	amod||requirements-32/NNS||daily-30/JJ	nn||requirements-32/NNS||insulin-31/NN	prep_with||investigated-2/VBD||requirements-32/NNS	conj_and||function-12/NN||requirements-32/NNS	prep_with||investigated-2/VBD||diabeticketoacidosis-34/NNS	conj_and||function-12/NN||diabeticketoacidosis-34/NNS	appos||diabeticketoacidosis-34/NNS||dka-36/NN	amod||autoantibodies-40/NNS||diabetes-related-39/JJ	prep_with||investigated-2/VBD||autoantibodies-40/NNS	conj_and||function-12/NN||autoantibodies-40/NNS	nn||ica-46/NN||ia-2a-42/NN	dep||ica-46/NN||gada-44/NN	appos||autoantibodies-40/NNS||ica-46/NN	dep||ica-46/NN||znt8ab-48/NNP	prep_in||investigated-2/VBD||children-51/NNS	det||year-55/NN||the-53/DT	amod||year-55/NN||first-54/JJ	prep_during||children-51/NNS||year-55/NN	prep_after||investigated-2/VBD||diagnosis-57/NN	prep_of||diagnosis-57/NN||type1diabetes-59/CD	type1diabetes-59||insulin-31||yes||we investigated the association of the c1858t variant with residual beta-cell function (as assessed by stimulated c-peptide, proinsulin and insulin dose-adjusted hba1c), glycemic control, daily insulin requirements, diabeticketoacidosis (dka) and diabetes-related autoantibodies (ia-2a, gada, ica, znt8ab) in children during the first year after diagnosis of type1diabetes.
nsubj||alter-7/VB||expression-1/NN	prep_of||expression-1/NN||chemerin-3/NN	aux||alter-7/VB||did-4/VBD	neg||alter-7/VB||not-5/RB	advmod||alter-7/VB||significantly-6/RB	root||ROOT-0/null||alter-7/VB	dobj||alter-7/VB||weight-8/NN	nn||levels-11/NNS||lipid-10/NN	dobj||alter-7/VB||levels-11/NNS	conj_and||weight-8/NN||levels-11/NNS	dobj||alter-7/VB||extent-14/NN	conj_and||weight-8/NN||extent-14/NN	prep_of||extent-14/NN||atherosclerosis-16/NNS	atherosclerosis-16||lipid-10||no_rel||expression of chemerin did not significantly alter weight, lipid levels, and extent of atherosclerosis.
nsubj||result-6/VBP||deficiencies-1/NNS	prep_in||deficiencies-1/NNS||gla-3/FW	prep_in||deficiencies-1/NNS||sda-5/FW	conj_and||gla-3/FW||sda-5/FW	root||ROOT-0/null||result-6/VBP	amod||susceptibility-9/NN||increased-8/VBN	prep_in||result-6/VBP||susceptibility-9/NN	prep_to||susceptibility-9/NN||bacterialinfection-11/NN	nsubjpass||associated-15/VBN||bacterialinfection-11/NN	auxpass||associated-15/VBN||is-14/VBZ	rcmod||bacterialinfection-11/NN||associated-15/VBN	amod||expression-19/NN||reduced-17/VBN	amod||expression-19/NN||basal-18/JJ	prep_with||associated-15/VBN||expression-19/NN	det||number-22/NN||a-21/DT	prep_of||expression-19/NN||number-22/NN	amod||$-26/NNS||immune-specific-24/JJ	amod||$-26/NNS||genesâ-25/JJ	prep_of||number-22/NN||$-26/NNS	dep||â-35/JJ||spp-1-29/JJ	conj_and||â-35/JJ||lys-7-31/JJ	amod||$-36/NNS||lys-7-31/JJ	conj_and||â-35/JJ||lys-2-34/JJ	amod||$-36/NNS||lys-2-34/JJ	amod||$-36/NNS||â-35/JJ	prep_including||$-26/NNS||$-36/NNS	nsubj||encode-39/VBP||$-36/NNS	rcmod||$-36/NNS||encode-39/VBP	amod||peptides-41/NNS||antimicrobial-40/JJ	dobj||encode-39/VBP||peptides-41/NNS	lys--1||gla-3||no_rel||deficiencies in gla and sda result in increased susceptibility to bacterialinfection, which is associated with reduced basal expression of a number of immune-specific genesâ€”including spp-1 , lys-7 , and lys-2 â€”that encode antimicrobial peptides.
num||hundred-2/CD||one-1/CD	nsubjpass||randomized-18/VBN||hundred-2/CD	nsubj||receive-20/VB||hundred-2/CD	amod||women-5/NNS||thirty-seven-4/JJ	conj_and||hundred-2/CD||women-5/NNS	nsubjpass||randomized-18/VBN||women-5/NNS	nsubj||receive-20/VB||women-5/NNS	num||utis-11/NNS||two-7/CD	conj_or||two-7/CD||more-9/JJR	num||utis-11/NNS||more-9/JJR	amod||utis-11/NNS||antibiotic-treated-10/JJ	prep_with||women-5/NNS||utis-11/NNS	det||months-16/NNS||the-13/DT	amod||months-16/NNS||previous-14/JJ	num||months-16/NNS||12-15/CD	prep_in||utis-11/NNS||months-16/NNS	auxpass||randomized-18/VBN||were-17/VBD	root||ROOT-0/null||randomized-18/VBN	aux||receive-20/VB||to-19/TO	xcomp||randomized-18/VBN||receive-20/VB	det||mg-23/NN||either-21/DT	num||mg-23/NN||500-22/CD	dobj||receive-20/VB||mg-23/NN	nn||extract-26/NNS||cranberry-25/NN	prep_of||mg-23/NN||extract-26/NNS	num||mg-29/NN||100-28/CD	dobj||receive-20/VB||mg-29/NN	conj_or||mg-23/NN||mg-29/NN	prep_of||mg-29/NN||trimethoprim-31/NN	num||months-34/NNS||6-33/CD	prep_for||receive-20/VB||months-34/NNS	utis-11||trimethoprim-31||yes||one hundred and thirty-seven women with two or more antibiotic-treated utis in the previous 12 months were randomized to receive either 500 mg of cranberry extract or 100 mg of trimethoprim for 6 months.
det||screen-3/NN||a-2/DT	prep_during||identified-28/VBN||screen-3/NN	prep_for||screen-3/NN||molecules-5/NNS	nsubj||activate-7/VBP||molecules-5/NNS	rcmod||molecules-5/NNS||activate-7/VBP	det||ahr-9/NN||the-8/DT	dobj||activate-7/VBP||ahr-9/NN	nsubjpass||identified-28/VBN||leflunomide-11/NN	det||drug-15/NN||an-13/DT	amod||drug-15/NN||immunomodulatory-14/JJ	appos||leflunomide-11/NN||drug-15/NN	advmod||used-17/VBN||presently-16/RB	vmod||drug-15/NN||used-17/VBN	det||clinic-20/NN||the-19/DT	prep_in||used-17/VBN||clinic-20/NN	det||treatment-23/NN||the-22/DT	prep_for||clinic-20/NN||treatment-23/NN	prep_of||treatment-23/NN||rheumatoidarthritis-25/NNS	auxpass||identified-28/VBN||was-27/VBD	root||ROOT-0/null||identified-28/VBN	det||agonist-32/NN||an-30/DT	nn||agonist-32/NN||ahr-31/NN	prep_as||identified-28/VBN||agonist-32/NN	rheumatoidarthritis-25||leflunomide-11||yes||during a screen for molecules that activate the ahr, leflunomide, an immunomodulatory drug presently used in the clinic for the treatment of rheumatoidarthritis, was identified as an ahr agonist.
det||series-2/NN||a-1/DT	nsubj||established-8/VBN||series-2/NN	amod||trials-6/NNS||pivotal-4/JJ	amod||trials-6/NNS||clinical-5/JJ	prep_of||series-2/NN||trials-6/NNS	aux||established-8/VBN||have-7/VBP	root||ROOT-0/null||established-8/VBN	det||role-10/NN||a-9/DT	dobj||established-8/VBN||role-10/NN	prep_for||role-10/NN||tmz-12/NN	det||treatment-15/NN||the-14/DT	prep_in||established-8/VBN||treatment-15/NN	amod||astrocytomas-18/NNS||malignant-17/JJ	prep_of||treatment-15/NN||astrocytomas-18/NNS	astrocytomas-18||tmz-12||yes||a series of pivotal clinical trials have established a role for tmz in the treatment of malignant astrocytomas.
det||applicability-3/NN||the-1/DT	amod||applicability-3/NN||clinical-2/JJ	nsubjpass||exemplified-8/VBN||applicability-3/NN	amod||proteasomes-6/NNS||targeting-5/VBG	prep_of||applicability-3/NN||proteasomes-6/NNS	auxpass||exemplified-8/VBN||is-7/VBZ	root||ROOT-0/null||exemplified-8/VBN	det||approval-13/NN||the-10/DT	amod||approval-13/NN||recent-11/JJ	nn||approval-13/NN||fda-12/NN	agent||exemplified-8/VBN||approval-13/NN	det||inhibitor-18/NN||the-15/DT	amod||inhibitor-18/NN||first-16/JJ	nn||inhibitor-18/NN||proteasome-17/NN	prep_of||approval-13/NN||inhibitor-18/NN	appos||inhibitor-18/NN||bortezomib-20/NN	det||treatment-24/NN||the-23/DT	prep_for||exemplified-8/VBN||treatment-24/NN	amod||multiplemyeloma-27/NN||relapsed/refractory-26/JJ	prep_of||treatment-24/NN||multiplemyeloma-27/NN	multiplemyeloma-27||bortezomib-20||yes||the clinical applicability of targeting proteasomes is exemplified by the recent fda approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiplemyeloma.
det||series-4/NN||this-2/DT	amod||series-4/NN||thematic-3/JJ	nsubj||presents-5/VBZ||series-4/NN	root||ROOT-0/null||presents-5/VBZ	det||section-8/NN||a-6/DT	amod||section-8/NN||cross-7/JJ	dobj||presents-5/VBZ||section-8/NN	prepc_of||section-8/NN||cutting-10/VBG	nn||approaches-12/NNS||edge-11/NN	dobj||cutting-10/VBG||approaches-12/NNS	det||goal-15/NN||the-14/DT	prep_with||cutting-10/VBG||goal-15/NN	prepc_of||goal-15/NN||transferring-17/VBG	amod||principles-20/NNS||basic-18/JJ	nn||principles-20/NNS||neuroscience-19/NN	nsubj||bedside-29/JJ||principles-20/NNS	det||laboratory-23/NN||the-22/DT	prep_from||principles-20/NNS||laboratory-23/NN	det||proverbial-26/JJ||the-25/DT	prep_to||laboratory-23/NN||proverbial-26/JJ	xcomp||transferring-17/VBG||bedside-29/JJ	cross-7||basic-18||no_rel||" this thematic series presents a cross section of cutting edge approaches with the goal of transferring basic neuroscience principles from the laboratory to the proverbial ""bedside""."
nsubj||included-4/VBD||methods-1/NNS	det||analysis-3/NN||this-2/DT	dep||methods-1/NNS||analysis-3/NN	root||ROOT-0/null||included-4/VBD	num||patients-6/NNS||6139-5/CD	dobj||included-4/VBD||patients-6/NNS	prep_with||included-4/VBD||type2diabetes-8/NNS	vmod||type2diabetes-8/NNS||receiving-9/VBG	det||mg/day-13/NN||either-10/DT	nn||mg/day-13/NN||sitagliptin-11/NN	num||mg/day-13/NN||100-12/CD	dobj||receiving-9/VBG||mg/day-13/NN	dep||mg/day-13/NN||n-15/VBN	dep||3415-17/CD||=-16/SYM	ccomp||n-15/VBN||3415-17/CD	det||agent-22/NN||a-20/DT	nn||agent-22/NN||comparator-21/NN	dobj||receiving-9/VBG||agent-22/NN	conj_or||mg/day-13/NN||agent-22/NN	dep||agent-22/NN||placebo-24/NN	det||comparator-28/NN||an-26/DT	amod||comparator-28/NN||active-27/JJ	dep||agent-22/NN||comparator-28/NN	conj_or||placebo-24/NN||comparator-28/NN	dep||agent-22/NN||n-31/VBN	dep||2724-33/CD||=-32/SYM	ccomp||n-31/VBN||2724-33/CD	amod||group-36/NN||non-exposed-35/JJ	dobj||n-31/VBN||group-36/NN	parataxis||n-31/VBN||group-36/NN	type2diabetes-8||sitagliptin-11||yes||methods this analysis included 6139 patients with type2diabetes receiving either sitagliptin 100 mg/day (n = 3415) or a comparator agent (placebo or an active comparator) (n = 2724; non-exposed group).
amod||regimens-3/NNS||heterologous-1/JJ	amod||regimens-3/NNS||prime-boost-2/JJ	nsubj||represent-11/VBP||regimens-3/NNS	vmod||regimens-3/NNS||utilizing-4/VBG	dobj||utilizing-4/VBG||bcg-5/NN	det||vaccine-9/NN||a-7/DT	amod||vaccine-9/NN||prime-8/JJ	prep_as||utilizing-4/VBG||vaccine-9/NN	advmod||represent-11/VBP||probably-10/RB	root||ROOT-0/null||represent-11/VBP	det||hope-14/NN||the-12/DT	amod||hope-14/NN||best-13/JJS	dobj||represent-11/VBP||hope-14/NN	det||development-17/NN||the-16/DT	prep_for||hope-14/NN||development-17/NN	amod||tuberculosis-20/JJ||novel-19/JJ	amod||vaccines-24/NNS||tuberculosis-20/JJ	appos||vaccines-24/NNS||tb-22/NN	prep_of||development-17/NN||vaccines-24/NNS	tuberculosis-20||bcg-5||yes||heterologous prime-boost regimens utilizing bcg as a prime vaccine probably represent the best hope for the development of novel tuberculosis (tb) vaccines.
nsubj||classified-9/VBD||two-thirds-1/NNS	det||plhiv-4/NN||the-3/DT	prep_of||two-thirds-1/NNS||plhiv-4/NN	num||%-7/NN||66-6/CD	appos||plhiv-4/NN||%-7/NN	root||ROOT-0/null||classified-9/VBD	dobj||classified-9/VBD||themselves-10/PRP	auxpass||given-13/VBN||being-12/VBG	prepc_with||classified-9/VBD||given-13/VBN	det||aids-15/NNS||an-14/DT	iobj||given-13/VBN||aids-15/NNS	amod||stage-18/NN||advanced-17/JJ	dep||aids-15/NNS||stage-18/NN	prep_of||stage-18/NN||hiv-20/NN	dobj||given-13/VBN||diagnosis-22/NN	num||%-25/NN||48-24/CD	nsubj||were-26/VBD||%-25/NN	ccomp||classified-9/VBD||were-26/VBD	conj_and||classified-9/VBD||were-26/VBD	advmod||were-26/VBD||currently-27/RB	prep_on||were-26/VBD||art-29/NN	num||%-32/NN||35-31/CD	nsubj||were-33/VBD||%-32/NN	conj_and||classified-9/VBD||were-33/VBD	advmod||were-33/VBD||currently-34/RB	det||grant-38/NN||a-36/DT	nn||grant-38/NN||disability-37/NN	prep_on||were-33/VBD||grant-38/NN	prep_for||grant-38/NN||hiv/aids-40/NNS	num||%-44/NN||13-43/CD	prep_for||stopped-50/VBN||%-44/NN	det||grant-47/NN||the-45/DT	nn||grant-47/NN||disability-46/NN	nsubjpass||stopped-50/VBN||grant-47/NN	aux||stopped-50/VBN||had-48/VBD	auxpass||stopped-50/VBN||been-49/VBN	conj_and||classified-9/VBD||stopped-50/VBN	aids-15||hiv-20||no||two-thirds of the plhiv (66%) classified themselves with being given an aids (advanced stage of hiv) diagnosis, 48% were currently on art, 35% were currently on a disability grant for hiv/aids and for 13% the disability grant had been stopped.
advmod||analyzed-4/VBD||first-1/RB	nsubj||analyzed-4/VBD||we-3/PRP	root||ROOT-0/null||analyzed-4/VBD	nsubj||confirmed-6/VBD||culture-5/NN	ccomp||analyzed-4/VBD||confirmed-6/VBD	nn||disease-8/NN||tb-7/NN	dobj||confirmed-6/VBD||disease-8/NN	prepc_compared_to||confirmed-6/VBD||to-10/TO	nn||infection-13/NN||latent-11/NN	nn||infection-13/NN||mtb-12/NN	pobj||confirmed-6/VBD||infection-13/NN	appos||infection-13/NN||ltbi-15/NNP	pobj||confirmed-6/VBD||lack-18/NN	conj_or||infection-13/NN||lack-18/NN	nn||infection-21/NN||mtb-20/NN	prep_of||lack-18/NN||infection-21/NN	tb-7||mtb-20||no||first, we analyzed culture confirmed tb disease compared to latent mtb infection (ltbi) or lack of mtb infection.
nsubj||derivative-6/NN||minocycline-1/NN	cop||derivative-6/NN||is-2/VBZ	det||derivative-6/NN||a-3/DT	amod||derivative-6/NN||semi-synthetic-4/JJ	nn||derivative-6/NN||tetracycline-5/NN	root||ROOT-0/null||derivative-6/NN	advmod||used-8/VBN||commonly-7/RB	vmod||derivative-6/NN||used-8/VBN	det||treatment-11/NN||the-10/DT	prep_in||used-8/VBN||treatment-11/NN	prep_of||treatment-11/NN||acne-13/NN	acne-13||minocycline-1||yes||minocycline is a semi-synthetic tetracycline derivative commonly used in the treatment of acne.
amod||information-2/NN||published-1/VBN	nsubj||limited-22/JJ||information-2/NN	det||use-5/NN||the-4/DT	prep_on||information-2/NN||use-5/NN	amod||chelatingagents-8/NNS||oral-7/JJ	prep_of||use-5/NN||chelatingagents-8/NNS	det||treatment-11/NN||the-10/DT	prep_for||chelatingagents-8/NNS||treatment-11/NN	prep_of||treatment-11/NN||anaemia-13/NN	det||context-16/NN||the-15/DT	prep_in||anaemia-13/NN||context-16/NN	amod||intoxication-20/NN||acute-18/JJ	amod||intoxication-20/NN||lead-19/JJ	prep_of||context-16/NN||intoxication-20/NN	cop||limited-22/JJ||is-21/VBZ	root||ROOT-0/null||limited-22/JJ	anaemia-13||chelatingagents-8||no_rel||published information on the use of oral chelatingagents for the treatment of anaemia in the context of acute lead intoxication is limited.
amod||infection-6/NN||chronichepatitisc-1/JJ	nn||infection-6/NN||virus-2/NN	nn||infection-6/NN||hcv-4/NN	nsubj||represent-10/VBP||infection-6/NN	amod||livercirrhosis-9/NNS||associated-8/JJ	conj_and||infection-6/NN||livercirrhosis-9/NNS	nsubj||represent-10/VBP||livercirrhosis-9/NNS	root||ROOT-0/null||represent-10/VBP	det||factor-14/NN||a-11/DT	amod||factor-14/NN||major-12/JJ	nn||factor-14/NN||risk-13/NN	dobj||represent-10/VBP||factor-14/NN	amod||development-21/NN||hepatocellular-16/JJ	nn||development-21/NN||carcinoma-17/NN	appos||development-21/NN||hcc-19/NN	prep_for||factor-14/NN||development-21/NN	chronichepatitisc-1||hcv-4||no||chronichepatitisc virus (hcv) infection and associated livercirrhosis represent a major risk factor for hepatocellular carcinoma (hcc) development.
nn||markers-6/NNS||hbvdna-1/NN	conj_and||hbvdna-1/NN||other-3/JJ	nn||markers-6/NNS||other-3/JJ	amod||markers-6/NNS||serum-4/JJ	nn||markers-6/NNS||hbv-5/NN	nsubjpass||tested-29/VBN||markers-6/NNS	amod||antigen-10/NN||hepatitisb-8/JJ	amod||antigen-10/NN||e-9/JJ	prep_including||markers-6/NNS||antigen-10/NN	appos||antigen-10/NN||hbeag-12/NN	amod||antibody-17/NN||hepatitisb-15/JJ	nn||antibody-17/NN||core-16/NN	prep_including||markers-6/NNS||antibody-17/NN	conj_and||antigen-10/NN||antibody-17/NN	dep||antibody-17/NN||anti-hbc-19/JJ	amod||antibody-24/NN||hepatitisb-22/JJ	nn||antibody-24/NN||surface-23/NN	prep_including||markers-6/NNS||antibody-24/NN	conj_and||antigen-10/NN||antibody-24/NN	appos||antibody-24/NN||anti-hbs-26/NNS	auxpass||tested-29/VBN||were-28/VBD	root||ROOT-0/null||tested-29/VBN	prepc_among||tested-29/VBN||hbsag-31/VBG	amod||women-34/NNS||positive-32/JJ	amod||women-34/NNS||pregnant-33/JJ	dobj||hbsag-31/VBG||women-34/NNS	hepatitisb-22||hbsag-31||yes||hbvdna and other serum hbv markers including hepatitisb e antigen (hbeag), hepatitisb core antibody (anti-hbc) and hepatitisb surface antibody (anti-hbs) were tested among hbsag positive pregnant women.
nsubj||predict-3/VB||atp-cra-1/NN	aux||predict-3/VB||could-2/MD	root||ROOT-0/null||predict-3/VB	amod||response-5/NN||clinical-4/JJ	dobj||predict-3/VB||response-5/NN	nn||chemotherapy-10/NN||paclitaxel-7/NN	conj_and||paclitaxel-7/NN||cisplatin-9/NN	nn||chemotherapy-10/NN||cisplatin-9/NN	prep_to||predict-3/VB||chemotherapy-10/NN	amod||accuracy-13/NN||high-12/JJ	prep_with||predict-3/VB||accuracy-13/NN	amod||patients-18/NNS||advanced-15/JJ	amod||patients-18/NNS||gastric-16/JJ	nn||patients-18/NNS||cancer-17/NN	prep_in||accuracy-13/NN||patients-18/NNS	cancer-17||atp--1||no_rel||atp-cra could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients.
nsubj||complication-4/NN||diabeticneuropathy-1/NN	cop||complication-4/NN||is-2/VBZ	det||complication-4/NN||a-3/DT	root||ROOT-0/null||complication-4/NN	prep_of||complication-4/NN||diabetesmellitus-6/NNS	nsubj||develops-8/VBZ||diabetesmellitus-6/NNS	rcmod||diabetesmellitus-6/NNS||develops-8/VBZ	quantmod||50-11/CD||about-10/RB	num||%-12/NN||50-11/CD	prep_in||develops-8/VBZ||%-12/NN	prep_of||%-12/NN||people-14/NNS	prep_with||people-14/NNS||diabetes-16/NN	diabeticneuropathy-1||diabetesmellitus-6||no||diabeticneuropathy is a complication of diabetesmellitus that develops in about 50% of people with diabetes.
nsubjpass||recovered-3/VBN||respiratoryinfection-1/NN	auxpass||recovered-3/VBN||was-2/VBD	root||ROOT-0/null||recovered-3/VBN	amod||care-6/NN||supportive-5/JJ	agent||recovered-3/VBN||care-6/NN	nsubjpass||improved-11/VBN||cholestasis-9/NNS	auxpass||improved-11/VBN||was-10/VBD	conj_and||recovered-3/VBN||improved-11/VBN	advmod||improved-11/VBN||slowly-12/RB	amod||feeding-15/NN||sufficient-14/JJ	prep_with||improved-11/VBN||feeding-15/NN	prep_with||improved-11/VBN||supplementation-17/NN	conj_and||feeding-15/NN||supplementation-17/NN	amod||enzymes-21/NNS||pancreatic-19/JJ	nn||enzymes-21/NNS||exocrine-20/NN	prep_of||feeding-15/NN||enzymes-21/NNS	enzymes-21||cholestasis-9||no_rel||respiratoryinfection was recovered by supportive care, and cholestasis was improved slowly with sufficient feeding and supplementation of pancreatic exocrine enzymes.
det||decade-4/NN||the-2/DT	amod||decade-4/NN||past-3/JJ	prep_during||contributed-17/VBN||decade-4/NN	nsubj||contributed-17/VBN||progress-6/NN	amod||therapy-9/NN||endocrine-8/JJ	prep_in||progress-6/NN||therapy-9/NN	det||use-12/NN||the-11/DT	conj_and||progress-6/NN||use-12/NN	nsubj||contributed-17/VBN||use-12/NN	prep_of||use-12/NN||trastuzumab-14/NN	aux||contributed-17/VBN||has-15/VBZ	advmod||contributed-17/VBN||significantly-16/RB	root||ROOT-0/null||contributed-17/VBN	det||decline-20/NN||the-19/DT	prep_to||contributed-17/VBN||decline-20/NN	nn||mortality-24/NN||breast-22/NN	nn||mortality-24/NN||cancer-23/NN	prep_in||decline-20/NN||mortality-24/NN	nn||receptor-positive-27/NN||hormone-26/NN	prep_for||mortality-24/NN||receptor-positive-27/NN	amod||her2-31/NNS||erbb2-29/JJ	prep_in||decline-20/NN||her2-31/NNS	conj_and||mortality-24/NN||her2-31/NNS	amod||cases-35/NNS||positive-34/JJ	prep_in||decline-20/NN||cases-35/NNS	conj_and||mortality-24/NN||cases-35/NNS	prep_in||decline-20/NN||respectively-37/RB	amod||mortality-24/NN||respectively-37/RB	conj_and||mortality-24/NN||respectively-37/RB	cancer-23||hormone-26||no_rel||during the past decade, progress in endocrine therapy and the use of trastuzumab has significantly contributed to the decline in breast cancer mortality for hormone receptor-positive and erbb2 (her2)-positive cases, respectively.
amod||regimens-3/NNS||non-anthracycline-1/JJ	nn||regimens-3/NNS||preoperative-2/NN	nsubj||proposition-8/NN||regimens-3/NNS	cop||proposition-8/NN||are-4/VBP	det||proposition-8/NN||a-5/DT	advmod||interesting-7/JJ||particularly-6/RB	amod||proposition-8/NN||interesting-7/JJ	root||ROOT-0/null||proposition-8/NN	amod||her2-17/NN||human-10/JJ	nn||her2-17/NN||epidermal-11/NN	nn||her2-17/NN||growth-12/NN	nn||her2-17/NN||factor-13/NN	nn||her2-17/NN||receptor-14/NN	num||her2-17/NN||2-15/CD	prep_in||proposition-8/NN||her2-17/NN	amod||cancer-22/NN||positive-20/JJ	nn||cancer-22/NN||breast-21/NN	dep||her2-17/NN||cancer-22/NN	mark||offer-26/VBP||as-24/IN	nsubj||offer-26/VBP||they-25/PRP	nsubjpass||used-33/VBN||they-25/PRP	dep||cancer-22/NN||offer-26/VBP	advmod||cardiotoxicity-28/JJ||less-27/RBR	acomp||offer-26/VBP||cardiotoxicity-28/JJ	advmod||used-33/VBN||thus-30/RB	aux||used-33/VBN||can-31/MD	auxpass||used-33/VBN||be-32/VB	dep||cancer-22/NN||used-33/VBN	conj_and||offer-26/VBP||used-33/VBN	advmod||used-33/VBN||concomitantly-34/RB	amod||therapy-38/NN||preoperative-36/JJ	nn||therapy-38/NN||trastuzumab-37/NN	prep_with||used-33/VBN||therapy-38/NN	cancer-22||trastuzumab-37||no_rel||non-anthracycline preoperative regimens are a particularly interesting proposition in human epidermal growth factor receptor 2 (her2)-positive breast cancer, as they offer less cardiotoxicity and thus can be used concomitantly with preoperative trastuzumab therapy.
det||mutation-3/NN||the-1/DT	amod||mutation-3/NN||d313y-2/JJ	nsubj||resulted-4/VBD||mutation-3/NN	nsubj||decreased-15/VBD||mutation-3/NN	root||ROOT-0/null||resulted-4/VBD	det||activity-10/NN||a-6/DT	amod||activity-10/NN||normal-7/JJ	nn||activity-10/NN||gla-8/NN	nn||activity-10/NN||enzyme-9/NN	prep_in||resulted-4/VBD||activity-10/NN	prep_in||resulted-4/VBD||leukocytes-12/NNS	advmod||decreased-15/VBD||severely-14/RB	conj_and||resulted-4/VBD||decreased-15/VBD	dobj||decreased-15/VBD||activities-16/NNS	prep_in||decreased-15/VBD||plasma-18/NN	enzyme-9||gla-8||no_rel||the d313y mutation resulted in a normal gla enzyme activity in leukocytes and severely decreased activities in plasma.
advmod||added-2/VBD||when-1/WRB	advcl||demonstrates-15/VBZ||added-2/VBD	amod||agents-6/NNS||oral-4/JJ	amod||agents-6/NNS||anti-diabetes-5/JJ	prep_to||added-2/VBD||agents-6/NNS	appos||agents-6/NNS||oads-8/NNS	prep_in||added-2/VBD||type2diabetes-11/CD	nn||detemir-14/NN||insulin-13/NN	nsubj||demonstrates-15/VBZ||detemir-14/NN	root||ROOT-0/null||demonstrates-15/VBZ	dobj||demonstrates-15/VBZ||superiority-16/NN	amod||options-21/NNS||other-18/JJ	amod||options-21/NNS||basal-19/JJ	nn||options-21/NNS||insulin-20/NN	prep_to||demonstrates-15/VBZ||options-21/NNS	type2diabetes-11||insulin-20||yes||when added to oral anti-diabetes agents (oads) in type2diabetes, insulin detemir demonstrates superiority to other basal insulin options.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||unknown-3/JJ	mark||increase-8/VB||whether-4/IN	nsubj||increase-8/VB||exenatide-5/NN	conj_or||exenatide-5/NN||sitagliptin-7/NN	nsubj||increase-8/VB||sitagliptin-7/NN	ccomp||remains-2/VBZ||increase-8/VB	det||risk-10/NN||the-9/DT	dobj||increase-8/VB||risk-10/NN	amod||pancreatitis-13/NNS||acute-12/JJ	prep_of||risk-10/NN||pancreatitis-13/NNS	pancreatitis-13||sitagliptin-7||no_rel||it remains unknown whether exenatide or sitagliptin increase the risk of acute pancreatitis.
det||review-3/NN||a-1/DT	amod||review-3/NN||systematic-2/JJ	nsubjpass||performed-18/VBN||review-3/NN	det||literature-6/NN||the-5/DT	prep_of||review-3/NN||literature-6/NN	amod||weights-9/NNS||hrql-8/JJ	prep_on||literature-6/NN||weights-9/NNS	prep_for||weights-9/NNS||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv/aids-14/NNS	prep_in||hiv/aids-14/NNS||africa-16/NN	auxpass||performed-18/VBN||was-17/VBD	root||ROOT-0/null||performed-18/VBN	det||findings-22/NNS||the-21/DT	nsubjpass||presented-24/VBN||findings-22/NNS	nsubjpass||interpreted-26/VBN||findings-22/NNS	auxpass||presented-24/VBN||are-23/VBP	conj_and||performed-18/VBN||presented-24/VBN	conj_and||performed-18/VBN||interpreted-26/VBN	conj_and||presented-24/VBN||interpreted-26/VBN	aids--1||hiv--1||no||a systematic review of the literature on hrql weights for people living with hiv/aids in africa was performed, and the findings are presented and interpreted.
nsubj||compiled-3/VBN||we-1/PRP	aux||compiled-3/VBN||have-2/VBP	root||ROOT-0/null||compiled-3/VBN	det||experience-6/NN||the-4/DT	nn||experience-6/NN||treatment-5/NN	dobj||compiled-3/VBN||experience-6/NN	num||centers-10/NNS||seven-8/CD	amod||centers-10/NNS||neurosurgical-9/JJ	prep_of||experience-6/NN||centers-10/NNS	vmod||centers-10/NNS||using-11/VBG	dobj||using-11/VBG||implantation-12/NN	amod||wafers-15/NNS||carmustine-14/JJ	prep_of||implantation-12/NN||wafers-15/NNS	amod||surgery-18/NN||primary-17/JJ	prep_at||using-11/VBG||surgery-18/NN	vmod||surgery-18/NN||followed-19/VBN	amod||weeks-22/NNS||6â-21/JJ	agent||followed-19/VBN||weeks-22/NNS	nn||therapy-25/NN||radiation-24/NN	prep_of||weeks-22/NNS||therapy-25/NN	dep||therapy-25/NN||59â-27/NNS	dep||59â-27/NNS||$-28/$	amod||gy-31/NNS||60â-30/JJ	npadvmod||diagnosed-41/RB||gy-31/NNS	cc||gy-31/NNS||and-33/CC	amod||tmz-36/NN||75â-34/JJ	amod||tmz-36/NN||mg/m2/day-35/JJ	dep||gy-31/NNS||tmz-36/NN	prep_in||gy-31/NNS||patients-38/NNS	prep||patients-38/NNS||with-39/IN	pcomp||with-39/IN||newly-40/RB	dep||glioblastoma-42/CD||diagnosed-41/RB	num||$-28/$||glioblastoma-42/CD	vmod||therapy-25/NN||followed-43/VBN	nn||monochemotherapy-46/NN||tmz-45/NN	agent||followed-43/VBN||monochemotherapy-46/NN	glioblastoma-42||carmustine-14||yes||we have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6â weeks of radiation therapy (59â€“60â gy) and 75â mg/m2/day tmz in patients with newly diagnosed glioblastoma followed by tmz monochemotherapy.
amod||patients-2/NNS||many-1/JJ	nsubj||take-5/VBP||patients-2/NNS	prep_with||patients-2/NNS||osteoarthritis-4/NNS	root||ROOT-0/null||take-5/VBP	amod||anti-inflammatorydrugs-7/NNS||nonsteroidal-6/JJ	iobj||take-5/VBP||anti-inflammatorydrugs-7/NNS	appos||term-12/NN||nsaids-9/NNS	amod||term-12/NN||long-11/JJ	dobj||take-5/VBP||term-12/NN	nn||control-15/NN||pain-14/NN	prep_for||term-12/NN||control-15/NN	pain-14||nsaids-9||no_rel||many patients with osteoarthritis take nonsteroidal anti-inflammatorydrugs (nsaids) long term for pain control.
nn||concentrations-3/NNS||serum-1/NN	nn||concentrations-3/NNS||adiponectin-2/NN	nsubjpass||measured-5/VBN||concentrations-3/NNS	auxpass||measured-5/VBN||were-4/VBD	root||ROOT-0/null||measured-5/VBN	num||patients-9/NNS||232-7/CD	amod||patients-9/NNS||fasting-8/JJ	prep_in||measured-5/VBN||patients-9/NNS	amod||liverdisease-12/NN||chronic-11/JJ	prep_with||patients-9/NNS||liverdisease-12/NN	num||liverdisease-12/NN||64-13/CD	amod||-rrb--18/NNS||nafld-15/JJ	amod||-rrb--18/NNS||-lrb--16/JJ	amod||-rrb--18/NNS||non-alcoholicfattyliverdisease-17/JJ	prep_with||liverdisease-12/NN||-rrb--18/NNS	prep_with||patients-9/NNS||123-20/CD	conj_or||liverdisease-12/NN||123-20/CD	amod||hepatitis-28/NNP||other-22/JJ	amod||hepatitis-28/NNP||chronic-23/JJ	nn||hepatitis-28/NNP||liverdisease-24/NN	nn||hepatitis-28/NNP||-lrb--25/NNP	nn||hepatitis-28/NNP||e.g.-26/NNP	nn||hepatitis-28/NNP||viral-27/NNP	prep_with||123-20/CD||hepatitis-28/NNP	prep_with||patients-9/NNS||n-30/NN	conj_or||liverdisease-12/NN||n-30/NN	dep||71-32/CD||=-31/SYM	rcmod||n-30/NN||71-32/CD	prep_with||patients-9/NNS||autoimmunedisease-34/NN	conj_or||liverdisease-12/NN||autoimmunedisease-34/NN	appos||autoimmunedisease-34/NN||n-36/NN	dep||18-38/CD||=-37/SYM	rcmod||n-36/NN||18-38/CD	amod||liverdisease-41/NN||alcohol-induced-40/JJ	prep_with||patients-9/NNS||liverdisease-41/NN	conj_or||liverdisease-12/NN||liverdisease-41/NN	appos||liverdisease-41/NN||n-43/NN	dep||3-45/CD||=-44/SYM	rcmod||n-43/NN||3-45/CD	amod||enzymes-50/NNS||elevated-48/JJ	nn||enzymes-50/NNS||liver-49/NN	prep_with||patients-9/NNS||enzymes-50/NNS	conj_or||liverdisease-12/NN||enzymes-50/NNS	amod||origin-53/NN||unknown-52/JJ	prep_of||enzymes-50/NNS||origin-53/NN	prep_in||measured-5/VBN||n-55/NN	conj_and||patients-9/NNS||n-55/NN	dep||-rrb--58/NNS||=-56/SYM	num||-rrb--58/NNS||31-57/CD	rcmod||n-55/NN||-rrb--58/NNS	prep_in||measured-5/VBN||45-60/CD	conj_and||patients-9/NNS||45-60/CD	prep_with||45-60/CD||cirrhosis-62/NNS	alcoholicfattyliver--1||alcohol--1||no||serum adiponectin concentrations were measured in 232 fasting patients with chronic liverdisease 64 with nafld -lrb- non-alcoholicfattyliverdisease -rrb- , 123 with other chronic liverdisease -lrb- e.g. viral hepatitis , n = 71 ; autoimmunedisease , n = 18 ; alcohol-induced liverdisease , n = 3 ; or elevated liver enzymes of unknown origin , n = 31 -rrb- and 45 with cirrhosis .
mark||involve-13/VBP||although-1/IN	det||manifestations-6/NNS||the-2/DT	advmod||frequent-4/JJ||most-3/RBS	amod||manifestations-6/NNS||frequent-4/JJ	amod||manifestations-6/NNS||extra-pulmonary-5/JJ	nsubj||involve-13/VBP||manifestations-6/NNS	nn||infection-12/NN||respiratorysyncytialvirus-8/NNP	appos||infection-12/NN||rsv-10/NN	prep_of||manifestations-6/NNS||infection-12/NN	advcl||collected-34/VBN||involve-13/VBP	det||system-16/NN||the-14/DT	amod||system-16/NN||cardiovascular-15/JJ	dobj||involve-13/VBP||system-16/NN	neg||data-19/NNS||no-18/DT	nsubjpass||collected-34/VBN||data-19/NNS	nn||function-22/NN||heart-21/NN	prep_regarding||data-19/NNS||function-22/NN	prep_in||function-22/NN||infants-24/NNS	prep_with||infants-24/NNS||bronchiolitis-26/NNS	vmod||bronchiolitis-26/NNS||associated-27/VBN	prep_with||associated-27/VBN||rsvinfection-29/NN	aux||collected-34/VBN||have-30/VBP	advmod||collected-34/VBN||yet-31/RB	auxpass||collected-34/VBN||been-32/VBN	advmod||collected-34/VBN||systematically-33/RB	root||ROOT-0/null||collected-34/VBN	rsvinfection-29||respiratorysyncytialvirus-8||no||although the most frequent extra-pulmonary manifestations of respiratorysyncytialvirus (rsv) infection involve the cardiovascular system, no data regarding heart function in infants with bronchiolitis associated with rsvinfection have yet been systematically collected.
advmod||treated-5/VBN||when-1/WRB	amod||rotavirus-3/NNS||intact-2/JJ	nsubjpass||treated-5/VBN||rotavirus-3/NNS	auxpass||treated-5/VBN||was-4/VBD	advcl||degraded-18/JJ||treated-5/VBN	amod||endonuclease-8/NN||benzonase-7/JJ	prep_with||treated-5/VBN||endonuclease-8/NN	amod||double-stranded-11/NN||genomic-10/JJ	nsubj||degraded-18/JJ||double-stranded-11/NN	appos||double-stranded-11/NN||ds-13/NN	advmod||degraded-18/JJ||rna-15/RB	cop||degraded-18/JJ||was-16/VBD	neg||degraded-18/JJ||not-17/RB	root||ROOT-0/null||degraded-18/JJ	advmod||treated-28/VBN||when-21/WRB	nsubjpass||treated-28/VBN||sera-22/NN	prep_of||sera-22/NN||patients-24/NNS	prep_with||patients-24/NNS||antigenemia-26/NN	auxpass||treated-28/VBN||were-27/VBD	advcl||degraded-36/JJ||treated-28/VBN	amod||endonuclease-31/NN||benzonase-30/JJ	prep_with||treated-28/VBN||endonuclease-31/NN	amod||dsrna-34/NN||genomic-33/JJ	nsubj||degraded-36/JJ||dsrna-34/NN	cop||degraded-36/JJ||was-35/VBD	conj_but||degraded-18/JJ||degraded-36/JJ	xcomp||degraded-36/JJ||indicating-38/VBG	amod||dsrna-40/NN||genomic-39/JJ	nsubj||free-42/JJ||dsrna-40/NN	cop||free-42/JJ||was-41/VBD	ccomp||indicating-38/VBG||free-42/JJ	prep_in||free-42/JJ||sera-44/NN	ccomp||indicating-38/VBG||not-46/RB	conj_and||free-42/JJ||not-46/RB	neg||free-42/JJ||not-46/RB	nn||protein-50/NN||virus-48/NN	nn||protein-50/NN||capsid-49/NN	prep_inside||free-42/JJ||protein-50/NN	ds-13||virus-48||no_rel||when intact rotavirus was treated with benzonase endonuclease, genomic double-stranded (ds) rna was not degraded, but when sera of patients with antigenemia were treated with benzonase endonuclease, genomic dsrna was degraded, indicating genomic dsrna was free in sera and not inside virus capsid protein.
nsubjpass||used-5/VBN||candesartan-1/NN	aux||used-5/VBN||may-2/MD	auxpass||used-5/VBN||be-3/VB	advmod||used-5/VBN||safely-4/RB	root||ROOT-0/null||used-5/VBN	prep_for||used-5/VBN||patients-7/NNS	prep_with||patients-7/NNS||hypertension-9/NN	nn||metabolism-14/NN||lipid-13/NN	prep_with_respect_to||hypertension-9/NN||metabolism-14/NN	mark||small-25/JJ||because-16/IN	det||effect-18/NN||the-17/DT	nsubj||small-25/JJ||effect-18/NN	prep_of||effect-18/NN||candesartan-20/NN	prep_on||candesartan-20/NN||lipids-22/NNS	aux||small-25/JJ||may-23/MD	cop||small-25/JJ||be-24/VB	advcl||used-5/VBN||small-25/JJ	hypertension-9||candesartan-20||yes||candesartan may be safely used for patients with hypertension with respect to lipid metabolism, because the effect of candesartan on lipids may be small.
det||polymorphisms-2/NNS||these-1/DT	nsubj||contribute-5/VB||polymorphisms-2/NNS	aux||contribute-5/VB||might-3/MD	advmod||contribute-5/VB||ultimately-4/RB	root||ROOT-0/null||contribute-5/VB	nn||risk-9/NN||lung-7/NN	nn||risk-9/NN||cancer-8/NN	prep_to||contribute-5/VB||risk-9/NN	poss||effect-12/NN||their-11/PRP$	prep_via||risk-9/NN||effect-12/NN	det||response-18/NN||the-14/DT	amod||response-18/NN||airway-15/JJ	nn||response-18/NN||gene-16/NN	nn||response-18/NN||expression-17/NN	prep_on||effect-12/NN||response-18/NN	amod||exposure-21/NN||tobacco-smoke-20/JJ	prep_to||contribute-5/VB||exposure-21/NN	tobacco--1||cancer-8||no_rel||these polymorphisms might ultimately contribute to lung cancer risk via their effect on the airway gene expression response to tobacco-smoke exposure.
det||organization-4/NN||the-1/DT	nn||organization-4/NN||world-2/NN	nn||organization-4/NN||health-3/NN	nsubj||estimated-6/VBN||organization-4/NN	aux||estimated-6/VBN||has-5/VBZ	root||ROOT-0/null||estimated-6/VBN	mark||develop-12/VBP||that-7/IN	number||million-9/CD||8-8/CD	nsubj||develop-12/VBP||million-9/CD	prep_of||million-9/CD||people-11/NNS	ccomp||estimated-6/VBN||develop-12/VBP	amod||tb-14/NN||active-13/JJ	dobj||develop-12/VBP||tb-14/NN	det||year-16/NN||every-15/DT	tmod||develop-12/VBP||year-16/NN	det||situation-19/NN||the-18/DT	nsubjpass||complicated-21/VBN||situation-19/NN	auxpass||complicated-21/VBN||is-20/VBZ	ccomp||estimated-6/VBN||complicated-21/VBN	conj_and||develop-12/VBP||complicated-21/VBN	det||increase-24/NN||an-23/DT	agent||complicated-21/VBN||increase-24/NN	amod||strains-27/NNS||mycobacteriumtuberculosis-26/JJ	prep_of||increase-24/NN||strains-27/NNS	amod||strains-27/NNS||resistant-28/JJ	prep_to||resistant-28/JJ||drugs-30/NNS	vmod||drugs-30/NNS||used-31/VBN	nn||mdr-35/NN||antitubercular-33/NN	nn||mdr-35/NN||therapy-34/NN	prep_in||used-31/VBN||mdr-35/NN	amod||strains-27/NNS||xdr-tb-37/JJ	conj_and||resistant-28/JJ||xdr-tb-37/JJ	antitubercular-33||tb-14||no_rel||the world health organization has estimated that 8 million of people develop active tb every year and the situation is complicated by an increase of mycobacteriumtuberculosis strains resistant to drugs used in antitubercular therapy mdr and xdr-tb.
vmod||demonstrated-30/VBD||using-1/VBG	det||model-5/NN||an-2/DT	dep||vitro-4/NN||in-3/IN	amod||model-5/NN||vitro-4/NN	dobj||using-1/VBG||model-5/NN	vmod||model-5/NN||designed-6/VBN	aux||recapitulate-8/VB||to-7/TO	xcomp||designed-6/VBN||recapitulate-8/VB	amod||events-10/NNS||cellular-9/JJ	dobj||recapitulate-8/VB||events-10/NNS	vmod||events-10/NNS||implicated-11/VBN	prep_in||implicated-11/VBN||mycobacterialinfection-13/NN	prep_in||implicated-11/VBN||dissemination-15/NN	conj_and||mycobacterialinfection-13/NN||dissemination-15/NN	prep_in||implicated-11/VBN||vivo-17/NN	dep||phagocytosis-21/JJ||i.e.-19/FW	dep||vivo-17/NN||phagocytosis-21/JJ	amod||mycobacteria-26/NN||apoptotic-23/JJ	amod||mycobacteria-26/NN||macrophages-24/JJ	amod||mycobacteria-26/NN||containing-25/JJ	prep_of||phagocytosis-21/JJ||mycobacteria-26/NN	nsubj||demonstrated-30/VBD||we-29/PRP	root||ROOT-0/null||demonstrated-30/VBD	amod||recovery-32/NN||reduced-31/VBN	dobj||demonstrated-30/VBD||recovery-32/NN	amod||mycobacteria-35/NN||viable-34/JJ	prep_of||recovery-32/NN||mycobacteria-35/NN	amod||macrophages-41/NNS||cd36-37/JJ	dep||macrophages-41/NNS||/-39/NNP	prep_within||mycobacteria-35/NN||macrophages-41/NNS	mycobacterialinfection-13||mycobacteria-35||no||using an in vitro model designed to recapitulate cellular events implicated in mycobacterialinfection and dissemination in vivo (i.e., phagocytosis of apoptotic macrophages containing mycobacteria), we demonstrated reduced recovery of viable mycobacteria within cd36 -/- macrophages.
prep_in||review-6/VBP||addition-2/NN	nsubj||review-6/VBP||we-4/PRP	advmod||review-6/VBP||specifically-5/RB	root||ROOT-0/null||review-6/VBP	det||role-8/NN||the-7/DT	dobj||review-6/VBP||role-8/NN	amod||divalproex-11/NN||extended-release-10/JJ	prep_of||role-8/NN||divalproex-11/NN	prep_in||divalproex-11/NN||bipolardisorder-13/NN	det||analysis-17/NN||a-15/DT	amod||analysis-17/NN||critical-16/JJ	prep_through||review-6/VBP||analysis-17/NN	det||literature-24/NN||the-19/DT	advmod||available-21/JJ||currently-20/RB	amod||literature-24/NN||available-21/JJ	amod||literature-24/NN||published-22/JJ	amod||literature-24/NN||primary-23/JJ	prep_of||analysis-17/NN||literature-24/NN	bipolardisorder-13||divalproex-11||yes||in addition, we specifically review the role of extended-release divalproex in bipolardisorder through a critical analysis of the currently available published primary literature.
amod||group-2/NN||hypothyroid-1/JJ	nsubjpass||treated-6/VBN||group-2/NN	prep_of||group-2/NN||mice-4/NNS	auxpass||treated-6/VBN||were-5/VBD	root||ROOT-0/null||treated-6/VBN	num||%-9/NN||0.02-8/CD	prep_with||treated-6/VBN||%-9/NN	amod||%-9/NN||methimazole-10/JJ	prepc_in||methimazole-10/JJ||drinking-12/VBG	nn||group-16/NN||water-13/NN	conj_and||water-13/NN||hyperthyroid-15/JJ	nn||group-16/NN||hyperthyroid-15/JJ	dobj||drinking-12/VBG||group-16/NN	prep_of||group-16/NN||mice-18/NNS	vmod||mice-18/NNS||received-19/VBN	amod||injection-21/NN||intraperitoneal-20/JJ	dobj||received-19/VBN||injection-21/NN	num||î-24/NN||4-23/CD	dep||injection-21/NN||î-24/NN	num||g-26/NN||1/4-25/CD	dep||î-24/NN||g-26/NN	amod||g-26/NN||l-t4-27/JJ	advmod||week-30/NN||twice-28/RB	det||week-30/NN||a-29/DT	tmod||l-t4-27/JJ||week-30/NN	num||weeks-34/NNS||four-33/CD	prep_for||injection-21/NN||weeks-34/NNS	hypothyroid-1||t4--1||yes||hypothyroid group of mice were treated with 0.02% methimazole in drinking water and hyperthyroid group of mice received intraperitoneal injection (4 î¼g l-t4 twice a week) for four weeks.
advmod||active-2/JJ||highly-1/RB	amod||therapy-4/NN||active-2/JJ	amod||therapy-4/NN||antiretroviral-3/JJ	nsubj||changed-9/VBN||therapy-4/NN	appos||therapy-4/NN||haart-6/NN	aux||changed-9/VBN||has-8/VBZ	root||ROOT-0/null||changed-9/VBN	det||face-11/NN||the-10/DT	dobj||changed-9/VBN||face-11/NN	prep_of||face-11/NN||humanimmunodeficiencyvirus-13/NNS	appos||humanimmunodeficiencyvirus-13/NNS||hiv-15/NN	vmod||humanimmunodeficiencyvirus-13/NNS||acquired-17/VBN	amod||syndrome-19/NN||immunedeficiency-18/JJ	dobj||acquired-17/VBN||syndrome-19/NN	appos||syndrome-19/NN||aids-21/NNS	agent||acquired-17/VBN||leading-24/VBG	amod||decreases-27/NNS||dramatic-26/JJ	prep_to||leading-24/VBG||decreases-27/NNS	amod||morbidity-30/NN||hiv-related-29/JJ	prep_in||decreases-27/NNS||morbidity-30/NN	prep_in||decreases-27/NNS||mortality-32/NN	conj_and||morbidity-30/NN||mortality-32/NN	det||developed-35/JJ||the-34/DT	prep_in||leading-24/VBG||developed-35/JJ	agent||acquired-17/VBN||developing-39/VBG	conj_and||leading-24/VBG||developing-39/VBG	dobj||developing-39/VBG||world-40/NN	aids-21||hiv-15||no||highly active antiretroviral therapy (haart) has changed the face of humanimmunodeficiencyvirus (hiv) acquired immunedeficiency syndrome (aids) by leading to dramatic decreases in hiv-related morbidity and mortality in the developed as well as developing world.
amod||supplementation-3/NN||chronic-1/JJ	nn||supplementation-3/NN||leucine-2/NN	nsubj||improves-5/VBZ||supplementation-3/NN	advmod||improves-5/VBZ||significantly-4/RB	root||ROOT-0/null||improves-5/VBZ	amod||control-7/NN||glycemic-6/JJ	dobj||improves-5/VBZ||control-7/NN	amod||models-11/NNS||multiple-9/JJ	nn||models-11/NNS||mouse-10/NN	prep_in||control-7/NN||models-11/NNS	prep_of||models-11/NNS||obesity-13/NN	prep_of||models-11/NNS||diabetes-15/NN	conj_and||obesity-13/NN||diabetes-15/NN	amod||etiologies-18/NNS||distinct-17/JJ	prep_with||improves-5/VBZ||etiologies-18/NNS	obesity-13||leucine-2||no_rel||chronic leucine supplementation significantly improves glycemic control in multiple mouse models of obesity and diabetes with distinct etiologies.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||individuals-4/NNS||425-3/CD	dobj||identified-2/VBD||individuals-4/NNS	vmod||individuals-4/NNS||divided-6/VBN	num||categories-9/NNS||seven-8/CD	prep_into||divided-6/VBN||categories-9/NNS	prepc_according_to||divided-6/VBN||to-11/TO	amod||status-14/NN||carbohydrate-12/JJ	nn||status-14/NN||metabolism-13/NN	pobj||divided-6/VBN||status-14/NN	amod||-RSB--21/NNP||normal-16/JJ	nn||-RSB--21/NNP||glucose-17/NN	nn||-RSB--21/NNP||tolerance-18/NN	nn||-RSB--21/NNP||-LSB--19/NNP	nn||-RSB--21/NNP||ngt-20/FW	dep||individuals-4/NNS||-RSB--21/NNP	amod||glucose-25/NN||impaired-23/VBN	amod||glucose-25/NN||fasting-24/JJ	appos||-RSB--21/NNP||glucose-25/NN	nn||-RSB--30/FW||impairedglucosetolerance-27/FW	nn||-RSB--30/FW||-LSB--28/FW	nn||-RSB--30/FW||igt-29/FW	appos||glucose-25/NN||-RSB--30/FW	advmod||diagnosed-34/VBN||newly-33/RB	amod||type2diabetes-35/NNS||diagnosed-34/VBN	appos||-RSB--21/NNP||type2diabetes-35/NNS	conj_and||glucose-25/NN||type2diabetes-35/NNS	nn||duration-39/NN||diabetes-38/NN	dobj||identified-2/VBD||duration-39/NN	conj_and||individuals-4/NNS||duration-39/NN	dep||duration-39/NN||0â-41/VBN	dobj||0â-41/VBN||$-42/$	num||$-42/$||9-44/CD	amod||$-47/$||10â-46/JJ	appos||$-42/$||$-47/$	num||$-47/$||19-49/CD	amod||‰-53/NNS||â-52/JJ	appos||$-42/$||‰-53/NNS	conj_and||$-47/$||‰-53/NNS	dep||years-56/NNS||¥-54/SYM	num||years-56/NNS||20-55/CD	dep||0â-41/VBN||years-56/NNS	type2diabetes-35||glucose-25||no_rel||we identified 425 individuals, divided into seven categories according to carbohydrate metabolism status (normal glucose tolerance [ngt], impaired fasting glucose, impairedglucosetolerance [igt], and newly diagnosed type2diabetes) and diabetes duration (0â€“9, 10â€“19, and â‰¥20 years).
amod||patients-5/NNS||atrialfibrillation-1/JJ	amod||patients-5/NNS||af-3/JJ	nsubj||anticoagulation-14/NN||patients-5/NNS	det||risk-9/NN||a-7/DT	amod||risk-9/NN||high-8/JJ	prep_with||patients-5/NNS||risk-9/NN	prep_of||risk-9/NN||stroke-11/NN	cop||anticoagulation-14/NN||are-12/VBP	amod||anticoagulation-14/NN||recommended-13/VBN	root||ROOT-0/null||anticoagulation-14/NN	prep_with||anticoagulation-14/NN||warfarin-16/NN	stroke-11||warfarin-16||yes||atrialfibrillation (af) patients with a high risk of stroke are recommended anticoagulation with warfarin.
nsubj||discovered-3/VBD||we-1/PRP	advmod||discovered-3/VBD||previously-2/RB	root||ROOT-0/null||discovered-3/VBD	det||facet-7/NN||an-4/DT	amod||facet-7/NN||addictive-5/JJ	amod||facet-7/NN||molecular-6/JJ	dobj||discovered-3/VBD||facet-7/NN	prep_of||facet-7/NN||anorexia-9/NNP	vmod||discovered-3/VBD||involving-11/VBG	dobj||involving-11/VBG||production-12/NN	det||accumbens-17/NNS||the-15/DT	nn||accumbens-17/NNS||nucleus-16/NN	prep_in||discovered-3/VBD||accumbens-17/NNS	appos||accumbens-17/NNS||nac-19/NN	det||transcripts-25/NNS||the-23/DT	amod||transcripts-25/NNS||same-24/JJ	prep_of||accumbens-17/NNS||transcripts-25/NNS	vmod||transcripts-25/NNS||stimulated-26/VBN	prep_in||stimulated-26/VBN||response-28/NN	prep_to||stimulated-26/VBN||cocaine-30/NN	prep_to||stimulated-26/VBN||amphetamine-32/NN	conj_and||cocaine-30/NN||amphetamine-32/NN	appos||cocaine-30/NN||cart-34/NN	prep_upon||stimulated-26/VBN||stimulation-37/NN	det||receptors-41/NNS||the-39/DT	amod||receptors-41/NNS||5-ht4-40/JJ	prep_of||stimulation-37/NN||receptors-41/NNS	dep||receptors-41/NNS||5-htr4-43/JJ	prep_of||stimulation-37/NN||mdma-46/NN	conj_or||receptors-41/NNS||mdma-46/NN	appos||receptors-41/NNS||ecstasy-48/NN	nac-19||anorexia-9||no_rel||we previously discovered an addictive molecular facet of anorexia, involving production, in the nucleus accumbens (nac), of the same transcripts stimulated in response to cocaine and amphetamine (cart) upon stimulation of the 5-ht4 receptors (5-htr4) or mdma (ecstasy).
advmod||reversed-10/VBD||moreover-1/RB	amod||hc-030031-4/NN||oral-3/JJ	nsubj||reversed-10/VBD||hc-030031-4/NN	num||mg/kg-7/NN||100-6/CD	appos||hc-030031-4/NN||mg/kg-7/NN	advmod||reversed-10/VBD||significantly-9/RB	root||ROOT-0/null||reversed-10/VBD	amod||hypersensitivity-12/NN||mechanical-11/JJ	dobj||reversed-10/VBD||hypersensitivity-12/NN	det||models-17/NNS||the-14/DT	amod||models-17/NNS||more-15/JJR	amod||models-17/NNS||chronic-16/JJ	prep_in||reversed-10/VBD||models-17/NNS	amod||adjuvant-21/NN||complete-19/JJ	nn||adjuvant-21/NN||freunds-20/NNS	prep_of||models-17/NNS||adjuvant-21/NN	appos||adjuvant-21/NN||cfa-23/NN	advmod||inflammatory-27/JJ||induced-26/RB	amod||pain-28/NN||inflammatory-27/JJ	prep_of||models-17/NNS||pain-28/NN	conj_and||adjuvant-21/NN||pain-28/NN	det||model-34/NN||the-30/DT	amod||model-34/NN||spinal-31/JJ	nn||model-34/NN||nerve-32/NN	nn||model-34/NN||ligation-33/NN	prep_of||models-17/NNS||model-34/NN	conj_and||adjuvant-21/NN||model-34/NN	prep_of||model-34/NN||neuropathicpain-36/NN	hc--1||hypersensitivity-12||no_rel||moreover, oral hc-030031 (100 mg/kg) significantly reversed mechanical hypersensitivity in the more chronic models of complete freunds adjuvant (cfa)-induced inflammatory pain and the spinal nerve ligation model of neuropathicpain.
det||efficacy-2/NN||the-1/DT	nsubjpass||assessed-13/VBN||efficacy-2/NN	conj_and||efficacy-2/NN||safety-4/NN	nsubjpass||assessed-13/VBN||safety-4/NN	det||incb13739-11/NNS||the-6/DT	amod||incb13739-11/NNS||11î-7/JJ	punct||incb13739-11/NNS||²-8/''	amod||incb13739-11/NNS||hsd1-9/JJ	nn||incb13739-11/NNS||inhibitor-10/NN	prep_of||efficacy-2/NN||incb13739-11/NNS	auxpass||assessed-13/VBN||were-12/VBD	root||ROOT-0/null||assessed-13/VBN	advmod||added-15/VBD||when-14/WRB	advcl||assessed-13/VBN||added-15/VBD	amod||monotherapy-19/NN||ongoing-17/JJ	nn||monotherapy-19/NN||metformin-18/NN	prep_to||added-15/VBD||monotherapy-19/NN	prep_in||monotherapy-19/NN||patients-21/NNS	prep_with||added-15/VBD||type2diabetes-23/NNS	vmod||type2diabetes-23/NNS||exhibiting-24/VBG	amod||glycemic-26/JJ||inadequate-25/JJ	amod||control-27/NN||glycemic-26/JJ	dobj||exhibiting-24/VBG||control-27/NN	amod||7â-30/NNS||a1c-29/JJ	nsubj||$-31/VBZ||7â-30/NNS	parataxis||exhibiting-24/VBG||$-31/VBZ	num||%-34/NN||11-33/CD	dobj||$-31/VBZ||%-34/NN	type2diabetes-23||metformin-18||yes||the efficacy and safety of the 11î²hsd1 inhibitor incb13739 were assessed when added to ongoing metformin monotherapy in patients with type2diabetes exhibiting inadequate glycemic control (a1c 7â€“11%).
advmod||frequent-10/JJ||however-1/RB	det||âˆ-4/NN||the-3/DT	poss||variant-7/NN||âˆ-4/NN	amod||variant-7/NN||336a-6/JJ	nsubj||frequent-10/JJ||variant-7/NN	cop||frequent-10/JJ||was-8/VBD	advmod||frequent-10/JJ||more-9/RBR	root||ROOT-0/null||frequent-10/JJ	amod||patients-13/NNS||htlv-1-infected-12/JJ	prep_in||frequent-10/JJ||patients-13/NNS	amod||tropicalspasticparaparesis-17/NNS||-LSB--14/JJ	amod||tropicalspasticparaparesis-17/NNS||htlv-1-associatedmyelopathy-15/JJ	amod||tropicalspasticparaparesis-17/NNS||/-16/JJ	dep||patients-13/NNS||tropicalspasticparaparesis-17/NNS	appos||tropicalspasticparaparesis-17/NNS||ham/tsp-19/NN	quantmod||$-23/$||80â-22/RB	num||%-25/NN||$-23/$	num||$-23/$||š-24/CD	appos||tropicalspasticparaparesis-17/NNS||%-25/NN	amod||asymptomatic-28/JJ||healthy-27/JJ	amod||carriers-30/NNS||asymptomatic-28/JJ	amod||carriers-30/NNS||htlv-1-29/JJ	appos||tropicalspasticparaparesis-17/NNS||carriers-30/NNS	amod||-RSB--36/NNS||90â-32/JJ	dep||%-35/NN||$-33/$	num||$-33/$||š-34/CD	amod||-RSB--36/NNS||%-35/NN	appos||tropicalspasticparaparesis-17/NNS||-RSB--36/NNS	mark||70â-43/NNS||than-37/IN	det||group-41/NN||the-39/DT	nn||group-41/NN||control-40/NN	prep_in||70â-43/NNS||group-41/NN	dep||-RSB--36/NNS||70â-43/NNS	dep||%-46/NN||$-44/$	num||$-44/$||š-45/CD	amod||70â-43/NNS||%-46/NN	dep||70â-43/NNS||-LSB--48/FW	dep||70â-43/NNS||p-49/NN	dep||0.0197-51/CD||=-50/SYM	rcmod||p-49/NN||0.0197-51/CD	nn||ratio-54/NN||odds-53/NNS	appos||tropicalspasticparaparesis-17/NNS||ratio-54/NN	cc||=-58/NNP||or-56/CC	dep||ratio-54/NN||=-58/NNP	num||=-58/NNP||2.511-59/CD	num||=-58/NNP||95â-61/CD	dep||%-64/NN||$-62/$	num||$-62/$||š-63/CD	amod||interval-66/NN||%-64/NN	nn||interval-66/NN||confidence-65/NN	nsubj||=-70/VBZ||interval-66/NN	discourse||interval-66/NN||ci-68/UH	rcmod||=-58/NNP||=-70/VBZ	num||â-72/NNS||1.218-71/CD	dobj||=-70/VBZ||â-72/NNS	num||â-72/NNS||$-73/$	num||$-73/$||5.179-75/CD	tropicalspasticparaparesis-17||htlv-1-29||no||however, the âˆ’336a variant was more frequent in htlv-1-infected patients [htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp), 80â€š%; healthy asymptomatic htlv-1 carriers, 90â€š%] than in the control group (70â€š%) [ p =0.0197, odds ratio (or)=2.511, 95â€š% confidence interval (ci)=1.218â€“5.179).
advmod||initiated-7/VBN||subsequently-1/RB	det||project-5/NN||a-3/DT	nn||project-5/NN||pilot-4/NN	nsubjpass||initiated-7/VBN||project-5/NN	auxpass||initiated-7/VBN||was-6/VBD	root||ROOT-0/null||initiated-7/VBN	dobj||used-18/VBD||which-9/WDT	amod||organizations-11/NNS||non-governmental-10/JJ	nsubj||used-18/VBD||organizations-11/NNS	nsubj||aids-39/VBZ||organizations-11/NNS	appos||organizations-11/NNS||ngos-13/NNS	amod||countries-17/NNS||developing-16/VBG	prep_in||organizations-11/NNS||countries-17/NNS	prepc_in||initiated-7/VBN||used-18/VBD	dobj||used-18/VBD||benchmarks-19/NNS	aux||ascertain-21/VB||to-20/TO	vmod||used-18/VBD||ascertain-21/VB	mark||addressed-27/VBN||whether-22/IN	det||issues-25/NNS||these-23/DT	amod||issues-25/NNS||neglected-24/VBN	nsubjpass||addressed-27/VBN||issues-25/NNS	auxpass||addressed-27/VBN||were-26/VBD	ccomp||ascertain-21/VB||addressed-27/VBN	amod||programmes-30/NNS||local-29/JJ	prep_in||addressed-27/VBN||programmes-30/NNS	prep_in||addressed-27/VBN||interventions-32/NNS	conj_and||programmes-30/NNS||interventions-32/NNS	xcomp||addressed-27/VBN||serving-33/VBG	dobj||serving-33/VBG||women-34/NNS	vmod||women-34/NNS||affected-35/VBN	agent||affected-35/VBN||hiv-37/NN	prepc_in||initiated-7/VBN||aids-39/VBZ	conj_and||used-18/VBD||aids-39/VBZ	aids-39||hiv-37||no||subsequently, a pilot project was initiated in which non-governmental organizations (ngos) in developing countries used benchmarks to ascertain whether these neglected issues were addressed in local programmes and interventions serving women affected by hiv and aids.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||analgesic-2/JJ	nsubjpass||assessed-8/VBN||efficacy-3/NN	det||block-6/NN||the-5/DT	prep_of||efficacy-3/NN||block-6/NN	auxpass||assessed-8/VBN||was-7/VBD	root||ROOT-0/null||assessed-8/VBN	amod||anesthetics-11/NNS||intraoperative-10/JJ	prep_with||assessed-8/VBN||anesthetics-11/NNS	appos||anesthetics-11/NNS||desflurane-13/NN	appos||anesthetics-11/NNS||numbers-16/NNS	prep_of||numbers-16/NNS||patients-18/NNS	vmod||patients-18/NNS||needing-19/VBG	amod||analgesics-21/NNS||postoperative-20/JJ	dobj||needing-19/VBG||analgesics-21/NNS	det||time-24/NN||the-23/DT	appos||anesthetics-11/NNS||time-24/NN	conj_and||numbers-16/NNS||time-24/NN	det||analgesics-28/NNS||the-26/DT	amod||analgesics-28/NNS||first-27/JJ	prep_to||time-24/NN||analgesics-28/NNS	vmod||analgesics-28/NNS||required-29/VBN	nn||intensity-33/NN||pain-32/NN	appos||anesthetics-11/NNS||intensity-33/NN	conj_and||numbers-16/NNS||intensity-33/NN	amod||scale-37/NN||visual-35/JJ	amod||scale-37/NN||analog-36/JJ	prep_by||intensity-33/NN||scale-37/NN	appos||scale-37/NN||vas-39/NN	pain-32||desflurane-13||yes||the analgesic efficacy of the block was assessed with intraoperative anesthetics (desflurane), numbers of patients needing postoperative analgesics, the time to the first analgesics required, and pain intensity by visual analog scale (vas).
amod||chemotherapy-2/NN||mass-1/JJ	nsubj||strategy-9/NN||chemotherapy-2/NN	prep_with||chemotherapy-2/NN||praziquantel-4/NN	cop||strategy-9/NN||is-5/VBZ	det||strategy-9/NN||the-6/DT	amod||strategy-9/NN||main-7/JJ	nn||strategy-9/NN||control-8/NN	root||ROOT-0/null||strategy-9/NN	prep_for||strategy-9/NN||schistosomiasis-11/NNS	prep_in||schistosomiasis-11/NNS||mali-13/NNS	schistosomiasis-11||praziquantel-4||yes||mass chemotherapy with praziquantel is the main control strategy for schistosomiasis in mali.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||determine-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||risk-10/NN||the-9/DT	dobj||determine-8/VB||risk-10/NN	prep_of||risk-10/NN||peanutallergy-12/NN	prep_in||determine-8/VB||siblings-14/NNS	amod||children-17/NNS||peanut-allergic-16/JJ	prep_of||siblings-14/NNS||children-17/NNS	peanutallergy-12||peanut--1||no||the objective of this study was to determine the risk of peanutallergy in siblings of peanut-allergic children.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||m.tuberculosis-36||no||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
nn||department-2/NN||emergency-1/NN	nsubjpass||treated-15/VBN||department-2/NN	dep||treated-15/VBN||ed-4/NN	nsubjpass||treated-15/VBN||patients-6/NNS	amod||thromboembolism-9/NN||venous-8/JJ	prep_with||patients-6/NNS||thromboembolism-9/NN	appos||patients-6/NNS||vte-11/NN	auxpass||treated-15/VBN||are-13/VBP	advmod||treated-15/VBN||eventually-14/RB	root||ROOT-0/null||treated-15/VBN	det||dose-19/NN||a-17/DT	amod||dose-19/NN||standard-18/JJ	prep_with||treated-15/VBN||dose-19/NN	prep_of||dose-19/NN||warfarin-21/NN	det||fact-24/NN||the-23/DT	prep_despite||treated-15/VBN||fact-24/NN	mark||known-31/VBN||that-25/IN	det||number-27/NN||a-26/DT	nsubjpass||known-31/VBN||number-27/NN	nsubj||sensitive-34/JJ||number-27/NN	nsubj||warfarin-36/VB||number-27/NN	nsubj||experience-39/VB||number-27/NN	prep_of||number-27/NN||patients-29/NNS	auxpass||known-31/VBN||are-30/VBP	ccomp||treated-15/VBN||known-31/VBN	aux||sensitive-34/JJ||to-32/TO	cop||sensitive-34/JJ||be-33/VB	xcomp||known-31/VBN||sensitive-34/JJ	aux||warfarin-36/VB||to-35/TO	xcomp||sensitive-34/JJ||warfarin-36/VB	aux||experience-39/VB||may-38/MD	ccomp||treated-15/VBN||experience-39/VB	conj_and||known-31/VBN||experience-39/VB	amod||inrs-41/NNS||supra-therapeutic-40/JJ	dobj||experience-39/VB||inrs-41/NNS	amod||events-45/NNS||adverse-43/JJ	amod||events-45/NNS||bleeding-44/VBG	dobj||experience-39/VB||events-45/NNS	conj_and||inrs-41/NNS||events-45/NNS	thromboembolism-9||warfarin-36||yes||emergency department (ed) patients with venous thromboembolism (vte) are eventually treated with a standard dose of warfarin despite the fact that a number of patients are known to be sensitive to warfarin and may experience supra-therapeutic inrs and adverse bleeding events.
nsubj||provides-3/VBZ||it-1/PRP	advmod||provides-3/VBZ||also-2/RB	root||ROOT-0/null||provides-3/VBZ	det||information-5/NN||the-4/DT	dobj||provides-3/VBZ||information-5/NN	aux||design-7/VB||to-6/TO	vmod||information-5/NN||design-7/VB	vmod||information-5/NN||introduce-9/VB	conj_and||design-7/VB||introduce-9/VB	amod||genes-12/NNS||safe-10/JJ	nn||genes-12/NNS||gluten-11/NN	dobj||design-7/VB||genes-12/NNS	amod||cereals-15/NNS||other-14/JJ	prep_in||design-7/VB||cereals-15/NNS	nsubj||exhibit-19/VB||cereals-15/NNS	aux||exhibit-19/VB||would-18/MD	rcmod||cereals-15/NNS||exhibit-19/VB	amod||quality-21/NN||improved-20/VBN	dobj||exhibit-19/VB||quality-21/NN	prepc_while||exhibit-19/VB||remaining-23/VBG	acomp||remaining-23/VBG||safe-24/JJ	prep_for||safe-24/JJ||consumption-26/NN	amod||patients-29/NNS||celiacdisease-28/JJ	prep_by||remaining-23/VBG||patients-29/NNS	celiacdisease-28||gluten-11||no||it also provides the information to design and introduce safe gluten genes in other cereals, which would exhibit improved quality while remaining safe for consumption by celiacdisease patients.
amod||toxin-2/NN||lethal-1/JJ	nsubj||factor-10/NN||toxin-2/NN	appos||toxin-2/NN||lt-4/NN	cop||factor-10/NN||is-6/VBZ	det||factor-10/NN||a-7/DT	amod||factor-10/NN||critical-8/JJ	nn||factor-10/NN||virulence-9/NN	root||ROOT-0/null||factor-10/NN	prep_of||factor-10/NN||bacillusanthracis-12/NNS	det||agent-16/NN||the-14/DT	amod||agent-16/NN||etiological-15/JJ	appos||bacillusanthracis-12/NNS||agent-16/NN	prep_of||agent-16/NN||anthrax-18/NN	dep||fatal-24/JJ||whose-20/WP$	amod||form-22/NN||pulmonary-21/JJ	nsubj||fatal-24/JJ||form-22/NN	cop||fatal-24/JJ||is-23/VBZ	dep||bacillusanthracis-12/NNS||fatal-24/JJ	det||absence-27/NN||the-26/DT	prep_in||fatal-24/JJ||absence-27/NN	prep_of||absence-27/NN||treatment-29/NN	anthrax-18||bacillusanthracis-12||no||lethal toxin (lt) is a critical virulence factor of bacillusanthracis , the etiological agent of anthrax, whose pulmonary form is fatal in the absence of treatment.
prep_among||used-6/VBN||them-2/PRP	nsubjpass||used-6/VBN||doxycycline-4/NN	nsubjpass||used-6/VBN||doxycycline-4/NN	auxpass||used-6/VBN||is-5/VBZ	root||ROOT-0/null||used-6/VBN	conj_or||used-6/VBN||used-6/VBN	advmod||used-6/VBN||alone-7/RB	nn||chemoprophylaxis-10/NNS||malaria-9/NN	prep_for||used-6/VBN||chemoprophylaxis-10/NNS	prep_in||used-6/VBN||combination-13/NN	nn||derivatives-18/NNS||quinine-15/NN	conj_or||quinine-15/NN||artemisinin-17/NN	nn||derivatives-18/NNS||artemisinin-17/NN	prep_with||used-6/VBN||derivatives-18/NNS	nn||treatment-21/NN||malaria-20/NN	prep_for||derivatives-18/NNS||treatment-21/NN	malaria-20||quinine-15||yes||among them, doxycycline is used alone for malaria chemoprophylaxis or in combination with quinine or artemisinin derivatives for malaria treatment.
nsubj||becoming-3/VBG||neuroaids-1/NNS	aux||becoming-3/VBG||is-2/VBZ	root||ROOT-0/null||becoming-3/VBG	det||problem-7/NN||a-4/DT	amod||problem-7/NN||major-5/JJ	nn||problem-7/NN||health-6/NN	xcomp||becoming-3/VBG||problem-7/NN	nn||patients-10/NNS||aids-9/NNS	prep_among||becoming-3/VBG||patients-10/NNS	amod||survivors-14/NNS||long-term-12/JJ	nn||survivors-14/NNS||hiv-13/NN	prep_among||becoming-3/VBG||survivors-14/NNS	conj_and||patients-10/NNS||survivors-14/NNS	aids-9||hiv-13||no||neuroaids is becoming a major health problem among aids patients and long-term hiv survivors.
nsubjpass||conducted-9/VBN||objective-1/NN	nsubj||assess-11/VB||objective-1/NN	det||survey-7/NN||this-2/DT	amod||survey-7/NN||prospective-3/JJ	amod||survey-7/NN||post-marketing-4/JJ	nn||survey-7/NN||drug-5/NN	nn||survey-7/NN||use-6/NN	dep||objective-1/NN||survey-7/NN	auxpass||conducted-9/VBN||was-8/VBD	root||ROOT-0/null||conducted-9/VBN	aux||assess-11/VB||to-10/TO	xcomp||conducted-9/VBN||assess-11/VB	det||safety-13/NN||the-12/DT	dobj||assess-11/VB||safety-13/NN	dobj||assess-11/VB||efficacy-15/NN	conj_and||safety-13/NN||efficacy-15/NN	det||²-19/NN||the-17/DT	nn||²-19/NN||î-18/NN	prep_of||safety-13/NN||²-19/NN	nsubj||artistâ-28/VBD||adrenergicreceptorantagonist-21/NN	nn||²-24/NNS||î-23/NN	dep||adrenergicreceptorantagonist-21/NN||²-24/NNS	dep||²-24/NNS||blocker-26/NN	parataxis||conducted-9/VBN||artistâ-28/VBD	amod||tablets-30/NNS||®-29/JJ	dobj||artistâ-28/VBD||tablets-30/NNS	dep||tablets-30/NNS||carvedilol-32/JJ	prep_in||artistâ-28/VBD||patients-35/NNS	prep_with||patients-35/NNS||hypertension-37/NN	prep_in||artistâ-28/VBD||japan-39/NN	hypertension-37||carvedilol-32||yes||objective this prospective post-marketing drug use survey was conducted to assess the safety and efficacy of the î²-adrenergicreceptorantagonist (î²-blocker) artistâ® tablets (carvedilol) in patients with hypertension in japan.
det||administration-2/NN||the-1/DT	nsubjpass||reported-10/VBN||administration-2/NN	nsubj||effective-13/JJ||administration-2/NN	det||dose-6/NN||a-4/DT	amod||dose-6/NN||single-5/JJ	prep_of||administration-2/NN||dose-6/NN	prep_of||dose-6/NN||propofol-8/NN	auxpass||reported-10/VBN||is-9/VBZ	root||ROOT-0/null||reported-10/VBN	aux||effective-13/JJ||to-11/TO	cop||effective-13/JJ||be-12/VB	xcomp||reported-10/VBN||effective-13/JJ	prepc_in||effective-13/JJ||decreasing-15/VBG	det||incidence-17/NN||the-16/DT	dobj||decreasing-15/VBG||incidence-17/NN	dobj||decreasing-15/VBG||severity-19/NN	conj_and||incidence-17/NN||severity-19/NN	nn||agitation-22/NN||emergence-21/NN	prep_of||incidence-17/NN||agitation-22/NN	appos||agitation-22/NN||ea-24/NN	prep_in||decreasing-15/VBG||children-27/NNS	amod||anesthesia-30/NN||sevoflurane-29/JJ	prep_following||children-27/NNS||anesthesia-30/NN	agitation-22||propofol-8||yes||the administration of a single dose of propofol is reported to be effective in decreasing the incidence and severity of emergence agitation (ea) in children following sevoflurane anesthesia.
nn||analyses-2/NNS||ihc-1/NN	nsubjpass||performed-4/VBN||analyses-2/NNS	auxpass||performed-4/VBN||were-3/VBD	root||ROOT-0/null||performed-4/VBN	det||block-8/NN||each-6/DT	nn||block-8/NN||cell-7/NN	prep_on||performed-4/VBN||block-8/NN	prep_with||block-8/NN||antibodies-10/NNS	nn||receptor-13/NN||estrogen-12/NN	prep_to||performed-4/VBN||receptor-13/NN	appos||receptor-13/NN||er-15/NN	amod||receptor-19/NN||progesterone-18/JJ	appos||receptor-13/NN||receptor-19/NN	appos||receptor-19/NN||pr-21/NN	amod||receptor-33/NN||her2-24/JJ	conj_and||her2-24/JJ||egfr-26/JJ	amod||receptor-33/NN||egfr-26/JJ	conj_and||her2-24/JJ||ck5/6-28/JJ	amod||receptor-33/NN||ck5/6-28/JJ	conj_and||her2-24/JJ||ki-67-30/JJ	amod||receptor-33/NN||ki-67-30/JJ	conj_and||her2-24/JJ||androgen-32/JJ	amod||receptor-33/NN||androgen-32/JJ	appos||receptor-13/NN||receptor-33/NN	appos||receptor-13/NN||ar-35/NN	ar-35||estrogen-12||no_rel||ihc analyses were performed on each cell block with antibodies to estrogen receptor (er), progesterone receptor (pr), her2, egfr, ck5/6, ki-67 and androgen receptor (ar).
det||patient-2/NN||the-1/DT	nsubj||taken-4/VBN||patient-2/NN	aux||taken-4/VBN||had-3/VBD	root||ROOT-0/null||taken-4/VBN	neg||medications-8/NNS||no-5/DT	amod||medications-8/NNS||other-6/JJ	amod||medications-8/NNS||over-the-counter-7/JJ	dobj||taken-4/VBN||medications-8/NNS	det||causes-14/NNS||all-11/DT	amod||causes-14/NNS||other-12/JJ	amod||causes-14/NNS||possible-13/JJ	nsubjpass||excluded-18/VBN||causes-14/NNS	prep_of||causes-14/NNS||nephroticsyndrome-16/NN	auxpass||excluded-18/VBN||were-17/VBD	conj_and||taken-4/VBN||excluded-18/VBN	over-the-counter-7||nephroticsyndrome-16||no_rel||the patient had taken no other over-the-counter medications, and all other possible causes of nephroticsyndrome were excluded.
advmod||studied-144/VBN||therefore-1/RB	mark||gain-6/VB||in-3/IN	dep||gain-6/VB||order-4/NN	aux||gain-6/VB||to-5/TO	advcl||studied-144/VBN||gain-6/VB	amod||knowledge-8/NN||further-7/JJ	dobj||gain-6/VB||knowledge-8/NN	nn||development-12/NN||fish-10/NN	amod||development-12/NN||larval-11/JJ	prep_of||knowledge-8/NN||development-12/NN	poss||disruption-15/NN||its-14/PRP$	prep_of||knowledge-8/NN||disruption-15/NN	conj_and||development-12/NN||disruption-15/NN	amod||imbalance-19/NN||nutritional-17/JJ	nn||imbalance-19/NN||va-18/NN	prep_by||gain-6/VB||imbalance-19/NN	det||expression-23/NN||the-21/DT	amod||expression-23/NN||relative-22/JJ	nsubjpass||studied-144/VBN||expression-23/NN	det||rars-26/NNS||some-25/DT	prep_of||expression-23/NN||rars-26/NNS	prep_of||expression-23/NN||rxrs-28/NNS	conj_and||rars-26/NNS||rxrs-28/NNS	amod||genes-34/NNS||several-33/JJ	prep_of||expression-23/NN||genes-34/NNS	conj_and||rars-26/NNS||genes-34/NNS	vmod||genes-34/NNS||involved-35/VBN	prep_in||involved-35/VBN||morpho-37/NN	conj_and||rars-26/NNS||skeletogenesis-40/NNS	conj_and||genes-34/NNS||skeletogenesis-40/NNS	amod||receptors-45/NNS||peroxisome-43/JJ	amod||receptors-45/NNS||proliferator-activated-44/JJ	prep_such_as||skeletogenesis-40/NNS||receptors-45/NNS	dep||receptors-45/NNS||ppara-47/NN	appos||ppara-47/NN||pparb-49/NN	appos||ppara-47/NN||pparg-51/NN	conj_and||pparb-49/NN||pparg-51/NN	amod||protein-55/NN||retinol-binding-54/JJ	dep||skeletogenesis-40/NNS||protein-55/NN	appos||protein-55/NN||rbp-57/NN	amod||factors-62/NNS||insulin-like-60/JJ	nn||factors-62/NNS||growth-61/NN	dep||skeletogenesis-40/NNS||factors-62/NNS	dep||factors-62/NNS||i-63/NN	dep||factors-62/NNS||ii-65/NN	conj_and||i-63/NN||ii-65/NN	dep||i-63/NN||igf1-67/NNS	dep||i-63/NN||igf2-69/NNS	conj_and||igf1-67/NNS||igf2-69/NNS	advmod||igf1-67/NNS||respectively-71/RB	nn||protein-76/NN||bone-74/NN	amod||protein-76/NN||morphogenetic-75/JJ	dep||skeletogenesis-40/NNS||protein-76/NN	dep||protein-76/NN||2-77/CD	appos||2-77/CD||bmp2-79/NNP	amod||²-86/NNS||transforming-82/JJ	nn||²-86/NNS||growth-83/NN	nn||²-86/NNS||factor-84/NN	nn||²-86/NNS||î-85/NN	dep||skeletogenesis-40/NNS||²-86/NNS	dep||²-86/NNS||-1-87/CD	appos||-1-87/CD||tgfb1-89/NNP	conj_and||rars-26/NNS||genes-93/NNS	conj_and||genes-34/NNS||genes-93/NNS	vmod||genes-93/NNS||encoding-94/VBG	amod||proteins-101/NNS||different-95/JJ	nn||proteins-101/NNS||extracellular-96/NN	nn||proteins-101/NNS||matrix-97/NN	appos||proteins-101/NNS||ecm-99/NN	dobj||encoding-94/VBG||proteins-101/NNS	nn||protein-106/NN||matrix-104/NN	nn||protein-106/NN||gla-105/NN	prep_such_as||proteins-101/NNS||protein-106/NN	appos||protein-106/NN||mgp-108/NN	prep_such_as||proteins-101/NNS||osteocalcin-111/NN	conj_and||protein-106/NN||osteocalcin-111/NN	appos||osteocalcin-111/NN||bglap-113/NN	prep_such_as||proteins-101/NNS||osteopontin-116/NN	conj_and||protein-106/NN||osteopontin-116/NN	appos||osteopontin-116/NN||spp1-118/NNP	amod||acidic-123/NNS||secreted-121/JJ	nn||acidic-123/NNS||protein-122/NN	prep_such_as||proteins-101/NNS||acidic-123/NNS	conj_and||protein-106/NN||acidic-123/NNS	amod||chain-138/NN||rich-125/JJ	prep_in||rich-125/JJ||cysteine-127/NN	dep||cysteine-127/NN||sparc-129/JJ	nn||î-135/NN||type-132/FW	nn||î-135/NN||i-133/FW	nn||î-135/NN||collagen-134/NN	prep_in||rich-125/JJ||î-135/NN	conj_and||cysteine-127/NN||î-135/NN	number||1-137/CD||±-136/CD	dep||î-135/NN||1-137/CD	prep_such_as||proteins-101/NNS||chain-138/NN	conj_and||protein-106/NN||chain-138/NN	appos||chain-138/NN||col1a1-140/NNP	aux||studied-144/VBN||have-142/VBP	auxpass||studied-144/VBN||been-143/VBN	root||ROOT-0/null||studied-144/VBN	amod||bream-148/NN||gilthead-146/JJ	nn||bream-148/NN||sea-147/NN	prep_in||studied-144/VBN||bream-148/NN	retinol--1||gla-105||no_rel||therefore, in order to gain further knowledge of fish larval development and its disruption by nutritional va imbalance, the relative expression of some rars and rxrs , as well as several genes involved in morpho- and skeletogenesis such as peroxisome proliferator-activated receptors ( ppara , pparb and pparg ); retinol-binding protein ( rbp ); insulin-like growth factors i and ii ( igf1 and igf2 , respectively); bone morphogenetic protein 2 ( bmp2 ); transforming growth factor î²-1 ( tgfb1 ); and genes encoding different extracellular matrix (ecm) proteins such as matrix gla protein ( mgp ), osteocalcin ( bglap ), osteopontin ( spp1 ), secreted protein acidic and rich in cysteine ( sparc ) and type i collagen î±1 chain ( col1a1 ) have been studied in gilthead sea bream.
det||analysis-4/NN||the-2/DT	amod||analysis-4/NN||multivariate-3/JJ	prep_in||remain-76/VBP||analysis-4/NN	nn||>-7/NNS||sa-6/NN	nsubj||remain-76/VBP||>-7/NNS	number||cm/sec-9/JJ||9-8/CD	amod||>-7/NNS||cm/sec-9/JJ	dep||>-7/NNS||hazard-11/NN	dep||hazard-11/NN||ratio-12/NN	appos||ratio-12/NN||hr-14/NN	amod||ratio-12/NN||5.559-17/CD	number||%-20/NN||95-19/CD	amod||interval-22/NN||%-20/NN	nn||interval-22/NN||confidence-21/NN	dep||ratio-12/NN||interval-22/NN	appos||interval-22/NN||ci-24/NN	number||14.305-29/CD||2.160-27/CD	dep||14.305-29/CD||to-28/TO	dep||ratio-12/NN||14.305-29/CD	conj_and||interval-22/NN||14.305-29/CD	dep||0.0001-33/CD||p-31/RB	number||0.0001-33/CD||<-32/CD	dep||14.305-29/CD||0.0001-33/CD	dep||ratio-12/NN||dose-36/NN	conj_and||interval-22/NN||dose-36/NN	prep_of||dose-36/NN||norepinephrine-38/NN	dep||dose-36/NN||hr-40/NN	appos||hr-40/NN||1.964-42/CD	number||%-45/NN||95-44/CD	amod||ci-46/NN||%-45/NN	dep||1.964-42/CD||ci-46/NN	number||2.883-50/CD||1.338-48/CD	dep||2.883-50/CD||to-49/TO	appos||ci-46/NN||2.883-50/CD	dep||2.883-50/CD||p-52/NN	dep||0.001-54/CD||=-53/SYM	rcmod||p-52/NN||0.001-54/CD	dep||ratio-12/NN||pao2/fio2-58/NNS	conj_and||interval-22/NN||pao2/fio2-58/NNS	dep||pao2/fio2-58/NNS||hr-60/NN	dep||hr-60/NN||0.992-62/CD	num||ci-66/NN||95-64/CD	nn||ci-66/NN||%-65/NN	dep||ratio-12/NN||ci-66/NN	number||0.999-70/CD||0.984-68/CD	dep||0.999-70/CD||to-69/TO	appos||ci-66/NN||0.999-70/CD	dep||ratio-12/NN||p-72/NN	dep||0.031-74/CD||=-73/SYM	rcmod||p-72/NN||0.031-74/CD	root||ROOT-0/null||remain-76/VBP	amod||predictors-78/NNS||independent-77/JJ	xcomp||remain-76/VBP||predictors-78/NNS	amod||mortality-81/NN||90-day-80/JJ	prep_of||predictors-78/NNS||mortality-81/NN	amod||patients-84/NNS||septic-shock-83/JJ	prep_in||mortality-81/NN||patients-84/NNS	shock--1||norepinephrine-38||yes||in the multivariate analysis, sa > 9 cm/sec (hazard ratio (hr), 5.559; 95% confidence interval (ci), 2.160 to 14.305; p < 0.0001), dose of norepinephrine (hr, 1.964; 95% ci, 1.338 to 2.883; p = 0.001), and pao2/fio2 (hr, 0.992; 95% ci, 0.984 to 0.999; p = 0.031) remain independent predictors of 90-day mortality in septic-shock patients.
amod||activity-2/NN||sympathetic-1/JJ	nsubjpass||measured-4/VBN||activity-2/NN	auxpass||measured-4/VBN||was-3/VBD	root||ROOT-0/null||measured-4/VBN	num||patients-7/NNS||eight-6/CD	prep_in||measured-4/VBN||patients-7/NNS	nn||patients-10/NNS||chf-9/NN	prep_with||patients-7/NNS||patients-10/NNS	amod||weeks-13/NNS||8â-12/JJ	prep_during||measured-4/VBN||weeks-13/NNS	nn||weeks-18/NNS||discontinuation-15/NN	conj_and||discontinuation-15/NN||4â-17/JJ	nn||weeks-18/NNS||4â-17/JJ	prep_after||weeks-13/NNS||weeks-18/NNS	prep_after||measured-4/VBN||restart-20/NNP	nn||therapy-23/NN||statin-22/NN	prep_of||restart-20/NNP||therapy-23/NN	agent||measured-4/VBN||microneurography-25/NN	amod||muscle-28/NN||direct-27/JJ	prep_for||microneurography-25/NN||muscle-28/NN	amod||recording-31/NN||sympathetic-29/JJ	nn||recording-31/NN||nerve-30/NN	dep||muscle-28/NN||recording-31/NN	appos||recording-31/NN||msna-33/NNP	prep_for||microneurography-25/NN||measurement-36/NN	conj_and||muscle-28/NN||measurement-36/NN	amod||concentrations-41/NNS||arterial-38/JJ	nn||concentrations-41/NNS||plasma-39/NN	nn||concentrations-41/NNS||norepinephrine-40/NN	prep_of||measurement-36/NN||concentrations-41/NNS	norepinephrine-40||chf-9||no_rel||sympathetic activity was measured in eight patients with chf patients during 8â weeks after discontinuation and 4â weeks after restart of statin therapy by microneurography for direct muscle sympathetic nerve recording (msna) and measurement of arterial plasma norepinephrine concentrations.
amod||studies-2/NNS||recent-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||limited-14/VBN||that-5/IN	det||effects-7/NNS||the-6/DT	nsubjpass||limited-14/VBN||effects-7/NNS	prep_of||effects-7/NNS||bisphosphonates-9/NNS	prep_on||bisphosphonates-9/NNS||breasttumours-11/NNS	auxpass||limited-14/VBN||are-12/VBP	neg||limited-14/VBN||not-13/RB	ccomp||shown-4/VBN||limited-14/VBN	prep_to||limited-14/VBN||bone-16/NN	mark||achieved-25/VBN||that-19/IN	amod||effects-22/NNS||prolonged-20/JJ	amod||effects-22/NNS||anti-tumour-21/JJ	nsubjpass||achieved-25/VBN||effects-22/NNS	aux||achieved-25/VBN||may-23/MD	auxpass||achieved-25/VBN||be-24/VB	ccomp||shown-4/VBN||achieved-25/VBN	conj_and||limited-14/VBN||achieved-25/VBN	poss||inclusion-28/NN||their-27/PRP$	prep_following||achieved-25/VBN||inclusion-28/NN	nn||therapy-31/NN||combination-30/NN	prep_in||inclusion-28/NN||therapy-31/NN	tumour--1||bisphosphonates-9||no_rel||recent studies have shown that the effects of bisphosphonates on breasttumours are not limited to bone, and that prolonged anti-tumour effects may be achieved following their inclusion in combination therapy.
det||prescription-3/NN||a-1/DT	nn||prescription-3/NN||retrospective-2/NN	nsubjpass||conducted-9/VBN||prescription-3/NN	amod||analysis-7/NN||medical-5/JJ	nn||analysis-7/NN||claims-6/NNS	conj_and||prescription-3/NN||analysis-7/NN	nsubjpass||conducted-9/VBN||analysis-7/NN	auxpass||conducted-9/VBN||was-8/VBD	root||ROOT-0/null||conducted-9/VBN	xcomp||conducted-9/VBN||using-10/VBG	det||sample-13/NN||a-11/DT	amod||sample-13/NN||random-12/JJ	dobj||using-10/VBG||sample-13/NN	amod||users-16/NNS||mesalamine-15/JJ	prep_of||sample-13/NN||users-16/NNS	prep_with||using-10/VBG||uc-18/NN	uc-18||mesalamine-15||yes||a retrospective prescription and medical claims analysis was conducted using a random sample of mesalamine users with uc.
det||substudy-6/NN||this-2/DT	amod||substudy-6/NN||randomized-3/JJ	amod||substudy-6/NN||placebo-controlled-5/JJ	prep_in||received-12/VBD||substudy-6/NN	num||patients-9/NNS||122-8/CD	nsubj||received-12/VBD||patients-9/NNS	prep_with||patients-9/NNS||jia-11/NN	root||ROOT-0/null||received-12/VBD	number||3-14/CD||infliximab-13/CD	dobj||received-12/VBD||3-14/CD	xcomp||received-12/VBD||mg/kg-15/VBG	amod||methotrexate-17/NN||+-16/JJ	dobj||mg/kg-15/VBG||methotrexate-17/NN	appos||methotrexate-17/NN||mtx-19/NN	dep||methotrexate-17/NN||n-22/VBN	dep||60-24/CD||=-23/SYM	ccomp||n-22/VBN||60-24/CD	nn||mtx-29/NN||placebo-27/NN	amod||mtx-29/NN||+-28/VBG	dobj||mg/kg-15/VBG||mtx-29/NN	conj_or||methotrexate-17/NN||mtx-29/NN	dep||mtx-29/NN||n-31/VBN	dep||62-33/CD||=-32/SYM	ccomp||n-31/VBN||62-33/CD	prep_at||received-12/VBD||weeks-36/NNS	dep||weeks-36/NNS||0-37/CD	num||0-37/CD||2-39/CD	dep||weeks-36/NNS||6-42/CD	conj_and||0-37/CD||6-42/CD	jia-11||mtx-29||yes||in this randomized, placebo-controlled substudy, 122 patients with jia received infliximab 3 mg/kg + methotrexate (mtx)(n = 60) or placebo + mtx (n = 62) at weeks 0, 2, and 6.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-29/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-29/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||-RSB--24/NNS||nonsteroidalanti-inflammatorydrugs-21/JJ	amod||-RSB--24/NNS||-LSB--22/JJ	nn||-RSB--24/NNS||nsaids-23/NNS	prep_with||associated-19/VBN||-RSB--24/NNS	det||guidelines-28/NNS||these-27/DT	nsubj||propose-29/VBP||guidelines-28/NNS	root||ROOT-0/null||propose-29/VBP	dobj||propose-29/VBP||acetaminophen-30/NN	det||anti-inflammatoryagents-35/NNS||the-32/DT	amod||anti-inflammatoryagents-35/NNS||first-33/JJ	nn||anti-inflammatoryagents-35/NNS||choice-34/NN	prep_as||propose-29/VBP||anti-inflammatoryagents-35/NNS	nonsteroidalanti-inflammatorydrugs-21||ulcer-7||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidalanti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
det||study-3/NN||the-1/DT	nn||study-3/NN||action-2/NN	nsubj||trial-21/NN||study-3/NN	amod||investigation-8/NN||attentiondeficithyperactivitydisorder-5/JJ	amod||investigation-8/NN||controlled-6/VBN	nn||investigation-8/NN||trial-7/NN	dep||study-3/NN||investigation-8/NN	det||non-stimulant-11/NN||a-10/DT	prep_of||investigation-8/NN||non-stimulant-11/NN	cop||trial-21/NN||is-13/VBZ	det||trial-21/NN||a-14/DT	amod||trial-21/NN||multi-center-15/JJ	amod||trial-21/NN||double-blind-17/JJ	amod||trial-21/NN||randomized-19/JJ	amod||trial-21/NN||cross-over-20/JJ	root||ROOT-0/null||trial-21/NN	det||medication-25/NN||the-23/DT	amod||medication-25/NN||non-stimulant-24/JJ	prep_of||trial-21/NN||medication-25/NN	appos||medication-25/NN||atomoxetine-27/NN	prep_in||medication-25/NN||children-30/NNS	prep_in||medication-25/NN||adolescents-32/NNS	conj_and||children-30/NNS||adolescents-32/NNS	prep_with||children-30/NNS||attentiondeficithyperactivitydisorder-34/NN	dep||medication-25/NN||adhd-36/VBN	attentiondeficithyperactivitydisorder-34||atomoxetine-27||yes||the action study ( attentiondeficithyperactivitydisorder controlled trial investigation of a non-stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication, atomoxetine, in children and adolescents with attentiondeficithyperactivitydisorder (adhd).
det||population-2/NN||the-1/DT	nsubj||comprised-3/VBN||population-2/NN	nsubj||receiving-13/VBG||population-2/NN	root||ROOT-0/null||comprised-3/VBN	dobj||comprised-3/VBN||patients-4/NNS	det||diagnosis-8/NN||a-6/DT	amod||diagnosis-8/NN||first-7/JJ	prep_with||comprised-3/VBN||diagnosis-8/NN	amod||depressivedisorder-11/NN||major-10/JJ	prep_of||diagnosis-8/NN||depressivedisorder-11/NN	conj_and||comprised-3/VBN||receiving-13/VBG	det||one-18/NN||the-15/DT	amod||one-18/NN||first-16/JJ	nn||one-18/NN||time-17/NN	prep_for||receiving-13/VBG||one-18/NN	det||escitalopram-23/NN||the-20/DT	amod||escitalopram-23/NN||following-21/JJ	nn||escitalopram-23/NN||ssris-22/NNS	prep_of||one-18/NN||escitalopram-23/NN	appos||escitalopram-23/NN||sertraline-25/NN	appos||escitalopram-23/NN||paroxetine-27/NN	conj_and||sertraline-25/NN||paroxetine-27/NN	appos||escitalopram-23/NN||citalopram-30/NN	conj_and||sertraline-25/NN||citalopram-30/NN	depressivedisorder-11||escitalopram-23||yes||the population comprised patients with a first diagnosis of major depressivedisorder and receiving for the first time one of the following ssris escitalopram, sertraline, paroxetine, and citalopram.
prepc_compared_with||lower-10/JJR||with-2/IN	pobj||lower-10/JJR||adolescents-3/NNS	prep_with||adolescents-3/NNS||ngt-5/NN	amod||insulin-8/NN||first-phase-7/JJ	nsubj||lower-10/JJR||insulin-8/NN	cop||lower-10/JJR||was-9/VBD	root||ROOT-0/null||lower-10/JJR	det||function-38/NN||those-12/DT	prep_with||igt-16/JJ||ifg-14/NN	amod||function-38/NN||igt-16/JJ	conj_and||igt-16/JJ||ifg/igt-19/JJ	amod||function-38/NN||ifg/igt-19/JJ	amod||deterioration-22/NN||further-21/JJ	prep_with||ifg/igt-19/JJ||deterioration-22/NN	prep_in||deterioration-22/NN||those-24/DT	prep_with||those-24/DT||type2diabetes-26/CD	dep||ifg/igt-19/JJ||p-28/NNP	number||0.001-30/CD||<-29/CD	num||p-28/NNP||0.001-30/CD	advmod||²-35/JJ||î-34/RB	conj_and||igt-16/JJ||²-35/JJ	amod||function-38/NN||²-35/JJ	nn||function-38/NN||cell-37/NN	prep_in||lower-10/JJR||function-38/NN	advmod||function-38/NN||relative-39/JJ	nn||sensitivity-42/NN||insulin-41/NN	prep_to||relative-39/JJ||sensitivity-42/NN	nn||-RSB--49/NNP||glucose-44/NN	nn||-RSB--49/NNP||disposition-45/NN	nn||-RSB--49/NNP||index-46/NN	nn||-RSB--49/NNP||-LSB--47/NNP	nn||-RSB--49/NNP||gdi-48/NNP	nsubj||lower-53/JJR||-RSB--49/NNP	cop||lower-53/JJR||was-51/VBD	advmod||lower-53/JJR||also-52/RB	rcmod||sensitivity-42/NN||lower-53/JJR	prep_in||lower-53/JJR||those-55/DT	prep_with||those-55/DT||ifg-57/NN	prep_with||those-55/DT||igt-59/NN	conj_and||ifg-57/NN||igt-59/NN	prep_with||those-55/DT||ifg/igt-62/NN	conj_and||ifg-57/NN||ifg/igt-62/NN	dep||ifg-57/NN||40-64/CD	dep||ifg-57/NN||47-66/CD	conj_and||40-64/CD||47-66/CD	num||%-70/NN||47-69/CD	dep||ifg-57/NN||%-70/NN	conj_and||40-64/CD||%-70/NN	advmod||%-70/NN||respectively-72/RB	det||decrease-78/NN||a-76/DT	amod||decrease-78/NN||further-77/JJ	prep_with||lower-10/JJR||decrease-78/NN	num||%-81/NN||80-80/CD	appos||decrease-78/NN||%-81/NN	prep_in||decrease-78/NN||those-84/DT	prep_with||those-84/DT||type2diabetes-86/NNS	appos||type2diabetes-86/NNS||p-88/NNP	number||0.001-90/CD||<-89/CD	num||p-88/NNP||0.001-90/CD	type2diabetes-86||insulin-41||yes||compared with adolescents with ngt, first-phase insulin was lower in those with ifg, igt, and ifg/igt with further deterioration in those with type2diabetes ( p < 0.001), and î²-cell function relative to insulin sensitivity (glucose disposition index [gdi]) was also lower in those with ifg, igt, and ifg/igt (40, 47, and 47%, respectively), with a further decrease (80%) in those with type2diabetes ( p < 0.001).
det||study-7/NN||this-1/DT	amod||study-7/NN||26-week-2/JJ	amod||study-7/NN||double-blind-4/JJ	amod||study-7/NN||parallel-group-6/JJ	root||ROOT-0/null||study-7/NN	vmod||study-7/NN||randomized-8/VBN	amod||patients-10/NNS||655-9/JJ	dobj||randomized-8/VBN||patients-10/NNS	advmod||controlled-13/JJ||inadequately-12/RB	amod||monotherapy-25/NNS||controlled-13/JJ	amod||monotherapy-25/NNS||type2diabetes-14/JJ	num||arms-17/NNS||four-16/CD	prep_to||type2diabetes-14/JJ||arms-17/NNS	num||alogliptin-20/NN||25-18/CD	nn||alogliptin-20/NN||mg-19/NN	nsubj||-lrb--21/VBZ||alogliptin-20/NN	rcmod||arms-17/NNS||-lrb--21/VBZ	amod||monotherapy-25/NNS||a25-22/JJ	amod||monotherapy-25/NNS||-rrb--23/JJ	nn||monotherapy-25/NNS||q.d.-24/NN	prep_with||randomized-8/VBN||monotherapy-25/NNS	number||mg-28/CD||30-27/CD	num||monotherapy-34/NN||mg-28/CD	amod||monotherapy-34/NN||pioglitazone-29/JJ	amod||monotherapy-34/NN||-lrb--30/JJ	amod||monotherapy-34/NN||p30-31/JJ	amod||monotherapy-34/NN||-rrb--32/JJ	nn||monotherapy-34/NN||q.d.-33/NN	prep_with||randomized-8/VBN||monotherapy-34/NN	conj_or||monotherapy-25/NNS||monotherapy-34/NN	num||a12-39/NNS||12.5-37/CD	amod||a12-39/NNS||-lrb--38/JJ	prep_with||randomized-8/VBN||a12-39/NNS	conj_or||monotherapy-25/NNS||a12-39/NNS	num||-rrb--41/NNS||.5-40/CD	dep||a12-39/NNS||-rrb--41/NNS	num||q.d.-46/NN||25-43/CD	nn||q.d.-46/NN||mg-44/NN	nn||q.d.-46/NN||alogliptin-45/NN	prep_with||randomized-8/VBN||q.d.-46/NN	conj_or||monotherapy-25/NNS||q.d.-46/NN	prep||q.d.-46/NN||plus-47/CC	amod||therapy-54/NN||pioglitazone-48/JJ	nn||therapy-54/NN||-lrb--49/NNP	amod||therapy-54/NN||p30-50/JJ	amod||therapy-54/NN||-rrb--51/JJ	nn||therapy-54/NN||q.d.-52/NN	nn||therapy-54/NN||combination-53/NN	pobj||plus-47/CC||therapy-54/NN	pioglitazone-48||type2diabetes-14||no_rel||this 26-week , double-blind , parallel-group study randomized 655 patients with inadequately controlled type2diabetes to four arms 25 mg alogliptin -lrb- a25 -rrb- q.d. monotherapy , 30 mg pioglitazone -lrb- p30 -rrb- q.d. monotherapy , or 12.5 -lrb- a12 .5 -rrb- or 25 mg alogliptin q.d. plus pioglitazone -lrb- p30 -rrb- q.d. combination therapy .
prep_above||noted-7/VBN||all-2/DT	nsubjpass||noted-7/VBN||it-4/PRP	aux||noted-7/VBN||should-5/MD	auxpass||noted-7/VBN||be-6/VB	root||ROOT-0/null||noted-7/VBN	det||ability-9/NN||the-8/DT	dobj||noted-7/VBN||ability-9/NN	amod||assay-13/NN||r5-enzyme-linked-11/JJ	nn||assay-13/NN||immunosorbent-12/NN	prep_of||ability-9/NN||assay-13/NN	amod||methods-17/NNS||other-16/JJ	prep_of||ability-9/NN||methods-17/NNS	conj_and||assay-13/NN||methods-17/NNS	aux||measure-20/VB||to-19/TO	vmod||noted-7/VBN||measure-20/VB	poss||toxicity-23/NN||gluten-21/NN	nsubj||validated-29/JJ||toxicity-23/NN	amod||patients-26/NNS||celiacdisease-25/JJ	prep_toward||toxicity-23/NN||patients-26/NNS	cop||validated-29/JJ||is-27/VBZ	neg||validated-29/JJ||not-28/RB	ccomp||measure-20/VB||validated-29/JJ	advmod||validated-29/JJ||clinically-30/RB	celiacdisease-25||gluten-21||no||above all, it should be noted the ability of r5-enzyme-linked immunosorbent assay, and other methods, to measure gluten's toxicity toward celiacdisease patients is not validated clinically.
nsubj||thromboembolism-20/VBP||conclusions-1/NNS	det||findings-3/NNS||these-2/DT	nsubj||contribute-4/VBP||findings-3/NNS	rcmod||conclusions-1/NNS||contribute-4/VBP	amod||evidence-7/NN||emerging-6/VBG	prep_to||contribute-4/VBP||evidence-7/NN	mark||carries-14/VBZ||that-8/IN	det||oralcontraceptive-11/NN||the-9/DT	amod||oralcontraceptive-11/NN||combined-10/VBN	nsubj||carries-14/VBZ||oralcontraceptive-11/NN	vmod||oralcontraceptive-11/NN||containing-12/VBG	dobj||containing-12/VBG||drospirenone-13/NN	ccomp||evidence-7/NN||carries-14/VBZ	det||risk-17/NN||a-15/DT	amod||risk-17/NN||higher-16/JJR	dobj||carries-14/VBZ||risk-17/NN	prep_of||risk-17/NN||venous-19/NNS	root||ROOT-0/null||thromboembolism-20/VBP	mark||do-22/VBP||than-21/IN	advcl||thromboembolism-20/VBP||do-22/VBP	dobj||do-22/VBP||formulations-23/NNS	vmod||formulations-23/NNS||containing-24/VBG	acomp||containing-24/VBG||levonorgestrel-25/JJ	thromboembolism-20||drospirenone-13||no||conclusions these findings contribute to emerging evidence that the combined oralcontraceptive containing drospirenone carries a higher risk of venous thromboembolism than do formulations containing levonorgestrel.
det||case-2/NN||this-1/DT	nsubj||suggests-3/VBZ||case-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||offer-7/VB||that-4/IN	nsubj||offer-7/VB||bivalirudin-5/NN	aux||offer-7/VB||could-6/MD	ccomp||suggests-3/VBZ||offer-7/VB	dobj||offer-7/VB||promise-8/NN	prep_for||promise-8/NN||use-10/NN	prep_in||offer-7/VB||patients-12/NNS	amod||thrombocytopaenia-15/NN||heparin-induced-14/JJ	prep_with||offer-7/VB||thrombocytopaenia-15/NN	dep||offer-7/VB||hit-17/VBN	prep_after||offer-7/VB||thrombolysis-20/NNS	amod||pulmonaryembolism-23/NN||massive-22/JJ	prep_for||thrombolysis-20/NNS||pulmonaryembolism-23/NN	hit-17||heparin--1||no||this case suggests that bivalirudin could offer promise for use in patients with heparin-induced thrombocytopaenia (hit) after thrombolysis for massive pulmonaryembolism.
prep_in||trait-9/NN||conclusion-2/NN	nsubj||trait-9/NN||hvga-4/NN	nsubj||stands-17/VBZ||hvga-4/NN	cop||trait-9/NN||is-5/VBZ	det||trait-9/NN||a-6/DT	amod||trait-9/NN||critical-7/JJ	nn||trait-9/NN||virulence-8/NN	root||ROOT-0/null||trait-9/NN	prep_of||trait-9/NN||gbs-11/NN	det||context-15/NN||the-13/DT	amod||context-15/NN||neonatal-14/JJ	prep_in||gbs-11/NN||context-15/NN	conj_and||trait-9/NN||stands-17/VBZ	det||target-21/NN||a-19/DT	amod||target-21/NN||promising-20/JJ	prep_as||stands-17/VBZ||target-21/NN	det||development-24/NN||the-23/DT	prep_for||target-21/NN||development-24/NN	amod||diagnostic-27/JJ||novel-26/JJ	prep_of||development-24/NN||diagnostic-27/JJ	amod||strategies-30/NNS||antibacterial-29/JJ	prep_of||development-24/NN||strategies-30/NNS	conj_and||diagnostic-27/JJ||strategies-30/NNS	antibacterial-29||gbs-11||no_rel||in conclusion, hvga is a critical virulence trait of gbs in the neonatal context and stands as a promising target for the development of novel diagnostic and antibacterial strategies.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||sequence-11/NN||the-9/DT	amod||sequence-11/NN||genome-10/JJ	nsubj||isolate-16/VB||sequence-11/NN	det||mrsa-15/NN||an-13/DT	amod||mrsa-15/NN||st398-14/JJ	prep_of||sequence-11/NN||mrsa-15/NN	ccomp||compare-8/VB||isolate-16/VB	amod||genomes-20/NNS||other-18/JJ	nn||genomes-20/NNS||s.aureus-19/NNS	prep_with||isolate-16/VB||genomes-20/NNS	mark||identify-24/VB||in-21/IN	dep||identify-24/VB||order-22/NN	aux||identify-24/VB||to-23/TO	advcl||isolate-16/VB||identify-24/VB	amod||traits-26/NNS||genetic-25/JJ	dobj||identify-24/VB||traits-26/NNS	nsubj||explain-29/VB||traits-26/NNS	aux||explain-29/VB||may-28/MD	rcmod||traits-26/NNS||explain-29/VB	det||success-31/NN||the-30/DT	dobj||explain-29/VB||success-31/NN	det||lineage-35/NN||this-33/DT	amod||lineage-35/NN||particular-34/JJ	prep_of||success-31/NN||lineage-35/NN	mrsa-15||s.aureus-19||no||the aim of this study was to compare the genome sequence of an st398 mrsa isolate with other s.aureus genomes in order to identify genetic traits that may explain the success of this particular lineage .
det||end-3/NN||the-2/DT	prep_at||superior-10/JJ||end-3/NN	amod||treatment-6/NN||48-week-5/JJ	prep_of||end-3/NN||treatment-6/NN	nsubj||superior-10/JJ||tenofovir-8/NN	nsubj||adefovir-12/VB||tenofovir-8/NN	cop||superior-10/JJ||was-9/VBD	root||ROOT-0/null||superior-10/JJ	aux||adefovir-12/VB||to-11/TO	xcomp||superior-10/JJ||adefovir-12/VB	det||suppression-16/NN||the-14/DT	amod||suppression-16/NN||hbv-dna-15/JJ	prep_at||adefovir-12/VB||suppression-16/NN	nn||rr-20/NN||patients-18/NNS	amod||rr-20/NN||-LSB--19/JJ	prep_in||suppression-16/NN||rr-20/NN	dep||2.59-22/NNS||=-21/SYM	dep||rr-20/NN||2.59-22/NNS	number||%-25/NN||95-24/CD	amod||ci-26/NN||%-25/NN	dep||suppression-16/NN||ci-26/NN	number||.67-29/CD||1.01-6-28/CD	dep||ci-26/NN||.67-29/CD	vmod||ci-26/NN||p-32/VBN	dep||-RSB--35/NNS||=-33/SYM	num||-RSB--35/NNS||0.05-34/CD	ccomp||p-32/VBN||-RSB--35/NNS	hbv--1||adefovir-12||yes||at the end of 48-week treatment, tenofovir was superior to adefovir at the hbv-dna suppression in patients[rr = 2.59; 95%ci(1.01-6.67), p = 0.05].
aux||examine-2/VB||to-1/TO	root||ROOT-0/null||examine-2/VB	det||change-4/NN||the-3/DT	dobj||examine-2/VB||change-4/NN	nn||weight-7/NN||body-6/NN	prep_in||change-4/NN||weight-7/NN	advmod||intake-10/VBN||dietary-9/RB	conj_and||examine-2/VB||intake-10/VBN	det||treatment-14/NN||a-12/DT	amod||treatment-14/NN||1-year-13/JJ	prep_during||intake-10/VBN||treatment-14/NN	prep_with||treatment-14/NN||orlistat-16/NN	det||loss-21/NN||an-18/DT	amod||loss-21/NN||initial-19/JJ	nn||loss-21/NN||weight-20/NN	prep_after||intake-10/VBN||loss-21/NN	amod||subjects-24/NNS||obese-23/JJ	prep_in||loss-21/NN||subjects-24/NNS	prep_with||intake-10/VBN||srbd-26/NN	obese-23||orlistat-16||yes||to examine the change in body weight and dietary intake during a 1-year treatment with orlistat after an initial weight loss in obese subjects with srbd.
amod||reports-2/NNS||recent-1/JJ	nsubj||show-3/VBP||reports-2/NNS	root||ROOT-0/null||show-3/VBP	mark||-lrb--10/VBD||that-4/IN	det||prevalence-6/NN||the-5/DT	nsubj||-lrb--10/VBD||prevalence-6/NN	amod||s.aureus-9/NNS||methicillin-resistant-8/JJ	prep_of||prevalence-6/NN||s.aureus-9/NNS	ccomp||show-3/VBP||-lrb--10/VBD	amod||infections-13/NNS||mrsa-11/JJ	amod||infections-13/NNS||-rrb--12/JJ	nsubj||increasing-22/VBG||infections-13/NNS	amod||patients-20/NNS||cystic-15/JJ	nn||patients-20/NNS||fibrosis-16/NN	nn||patients-20/NNS||-lrb--17/NN	nn||patients-20/NNS||cf-18/NN	amod||patients-20/NNS||-rrb--19/JJ	prep_in||infections-13/NNS||patients-20/NNS	aux||increasing-22/VBG||is-21/VBZ	ccomp||-lrb--10/VBD||increasing-22/VBG	mrsa-11||s.aureus-9||no||recent reports show that the prevalence of methicillin-resistant s.aureus -lrb- mrsa -rrb- infections in cystic fibrosis -lrb- cf -rrb- patients is increasing .
det||analysis-2/NN||this-1/DT	nsubj||illustrates-14/VBZ||analysis-2/NN	nn||patterns-5/NNS||workforce-4/NN	prep_of||analysis-2/NN||patterns-5/NNS	num||facilities-8/NNS||30-7/CD	prep_across||patterns-5/NNS||facilities-8/NNS	num||districts-11/NNS||three-10/CD	prep_in||facilities-8/NNS||districts-11/NNS	prep_of||districts-11/NNS||zambia-13/NN	root||ROOT-0/null||illustrates-14/VBZ	mark||been-25/VBN||that-15/IN	det||achievements-18/NNS||the-16/DT	amod||achievements-18/NNS||remarkable-17/JJ	nsubj||been-25/VBN||achievements-18/NNS	amod||delivery-23/NN||scaling-up-20/JJ	nn||delivery-23/NN||hiv/aids-21/NN	nn||delivery-23/NN||service-22/NN	prep_in||achievements-18/NNS||delivery-23/NN	aux||been-25/VBN||has-24/VBZ	ccomp||illustrates-14/VBZ||been-25/VBN	det||back-28/NN||the-27/DT	prep_on||been-25/VBN||back-28/NN	amod||levels-33/NNS||sustained-30/JJ	amod||levels-33/NNS||non-hiv-31/JJ	nn||levels-33/NNS||workload-32/NN	prep_of||back-28/NN||levels-33/NNS	amod||workload-37/NN||increasing-35/VBG	nn||workload-37/NN||hiv-36/NN	prep_of||back-28/NN||workload-37/NN	conj_and||levels-33/NNS||workload-37/NN	amod||numbers-42/NNS||stagnant-39/JJ	nn||numbers-42/NNS||health-40/NN	nn||numbers-42/NNS||worker-41/NN	prep_of||back-28/NN||numbers-42/NNS	conj_and||levels-33/NNS||numbers-42/NNS	aids--1||hiv-36||no||this analysis of workforce patterns across 30 facilities in three districts of zambia illustrates that the remarkable achievements in scaling-up hiv/aids service delivery has been on the back of sustained non-hiv workload levels, increasing hiv workload and stagnant health worker numbers.
nn||t3-2/NNS||serum-1/NN	nsubjpass||decreased-6/VBN||t3-2/NNS	conj_and||t3-2/NNS||t4-4/NNS	nsubjpass||decreased-6/VBN||t4-4/NNS	auxpass||decreased-6/VBN||were-5/VBD	root||ROOT-0/null||decreased-6/VBN	num||children-9/NNS||34/78-8/CD	prep_in||decreased-6/VBN||children-9/NNS	nn||infections-12/NNS||cns-11/NN	prep_with||children-9/NNS||infections-12/NNS	nsubj||lower-19/JJR||t3-14/NNS	nsubj||higher-33/JJR||t3-14/NNS	conj_and||t3-14/NNS||t4-16/NNS	nsubj||lower-19/JJR||t4-16/NNS	cop||lower-19/JJR||were-17/VBD	advmod||lower-19/JJR||much-18/RB	dep||decreased-6/VBN||lower-19/JJR	prep_than||lower-19/JJR||those-21/DT	amod||adult-24/NN||healthy-23/JJ	prep_of||those-21/DT||adult-24/NN	dep||<-27/JJ||p-26/RB	dep||lower-19/JJR||<-27/JJ	dep||<-27/JJ||0.05-28/CD	advmod||higher-33/JJR||still-32/RB	dep||decreased-6/VBN||higher-33/JJR	conj_but||lower-19/JJR||higher-33/JJR	prep_than||higher-33/JJR||that-35/DT	det||hypothyroidism-39/NN||the-37/DT	amod||hypothyroidism-39/NN||primary-38/JJ	prep_of||that-35/DT||hypothyroidism-39/NN	dep||<-42/JJ||p-41/RB	dep||higher-33/JJR||<-42/JJ	dep||<-42/JJ||0.05-43/CD	nn||levels-48/NNS||tsh-47/NN	nsubj||differences-52/NNS||levels-48/NNS	cop||differences-52/NNS||were-49/VBD	neg||differences-52/NNS||not-50/RB	amod||differences-52/NNS||significant-51/JJ	conj_and||decreased-6/VBN||differences-52/NNS	prep_among||differences-52/NNS||children-54/NNS	nn||infections-57/NNS||cns-56/NN	prep_with||children-54/NNS||infections-57/NNS	prep_with||children-54/NNS||children-59/NNS	conj_and||infections-57/NNS||children-59/NNS	amod||infections-62/NNS||non-cns-61/JJ	prep_with||children-54/NNS||infections-62/NNS	dep||children-54/NNS||p-64/VBN	num||0.05-66/CD||>-65/CD	dobj||p-64/VBN||0.05-66/CD	hypothyroidism-39||t4-16||yes||serum t3 and t4 were decreased in 34/78 children with cns infections, t3 and t4 were much lower than those of healthy adult (p < 0.05), but still higher than that of the primary hypothyroidism (p < 0.05), and tsh levels were not significant differences among children with cns infections and children with non-cns infections (p > 0.05).
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	interferon--1||melanoma-54||no_rel||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
nsubj||describe-2/VBP||we-1/PRP	nsubj||illustrate-13/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	amod||choices-4/NNS||several-3/JJ	dobj||describe-2/VBP||choices-4/NNS	nn||studies-7/NNS||weighting-6/NN	prep_for||describe-2/VBP||studies-7/NNS	det||meta-analysis-10/NNS||the-9/DT	prep_in||studies-7/NNS||meta-analysis-10/NNS	conj_and||describe-2/VBP||illustrate-13/VBP	dobj||illustrate-13/VBP||methods-14/NNS	xcomp||illustrate-13/VBP||using-15/VBG	det||meta-analysis-17/NNS||a-16/DT	dobj||using-15/VBG||meta-analysis-17/NNS	prep_of||meta-analysis-17/NNS||trials-19/NNS	prep_of||trials-19/NNS||haloperidol-21/NN	prep_for||using-15/VBG||schizophrenia-23/NN	schizophrenia-23||haloperidol-21||yes||we describe several choices for weighting studies in the meta-analysis, and illustrate methods using a meta-analysis of trials of haloperidol for schizophrenia.
amod||strains-5/NNS||methicillin-resistantstaphylococcusaureus-1/JJ	appos||strains-5/NNS||mrsa-3/NNP	nsubj||become-7/VBN||strains-5/NNS	aux||become-7/VBN||have-6/VBP	ccomp||isolates-29/VBZ||become-7/VBN	amod||causes-9/NNS||common-8/JJ	xcomp||become-7/VBN||causes-9/NNS	prep_of||causes-9/NNS||skin-11/NN	prep_of||causes-9/NNS||softtissueinfections-13/NNS	conj_and||skin-11/NN||softtissueinfections-13/NNS	appos||causes-9/NNS||ssti-15/NNP	advmod||healthy-19/JJ||previously-18/RB	amod||people-20/NNS||healthy-19/JJ	prep_among||become-7/VBN||people-20/NNS	det||role-23/NN||a-22/DT	nsubj||isolates-29/VBZ||role-23/NN	prep_of||role-23/NN||methicillin-susceptible-25/NN	appos||methicillin-susceptible-25/NN||mssa-27/NNP	root||ROOT-0/null||isolates-29/VBZ	det||mid-1990s-32/NNS||the-31/DT	prep_before||isolates-29/VBZ||mid-1990s-32/NNS	softtissueinfections-13||methicillin--1||yes||methicillin-resistantstaphylococcusaureus (mrsa) strains have become common causes of skin and softtissueinfections (ssti) among previously healthy people, a role of methicillin-susceptible (mssa) isolates before the mid-1990s.
nn||concentrations-2/NNS||serum-1/NN	nsubjpass||measured-50/VBN||concentrations-2/NNS	amod||cytokines-5/NNS||proinflammatory-4/JJ	prep_of||concentrations-2/NNS||cytokines-5/NNS	amod||interleukin-6-8/JJ||interleukin-1alpha-6/JJ	amod||cytokines-5/NNS||interleukin-6-8/JJ	nn||necrosis-11/NNS||tumor-10/NN	prep_of||concentrations-2/NNS||necrosis-11/NNS	conj_and||cytokines-5/NNS||necrosis-11/NNS	amod||colonystimulatingfactor-15/NN||factor-alpha-12/JJ	amod||colonystimulatingfactor-15/NN||granulocyte-macrophage-14/JJ	dep||necrosis-11/NNS||colonystimulatingfactor-15/NN	dep||colonystimulatingfactor-15/NN||gm-csf-17/JJ	det||markers-22/NNS||some-20/DT	amod||markers-22/NNS||biochemical-21/JJ	prep_of||concentrations-2/NNS||markers-22/NNS	conj_and||cytokines-5/NNS||markers-22/NNS	prep_of||markers-22/NNS||osteoporosis-24/NN	nn||alkaline-31/NN||osteocalcin-26/NN	conj_and||osteocalcin-26/NN||total-28/NN	nn||alkaline-31/NN||total-28/NN	conj_and||osteocalcin-26/NN||bone-30/NN	nn||alkaline-31/NN||bone-30/NN	dep||concentrations-2/NNS||alkaline-31/NN	amod||telopeptides-41/NNS||phosphatase-32/JJ	amod||telopeptides-41/NNS||procollagen-34/JJ	nn||telopeptides-41/NNS||type-35/NN	amod||telopeptides-41/NNS||i-36/JJ	amod||telopeptides-41/NNS||carboxyterminal-37/JJ	amod||telopeptides-41/NNS||propeptide-38/JJ	amod||telopeptides-41/NNS||carboxyterminal-40/JJ	dep||alkaline-31/NN||telopeptides-41/NNS	nn||collagen-45/NN||type-43/FW	nn||collagen-45/NN||i-44/FW	prep_of||telopeptides-41/NNS||collagen-45/NN	dep||collagen-45/NN||ctx-47/NN	auxpass||measured-50/VBN||were-49/VBD	root||ROOT-0/null||measured-50/VBN	ctx-47||osteoporosis-24||no_rel||serum concentrations of proinflammatory cytokines interleukin-1alpha, interleukin-6, tumor necrosis factor-alpha, granulocyte-macrophage colonystimulatingfactor (gm-csf) and some biochemical markers of osteoporosis (osteocalcin, total and bone alkaline phosphatase, procollagen type i carboxyterminal propeptide, carboxyterminal telopeptides of type i collagen--ctx) were measured.
advmod||believed-15/VBN||currently-1/RB	det||avianinfluenzavirus-6/NNS||the-3/DT	advmod||pathogenic-5/JJ||highly-4/RB	amod||avianinfluenzavirus-6/NNS||pathogenic-5/JJ	nsubjpass||believed-15/VBN||avianinfluenzavirus-6/NNS	nsubj||reached-18/VBN||avianinfluenzavirus-6/NNS	appos||avianinfluenzavirus-6/NNS||hpaiv-8/NNP	det||h5n1-13/NN||the-11/DT	amod||h5n1-13/NN||subtype-12/JJ	prep_of||avianinfluenzavirus-6/NNS||h5n1-13/NN	auxpass||believed-15/VBN||is-14/VBZ	root||ROOT-0/null||believed-15/VBN	aux||reached-18/VBN||to-16/TO	aux||reached-18/VBN||have-17/VB	xcomp||believed-15/VBN||reached-18/VBN	det||cycle-21/NN||an-19/DT	amod||cycle-21/NN||endemic-20/JJ	dobj||reached-18/VBN||cycle-21/NN	prep_in||cycle-21/NN||vietnam-23/NN	h5n1-13||avianinfluenzavirus-6||no||currently, the highly pathogenic avianinfluenzavirus (hpaiv) of the subtype h5n1 is believed to have reached an endemic cycle in vietnam.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	nsubj||investigate-7/VB||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	aux||investigate-7/VB||to-6/TO	xcomp||conducted-5/VBN||investigate-7/VB	mark||coordinated-12/VBN||whether-8/IN	poss||responses-10/NNS||their-9/PRP$	nsubjpass||coordinated-12/VBN||responses-10/NNS	nsubj||bacteria-specific-15/JJ||responses-10/NNS	auxpass||coordinated-12/VBN||are-11/VBP	ccomp||investigate-7/VB||coordinated-12/VBN	cop||bacteria-specific-15/JJ||are-14/VBP	ccomp||investigate-7/VB||bacteria-specific-15/JJ	conj_and||coordinated-12/VBN||bacteria-specific-15/JJ	det||cavity-19/NN||the-17/DT	amod||cavity-19/NN||oral-18/JJ	prep_in||bacteria-specific-15/JJ||cavity-19/NN	cavity-19||bacteria---1||no||the present study was conducted to investigate whether their responses are coordinated and are bacteria-specific in the oral cavity.
nsubj||evolved-10/VBN||treatment-1/NN	amod||infection-8/NN||chronichepatitisc-3/JJ	nn||infection-8/NN||virus-4/NN	appos||infection-8/NN||hcv-6/NN	prep_for||treatment-1/NN||infection-8/NN	aux||evolved-10/VBN||has-9/VBZ	root||ROOT-0/null||evolved-10/VBN	advmod||evolved-10/VBN||considerably-11/RB	det||years-15/NNS||the-13/DT	amod||years-15/NNS||last-14/JJ	prep_in||evolved-10/VBN||years-15/NNS	chronichepatitisc-3||hcv-6||no||treatment for chronichepatitisc virus (hcv) infection has evolved considerably in the last years.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	cancer-14||hormone--1||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
